<SEC-DOCUMENT>0000943819-22-000010.txt : 20220812
<SEC-HEADER>0000943819-22-000010.hdr.sgml : 20220812
<ACCEPTANCE-DATETIME>20220811210945
ACCESSION NUMBER:		0000943819-22-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		111
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220812
DATE AS OF CHANGE:		20220811

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RESMED INC
		CENTRAL INDEX KEY:			0000943819
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980152841
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15317
		FILM NUMBER:		221157548

	BUSINESS ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		8587462400

	MAIL ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>rmd-20220630.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:847d2812-be5d-4010-ae3d-4823a56f6339,g:501af745-9083-47bc-ad44-e407829835be,d:1f60984bb51544a482851b08d4a3bf6b--><html xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:rmd="http://investor.resmed.com/20220630" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>rmd-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl80L2ZyYWc6OWIxZmJiNjllOWE1NDA1Mjk4NjZkNTEyYjI2YmUzNjgvdGFibGU6Yzc3NDljNzg0ZWUxNDFkZWE3NTBlYTM3YTQ1OWM4MTkvdGFibGVyYW5nZTpjNzc0OWM3ODRlZTE0MWRlYTc1MGVhMzdhNDU5YzgxOV80LTEtMS0xLTI4NzY5_ba9732cf-c420-44a4-9879-69a0fb2ff3be">false</ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl80L2ZyYWc6OWIxZmJiNjllOWE1NDA1Mjk4NjZkNTEyYjI2YmUzNjgvdGFibGU6Yzc3NDljNzg0ZWUxNDFkZWE3NTBlYTM3YTQ1OWM4MTkvdGFibGVyYW5nZTpjNzc0OWM3ODRlZTE0MWRlYTc1MGVhMzdhNDU5YzgxOV81LTEtMS0xLTI4NzY5_80deab20-2d0d-47e2-8cea-7d5d5c153fe6">FY</ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl80L2ZyYWc6OWIxZmJiNjllOWE1NDA1Mjk4NjZkNTEyYjI2YmUzNjgvdGFibGU6Yzc3NDljNzg0ZWUxNDFkZWE3NTBlYTM3YTQ1OWM4MTkvdGFibGVyYW5nZTpjNzc0OWM3ODRlZTE0MWRlYTc1MGVhMzdhNDU5YzgxOV82LTEtMS0xLTI4NzY5_86c63fe3-5b22-4767-a9ec-9db11f3d58ec">0000943819</ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl80L2ZyYWc6OWIxZmJiNjllOWE1NDA1Mjk4NjZkNTEyYjI2YmUzNjgvdGFibGU6Yzc3NDljNzg0ZWUxNDFkZWE3NTBlYTM3YTQ1OWM4MTkvdGFibGVyYW5nZTpjNzc0OWM3ODRlZTE0MWRlYTc1MGVhMzdhNDU5YzgxOV83LTEtMS0xLTMxMTg3_10f6d05a-1bbb-49a6-8413-41339f295ee1">2022</ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl80L2ZyYWc6OWIxZmJiNjllOWE1NDA1Mjk4NjZkNTEyYjI2YmUzNjgvdGV4dHJlZ2lvbjo5YjFmYmI2OWU5YTU0MDUyOTg2NmQ1MTJiMjZiZTM2OF8zMjk4NTM0ODgzMzM3_24b691e5-e80d-4ef1-9b6f-a46ad70b0a55">&#9744;</ix:nonNumeric><ix:nonNumeric contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTgtMC0xLTEtMzI2Mjg_0c2fd2af-5aa3-40db-a89c-1b133efc80c3">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="rmd-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbdef3fca1f842ffb539ee7a7469d218_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie905261def8d433cbf089eb034507510_I20220808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60b746abe48d479dab43b5fa3772e0b6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6e67c47d1fc44c41b072ad44589d1ad5_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a9b9cae84c447429471e59078cc7791_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e1f5a8c9d8a4df7afb7de1694802ffb_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1968e917afd4a069dcce0cf81596189_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f3256c15f5423dae9d0f83d1016c16_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib50fa129c39f4e95a4ced80f5095f914_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if72cc941e4114d088386f9562860391b_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i607c9c75962444d08f128d8d1dd51b12_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79dd5c34ff9f422d9e66e42855b0fe44_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eec134b8bd6450baec5eba43690fb81_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f27f1170fa649259d40577a59061c34_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e9c77435e45485c85034973f776a026_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6113f72766ae4bf3a6b6822df9ec9799_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1d7efe198194679bd87c4519fbad23e_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08a4d2be57e74a8ab5b264970b29954e_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i747690daf6804d479047c828f5efc32a_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6592376d0e874a54b0c74878697fe0fa_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0787de141ff41878aae7892528f698a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37d85afb3c0245f5af0854c9191a8cb0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88f72c5541674f6592c342e22fc4e04e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8394569b4f94ef8955d0f57473de626_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeeb2746c953419385544cd7004bbac7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iade2a38a39f64c389d5899176b764aea_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic737aa421e0a4e9782bc67d50120cb7f_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1c1ddd15e1e47c9af2f8d75690aff1e_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i514c68b0178849528b98da7c305b377b_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if89490bfd4ff476b8ef0c46da716b643_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9052a046d6444bdb2321e25b6d1995e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5143bf6786f34585b5c51f7be503d02b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie47e6eabf77f427ba2b95ab6114f5051_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacae05028f8d4777a29f62e32c114e8d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a5cda1b02464bfd8426853a49a7491c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia489861770004d4582aa5f3dc793010f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie65c792136c946adbf377040f6366deb_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iece2a9fb6a58447ab6a18eaf650b57f8_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id598a508533f4a93af0cf893cdbc877c_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib389da5f9ca94f9e9783af8916ff3c69_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c44d305aea24f8c93d48ef038dd79ea_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i546cf7e76487425b8bfe97c8dd15a832_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b80b9e773a48ddbfec64e8038faa6d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77cc3f7b15ee461d972d81d7d0806848_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>rmd:segment</xbrli:measure></xbrli:unit><xbrli:context id="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i395a6823166d44c89daa1c281c702cd0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:AccountsReceivableNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3515d2e0a2ec4ac79cc7dc24382770f9_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:AccountsReceivableNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c52baae5bad475ebef7771a9b519ff5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie196dbd7b3fd443b991a4e53f748a874_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if99f07887f7a46228ef1235e19d7b4a5_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28a3ce23547b4f28a6b1d773a88cbc9b_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i209e45ce8baa40da9ad533b396e1a091_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie01fa7efbed74149bb3ddb5b137cf86b_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44cbe9d650c44532ad24d4a6fe3dfc94_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i633d55b64edf4c93a09ab4cc0f22c9e6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4960aeb688d4da1892eaa0e59da4d2e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4cdad6ff0a54f4a86b3bb451325b302_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a380d27436f42cd821417665d91070c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:VehiclesAndAircraftMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c114ee233de43edb2dac04cb12f71bc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:VehiclesAndAircraftMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c2b6d7ce5de4befb6c1ee57c860ff72_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ClinicalDemonstrationAndRentalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42c790c4b0d45ecb0af64685365f55f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ClinicalDemonstrationAndRentalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffb9a63338dc4ffe875023dc79c7905a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59a6908e2b224904a2ee86392a3bed03_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i930755293b68471bac0a4f69a1579932_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieba697dd91864c6794a754cb2f07b007_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62e565965d9f49f2aa99102b8387476a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1327c3ca8f3445da9935a8f2dc5e53a2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia68dbe4ac6c24607ab0fe9092c69e114_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i673b7f5418864027b262473e75a24496_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i585a12bee5294dd7a4971ee1e63765a6_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic386a2f3fc574a6eaa1bc26205d89225_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d3f3a2e554e4ce498a8c2eac0e1773c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5920b8d4566429aacc99c4cb598b86b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i383529560350461f9474da7a3e151953_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:DevelopedOrCoreProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if91504ce254047b09ff93066ad7e7365_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:DevelopedOrCoreProductTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27a41c0bc031463eb9e124aa25b7e462_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie60c3c5babf44f189d82c62d83c1ba0e_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id414856654b6425f94e23c727ecf7d42_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26192f7e58a3451690f985df3d035304_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i275c6f7ccc89416f8b114a73abdb1eb2_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:IdentifiedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide28368adb344db981e13dc7ab3f39e6_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:IdentifiedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e17c04c42c84b1da53be06c8c07c44b_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i346adc043b664e69a5d86956607aa19d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15585071980b44609c4244d0667080d3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ecaa50f2b0842ebaa2fada9c7ce2d1a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28ab83892aae4ba397a55655fbf05f29_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12742f5ecfc34a62988f7e0587db5dd6_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida2475934ea241ca9c2d0a10c164d26b_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i986baaa416044ab0b8a0147a14087047_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia249219ca61d4c4ea23e703cf2260422_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b6f2c0aa8974e7cb7f65b5033462701_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84ec92f010cb4996b46b1526ee19a1bc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e4cd11b6bc34d7895326f826a7c3f0d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd1dcdc316cf456186c44ff5d3915ada_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if003111e277449988551264e5889944a_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01c095726ae74638a2cadaaac6191673_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd4cbd01865547d0b68850bcd7ca2e04_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15e467c7054a4a68be2dda7a759368b3_I20220629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i423b2284861f4712a8115af92f3cb518_D20220629-20220629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ifa80124e3bf34fd6856246349e38455b_I20180417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeda0a0993ea40a2b71c2c39f3e0b04e_D20180417-20180417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-17</xbrli:startDate><xbrli:endDate>2018-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1310207dfcac4a1e9c44860aeeda4bc2_I20220629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">rmd:ResmedLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i979ebcc3a5a0402b874813dc295d674e_D20220629-20220629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7f649a73f7b49bb986cbfd39350e44a_D20220629-20220629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd7c672f30f84268aabf143857e5170f_D20220629-20220629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97c8b018596f4013a44574b3fd63633c_D20220629-20220629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f542b063f24d7092707acc8b5cf64c_D20220629-20220629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-29</xbrli:startDate><xbrli:endDate>2022-06-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i806485f7ccaf4c9d9c68aad92130fec2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e7501df49b4377bbb3fff86c0f16b9_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7e0730b8e7c4927a93f00a20c7493ce_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie854b85863de4deb8101483d69a0c966_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia73b672018ee4f70af77e8d5c26893a7_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f8645a6deef4fda9ef586462b0c447a_I20190710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc2d01b0be2456a84c67fc7a3d70988_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bb1537c0dcc4eacb698500930b3471e_I20190710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b7a51beb7fb4fe981c3f830e45c4d63_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378917c231c447fcbef3c0d8863c6fc3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54370628e55148a3a1429b5d08709d48_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7df9e6108fe8406e80413d06c6ed765e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie375d6fcc5c94de8a1dfe85679cc6bdb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb4434050d394cafb018a6065a45a957_I20140221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-02-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d6484ce8c1e4238876a0b1d7f21a064_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie03f859a83a14b7c9c6464075801b456_I19970430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>1997-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13c812eb8e4e4d0aad3396a4505d0c90_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i656e88285e1a478db38df173815049c6_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac8a769569584c06896d492161d46522_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmd:NonEmployeeDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i526a12fca7d14513aa82f1d9a8b37b84_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6fbf790ad4041668dd19efbe5c7bd93_D20171031-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-31</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i344f9115454b46148a3452f1abac3c9d_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b10950bdf1f4749b316223621791474_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb58c060ef9941f3a97cea8bbad422e5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e2263b05ec742b9a74b344a4f2f2337_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59e177a09e1f49aca07dc9b8742b6dd6_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica54b0da1e614213bd2547419b667106_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6090a2e6715142fabdaedef101bd1b85_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec931243b75f437e8ee3cf1efa936e50_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26cfb703ae174ae99bbfb51030982257_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i139858d21bb440a48d56f47a4a84ed88_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib903a532663446a585c6512ab8c06b0b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i612e2c48c8604ebb820bf12238b6faad_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="offering"><xbrli:measure>rmd:offering</xbrli:measure></xbrli:unit><xbrli:context id="ia01026de6a5a497cb302f143e7c8b8da_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i545f14bf17d3466d878853ee4c40b693_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if26c7573938546c58712775f705c6f91_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86d83628870e4c1298a21564eac48efe_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1957b8b04bc43568cb3bf406005b986_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8173e7992c53414cbda9b33e54540412_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b1efe55196841488562ed5eb81ff415_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6a5f8517549459ba24dc64abf4f2a39_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i626584014ac5497faaf5bbe0805c20a9_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3568fe5aef9349ee949f734d37ba293a_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8f8a68565f04e4593882f783d3a8493_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75b466de52734147a35094bafe68a210_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id24b9ea32ab54d4ebbb79eacdf21d5a2_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1b4834996c24c4697613536e66c2ae0_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fb5f975b0f146af9d0eacbd9ea5d417_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i042c41ef5a4940c9bbbd03a03a164b31_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia284c8ce0cc44849a9f6fd2717f955a6_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bbffc1218e846ceaa11fd8c25583530_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefa02d71c77a4a088959735053a1a4df_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89b566ef2524af98f09b1c2e5a3555c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fd69e2cd46e4080ad9064bd38b12c4c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e1c0e023852448f9bf3bd384a272726_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOperatingLossCarryforwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie01584a76c914617a10b30795533bc02_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b678d1321a48be9f80648f4a12cf05_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fd3564ce052488e9f5ba664a5d9dcec_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d4e9f2528d046f9a73bbe9b0ae46a0e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b2d239a762c46e39be91927daa68806_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01201a3e634542d49bf58f119957d890_D20210928-20210928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-28</xbrli:startDate><xbrli:endDate>2021-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9615d030beef4655919952e7c42dddb0_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:DevicesAndMasksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e575d821d774882967b5b2ac809400a_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:DevicesAndMasksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2565ea6b2b0f49e596d06ef86c0ee019_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:DevicesAndMasksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f176c13cb464db58e7e974bbe583ad2_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd1b88dba5e4ed4b2bc90aa0129b7e1_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bcaef51aed54c3cbc31f6f73f6fc4dc_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0095199e4b29470582f73f47f8ae065a_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d1e579aaa5456ba8a0c4cb4315ddc8_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46269d456ce141c8be9efcf422648c0d_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b423ab980a64f30b1a30f8d6aab58ed_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic40263e3a7e448478aaec5362e3d5ac0_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dc746d3d9604ed8b657848caa1d88b5_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25c6b0cc200a4b599e158f399e3c9bc6_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4aa667d360a42a0a82284e45233a24c_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0034c7a4e6a54939a36c81c60d8ae04f_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddb9b1ba3cc948fbbeafc80d5fb888c0_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fdc782505914ae19cc4a5145a64302a_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3506717407b495e8b465b435329e9fa_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i683f2eada0d04fcaad952c8b3d263517_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ceba21d091145f1abfd5e8ee8280f34_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i028290f735164715bb94548227192afe_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ad2b08ec7164637b1de52cff54bc7fc_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i768e903ad73a409983ef36a9cb3bcdd6_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44e5f807c4204737a2770ffd84a1ef8f_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd4f488d02b44960a0dd40ec6011ee0a_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb162e7018f4f9389dece5e2798edd4_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ea25fdac2444049f2441242da65d68_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40bcfef9b6e54021ae8c2ff8aa045971_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4299c9c5641b4278bb02f064ee36224e_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5f83c48a7d8454394b43a87b7ab93e4_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic436f1cc5c3141c789df791a0cf3e876_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88324fb286c04ba5950e6cd05648d664_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1959ef64c9d48daae526f9ad86dc1e1_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90adc12d32e34e8fb47d50b8d5bfd24e_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id83a2708a5314366ab3b2d2063c1580c_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic087066b2dfa4a2e80b6055dc86ad478_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf3b5cebac484aafa9c12aabc31f71fb_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfe214ef394c40078ff0a1c3b2002cd8_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7afa8a0a280436aaa2a6358ed31ae72_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafa91ad16e1d42898125c674a44f12c7_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if750331b61d34ff6a35ce16115a39bd1_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ac972a28ea4f66852dc6a23c05796a_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0e3f2f8bd246a08869b10ecf87c8d4_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f9858995a6f4d25962cfd62c79b79f3_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idce2674b8c0341a2b7fc01fb9809ffb6_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i499a1d7dca454b16aab049bf997c138b_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbe3bf1b0b23497a9f774cd1b2469607_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02220a87b54b4e30a843706e1e0d6a7e_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3f7bb52ca32454e94bfcd08e2c8c5f7_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic07d827f23644728992537f14148e061_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i337e5645c4c44331a1f07eba81269258_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ceddc8dd80a49a4bd587e39d47f45e3_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf573c1bd70f41baafb0fa6b1cf4e06c_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cabc22c13c84f4f933c6296d351e8b4_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if647eaf645944411be01eae84919f4b8_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc7308901fa84fdeb1d8b362b2f75a0d_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac5bed93d8d840fca4ddaeae7fa58ef1_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fa8a519bc734ac19f7310d6f9acfb13_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24ea923c1eda4ec59fcf09d914cfe556_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d85bfd9205c4954829266c748d0e737_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78fc5da4e0e04d37ac8a97438b29039d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e84ef532ade41228f75e995126162ff_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i801dcbebc4da489dbeb89de396b518f1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93b19ef8b4f64d11a5fe3c85245bf6bd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if07211d598314591ab29d17f48c0e9b1_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i064d1782e2d845f99c9be5eafe7335b0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fc521c6602c417dab7cde075c1c6ca0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccd6677e07da4b36bdfc0d4628b747e6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a85455cff5b488bb43b5e15307964ce_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dc2d374954548eeae4da26ee6deb2da_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d640c7e949347a48920659088e1b6d5_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2897b37cef246bfbcd8a111b95babe4_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3265cc74d27c4d9c9e39b63c16e194b9_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a3c9df979694466b84d35627592feac_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78253a41a7f9462cae9e61f99722631b_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38c21a3a43d242b5971df394c22e9de8_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21c42c4d4e154021ad486dec830521c6_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaaf7972675048e690091ac44e072096_D20220616-20220616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-16</xbrli:startDate><xbrli:endDate>2022-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patent"><xbrli:measure>rmd:patent</xbrli:measure></xbrli:unit><xbrli:context id="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">rmd:PortableOxygenConcentratorBusinessClosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88d0acfca2694a179ae914e7b68a3e34_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff6f98dd6cf448e09b965f01db37b08e_D20210701-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89a45cd403ed4145a2219c018be81ad4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8bfa1b0d361426ca8e6bfee5712cfe9_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id60995957b3746049536126104cd8336_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c57ecbf703c4d4b8b48d4fd7f8af6fe_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d3ead733d44cfc87b7a8de6f4c25ba_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c161b6547684d3dbda4b1b823202c32_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000943819</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1f60984bb51544a482851b08d4a3bf6b_1"></div><div style="min-height:13.5pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________________________</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDUx_a29ccd3a-27e1-4277-b871-6688dadbe11e">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">[<ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDYz_f10083cf-4376-46f4-889d-ea2f254c26d4">X</ix:nonNumeric>] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8zMjk4NTM0ODg4MTUy_07f57489-363a-48a0-ba46-0c9abad751cb"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8zMjk4NTM0ODg4MTUy_38804042-7412-4a45-a431-bc7521cb77d7">June 30</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDU0_463350aa-76c0-4bee-8fae-67f2ac2f5463">001-15317</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDY5_eb6c7c8a-3bdb-4ece-ba3e-3ff06a9de255">ResMed Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________________________</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDYw_e454bb39-ae2b-4a04-afd7-37102dd6f0d3">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDY1_0703618d-ee96-48e4-883a-4afe635ead24">98-0152841</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(IRS Employer Identification No.)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8xMDk5NTExNjMyNDEw_e6fb7e96-0e50-4d80-934d-255e8d11b511">9001 Spectrum Center Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8xMDk5NTExNjMyNDY3_6d546b2b-44a1-48fa-ad3b-3c2b569c64e9">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8xMDk5NTExNjMyNDc0_e55eb118-ef95-41dd-b4d2-5e7d7e800cd5">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8xMDk5NTExNjMyNDM2_74990f51-352e-4fc3-8340-877172d9c332">92123</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8zMjk4NTM0ODg4MTkx_12560661-44ab-4e58-89f7-86df6f5525a4">United States</ix:nonNumeric> of America</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDcy_9133d9f2-eb64-42cb-b4bf-697b5e11a379">858</ix:nonNumeric>) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDU2_851060c3-d225-4cd3-92a5-93e37c0ce91e">836-5000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.537%"><tr><td style="width:1.0%"></td><td style="width:37.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDA5NjZjMWY3ZmEwNDZiMmI3YjE2MDVkZmRlODQxYTIvdGFibGVyYW5nZTo0MDk2NmMxZjdmYTA0NmIyYjdiMTYwNWRmZGU4NDFhMl8xLTAtMS0xLTI4NzY5_02cd059a-d7ed-4f48-9427-cf0f6d863c6f">Common Stock, par value $0.004 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDA5NjZjMWY3ZmEwNDZiMmI3YjE2MDVkZmRlODQxYTIvdGFibGVyYW5nZTo0MDk2NmMxZjdmYTA0NmIyYjdiMTYwNWRmZGU4NDFhMl8xLTItMS0xLTI4NzY5_243fcb6b-50ea-4de8-9bfb-bab9e9204266">RMD</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDA5NjZjMWY3ZmEwNDZiMmI3YjE2MDVkZmRlODQxYTIvdGFibGVyYW5nZTo0MDk2NmMxZjdmYTA0NmIyYjdiMTYwNWRmZGU4NDFhMl8xLTQtMS0xLTI4NzY5_68ce2832-7e41-45b6-be8e-abba97a305af">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">___________________________________________________________________________________________</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDUw_79757c81-e61e-4894-a506-78297d64489c">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDcz_da45da5c-4fd3-4d84-9641-a75e7feaa300">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">x</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDc0_e2f5e15b-8f24-4b18-a361-29c5dfa58a3d">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDU4_4cf06f8e-21f5-4701-932d-1f4c956ba749">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;<ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDYx_fb5a8ede-00fd-400a-8fcf-701afaa1edfe">large accelerated filer</ix:nonNumeric>,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.537%"><tr><td style="width:1.0%"></td><td style="width:33.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDEwYTdlNTM3YWE5NGZkMThiZDQ0OTQwY2Q2ZDkzMGMvdGFibGVyYW5nZTo0MTBhN2U1MzdhYTk0ZmQxOGJkNDQ5NDBjZDZkOTMwY18wLTAtMS0xLTI4NzY5_1a4194f3-aa98-4f9f-bb4a-161d0b3d92b0">Large Accelerated Filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:108%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated Filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:108%">&#168;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:108%">&#168;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:108%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDEwYTdlNTM3YWE5NGZkMThiZDQ0OTQwY2Q2ZDkzMGMvdGFibGVyYW5nZTo0MTBhN2U1MzdhYTk0ZmQxOGJkNDQ5NDBjZDZkOTMwY18xLTMtMS0xLTI4NzY5_e8990d8f-eac3-42d0-b419-5da423cf9bb0">&#168;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:108%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDEwYTdlNTM3YWE5NGZkMThiZDQ0OTQwY2Q2ZDkzMGMvdGFibGVyYW5nZTo0MTBhN2U1MzdhYTk0ZmQxOGJkNDQ5NDBjZDZkOTMwY18yLTEtMS0xLTI4NzY5_8cacd345-b786-4449-b3d1-ef5d977065b9">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#160;</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDY2_13450e07-5c64-40fb-aad7-bf3f3b6ee8b8">x</ix:nonNumeric></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDY3_2e61c3a8-14d5-4f0e-a9db-cb3644c0e1e3">x</ix:nonNumeric></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates of registrant as of December 31, 2021 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), computed by reference to the closing sale price of such stock on the New York Stock Exchange, was $<ix:nonFraction unitRef="usd" contextRef="ibbdef3fca1f842ffb539ee7a7469d218_I20211231" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8xMDk5NTExNjMyNTE0_51dd1083-cbc7-47fe-92d4-f750457e5519">37,771,141,000</ix:nonFraction>. All directors, executive officers, and 10% stockholders of registrant are considered affiliates.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">At August&#160;8, 2022, the registrant had <ix:nonFraction unitRef="shares" contextRef="ie905261def8d433cbf089eb034507510_I20220808" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8zMjk4NTM0ODg4MTE0_3486d6db-4ce8-4c47-81b3-5ee8b2276400">146,424,981</ix:nonFraction> shares of Common Stock, $0.004 par value, issued and outstanding. This number excludes 41,836,234 shares held by the registrant as treasury shares.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the registrant&#8217;s definitive Proxy Statement to be delivered to stockholders in connection with the registrant&#8217;s 2022 Annual Meeting of Stockholders, to be filed subsequent to the date hereof, are incorporated by reference into Part III of this report.</span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:justify"><span><br/></span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:10pt"><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.932%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_13">Cautionary Note Regarding Forward Looking Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_13">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_10">Part I</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_16">Item 1</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_16">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_16">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_19">Item 1A</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_19">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_19">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_22">Item 1B</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_22">41</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_25">Item 2</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_25">Properties</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_25">41</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_28">Item 3</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_28">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_28">42</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_31">Item 4</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_31">42</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_34">Part II</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_37">Item 5</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_37">43</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_40">Item 6</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_40">Selected Financial Data</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_40">44</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_43">Item 7</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_43">46</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_79">Item 7A</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_79">Quantitative and Qualitative Disclosures About Market and Business Risks</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_79">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_82">Item 8</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_82">Consolidated Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_82">61</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_169">Item 9</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_169">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_169">92</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_172">Item 9A</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_172">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_172">92</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_181">Item 9B</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_181">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_181">95</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_184">Part III</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_187">Item 10</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_187">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_187">96</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_190">Item 11</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_190">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_190">96</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_193">Item 12</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_193">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_193">96</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_196">Item 13</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_196">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_196">96</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_199">Item 14</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_199">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_199">96</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_202">Part IV</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_205">Item 15</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_205">Exhibits and Consolidated Financial Statement Schedules </a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_205">97</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_208">Item 16</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_208">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_208">98</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_211">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_211">99</a></span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this 10-K, the terms &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; and &#8220;the Company&#8221; refer to ResMed Inc., a Delaware corporation, and its subsidiaries, on a consolidated basis, unless otherwise stated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:justify"><span><br/></span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_10"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_13"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Note Regarding Forward-Looking Statements </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains or may contain certain forward-looking statements and information that are based on the beliefs of our management as well as estimates and assumptions made by, and information currently available to, our management. All statements other than statements regarding historical facts are forward-looking statements. The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;anticipate,&#8221; &#8220;will continue,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;plan,&#8221; &#8220;future&#8221; and other similar expressions, and negative statements of such expressions, generally identify forward-looking statements, including, in particular, statements regarding expectations of future revenue or earnings, expenses, new product development, new product launches, new markets for our products, litigation, tax outlook and the impact of COVID-19. These forward-looking statements are made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements reflect the views of our management at the time the statements are made and are subject to a number of risks, uncertainties, estimates and assumptions, including, without limitation, and in addition to those identified in the text surrounding such statements, those identified in Part I, Item 1A &#8220;Risk Factors&#8221; and elsewhere in this report. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, important factors to consider in evaluating such forward-looking statements include changes or developments in healthcare reform, social, economic, market, legal or regulatory circumstances, including the impact of public health crises such as the novel strain of coronavirus (COVID-19) and its variants that continues to spread globally; changes in our business or growth strategy or an inability to execute our strategy due to changes in our industry or the economy generally, the emergence of new or growing competitors, disruptions and delays in the supply chain, the actions or omissions of third parties, including suppliers, customers, competitors and governmental authorities, geopolitical and economic conditions in foreign jurisdictions where we do business, and various other factors. Furthermore, many of these risks and uncertainties are currently amplified by and may continue to be amplified by the COVID-19 pandemic and the impact of varying private and governmental responses that affect our customers, employees, vendors and the economies and communities where they operate. If any one or more of these risks or uncertainties materialize, or underlying estimates or assumptions prove incorrect, actual results may vary significantly from those expressed in our forward-looking statements, and there can be no assurance that the forward-looking statements contained in this report will in fact occur.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_16"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1 BUSINESS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global leader in digital health and cloud-connected medical devices. We design innovative solutions to treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, our products improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our formation in 1989, we commercialized a treatment for obstructive sleep apnea, or OSA. This treatment,  continuous positive airway pressure, or CPAP, was the first successful noninvasive treatment for OSA. CPAP systems deliver pressurized air, typically through a mask, to prevent collapse of the upper airway during sleep.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the development of CPAP, we have expanded our business by developing or acquiring a number of innovative products and solutions for a broad range of respiratory disorders including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, and dental devices. We offer a comprehensive digital solution suite for patients with COPD or asthma, including those using inhalers, as well as non-invasive or invasive ventilation. In addition, we are a leading provider of cloud-based software health applications and devices designed to provide connected care, enabling clinicians to manage more patients efficiently and effectively, as well as enabling and encouraging patients&#8217; long-term adherence to and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-1-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">satisfaction with their therapy. We also provide management software to agencies providing out-of-hospital care, including but not limited to home medical equipment, or HME, home health and hospice, skilled nursing, life plan community, senior living, and private duty services. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ over 8,100 people and sell our products in over 140 countries through a combination of wholly owned subsidiaries and independent distributors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is www.resmed.com. Information contained on our website is not part of or incorporated into this report. We make our periodic reports, together with any amendments, available on our website, free of charge, as soon as reasonably practicable after we electronically file or furnish the reports with the Securities and Exchange Commission, or SEC. The SEC maintains an internet site, www.sec.gov, which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate History</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Australian subsidiary, ResMed Holdings Limited, was originally organized in 1989 by Dr. Peter Farrell to acquire from Baxter Center for Medical Research Pty Limited, or Baxter, the rights to certain technology relating to CPAP treatment as well as Baxter&#8217;s existing CPAP device business. Baxter acquired the rights to the technology in 1987 and sold CPAP devices in Australia from 1988 until our acquisition of the business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ResMed Inc., a Delaware corporation, was formed in March 1994 as the ultimate holding company for our operating subsidiaries. In June 1995, we completed an initial public offering of common stock and our common stock began trading on the NASDAQ National Market. In September 1999, we transferred our principal listing to the New York Stock Exchange, or NYSE, trading under the ticker symbol &#8220;RMD&#8221;. In November 1999, we established a secondary listing of our common stock via Chess Depositary Instruments, or CDIs, on the Australian Stock Exchange (now known as the Australian Securities Exchange), or ASX, also under the symbol &#8220;RMD&#8221;. Ten CDIs on the ASX represent one share of our common stock on the NYSE. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since formation we have acquired a number of businesses, including distributors, suppliers, developers of medical equipment and related technologies and software solution providers. For example, in the United States our sleep and respiratory care products are sold by ResMed Corp., and our software is sold principally by our Brightree and MatrixCare subsidiaries.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in two segments, which are the Sleep and Respiratory Care segment and the Software as a Service, or SaaS, segment. See Note 14 &#8211; Segment Information of the Notes to Financial Statements (Part II, Item 8) for financial information regarding segment reporting. Financial information about our revenues from and assets located in foreign countries is also included in the notes to our consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Market</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on the sleep and related respiratory care markets, both of which we believe are globally underpenetrated markets, and where we believe our products can improve patient outcomes, create efficiencies for our customers, help physicians and providers better manage chronic disease and reduce overall healthcare system costs. Additionally, our software solutions are focused on the out-of-hospital care market, which we believe is fragmented and underserved and where we see significant opportunity to transform and significantly improve out-of-hospital healthcare through a strategy of enabling better patient care, improving clinical decision support, and driving interoperability across out-of-hospital care settings.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sleep and Respiratory Care</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sleep</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sleep is a complex neurological process that includes two distinct states: rapid eye movement, or REM, sleep and non-rapid eye movement, or non-REM, sleep. REM sleep, which is about 20-25% of total sleep experienced by adults, is characterized by a high level of brain activity, bursts of rapid eye movement, increased heart and respiration rates, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-2-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">paralysis of many muscles. Non-REM sleep is subdivided into four stages that generally parallel sleep depth; stage 1 is the lightest and stage 4 is the deepest.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upper airway has no rigid support and is held open by active contraction of upper airway muscles. Normally, during REM sleep and deeper levels of non-REM sleep, upper airway muscles relax and the airway narrows. Individuals with narrow upper airways or poor muscle tone are prone to temporary collapses of the upper airway during sleep, called apneas, and to near closures of the upper airway called hypopneas. These breathing events result in a lowering of blood oxygen concentration, causing the central nervous system to react to the lack of oxygen or increased carbon dioxide and signaling the body to respond. Typically, the individual subconsciously arouses from sleep, causing the throat muscles to contract, opening the airway. After a few gasping breaths, blood oxygen levels increase and the individual can resume a deeper sleep until the cycle repeats itself. Sufferers of OSA typically experience ten or more such cycles per hour. While these awakenings greatly impair the quality of sleep, the individual is not normally aware of these disruptions. In addition, OSA has been recognized as a cause of hypertension and a significant comorbidity for heart disease, stroke and type 2 diabetes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A long-term epidemiology study published in 2013 estimated that 26% of adults age 30-70 have some form of obstructive sleep apnea. Another study published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lancet Respiratory Medicine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2019 estimated that mild to severe OSA impacts more than 936 million people worldwide, including 54 million Americans. Of those impacted, it was estimated that more than 424 million would have moderate to severe sleep apnea. Despite the high prevalence of OSA, there is a general lack of awareness of OSA among both the medical community and the general public. It is estimated that less than 20% of those with OSA have been diagnosed or treated. Many healthcare professionals are often unable to diagnose OSA because they are unaware that such non-specific symptoms as excessive daytime sleepiness, snoring, hypertension, and irritability are characteristic of OSA.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While sleep apnea has been diagnosed in a broad cross-section of the population, until recently, it has typically been diagnosed among middle-aged men who are obese. However, we believe the importance of sleep apnea in women is increasingly being recognized, with nearly 40% of new PAP patients being female. A strong association has been discovered between sleep apnea and a number of cardiovascular and metabolic diseases. Studies have shown that sleep apnea is present in approximately 83% of patients with drug-resistant hypertension, approximately 77% of patients with obesity, approximately 76% of patients with chronic heart failure and approximately 72% of patients with type 2 diabetes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A study presented at the European Respiratory Society (ERS) International Congress in 2021 and later published in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CHEST </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2022 found that using PAP therapy as directed can significantly increase sleep apnea patients&#8217; chances of living longer. The study concluded that people with obstructive sleep apnea who continued PAP therapy were 39% more likely to survive over a three-year period than OSA patients who didn&#8217;t. Researchers found that the survival rate gap remained significant when accounting for patients&#8217; ages, overall health, other pre-existing conditions, and causes of death.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sleep-Disordered Breathing and Obstructive Sleep Apnea. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sleep-disordered breathing, or SDB, encompasses all disease processes that cause abnormal breathing patterns during sleep. Manifestations include OSA, central sleep apnea, or CSA, and hypoventilation syndromes that occur during sleep. Hypoventilation syndromes are generally associated with obesity, chronic obstructive lung disease and neuromuscular disease. OSA is the most common form of SDB.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sleep fragmentation and the loss of the deeper levels of sleep caused by OSA can lead to excessive daytime sleepiness, reduced cognitive function, including memory loss and lack of concentration, depression and irritability. OSA sufferers also experience an increase in heart rate and an elevation of blood pressure during the cycle of apneas. Several studies indicate that the oxygen desaturation, increased heart rate and elevated blood pressure caused by OSA may be associated with increased risk of cardiovascular morbidity and mortality due to angina, stroke and heart attack. Patients with OSA have been shown to have impaired daytime performance in a variety of cognitive functions including problem solving, response speed and visual motor coordination, and studies have linked OSA to increased occurrences of traffic and workplace accidents.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, an individual seeking treatment for the symptoms of OSA is referred by a general practitioner to a sleep specialist for further evaluation. The diagnosis of OSA typically requires monitoring the patient during sleep at either a sleep clinic or the patient&#8217;s home. During overnight testing, respiratory parameters and sleep patterns may be monitored, along with other vital signs such as heart rate and blood oxygen levels. Simpler tests, using devices such as our ApneaLink Air, NightOwl, or our automatic positive airway pressure devices, monitor airflow during sleep, and use computer </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs to analyze airflow patterns. These tests allow sleep clinicians to detect any sleep disturbances such as apneas, hypopneas or subconscious awakenings. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before 1981, the primary treatment for OSA was a tracheotomy, a surgical procedure to create a hole in the patient&#8217;s windpipe. Alternative surgical treatments have involved either uvulopalatopharyngoplasty, or UPPP, in which surgery is performed on the upper airway to remove excess tissue and to streamline the shape of the airway or implanting a device to add support to the soft palate. UPPP alone has a poor success rate; however, when performed in conjunction with multi-stage upper airway surgical procedures, a greater success rate has been claimed. These combined procedures, performed by highly specialized surgeons, are expensive and involve prolonged and often painful recovery periods. Surgical treatments are not considered first line therapy for OSA. Other alternative treatments available today include nasal surgery, mandibular advancement surgery, dental appliances, palatal implants, somnoplasty, nasal devices and electrical stimulation of the nerves or muscles. Alternative pharmaceutical therapy treatments are reported to be under development.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A variety of devices are marketed for the treatment of OSA. Most are only partially effective, but CPAP is a reliable treatment for all severities of OSA and is considered first-line therapy. Use of mandibular advancement devices is increasingly used as a second-line option in patients unable to use CPAP or those with mild OSA. These devices cause the mandible and tongue to be pulled forward and improve the dimensions of the upper airway. CPAP is a non-invasive means of treating OSA. CPAP was first used as a treatment for OSA in 1980 by Dr. Colin Sullivan, the past Chairman of our Medical Advisory Board and was commercialized for treatment of OSA in the United States, or U.S., in the mid-1980s. During CPAP treatment, a patient sleeps with a nasal interface connected to a small portable air device that delivers room air at a positive pressure. The patient breathes in air from the device and breathes out through an exhaust port in the interface. Continuous air pressure applied in this manner acts as a pneumatic splint to keep the upper airway open and unobstructed. Interfaces include nasal masks and nasal pillows. Sometimes, when a patient leaks air through their mouth, a full-face mask may need to be used, rather than a nasal interface.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CPAP is not a cure and, therefore, must be used on a nightly basis as long as treatment is required. Patient compliance has been a major factor in the efficacy of CPAP treatment. Early generations of CPAP units provided limited patient comfort and convenience. Patients experienced soreness from the repeated use of nasal masks and had difficulty falling asleep with the CPAP device operating at the prescribed pressure. In recent years, product innovations to improve patient comfort and compliance have been developed. These include more comfortable patient interface systems; delay timers that gradually raise air pressure allowing the patient to fall asleep more easily; bilevel air devices, including our AirCurve 10 Series and Lumis devices, which provide different air pressures for inhalation and exhalation; heated humidification systems to make the airflow more comfortable; and auto-titration devices that modulate the average pressure delivered during the night.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Respiratory Care</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our aim is to provide respiratory care solutions to patients with COPD, asthma, and other chronic respiratory diseases, such as overlap syndrome, obesity hypoventilation syndrome, or OHS, and neuromuscular disease, including amyotrophic lateral sclerosis, or ALS. We aim to improve their quality of life, slow down disease progression and reduce the costs of patient management.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products cover patients ranging from those who only require therapy from CPAP systems at night to those who are dependent on non-invasive or invasive ventilation for life-support. Our devices are predominantly used in the home and, to a lesser extent, in general hospital wards and respiratory wards. We supply CPAP and bilevel device systems, non-invasive and invasive ventilators, humidifiers and accessories, including masks and tubing. We also provide data management systems designed to improve the management of patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus, COVID-19, as a pandemic. We have observed increased demand for our ventilator devices and masks, and during the first six months of the pandemic worked closely with governments, health authorities, hospitals, and physicians in over 100 countries to assess their needs and deliver the ventilation therapy that is essential to treat the respiratory complications of COVID-19. Although there is still substantial uncertainty associated with the COVID-19 pandemic, we believe the global demand for ventilators and other respiratory support devices used to treat COVID-19 patients has largely been met. Our primary focus with regards to the pandemic remains preservation of life; our strategy is to maximize the availability of ResMed ventilators and other respiratory support devices for the patients that need them most. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chronic Obstructive Pulmonary Disease. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COPD encompasses a group of lung diseases defined by persistent airflow limitation, prolongation of exhalation and loss of elasticity in the lungs. It is a progressive and debilitating disease and is associated with an increased inflammatory response in the airways. Symptoms encountered with COPD include shortness of breath as well as chronic cough and increased sputum production. COPD includes diseases such as emphysema and chronic bronchitis. A recent study based on recent epidemiology data estimates that there are over 380 million people worldwide who suffer from COPD, the world&#8217;s third leading cause of death.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with COPD can have different clinical presentations. Patients with chronic bronchitis present with low level of oxygen (hypoxemia) and elevated levels of carbon dioxide (hypercapnia), a chronic productive cough, cor pulmonale and are commonly overweight. Patients with emphysema have more normal blood gases, are usually thin and hyperinflated and have a decreased diffusion capacity. During sleep, chronic bronchitic patients display more severe hypoxemia. In general, the more hypoxic a COPD patient is during the day the more severe the hypoxemia experienced during sleep. Hypercapnia as a consequence of hypoventilation also occurs in COPD patients and is more pronounced in REM sleep. Some COPD patients may also suffer from comorbid OSA, a condition known as Overlap Syndrome.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Home non-invasive ventilation has the potential to reduce healthcare costs associated with the management of patients with severe COPD by significantly increasing the time between hospital readmissions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overlap Syndrome. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In patients with COPD-OSA Overlap Syndrome, CPAP has been shown to provide benefits in relation to reducing mortality, decreasing hospitalizations and improving lung function and gas exchange. Non-invasive ventilation, or NIV, has been demonstrated to improve outcomes in patients with acute exacerbations of COPD through its ability to improve respiratory acidosis and decrease dyspnea and work of breathing. It may also increase survival rates and reduce length of hospital stays, as well as reducing complicating factors such as ventilator-associated pneumonia. In patients with stable COPD, the advantages of home NIV are less clear, but clinical studies have shown improvements in dyspnea scores and health-related quality-of-life measures and reductions in hospital readmissions and intensive care stays.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Obesity Hypoventilation Syndrome. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OHS is characterized by the combination of obesity, chronic alveolar hypoventilation leading to daytime hypercapnia and hypoxia and sleep apnea after the exclusion of other causes of alveolar hypoventilation. An estimated 90% of patients with OHS also have OSA. In patients with OHS, positive airway therapy, both CPAP and NIV, has been shown to effectively treat upper airway obstruction and reverse daytime respiratory failure as well as reduce the work of breathing and improve respiratory drive. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neuromuscular Disease. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuromuscular disease is a broad term that encompasses many diseases that either directly (via intrinsic muscle pathology) or indirectly (via nerve pathology) impair the functioning of muscles. Symptoms of neuromuscular disease and respiratory failure include increasing generalized weakness and fatigue, dysphagia, dyspnoea on exertion and at rest, sleepiness, morning headache, difficulties with concentration and mood changes. Most neuromuscular diseases are characterized by progressive muscular impairment leading to loss of ambulation, being wheelchair-bound, swallowing difficulties, respiratory muscle weakness and, eventually, death from respiratory failure. Neuromuscular disorders can progress rapidly or slowly. Rapidly progressive conditions, such as ALS and Duchenne muscular dystrophy in teenagers, are characterized by muscle impairment which worsens over months and can result in death within a few years. Variable or slowly progressive conditions, such as myotonic muscular dystrophy, are characterized by muscle impairment that worsens over years and may mildly reduce life expectancy. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NIV treatment to patients with neuromuscular disease may lead to improvements in respiratory failure symptoms and daytime arterial blood gases. In ALS patients, NIV treatment has been associated with an improvement in quality of life measures, sleep-related symptoms and survival. Studies have demonstrated that patients with Duchenne muscular dystrophy may improve in quality of life measures and may increase chance of survival with NIV treatment.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Software as a Service</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to multiple acquisitions, including Brightree in April 2016, HEALTHCAREfirst in July 2018 and MatrixCare in November 2018, our operations now include platforms that comprise our SaaS business. Our SaaS strategy is to develop a portfolio that assists durable or home medical equipment (DME/HME) providers, and other long-term care providers operate more effectively and efficiently across various out-of-hospital care settings. With a comprehensive set of software and services offerings, our SaaS solutions enable providers to streamline workflow and deliver an improved patient experience across our existing vertical markets including HME and home infusion, facility-based organizations including skilled nursing, senior living, and life plan communities, home health and hospice providers, and to adjacent provider </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">markets through a growing portfolio of value-added solutions with broad market applicability. Our offerings can help providers perform analytics, manage documentation and implement new reimbursement requirements as well as more effectively transfer data as patients move between different care settings. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Strategy</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the sleep apnea and respiratory care markets will continue to grow in the future due to a number of factors, including increasing awareness of OSA, CSA and COPD, improved understanding of the role of sleep apnea treatment in the management of cardiac, neurologic, metabolic and related disorders, improved understanding of the role of non-invasive ventilation in the management of COPD, and an increase in the use of digital and product technology to improve patient outcomes and create efficiencies for customers and providers. Our strategy for expanding our business operations and capitalizing on the growth of the sleep apnea and respiratory care markets, as well as growth in out-of-hospital care settings, consists of the following key elements:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Continue Product Development and Innovation in Sleep Apnea and Respiratory Care Products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to ongoing innovation in developing products for the diagnosis and treatment of sleep apnea. We have been a leading innovator of products designed to treat sleep apnea more effectively, increase patient comfort and encourage compliance with prescribed therapy. In recent years we have introduced a full suite of masks in our AirFit and AirTouch ranges as well as advanced and expanded the integrations of our therapy-based software solutions, including AirView, to promote greater patient adherence. Our recent acquisitions have included a portfolio of sleep apnea products through our acquisition of Curative Medical.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Likewise, we are committed to ongoing innovation of our respiratory care products that serve the needs of patients with COPD and neuromuscular diseases, providing advanced and expanded the integrations of our therapy-based software solutions including AirView for Respiratory Care, enabling clinicians to remotely monitor patients on some ventilation devices and bilevel devices. We acquired a digital health platform for inhalers through our acquisition of Propeller Health in 2019, rounding out our portfolio to treat COPD patients through their therapy journey across different stages of their disease.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Broaden our digital health technology foundation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Digital enablement is central to our strategy. Our cloud-based digital health applications, along with our devices, are designed to provide connected care to improve patient outcomes and efficiencies for our customers, allowing fewer professionals to manage more patients and empowering patients to track their own health outcomes. We are expanding our cloud-based patient management and engagement platforms, such as AirView, enabling remote monitoring, over-the-air trouble shooting and changing of device settings, U-Sleep enabling automated patient coaching through a text, email or interactive voice phone call and myAir, a patient engagement application that provides sleep data and a daily score based on their previous night&#8217;s data. In the United States we have released ResMed MaskSelector, an easy-to-use digital tool to make mask selection and sizing easier and more effective, and HelloSleep, an application to help patients prepare for their fitting and first nights of therapy. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the combination of continued product development, product and technology acquisitions and innovation are key factors to our ongoing success. Approximately 17% of our employees are devoted to research and development activities. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand SaaS Solutions in Out-of-Hospital Care Settings. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vision is to transform and significantly improve out-of-hospital (OOH) healthcare through a strategy of enabling better patient care, improving clinical decision support, and driving interoperability across out-of-hospital healthcare settings. Since acquiring Brightree in 2016, plus MatrixCare and HEALTHCAREfirst in 2018, we offer software solutions across multiple out-of-hospital healthcare settings including HME, home health and hospice, skilled nursing, life plan communities, senior living, and private duty. Our announced acquisition of MEDIFOX DAN in June 2022, pending regulatory clearances, will expand ResMed&#8217;s SaaS business outside the U.S. to Germany, and will add new out-of-hospital care sectors to the business&#8217; ecosystem, including outpatient therapy. We are connecting capabilities across the platforms in these out-of-hospital care settings to help our customers be more efficient, better serve people, keep them out-of-hospital, and in lower-cost, higher-quality care settings. Today, our SaaS solutions serve OOH customers combining over 115 million individual accounts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand Geographic Presence. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our products in more than 140 countries to sleep clinics, home healthcare dealers, patients and third-party payors. We intend to increase our sales and marketing efforts in our principal markets, as well as expand the depth of our presence in other high-growth geographic regions. In 2016, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-6-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we acquired Curative Medical to invest in the China market and expand our growth potential in sleep apnea, COPD and respiratory care in China. In 2019, we acquired HB Healthcare, a privately owned HME that serves both reimbursed and cash-pay customers of sleep and respiratory care devices in South Korea. In 2021, we acquired Tong-il, another leading sleep and respiratory care HME provider in South Korea, reinforcing both our commitment and capability to serve millions of South Korean patients living with sleep apnea, COPD, and other chronic respiratory diseases.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Increase Public and Clinical Awareness. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to expand our existing promotional activities to increase awareness of sleep apnea, COPD and other clinical conditions that can be treated with our industry-leading solutions. These promotional activities target both the population predisposed to sleep apnea and medical specialists, such as pulmonologists, sleep medicine specialists, primary care physicians, cardiologists, neurologists and other medical subspecialists who treat these conditions and their associated comorbidities. We target special interest groups, including the National Stroke Association, the American Heart Association, COPD Foundation and the National Sleep Foundation, to further increase awareness of the relationship between OSA, COPD, neuromuscular disease and comorbidities such as cardiac disease, diabetes, hypertension and obesity. The programs also support our efforts to inform the community of the dangers of sleep apnea with regard to occupational health and safety, especially in the transport industry. We have helped establish a center for clinical care and medical research at the University of California, San Diego, in the fields of sleep apnea and COPD. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand into New Clinical Applications. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually seek to identify new applications of our technology for significant unmet medical needs. Studies have established a clinical association between OSA and both stroke and chronic heart failure, and have recognized sleep apnea as a cause of hypertension or high blood pressure. Research also indicates that sleep apnea is independently associated with glucose intolerance and insulin resistance. Additionally, research supported by ResMed has demonstrated that the addition of non-invasive ventilation to patients with severe COPD who are receiving oxygen therapy, provides meaningful clinical benefits to the patient, and the broader healthcare system. We maintain close working relationships with a number of prominent physicians to explore new medical applications for our products and technology.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Leverage the Experience of our Management Team. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior management team has extensive experience in the medical device industry in general, and in the fields of sleep apnea, respiratory care and healthcare informatics in particular. We intend to continue to leverage the experience and expertise of these individuals to maintain our innovative approach to the development of products and solutions, and to increase awareness of the serious medical problems caused by sleep apnea and the use of non-invasive ventilation, and in-home life-support ventilation to treat COPD and other chronic respiratory diseases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices and cloud-based software informatics solutions. For purposes of the following discussion, we refer to our air flow generators and ventilators collectively as devices.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Devices</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We produce cloud-connected CPAP, APAP, bilevel, and ASV devices that deliver positive airway pressure through a patient interface, either a mask or cannula. Our APAP devices, known as AutoSet, are based on a proprietary technology to monitor breathing and can also be used in the diagnosis, treatment and management of OSA. During fiscal year 2017, we launched AirMini, a small portable CPAP combining the same proven therapy modes used in the AirSense 10 with effective waterless humidification enabling portable convenience. We commenced a controlled product launch of AirSense 11 in fiscal year 2021, which was followed by a broader launch throughout fiscal year 2022. AirSense 11 introduced new features such as a touch screen, algorithms for patients new to therapy and digital enhancements, such as over-the-air update capabilities. We also acquired a line of Chinese-developed and manufactured sleep and ventilation devices with the acquisition of Curative Medical in fiscal year 2016. Devices in total accounted for approximately 52%, 50% and 51% of our net revenues in fiscal years 2022, 2021 and 2020, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-7-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below provide a selection of products, as known by our trademarks.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CPAP, APAP &amp; BILEVEL<br/>PRODUCTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AirSense 11</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AutoSet</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">CPAP</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">Elite</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Combining enhanced digital health technology with effective therapy modes, AirSense&#8482; 11 APAP and CPAP machines are designed to make starting sleep apnea therapy, and adhering to it, easier and more convenient than ever before. Our newest device, AirSense 11 includes new features like Personal Therapy Assistant and Care Check-In designed to provide tailored guidance to PAP users, helping ease them into therapy and comfortable nightly use. Other features include the availability of remote software updates so users can enjoy the latest version of these tools every night.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AirSense 10</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AutoSet</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AutoSet for Her</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">CPAP</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">Elite</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">Card-to-Cloud</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AirSense&#8482; 10 is one of the world&#8217;s most widely used series of CPAP and APAP machines, each designed to deliver high-quality therapy for a better night&#8217;s sleep. Features include a built-in humidifier, Climate Control Auto setting to provide breathing comfort, AutoRamp&#8482; with sleep onset detection, and expiratory pressure relief (EPR&#8482;).</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AirCurve 10 Bilevel</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirCurve 10 S</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirCurve 10 VAuto</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirCurve 10 ASV</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">AirCurve 10 VAuto </span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;padding-left:5pt">Card-to-Cloud</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AirCurve&#8482; 10 bilevel machines&#8239;include&#8239;two pressure level settings:&#8239;a&#8239;higher&#8239;pressure when you&#8239;inhale, and a&#8239;lower pressure&#8239;that makes it easier to exhale. AirCurve 10 S and AirCurve 10 VAuto both treat obstructive sleep apnea, while AirCurve 10 ASV treats central sleep apnea. All machines include a built-in humidifier and Climate Control Auto setting to provide breathing comfort. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AirMini portable CPAP</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The smallest portable CPAP on the market today, AirMini features the same auto-adjusting therapy modes used in the AirSense&#8482; 10 Auto. The device also features built-in Bluetooth connectivity and effective waterless humidification enabled by HumidX technology.</span></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">VENTILATION<br/>PRODUCTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stellar 150</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ResMed Stellar&#8482; 150 ventilator is suitable for invasive and non-invasive ventilation, either at home or in a healthcare setting. It is not a life support ventilator. Stellar 150 also includes iVAPS&#8482; (intelligent Volume-Assured Pressure Support) 1 technology to adjust to your changing respiratory needs.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Astral 100 and 150</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ResMed Astral&#8482; 100 and Astral 150 provide personalized care every step of the way. With both invasive and non-invasive options, they offer a lightweight design, exceptional battery life and adaptive technologies to provide greater mobility and peace of mind.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AirCurve 10 ST-A</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Designed for people with respiratory conditions that affect breathing such as restrictive lung disorders, severe COPD and hypoventilation, AirCurve&#8482; 10 ST-A combines user-friendly controls, an intuitive interface and automatic features to make ventilation therapy effective, comfortable and hassle-free.</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mask Systems, Diagnostic Products, Accessories and Other Products </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Masks, diagnostic products and accessories together accounted for approximately 37%, 38% and 37% of our net revenues in fiscal years 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mask Systems</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mask systems are one of the most important elements of sleep apnea treatment systems. Masks are a primary determinant of patient comfort and as such may drive or impede patient compliance with therapy. We have been a consistent innovator in small nasal, nasal pillows and full-face masks, by improving patient comfort while minimizing size and weight.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides an of overview of our mask systems by category.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">CATEGORY</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimalist</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AirFit F30, AirFit P10, and AirFit N30 minimalist masks feature our lightest, lowest profile designs. The features of these masks are focused on minimizing contact with the patient&#8217;s face to reduce red marks and irritation. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Freedom</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AirFit N30i, AirFit P30i, and AirFit F30i freedom masks, which feature top-of-head tubing design allowing flexibility to easily switch sleep positions. </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ultra Soft</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The AirTouch F20 and AirTouch N20 masks feature a soft and breathable AirTouch cushion designed to enhance CPAP mask comfort. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Universal Fit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AirFit F20 and AirFit N20 masks are designed to fit a wide range of faces due to the InfinitySeal silicone cushion that adapts to unique facial contours, which increases comfort, improves the fit and reduces leakage. </span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-8-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diagnostic Products</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals and at home. These diagnostic systems record relevant respiratory and sleep data, which can be analyzed by a sleep specialist or physician who can then tailor an appropriate OSA treatment regimen for the patient. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PRODUCTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ApneaLink Air</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow and snoring. Works with AirView Diagnostics to provide comprehensive diagnostic solution to clinicians.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">NightOwl</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A portable, cloud-connected, fully disposable diagnostic device that measures AHI based on peripheral arterial tone (PAT), actigraphy, and oximetry over several nights to capture variability and help avoid misdiagnosis.</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Connected Solutions and Other Products</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a suite of products that are designed to allow fewer professionals to manage more patients and empower patients to track their own health outcomes. We are expanding our cloud-based patient management and engagement platforms, such as AirView, enabling remote monitoring, over-the-air trouble shooting and changing of device settings, U-Sleep enabling automated patient coaching through a text, email or interactive voice phone call and myAir, a patient engagement application that provides sleep data and a daily score based on their previous night&#8217;s data.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PRODUCTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">AirView</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A cloud-based system enabling remote monitoring and changing of patients&#8217; device settings. AirView also makes it easier to simplify workflows and collaborate more efficiently across the patient&#8217;s care network.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">myAir</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A personalized therapy management application for patients with sleep apnea providing support, education and troubleshooting tools for increased patient engagement and improved compliance.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U-Sleep</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A compliance monitoring solution that enables HMEs to streamline their sleep programs to achieve better business and patient outcomes. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Connectivity Module</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A module providing cellular connection between our compatible ventilation devices (e.g., Astral, Stellar) and our AirView&#8482; system.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Propeller </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Propeller's inhaler sensors track medication usage and pair with a companion smartphone application, giving people with asthma or COPD a better understanding of their disease and promoting increased adherence to treatment. The Propeller Provider Portal gives clinicians the timely and accurate information they need to make better treatment decisions. </span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SaaS Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following multiple acquisitions, including Brightree in April 2016, HEALTHCARE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">first</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in July 2018 and MatrixCare in November 2018, we now supply out-of-hospital software products designed to support the professionals and caregivers helping people stay healthy in the home or care setting of their choice. SaaS revenue accounted for approximately 11%, 12% and 12% of our net revenue in fiscal years 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PRODUCTS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DESCRIPTION</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Brightree solutions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Brightree enables out-of-hospital care organizations to improve their business performance and deliver better health outcomes. As an industry-leading cloud-based healthcare IT company, Brightree provides solutions and services for thousands of organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MatrixCare solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MatrixCare&#8217;s EHR software as a service solutions are used by skilled nursing and senior living providers, life plan communities (CCRCs), and home health and hospice organizations to improve efficiencies and promote a better quality of life for the people they serve.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">HEALTHCAREfirst <br/>solutions<br/>&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HEALTHCAREfirst offers electronic health record, or EHR, software, billing and coding services, and advanced analytics that enable home health and hospice agencies to optimize their clinical, financial and administrative processes.</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Development and Clinical Trials </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a strong track record of innovation in the sleep and respiratory care markets. In 1989, we introduced our first CPAP device. Since then we have been committed to an ongoing program of product advancement and development. Currently, our product development and clinical trial efforts are focused on not only improving our current product offerings and usability, but also expanding into new product applications. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-9-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually seek to identify new applications of our technology for significant unmet medical needs. Sleep apnea is associated with a number of symptoms beyond excessive daytime sleepiness and irritability. Studies have established a clinical association between untreated sleep apnea and systemic hypertension, diabetes, coronary artery disease, stroke, atrial fibrillation, chronic heart failure, and mortality. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across the sleep and respiratory care platforms, we support clinical trials in many countries including the United States, Germany, Netherlands, France, Japan, the United Kingdom, Switzerland, China, Spain, Canada, Singapore, and Australia to develop new clinical applications for our technology. We also continue to support some of the largest sleep apnea studies in history by performing advanced statistical analyses on millions of real-world clinical data points collected through our cloud-connected devices and patient engagement tools. These studies, which we have begun to publish, provide clinical insights around patient management, device settings and predictors of patient adherence that inform our product development efforts.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consult with physicians at major medical centers throughout the world to identify clinical and technological trends in the treatment of sleep apnea, COPD and the other conditions associated with these diseases. New product ideas are also identified by our marketing staff, direct sales force and network of distributors, customers, clinicians and patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales and Marketing </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market our products in more than 140 countries through a network of distributors and our direct sales force. We attempt to tailor our marketing approach to each national market, based on regional awareness of sleep apnea as a health problem, physician referral patterns, consumer preferences and local reimbursement policies. See Note 14 &#8211; Segment Information of the Notes to Consolidated Financial Statements (Part II, Item 8) for financial information about our geographic areas.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States, Canada, and Latin America.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our products are typically purchased by a home healthcare dealer who then sells the products to the patient. The decision to purchase our products, as opposed to those of our competitors, is made or influenced by one or more of the following individuals or organizations: the prescribing physician and their staff; the home healthcare dealer; the insurer and the patient. In the United States, Canada, and Latin America, our sales and marketing activities are conducted through a field sales organization made up of regional territory representatives, program development specialists and regional sales directors. Our field sales organization markets and sells products to home healthcare dealer branch locations throughout the United States, Canada, and Latin America. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also market our products directly to physicians and sleep clinics. Patients who are diagnosed with OSA or another respiratory condition and prescribed our products are typically referred by the diagnosing physician or sleep clinic to a home healthcare dealer to fill the prescription. The home healthcare dealer, in consultation with the referring physician, will assist the patient in selecting the equipment, fit the patient with the appropriate mask and set the device pressure to the prescribed level. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our SaaS solutions are sold to providers of healthcare in various out-of-hospital settings. We market and sell our Brightree business management software and service solutions to providers in the U.S. and our primary markets are HME, pharmacy, home infusion, orthotics and prosthetics. Our sales activities for Brightree products are conducted through a sales organization made up of strategic account managers, sales engineers and sales directors. We develop, market and sell our MatrixCare care management and related ancillary solutions to providers in the U.S. and our primary markets are senior living; skilled nursing; life plan communities; home health, home care, and hospice agencies as well as related accountable care organizations. Our MatrixCare management solutions are primarily sold through direct sales and ancillary solutions are sold both through direct sales and channel partners.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Combined Europe, Asia, and other markets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We market our products in most major countries in combined Europe, Asia and other markets. We have wholly owned subsidiaries in Australia, Austria, China, Czech Republic, Denmark, Finland, France, Germany, India, Ireland, Japan, Korea, Netherlands, New Zealand, Norway, Poland, Sweden, Switzerland, Taiwan, Thailand, and the United Kingdom. We use a combination of our direct sales force and independent distributors to sell our products in combined Europe, Asia and other markets. We select independent distributors in each country based on their knowledge of respiratory medicine and a commitment to sleep apnea therapy. In countries where we sell our products direct, a local senior manager is responsible for direct national sales. In many countries we sell our products to home healthcare dealers or hospitals who then sell the products to the patients. In Germany, Australia, New Zealand, and South Korea, we also operate home healthcare business models, in which we provide products and services directly to patients. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We only sell our SaaS products in the United States; however we will also have sales in Germany once ResMed&#8217;s acquisition of MEDIFOX DAN is complete. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate a globally distributed manufacturing network designed to optimize quality, cost control, time to market for new product introduction and supply chain resilience. Our manufacturing operations consist of specialist component production as well as assembly and testing of our devices, masks and accessories. Of the numerous raw materials, parts and components purchased for assembly of our therapeutic and diagnostic sleep disorder products, many are available from multiple vendors. We also purchase uniquely configured components from various suppliers, including some who are single-source suppliers for us. Any reduction or halt in supply from one of these suppliers could limit our ability to manufacture our products or devices until a replacement supplier is found and qualified. We generally manufacture to our internal sales forecasts and fill orders as received. We strive for continuous improvement in manufacturing processes to deliver year-on-year improvement in output, cost and product quality. Each manufacturing site and team are responsible for the quality of their product group and decisions are based on performance and quality measures, including customer feedback. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has continued to impact the global supply chain, primarily through constraints on raw materials and electronic components, including semiconductor chips. These constraints have impacted and may continue to impact our ability to manufacture products in quantities necessary to satisfy customer demand, which could negatively impact our results of operations. Additionally, we have observed a reduction in both inbound and outbound transportation capacity as a result of port closures and delays associated with the pandemic, which is causing longer lead times in receiving raw materials into and distributing finished goods out of our manufacturing facilities, as well as increased freight costs. We are actively working to mitigate the impact of the widespread supply chain and logistics issues. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quality management system is based upon the requirements of ISO 9001, ISO 13485, FDA Quality System Regulation for Medical Devices, European Medical Device Regulation (&#8220;MDR&#8221;), the Medical Device Directive (93/42/EEC) and other applicable regulations for the markets in which we sell. Our main manufacturing sites are certified to ISO 13485 and are audited at regular intervals by a Notified Body. Additionally, our Sydney, Tuas, San Diego, Atlanta and Moreno Valley sites are certified under the Medical Device Single Audit Program or MDSAP, an audit of medical device manufacturers&#8217; quality management system to satisfy multiple regulatory requirements. MDSAP audits are conducted by a MDSAP recognized auditing organization and can fulfill the needs of multiple regulatory jurisdictions (e.g., Australia, Brazil, Canada, Japan, and the United States of America).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our main manufacturing facilities are located in Tuas, Singapore; Sydney, Australia; Chatsworth, California; Johor Bahru, Malaysia; Atlanta, Georgia and Suzhou, China. Refer to Item 2 for additional details on these properties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Third-Party Coverage and Reimbursement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of medical care in many of the countries in which we operate is funded in substantial part by government and private insurance programs. In Germany and Korea, we receive payments directly from these payors. While we do not generally receive direct payments for our products from payors in other countries, our success depends on the ability of patients to obtain coverage and adequate reimbursement from those payors. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our products are purchased primarily by home healthcare dealers, hospitals or sleep clinics, who invoice third-party payors directly for reimbursement. Domestic third-party payors include government payors such as Medicare and Medicaid and commercial health insurance plans. These payors may deny coverage and reimbursement if they determine that a device is not used in accordance with certain covered treatment methods, or is experimental, unnecessary or inappropriate. The long-term trend towards cost-containment, through managed healthcare, or other legislative proposals to reform healthcare, could control or significantly influence the purchase of healthcare services and products and could result in lower prices for our products. In some foreign markets, such as France, Germany, and Japan, government reimbursement is currently available for purchase or rental of our products, subject to constraints such as price controls or unit sales limitations. In Australia, China, and some other foreign markets, there is currently limited or no reimbursement for devices that treat OSA.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare reform in the United States continues to bring significant changes to the third-party payor landscape. In 2011, the Centers for Medicare &amp; Medicaid Services, or CMS, implemented the Durable Medical Equipment, Prosthetics, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-11-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orthotics and Supplies (DMEPOS) competitive bidding program, which included DME that we manufacture and develop, specifically, CPAP and respiratory assist devices (or bilevel devices), and related supplies and accessories. CMS is required by law to recompete these contracts at least once every three years. In addition, the 2010 Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, required CMS to roll out the competitive bidding process nationally or adjust prices in non-competitive bidding areas, also known as the non-bid or Round 3 areas, to match competitive bidding prices by 2016. CMS phased in the new rates beginning January 1, 2016, and the rates became fully effective July 1, 2016. The implementation of the competitive acquisition program has resulted in reduced Medicare payment for CPAP and respiratory assist devices, and related supplies and accessories in both competitive bidding areas and non-competitive bidding areas. Through an Interim Final Rule issued in May 2018, CMS increased the fee schedule amounts for certain DME in non-bid areas that qualify as rural and non-contiguous, setting payment for these areas for June 1, 2018 to December 31, 2018 at a 50/50 blended reimbursement rate based on the pre-competitive bidding reimbursement rate and the adjusted reimbursement rate set through competitive bidding.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the lapse of competitive bid contracts as of December 31, 2018, effective January 1, 2019, Medicare beneficiaries could receive DME from any Medicare-enrolled supplier during a temporary gap in the competitive bidding program between January 1, 2019 and December 31, 2020. Pricing in competitive bidding areas and non-rural, contiguous non-bid areas continued to use adjusted fee schedule amounts, subject to annual Consumer Price Index (CPI) adjustments, during this temporary gap period beginning in 2019 through December 31, 2020. On December 28, 2021, CMS released a Final Rule that, among other things, extended the blended fee schedule amounts for non-bid rural and non-contiguous areas through the end of the COVID-19 public health emergency, which has been renewed through October 13, 2022, and a blended fee schedule amount was implemented for all other areas for the same period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS competed 16 product categories in Round 2021 of the DMEPOS competitive bidding program, which took effect on January 1, 2021 and extends through December 31, 2021. There have been some revisions to the bidding methodology including the plan to implement surety bond requirements, lead item pricing, and setting reimbursement rates at the maximum winning bid rate instead of the median winning bid rate. Although CMS previously expanded the categories of devices subject to competitive bidding to include non-invasive ventilators, or NIVs, starting in 2021, in response to the COVID-19 pandemic, CMS removed NIVs from Round 2021 of the DMEPOS Competitive Bidding Program. Of the 15 remaining product categories that were bid for in Round 2021, CMS awarded competitive bidding contracts for only two categories, off-the-shelf (OTS) back braces and OTS knee braces. All other product categories were removed from Round 2021. Payment for the items where contracts were not awarded will be based on adjusted fee schedule amounts, pending further rulemaking.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Protecting Medicare and American Farmers From Sequester Cuts Act was signed into law Dec 10, 2021. The law extended the 2% Medicare sequester moratorium through March 31, 2022, and adjusted the sequester to 1% between April 1, 2022, and June 30, 2022 and reinstates the full 2% sequestration cut beginning July 1, 2022. The payment reduction applicable to healthcare providers applies to the approved Medicare payment amount, after the deductible and coinsurance are applied. The reduction in payment does not affect the 20% coinsurance owed by the patient. Further, the law eliminated the potential for an additional 4% Medicare sequester in 2022 due to statutory pay-as-you-go (PAYGO) requirement for one year. The cuts will take effect in 2023 after adjournment of the first session of the 117th Congress.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA, which was passed both to expand the number of individuals with healthcare coverage and to develop additional revenue sources, also included, among other things, a deductible excise tax equal to 2.3% of the price for which medical devices are sold in the United States on any entity that manufactures or imports medical devices, with limited exceptions, beginning in 2013. However, this excise tax was subsequently suspended by the U.S. Congress for medical device sales, beginning in 2016 and permanently repealed, effective January 1, 2020. The ACA also provided for a number of Medicare regulatory requirements, including new face-to-face encounter requirements for DME and home health services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-12-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. </span></div><div style="margin-top:10pt;padding-right:7.2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011 was signed into law, which, among other things, resulted in reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through December 31, 2021, unless additional Congressional action is taken. In addition, on January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that the ACA, these new laws and other healthcare reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for our products and services. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may have a material adverse impact on our revenues, profit margins, profitability, operating cash flows and results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Service and Warranty </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally offer either one-year or two-year limited warranties on our devices. In some regions and for certain customers we also offer extended warranties on our devices for one to three years in addition to our limited warranty. Warranties on mask systems are for 90 days. Our distributors either repair our products with parts supplied by us or arrange shipment of products to our facilities for repair or replacement. We receive returns of our products from the field for various reasons. We believe that the level of returns experienced to date is consistent with levels typically experienced by manufacturers of similar devices. We provide for warranties and returns based on historical data. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for our products and services are highly competitive. We believe that the principal competitive factors in all of our markets are product features, value-added solutions, reliability and price. Customer support, reputation and efficient distribution are also important factors. We compete on a market-by-market basis with various companies, some of which have greater financial, research, manufacturing and marketing resources than us. The disparity between our resources and those of our competitors may increase as a result of the trend towards consolidation in the healthcare industry. In addition, some of our competitors are affiliates of customers of ours, which may make it difficult to compete with them. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary Sleep and Respiratory Care competitors include Philips BV; Fisher &amp; Paykel Healthcare Corporation Limited; DeVilbiss Healthcare; Apex Medical Corporation; BMC Medical Co. Ltd.; and regional and new entrant manufacturers seeking to enter our markets. Finally, our products compete with surgical procedures, nerve stimulation devices and dental appliances designed to treat OSA and other sleep apnea-related respiratory conditions. The development of new or innovative procedures, devices or therapies, such as pharmaceutical, by others could result in our products becoming obsolete or noncompetitive, which would harm our revenues and financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For our SaaS business, the market is highly competitive, rapidly evolving, and subject to changing technology, low barriers to entry, shifting customer needs and frequent introductions of new products and services. The development of new or innovative solutions by others could result in our solutions becoming obsolete or noncompetitive, which would harm our revenues and financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product developed by us will have to compete for market acceptance and market share. An important factor in such competition may be the timing of market introduction of competitive products and solutions. Accordingly, the speed with which we can develop products and solutions, complete clinical testing and regulatory clearance processes and provide commercial supply of products and solutions to the market are important competitive factors. In addition, our ability to compete will continue to be dependent on successfully protecting our patents and other intellectual property. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-13-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights and Related Litigation </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of patents, designs, trademarks, trade secrets, copyrights, and non-disclosure agreements to protect our proprietary technology and rights. Some of these patents, patent applications and designs relate to significant aspects and features of our products. We believe the combination of these rights, in aggregate, are of material importance to each of our businesses. Through our various subsidiaries, as of the date of this report, we own or have licensed rights to approximately 9,100 pending, allowed or granted patents and designs. Patents and designs have various statutory terms based on the legislation in individual jurisdictions which may be subject to change. Of our patents, 565 U.S. patents and 1,435 foreign patents are due to expire in the next five years. We believe that the expiration of these patents will not have a material adverse impact on our competitive position.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation has been necessary in the past and may be necessary in the future to enforce patents issued to us, to protect our rights, or to defend third-party claims of infringement by us of the proprietary rights of others. The defense and prosecution of patent claims, including pending claims, as well as participation in other inter-party proceedings, can be expensive and time-consuming, even in those instances in which the outcome is favorable to us. Patent laws regarding the enforceability of patents vary from country to country. Therefore, there can be no assurance that patent issues will be uniformly resolved, or that local laws will provide us with consistent rights and benefits.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulations </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FDA</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products are subject to extensive regulation particularly as to safety, efficacy and adherence to FDA Quality System Regulation, and related manufacturing standards. Medical device products are subject to rigorous FDA and other governmental agency regulations in the United States and similar regulations of foreign agencies abroad. The FDA regulates the design, development, research, preclinical and clinical testing, introduction, manufacture, advertising, labeling, packaging, marketing, distribution, import and export, and record keeping for such products, in order to ensure that medical products distributed in the United States are safe and effective for their intended use. In addition, the FDA is authorized to establish special controls to provide reasonable assurance of the safety and effectiveness of most devices. Non-compliance with applicable requirements can result in import detentions, fines, civil and administrative penalties, injunctions, suspensions or losses of regulatory approvals, recall or seizure of products, operating restrictions, refusal of the government to approve product export applications or allow us to enter into supply contracts, and criminal prosecution. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an exemption applies, the FDA requires that a manufacturer introducing a new medical device or a new indication for use of an existing medical device obtain either a Section 510(k) premarket notification clearance or a premarket approval, or PMA, before introducing it into the U.S. market. The type of marketing authorization is generally linked to the classification of the device. The FDA classifies medical devices into one of three classes (Class I, II or III) based on the degree of risk the FDA determines to be associated with a device and the level of regulatory control deemed necessary to ensure the device&#8217;s safety and effectiveness.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products currently marketed in the United States are marketed pursuant to 510(k) pre-marketing clearances and are either Class I or Class II devices. The process of obtaining a Section 510(k) clearance generally requires the submission of performance data and often clinical data, which in some cases can be extensive, to demonstrate that the device is &#8220;substantially equivalent&#8221; to a device that was on the market before 1976 or to a device that has been found by the FDA to be &#8220;substantially equivalent&#8221; to such a pre-1976 device, a predecessor device is referred to as &#8220;predicate device.&#8221; As a result, FDA clearance requirements may extend the development process for a considerable length of time. In addition, in some cases, the FDA may require additional review by an advisory panel, which can further lengthen the process. The PMA process, which is reserved for new devices that are not substantially equivalent to any predicate device and for high-risk devices or those that are used to support or sustain human life, may take several years and requires the submission of extensive performance and clinical information. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical devices can be marketed only for the indications for which they are cleared or approved. After a device has received 510(k) clearance for a specific intended use, any change or modification that significantly affects its safety or effectiveness, such as a significant change in the design, materials, method of manufacture or intended use, may require a new 510(k) clearance or PMA approval and payment of an FDA user fee. The determination as to whether or not a modification could significantly affect the device&#8217;s safety or effectiveness is initially left to the manufacturer using available FDA guidance; however, the FDA may review this determination to evaluate the regulatory status of the modified </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-14-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product at any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained. The manufacturer may also be subject to significant regulatory fines or penalties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any devices we manufacture and distribute pursuant to clearance or approval by the FDA are subject to pervasive and continuing regulation by the FDA and certain state agencies. These include product listing and establishment registration requirements, which help facilitate FDA inspections and other regulatory actions. As a medical device manufacturer, all of our manufacturing facilities are subject to inspection on a routine basis by the FDA. We are required to adhere to applicable regulations setting forth detailed cGMP requirements, as set forth in the QSR, which require, manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all phases of the design and manufacturing process. Noncompliance with these standards can result in, among other things, fines, injunctions, civil penalties, recalls or seizures of products, total or partial suspension of production, refusal of the government to grant 510(k) clearance or PMA approval of devices, withdrawal of marketing approvals and criminal prosecutions. We believe that our design, manufacturing and quality control procedures are in compliance with the FDA&#8217;s regulatory requirements. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must also comply with post-market surveillance regulations, including medical device reporting requirements which require that we review and report to the FDA any incident in which our products may have caused or contributed to a death or serious injury. We must also report any incident in which our product has malfunctioned if that malfunction would likely cause or contribute to a death or serious injury if it were to recur.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Labeling and promotional activities are subject to scrutiny by the FDA and, in certain circumstances, by the Federal Trade Commission. Medical devices approved or cleared by the FDA may not be promoted for unapproved or uncleared uses, otherwise known as &#8220;off-label&#8221; promotion. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including substantial monetary penalties and criminal prosecution.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of medical devices outside the United States are subject to regulatory requirements that vary widely from country to country. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EEA</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the European Economic Area, (which is comprised of the 27 member states of the European Union plus Norway, Iceland and Liechtenstein), or EEA, medical devices need to comply with specific requirements. These requirements were previously known as "Essential Requirements" under the former EU Medical Devices Directive (Council Directive 93/42/EEC, or MDD) and are now defined "General Safety and Performance Requirements (GSPR)" under the new EU Medical Devices Regulation (Regulation (EU) 2017/745, or MDR). While the requirements set forth in the MDR are generally consistent with those laid out in the MDD (with a few exceptions), the GSPR are described more in detail compared to the Essential Requirements. Compliance with the Essential Requirements (under the MDD) or the GSPR (under the MDR) is a prerequisite to be able to affix the CE marking to medical devices, without which they cannot be marketed or sold in the EEA. To demonstrate compliance with the Essential Requirements/GSPR and affix the CE marking, manufacturers of medical devices must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. Except for low-risk medical devices (Class I with no measuring function and which are not sterile), where the manufacturer can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the Essential Requirements/GSPR, a conformity assessment procedure requires the intervention of a Notified Body, which is a third-party organization designated by a competent authority of an EEA country to conduct conformity assessments. Depending on the relevant conformity assessment procedure, the Notified Body would audit and examine the Technical File and the quality system for the manufacture, design and final inspection of the devices. The Notified Body issues a CE Certificate of Conformity following successful completion of a conformity assessment procedure conducted in relation to the medical device and its manufacturer and their conformity with the Essential Requirements/GSPR. This Certificate entitles the manufacturer to affix the CE marking to its medical devices after having prepared and signed a related EC Declaration of Conformity.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a general rule, demonstration of conformity of medical devices and their manufacturers with the Essential Requirements/GSPR must be based, among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use, that the known and foreseeable risks, and any adverse </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-15-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">events, are minimized and acceptable when weighed against the benefits of its intended performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All manufacturers placing medical devices into the market in the EEA must comply with the EU Medical Device Vigilance System. Under the MDR, incidents must be reported centrally in the European EUDAMED database (although transitional provisions are in place until EUDAMED is fully functional), and manufacturers are required to take Field Safety Corrective Actions, or FSCAs, to prevent or reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance of a device, as well as any inadequacy in the labeling or the instructions for use. The MDR considers "serious incidents" those incidents which, directly or indirectly, led, might lead to or might have led to the death of a patient or user or of other persons, a serious deterioration in their state of health, or a serious public health threat. An FSCA may include the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its legal representative to its customers and/or to the end users of the device through Field Safety Notices. Where appropriate, our products commercialized in Europe are CE marked and classified as either Class I or Class II. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2017, the European Parliament passed the MDR, which repeals and replaces the MDD. Unlike directives, which must be implemented into the national laws of the EEA member states, the regulations would be directly applicable (i.e., without the need for adoption of EEA member State laws implementing them) in all EEA member states and are intended to eliminate current differences in the regulation of medical devices among EEA member States. The MDR, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory framework across the EEA for medical devices and ensure a high level of safety and health while supporting innovation. Regulation (EU) 2017/746 (IVDR), applicable as of May 26, 2022, provides for the regulatory framework applicable to in vitro diagnostic medical devices.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MDR was meant to become applicable three years after publication (in May 2020). However, on April 23, 2020, to allow EEA national authorities, notified bodies, manufacturers and other actors to focus fully on urgent priorities related to the COVID-19 pandemic, the European Council and Parliament adopted Regulation 2020/561, postponing the date of application of the MDR by one year. The MDR thus became applicable on May 26, 2021. The MDR transitional provisions allow the placing on the market of devices with a CE Certificate issued in accordance with the MDD until May 26, 2024, under certain conditions. Moreover, the MDR provides that the following medical devices with a CE Certificate issued in accordance with the MDD may continue to be made available on the market or put into service until May 26, 2025. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Devices placed on the market in compliance with the MDD prior to May 26, 2021; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Devices placed on the market after May 26, 2021, benefiting from the described MDR transitional provisions. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MDR, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthens the rules on placing devices on the market and reinforces surveillance once they are available;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishes explicit provisions on manufacturers' responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improves the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sets up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the EU; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">strengthens rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received certification or initiated the MDR certification process at several locations, including Sydney, Australia; San Diego, California; and Lyon, France. We continue to transition our certification profile to meet the new MDR requirements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-16-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other regulatory bodies</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our devices are sold in multiple countries and often need to be registered with local regulatory bodies such as the Therapeutic Goods Administration in Australia, Health Canada in Canada and CFDA in China. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Healthcare Laws</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of laws and regulations that may restrict our business practices, including, without limitation, anti-kickback, false claims and transparency laws with respect to payments and other transfers of value made to physicians and other healthcare providers. The government has interpreted these laws broadly to apply to the marketing and sales activities of manufacturers and distributors as well as revenue cycle management companies like us.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute prohibits, among other things, persons or entities from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. In addition, a person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. A claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. The civil False Claims Act also applies to false submissions that cause the government to be paid less than the amount to which it is entitled, such as a rebate. Intent to deceive is not required to establish liability under the civil False Claims Act. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Private suits filed under the civil False Claims Act, known as qui tam actions, can be brought by individuals on behalf of the government. These individuals may share in any amounts paid by the entity to the government in fines or settlement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Civil Monetary Penalties Law prohibits, among other things, the offering or transfer of remuneration to a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary&#8217;s selection of a particular provider, practitioner, or supplier of services reimbursable by Medicare or a state healthcare program, unless an exception applies.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there has been a recent trend of increased federal and state regulation of payments and transfers of value provided to healthcare professionals or entities. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, biologicals, and medical devices or supplies that require premarket approval by or notification to the FDA, and for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, to report annually to CMS information related to (i) payments and other transfers of value to teaching hospitals, physicians (as defined by statute) and, beginning in 2022, physician assistants, nurse practitioners and other practitioners, and (ii) ownership and investment interests held by such providers and their immediate family members. Applicable manufacturers are required to submit annual reports to CMS. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, many U.S. states and countries outside the U.S. have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under government programs. In addition, in the U.S., certain states also mandate implementation of commercial compliance programs, impose </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-17-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restrictions on device manufacturer marketing practices and/or require the tracking and reporting of gifts, compensation and other remuneration to healthcare professionals and entities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FCPA and Other Anti-Bribery and Anti-Corruption Laws </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA would include interactions with certain healthcare professionals in many countries, either directly or through our contracted distributors. Our present and future business has been and will continue to be subject to various other U.S. and foreign laws, rules and/or regulations. The shifting commercial compliance environment and the need to build and maintain robust systems to comply with different compliance or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government healthcare programs, additional integrity oversight and reporting obligations, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Data Privacy and Security Laws</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which we collectively refer to as HIPAA, the Department of Health and Human Services, or HHS, has issued regulations, including the HIPAA Privacy, Security and Breach Notification Rules, to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including health care providers and their business associates, as well as covered subcontractors. HIPAA also regulates standardization of data content, codes and formats used in health care transactions and standardization of identifiers for health plans and providers. Penalties for violations of HIPAA regulations include significant civil and criminal penalties for each violation. In addition to federal privacy and security regulations, there are a number of state laws governing confidentiality and security of personal information that are applicable to our business. For example, the California Consumer Privacy Act, or the CCPA, became effective on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although the law includes limited exceptions, including for &#8220;protected health information&#8221; maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context. CCPA&#8217;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and the CCPA may increase our compliance costs and potential liability. Further, the California Privacy Rights Act, or CPRA, effective January 1, 2023, and replacing the CCPA, will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. In addition to California, several U.S. states, including Colorado, Virginia, and Utah have adopted their own comprehensive data protection laws, with varying implementation dates starting January 1, 2023. The application of the laws and the requirements contained therein is not uniform. We may be required to undertake additional compliance investment and potentially change our business processes to evaluate the application of these laws to our business and to implement compliance measures. If we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. Similar privacy laws have been proposed at the federal level and in other states.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these comprehensive data protection laws, to date, at least three states have adopted laws specifically regulating the collection, use, storage, and disclosure of biometrics, and additional states may seek to regulate&#8212;and/or restrict the use of&#8212;biometrics in the future. Certain of our products use, or permit the use of, information that could be classified as a biometric under these or other laws. If we are subject to or affected by these or other laws, we may be </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-18-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required to modify the way in which we make available our product or certain features of our product. We also may be required to implement additional practices or processes or otherwise invest our resources to comply with these and other regulations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some of our operations, such as those involving our cloud-based software digital health applications, we are a business associate under HIPAA and therefore required to comply with the HIPAA Security Rule, Breach Notification Rule and certain provisions of the HIPAA Privacy Rule, as well as the terms of our business associate agreements that we enter into with our covered entity customers, and are subject to significant civil and criminal penalties for failure to do so.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the General Data Protection Regulation, or GDPR, went into effect in May 2018. The GDPR imposes stringent data protection requirements for the processing of personal data in the European Economic Area, or EEA. The GDPR has increased our obligations, for example, by requiring more robust disclosures to individuals, strengthening individual data rights, instituting procedures for mandatory and data breach notifications to regulators within a short timeframe, limiting retention periods and secondary use of information (including for research purposes), increasing requirements pertaining to health data and pseudonymized (i.e., key-coded) data and imposing additional obligations when we contract with third party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EEA, including to the United States; recent legal developments in Europe have created complexity regarding such transfers of personal data from the EEA to the United States. For example, the European Commission and the United Kingdom have adopted new standard contractual clauses under which entities may transfer personal data from the European Union and the United Kingdom, which we may be required to implement. We must evaluate such data transfers on a case-by-case basis to ensure continued permissibility under current law and consistent with new standard contractual clauses. European data protection law provides that EEA member states may make their own further laws and regulations limiting the processing of genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase and harm our business and financial condition. EEA member states may modify or impose additional conditions to be able to transmit electronic marketing communications. Failure to comply with the requirements of GDPR and the applicable national data protection and marketing laws of the EEA member states may result in fines of up to &#8364;20.0 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties as well as individual claims for compensation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the United Kingdom has adopted the UK General Data Protection Regulation ("UK GDPR"), which also has the potential to impose significant data protection fines up to the greater of &#163;17.5 million or 4% of global turnover.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous other state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, confidentiality and security of patient health information and other personal information. In addition, Congress and some states are considering new laws and regulations that further protect the privacy and security of medical records or medical information. All 50 states have passed laws regulating the actions that a business must take if it experiences a data breach, such as prompt disclosure to affected customers. The Federal Trade Commission, or FTC, and states&#8217; Attorneys General have also brought enforcement actions and prosecuted some data breach cases as unfair and/or deceptive acts or practices under the FTC Act. In addition to data breach notification laws, some states have enacted statutes and rules requiring businesses to reasonably protect certain types of personal information they hold or to otherwise comply with certain specified data security requirements for personal information. These laws may apply directly to our business or indirectly by contract when we provide services to other companies. The FTC also has focused on the use of artificial intelligence (AI) and the potential bias in AI as one of its enforcement and policy priorities, including the use of AI in the healthcare space. Our services and products may use AI now or in the future. We intend to continue to comprehensively protect all personal information and to comply with all applicable laws regarding the protection of such information as well as to monitor developments regarding the use of AI that could be relevant to our products and services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations, damage our reputation and customers&#8217; trust.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-19-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At ResMed, our mission of transforming patient care in the out-of-hospital setting through innovative solutions and tech-driven integrated care is achieved by our commitment and efforts in fostering an inclusive environment that creates a strong sense of belonging, unlocking the potential, passion and creativity of our people.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Code of Business Conduct &amp; Ethics, Diversity and Inclusion programs and other practices and policies on workplace behavior, discrimination and harassment, health and safety, and employee benefits reinforce this environment and facilitate talent attraction, retention, and development.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had approximately 8,160 employees or contingent workers, of which approximately 3,480 were employed in cost of sales activities including areas such as warehousing and manufacturing, 1,350 in research and development and 3,330 in sales, marketing and administration. Of our employees and contingent workers, approximately 3,020 (37%) were located in the United States, Canada and Latin America, 2,370 (29%) in Asia, 1,360 (17%) in Australia and 1,410 (17%) in Europe. We believe that the success of our business will depend, in part, on our ability to attract and retain qualified personnel. ResMed&#8217;s global turnover rate for fiscal year 2022 was approximately 17%.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Diversity &amp; Inclusion</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our values of belonging, inclusion and diversity for success (&#8220;BIDS&#8221;) enable us to unlock the strengths of our people to transform healthcare and improve lives. We are in our second year of building out a strategic BIDS practice that strives to impact people, patients, and products. Our objectives include expanding Employee Resource Groups (&#8220;ERG&#8221;), creating and delivering learning &amp; development opportunities in support of BIDS values, identifying new and different hiring practices &amp; measurements, emphasizing accessibility &amp; disability inclusion, promoting inclusive leadership behaviors &amp; practices, and exploring new community partnerships for sourcing. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Resource Groups.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to place a high value on inclusion-building initiatives that create opportunities around cultural awareness and social learnings; this is largely done through engaging employees in our ERG programs supported by employees who share a common interest in community building, professional development, improving corporate culture and delivering sustained business results. We maintain our ERG chapters worldwide and currently have twelve groups: Black, Asia-American-Pacific Islander, LGBTQIA+, Hispanic and Latin, Veterans, Women, Women in Sales, Women in SaaS, Parents, Differently Able, and Mosaics in Ireland and France that collectively focus on local and culturally appropriate inclusion-building needs. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Learning &amp; Development of D&amp;I Values.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our leaders across the organization work directly with the Director of Diversity to identify and provide awareness trainings for their teams. In 2022, we launched a day of learning in each region for employees to learn more about diversity and inclusion with the theme of Unconscious Bias. Additionally, we launched a BIDS Certificate program, and the Director of Diversity also delivered multiple trainings globally.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategic Inclusive Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A Global Council of Ambassadors meets every two months to review and assess developments, observations, and impressions related to ongoing diversity and inclusion efforts. In 2022, we updated our internal policies and Employee Handbook to formalize certain inclusivity initiatives. Additionally, we assessed the language within the source code of our products and platforms to ensure that it is inclusive and does not perpetuate racist stereotypes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leadership Engagement.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C-Suite Executives, alongside the COO and CEO, receive quarterly updates on diversity data and inclusion-building efforts. Additionally, the CEO and senior leaders across the organization have diversity and inclusion objectives embedded in their annual and quarterly goals. Each ERG is supported by an Executive Sponsor.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sourcing &amp; Recruiting. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We train our recruiting workforce on the value of hiring diverse teams and diversity sourcing strategies, and we partner with external organizations that develop and supply diverse talent. In addition, we are building a diversity dashboard to better understand our metrics around applicants, candidates, and the current workforce. In 2022, we launched campaigns focused on collecting internal data and gathering diverse prospective candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-20-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Talent Development &amp; Retention</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Building and strengthening our talent pipeline is imperative to our success. Our approach to talent and performance is designed to ensure employees and managers have regular feedback conversations about performance goals and development, to enable our high-performance culture, and to create an environment where we achieve our strategy. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At ResMed, we have specific career and development pathways designed for specific roles in consultation with operational management, human resources, and learning and development specialists. We provide online courses that are role-specific, with formal tracking of employee completion and performance. Online and face-to-face courses on operational compliance issues are developed and delivered in-house. Online compliance courses on ResMed&#8217;s Code of Business Conduct and Ethics, diversity and inclusion, US Foreign Corrupt Practices Act, and health &amp; safety are developed by our Learning and Development team with external subject-matter advisers.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Compensation &amp; Benefits </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our compensation philosophy is to reinforce and align with our mission, business strategy, and financial needs as we grow. We provide market-competitive compensation and benefits based on benchmarking surveys we conduct regularly for all position levels against relevant peer companies. Our annual and long-term incentive packages are linked directly to business and individual performance, with a balance of short- and long-term financial and strategic objectives. We have an employee stock purchase plan, in addition to formal service awards internally. Eligibility for non-salary benefits such as salary continuance, life insurance, health insurance, and similar benefits, follows local regulations and practices. Equal opportunity and pay equity are integral to our pay philosophy, and we have processes in place to identify and address any potential pay equity issues where appropriate. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Safety &amp; COVID-19 Related Measures</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe maintaining a physically safe and mentally healthy working environment is essential in supporting our people to deliver their best work. We employ global standards to provide the framework for our locally compliant, integrated and effective health and safety management systems which enable the capability, autonomy &amp; accountability of the leaders to manage local sites. Our approach is to place health &amp; safety as a positive contributor to innovation, continuous improvement and business sustainability through focusing on making work easier, which in turn makes work safer and more efficient. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic spread, we implemented and maintained significant changes that we determined were in the best interest of our employees. These included work from home flexibility, adjusted attendance policies and additional safety measures for our on-site workforce. We have since re-opened our offices, consistent with local public health guidance and protocols, and continue to support flexible working globally. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Engagement &amp; Wellbeing</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly seek employee feedback and sentiment about our workplace through global engagement surveys that enable our people to comment on matters related to their employment experience. We openly share the survey results throughout the company and encourage teams to put in place action plans at global and local levels to address priority issues. Where benchmarks are available, our results are evaluated against comparable peer groups. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to improving the quality of life of our employees and their families. Our health and wellbeing programs differ by country and may include company-sponsored health insurance, retirement savings plans, sleep apnea screening and treatment, smoking cessation, gym membership discounts, seasonal flu vaccinations, mental health assistance, and many other programs to drive healthy behaviors and awareness. Additionally, we have implemented a company-wide ResMed Day for our people to focus on their mental, social and physical health.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-21-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_19"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A RISK FACTORS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described below in addition to the other cautionary statements and risks described elsewhere, and the other information contained, in this Report and in our other filings with the SEC, including our subsequent reports on Forms 10-Q and 8-K. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or uncertainties actually occurs with material adverse effects on us, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock will likely decline, and you may lose all or part of your investment.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the risks that are more fully described in the following section below:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Our Business and Industry</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our inability to compete successfully in our markets may harm our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidation in the health care industry could have an adverse effect on our revenues and results of operations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business, financial condition and results of operations could continue to be harmed by the effects of the COVID-19 pandemic or similar public health crises. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to various risks relating to international activities that could affect our overall profitability. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products are the subject of clinical trials conducted by us, our competitors, or other third parties, the results of which may be unfavorable, or perceived as unfavorable, and could have a material adverse effect on our business, financial condition, and results of operations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to potential product liability claims that may exceed the scope and amount of our insurance coverage, which would expose us to liability for uninsured claims. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our intellectual property may not protect our products, and/or our products may infringe on the intellectual property rights of third parties. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to attract, develop and retain key employees our business may suffer.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our leverage and debt service obligations could adversely affect our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Manufacturing, IT Systems, Commercial Operations and Plans for Future Growth</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruptions in the supply of components from our suppliers could result in a significant reduction in sales and profitability.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are increasingly dependent on information technology systems and infrastructure. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Actual or attempted breaches of security, unauthorized disclosure of information, denial of service attacks or the perception that personal and/or other sensitive or confidential information in our possession is not secure, could result in a material loss of business, substantial legal liability or significant harm to our reputation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to realize the anticipated benefits from acquisitions, which could adversely affect our operating results. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business depends on our ability to market effectively to dealers of home healthcare products and sleep clinics. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our SaaS business depends substantially on customers entering into, renewing, upgrading and expanding their agreements for cloud services, term licenses, and maintenance and support agreements with us. Any decline in our customer renewals, upgrades or expansions could adversely affect our future operating results. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If our SaaS products fail to perform properly or if we fail to develop enhancements, we could lose customers, become subject to service performance or warranty claims and our market share could decline. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-22-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If there are interruptions or performance problems associated with our technology or infrastructure, our existing SaaS customers may experience service outages, and our new customers may experience delays in the deployment of our platforms. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to support our continued growth, our business could suffer. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Climate change and related natural disasters, or other events beyond our control, could negatively impact our business operations and financial condition. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to Non-Compliance with Laws, Regulations and Healthcare Industry Shifts</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare reform may have a material adverse effect on our industry and our results of operations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Government and private insurance plans may not adequately reimburse our customers for our products, which could result in reductions in sales or selling prices for our products. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to comply with anti-kickback and fraud regulations could result in substantial penalties and changes in our business operations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our use and disclosure of personal information, including health information, is subject to federal, state and foreign privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business activities are subject to extensive regulation, and any failure to comply could have a material adverse effect on our business, financial condition, or results of operations. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Product sales, introductions or modifications may be delayed or canceled as a result of FDA regulations or similar foreign regulations, which could cause our sales and profits to decline. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to substantial regulation related to quality standards applicable to our manufacturing and quality processes. Our failure to comply with these standards could have an adverse effect on our business, financial condition, or results of operations.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Off-label marketing of our products could result in substantial penalties.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Laws regulating consumer contacts could adversely affect our business operations or create liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tax laws, regulations, and enforcement practices are evolving and may have a material adverse effect on our results of operations, cash flows and financial position.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to tax audits by various tax authorities in many jurisdictions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Risks Related to the Securities Markets and Ownership of Our Common Stock</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our results of operations may be materially affected by global economic conditions generally, including conditions in the financial markets.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly operating results are subject to fluctuation for a variety of reasons.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delaware law and provisions in our charter could make it difficult for another company to acquire us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-23-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our inability to compete successfully in our markets may harm our business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for our products, which encompass Sleep and Respiratory Care products and SaaS offerings, are highly competitive and are characterized by frequent product improvements and evolving technology. Our ability to compete successfully depends, in part, on our ability to develop, manufacture and market innovative new products. For our Sleep and Respiratory Care business, the development of innovative new products by our competitors or the discovery of alternative treatments or potential cures for the conditions that our products treat could make our products noncompetitive or obsolete. Current competitors, new entrants, academics, and others are trying to develop new devices, alternative treatments or cures, and pharmaceutical solutions to the conditions our products treat. For SaaS, the market for business management software is highly competitive, rapidly evolving, subject to changing technology, with low barriers to entry, shifting customer needs and frequent introductions of new products and services. Many prospective customers have invested substantial personnel and financial resources to implement and integrate their current business management software into their operations and, therefore, may be reluctant or unwilling to change from their current solution or provider to one of our platforms or products.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some of our competitors have greater financial, research and development, manufacturing and marketing resources than we do. The past several years have seen a trend towards consolidation in the healthcare industry and in the markets for our products. Industry consolidation could result in greater competition if our competitors combine their resources, if our competitors are acquired by other companies with greater resources than ours, or if our competitors become affiliated with customers of ours. This competition could increase pressure on us to reduce the selling prices of our products or could cause us to increase our spending on research and development and sales and marketing. If we are unable to develop innovative new products, maintain competitive pricing, and offer products that consumers perceive to be as good as those of our competitors, our sales and gross margins could decrease which would harm our business. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidation in the health care industry could have an adverse effect on our revenues and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many home health care dealers and out-of-hospital health providers are consolidating, which may result in greater concentration of purchasing power. As the health care industry consolidates, competition to provide goods and services to industry participants may become more intense. These industry participants may try to use their market power to negotiate price concessions or reductions for medical devices and components produced by us. If we are forced to reduce our prices because of consolidation in the health care industry, our revenues may decrease and our consolidated earnings, financial condition, and/or cash flows may suffer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business, financial condition and results of operations could continue to be harmed by the effects of the COVID-19 pandemic or similar public health crises.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are subject to risks associated with public health threats, including the global COVID-19 pandemic, which have had and may continue to have an adverse impact on certain aspects of our business. The extent to which the COVID-19 pandemic and measures taken in response thereto impact our business, results of operations, and financial condition will depend on future developments which are highly uncertain and are difficult to predict. These developments include, but are not limited to, future resurgences of the virus and its variants, actions taken to contain the virus or address its impact, and the timing, distribution, and efficacy of vaccines and other treatments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there is still substantial uncertainty associated with the COVID-19 pandemic, we believe the global demand for ventilators and other respiratory support devices used to treat COVID-19 patients has largely been met. In most markets, diagnostic pathways for sleep apnea treatment, including physician practices, HME distributors, and sleep clinics have largely recovered towards pre-pandemic levels. Likewise, within our SaaS business we have observed stabilizing patient flow in out-of-hospital care settings impacted by COVID-19.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has continued to impact the global supply chain, primarily through constraints on raw materials and electronic components. These constraints on raw materials and electronic components are also impacting companies outside of our direct industry, which is resulting in a competitive supply environment causing higher costs, requiring us to commit to minimum purchase obligations as well as make upfront payments to our suppliers. Further, we are being allocated certain components from our suppliers, particularly semiconductor chips, and we are thus being forced to allocate our outbound products to our customers. These disruptions have impacted and may continue to impact our ability to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-24-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">produce and supply products in quantities necessary to satisfy customer demand, which could negatively impact our results of operations. Additionally, we have observed a reduction in both inbound and outbound transportation capacity as a result of port closures and delays associated with the pandemic, which is causing longer lead times in receiving raw materials into and distributing finished goods out of our manufacturing facilities, as well as increased freight costs. These highly competitive and constrained supply chain conditions are increasing our cost of sales, which has and may continue to adversely impact our profitability. Given the ongoing uncertainty regarding the duration and extent of the COVID-19 pandemic, we are uncertain as to the duration and extent of constraint on our supply chain.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect COVID-19 may continue to negatively impact certain aspects of our business, given the rapid and evolving nature of the virus and the uncertainty about its impact on society and the global economy, we cannot predict the extent to which it will affect our global operations. Furthermore, future public health crises are possible and could involve some or all of the risks discussed above.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to various risks relating to international activities that could affect our overall profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture substantially all of our products outside the United States and sell a significant portion of our products in non-U.S. markets. Sales in combined Europe, Asia and other markets accounted for approximately 37% and 39% of our net revenues in the years ended June&#160;30, 2022 and June&#160;30, 2021 respectively. Our sales and operations outside of the U.S. are subject to several difficulties and risks that are separate and distinct from those we face in the U.S., including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in currency exchange rates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic conditions such as inflation or recession;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tariffs and other trade barriers; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with foreign medical device manufacturing regulations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty in enforcing agreements and collecting receivables through foreign legal systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduction in third-party payor reimbursement for our products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain import licenses; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of public health epidemics/pandemics on the global economy, such as COVID-19 that has spread globally;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of global geopolitical tensions and/or conflicts;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in trade policies and in U.S. and foreign tax policies; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">possible changes in export or import restrictions;  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the modification or introduction of other governmental policies with potentially adverse effects; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on our ability under local laws to protect our intellectual property.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the United States adopted the Uyghur Forced Labor Prevention Act (&#8220;UFLPA&#8221;) which creates a rebuttable presumption that any goods, wares, articles, and merchandise mined, produced, or manufactured in whole or in part in the Xinjiang Uyghur Administrative Region of China or that are produced by certain entities are prohibited from importation into the United States and are not entitled to entry. These import restrictions came into effect in June 2022. Additionally, the military conflict between Russia and Ukraine has resulted in the implementation of sanctions by the U.S. and other governments against Russia and has caused significant volatility and disruptions to the global markets. While we are not presently aware of any direct impacts these restrictions have had on our suppliers&#8217; supply chains, disruptions resulting from the conflict in Ukraine and the UFLPA may materially and negatively impact our suppliers&#8217; ability to obtain a sufficient supply of raw materials necessary to meet the quantity and/or timing of our product demands. Further, it is not possible to predict the short- and long-term implications of this conflict, which could include but are not limited to further sanctions, uncertainty about economic and political stability, increases in inflation rate and energy prices, cyber-attacks, supply chain challenges and adverse effects on currency exchange rates and financial markets. We are continuing to monitor the situation in China, Ukraine, and globally as well as assess its potential impact on our business. Although our sales into Russia and Ukraine did not constitute a material portion of our total revenue in 2022, further escalation of geopolitical tensions, or new geopolitical tensions, could have a broader impact that expands into other markets where we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-25-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">do business, which could adversely affect our business and/or our supply chain, business partners or customers in the broader region.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above factors may have a material adverse effect on our ability to increase or maintain our non-U.S. sales.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our products are the subject of clinical trials conducted by us, our competitors, or other third parties, the results of which may be unfavorable, or perceived as unfavorable, and could have a material adverse effect on our business, financial condition, and results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a part of the regulatory process to obtain marketing clearance for new products and new indications for existing products, or for other reasons, we conduct and participate in numerous clinical trials with a variety of study designs, patient populations, and trial endpoints. We, our competitors, or other third parties may also conduct clinical trials involving our commercially marketed products. The results of clinical trials may be unfavorable or inconsistent with previous findings, or could identify safety signals associated with our products. Current or future clinical trials may not meet primary endpoints, may reveal disadvantages of our products and solutions for various markets we address, or could generate unfavorable or inconsistent clinical data. Clinical data, or the market&#8217;s or regulatory bodies&#8217; perception of the clinical data, may adversely impact our ability to obtain product clearances or approvals, and our position in, and share of, the markets in which we participate. Moreover, if these clinical trials identify serious safety issues associated with our marketed products, potentially adverse consequences could result, including that regulatory authorities could withdraw clearances or approvals of our products, we could be required to halt the marketing and sales of our products or recall our products, we could be required to update our product labeling with additional warnings, we could be sued and held liable for harm caused to patients, and our reputation may suffer. Any of these could have a material adverse impact on our business, financial condition, and results of operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to potential product liability claims that may exceed the scope and amount of our insurance coverage, which would expose us to liability for uninsured claims. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to potential product liability claims as a result of the design, manufacture and marketing of medical devices. Any product liability claim brought against us, with or without merit, could result in the increase of our product liability insurance rates. In addition, we would have to pay any amount awarded by a court in excess of our policy limits. Our insurance policies have various exclusions, and thus we may be subject to a product liability claim for which we have no insurance coverage, in which case, we may have to pay the entire amount of any award. We cannot assure you that our insurance coverage will be adequate or that all claims brought against us will be covered by our insurance and we cannot assure you that we will be able to obtain insurance in the future on terms acceptable to us or at all. A successful product liability claim brought against us in excess of our insurance coverage, if any, may require us to pay substantial amounts, which could harm our business. We may also be affected by the product recalls and other risks associated with the products of our competitors if customers and patients are uncertain if issues affecting our competitors may also affect us. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our intellectual property may not protect our products, and/or our products may infringe on the intellectual property rights of third parties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of patents, trade secrets and non-disclosure agreements to protect our intellectual property. Our success depends, in part, on our ability to obtain and maintain U.S. and foreign patent protection for our products, their uses and our processes to preserve our trade secrets and to operate without infringing on the proprietary rights of third-parties. We have a number of pending patent applications, and we do not know whether any patents will issue from any of these applications. We do not know whether any of the claims in our issued patents or pending applications will provide us with any significant protection against competitive products or otherwise be commercially valuable. Legal standards regarding the validity of patents and the proper scope of their claims are still evolving, and there is no consistent law or policy regarding the valid breadth of claims. Additionally, there may be third-party patents, patent applications and other intellectual property relevant to our products and technology which are not known to us and that block or compete with our products. We face the risks that: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-parties will infringe our intellectual property rights; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our non-disclosure agreements will be breached; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will not have adequate remedies for infringement; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our trade secrets will become known to or independently developed by our competitors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-parties will be issued patents that may prevent the sale of our products or require us to license and pay fees or royalties in order for us to be able to market some of our products; or</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-26-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-parties may assert patents and other intellectual property rights against our suppliers, causing interruption in supply of components or other essential inputs. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation may be necessary to enforce patents issued to us, to protect our proprietary rights, or to defend third-party claims that we have infringed on proprietary rights of others. If the outcome of any litigation or proceeding brought against us were adverse, we could be subject to significant liabilities to third-parties, could be required to obtain licenses from third-parties, could be forced to design around the patents at issue or could be required to cease sales of the affected products. A license may not be available at all or on commercially viable terms, and we may not be able to redesign our products to avoid infringement. Additionally, the laws regarding the enforceability of patents vary from country to country, and we cannot assure you that any patent issues we face will be uniformly resolved, or that local laws will provide us with consistent rights and benefits.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we fail to attract, develop and retain key employees our business may suffer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our ability to compete effectively depends on our ability to attract and retain key employees, including people in senior management, sales, marketing, technology, and research and development positions. Competition for top talent in the healthcare, technology and SaaS industries can be intense. Our ability to recruit and retain such talent will depend on a number of factors, including hiring practices of our competitors, compensation and benefits, work location, work environment and industry economic conditions. If we cannot effectively recruit, develop and retain qualified employees to drive our strategic goals, our business could suffer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our leverage and debt service obligations could adversely affect our business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, our total consolidated debt was $0.8 billion and we may incur additional indebtedness in the future, including as a result of our pending acquisition of MEDIFOX DAN, which is expected to close during our fiscal year 2023. Our indebtedness could have adverse consequences, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making it more difficult to satisfy our financial obligations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increasing our vulnerability to adverse economic, regulatory and industry conditions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to compete and our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limiting our ability to borrow additional funds for working capital, capital expenditure, acquisitions and general corporate or other purposes; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposing us to greater interest rate risk.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our debt service obligations will require us to use a portion of our operating cash flow to pay interest and principal in indebtedness, which could impede our growth. Our ability to make payments on, and to refinance, our indebtedness, and to fund capital expenditures will depend on our ability to generate cash in the future. This is subject to general economic, financial, competitive, legislative, regulatory, and other factors, many of which are beyond our control.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Manufacturing, IT Systems, Commercial Operations and Plans for Future Growth</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disruptions in the supply of components from our suppliers could result in a significant reduction in sales and profitability. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase configured components for our devices from various suppliers, including some who are single-source suppliers for us. Disruptions to our suppliers, including disruptions in connection with COVID-19 and its variants, may limit our ability to manufacture our devices in a timely or cost-effective manner, which could result in a significant reduction in sales and profitability. We cannot assure you that a replacement supplier would be able to configure its components for our devices on a timely basis or, in the alternative, that we would be able to reconfigure our devices to integrate the replacement part. A reduction, delay or halt in supply while a replacement supplier reconfigures its components, or while we reconfigure our devices for the replacement part, would limit our ability to manufacture our devices in a timely or cost-effective manner, which could result in a significant reduction in sales and profitability. We cannot assure you that our inventories would be adequate to meet our production needs during any prolonged interruption of supply.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, a global semiconductor supply shortage is having wide-ranging effects across multiple industries, and it has impacted suppliers that incorporate semiconductors into the parts they supply to us. High demand and shortages of supply have adversely affected and could materially adversely affect our ability to obtain sufficient quantities of semiconductors </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-27-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and electronic components on commercially reasonable terms or at all. While we have entered into agreements for the supply of many components, there can be no assurance we will be able to extend or renew these agreements on similar terms or that suppliers will fulfill their commitments under existing agreements. Furthermore, in order to secure such necessary components, we may be obligated to purchase them at prices that are higher than those available in the current market and/or may incur significant price increases from these suppliers in the future. In addition, we may be required to commit to greater purchase volumes and/or make prepayments to our suppliers. Extended lead times and decreased availability of key components may also cause an adverse effect on our financial condition or results of operations. Delays in our ability to produce and deliver our devices could cause our customers to purchase alternative products from our competitors. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the global semiconductor supply shortage, we have recently expanded our global offering of devices to include Card-to-Cloud (C2C) versions of our prior model AirSense 10 and AirCurve 10 offerings that do not incorporate a communications module. We introduced C2C models to address the growing backlog of patients waiting for therapy with ResMed devices. Because C2C devices do not include communications capability they involve a more manual workflow for our customers, and may face resistance in the market as the backlog of patients waiting for treatment is reduced. The C2C offering, while appropriate in the short term, also may not be consistent with our long term strategy of connecting all devices with AirView.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, increases in product demand, including in response to a product recall by one of our competitors, Philips, have resulted and could continue to result in shipment delays, higher costs for materials and components, and increased expenditures for freight and other expenses, which have and could continue to negatively impact our profit margins. If supply constraints continue, our ability to meet demand and our corresponding ability to sell affected products may be materially reduced. We have and may continue to be required to allocate or prioritize orders for our devices, and our failure to timely deliver desirable products to meet demand may harm relationships with our customers. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are increasingly dependent on information technology systems and infrastructure.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our technology systems are potentially vulnerable to breakdown or other interruption by fire, power loss, system malfunction, unauthorized access and other events. Likewise, data privacy breaches by employees and others with both permitted and unauthorized access to our systems may pose a risk that sensitive data may be exposed to unauthorized persons or to the public, or may be permanently lost. While we have invested heavily in the protection of data and information technology and in related training, there can be no assurance that our efforts will prevent significant breakdowns, breaches in our systems or other cyber incidents that could have a material adverse effect upon the reputation, business, operations or financial condition of the company. In addition, significant implementation issues may arise as we continue to consolidate and outsource certain computer operations and application support activities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Actual or attempted breaches of security, unauthorized disclosure of information, denial of service attacks or the perception that personal and/or other sensitive or confidential information in our possession is not secure, could result in a material loss of business, substantial legal liability or significant harm to our reputation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Despite the implementation of security measures, our internal computer and information technology systems and those of our vendors and customers are vulnerable to attack and damage from computer viruses, malware, denial of service attacks, unauthorized access, or other harm, including from threat actors seeking to cause disruption to our business. We face risks related to the protection of information that we maintain&#8212;or engage a third-party to maintain on our behalf&#8212;including unauthorized access, acquisition, use, disclosure, or modification of such information. Cyberattacks are increasing in their frequency, sophistication and intensity and have become increasingly difficult to detect. Cyberattacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. A material cyberattack or security incident could cause interruptions in our operations and could result in a material disruption of our business operations, damage to our reputation, financial condition, results of operations, cash flows and prospects.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive, collect, process, use and store a large amount of information from our clients, our patients and our own employees, including personal information, protected health and other sensitive and confidential information. This data is often accessed by us through transmissions over public and private networks, including the Internet. The secure transmission of such information over the Internet and other mechanisms is essential to maintain confidence in our information technology systems. We have implemented security measures, technical controls and contractual precautions designed to identify, detect and prevent unauthorized access, alteration, use or disclosure of our clients&#8217;, patients&#8217; and employees&#8217; data. However, the techniques used in these attacks change frequently and may be difficult to detect for periods </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-28-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of time and we may face difficulties in anticipating and implementing adequate preventative measures. We may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Beyond external criminal activity, systems that access or control access to our services and databases may be compromised as a result of human error, fraud or malice on the part of employees or third parties, or may result from accidental technological failure. Because the techniques used to circumvent security systems can be highly sophisticated and change frequently, often are not recognized until launched against a target and may originate from less regulated and remote areas around the world, we may be unable to proactively address all possible techniques or implement adequate preventive measures for all situations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If someone is able to circumvent or breach our security systems, they could steal any information located therein or cause serious and potentially long lasting disruption to our operations. Security breaches or attempts thereof could also damage our reputation and expose us to a risk of monetary loss and/or litigation, fines and sanctions. We also face risks associated with security breaches affecting third parties that conduct business with us or our clients and others who interact with our data. While we maintain insurance that covers certain security incidents, we may not carry appropriate insurance or maintain sufficient coverage to compensate for all potential liability. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to diverse laws and regulations relating to data privacy and security, including HIPAA and European data privacy laws. Complying with these numerous and complex regulations is expensive and difficult, and failure to comply with these regulations could result in regulatory scrutiny, fines, civil liability or damage to our reputation. In addition, any security breach or attempt thereof could result in liability for stolen assets or information, additional costs associated with repairing any system damage, incentives offered to clients or other business partners to maintain business relationships after a breach, and implementation of measures to prevent future breaches, including organizational changes, deployment of additional personnel and protection technologies, employee training and engagement of third-party experts and consultants. Additionally, the costs incurred to remediate any data security or privacy incident could be substantial.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that any of our third-party service providers with access to our, or our clients, patients and/or employees&#8217; personally identifiable and other sensitive or confidential information will maintain appropriate policies and practices regarding data privacy and security in compliance with all applicable laws or that they will not experience data security breaches or attempts thereof, which could have a corresponding effect on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We may not be able to realize the anticipated benefits from acquisitions, which could adversely affect our operating results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Part of our growth strategy includes acquiring businesses consistent with our commitment to innovation in developing products for the diagnosis and treatment of sleep apnea and respiratory care as well as our SaaS business. For example, we acquired MatrixCare in November 2018, Propeller Health in January 2019, and in June 2022 we signed a definitive agreement to acquire MEDIFOX DAN which is expected to close during our fiscal year 2023. The MEDIFOX DAN acquisition remains subject to regulatory clearances and other customary closing conditions and should the acquisition fail to close, we will not realize the benefits that we expect to receive from the acquisition. Moreover, the success of our acquisitions will depend, in part, on our ability to successfully integrate the business and operations of the acquired companies. Additionally, our management may have their attention diverted while trying to integrate these businesses. If we are not able to successfully integrate the operations, we may not realize the anticipated benefits of the acquisitions fully or at all, or may take longer to realize than expected. Acquisitions involve numerous risks and could create unforeseen operating difficulties and expenditures. There can be no assurance that any of the acquisitions we make will be successful or will be, or will remain, profitable. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we have recorded intangible assets, including goodwill, in connection with our acquisitions. At least on an annual basis, we must evaluate whether facts and circumstances indicate any impairment of the intangible assets&#8217; values. The qualitative and quantitative analysis used to test goodwill is dependent upon various considerations and assumptions, including macroeconomic conditions, industry and market characteristics, projections of acquired companies&#8217; future revenue, discount rates, and expectations of future cash flows. While we have made such assumptions in good faith and believe them to be reasonable, the assumptions may turn out to be materially inaccurate, including for reasons beyond our control. Changes in such assumptions may cause a change in circumstances indicating that the carrying value of intangible assets may be impaired. Consequently, we may be required to record a significant charge to earnings in the financial statements during the period in which any impairment of intangible assets is determined.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business depends on our ability to market effectively to dealers of home healthcare products and sleep clinics. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market our products primarily to home healthcare dealers and to sleep clinics that diagnose OSA and other sleep </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-29-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disorders, as well as to non-sleep specialist physician practices that diagnose and treat sleep disorders. We believe that these groups play a significant role in determining which brand of product a patient will use. The success of our business depends on our ability to market effectively to these groups to ensure that our products are properly marketed and sold by these third-parties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited resources to market to the sleep clinics, home healthcare dealer branch locations and to the non-sleep specialists, most of whom use, sell or recommend several brands of products. In addition, home healthcare dealers have experienced price pressures as government and third-party reimbursement has declined for home healthcare products, and home healthcare dealers are requiring price discounts and longer periods of time to pay for products purchased from us. We cannot assure you that physicians will continue to prescribe our products, or that home healthcare dealers or patients will not substitute competing products when a prescription specifying our products has been written. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have expanded our marketing activities in some markets to target the population with a predisposition to sleep-disordered breathing as well as primary care physicians and various medical specialists. We cannot assure you that these marketing efforts will be successful in increasing awareness or sales of our products. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our SaaS business depends substantially on customers entering into, renewing, upgrading and expanding their agreements for cloud services, term licenses, and maintenance and support agreements with us. Any decline in our customer renewals, upgrades or expansions could adversely affect our future operating results. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically enter into term-based agreements for our licensed on-premises offerings, cloud services, and maintenance and support services, which customers have discretion to renew or terminate at the end of the initial term. In order for us to improve our operating results, it is important that new customers enter into renewable agreements, and our existing customers renew, upgrade and expand their term-based agreements when the initial contract term expires. Our customers have no obligation to renew, upgrade or expand their agreements with us after the terms have expired. Our customers&#8217; renewal, upgrade and expansion rates may decline or fluctuate as a result of a number of factors, including their satisfaction or dissatisfaction with our offerings, our pricing, the effects of general economic conditions, competitive offerings or alterations or reductions in our customers&#8217; spending levels. If our customers do not renew, upgrade or expand their agreements with us or renew on terms less favorable to us, our revenues may decline.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If our SaaS products fail to perform properly or if we fail to develop enhancements, we could lose customers, become subject to service performance or warranty claims and our market share could decline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our SaaS operations are dependent upon our ability to prevent system interruptions and, as we continue to grow, we will need to devote additional resources to improving our infrastructure in order to maintain the performance of our products and solutions. The applications underlying our SaaS products are inherently complex and may contain material defects or errors, which may cause disruptions in availability or other performance problems. We have from time to time found defects in our products and may discover additional defects in the future that could result in data unavailability, unauthorized access to, loss, corruption or other harm to our customers&#8217; data. While we implement bug fixes and upgrades as part of our regularly scheduled system maintenance, we may not be able to detect and correct defects or errors before implementing our products and solutions. Consequently, we or our customers may discover defects or errors after our products and solutions have been deployed. If we fail to perform timely maintenance, or if customers are otherwise dissatisfied with the frequency and/or duration of our maintenance services and related system outages, our existing customers could elect not to renew their contracts, delay or withhold payment, or potential customers may not adopt our products and solutions and our brand and reputation could be harmed. In addition, the occurrence of any material defects, errors, disruptions in service or other performance problems with our software could result in warranty or other legal claims against us and diversion of our resources. The costs incurred in addressing and correcting any material defects or errors in our software and expanding our infrastructure and architecture in order to accommodate increased demand for our products and solutions may be substantial and could adversely affect our operating results. Further, if we fail to innovate or adequately invest in new technologies, we could lose our competitive position in the markets that we serve. To the extent that we fail to introduce new and innovative products, or such products are not accepted in the market or suffer significant delays in development, our financial results may suffer. An inability, for technological or other reasons, to successfully develop and introduce new products on a timely basis could reduce our growth rate or otherwise have an adverse effect on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If there are interruptions or performance problems associated with our technology or infrastructure, our existing SaaS customers may experience service outages, and our new customers may experience delays in the deployment of our platforms. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on services from various third parties as well as our own technical operations infrastructure to distribute our SaaS products via the Internet. If a service provider fails to provide sufficient capacity to support our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-30-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">platform or otherwise experiences service outages, such failure could interrupt our customers&#8217; access to our service, which could adversely affect their perception of our platform's reliability and our revenues. Any disruptions in these services, including as a result of actions outside of our control, would significantly impact the continued performance of our SaaS products. In the future, these services may not be available to us on commercially reasonable terms, or at all. Any loss of the right to use any of these services could result in decreased functionality of our SaaS products until equivalent technology is either developed by us or, if available from another provider, is identified, obtained and integrated into our infrastructure. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet our business needs, we must maintain sufficient excess capacity in our operations infrastructure to ensure that our SaaS products are accessible. Design and mechanical errors, spikes in usage volume and failure to follow system protocols and procedures could cause our systems to fail, resulting in interruptions in our SaaS products. Any interruptions or delays in our service, whether or not caused by our products, or as a result of third-party error, our own error, natural disasters or security breaches, whether accidental or willful, could harm our relationships with customers and cause our revenue to decrease and/or our expenses to increase. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the above circumstances or events may harm our reputation, cause customers to terminate their agreements with us, impair our ability to obtain contract renewals from existing customers, impair our ability to grow our customer base, result in the expenditure of significant financial, technical and engineering resources, subject us to financial penalties and liabilities under our service level agreements, and otherwise harm our business, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to support our continued growth, our business could suffer. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to grow, the complexity of our operations increases, placing greater demands on our management. Our ability to manage our growth effectively depends on our ability to implement and improve our financial and management information systems on a timely basis and to effect other changes in our business including the ability to monitor and improve manufacturing systems, information technology, and quality and regulatory compliance systems, among others. Unexpected difficulties during expansion, the failure to attract and retain qualified employees, the failure to successfully replace or upgrade our management information systems, the failure to manage costs or our inability to respond effectively to growth or plan for future expansion could cause our growth to stop. If we fail to manage our growth effectively and efficiently, our costs could increase faster than our revenues and our business results could suffer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Climate change and related natural disasters, or other events beyond our control, could negatively impact our business operations and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Natural disasters and other business disruptions could adversely affect our business and financial condition, and global climate change could result in certain types of natural disasters occurring more frequently or with more intense effects. The impacts of climate change may include physical risks (such as frequency and severity of extreme weather conditions), social and human effects (such as population dislocations or harm to health and well-being), compliance costs and transition risks, shifts in market trends and other adverse effects. Such impacts may disrupt parties in our supply chain, our customers, and our operations. For example, if a natural disaster strikes our manufacturing facilities, we will be unable to manufacture our products for a substantial amount of time and our sales and profitability will decline. Our facilities and the manufacturing equipment we use to produce our products would be costly to replace and could require substantial lead-time to repair or replace. In the event our facilities were affected by natural or man-made disasters, we could be forced to rely on third-party manufacturers. Although we believe we possess adequate insurance for the disruption of our business from causalities, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the increasing concern over climate change has resulted and may continue to result in more legal and regulatory requirements designed to mitigate the effects of climate change on the environment, including regulating greenhouse gas emissions, alternative energy policies and sustainability initiatives. If such laws or regulations are more stringent than current legal or regulatory requirements, we may experience increased compliance burdens and costs to meet the regulatory obligations. Further, there may be increasing scrutiny and changing expectations from the market and other stakeholders with respect to Environmental, Social and Governance (ESG) practices. Any such regulatory changes or increased market expectations could also have a significant effect on our operating and financial decisions, including those involving capital expenditures to reduce emissions and comply with other regulatory requirements or stakeholder expectations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-31-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Non-Compliance with Laws, Regulations and Healthcare Industry Shifts</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare reform may have a material adverse effect on our industry and our results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the ACA was signed into law in the United States. The ACA made changes that significantly impacted the healthcare industry, including medical device manufacturers. One of the principal purposes of the ACA was to expand health insurance coverage to millions of Americans who were uninsured. The ACA required adults not covered by an employer or government-sponsored insurance plan to maintain health insurance coverage or pay a penalty, a provision commonly referred to as the individual mandate. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA also contained a number of provisions designed to generate the revenues necessary to fund the coverage expansions. This included new fees or taxes on certain health-related industries, including medical device manufacturers. Beginning in 2013, entities that manufacture, produce or import medical devices were required to pay an excise tax in an amount equal to 2.3% of the price for which such devices are sold in the United States. This excise tax was applicable to our products that are primarily used in hospitals and sleep labs, which includes the ApneaLink, VPAP Tx and certain Respiratory Care products. Through a series of legislative amendments, the tax was suspended beginning in 2016, and permanently repealed effective January 1, 2020. In addition to the competitive bidding changes discussed above, the ACA also included, among other things, directions to develop organizations that are paid under a new payment methodology for voluntary coordination of care by groups of providers, such as physicians and hospitals, and the establishment of a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research. The increased funding and focus on comparative clinical effectiveness research, which compares and evaluates the risks and benefits, clinical outcomes, effectiveness and appropriateness of products, may result in lower reimbursements by payors for our products and decreased profits to us. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other federal legislative changes have been proposed and adopted since the ACA was enacted. These changes included an aggregate reduction in Medicare payments to providers of 2% per fiscal year, which went into effect on April 1, 2013. The CARES Act, which was signed into law in March 2020 and subsequently amended, suspended the payment reductions from May 1, 2020 through December 31, 2020, and extended the sequester by one additional year, through 2030. In addition, on January 2, 2013, the American Taxpayer Relief Act of 2012, was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full impact on our business of the ACA and other new laws is uncertain. Nor is it clear whether other legislative changes will be adopted, if any, or how such changes would affect the demand for our products. Future actions by the administration and the U.S. Congress including, but not limited to, repeal or replacement of the ACA could have a material adverse impact on our results of operations or financial condition. Additionally, all or a portion of the ACA and related subsequent legislation may be modified, repealed or otherwise invalidated through other judicial challenge. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact the ACA or our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various healthcare reform proposals have also emerged at the state level within the United States. The ACA as well as other federal and/or state healthcare reform measures that may be adopted in the future, singularly or in the aggregate, could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government and private insurance plans may not adequately reimburse our customers for our products, which could result in reductions in sales or selling prices for our products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to sell our products depends in large part on the extent to which coverage and adequate reimbursement for our products will be available from government health administration authorities, private health insurers and other organizations. These third-party payers are increasingly challenging the prices charged for medical products and services and can, without notice, deny coverage for our products or treatments that may include the use of our products. Therefore, even if a product is approved for marketing, we cannot </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-32-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">make assurances that coverage and reimbursement will be available for the product, that the reimbursement amount will be adequate or that the reimbursement amount, even if initially adequate, will not be subsequently reduced. For example, in some markets, such as Spain, France and Germany, government coverage and reimbursement are currently available for the purchase or rental of our products but are subject to constraints such as price controls or unit sales limitations. In other markets, such as Australia, there is currently limited or no reimbursement for devices that treat sleep apnea conditions. As we continue to develop new products, those products will generally not qualify for coverage and reimbursement until they are approved for marketing, if at all. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we sell our products primarily to home healthcare dealers, hospitals and sleep clinics. Reductions in reimbursement to our customers by third-party payers, if they occur, may have a material impact on our customers and, therefore, may indirectly affect our pricing and sales to, or the collectability of receivables we have from, those customers. A development negatively affecting reimbursement stems from the Medicare competitive bidding program mandated by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). Under the program, our customers who provide DME must compete to offer products in designated competitive bidding areas, or CBAs. In addition, under the ACA, in 2016, CMS adjusted the prices in non-competitive bidding areas to match competitive bidding prices. CMS phased in the new rates beginning January 1, 2016, and were fully effective July 1, 2016. This program has significantly reduced the Medicare reimbursement to our customers compared with reimbursement in 2011, at the beginning of the program. The 21st Century Cures Act retroactively adjusted rates in non-bid areas to allow for the higher phase-in rates to be paid for items furnished between July 1, 2016 and December 31, 2016, rather than the lower fully-adjusted rates. Rules issued by CMS in 2018 resumed the higher phase-in rates in rural and non-contiguous non-competitive bidding areas for items furnished between June 1, 2018 and December 31, 2020. Pursuant to the CARES Act, these higher phase-in rates were extended through December 31, 2020, or through the end of the COVID-19 public health emergency, and were implemented in areas other than rural areas and noncontiguous areas for the same period. On March 7, 2019, CMS announced it would initiate a new round of competitive bidding, named Round 2021, with contracts effective on January 1, 2021 through December 31, 2023. In addition to adopting new bidding processes, CMS expanded the product categories included in competitive bidding to include non-invasive ventilators. However, due to the COVID-19 pandemic, CMS removed NIVs from Round 2021 of the DMEPOS Competitive Bidding Program. CPAP, and respiratory assist devices, and related supplies and accessories, which had been included in prior rounds of competitive bidding, were included in the 15 remaining product categories that were bid for in Round 2021. However, CMS did not award competitive bidding contracts for any product categories other than OTS back and knee braces. Payment for items where contracts were not awarded &#8211; including CPAP and respiratory assist devices &#8211; will be based on adjusted fee schedule amounts. At this time, we cannot predict the full impact the competitive bidding program and the developments in the competitive bidding program will have on our business and financial condition. If changes are made to this program in the future, it could affect amounts being recovered by our customers.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to Medicare reimbursement, the Protecting Medicare and American Farmers From Sequester Cuts Act was signed into law Dec 10, 2021. The law extended the 2% Medicare sequester moratorium through March 31, 2022, adjusted the sequester to 1% between April 1, 2022, and June 30, 2022 and reinstated the full 2% sequestration cut beginning July 1, 2022. The reduction in payment to healthcare providers is to the calculated Medicare payment after the approved amount is determined, and the deductible and coinsurance are applied, and not the 20% coinsurance owed by the patient. Further, the law eliminated the potential for an additional 4% Medicare sequester in 2022 due to statutory pay-as-you-go (PAYGO) requirement for one year. These additional cuts will take effect in 2023 after adjournment of the first session of the 117th Congress.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our products are the subject of periodic studies by third party agencies, including the Agency for Healthcare Research and Quality in the United States, intended to review the comparative effectiveness of different treatments of the same illness. Although the results of comparative effectiveness studies are not intended to mandate any reimbursement policies for public or private payers, it is not clear what, if any, effect such research will have on the sales of our products. Decreases in third-party reimbursement for our products or a decision by a third-party payer to not cover our products as a result of a third-party study could have a material adverse effect on our sales, results of operations and financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Failure to comply with anti-kickback and fraud regulations could result in substantial penalties and changes in our business operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to healthcare fraud and abuse regulation and enforcement by federal, state and foreign governments, which could significantly impact our business. We also are subject to foreign fraud and abuse laws, which vary by country.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-33-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the laws that may affect our ability to operate include, but are not limited to:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly, in cash or in kind, in exchange for or to induce either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of this statute or specific intent to violate the Anti-Kickback Statute itself to have committed a violation. The U.S. government has interpreted this law broadly to apply to the marketing and sales activities of manufacturers, distributors and revenue cycle management companies like us. Violations of the federal Anti-Kickback Statute may result in significant civil monetary penalties for each violation, plus up to three times the remuneration involved. Violations of the Federal Anti-Kickback Statute can also result in significant criminal penalties and imprisonment;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the False Claims Act, and civil monetary penalty laws, that prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment or approval to the federal government that are false or fraudulent, knowingly making a false statement material to an obligation to pay or transmit money or property to the federal government or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay or transmit money or property to the federal government. These laws may apply to manufacturers and distributors who provide information on coverage, coding, and reimbursement of their products to persons who do bill third-party payors. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Violations can result in debarment, suspension or exclusion from participation in government healthcare programs, including Medicare and Medicaid. When an entity is determined to have violated the federal civil False Claims Act, the government may impose significant civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, which created federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. A person or entity does not need to have actual knowledge of these statutes or specific intent to violate them to have committed a violation; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Sunshine Act requirements under the ACA, which impose reporting and disclosure requirements on device and drug manufacturers for any &#8220;transfer of value&#8221; made or distributed by certain manufacturers of drugs, devices, biologics, and medical supplies to physicians (including doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals, and ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, applicable manufacturers also will be required to report such information regarding payments and transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse midwives;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm customers; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign law equivalents of each of the above federal laws, such as state anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require device companies to comply with the industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of these laws are uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Additionally, as a result of these types of investigations, healthcare providers and entities may face litigation or have to agree to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-34-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settlements that can include monetary penalties and onerous compliance and reporting requirements as part of a consent decree or corporate integrity agreement. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us now or in the future, we may be subject to penalties, including civil and criminal penalties, damages, fines, disgorgement, exclusion from governmental health care programs, additional compliance and reporting obligations, imprisonment and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, we entered into a settlement agreement with the U.S. Department of Justice and the U.S. Attorneys&#8217; Offices for the District Court of South Carolina, the Southern District of California, the Northern District of Iowa and the Eastern District of New York. The agreement resolved five lawsuits originally brought by whistleblowers under the qui tam provisions of the False Claims Act and allegations that we: (a) provided DME companies with free telephone call center services and other free patient outreach services that enabled these companies to order resupplies for their patients with sleep apnea, (b) provided sleep labs with free and below-cost positive airway pressure masks and diagnostic machines, as well as free installation of these machines, (c) arranged for, and fully guaranteed the payments due on, interest-free loans that DME supplies acquired from third-party financial institutions for the purchase of our equipment, and (d) provided non-sleep specialist physicians free home sleep testing devices referred to as &#8220;ApneaLink.&#8221; We agreed with the government to civilly resolve these matters for a payment of $39.5 million ($37.5 million to the federal government and $2 million to the various states) and we incurred additional fees and administrative costs that typically accompany such a resolution amounting to $1.1 million. The specific allegations and the resolution of those allegations are contained in the Company&#8217;s settlement agreement with the adverse parties. The total final costs relating to these matters was $40.6 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneous with the civil settlement, we also entered into a five-year Corporate Integrity Agreement, or CIA, with the Department of Health and Human Services Office of Inspector General. The CIA required, among other things, that we implement additional controls around our product pricing and sales and that we conduct internal and external monitoring of our arrangements with referrals sources. The settlement agreement with the government and the CIA could result in reputational harm or the curtailment or restructuring of our operations, any of which could materially adversely affect our financial results and our ability to operate our business. In addition, our failure to comply with our obligations under the CIA could result in monetary penalties and our exclusion from participating in federal healthcare programs. The costs associated with compliance with the CIA, or any liability or consequences associated with its breach, could have an adverse effect on our operations, liquidity and financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our use and disclosure of personal information, including health information, is subject to federal, state and foreign privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The privacy and security of personal information whether stored, maintained, received or transmitted electronically or in paper form is a major issue in the U.S. and abroad. While we strive to comply with all applicable privacy and security laws and regulations, as well as our own posted privacy policies, legal standards for privacy, including but not limited to &#8220;unfairness&#8221; and &#8220;deception,&#8221; as enforced by the FTC and state attorneys general, continue to evolve and any failure or perceived failure to comply may result in proceedings or actions against us by government entities or others, or could cause us to lose audience and customers, which could have a material adverse effect on our business. Recently, there has been an increase in public awareness of privacy issues in the wake of revelations about the activities of various government agencies and in the number of private privacy-related lawsuits filed against companies. Concerns about our practices with regard to the collection, use, disclosure, security or deletion of personally identifiable information or other privacy-related matters, even if unfounded and even if we are in compliance with applicable laws, could damage our reputation and harm our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous foreign, federal and state laws and regulations govern collection, dissemination, use and confidentiality of personally identifiable health information, including (i) state privacy and confidentiality laws (including state laws requiring disclosure of breaches); (ii) HIPAA; and (iii) European and other foreign data protection laws, including the EU GDPR and the UK GDPR.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA establishes a set of national privacy and security standards for the protection of individually identifiable health information, or protected health information, by health plans, healthcare clearinghouses and healthcare providers that submit certain covered transactions electronically, or covered entities, and their &#8220;business associates,&#8221; which are persons or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-35-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">entities that perform certain services for, or on behalf of, a covered entity that involve creating, receiving, maintaining or transmitting protected health information, as well as their covered subcontractors. Certain portions of our business, such as the cloud-based software digital health applications, are subject to HIPAA as a business associate of our covered entity clients. To provide our covered entity clients with services that involve access to PHI, HIPAA requires us to enter into business associate agreements that require us to safeguard PHI in accordance with HIPAA. As a business associate, we are also directly liable for compliance with HIPAA. Penalties for violations of HIPAA regulations include civil and criminal penalties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA authorizes state attorneys&#8217; general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs and attorneys&#8217; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for HIPAA violations, its standards have been used as the basis for a duty of care claim in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA further requires business associates like us to notify our covered entity clients &#8220;without unreasonable delay and in no case later than 60 calendar days after discovery of the breach.&#8221; Covered entities must notify affected individuals &#8220;without unreasonable delay and in no case later than 60 calendar days after discovery of the breach&#8221; if their unsecured PHI is subject to an unauthorized access, use or disclosure. If a breach affects 500 patients or more, covered entities must report it to HHS and local media without unreasonable delay, and HHS will post the name of the breaching entity on its public website. If a breach affects fewer than 500 individuals, the covered entity must log it and notify HHS at least annually.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to properly protect the privacy and security of health information entrusted to us, our solutions may be perceived as not secure, we may incur significant liabilities and customers may curtail their use of or stop using our solutions. In addition, if we fail to comply with the terms of our business associate agreements with our clients, we are liable not only contractually but also directly under HIPAA.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the California Consumer Privacy Act of 2018, or CCPA, became effective on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA includes civil penalties for violations, as well as a private right of action for data breaches. Although the law includes limited exceptions, including for &#8220;protected health information&#8221; maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context. The CCPA may increase our compliance costs and potential liability. Further, the California Privacy Rights Act, or CPRA, which becomes effective on January 1, 2023, superseding the CCPA, will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Several additional US states have implemented comprehensive data privacy laws, which will become effective starting in January 1, 2023. If we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection law, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to these comprehensive data protection laws, to date, at least three states have adopted laws specifically regulating the collection, use, storage, and disclosure of biometrics, and additional states may seek to regulate&#8212;and/or restrict the use of&#8212;biometrics in the future. Certain of our products use, or permit the use of, information that could be classified as a biometric under these or other laws. If we are subject to or affected by these or other laws, we may be required to modify the way in which we make available our product or certain features of our product. We also may be required to implement additional practices or processes or otherwise invest our resources to comply with these and other regulations. If we are unable to comply with these laws, or if these laws require us to change our products or services, we may encounter liability that could adversely affect our financial condition. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to laws and regulations in non-U.S. countries covering data privacy and the protection of health-related and other personal information. For example, EU member states, the United Kingdom, and other jurisdictions have adopted data protection laws and regulations, which impose significant compliance obligations. Laws and regulations in these jurisdictions apply broadly to the collection, use, storage, disclosure and security of personal information that identifies or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-36-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be used to identify an individual, such as names, contact information, and sensitive personal data such as health data. These laws and regulations are subject to frequent revisions and differing interpretations and have generally become more stringent over time. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the GDPR went into effect in May 2018. The GDPR imposes stringent data protection requirements for the processing of personal data in the European Economic Area, or EEA. The GDPR imposes several stringent requirements for controllers and processors of personal data, and increased our obligations, for example, by imposing higher standards for obtaining consent from individuals to process their personal data, requiring more robust disclosures to individuals, strengthening individual data rights, shortening timelines for data breach notifications, limiting retention periods and secondary use of information (including for research purposes), increasing requirements pertaining to health data and pseudonymized (i.e., key-coded) data and imposing additional obligations when we contract with third party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EEA, including to the United States, and recent legal developments in Europe have created complexity regarding such transfers of personal data from the EEA to the United States. For example, the European Commission and the United Kingdom have adopted new standard contractual clauses under which entities may transfer personal data from the European Union and the United Kingdom, which we may be required to implement. We must evaluate such data transfers on a case-by-case basis to ensure continued permissibility under current law and consistent with the new standard contractual clauses. European data protection law provides that EEA member states may make their own further laws and regulations limiting the processing of genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase, and harm our business and financial condition. Failure to comply with the requirements of GDPR and the applicable national data protection and marketing laws of the EEA member states may result in fines of up to &#8364;20.0 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties as well as individual claims for compensation. EU Member States and the UK also have established laws pertaining to electronic monitoring, which could require us to take additional compliance measures. Failure to comply with such laws may subject us to penalties. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom also has adopted its version of the General Data Protection Regulation (&#8220;UK GDPR&#8221;). The United Kingdom GDPR mirrors the fines under the GDPR, i.e., fines up to the greater of &#163;17.5 million or 4% of global turnover. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. Any failure or perceived failure by us to comply with privacy or security laws, policies, legal obligations or industry standards or any security incident that results in the unauthorized release or transfer of personally identifiable information may also result in governmental enforcement actions and investigations, fines and penalties, litigation and/or adverse publicity, including by consumer advocacy groups, and could cause our customers to lose trust in us, which could have an adverse effect on our reputation and business. Such failures could have a material adverse effect on our financial condition and operations. If the third parties we work with violate applicable laws, contractual obligations or suffer a security incident, such violations may also put us in breach of our obligations under privacy laws and regulations and/or could in turn have a material adverse effect on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business activities are subject to extensive regulation, and any failure to comply could have a material adverse effect on our business, financial condition, or results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are subject to extensive U.S. federal, state, local and international regulations regarding our business activities. Failure to comply with these regulations could result in, among other things, recalls of our products, substantial fines and criminal charges against us or against our employees. Furthermore, certain of our products could be subject to recall if the Food and Drug Administration, or the FDA, other regulators or we determine, for any reason, that those products are not safe or effective. Any recall or other regulatory action could increase our costs, damage our reputation, affect our ability to supply customers with the quantity of products they require and materially affect our operating results. Certain of our products and services include the use of artificial intelligence (AI), which is intended to enhance the operation of our products and services. The FTC recently has issued a report expressing a concern regarding AI and bias across industry sectors, including in the healthcare space, and has suggested that such bias could lead to unfair and deceptive practices, among other concerns. Any changes to our ability to use AI or concerns about bias could require us to modify our products and services or could have other negative financial impact on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product sales, introductions or modifications may be delayed or canceled as a result of FDA regulations or similar foreign regulations, which could cause our sales and profits to decline. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless a product is exempt, before we can </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-37-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market or sell a new medical device in the United States, we must obtain FDA clearance or approval, which can be a lengthy and time-consuming process. We generally receive clearance from the FDA to market our products in the United States under Section 510(k) of the Federal Food, Drug, and Cosmetic Act or our products are exempt from the Section 510(k) clearance process. The 510(k) clearance process can be expensive, time-consuming and uncertain. In the 510(k) clearance process, the FDA must determine that a proposed device is &#8220;substantially equivalent&#8221; to a device legally on the market, known as a &#8220;predicate&#8221; device, with respect to intended use, technology and safety and effectiveness, in order to clear the proposed device for marketing. The FDA has a high degree of latitude when evaluating submissions and may determine that a proposed device submitted for 510(k) clearance is not substantially equivalent to a predicate device. After a device receives 510(k) premarket notification clearance from the FDA, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in the intended use of the device, technology, materials, packaging, and certain manufacturing processes may require a new 510(k) clearance or premarket approval. We have modified some of our Section 510(k) approved products without submitting new Section 510(k) notices, which we do not believe were required. However, if the FDA disagrees with us and requires us to submit new Section 510(k) notifications for modifications to our existing products, we may be required to stop marketing the products while the FDA reviews the Section 510(k) notification.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any new product introduction or existing product modification could be subjected to a lengthier, more rigorous FDA examination process. For example, in certain cases we may need to conduct clinical trials of a new product before submitting a 510(k) notice. We may also be required to obtain premarket approvals for certain of our products. Indeed, recent trends in the FDA&#8217;s review of premarket notification submissions suggest that the FDA is often requiring manufacturers to provide new, more expansive, or different information regarding a particular device than what the manufacturer anticipated upon 510(k) submission. This has resulted in increasing uncertainty and delay in the premarket notification review process. For example, in November 2018, FDA officials announced steps that the FDA intended to take to modernize the 510(k) premarket notification pathway. Among other things, the FDA announced that it planned to develop proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. In September 2019, the FDA also issued revised final guidance establishing a &#8220;Safety and Performance Based Pathway&#8221; for &#8220;manufacturers of certain well-understood device types&#8221; allowing manufacturers to rely on objective safety and performance criteria recognized by the FDA to demonstrate substantial equivalence, obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA has developed and maintains a list of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">device types appropriate for the &#8220;safety and performance based&#8221; pathway and continues to develop product-specific guidance documents that identify the performance criteria and recommended testing methodologies for each such device type, where feasible. Some of these proposals have not yet been finalized or adopted, although the FDA may work with Congress to implement such proposals through legislation. Accordingly, it is unclear the extent to which any proposals, if adopted, could impose additional regulatory requirements on us that could delay our ability to obtain new 510(k) clearances, increase the costs of compliance, or restrict our ability to maintain our current clearances, or otherwise create competition that may negatively affect our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s ongoing review of the 510(k) program may make it more difficult for us to make modifications to our previously cleared products, either by imposing stricter requirements on when a manufacturer must submit a new 510(k) for a modification to a previously cleared product, or by applying more onerous review criteria to such submissions. FDA continues to review its 510(k) clearance process which could result in additional changes to regulatory requirements or guidance documents which could increase the costs of compliance or restrict our ability to maintain current clearances. The requirements of the more rigorous premarket approval process and/or significant changes to the 510(k) clearance process could delay product introductions and increase the costs associated with FDA compliance. Marketing and sale of our products outside the United States are also subject to regulatory clearances and approvals, and if we fail to obtain these regulatory approvals, our sales could suffer. We cannot assure you that any new products we develop will receive required regulatory approvals from U.S. or foreign regulatory agencies. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to substantial regulation related to quality standards applicable to our manufacturing and quality processes. Our failure to comply with these standards could have an adverse effect on our business, financial condition, or results of operations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the approval, manufacturing, and sales and marketing of many of our products in the United States. Significant government regulation also exists in Canada, Japan, Europe, and other countries in which we conduct business. As a device manufacturer, we are required to register with the FDA and are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-38-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to periodic inspection by the FDA for compliance with the FDA&#8217;s Quality System Regulation requirements, which require manufacturers of medical devices to adhere to certain regulations, including testing, quality control and documentation procedures. In addition, the federal Medical Device Reporting regulations require us to provide information to the FDA whenever there is evidence that reasonably suggests that a device may have caused or contributed to a death or serious injury or, if a malfunction were to occur, could cause or contribute to a death or serious injury. Compliance with applicable regulatory requirements is subject to continual review and is rigorously monitored through periodic inspections by the FDA. In the European Union, we are required to maintain certain ISO certifications in order to sell our products and must undergo periodic inspections by notified bodies to obtain and maintain these certifications. Failure to comply with current governmental regulations and quality assurance guidelines could lead to temporary manufacturing shutdowns, product recalls or related field actions, product shortages or delays in product manufacturing. Efficacy or safety concerns, an increase in trends of adverse events in the marketplace, and/or manufacturing quality issues with respect to our products could lead to product recalls or related field actions, withdrawals, and/or declining sales.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared or approved or commercialized in a timely manner or at all, which could negatively impact our business. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and clear or approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for medical devices or modifications to cleared or approved medical devices to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone most foreign inspections of manufacturing facilities, and subsequently, on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-label marketing of our products could result in substantial penalties. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates the promotional claims that may be made about FDA-cleared products. In particular, clearance under Section 510(k) only permits us to market our products for the uses indicated on the labeling cleared by the FDA. We may request additional label indications for our current products, and the FDA may deny those requests outright, require additional expensive clinical data to support any additional indications or impose limitations on the intended use of any cleared products as a condition of clearance. If the FDA determines that we have marketed our products for off-label use, we could be subject to fines, injunctions or other penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs, and the curtailment of our operations. Any of these events could significantly harm our business and results of operations and cause our stock price to decline.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Laws regulating consumer contacts could adversely affect our business operations or create liabilities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business activities include contacts with consumers in different parts of the world. Certain laws, such as the U.S. Telephone Consumer Protection Act, regulate telemarketing practices and certain automated outbound contacts with consumers, such as phone calls, texts or emails. Our use of outbound contacts may be restricted by existing laws, or by laws, regulations, or regulatory decisions that may be adopted in the future. Similarly, certain data privacy laws, including CCPA, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-39-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsequently CPRA, and the GDPR require disclosure of our privacy practices to consumers. If we are found to have violated these laws or regulations, we may be subjected to substantial fines, penalties, or liabilities to consumers. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax laws, regulations, and enforcement practices are evolving and may have a material adverse effect on our results of operations, cash flows and financial position. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax laws, regulations, and administrative practices in various jurisdictions are evolving and may be subject to significant changes due to economic, political, and other conditions. There are many transactions that occur during the ordinary course of business for which the ultimate tax determination is uncertain, and significant judgment is required in evaluating and estimating our provision and accruals for taxes. Governments are increasingly focused on ways to increase tax revenues, particularly from multinational corporations, which may lead to an increase in audit activity and aggressive positions taken by tax authorities. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes or clarifications to U.S. tax laws could materially affect the tax treatment of our domestic and foreign earnings. The Organisation for Economic Co-operation and Development, an international association of 34 countries, including the United States, released the final reports from its Base Erosion and Profit Shifting, or BEPS, Action Plans, which aim to standardize and modernize global tax policies. The BEPS Action Plans propose revisions to numerous tax rules, including country-by-country reporting, permanent establishment, hybrid entities and instruments, transfer pricing, and tax treaties. The BEPS Action Plans have been or are being enacted by countries where we have operations. Additionally</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the U.S. Treasury department recently proposed the adoption of a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">global minimum</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> rate of at least 15%, which, if enacted, could negatively impact our effective tax rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments in relevant tax laws, regulations, administrative practices and enforcement practices could have a material adverse effect on our operating results, financial position and cash flows, including the need to obtain additional financing.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We are subject to tax audits by various tax authorities in many jurisdictions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax returns are based on calculations and assumptions that require significant judgment and are subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws.  We regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2021, we concluded the settlement agreement with the Australian Taxation Office (&#8220;ATO&#8221;) in relation to the previously disclosed transfer pricing dispute for the tax years 2009 through 2018 (&#8220;ATO settlement&#8221;). The ATO settlement fully resolved the dispute for all prior years, with no admission of liability and provides clarity in relation to certain future taxation principles.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final net impact of the ATO settlement was $238.7 million, which represents a gross amount of $381.7 million, including interest and penalties of $48.1 million, and adjustments for credits and deductions of $143.0 million. As a result of the ATO settlement and due to movements in foreign currencies, we recorded a benefit of $14.1 million within other comprehensive income, and a $4.1 million reduction of tax credits, which was recorded to income tax expense. As a result of the ATO settlement, we reversed our previously recorded uncertain tax position.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, we remitted final payment to the ATO of $284.8 million, consisting of the agreed settlement amount of $381.7 million less prior remittances made to the ATO of $96.9 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax years 2018 to 2021 remain subject to future examination by the major tax jurisdictions in which we are subject to tax. Any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Securities Markets and Ownership of Our Common Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our results of operations may be materially affected by global economic conditions generally, including conditions in the financial markets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global economic conditions could make it difficult for us, our customers and our suppliers to accurately forecast and plan future business activities. Adverse economic conditions, including inflation and higher interest rates, could cause customers to reduce or delay their purchases, which could impact our revenue, our ability to manage inventory levels, collect customer receivables, and potentially decrease our profitability. In addition, prevailing economic conditions could constrain the supply of components used in the manufacturing of our products, which may result in higher costs and impact our ability to meet customer demand. We cannot predict the timing, strength, or duration of any economic </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-40-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">slowdown, or the speed of any subsequent economic recovery. If the economy or markets in which we operate were to deteriorate, our business, financial condition, and results of operations may be adversely affected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our quarterly operating results are subject to fluctuation for a variety of reasons. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results have, from time to time, fluctuated on a quarterly basis and may be subject to similar fluctuations in the future. These fluctuations may result from a number of factors, including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the introduction of new products by us or our competitors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the geographic mix of product sales; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success and costs of our marketing efforts in new regions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in third-party payor reimbursement; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timing of regulatory clearances and approvals; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with acquiring and integrating new businesses, technologies and product offerings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timing of orders by distributors; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures incurred for research and development; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive pricing in different regions; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of foreign currency transaction gains or losses; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other activities, including product recalls, by our competitors. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our quarterly operating results may cause the market price of our common stock to fluctuate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Delaware law and provisions in our charter could make it difficult for another company to acquire us. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation may have the effect of delaying or preventing changes in control or management which might be beneficial to us or our security holders. In particular, our board of directors has the authority to issue up to 2.0 million shares of preferred stock and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without further vote or action by the stockholders. The rights of the holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control, may discourage bids for our common stock at a premium over the market price of our common stock and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_22"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B UNRESOLVED STAFF COMMENTS </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received no written comments regarding our periodic or current reports from the staff of the SEC that were issued 180 days or more before the end of our fiscal year 2022 that remain unresolved.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_25"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2 PROPERTIES </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our operations in both owned and leased properties. Our principal executive offices and U.S. sales facilities consist of approximately 230,000 square feet and are located on Spectrum Center Boulevard in San Diego, California, in a building we own. We have our primary research and development facilities, as well as office and manufacturing facilities at our owned site in Sydney, Australia. Other facilities are in Atlanta, Georgia, Moreno Valley, California, Chatsworth, California, and Bloomington, Minnesota, U.S.A.; Singapore; Munich, Germany; Lyon, France; Suzhou, China; Halifax, Canada; and Johor Bahru, Malaysia. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-41-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART I</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B &#8212; 4</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our facilities are adequate to meet the needs of our current business operations. At June&#160;30, 2022, our principal owned and leased properties were as follows:</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ownership Status<br/>(Owned / Leased)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square<br/>footage</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Primary Usage</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">San Diego, California</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate headquarters, engineering, research and development, sales and administration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sydney, Australia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, engineering, research and development, sales and administration</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Suzhou, China</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Owned</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, warehouse, engineering, research and development</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Atlanta, Georgia</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, warehouse and distribution, SaaS sales and administration, engineering, research and development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">305,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, engineering, research and development, sales and administration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Moreno Valley, California</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warehouse and distribution</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johor, Malaysia</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, engineering, research and development</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chatsworth, California</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Manufacturing, engineering, research and development</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Munich, Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales&#160;and&#160;distribution</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lyon, France</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales and distribution </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bloomington, Minnesota</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SaaS sales and administration, engineering, research and development</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Halifax, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Engineering, research and development</span></td></tr></table></div><div id="i1f60984bb51544a482851b08d4a3bf6b_28"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3 LEGAL PROCEEDINGS </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in various legal proceedings, claims, investigations and litigation that arise in the ordinary course of our business. See Note 16 &#8211; Legal Actions, Contingencies and Commitments of the Notes to Consolidated Financial Statements (Part II, Item 8) included in this report, which is incorporated by reference herein.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation is inherently uncertain. Accordingly, we cannot predict with certainty the outcome of these matters. But we do not expect the outcome of these matters to have a material adverse effect on our consolidated financial statements when taken as a whole.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_31"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4 MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-42-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_34"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_37"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5 MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the NYSE under the symbol &#8220;RMD&#8221;. As of July 31, 2022, there were 26 holders of record of our common stock, although the actual number of stockholders of our common stock is greater than this number of holders of record and many of these holders of record own shares as nominees on behalf of other beneficial owners.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included under Item 12 of Part III of this Report, &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters,&#8221; is hereby incorporated by reference into this Item 5 of Part II of this Report.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2014, our board of directors approved our current share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases after February 21, 2014 have been executed under this program.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal year 2019, we temporarily suspended our share repurchase program due to recent acquisitions, and more recently, as a response to the COVID-19 pandemic. As a result, we did not repurchase any shares during the twelve months ended June&#160;30, 2022. However, there is no expiration date for this program, and we may, at any time, elect to resume the share repurchase program as the circumstances allow. Since the inception of the share buyback programs, we have repurchased 41.8 million shares at a total cost of $1.6 billion. June&#160;30, 2022, 12.9 million additional shares can be repurchased under the approved share repurchase program.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERFORMANCE GRAPH</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This performance graph is furnished and shall not be deemed &#8220;filed&#8221; with the SEC or subject to Section 18 of the Exchange Act, nor shall it be deemed incorporated by reference in any of our filings under the Securities Act of 1933, as amended. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-43-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the cumulative total stockholders return on our common stock from June 30, 2017 through June&#160;30, 2022, with the comparable cumulative return of the S&amp;P 500 index, the S&amp;P 500 Health Care index, and the Dow Jones U.S. Medical Devices index. The graph assumes that $100 was invested in our common stock and each index on June 30, 2017. In addition, the graph assumes the reinvestment of all dividends paid. The stock price performance on the following graph is not necessarily indicative of future stock price performance. </span></div><div style="margin-top:10pt;text-align:center"><img src="rmd-20220630_g1.jpg" alt="rmd-20220630_g1.jpg" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total indexed return of stock price plus reinvestments of dividends, assuming an initial investment of $100 at June 30, 2017, for the indicated periods.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Index</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ResMed Inc.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P 500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P 500 Health Care</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dow Jones U.S. Medical Devices</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184</span></td></tr></table></div><div id="i1f60984bb51544a482851b08d4a3bf6b_40"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6 SELECTED FINANCIAL DATA </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes certain selected consolidated financial data for, and as of the end of, each of the fiscal years in the five-year period ended June&#160;30, 2022. The data set forth below should be read together with Item 7 of Part II of this report, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and Item 8 of Part II of this report, &#8220;Consolidated Financial Statements and Supplementary Data&#8221;, and related notes included elsewhere in this report. The consolidated statement of income data for the years ended June&#160;30, 2022, 2021 and 2020 and the consolidated balance sheet data as of June&#160;30, 2022 and 2021 are derived from our audited consolidated financial statements included elsewhere in this report. The consolidated statement of income data for the years ended June&#160;30, 2019 and 2018 and the consolidated balance sheet data as of June&#160;30, 2020, 2019 and 2018 are derived from our audited consolidated financial </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-44-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements not included in this report. Historical results do not necessarily indicate the results to be expected in the future, and the results for the years presented should not be considered to indicate our future results of operations.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Statement of Income Data </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,196,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,957,013&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,606,572&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,340,196&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization shown separately below)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,514,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,312,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,189,624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,069,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">978,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,553,816&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,357,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,239,227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,112,501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,005,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024,311&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,839,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,717,786&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">739,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">676,689&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">645,010&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">600,369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">180,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,432&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,024,025&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935,422&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908,127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">914,808&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">793,067&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">809,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">579,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">541,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,627)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39,356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33,857)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,977)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25,058)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,005)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,157)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,542)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (loss), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39,803)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,016)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76,571)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60,416)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,519)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">883,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">779,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621,674&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">404,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">315,588&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.83&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.21&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic shares outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted shares outstanding </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144,484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data (In thousands):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,242,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">662,991&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">920,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">589,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">554,468&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,095,853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,728,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,587,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,107,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,063,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, less current maturities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">765,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,164,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,258,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269,988&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,360,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,885,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,497,027&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,072,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,058,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-45-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_43"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7 MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_46"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of financial condition and results of operations (&#8220;MD&amp;A&#8221;) is intended to help the reader understand our results of operations and financial condition. It is provided as a supplement to, and should be read in conjunction with the selected financial data and consolidated financial statements and notes included in this report.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global leader in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including SDB, COPD, neuromuscular disease and other chronic diseases. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Our products and solutions are designed to improve patient quality of life, reduce the impact of chronic disease and lower healthcare costs as global healthcare systems continue to drive a shift in care from hospitals to the home and lower cost settings. Our cloud-based digital health applications, along with our devices, are designed to provide connected care to improve patient outcomes and efficiencies for our customers.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the development of continuous positive airway pressure therapy, we have expanded our business by developing or acquiring a number of products and solutions for a broader range of respiratory disorders including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes and customer and provider business processes. Our growth has been fueled by geographic expansion, our research and product development efforts, acquisitions and an increasing awareness of SDB and other respiratory conditions like chronic obstructive pulmonary disease as significant health concerns. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to ongoing investment in research and development and product enhancements. During fiscal year 2022, we invested $253.6 million on research and development activities, which represents 7.1% of net revenues with a continued focus on the development and commercialization of new, innovative products and solutions that improve patient outcomes, create efficiencies for our customers and help physicians and providers better manage chronic disease and lower healthcare costs. During fiscal year 2022 we continued the launch of AirSense 11, which introduces new features such as a touch screen, algorithms for patients new to therapy and digital enhancements and over-the-air update capabilities. Due to multiple acquisitions, including Brightree in April 2016, HEALTHCAREfirst in July 2018 and MatrixCare in November 2018, and our pending acquisition of MEDIFOX DAN which is expected to close during fiscal year 2023 subject to regulatory clearances, our operations now include out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. These platforms comprise our SaaS business. These products, our cloud-based remote monitoring and therapy management system, and a robust product pipeline, should continue to provide us with a strong platform for future growth. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#8220;Sleep and Respiratory Care&#8221;) and the supply of business management software as a service to out-of-hospital health providers (&#8220;SaaS&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue in fiscal year 2022 increased to $3,578.1 million, an increase of 12% compared to fiscal year 2021. Gross profit increased for the year ended June&#160;30, 2022 to $2,024.3 million, from $1,839.1 million for the year ended June&#160;30, 2021, an increase of $185.2 million or 10%. Our net income for the year ended June&#160;30, 2022 was $779.4 million or $5.30 per diluted share compared to net income of $474.5 million or $3.24 per diluted share for the year ended June&#160;30, 2021. Unrecognized tax benefits as described at Note 13 &#8211; Income Taxes impacted our diluted earnings per share by $1.70 for the year ended June 30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating cash flow for fiscal year 2022 was $351.1 million and at June&#160;30, 2022, our cash and cash equivalents totaled $273.7 million. At June&#160;30, 2022, our total assets were $5.1 billion and our stockholders&#8217; equity was $3.4 billion. We paid a quarterly dividend of $0.42 per share during fiscal 2022 with a total amount of $245.3 million paid to stockholders.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-46-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to provide a framework for assessing how our underlying businesses performed, excluding the effect of foreign currency fluctuations, we provide certain financial information on a &#8220;constant currency basis&#8221;, which is in addition to the actual financial information presented. In order to calculate our constant currency information, we translate the current period financial information using the foreign currency exchange rates that were in effect during the previous comparable period. However, constant currency measures should not be considered in isolation or as an alternative to U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion related to the results of operations and changes in financial condition for the fiscal year ended June&#160;30, 2021 compared to fiscal year June&#160;30, 2020, please refer to Item 7 of Part II, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in our Annual Report for the Year Ended June&#160;30, 2021, which was filed with the United States Securities and Exchange Commission on August 16, 2021.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_49"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Trends and Economic Factors Affecting Our Business </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Supply Chain Disruptions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has continued to impact the global supply chain, primarily through a lack of availability of raw materials and electronic components. The lack of raw materials and electronic components is also impacting companies outside of our direct industry, which is resulting in a competitive supply environment causing higher costs, requiring us to commit to minimum purchase obligations as well as make upfront payments to our suppliers. Additionally, we have observed a reduction in both inbound and outbound transportation capacity as a result of port closures and delays associated with the pandemic, which is causing longer lead times in receiving raw materials into and distributing finished goods out of our manufacturing facilities, in addition to increased freight costs. These highly competitive and constrained supply chain conditions are increasing our cost of sales, which has and may continue to decrease our gross margin. Given the ongoing uncertainty regarding the duration and extent of the COVID-19 pandemic, we are uncertain as to the duration and extent of constraint on our supply chain.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Competitor Recall</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ongoing product recall by one of our competitors, Philips, has resulted in increased demand for our sleep and respiratory care devices. The supply chain disruptions outlined above have constrained and restricted our ability to meet this increased demand and we expect these constraints will continue into the fiscal year ending June 30, 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">COVID-19</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although there is still substantial uncertainty associated with the COVID-19 pandemic, we believe the global demand for ventilators and other respiratory support devices used to treat COVID-19 patients has largely been met. We did not observe material incremental demand for our ventilator devices and masks associated with the pandemic during the twelve months ended June&#160;30, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most markets, diagnostic pathways for sleep apnea treatment, including physician practices, home medical equipment (&#8220;HME&#8221;) distributors, and sleep clinics have largely recovered towards pre-pandemic levels as vaccines and boosters roll out globally. Likewise, we have continued to observe stabilizing patient flow in our out-of-hospital care settings within our SaaS business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue to operate without any significant negative impacts will in part depend on our ability to protect our employees. We have endeavored and continue to follow recommended actions of government and health authorities to protect our employees worldwide as we progressively reopen our offices around the world. The pandemic has not negatively impacted our liquidity position.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Impact on Our Business</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these trends, we were not able to meet all the demand available in the market during the twelve months ended June&#160;30, 2022. We are being allocated components from our suppliers, particularly semiconductor chips, and we are thus being forced to allocate our outbound products to our customers. We have established an allocation process with clear </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-47-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">guiding principles that give priority to the production and delivery of devices to meet the needs of the highest acuity patients first. </span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_52"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Ended June&#160;30, 2022 Compared to Fiscal Year Ended June&#160;30, 2021</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Revenues </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue for the year ended June&#160;30, 2022 increased to $3,578.1 million from $3,196.8 million for the year ended June&#160;30, 2021, an increase of $381.3 million or 12% (a 13% increase on a constant currency basis). The following table summarizes our net revenue disaggregated by segment, product and region for the year ended June&#160;30, 2022 compared to the year ended June&#160;30, 2021 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Constant<br/>Currency*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S., Canada and Latin America</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">863,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">841,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,981,807&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,705,113&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,382,636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,078,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Europe, Asia and other markets </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">746,379&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,195,491&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,118,122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,866,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,610,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,310,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,213,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,177,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823,235&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,196,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Constant currency numbers exclude the impact of movements in international currencies.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sleep and Respiratory Care</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from our Sleep and Respiratory Care business for the year ended June&#160;30, 2022 increased to $3,177.3 million from $2,823.2 million for the year ended June&#160;30, 2021, an increase of $354.1 million or 13%. Movements in international currencies against the U.S. dollar negatively impacted net revenues by approximately $43.0 million for the year ended June&#160;30, 2022. Excluding the impact of currency movements, total net revenue from our Sleep and Respiratory Care business for the year ended June&#160;30, 2022 increased by 14% compared to the year ended June&#160;30, 2021. The increase in net revenue was primarily attributable to an increase in unit sales of our devices and masks, including recovery of core sleep patient flow that was previously impacted by the pandemic and increased demand following a recent product recall by one of our competitors, partially offset by decreased COVID-19 related demand for our ventilators. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from our Sleep and Respiratory Care business in the United States, Canada and Latin America for the year ended June&#160;30, 2022 increased to $1,981.8 million from $1,705.1 million for the year ended June&#160;30, 2021, an increase of $276.7 million or 16%. The increase was primarily due to an increase in unit sales of our devices and masks, including recovery of core sleep patient flow that was previously impacted by the pandemic and increased demand following a recent product recall by one of our competitors, partially offset by decreased COVID-19 related demand for our ventilators.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from our Sleep and Respiratory Care business in combined Europe, Asia and other markets increased for the year ended June&#160;30, 2022 to $1,195.5 million from $1,118.1 million for the year ended June&#160;30, 2021, an increase of $77.4 million or 7% (an increase of 11% on a constant currency basis). The constant currency increase in sales in combined Europe, Asia and other markets predominantly reflects an increase in unit sales of our devices and masks, including </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-48-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recovery of core sleep patient flow that was previously impacted by the pandemic, partially offset by decreased COVID-19-related demand for our ventilators. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from devices for the year ended June&#160;30, 2022 increased to $1,866.9 million from $1,610.0 million for the year ended June&#160;30, 2021, an increase of $256.9 million or 16%, including an increase of 24% in the United States, Canada and Latin America and an increase of 7% in combined Europe, Asia and other markets (a 10% increase on a constant currency basis). Excluding the impact of foreign currency movements, device sales for the year ended June&#160;30, 2022 increased by 17%.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenue from masks and other for the year ended June&#160;30, 2022 increased to $1,310.4 million from $1,213.2 million for the year ended June&#160;30, 2021, an increase of 8%, including an increase of 8% in the United States, Canada and Latin America and an increase of 7% in combined Europe, Asia and other markets (a 12% increase on a constant currency basis). Excluding the impact of foreign currency movements, masks and other sales increased by 9%, compared to the year ended June&#160;30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Software as a Service</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net revenue from our SaaS business for the year ended June&#160;30, 2022 was $400.8 million, compared to $373.6 million for the year ended June&#160;30, 2021, an increase of $27.2 million or 7%. The increase was predominantly due to continued growth in our HME and Home Health and Hospice verticals, in addition to stabilizing patient flow in our Facilities vertical.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_748"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gross Profit and Gross Margin. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit increased for the year ended June&#160;30, 2022 to $2,024.3 million from $1,839.1 million for the year ended June&#160;30, 2021, an increase of $185.2 million or 10%. Gross margin, which is gross profit as a percentage of net revenue, was 56.6% for the year ended June&#160;30, 2022, compared with the 57.5% for the year ended June&#160;30, 2021. The decrease in gross margin was due primarily to higher logistics and manufacturing costs, partially offset by favorable changes in product mix </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as we sold an increased proportion of higher acuity devices, in addition to higher</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> average selling prices.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_758"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Constant Currency</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">739,372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">670,387&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,985&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">as a % of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">225,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">as a % of net revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nil</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Selling, General and Administrative Expenses </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased for the year ended June&#160;30, 2022 to $739.4 million from $670.4 million for the year ended June&#160;30, 2021, an increase of $69.0 million or 10%. Selling, general and administrative expenses, as reported in U.S. dollars, were favorably impacted by the movement of international currencies against the U.S. dollar, which decreased our expenses by approximately $13.3 million. Excluding the impact of foreign currency movements, selling, general and administrative expenses for the year ended June&#160;30, 2022 increased by 12% compared to the year ended June&#160;30, 2021. As a percentage of net revenue, selling, general and administrative expenses for the year ended June&#160;30, 2022 improved to 20.7% compared to 21.0% for the year ended June&#160;30, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constant currency increase in selling, general and administrative expenses was primarily due to increases in employee-related costs for the year ended June&#160;30, 2022 compared to the year ended June&#160;30, 2021.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development Expenses </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased for the year ended June&#160;30, 2022 to $253.6 million from $225.3 million for the year ended June&#160;30, 2021, an increase of $28.3 million or 13%. Research and development expenses were favorably </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-49-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impacted by the movement of international currencies against the U.S. dollar, which decreased our expenses by approximately $3.0 million, as reported in U.S. dollars. Excluding the impact of foreign currency movements, research and development expenses for the year ended June&#160;30, 2022 increased by 14% compared to the year ended June&#160;30, 2021. As a percentage of net revenue, research and development expenses were 7.1% for the year ended June&#160;30, 2022 compared to 7.0% for the year ended June&#160;30, 2021. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constant currency increase in research and development expenses was primarily due to increased investment in our digital health technologies and SaaS solutions.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amortization of Acquired Intangible Assets </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquired intangible assets was consistent at $31.1 million for the years ended the year ended June&#160;30, 2022 and June&#160;30, 2021. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Restructuring Expenses </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we closed our Portable Oxygen Concentrator business, which was part of the Sleep and Respiratory Care segment. During the year ended June 30, 2021, we recognized restructuring expenses of $13.9 million primarily related to inventory write-downs of $5.2 million, accelerated amortization of acquired intangible assets of $5.1 million, asset impairments of $2.3 million, employee-related costs of $0.7 million and contract cancellation costs of $0.6 million. Of the total expense recognized during the year ended June 30, 2021, the inventory write-down of $5.2 million is presented within cost of sales and the remaining $8.7 million in restructuring costs is separately disclosed as restructuring expenses on the consolidated statements of income. We do not expect to incur additional expenses in connection with this activity in the future.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_771"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Other Income (Loss), Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our other income (loss) (in thousands):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest (expense) income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,312)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,627)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,315&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26,717)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (loss), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39,803)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,016)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,787)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income (loss), net for the year ended June&#160;30, 2022 was a loss of $39.8 million, compared to a loss of $20.0 million for the year ended June&#160;30, 2021. The increase in loss was primarily due to losses associated with our investments in marketable and non-marketable equity securities, which were a loss of $12.2 million for the year ended June&#160;30, 2022 compared to a gain of $14.5 million for the year ended June&#160;30, 2021. This was partially offset by lower losses attributable to equity method investments for the year ended June&#160;30, 2022 of $8.5 million compared to $11.2 million for the year ended June&#160;30, 2021. Additionally, interest expense, net, decreased to $22.3 million for the year ended June&#160;30, 2022 compared to $23.6 million for the year ended June&#160;30, 2021. </span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_781"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective income tax rate decreased to 18.8% for the year ended June&#160;30, 2022 from 46.3% for the year ended June&#160;30, 2021. Our effective rate of 18.8% for the year ended June&#160;30, 2022 differs from the statutory rate of 21.0% primarily due to research credits, foreign operations and windfall tax benefits related to the vesting or settlement of employee share-based awards. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our effective tax rate for the year ended June&#160;30, 2022 was primarily related to the decrease in unrecognized tax benefits recorded in connection with the Australian Tax Office ("ATO") transfer pricing dispute, outlined below. Excluding the impact of the unrecognized tax benefit, our effective income tax rate for the year ended June&#160;30, 2021 was 18.2%. The increase in our effective tax rate, excluding the impact of the unrecognized tax benefit for the year ended June&#160;30, 2021, was due to a change in the geographic mix of earnings for the year ended June&#160;30, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-50-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2021, we concluded the settlement agreement with the ATO in relation to the previously disclosed transfer pricing dispute for the tax years 2009 through 2018 (&#8220;ATO settlement&#8221;). The ATO settlement fully resolved the dispute for all prior years, with no admission of liability and provides clarity in relation to certain future taxation principles.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final net impact of the ATO settlement was $238.7&#160;million, which represents a gross amount of $381.7&#160;million, including interest and penalties of $48.1&#160;million, and adjustments for credits and deductions of $143.0&#160;million. As a result of the ATO settlement and due to movements in foreign currencies, we recorded a benefit of $14.1&#160;million within other comprehensive income, and a $4.1&#160;million reduction of tax credits, which was recorded to income tax expense. As a result of the ATO settlement, we reversed our previously recorded uncertain tax position.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, we remitted final payment to the ATO of $284.8&#160;million, consisting of the agreed settlement amount of $381.7&#160;million less prior remittances made to the ATO of $96.9&#160;million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Singapore operations operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2030. As a result of the U.S. Tax Act, we treated all non-U.S. historical earnings as taxable during the year ended June 30, 2018. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax, if repatriated.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_793"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Income and Earnings per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the factors above, our net income for the year ended June&#160;30, 2022 was $779.4 million compared to net income of $474.5 million for the year ended June&#160;30, 2021. Our earnings per diluted share for the year ended June&#160;30, 2022 was $5.30 compared to $3.24 for the year ended June&#160;30, 2021, an increase of 64%. Unrecognized tax benefits as described at Note 13 &#8211; Income Taxes reduced our diluted earnings per share for the year ended June 30, 2021 by $1.70 per share.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_55"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Non-GAAP Financial Measures</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to financial information prepared in accordance with GAAP, our management uses certain non-GAAP financial measures, such as non-GAAP revenue, non-GAAP cost of sales, non-GAAP gross profit, non-GAAP gross margin, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted earnings per share, in evaluating the performance of our business. We believe that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, can provide investors better insight when evaluating our performance from core operations and can provide more consistent financial reporting across periods. For these reasons, we use non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. These non-GAAP financial measures should be considered in addition to, and not superior to or as a substitute for, GAAP financial measures. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure. Non-GAAP financial measures as presented herein may not be comparable to similarly titled measures used by other companies. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measure &#8220;non-GAAP cost of sales&#8221; is equal to GAAP cost of sales less amortization of acquired intangible assets relating to cost of sales and restructuring expense associated with inventory write-downs following the closure of the portable oxygen concentrator business. The measure &#8220;non-GAAP gross profit&#8221; is the difference between GAAP net revenue and non-GAAP cost of sales, and &#8220;non-GAAP gross margin&#8221; is the ratio of non-GAAP gross profit to GAAP net revenue. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-51-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in thousands, except percentages):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP Net revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,196,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP Cost of sales</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,553,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,357,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Less:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Amortization of acquired intangibles</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39,650)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45,127)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Less:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Restructuring - cost of sales</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP cost of sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,514,166&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,307,366&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP gross profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024,311&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,839,100&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP gross profit</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,063,961&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,889,459&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP gross margin</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measure &#8220;non-GAAP income from operations&#8221; is equal to GAAP income from operations once adjusted for amortization of acquired intangibles, acquisition-related expenses and restructuring expense associated with the closure of the portable oxygen concentrator business. Non-GAAP income from operations is reconciled with GAAP income from operations below (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP income from operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">903,678&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangibles - cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangibles - operating expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring - cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring - operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP income from operations </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,072,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">993,788&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measure &#8220;non-GAAP net income&#8221; is equal to GAAP net income once adjusted for amortization of acquired intangibles (net of tax), acquisition-related expenses, reserve for disputed tax positions, restructuring expenses (net of tax) and (gain) loss on equity investments. The measure &#8220;non-GAAP diluted earnings per share&#8221; is the ratio of non-GAAP net income to diluted shares outstanding. These non-GAAP measures are reconciled to their most directly comparable GAAP financial measures below (in thousands, except for per share amounts):</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-52-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">779,437&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangibles - cost of sales, net of tax </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangibles - operating expenses, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,589&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserve for disputed tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring - cost of sales, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring - operating expenses, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,549)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850,771&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">780,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,043&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,451&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP diluted earnings per share</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP diluted earnings per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i1f60984bb51544a482851b08d4a3bf6b_58"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal sources of liquidity are our existing cash and cash equivalents, cash generated from operations and access to our revolving credit facility. Our primary uses of cash have been for research and development activities, selling and marketing activities, capital expenditures, strategic acquisitions and investments, dividend payments and repayment of debt obligations. We expect that cash provided by operating activities may fluctuate in future periods as a result of several factors, including fluctuations in our operating results, which include impacts from the COVID-19 pandemic, supply chain disruptions, working capital requirements and capital deployment decisions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors including our growth rate in net revenue, third-party reimbursement of our products for our customers, the timing and extent of spending to support research development efforts, the expansion of selling, general and administrative activities, the timing of introductions of new products, the expenditures associated with possible future acquisitions, investments or other business combination transactions, including our pending acquisition of MEDIFOX DAN, and impacts from the COVID-19 pandemic. As we assess inorganic growth strategies, we may need to supplement our internally generated cash flow with outside sources. If we are required to access the debt market, we believe that we will be able to secure reasonable borrowing rates. As part of our liquidity strategy, we will continue to monitor our current level of earnings and cash flow generation as well as our ability to access the market considering those earning levels. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and June&#160;30, 2021, we had cash and cash equivalents of $273.7 million and $295.3 million, respectively. Our cash and cash equivalents held within the United States at June&#160;30, 2022 and June&#160;30, 2021 were $70.0 million and $106.7 million, respectively. Our remaining cash and cash equivalent balances at June&#160;30, 2022 and June&#160;30, 2021, were $203.7 million and $188.6 million, respectively. Our cash and cash equivalent balances are held at highly rated financial institutions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had $1.4 billion available for draw down under the revolving credit facility and a combined total of $1.7 billion in cash and available liquidity under the revolving credit facility. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We repatriated $100.0 million and $560.1 million to the United States during the years ended June&#160;30, 2022 and 2021, respectively, from earnings generated in each of those years. The amount of the current year foreign earnings that we have repatriated to the United States in the past has been determined, and the amount that we expect to repatriate during fiscal year 2023 will be determined, based on a variety of factors, including current year earnings of our foreign subsidiaries, foreign investment needs and the cash flow needs we have in the United States, such as for the repayment of debt, dividend distributions, and other domestic obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the U.S. Tax Act, we treated all non-U.S. historical earnings as taxable, which resulted in additional tax expense of $126.9 million which was payable over the proceeding eight years; the additional tax expense associated with the U.S. Tax Act was reduced to $94.2 million during the current year as a result of the ATO Settlement discussed in Note 13 &#8211; Income Taxes of the Notes to the Consolidated Financial Statements (Part II, Item 8). Therefore, future repatriation of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-53-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax if repatriated, except as discussed in Note 13 &#8211; Income Taxes of the Notes to the Consolidated Financial Statements (Part II, Item 8).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our current sources of liquidity will be sufficient to fund our operations, including expected capital expenditures, for the next 12 months and beyond.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revolving Credit Agreement, Term Credit Agreement and Senior Notes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;29, 2022, we entered into a second amended and restated credit agreement (as amended from time to time, the &#8220;Revolving Credit Agreement&#8221;). The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $1,500.0 million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $1,000.0 million and 1.00 times the EBITDA for the trailing twelve-month measurement period. Additionally, on June&#160;29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement (the &#8220;Term Credit Agreement&#8221;). The Term Credit Agreement, among other things, provides ResMed Limited a senior unsecured term credit facility of $200.0 million. The Revolving Credit Agreement and Term Credit Agreement each terminate on Jun&#160;29, 2027, when all unpaid principal and interest under the loans must be repaid. As of June&#160;30, 2022, we had $1.4 billion available for draw down under the revolving credit facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July&#160;10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July&#160;10, 2029 (&#8220;Senior Notes&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;30, 2022, there was a total of $780.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes. We expect to satisfy all of our liquidity and long-term debt requirements through a combination of cash on hand, cash generated from operations and debt facilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Flow Summary</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">736,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(229,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(158,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(128,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(764,632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21,568)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(167,878)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities was $351.1 million for the twelve months ended June 30, 2022, compared to cash provided of $736.7 million for the twelve months ended June 30, 2021. The $385.6 million decrease in cash flow from operations was primarily due to the payment of our tax settlement with the ATO of $284.8 million and greater purchases and prepayments of inventory to secure adequate components for the increasing sales demand, partly offset by an increase in operating profit and other net changes in working capital balances compared to the twelve months ended June 30, 2021. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities was $229.9 million for the twelve months ended June 30, 2022, compared to cash used of $158.5 million for the twelve months ended June 30, 2021. The $71.5 million increase in cash flow used in investing activities was primarily due to an increase in purchases of property, plant and equipment and an increase in payments on maturity of foreign currency contracts compared to the twelve months ended June 30, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-54-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities was $128.4 million for the twelve months ended June 30, 2022, compared to cash used of $764.6 million for the twelve months ended June 30, 2021. The $636.3 million decrease in cash flow used in financing activities was primarily due to borrowing activity under our Revolving Credit Agreement. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the twelve months ended June 30, 2022, we paid cash dividends of $1.68 per common share totaling $245.3 million. On August&#160;11, 2022, our board of directors declared a cash dividend of $0.44 per common share, to be paid on September&#160;22, 2022, to shareholders of record as of the close of business on August&#160;18, 2022. Future dividends are subject to approval by our board of directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations and Commitments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of contractual obligations at June&#160;30, 2022 are as follows (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">781,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest on debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,707,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,251,476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MEDIFOX DAN acquisition consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994,245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,754,388&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,311,530&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497,898&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,027&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520,504&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">308,506&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of other commercial commitments at June&#160;30, 2022 are as follows (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount of Commitment Expiration Per Period</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Standby letter of credit</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,672&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,673&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Guarantees*</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,516&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,679&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,712&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">These guarantees mainly relate to requirements under contractual obligations with insurance companies transacting with our German subsidiaries and guarantees provided under our facility leasing obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 16 - Legal Actions, Contingencies and Commitments of the Notes to the Consolidated Financial Statements (Part II, Item 8) for details of our contingent obligations under recourse provisions.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_61"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that we have two operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment. See Note 14 &#8211; Segment Information of the Notes to the Consolidated Financial Statements (Part II, Item 8) for financial information regarding segment reporting. Financial information about our revenues from and assets located in foreign countries is also included in the notes to the consolidated financial statements included in this report.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_70"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Principles and Estimates </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, goodwill, potentially impaired assets, intangible assets, income taxes and contingencies.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-55-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state these accounting policies in the notes to the financial statements and at relevant sections in this discussion and analysis. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our consolidated financial statements: </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Valuation of Goodwill, Intangible and Other Long-Lived Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make assumptions in establishing the carrying value, fair value and estimated lives of our goodwill, intangibles and other long-lived assets. Our goodwill impairment tests are performed at our reporting unit level, which is one level below our operating segments. The criteria used for these evaluations include management&#8217;s estimate of the asset&#8217;s continuing ability to generate positive income from operations and positive cash flow in future periods compared to the carrying value of the asset, as well as the strategic significance of any identifiable intangible asset in our business objectives. If assets are considered to be impaired, we recognize as an impairment the amount by which the carrying value of the assets exceeds their fair value, and for goodwill is limited to the value of goodwill allocated to the impaired reporting unit, as described in Step 1 below. Factors that would influence the likelihood of a material change in our reported results include significant changes in the asset&#8217;s ability to generate positive cash flow, loss of legal ownership or title to the asset, a significant decline in the economic and competitive environment on which the asset depends, significant changes in our strategic business objectives, utilization of the asset, and a significant change in the economic and/or political conditions in certain countries. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct an annual review for goodwill impairment at our reporting unit level based on the following steps: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 0 or Qualitative assessment &#8211; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 1 &#8211; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#8217;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the annual reviews for the years ended June&#160;30, 2022, 2021 and 2020, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Income Tax. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess our income tax positions and record tax benefits for all years subject to audit based upon management&#8217;s evaluation of the facts, circumstances and information available at the reporting date. If we determine that it is not more likely than not that we would be able to realize all or part of our net deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to income tax expense in the period such determination is made. Alternatively, if we determine that it is more likely than not that the net deferred tax assets would be realized, any previously provided valuation allowance is reversed. These changes to the valuation allowance and resulting increases or decreases in income tax expense may have a material effect on our operating results.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. While we believe we have appropriate support for the positions taken on our tax returns, we regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Based on our regular </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-56-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment, we may adjust the income tax provision and deferred taxes in the period in which the facts that give rise to a revision become known.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2021, we concluded the settlement agreement with the Australian Taxation Office (&#8220;ATO&#8221;) in relation to the previously disclosed transfer pricing dispute for the tax years 2009 through 2018 (&#8220;ATO settlement&#8221;). The ATO settlement fully resolved the dispute for all prior years, with no admission of liability and provides clarity in relation to certain future taxation principles.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final net impact of the ATO settlement was $238.7&#160;million, which represents a gross amount of $381.7&#160;million, including interest and penalties of $48.1&#160;million, and adjustments for credits and deductions of $143.0&#160;million. As a result of the ATO settlement and due to movements in foreign currencies, we recorded a benefit of $14.1&#160;million within other comprehensive income, and a $4.1&#160;million reduction of tax credits, which was recorded to income tax expense. As a result of the ATO settlement, we reversed our previously recorded uncertain tax position.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, we remitted final payment to the ATO of $284.8&#160;million, consisting of the agreed settlement amount of $381.7&#160;million less prior remittances made to the ATO of $96.9&#160;million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax years 2018 to 2021 remain subject to future examination by the major tax jurisdictions in which we are subject to tax.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Revenue Recognition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#8220;Sleep and Respiratory Care&#8221;) and the supply of business management software as a service to out-of-hospital health providers (&#8220;SaaS&#8221;). For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with professional services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one to five years. Our contracts do not contain significant financing components.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns offered to our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty-related returns, are infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#8217;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates on a quarterly basis based on actual sales results and updated forecasts for the remaining rebate periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-57-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_73"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 3 &#8211; New Accounting Pronouncements of the Notes to Consolidated Financial Statements (Part II, Item 8) for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial positions and cash flows. </span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_76"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we are not involved in any significant off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-58-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_79"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Quantitative and Qualitative Disclosures About Market and Business Risks</span></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET AND BUSINESS RISKS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Market Risk </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reporting currency is the U.S. dollar, although the financial statements of our non-U.S. subsidiaries are maintained in their respective local currencies. We transact business in various foreign currencies, including a number of major European currencies as well as the Australian dollar. We have significant foreign currency exposure through both our Australian and Singapore manufacturing activities and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures predominantly denominated in euros, Australian dollars and Singapore dollars. Under this program, increases or decreases in our foreign-currency-denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not enter into financial instruments for trading or speculative purposes. The foreign currency derivatives portfolio is recorded in the consolidated balance sheets at fair value and included in Other assets current, Other assets non-current, Accrued expenses and Other liabilities non-current. All movements in the fair value of the foreign currency derivatives are recorded within Other income, net, on our consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information (in U.S. dollars) on our significant foreign-currency-denominated financial assets by legal entity functional currency as of June&#160;30, 2022 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S.<br/>Dollar<br/>(USD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Euro<br/>(EUR)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Canadian<br/>Dollar<br/>(CAD)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chinese<br/>Yuan<br/>(CNY)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUD Functional:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Assets/(Liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,884)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency Hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(60,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,745&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,487)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,972&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USD Functional:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Assets/(Liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency Hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,423)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,804)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SGD Functional:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Assets/(Liabilities)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency Hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(385,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,802)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,852&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information about our foreign currency derivative financial instruments and presents the information in U.S. dollar equivalents. The table summarizes information on instruments and transactions that are sensitive to foreign currency exchange rates, including foreign currency call options, collars and forward contracts held at June&#160;30, 2022. The table presents the notional amounts and weighted average exchange rates by contractual maturity dates for our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-59-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES<br/>Quantitative and Qualitative Disclosures About Market and Business Risks</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign currency derivative financial instruments. These notional amounts generally are used to calculate payments to be exchanged under the options contracts (in thousands, except exchange rates): </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Fair Value Assets / (Liabilities)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Foreign Exchange Contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Year 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Year 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, <br/>2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, <br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">USD/AUD</span></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Contract amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">60,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">60,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(190)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(652)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Ave. contractual exchange rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USD 1 = <br/>AUD 0.6928</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USD 1 = <br/>AUD 0.6928</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">AUD/EUR</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Contract amount</span></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">88,959</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">15,699</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">104,658</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(413)</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">1,172&#160;</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Ave. contractual exchange rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUD 1 = <br/>EUR 0.6867</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUD 1 = <br/>EUR 0.6800</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUD 1 = <br/>EUR 0.6857</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">SGD/EUR</span></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Contract amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">20,931</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">20,931</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(88)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Ave. contractual exchange rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SGD 1 =<br/>Euro 0.7117</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SGD 1 =<br/>Euro 0.7117</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">SGD/USD</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Contract amount</span></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">385,000</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">&#8212;</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">385,000</span></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(1,172)</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="2" style="background-color:#CCEEFF;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(177)</span></td><td style="background-color:#CCEEFF;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Ave. contractual exchange rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SGD 1 =<br/>USD 0.7216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SGD 1 =<br/>USD 0.7216</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">AUD/CNY</span></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;padding:0 1pt"></td><td colspan="3" style="background-color:#CCEEFF;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Contract amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,941</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,941</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(130)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Ave. contractual exchange rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUD 1 =<br/>CNY 4.6449</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AUD 1 =<br/>CNY 4.6449</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">EUR/USD</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Contract amount</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Ave. contractual exchange rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USD 1 =<br/>EUR </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USD 1 =<br/>EUR </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">USD/CAD</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Contract amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,423</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,423</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#CCEEFF;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Ave. contractual exchange rate</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USD 1 =<br/>CAD 1.2902</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">USD 1 =<br/>CAD 1.2902</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risk associated with changes in interest rates affecting the return on our cash and cash equivalents and debt. At June&#160;30, 2022, we held cash and cash equivalents of $273.7 million principally comprising of bank term deposits and at-call accounts and are invested at both short-term fixed interest rates and variable interest rates. At June&#160;30, 2022, there was $280.0 million outstanding under the revolving credit and term loan facilities, which were subject to variable interest rates. A hypothetical 10% change in interest rates during the year ended June&#160;30, 2022, would not have had a material impact on pretax income. We have no interest rate hedging agreements. On July&#160;10, 2019, we entered into the Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July&#160;10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July&#160;10, 2029. The interest rate on these notes is fixed and not subject to fluctuation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflationary factors such as increases in the cost of our products, freight, overhead costs or wage rates may adversely affect our operating results. Sustained inflationary pressures in the future may have an adverse effect on our ability to maintain current levels of gross margin and operating expenses as a percentage of net revenue if we are unable to offset such higher costs through price increases.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-60-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_82"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8 CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference to the financial statements set forth in Item 15 of Part IV of this report, &#8220;Exhibits and Consolidated Financial Statement Schedules.&#8221;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Index to Consolidated Financial Statements </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_85">Report of Independent Registered Public Accounting Firm </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">(<ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84Mi9mcmFnOjAyNzliZjgxMzY5ZTRhYTQ5ZTllMDFkZDkwMTU4MDk4L3RhYmxlOjFjOTYwNmFhZGFkYjRlYThiMTAyYTMyNDBmZDdjYTgwL3RhYmxlcmFuZ2U6MWM5NjA2YWFkYWRiNGVhOGIxMDJhMzI0MGZkN2NhODBfMC0wLTEtMS00ODg1OS90ZXh0cmVnaW9uOjY2ZDlmMjczZDE2MTRjMTBiMmMzNjQ3MGRkY2NkMDVhXzMyOTg1MzQ4ODM3MTM_b2bde88a-bab1-4e12-9b86-363a5131743f">KPMG LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84Mi9mcmFnOjAyNzliZjgxMzY5ZTRhYTQ5ZTllMDFkZDkwMTU4MDk4L3RhYmxlOjFjOTYwNmFhZGFkYjRlYThiMTAyYTMyNDBmZDdjYTgwL3RhYmxlcmFuZ2U6MWM5NjA2YWFkYWRiNGVhOGIxMDJhMzI0MGZkN2NhODBfMC0wLTEtMS00ODg1OS90ZXh0cmVnaW9uOjY2ZDlmMjczZDE2MTRjMTBiMmMzNjQ3MGRkY2NkMDVhXzMyOTg1MzQ4ODM3Mjk_58e7adfd-0c8c-4dae-a29e-1f66375ed216">San Diego, CA</ix:nonNumeric>, Auditor Firm ID: <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84Mi9mcmFnOjAyNzliZjgxMzY5ZTRhYTQ5ZTllMDFkZDkwMTU4MDk4L3RhYmxlOjFjOTYwNmFhZGFkYjRlYThiMTAyYTMyNDBmZDdjYTgwL3RhYmxlcmFuZ2U6MWM5NjA2YWFkYWRiNGVhOGIxMDJhMzI0MGZkN2NhODBfMC0wLTEtMS00ODg1OS90ZXh0cmVnaW9uOjY2ZDlmMjczZDE2MTRjMTBiMmMzNjQ3MGRkY2NkMDVhXzMyOTg1MzQ4ODM3MzU_cd7606ec-3161-484b-9458-84fcce531ed4">185</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_85">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_88">Consolidated Balance Sheets as of June 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_88">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_88"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_88">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_88">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_91">Consolidated Statements of Income for the years ended June 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_91">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_91">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_91">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_91"> and 2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_91">02</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_91">0</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_91">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_94">Consolidated Statements of Comprehensive Income for the years ended June 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_94">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_94">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_94">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_94"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_94">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_94">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_97">Consolidated Statements of Stockholders&#8217; Equity for the years ended June 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_97">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_97">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_97">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_97"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_97">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_97">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_100">Consolidated Statements of Cash Flows for the years ended June 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_100">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_100">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_100">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_100"> and 20</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_100">20</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_100">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_103">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_103">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_166">Schedule II &#8211; Valuation and Qualifying Accounts and Reserves</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i1f60984bb51544a482851b08d4a3bf6b_166">91</a></span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Supplementary Data </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarterly Financial Information (unaudited)&#8212;The quarterly results for the years ended June&#160;30, 2022 and 2021 are summarized below (in thousands, except per share amounts): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal<br/>Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">904,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">894,874&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">864,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">914,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">506,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">491,197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,012&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">779,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Second<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Third<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fourth<br/>Quarter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal<br/>Year</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">800,011&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">768,767&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">876,103&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,196,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">447,258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,839,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78,481)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings (loss) per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings (loss) per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: the amounts for each quarter are computed independently and, due to the computation formula, the sum of the four quarters may not equal the year. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-61-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_85"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ResMed Inc.:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on the Consolidated Financial Statements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of ResMed Inc. and subsidiaries (the Company) as of June 30, 2022 and 2021, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended June 30, 2022, and the related notes and financial statement schedule II (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2022 and 2021, and the results of its operations and its cash flows for each of the years in the three-year period ended June 30, 2022, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of June 30, 2022, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated August 11, 2022 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of goodwill triggering events</span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Notes 2(i) and 5 to the consolidated financial statements, the Company&#8217;s goodwill balance was $1,936 million as of June 30, 2022. The Company performs goodwill impairment testing on an annual basis and whenever events or changes in circumstances indicate that the carrying value of a reporting unit, including goodwill, might exceed the fair value of the reporting unit. In the current year, the Company performed qualitative, or Step 0, assessments to determine whether there was a greater than 50 percent likelihood that the fair value of each reporting unit was less than its carrying value. After completing Step 0, the Company determined that goodwill was not more likely than not impaired and, therefore, no Step 1, or quantitative assessment, was necessary.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-62-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></td></tr></table></div></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the evaluation of goodwill triggering events as a critical audit matter. The evaluation of potential triggering events, including macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, market capitalization and events specific to the entity and reporting units, required a higher degree of auditor judgment. These potential triggering events could have a significant effect on the Company&#8217;s Step 0 assessment and the determination of whether further quantitative analysis of goodwill impairment was required. </span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the evaluation of goodwill impairment. This included a control related to the Company&#8217;s assessment of potential goodwill triggering events. We evaluated the Company&#8217;s Step 0 assessment for its reporting units by:</span></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">considering macroeconomic conditions including gross domestic product, labor market, and inflation by key regions around the world for negative indicators</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">evaluating information from analyst reports in the enterprise software and sleep and respiratory care industries, which were compared to industry and market considerations used by the Company</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analyzing information including changes in the costs of raw materials and labor, the financial performance of the reporting units, the Company&#8217;s market capitalization, and other entity and reporting-unit specific events.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1994.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 11, 2022</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-63-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_88"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_1">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022 and 2021</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In US$ and in thousands, except share and per share data)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMy0xLTEtMS0yODc2OQ_4d4fff31-b5f9-49b6-b309-a04415165147">273,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMy0zLTEtMS0yODc2OQ_2b1f3152-56e6-4c76-ac49-1622a9c1bdc1">295,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net of allowances of $<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNC0wLTEtMS0yODc2OS90ZXh0cmVnaW9uOmRkMTBiNGFiMTU2NjQ0ZWM4ZDQxOTg1MWNkNTU3Y2MwXzQzOTgwNDY1MTExOTI_d1ad8520-3759-4f9f-8eee-5401e81b6823">23,259</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNC0wLTEtMS0yODc2OS90ZXh0cmVnaW9uOmRkMTBiNGFiMTU2NjQ0ZWM4ZDQxOTg1MWNkNTU3Y2MwXzQzOTgwNDY1MTExOTY_d48d17fa-5b95-40ee-8b56-b8ffa4405424">32,138</ix:nonFraction> at June&#160;30, 2022 and June&#160;30, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNC0xLTEtMS0yODc2OQ_090fc419-9c08-4cc6-bcd4-1d199f0240d5">575,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNC0zLTEtMS0yODc2OQ_2412db8b-696c-49d5-a531-4a8dde6fdf92">614,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories (note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNS0xLTEtMS0yODc2OQ_6fb1a7b1-5bd5-4a15-a8b7-a9a1bd20f717">743,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNS0zLTEtMS0yODc2OQ_872abad2-465d-4cd7-85d2-452525646ff5">457,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets (note 4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNy0xLTEtMS0yODc2OQ_44c5db3c-dc77-4993-80c6-b6e7c1836839">337,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNy0zLTEtMS0yODc2OQ_c1185f6c-0b22-4f3d-823f-e78bf39f2e39">208,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfOC0xLTEtMS0yODc2OQ_2b4a5cdb-77c6-47b3-a9fc-8408aa31e1aa">1,931,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfOC0zLTEtMS0yODc2OQ_e912178d-eb1e-40a1-b65d-3b6e0f7ba0da">1,574,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net (note 4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTAtMS0xLTEtMjg3Njk_290d47f7-ed19-4f1d-af92-2d47099e337a">498,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTAtMy0xLTEtMjg3Njk_a8c95fcc-f1dc-4521-af4a-1db2d0f36370">463,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTEtMS0xLTEtMjg3Njk_d58df8db-74a3-4d34-a27b-049e78422c81">132,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTEtMy0xLTEtMjg3Njk_add4b120-bab9-4bef-bcce-b688044d7030">128,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill (note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTItMS0xLTEtMjg3Njk_d19a549f-1b55-41ef-83fa-35dadb4a4275">1,936,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTItMy0xLTEtMjg3Njk_6cc56a87-cba8-4508-a807-52809ec381a7">1,927,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangible assets, net (note 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTMtMS0xLTEtMjg3Njk_c933d4b1-2923-457a-af9c-34b58b38a387">345,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTMtMy0xLTEtMjg3Njk_3dfeaa92-86f9-4842-8108-9424fa687fd0">392,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes (note 13)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTQtMS0xLTEtMjg3Njk_e27752bd-4ee4-49f3-99e4-c99066dba718">79,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTQtMy0xLTEtMjg3Njk_f578adbb-defd-4edf-8684-bc1fc2e6bd73">79,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTUtMS0xLTEtMjg3Njk_e0854e77-0179-419a-be10-5a384f3a4b25">171,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTUtMy0xLTEtMjg3Njk_235d08a3-2f79-496e-9b19-1232b9cb14fb">160,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTYtMS0xLTEtMjg3Njk_11984e2f-9fba-4482-9f70-63237ebfcf94">3,164,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTYtMy0xLTEtMjg3Njk_b6ea646b-c76f-4858-a04c-d7c947165ca4">3,153,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTctMS0xLTEtMjg3Njk_9678080a-b005-4ff2-9aad-566d3e31be9a">5,095,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTctMy0xLTEtMjg3Njk_a5908e21-8c24-4aa7-a30e-c62da3558725">4,728,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjAtMS0xLTEtMjg3Njk_cf89916d-747b-470c-9dcd-d5ef1238b045">159,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjAtMy0xLTEtMjg3Njk_65e2e077-3a4f-492c-bdfa-1903207ea682">138,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses (note 7)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjEtMS0xLTEtMjg3Njk_efa32ff4-561f-4f97-bd7a-afe010d1ceaa">344,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjEtMy0xLTEtMjg3Njk_b591c108-851c-4178-bd66-d459d526b972">320,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities, current (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjItMS0xLTEtMjg3Njk_64edfd01-c896-4b10-8a3d-af99598210f2">21,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjItMy0xLTEtMjg3Njk_30a284ab-7005-482b-965b-80152afd01ff">23,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjMtMS0xLTEtMjg3Njk_05af2c77-7f15-4384-95ff-1599400ddd7c">108,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjMtMy0xLTEtMjg3Njk_dc2e1210-a3b9-4f8d-b827-b3119f77bd48">109,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes payable (note 13)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjQtMS0xLTEtMjg3Njk_029bfc0d-7698-480a-9b7c-cb87056dc683">44,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjQtMy0xLTEtMjg3Njk_ab176395-ec2f-4582-918b-1142a4c5df72">307,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt, net (note 9)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjUtMS0xLTEtMjg3Njk_89fb83fd-a781-49ec-9115-f304b9f78bf4">9,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjUtMy0xLTEtMjg3Njk_62ad52e0-7971-4699-9fb9-7aa601cb4189">12,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjYtMS0xLTEtMjg3Njk_ce8c1b8d-02ae-4066-abde-55aaff018b10">689,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjYtMy0xLTEtMjg3Njk_f5e30c8b-f6b3-434d-a163-bb8fa64380ef">911,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjgtMS0xLTEtMjg3Njk_645a01bf-c8af-4133-94d6-9b85e5fbe33e">95,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjgtMy0xLTEtMjg3Njk_f792d645-73d0-4810-a91a-2a1fbe4207a6">91,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes (note 13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjktMS0xLTEtMjg3Njk_db2c02dc-12aa-451b-87b1-11e625ea1128">9,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjktMy0xLTEtMjg3Njk_c8dc72c7-09bd-46b6-be18-3e03d71864a1">11,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzAtMS0xLTEtMjg3Njk_bc8d94b6-44d2-413c-bcfc-3d53e2138566">120,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzAtMy0xLTEtMjg3Njk_a3eff863-abe1-4642-b4a3-4a570b455c66">114,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzEtMS0xLTEtMjg3Njk_495de5d3-2a2b-42b3-8e77-2a10bc0e8517">5,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzEtMy0xLTEtMjg3Njk_b0a54dd1-43fb-438a-86fd-773f976bed87">6,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzItMS0xLTEtMjg3Njk_eeddd6a0-e93c-4b52-8474-dc7e0e24820f">765,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzItMy0xLTEtMjg3Njk_cb5a182b-34fc-4061-a938-8266ed293314">643,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term income taxes payable (note 13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzMtMS0xLTEtMjg3Njk_df7eaf17-174f-48d4-ab73-dfb3fc3f1698">48,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzMtMy0xLTEtMjg3Njk_e068fe1d-89b1-4c77-8ffb-8ab9cbc52547">62,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzQtMS0xLTEtMjg3Njk_b76f41be-50fb-4d2f-b76a-3091fef8a16b">1,045,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzQtMy0xLTEtMjg3Njk_dbe3d244-141a-469f-87b3-1a48d8100dab">930,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzUtMS0xLTEtMjg3Njk_7d367104-8049-4348-81be-b940d9e4bf5d">1,735,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzUtMy0xLTEtMjg3Njk_4efb3567-ec0c-4dc0-9e67-9c80650a8551">1,842,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (note 16)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzYtMS0xLTEtMjg3Njk_c2c6eb6a-1322-4e98-9a30-5a4094fa6948"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzYtMy0xLTEtMjg3Njk_210085c8-8371-4e84-abcc-e23af165caa4"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTcx_e3cc88ff-60ef-49fa-bbe2-1f752eb6a0d4"><ix:nonFraction unitRef="usdPerShare" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTcx_eaba2288-df04-4670-a4f1-eec1b4623eef">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTc1_36d3c7ff-726b-4bec-816c-bcebb58c677f"><ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTc1_ca0c5f7f-8c7d-421c-9af4-5118b045ef6c">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTc5_b94bd01f-199b-4222-9fa0-fbbfcf6240f6"><ix:nonFraction unitRef="shares" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTc5_f692d70f-fde0-418d-96fa-32de7052a92c">none</ix:nonFraction></ix:nonFraction> issued</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMS0xLTEtMjg3Njk_c2530a30-15d0-4617-bf4d-0353bbec04ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMy0xLTEtMjg3Njk_9f041d19-20e2-4594-9a0d-ea74c3719b91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV8xOA_38582792-ef0f-4fa5-a6a8-bfa4708aeeca"><ix:nonFraction unitRef="usdPerShare" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV8xOA_cbe19e59-bf4f-49fd-af9a-3d88f1249ecb">0.004</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjM0_227b93dd-370e-42f0-b6ab-fa3852b7ffa7"><ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjM0_470985a6-1fcc-4590-8840-a2bf0ac0ef79">350,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjM4_91b3a2ad-c295-41c8-8500-3eaaefe5a5d4">188,246,955</ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjQy_d7eec664-1502-4ae3-9ffb-1b5cc8bdc273">146,410,721</ix:nonFraction> outstanding at June&#160;30, 2022 and <ix:nonFraction unitRef="shares" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjUw_d25996c4-5121-4bc1-90c0-218a823f05ec">187,484,592</ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjU0_b9f62a7d-4fd6-45bf-afbe-2aa66066e609">145,648,358</ix:nonFraction> outstanding at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMS0xLTEtMjg3Njk_dee8229e-5707-49e9-9383-8220aa1c4ece">586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:CommonStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMy0xLTEtMjg3Njk_eb1d31f4-19d6-4108-b722-3285774ca778">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDAtMS0xLTEtMjg3Njk_03c7e85f-5a61-4328-b36f-7ca3838c5df6">1,682,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDAtMy0xLTEtMjg3Njk_12c348ea-7bb3-49e2-b201-cdcded328091">1,622,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDEtMS0xLTEtMjg3Njk_52b2e355-19c6-4f2a-808a-301e8ef2a29e">3,613,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDEtMy0xLTEtMjg3Njk_17e8acd1-5dcc-4088-a57d-697f77c642d7">3,079,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDItMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjplZmJlM2E5Zjk0ZDM0MDA1ODZkMDg3NTViMzljNmNjY180Mzk4MDQ2NTExMTU2_6ba1b7e2-323b-4367-88e7-2cfdebafeb01"><ix:nonFraction unitRef="shares" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDItMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjplZmJlM2E5Zjk0ZDM0MDA1ODZkMDg3NTViMzljNmNjY180Mzk4MDQ2NTExMTU2_ff116868-affc-4014-a141-0f613b043abf">41,836,234</ix:nonFraction></ix:nonFraction> shares at June&#160;30, 2022 and June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDItMS0xLTEtMjg3Njk_4dc5819f-427a-4088-b4c9-4082af233bc2">1,623,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDItMy0xLTEtMjg3Njk_bf0e9787-8257-435c-aa74-4995dbb7205d">1,623,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDMtMS0xLTEtMjg3Njk_6a2754f1-0f13-4c6f-92bb-87e2ccf54789">312,747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDMtMy0xLTEtMjg3Njk_321f3643-fa54-4ec2-8c4b-6ea5549c641e">193,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDQtMS0xLTEtMjg3Njk_e3e33d01-9c11-469e-b415-b6dc61fb8f76">3,360,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDQtMy0xLTEtMjg3Njk_076e6310-e1dc-48ba-aee2-a3c10abf90cd">2,885,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDUtMS0xLTEtMjg3Njk_3411bf3f-5eaa-46df-b31e-2330f09a09a7">5,095,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDUtMy0xLTEtMjg3Njk_1540d727-d0d2-4c7c-8d0a-4e601fb6cfff">4,728,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-64-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_91"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_1">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years Ended June&#160;30, 2022, 2021 and 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In US$ and in thousands, except share and per share data)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue - Sleep and Respiratory Care products</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e67c47d1fc44c41b072ad44589d1ad5_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMS0xLTEtMS0yODc2OQ_15dcc600-36be-411c-812d-2bef46b3e2b5">3,177,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9b9cae84c447429471e59078cc7791_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMS0zLTEtMS0yODc2OQ_169cf5f4-82b9-448d-89e8-cf8037839e2d">2,823,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e1f5a8c9d8a4df7afb7de1694802ffb_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMS01LTEtMS0yODc2OQ_01d3b3a8-91cd-4448-900e-0ec09a6d894d">2,602,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue - Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1968e917afd4a069dcce0cf81596189_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMi0xLTEtMS0yODc2OQ_c3efcfa1-ff4f-4a6a-9325-7d8a8e6985ab">400,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f3256c15f5423dae9d0f83d1016c16_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMi0zLTEtMS0yODc2OQ_34fc1f6d-b50b-4619-93f5-3bc58597f7fe">373,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50fa129c39f4e95a4ced80f5095f914_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMi01LTEtMS0yODc2OQ_8de7151b-8ae6-4046-85ea-17670c34a819">354,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMy0xLTEtMS0yODc2OQ_822fa376-6528-43f2-919a-dd21f258a0be">3,578,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMy0zLTEtMS0yODc2OQ_227a2034-b64b-4859-850a-edd502484986">3,196,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMy01LTEtMS0yODc2OQ_77acf33c-fbd6-4589-a56e-0518c8bd1d5e">2,957,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales - Sleep and Respiratory Care products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e67c47d1fc44c41b072ad44589d1ad5_D20210701-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNS0xLTEtMS0yODc2OQ_53de7f24-6e74-4383-a55e-2dde4b698bc3">1,365,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9b9cae84c447429471e59078cc7791_D20200701-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNS0zLTEtMS0yODc2OQ_5306f785-423d-4560-9d0b-63663c81de88">1,177,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e1f5a8c9d8a4df7afb7de1694802ffb_D20190701-20200630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNS01LTEtMS0yODc2OQ_3f971b17-d48e-415c-826a-768828871e7f">1,067,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales - Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1968e917afd4a069dcce0cf81596189_D20210701-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNi0xLTEtMS0yODc2OQ_60094c60-5423-4e89-8b86-4fe175eab5eb">148,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f3256c15f5423dae9d0f83d1016c16_D20200701-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNi0zLTEtMS0yODc2OQ_024f7592-33ca-4828-aa0f-ef8a8082ae74">135,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50fa129c39f4e95a4ced80f5095f914_D20190701-20200630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNi01LTEtMS0yODc2OQ_bc47fcc6-f788-44b6-aaf2-9db5d047c435">121,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales (exclusive of amortization shown separately below)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNy0xLTEtMS0yODc2OQ_e38b4ee8-bb0e-41d4-896e-5e3ff3386ade">1,514,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNy0zLTEtMS0yODc2OQ_bc53e09d-0cd3-4f99-b80e-1caefc855384">1,312,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNy01LTEtMS0yODc2OQ_97d0e88e-6ce7-433f-a35d-44e79baa425b">1,189,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets - Sleep and Respiratory Care products</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e67c47d1fc44c41b072ad44589d1ad5_D20210701-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfOS0xLTEtMS0yODc2OQ_a857617d-d935-4fca-892c-7f08ed6590a4">4,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9b9cae84c447429471e59078cc7791_D20200701-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfOS0zLTEtMS0yODc2OQ_0acd15c3-3478-43a3-80fa-a367ad4a7798">4,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e1f5a8c9d8a4df7afb7de1694802ffb_D20190701-20200630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfOS01LTEtMS0yODc2OQ_39bb27d7-1888-4b39-928d-4fe04ce07c17">8,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets - Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1968e917afd4a069dcce0cf81596189_D20210701-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTAtMS0xLTEtMjg3Njk_7204dd00-4660-4b3b-a1c8-4d3594c049f3">35,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f3256c15f5423dae9d0f83d1016c16_D20200701-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTAtMy0xLTEtMjg3Njk_1e54f0ad-e7e9-4080-a462-d75476e8862b">40,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50fa129c39f4e95a4ced80f5095f914_D20190701-20200630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTAtNS0xLTEtMjg3Njk_a90dc633-7a41-4e6c-aba1-f04031b3e507">41,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTEtMS0xLTEtMjg3Njk_089e3d7f-9c70-4b68-a08a-c74c8501d8f4">39,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTEtMy0xLTEtMjg3Njk_edd956f8-2e46-4ded-98d0-fde08cf30dbf">45,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTEtNS0xLTEtMjg3Njk_65adb489-eb72-4dbd-815f-d25e1effed13">49,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTItMS0xLTEtMjg3Njk_783b4260-0638-4840-ac40-56063be85d16">1,553,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTItMy0xLTEtMjg3Njk_86ffd1e2-25b1-4e47-87a8-1a5024ebc352">1,357,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTItNS0xLTEtMjg3Njk_2e5f7909-1804-430b-9b2d-30286dd7c0ac">1,239,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTMtMS0xLTEtMjg3Njk_09a23d20-5ab5-4392-a6da-6bc14f44313b">2,024,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTMtMy0xLTEtMjg3Njk_dfc6384a-9e58-4c3a-9582-01ec50087837">1,839,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTMtNS0xLTEtMjg3Njk_6f0a918c-bc06-47e8-8286-18e4b899745f">1,717,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTUtMS0xLTEtMjg3Njk_a9c0dbc7-6880-47b2-89dd-3a14161b904f">739,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTUtMy0xLTEtMjg3Njk_37e7f527-6a9d-4c79-9fc4-5f5b8619d4a1">670,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTUtNS0xLTEtMjg3Njk_802b7d89-e4bc-492d-aac3-ab2597445f4d">676,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTYtMS0xLTEtMjg3Njk_70b0b189-8931-46a7-9191-785b8be17d4f">253,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTYtMy0xLTEtMjg3Njk_b2101ee6-eb0b-406e-9d1c-e0945be77a69">225,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTYtNS0xLTEtMjg3Njk_350d48d1-14eb-421b-be8f-b3d3169da69b">201,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTctMS0xLTEtMjg3Njk_1842e7ef-bcab-43af-aa62-92c22b0b5d48">31,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTctMy0xLTEtMjg3Njk_254a95b9-b90f-42e8-a2d2-20ee93fc2511">31,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTctNS0xLTEtMjg3Njk_8c819f29-ddfe-43b5-93c2-6182747e5836">30,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses (note 17)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTgtMS0xLTEtMjg3Njk_d45e4390-540f-4c14-92ef-aed34a434fd5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTgtMy0xLTEtMjg3Njk_acb0b8a9-ccfb-4b04-856c-73933728bb36">8,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTgtNS0xLTEtMjg3Njk_497bdad2-6fac-443c-a622-b0ed66c78524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTktMS0xLTEtMjg3Njk_41cc15bd-f927-42fd-b906-9d7476f4459b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTktMy0xLTEtMjg3Njk_16b3e167-67ba-4bbc-b7ee-c5ac0c9175a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:LitigationSettlementExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTktNS0xLTEtMjg3Njk_7474bb4f-d676-40cd-b052-2c3e1cbc8c41">600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjEtMS0xLTEtMjg3Njk_9dc9b323-7dce-4757-8778-89ff6afc6292">1,024,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjEtMy0xLTEtMjg3Njk_d29052bf-f7fd-4c24-a834-04993079688e">935,422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjEtNS0xLTEtMjg3Njk_edec9b21-19d0-435d-8242-0a832d7626e6">908,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjItMS0xLTEtMjg3Njk_d0a94909-7f60-440f-b4e5-e12d543dc0ca">1,000,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjItMy0xLTEtMjg3Njk_c49e3681-df65-43c2-96cd-accce731a68e">903,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjItNS0xLTEtMjg3Njk_1dfa0b83-5878-4553-9cc8-a8971b12c1a4">809,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other income (loss), net:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjQtMS0xLTEtMjg3Njk_56117148-a66e-420c-a28a-1e2b394a097a">22,312</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjQtMy0xLTEtMjg3Njk_4afb7dd5-209f-4c7d-a6d6-b384b1ff9e86">23,627</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjQtNS0xLTEtMjg3Njk_2f3419fe-93bf-4281-b70f-f1c3597a7304">39,356</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments (note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjUtMS0xLTEtMjg3Njk_42dd9bc3-1ea6-47ec-966d-ea46143a162d">8,486</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjUtMy0xLTEtMjg3Njk_13d15082-272c-4744-8824-90ab7629d7f6">11,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjUtNS0xLTEtMjg3Njk_36083b66-4bb1-4554-a69a-ca4972df89df">25,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain (loss) on equity investments (note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjYtMS0xLTEtMjg3Njk_aa3663ba-4b25-4659-9e26-c110deae2fe0">12,202</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjYtMy0xLTEtMjg3Njk_53cdadd1-14e7-4ebf-ab23-c6559bb2f2bd">14,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjYtNS0xLTEtMjg3Njk_9fc11c08-afe1-4589-af2d-e360c4b4d3b9">14,519</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjctMS0xLTEtMjg3Njk_3fcd12ea-13ef-4c7d-8288-74fff4cf309b">3,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjctMy0xLTEtMjg3Njk_d5e194af-06c3-44f4-9e96-dedd9681b21a">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjctNS0xLTEtMjg3Njk_402e94e4-8602-4aac-a6ee-0f019c3a3fd7">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other income (loss), net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjgtMS0xLTEtMjg3Njk_99ecdc05-75c5-4506-9e9c-9c38c9a7fc20">39,803</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjgtMy0xLTEtMjg3Njk_c2bead58-4eaa-4c6e-b03f-d54b8cb71256">20,016</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjgtNS0xLTEtMjg3Njk_02ef9d61-ecfd-49c4-8415-b5113a3dbdef">76,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjktMS0xLTEtMjg3Njk_45e368be-fa4c-4fba-9dbb-9694031a9bb0">960,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjktMy0xLTEtMjg3Njk_905bdc80-d74e-4b59-bbb0-470b5865906e">883,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjktNS0xLTEtMjg3Njk_6394be87-c60e-4f01-afa8-fe911451bf27">733,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes (note 13)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzAtMS0xLTEtMjg3Njk_b0bdb219-1685-4996-b785-14cf3e77772c">181,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzAtMy0xLTEtMjg3Njk_dc925bd9-aad1-4cf8-9d37-33a15d329338">409,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzAtNS0xLTEtMjg3Njk_d1f32b6a-c1c0-420b-845f-dc4c559c1b5d">111,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzEtMS0xLTEtMjg3Njk_b0c06fce-a788-4e86-9c05-f6534ba74852">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzEtMy0xLTEtMjg3Njk_042778dd-8240-41f4-9ca7-6efb5fdbbcef">474,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzEtNS0xLTEtMjg3Njk_2d6dfa79-2e8b-4367-b106-6ee3257f19db">621,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share (note 12)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzMtMS0xLTEtMjg3Njk_ad7be7e7-0f95-4846-901d-b33bf19e841b">5.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzMtMy0xLTEtMjg3Njk_dba79c2a-0c30-43d2-b8ca-de42666df6ec">3.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzMtNS0xLTEtMjg3Njk_9fa7865d-5b41-49b6-895f-893b6d9210d8">4.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share (note 12)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzQtMS0xLTEtMjg3Njk_303837ea-ae14-4e75-a7e1-71fa95ef76a0">5.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzQtMy0xLTEtMjg3Njk_9515fc52-b90b-4013-bb5e-e46be04662d7">3.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzQtNS0xLTEtMjg3Njk_44e4ccb0-fcb9-46d1-b538-36734fe853ef">4.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend declared per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzUtMS0xLTEtMjg3Njk_9b01bda4-5504-40c9-af8d-688879a08284">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzUtMy0xLTEtMjg3Njk_70e3f666-0b0e-4a0c-b557-a0df8f36eff2">1.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzUtNS0xLTEtMjg3Njk_81806d47-73e5-4027-9614-00a20d151720">1.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic shares outstanding (000's)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzYtMS0xLTEtMjg3Njk_8ca515f1-a545-44b5-b8f4-762555fc5951">146,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzYtMy0xLTEtMjg3Njk_38a0427b-3cfe-41d5-b3aa-7c00dc3d7d80">145,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzYtNS0xLTEtMjg3Njk_051ef519-0ce3-4d37-914d-d6d432af1810">144,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted shares outstanding (000's)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzctMS0xLTEtMjg3Njk_917a6c9f-5142-43a1-ad1b-081e99fd6406">147,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzctMy0xLTEtMjg3Njk_d53acd1f-65c5-4330-bf36-c0deb0cda4ef">146,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzctNS0xLTEtMjg3Njk_bd6323ed-3454-4a6b-9856-e77c40288961">145,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-65-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_94"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_1">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Comprehensive Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years Ended June&#160;30, 2022, 2021 and 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In US$ and in thousands)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMS0xLTEtMS0yODc2OQ_b98de0fb-72cb-4acc-94f5-b50a77216cc6">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMS0zLTEtMS0yODc2OQ_04e71553-98e6-4c95-9db8-0e397173554f">474,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMS01LTEtMS0yODc2OQ_521b3c3f-db49-4a3c-b6e1-12275f8b75ea">621,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation (loss) gain adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMy0xLTEtMS0yODc2OQ_26a9d11a-e114-4133-93ea-e9ba7a012024">119,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMy0zLTEtMS0yODc2OQ_2e5eb6be-2d6c-46d0-8993-8689da61540c">90,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMy01LTEtMS0yODc2OQ_152a50b8-4ce5-4839-9123-8959acec9f6b">30,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfNC0xLTEtMS0yODc2OQ_4e75c1de-c75d-4313-be64-8fd77900ba72">660,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfNC0zLTEtMS0yODc2OQ_95d45051-59ff-490a-917c-955cfeb164a6">565,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfNC01LTEtMS0yODc2OQ_f1a7889b-f726-4f71-ac96-a9745af71db0">590,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-66-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_97"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_1">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended June&#160;30, 2022, 2021 and 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In US$ and in thousands)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.015%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive <br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June&#160;30, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i607c9c75962444d08f128d8d1dd51b12_I20190630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi0xLTEtMS0yODc2OQ_20663a6c-c513-4b47-b96c-3ae54b5b4fa4">185,491</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607c9c75962444d08f128d8d1dd51b12_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi0zLTEtMS0yODc2OQ_d44e0aea-83ef-46e6-ba6d-0d2a490cff88">575</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79dd5c34ff9f422d9e66e42855b0fe44_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi01LTEtMS0yODc2OQ_ff27b437-ab1b-4b2a-8742-4568f253cff7">1,511,473</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5eec134b8bd6450baec5eba43690fb81_I20190630" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi03LTEtMS0yODc2OQ_bd32af8e-e6fd-4e37-a355-b52fb52522ed">41,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5eec134b8bd6450baec5eba43690fb81_I20190630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi05LTEtMS0yODc2OQ_09af3568-e4ab-4de8-b668-b51629f1d184">1,623,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f27f1170fa649259d40577a59061c34_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi0xMS0xLTEtMjg3Njk_7acefa27-c327-433c-a14c-aa41b49f76c1">2,436,410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0e9c77435e45485c85034973f776a026_I20190630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi0xMy0xLTEtMjg3Njk_f45ba878-7225-4c05-8d8f-1adc50f257f9">253,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6113f72766ae4bf3a6b6822df9ec9799_I20190630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi0xNS0xLTEtMjg3Njk_6e46f3b2-ce0a-4dd2-99b4-c3ae4c620338">2,072,193</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on exercise of options (note 11) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMy0xLTEtMS0yODc2OQ_18934e6b-968b-4abb-9bc2-9bf0773d3e42">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMy0zLTEtMS0yODc2OQ_5f6eafb6-f883-44ef-9c1f-64a567f47271">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d7efe198194679bd87c4519fbad23e_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMy01LTEtMS0yODc2OQ_da3222ec-bb3d-48fc-9f7b-9b0734017a11">19,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMy0xNS0xLTEtMjg3Njk_48b8518d-fb40-467e-a170-fd97fbe94ccb">19,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNC0xLTEtMS0yODc2OQ_3e362d9a-a499-4715-b8e0-939002311f47">617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNC0zLTEtMS0yODc2OQ_1ff5316f-948a-4189-b28b-028d47f49825">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1d7efe198194679bd87c4519fbad23e_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNC01LTEtMS0yODc2OQ_8e417eec-0c9d-4f05-9e4b-1257162be8c8">46,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNC0xNS0xLTEtMjg3Njk_ca9b14cf-c638-4bca-8f8b-ab95ff045466">46,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on employee stock purchase plan (note 11) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNS0xLTEtMS0yODc2OQ_a20968c5-d0bc-4a0f-a036-28f66b12a448">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNS0zLTEtMS0yODc2OQ_c8244c6e-d51c-484f-bf8b-79332a1e1965">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d7efe198194679bd87c4519fbad23e_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNS01LTEtMS0yODc2OQ_fa3f02d0-f7b5-4c88-934d-4611fbec8d1e">28,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNS0xNS0xLTEtMjg3Njk_13c80f57-5dc1-4568-9e69-ebf6402bf756">28,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d7efe198194679bd87c4519fbad23e_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNy01LTEtMS0yODc2OQ_e0b8c0af-8f38-444b-9b55-d7f01670bf6d">57,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNy0xNS0xLTEtMjg3Njk_b6d11b62-0315-4e18-9f2f-a194f4e35d2d">57,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08a4d2be57e74a8ab5b264970b29954e_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfOC0xMy0xLTEtMjg3Njk_33d4a0d1-06bf-4f07-97e5-9aaf03905d22">30,973</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfOC0xNS0xLTEtMjg3Njk_17cea6f3-c6dc-48b1-b61f-24b73b8d951d">30,973</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i747690daf6804d479047c828f5efc32a_D20190701-20200630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfOS0xMS0xLTEtMjg3Njk_be736e8e-4539-432a-b828-45e85ca3f890">621,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfOS0xNS0xLTEtMjg3Njk_bcf88d16-3717-4bd0-857e-d91972bc0a55">621,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTEtMC0xLTEtMjkzNTMvdGV4dHJlZ2lvbjo5MTFlYzgxMWFlMDI0NTgyYTBkNDgzMWRmNWRjMzZjMV80Mzk4MDQ2NTExMTYw_ec03ea38-22e8-4069-b8c4-7066d574dbe0">1.56</ix:nonFraction> per common share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i747690daf6804d479047c828f5efc32a_D20190701-20200630" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTEtMTEtMS0xLTI4NzY5_24c41966-b291-479e-9316-788ebc9f1ffe">225,093</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTEtMTUtMS0xLTI4NzY5_25e89762-0be5-40d4-b0e9-0e44c16446e2">225,093</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6592376d0e874a54b0c74878697fe0fa_I20200630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItMS0xLTEtMjg3Njk_cd3fdd7d-0142-4472-b939-cf758ebebd29">186,723</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6592376d0e874a54b0c74878697fe0fa_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItMy0xLTEtMjg3Njk_3b9ea6a2-eaa0-46ed-a59c-54f947f9ca9f">580</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0787de141ff41878aae7892528f698a_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItNS0xLTEtMjg3Njk_b2d4318e-762e-4370-971e-e7ae9f14d2b0">1,570,694</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i37d85afb3c0245f5af0854c9191a8cb0_I20200630" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItNy0xLTEtMjg3Njk_f5364c79-70fd-4fb1-a16f-41589bf0bbcf">41,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i37d85afb3c0245f5af0854c9191a8cb0_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItOS0xLTEtMjg3Njk_6b293d30-0097-49de-99a5-e63ab69fb060">1,623,256</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f72c5541674f6592c342e22fc4e04e_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItMTEtMS0xLTI4NzY5_89873027-e0dc-4d66-bd0c-69d4e722ccac">2,832,991</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8394569b4f94ef8955d0f57473de626_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItMTMtMS0xLTI4NzY5_3665210d-e58a-4fe6-85c7-6e427fa95570">283,982</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItMTUtMS0xLTI4NzY5_5d9541f4-5736-4fc0-8840-cd9a66aa78f1">2,497,027</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on exercise of options (note 11) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTMtMS0xLTEtMjg3Njk_0aeed296-8f68-4a72-a8de-3c887e5611d7">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTMtMy0xLTEtMjg3Njk_5834eac9-be45-4bca-b928-ea777425c80a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic737aa421e0a4e9782bc67d50120cb7f_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTMtNS0xLTEtMjg3Njk_895116fc-b72e-480a-a9cc-20cd3507f52f">3,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTMtMTUtMS0xLTI4NzY5_0ff723f7-5702-4d80-b3df-4c65319f5a57">3,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTQtMS0xLTEtMjg3Njk_dd546484-0915-4ec1-850c-a9ee1d44ec22">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTQtMy0xLTEtMjg3Njk_77023d9d-556a-4649-b80e-5f6d39b5c1c7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic737aa421e0a4e9782bc67d50120cb7f_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTQtNS0xLTEtMjg3Njk_10ccb5b0-8221-4d43-9583-57a06a6c8c05">50,209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTQtMTUtMS0xLTI4NzY5_d2ea2c7e-1363-4e16-aa07-89e8603cee7a">50,207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on employee stock purchase plan (note 11) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTUtMS0xLTEtMjg3Njk_c5bb7af5-96bd-41bf-91ba-a2fed518d86c">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTUtMy0xLTEtMjg3Njk_51ed60b7-8bf3-42e0-b8d8-dfb225449912">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic737aa421e0a4e9782bc67d50120cb7f_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTUtNS0xLTEtMjg3Njk_9826ed03-c532-496f-98da-9fcac826263d">33,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTUtMTUtMS0xLTI4NzY5_e38b7a6d-ef41-43ac-a2e0-10f39662891f">33,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic737aa421e0a4e9782bc67d50120cb7f_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTYtNS0xLTEtMjg3Njk_1663f8f4-7be7-4ef9-9b00-38a911355dd7">63,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTYtMTUtMS0xLTI4NzY5_1db25e78-2359-4eb0-b4c3-492645330c3d">63,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1c1ddd15e1e47c9af2f8d75690aff1e_D20200701-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTctMTMtMS0xLTI4NzY5_6dce46cf-e065-43db-ae29-d26404748cee">90,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTctMTUtMS0xLTI4NzY5_a5495d35-3451-49f2-b648-34446e4b782a">90,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514c68b0178849528b98da7c305b377b_D20200701-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTgtMTEtMS0xLTI4NzY5_c63c11ed-bf24-4e39-b4cf-576fa0eb322b">474,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTgtMTUtMS0xLTI4NzY5_67a4b00a-51d4-46eb-a735-167d4ef6a795">474,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTgtMC0xLTEtMzI2Mjg_0c2fd2af-5aa3-40db-a89c-1b133efc80c3">Cumulative effect adjustment from adoption of the credit loss standard, net of tax</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if89490bfd4ff476b8ef0c46da716b643_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTctMTEtMS0xLTMyNjg2_459e075d-322f-4e1e-96b6-1a0fd016a8e3">1,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9052a046d6444bdb2321e25b6d1995e_I20200630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTctMTUtMS0xLTMyNjg2_fe9f123a-fc12-4fd7-8fd6-b331d1482316">1,143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTktMC0xLTEtMjkzNTkvdGV4dHJlZ2lvbjo3YjI1ZmQ3YmMyMjU0ZDQ5OGZlYzUxMjAwNGYwZjY0Zl80Mzk4MDQ2NTExMTYw_3e64c28f-e591-4c90-b084-068531c3acb3">1.56</ix:nonFraction> per common share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i514c68b0178849528b98da7c305b377b_D20200701-20210630" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTktMTEtMS0xLTI4NzY5_b2b6c712-ac8d-4b7c-bb4a-863628813024">226,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTktMTUtMS0xLTI4NzY5_e0f5403d-8372-49a4-b1d2-fe756c743cf9">226,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5143bf6786f34585b5c51f7be503d02b_I20210630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtMS0xLTEtMjg3Njk_e0ec0255-586f-4ad9-be81-9f6900942674">187,485</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5143bf6786f34585b5c51f7be503d02b_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtMy0xLTEtMjg3Njk_8254b1b1-011c-41f9-9db9-0215afc72299">583</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie47e6eabf77f427ba2b95ab6114f5051_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtNS0xLTEtMjg3Njk_ba538c5a-d27d-441a-9a19-bc25724d709e">1,622,199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iacae05028f8d4777a29f62e32c114e8d_I20210630" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtNy0xLTEtMjg3Njk_7bdeea47-3af1-40ee-90aa-9475acd27293">41,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacae05028f8d4777a29f62e32c114e8d_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtOS0xLTEtMjg3Njk_c5576e50-a197-4f61-88c7-85219d85b040">1,623,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5cda1b02464bfd8426853a49a7491c_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtMTEtMS0xLTI4NzY5_bda172a2-4658-4f5a-b95f-76eed2118ece">3,079,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia489861770004d4582aa5f3dc793010f_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtMTMtMS0xLTI4NzY5_79dfc92d-1220-45e2-8de1-67c24fc4d9c4">193,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtMTUtMS0xLTI4NzY5_b1255898-d761-4622-bdbe-4c64167c7647">2,885,679</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on exercise of options (note 11) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjEtMS0xLTEtMjg3Njk_3b4fa790-864a-4811-9a36-a0f80e3e40dd">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjEtMy0xLTEtMjg3Njk_211ac075-a93b-4007-acf7-902b1714e88b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65c792136c946adbf377040f6366deb_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjEtNS0xLTEtMjg3Njk_593e4646-04cf-4f14-b8c5-0c718505577b">11,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjEtMTUtMS0xLTI4NzY5_23c4038e-c880-4e96-9b99-405ba3c0c8a8">11,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11) </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjItMS0xLTEtMjg3Njk_788a739a-5fd7-4945-a7ae-fa6645ddee98">369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjItMy0xLTEtMjg3Njk_0bef8c75-1ef7-421e-b32d-2df0413e3926">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie65c792136c946adbf377040f6366deb_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjItNS0xLTEtMjg3Njk_908ee341-e543-4980-8a67-c71fac2a0955">52,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjItMTUtMS0xLTI4NzY5_78d826ee-7aa1-4b96-ba18-55e7a10d292a">52,406</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock issued on employee stock purchase plan (note 11) </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjMtMS0xLTEtMjg3Njk_2df04a1d-9b71-4d7f-8dbf-a93d0cfb6945">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjMtMy0xLTEtMjg3Njk_d0c267c8-ccb3-4e27-8552-e7ce933ee9dc">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65c792136c946adbf377040f6366deb_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjMtNS0xLTEtMjg3Njk_c3ab8d06-762e-4c75-ab89-69c3f80f6b77">36,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjMtMTUtMS0xLTI4NzY5_7510e3a1-5bd8-49bf-b0e3-3768e58760be">36,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie65c792136c946adbf377040f6366deb_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjQtNS0xLTEtMjg3Njk_1ebfc995-869d-4da8-8711-24a38c4d6fbf">65,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjQtMTUtMS0xLTI4NzY5_7989be7b-0f2e-4d00-b949-32edd16b83b1">65,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iece2a9fb6a58447ab6a18eaf650b57f8_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjUtMTMtMS0xLTI4NzY5_d9851501-bf66-4cc2-a56e-18f073b603b0">119,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjUtMTUtMS0xLTI4NzY5_fcdfd029-1667-4774-b884-515983828692">119,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id598a508533f4a93af0cf893cdbc877c_D20210701-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjYtMTEtMS0xLTI4NzY5_230386a4-ce1e-43d2-873d-a22ba81835cc">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjYtMTUtMS0xLTI4NzY5_218e6338-50af-489a-a16e-8935d3b36967">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjgtMC0xLTEtMjkzNjUvdGV4dHJlZ2lvbjpkNTdlNDk0NGQzYTE0YjM1YTE1YzllZDcwNzE2ODlkYl80Mzk4MDQ2NTExMTYw_5b46a93b-a003-4b8f-a197-9597fa7d7676">1.68</ix:nonFraction> per common share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id598a508533f4a93af0cf893cdbc877c_D20210701-20220630" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjgtMTEtMS0xLTI4NzY5_bbc0b369-22c8-44eb-97de-df8ef8fd6acc">245,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjgtMTUtMS0xLTI4NzY5_82908ccb-e5c1-4bb1-a7c5-5abc4eec9502">245,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance, June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib389da5f9ca94f9e9783af8916ff3c69_I20220630" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktMS0xLTEtMjg3Njk_77eefe95-a815-4383-a90b-56617b6d8ff6">188,247</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib389da5f9ca94f9e9783af8916ff3c69_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktMy0xLTEtMjg3Njk_adfffab0-a613-4b1b-b032-6a79a3350e44">586</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c44d305aea24f8c93d48ef038dd79ea_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktNS0xLTEtMjg3Njk_5e533c17-0385-4068-b064-9256221f6d9c">1,682,432</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i546cf7e76487425b8bfe97c8dd15a832_I20220630" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktNy0xLTEtMjg3Njk_12dcb0d1-91fa-4965-b7fb-f35344350326">41,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i546cf7e76487425b8bfe97c8dd15a832_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktOS0xLTEtMjg3Njk_5044d8a5-25dc-40d0-adbc-d7c58f01c682">1,623,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12b80b9e773a48ddbfec64e8038faa6d_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktMTEtMS0xLTI4NzY5_f867fbc3-4a9a-4600-9c84-5f9d4e66e3b3">3,613,736</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i77cc3f7b15ee461d972d81d7d0806848_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktMTMtMS0xLTI4NzY5_f9fa95b0-0a94-4224-89aa-5cd7707cea93">312,747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktMTUtMS0xLTI4NzY5_2fb13893-b486-48b6-9680-178713509e3e">3,360,751</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-67-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_100"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_1">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:108%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Years ended June&#160;30, 2022, 2021 and 2020</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In US$ and in thousands)</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzItMS0xLTEtMjg3Njk_fcc3c9a7-289f-4cd2-b8bf-d90829e8319f">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzItMy0xLTEtMjg3Njk_ae07bdea-e10c-4181-8fa8-d29eaeb88a12">474,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzItNS0xLTEtMjg3Njk_fc372edc-2330-4254-8db5-e54c1627cc8f">621,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustment to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQtMS0xLTEtMjg3Njk_bd0a424d-e0cb-4ad0-a678-194dbbcc5ae5">159,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQtMy0xLTEtMjg3Njk_493b6d23-7f91-4b6f-8946-aae0b8d63896">156,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQtNS0xLTEtMjg3Njk_316d8da2-f7d1-43d8-9530-ad36ea4af7d8">154,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzUtMS0xLTEtMjg3Njk_07aa1c45-0ee8-46aa-a45a-9e0b4052c777">34,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzUtMy0xLTEtMjg3Njk_1671f293-eb44-4f9a-92e0-5b4afa0efcef">34,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzUtNS0xLTEtMjg3Njk_31bbbcd9-e804-4509-af2c-f6b739c9f066">26,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzYtMS0xLTEtMjg3Njk_0e09d417-faef-44e1-acf9-f4ab45585f2f">65,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzYtMy0xLTEtMjg3Njk_cf347719-2d9e-4029-9e2a-36b1a3e1a3f7">63,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzYtNS0xLTEtMjg3Njk_63a4b88b-c889-477c-b31c-2a31a960ef1f">57,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments (note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzctMS0xLTEtMjg3Njk_5b989f2a-2534-4c42-b76f-7a1d10d0ec6b">8,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzctMy0xLTEtMjg3Njk_bb90bab9-f452-4e98-bf2e-e60a00dbce15">11,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzctNS0xLTEtMjg3Njk_42a28ff9-afbd-4746-bd01-d3b05a00d848">25,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investments (note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzgtMS0xLTEtMjg3Njk_e697e3e9-a4e9-4612-b777-c118a13dbac2">12,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzgtMy0xLTEtMjg3Njk_5875c12d-658e-4775-921b-079c03598648">14,515</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzgtNS0xLTEtMjg3Njk_50ccb31b-011f-4319-a520-d37c11e066d9">14,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses (note 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzktMS0xLTEtMjg3Njk_39910764-8d09-4c01-aae3-1ee6d943d6c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzktMy0xLTEtMjg3Njk_8b616095-d382-4a8a-aa11-23d89cdc24fa">8,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzktNS0xLTEtMjg3Njk_94effe38-f6c1-44d9-b70a-4a249937f671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value of business combination contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzExLTEtMS0xLTI4NzY5_306b41a7-1fba-4d61-ae94-96b28b099419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzExLTMtMS0xLTI4NzY5_046c1354-6159-4dab-8ac0-ef634c6be96b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzExLTUtMS0xLTI4NzY5_20582fae-53dd-4b13-adc6-8ffb6cdec97c">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzEzLTEtMS0xLTI4NzY5_e0bcba6f-73fe-43a6-a3b0-6816c007f6fb">19,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzEzLTMtMS0xLTI4NzY5_56437ed0-60c7-44ed-98bb-74f7313bf737">129,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzEzLTUtMS0xLTI4NzY5_8cdc6a5e-5ada-47e0-89e1-909f5d8cf788">54,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE0LTEtMS0xLTI4NzY5_319b9e9b-604b-403d-8315-55d71523779b">311,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE0LTMtMS0xLTI4NzY5_050c677d-2265-44ce-8fd1-870ea2477f6f">21,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE0LTUtMS0xLTI4NzY5_b3904d90-8aa1-42ae-9396-ea50608a4783">69,881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses, net deferred income taxes and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE1LTEtMS0xLTI4NzY5_a3d39413-13fc-49df-8569-7e151e3733ca">168,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE1LTMtMS0xLTI4NzY5_e5bb0dec-7e85-4c4a-93a1-ff11188fb1f6">58,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE1LTUtMS0xLTI4NzY5_3ac3baef-eacd-4eda-8512-c73095230a77">58,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE2LTEtMS0xLTI4NzY5_bbc57bb5-c281-460e-b3f2-ed058dcc6a54">247,632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE2LTMtMS0xLTI4NzY5_7ce171b7-1022-4b94-a84a-dbedfa0a2083">210,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE2LTUtMS0xLTI4NzY5_98f3aac0-975f-4ec2-a8fd-079966e094db">23,424</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE3LTEtMS0xLTI4NzY5_edb3f7e8-e5ab-451b-9625-6941b8f7fb60">351,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE3LTMtMS0xLTI4NzY5_9610fa70-8cce-4992-a287-c4f2f30b6ba6">736,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE3LTUtMS0xLTI4NzY5_69b0974d-c9a1-4c53-bbd7-c0efbccc2187">802,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE5LTEtMS0xLTI4NzY5_0fea0a49-f6ea-40a8-9f9e-49d4358f203f">134,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE5LTMtMS0xLTI4NzY5_5ac6df44-23a3-4a0e-a4c3-90d5e980d242">102,712</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE5LTUtMS0xLTI4NzY5_a4118f81-7a3c-46ed-bc47-3042a3ce0b37">95,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patent registration costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIwLTEtMS0xLTI4NzY5_59862611-3064-465b-a3bd-bf34dd92b556">21,201</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIwLTMtMS0xLTI4NzY5_11dbb0fa-8967-47ba-862b-f31b27b66aba">14,114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIwLTUtMS0xLTI4NzY5_896929a6-16d6-4e67-90f5-f8f2b99e4b60">10,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIxLTEtMS0xLTI4NzY5_586299e4-c73f-4c1c-9ca5-047bcfbf799f">42,784</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIxLTMtMS0xLTI4NzY5_d721f266-be1b-4c25-9a55-0fdb0cb76fd4">39,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIxLTUtMS0xLTI4NzY5_2ca3b0f7-2efd-4b0a-9032-3e8c1a96ba07">27,910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of investments (note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIyLTEtMS0xLTI4NzY5_25dae9f6-118a-40b8-aa9a-97ca82361d24">20,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIyLTMtMS0xLTI4NzY5_fd8167da-5151-4c85-8d24-c69332ebbcf7">21,788</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIyLTUtMS0xLTI4NzY5_b3eb91ed-d3a8-49f3-aead-00d0378df42f">31,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of investment (note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIzLTEtMS0xLTMyNzky_0c0456dc-23af-4f87-9f16-160ce52ff33f">6,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIyLTMtMS0xLTMyODM2_940667c3-9319-419f-8fc4-40c290f071f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIyLTUtMS0xLTMyODM2_87a161dd-2b0c-4bfb-a1a2-202d29316f54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) / proceeds on maturity of foreign currency contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIzLTEtMS0xLTI4NzY5_bf0c0e88-3707-4ea6-831e-29ab11d80d18">17,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIzLTMtMS0xLTI4NzY5_ff2a563b-c4eb-41e9-9d2c-c754753e2e8f">19,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIzLTUtMS0xLTI4NzY5_267eec75-09ad-40d5-ad64-26062e223844">14,397</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI0LTEtMS0xLTI4NzY5_37c62d4d-7447-469c-a9d5-b872fa071e5d">229,918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI0LTMtMS0xLTI4NzY5_ffe55260-0c28-40db-b56a-f1bc103f30bb">158,462</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI0LTUtMS0xLTI4NzY5_d16f38be-121f-4ff8-bf93-affa93664d09">179,861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI2LTEtMS0xLTI4NzY5_7f014e80-1208-4580-8cbd-4f6240f38b12">47,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI2LTMtMS0xLTI4NzY5_619c9377-c7fc-4dc0-a7eb-1e6d22ab348b">37,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI2LTUtMS0xLTI4NzY5_33511085-adc1-48ba-a4fd-2e182f49036e">48,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI3LTEtMS0xLTI4NzY5_dbf2dd53-b6f5-4568-afc5-5fd5b74ba4d2">52,406</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI3LTMtMS0xLTI4NzY5_2070a870-096e-4d25-977f-24136e5af8a5">50,209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI3LTUtMS0xLTI4NzY5_6501e559-51e7-4644-91e4-52ed1d7088a9">46,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments of business combination contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI5LTEtMS0xLTI4NzY5_c86baff0-cb82-4d74-a873-241a359ca646">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI5LTMtMS0xLTI4NzY5_5423321e-0357-48da-84fe-5b75b8b93cf7">3,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI5LTUtMS0xLTI4NzY5_60146410-89da-468d-b07f-47089373161c">302</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from borrowings, net of borrowing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMwLTEtMS0xLTI4NzY5_1eae7688-d0ca-43e0-8c36-1b8276ab256f">288,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMwLTMtMS0xLTI4NzY5_2d4eb4ae-b20a-4559-9df5-cc840dd0cc0a">90,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMwLTUtMS0xLTI4NzY5_07f1ea98-9071-4624-94e3-528cef807a07">1,190,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMxLTEtMS0xLTI4NzY5_d8cc56d7-b3ae-4fb2-a9b2-20fbac011f86">166,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMxLTMtMS0xLTI4NzY5_1f0fb139-3f77-4bb8-bdd7-9af56b447f24">612,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMxLTUtMS0xLTI4NzY5_ef618279-f1cb-400a-8904-72c1059213a0">1,284,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMyLTEtMS0xLTI4NzY5_aadc6920-108e-46b8-a3aa-144db42a233e">245,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMyLTMtMS0xLTI4NzY5_b4d75bfe-af6e-4abb-b0c9-35821efbae14">226,713</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMyLTUtMS0xLTI4NzY5_0283c8f7-43d4-44c3-aaa4-6c2ce29a9eea">225,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMzLTEtMS0xLTI4NzY5_61d39867-a1a0-43f7-b172-c0f632e175af">128,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMzLTMtMS0xLTI4NzY5_d516ba33-b632-4dae-b4f6-6b02791b4396">764,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMzLTUtMS0xLTI4NzY5_4bf530d1-6012-4804-81e4-44b5b41ca7fe">317,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM0LTEtMS0xLTI4NzY5_e759d3ed-127a-495a-a875-e4ff13d8c93b">14,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM0LTMtMS0xLTI4NzY5_44c19765-c384-4868-a802-4bedf5f5e8ce">18,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM0LTUtMS0xLTI4NzY5_e45b5656-92f8-4195-94e0-4987eed85333">10,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM1LTEtMS0xLTI4NzY5_36ec29df-aa7c-45bd-80c6-52dc4a37b5db">21,568</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM1LTMtMS0xLTI4NzY5_0901e557-1689-4306-a886-270c5dab16ff">167,878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM1LTUtMS0xLTI4NzY5_7f65a64e-112e-42f6-83e7-99d66d92c7aa">316,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM2LTEtMS0xLTI4NzY5_95c7b01d-64e1-4e07-89b2-124ed3b1343d">295,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM2LTMtMS0xLTI4NzY5_326240e1-5b11-44a3-a9e9-f0034f21f1da">463,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6113f72766ae4bf3a6b6822df9ec9799_I20190630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM2LTUtMS0xLTI4NzY5_d7faabb1-5c23-482d-96e6-dde960e6a001">147,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM3LTEtMS0xLTI4NzY5_8ec1d0fe-a35a-4ba6-8e68-da6f37032174">273,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM3LTMtMS0xLTI4NzY5_3fd963b6-5804-493f-afc8-5c394823a0fa">295,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM3LTUtMS0xLTI4NzY5_59e878e1-0093-4a58-bd81-2a7fb577be97">463,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes paid, net of refunds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM5LTEtMS0xLTI4NzY5_29c87a51-7a42-43bb-b282-08a19fc9a871">478,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM5LTMtMS0xLTI4NzY5_8b284f02-0c73-4d0f-8200-46a6e737a0ac">221,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM5LTUtMS0xLTI4NzY5_9268499c-4f1a-4f62-9f89-9e94c75c92bf">180,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQwLTEtMS0xLTI4NzY5_a1015100-33f5-47f8-8635-6d63c6fc42e4">22,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQwLTMtMS0xLTI4NzY5_d58e2796-0b32-43d8-9b2c-ad9ecff96a95">23,989</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQwLTUtMS0xLTI4NzY5_08cf37b8-c7bf-4982-9f4a-96aa839d3ef7">40,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of assets acquired, excluding cash</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQxLTEtMS0xLTI4NzY5_c5f9ca1c-509a-4fbd-a5b7-d264b0c782d6">15,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQxLTMtMS0xLTI4NzY5_02e15f20-78e8-4981-84c8-7a6ca5f268cf">16,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQxLTUtMS0xLTI4NzY5_e0940ae8-59d2-4613-9570-06d53ab66545">14,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQyLTEtMS0xLTI4NzY5_15eb194d-d7f3-4592-ad81-896a858cd1bb">4,672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQyLTMtMS0xLTI4NzY5_7bee8254-a317-4eaf-93de-e14bc8d9e9d3">1,543</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQyLTUtMS0xLTI4NzY5_3ee4214a-d88b-49b3-8995-678739fd9b68">4,292</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill on acquisition</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTEtMS0xLTI4NzY5_0ac034a2-721c-411a-a938-4d788b5a47c3">38,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTMtMS0xLTI4NzY5_0e8db78b-01e5-486b-9d03-58c7421ed008">24,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTUtMS0xLTI4NzY5_8578f782-85ea-4d83-9b6c-db1b3eb27652">20,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Previously held equity interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTEtMS0xLTMyODQ3_b5778fb4-d028-4020-90fd-8b8e116bc00c">4,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTMtMS0xLTMyODQ3_51aa0302-6149-420d-bcf9-39bc2883f854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTUtMS0xLTMyODQ3_a62a15fb-8988-41a7-9b63-cea191fb3ee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="rmd:DeferredPaymentObligationsForAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ0LTEtMS0xLTI4NzY5_e4d5d7b0-7e6a-4d73-95dc-68546a7da49d">3,067</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="rmd:DeferredPaymentObligationsForAcquisitions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ0LTMtMS0xLTI4NzY5_9b5e8991-8b51-46d7-a7d4-d637594a016f">3,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="rmd:DeferredPaymentObligationsForAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ0LTUtMS0xLTI4NzY5_17913938-790b-4a0d-9b14-e68e18bb1ccb">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value of contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" sign="-" xsi:nil="true" name="rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ1LTEtMS0xLTI4NzY5_32081517-1331-4ac2-9158-6643a47b560d"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ1LTMtMS0xLTI4NzY5_c2fb0ab0-476a-4e21-8bc6-c50259490f2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ1LTUtMS0xLTI4NzY5_51e0bee4-0816-4ee7-9118-9ae979028660">3,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for acquisitions</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ2LTEtMS0xLTI4NzY5_93f01a0e-3cdc-4394-96ae-da00c4845af7">42,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ2LTMtMS0xLTI4NzY5_56391dd7-2a8d-48a9-9d39-095f6ccaa480">43,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ2LTUtMS0xLTI4NzY5_5116ec29-d97c-41f5-8554-724061a408f3">27,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-68-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_103"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_106"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDYvZnJhZzo3MGQ1MGI3YWU2OWU0OThkOGMwY2E4OTMzYmYzNmYyMy90ZXh0cmVnaW9uOjcwZDUwYjdhZTY5ZTQ5OGQ4YzBjYTg5MzNiZjM2ZjIzXzk0OQ_3bbbc1b0-67df-4d6c-ba68-2a7ba357e114" continuedAt="ic8aee19e3f8c49eca2802b19efc566d7" escape="true">Organization and Basis of Presentation </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic8aee19e3f8c49eca2802b19efc566d7">ResMed Inc. (referred to herein as &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or the &#8220;Company&#8221;) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (&#8220;SaaS&#8221;) business in the United States that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.</ix:continuation> </span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_109"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjk3_24905f9a-04e6-4780-a244-67e5981a489d" continuedAt="i00b4125450fb4b2daa1ffdf3df06433c" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="i00b4125450fb4b2daa1ffdf3df06433c" continuedAt="i14962e9782484fcd8f07f42350b67856"><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjkz_4b1e4306-018f-4441-ae7f-96f63f96b478" continuedAt="ic81efc8ec08848adb60e19562b3e8875" escape="true">Basis of Consolidation </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic81efc8ec08848adb60e19562b3e8875">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Certain prior period amounts have been reclassified to conform to the current period presentation. Actual results could differ from management&#8217;s estimates.</ix:continuation></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg5_92a74d9a-32bc-4387-86a4-b3d942b9df75" continuedAt="i1becfaecba124e43872faac6b2241507" escape="true">Revenue Recognition </ix:nonNumeric></span></div><ix:continuation id="i1becfaecba124e43872faac6b2241507" continuedAt="i00fa6df8890b4400abf70bf14d24d7f7"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standard Codification (&#8220;ASC&#8221;) Topic 606, &#8220;Revenue from Contracts with Customers&#8221;, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have <ix:nonFraction unitRef="segment" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzMyOTg1MzQ5MTU5OTY_e4da161c-7f34-4bf9-85f2-5020b2bd0320">two</ix:nonFraction> operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#8220;Sleep and Respiratory Care&#8221;) and the supply of business management software as a service to out-of-hospital health providers (&#8220;SaaS&#8221;). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 14 &#8211; Segment Information for our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2022, 2021 and 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance obligations and contract balances</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with professional services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of <ix:nonNumeric contextRef="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630" name="rmd:TermOfContractUnderRevenueRecognition" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE1OTg_8a0cf1c7-d9ed-4fbf-8495-294d3c5058db">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630" name="rmd:TermOfContractUnderRevenueRecognition" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2MDM_1cbf6f31-e5fa-465c-8a28-0999caac7a83">five years</ix:nonNumeric>. Our contracts do not contain significant financing components. </span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-69-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i14962e9782484fcd8f07f42350b67856" continuedAt="id42ff49e1047406aab6d33610a6ade15"><ix:continuation id="i00fa6df8890b4400abf70bf14d24d7f7"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjkw_a60cb440-4383-460e-90ff-4f54a628f9d6" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances as of June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i395a6823166d44c89daa1c281c702cd0_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzItMS0xLTEtMjg3Njk_562c25d5-cbdd-48ea-abca-2d22aa0c57c8">575,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3515d2e0a2ec4ac79cc7dc24382770f9_I20210630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzItMy0xLTEtMjg3Njk_7939e1ec-1508-4b3c-a2f3-409e4ee0ffa1">614,292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c52baae5bad475ebef7771a9b519ff5_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzMtMS0xLTEtMjg3Njk_789263b1-f027-424c-bdc8-2ac3aa87a6ca">25,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie196dbd7b3fd443b991a4e53f748a874_I20210630" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzMtMy0xLTEtMjg3Njk_abe94fe9-8ce8-42a4-9f2f-eb2d9a15bee4">10,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c52baae5bad475ebef7771a9b519ff5_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzQtMS0xLTEtMjg3Njk_0e6dd7db-ffbf-44b5-b6ee-dd73fac27b32">8,840</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie196dbd7b3fd443b991a4e53f748a874_I20210630" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzQtMy0xLTEtMjg3Njk_9e9f5f82-5e92-4ead-933d-cfb89b3e89ca">6,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzctMS0xLTEtMjg3Njk_41a7625a-f59c-48c3-b805-3885fffbb6ac">108,667</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzctMy0xLTEtMjg3Njk_d4d1e0ff-37d5-4036-9da1-23cc45dd607f">109,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (current liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzgtMS0xLTEtMjg3Njk_16f81069-11d5-48ae-b32e-94339193303f">95,455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzgtMy0xLTEtMjg3Njk_d3376135-2473-4ead-9751-981654e6b743">91,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (non-current liabilities)</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction price determination</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns offered to our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty-related returns, are infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#8217;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates on a quarterly basis based on actual sales results and updated forecasts for the remaining rebate periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting and practical expedient elections</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have adopted two practical expedients including the &#8220;right to invoice&#8221; practical expedient, which allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date and which is relevant for some of our SaaS contracts. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-70-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="id42ff49e1047406aab6d33610a6ade15" continuedAt="i9a027e43933c410194c17af0c37e3ca3"><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="rmd:ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg4_d4c1cdc3-2dcb-46fb-a4c7-0b42dca91f50" continuedAt="i7b5b65d32dcc472583a266ed1b4d8f98" escape="true">Concentration of Credit Risk and Significant Customers</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7b5b65d32dcc472583a266ed1b4d8f98">Financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, derivatives and trade receivables. Our cash and cash equivalents are generally held with large, diverse financial institutions to reduce the amount of exposure to any single financial institution. Our derivative contracts are transacted with various financial institutions with high credit standings and any exposure to counterparty credit-related losses in these contracts is largely mitigated with collateralization and master-netting agreements. The risk with respect to trade receivables is mitigated by credit evaluations we perform on our customers, the short duration of our payment terms for the significant majority of our customer contracts and by the diversification of our customer base. No single customer accounted for 10% or more of our total revenues for any of the periods presented.</ix:continuation></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"> <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjgz_a018afda-52e8-43c4-9d23-535f00482bc7" continuedAt="i7f8a70a069624a099e2c7a7f343061e0" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="i7f8a70a069624a099e2c7a7f343061e0" continuedAt="if75ccf5f38ce442aa9febd873cba1261"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We measure our financial instruments at fair value at each reporting period using a fair value hierarchy that requires that we maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Other inputs that are directly or indirectly observable in the marketplace.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if75ccf5f38ce442aa9febd873cba1261">The carrying value of cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt related to our Revolving Credit and Term Credit Agreements approximates its fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates which are regularly reset. The carrying value of long-term debt related to our Senior Notes can differ to its fair value as the principal amounts outstanding are subject to fixed interest rates as outlined in Note 9 - Debt. Foreign currency hedging instruments are marked to market and therefore reflect their fair value. In addition, we measure investments in publicly held equity securities and privately held equity securities for which there has been an observable price change in an identical or similar security, at fair value. We do not hold or issue financial instruments for trading purposes.</ix:continuation> </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjk0_79620629-52f1-4aa0-85ca-d85934552960" continuedAt="ibdafce7c3d31444e9924d3201857a96f" escape="true">Cash and Cash Equivalents </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibdafce7c3d31444e9924d3201857a96f">Cash equivalents include certificates of deposit and other highly liquid investments and we state them at cost, which approximates market. We consider investments with original maturities of 90 days or less to be cash equivalents for purposes of the consolidated statements of cash flows.</ix:continuation></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjgy_d3ac9cb8-afbe-48a4-bc47-3cb4ef0b1069" continuedAt="ifcb3b3ae7ae04deeae9701ba80fc4473" escape="true">Inventories </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifcb3b3ae7ae04deeae9701ba80fc4473">We state inventories at the lower of cost (determined principally by the first-in, first-out method) or net realizable value. We include material, labor and manufacturing overhead costs in finished goods and work-in-process inventories. We review and provide for any product obsolescence in our manufacturing and distribution operations by assessing throughout the year individual products and components (based on estimated future usage and sales).</ix:continuation></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjkx_c6b8f918-3f26-4a45-818e-ee8f8ae72e11" continuedAt="icc9035636b08419ea977e7a3159a92aa" escape="true">Property, Plant and Equipment </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icc9035636b08419ea977e7a3159a92aa">We record property, plant and equipment, including rental and demonstration equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally <ix:nonNumeric contextRef="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2MTc_ce90ca2e-78b6-4034-9c3e-10ddf195c444">two years</ix:nonNumeric> to <ix:nonNumeric contextRef="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2MjI_963024d7-4b44-4128-8db0-99b19d098e80">ten years</ix:nonNumeric> except for buildings which are depreciated over an estimated useful life of <ix:nonNumeric contextRef="if99f07887f7a46228ef1235e19d7b4a5_D20210701-20220630" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2Mjc_af04786f-7ae8-4598-9b54-23b34ffd3d6a">forty years</ix:nonNumeric> and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.</ix:continuation></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-71-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i9a027e43933c410194c17af0c37e3ca3" continuedAt="i68edc28d465443a09ef1f12ad17f7940"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for property, plant, and equipment was $<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2MzI_de64f410-2c57-455d-912d-c0601bab61d3">81.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2NDA_dd08a4b2-276a-4d29-ba5e-0388dcbdc73f">78.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2NDQ_addd031d-349e-4fad-a669-899cc44286ba">65.6</ix:nonFraction> million for the years ended June&#160;30, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjk1_d387a622-749c-43fb-b2a2-9d7f7afde145" continuedAt="i103b29f91a304a5db7de29695421ea47" escape="true">Intangible Assets </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i103b29f91a304a5db7de29695421ea47" continuedAt="ie246428b7dd349e8bfbb9f4f11db069a">We capitalize the registration costs for new patents and amortize the costs over the estimated useful life of the patent, which is generally <ix:nonNumeric contextRef="i28a3ce23547b4f28a6b1d773a88cbc9b_D20210701-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzMyOTg1MzQ5MTUxNzE_2581100a-2b30-4036-aff8-d5370d99165f">ten years</ix:nonNumeric>. If a patent is superseded or a product is retired, any unamortized costs are written off immediately.</ix:continuation></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie246428b7dd349e8bfbb9f4f11db069a">We amortize all of our other intangible assets on a straight-line basis over their estimated useful lives, which range from <ix:nonNumeric contextRef="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2NjU_3f050888-59c7-4bd2-abf7-668aadbead29">two years</ix:nonNumeric> to <ix:nonNumeric contextRef="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2NzA_0fc8d6f0-b8db-44cb-985c-61525203fefc">fifteen years</ix:nonNumeric>. We take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists and, at least annually, evaluate the recoverability of intangible assets. We have <ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzM4NDgyOTA3MTk5NTQ_20a12df2-55d9-4045-b2cc-6098b491f4a0"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzM4NDgyOTA3MTk5NTQ_ddcae2ad-5f9a-4f7a-a620-42be896540b4"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzM4NDgyOTA3MTk5NTQ_f635ffe3-0b37-4b5a-8317-e09783115a05">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t identified any impairment of intangible assets during any of the periods presented.</ix:continuation> </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjc4_e4e69fb3-a67d-4c6a-911f-b100bad06f0d" continuedAt="i6b2dd3d196304abc8a90c94028231ac4" escape="true">Goodwill </ix:nonNumeric></span></div><ix:continuation id="i6b2dd3d196304abc8a90c94028231ac4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our annual review for goodwill impairment during the final quarter of the fiscal year. Our goodwill impairment review is performed at our reporting unit level, which is one level below our operating segments and involves the following steps: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 0 or Qualitative assessment &#8211; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 1 &#8211; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#8217;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the annual reviews for the years ended June&#160;30, 2022, 2021 and 2020, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjky_90fbfa53-539e-4f6e-98b8-b02f7680af51" continuedAt="iea156cf7c2924aa8a32a9fa119910d00" escape="true">Equity investments </ix:nonNumeric></span></div><ix:continuation id="iea156cf7c2924aa8a32a9fa119910d00" continuedAt="i2f77fe401a6d4489b11fb0d644ae39fe"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our accounting for investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the consolidated statements of operations.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-72-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i68edc28d465443a09ef1f12ad17f7940" continuedAt="i1b4a7c1090004b70b4eca3f2c1d2e628"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2f77fe401a6d4489b11fb0d644ae39fe">Equity investments whereby we have significant influence but not control over the investee, and are not the primary beneficiary of the investee&#8217;s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the consolidated statements of operations.</ix:continuation> </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg0_4192664e-0ddf-406a-bf97-08ca5576e3b7" continuedAt="i014f668725574deeb21ba9e4c76578e2" escape="true">Research and Development </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i014f668725574deeb21ba9e4c76578e2">We record all research and development expenses in the period we incur them.</ix:continuation></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjk2_bc821e98-a9f9-454b-817f-23307a7c3a11" continuedAt="i03b8429af350421bbb78ea02866aa405" escape="true">Foreign Currency </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i03b8429af350421bbb78ea02866aa405">The consolidated financial statements of our non-U.S. subsidiaries, whose functional currencies are other than the U.S. dollar, are translated into U.S. dollars for financial reporting purposes. We translate assets and liabilities of non-U.S. subsidiaries whose functional currencies are other than the U.S. dollar at period end exchange rates, but translate revenue and expense transactions at average exchange rates for the period. We recognize cumulative translation adjustments as part of comprehensive income, as detailed in the consolidated statements of comprehensive income, and include those adjustments in accumulated other comprehensive income in the consolidated balance sheets until such time the relevant subsidiary is sold or substantially or completely liquidated. We reflect gains and losses on transactions denominated in other than the functional currency of an entity in our results of operations.</ix:continuation></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.01pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg1_ec5421ff-447c-4972-8627-fa27e900d5aa" continuedAt="i10dc3c78e2d24376a3f9b9079fdb3f92" escape="true">Foreign Exchange Risk Management </ix:nonNumeric></span></div><ix:continuation id="i10dc3c78e2d24376a3f9b9079fdb3f92" continuedAt="i0bde8e3391c2466582e7c2f4c4ddc348"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our consolidated statements of income and through changes in our operating assets and liabilities within our consolidated statements of cash flows. We classify purchases of foreign currency derivatives and proceeds received from the exercise of foreign currency derivatives as an investing activity within our consolidated statements of cash flows. We do not enter into financial instruments for trading or speculative purposes.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0bde8e3391c2466582e7c2f4c4ddc348">We held foreign currency instruments with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2ODg_9bc7bafe-f680-40f9-947f-cbf96b388113">602.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2OTQ_58b12b34-b529-4bd9-aa6d-cf8f8b8ff91c">556.4</ix:nonFraction> million at June&#160;30, 2022 and June&#160;30, 2021, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to June&#160;30, 2024.</ix:continuation> </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(n)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg2_a0a4fada-6200-4cf1-ad02-3432c19f7414" continuedAt="ibde10b083ed840df80436e8f978e291d" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="ibde10b083ed840df80436e8f978e291d"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using the enacted tax rates we expect to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions are reflected in income tax expense.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-73-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i1b4a7c1090004b70b4eca3f2c1d2e628" continuedAt="i8e1c79a299c74e9ebc3059f91882f599"><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(o)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:StandardProductWarrantyPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjc5_b455d506-4092-4a8c-a415-10ff99ecb760" continuedAt="iceb389be68704cf5b9922d5aa5e02012" escape="true">Provision for Warranty</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iceb389be68704cf5b9922d5aa5e02012">We provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.</ix:continuation></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(p)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="rmd:AllowanceForDoubtfulAccountsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjgw_a59c6225-ddb7-40ed-80b1-1755d939914e" continuedAt="i82feb26d4ac141ddac4a53486285eeea" escape="true">Allowance for Credit Losses</ix:nonNumeric></span></div><ix:continuation id="i82feb26d4ac141ddac4a53486285eeea"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses on customer receivables based on our historical write-off experience, an assessment of our customers&#8217; financial conditions and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions. Customer receivables are charged against the allowance when they are deemed uncollectible. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also contingently liable, within certain limits, in the event of a customer default, to independent financing companies in connection with customer financing programs. We monitor the collection status of these installment receivables and provide for estimated losses separately under accrued expenses within our consolidated balance sheets based upon our historical collection experience with such receivables and a current assessment of our credit exposure.</span></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(q)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg3_b7dea212-ca60-40fa-bb47-ea8e751b084e" continuedAt="ia1b94deb221e4c5c90bd79079bb36df0" escape="true">Impairment of Long-Lived Assets </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia1b94deb221e4c5c90bd79079bb36df0">We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, we recognize as the impairment the amount by which the carrying amount of the assets exceeds the fair value of the assets. We report assets to be disposed of at the lower of the carrying amount or fair value less costs to sell. We did not recognize impairment charges in relation to long-lived assets during the fiscal years ended June&#160;30, 2022, 2021 and 2020.</ix:continuation></span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(r)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjgx_d4f33a23-4878-448b-9f5e-5bf40610f88f" continuedAt="ie9d05597534649c7bc431dd545a728ca" escape="true">Contingencies</ix:nonNumeric></span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8e1c79a299c74e9ebc3059f91882f599"><ix:continuation id="ie9d05597534649c7bc431dd545a728ca">We record a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded.</ix:continuation></ix:continuation> </span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_112"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTIvZnJhZzo3ZDNkMWNhMmQ5NWM0MTE1ODg2NDAyYTBiOGFlMGJjZC90ZXh0cmVnaW9uOjdkM2QxY2EyZDk1YzQxMTU4ODY0MDJhMGI4YWUwYmNkXzI5ODg_e2bb1cf9-d032-4b80-b238-4a35bcf1f89d" continuedAt="iffc7d543384d425c8ad1ed0828f9d90c" escape="true">New Accounting Pronouncements </ix:nonNumeric></span></div><ix:continuation id="iffc7d543384d425c8ad1ed0828f9d90c"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTIvZnJhZzo3ZDNkMWNhMmQ5NWM0MTE1ODg2NDAyYTBiOGFlMGJjZC90ZXh0cmVnaW9uOjdkM2QxY2EyZDk1YzQxMTU4ODY0MDJhMGI4YWUwYmNkXzM4NDgyOTA3MDAyMDY_369be4dd-7ac5-4e90-b744-3d697e6572a9" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ASU No. 2021-08 &#8220;Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, &#8220;Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221; (Topic 805), which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The guidance is effective for us beginning in the first quarter of the year ending June 30, 2024 and early adoption is permitted. We elected to early adopt this standard in the second quarter of our fiscal year ending June 30, 2022. Adoption of ASU 2021-08 did not have a material impact on our consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-74-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_115"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(4) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="rmd:SupplementalBalanceSheetInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90ZXh0cmVnaW9uOmQxZWI2NGQ1ZjJiNTQ0MTM5ZGZkMTUyMWE2NzNjZjhiXzE3Nw_8a7012a8-bc9d-472a-a464-c763f9777627" continuedAt="ic4da60b07c2248a295156a2d4ec926e1" escape="true">Supplemental Balance Sheet Information</ix:nonNumeric></span></div><ix:continuation id="ic4da60b07c2248a295156a2d4ec926e1"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90ZXh0cmVnaW9uOmQxZWI2NGQ1ZjJiNTQ0MTM5ZGZkMTUyMWE2NzNjZjhiXzE3OA_a0dec28d-646e-4c70-af26-96f058aaa4d4" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in the consolidated balance sheets consisted of the following as of June&#160;30, 2022 and June&#160;30, 2021 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventories</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzEtMS0xLTEtMjg3Njk_4f80c2f3-56d4-45a0-8b31-5c643e3420d6">355,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzEtMy0xLTEtMjg3Njk_9bb9ad4a-d8bb-4c5f-aab8-1c67171ab731">155,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzItMS0xLTEtMjg3Njk_9b2845be-49a1-47ba-841b-e54b7cb0b950">3,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzItMy0xLTEtMjg3Njk_795bac3b-a812-43d1-a1e4-8a444d26cc06">4,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzMtMS0xLTEtMjg3Njk_46a8abf2-1df3-4ddc-b19d-40d1c3044ae6">385,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzMtMy0xLTEtMjg3Njk_703d7be7-ff2d-49d3-b493-b0bf03b1cf2d">296,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzQtMS0xLTEtMjg3Njk_bb4512a6-9bbd-451f-88bd-fffeb79cbdbf">743,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzQtMy0xLTEtMjg3Njk_c0cad105-efc2-4c0f-84b6-6e4f2e433c8c">457,033</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90ZXh0cmVnaW9uOmQxZWI2NGQ1ZjJiNTQ0MTM5ZGZkMTUyMWE2NzNjZjhiXzMyOTg1MzQ4ODM1NDc_b8969683-21dc-49c3-b833-c612e429812c" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzEtMS0xLTEtNTU4Mzk_edc3273b-96cf-4b2e-9b3c-48487197e12f">99,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzEtMy0xLTEtNTU4Mzk_a8fd54b4-5d90-48f1-87da-7287a50e579a">72,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="rmd:PrepaidInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzItMS0xLTEtNTU4Mzk_d694e4bc-cad3-45af-a5f3-5358c0b47990">107,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="rmd:PrepaidInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzItMy0xLTEtNTU4Mzk_1d972d19-a2bb-4c9b-ae0c-b1c981549e5a">6,952</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzMtMS0xLTEtNTU4Mzk_f6b30b40-0981-4815-a205-89ab77776d28">131,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzMtMy0xLTEtNTU4Mzk_8810a373-c2ac-41bc-ba9a-142f29044a43">128,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzQtMS0xLTEtNTU4Mzk_66734cd8-3882-4af5-a90c-27fb416a7ccc">337,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzQtMy0xLTEtNTU4Mzk_3feb3022-7cc1-4cec-9f4d-427e1f3e8a7f">208,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:10pt"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90ZXh0cmVnaW9uOmQxZWI2NGQ1ZjJiNTQ0MTM5ZGZkMTUyMWE2NzNjZjhiXzE3OQ_05aa1a4e-8058-45e9-93bd-475d96cf133e" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i209e45ce8baa40da9ad533b396e1a091_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzEtMS0xLTEtMjg3Njk_df5445f1-a2ee-49a3-9751-1e337ffee82e">390,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie01fa7efbed74149bb3ddb5b137cf86b_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzEtMy0xLTEtMjg3Njk_e1815257-1f15-48c1-879a-2847712db1dd">349,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cbe9d650c44532ad24d4a6fe3dfc94_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzItMS0xLTEtMjg3Njk_4ee8d646-3a06-480d-b8c5-2110a10269c0">199,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i633d55b64edf4c93a09ab4cc0f22c9e6_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzItMy0xLTEtMjg3Njk_a112e3b7-7d30-4a84-9834-84a1dcf77d7a">194,386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4960aeb688d4da1892eaa0e59da4d2e_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzMtMS0xLTEtMjg3Njk_1c46a408-3226-4bb0-ad44-26955c430193">54,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4cdad6ff0a54f4a86b3bb451325b302_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzMtMy0xLTEtMjg3Njk_8bb395b2-d706-4d0d-9bd3-0805a92a6e98">54,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vehicles and aircraft</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a380d27436f42cd821417665d91070c_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzQtMS0xLTEtMjg3Njk_62033174-eeca-433e-a15e-ef207b7ec5ae">19,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c114ee233de43edb2dac04cb12f71bc_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzQtMy0xLTEtMjg3Njk_435affb1-ec3f-4820-81b4-9e703d50aa66">5,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical, demonstration and rental equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c2b6d7ce5de4befb6c1ee57c860ff72_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzUtMS0xLTEtMjg3Njk_b3dc9b86-cc5e-4b9c-aff5-304fd7f7d545">105,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42c790c4b0d45ecb0af64685365f55f_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzUtMy0xLTEtMjg3Njk_6b6c1a41-6b44-453f-8c8d-931103e68d50">110,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffb9a63338dc4ffe875023dc79c7905a_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzYtMS0xLTEtMjg3Njk_7131c0aa-c2a9-456b-a91c-3f7d1d0ec5da">80,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a6908e2b224904a2ee86392a3bed03_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzYtMy0xLTEtMjg3Njk_9f22e399-6f0c-4004-8243-ca5ebec34a42">77,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i930755293b68471bac0a4f69a1579932_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzctMS0xLTEtMjg3Njk_91014786-28c2-43ec-94a2-8803e97944ff">51,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieba697dd91864c6794a754cb2f07b007_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzctMy0xLTEtMjg3Njk_1cedaa4c-1eab-469e-a3f3-bcbcefda19a9">54,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62e565965d9f49f2aa99102b8387476a_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzgtMS0xLTEtMjg3Njk_ae5950e5-8491-493b-b5fa-0feb0007ae60">229,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1327c3ca8f3445da9935a8f2dc5e53a2_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzgtMy0xLTEtMjg3Njk_cd35176a-bff9-40ca-b9bd-317befebb054">239,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzktMS0xLTEtMjg3Njk_f9352641-678c-4b38-9637-620e864e4fe3">1,131,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzktMy0xLTEtMjg3Njk_efad08f5-b8cb-4242-9eb4-655dac10f68a">1,085,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzEwLTEtMS0xLTI4NzY5_8d8d7d02-1022-4328-ac44-dcef24765613">633,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzEwLTMtMS0xLTI4NzY5_167cebdf-079b-4ef5-9223-e44aa2bf4236">622,139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzExLTEtMS0xLTI4NzY5_70b06218-fe00-45db-b1d9-45527d4dcb1f">498,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzExLTMtMS0xLTI4NzY5_b35ad260-4f29-4249-a56c-f92fc93b53c6">463,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div id="i1f60984bb51544a482851b08d4a3bf6b_118"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(5) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzEwMzY_510c5617-479a-4bd6-af20-941f772a6d4b" continuedAt="iefd90e71a6194be3a38c43272c9fc76e" escape="true">Goodwill and Other Intangible Assets, net</ix:nonNumeric></span></div><ix:continuation id="iefd90e71a6194be3a38c43272c9fc76e" continuedAt="i70954972b6e34d078f24901194e256ec"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the years ended June&#160;30, 2022 and June&#160;30, 2021, we have not recorded any goodwill impairments. <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzEwMzc_ae7c4507-dc5c-440f-8c68-62227c188904" continuedAt="i51c74cf874654aae862ad7d1f707fb24" escape="true">Changes in the carrying amount of goodwill is comprised of the following for the year ended June&#160;30, 2022 (in thousands): </ix:nonNumeric></span></div><div style="margin-top:10pt"><ix:continuation id="i51c74cf874654aae862ad7d1f707fb24"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sleep and <br/>Respiratory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SaaS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia68dbe4ac6c24607ab0fe9092c69e114_I20210630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzItMS0xLTEtMjg3Njk_ad09954a-737b-4405-823e-5e162de1ff54">633,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i673b7f5418864027b262473e75a24496_I20210630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzItMy0xLTEtMjg3Njk_f3fb2f2e-3146-4daf-9d80-6d9c8c3b00ff">1,294,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzItNS0xLTEtMjg3Njk_a95d3e66-d1f9-444e-9286-14d256f7b528">1,927,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i585a12bee5294dd7a4971ee1e63765a6_D20210701-20220630" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzMtMS0xLTEtMjg3Njk_c887e8cb-05c5-4972-bc03-a2973b63ce53">38,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic386a2f3fc574a6eaa1bc26205d89225_D20210701-20220630" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzMtMy0xLTEtMjg3Njk_c08e7546-a492-46b1-875c-7cea5a9ff92a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzMtNS0xLTEtMjg3Njk_7b7ae1d6-e980-478e-89bc-e7918fc53025">38,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i585a12bee5294dd7a4971ee1e63765a6_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzQtMS0xLTEtMjg3Njk_8efbded4-5a9a-472b-97c1-8baf6d9da6bf">30,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic386a2f3fc574a6eaa1bc26205d89225_D20210701-20220630" decimals="-3" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzQtMy0xLTEtMjg3Njk_831b6bd6-51ee-4462-aa93-ede8a9a73f37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzQtNS0xLTEtMjg3Njk_4d987d0a-f2cc-4eaf-951a-bd00264d61c1">30,412</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d3f3a2e554e4ce498a8c2eac0e1773c_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzUtMS0xLTEtMjg3Njk_f25c1b14-60c7-4091-b05b-04bb1f59c984">641,724</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5920b8d4566429aacc99c4cb598b86b_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzUtMy0xLTEtMjg3Njk_faa415e2-dc3a-4bf9-8f9b-0fcd6b93dcf9">1,294,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzUtNS0xLTEtMjg3Njk_4cdeff73-e264-479a-bf4a-9f1dae173de5">1,936,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-75-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i70954972b6e34d078f24901194e256ec"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzM4NDgyOTA2OTgyNzE_7c8f89db-dc83-4225-858d-249f61552867" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangibles, net are comprised of the following as of June&#160;30, 2022 and June&#160;30, 2021 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383529560350461f9474da7a3e151953_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzEtMS0xLTEtMjg3Njk_1e844e6b-9093-42c0-96e4-320122abf61e">350,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if91504ce254047b09ff93066ad7e7365_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzEtMy0xLTEtMjg3Njk_6239015e-0a0e-443d-9d84-46255bc39f59">383,319</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i383529560350461f9474da7a3e151953_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzItMS0xLTEtMjg3Njk_3d240e5d-4ee4-443c-a1df-4f4e5a18d13e">239,647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if91504ce254047b09ff93066ad7e7365_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzItMy0xLTEtMjg3Njk_61b651f1-abe4-470d-9eb3-c9e616ea475b">239,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i383529560350461f9474da7a3e151953_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzMtMS0xLTEtMjg3Njk_093540ef-bb52-4e6f-84b8-646bad34cdba">111,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if91504ce254047b09ff93066ad7e7365_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzMtMy0xLTEtMjg3Njk_3e23d714-c1fb-4dd4-afb5-e2d02f2687e9">144,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27a41c0bc031463eb9e124aa25b7e462_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzQtMS0xLTEtMjg3Njk_dd2845da-35e9-4352-89ab-82d6e8e73fff">257,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie60c3c5babf44f189d82c62d83c1ba0e_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzQtMy0xLTEtMjg3Njk_eb6e44ed-172a-48d4-b09d-7a62ab262447">272,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27a41c0bc031463eb9e124aa25b7e462_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzUtMS0xLTEtMjg3Njk_e5d8ee3a-57b5-42e6-94ff-0dde17323736">91,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie60c3c5babf44f189d82c62d83c1ba0e_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzUtMy0xLTEtMjg3Njk_ebcc9713-a6c9-42ce-82fe-b5cec8d93e72">90,976</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27a41c0bc031463eb9e124aa25b7e462_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzYtMS0xLTEtMjg3Njk_b9c18ee7-8d6d-4b9b-9ae3-98c9ccec8f69">165,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie60c3c5babf44f189d82c62d83c1ba0e_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzYtMy0xLTEtMjg3Njk_568c30a5-d828-4a4a-8e35-43e97cd0b673">181,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id414856654b6425f94e23c727ecf7d42_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzctMS0xLTEtMjg3Njk_6d1839c9-5f59-4b27-a144-92dd77119870">204,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26192f7e58a3451690f985df3d035304_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzctMy0xLTEtMjg3Njk_7e684987-f976-4bf8-b521-f96743417517">197,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id414856654b6425f94e23c727ecf7d42_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzgtMS0xLTEtMjg3Njk_1e80fdff-88b0-4b34-abc4-d8abb3316958">134,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26192f7e58a3451690f985df3d035304_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzgtMy0xLTEtMjg3Njk_c3cd3e52-9103-46f4-a675-4110de49cc97">131,077</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id414856654b6425f94e23c727ecf7d42_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzktMS0xLTEtMjg3Njk_2b1d3102-abc6-4990-9357-4f9def9c1495">69,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26192f7e58a3451690f985df3d035304_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzktMy0xLTEtMjg3Njk_d852100b-4ddc-41b5-b6b0-8942000112ee">66,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other intangibles, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzEwLTEtMS0xLTI4NzY5_cfb07f85-1431-4291-9cf6-33957ce85b82">345,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzEwLTMtMS0xLTI4NzY5_f1026d7a-dc1b-478a-9fe6-30fdbdf5f2dd">392,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, and we amortize them over the estimated useful life of the assets, generally between <ix:nonNumeric contextRef="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIxODM_3f050888-59c7-4bd2-abf7-668aadbead29">two years</ix:nonNumeric> and <ix:nonNumeric contextRef="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIxODg_0fc8d6f0-b8db-44cb-985c-61525203fefc">fifteen years</ix:nonNumeric>. There are no expected residual values related to these intangible assets. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to identified intangible assets for the years ended June&#160;30, 2022 and June&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i275c6f7ccc89416f8b114a73abdb1eb2_D20210701-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIyMDE_b6dc7354-1986-4004-b1c6-7ebc6d839125">70.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ide28368adb344db981e13dc7ab3f39e6_D20200701-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIyMDU_a67be815-f226-4f06-ace4-59260a0e7b56">76.2</ix:nonFraction> million, respectively. Amortization expense related to patents for the years ended June&#160;30, 2022 and June&#160;30, 2021 was $<ix:nonFraction unitRef="usd" contextRef="i28a3ce23547b4f28a6b1d773a88cbc9b_D20210701-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIyMTc_0ff29332-61f4-44c0-bc05-ad60b17b3ee8">6.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5e17c04c42c84b1da53be06c8c07c44b_D20200701-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIyMjE_053b3926-4445-4e54-94f8-287ca7ee758f">5.3</ix:nonFraction> million, respectively. <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzEwMzU_1a35170f-1405-4e76-9650-35631b2df1c1" continuedAt="i8b01114ada13491d9d9c55cc302c1a66" escape="true">Total estimated annual amortization expense for the years ending June 30, 2023 through June 30, 2027, is shown below (in thousands): </ix:nonNumeric></span></div><div style="margin-top:10pt"><ix:continuation id="i8b01114ada13491d9d9c55cc302c1a66"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June&#160;30</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTpiYzVhOWVkMTJhNTM0MzVmOTdmMGY3YTA4ZWEwOTNiZC90YWJsZXJhbmdlOmJjNWE5ZWQxMmE1MzQzNWY5N2YwZjdhMDhlYTA5M2JkXzItMS0xLTEtMjg3Njk_bd3f3638-0d00-46d6-98e2-fd1f45492d58">61,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTpiYzVhOWVkMTJhNTM0MzVmOTdmMGY3YTA4ZWEwOTNiZC90YWJsZXJhbmdlOmJjNWE5ZWQxMmE1MzQzNWY5N2YwZjdhMDhlYTA5M2JkXzItMy0xLTEtMjg3Njk_433d1392-5a16-4822-a2fd-bb6f421c5a3d">57,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTpiYzVhOWVkMTJhNTM0MzVmOTdmMGY3YTA4ZWEwOTNiZC90YWJsZXJhbmdlOmJjNWE5ZWQxMmE1MzQzNWY5N2YwZjdhMDhlYTA5M2JkXzItNS0xLTEtMjg3Njk_78289868-62d9-45c1-b313-4fc9b34db03f">53,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTpiYzVhOWVkMTJhNTM0MzVmOTdmMGY3YTA4ZWEwOTNiZC90YWJsZXJhbmdlOmJjNWE5ZWQxMmE1MzQzNWY5N2YwZjdhMDhlYTA5M2JkXzItNy0xLTEtMjg3Njk_521672a7-853e-4306-9252-5af2d45034af">47,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTpiYzVhOWVkMTJhNTM0MzVmOTdmMGY3YTA4ZWEwOTNiZC90YWJsZXJhbmdlOmJjNWE5ZWQxMmE1MzQzNWY5N2YwZjdhMDhlYTA5M2JkXzItOS0xLTEtMjg3Njk_018811ff-1ac5-4c3e-8873-da34d6635a6b">29,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i1f60984bb51544a482851b08d4a3bf6b_121"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(6) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:InvestmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzgzNw_286e4d88-893f-4710-b005-63d742d8b840" continuedAt="if9854d6a475a4a88a4c45c3a685ac24f" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="if9854d6a475a4a88a4c45c3a685ac24f" continuedAt="i55038a7e1977426485f6591f296f97cb"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="rmd:ScheduleOfInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzgzOA_bb99fec1-0315-4b6c-8d25-91740cc64ff4" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments by measurement category as of June&#160;30, 2022 and June&#160;30, 2021 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="rmd:MarketableEquityInvestmentsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzEtMS0xLTEtMjg3Njk_29c0fd30-0a25-46fe-9075-b3168d5641c6">9,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="rmd:MarketableEquityInvestmentsFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzEtMy0xLTEtMjg3Njk_aa099215-e9f3-47d5-9069-a0b438af9245">29,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement alternative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzItMS0xLTEtMjg3Njk_fb2beecf-f1af-4a15-8efb-5359ff48ec19">39,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzItMy0xLTEtMjg3Njk_7c3f090d-46ea-40ae-bb7d-85c33bcc1d95">23,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzMtMS0xLTEtMjg3Njk_8df02a8f-5c1b-484a-8e29-fad2e5c2276e">9,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzMtMy0xLTEtMjg3Njk_be704870-e20b-434a-af7e-496f307e55ad">17,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="rmd:EquityInvestmentsTotalByMeasurementCategory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzQtMS0xLTEtMjg3Njk_026d23d9-31d5-4218-85e4-f6fa49087517">58,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="rmd:EquityInvestmentsTotalByMeasurementCategory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzQtMy0xLTEtMjg3Njk_c5274aa9-99cd-4241-8ced-42b62c56bff2">69,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="rmd:ScheduleOfChangesInEquityInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzgzOQ_6afeefa3-9445-46ca-b2b0-c2f4120a5967" continuedAt="i537f1d5630b64e11af110598e0528f64" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2022 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346adc043b664e69a5d86956607aa19d_I20210630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzEtMS0xLTEtMjg3Njk_5fb84cd4-86c3-4989-9a15-ffe1d7929922">23,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15585071980b44609c4244d0667080d3_I20210630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzEtMy0xLTEtMjg3Njk_949536e2-11d1-4a4c-83b7-36daf6c82a3e">29,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ecaa50f2b0842ebaa2fada9c7ce2d1a_I20210630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzEtNS0xLTEtMjg3Njk_76058318-b70b-4d7d-b556-efcea6087f1c">17,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzEtNy0xLTEtMjg3Njk_8c20c570-fcf5-43bc-acdd-98a713a3a42c">69,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net additions (reductions) to investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ab83892aae4ba397a55655fbf05f29_D20210701-20220630" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzItMS0xLTEtMjg3Njk_894ab772-1705-409d-9479-3bf9ba7bb45c">11,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12742f5ecfc34a62988f7e0587db5dd6_D20210701-20220630" decimals="-3" sign="-" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzItMy0xLTEtMjg3Njk_4ea81470-5886-478a-abcb-ce30aecda9b6">3,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida2475934ea241ca9c2d0a10c164d26b_D20210701-20220630" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzItNS0xLTEtMjg3Njk_a72d4418-9732-4827-bc7e-21b8acc9883f">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzItNy0xLTEtMjg3Njk_e1e15fca-98bc-4f4b-bc24-32e3833ce532">9,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ab83892aae4ba397a55655fbf05f29_D20210701-20220630" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzMtMS0xLTEtMjg3Njk_63238a08-47bf-4338-b4a0-3bffa7a1dcb0">5,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzMtNy0xLTEtMjg3Njk_537712fb-0448-498d-a0c6-299086713433">5,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i12742f5ecfc34a62988f7e0587db5dd6_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzQtMy0xLTEtMjg3Njk_90f18c59-8c24-4d9c-84bf-a9db6f9c473d">18,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzQtNy0xLTEtMjg3Njk_07ff6f3f-5a4c-453b-95c5-17dad620a986">18,341</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains on marketable and non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ab83892aae4ba397a55655fbf05f29_D20210701-20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzUtMS0xLTEtMjg3Njk_05a761d3-4d54-4cc5-aeb0-c478b74a4e50">2,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12742f5ecfc34a62988f7e0587db5dd6_D20210701-20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzUtMy0xLTEtMjg3Njk_a6da4433-da84-44b8-a3dc-dc8ca8a5fe54">1,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzUtNy0xLTEtMjg3Njk_64a4fa49-8d17-4ec4-9380-a1a1182f6700">3,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ab83892aae4ba397a55655fbf05f29_D20210701-20220630" decimals="-3" name="us-gaap:ImpairmentOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzYtMS0xLTEtMzM2MTA_7a6a3c27-0f39-4daf-9fbc-4a99e1357598">3,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:ImpairmentOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzYtNy0xLTEtMzM2MTA_d0fdb045-88e6-42f3-98b7-8a6a903cbc5d">3,209</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ida2475934ea241ca9c2d0a10c164d26b_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzYtNS0xLTEtMjg3Njk_a8b21223-8a3d-4d2f-bce8-83f3ef694450">8,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzYtNy0xLTEtMjg3Njk_879dda50-bc18-4b9f-9c80-7a77018fd165">8,486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986baaa416044ab0b8a0147a14087047_I20220630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzctMS0xLTEtMjg3Njk_ad3fc8ce-1e53-46f8-8d9f-003a08b83ee5">39,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia249219ca61d4c4ea23e703cf2260422_I20220630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzctMy0xLTEtMjg3Njk_8b43a982-736f-4ccc-92bf-d0d11e2dc9e7">9,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b6f2c0aa8974e7cb7f65b5033462701_I20220630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzctNS0xLTEtMjg3Njk_074d509c-6a39-43db-8a23-484a0e382b92">9,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzctNy0xLTEtMjg3Njk_05a5f0f8-ae7c-466d-9de6-f5d3e546a298">58,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Net additions (reductions) to investments includes additions from purchases, reductions due to exits of securities, or reclassifications due to our acquisition of an investee in which we held a prior equity interest. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-76-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i55038a7e1977426485f6591f296f97cb" continuedAt="ibef9614800fd4ea28a2b4138b07a99df"><ix:continuation id="i537f1d5630b64e11af110598e0528f64" continuedAt="i866c74b756fa4cbc9a5400de66bc061b"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2021(in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84ec92f010cb4996b46b1526ee19a1bc_I20200630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzEtMS0xLTEtMjg3Njk_13ac187c-bef9-4d57-b44a-246af6b5fa80">30,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4cd11b6bc34d7895326f826a7c3f0d_I20200630" decimals="-3" name="rmd:EquityInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzEtMy0xLTEtMjg3Njk_a5fd00e6-7033-44d5-bced-309cb0d4af98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd1dcdc316cf456186c44ff5d3915ada_I20200630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzEtNS0xLTEtMjg3Njk_6106b7df-548a-4365-947b-d5652c37858b">14,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzEtNy0xLTEtMjg3Njk_3c42abc8-1d9b-4f6a-83c6-ef28800ae9ee">44,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if003111e277449988551264e5889944a_D20200701-20210630" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzItMS0xLTEtMjg3Njk_e36849a3-f054-4f04-95be-8fa67d67f5fe">2,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c095726ae74638a2cadaaac6191673_D20200701-20210630" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzItMy0xLTEtMjg3Njk_bc21f7dc-8b7d-44aa-97f6-681818efc601">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd4cbd01865547d0b68850bcd7ca2e04_D20200701-20210630" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzItNS0xLTEtMjg3Njk_50e1ccb8-b777-428e-831a-2a037a78614f">14,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="rmd:AdditionalEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzItNy0xLTEtMjg3Njk_e364894d-7ed6-480b-85f5-c0584fc2a7b1">21,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if003111e277449988551264e5889944a_D20200701-20210630" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzMtMS0xLTEtMzM1NjU_1c8031ef-41be-40c8-ab0c-cb95cc17216c">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzMtNy0xLTEtMzM1NjU_54b55d55-3935-4970-adb4-b7e085aa2784">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c095726ae74638a2cadaaac6191673_D20200701-20210630" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzQtMy0xLTEtMzM1NjU_f045bd68-2428-4f86-92c7-604b5e10ee2f">13,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzQtNy0xLTEtMzM1NjU_1498af72-94fe-40f5-9534-de0f0c32522b">13,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if003111e277449988551264e5889944a_D20200701-20210630" decimals="-3" sign="-" name="rmd:ReclassificationsInEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzMtMS0xLTEtMjg3Njk_384ab9bd-2429-4978-8484-8fbe415e89d2">10,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01c095726ae74638a2cadaaac6191673_D20200701-20210630" decimals="-3" name="rmd:ReclassificationsInEquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzMtMy0xLTEtMjg3Njk_6ad21bfe-8e4f-4b24-adc3-8d712c19a930">10,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="rmd:ReclassificationsInEquityInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzMtNy0xLTEtMjg3Njk_c4c9ffe6-3547-4cc7-811a-6a3259a46007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd4cbd01865547d0b68850bcd7ca2e04_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzQtNS0xLTEtMjg3Njk_cf9c04d4-68b2-4608-8976-4360cf5f59f6">11,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzQtNy0xLTEtMjg3Njk_3cbd8b96-d248-4fed-9c67-e4708d19fbec">11,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346adc043b664e69a5d86956607aa19d_I20210630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzUtMS0xLTEtMjg3Njk_d3a57df8-e1c4-48ad-9547-2db195bbaa99">23,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15585071980b44609c4244d0667080d3_I20210630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzUtMy0xLTEtMjg3Njk_53b15f65-ce01-4bee-89b2-63a4f7c3c98c">29,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ecaa50f2b0842ebaa2fada9c7ce2d1a_I20210630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzUtNS0xLTEtMjg3Njk_b91012fb-604c-47c1-8389-0caf691c778b">17,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="rmd:EquityInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzUtNy0xLTEtMjg3Njk_cb57f293-b05a-4286-a039-0e87a4eb68f1">69,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i866c74b756fa4cbc9a5400de66bc061b" continuedAt="id40ab2dacddb4a429f839c6f652ca379">(2)</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"><ix:continuation id="id40ab2dacddb4a429f839c6f652ca379">During the year ended June&#160;30, 2021, one of our investments, which was previously accounted for under the measurement alternative, completed its initial public offering which resulted in a change of accounting methodology to fair value.</ix:continuation> </span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibef9614800fd4ea28a2b4138b07a99df">Net unrealized gains and losses recognized in the years ended June&#160;30, 2022, 2021 and 2020 for equity investments in non-marketable and marketable securities still held as of those respective dates were a loss of $<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzQzOTgwNDY1MTM0NDc_91d1f50d-001f-4e6b-9c0b-8fa43006f394">16.2</ix:nonFraction> million, a gain of $<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzQzOTgwNDY1MTM0NjQ_d5092c65-0a65-42f7-8be0-8556fa7d54ca">14.5</ix:nonFraction> million, and a loss of $<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzQzOTgwNDY1MTM0ODE_d9f908d4-6983-46b1-bcad-14a57d2b9127">14.5</ix:nonFraction> million, respectively.</ix:continuation> </span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_124"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(7) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90ZXh0cmVnaW9uOmJkOTlkNzNmZGVmYTRiMWVhY2E2MGJkMTA1MjRjN2E1Xzk5_5e20447c-51dc-4a9c-81a7-6de18c63c8cc" continuedAt="i09ee30155cec4489aa7a881b38139a39" escape="true">Accrued Expenses </ix:nonNumeric></span></div><ix:continuation id="i09ee30155cec4489aa7a881b38139a39"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90ZXh0cmVnaW9uOmJkOTlkNzNmZGVmYTRiMWVhY2E2MGJkMTA1MjRjN2E1XzEwMA_9e518cc3-508d-43c4-a5a6-2b6fb5779fa2" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses at June&#160;30, 2022 and June&#160;30, 2021 consist of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product warranties (note 8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzEtMS0xLTEtMjg3Njk_b04e99ff-3f17-4fad-93df-d790f8c48fee">25,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzEtMy0xLTEtMjg3Njk_ea30f838-43d0-4992-9785-79f1ccf85e29">22,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting and professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzItMS0xLTEtMjg3Njk_26e919f9-059c-4001-b5a1-c3c304ca9452">25,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzItMy0xLTEtMjg3Njk_eb85dfe4-0be9-4d27-a6e0-c0b65529d6a1">21,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value added taxes and other taxes due</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzMtMS0xLTEtMjg3Njk_0b189980-83f7-4056-a03f-05e0d82cda21">26,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzMtMy0xLTEtMjg3Njk_16c8c46f-b4a1-4757-a4d2-2101268a10a6">26,542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzQtMS0xLTEtMjg3Njk_1480d4f3-9380-486b-9b03-42e26ce6c0e1">194,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzQtMy0xLTEtMjg3Njk_0d00ab98-1fe1-4034-90d9-56ed769574ba">199,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promotional and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzUtMS0xLTEtMjg3Njk_834dd4c9-55bb-4338-ab13-2f2abe304976">6,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AccruedMarketingCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzUtMy0xLTEtMjg3Njk_1b3aed69-740a-476e-b781-cfcb6f2e84d3">4,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzYtMS0xLTEtMjg3Njk_66e0ba83-3fb8-422b-9c40-f253b1b914cc">7,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzYtMy0xLTEtMjg3Njk_c73242e7-a6a6-4be9-a515-08c284959949">8,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Logistics and occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="rmd:AccruedLogisticsAndOccupancyExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzctMS0xLTEtMjg3Njk_18909ebf-1e75-4327-bf5c-11d15896f757">32,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="rmd:AccruedLogisticsAndOccupancyExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzctMy0xLTEtMjg3Njk_40bcc186-b67e-443c-9a35-c6bd7fd304d0">14,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory in transit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="rmd:AccruedInventoryInTransit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzgtMS0xLTEtMjg3Njk_b9930382-3ad0-4118-a38c-060f625f41e5">11,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="rmd:AccruedInventoryInTransit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzgtMy0xLTEtMjg3Njk_669e3c8a-cf65-4842-ad67-a0f002500b1b">7,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzktMS0xLTEtMjg3Njk_2a2e8a55-672f-45c2-979c-b7c79d0e89cd">14,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzktMy0xLTEtMjg3Njk_318fad8b-de95-4b80-9208-34ead81ec615">16,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzEwLTEtMS0xLTI4NzY5_0af66513-70e4-4b41-b234-f49becf7a4a6">344,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzEwLTMtMS0xLTI4NzY5_a2ec5704-c6d7-4b3d-a00a-6862bd6181f5">320,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1f60984bb51544a482851b08d4a3bf6b_127"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(8) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ProductWarrantyDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90ZXh0cmVnaW9uOjMzNmYyMDczZWI5NTQ1NTc4MWY1Y2QyNDZmZTI4MDkzXzIzNg_bb23abde-fa67-4804-ac31-d016aab29e7f" continuedAt="i8445935359ce478aa2f9cbd5551412e5" escape="true">Product Warranties</ix:nonNumeric></span></div><ix:continuation id="i8445935359ce478aa2f9cbd5551412e5"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include the liability for warranty costs in accrued expenses in our consolidated balance sheets. <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90ZXh0cmVnaW9uOjMzNmYyMDczZWI5NTQ1NTc4MWY1Y2QyNDZmZTI4MDkzXzIzNQ_9a3ec0fc-3de3-4217-b785-d4ed2cd44257" continuedAt="i966272ec3cfe41cd84460017586bfb0e" escape="true">Changes in the liability for product warranty for the years ended June&#160;30, 2022 and June&#160;30, 2021 are as follows (in thousands):</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><ix:continuation id="i966272ec3cfe41cd84460017586bfb0e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzEtMS0xLTEtMjg3Njk_dbf9d2d9-f47b-44d1-86da-f66798412cfb">22,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzEtMy0xLTEtMjg3Njk_32b770ee-a15a-4aee-843c-80ba42c938c4">21,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warranty accruals for the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzItMS0xLTEtMjg3Njk_10a1f5ab-f798-408f-88da-cf50373f965e">17,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:ProductWarrantyAccrualWarrantiesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzItMy0xLTEtMjg3Njk_174d661e-ad47-47c5-8c88-ba7e6143e810">14,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warranty costs incurred for the period </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzMtMS0xLTEtMjg3Njk_37e4f016-72db-4998-a03a-9e34f458a26e">12,124</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:ProductWarrantyAccrualPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzMtMy0xLTEtMjg3Njk_2f33d89d-1c21-4002-ae55-b6dd417edd57">14,858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzQtMS0xLTEtMjg3Njk_03ec23ba-77fc-4249-88bb-1e52c3562ff3">1,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzQtMy0xLTEtMjg3Njk_ba05d745-b42d-4cc3-af9b-3e8050ccea04">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzUtMS0xLTEtMjg3Njk_0a8b6442-ee06-43e2-97de-a4e69627fb4c">25,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:ProductWarrantyAccrual" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzUtMy0xLTEtMjg3Njk_ec8edf7b-a04b-4af5-81f0-513e1f164d1d">22,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-77-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_130"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(9) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzY4NTQ_c6d8955e-d0b7-4d79-ac94-78a69dae67db" continuedAt="ie47aa3cd742d4e32acb5ee5f91db3ae3" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="ie47aa3cd742d4e32acb5ee5f91db3ae3" continuedAt="ie80005a485d045a9b6dedbb902d89099"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzY4NTU_351c0fce-a01b-46a6-87b9-9f2634dadfb3" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at June&#160;30, 2022 and June&#160;30, 2021 consists of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="rmd:ShortTermDebtGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzMtMS0xLTEtMjg3Njk_9a405bf2-d5c7-48e5-9a4a-f8b5c76220aa">10,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="rmd:ShortTermDebtGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzMtMy0xLTEtMjg3Njk_91e711f3-33ed-4cdd-bdfd-68f3e4ee8b18">12,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredFinanceCostsCurrentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzItMS0xLTEtNDcxMDY_089bca7d-b9f8-4c0f-8250-caf40a8b694e">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzItMy0xLTEtNDcxMDY_e5b8c6f8-91c9-4709-bf31-9c85888e5dad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzMtMS0xLTEtNDcxMDY_0cbc7496-274d-4245-8f3a-5294eef6dbd6">9,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzMtMy0xLTEtNDcxMDY_c8b68f31-ae02-48e5-a13d-a1ca340936d1">12,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzUtMS0xLTEtMjg3Njk_f4b444f7-8ea3-402f-9592-568de026b8ed">770,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzUtMy0xLTEtMjg3Njk_02714b06-8fed-438a-9a37-0d4a7837dc5b">646,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredFinanceCostsNoncurrentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzYtMS0xLTEtMjg3Njk_5a3807ca-e42c-4331-aeca-7acfdc198fce">4,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredFinanceCostsNoncurrentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzYtMy0xLTEtMjg3Njk_36abbfc8-0e1f-44dc-874a-51d567571212">2,649</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzctMS0xLTEtMjg3Njk_63215acf-ad26-4564-8377-3588ea2335fe">765,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzctMy0xLTEtMjg3Njk_c65285f3-e784-4d88-8f20-6e58750a33db">643,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzgtMS0xLTEtMjg3Njk_6ea89b50-c449-45e8-8eb5-5b8a3d0c365f">775,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzgtMy0xLTEtMjg3Njk_751b4b5b-b1b9-4ea9-9345-edcf681e9368">655,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;29, 2022, we entered into a second amended and restated credit agreement (the &#8220;Revolving Credit Agreement&#8221;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, and Wells Fargo Bank, National Association, as documentation agent. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $<ix:nonFraction unitRef="usd" contextRef="i15e467c7054a4a68be2dda7a759368b3_I20220629" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwMDc_fa2d7143-bcdf-4d4d-8a0b-cce8302b1c0f">1,500.0</ix:nonFraction> million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $<ix:nonFraction unitRef="usd" contextRef="i423b2284861f4712a8115af92f3cb518_D20220629-20220629" decimals="-5" name="rmd:UncommittedOptionToIncreaseCreditFacility" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwMTE_53e180b8-0a9e-499c-964e-f361eaf589b1">1,000.0</ix:nonFraction> million and <ix:nonFraction unitRef="number" contextRef="i15e467c7054a4a68be2dda7a759368b3_I20220629" decimals="INF" name="rmd:DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzMyOTg1MzQ4OTk4ODY_9558863d-d3b7-49e3-9cd8-1eac124c9352">1.00</ix:nonFraction> times the EBITDA (as defined in the Revolving Credit Agreement) for the trailing twelve-month measurement period. The Revolving Credit Facility amends and restates that certain Amended and Restated Credit Agreement, dated as of April 17, 2018, among ResMed, MUFG Union Bank, N.A., Westpac Banking Corporation and the lenders party thereto which provided ResMed with a senior unsecured revolving credit facility in an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="ifa80124e3bf34fd6856246349e38455b_I20180417" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzMyOTg1MzQ5MDA2ODg_9105e895-295a-4c68-a319-2b3ffc336248">1,600.0</ix:nonFraction> million with an uncommitted option to increase such facility by an additional $<ix:nonFraction unitRef="usd" contextRef="ibeda0a0993ea40a2b71c2c39f3e0b04e_D20180417-20180417" decimals="-5" name="rmd:UncommittedOptionToIncreaseCreditFacility" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzMyOTg1MzQ5MDA3MDQ_8c8991fa-8dbc-4b82-9ad0-ee8c15e1739d">300.0</ix:nonFraction> million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on June&#160;29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement (the &#8220;Term Credit Agreement&#8221;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner, which amends that certain Syndicated Facility Agreement dated as of April 17, 2018. The Term Credit Agreement, among other things, provides ResMed Pty a senior unsecured term credit facility of $<ix:nonFraction unitRef="usd" contextRef="i1310207dfcac4a1e9c44860aeeda4bc2_I20220629" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwMTk_5bfadd19-79da-4ffc-b969-77eba02b8728">200.0</ix:nonFraction> million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Pty Limited&#8217;s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Agreement and Term Credit Agreement each terminate on June&#160;29, 2027, when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a $<ix:nonFraction unitRef="usd" contextRef="i979ebcc3a5a0402b874813dc295d674e_D20220629-20220629" decimals="-5" name="us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwNTc_f7f0df8f-d3e4-4918-92ef-b6509e1f569d">5.0</ix:nonFraction> million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to the Adjusted Term SOFR (as defined in the Revolving Credit Facility) plus <ix:nonFraction unitRef="number" contextRef="ie7f649a73f7b49bb986cbfd39350e44a_D20220629-20220629" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwNjE_e2464cf0-0d48-4d96-a8d1-dd286c1a36f1">0.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ifd7c672f30f84268aabf143857e5170f_D20220629-20220629" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwNjU_0a6b7b6f-26a6-449a-bf03-17eeb872f1d8">1.50</ix:nonFraction>% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus <ix:nonFraction unitRef="number" contextRef="i97c8b018596f4013a44574b3fd63633c_D20220629-20220629" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwNjk_58a17c9a-4546-4767-846d-904535f241ab">0.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i20f542b063f24d7092707acc8b5cf64c_D20220629-20220629" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwNzM_7a38097a-43da-4193-b4de-78a118a49007">0.50</ix:nonFraction>% (depending on the then-applicable leverage ratio). At June&#160;30, 2022, the interest rate that was being charged on the outstanding principal amounts was <ix:nonFraction unitRef="number" contextRef="i806485f7ccaf4c9d9c68aad92130fec2_I20220630" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwODE_0f1e70d1-6643-4b7d-8164-e5b9630152e1">3.00</ix:nonFraction>%. An applicable commitment fee of <ix:nonFraction unitRef="number" contextRef="i59e7501df49b4377bbb3fff86c0f16b9_D20210701-20220630" decimals="5" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwODU_28618f5c-06fe-4762-96b1-c725cab9f40e">0.075</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if7e0730b8e7c4927a93f00a20c7493ce_D20210701-20220630" decimals="5" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwOTA_b466152c-2362-4cbb-90a9-712692ff6ed4">0.150</ix:nonFraction>% (depending on the then-applicable leverage ratio) applies </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-78-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="ie80005a485d045a9b6dedbb902d89099" continuedAt="ie48700830bb844038c2b11db060717ba"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the unused portion of the revolving credit facility. As of June&#160;30, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="ie854b85863de4deb8101483d69a0c966_I20220630" decimals="-8" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwOTg_250dd10b-52a6-4bdf-b1cc-16bcba6c9be9">1.4</ix:nonFraction> billion available for draw down under the revolving credit facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As the Revolving Credit and Term Credit Agreements&#8217; interest rate is calculated as Adjusted Term SOFR plus the spreads described above, its carrying amount is equivalent to its fair value as at June&#160;30, 2022 and June&#160;30, 2021, which was $<ix:nonFraction unitRef="usd" contextRef="ie854b85863de4deb8101483d69a0c966_I20220630" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxMTE_b9d2cb8d-7f1c-4f5e-94df-0f28fb4a10b6">280.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia73b672018ee4f70af77e8d5c26893a7_I20210630" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxMTU_76ce444e-f9e5-457d-9422-c877f2080529">158.0</ix:nonFraction> million, respectively. Quoted market prices in active markets for identical liabilities based inputs (Level 2) were used to estimate fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $<ix:nonFraction unitRef="usd" contextRef="i5f8645a6deef4fda9ef586462b0c447a_I20190710" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxMjQ_041b3a49-8e66-443f-8436-43fd92ee8f12">250.0</ix:nonFraction> million principal amount of our <ix:nonFraction unitRef="number" contextRef="i5bc2d01b0be2456a84c67fc7a3d70988_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxMjg_9f43ac14-2f4c-4d4c-bf0c-7666b329ab46">3.24</ix:nonFraction>% senior notes due July&#160;10, 2026, and $<ix:nonFraction unitRef="usd" contextRef="i9bb1537c0dcc4eacb698500930b3471e_I20190710" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxNDk_d759b172-4c20-4b72-94f2-c5c9036fbf73">250.0</ix:nonFraction> million principal amount of our <ix:nonFraction unitRef="number" contextRef="i6b7a51beb7fb4fe981c3f830e45c4d63_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxNTM_3d5dc3fa-996c-44fc-b27d-6949ee237539">3.45</ix:nonFraction>% senior notes due July&#160;10, 2029 (collectively referred to as the &#8220;Senior Notes&#8221;). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA (as defined in the Note Purchase Agreement) of no more than <ix:nonFraction unitRef="number" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="2" name="rmd:DebtToConsolidatedEbitdaRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxODI_47be0962-d6ad-4e13-9c67-e282f1de7848">3.50</ix:nonFraction> to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed <ix:nonFraction unitRef="number" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="INF" name="rmd:LineOfCreditFacilityCollateralPercentageOfTheCompany" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxOTA_d581a82b-8251-4634-a66e-2c1a2437e75e">10.0</ix:nonFraction>% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter. This ratio is calculated at the end of each reporting period for which the Note Purchase Agreement requires us to deliver financial statements, using the results of the 12 consecutive month period ending with such reporting period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of June&#160;30, 2022, the Senior Notes have a carrying amount of $<ix:nonFraction unitRef="usd" contextRef="i378917c231c447fcbef3c0d8863c6fc3_I20220630" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxOTU_a091e0d1-6d62-42e2-a602-dcb9e3b6b87b">500.0</ix:nonFraction> million, excluding deferred borrowing costs, and an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i378917c231c447fcbef3c0d8863c6fc3_I20220630" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxOTk_5c952c0b-d11c-49eb-8de1-e53241915848">477.7</ix:nonFraction> million. Quoted market prices in active markets for identical liabilities based inputs (Level 2) were used to estimate fair value.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie48700830bb844038c2b11db060717ba">At June&#160;30, 2022, we were in compliance with our debt covenants and there was $<ix:nonFraction unitRef="usd" contextRef="i54370628e55148a3a1429b5d08709d48_I20220630" decimals="-5" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgyMDM_ea48eb2a-4a83-42b8-8477-2479fc3131fe">780.0</ix:nonFraction> million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes.</ix:continuation> </span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_133"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(10) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDQ_1f8cd600-693b-4bcc-89d3-b138591f93f5" continuedAt="ida7fdd6a75db4fc99306d2dde4c25ba0" escape="true"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:LessorSalesTypeLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDQ_ccbd6cdd-f660-4678-b41b-ecf73103644b" continuedAt="ice8f18bc348d46ce87a3e91444ed1360" escape="true"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDQ_d291c509-90cd-4f72-962e-2675790aed56" continuedAt="id9eac8a8c5cb4235bc49ec32f70c6f37" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="ida7fdd6a75db4fc99306d2dde4c25ba0" continuedAt="i3845c57efb3c4c4fae240be8af42fc18"><ix:continuation id="ice8f18bc348d46ce87a3e91444ed1360" continuedAt="i14309797acb84431b57236fe6c8bce59"><ix:continuation id="id9eac8a8c5cb4235bc49ec32f70c6f37" continuedAt="ia537a537d32d4d36aeea5d2f004d76fc"><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Leases where ResMed is the Lessee</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether a contract is, or contains, a lease at inception. ROU assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the lease term as the non-cancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than <ix:nonNumeric contextRef="i7df9e6108fe8406e80413d06c6ed765e_I20220630" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQzNTg_90e8f943-1316-4999-8535-32edca3e691b">1</ix:nonNumeric> year to <ix:nonNumeric contextRef="ie375d6fcc5c94de8a1dfe85679cc6bdb_I20220630" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQzNjI_77d3a070-c8f6-44e1-9535-f06e81537b82">14</ix:nonNumeric> years, some of which include options to extend or terminate the leases.</span></div></ix:continuation></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-79-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i3845c57efb3c4c4fae240be8af42fc18" continuedAt="i53082705519f455a82a6377266e13f3f"><ix:continuation id="i14309797acb84431b57236fe6c8bce59" continuedAt="ia2ff5a0f9bd842c6b9bcad5f1882a92e"><ix:continuation id="ia537a537d32d4d36aeea5d2f004d76fc" continuedAt="ia7820083b9284c98a371b557d2f84f4e"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs for the years ended June&#160;30, 2022, 2021 and 2020 were $<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQzNjY_64b582cf-5207-4d22-9f57-2c9b41bd213f">35.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzEwOTk1MTE2MzExMzY_57834613-9353-46d8-8e60-95ca20e8a08f">35.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzEwOTk1MTE2MzEzMTc_2c89cab3-6993-4569-acb5-def00500ede2">26.5</ix:nonFraction> million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2022, 2021 and 2020. </span></div><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDU_7488d0fc-914c-496d-9656-4218842f63fb" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancellable operating leases as of June&#160;30, 2022 are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtMS0xLTEtMjg3Njk_5b943f07-7758-47e4-b8ad-1a3bf710475e">161,219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtMy0xLTEtMjg3Njk_89caa28c-3333-48a0-81f2-cf00ed5bd2d5">25,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtNS0xLTEtMjg3Njk_8a7ab0ad-01f9-479a-a224-e1280bb26b21">19,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtNy0xLTEtMjg3Njk_bb496c6b-519e-4d30-91b3-db05ba15af9f">16,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtOS0xLTEtMjg3Njk_f256fc02-f17c-499b-b262-ed0d98176a00">15,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtMTEtMS0xLTI4NzY5_baa83654-e4fc-49c5-9511-42eb2591ab33">15,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtMTMtMS0xLTI4NzY5_73dbc832-af13-426a-8ac3-5b8908039bd1">68,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzItMS0xLTEtMjg3Njk_5ac6e2b6-be06-4d7e-9a0a-292d8b6af311">18,910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzMtMS0xLTEtMjg3Njk_1605becb-f3e4-4c54-8d49-ebcd4eaa08ae">142,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had additional operating lease commitments of $<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-5" name="rmd:LesseeOperatingLeaseLeaseNotYetCommencedCommitments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQ0MTc_9dde02b7-1370-4fd2-95e0-85308f6b7243">0.7</ix:nonFraction> million for office space that have not yet commenced. These leases will commence during the year ended June 30, 2023 with lease terms of <ix:nonNumeric contextRef="i7df9e6108fe8406e80413d06c6ed765e_I20220630" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQ0MzA_333a7ecd-a89a-44cf-9b1e-9d59c35266a4">1</ix:nonNumeric> year to <ix:nonNumeric contextRef="ie375d6fcc5c94de8a1dfe85679cc6bdb_I20220630" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQ0MjY_ae6fe994-2a9d-4046-a824-c1fb1d43537f">5</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="rmd:ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDA_846a0f24-622e-4f07-b014-d57084d6441c" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental information related to operating leases for the years ended June&#160;30, 2022 and June&#160;30, 2021 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average inputs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzMtMS0xLTEtMjg3Njk_8a3b2e9c-9467-4c51-9e87-3df4b0ef37fa">8.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzMtMy0xLTEtMjg3Njk_b14c1b4b-0c82-4290-97ed-42595ee91ebf">8.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzQtMS0xLTEtMjg3Njk_dfd3afbe-013e-47b5-83cf-0f3825f60499">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzQtMy0xLTEtMjg3Njk_57fe47c3-c176-487a-9966-01750ac4e1cc">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzctMS0xLTEtMjg3Njk_920a4c7f-4809-4e43-bb82-7feeafd8cc6c">26,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzctMy0xLTEtMjg3Njk_8951cb7b-0fcf-4948-b7e2-899b86479734">27,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzgtMS0xLTEtMjg3Njk_cbbbaaa6-760a-4d35-b996-592e448c0b6a">41,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzgtMy0xLTEtMjg3Njk_75661c88-6299-4dbb-820b-27a1f5821bf2">36,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Leases where ResMed is the Lessor</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease sleep and respiratory medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts include sales-type and operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. </span></div><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDE_748003ce-aeba-4587-82bc-9787981bffc2" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease revenue for the years ended June&#160;30, 2022, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:SalesTypeLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzEtMS0xLTEtMjg3Njk_9271ebde-3f15-4270-9bfe-e0eb7a6f9e3b">9,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:SalesTypeLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzEtMy0xLTEtMjg3Njk_75e7c31e-b9fd-48fc-aae0-cd6f9fea85ff">9,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:SalesTypeLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzEtNS0xLTEtNDQ0MjQ_755e3204-14f3-45eb-9a97-403419199b7b">13,457</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzItMS0xLTEtMjg3Njk_46621917-1385-4d21-893f-e62edb370e75">90,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzItMy0xLTEtMjg3Njk_2f1db708-f9d7-4916-ad6b-e4a32ea8ef60">93,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzItNS0xLTEtNDQ0MjQ_da0a5637-2e90-41ac-b56e-e7b8d96182cd">87,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="rmd:LessorLeaseRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzMtMS0xLTEtMjg3Njk_b81b51b7-9ea5-4fd4-8cc3-54b0ff27b0d3">99,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="rmd:LessorLeaseRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzMtMy0xLTEtMjg3Njk_b612dd81-aa5c-437e-be43-052152186426">103,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="rmd:LessorLeaseRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzMtNS0xLTEtNDQ0MjQ_d4e3a5ee-dd81-477e-8eb5-be4ecb4d6396">101,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="rmd:SalesTypeLeaseNetInvestmentInLeaseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDI_b0ab6897-218e-486e-95fa-1a3ef8066d04" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment in sales-type leases were classified in the consolidated balance sheets as of June&#160;30, 2022 and June&#160;30, 2021 as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:SalesTypeLeaseLeaseReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzEtMS0xLTEtMjg3Njk_def8206b-af3a-45ad-8a0b-677fee6b32df">6,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:SalesTypeLeaseLeaseReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzEtMy0xLTEtMjg3Njk_bccd8c19-7b04-4be3-85fa-a74fe74b8a0c">8,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="rmd:SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzItMS0xLTEtMjg3Njk_03f8c016-40f6-44eb-a3f3-8ee254e7cf18">7,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="rmd:SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzItMy0xLTEtMjg3Njk_338b4081-d25d-438f-b359-ad45e7e1b0f6">6,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:SalesTypeLeaseNetInvestmentInLease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzMtMS0xLTEtMjg3Njk_46157842-a89d-45c8-91c6-d7ebb2155ac0">14,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:SalesTypeLeaseNetInvestmentInLease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzMtMy0xLTEtMjg3Njk_2a2d81b9-a831-403c-8ce5-d07420bb3785">14,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-80-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i53082705519f455a82a6377266e13f3f"><ix:continuation id="ia2ff5a0f9bd842c6b9bcad5f1882a92e"><ix:continuation id="ia7820083b9284c98a371b557d2f84f4e"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDM_f01c1650-1f4f-4630-8da4-aed271d12b08" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of sales-type leases as of June&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtMS0xLTEtMjg3Njk_51df47c8-3a2d-413e-9d1b-df8e4cb8b3ff">16,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtMy0xLTEtMjg3Njk_98acbbab-6422-4ae9-8515-814a7aff6067">6,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtNS0xLTEtMjg3Njk_25329ceb-a592-45f9-8a79-39b5cd4a0781">4,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtNy0xLTEtMjg3Njk_b8f82e15-4cca-472b-a2d3-736e20d63cdb">2,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtOS0xLTEtMjg3Njk_78cc0509-28c7-445b-a85a-5d8b79dc8eb4">1,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtMTEtMS0xLTI4NzY5_2604c8d8-f7de-4239-9958-a8c9d5ac24fe">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtMTMtMS0xLTI4NzY5_faed0581-9f0e-46c5-a36d-dba39b81f320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzItMS0xLTEtMjg3Njk_846254c0-05e4-49cd-906e-8611abeaaede">1,960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzMtMS0xLTEtMjg3Njk_4cc6c567-9410-4faa-9267-c054a3f1a541">14,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation></ix:continuation><div id="i1f60984bb51544a482851b08d4a3bf6b_136"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(11) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzg0ODg_0bd11a8b-ea05-4cda-ab77-63618682a9d4" continuedAt="ie3fd704e6a6f40aa81d40f9c0028b761" escape="true">Stockholders&#8217; Equity </ix:nonNumeric></span></div><ix:continuation id="ie3fd704e6a6f40aa81d40f9c0028b761" continuedAt="id7dd5d5b2e614b179b43a5fd4a17e0a8"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On February&#160;21, 2014, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="icb4434050d394cafb018a6065a45a957_I20140221" decimals="INF" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2MTA_87f2de80-a485-404b-a9e5-329846259ff8">20.0</ix:nonFraction> million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. The <ix:nonFraction unitRef="shares" contextRef="icb4434050d394cafb018a6065a45a957_I20140221" decimals="INF" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2MTc_87f2de80-a485-404b-a9e5-329846259ff8">20.0</ix:nonFraction> million shares the program authorizes us to purchase are in addition to the shares we repurchased on or before February&#160;21, 2014 under our previous programs. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases since February&#160;21, 2014 have been executed in accordance with this program. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have temporarily suspended our repurchase program and, accordingly, did not repurchase any shares during fiscal years 2022 or 2021. As of June&#160;30, 2022, we have repurchased a total of <ix:nonFraction unitRef="shares" contextRef="i9d6484ce8c1e4238876a0b1d7f21a064_I20220630" decimals="-5" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2NTc_b2195d26-a051-4689-bc3f-27700a8c9906">41.8</ix:nonFraction> million shares at a cost of $<ix:nonFraction unitRef="usd" contextRef="i9d6484ce8c1e4238876a0b1d7f21a064_I20220630" decimals="-8" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2NjI_079858f3-adca-4ef5-af09-4f83d27425e7">1.6</ix:nonFraction> billion. Shares that are repurchased are classified as &#8220;treasury stock pending future use&#8221; and reduce the number of shares outstanding used in calculating earnings per share. At June&#160;30, 2022, <ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-5" name="us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2NzE_bd62a09c-fbb7-4b70-aeab-441cd963a378">12.9</ix:nonFraction> million additional shares can be repurchased under the approved share repurchase program.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In April 1997, our board of directors authorized <ix:nonFraction unitRef="shares" contextRef="ie03f859a83a14b7c9c6464075801b456_I19970430" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2ODE_3cf7a9d7-2412-45d6-b860-e0b1138d63de">2.0</ix:nonFraction> million shares of <ix:nonFraction unitRef="usdPerShare" contextRef="ie03f859a83a14b7c9c6464075801b456_I19970430" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2ODU_eae776a6-2e35-4224-bcf6-16696e2cc10a">0.01</ix:nonFraction> par value preferred stock. <ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2OTM_3facc649-52b7-4364-90a9-2b01775e97f9"><ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2OTM_b33a7f03-4ddf-4a6e-b448-30e68b92d34a">No</ix:nonFraction></ix:nonFraction> such shares were issued or outstanding at June&#160;30, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options and Restricted Stock Units.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have granted stock options, restricted stock units (&#8220;RSUs&#8221;) and performance restricted stock units (&#8220;PRSUs&#8221;) to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the &#8220;2009 Plan&#8221;). Options and restricted stock units vest over <ix:nonNumeric contextRef="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MDQ_9d11f36e-f635-4522-8f73-6c8ed6c1311d">one year</ix:nonNumeric> to <ix:nonNumeric contextRef="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MDk_a22bfa4d-eb51-4d03-9a59-b06e8cc76765">four years</ix:nonNumeric> and the options have expiration dates of <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MTQ_922f511f-8a5d-41c5-97e6-1f09bb9c388d">seven years</ix:nonNumeric> from the date of grant. We have granted the options with an exercise price equal to the market value as determined at the date of grant. We have granted PRSUs that are subject to a market condition, with the ultimate realizable number of PRSUs dependent on relative total stockholder return over a period of <ix:nonNumeric contextRef="i13c812eb8e4e4d0aad3396a4505d0c90_D20210701-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MTk_9932109c-e295-4cbc-80c1-9c42b0011095">three years</ix:nonNumeric>, up to a maximum amount to be issued under the award of <ix:nonFraction unitRef="number" contextRef="i13c812eb8e4e4d0aad3396a4505d0c90_D20210701-20220630" decimals="2" name="rmd:VestingAmountMaximumPercentageOfOriginalGrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MjQ_a2c1597f-538b-4154-98f9-54fcca78748d">225</ix:nonFraction>% of the original grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the annual meeting of our stockholders in November 2017, our stockholders approved an amendment and restatement to the 2009 Plan to increase the number of shares of common stock that may be issued or transferred pursuant to awards under the 2009 Plan by <ix:nonFraction unitRef="shares" contextRef="i656e88285e1a478db38df173815049c6_I20171130" decimals="-5" name="rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MzQ_8a8dec6f-f046-4363-95f9-a962bb433f1f">7.4</ix:nonFraction> million. The amendment and restatement imposes a maximum award amount which may be granted under the 2009 Plan to non-employee director in a calendar year, which when taken together with any other cash fees earned for services as a non-employee director during the calendar year, has a total value of $<ix:nonFraction unitRef="usd" contextRef="iac8a769569584c06896d492161d46522_D20171101-20171130" decimals="-5" name="rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3Mzk_db0d0b50-9a72-454f-bc28-18ec6465cb8c">0.7</ix:nonFraction> million, or $<ix:nonFraction unitRef="usd" contextRef="i526a12fca7d14513aa82f1d9a8b37b84_D20171101-20171130" decimals="-5" name="rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3NDg_63c46899-6a86-4bdc-95a6-1c8f66a3d82f">1.2</ix:nonFraction> million in the case of a non-employee director who is also serving as chairman of our board of directors. The amendment and restatement also increased the maximum amount payable pursuant to cash-denominated performance awards granted in any calendar year from $<ix:nonFraction unitRef="usd" contextRef="ib6fbf790ad4041668dd19efbe5c7bd93_D20171031-20171031" decimals="-5" name="rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3NTQ_4304f846-fd2d-4402-9419-a799b46f6f23">3.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i344f9115454b46148a3452f1abac3c9d_D20171101-20171130" decimals="-5" name="rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3NTk_0f344b02-4b08-4041-b2a3-4a7a61035985">5.0</ix:nonFraction> million. In addition, the amendment and restatement extended the existing prohibition on the payment of dividends or dividend equivalents on unvested awards to apply to all awards, including time-based restricted stock, deferred stock and stock payment. The term of the 2009 Plan was extended by <ix:nonNumeric contextRef="i1b10950bdf1f4749b316223621791474_D20171101-20171130" name="rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3NjQ_f066bea0-e345-472f-96f0-ce0919fd7524">four years</ix:nonNumeric> so that the plan expires on September&#160;11, 2027.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is <ix:nonFraction unitRef="shares" contextRef="icb58c060ef9941f3a97cea8bbad422e5_I20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3NzM_d778ad7a-692d-499c-930c-8f365404ddf6">51.1</ix:nonFraction> million. The number of securities remaining available for future issuance under the 2009 Plan at June&#160;30, 2022 is <ix:nonFraction unitRef="shares" contextRef="icb58c060ef9941f3a97cea8bbad422e5_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3ODI_0d38b8b8-3dcd-4dea-809d-99ad7d86aba8">15.3</ix:nonFraction> million. The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) <ix:nonFraction unitRef="number" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="rmd:ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3OTQ_c2491cad-5620-4e5d-bfab-f4c426b5376f">2.8</ix:nonFraction> shares for each one share of common stock delivered in settlement of any &#8220;full-value award,&#8221; which is any award other than a stock option, stock appreciation right or other award for which the holder pays a purchase price and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, which may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed <ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-6" name="rmd:MaximumNumberOfSharesSubjectToAwardsGranted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3OTg_f9203288-0462-41b4-9aa6-2788922c765b">3</ix:nonFraction> million shares of our common stock (except in a participant&#8217;s initial year of hiring up to <ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="INF" name="rmd:NumberOfCommonStockGranted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4MTE_5bf8f86d-21df-4013-89bd-9b4bd43bc92f">4.5</ix:nonFraction> million shares of our common stock may be granted). </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-81-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="id7dd5d5b2e614b179b43a5fd4a17e0a8" continuedAt="i8d48fbd9928e469882a6b089a859355b"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain regions, shares are withheld on behalf of employees to satisfy statutory tax withholding requirements upon exercise or vesting of awards. The number of shares withheld is based upon the closing price of our common stock on the trading day of the applicable settlement date. The remaining shares are delivered to the recipient as shares of our common stock. The amount remitted to the tax authorities for the employees&#8217; tax obligation is reflected as a financing activity on our consolidated statements of cash flows. Shares withheld by us as a result of the net settlement are not considered issued and outstanding and are added to the reserves of the 2009 Plan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs and PRSUs that vested during the years ended June&#160;30, 2022, 2021 and 2020, was $<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4NTk_820977f1-3507-484b-8e0b-77df6805262a">65.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4NjY_0608396e-bc08-482a-9691-6b189120bf52">59.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4NzA_27b376fc-5517-4f22-b9b1-520f4e7496b3">56.8</ix:nonFraction> million, respectively.</span></div><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzg0ODk_49afd047-18ff-4a52-b1d9-8c771b03fb4f" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of RSUs, including PRSUs, during year ended June&#160;30, 2022 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock<br/>Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant-Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e2263b05ec742b9a74b344a4f2f2337_I20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzEtMS0xLTEtMjg3Njk_5d1edca4-ef91-447f-8ba7-32ab3a409ede">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e2263b05ec742b9a74b344a4f2f2337_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzEtMy0xLTEtMjg3Njk_5f956007-2581-42e8-b138-09f3bd27851e">145.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i59e177a09e1f49aca07dc9b8742b6dd6_D20200701-20210630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzEtNS0xLTEtMjg3Njk_a2c13bde-e3d5-4158-b12f-1abfbfc8d626">1.5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzItMS0xLTEtMjg3Njk_f6aae33d-99a3-4eab-9e55-13a83f45879e">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzItMy0xLTEtMjg3Njk_fb99f5f6-620f-4840-93b4-0803523b30fc">259.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzMtMS0xLTEtMjg3Njk_626242d3-2793-490f-88ab-c50b48304ade">575</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzMtMy0xLTEtMjg3Njk_e2179669-ce77-4818-b8ab-c7f70637755f">113.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance factor adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzQtMS0xLTEtMjg3Njk_fa8e67bc-1dc9-46aa-998f-93badf2d72ee">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630" decimals="2" name="rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzQtMy0xLTEtMjg3Njk_8c3393d8-f9f4-4727-84f4-01a4636cda22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzYtMS0xLTEtMjg3Njk_273b23cf-6ad7-4a02-b224-5ebab4c29e1f">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzYtMy0xLTEtMjg3Njk_6414a6d5-c9ca-48cb-a2d8-2a00f04c1000">184.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6090a2e6715142fabdaedef101bd1b85_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzctMS0xLTEtMjg3Njk_dee12f4d-bf1a-45fb-bdec-b2b4718d3004">681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6090a2e6715142fabdaedef101bd1b85_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzctMy0xLTEtMjg3Njk_51fdd5f4-6b33-4848-ac39-dd6c3f45dd30">203.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzctNS0xLTEtMjg3Njk_756469c1-14e8-4f4d-b622-4e941681e6c2">1.6</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt">Includes <ix:nonFraction unitRef="shares" contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630" decimals="INF" name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4NDY_e48e65bf-dbef-4de9-8e0e-814ba4ac2273">206</ix:nonFraction> thousand shares netted for tax.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzg0OTE_b3fb2dc0-afc7-45e0-95d6-869ff2aac227" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity during the year ended June&#160;30, 2022 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzEtMS0xLTEtMjg3Njk_34ba8cc8-6f9d-40fc-bc55-ff1a87fface0">1,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzEtMy0xLTEtMjg3Njk_7cb19a28-7f06-4472-85e9-010948dcd0fc">97.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzEtNS0xLTEtMjg3Njk_80aa2828-f1e6-40a7-9e1c-cc74ba1d014d">3.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzItMS0xLTEtMjg3Njk_e254bf4b-30ab-4ccb-b6e6-03f004ae4ed0">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzItMy0xLTEtMjg3Njk_09955a82-d533-4ee0-bc6a-12852ce6290f">256.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzMtMS0xLTEtMjg3Njk_dcd2f932-8dbd-41a4-8ff3-0351af797588">177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzMtMy0xLTEtMjg3Njk_8d859fbc-d8d1-4818-bd4c-dac56b98fa78">63.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzQtMS0xLTEtMjg3Njk_db718a71-b13a-4d57-b8ff-353a3a57bdac">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzQtMy0xLTEtMjg3Njk_ce01b098-5fe5-42ae-a179-20bd98069bd7">110.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzUtMS0xLTEtMjg3Njk_9770d8fb-747c-467b-a8cc-c73c054f8bd6">938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzUtMy0xLTEtMjg3Njk_632328fa-b3eb-433d-91c1-1a8425ad525a">112.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzUtNS0xLTEtMjg3Njk_573b7519-fc61-4214-aa44-da391c097e4b">3.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzYtMS0xLTEtMjg3Njk_0601f53f-7a90-4c3e-a029-db83859dc99e">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzYtMy0xLTEtMjg3Njk_acc1b646-3a4a-4c71-9a99-e26cf2aafa1c">96.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzYtNS0xLTEtMjg3Njk_4333fe02-19b0-421d-bbe1-80d6b915ce4e">2.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzctMS0xLTEtMjg3Njk_088555e1-4159-41a5-a3a5-6e67d528a2e8">932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzctMy0xLTEtMjg3Njk_a31ef05e-bfae-4c8b-8a5d-382915476adb">112.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzctNS0xLTEtMjg3Njk_b27d7534-df47-4c44-87a4-b5fc9464fed5">3.2</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the fiscal years 2022, 2021 and 2020, was $<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4OTY_34539ae1-ac26-4e1e-99a2-bebd4fd70230">33.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5MDA_b1f7d037-7291-476a-8fee-d8901cf10e19">8.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5MDQ_59cd5922-f96a-4f0a-84b2-1947a224580d">31.2</ix:nonFraction> million, respectively. As at June&#160;30, 2022, the aggregate intrinsic value of options outstanding, exercisable, and vested and expected to vest were $<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5MjA_5decf4e4-f0b1-4c69-b02f-0fbf6bdf02df">93.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5MjQ_f1097883-37f9-4f99-b968-2712ecae52c4">89.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5Mjg_2892098f-0611-4b4b-bd5f-31a41bd41b8a">93.4</ix:nonFraction> million respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan (the &#8220;ESPP&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors&#8217; compensation committee of no less than <ix:nonNumeric contextRef="iec931243b75f437e8ee3cf1efa936e50_D20210701-20220630" name="rmd:EmployeeStockPurchasePlanOfferingPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5NDE_a26e39fb-21aa-4a3e-8826-314987b2b625">3</ix:nonNumeric> months and no more than <ix:nonNumeric contextRef="i26cfb703ae174ae99bbfb51030982257_D20210701-20220630" name="rmd:EmployeeStockPurchasePlanOfferingPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5NDU_7eafe8db-d579-40e1-9202-a0eff86a4a87">27</ix:nonNumeric> months. The purchase price for our common stock under the ESPP will be the lower of <ix:nonFraction unitRef="number" contextRef="i139858d21bb440a48d56f47a4a84ed88_D20210701-20220630" decimals="INF" name="rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5NDk_816a7489-cce4-416c-bdd1-ee4b1da70efa">85</ix:nonFraction>% of the fair market value of our common stock on the date of grant or <ix:nonFraction unitRef="number" contextRef="i139858d21bb440a48d56f47a4a84ed88_D20210701-20220630" decimals="INF" name="rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5NTY_ef764f3e-bd10-493e-ae4a-be0d8c254b77">85</ix:nonFraction>% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $<ix:nonFraction unitRef="usd" contextRef="ib903a532663446a585c6512ab8c06b0b_I20220630" decimals="-3" name="us-gaap:CommonStockSharesSubscriptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5NjM_cb9c26dd-e292-4c06-8bc6-e3143c4c1ecd">25,000</ix:nonFraction> in common stock during any calendar year. At June&#160;30, 2022, the number of shares remaining available for future issuance under the ESPP is <ix:nonFraction unitRef="shares" contextRef="i612e2c48c8604ebb820bf12238b6faad_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5Nzk_ae960a2b-ab2a-4e69-9350-a11c552c0ccb">1.5</ix:nonFraction> million shares.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-82-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i8d48fbd9928e469882a6b089a859355b" continuedAt="ifd9ae63c66484a288db621d7fe70b6bf"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During years ended June&#160;30, 2022, 2021 and 2020, we issued <ix:nonFraction unitRef="shares" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5OTI_97c904eb-b2c7-437a-a4db-5f4b6a83a618">216,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAwMDE_b060f438-7e89-46b6-b217-bb73afc6eadb">229,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAwMDU_793ce748-2a7c-4095-ba05-d8f4fd7c8fc2">265,000</ix:nonFraction> shares to our employees in <ix:nonFraction unitRef="offering" contextRef="i139858d21bb440a48d56f47a4a84ed88_D20210701-20220630" decimals="INF" name="rmd:NumberOfOfferings" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5OTY_c8c73648-c7ad-4500-ae6e-5560132a2751">two</ix:nonFraction> offerings and we recognized $<ix:nonFraction unitRef="usd" contextRef="i139858d21bb440a48d56f47a4a84ed88_D20210701-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAwMDk_4be44aff-9767-4c09-912c-c105dc0d2166">11.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ia01026de6a5a497cb302f143e7c8b8da_D20200701-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAwMTM_c1b49e2a-c539-46b1-8fd0-6432d2346e24">10.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i545f14bf17d3466d878853ee4c40b693_D20190701-20200630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAwMjM_1745ffc0-b4e9-427c-92c6-4a8a0e21dab4">8.0</ix:nonFraction> million, respectively, of stock compensation expense associated with the ESPP.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock&#8211;based Employee compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the ESPP using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period. The fair value of performance restricted stock units is measured using a Monte-Carlo simulation valuation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the assumptions in the following tables. The risk-free interest rate is estimated using the U.S. Treasury yield curve and is based on the term of the award. The expected term of awards is estimated from the vesting period of the award, as well as historical exercise behavior, and represents the period of time the awards granted are expected to be outstanding. Expected volatility is estimated based upon the historical volatility of ResMed stock.</span></div><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzg0OTI_f0296d1d-4ec3-40cd-8c24-1755f2fb0816" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June&#160;30, 2022, 2021 and 2020: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzItMS0xLTEtMjg3Njk_2b561c53-1c88-4b0c-877c-f9c2e84f7335">72.16</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if26c7573938546c58712775f705c6f91_D20200701-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzItMy0xLTEtMjg3Njk_910f236c-4a34-4534-9c92-c40669867f2b">53.67</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i86d83628870e4c1298a21564eac48efe_D20190701-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzItNS0xLTEtMjg3Njk_017969e1-cedc-4670-b299-1b6e359afa11">32.14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzMtMS0xLTEtMjg3Njk_bf6a9029-08af-4004-90db-99f54d90b3ba">1.29</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if26c7573938546c58712775f705c6f91_D20200701-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzMtMy0xLTEtMjg3Njk_fef12e44-e2d3-4130-818a-87b8cc99ae5d">0.37</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86d83628870e4c1298a21564eac48efe_D20190701-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzMtNS0xLTEtMjg3Njk_383ada63-fce1-4f44-834c-3143f41657dc">1.58</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzQtMS0xLTEtMjg3Njk_1e39d1e7-f87e-45ac-bf97-e184acad47fd">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if26c7573938546c58712775f705c6f91_D20200701-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzQtMy0xLTEtMjg3Njk_3c3b11a4-12fa-47fe-acd5-4de3e94da3ca">4.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86d83628870e4c1298a21564eac48efe_D20190701-20200630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzQtNS0xLTEtMjg3Njk_02a86aa1-b6be-4d5e-b0c7-9c8aa100a6f8">4.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzUtMS0xLTEtMjg3Njk_b4066833-1900-4b23-9db8-da5370b8fbfe">0.66</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if26c7573938546c58712775f705c6f91_D20200701-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzUtMy0xLTEtMjg3Njk_8cd433b4-fe31-48ca-9643-59dee46b6913">0.75</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86d83628870e4c1298a21564eac48efe_D20190701-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzUtNS0xLTEtMjg3Njk_fec3e1e8-493d-4e7e-8795-22483b5e11ab">1.07</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzYtMS0xLTEtMjg3Njk_bb8815aa-44db-4ccc-9af0-1b857761f263">32</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if26c7573938546c58712775f705c6f91_D20200701-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzYtMy0xLTEtMjg3Njk_10ffe52d-6461-4629-96e2-63f6988cd5c8">31</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86d83628870e4c1298a21564eac48efe_D20190701-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzYtNS0xLTEtMjg3Njk_657e053c-9aae-48d1-b10c-835cb51f16d0">25</ix:nonFraction>%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESPP purchase rights:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzktMS0xLTEtMjg3Njk_c3ce13c5-49a9-44cb-8f66-630e01982331">50.46</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzktMy0xLTEtMjg3Njk_47f15316-4229-4704-bcd1-b27db4b7999d">48.18</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzktNS0xLTEtMjg3Njk_59ef2b4e-e3f5-448b-8993-e55c177f35b8">31.82</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEwLTEtMS0xLTI4NzY5_8695d0e8-31c5-4ca0-8335-7c14a4ea77ed">0.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEwLTMtMS0xLTI4NzY5_b9ba4ac6-163f-4aed-bb57-156a7d47ad21">0.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEwLTUtMS0xLTI4NzY5_fd6cbfad-3ff8-4a99-bcd8-a2406a35b71c">1.6</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzExLTEtMS0xLTI4NzY5_f29d6418-8b88-4e29-8503-f008edd912b6">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzExLTMtMS0xLTI4NzY5_f86cf328-4988-40e6-8eda-d35bf65a3575">6</ix:nonNumeric> months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzExLTUtMS0xLTI4NzY5_0c1edd3c-162f-4474-a9b5-856d0016c6ed">6</ix:nonNumeric> months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1957b8b04bc43568cb3bf406005b986_D20210701-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTEtMS0xLTI4NzY5L3RleHRyZWdpb246YjdkODA5NzIyN2Q0NDc3ZGFlYTdhMjkyMTQ3MzMzMDFfNDM5ODA0NjUxMTEzOA_96db433d-2b76-445d-b4b8-686ca40ef4db">0.63</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i8173e7992c53414cbda9b33e54540412_D20210701-20220630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTEtMS0xLTI4NzY5L3RleHRyZWdpb246YjdkODA5NzIyN2Q0NDc3ZGFlYTdhMjkyMTQ3MzMzMDFfNDM5ODA0NjUxMTE0Mg_6b3fd004-a2c1-45de-8bf2-3cd231f04f07">0.98</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b1efe55196841488562ed5eb81ff415_D20200701-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTMtMS0xLTI4NzY5L3RleHRyZWdpb246NjNlNmVlZjJiNTU1NGE2ZmIyYWMxNTZkNWM2OWFkZGVfNDM5ODA0NjUxMTE0MA_41b53981-5ebf-44cc-b0c8-393f7b246c2c">0.79</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic6a5f8517549459ba24dc64abf4f2a39_D20200701-20210630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTMtMS0xLTI4NzY5L3RleHRyZWdpb246NjNlNmVlZjJiNTU1NGE2ZmIyYWMxNTZkNWM2OWFkZGVfNDM5ODA0NjUxMTE0NA_b1063405-64bb-4b5d-aca0-07c2ae7f1abd">0.98</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i626584014ac5497faaf5bbe0805c20a9_D20190701-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTUtMS0xLTI4NzY5L3RleHRyZWdpb246N2IzMjAwMWFkMzk5NGE2NGI0ZjUyNWFkMTBlY2JhOTBfNDM5ODA0NjUxMTEzOA_ad723028-1b10-498e-90be-54ff9328508f">0.98</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i3568fe5aef9349ee949f734d37ba293a_D20190701-20200630" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTUtMS0xLTI4NzY5L3RleHRyZWdpb246N2IzMjAwMWFkMzk5NGE2NGI0ZjUyNWFkMTBlY2JhOTBfNDM5ODA0NjUxMTE0Mg_9c87ad12-f9b5-4566-8e3f-c9034d5a01c3">1.42</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTEtMS0xLTI4NzY5L3RleHRyZWdpb246ZDM5YzQyZjIwMThiNGQ3M2I3YzM1NzYyOWIwZDEwNGRfNDM5ODA0NjUxMTEzMA_be28b58f-c9ee-4f9a-b6a3-31ad11281bcf">20</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTEtMS0xLTI4NzY5L3RleHRyZWdpb246ZDM5YzQyZjIwMThiNGQ3M2I3YzM1NzYyOWIwZDEwNGRfNDM5ODA0NjUxMTEzNA_371c377a-bedd-4316-ad01-055c96b587c8">34</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTMtMS0xLTI4NzY5L3RleHRyZWdpb246MDljM2Y5MGExZWU3NDllNDkwZTE1YzM3OTUzOGQ2OTlfNDM5ODA0NjUxMTEzMA_8596487f-25e7-4384-9492-d6f2af457761">30</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTMtMS0xLTI4NzY5L3RleHRyZWdpb246MDljM2Y5MGExZWU3NDllNDkwZTE1YzM3OTUzOGQ2OTlfNDM5ODA0NjUxMTEzNA_0146aad5-c084-48bb-91d9-f710dc1a5a4d">60</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTUtMS0xLTI4NzY5L3RleHRyZWdpb246NDY0Nzc1ZTZhNDZlNGIxOTg2YTViNWIxOTFmZmZjMmJfMTA5OTUxMTYyNzc5Mw_8507f1b6-54e5-4bf8-8830-1c122dafe001">23</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTUtMS0xLTI4NzY5L3RleHRyZWdpb246NDY0Nzc1ZTZhNDZlNGIxOTg2YTViNWIxOTFmZmZjMmJfMTA5OTUxMTYyNzgwMA_8660120c-6fb5-4fbb-9ef9-33524d16cade">60</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzg0OTM_c45a62b7-be84-45ca-a5dd-099fbc17c843" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June&#160;30, 2022, 2021 and 2020 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f8a68565f04e4593882f783d3a8493_D20210701-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzEtMS0xLTEtMjg3Njk_c66ffbed-8bc3-49bf-bc48-95b287b82764">5,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b466de52734147a35094bafe68a210_D20200701-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzEtMy0xLTEtMjg3Njk_80ee8330-79a7-4e58-9f5b-b39eec2c2f97">4,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id24b9ea32ab54d4ebbb79eacdf21d5a2_D20190701-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzEtNS0xLTEtMjg3Njk_e87b5f65-e55a-4ba0-9aed-f6864ed18556">3,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1b4834996c24c4697613536e66c2ae0_D20210701-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzItMS0xLTEtMjg3Njk_cddd0362-d9e6-4834-9f85-d622b7f3aac8">50,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb5f975b0f146af9d0eacbd9ea5d417_D20200701-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzItMy0xLTEtMjg3Njk_21961bad-a167-4ca3-882c-671465db2ff0">51,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042c41ef5a4940c9bbbd03a03a164b31_D20190701-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzItNS0xLTEtMjg3Njk_5be8c3a2-af92-47cc-bfa8-2d016f441763">47,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia284c8ce0cc44849a9f6fd2717f955a6_D20210701-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzMtMS0xLTEtMjg3Njk_b6eec7d8-0dfb-4bd6-ad06-e2d94eca14af">9,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbffc1218e846ceaa11fd8c25583530_D20200701-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzMtMy0xLTEtMjg3Njk_b19d3518-48cf-4b74-9b0c-33612d06450c">8,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefa02d71c77a4a088959735053a1a4df_D20190701-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzMtNS0xLTEtMjg3Njk_ddc10136-fa27-47ff-a786-54af8acb867a">6,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzQtMS0xLTEtMjg3Njk_79206d93-31e7-48c6-a9a0-788e0a2da5a5">65,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzQtMy0xLTEtMjg3Njk_a6147f32-be04-4b7e-8390-645196012f25">63,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzQtNS0xLTEtMjg3Njk_61bde3f4-3a1a-48b3-bf87-e6449a7832d0">57,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzUtMS0xLTEtMjg3Njk_dabc51b7-759a-4fe2-9ef1-2d68195613f6">29,262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzUtMy0xLTEtMjg3Njk_5cd96dac-2115-48ad-91df-e2ff59fdee28">23,346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzUtNS0xLTEtMjg3Njk_b240716e-ddb8-4caf-8869-35de6b61cae7">39,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs, net of tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzYtMS0xLTEtMjg3Njk_a3b49c09-3592-49a9-918c-4fce2d19cf1b">35,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzYtMy0xLTEtMjg3Njk_16e8b328-1902-4ade-b44c-6e3c64293761">40,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzYtNS0xLTEtMjg3Njk_226589e7-54bb-45d7-8886-36ed1218af9f">18,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifd9ae63c66484a288db621d7fe70b6bf">At June&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAxMDM_fbdc1969-3ed4-4291-9ed8-6e4404fbdb91">104.0</ix:nonFraction> million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAxMDg_b9c4903f-760f-428a-a6a8-e6ce3b8ca96b">2.2</ix:nonNumeric> years.</ix:continuation> </span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_139"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(12) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90ZXh0cmVnaW9uOmRmYzRjNGM0ZGZkYzRlNWY5Njc0MWFlODczNzg0N2UwXzg0Nw_d480ca9a-18c6-4b2d-969b-7c5d9e13327f" continuedAt="i8679d7c74b78437e8abbac43cd5d8c6f" escape="true">Earnings Per Share </ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8679d7c74b78437e8abbac43cd5d8c6f" continuedAt="i96b517cefb2547798dbb85185a35adf4">We compute basic earnings per share by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive </ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-83-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i96b517cefb2547798dbb85185a35adf4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock equivalents such as stock options and restricted stock units. The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were <ix:nonFraction unitRef="shares" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90ZXh0cmVnaW9uOmRmYzRjNGM0ZGZkYzRlNWY5Njc0MWFlODczNzg0N2UwXzQzOTgwNDY1MTIwMTY_69ee3ad4-3e72-4d78-b551-aa131644c497">67,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90ZXh0cmVnaW9uOmRmYzRjNGM0ZGZkYzRlNWY5Njc0MWFlODczNzg0N2UwXzQzOTgwNDY1MTIwMjA_f5f1c7a3-a3b3-45a9-8df2-e3cda15bcc0b">141,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90ZXh0cmVnaW9uOmRmYzRjNGM0ZGZkYzRlNWY5Njc0MWFlODczNzg0N2UwXzQzOTgwNDY1MTIwMjQ_d08df6cc-6906-44e8-8fc2-cd8ad7c3a1d7">164,000</ix:nonFraction> for the years ended June&#160;30, 2022, 2021 and 2020, respectively, as the effect would have been anti-dilutive. </span></div><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90ZXh0cmVnaW9uOmRmYzRjNGM0ZGZkYzRlNWY5Njc0MWFlODczNzg0N2UwXzg0Ng_bdc01fa1-7328-4681-b880-d3a7ee494a7d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share for the years ended June&#160;30, 2022, 2021 and 2020 are calculated as follows (in thousands except per share data): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzItMS0xLTEtMjg3Njk_6f22673d-bf77-4c52-9ef8-244838e72c06">779,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzItMy0xLTEtMjg3Njk_738e886d-274a-4ecb-8739-709699c3b50b">474,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzItNS0xLTEtMjg3Njk_31c79214-a275-487d-aaa2-98338c531deb">621,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzQtMS0xLTEtMjg3Njk_01795855-f0cb-4f23-9136-db132868ddbf">146,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzQtMy0xLTEtMjg3Njk_c5d5e820-6b44-4fd9-ac04-5598100ba916">145,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzQtNS0xLTEtMjg3Njk_54c7270a-7bdc-469e-8909-d4ce8f7fe5f7">144,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzYtMS0xLTEtMjg3Njk_d999ec2f-75ca-4a12-b819-ea08c1968619">977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzYtMy0xLTEtMjg3Njk_b1d68146-2323-4f71-b03e-47ba1a553a26">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzYtNS0xLTEtMjg3Njk_034bb6be-a2eb-4a23-8f7e-469197f0a1c0">1,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted average shares </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzctMS0xLTEtMjg3Njk_d7d72267-407b-49d9-9fb9-b056219ceb90">147,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzctMy0xLTEtMjg3Njk_c072d0c1-d0e4-4026-97f5-16c9c8ba04c6">146,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzctNS0xLTEtMjg3Njk_3867b0cc-84cc-4312-a6d8-96f04356b290">145,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzgtMS0xLTEtMjg3Njk_c1c20131-1272-4f64-af5e-62a1d7b7d7af">5.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzgtMy0xLTEtMjg3Njk_49cb813f-31f0-4bae-be5d-8a1cfc2039e7">3.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzgtNS0xLTEtMjg3Njk_86987e20-c744-43a2-b5a3-ad368e8fd990">4.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzktMS0xLTEtMjg3Njk_83bd6869-150e-4695-acba-e3a1a29e0e69">5.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzktMy0xLTEtMjg3Njk_429e2514-8135-42ee-a1f3-051feb9b6f35">3.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzktNS0xLTEtMjg3Njk_fb360192-d81d-4067-a8cf-47fa2d4d3500">4.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1f60984bb51544a482851b08d4a3bf6b_145"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(13) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MjM_b665cb87-54a1-4788-af71-0e920248e81b" continuedAt="i6763e85285f64055912c9eb080e5a5c8" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i6763e85285f64055912c9eb080e5a5c8" continuedAt="ib44458343e534f028d47b3a6dfc22dd0"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MTg_12dc79dd-a864-41e7-8dce-e32b5d5c6463" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes for the years ended June&#160;30, 2022, 2021 and 2020, was taxed under the following jurisdictions (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzEtMS0xLTEtMjg3Njk_24daa3ca-49ef-40b9-a7a1-4915f83495ab">85,919</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzEtMy0xLTEtMjg3Njk_fac78196-85de-40bf-900b-bd1a8d281355">71,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzEtNS0xLTEtMjg3Njk_879100ae-0496-4f04-9873-1f68bb558e28">60,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzItMS0xLTEtMjg3Njk_431b57d4-5b39-45df-a830-5e0316d95ce1">1,046,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzItMy0xLTEtMjg3Njk_7193dcc9-824f-4676-8b42-ee31edbcfb96">811,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzItNS0xLTEtMjg3Njk_c2d36d6e-4212-4b8b-9cb9-4197d2203b04">672,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzMtMS0xLTEtMjg3Njk_46cd9249-e662-41ee-93bc-9ed24d6d7b84">960,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzMtMy0xLTEtMjg3Njk_e1023777-6b18-47f3-97ee-6b9ebb6ce529">883,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzMtNS0xLTEtMjg3Njk_56962dc6-f037-49e8-a233-0fed6a21afdc">733,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MTk_f211683b-fe34-4e0d-bbba-a01980fba2ba" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is presented below (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:28.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.101%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.106%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzEtMi0xLTEtMjg3Njk_00007b36-175e-4b1f-8d7e-8442820a047c">4,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzEtNC0xLTEtMjg3Njk_2663b88c-d599-4277-bb00-5d09504efad0">115,109</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzEtNi0xLTEtMjg3Njk_bc40daf3-bed5-4bb4-8a15-67ec771679e5">9,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzItMi0xLTEtMjg3Njk_dc4e128d-c7dd-4b81-986f-f8efc7292113">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzItNC0xLTEtMjg3Njk_53d691c5-56f0-4b8c-9818-eb3655a0dd77">9,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzItNi0xLTEtMjg3Njk_a7726d2d-0fd7-44e1-adf4-396eedba9bc0">6,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzMtMi0xLTEtMjg3Njk_e29cd60a-ed9c-4ec9-877c-c2f261c4c8a9">177,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzMtNC0xLTEtMjg3Njk_bb7c83fc-99b2-4785-89fb-63af87e0713a">531,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzMtNi0xLTEtMjg3Njk_2212e573-81d4-4dc8-a26c-a1a7b1a5a148">124,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzQtMi0xLTEtMjg3Njk_6b18cdc7-31d1-4acc-bae2-1b768a2fa2e7">192,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzQtNC0xLTEtMjg3Njk_7c212615-1850-4d85-85ed-715a106290b2">425,744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzQtNi0xLTEtMjg3Njk_99d56105-3a39-4da2-8824-49822a7e1621">141,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred: </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzUtMi0xLTEtMjg3Njk_30cf1652-7dbe-41bf-a497-6b0c02f3df52">12,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzUtNC0xLTEtMjg3Njk_1b9d368c-3462-49dd-9344-64f3d2cea104">22,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzUtNi0xLTEtMjg3Njk_a324572c-367a-4060-a6c7-f5e995b8e9d1">13,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzYtMi0xLTEtMjg3Njk_1ecbad81-1251-45a4-9c3f-795bb7b734ea">2,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzYtNC0xLTEtMjg3Njk_13ffebfb-e956-438c-af74-019c2b18b593">4,205</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzYtNi0xLTEtMjg3Njk_72ebf7ca-8bb3-476f-91ed-3ba1b712879b">3,335</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzctMi0xLTEtMjg3Njk_9ebbb0ce-9157-4bb6-b409-f7e40ae382ff">3,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzctNC0xLTEtMjg3Njk_6e3bf86e-85f3-424d-99ba-1cf4484a34f1">10,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzctNi0xLTEtMjg3Njk_ed0c8edc-85d2-4f7f-9b87-f174da77710b">13,541</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzgtMi0xLTEtMjg3Njk_c0c9a41b-75a3-429e-a5b5-3999a8546151">11,818</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzgtNC0xLTEtMjg3Njk_cd1bb379-f403-4d5b-9e4f-891487382c6f">16,587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzgtNi0xLTEtMjg3Njk_937857a2-28e4-4105-b95b-b99caab3c656">29,876</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzktMi0xLTEtMjg3Njk_42a717cc-d079-4e1b-9415-5c92bd2a600a">181,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzktNC0xLTEtMjg3Njk_d0c3bd74-bd85-4805-9409-bbcd561bceee">409,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzktNi0xLTEtMjg3Njk_b0c2bb83-08bf-427d-b099-c7703ba5c95e">111,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-84-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="ib44458343e534f028d47b3a6dfc22dd0" continuedAt="idd34c8522246475493af58eb99129b0a"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MjA_ebc67721-3e51-49f3-90ac-7c4afae351ba" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. federal income tax rate of 21% for the years ended June&#160;30, 2022, 2021 and 2020, to pretax income as a result of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes computed at statutory U.S. rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEtMS0xLTEtMjg3Njk_c6f46f3d-2f93-4d03-a1f6-dda387d09934">201,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEtMy0xLTEtMjg3Njk_ad0bb3d3-c011-4355-867a-207d4c3d401e">185,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEtNS0xLTEtMjg3Njk_e0a55229-f3be-4c67-b2d5-010e4e8a1e39">153,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase (decrease) in income taxes resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of U.S. tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzMtMS0xLTEtMjg3Njk_ad11dfc5-dee5-468e-8b91-e3efd2e33dc1">5,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzMtMy0xLTEtMjg3Njk_d8a24cde-865f-4eb2-aedd-1735ea1eea27">4,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzMtNS0xLTEtMjg3Njk_7e84d6b3-28f0-48b0-813e-a39086888327">3,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzQtMS0xLTEtMjg3Njk_d20a8d5c-c0dc-45ae-adcd-4029ab0e6972">17,517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzQtMy0xLTEtMjg3Njk_74622a0c-9aa6-4c78-ba9d-76efd9acfe1e">20,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzQtNS0xLTEtMjg3Njk_9015cbcf-974a-4602-8a3d-873712a986d6">13,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzUtMS0xLTEtMjg3Njk_23121f08-6e1b-4b03-a7b5-dc00e3cd3d6e">858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzUtMy0xLTEtMjg3Njk_ffa6f363-5a92-4e97-b0a5-0a22767dbe04">3,785</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzUtNS0xLTEtMjg3Njk_aa625075-eac3-43a7-ac58-b040e4f9348a">7,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of non-U.S. tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzYtMS0xLTEtMjg3Njk_d3b0c8a1-a17b-453a-b474-3757e2a32168">4,384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzYtMy0xLTEtMjg3Njk_3e2c62cb-71f3-4770-af41-a1138f7b4520">12,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzYtNS0xLTEtMjg3Njk_2caeafba-b402-4dcf-b34c-22cc2ea409e2">20,935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzctMS0xLTEtMjg3Njk_70b7adef-2d00-4172-a1c9-388804796caf">2,299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzctMy0xLTEtMjg3Njk_d00cd68f-c815-4ce3-baff-b8f1816e6a93">7,210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzctNS0xLTEtMjg3Njk_2e68c436-cee8-4f8a-9034-a3c524949f05">4,026</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzgtMS0xLTEtMjg3Njk_0f1ef5e7-6a48-403c-bead-3b9c9bd116b5">11,294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzgtMy0xLTEtMjg3Njk_cfb6c579-5527-4e48-93b8-b1ef5bac4b28">4,498</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzgtNS0xLTEtMjg3Njk_159baf53-ee86-43b6-8ab5-a6db4ddb3020">20,696</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Uncertain tax position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="rmd:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzktMS0xLTEtMjg3Njk_b4c1d05e-83f4-46e1-b4ab-6c4f32ca3e64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="rmd:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzktMy0xLTEtMjg3Njk_03ff2d22-4b47-40c7-90c5-2a21d2edfef6">248,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="rmd:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzktNS0xLTEtMjg3Njk_cf296345-c45b-47a0-b29c-96197d9d354d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzExLTEtMS0xLTI4NzY5_fac2055d-8587-4fce-949c-3bef719a042e">8,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzExLTMtMS0xLTI4NzY5_10d9835f-81e7-4f07-8f83-fa9000738a48">17,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzExLTUtMS0xLTI4NzY5_b42b02f2-3891-43f6-8b31-c5e2feff8b56">5,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEyLTEtMS0xLTI4NzY5_9ef46c07-606b-408f-91f8-ab3c8d7d93bf">181,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEyLTMtMS0xLTI4NzY5_131e7920-c98f-4b81-af00-2c81a49619d1">409,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEyLTUtMS0xLTI4NzY5_3ce21bf5-c0d8-415a-a12d-c80e48496e66">111,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="rmd:ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MjE_56618620-92cd-4990-8eee-59761f9c85a3" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported net deferred tax assets and liabilities in our consolidated balance sheets at June&#160;30, 2022 and June&#160;30, 2021, as follows (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzEtMS0xLTEtMjg3Njk_181435aa-a03e-4190-8e2a-37fae4c19d5d">79,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzEtMy0xLTEtMjg3Njk_bfa28096-cf27-4569-be29-a0cbf3c59a81">79,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzItMS0xLTEtMjg3Njk_57d13408-85ca-4efd-8b48-52b9edca6b13">9,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzItMy0xLTEtMjg3Njk_3318b7f9-714d-40d3-9bce-a9a773a3f59c">11,319</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzMtMS0xLTEtMjg3Njk_51cc6035-ad04-4b0e-ac3a-75b9f45a8954">70,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzMtMy0xLTEtMjg3Njk_d7fd4c22-13df-454b-93a2-feea2ece5252">68,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MjI_c0d425e3-0743-4b49-8cd8-ba9f33e940f8" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our deferred tax assets and liabilities at June&#160;30, 2022 and June&#160;30, 2021, are as follows (in thousands): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Employee liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzItMS0xLTEtMjg3Njk_1c7bb43e-ee67-473d-bad2-d6bc4e66e1eb">28,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzItMy0xLTEtMjg3Njk_348347d6-ce73-4416-b85e-788da61f66e2">30,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Tax credit carry overs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzMtMS0xLTEtMjg3Njk_36459634-f026-4a83-a628-d4a5fc88a356">7,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzMtMy0xLTEtMjg3Njk_f1f058bd-6cae-4896-a7fc-a2ee511b42ca">13,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzQtMS0xLTEtMjg3Njk_ca31213c-c764-41f9-ab65-35f8fdee612d">10,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzQtMy0xLTEtMjg3Njk_6dae30a2-ec36-4ace-a31b-40408dda3a12">11,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzUtMS0xLTEtMjg3Njk_0dfed984-1a12-4acb-922e-b714e30a8189">4,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzUtMy0xLTEtMjg3Njk_b26acabf-b427-4064-bc66-ee7e09d7d830">4,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for doubtful debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzYtMS0xLTEtMjg3Njk_1b1a59a9-e980-45c1-9c05-bf77c381b9f4">5,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzYtMy0xLTEtMjg3Njk_7c312a6d-c0d9-461f-baf9-5819321c30d4">7,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzctMS0xLTEtMjg3Njk_f0cb4f66-aa48-4fcc-80d6-110a7af7a0e1">27,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzctMy0xLTEtMjg3Njk_1ecca42e-4118-4ba6-ba13-d5a937c80638">33,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Capital loss carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzgtMS0xLTEtMjg3Njk_793f12fe-3e7d-48af-b652-acfd7742c842">4,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzgtMy0xLTEtMjg3Njk_f8da2c39-c665-4ded-9a0e-03c54954ec43">6,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzktMS0xLTEtMjg3Njk_27c62c1e-4a1b-4e60-acf3-cce4d5f7270d">6,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzktMy0xLTEtMjg3Njk_1aa15bdf-00e1-42cc-8be4-e7fd914d79ef">6,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEwLTEtMS0xLTI4NzY5_1ce1e093-206a-4cb3-9683-a79740fbe9f8">25,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEwLTMtMS0xLTI4NzY5_40faa700-6757-497d-9340-d37dcabcee98">17,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Research and development capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzExLTEtMS0xLTI4NzY5_4781fb2b-659a-4861-9822-7599498f8882">82,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzExLTMtMS0xLTI4NzY5_fe6f7a12-0544-491c-ad59-1089b402e8f9">58,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="rmd:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEyLTEtMS0xLTI4NzY5_5e47296e-5294-452a-bafd-66d93a48a62d">21,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="rmd:DeferredTaxAssetsLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEyLTMtMS0xLTI4NzY5_7fc49019-9831-4c23-82e4-e29bbfd57793">25,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" sign="-" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEzLTEtMS0xLTI4NzY5_e4f4d8ca-44c9-4500-9435-9045bce9d39c">3,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" sign="-" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEzLTMtMS0xLTI4NzY5_a1a8d9cd-0656-45db-947f-76fca655ed3b">4,911</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE0LTEtMS0xLTI4NzY5_f0f1525d-6fb0-4b7a-9a68-77e246d3de1a">221,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE0LTMtMS0xLTI4NzY5_c5fd02c3-8ac3-4aa8-aa2b-1dbf8040dd5d">210,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE1LTEtMS0xLTI4NzY5_4f8659f3-f34c-4203-99a4-cab3a4fbfcae">13,572</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE1LTMtMS0xLTI4NzY5_0b9c790d-8796-48bd-89e2-0e6f9d553aa6">13,106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE2LTEtMS0xLTI4NzY5_a28369f1-4179-431a-9460-b69965c97dc7">207,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE2LTMtMS0xLTI4NzY5_d6be09d3-9906-4e95-8dbb-e00da3fa9236">197,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Goodwill and other intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE4LTEtMS0xLTI4NzY5_3495aef9-de86-4afb-9573-743eff56d82c">108,078</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE4LTMtMS0xLTI4NzY5_954d8782-cb5e-4265-89a0-328352a60d55">104,563</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="rmd:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE5LTEtMS0xLTI4NzY5_557dc333-22e2-4b86-b96f-da3b8828e6c3">20,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="rmd:DeferredTaxLiabilitiesRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE5LTMtMS0xLTI4NzY5_03d794ee-306c-4da5-93c2-31f53cc1d52f">23,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIxLTEtMS0xLTUwNjgz_206dc147-0107-47c8-9d08-2a8e9ba82e7d">9,491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIxLTMtMS0xLTUwNjgz_6c6636d2-2cc7-41f6-ba63-ecc8ba3cbb91">940</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIwLTEtMS0xLTI4NzY5_2eac27c8-3f0e-4ae0-840b-7ba9137efe67">137,914</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIwLTMtMS0xLTI4NzY5_14f6aca9-d9f7-4157-bffb-e78c9b401aa3">129,196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIxLTEtMS0xLTI4NzY5_1212ca5e-1483-4145-9d3b-bba42243f93a">70,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIxLTMtMS0xLTI4NzY5_f46cd8f3-ac32-4de4-91c1-ebcb2df98ca3">68,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-85-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="idd34c8522246475493af58eb99129b0a"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had $<ix:nonFraction unitRef="usd" contextRef="ic89b566ef2524af98f09b1c2e5a3555c_I20220630" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTc5NTU_4269d733-0483-43c5-820d-f5ddcde0450c">19.8</ix:nonFraction> million of U.S. federal and state net operating loss carryforwards and $<ix:nonFraction unitRef="usd" contextRef="i0fd69e2cd46e4080ad9064bd38b12c4c_I20220630" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTc5NTk_5841bb4d-9d46-48a1-aff3-cb1a3b68be45">6.9</ix:nonFraction> million of non-U.S. net operating loss carryforwards, which expire in various years beginning in 2023 or carry forward indefinitely. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance at June&#160;30, 2022 relates to a provision for uncertainty of the utilization of net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i0e1c0e023852448f9bf3bd384a272726_I20220630" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNDY_50366eba-f83d-4490-81a5-a36055aeba21">0.8</ix:nonFraction> million and capital loss and other items of $<ix:nonFraction unitRef="usd" contextRef="i0e1c0e023852448f9bf3bd384a272726_I20220630" decimals="-5" name="rmd:OperatingLossCarryforwardsCapitalLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNTA_853e71fc-2159-480a-9dc9-b6efc29f795c">12.7</ix:nonFraction> million. We believe that it is more likely than not that the benefits of deferred tax assets, net of any valuation allowance, will be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our manufacturing operations and administrative functions in Singapore operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2030. The end of certain tax holidays may be extended if specific conditions are met. The net impact of these tax holidays and tax incentive programs increased our net income by $<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-5" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNjA_23f74c42-6327-4d49-ac08-6b922a2d1b02">38.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usdPerShare" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNjQ_fb22b40b-628e-4cb2-b542-974b6c59c4b3">0.26</ix:nonFraction> per diluted share) for the year ended June&#160;30, 2022, $<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-5" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNzQ_5f6f0f75-cd99-4ea3-b7cd-6d561af6a562">33.6</ix:nonFraction> million ($<ix:nonFraction unitRef="usdPerShare" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNzg_7fee4998-a773-4624-ab0d-edac7dc41032">0.23</ix:nonFraction> per diluted share) for the year ended June&#160;30, 2021, and $<ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-5" name="us-gaap:IncomeTaxHolidayAggregateDollarAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxODI_06370ca2-aca6-43a6-bf3d-49e8a229ad09">43.8</ix:nonFraction> million ($<ix:nonFraction unitRef="usdPerShare" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="2" name="us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxODY_7458f6ba-0d47-4a3c-a4b4-694b08519d89">0.30</ix:nonFraction> per diluted share) for the year ended June&#160;30, 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Tax Cuts and Jobs Act of 2017 (the &#8221;U.S. Tax Act&#8221;), we have treated all non-U.S. historical earnings as taxable. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax if repatriated. The total amount of these undistributed earnings at June&#160;30, 2022 amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-8" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MzEzNDk_2dc0c63d-8ca0-4a9a-8f18-cf084089dea7">3.6</ix:nonFraction> billion. On June 14, 2019, the U.S. Treasury Department issued final and temporary regulations relating to the repatriation of non-U.S. earnings. As a result, in the event our non-U.S. earnings had not been permanently reinvested, approximately $<ix:nonFraction unitRef="usd" contextRef="ic89b566ef2524af98f09b1c2e5a3555c_I20220630" decimals="-5" name="us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MzEzNTc_5cbfc8a1-bed9-434b-8739-e33ba53c6852">194.9</ix:nonFraction>&#160;million in U.S. federal deferred taxes and $<ix:nonFraction unitRef="usd" contextRef="ie01584a76c914617a10b30795533bc02_I20220630" decimals="-5" name="us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MzEzNDE_696c9cd3-3a56-4216-90e6-19347bc8b664">5.2</ix:nonFraction>&#160;million in U.S. state deferred taxes would have been recognized in the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for uncertainty in income taxes, we recognize a tax benefit in the financial statements for an uncertain tax position only if management&#8217;s assessment is that the position is &#8220;more likely than not&#8221; (that is, a likelihood greater than <ix:nonFraction unitRef="number" contextRef="ia4b678d1321a48be9f80648f4a12cf05_D20210701-20220630" decimals="2" name="rmd:PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" format="ixt:num-dot-decimal" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTAyNzM_b15a819c-c05b-454f-bc12-8bfee6ec2e03">50</ix:nonFraction> percent) to be allowed by the tax jurisdiction based solely on the technical merits of the position. The term &#8220;tax position&#8221; refers to a position in a previously filed tax return or a position expected to be taken in a future tax return that is reflected in measuring current or deferred income tax assets and liabilities for annual periods. We recognize interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying consolidated statements of income. Accrued interest and penalties are included within the related tax liability line in the consolidated balance sheets. Based on all known facts and circumstances and current tax law, we believe the total amount of unrecognized tax benefits on June 30, 2022, is not material to our results of operations, financial condition or cash flows, and if recognized, would not have a material impact on our effective tax rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2021, we concluded the settlement agreement with the Australian Taxation Office (&#8220;ATO&#8221;) in relation to the previously disclosed transfer pricing dispute for the tax years 2009 through 2018 (&#8220;ATO settlement&#8221;). The ATO settlement fully resolved the dispute for all prior years, with no admission of liability and provides clarity in relation to certain future taxation principles.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final net impact of the ATO settlement was $<ix:nonFraction unitRef="usd" contextRef="i6fd3564ce052488e9f5ba664a5d9dcec_D20210701-20220630" decimals="-5" name="rmd:IncomeTaxExaminationNetImpactOfSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUxOTc_be59de5d-4728-4188-a77f-2e26d616af01">238.7</ix:nonFraction>&#160;million, which represents a gross amount of $<ix:nonFraction unitRef="usd" contextRef="i6fd3564ce052488e9f5ba664a5d9dcec_D20210701-20220630" decimals="-5" name="rmd:IncomeTaxExaminationGrossSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyMTM_7137e92d-deec-4140-b840-0fb9a4b10c43">381.7</ix:nonFraction>&#160;million, including interest and penalties of $<ix:nonFraction unitRef="usd" contextRef="i6fd3564ce052488e9f5ba664a5d9dcec_D20210701-20220630" decimals="-5" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyMjk_5f0c6fbc-0959-4b1d-bb22-23a13eac21a6">48.1</ix:nonFraction>&#160;million, and adjustments for credits and deductions of $<ix:nonFraction unitRef="usd" contextRef="i8d4e9f2528d046f9a73bbe9b0ae46a0e_I20220630" decimals="-5" name="us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyNDQ_08b2a467-3b90-4fdd-baa2-d6fd6fbeb062">143.0</ix:nonFraction>&#160;million. As a result of the ATO settlement and due to movements in foreign currencies, we recorded a benefit of $<ix:nonFraction unitRef="usd" contextRef="i9b2d239a762c46e39be91927daa68806_D20210701-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyNjA_2c37edbe-3ad5-4b18-939b-e276d4a01c20">14.1</ix:nonFraction>&#160;million within other comprehensive income, and a $<ix:nonFraction unitRef="usd" contextRef="i9b2d239a762c46e39be91927daa68806_D20210701-20220630" decimals="-5" name="us-gaap:IncomeTaxCreditsAndAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyNzU_cf30d83d-8a78-49f5-a396-e8bee9535894">4.1</ix:nonFraction>&#160;million reduction of tax credits, which was recorded to income tax expense. As a result of the ATO settlement, we reversed our previously recorded uncertain tax position.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, we remitted final payment to the ATO of $<ix:nonFraction unitRef="usd" contextRef="i01201a3e634542d49bf58f119957d890_D20210928-20210928" decimals="-5" name="rmd:IncomeTaxExaminationRemittedFinalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyODk_c2663f44-5483-4c91-a2b1-bab5363d0b9b">284.8</ix:nonFraction>&#160;million, consisting of the agreed settlement amount of $<ix:nonFraction unitRef="usd" contextRef="i01201a3e634542d49bf58f119957d890_D20210928-20210928" decimals="-5" name="rmd:IncomeTaxExaminationGrossSettlement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUzMDU_2c1cae61-57e2-4cff-a70f-be74729d2b86">381.7</ix:nonFraction>&#160;million less prior remittances made to the ATO of $<ix:nonFraction unitRef="usd" contextRef="i01201a3e634542d49bf58f119957d890_D20210928-20210928" decimals="-5" name="rmd:IncomeTaxExaminationPriorRemittancePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUzMjE_3692d3f4-66d3-4ad4-8c42-589eb20c6e4e">96.9</ix:nonFraction>&#160;million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax years 2018 to 2021 remain subject to future examination by the major tax jurisdictions in which we are subject to tax.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-86-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_148"></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(14) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzIwNDM_d9517905-974a-463a-b15d-1089e0eb487c" continuedAt="i942b5437a16c46a2bf423c01549c46be" escape="true">Segment Information </ix:nonNumeric></span></div><ix:continuation id="i942b5437a16c46a2bf423c01549c46be" continuedAt="i81baec7a1f8f4208ba5004fd3a57306f"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="segment" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzMyOTg1MzQ4ODU1MTU_1d36c621-febe-4851-8009-5e727ad476aa">two</ix:nonFraction> operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment. We evaluate the performance of our segments based on net sales and income from operations. The accounting policies of the segments are the same as those described in note 2 &#8211; Summary of Significant Accounting Policies. Segment net sales and segment income from operations do not include inter-segment profits and revenue is allocated to a geographic area based on where the products are shipped to or where the services are performed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate headquarters costs including stock-based compensation, amortization expense of acquired intangibles, restructuring expenses, litigation settlement expenses, deferred revenue fair value adjustment, net interest expense (income), loss attributable to equity method investments, gains and losses on equity investments, and other, net. We neither discretely allocate assets to our operating segments, nor does our Chief Operating Decision Maker evaluate the operating segments using discrete asset information.</span></div><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzIwNDQ_6f58e94b-e0f7-4589-aaf4-947dd0dd3a0c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a reconciliation of net revenues, depreciation and amortization and net operating profit by reportable segments for the years ended June&#160;30, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net revenue by segment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9615d030beef4655919952e7c42dddb0_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzItMS0xLTEtMjg3Njk_7e20d86e-fdb7-4a20-a042-7d67d18c3353">3,177,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e575d821d774882967b5b2ac809400a_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzItMy0xLTEtMjg3Njk_cce1f64a-63d6-46e7-af4d-d06005549570">2,823,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2565ea6b2b0f49e596d06ef86c0ee019_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzItNS0xLTEtMjg3Njk_1813016a-95c0-4c87-8a65-5621fa3e9802">2,602,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f176c13cb464db58e7e974bbe583ad2_D20210701-20220630" decimals="-3" name="rmd:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzQtMS0xLTEtMjg3Njk_d6ff136e-9ea6-4ea3-aa3a-829768e7b7bb">400,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd1b88dba5e4ed4b2bc90aa0129b7e1_D20200701-20210630" decimals="-3" name="rmd:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzQtMy0xLTEtMjg3Njk_0df029ee-cc35-43ed-9006-c07814463894">373,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcaef51aed54c3cbc31f6f73f6fc4dc_D20190701-20200630" decimals="-3" name="rmd:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzQtNS0xLTEtMjg3Njk_c484b1c2-aa28-4a5e-ac7a-cd1d72d5d7d6">356,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue fair value adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0095199e4b29470582f73f47f8ae065a_D20210701-20220630" decimals="-3" name="rmd:DeferredRevenueFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzUtMS0xLTEtMjg3Njk_951f17db-2099-4faa-bb0a-cf8674d7456a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d1e579aaa5456ba8a0c4cb4315ddc8_D20200701-20210630" decimals="-3" name="rmd:DeferredRevenueFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzUtMy0xLTEtMjg3Njk_81fa88d6-5483-4caf-bc77-b91a345a8829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46269d456ce141c8be9efcf422648c0d_D20190701-20200630" decimals="-3" name="rmd:DeferredRevenueFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzUtNS0xLTEtMjg3Njk_0851f1a5-9be2-4fad-aa1c-2a5c2904566e">2,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f176c13cb464db58e7e974bbe583ad2_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzYtMS0xLTEtMjg3Njk_0c75c916-202b-4ae2-86af-eff14290d4d2">400,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd1b88dba5e4ed4b2bc90aa0129b7e1_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzYtMy0xLTEtMjg3Njk_1c374056-34d1-4b5d-a719-9f3b716af29b">373,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcaef51aed54c3cbc31f6f73f6fc4dc_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzYtNS0xLTEtMjg3Njk_7f3146ef-3b10-494d-9c57-cd72b217ae2b">354,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzctMS0xLTEtMjg3Njk_676afb92-71e0-442f-b6f9-52fa658bb671">3,578,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzctMy0xLTEtMjg3Njk_19ee5fcd-68f2-462f-a9f6-2c8ab272f5cd">3,196,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzctNS0xLTEtMjg3Njk_4032e9ca-c571-4128-a07c-88a69d375cf2">2,957,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation and amortization by segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9615d030beef4655919952e7c42dddb0_D20210701-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEwLTEtMS0xLTI4NzY5_009784c2-8e15-4237-a627-d108bd048263">79,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e575d821d774882967b5b2ac809400a_D20200701-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEwLTMtMS0xLTI4NzY5_b7314aa2-1cac-420b-8efb-e53fe52aed20">73,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2565ea6b2b0f49e596d06ef86c0ee019_D20190701-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEwLTUtMS0xLTI4NzY5_b08abc2e-0c25-4dd2-85bd-fb215c41d1ad">69,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f176c13cb464db58e7e974bbe583ad2_D20210701-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzExLTEtMS0xLTI4NzY5_18fd156a-9f9d-4534-a109-a664082e666e">7,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd1b88dba5e4ed4b2bc90aa0129b7e1_D20200701-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzExLTMtMS0xLTI4NzY5_15639d27-9a9f-4b31-948f-a7cde524f953">5,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcaef51aed54c3cbc31f6f73f6fc4dc_D20190701-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzExLTUtMS0xLTI4NzY5_9325361b-20de-4487-8c03-61072f869d45">3,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets and corporate assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b423ab980a64f30b1a30f8d6aab58ed_D20210701-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEyLTEtMS0xLTI4NzY5_a4179cda-2e52-4f50-96e6-21c0cc2219b4">72,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic40263e3a7e448478aaec5362e3d5ac0_D20200701-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEyLTMtMS0xLTI4NzY5_4b37547b-7835-4f7e-8fba-b50defb43475">78,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dc746d3d9604ed8b657848caa1d88b5_D20190701-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEyLTUtMS0xLTI4NzY5_bfdfdc5d-ca28-478e-85e1-2f81d4b5b258">81,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEzLTEtMS0xLTI4NzY5_e1272e33-64a1-4915-9cad-002fe64bed4b">159,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEzLTMtMS0xLTI4NzY5_a17f8749-9e70-4565-9135-0acb63beef8a">156,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEzLTUtMS0xLTI4NzY5_f11d2a0a-5559-401c-a846-4987f1f60c2e">154,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net operating profit by segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9615d030beef4655919952e7c42dddb0_D20210701-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE2LTEtMS0xLTI4NzY5_be690ee7-3438-4409-8668-a9798522c73f">1,132,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e575d821d774882967b5b2ac809400a_D20200701-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE2LTMtMS0xLTI4NzY5_ed188bdc-6c67-4d28-afd8-9819264f5914">1,036,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2565ea6b2b0f49e596d06ef86c0ee019_D20190701-20200630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE2LTUtMS0xLTI4NzY5_5bea979c-050f-4609-a25c-e474d88792fd">934,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f176c13cb464db58e7e974bbe583ad2_D20210701-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE3LTEtMS0xLTI4NzY5_1a44ddbe-da76-49e7-b3fc-eebfe7c0cfba">93,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd1b88dba5e4ed4b2bc90aa0129b7e1_D20200701-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE3LTMtMS0xLTI4NzY5_5db67901-7132-4e88-b4ed-7c6f064e4c2c">93,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bcaef51aed54c3cbc31f6f73f6fc4dc_D20190701-20200630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE3LTUtMS0xLTI4NzY5_86c12e4b-fdcd-46e2-8b49-893155c2e96e">82,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25c6b0cc200a4b599e158f399e3c9bc6_D20210701-20220630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE4LTEtMS0xLTI4NzY5_0b191cc2-8aba-4997-b1ad-e1cb634f2f4e">1,226,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4aa667d360a42a0a82284e45233a24c_D20200701-20210630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE4LTMtMS0xLTI4NzY5_d50e69d3-f8f4-4f45-98a0-90e1b4b7851a">1,129,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0034c7a4e6a54939a36c81c60d8ae04f_D20190701-20200630" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE4LTUtMS0xLTI4NzY5_edf97cf8-970d-4f21-a957-16512b57fcaa">1,016,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciling items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630" decimals="-3" name="rmd:UnallocatedCorporateCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIxLTEtMS0xLTI4NzY5_c16cca75-c7e3-4648-a31a-95c10f2bc8b0">155,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630" decimals="-3" name="rmd:UnallocatedCorporateCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIxLTMtMS0xLTI4NzY5_cc84c244-fa75-4e2f-91cd-9865c140f8d7">141,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630" decimals="-3" name="rmd:UnallocatedCorporateCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIxLTUtMS0xLTI4NzY5_e999843a-8136-42d3-8ee5-cbb0de21da95">125,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIyLTEtMS0xLTI4NzY5_af24df31-5cf5-49d1-9eb7-6328a4eac4c2">70,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIyLTMtMS0xLTI4NzY5_e0df6ff6-da01-4c10-bd40-4a373eec09b8">76,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630" decimals="-3" name="rmd:AmortizationOfAcquiredIntangibleAssets1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIyLTUtMS0xLTI4NzY5_1f106dac-2ea9-49c5-a3c8-3ddd53362a28">79,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIzLTEtMS0xLTI4NzY5_d85db423-2ae9-43ab-be19-c0b1da2c4552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIzLTMtMS0xLTI4NzY5_ce0ef0f8-f6ab-496e-ac80-6930dc97298b">8,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIzLTUtMS0xLTI4NzY5_cf2952db-0e31-4de2-876f-94dfcca397ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI0LTEtMS0xLTI4NzY5_705c5c9b-0286-429e-ab62-e823567499b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI0LTMtMS0xLTI4NzY5_fdb9de49-2b3c-46dc-85ac-df04d291967d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:LitigationSettlementExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI0LTUtMS0xLTI4NzY5_4ca9542c-7440-4463-9293-4424ded6c1b2">600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue fair value adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630" decimals="-3" name="rmd:DeferredRevenueFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI2LTEtMS0xLTI4NzY5_5749dc31-02b4-46ae-bfe1-926cce4dc317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630" decimals="-3" name="rmd:DeferredRevenueFairValueAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI2LTMtMS0xLTI4NzY5_0179159d-8708-4453-9c80-5e7f534e4c41">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630" decimals="-3" name="rmd:DeferredRevenueFairValueAdjustment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI2LTUtMS0xLTI4NzY5_848bdec9-8b97-46b2-bf3a-8909d0708761">2,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI3LTEtMS0xLTI4NzY5_65bf1cc7-7df7-4e25-9cd8-acecf0a1e1c5">22,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI3LTMtMS0xLTI4NzY5_c7cd3a49-90ca-4982-92a8-d3d9260d0a42">23,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI3LTUtMS0xLTI4NzY5_45ff0835-38de-4027-9359-9d214ca38607">39,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTEtMS0xLTI4NzY5_00fee2b7-9c3b-44a7-85aa-0c99c82a7944">8,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTMtMS0xLTI4NzY5_9e915339-2919-4793-85c3-5605dea17247">11,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTUtMS0xLTI4NzY5_5fcafc6e-b039-4a24-9c77-b9de8736b36f">25,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTEtMS0xLTM4Mzc4_690206fc-f1c0-42a8-8f98-837dc59c835e">12,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTMtMS0xLTM4Mzc4_43f2f49f-bd59-41b6-a0d9-ce3a37298bd9">14,515</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630" decimals="-3" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTUtMS0xLTM4Mzc4_341a8546-4e46-49e9-961d-e43e9c1b5c43">14,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI5LTEtMS0xLTI4NzY5_2d9d2d31-a723-4939-94e1-73f18e9a67bf">3,197</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI5LTMtMS0xLTI4NzY5_ec79a8c1-e5a2-4b91-91b3-ed3627d3681d">301</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI5LTUtMS0xLTI4NzY5_3d0d7fc7-de13-4d38-a132-08fa4df8b26d">2,362</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzMwLTEtMS0xLTI4NzY5_90d14428-d17a-4241-bfe3-70cff636ec52">960,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzMwLTMtMS0xLTI4NzY5_7be746c5-e220-456a-8353-429e8d93dabc">883,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzMwLTUtMS0xLTI4NzY5_eff902fa-e74d-4833-b9c1-2e8609a42989">733,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The deferred revenue fair value adjustment is a purchase price accounting adjustment related to MatrixCare which was acquired on November 13, 2018.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-87-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i81baec7a1f8f4208ba5004fd3a57306f"><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="rmd:ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzIwNDY_14cf95bc-cd47-43be-8286-ff03699dd7ab" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S., Canada and Latin America</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb9b1ba3cc948fbbeafc80d5fb888c0_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzItMS0xLTEtMjg3Njk_6694a93d-54e5-41d1-ae82-0b8ddd34a732">1,070,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fdc782505914ae19cc4a5145a64302a_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzItMy0xLTEtMjg3Njk_7e406a41-8cc9-4351-9281-69083de9146f">863,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3506717407b495e8b465b435329e9fa_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzItNS0xLTEtMjg3Njk_4fe6c4e0-0023-4ff5-bb71-961550c041ee">792,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i683f2eada0d04fcaad952c8b3d263517_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzMtMS0xLTEtMjg3Njk_438f5489-1b98-4240-b062-d6dccd776d17">911,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ceba21d091145f1abfd5e8ee8280f34_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzMtMy0xLTEtMjg3Njk_e7a3efd6-a32f-449c-8c9c-78de80429718">841,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i028290f735164715bb94548227192afe_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzMtNS0xLTEtMjg3Njk_a020b048-4ebe-4a60-ad29-531db5304cd9">779,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad2b08ec7164637b1de52cff54bc7fc_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzQtMS0xLTEtMjg3Njk_15a3f6b0-0ea7-4163-a976-a28c2ae0874c">1,981,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i768e903ad73a409983ef36a9cb3bcdd6_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzQtMy0xLTEtMjg3Njk_dc1d9ed2-c162-4ca1-a64b-df4f94e1a170">1,705,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e5f807c4204737a2770ffd84a1ef8f_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzQtNS0xLTEtMjg3Njk_5d6a54cf-1a2d-4695-bbbf-10696440cdee">1,572,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd4f488d02b44960a0dd40ec6011ee0a_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzUtMS0xLTEtMjg3Njk_5e0b2a60-67f8-4ea7-aaa7-063199613f5b">400,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb162e7018f4f9389dece5e2798edd4_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzUtMy0xLTEtMjg3Njk_27719889-4302-40a3-88d1-1c51c05ff029">373,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69ea25fdac2444049f2441242da65d68_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzUtNS0xLTEtMjg3Njk_75b453e6-d056-4458-ac63-1f18d090a174">354,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40bcfef9b6e54021ae8c2ff8aa045971_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzYtMS0xLTEtMjg3Njk_dfdab53c-5c31-4c2b-8f83-7fff444da122">2,382,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4299c9c5641b4278bb02f064ee36224e_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzYtMy0xLTEtMjg3Njk_15c8668a-5d85-4545-b1e6-637d34b05fef">2,078,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5f83c48a7d8454394b43a87b7ab93e4_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzYtNS0xLTEtMjg3Njk_612bac24-fbbc-4fc6-83af-f5bdd54d8b06">1,926,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Europe, Asia and other markets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic436f1cc5c3141c789df791a0cf3e876_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzktMS0xLTEtMjg3Njk_fd45fa68-faf7-4e6f-82e8-fdb78afa7658">796,488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88324fb286c04ba5950e6cd05648d664_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzktMy0xLTEtMjg3Njk_26695a16-c42e-4b2c-bd86-5ac5a5d53cdf">746,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1959ef64c9d48daae526f9ad86dc1e1_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzktNS0xLTEtMjg3Njk_1fd27115-5782-4435-a9d2-2fbeeeb32049">715,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90adc12d32e34e8fb47d50b8d5bfd24e_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzEwLTEtMS0xLTI4NzY5_a9140573-f784-4630-a723-f246f806411e">399,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id83a2708a5314366ab3b2d2063c1580c_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzEwLTMtMS0xLTI4NzY5_4ccc020b-c7d5-4285-a792-ffbed2ad637c">371,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic087066b2dfa4a2e80b6055dc86ad478_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzEwLTUtMS0xLTI4NzY5_5b904f84-ce5c-43ba-a1e8-ea1cede760ba">314,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3b5cebac484aafa9c12aabc31f71fb_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzExLTEtMS0xLTI4NzY5_cdb8cfb7-5196-48be-adda-6f117eb0264d">1,195,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfe214ef394c40078ff0a1c3b2002cd8_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzExLTMtMS0xLTI4NzY5_ce4c6ca7-e93b-4d93-bd57-5814c433bb37">1,118,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7afa8a0a280436aaa2a6358ed31ae72_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzExLTUtMS0xLTI4NzY5_0caf8368-23d4-443b-971f-143743df9ca0">1,030,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa91ad16e1d42898125c674a44f12c7_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE0LTEtMS0xLTI4NzY5_df20859c-0c11-4fb2-8a34-da2d0c3b0b46">1,866,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if750331b61d34ff6a35ce16115a39bd1_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE0LTMtMS0xLTI4NzY5_71d0a5be-3794-4881-95cb-f9fb5660e542">1,610,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20ac972a28ea4f66852dc6a23c05796a_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE0LTUtMS0xLTI4NzY5_6b0fe553-db5f-4ed6-9ca7-a4e8daed66ce">1,507,822</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c0e3f2f8bd246a08869b10ecf87c8d4_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE1LTEtMS0xLTI4NzY5_3b793570-8baf-4c92-8672-1d10095fbe4c">1,310,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9858995a6f4d25962cfd62c79b79f3_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE1LTMtMS0xLTI4NzY5_fd206006-1d77-4c27-8beb-aa6f1069fa3c">1,213,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce2674b8c0341a2b7fc01fb9809ffb6_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE1LTUtMS0xLTI4NzY5_d4402c21-101e-4bac-9ff8-6fcb224e6f15">1,094,559</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i499a1d7dca454b16aab049bf997c138b_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE2LTEtMS0xLTI4NzY5_53ec5e07-7203-4513-b90f-1894e0c084d9">3,177,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbe3bf1b0b23497a9f774cd1b2469607_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE2LTMtMS0xLTI4NzY5_9d0e6955-b43f-42b1-9e6f-a2d6c43dd0d4">2,823,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02220a87b54b4e30a843706e1e0d6a7e_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE2LTUtMS0xLTI4NzY5_e422032e-6701-4a63-ac4f-9c0a2a696de1">2,602,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3f7bb52ca32454e94bfcd08e2c8c5f7_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE3LTEtMS0xLTI4NzY5_0f58ab89-3920-4189-ac11-c0ff995cdc4d">400,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic07d827f23644728992537f14148e061_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE3LTMtMS0xLTI4NzY5_d9ccfb1a-3224-47ff-a181-5c43a6b41448">373,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i337e5645c4c44331a1f07eba81269258_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE3LTUtMS0xLTI4NzY5_3acb0d9a-c23f-4942-93bd-899ec3aaef49">354,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ceddc8dd80a49a4bd587e39d47f45e3_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE4LTEtMS0xLTI4NzY5_555e071c-6b23-4bd1-8dbf-acc60ca77076">3,578,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf573c1bd70f41baafb0fa6b1cf4e06c_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE4LTMtMS0xLTI4NzY5_d0e9fa3a-38e3-48e5-8552-bb8cc0107670">3,196,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cabc22c13c84f4f933c6296d351e8b4_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE4LTUtMS0xLTI4NzY5_d5d6e790-2823-4c77-940c-487b9a7bf13e">2,957,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzIwNDc_6ac81370-fc71-49d5-823f-30e79eb004d7" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue information by geographic area for the years ended June&#160;30, 2022, 2021 and 2020 is summarized below (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if647eaf645944411be01eae84919f4b8_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzEtMS0xLTEtMjg3Njk_538bc06c-3bec-4d05-9f49-945c5d8dfad9">2,249,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc7308901fa84fdeb1d8b362b2f75a0d_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzEtMy0xLTEtMjg3Njk_825efd37-7b63-4fec-900c-d9d773dc9326">1,962,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5bed93d8d840fca4ddaeae7fa58ef1_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzEtNS0xLTEtMjg3Njk_a5532df1-920e-4ab7-af3e-0aaaf882c599">1,828,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fa8a519bc734ac19f7310d6f9acfb13_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzItMS0xLTEtMjg3Njk_811fd0a6-59e4-4758-acbb-b17b8840acef">1,328,746</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24ea923c1eda4ec59fcf09d914cfe556_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzItMy0xLTEtMjg3Njk_9e0be08c-3dac-476e-86fc-4c320d8fc4fd">1,234,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d85bfd9205c4954829266c748d0e737_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzItNS0xLTEtMjg3Njk_1e1a5653-48d6-4020-a39a-717eeceba67d">1,128,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzMtMS0xLTEtMjg3Njk_61dbde4e-f6ee-4846-b038-6b14790d858f">3,578,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzMtMy0xLTEtMjg3Njk_eed0f502-9b6f-4255-a6ca-1c70dadf3308">3,196,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzMtNS0xLTEtMjg3Njk_5ee9a902-deb7-46f4-ad47-ea022b0163f3">2,957,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets of geographic areas are those assets used in our operations in each geographical area, and excludes goodwill, other intangible assets, and deferred tax assets. <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzIwNDg_7bb9057c-851d-4591-a420-e2e5a02edae5" continuedAt="i9b632f7b68374a0d986a55f8e1d52114" escape="true">Long-lived assets by geographic area as of June&#160;30, 2022 and 2021 is summarized below (in thousands):</ix:nonNumeric></span></div><div style="margin-top:10pt"><ix:continuation id="i9b632f7b68374a0d986a55f8e1d52114"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fc5da4e0e04d37ac8a97438b29039d_I20210630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzEtMS0xLTEtMjg3Njk_435bc936-1846-47de-a63f-73c5f78b8d85">192,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e84ef532ade41228f75e995126162ff_I20200630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzEtMy0xLTEtMjg3Njk_1663c8a1-f5e5-45b4-8588-9a55bd500a6d">186,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i801dcbebc4da489dbeb89de396b518f1_I20210630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzItMS0xLTEtMjg3Njk_6c96a81c-9e5f-4869-b534-96e7513cac6a">169,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93b19ef8b4f64d11a5fe3c85245bf6bd_I20200630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzItMy0xLTEtMjg3Njk_04448d62-b4d5-487d-be3b-f7d289cfbb87">159,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07211d598314591ab29d17f48c0e9b1_I20210630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzMtMS0xLTEtMjg3Njk_05e31368-8fa1-4cde-b3f8-1f8a272bb139">72,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064d1782e2d845f99c9be5eafe7335b0_I20200630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzMtMy0xLTEtMjg3Njk_f02c5f2b-68a9-45ed-8c1e-2c528e6ebde3">64,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fc521c6602c417dab7cde075c1c6ca0_I20210630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzQtMS0xLTEtMjg3Njk_5bb30bfc-18ad-4094-9bf2-695bdca770fa">63,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd6677e07da4b36bdfc0d4628b747e6_I20200630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzQtMy0xLTEtMjg3Njk_fe1000c9-b32b-4a5c-be85-7010ac8ac7bb">53,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzUtMS0xLTEtMjg3Njk_e86cb03c-db97-47af-89ea-47fb5803449d">498,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzUtMy0xLTEtMjg3Njk_b516dbe3-c4ab-49b4-b024-8f738372ff70">463,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div id="i1f60984bb51544a482851b08d4a3bf6b_151"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(15) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzEyNDg_01c525d9-cffe-452e-8e62-8b787d5a52a3" continuedAt="icbbe0adf489f4e2fa20dcab225fec7b3" escape="true">Employee Retirement Plans </ix:nonNumeric></span></div><ix:continuation id="icbbe0adf489f4e2fa20dcab225fec7b3" continuedAt="i07753fdf54c6492fba1424e060882e2b"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contribute to a number of employee retirement plans for the benefit of our employees. Details of the main plans are as follows: </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Australia </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contribute to defined contribution plans for each employee resident in Australia at the rate of approximately <ix:nonFraction unitRef="number" contextRef="i8a85455cff5b488bb43b5e15307964ce_D20210701-20220630" decimals="3" name="rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTIzODM_877f1a4d-4e77-4687-aee8-f41f35f47e69">10.0</ix:nonFraction>% of salaries. Employees may contribute additional funds to the plans. All Australian employees, after serving a qualifying period, are entitled to benefits on retirement, disability or death. Our total contributions to the plans for the years ended June&#160;30, 2022, 2021 and 2020, were $<ix:nonFraction unitRef="usd" contextRef="i8a85455cff5b488bb43b5e15307964ce_D20210701-20220630" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTIzODc_61d1783e-b17b-4eea-a81c-f6408374be32">11.8</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2dc2d374954548eeae4da26ee6deb2da_D20200701-20210630" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTIzOTE_ef3bb145-2aa9-46c5-a6ae-54935794d1d8">10.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9d640c7e949347a48920659088e1b6d5_D20190701-20200630" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTIzOTU_e1b16af2-7db8-46f1-aaff-f66bab377f91">9.5</ix:nonFraction> million, respectively. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-88-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i07753fdf54c6492fba1424e060882e2b"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a defined contribution plan available to substantially all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of <ix:nonFraction unitRef="number" contextRef="if2897b37cef246bfbcd8a111b95babe4_D20210701-20220630" decimals="3" name="rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0MTE_a6889b2c-e82c-49ae-9639-0d7c4fed2bbc">4.0</ix:nonFraction>% of the employee&#8217;s salary. Our total contributions to the plan were $<ix:nonFraction unitRef="usd" contextRef="if2897b37cef246bfbcd8a111b95babe4_D20210701-20220630" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0MTU_edf60f73-3ddf-4713-ad0f-a2930f57c3b4">11.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3265cc74d27c4d9c9e39b63c16e194b9_D20200701-20210630" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0MTk_68e8853b-9ec8-4e0a-bae8-c661dce75234">9.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0a3c9df979694466b84d35627592feac_D20190701-20200630" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0MjM_681dec84-4709-4354-84c4-2fa15a045957">9.3</ix:nonFraction> million in fiscal 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Singapore </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a defined contribution plan available to substantially all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of <ix:nonFraction unitRef="number" contextRef="i78253a41a7f9462cae9e61f99722631b_D20210701-20220630" decimals="3" name="rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0NjY_2205cbec-32b2-4bcf-bd9b-94b52cbcaa9f">17.0</ix:nonFraction>% of the employee&#8217;s salary. Our total contributions to the plan were $<ix:nonFraction unitRef="usd" contextRef="i78253a41a7f9462cae9e61f99722631b_D20210701-20220630" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0NzA_e7b00f22-efcc-42a9-9c9b-2281fe506436">3.1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i38c21a3a43d242b5971df394c22e9de8_D20200701-20210630" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0NzQ_5d4369ca-ab2c-410a-b795-ba617a9765ed">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i21c42c4d4e154021ad486dec830521c6_D20190701-20200630" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0Nzg_5b03e3e4-1fbc-491d-9532-afd44440acba">2.9</ix:nonFraction> million in fiscal 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div id="i1f60984bb51544a482851b08d4a3bf6b_154"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(16) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzIwNTU_3e2590e7-e70d-4991-b891-d3352df436e3" continuedAt="i8495d7df0d9f4fbdbcb2791eb08edda5" escape="true">Legal Actions, Contingencies and Commitments</ix:nonNumeric></span></div><ix:continuation id="i8495d7df0d9f4fbdbcb2791eb08edda5" continuedAt="i31b4fb8e07d8498eba963e2c95153433"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, New York University filed a complaint for patent infringement in the United States District Court, District of Delaware against ResMed Inc., case no. 1:21-cv-00813 (CFC). The complaint alleges that the AutoSet or AutoRamp features of ResMed&#8217;s AirSense 10 AutoSet flow generators infringe one or more claims of various NYU patents, including U.S. Patent Nos. 6,988,994; 9,108,009; 9,168,344; 9,427,539; 9,533,115; 9,867,955; and 10,384,024. According to the complaint, the NYU patents are directed to systems and methods for diagnosis and treating sleeping disorders during different sleep states. The complaint seeks monetary damages and attorneys&#8217; fees. ResMed answered the complaint on September 30, 2021 and filed a motion to dismiss the complaint on the basis that the patents are invalid because the subject matter of the patents is not patentable under the Supreme Court and Federal Circuit precedent. The motion to dismiss was granted in part and denied in part. The matter is proceeding to discovery. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2021, the International Trade Commission instituted In Re Certain UMTS and LTE Cellular Communications Modules and Products Containing the Same, Investigation No. 337-TA-1240, by complainants Philips RS North America, LLC and Koninklijke Philips N.V. (collectively &#8220;Philips&#8221;) against Quectel Wireless Solutions Co., Ltd; Thales DIS AIS USA, LLC, Thales DIS AIS Deutschland GmbH; Telit Wireless Solutions, Inc., Telit Communications PLC, CalAmp. Corp., Xirgo Technologies, LLC, and Laird Connectivity, Inc. (collectively &#8220;respondents&#8221;). In the ITC investigation, Philips seeks an order excluding communications modules, and products that contain them, from importation into the United States based on alleged infringement of 3G and 4G standard essential patents held by Philips. On October 6-14, 2021, the administrative law judge held a hearing on the merits. The administrative law judge issued an initial determination on April 1, 2022, finding no violation of any of the Philips patents asserted in the ITC. Philips sought review by the full International Trade Commission. On July 6, 2022, the Commission affirmed the administrative law judge&#8217;s determination that there was no violation of asserted Philips patents. The Commission terminated the ITC proceedings. Philips may appeal the ITC&#8217;s decision or return to the district court to pursue its civil case for damages and an injunction. On December 17, 2020, Philips filed companion cases for patent infringement against the same defendants in the United States District Court for the District of Delaware, case nos. 1:20-cv-01707, 01708, 01709, 01710, 01711, and 01713 (CFC) seeking damages, an injunction, and a declaration from the court on the amount of a fair reasonable and non-discriminatory license rate for the standard essential patents it is asserting against the communications module defendants. The district court cases have been stayed pending the resolution of the ITC proceedings. ResMed is not a party to the ITC investigation or the district court cases but sells products that incorporate some of the communications modules at issue in the cases. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, Cleveland Medical Devices Inc. filed suit for patent infringement against ResMed Inc. in the United States District Court for the District of Delaware, case no. 1:22-cv-00794. Cleveland Medical asserts that numerous ResMed connected devices, when combined with ResMed&#8217;s AirView and ResScan data platforms, infringe one or more of <ix:nonFraction unitRef="patent" contextRef="ieaaf7972675048e690091ac44e072096_D20220616-20220616" decimals="INF" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzMyOTg1MzQ5MjYxODA_743a2177-b7e8-4650-8187-8f2b36c6fe5c">eight</ix:nonFraction> Cleveland Medical patents, including U.S. Patent Nos. 10,076,269; 10,426,399; 10,925,535; 11,064,937; 10,028,698; 10,478,118; 11,202,603; and 11,234,637. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on currently available information, we are unable to make a reasonable estimate of loss or range of losses, if any, arising from matters that remain open.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-89-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:85.5pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div></td></tr></table></div></div><ix:continuation id="i31b4fb8e07d8498eba963e2c95153433"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Obligations Under Recourse Provisions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use independent financing institutions to offer some of our customers financing for the purchase of some of our products. Under these arrangements, if the customer qualifies under the financing institutions&#8217; credit criteria and finances the transaction, the customers repay the financing institution on a fixed payment plan. For some of these arrangements, the customer&#8217;s receivable balance is with limited recourse whereby we are responsible for repaying the financing company should the customer default. We record a contingent provision, which is estimated based on historical default rates. This is applied to receivables sold with recourse and is recorded in accrued expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2022 and 2021, receivables sold with limited recourse were $<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-5" name="rmd:ReceivablesSoldWithLimitedRecourse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMxODE_09cfaeb3-6412-42c4-a5cb-f740e4fd56c3">157.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-5" name="rmd:ReceivablesSoldWithLimitedRecourse" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMxODU_079b9b21-289c-45ad-aae2-3ea882b75b42">153.0</ix:nonFraction> million, respectively. As of June&#160;30, 2022, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $<ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-5" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMxODk_c2d26372-d551-4a95-8b9d-97f02226e5dc">24.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-5" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMyNjM_bc511a55-49e6-4902-a789-5821e61c3f3e">2.1</ix:nonFraction> million, respectively. As of June&#160;30, 2021, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $<ix:nonFraction unitRef="usd" contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630" decimals="-5" name="us-gaap:GuaranteeObligationsMaximumExposure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMyNjc_a869da0c-80c9-43df-b870-1b34bda667de">30.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630" decimals="-5" name="us-gaap:LossContingencyAccrualProvision" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMyMDE_7337cd38-576c-4c10-8ea6-cd3f0831db9c">8.2</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements to purchase goods or services that are not cancelable without penalty, primarily related to supply arrangements. In addition, in June 2022 we signed a definitive agreement to acquire MEDIFOX DAN which is expected to close during our fiscal year 2023. The MEDIFOX DAN acquisition remains subject to regulatory clearances and other customary closing conditions. Upon closing, acquisition consideration will be paid, in part, with funds available for draw under our Revolving Credit Agreement. </span></div><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzIwNTY_2d813be4-50eb-43b1-845e-c7e6d82a39e2" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations under our purchase agreements and the MEDIFOX DAN acquisition agreement at June&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.997%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June&#160;30</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum purchase obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PurchaseObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItMS0xLTEtMjg3Njk_f8fff202-0046-4991-975f-c1cd3f09ff55">1,707,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItMy0xLTEtMjg3Njk_2c8d2b8c-11cf-462f-ac43-2007a6deecd9">1,251,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PurchaseObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItNS0xLTEtMjg3Njk_a6b20b8c-6f27-4abf-aa7d-868f5d04331e">440,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PurchaseObligationDueInThirdYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItNy0xLTEtMjg3Njk_ce3b69f0-4fab-471a-938e-826bfa756c47">13,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PurchaseObligationDueInFourthYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItOS0xLTEtMjg3Njk_31b88ce7-4401-4d57-83ee-ff39a14a500f">1,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PurchaseObligationDueInFifthYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItMTEtMS0xLTI4NzY5_6645e90d-f22d-42b6-9225-a1e425ed1533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:PurchaseObligationDueAfterFifthYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItMTMtMS0xLTI4NzY5_f35885b2-c87b-443a-af7a-24424c64b89a">1,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MEDIFOX DAN acquisition consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtMS0xLTEtNTM5NTM_75985930-5594-4555-bfb3-e9728ae23971">994,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OtherCommitmentDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtMy0xLTEtNTM5NTM_e4880aa6-0952-4544-abc5-9901a35d52e8">994,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OtherCommitmentDueInSecondYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtNS0xLTEtNTM5NTM_e7b9d537-ef0e-45fa-a4fd-6db7127d7ca4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OtherCommitmentDueInThirdYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtNy0xLTEtNTM5NTM_c8cfaefc-89cd-40bb-9630-bc4e69c0151a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OtherCommitmentDueInFourthYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtOS0xLTEtNTM5NTM_2969147a-d0a1-40fd-8e2e-87cda8df5fa0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OtherCommitmentDueInFifthYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtMTEtMS0xLTUzOTUz_ff270439-9737-428d-9764-0aa9ef9d95ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:OtherCommitmentDueAfterFifthYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtMTMtMS0xLTUzOTUz_eceadaea-3342-4f8a-ab7d-704fd66d0c12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtMS0xLTEtNTM5NTM_8cf6a3cf-c9d7-4ac4-8438-0c3cec06db0a">2,702,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ContractualObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtMy0xLTEtNTM5NTM_5f91bb3e-8164-4da7-b28a-c610948b84eb">2,245,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ContractualObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtNS0xLTEtNTM5NTM_a51919a0-0119-4e9e-9733-a3cf075473fc">440,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ContractualObligationDueInThirdYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtNy0xLTEtNTM5NTM_affcb191-4cae-4a90-9fa5-9a19e379fc43">13,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ContractualObligationDueInFourthYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtOS0xLTEtNTM5NTM_c479de26-4e87-400f-884d-5fc7b8c53f9a">1,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ContractualObligationDueInFifthYear" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtMTEtMS0xLTUzOTUz_3cf235c4-16bb-4c88-a302-7d1e212353b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630" decimals="-3" name="us-gaap:ContractualObligationDueAfterFifthYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtMTMtMS0xLTUzOTUz_343ac9e0-8532-4c14-aef7-41715e64ae0a">1,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i1f60984bb51544a482851b08d4a3bf6b_160"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(17) <ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzE0NTU_9d363214-f03b-4559-8c7d-6456dc2f9292" continuedAt="ie1c56ab11a944394a6a05b1d74abb9e6" escape="true">Restructuring Expenses </ix:nonNumeric></span></div><ix:continuation id="ie1c56ab11a944394a6a05b1d74abb9e6"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we closed our Portable Oxygen Concentrator business, which was part of the Sleep and Respiratory Care segment. During the year ended June 30, 2021, we recognized restructuring expenses of $<ix:nonFraction unitRef="usd" contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630" decimals="-5" name="us-gaap:RestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwMjI_c911dc95-ddfe-47a2-b7be-f30b69548ec2">13.9</ix:nonFraction>&#160;million primarily related to inventory write-downs of $<ix:nonFraction unitRef="usd" contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwMzc_f1d293ca-fce8-4cdb-9ec3-db660a7c2d72">5.2</ix:nonFraction>&#160;million, accelerated amortization of acquired intangible assets of $<ix:nonFraction unitRef="usd" contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630" decimals="-5" name="us-gaap:AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwNTE_ba92233a-9da3-4f75-8d88-279c2fb01b5d">5.1</ix:nonFraction>&#160;million, asset impairments of $<ix:nonFraction unitRef="usd" contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwNjU_e6f908a3-c3fa-4562-b507-40e02fac0836">2.3</ix:nonFraction>&#160;million, employee-related costs of $<ix:nonFraction unitRef="usd" contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwNzk_8e668d21-bae0-4959-8a3b-46cbaa0880a4">0.7</ix:nonFraction>&#160;million and contract cancellation costs of $<ix:nonFraction unitRef="usd" contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630" decimals="-5" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwOTM_68a28adf-720a-4636-a9b1-8579a7ccd76d">0.6</ix:nonFraction>&#160;million. Of the total expense recognized during year ended June 30, 2021, the inventory write-down of $<ix:nonFraction unitRef="usd" contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630" decimals="-5" name="rmd:RestructuringAndRelatedCostCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUxMDc_421194a5-2f5f-4383-ae0f-054376270544">5.2</ix:nonFraction>&#160;million is presented within cost of sales and the remaining $<ix:nonFraction unitRef="usd" contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUxMjE_f567664e-b955-4429-bfb4-aab697ef9e6a">8.7</ix:nonFraction>&#160;million in restructuring costs is separately disclosed as restructuring expenses on the consolidated statements of operations. The restructure was completed as of June 30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended June&#160;30, 2022 and 2020 we did <ix:nonFraction unitRef="usd" contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" decimals="-5" name="us-gaap:RestructuringCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUxNDE_6084e065-ede1-453f-b81d-2343e8ca4b69"><ix:nonFraction unitRef="usd" contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630" decimals="-5" name="us-gaap:RestructuringCosts" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUxNDE_b357e216-7e74-4d45-b73a-156eb1c1fca3">no</ix:nonFraction></ix:nonFraction>t incur material restructuring expenses.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-90-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_166"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8</span></td></tr></table></div></div><ix:nonNumeric contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90ZXh0cmVnaW9uOmZiOTYzZGI1MzdlMTQxMjI4ZWJjODc5ZWFkZTNjZGE3XzYwMQ_94b7dee3-8406-4383-8d85-af2e2d9a65ba" escape="true"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS AND RESERVES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, 2021 and 2020</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning<br/>of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to costs and expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>(deductions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of<br/>Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d0acfca2694a179ae914e7b68a3e34_I20210630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzMtMS0xLTEtMjg3Njk_972bdfef-429d-48b5-aac4-c2e368d700af">32,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6f98dd6cf448e09b965f01db37b08e_D20210701-20220630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzMtMy0xLTEtMjg3Njk_80459b1e-e5e8-4a4d-b3ed-145e325f3ce3">2,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iff6f98dd6cf448e09b965f01db37b08e_D20210701-20220630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzMtNS0xLTEtMjg3Njk_7c521c8e-43e5-47ea-9acb-8cb0a43878a4">11,499</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89a45cd403ed4145a2219c018be81ad4_I20220630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzMtNy0xLTEtMjg3Njk_196c566a-1872-4a93-9e35-b58c9a15cc3d">23,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8bfa1b0d361426ca8e6bfee5712cfe9_I20200630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzYtMS0xLTEtMjg3Njk_60c93c89-4a8b-4c77-a0ee-d16cb65b54e1">30,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id60995957b3746049536126104cd8336_D20200701-20210630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzYtMy0xLTEtMjg3Njk_2fefbb58-d82d-4540-8631-38a0d5ed10ce">7,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id60995957b3746049536126104cd8336_D20200701-20210630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzYtNS0xLTEtMjg3Njk_78e5db47-11f3-43db-8c82-6987c3293651">5,680</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d0acfca2694a179ae914e7b68a3e34_I20210630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzYtNy0xLTEtMjg3Njk_20d715fe-b3b3-41d9-84e2-1df97bc04c89">32,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c57ecbf703c4d4b8b48d4fd7f8af6fe_I20190630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzktMS0xLTEtMjg3Njk_01cfda94-dbb1-4e79-b0d0-c5d6267b7902">25,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5d3ead733d44cfc87b7a8de6f4c25ba_D20190701-20200630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzktMy0xLTEtMjg3Njk_55fa629b-feb0-496f-ba62-f539bae3c678">18,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5d3ead733d44cfc87b7a8de6f4c25ba_D20190701-20200630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzktNS0xLTEtMjg3Njk_387c1569-7dcd-4c1b-a350-628a4f36c501">14,946</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c161b6547684d3dbda4b1b823202c32_I20200630" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzktNy0xLTEtMjg3Njk_2729a14c-cfde-4846-a665-ea1f237ceb95">28,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Beginning balance is adjusted to reflect the cumulative pre-tax effect of adopting Accounting Standards Update No. 2016-13, &#8220;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments&#8221; (Topic 326), effective July 1, 2021. </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying report of independent registered public accounting firm.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-91-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_169"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 9 &#8211; 9B</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_172"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A CONTROLS AND PROCEDURES </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June&#160;30, 2022. Based on the foregoing, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June&#160;30, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-92-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_175"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 9 &#8211; 9B</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. Our internal control over financial reporting includes those policies and procedures that: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of our internal control over financial reporting as of June&#160;30, 2022. In making this assessment, management used the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management&#8217;s assessment included an evaluation of the design of our internal control over financial reporting and testing of the operational effectiveness of our internal control over financial reporting. Management reviewed the results of its assessment with the audit committee of our board of directors. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on that assessment under the framework in Internal Control-Integrated Framework (2013), management concluded that the company&#8217;s internal control over financial reporting was effective as of June&#160;30, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KPMG LLP, independent registered public accounting firm, who audited and reported on the consolidated financial statements of ResMed Inc. included in this report, has issued an attestation report on the effectiveness of internal control over financial reporting.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-93-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_178"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 9 &#8211; 9B</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ResMed Inc.:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited ResMed Inc. and subsidiaries' (the Company) internal control over financial reporting as of June 30, 2022, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of June 30, 2022, based on criteria established in Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of June 30, 2022 and 2021, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended June 30, 2022, and the related notes and financial statement schedule II (collectively, the consolidated financial statements), and our report dated August 11, 2022 expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ KPMG LLP</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 11, 2022</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-94-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_181"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART II</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 9 &#8211; 9B</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B OTHER INFORMATION</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-95-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_184"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART III</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 10 &#8211; 14</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_187"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10 DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is incorporated by reference from our definitive proxy statement for our next annual meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June&#160;30, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed as exhibits to this report for the year ended June&#160;30, 2022, the certifications of our chief executive officer and chief financial officer required by Section 302 of the Sarbanes-Oxley Act of 2002. </span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct &amp; Ethics that applies to our board of directors and all of our employees, including our chief executive officer and principal financial officer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our code of conduct is available at our website by visiting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">https://investor.resmed.com/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clicking through &#8220;Investors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Corporate Governance Documents,&#8221; and &#8220;Code of Conduct -English.&#8221; When required by the rules of the NYSE, or the Securities and Exchange Commission, or SEC, we will disclose any future amendment to, or waiver of, any provision of the code of conduct for our chief executive officer and principal financial officer or any member or members of our board of directors on our website within four business days following the date of such amendment or waiver</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_190"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11 EXECUTIVE COMPENSATION </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is incorporated by reference from our definitive proxy statement for our next annual meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June&#160;30, 2022. </span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_193"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is incorporated by reference from our definitive proxy statement for our next annual meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June&#160;30, 2022. </span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_196"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is incorporated by reference from our definitive proxy statement for our next annual meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June&#160;30, 2022.</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_199"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14 PRINCIPAL ACCOUNTING FEES AND SERVICES </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this Item is incorporated by reference from our definitive proxy statement for our next annual meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June&#160;30, 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-96-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_202"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART IV</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 15 &#8211; 16</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_205"></div><div style="-sec-extract:summary;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15 EXHIBITS AND CONSOLIDATED FINANCIAL STATEMENT SCHEDULES </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this report: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Financial Statements and Schedules &#8211; The index to our consolidated financial statements and schedules are set forth in the &#8220;Index to Consolidated Financial Statements&#8221; under Item 8 of this report.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit Lists</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312518322531/d650415dex21.htm">Agreement and Plan of Merger, dated November 5, 2018, by and among ResMed Operations Inc., Evolved Sub, Inc., ResMed Inc., OPEL GI Holdings Limited, in its capacity as the agent acting on behalf of the holders of common stock of MatrixCare Holdings, Inc., and MatrixCare Holdings, Inc.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312518322531/d650415dex21.htm"> (Incorporated by reference to Exhibit 2.1 to the Registrant&#8217;s Report on Form 8-K filed on November 8, 2018)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312513416916/d604032dex31.htm">First Restated Certificate of Incorporation of ResMed Inc., as amended.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312513416916/d604032dex31.htm"> (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Report on Form 10-Q for the quarter ended September 30, 2013)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312521271405/d215540dex31.htm">Seventh Amended and Restated Bylaws of ResMed Inc., a Delaware Corporation (as Approved and Adopted by Board Resolution September 10, 2021) (Incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Report on Form 8-K filed on September 13, 2021)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of certificate evidencing shares of Common Stock. (Incorporated by reference to Exhibit 4.1 to the Registrant&#8217;s Registration Statement on Form S-1 (No. 33-91094) declared effective on June 1, 1995)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381920000013/rmd-20200630xex4_2.htm">Description of ResMed Inc.&#8217;s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381920000013/rmd-20200630xex4_2.htm"> (Incorporated by reference to Exhibit 4.2 to the Registrant&#8217;s Report on Form 10-K filed on August 13, 2020)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312509136727/dex101.htm">Form of Indemnification Agreements for our directors and officers.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312509136727/dex101.htm"> (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 8-K filed on June 24, 2009)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312509136727/dex102.htm">Form of Access Agreement for directors.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312509136727/dex102.htm"> (Incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Report on Form 8-K filed on June 24, 2009)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex103-updatedformofexecuti.htm">Updated Form of Executive Agreement.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312517293062/d456787ddef14a.htm">Amendment and Restatement to the ResMed Inc. 2009 Incentive Award Plan.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312517293062/d456787ddef14a.htm"> (Incorporated by reference to Appendix B of ResMed Inc.&#8217;s Proxy Statement filed with the Securities and Exchange Commission on September 25, 2017)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381921000014/rmd-20210521xex4_4.htm">ResMed Inc. Deferred Compensation Plan.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381921000014/rmd-20210521xex4_4.htm"> (Incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Report on Form S-8 filed on May 21, 2021)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex106-formofrestrictedstoc.htm">Form of Restricted Stock Unit Award Agreement for Directors.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex107-formofstockoptiongra.htm">Form of Stock Option Grant for Executive Officers.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex108-formofstockoptiongra.htm">Form of Stock Option Grant for Directors.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9*</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex109-formofpsuagreementfo.htm">Form of Performance-Based Restricted Stock Unit Award Agreement for Executive Officers. </a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10*</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex1010-formofexecutiverest.htm">Form of Executive Restricted Stock Unit Award Agreement for Executive Officers.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex101.htm">Second Amended and Restated Credit Agreement dated as of June 29, 2022, by and among ResMed Inc., as borrower, MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank Australia Limited, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, Wells Fargo Bank, National Association, as documentation agent, and each of the lenders identified therein</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex101.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex101.htm"> (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 8-K filed on June 29, 2022)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex102.htm">Second Amended and Restated Unconditional Guaranty dated as of June 29, 2022, by each of the Revolving Facility Guarantors, in favor of MUFG Union Bank, N.A., in its capacity as administrative agent under the Revolving Credit Agreement. (Incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Report on Form 8-K filed on June 29, 2022)</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-97-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART IV</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Items 15 &#8211; 16</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex103.htm">Second Amendment to Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement, dated as of June 29, 2022, by and among ResMed Pty Limited, as borrower, ResMed, Inc., the other parties party thereto, and MUFG Union Bank, N.A., as administrative agent.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex103.htm"> (Incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Report on Form 8-K filed on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex103.htm">June </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex103.htm">29, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312522186327/d363805dex103.htm">)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">10.14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312518122818/d572927dex104.htm">Unconditional Guaranty dated as of April 17, 2018, by each of the guarantors identified on the Term Facility Guaranty&#8217;s signature pages as a guarantor, in favor of MUFG Union Bank, N.A., in its capacity as administrative agent under the Term Credit Agreement. (Incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Report on Form 8-K filed on April 19, 2018).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">10.15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312518291742/d612931ddef14a.htm">The ResMed Inc. 2018 Employee Stock Purchase Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312518291742/d612931ddef14a.htm">. (Incorporated by reference to Appendix B of ResMed Inc.&#8217;s Proxy Statement filed with the Securities and Exchange Commission on October 3, 2018.)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">10.16</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312519194005/d755232dex101.htm">Note Purchase Agreement, dated July 10, 2019 by and among ResMed Inc. and the purchasers party to that agreement (including form of 3.24% Series A Senior Note due 2026, form of Series B 3.45% Senior Note due 2029, and form of Subsidiary Guaranty Agreement).</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000119312519194005/d755232dex101.htm"> (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Report on Form 8-K filed on July 15, 2019)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">10.17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/943819/000094381922000003/rmd-20211231xex10_1.htm">Separation Agreement and General Release of Claims, dated September 29, 2021, by and between Rajwant Sodhi and ResMed Inc., including Consulting Agreement, as Exhibit A, effective as of September 2, 2021. (Incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on January 27, 2022)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">21.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="exhibit211-subsidiaries.htm">Subsidiaries of the Registrant.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">23.1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="exhibit231-auditorconsent.htm">Consent of Independent Registered Public Accounting Firm.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">  </span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">31.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="ex311-ceocertification.htm">Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="ex311-ceocertification.htm"> </a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="ex312-cfocertification.htm">Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002.  </a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">32.1</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline" href="ex321-ceoandcfocertificati.htm">Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.  </a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">101</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">The following materials from ResMed Inc.&#8217;s Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2022 formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Income, (iii) the Consolidated Statements of Stockholders&#8217; Equity and Comprehensive Income, (iv) the Consolidated Statements of Cash Flows and (v) related notes.</span></div></td></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Management contract or compensatory plan or arrangement</span></div><div id="i1f60984bb51544a482851b08d4a3bf6b_208"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16 FORM 10-K SUMMARY</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-98-</span></div></div></div><div id="i1f60984bb51544a482851b08d4a3bf6b_211"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART IV</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized persons below. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DATED August&#160;11, 2022</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ResMed Inc. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">/s/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:108%">MICHAEL J. FARRELL</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">Michael J. Farrell</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">Chief executive officer </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-99-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i1f60984bb51544a482851b08d4a3bf6b_7">Table of Contents</a></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PART IV</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signatures</span></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div></td></tr></table></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated. </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:35.083%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.566%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SIGNATURE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DATE</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ MICHAEL J. FARRELL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief executive officer and director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael J. Farrell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ BRETT A. SANDERCOCK</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief financial officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brett A. Sandercock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer and<br/>Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ PETER C. FARRELL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-executive chairman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter C. Farrell</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ CAROL J. BURT</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carol J. Burt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ JAN De WITTE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jan De Witte</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ KAREN DREXLER </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Karen Drexler</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ HARJIT GILL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Harjit Gill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ JOHN HERNANDEZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hernandez</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ RICHARD SULPIZIO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard Sulpizio</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ DESNEY TAN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Desney Tan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/S/ RON TAYLOR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ron Taylor</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-100-</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>ex103-updatedformofexecuti.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i154275f34ab9441094646961502e27f5_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.3</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXECUTIVE AGREEMENT<br>Executive Officer</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Executive Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is made effective as of the ____ day of ________, 20__ (the &#8220;Effective Date&#8221;) between ResMed Inc., a Delaware corporation and its subsidiaries (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and _________________ (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company currently employs Executive as an executive officer of the Company&#59; and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company believes it to be in the best interests of its stockholders to attract, retain and motivate key officers and to ensure continuity of management, and that this will further those interests&#59; and </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Company recognizes that the possibility of a Change of Control of the Company may result in the departure of key executives to the detriment of the Company and its stockholders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;In consideration of Executive's continued employment as an executive officer with the Company and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive agree as follows&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Term of Agreement<br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">This Agreement shall be for an initial term that continues in effect, through the third anniversary of the Effective Date.  The term of this Agreement shall automatically be extended for one or more additional terms of three (3) years each.  This Agreement may be terminated effective as of the last day of any of the initial or extended term, provided that written notice of such termination is provided to Executive prior to the date that is 60 days before the last day of such term.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">Notwithstanding the foregoing, the term of this Agreement shall terminate upon the expiration of the &#8220;Restricted Period&#8221;, subject to all rights and benefits hereunder having been paid and satisfied in full.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Certain Definitions</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Short-term Incentive Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean ___% of Executive&#8217;s Termination Base Salary.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Executive&#8217;s conviction or plea of guilty or nolo contendere of a misdemeanor involving moral turpitude, dishonesty or a breach of trust as regards the Company or any subsidiary of the Company or Executive&#8217;s conviction or plea of guilty or nolo contendere of a felony&#59; or </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Executive's commission of any act of theft, fraud, embezzlement or misappropriation against the Company, regardless of whether a criminal conviction is obtained&#59; or </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Executive's willful and continued failure to devote substantially all of Executive&#8217;s business time to the Company&#8217;s business affairs, (excluding failures due to illness, incapacity, vacations, incidental civic activities and </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">incidental personal time) or Executive's material breach of the terms of any employment-related agreement with the Company, which failure or breach is not remedied within a reasonable time after written demand is delivered by the Company, which demand specifically identifies the manner in which the Company believes that Executive has failed to devote substantially all of Executive&#8217;s business time to the Company's business affairs or has breached such agreement&#59; or </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;Executive's willful failure to comply with any corporate policies, which failure results or is likely to result in substantial injury, financial or otherwise, to the Company or its reputation, or a violation of any corporate policy relating to harassment, discrimination, or sexual misconduct (including, but not limited to, such actions based on sex, gender, gender expression, race, religion, national origin, or other protected class)&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;Executive's unauthorized disclosure or use of confidential information of the Company, which results or is likely to result in substantial injury, financial or otherwise, to the Company or its reputation&#59; or </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;Executive's willful violation of any rules or regulations of any governmental or regulatory body, which violation results or is likely to result in substantial injury, financial or otherwise, to the Company or its reputation&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;Executive's abuse of drugs, alcohol or illegal substances (to the extent not inconsistent with the Americans with Disability Act or similar state law), which results or is likely to result in substantial injury, financial or otherwise, to the Company or its reputation. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; of the Company means the occurrence of any of the following events for purposes of this Agreement&#58; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;a transaction or series of transactions whereby any &#8220;person&#8221; or related &#8220;group&#8221; of &#8220;persons&#8221; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 under the Exchange Act) of securities of the Company possessing more than 50% of the total combined voting power of the Company&#8217;s securities outstanding immediately after such acquisition, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">other than&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;an acquisition by an employee benefit plan or any trustee holding securities under any employee benefit plan (or related trust) sponsored or maintained by the Company or any person controlled by the Company&#59; or</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;an acquisition by the Company or a &#8220;person&#8221; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, the Company&#59; or</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;an acquisition pursuant to the offering of shares of Common Stock by the Company to the general public through a registration statement filed with the Securities and Exchange Commission&#59; or</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;an acquisition of voting securities pursuant to a transaction described in clause (iii) below that would not be a Change of Control under clause (iii)&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;individuals who, as of the date hereof, constitute the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Incumbent Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) cease for any reason to constitute at least a majority of the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided, however,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that any individual becoming a director subsequent to the date hereof whose election, or nomination for election by the Company&#8217;s stockholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered to be members of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office was a result of an actual or threatened election contest with respect to the election or removal of directors&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;The consummation by the Company (whether directly involving the Company or indirectly involving the Company through one or more intermediaries) of (x)&#160;a merger, consolidation, reorganization, or business combination or (y)&#160;a sale or other disposition of all or substantially all of the Company&#8217;s assets in any single transaction or series of related transactions or (z)&#160;the acquisition of assets or stock of another entity, in each case </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">other than</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> a transaction&#58;</font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;which results in the Company&#8217;s voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into voting securities of the Successor Entity) directly or indirectly, at least a majority of the combined voting power of the Successor Entity&#8217;s outstanding voting securities immediately after the transaction&#59; or </font></div><div style="margin-bottom:12pt;padding-left:144pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;after which more than 50% of the members of the board of directors of the Successor Entity were members of the Incumbent Board at the time of the Board&#8217;s approval of the transaction or the agreement providing for the transaction.</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;The Company&#8217;s stockholders approve a liquidation or dissolution of the Company.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of subsection (i) above, the calculation of voting power shall be made as if the date of the acquisition were a record date for a vote of the Company&#8217;s stockholders, and for purposes of subsection (iii) above, the calculation of voting power shall be made as if the date of the consummation of the transaction or at the consummation of the last of a series of related transactions were a record date for a vote of the Company&#8217;s stockholders. For purposes of subsection (iii) &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Successor Entity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Company or the &#8220;person&#8221; that, as a result of the transaction, controls, directly or indirectly, the Company or owns, directly or indirectly, all or substantially all of the Company&#8217;s assets or otherwise succeeds to the business of the Company.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the United States Internal Revenue Code of 1986, as amended from time to time.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.67pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the date of Executive&#8217;s Separation from Service.  </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.33pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a physical or mental incapacity as a result of which Executive becomes unable to continue the proper performance of Executive&#8217;s duties hereunder for six consecutive calendar months or for shorter periods aggregating 180 business days in any 12-month period, but only to the extent that such definition does not violate the Americans with Disabilities Act.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Employee Retirement Income Security Act of 1974, as amended from time to time.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the Company's stock option plans, restricted stock plans, incentive plans, equity participation plans, or other similar plans, and any stock option or restricted stock agreements or other award agreements used in connection therewith.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:29.01pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the executive officer of the Company who is a party to this Agreement.  In the event of the Executive&#8217;s death after becoming entitled to any payment, benefit or right under Section&#160;3 or 4, but prior to the receipt of such payment or benefit or exercise of any right, then the term &#8220;Executive&#8221; shall include Executive&#8217;s estate.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">J.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean any of the following material negative circumstances that occurs without the express written consent of Executive, if Executive has given the Company written notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within 90 days of the initial existence of such circumstances and the Company has failed to cure such circumstances within 30 days of such notice&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;The assignment to Executive by the Company of duties, responsibilities, authority, or reporting relationship that are materially diminished when compared to Executive&#8217;s duties, responsibilities, authority, or reporting relationship with the Company immediately prior to the Change of Control (including no longer reporting to the chief executive officer or board of the parent company), except in connection with the termination of Executive&#8217;s employment for Cause, death or Disability or by Executive other than for Good Reason&#59; or</font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;A material reduction by the Company in Executive&#8217;s base salary as in effect at the time of the Change of Control&#59; or</font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;Any material diminution by the Company in the aggregate benefits provided to Executive under the Company&#8217;s benefit plans and arrangements in which Executive is participating at the time of the Change of Control, unless an equitable arrangement (embodied in an ongoing substitute or alternative plan) has been made with respect to such plan or arrangement&#59; or</font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;Any failure by the Company to continue in effect, or any material reduction in target short-term incentive opportunity or any material increase in target performance objectives under, any short-term incentive or incentive plan or arrangement in which Executive is participating at the time of the Change of Control, which results in a material negative change in Executive&#8217;s short-term incentive or incentive compensation, unless an equitable arrangement (embodied in an ongoing substitute or alternative plan) has been made with respect to such plan or arrangement with a comparable target short-term incentive opportunity and comparable target performance objectives&#59; or</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;Any material diminution by the Company in the budget over which Executive retains authority at the time of the Change of Control&#59; </font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;Any action by the Company that either&#58;</font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(A) requires Executive be based anywhere that is at least fifty (50) miles away from both (i) Executive&#8217;s office location as of the date of the Change of Control and (ii) Executive&#8217;s then primary residence, except for required travel by Executive on the Company&#8217;s business&#59; or </font></div><div style="padding-left:144pt"><font><br></font></div><div style="padding-left:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(B) changes the Company&#8217;s remote work policies in a way that substantially restricts Executive&#8217;s ability to perform Executive&#8217;s duties and responsibilities remotely, except for required travel by Executive on the Company&#8217;s business&#59; or</font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;Any failure by the Company to obtain the assumption of this Agreement by any successor or assign of the Company&#59; or</font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;Any other action or inaction by the Company that constitutes a material breach by the Company of the agreement under which Executive provides services to the Company at the time of the Change of Control.</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-31.5pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For these purposes, a material reduction of Executive&#8217;s base salary or target short-term incentive opportunity will be deemed to have occurred if the salary or target short-term incentive opportunity has been reduced by 10% or more from the base salary or target short-term incentive opportunity, as applicable, in effect at the time of the Change of Control.</font></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive&#8217;s voluntary termination of employment for Good Reason must occur not later than two years after the initial existence of the circumstances constituting &#8220;Good Reason.&#8221;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">K.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Notice of Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean a written notice delivered to the other party indicating the specific termination provision in this Agreement relied upon for termination of Executive's employment and shall set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive's employment under the provision so indicated.  Any purported termination by either party other than pursuant to a Notice of Termination shall not be effective.  </font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">L.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.67pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the later of the Separation from Service or the date of the Change of Control. </font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">M.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the period of one (1) year following the Date of Termination of Executive, which termination is covered by Section 3 hereof.</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">N.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; of Executive shall mean Executive&#8217;s termination of employment with the Company and its subsidiaries and if Executive&#8217;s compensation is subject to taxation under the Code such termination must also qualify as a &#8220;separation from service,&#8221; as defined in Treasury Regulation Section 1.409A-1(h).</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">O.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Termination Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the greatest annual rate of Executive's base salary in effect during the three-year period ending on the Date of Termination.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Change of Control Benefits.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> <br> </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">In the event that&#58;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Executive provides Notice of Good Reason at any time during the six-month period prior to the date of a Change of Control, or during the twelve (12) month period commencing on the date of a Change of Control, and Executive has a Separation from Service by reason of Executive&#8217;s voluntary termination of employment for Good Reason, or</font></div><div style="padding-left:108pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Executive has a Separation from Service by reason of the Company&#8217;s termination of Executive&#8217;s employment other than for Cause during the six-month period prior to the date of the Change of Control (and such termination is at the request of the successor entity of such Change of Control, or is otherwise made in anticipation of the Change of Control), or during the twelve (12) month period commencing on the date of the Change of Control,</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">then Executive shall receive the benefits from the Company as provided under Section 3.B.  A portion of the benefits provided under Section 3.B is deemed consideration for Executive&#8217;s covenants under Section 13.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">The benefits to be provided by the Company in the event of a Separation from Service covered by Section 3.A shall be as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;The Company shall pay to Executive when otherwise due Executive's then effective base salary through the Date of Termination.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;The Company shall pay to Executive an amount equal to ______________ times Executive&#8217;s Termination Base Salary, payable in a lump sum within thirty (30) days following the Payment Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, in no event shall such lump sum payment be paid after the last day of the applicable two and one half month period of the &#8220;short-term deferral&#8221; exemption under Treasury Regulation Section 1.409A-1(b)(4).</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;The Company shall pay to Executive an amount equal to _____________ times the higher of (i) the highest actual annual short-term incentive received by Executive during the three years prior to the fiscal year in which the Date of Termination occurs, or (ii) Executive&#8217;s Short-term Incentive Amount, payable in a lump sum within thirty (30) days following such Payment Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, in no event shall such lump sum payment be paid after the last day of the applicable two and one half month period of the &#8220;short-term deferral&#8221; exemption under Treasury Regulation Section 1.409A-1(b)(4).</font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;In consideration of service through the Date of Termination, the Company shall pay to Executive Executive&#8217;s Short-term Incentive Amount, pro-rated through and including the Date of Termination (on the basis of a 365 day year), payable in a lump sum within thirty (30) days following the Payment Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, in no event shall such lump sum payment be paid after the last day of the applicable two and one half month period of the &#8220;short-term deferral&#8221; exemption under Treasury Regulation Section 1.409A-1(b)(4). </font></div><div style="padding-left:108pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;Notwithstanding any provisions to the contrary in any of the Company&#8217;s Equity Plans, (i) all outstanding unvested stock options of Executive shall be and become fully vested and exercisable as to all shares of stock covered thereby, and (ii) all outstanding shares of restricted stock, all restricted shares, restricted stock units, performance shares and performance units of Executive shall be and become vested and nonforfeitable and all restrictions thereon shall lapse, in each case as of the Date of Termination. The number of shares to become vested under Total Shareholder Return performance stock unit grants will be determined under the prorated calculation described in Appendix II of the grant agreement. </font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)&#160;&#160;&#160;&#160;The Company shall pay to Executive an amount equal to _____________ times the annual amount the Company would be required to contribute on Executive&#8217;s behalf to the 401(k) plan, deferred compensation plan, superannuation plan, government or private pension plan, and any similar plan then in effect, based on Executive&#8217;s Termination Base Salary and the applicable maximum Company contribution percentages in effect as of the Date of Termination, payable in a lump sum within thirty (30) days following the Payment Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, in no event shall such lump sum payment be paid after the last day of the applicable two and one half month period of the &#8220;short-term deferral&#8221; exemption under Treasury Regulation Section 1.409A-1(b)(4). </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)&#160;&#160;&#160;&#160;Effective as of the Payment Date, Executive shall become and be fully vested in Executive's accrued benefits under all qualified pension, nonqualified pension, profit sharing, 401(k), deferred compensation, superannuation plan, government or private pension plan, and supplemental plans maintained by the Company for Executive's benefit, except to that the extent the acceleration of vesting of such benefits would violate any applicable law or require the Company to accelerate the vesting of the accrued benefits of all participants in such plan or plans, in which case the Company shall pay Executive a lump sum payment, within thirty (30) days following the Payment Date, in an amount equal to the present value of such unvested accrued benefits&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, in no event shall such lump sum payment be paid after the last day of the applicable two and one half month period of the &#8220;short-term deferral&#8221; exemption under Treasury Regulation Section 1.409A-1(b)(4).  In addition, if such a lump sum payment is payable, the Company shall make an additional gross-up payment to Executive in an amount such that the net amount of the lump sum payment and such additional gross-up payment retained by Executive, after the calculation and deduction of all federal, foreign, state and local income tax and employment tax (including any interest or penalties imposed with respect to such taxes) on such lump sum payment and additional gross-up payment, and taking into account any lost or reduced tax deductions on account of such gross-up payment, shall be equal to such lump sum payment. Such additional gross-up payment shall be made in a lump sum payment within thirty (30) days following the Payment Date&#59; provided, that, in no event shall such lump sum payment be paid after the last day of the applicable two and one half month period of the &#8220;short-term deferral&#8221; exemption under Treasury Regulation Section 1.409A-1(b)(4). </font></div><div style="padding-left:108pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii)&#160;&#160;&#160;&#160;The Company shall provide Executive with additional benefits described in Section 4 hereof.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:108pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;Additional Benefits.<br>  </font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Medical and Dental Health Benefits Premiums</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event of a Separation from Service covered by Section 3.A, the Company shall pay to Executive an amount equal to _____________ multiplied times the Medical and Dental Premium (as defined below), payable in a lump sum within thirty (30) days following the Payment Date&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that, in no event shall such lump sum payment be paid after the last day of the applicable two and one half month period of the &#8220;short-term deferral&#8221; exemption under Treasury Regulation Section 1.409A-1(b)(4).  For purposes of this Section 4.A, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Medical and Dental Premium</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall equal&#58;<br>(i) the monthly premium for the COBRA Continuation Coverage (determined as of the Date of Termination), less (ii) the monthly contribution required to be paid by Executive for the coverage for Executive and Executive&#8217;s family under the Company&#8217;s group medical and dental benefits plan (as in effect on the Date of Termination).  For purposes of this Section 4.A, &#8220;COBRA Continuation Coverage&#8221; shall mean the continuation coverage required to be provided to Executive and Executive&#8217;s family under the Company&#8217;s group medical and dental benefits plans following Executive&#8217;s Separation from Service in accordance with Title I, Subtitle B, Part 6 of ERISA and Section 4980B(f) of the Code (and if Executive is not a resident or citizen of the United States, and receives medical or dental benefits from the Company, then the calculation will presume Executive would be so covered by such provisions of ERISA and the Code).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, the Company shall make an additional lump sum gross-up payment to Executive in an amount such that the net amount of the lump sum payment and such additional lump sum gross-up payment retained by Executive, after the calculation and deduction of all federal, state and local income tax and employment tax (including any interest or penalties imposed with respect to such taxes) on such lump sum payment and additional lump sum gross-up payment, and taking into account any lost or reduced tax deductions on account of such gross-up payment, shall be equal to such lump sum payment.  Such additional lump sum gross-up payment shall be made in a lump sum payment within thirty (30) days following the Payment Date&#59; provided, that, in no event shall such lump sum payment be paid after the last day of the applicable two and one half month period of the &#8220;short-term deferral&#8221; exemption under Treasury Regulation Section 1.409A-1(b)(4).  Notwithstanding the foregoing, with regard to any such additional lump sum gross-up payment, if the Company determines in its sole discretion that it cannot provide the foregoing benefit without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide to Executive a comparable payment or benefit in a manner that preserves the intended economic benefit of such amount. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt;text-decoration:underline">Relocation Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event of a Separation from Service covered by Section 3.A, the Company shall honor any separate agreement it has entered into with Executive to reimburse Executive upon termination of employment in an amount equal to the expenses incurred by Executive in connection with Executive&#8217;s relocation at the request of the Company&#59; provided that notwithstanding the terms of such agreement, all such payments shall be made in a lump sum payment within thirty (30) days following the Payment Date.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If the Company has not entered into a separate agreement with Executive regarding reimbursement of expenses incurred in relocation, then no amounts shall be payable to Executive pursuant to this Section 4.B.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;Best Pay Provision.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">Notwithstanding any other provisions of this Agreement, in the event that any payment or benefit received or to be received by Executive (including any payment or benefit received in connection with a change in ownership or control of the Company, including a Change of Control, or the termination of Executive&#8217;s employment, including a Separation from Service, whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement) (all such payments and benefits, including the payments and benefits under Sections 3 and 4 of this Agreement, being hereinafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Total Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) would be subject (in whole or part), to the excise tax imposed under Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then, after taking into account any reduction in the Total Payments provided by reason of Section 280G of the Code in such other plan, arrangement or agreement, the cash severance payments shall first be reduced, and the noncash severance payments shall thereafter be reduced, to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax but only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such reduced Total Payments) is greater than or equal to (ii) the net amount of such Total Payments without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Total Payments and the amount of Excise Tax to which Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions attributable to such unreduced Total Payments).  The Total Payments shall be reduced by the Company in its reasonable discretion in the following order&#58; (w) reduction of any cash severance payments otherwise payable to Executive that are exempt from Section 409A of the Code, (x) reduction of any other cash payments or benefits otherwise payable to Executive that are exempt from Section 409A of the Code, but excluding any payment attributable to the acceleration of vesting or payment with respect to any stock option or other equity award with respect to the Company&#8217;s common stock that are exempt from Section 409A of the Code, (y) reduction of any other payments or benefits otherwise payable to Executive on a pro-rata basis or such other manner that complies with Section 409A of the Code, but excluding any payment attributable to the acceleration of vesting and payment with respect to any stock option or other equity award with respect to the Company&#8217;s common stock that are exempt from Section 409A of the Code, and (z) reduction of any payments attributable to the acceleration of vesting or payment with respect to any stock option or other equity award with respect to the Company's common stock that are exempt from Section 409A of the Code, provided, that reduction of any payments attributable to accelerating vested stock options or other equity awards shall be first applied to stock options and equity awards that would otherwise vest last in time.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">For purposes of determining whether and the extent to which the Total Payments will be subject to the Excise Tax, (i) no portion of the Total Payments the receipt or enjoyment of which Executive shall have waived at such time and in such manner as not to constitute a &#8220;payment&#8221; within the meaning of Section 280G(b) of the Code shall be taken into account, (ii) no portion of the Total Payments shall be taken into account which, in the written opinion of Company&#8217;s independent certified public accounts, or the independent auditors of nationally recognized standing selected by the Company, as determined by the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accountants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), does not constitute a &#8220;parachute payment&#8221; within the meaning of </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of the Code) and, in calculating the Excise Tax, no portion of such Total Payments shall be taken into account which, in the opinion of the Accountants, constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of the Code, in excess of the &#8220;base amount&#8221; (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable compensation, and (iii) the value of any non cash benefit or any deferred payment or benefit included in the Total Payments shall be determined by the Accountants in accordance with the principles of Sections 280G(d)(3) and (4) of the Code.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with and Exemption from Section 409A of the Code.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.&#160;&#160;&#160;&#160;Certain payments and benefits payable under this Agreement are intended to comply with, or be exempt from, the requirements of Section 409A of the Code.  This Agreement shall be interpreted in accordance with the applicable requirements of, and exemptions from, Section 409A of the Code and the Treasury Regulations thereunder.  To the extent the payments and benefits under this Agreement are subject to Section 409A of the Code, this Agreement shall be interpreted, construed and administered in a manner that satisfies the requirements of Sections 409A(a)(2), (3) and (4) of the Code, the Treasury Regulations thereunder and any applicable transitional relief or other authority thereunder.  If the Company and Executive determine that any compensation, benefits or other payments that are payable under this Agreement and intended to comply with Sections 409A(a)(2), (3) and (4) of the Code do not comply with Section 409A of the Code, the Treasury Regulations thereunder and other applicable authority issued by the Internal Revenue Service, to the extent permitted under Section 409A of the Code, the Treasury Regulations thereunder and any applicable authority issued by the Internal Revenue Service, the Company and Executive agree to amend this Agreement, or take such other actions as the Company and the  Executive deem reasonably necessary or appropriate, to cause such compensation, benefits and other payments to comply with the requirements of Section 409A of the Code, the Treasury Regulations thereunder and other applicable authority issued by the Internal Revenue Service, while providing compensation, benefits and other payments that are, in the aggregate, no less favorable then the compensation, benefits and other payments provided under this Agreement.  In the case of any compensation, benefits or other payments that are payable under this Agreement and intended to comply with Sections 409A(a)(2), (3) and (4) of the Code, if any provision of the Agreement would cause such compensation, benefits or other payments to fail to so comply, such provision shall not be effective and shall be null and void with respect to such compensation, benefits or other payments, to the extent such provision would cause a failure to comply</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and such provision shall otherwise remain in full force and effect.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.&#160;&#160;&#160;&#160;If Executive is a &#8220;specified employee,&#8221; as defined in Treasury Regulation Section 1.409A-1(i), on the date of Executive&#8217;s Separation from Service, to the extent required by Section 409A of the Code and the Treasury Regulations thereunder, any payments or benefits under this Agreement subject to Section 409A of the Code shall be delayed in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, and such payments or benefits shall be paid or distributed to Executive during the thirty (30) day period commencing on the earlier of (i) the expiration of the six-month period measured from the date of Executive&#8217;s Separation from Service or (ii) the date of the Executive&#8217;s death.  Upon the expiration of the applicable six-month period under Section </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">409A(a)(2)(B)(i) of the Code, all payments deferred pursuant to this Section 6 shall be paid in a lump sum payment to Executive.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.&#160;&#160;&#160;&#160;In any case where Executive&#8217;s Date of Termination and the Release Expiration Date (as defined in Section 13.E, below) fall in two separate taxable years, any payments required to be made to executive that are conditioned on a release of claims under Section 13.E and constitute nonqualified deferred compensation for purposes of Code Section 409A shall be made in the later taxable year.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.&#160;&#160;&#160;&#160;The provisions of this Section 6 shall be effective only if Executive&#8217;s compensation is subject to taxation under the Code.  This Agreement is not intended to provide for any deferral of compensation subject to Code Section 409A and, accordingly, the benefits provided pursuant to this Agreement shall be paid not later than the later of&#58;  (i) the fifteenth day of the third month following Executive&#8217;s first taxable year in which such benefit is no longer subject to a substantial risk of forfeiture, and (ii) the fifteenth day of the third month following the first taxable year of the Company in which such benefit is no longer subject to a substantial risk of forfeiture, as determined in accordance with Code Section 409A and Treasury Regulation Section 1.409A-1(b)(4).  For purposes of this Section 6.D, &#8220;substantial risk of forfeiture&#8221; shall have the meaning set forth in Treasury Regulation Section 1.409A-1(d). Notwithstanding the provisions of this Section 6, the timing of the settlement of equity awards, that may constitute nonqualified deferred compensation for purposes of Code Section 409A, will be governed by the provisions of those agreements. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;Mitigation.<br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive shall not be required to mitigate the amount of any payment provided for in this Agreement by seeking other employment or otherwise nor, except as provided in Section 4.A, shall the amount of any payment or benefit provided for in this Agreement be reduced by any compensation earned or benefit received by Executive as the result of employment by another employer or self-employment, by retirement benefits, by offset against any amount claimed to be owed by Executive to the Company or otherwise.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;Successor Agreement.<br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and&#47;or assets of the Company to expressly assume this Agreement and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had taken place.  All references herein to Company shall include the successor entity.  </font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.    &#160;&#160;&#160;&#160;Indemnity.<br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In any situation where under applicable law the Company has the power to indemnify, advance expenses to and defend Executive in respect of any judgments, fines, settlements, loss, cost or expense (including attorneys fees) of any nature related to or arising out of Executive's activities as an agent, employee, officer or director of the Company or in any other capacity on behalf of or at the request of the Company, then the Company shall promptly on written request, indemnify Executive, advance expenses (including attorney's fees) to Executive and defend Executive to the fullest extent permitted by applicable law, including but not limited to making such findings and determinations and taking any and all such actions as the Company may, under applicable law, be permitted to have the discretion to take so as to effectuate such indemnification, </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">advancement or defense.  Such agreement by the Company shall not be deemed to impair any other obligation of the Company respecting Executive's indemnification or defense otherwise arising out of this or any other agreement or promise of the Company under any statute.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;Notice.<br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For the purpose of this Agreement, notices and all other communications provided for in this Agreement shall be in writing and delivered by United States certified or registered mail (return receipt requested, postage prepaid) or by courier guaranteeing overnight delivery or by hand delivery (with signed receipt required), addressed to the respective addresses set forth below, and such notice or communication shall be deemed to have been duly given two days after deposit in the mail, one day after deposit with such overnight carrier or upon delivery with hand delivery.  The addresses set forth below may be changed by a writing in accordance herewith.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.192%"><tr><td style="width:1.0%"></td><td style="width:52.772%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.028%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company&#58;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ResMed Inc.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9001 Spectrum Center Blvd.</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">San Diego, CA  92123</font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attn&#58;  Chief Executive Officer </font></div><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">with a copy to General Counsel</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Executive&#58;</font></div></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Dispute Resolution.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any dispute arises out of this Agreement, the &#8220;complaining party&#8221; shall give the &#8220;other party&#8221; written notice of such dispute.  The other party shall have ten (10) business days to resolve the dispute to the complaining party's satisfaction.  If the dispute is not resolved by the end of such period, the complaining party may by written notice (the &#8220;Notice&#8221;) demand arbitration of the dispute as set out below, and each party hereto expressly agrees to submit to, and be bound by, such arbitration.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">Each party will, within ten (10) business days of the Notice, nominate an arbitrator.  Each nominated arbitrator must be someone experienced in dispute resolution and of good character without moral turpitude and not within the employ or direct or indirect influence of the nominating party.  The two nominated arbitrators will, within ten (10) business days of nomination, agree upon a third arbitrator.  If two (2) appointed arbitrators cannot agree on a third arbitrator within such period, the parties may seek such an appointment through any permitted court proceeding or by the American Arbitration Association (&#8220;AAA&#8221;).  The three arbitrators will set the rules and timing of the arbitration, but will generally follow the rules of the AAA and this Agreement where same are applicable and shall provide for written fact findings.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">The arbitration hearing will in no event take place more than ninety (90) days after the appointment of the third arbitrator.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt">The arbitration will take place in San Diego County, California, unless otherwise unanimously agreed to by the parties.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt">The results of the arbitration and the decision of the arbitrators will be final and binding on the parties and each party agrees and acknowledges that these results shall be enforceable in a court of law.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.67pt">Reimbursement of Legal Fees.  </font></div><div style="margin-top:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Subject to subsection (ii), the prevailing party (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">i.e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">., the Company or Executive, or in the event of Executive&#8217;s death or Disability, Executive&#8217;s representative) shall be entitled to reimbursement for all legal fees and expenses (including but not limited to fees and expenses in connection with any arbitration) incurred by such party in disputing any issue arising under this Agreement relating to Executive&#8217;s Separation from Service or in seeking to obtain or enforce any benefit or right provided by this Agreement.  </font></div><div style="padding-left:108pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;The prevailing party shall be reimbursed for legal fees and expenses pursuant to subsection (i) above only to the extent the arbitrator or court determines the following&#58;  (x) such party disputed such issue, or sought to obtain or enforce such benefit or right, in good faith, (y) such party had a reasonable basis for such claim, and (z) such party is the prevailing party.  In addition, in the event Executive is the prevailing party, the Company shall reimburse such legal fees and expenses only if such legal fees and expenses are incurred during the five (5) year period beginning on the date of Executive&#8217;s Separation from Service.   The legal fees and expenses, if any, paid to Executive for any taxable year of Executive shall not affect the legal fees and expenses paid to Executive for any other taxable year of Executive.  The legal fees and expenses, if any, shall be paid to Executive on or before the last day of Executive&#8217;s taxable year following the taxable year in which the fees or expenses are incurred.  Executive&#8217;s right to reimbursement of legal fees and expenses shall not be subject to liquidation or exchange for any other benefit.  Such right to reimbursement of legal fees and expenses shall be provided in a manner that complies with Treasury Regulation Section 1.409A-3(i)(1)(iv).  If Executive is a &#8220;specified employee&#8221; on the date of Executive&#8217;s Separation from Service, such right to reimbursement of legal fees and expenses shall be paid as provided in Section 6.B hereof.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;Governing Law.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement will be governed by and construed in accordance with the internal substantive laws, and not the choice of law rules, of the State of Delaware.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;Non-Competition, Non-Solicitation, Confidentiality and Non-Disparage Covenants.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges that he has been provided and will continue to be provided trade secret information of the Company in connection with Executive&#8217;s duties as an employee and officer of the Company.  Executive agrees that in order to prevent the misuse of trade secret information, (x) during the term of this Agreement, and (y) provided that Executive is not located in and does not relocate to the State of California during the term of this Agreement or the Restricted Period and in consideration of a portion of the payments being provided to Executive under Sections 3.B.(ii), (iii) and (vi) and a portion of the accelerated vesting provided under Sections 3.B.(v), throughout the Restricted Period, in each case, Executive shall not, anywhere in the world, directly or indirectly (i) engage without the prior express written consent of the Company, in any business or activity, whether as an employee, consultant, partner, principal, agent, representative, stockholder (except as a holder of less than 2% of the combined voting power of the outstanding stock of a publicly held </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">company) or in any other individual, corporate or representative capacity, or render any services or provide any advice to any business, activity, person or entity, if Executive knows or reasonably should know that such business, activity, service, person or entity, directly or indirectly, competes in any material manner with the Business&#59; or (ii)&#160;meaningfully assist, help or otherwise support, without the prior express written consent of the Company, any person, business, corporation, partnership or other entity or activity, whether as an employee, consultant, partner, principal, agent, representative, stockholder (other than in the capacity as a stockholder of less than 2% of the combined voting power of the outstanding shares of stock of a publicly held company) or in any other individual, corporate or representative capacity, to create, commence or otherwise initiate, or to develop, enhance or otherwise further, any business or activity if Executive knows or reasonably should know that such business or activity, directly or indirectly competes in any material manner with the Business.  For purposes of this Section 13, the term &#8220;Business&#8221; shall refer to the business of the Company as conducted on the Date of Termination.  As of the date of this Agreement, the business of the Company, generally, involves the development, manufacture and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders.  Executive acknowledges that the restrictions set forth in this Section 13.A. do not have the effect of preventing Executive from practicing Executive&#8217;s profession, trade or business, and they do not impose a financial hardship upon Executive.  Executive agrees that, in addition to any other remedies available to the Company under applicable law, in the event of a breach of this Section 13.A.&#58; (1) Executive shall immediately return (or otherwise pay) to the Company the twenty percent (20%) of the payments made under Sections 3.B.(ii), (iii) and (vi)&#59; and (2) twenty percent (20%) of all unexercised options, all shares of restricted stock and all other equity awards vested pursuant to Sections 3.B.(v) shall be surrendered by Executive and cancelled (or as to shares sold, the then current value of such shares shall be paid by Executive to the Company&#59; and (3) with respect to twenty percent (20%) to any options vested pursuant to Section 3.B.(v) that were exercised, Executive shall pay to the Company an amount equal to the difference between the exercise price and the closing price of such shares on the date of exercise multiplied by the number of shares subject to the options exercised. Executive acknowledges that twenty percent (20%) of the payment required under Sections 3.B.(ii), (iii) and (vi) and twenty percent (20%) of the accelerated vesting provided for under Section 3.B.(v) are provided to Executive solely in exchange for Executive&#8217;s agreement under this Section 13.A.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt;text-decoration:underline">Non-Solicitation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As an additional inducement for the Company to enter into this Agreement, Executive agrees that during the term of this Agreement and throughout the Restricted Period, Executive shall not, directly or indirectly solicit any person in the employment of the Company to (i) terminate such employment, or (ii) accept employment, or enter into any consulting arrangement, with anyone other than the Company.</font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Throughout the term of this Agreement, the Restricted Period and thereafter, Executive shall not, directly or indirectly, use for Executive&#8217;s personal benefit or for the benefit of any person, firm, corporation, association or other entity other than the Company, or disclose or make available to any person, firm, corporation, association or other entity for any reason or purpose whatsoever, any Confidential Information (as defined below).  Executive agrees that, upon termination of Executive&#8217;s employment with the Company, all Confidential Information in Executive&#8217;s possession that is in writing or other tangible form (together with all copies or duplicates thereof, including computer </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">files) shall be returned to the Company and shall not be retained by Executive or furnished to any third party, in any form except as provided herein&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Executive shall not be obligated to treat as confidential, or return to the Company copies of any Confidential Information that (i)&#160;was publicly known at the time of disclosure to Executive, (ii)&#160;becomes publicly known or available thereafter other than by any means in violation of this Agreement or any other duty owed to Company by any person or entity, or (iii)&#160;is lawfully disclosed to Executive by a third party.  As used in this Agreement, the term &#8220;Confidential Information&#8221; means&#58;  information disclosed to Executive or known by Executive as a consequence of or through Executive&#8217;s relationship with the Company, about the customers, employees, business methods, operations, public relations, contracts, organization, procedures, finances, customer lists, rates and prospects of the Company and its affiliates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Non-Disparage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Executive shall refrain during the term of this Agreement and throughout the Restricted Period, from publishing any oral or written statements about Company, any of its affiliates or any of Company&#8217;s or such affiliates&#8217; directors, officers, employees, consultants, agents or representatives that (i)&#160;are slanderous, libelous or defamatory, (ii)&#160;disclose private information about or confidential information of Company, any of its affiliates or any of Company&#8217;s or any such affiliates&#8217; business affairs, directors, officers, employees, consultants, agents or representatives, or (iii)&#160;place Company, any of its affiliates, or any of Company&#8217;s or any such affiliates&#8217; directors, officers, employees, consultants, agents or representatives in a false light before the public. A violation or threatened violation of this prohibition may be enjoined by the courts. The rights afforded Company and its affiliates under this provision are in addition to any and all rights and remedies otherwise afforded by law. Nothing in this agreement prevents Executive from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Executive has reason to believe is unlawful.&#160;</font></div><div style="padding-left:76.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.67pt;text-decoration:underline">General Release.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">  As an additional inducement for the Company to enter into this Agreement, and as a condition to payment and provision of benefits under this Agreement to Executive or Executive&#8217;s estate, Executive agrees that Executive (or Executive&#8217;s trust or estate, as applicable) shall execute and deliver to the Company within twenty-one (21) days (or such other period as required by law) following Executive&#8217;s Separation from Service, and not revoke within any revocation period required by law (the &#8220;Release Expiration Date&#8217;), a general release of claims in favor of the Company and its employees, directors, agents and affiliates in a form acceptable to the Company in its sole and absolute discretion. </font></div><div style="padding-left:40.5pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.33pt;text-decoration:underline">Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive agrees and acknowledges that Executive&#8217;s right to receive any of the benefits set forth in Sections 3 and 4 (to the extent Executive is otherwise entitled to such payments) is conditioned upon Executive&#8217;s compliance with the covenants in this Section&#160;13, and all benefits granted to Executive under this Agreement shall terminate immediately upon Executive&#8217;s breach of any covenant in this Section 13 and Executive shall be responsible for refunding to the Company the benefits previously received under this Agreement.  Notwithstanding the foregoing, in the event of a violation or breach of Section 13.A. the parties hereby agree that such a violation or breach shall be remedied as provided in Section 13.A.   </font></div><div style="margin-bottom:12pt;padding-left:76.5pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">Reasonable Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Executive acknowledges that these restrictions shall not prevent or unduly restrict Executive from practicing Executive&#8217;s profession, </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">or cause Executive economic hardship.  Executive represents that Executive (i) is familiar with the foregoing covenants not to compete and not to solicit, and (ii) is fully aware of the obligations hereunder, including, without limitation, the reasonableness of the length of time, scope and geographic coverage of these covenants.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.&#160;&#160;&#160;&#160;Other Severance Payments or Benefits.</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event Executive&#8217;s employment is terminated and such termination qualifies for benefits under Section&#160;3 of this Agreement, the payments and benefits provided for in Sections&#160;3 and 4 of this Agreement will be provided in lieu of any other severance payment or benefit under any other plan or program of the Company or agreement between Executive and the Company. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.&#160;&#160;&#160;&#160;Cooperation. </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">During Executive&#8217;s employment with the Company and thereafter, Executive agrees to cooperate with the Company and its agents, accountants and attorneys concerning any matter with which Executive was involved during Executive&#8217;s employment.  Such cooperation shall include, but not be limited to, providing information to, meeting with and reviewing documents provided by the Company and its agents, accountants and attorneys during normal business hours or other mutually agreeable hours upon reasonable notice and to be available for depositions and hearings, if necessary and upon reasonable notice. If Executive&#8217;s cooperation is required after the termination of Executive&#8217;s employment, the Company shall reimburse Executive for any reasonable out of pocket expenses incurred in performing the obligations hereunder.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.&#160;&#160;&#160;&#160;Entire Agreement&#59; No Oral Modifications. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement sets forth the entire agreement of the parties hereto in respect of the subject matter contained herein and supersedes all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto in respect of the subject matter contained herein.  No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by Executive and such officer as may be designated by the Board.  No waiver by either party hereto at any time of any breach by the other party hereto of or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.  </font></div><div style="padding-left:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">17.&#160;&#160;&#160;&#160;Severability&#59; Enforceability.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If at any time any provision of this Agreement shall be determined to be invalid or unenforceable by a court of competent jurisdiction, including by reason of being vague or unreasonable as to geographic area, duration or scope of activity, this Agreement shall be considered divisible and shall become and be immediately amended only as to such invalid or unenforceable provision as shall be determined to be reasonable and enforceable by a court of competent jurisdiction.  The parties hereby agree that this Agreement as so amended shall be valid and binding as though any invalid or unenforceable provision had not been included herein.  </font></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IN WITNESS WHEREOF, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the Company and the Executive have executed this Agreement to be effective the date first above written.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXECUTIVE</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RESMED INC.,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a Delaware corporation</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">And</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>3
<FILENAME>ex106-formofrestrictedstoc.htm
<DESCRIPTION>EX-10.6
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id38eebfd2c6d4b41a56ac7bbcaa13600_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:186%">Exhibit 10.6</font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Employee Directors</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ResMed Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Summary for Restricted Stock Unit</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Award Agreement</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Participant Name&#58; &#91;PARTICIPANT NAME&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Grant Date&#58; &#91;GRANT DATE&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Total Number of RSUs Granted&#58; &#91;QUANTITY GRANTED&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms of the Agreement, the RSUs shall vest and become nonforfeitable at the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Please refer to Appendix&#58; Vesting Schedule</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id38eebfd2c6d4b41a56ac7bbcaa13600_30"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RESMED INC.</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DIRECTOR RESTRICTED STOCK UNIT AWARD AGREEMENT </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Director Restricted Stock Unit Award Agreement, including any terms and conditions set forth in Appendices I and II hereto (collectively, the &#8220;Agreement&#8221;) sets forth the terms and conditions of the restricted stock units (&#8220;Restricted Stock Units&#8221; or &#8220;RSUs&#8221;) granted by ResMed Inc., a Delaware corporation (the &#8220;Company&#8221;), under the ResMed Inc. 2009 Incentive Award Plan, as amended from time to time (the &#8220;Plan&#8221;), and pursuant to the Summary of Restricted Stock Unit Award Grant (the &#8220;Summary&#8221;) displayed at the Web site of the Company&#8217;s plan administrator.  The Summary specifies the person to whom the RSUs are granted (&#8220;Holder&#8221;), the grant date of the RSUs (the &#8220;Grant Date&#8221;), the vesting schedule of the RSUs (the &#8220;Vesting Schedule&#8221;), the aggregate number of RSUs granted to Holder, and other specific details of the grant.  The Summary also indicates whether Holder has accepted the grant of RSUs.  The Summary is deemed part of this Agreement.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 1.</font></div><div style="margin-bottom:9pt;padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">GENERAL</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Summary.</font></div><div style="margin-bottom:9pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As used herein, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean a &#8220;disability&#8221; as defined in Treasury Regulation Section 1.409A-3(i)(4).</font></div><div style="margin-bottom:9pt;padding-left:36pt;padding-right:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As used herein, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">RSU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean a non-voting unit of measurement which represents the right to receive one share of Common Stock for each unit that vests (subject to adjustment as provided in Section 11.3 of the Plan) solely for purposes of the Plan and this Agreement.  The RSUs shall be used solely as a device for the determination of the issuance of shares of Common Stock to eventually be made to Holder if and to the extent such RSUs vest pursuant to Section 2.2 hereof.  The RSUs shall not be treated as property or as a trust fund of any kind.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Incorporation of Terms of Plan and Appendices I and II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The RSUs are subject to the terms and conditions of the Plan, and, to the extent applicable, Appendix I hereto (which sets forth additional terms and conditions that govern the Award if Holder is outside the United States of America) and Appendix II hereto (which sets forth special and&#47;or additional legal requirements, terms and conditions as may be required by Holder&#8217;s country), each of which is incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control.  To the extent applicable, in the event of any inconsistency between this Director Restricted Stock Unit Award Agreement and Appendices I and II, the terms of Appendices I and II shall control.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 2.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">GRANT OF RESTRICTED STOCK UNITS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Grant of RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective as of the Grant Date, the Company grants to Holder an award of RSUs as set forth in the Summary and this Agreement, upon the terms and conditions set forth in the Summary, the Plan and this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Subject to Sections 2.2(b), 2.2(c) and 2.3 hereof, the RSUs awarded pursuant to this Agreement will vest and become nonforfeitable with respect to all of the RSUs on the earlier of&#58; (i) the first November 11 following the Grant Date, or (ii) the date of the first (1st) annual meeting of the stockholders of the Company following the Grant Date, subject to Holder&#8217;s continued service through the applicable vesting date, as a condition to the vesting of the RSUs and the rights and benefits under this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Notwithstanding Section 2.2(a) hereof, and subject to Section 2.3 hereof, in the event of a Change in Control and Holder does not continue as a director of the successor entity to such Change in Control, the RSUs shall become fully vested and nonforfeitable as of the effective date of such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Change in Control.  Notwithstanding Section 2.2(a) hereof, if the Holder dies or has a Termination of Service due to Disability, the unvested RSUs shall become fully vested and nonforfeitable as of the date of such Holder&#8217;s death or Termination of Service due to Disability, as applicable.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Forfeiture, Termination and Cancellation upon Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as otherwise provided by the Administrator, upon Holder&#8217;s Termination of Service for any reason or no reason (other than Holder&#8217;s death or Disability), all then unvested RSUs subject to this Agreement will thereupon be automatically forfeited, terminated and cancelled as of the applicable termination date without payment of any consideration by the Company, and Holder, or Holder&#8217;s beneficiary or personal representative, as the case may be, shall have no further rights hereunder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Issuance of Shares upon Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  As soon as administratively practicable following the vesting of any RSUs pursuant to Section 2.2 hereof, but in no event later than sixty (60) days after such vesting date (for the avoidance of doubt, this deadline is intended to comply with the &#8220;short-term deferral&#8221; exemption from Section 409A of the Code), the Company shall deliver to Holder (or any transferee permitted under Section 3.2 hereof) a number of shares of Common Stock equal to the number of such RSUs that vested on the applicable vesting date, less to the extent applicable, the number of shares of Common Stock withheld in accordance with Section 2.5(b). The shares of Common Stock delivered hereby shall be represented either by one or more stock certificates or by book entry, as determined by the Company in its sole discretion. Notwithstanding the foregoing, in the event shares of Common Stock cannot be issued in the time frame specified above due to the effects of Section 2.6(a), (b) or (c) hereof, then the shares of Common Stock shall be issued as soon as administratively practicable after the Administrator determines that shares of Common Stock can again be issued in accordance with Sections 2.6(a), (b) and (c) hereof (but in no event later than the deadline required to comply with the &#8220;short-term deferral&#8221; exemption under Section 409A of the Code).</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Responsibility for Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Holder agrees and acknowledges that Holder will consult with his or her personal tax advisor regarding any income tax, social insurance contributions or other tax-related items legally applicable or deemed legally applicable to Holder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) that may arise in connection with the RSUs and Holder&#8217;s participation in the Plan.  Holder is relying solely on such advisor and is not relying in any part on any statement or representation of the Company or any of its agents in relation to the RSUs and this Agreement.  The Company shall not be responsible for payment of any Tax-Related Items, unless it is required to withhold Tax-Related Items under applicable law.  Holder further acknowledges that the Company (i) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSUs, including, but not limited to the grant of the RSUs, the vesting or settlement of the RSUs, the issuance of shares of Common Stock in settlement of the RSUs, the subsequent sale of the shares of Common Stock acquired at vesting and the receipt of any dividends&#59; and (ii) does not commit to and is under no obligation to structure the terms of the Award or any aspect of the RSUs to reduce or eliminate the Holder&#8217;s liability for Tax-Related Items or achieve any particular tax result.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company may take such action as it deems appropriate to ensure that all Tax-Related Items, which are Holder&#8217;s sole and absolute responsibility, are withheld or collected from Holder, if and to the extent required by applicable law.  If withholding of Tax-Related Items is required by applicable law, the Company will withhold shares of Common Stock upon the relevant taxable or tax withholding event, as applicable, unless the use of such withholding method is not feasible under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by one or a combination of the following methods&#58; (i) withholding from Holder&#8217;s cash fees or other compensation paid to Holder by the Company&#59; (ii) causing Holder to tender a cash payment (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, check or bank wire)&#59; (iii) withholding from the proceeds of the sale of shares of Common Stock issued upon vesting, either through a voluntary sale or through a mandatory sale arranged by the Company (on Holder&#8217;s behalf pursuant to this authorization)&#59; or (iv) any other method determined by the Company, to the extent permitted under the Plan and applicable laws.  Further, the Company may withhold or account for Tax-Related Items by considering statutory withholding amounts or other applicable withholding rates, including maximum rates applicable in the country in which tax is due (to the extent permitted by the Plan). In the event of over-withholding, Holder may receive a refund of any over-withheld amount in cash (with no entitlement to the Common Stock </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">equivalent) or, if not refunded, Holder may be able to seek a refund from the applicable tax authorities  In the event of under-withholding, Holder may be required to pay additional Tax-Related Items directly to the applicable tax authorities or to the Company.  If the obligation for Tax-Related Items is satisfied by withholding shares of Common Stock, for tax purposes, Holder will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares of Common Stock is held back solely for the purpose of paying the Tax-Related Items.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Company shall not be obligated to deliver any new certificate representing shares of Common Stock to Holder or Holder&#8217;s legal representative or enter such shares of Common Stock in book entry form unless and until Holder or Holder&#8217;s legal representative shall have paid or otherwise satisfied Holder&#8217;s obligations in connection with the Tax-Related Items resulting from the RSUs or the shares of Common Stock subject to the RSUs.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Conditions to Delivery of Common Stock&#59; Legal Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The shares of Common Stock deliverable hereunder, or any portion thereof, may be either previously authorized but unissued shares of Common Stock or issued shares of Common Stock which have then been reacquired by the Company.  Such shares of Common Stock shall be fully paid and nonassessable.  The Company shall not be required to issue or deliver any shares of Common Stock deliverable hereunder or portion thereof prior to fulfillment of all of the following conditions&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The admission of such shares of Common Stock to listing on all stock exchanges on which such Common Stock is then listed&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The completion and maintenance of any registration or other qualification of such shares of Common Stock under any U.S. and non-U.S. state or federal law or under rulings or regulations of the U.S. Securities and Exchange Commission or of any other governmental regulatory body, which the Administrator shall, in its absolute discretion, deem necessary or advisable&#59;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The obtaining of any approval or other clearance from any U.S. or non-U.S. state or federal governmental agency which the Administrator shall, in its absolute discretion, determine to be necessary or advisable&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The lapse of such reasonable period of time following the vesting of any RSUs as the Administrator may from time to time establish for reasons of administrative convenience.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Rights as Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Holder shall not be, nor have any of the rights or privileges of, a stockholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of the RSUs and any shares of Common Stock underlying the RSUs and deliverable hereunder unless and until such shares of Common Stock shall have been issued by the Company and held of record by such Holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).  No adjustment will be made for a dividend or other right for which the record date is prior to the date the shares of Common Stock are issued, except as provided in Section 11.3 of the Plan.  No Dividend Equivalent awards shall be awarded in respect of any unvested RSUs.</font></div><div style="padding-right:-18pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ARTICLE 3.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:118%">OTHER PROVISIONS</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Administrator shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules.  All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon Holder, the Company and all other interested persons.  No member of the Committee or the Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the RSUs.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:22.25pt;text-decoration:underline">Grant is Not Transferable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Except as set forth in Section 3.2(b), during the lifetime of Holder, the RSUs may not be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">distribution, unless and until the shares of Common Stock underlying the vested RSUs have been issued.  Neither the RSUs nor any interest or right therein shall be liable for the debts, contracts or engagements of Holder or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Notwithstanding the foregoing provisions of Section 3.2(a), for Holders who are exclusively subject to the laws of the United States, the Administrator, in its sole discretion, may permit the transfer of RSUs held by Holder (i) pursuant to a DRO, or (ii) by gift or contribution to a Permitted Transferee.  Any RSU that has been so transferred shall continue to be subject to all of the terms and conditions as applicable to the original Holder, and the transferee shall execute any and all such documents requested by the Administrator in connection with the transfer, including, without limitation, to evidence the transfer and to satisfy any requirements for an exemption for the transfer under applicable federal and state securities laws.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the limitation on the transferability of the RSUs contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Adjustments Upon Specified Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Administrator may accelerate the vesting of the RSUs and the issuance of shares of Common Stock with respect to vested RSUs in such circumstances as it, in its sole discretion, may determine&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, that if the RSUs were deemed to constitute &#8220;nonqualified deferred compensation&#8221; subject to Section 409A and Holder is subject to U.S. federal taxation, no acceleration of the issuance of the shares of Common Stock may occur other than as expressly permitted under Section 409A. In addition, upon the occurrence of certain events relating to the Common Stock contemplated by Section 11.3 of the Plan, the Administrator shall make any appropriate adjustments in the number of RSUs then outstanding and the number and kind of securities that may be issued in respect of the RSUs. Holder acknowledges that the RSUs are subject to amendment, modification and termination in certain events as provided in this Agreement and Section 11.3 of the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All notices required or permitted hereunder shall be in writing and shall be deemed to be properly given when personally delivered to the party entitled to receive the notice (which may include electronic delivery by email) or when sent by certified or registered mail, postage prepaid, properly addressed to the party entitled to receive such notice at the address stated below&#58;</font></div><div style="margin-bottom:9pt;padding-left:90pt;padding-right:90pt;text-align:center;text-indent:-108pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.596%"><tr><td style="width:1.0%"></td><td style="width:28.259%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.541%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">If to Company&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ResMed Inc.<br>9001 Spectrum Center Blvd. <br>San Diego, CA 92123<br>USA<br>Attn&#58; David Pendarvis, Corporate Secretary</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">If to Holder&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Address of the Holder on file with ResMed Inc.</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Titles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Governing Law &#47; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws.  For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Award of RSUs or this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Diego County, California, or the federal courts for the United States for the Southern District of California and no other courts, where this grant is made and&#47;or to be performed. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Conformity to Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Holder acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the U.S. Securities and Exchange Commission thereunder, and other U.S. or non-U.S. state and federal securities laws and regulations. Notwithstanding anything herein to the contrary, the Plan shall be administered, and the RSUs are granted, only in such a manner as to conform to such laws, rules and regulations.  To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Amendments, Suspension and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">that, except as may otherwise be provided by the Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">and subject to Section 3.8, Section 3.11, Section 3.14 and Section 3.17 hereof, no amendment, modification, suspension or termination of this Agreement shall adversely affect the RSUs in any material way without the prior written consent of Holder.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth in Section 3.2 hereof, this Agreement shall be binding upon Holder and his or her heirs, executors, administrators, successors and assigns.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of the Plan or this Agreement, the Plan, the RSUs and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule.  To the extent permitted by applicable law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Right to Continued Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Nothing in this Agreement or the Plan confers upon Holder any right to continue in service for any period of specific duration.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Plan, the Summary and this Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Holder with respect to the subject matter hereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties intend that this Agreement and the benefits provided hereunder be exempt from the requirements of Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) to the maximum extent possible, whether pursuant to the short-term deferral exception described in Treasury Regulation Section 1.409A-1(b)(4) or otherwise.  However, to the extent that the RSUs (or any portion thereof) may be subject to Section 409A, the parties intend that this Agreement and such benefits comply with the deferral, payout, and other limitations and restrictions imposed under Section 409A and this Agreement shall be interpreted, operated and administered in a manner consistent with such intent.  Notwithstanding any other provision of the Plan, the Summary or this Agreement, the Administrator shall have the right in its sole discretion (without any obligation to do so or to indemnify Holder or any other person for failure to do so) to adopt such amendments to the Plan, the Summary or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate either for the RSUs to be exempt from the application of Section 409A or to comply with the requirements of Section 409A.  Nothing in this Agreement, the Plan or the Summary shall provide a basis for any person to take action against the Company or any Subsidiary based on matters covered by Section 409A of the Code, including the tax treatment of any amount paid or RSUs granted under this Agreement, and neither the Company nor any of its Subsidiaries shall under any circumstances have any liability to Holder or his or her estate or any other party for any taxes, penalties or interest due on amounts paid or payable under this Agreement, including taxes, penalties or interest imposed under Section 409A.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Limitation on Holder&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Company as to amounts payable and shall not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets. Unless and until the RSUs will have vested in the manner set forth in Article 2 hereof, Holder will have no right to the issuance of shares of Common Stock with respect to the RSUs.  Holder shall have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Common Stock as a general unsecured creditor with respect to RSUs, as and when payable hereunder. </font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, decide (a) to deliver by electronic means any documents related to the RSUs granted under the Plan, Holder&#8217;s participation in the Plan, or future awards that may be granted under the Plan or (b) to request by electronic means Holder&#8217;s consent to participate in the Plan. Holder hereby consents to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an online or electronic system established and maintained by the Company or any third party designated by the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company reserves the right to impose other requirements on Holder&#8217;s participation in the Plan, on the RSUs or any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable or legal or administrative reasons, and to require Holder to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.18</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Participants Outside of the United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Holder is a resident of a jurisdiction outside of the United States and subject to the laws of such jurisdiction, then Holder hereby agrees to be subject to the additional requirements and disclosures set forth in Appendices I and II hereto, both the general terms and any specific terms for Holder&#8217;s country, which are hereby incorporated into this Agreement, regardless of the law that might be applied under principles of conflicts of laws.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.20</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Holder acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Holder or any other Holder.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.21</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:16.75pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company is not providing any tax, legal or financial advice with respect to the RSUs, nor is the Company making any recommendations regarding Holder&#8217;s participation in the Plan, or Holder&#8217;s acquisition or sale of the underlying shares of Common Stock.  Holder should consult with his or her own personal tax, legal and financial advisors regarding Holder&#8217;s participation in the Plan before taking any action related to the Plan and the RSUs.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:35.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereunto agree to the terms and conditions set forth in this Agreement.</font></div><div style="margin-bottom:0.09pt;text-align:justify;text-indent:0.35pt"><font><br></font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">RESMED INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">HOLDER</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Signed Electronically</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Signed Electronically</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#47;s&#47; Michael J. Farrell</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Michael J. Farrell</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPENDIX I</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Additional Terms and Conditions For Directors Outside the United States</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Appendix I includes additional terms and conditions that govern the Award granted to Holder under the Plan if Holder resides and&#47;or works in a country outside the United States of America (or if Holder later relocates to such a country).  Certain capitalized terms used but not defined in this Appendix I have the meanings set forth in the Plan, the Agreement and&#47;or the Summary.</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:26.84pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  Holder is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned below, including recipients located in countries which may not have a similar level of protection from the perspective of the data protection laws in Holder&#8217;s country.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:26.84pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company collects, processes and uses certain personal information about Holder, including, but not limited to, Holder&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, compensation, nationality, job title, any shares or directorships held in the Company, details of all RSUs under the Plan or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in Holder&#8217;s favor (&#8220;Data&#8221;), for the purposes of managing Holder&#8217;s participation in the Plan.  The legal basis, where required, for the processing of Data is Holder&#8217;s consent.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:27.46pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company transfers Data, or parts thereof, to Fidelity Stock Plan Services, LLC and certain of its affiliated companies (&#8220;Fidelity&#8221;), which assists the Company with the implementation, administration and management of the Plan.  Holder acknowledges and understands that Fidelity will open an account for Holder to receive and trade shares of Common Stock acquired under the Plan and that Holder will be asked to agree on separate terms and data processing practices with Fidelity, which is a condition of Holder&#8217;s ability to participate in the Plan.  In the future, the Company may select a different service provider and may share Data with such different service provider that serves in a similar manner.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:26.84pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company and Fidelity are based in the United States.  Holder understands that his or her country may have enacted data privacy laws that are different from the laws of the United States.  As a result, in the absence of appropriate safeguards such as standard data protection clauses, the processing of Holder&#8217;s Data in the United States or, as the case may be, other countries might not be subject to substantive data processing principles or supervision by data protection authorities.  In addition, Holder might not have enforceable rights regarding the processing of his or her Data in such countries.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">To the extent applicable to Holder, the Company provides appropriate safeguards for protecting Data that it receives in the United States through its adherence to data transfer agreements entered into between the Company and Subsidiaries within the European Union.  Otherwise, where required, the Company&#8217;s legal basis for the transfer of Data is Holder&#8217;s consent.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:27.46pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage Holder&#8217;s participation in the Plan, or as required to comply with applicable law, exercise or defense of legal rights, and archiving, back-up and deletion processes.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:29.29pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  Participation in the Plan is voluntary and Holder is providing the consents herein on a purely voluntary basis.  Holder understands that he or she may withdraw consent at any time with future effect for any or no reason.  If Holder does not consent, or if Holder later seeks to revoke his or her consent, Holder's service as a Director will not be affected&#59; the only consequence of refusing or withdrawing consent is that the Company would not be able to offer RSUs or other awards to Holder or administer or maintain Holder&#8217;s participation in the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:26.84pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  Holder understands that data subject rights vary depending on applicable law and that, depending on where Holder is based and subject to the conditions under applicable law, Holder may have, without limitation, the rights to (i) request access or copies of Data the Company processes, (ii) rectification of incorrect Data, (iii) deletion of Data, (iv) restrictions on processing of Data, (v) portability of Data, (vi) lodge complaints with competent authorities in Holder&#8217;s jurisdiction, and&#47;or (vii) receive a list with the names and addresses of any potential recipients of Data. To receive clarification regarding these rights or to exercise these rights, Holder understands that he or she can contact the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Holder acknowledges that, depending on Holder&#8217;s country, the broker&#8217;s country, or the country in which shares of Common Stock are listed, Holder may be subject to insider trading restrictions and&#47;or market abuse laws, which may affect Holder&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">., RSUs) or rights linked to the value of shares of Common Stock during such times as Holder is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws or regulations in the relevant jurisdiction).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  Holder is responsible to comply with any applicable restrictions, and Holder should speak to his or her personal advisor regarding this matter.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Foreign Assets&#47;Account and Tax Reporting, Exchange Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.84pt">Holder&#8217;s country may have certain foreign asset, account and&#47;or tax reporting requirements and exchange controls which may affect Holder&#8217;s ability to acquire or hold shares of Common Stock under the Plan or cash received from participating in the Plan (including from any dividends received or sale proceeds arising from the sale of shares of Common Stock) in a brokerage or bank account outside Holder&#8217;s country.  Holder understands that he or she may be required to report such accounts, assets or transactions to the tax or other authorities in Holder&#8217;s country.  Holder also may be required to repatriate sale proceeds or other funds received as a result of participation in the Plan to his or her country through a designated bank or broker and&#47;or within a certain time after receipt.  In addition, Holder may be subject to tax payment and&#47;or reporting obligations in connection with any income realized under the Plan and&#47;or from the sale of shares of Common Stock.  Holder acknowledges that he or she is responsible for complying with all such requirements, and that Holder should consult personal legal and tax advisors, as applicable, to ensure compliance.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:29.29pt">The Company shall not be liable for any foreign exchange rate fluctuation between Holder&#8217;s local currency and the United States Dollar that may affect the value of the RSUs or of any amounts due to Holder pursuant to the settlement of the RSUs or the subsequent sale of any shares of Common Stock acquired upon settlement.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event Holder has received this Agreement, including Appendices I and II, or any other document related to the Plan translated into a language other than English, the English version will control to the extent the meaning of the translated version differs from the English version.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPENDIX II</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain capitalized terms used but not defined in this Appendix II have the meanings set forth in the Plan, the Director Restricted Stock Unit Award Agreement, Appendix I and&#47;or the Summary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Appendix II includes special and&#47;or additional terms and conditions that govern the RSUs granted to Holder under the Plan if Holder is a resident of a jurisdiction outside of the United States and subject to the laws of such jurisdiction.  These terms and conditions are in addition to or, if so indicated, in place of, the terms and conditions set forth in the Agreement.  If Holder is a citizen or resident of a country other than the one in which he or she is currently residing and&#47;or transfers residency to another country after the grant of the RSUs, or is considered resident of another country for local law purposes, the Administrator shall, in its discretion, determine to what extent any country-specific terms and conditions contained herein shall be applicable to Holder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Belgium</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">There are no country-specific provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Singapore</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sale of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For any shares of Common Stock that are issued within six months of the Grant Date, Holder agrees that he or she will not dispose of the shares of Common Stock acquired prior to the six-month anniversary of the Grant Date, unless such sale or offer in Singapore is made pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the of the Singapore Securities and Futures Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;), or any other applicable provisions of the SFA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The offer of the Plan is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of SFA and not with a view to the RSUs or shares of Common Stock being subsequently offered for sale to another party.  The Plan has not been lodged or registered as a prospectus with a Monetary Authority of Singapore.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>4
<FILENAME>ex107-formofstockoptiongra.htm
<DESCRIPTION>EX-10.7
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3d5ae67d6e7f4860b2e6a8fc76e87c38_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Exhibit 10.7</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">ResMed Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Summary for Executive Stock Option Award Agreement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Grantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;PARTICIPANT NAME&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;GRANT DATE&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Number of Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#58;&#160;&#160;&#160;&#160;&#91;OPTIONS GRANTED&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Subject to the terms of the Agreement, one-third of the options granted shall vest and become nonforfeitable on each of the first three anniversaries of the Grant Date.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="i3d5ae67d6e7f4860b2e6a8fc76e87c38_4"></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">RESMED INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">EXECUTIVE STOCK OPTION AGREEMENT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Participant Name&#58;  &#91;Participant Name&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Grant Date&#58;  &#91;Grant Date&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Grant Price&#58;  &#91;Grant Price&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Number of Shares Granted&#58;  &#91;Shares Granted&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Acceptance Date&#58;  &#91;Acceptance Date&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Expiration Date&#58;  &#91;Expiration Date&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">This Executive Stock Option Agreement, including any country-specific terms and conditions set forth in the Appendix hereto (collectively, the &#8220;Agreement&#8221;), sets forth the terms of a stock option (the &#34;Option&#34;) granted by ResMed Inc., a Delaware corporation (the &#34;Company&#34;), pursuant to the ResMed Inc. 2009 Incentive Award Plan, as amended and restated (the &#34;Plan&#34;) and the Summary of Stock Option Grant (the &#8220;Summary&#8221;) displayed at the Web site of the Company&#8217;s plan administrator. The Plan and the Summary, which specifies the person to whom the Option is granted (the &#8220;Grantee&#8221;), electronic acceptance procedures and other specific details of the grant, are incorporated herein by reference.  Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Summary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Company hereby grants to Grantee an Option to purchase all or any part of the aggregate number of shares of the Common Stock specified in the Summary (the &#34;Option Shares&#34;) at the price specified in the Summary (the &#34;Option Price&#34;), during the period and subject to the conditions set forth in this Agreement and in the Summary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Option Period begins on the Grant Date specified in the Summary and ends on the Expiration Date specified in the Summary, subject to earlier termination of the Option Period in accordance with Section 7 hereof.  Any vested portion of the Option shall be exercised in accordance with the provisions of Sections 3, 4, 5, 6 and 7 hereof during the Option Period.  All rights to exercise the Option, and the Option Period, shall terminate on the Expiration Date or such earlier date specified in Section 7 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Option Vesting and Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;Subject to Sections 3(b), 3(c), 3(d) and 3(e) hereof, the Option shall vest and become exercisable in accordance with the Vesting Schedule specified in the Summary, subject to Grantee&#8217;s continued employment or service through applicable vesting dates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;Except as otherwise set forth in Sections 3(c), 3(d) and 3(e), vesting of the Option shall terminate upon Grantee&#8217;s Termination of Service.  For purposes of this Agreement, Grantee&#8217;s Termination of Service is deemed to occur as of the date Grantee is no longer actively providing services to the Company or a Subsidiary (regardless of the reason for such termination and whether or not later to be found invalid or in breach of applicable laws in the jurisdiction where Grantee is employed or rendering services or the terms of Grantee&#8217;s employment or service agreement, if any) and, unless otherwise provided in Sections 3(c), (d) and (e) hereof, Grantee's right to vest in the Options, if any, will terminate as of such date and the period during which Grantee may exercise vested Options after Termination of Service, if any, will begin on such date.  In both cases, the date of Termination of Service will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">., Grantee's period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under applicable laws in the jurisdiction where Grantee is employed or providing services or the terms of Grantee's employment or service contract, if any).  The Administrator shall have the exclusive discretion to determine when Grantee's Termination of Service for purposes of the Options has occurred (including whether Grantee may still be considered to be providing services while on a leave of absence).</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;In the event of a Change in Control (as defined in the Plan), the Option shall become fully vested and exercisable as of the date of such Change in Control, or if later, as of the date of Grantee&#8217;s Separation from Service (as defined in the Executive Agreement), if either of the following occurs&#58;</font></div><div style="margin-bottom:12pt;padding-left:117pt;text-align:justify;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;Grantee provides Notice of Good Reason (as defined in the then-current &#8220;Executive Agreement&#8221; between the Company and Grantee (&#8220;the Executive Agreement&#8221;)) at any time during the six-month period prior to the date of a Change in Control, or during the twelve (12) month period commencing on the date of a Change in Control, and Grantee has a Separation from Service by reason of Grantee&#8217;s voluntary termination of employment for Good Reason (as defined in the Executive Agreement), or</font></div><div style="margin-bottom:12pt;padding-left:117pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;Grantee has a Separation from Service reason by reason of the Company&#8217;s termination of Grantee&#8217;s employment other than for Cause (as defined in the Executive Agreement) during the six-month period prior to the date of the Change in Control (and such termination is at the request of the successor entity of such Change in Control, or is otherwise made in anticipation of the Change in Control), or during the twelve (12) month period commencing on the date of the Change in Control.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">d)&#160;&#160;&#160;&#160;If Grantee dies while employed by the Company or a Subsidiary or has a Termination of Service due to Disability, the unvested portion of the Option shall become fully vested and non-forfeitable as of the date of Grantee&#8217;s death or Termination of Service due to Disability, as applicable.  &#8220;Disability&#8221; shall mean a &#8220;disability&#8221; as defined in Treasury Regulation Section 1.409A-3(i)(4).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">e)&#160;&#160;&#160;&#160;If Grantee has a Termination of Service due to Retirement, a pro-rata portion of the unvested Options shall become vested and nonforfeitable as of the date of Grantee&#8217;s Termination of Service due to Retirement.  The number of the Options that will vest on the date of Grantee&#8217;s Termination of Service due to Retirement will be determined by (i) dividing the number of days Grantee was continuously employed or rendering services during the vesting period prior to the termination date by the total number of days of the vesting period (as measured from the Grant Date to the final vesting date of the Options), and multiplying the result of such division by the aggregate number of Option Shares granted to Grantee and (ii) subtracting from the result in 3(e)(i) any Options that previously vested pursuant to the Vesting Schedule.  Such pro-rata portion of the Options will be rounded down to the nearest whole share, except as otherwise set forth in Section 13 hereof.  Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in Grantee&#8217;s jurisdiction that likely would result in the favorable Retirement treatment that otherwise would apply to the Options pursuant to this Section 3(e) being deemed unlawful and&#47;or discriminatory, then the Company will not apply this favorable Retirement treatment at the time of Grantee&#8217;s Termination of Service and the Options will be treated as they would under the rules that otherwise would have applied if Grantee&#8217;s Termination of Service did not qualify as a Retirement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">f)&#160;&#160;&#160;&#160;For purposes of Section 3(e) hereof, &#8220;Retirement&#8221; shall mean a Termination of Service after (i) sixty (60) years of age and (ii) completion of five (5) years of continuous service with the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">g)&#160;&#160;&#160;&#160;For purposes of this Section 3, the employment relationship of an Employee of the Company or a Subsidiary will be treated as continuing intact while he is on military or sick leave or other bona fide leave of absence if such leave does not exceed ninety days, provided, however, that the period of the leave may exceed ninety days so long as Grantee&#8217;s right to re-employment is guaranteed either by statute or by contract, or in any other circumstance as may be required by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Except as provided in Section 10, this Option shall be exercisable during the Option Period in accordance with the Vesting Schedule (as the same may be </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">modified by Section 3 hereof) and at the Option Price per share specified on the Summary.  The installments provided for in the Summary are cumulative, such that each installment that vests but is not exercised, may be carried forward and exercised in the future, except that the Option may not be exercised after the Expiration Date or earlier Option termination date pursuant to Section 7 below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Automatic Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Notwithstanding anything in this Agreement to the contrary, in the event the Option has not been exercised on or before the Expiration Date of the Option, and the Fair Market Value of the Common Stock on the Expiration Date of the Option exceeds its Option Price per share by 1% or more, as determined by the Company (or its agent), the vested portion of the Option shall be exercised automatically on the Expiration Date.  The Option Price and any withholding obligations for Tax-Related Items (as defined in Section 12 herein) shall be satisfied by withholding shares of Common Stock otherwise issuable upon exercise of the Option having a Fair Market Value on the date of exercise that is sufficient to cover the aggregate Option Price and any Tax-Related Items.  The Company will thus issue Grantee shares of Common Stock upon such automatic exercise in an amount equal to the number of Option Shares subject to the Option, less the number of shares used to pay the aggregate Option Price and Tax-Related Items (based on the Fair Market Value of the Common Stock at the close of the market on the date of exercise).  Grantee shall pay the remaining portion, if any, of the Tax-Related Items to the Company in cash or by check (or, to the extent permitted by applicable law, by the Company or the Employer (as defined in Section 12 herein) withholding such amounts from Grantee&#8217;s wages through payroll deduction).  This Section 5 shall apply regardless of whether the Option is a Non-Qualified Stock Option or Incentive Stock Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Manner of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Exercise of the Option shall be by written notice as directed by the Company, details of which will be provided to Grantee.  The notice shall be accompanied by payment in full in cash, check, or a combination thereof, in the aggregate amount of the Option Price specified in the Summary multiplied by the number of Option Shares to be purchased by Grantee through such exercise, plus payment of all withholding obligations for Tax-Related Items.  In addition, the Option Price and associated Tax-Related Items may be paid through the delivery of a notice that Grantee has placed a market sell order with a broker with respect to the shares of Common Stock then issuable upon exercise of the Option, whereby the broker timely pays a sufficient portion of the net proceeds from the sale of shares of Common Stock to the Company in satisfaction of the Option Price and withholding obligations for Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exercise Rights in Event of Death or Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;If Grantee dies while employed by the Company or a Subsidiary, or within the first year after Termination of Service, without having fully exercised the Option, after giving effect to Section 3(d) regarding Option acceleration, if applicable, the executors, administrators, legatees or distributees of Grantee's estate shall have the right, for a period of one year after the date of Grantee's death, to exercise the vested, unexercised and unexpired portion, if any, of the Option as of the date of Grantee&#8217;s death, in whole or in part, except that the Option may not be exercised under this subsection 7(a) after the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;In the event of Grantee&#8217;s Termination of Service for any reason, and after giving effect to Section 3 regarding Option acceleration, if applicable, the then vested, unexercised and unexpired portion, if any, of Grantee&#8217;s Option as of the date of Termination of Service may be exercised until the earlier of (i) the first anniversary of such Termination of Service, or (ii) the Expiration Date specified in the Summary.  After this date, the Option shall be automatically cancelled and the Option Period shall terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;In the event of Grantee&#8217;s Termination of Service due to Retirement, and after giving effect to Section 3(e) regarding Option acceleration, if applicable, the then vested, unexercised and unexpired portion, if any, of Grantee&#8217;s Option as of the date of Termination of Service due to Retirement may be exercised until the earlier of (i) the third anniversary of such Termination of Service due to Retirement, or (ii) the Expiration Date specified in the Summary.  After this date, the Option shall be automatically cancelled and the Option Period shall terminate.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Transferability of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;Subject to subsection 8(b), the Option is not transferable by Grantee other than by will or by the laws of descent and distribution in the event of Grantee's death, in which event the Option may be exercised by the heirs or legal representatives of Grantee as provided in Section 7 hereof.  The Option may be exercised during the lifetime of Grantee only by Grantee.  Any attempt at assignment, transfer, pledge or disposition of the Option contrary to the provisions hereof or the levy of any execution, attachment or similar process upon the Option shall be null and void and without effect.  Any exercise of the Option by a person other than Grantee shall be accompanied by appropriate proofs of the right of such person to exercise the Option. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;Notwithstanding the foregoing provisions of subsection 8(a), for Grantees who are exclusively subject to the laws of the United States, the Administrator, in its sole discretion, may permit the transfer of a Non-Qualified Stock Option held by Grantee (i) pursuant to a DRO, or (ii) by gift or contribution to a permitted transferee.  Any Option that has been so transferred shall continue to be subject to all of the terms and conditions as applicable to the original Grantee, and the transferee shall execute any and all such documents requested by the Administrator in connection with the transfer, including without limitation to evidence the transfer and to satisfy any requirements for an exemption for the transfer under applicable federal and state securities laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Changes in Capital Structure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The number of Option Shares covered by this Option and the Option Price shall be equitably adjusted in the event of (i) the payment of any dividend or the making of any distribution of Common Stock to holders of record of Common Stock, (ii) any stock split, combination of shares, recapitalization or other similar change&#59; (iii) the merger or consolidation of the Company into or with any other corporation&#59; or (iv) the reorganization, dissolution, liquidation or winding up of the Company (collectively, the &#34;Event&#34;), and Grantee shall be entitled to receive such new, additional or other shares of stock of any class, or other property (including cash), as Grantee would have been entitled to receive as a matter of law in connection with such Event had Grantee held the Option Shares on the record date set for such Event.  In addition, upon such change, the Option Price of the Option Shares or other securities subject to any unexercised portions of this Option shall be adjusted proportionately so that Grantee shall have the right to purchase the number of Option Shares (as adjusted) under this Option at an Option Price (as adjusted) which Grantee could purchase for the total purchase price applicable to the unexercised portion of this Option immediately prior to such Event had Grantee held the Option Shares on the record date set for such Event.  Any fractional shares resulting from such calculation shall be eliminated.  The Administrator shall have the authority to determine the adjustments to be made under this Section 9 and any such determination shall be final, binding and conclusive. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Legal Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;If the listing, registration or qualification of the Option Shares upon any securities exchange or under any U.S. or non-U.S. federal, state or local law, or the consent or approval of any governmental regulatory body is necessary or advisable as a condition of or in connection with the purchase of the Option Shares, the Company shall not be obligated to issue or deliver the certificates representing the Option Shares as to which the Option has been exercised unless and until such listing, registration, qualification, consent or approval shall have been effected or obtained and is in effect.  This Option does not hereby impose on the Company a duty to so list, register, qualify, maintain or effect or obtain consent or approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;The Option Shares deliverable upon the exercise of the Option, or any portion thereof, may be either previously authorized but unissued shares or issued shares, which have then been reacquired by the Company.  Such shares shall be fully paid and nonassessable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;Grantee shall not be, nor have any of the rights or privileges of, a stockholder of the Company in respect of any Option Shares purchasable upon the exercise of any part of the Option unless and until such shares of Common Stock shall have been issued by the Company to Grantee, as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company, or by the issuance of a stock certificate in Grantee&#8217;s name.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">No Obligation to Exercise Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Grantee shall be under no obligation to exercise the Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Responsibility for Taxes</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;Regardless of any action the Company or, if different, the Subsidiary employing Grantee or for which Grantee otherwise provides services (the &#34;Employer&#34;) takes with respect to any or all income tax, social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to Grantee&#8217;s participation in the Plan and legally applicable or deemed legally applicable to Grantee (&#8220;Tax-Related Items&#8221;), Grantee acknowledges that the ultimate liability for all Tax-Related Items is and remains Grantee&#8217;s responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.  Grantee further acknowledges that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Options, including, but not limited to the grant, vesting or exercise of the Options, the issuance of Option Shares upon exercise of the Option&#59; the subsequent sale of the shares of Common Stock acquired at exercise and the receipt of any dividends&#59; and (ii) do not commit to and are under no obligation to structure the terms of the Award or any aspect of the Option to reduce or eliminate Grantee&#8217;s liability for Tax-Related Items or achieve any particular tax result.  Furthermore, if Grantee is subject to tax in more than one jurisdiction, Grantee acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;In connection with any relevant taxable or tax withholding event, as applicable, Grantee must pay or make adequate arrangements satisfactory to the Company and&#47;or the Employer to satisfy all Tax-Related Items.  In this regard, Grantee authorizes the Company and&#47;or the Employer, or their respective agents, in their sole discretion and without any notice to or additional authorization by Grantee, to satisfy their withholding obligations, if any, with regard to all Tax-Related Items by one or a combination of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(i) withholding from Grantee&#8217;s compensation or other wages payable to Grantee by the Company, the Employer and&#47;or any other Subsidiary&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(ii) causing Grantee to tender a cash payment (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">i</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">., check or bank wire)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(iii) withholding from the proceeds of the sale of shares of Common Stock issued upon exercise, either through a voluntary sale or through a mandatory sale arranged by the Company (on Grantee&#8217;s behalf pursuant to this authorization)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(iv) withholding shares of Common Stock otherwise to be issued upon exercise&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> that if Grantee is a Section 16 officer of the Company under the Exchange Act, then any withholding in shares of Common Stock will be approved by the Administrator&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(v) any other method determined by the Company, to the extent permitted under the Plan and applicable laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;The Company may withhold or account for Tax-Related Items by considering statutory withholding amounts or other applicable withholding rates, including maximum rates applicable in Grantee&#8217;s jurisdiction(s) (to the extent permitted by the Plan), in which case Grantee may receive a refund of any over-withheld amount in cash (with no entitlement to the Common Stock equivalent) or, if not refunded, Grantee may be able to seek a refund from the applicable tax authorities. In the event of under-withholding, Grantee may be required to pay additional Tax-Related Items directly to the applicable tax authorities or to the Company and&#47;or the Employer.  If the obligation for Tax-Related Items is satisfied by withholding shares of Common Stock, for tax purposes, Grantee will be deemed to have been issued the full number of shares of Common Stock subject to the exercised Options, notwithstanding that a number of the shares of Common Stock is held back solely for the purpose of paying the Tax-Related Items.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">d)&#160;&#160;&#160;&#160;Grantee agrees to pay to the Company and&#47;or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of Grantee&#8217;s participation in the Plan that cannot be satisfied by the means previously described.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">e)&#160;&#160;&#160;&#160;The Company shall not be obligated to deliver any new certificate representing shares of Common Stock to Grantee or Grantee&#8217;s legal representative or enter such shares of Common Stock in book entry form unless and until Grantee or Grantee&#8217;s legal representative shall have paid or otherwise satisfied Grantee&#8217;s obligations in connection with the Tax-Related Items resulting from the Options or the shares of Common Stock subject to the Options.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Fractional Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  No fractional shares or scrip representing fractional shares of Common Stock shall be issued upon the exercise of this Option, but the Company, in its discretion, shall issue one additional share of its Common Stock in lieu of each fraction of a share otherwise called for upon any exercise of this Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  All notices required or permitted hereunder shall be in writing and shall be deemed to be properly given when personally delivered to the party entitled to receive the notice (which may include electronic delivery by email) or when sent by certified or registered mail, postage prepaid, properly addressed to the party entitled to receive such notice at the address stated below&#58;</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.820%"><tr><td style="width:1.0%"></td><td style="width:23.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">If to Company&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">ResMed Inc.<br>9001 Spectrum Center Blvd. <br>San Diego, CA 92123<br>USA<br>Attn&#58; David Pendarvis, Corporate Secretary</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">If to Holder&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Address of the Holder on file with ResMed Inc. or its Subsidiary</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  This Option has been granted pursuant to the Plan adopted by the Board and approved by the stockholders of the Company, and is subject to the terms and provisions thereof.  By acceptance hereof Grantee acknowledges receipt of a copy of the Plan.  All questions of interpretation and application of the Plan and this Option shall be determined by the Company, and such determination shall be final, binding and conclusive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">No Rights to Employment or Future Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The grant of this Option does not entitle Grantee to any other benefit or to future awards or rights under the Plan.  The grant does not form an employment contract or relationship with the Company or any other Subsidiary or affiliate.  The Option does not create a right to further employment nor interfere with the Company and the Employer&#8217;s right to terminate the employment relationship at any time for any reason whatsoever, with or without cause, which rights to terminate are hereby expressly reserved (except to the extent that right is otherwise limited by law).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  By accepting the Options, Grantee acknowledges, understands and agrees that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">a)&#160;&#160;&#160;&#160;all decisions with respect to future awards of Options or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">b)&#160;&#160;&#160;&#160;Grantee is voluntarily participating in the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">c)&#160;&#160;&#160;&#160;the Options and the shares of Common Stock subject to the Options, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">d)&#160;&#160;&#160;&#160;the Options and the shares of Common Stock subject to the Options, and the income from and value of same, are not part of normal or expected compensation or salary for any </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">purpose, including (without limitation) calculating any severance, resignation, redundancy or end of service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">e)&#160;&#160;&#160;&#160;the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">f)&#160;&#160;&#160;&#160;if the underlying shares of Common Stock do not increase in value, the Option will have no value&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">g)&#160;&#160;&#160;&#160;if Grantee exercises the Option and obtains shares of Common Stock, the value of those shares of Common Stock acquired upon exercise may increase or decrease in value, even below the Option Price&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">h)&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from termination of the Options resulting from a Termination of Service (for any reason whatsoever, whether or not later to be found invalid or in breach of applicable laws in the jurisdiction where Grantee is employed or rendering services or the terms of Grantee&#8217;s employment or service agreement, if any)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">i)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company, the Options and the shares of Common Stock subject to the Options, and the income from and value of same, are not granted as consideration for, or in connection with, the service Grantee may provide as a director of a Subsidiary&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">j)&#160;&#160;&#160;&#160;the Company is not providing any tax, legal or financial advice with respect to the Options, nor is the Company making any recommendations regarding Grantee&#8217;s participation in the Plan, or Grantee&#8217;s acquisition or sale of the underlying shares of Common Stock&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">k)&#160;&#160;&#160;&#160;Grantee should consult with his or her own personal tax, legal and financial advisors regarding Grantee&#8217;s participation in the Plan before taking any action related to the Plan and the Options&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">l)&#160;&#160;&#160;&#160;the following provisions apply only if Grantee is providing services outside the United States&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(i) the Options and the shares of Common Stock subject to the Options, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(ii) neither the Company, the Employer nor any other Subsidiary shall be liable for any foreign exchange rate fluctuation between Grantee's local currency and the United States Dollar that may affect the value of the Options or of any amounts due to Grantee pursuant to the exercise of the Options or the subsequent sale of any shares of Common Stock acquired upon exercise.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Privacy Consent</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data (as defined below) by the Company and the transfer of Data to the recipients mentioned below, including recipients located in countries which may not have a similar level of protection from the perspective of the data protection laws in Grantee&#8217;s country.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  The Company and the Employer collect, process and use certain personal information about Grantee, including, but not limited to, Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">shares or directorships held in the Company, details of all Options under the Plan or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of managing Grantee&#8217;s participation in the Plan.  The legal basis, where required, for the processing of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  The Company transfers Data, or parts thereof, to Fidelity Stock Plan Services, LLC and certain of its affiliated companies (&#34;Fidelity&#34;), which assists the Company with the implementation, administration and management of the Plan.  Grantee acknowledges and understands that Fidelity will open an account for Grantee to receive and trade shares of Common Stock acquired under the Plan and that Grantee will be asked to agree on separate terms and data processing practices with Fidelity, which is a condition of Grantee&#8217;s ability to participate in the Plan.  In the future, the Company may select a different service provider and may share Data with such different service provider that serves in a similar manner.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  The Company and Fidelity are based in the United States.  Grantee understands that his or her country may have enacted data privacy laws that are different from the laws of the United States.  As a result, in the absence of appropriate safeguards such as standard data protection clauses, the processing of Grantee&#8217;s Data in the United States or, as the case may be, other countries might not be subject to substantive data processing principles or supervision by data protection authorities.  In addition, Grantee might not have enforceable rights regarding the processing of his or her Data in such countries.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">The Company provides appropriate safeguards for protecting Data that it receives in the United States through its adherence to data transfer agreements entered into between the Company and Subsidiaries within the European Union.  Otherwise, where required, the Company&#8217;s legal basis for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(e)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage Grantee&#8217;s participation in the Plan, or as required to comply with applicable law, exercise or defense of legal rights, and archiving, back-up and deletion processes.  This means Data may be retained even after Grantee&#8217;s Termination of Service.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(f)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  Participation in the Plan is voluntary and Grantee is providing the consents herein on a purely voluntary basis.  Grantee understands that he or she may withdraw consent at any time with future effect for any or no reason.  If Grantee does not consent, or if Grantee later seeks to revoke his or her consent, Grantee&#8217;s employment or service with the Employer will not be affected&#59; the only consequence of refusing or withdrawing consent is that the Company would not be able to offer Options or other awards to Grantee or administer or maintain Grantee&#8217;s participation in the Plan. </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(g)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  Grantee understands that data subject rights vary depending on applicable law and that, depending on where Grantee is based and subject to the conditions under applicable law, Grantee may have, without limitation, the rights to (i) request access or copies of Data the Company processes, (ii) rectification of incorrect Data, (iii) deletion of Data, (iv) restrictions on processing of Data, (v) portability of Data, (vi) lodge complaints with competent authorities in Grantee&#8217;s jurisdiction, and&#47;or (vii) receive a list with the names and addresses of any potential recipients of Data.  To receive clarification regarding these rights or to exercise these rights, Grantee understands that he or she can contact Grantee&#8217;s local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed under the laws of the State of Delaware without regard to conflicts of laws or principles.  For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Award of Options or this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Diego County, California, or the federal courts for the United States for the Southern District of California and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Counterparts and Additional Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Signatures to this Agreement may be provided in electronic format in accordance with the Company&#8217;s programs and policies permitting electronic delivery of signatures.  The Option shall be subject to such additional terms and rights of Grantee regarding the Option as set forth in any executive agreement, severance agreement or change in control agreement between Grantee and the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  This Agreement may not be amended in a material adverse way to  Grantee except by an instrument in writing signed by Grantee and the Company. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Notification of Disposition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  If this Option is designated as an Incentive Stock Option, Grantee shall give prompt notice to the Company of any disposition or other transfer of any shares of Common Stock acquired under this Agreement if such disposition or transfer is made (a) within two years from the Grant Date or (b) within one year after the transfer of such shares to Grantee.  Such notice shall specify the date of such disposition or other transfer and the amount realized, in cash, other property, assumption of indebtedness or other consideration, by Grantee in such disposition or other transfer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Conformity to Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Grantee acknowledges that the Plan is intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the U.S. Securities and Exchange Commission thereunder, and other U.S. or non-U.S. state and federal securities laws and regulations, as well as any other applicable U.S. or non-U.S. state and federal laws and regulations.  Notwithstanding anything herein to the contrary, the Plan shall be administered, and the Option is granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations.  To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Participants Outside of the United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in this Agreement, the Options shall be subject to any additional terms and conditions set forth in the Appendix attached hereto for Grantee&#8217;s country.  Moreover, if Grantee relocates to one of the countries included in the Appendix, the terms and conditions for such country will apply to Grantee, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The terms included in the Appendix constitute part of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">26.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Grantee acknowledges that he or she is proficient in the English language and understands the provisions in this Agreement and the Plan or has had the ability to consult with an advisor who is sufficiently proficient in the English language.  Further, in the event Grantee has received this Agreement, including the Appendix attached hereto, or any other document related to the Plan translated into a language other than English, the English version will control to the extent the meaning of the translated version differs from the English version.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">27.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, decide (a) to deliver by electronic means any documents related to the Options granted under the Plan, Grantee&#8217;s participation in the Plan, or future awards that may be granted under the Plan or (b) to request by electronic means Grantee&#8217;s consent to participate in the Plan.  Grantee hereby consents to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">through an online or electronic system established and maintained by the Company or any third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">28.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">29.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">. The Company reserves the right to impose other requirements on Grantee&#8217;s participation in the Plan, on the Options or any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Grantee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">30.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Grantee acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Grantee or any other permitted transferee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">31.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Grantee acknowledges that, depending on Grantee&#8217;s country, the broker&#8217;s country, or the country in which shares of Common Stock are listed, Grantee may be subject to insider trading restrictions and&#47;or market abuse laws, which may affect Grantee&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">., Options) or rights linked to the value of shares of Common Stock during such times as Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws or regulations in the relevant jurisdiction).  Further, Grantee understands that local insider trading laws and regulations prohibit the cancellation or amendment of orders Grantee may have placed before processing inside information.  Grantee also understands that he or she may be prohibited from (i) disclosing inside information to any third party, including fellow employees (other than on a &#8220;need to know&#8221; basis), and (ii) &#8220;tipping&#8221; third parties by sharing inside information with them, or otherwise causing third parties to buy or sell Company securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company.  Grantee is responsible for complying with any applicable restrictions, and Grantee should consult with his or her personal legal and financial advisors on this matter before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">32.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Foreign Assets&#47;Account and Tax Reporting, Exchange Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Grantee&#8217;s country may have certain foreign asset, account and&#47;or tax reporting requirements and exchange controls which may affect Grantee&#8217;s ability to acquire or hold shares of Common Stock under the Plan or cash received from participating in the Plan (including from any dividends received or sale proceeds arising from the sale of shares of Common Stock) in a brokerage or bank account outside Grantee&#8217;s country.  Grantee understands that he or she may be required to report such accounts, assets or transactions to the tax or other authorities in Grantee&#8217;s country.  Grantee also may be required to repatriate sale proceeds or other funds received as a result of participation in the Plan to his or her country through a designated bank or broker and&#47;or within a certain time after receipt.  In addition, Grantee may be subject to tax payment and&#47;or reporting obligations in connection with any income realized under the Plan and&#47;or from the sale of shares of Common Stock.  Grantee acknowledges that he or she is responsible for complying with all such requirements, and that Grantee should consult personal legal and tax advisors, as applicable, to ensure compliance.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereunto agree to the terms and conditions set forth above and in the Summary. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RESMED INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">GRANTEE</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed Electronically</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signed Electronically</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#47;s&#47; Michael J. Farrell</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Michael J. Farrell</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Acceptance designated electronically at the plan administrator's Web site)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Certain capitalized terms used but not defined in this Appendix have the meanings set forth in the Plan, the Agreement and&#47;or the Summary.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">This Appendix includes special and&#47;or additional terms and conditions that govern the Options granted to Grantee under the Plan if Grantee resides and&#47;or works in one of the countries listed below.  These terms and conditions are in addition to or, if so indicated, in place of, the terms and conditions set forth in the Agreement.  If Grantee is a citizen or resident of a country other than the one in which he or she is currently residing and&#47;or working, transfers residency and&#47;or employment to another country after the grant of Options, or is considered resident of another country for local law purposes, the Administrator shall, in its discretion, determine to what extent the terms and conditions contained herein shall be applicable to Grantee.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Notifications </font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">This Appendix also includes information regarding tax, securities law, exchange controls and certain other issues of which Grantee should be aware with respect to Grantee&#8217;s participation in the Plan.  The information is based on the securities, exchange control and other laws in effect in the respective countries as of November 2021.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that Grantee not rely on the information in this Appendix as the only source of information relating to the consequences of Grantee&#8217;s participation in the Plan because the information may be out of date at the time that the Options are exercised or shares of Common Stock acquired under the Plan are sold.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">In addition, the information contained herein is general in nature and may not apply to Grantee&#8217;s particular situation and the Company is not in a position to assure Grantee of any particular result.  Accordingly, Grantee should seek appropriate professional advice as to how the relevant laws in his or her country may apply to Grantee&#8217;s situation.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Finally, if Grantee is a citizen or resident of a country other than the one in which he or she is currently residing and&#47;or working, transfers residency and&#47;or employment to another country after the grant of Options, or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to Grantee in the same manner.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Australia</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Option Vesting and Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#58;  Notwithstanding Sections 3(d) and 3(e) of the Agreement, prior to Grantee's Termination of Service due to either Disability or Retirement, Grantee may elect to forfeit any Options that vested prior to Grantee's Termination of Service due to either Disability or Retirement or that would vest as a result of Sections 3(d) or 3(e) of the Agreement.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">The Company strongly recommends that Grantee consult with his or her personal legal and tax advisor in this regard.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Notifications</font></div><div style="margin-bottom:6pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  If Grantee acquires shares of Common Stock under the Plan and subsequently offers such shares for sale to a person or entity resident in Australia, the offer may be subject to disclosure requirements under Australian law.  Grantee should obtain legal advice as to his or her disclosure obligations prior to making any such offer.</font></div><div style="margin-bottom:6pt;margin-top:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Exchange control reporting is required for cash transactions exceeding AUD 10,000 and for international fund transfers, including for the remittance of the Options Price and&#47;or the repatriation of proceeds related to the sale of shares of Common Stock or </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">cash dividends paid on such shares.  If an Australian bank is assisting with the transaction, then the bank will file the required exchange control report on Grantee&#8217;s behalf.  If no Australian bank is assisting with the transaction, then Grantee will have to file the required exchange control report.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies (subject to the conditions in the Act).</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Germany</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Notifications</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Cross-border payments in excess of &#8364;12,500 (including payment of the Option Price and&#47;or the repatriation of proceeds related to the sale of shares of Common Stock or cash dividends) must be reported on a monthly basis to the German Federal Bank (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Bundesbank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">).  If Grantee makes or receives a payment in excess of this amount, Grantee must report the payment to Bundesbank electronically by the fifth day of the month following the month in which the payment was made&#47;received.  The form of the report (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Allgemeine Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;) can be accessed via the Bundesbank&#8217;s website (www.bundesbank.de) and is available in both German and English.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Singapore</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Sale of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  For any shares of Common Stock that are acquired within six months of the Grant Date, Grantee agrees that he or she will not dispose of the shares of Common Stock acquired prior to the six-month anniversary of the Grant Date, unless such sale or offer in Singapore is made pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the of the Singapore Securities and Futures Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;), or any other applicable provisions of the SFA.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Notifications</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The offer of the Plan is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of SFA and not with a view to the Options or shares of Common Stock being subsequently offered for sale to another party.  The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.</font></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Director Notification Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The directors, associate directors and shadow directors of a Singapore Subsidiary are subject to certain notification requirements under the Singapore Companies Act.  The directors, associate directors and shadow directors must notify the Singapore Subsidiary in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">., Options, shares of Common Stock, etc.) in the Company or any related company within two (2) business days of (i) its acquisition or disposal, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">e.g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">. when shares of Common Stock are sold), or (iii) becoming a director, associate director or shadow director.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>5
<FILENAME>ex108-formofstockoptiongra.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i55993845636d40539c49e69c5244e794_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:right;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.8</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ResMed Inc.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Summary for Director Stock Option Award Agreement</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Name of Participant&#58; &#160;&#160;&#160;&#160;&#91;PARTICIPANT NAME&#93;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Date of Grant&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;GRANT DATE&#93;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Grant Price&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;GRANT PRICE&#93;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Options Granted&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#91;QUANTITY GRANTED&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">Expiration Date&#58; &#160;&#160;&#160;&#160;&#91;EXPIRATION DATE&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms of the Agreement, the Options shall vest and become exercisable at the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first annual meeting of stockholders of the Company following the Grant Date.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt;text-align:center"><font style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%;text-decoration:underline">Please refer to Appendix&#58; Vesting Schedule</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="i55993845636d40539c49e69c5244e794_30"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Non-Employee Director</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RESMED INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">DIRECTOR STOCK OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Director Stock Option Agreement, including any specific terms and conditions set forth in Appendices I and II hereto (collectively, the &#34;Agreement&#34;) sets forth the terms of a Stock Option (the &#34;Option&#34;) granted by ResMed Inc., a Delaware corporation (the &#34;Company&#34;), pursuant to the ResMed Inc. 2009 Incentive Award Plan, as amended and restated (the &#34;Plan&#34;) and the Summary of Stock Option Grant (the &#8220;Summary&#8221;) displayed at the Web site of the Company&#8217;s plan administrator.  The Plan and the Summary, which specifies the person to whom the Option is granted (&#8220;Grantee&#8221;) and other specific details of the grant and the electronic acceptance of the Summary at the Web site of the Company&#8217;s plan administrator are incorporated herein by reference.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.31pt">Grantee is a non-employee director of the Company or a Subsidiary of the Company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.92pt">In consideration of services to be performed, Company desires to afford Grantee an opportunity to purchase shares of its Common Stock in accordance with the Plan, as hereinafter provided.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:25.92pt">Any capitalized terms not otherwise defined herein shall have the meaning accorded them under the Plan or in the Summary, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration, the parties hereto, intending to be legally bound, agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Grant of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Company hereby irrevocably grants to Grantee an Option to purchase all or any part of the aggregate number of shares of the Common Stock of Company specified in the Summary (the &#34;Option Shares&#34;) at the Option price specified in the Summary (the &#34;Option Price&#34;), during the period and subject to the conditions set forth in this Agreement and in the Summary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Option Period begins on the Grant Date specified in the Summary and ends on the Expiration Date specified in the Summary, subject to earlier termination of the Option Period in accordance with Section 7 hereof.  Any vested portion of the Option shall be exercised in accordance with the provisions of Sections 3, 4, 5, 6 and 7 hereof during the Option Period.  All rights to exercise the Option, and the Option Period, shall terminate on the Expiration Date or such earlier date specified in Section 7 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Option Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Option shall become vested in full on the earlier of (i) the first November 11 following the Grant Date, or (ii) the date of the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:100%;position:relative;top:-3.85pt;vertical-align:baseline">st </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">) annual meeting of stockholders of the Company following the Grant Date.  Option vesting shall cease and the Option shall be forfeited as of the Grantee&#8217;s Termination of Service.  Notwithstanding the foregoing, in the event of a Change in Control (as defined in the Plan) and the Grantee does not continue as a director of the successor entity to such Change in Control, the Option shall be and become fully vested and exercisable as of the effective date of such Change in Control. Notwithstanding the foregoing, if Grantee dies or has a Termination of Service due to Disability, the unvested portion of the Option shall become fully vested and exercisable as of the date of such Grantee&#8217;s death or Termination of Service due to Disability, as applicable.  For purposes of this agreement, &#8220;Disability&#8221; shall mean a &#8220;disability&#8221; as defined in Treasury Regulation Section 1.409A-3(i)(4).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Option Exercise Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Except as provided in Section 10, this Option shall be exercisable during the Option Period in accordance with the Vesting Schedule (as the same may be modified by Section 3 hereof) and at the Option Price per share specified on the Summary.  The installments provided for in the Summary are cumulative, such that each installment that vests but is not exercised, may be carried forward and exercised in any future year during the Option Period.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Automatic Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. Notwithstanding anything in this Agreement to the contrary, in the event the Option has not been exercised on or before the Expiration Date of the Option, and the Fair Market Value of the Common Stock on the Expiration Date of the Option exceeds its Option Price per share by 1% or more, as determined by the Company (or its agent), the vested portion of the Option shall be exercised automatically on the Expiration Date. The Option Price and any withholding obligations for Tax-Related Items (as defined in Section 11 herein) shall be paid through shares of Common Stock issuable upon exercise of the Option having a Fair Market Value at the close of the stock market on the date of exercise that is sufficient to cover the aggregate Option Price and any Tax-Related Items.  The Company will thus issue Grantee shares of Common Stock upon such automatic exercise in an amount equal to the number of Option Shares subject to the Option, less the number of shares used to pay the aggregate Option Price and any applicable Tax-Related Items (based on the Fair Market Value of the Common Stock at the close of the market on the date of exercise). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Manner of Exercise.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  Exercise of the Option shall be by written notice as directed by the Company, details of which will be provided to Grantee.  The notice shall be accompanied by payment in full in cash, check, or a combination thereof, in the aggregate amount of the Option Price specified in the Summary multiplied by the number of Option Shares to be purchased by Grantee through such exercise, plus payment of any applicable Tax-Related Items required to be withheld.  In addition, the Option Price and any associated Tax-Related Items may be paid through the delivery of a notice that Grantee has placed a market sell order with a broker with respect to the shares of Common Stock then issuable upon exercise of the Option, and the broker timely pays a sufficient portion of the net proceeds of the sale to the Company in satisfaction of the Option Price and any applicable Tax-Related Items withholding obligations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Rights in Event of Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event of Grantee&#8217;s Termination of Service for any reason, and after giving effect, to the extent applicable, to Section 3 regarding Option acceleration and Section 4 regarding the Option Exercise Period, the then vested, unexercised and unexpired portion, if any, of Grantee&#8217;s Option as of the date of Termination of Directorship may be exercised at any time until the earlier of (i) the third anniversary of such Termination of Service, or (ii) the Expiration Date specified in the Summary.  After this date, the Option shall be automatically cancelled and the Option Period shall terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Transferability of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Subject to subsection 8(b), the Option is not transferable by Grantee other than by will or by the laws of descent and distribution in the event of the Grantee's death, in which event the Option may be exercised by the heirs or legal representatives of the Grantee as provided in Section 7 hereof.  The Option may be exercised during the lifetime of the Grantee only by the Grantee.  Any attempt at assignment, transfer, pledge or disposition of the Option contrary to the provisions hereof or the levy of any execution, attachment or similar process upon the Option shall be null and void and without effect.  Any exercise of the Option by a person other than the Grantee shall be accompanied by appropriate proofs of the right of such person to exercise the Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Notwithstanding the foregoing provisions of subsection 8(a), for Grantees who are exclusively subject to the laws of the United States, the Administrator, in its sole discretion, may permit the transfer of a Non-Qualified Stock Option held by the Grantee (i) pursuant to a DRO, or (ii) by gift or contribution to a Permitted Transferee.  Any Option that has been so transferred shall continue to be subject to all of the terms and conditions as applicable to the original Grantee, and the transferee shall execute any and all such documents requested by the Administrator in connection with the transfer, including without limitation to evidence the transfer and to satisfy any requirements for an exemption for the transfer under applicable federal and state securities laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:27.75pt;text-decoration:underline">Changes in Capital Structure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The number of Option Shares covered by this Option and the Option Price shall be equitably adjusted in the event of (i) the payment of any dividend or the making of any distribution of Common Stock to holders of record of Common Stock, (ii) any stock split, combination of shares, recapitalization or other similar change&#59; (iii) the merger or consolidation of the Company into or with any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">other corporation&#59; or (iv) the reorganization, dissolution, liquidation or winding up of the Company (collectively, the &#34;Event&#34;), and the Grantee shall be entitled to receive such new, additional or other shares of stock of any class, or other property (including cash), as Grantee would have been entitled to receive as a matter of law in connection with such Event had Grantee held the Option Shares on the record date set for such Event.  In addition, upon such change, the Option Price of the Option Shares or other securities subject to any unexercised portions of this Option shall be adjusted proportionately so that Grantee shall have the right to purchase the number of Option Shares (as adjusted) under this Option at an Option Price (as adjusted) which Grantee could purchase for the total purchase price applicable to the unexercised portion of this Option immediately prior to such Event had Grantee held the Option Shares on the record date set for such Event.  Any fractional shares resulting from such calculation shall be eliminated.  The Administrator shall have the authority to determine the adjustments to be made under this Section 9 and any such determination shall be final, binding and conclusive.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">Notwithstanding the provision of this Agreement, in the event of a Change in Control, the Option shall be assumed or an equivalent option substituted by the successor corporation or a parent or subsidiary of the successor corporation.  In the event that the successor corporation refuses to assume or substitute for the Option, the Administrator may cause any or all of such Option to become fully exercisable prior to the consummation of such transaction and the Administrator shall notify Grantee of such acceleration and the Option shall be fully exercisable for a period of fifteen (15) days from the date of such notice, and the Option shall terminate upon the expiration of such period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Legal Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">If the listing, registration or qualification of the Option Shares upon any securities exchange or under any U.S. and non-U.S. state or federal law, or the consent or approval of any governmental regulatory body is necessary or advisable as a condition of or in connection with the purchase of the Option Shares, the Company shall not be obligated to issue or deliver the certificates representing the Option Shares as to which the Option has been exercised unless and until such listing, registration, qualification, consent or approval shall have been effected or obtained and is in effect.  This Option does not hereby impose on the Company a duty to so list, register, qualify, maintain or effect or obtain consent or approval.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The shares of stock deliverable upon the exercise of the Option, or any portion thereof, may be either previously authorized but unissued shares or issued shares, which have then been reacquired by the Company. Such shares shall be fully paid and nonassessable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Grantee shall not be, nor have any of the rights or privileges of, a stockholder of the Company in respect of any Option Shares purchasable upon the exercise of any part of the Option unless and until such shares of Common Stock shall have been issued by the  Company  to  the  Grantee,  as  evidenced  by  the  appropriate  entry  on  the  books  of  the Company or of a duly authorized transfer agent of the Company, or by the issuance of a stock certificate in Grantee&#8217;s name.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Responsibility for Taxes.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">Grantee agrees and acknowledges that Grantee will consult with his or her personal tax advisor regarding any income tax, social insurance contributions or other tax-related items legally applicable or deemed legally applicable to Grantee (&#8220;Tax-Related Items&#8221;) that may arise in connection with the Option and Grantee&#8217;s participation in the Plan.  Grantee is relying solely on such advisor and is not relying in any part on any statement or representation of the Company or any of its agents in relation to the Option or this Agreement.  The Company shall not be responsible for payment of any Tax-Related Items, unless it is required to withhold Tax-Related Items under applicable law.  Grantee further acknowledges that the Company (i) makes no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Option, including, but not limited to the grant, vesting or exercise of the Option, the issuance of Option Shares upon exercise of the Option, the subsequent sale of the Option Shares acquired at exercise and the receipt of any dividends&#59; and (ii) does not commit to and is under no obligation to structure the terms of the Award or any aspect of the Option to reduce or eliminate the Grantee&#8217;s liability for Tax-Related Items or achieve any particular tax result.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.18pt">The Company may take such action as it deems appropriate to ensure that all Tax-Related Items, which are Grantee&#8217;s sole and absolute responsibility, are withheld or collected from Grantee, if and to the extent required by applicable law.  If withholding of Tax-Related Items is required by applicable law, Grantee authorizes the Company, or its agents, in their sole discretion and without any notice to or additional authorization by Grantee, to satisfy applicable withholding obligations, if any, with regard to all Tax-Related Items by one or a combination of the following&#58; (i) withholding from Grantee&#8217;s cash fees or other compensation paid to Grantee by the Company&#59; (ii) causing Grantee to tender a cash payment (i.e., check or bank wire)&#59; (iii) withholding from the proceeds of the sale of Option Shares issued upon exercise, either through a voluntary sale or through a mandatory sale arranged by the Company (on Grantee&#8217;s behalf pursuant to this authorization)&#59; (iv) if approved in advance by the Administrator, withholding Option Shares otherwise to be issued upon exercise&#59; or (v) any other method determined by the Company, to the extent permitted under the Plan and applicable laws.  Further, the Company may withhold or account for Tax-Related Items by considering statutory withholding amounts or other applicable withholding rates, including maximum rates applicable in the country in which tax is due (to the extent permitted by the Plan). In the event of over-withholding, Grantee may receive a refund of any over-withheld amount in cash (with no entitlement to the Common Stock equivalent) or, if not refunded, Grantee may be able to seek a refund from the applicable tax authorities. In the event of under-withholding, Grantee may be required to pay additional Tax-Related Items directly to the applicable tax authorities or to the Company.  If the obligation for Tax-Related Items is satisfied by withholding shares of Common Stock, for tax purposes, Grantee will be deemed to have been issued the full number of Option Shares subject to the exercised Options, notwithstanding that a number of the Option Shares is held back solely for the purpose of paying the Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Company shall not be obligated to deliver any new certificate representing shares of Common Stock to Grantee or Grantee&#8217;s legal representative or enter such shares of Common Stock in book entry form unless and until Grantee or Grantee&#8217;s legal representative shall have paid or otherwise satisfied Grantee&#8217;s obligations in connection with the Tax-Related Items resulting from the Option or the Option Shares subject to the Options.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">No Obligation to Exercise Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Grantee shall be under no obligation to exercise the Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Fractional Option Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  No fractional shares or scrip representing fractional shares of Common Stock shall be issued upon the exercise of this Option, but the Company shall issue one additional share of its Common Stock in lieu of each fraction of a share otherwise called for upon any exercise of this Option.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All notices required or permitted hereunder shall be in writing and shall be deemed to be properly given when personally delivered to the party entitled to receive the notice or when sent by certified or registered mail, postage prepaid, properly addressed to the party entitled to receive such notice at the address stated below&#58;</font></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.358%"><tr><td style="width:1.0%"></td><td style="width:30.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:67.219%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:133%">If to Company&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">ResMed Inc.<br>9001 Spectrum Center Blvd. <br>San Diego, CA 92123<br>USA<br>Attn&#58; David Pendarvis, Corporate Secretary</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:133%">If to Grantee&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:133%">Address of the Grantee on file with ResMed Inc.</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Option has been granted pursuant to the Plan adopted by the Board of the Company and approved by the stockholders of the Company, and is subject to the terms and provisions thereof.  By acceptance, hereof Grantee acknowledges receipt of a copy of the Plan.  All questions of interpretation and application of the Plan and this Option shall be determined by the Company, and such determination shall be final, binding and conclusive.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">No Right to Continued Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Nothing in this Agreement or the Plan confers upon Grantee any right to continue in service for any period of specific duration.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Governing Law &#47; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement shall be governed by and construed under the laws of the State of Delaware without regard to conflicts of laws or principles. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Award of Options or this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Diego County, California, or the federal courts for the United States for the Southern District of California and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">19.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Signatures to this Agreement may be provided in electronic format in accordance with the Company&#8217;s programs and policies permitting electronic delivery of signatures.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">20.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Amendment.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  This Agreement may not be amended in a material adverse way to Grantee except by an instrument in writing signed by the Grantee and the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">21.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Conformity to Securities Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Grantee acknowledges that the Plan is intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the U.S. Securities and Exchange Commission thereunder, and other U.S. or non-U.S. state and federal securities laws and regulations, as well as any other applicable U.S. or non-U.S. state and federal laws and regulations.  Notwithstanding anything herein to the contrary, the Plan shall be administered, and the Option is granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations.  To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, decide (a) to deliver by electronic means any documents related to the Options granted under the Plan, Grantee&#8217;s participation in the Plan, or future awards that may be granted under the Plan or (b) to request by electronic means Grantee&#8217;s consent to participate in the Plan.  Grantee hereby consents to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an online or electronic system established and maintained by the Company or any third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">23.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company reserves the right to impose other requirements on Grantee&#8217;s participation in the Plan, on the Options or any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require Grantee to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">25.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Grantee acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Grantee or any other Permitted Transferee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">26.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">Participants Outside of the United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  If Grantee is a resident of a jurisdiction outside of the United States and subject to the laws of such jurisdiction, then Grantee hereby agrees to be subject to the additional requirements and disclosures set forth in Appendices I and II hereto, both the general </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">terms and any specific terms for Grantee&#8217;s country, which are hereby incorporated into this Agreement, regardless of the law that might be applied under principles of conflicts of laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">27.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:22.25pt;text-decoration:underline">No Advice Regarding Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company is not providing any tax, legal or financial advice with respect to the Options, nor is the Company making any recommendations regarding Grantee&#8217;s participation in the Plan, or Grantee&#8217;s acquisition or sale of the underlying shares of Common Stock.  Grantee should consult with his or her own personal tax, legal and financial advisors regarding Grantee&#8217;s participation in the Plan before taking any action related to the Plan and the Options.</font></div><div style="margin-bottom:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereunto agree to the terms and conditions set forth above and in the Summary.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">RESMED INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">GRANTEE</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Signed Electronically</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Signed Electronically</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:133%;text-decoration:underline">&#47;s&#47; Michael J. Farrell</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Michael J. Farrell</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">(Acceptance designated electronically at the plan administrator's Web site)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:0.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPENDIX I</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Additional Terms and Conditions For Directors Outside the United States</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Appendix I includes additional terms and conditions that govern the Award granted to Grantee under the Plan if Grantee resides and&#47;or works in a country outside the United States of America (or if Grantee later relocates to such a country).  Certain capitalized terms used but not defined in this Appendix I have the meanings set forth in the Plan, the Agreement and&#47;or the Summary.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:26.84pt;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  Grantee is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data to the recipients mentioned below, including recipients located in countries which may not have a similar level of protection from the perspective of the data protection laws in Grantee&#8217;s country.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:26.84pt;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company collects, processes and uses certain personal information about Grantee, including, but not limited to, Grantee&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, compensation, nationality, job title, any shares or directorships held in the Company, details of all Options under the Plan or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in Grantee&#8217;s favor (&#8220;Data&#8221;), for the purposes of managing Grantee&#8217;s participation in the Plan.  The legal basis, where required, for the processing of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:27.46pt;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company transfers Data, or parts thereof, to Fidelity Stock Plan Services, LLC and certain of its affiliated companies (&#8220;Fidelity&#8221;), which assists the Company with the implementation, administration and management of the Plan.  Grantee acknowledges and understands that Fidelity will open an account for Grantee to receive and trade shares of Common Stock acquired under the Plan and that Grantee will be asked to agree on separate terms and data processing practices with Fidelity, which is a condition of Grantee&#8217;s ability to participate in the Plan.  In the future, the Company may select a different service provider and may share Data with such different service provider that serves in a similar manner.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:26.84pt;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company and Fidelity are based in the United States.  Grantee understands that his or her country may have enacted data privacy laws that are different from the laws of the United States.  As a result, in the absence of appropriate safeguards such as standard data protection clauses, the processing of Grantee&#8217;s Data in the United States or, as the case may be, other countries might not be subject to substantive data processing principles or supervision by data protection authorities.  In addition, Grantee might not have enforceable rights regarding the processing of his or her Data in such countries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">To the extent applicable to Grantee, the Company provides appropriate safeguards for protecting Data that it receives in the United States through its adherence to data transfer agreements entered into between the Company and Subsidiaries within the European Union.  Otherwise, where required, the Company&#8217;s legal basis for the transfer of Data is Grantee&#8217;s consent.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:27.46pt;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage Grantee&#8217;s participation in the Plan, or as required to comply with applicable law, exercise or defense of legal rights, and archiving, back-up and deletion processes.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:28.68pt;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  Participation in the Plan is voluntary and Grantee is providing the consents herein on a purely voluntary basis.  Grantee understands that he or she may withdraw consent at any time with future effect for any or no reason.  If Grantee does not consent, or if Grantee later seeks to revoke his or her consent, Grantee's service as a Director will not be affected&#59; the only consequence of refusing or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">withdrawing consent is that the Company would not be able to offer Options or other awards to Grantee or administer or maintain Grantee&#8217;s participation in the Plan.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;padding-left:26.84pt;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  Grantee understands that data subject rights vary depending on applicable law and that, depending on where Grantee is based and subject to the conditions under applicable law, Grantee may have, without limitation, the rights to (i) request access or copies of Data the Company processes, (ii) rectification of incorrect Data, (iii) deletion of Data, (iv) restrictions on processing of Data, (v) portability of Data, (vi) lodge complaints with competent authorities in Grantee&#8217;s jurisdiction, and&#47;or (vii) receive a list with the names and addresses of any potential recipients of Data. To receive clarification regarding these rights or to exercise these rights, Grantee understands that he or she can contact the Company.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Insider Trading &#47; Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Grantee acknowledges that, depending on Grantee&#8217;s country, the broker&#8217;s country, or the country in which shares of Common Stock are listed, Grantee may be subject to insider trading restrictions and&#47;or market abuse laws, which may affect Grantee&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">., Options) or rights linked to the value of shares of Common Stock during such times as Grantee is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws or regulations in the relevant jurisdiction).  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.  Grantee is responsible to comply with any applicable restrictions, and Grantee should speak to his or her personal advisor regarding this matter.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Foreign Assets&#47;Account and Tax Reporting, Exchange Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:26.84pt">Grantee&#8217;s country may have certain foreign asset, account and&#47;or tax reporting requirements and exchange controls which may affect Grantee&#8217;s ability to acquire or hold shares of Common Stock under the Plan or cash received from participating in the Plan (including from any dividends received or sale proceeds arising from the sale of shares of Common Stock) in a brokerage or bank account outside Grantee&#8217;s country.  Grantee understands that he or she may be required to report such accounts, assets or transactions to the tax or other authorities in Grantee&#8217;s country.  Grantee also may be required to repatriate sale proceeds or other funds received as a result of participation in the Plan to his or her country through a designated bank or broker and&#47;or within a certain time after receipt.  In addition, Grantee may be subject to tax payment and&#47;or reporting obligations in connection with any income realized under the Plan and&#47;or from the sale of shares of Common Stock.  Grantee acknowledges that he or she is responsible for complying with all such requirements, and that Grantee should consult personal legal and tax advisors, as applicable, to ensure compliance.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:29.29pt">The Company shall not be liable for any foreign exchange rate fluctuation between Grantee&#8217;s local currency and the United States Dollar that may affect the value of the Options or of any amounts due to Grantee pursuant to the exercise of the Options or the subsequent sale of any shares of Common Stock acquired upon exercise.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  In the event Grantee has received this Agreement, including Appendices I and II, or any other document related to the Plan translated into a language other than English, the English version will control to the extent the meaning of the translated version differs from the English version.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">APPENDIX II</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain capitalized terms used but not defined in this Appendix II have the meanings set forth in the Plan, the Agreement, Appendix I and&#47;or the Summary.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Appendix II includes special and&#47;or additional terms and conditions that govern the Options granted to Grantee under the Plan if Grantee is a resident of a jurisdiction outside of the United States and subject to the laws of such jurisdiction.  These terms and conditions are in addition to or, if so indicated, in place of, the terms and conditions set forth in the Agreement.  If Grantee is a citizen or resident of a country other than the one in which he or she is currently residing and&#47;or transfers residency to another country after the grant of the Options, or is considered resident of another country for local law purposes, the Administrator shall, in its discretion, determine to what extent any country-specific terms and conditions contained herein shall be applicable to Grantee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Singapore</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sale of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For any shares of Common Stock that are acquired within six months of the Grant Date, Grantee agrees that he or she will not dispose of the shares of Common Stock acquired prior to the six-month anniversary of the Grant Date, unless such sale or offer in Singapore is made pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the of the Singapore Securities and Futures Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;), or any other applicable provisions of the SFA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The offer of the Plan is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of SFA and not with a view to the Options or shares of Common Stock being subsequently offered for sale to another party.  The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>6
<FILENAME>ex109-formofpsuagreementfo.htm
<DESCRIPTION>EX-10.9
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie6462b52fb6744d2bb37908d1d6689f9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.9</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ResMed Inc.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Summary for Performance-Based Restricted Stock Unit (&#8220;PSU&#8221;)</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Award Agreement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;     &#91;PARTICIPANT NAME&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;     &#91;GRANT DATE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Target Number of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  &#91;PSUs GRANTED&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Maximum Number of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;  225% of Target Number of PSUs</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58; &#160;&#160;&#160;&#160;&#91;GRANT DATE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> through &#91;FOURTH YEAR ANNIVERSARY&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the terms of the Agreement, including the terms requiring the satisfaction of specified Performance Goals, the PSUs shall vest and become nonforfeitable on the applicable Certification Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div></div><div id="ie6462b52fb6744d2bb37908d1d6689f9_64"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RESMED INC. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Performance-Based Restricted Stock Unit Award Agreement including any country-specific terms and conditions set forth in Appendix I hereto and the Performance Goals set forth in Appendix II hereto (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) sets forth the terms and conditions of the performance&#8211;based restricted stock units </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(&#8220;Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) granted by ResMed Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), under the ResMed Inc. 2009 Incentive Award Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), and pursuant to the Summary of Performance-Based Restricted Stock Unit Award Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Summary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) displayed at the Web site of the Company&#8217;s plan administrator.  The Summary specifies the person to whom the PSUs are granted (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the grant date of the PSUs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the vesting schedule of the PSUs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), the target number of PSUs granted to Holder, and other specific details of the grant.  The Summary is deemed part of this Agreement.</font></div><div style="padding-left:9pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:232%">ARTICLE 1.<br>GENERAL</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Summary.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As used herein, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean a &#8220;disability&#8221; as defined in Treasury Regulation Section 1.409A-3(i)(4).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As used herein, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Performance Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">PSU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean a non-voting unit of measurement which represents the right to receive one share of Common Stock for each unit that vests (subject to adjustment as provided in Section 11.3 of the Plan) solely for purposes of the Plan and this Agreement.  The PSUs shall be used solely as a device for the determination of the issuance of shares of Common Stock to eventually be made to Holder if and to the extent such PSUs are eligible for vesting and vest pursuant to Section 2.2 hereof.  The PSUs shall not be treated as property or as a trust fund of any kind.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">As used herein, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; shall mean a Termination of Service after (a) sixty (60) years of age and (b) completion of five (5) years of continuous service with the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incorporation of Terms of Plan, Summary and Appendices I and II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The PSUs are subject to the terms and conditions of the Plan, the Summary, Appendix I hereto (which sets forth special and&#47;or additional legal requirements, terms and conditions as may be required by Holder&#8217;s country) and Appendix II hereto (which sets forth certain Performance Goals applicable to the PSUs), each of which is incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control.  To the extent applicable, in the event of any inconsistency between this Performance-Based Restricted Stock Unit Award Agreement and Appendices I and II, the terms of Appendices I and II shall control.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:232%">ARTICLE 2.<br>GRANT OF PERFORMANCE STOCK UNITS</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grant of PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Effective as of the Grant Date, the Company grants to Holder an award of PSUs as set forth in the Summary, upon the terms and conditions set forth in the Summary, the Plan, and this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">PSUs subject to Performance Goals&#59; Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Appendix II attached hereto sets forth the Performance Goals that must be satisfied in order for the PSUs to be eligible for vesting.  The Performance Goals are based on the Company&#8217;s cumulative Absolute Total Stockholder Return achieved over a certain specified period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), all as set forth on Appendix II.  The Compensation Committee shall certify the extent to which the Performance Goals have been achieved and the PSUs are eligible for vesting, with such certification occurring as soon as practicable following the end of the applicable Performance Period and in any event no later than 90 days following the end of such Performance Period (such certification occurring on the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Certification Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;).  Except as set forth in Section 2.4(b), any unvested PSUs for which the Performance Goals have not been achieved shall be automatically forfeited, terminated and cancelled effective as of the applicable Certification Date, without the payment of any consideration by the Company, and Holder, or Holder&#8217;s beneficiary or personal representative, as the case may be, shall have no further rights with respect to such PSUs under the Agreement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Subject to Sections 2.2(c) and 2.4 hereof, the PSUs awarded pursuant to the Summary and eligible for vesting in accordance with Appendix II will vest and become nonforfeitable on the applicable Certification Date, subject to Holder&#8217;s continued employment or services through such Certification Date.  Unless otherwise determined by the Administrator, partial employment or service, even if substantial, during any portion of the Performance Period will not entitle Holder to any proportionate vesting or avoid or mitigate a termination of rights and benefits upon or following a Termination of Service as provided in Section 2.4 hereof or under the Plan.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Notwithstanding Section 2.2(b) hereof, Appendix II and the Summary, and subject to Section 2.4 hereof, in the event of a Change in Control of the Company, the PSUs, to the extent then outstanding and not previously forfeited, shall become vested and nonforfeitable as of the date of such Change in Control, based on performance under the Performance Goals, pro-rated as set forth on Appendix II, from the commencement of the Performance Period through the date of the Change in Control.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">No Right to Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Nothing in the Plan or this Agreement, nor Holder&#8217;s participation in the Plan, shall confer upon Holder any right to continue in the employ or service of the Company or any Subsidiary, or shall interfere with or restrict in any way the rights of the Company and any Subsidiary, which rights are hereby expressly reserved, to discharge or terminate the services of Holder at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Holder.  In the event that Holder is not an Employee, Director or Consultant of the Company, the grant will not be interpreted to form an employment or service contract with the Company.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Forfeiture, Termination and Cancellation upon Terminations of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Notwithstanding any contrary provision of this Agreement, except as provided in Section 2.4(b), upon Holder&#8217;s Termination of Service for any or no reason (other than Holder&#8217;s death, Disability, Retirement or termination without &#8220;cause&#8221; or for &#8220;good reason&#8221; as provided in Section 2.4(b)), all PSUs subject to this Agreement (whether unvested or eligible for vesting) will thereupon be automatically forfeited, terminated and cancelled as of the applicable termination date without payment of any consideration by the Company, and Holder, or Holder&#8217;s beneficiary or personal representative, as the case may be, shall have no further rights hereunder.  For purposes of this Agreement, the employment relationship of Holder will be treated as continuing intact while he or she is on military or sick leave or other bona fide leave of absence if such leave does not exceed ninety days, provided, however, that the period of the leave may exceed ninety days so long as Holder&#8217;s right to re-employment is guaranteed either by statute or by contract, or in any other circumstance as may be required by law.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, Appendix II and the Summary, (i) if Holder dies or has a Termination of Service due to Disability while serving as an Employee, Director or Consultant of the Company or a Subsidiary, as applicable, the PSUs shall become fully vested and nonforfeitable at 100% of the target number of PSUs as of the date of such Holder&#8217;s death or Termination of Service due to Disability, as applicable&#59; or (ii) if Holder has a Termination of Service by the Company without &#8220;cause,&#8221; by Holder for &#8220;good reason&#8221; (each as defined in Holder&#8217;s change in control agreement with the Company, if any) or due to Holder&#8217;s Retirement, in each case while serving </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">as an Employee, Director or Consultant of the Company or a Subsidiary, the PSUs shall become vested and nonforfeitable, as of the date of such Termination of Service, on a prorated basis, based on the number of days of Holder&#8217;s service with the Company or a Subsidiary during the original four-year Performance Period through the date of Holder&#8217;s Termination of Service, and based on performance under the Performance Goals, pro-rated as set forth on Appendix II, from the commencement of the Performance Period through the date of Holder&#8217;s Termination of Service.  Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in Holder&#8217;s jurisdiction that likely would result in the favorable Retirement treatment that otherwise would apply to the PSUs pursuant to this Section 2.4(b)(ii) being deemed unlawful and&#47;or discriminatory, then the Company will not apply this favorable Retirement treatment at the time of Holder&#8217;s Termination of Service and the PSUs will be treated as they would under the rules that otherwise would have applied if Holder&#8217;s Termination of Service did not qualify as a Retirement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">For purposes of this Agreement, Holder&#8217;s Termination of Service is deemed to occur as of the date Holder is no longer actively providing services to the Company or a Subsidiary (regardless of the reason for such termination and whether or not later to be found invalid or in breach of applicable laws in the jurisdiction where Holder is employed or rendering services or the terms of Holder&#8217;s employment or service agreement, if any) and, unless otherwise provided in this Section 2.4(b), Holder&#8217;s right to vest in the PSUs, if any, will terminate as of such date and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">., Holder&#8217;s period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under applicable laws in the jurisdiction where Holder is employed or providing services or the terms of Holder&#8217;s employment or service contract, if any).  The Administrator shall have the exclusive discretion to determine when Holder&#8217;s Termination of Service for purposes of the PSUs has occurred (including whether Holder may still be considered to be providing services while on a leave of absence).</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Issuance of Shares upon Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Subject to Appendix II, as soon as administratively practicable following the vesting of any PSUs pursuant to Section 2.2 or Section 2.4(b) hereof, but in no event later than 30 days after such vesting date, the Company shall deliver to Holder a number of shares of Common Stock equal to the number of such PSUs that vested on the applicable vesting date, less to the extent applicable, the number of shares of Common Stock withheld in accordance with Section 2.6(b).  The shares of Common Stock delivered hereby shall be represented either by one or more stock certificates or by book entry, as determined by the Company in its sole discretion.  Notwithstanding the foregoing&#58;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;in the event shares of Common Stock cannot be issued in the time frame specified above due to the effects of Sections 2.7(a), (b) or (c) hereof, then the shares of Common Stock shall be issued as soon as administratively practicable after the Administrator determines that shares of Common Stock can again be issued in accordance with Sections 2.7(a), (b) and (c) hereof, subject to compliance with Section 409A (as defined in Section 3.13 below)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;if the PSUs constitute &#8220;nonqualified deferred compensation&#8221; subject to Section 409A and Holder is subject to U.S. federal taxation, then&#58; (i) any PSUs that vest other than pursuant to Section 2.2(c) or Section 2.4(b) will be paid in the calendar year in which the original four-year Performance Period, or, if applicable, the Accelerated Performance Period ends (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Standard Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)&#59; (ii) to the extent that the PSUs vest upon a Change in Control under Section 2.2(c) and such event is not a &#8220;change in control event&#8221; within the meaning of Section 409A, any settlement of PSUs due upon such Change in Control shall instead be made within upon the earliest to occur of (A) the Standard Payment Date, (B) Holder&#8217;s &#8220;separation from service&#8221; within the meaning of Section 409A, (C) Holder&#8217;s Disability, or (D) Holder&#8217;s death&#59; and (iii) to the extent that the PSUs vest upon Holder&#8217;s Termination of Service, the PSUs shall be paid within thirty (30) days after the date on which Holder experiences a &#8220;separation from service&#8221; within the meaning of Section 409A&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, if Holder is a &#8220;specified employee&#8221; within the meaning of Section 409A as of the date of Holder&#8217;s separation from service, Holder&#8217;s vested PSUs shall instead be settled during the thirty (30) day period commencing on the earlier of (A) the expiration of the six (6) month period measured from the date of Holder&#8217;s separation from service or (B) the date of Holder&#8217;s death, to the extent that such delayed payment is required to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, or any successor provision thereto.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Responsibility for Taxes.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Regardless of any action the Company or, if different, the Subsidiary employing Holder or for which Holder otherwise provides services (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) takes with respect to any or all income tax, social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to Holder&#8217;s participation in the Plan and legally applicable or deemed legally applicable to Holder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), Holder acknowledges that the ultimate liability for all Tax-Related Items is and remains Holder&#8217;s responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.  Holder further acknowledges that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the PSUs, including, but not limited to the grant of the PSUs, the vesting or settlement of the PSUs, the issuance of shares of Common Stock in settlement of the PSUs, the subsequent sale of the shares of Common Stock acquired at vesting and the receipt of any dividends&#59; and (ii) do not commit to and are under no obligation to structure the terms of the Award or any aspect of the PSUs to reduce or eliminate Holder&#8217;s liability for Tax-Related Items or achieve any particular tax result.  Furthermore, if Holder is subject to tax in more than one jurisdiction, Holder acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;In connection with any relevant taxable or tax withholding event, as applicable, Holder must pay or make adequate arrangements satisfactory to the Company and&#47;or the Employer to satisfy all Tax-Related Items. In this regard, Holder hereby authorizes the Company and&#47;or the Employer, or their respective agents, in their sole discretion and without any notice to or additional authorization by Holder, to satisfy their withholding obligations, if any, with regard to all Tax-Related Items by one or a combination of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;withholding from Holder&#8217;s compensation or other wages payable to Holder by the Company, the Employer and&#47;or any other Subsidiary&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;causing Holder to tender a cash payment (i.e., check or bank wire)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;withholding from the proceeds of the sale of shares of Common Stock issued upon vesting, either through a voluntary sale or through a mandatory sale arranged by the Company (on Holder&#8217;s behalf pursuant to this authorization)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;withholding shares of Common Stock otherwise to be issued upon vesting&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;any other method determined by the Company, to the extent permitted under the Plan and applicable laws&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">howeve</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">r that if Holder is a Section 16 officer of the Company under the Exchange Act, then the Company will withhold shares of Common Stock upon the relevant taxable or tax withholding event, as applicable, unless the use of such withholding method is not feasible under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by one or a combination of methods (i)-(iii) or (v) above. Further, notwithstanding anything herein to the contrary, the Company may cause a portion of the PSUs to vest prior to the date(s) set forth in the Vesting Schedule in order to satisfy any Tax-Related Items that arise prior to the date of settlement of the PSUs&#59; provided that to the extent necessary to avoid a prohibited distribution under Section 409A, the number of PSUs so accelerated and settled shall be with respect to a number of shares of Common Stock with a value that does not exceed the liability for the Tax-Related Items</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The Company may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in Holder&#8217;s jurisdiction(s) (to the extent permitted by the Plan). In the event of over-withholding, Holder may receive a refund of any over-withheld amount in cash (with no entitlement to the Common Stock equivalent) or, if not refunded, Holder may be able to seek a refund from the applicable tax authorities.  In the event of under-withholding, Holder may be required to pay </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">additional Tax-Related Items directly to the applicable tax authorities or to the Company and&#47;or the Employer.  If the obligation for Tax-Related Items is satisfied by withholding shares of Common Stock, for tax purposes, Holder will be deemed to have been issued the full number of shares of Common Stock subject to the vested PSUs, notwithstanding that a number of the shares of Common Stock is held back solely for the purpose of paying the Tax-Related Items.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;Holder agrees to pay to the Company and&#47;or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of Holder&#8217;s participation in the Plan that cannot be satisfied by the means previously described.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;The Company shall not be obligated to deliver any new certificate representing shares of Common Stock to Holder or Holder&#8217;s legal representative or enter such shares of Common Stock in book entry form unless and until Holder or Holder&#8217;s legal representative shall have paid or otherwise satisfied Holder&#8217;s obligations in connection with the Tax-Related Items resulting from the PSUs or the shares of Common Stock subject to the PSUs.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Conditions to Delivery of Common Stock&#59; Legal Requirements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  The shares of Common Stock deliverable hereunder, or any portion thereof, may be either previously authorized but unissued shares of Common Stock or issued shares of Common Stock which have then been reacquired by the Company.  Such shares of Common Stock shall be fully paid and nonassessable.  The Company shall not be required to issue or deliver any shares of Common Stock deliverable hereunder or portion thereof prior to fulfillment of all of the following conditions</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#58;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;The admission of such shares of Common Stock to listing on all stock exchanges on which such Common Stock is then listed&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;The completion and maintenance of any registration or other qualification of such shares of Common Stock under any U.S. and non-U.S. state or federal law or under rulings or regulations of the U.S. Securities and Exchange Commission or of any other governmental regulatory body, which the Administrator shall, in its absolute discretion, deem necessary or advisable&#59;</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;The obtaining of any approval or other clearance from any U.S. or non-U.S. state or federal governmental agency which the Administrator shall, in its absolute discretion, determine to be necessary or advisable&#59; and</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;The lapse of such reasonable period of time following the vesting of any PSUs as the Administrator may from time to time establish for reasons of administrative convenience.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Rights as Stockholder</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Holder shall not be, nor have any of the rights or privileges of, a stockholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of the PSUs and any shares of Common Stock underlying the PSUs and deliverable hereunder unless and until such shares of Common Stock shall have been issued by the Company and held of record by such Holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).  No adjustment will be made for a dividend or other right for which the record date is prior to the date the shares of Common Stock are issued, except as provided in Section 11.3 of the Plan.  No Dividend Equivalent awards shall be awarded in respect of, and no dividends shall be paid with respect to, any PSUs.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:232%">ARTICLE 3.<br>OTHER PROVISIONS</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Administrator shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules.  All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon Holder, the Company and all other interested persons.  No member of the Committee or the Board </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the PSUs.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Grant is Not Transferable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;Except as set forth in Section 3.2(b), during the lifetime of Holder, the PSUs may not be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and distribution, unless and until the shares of Common Stock underlying the vested PSUs have been issued.  Neither the PSUs nor any interest or right therein shall be liable for the debts, contracts or engagements of Holder or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;Notwithstanding the foregoing provisions of subsection 3.2(a), for Holders who are exclusively subject to the laws of the United States, the Administrator, in its sole discretion, may permit the transfer of PSUs held by Holder pursuant to a DRO.  Any PSU that has been so transferred shall continue to be subject to all of the terms and conditions as applicable to the original Holder, and the transferee shall execute any and all such documents requested by the Administrator in connection with the transfer, including, without limitation, to evidence the transfer and to satisfy any requirements for an exemption for the transfer under applicable federal and state securities laws.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Subject to the limitation on the transferability of the PSUs contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Adjustments Upon Specified Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Administrator may accelerate the vesting of the PSUs and the issuance of shares of Common Stock with respect to vested PSUs in such circumstances as it, in its sole discretion, may determine&#59; provided, however, that if the PSUs constitute &#8220;nonqualified deferred compensation&#8221; subject to Section 409A and Holder is subject to U.S. federal taxation, no acceleration of the issuance of the shares of Common Stock may occur other than as expressly permitted under Section 409A.  In addition, upon the occurrence of certain events relating to the Common Stock contemplated by Section 11.3 of the Plan, the Administrator shall make any appropriate adjustments in the number of PSUs then outstanding and the number and kind of securities that may be issued in respect of the PSUs.  Holder acknowledges that the PSUs are subject to amendment, modification and termination in certain events as provided in this Agreement and Section 11.3 of the Plan.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  All notices required or permitted hereunder shall be in writing and shall be deemed to be properly given when personally delivered to the party entitled to receive the notice (which may include electronic delivery by email) or when sent by certified or registered mail, postage prepaid, properly addressed to the party entitled to receive such notice at the address stated below&#58;</font></div><div style="padding-left:36pt;padding-right:36pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.820%"><tr><td style="width:1.0%"></td><td style="width:23.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">If to Company&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">ResMed Inc.<br>9001 Spectrum Center Blvd. <br>San Diego, CA 92123<br>USA<br>Attn&#58; David Pendarvis, Corporate Secretary</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">If to Holder&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Address of the Holder on file with ResMed Inc. or its Subsidiary</font></td></tr></table></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Titles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law &#47; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">regardless of the law that might be applied under principles of conflicts of laws.  For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Award of PSUs or this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Diego County, California, or the federal courts for the United States for the Southern District of California and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Conformity to Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Holder acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the U.S. Securities and Exchange Commission thereunder, and other U.S. or non-U.S. state and federal securities laws and regulations, as well as any other applicable U.S. or non-U.S. state and federal laws and regulations.  Notwithstanding anything herein to the contrary, the Plan shall be administered, and the PSUs are granted, only in such a manner as to conform to such laws, rules and regulations.  To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Amendments, Suspension and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> that, except as may otherwise be provided by the Plan and subject to Section 3.8, Section 3.11, Section 3.13 and Section 3.21 hereof, no amendment, modification, suspension or termination of this Agreement shall adversely affect the PSUs in any material way without the prior written consent of Holder. </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth in Section 3.2 hereof, this Agreement shall be binding upon Holder and his or her heirs, executors, administrators, successors and assigns.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of the Plan or this Agreement, if Holder is subject to Section 16 of the Exchange Act, the Plan, the PSUs and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule.  To the extent permitted by applicable law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Plan, the Summary and this Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Holder with respect to the subject matter hereof.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The parties intend that this Agreement and the benefits provided hereunder be exempt from the requirements of Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, &#8220;Section 409A&#8221;) to the maximum extent possible, whether pursuant to the short-term deferral exception described in Treasury Regulation Section 1.409A-1(b)(4) or otherwise.  However, to the extent that the PSUs (or any portion thereof) may be subject to Section 409A, the parties intend that this Agreement and such benefits comply with the deferral, payout, and other limitations and restrictions imposed under Section 409A and this Agreement shall be interpreted, operated and administered in a manner consistent with such intent.  Notwithstanding any other provision of the Plan, the Summary or this Agreement, the Administrator shall have the right in its sole discretion (without any obligation to do so or to indemnify Holder or any other person for failure to do so) to adopt such amendments to the Plan, the Summary or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate either for the PSUs to be exempt from the application of Section 409A or to comply with the requirements of Section 409A.  Nothing in this Agreement, the Plan or the Summary shall provide a basis for any person to take action against the Company or any Subsidiary based on matters covered by </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Section 409A of the Code, including the tax treatment of any amount paid or PSUs granted under this Agreement, and neither the Company nor any of its Subsidiaries shall under any circumstances have any liability to Holder or his or her estate or any other party for any taxes, penalties or interest due on amounts paid or payable under this Agreement, including taxes, penalties or interest imposed under Section 409A.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Limitation on Holder&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Unless and until the PSUs will have vested in the manner set forth in Article 2 hereof, Holder will have no right to the issuance of shares of Common Stock with respect to the PSUs.  Holder shall have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the PSUs, and rights no greater than the right to receive the Common Stock as a general unsecured creditor with respect to PSUs, as and when payable hereunder.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Holder acknowledges that he or she is proficient in the English language and understands the provisions in this Agreement and the Plan or has had the ability to consult with an advisor who is sufficiently proficient in the English language.  Further, in the event Holder has received this Agreement, including Appendix I hereto (if any), or any other document related to the Plan translated into a language other than English, the English version will control to the extent the meaning of the translated version differs from the English version.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, decide (a) to deliver by electronic means any documents related to the PSUs granted under the Plan, Holder&#8217;s participation in the Plan, or future awards that may be granted under the Plan or (b) to request by electronic means Holder&#8217;s consent to participate in the Plan. Holder hereby consents to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an online or electronic system established and maintained by the Company or any third party designated by the Company.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  By accepting the PSUs, Holder acknowledges, understands and agrees that&#58; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;the grant of PSUs is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of PSUs, or benefits in lieu of PSUs, even if PSUs have been granted in the past&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;all decisions with respect to future awards of PSUs or other grants, if any, will be at the sole discretion of the Company&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;Holder is voluntarily participating in the Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;the PSUs and the shares of Common Stock subject to the PSUs, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;the PSUs and the shares of Common Stock subject to the PSUs, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose, including (without limitation) calculating any severance, resignation, redundancy or end of service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;no claim or entitlement to compensation or damages shall arise from termination of the PSUs resulting from a Termination of Service (for any reason whatsoever, whether or not later to be found invalid or in breach of employment laws in the jurisdiction where Holder is employed or rendering services or the terms of Holder&#8217;s employment or service agreement, if any)&#59;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;unless otherwise agreed with the Company, the PSUs and the shares of Common Stock subject to the PSUs, and the income from and value of same, are not granted as consideration for, or in connection with, the service Holder may provide as a director of a Subsidiary&#59; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the Company is not providing any tax, legal or financial advice with respect to the PSUs, nor is the Company making any recommendations regarding Holder&#8217;s participation in the Plan, or Holder&#8217;s acquisition or sale of the underlying shares of Common Stock&#59; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;Holder should consult with his or her own personal tax, legal and financial advisors regarding Holder&#8217;s participation in the Plan before taking any action related to the Plan and the PSUs&#59; and</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;the following provisions apply only if Holder is providing services outside the United States&#58;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;the PSUs and the shares of Common Stock subject to the PSUs, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose&#59; and</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;neither the Company, the Employer nor any other Subsidiary shall be liable for any foreign exchange rate fluctuation between Holder&#8217;s local currency and the United States Dollar that may affect the value of the PSUs or of any amounts due to Holder pursuant to the settlement of the PSUs or the subsequent sale of any shares of Common Stock acquired upon settlement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  Holder is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Company and the transfer of Data (as defined below) to the recipients mentioned below, including recipients located in countries which may not have a similar level of protection from the perspective of the data protection laws in Holder&#8217;s country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company and the Employer collect, process and use certain personal information about Holder, including, but not limited to, Holder&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any shares or directorships held in the Company, details of all PSUs under the Plan or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in Holder&#8217;s favor (&#8220;Data&#8221;), for the purposes of managing Holder&#8217;s participation in the Plan.  The legal basis, where required, for the processing of Data is Holder&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company transfers Data, or parts thereof, to Fidelity Stock Plan Services, LLC and certain of its affiliated companies (&#34;Fidelity&#34;), which assists the Company with the implementation, administration and management of the Plan.  Holder acknowledges and understands that Fidelity will open an account for Holder to receive and trade shares of Common Stock acquired under the Plan and that Holder will be asked to agree on separate terms and data processing practices with Fidelity, which is a condition of Holder&#8217;s ability to participate in the Plan.  In the future, the Company may select a different service provider and may share Data with such different service provider that serves in a similar manner.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company and Fidelity are based in the United States.  Holder understands that his or her country may have enacted data privacy laws that are different from the laws of the United States.  As a result, in the absence of appropriate safeguards such as standard data protection clauses, the processing of Holder&#8217;s Data in the United States or, as the case may be, other countries might not be subject to substantive data processing principles or supervision by data protection authorities.  In addition, Holder might not have enforceable rights regarding the processing of his or her Data in such countries.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">The Company provides appropriate safeguards for protecting Data that it receives in the United States through its adherence to data transfer agreements entered into between the Company and Subsidiaries within the European Union.  Otherwise, where required, the Company&#8217;s legal basis for the transfer of Data is Holder&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage Holder&#8217;s participation in the Plan, or as required to comply with applicable law, exercise or defense of legal rights, and archiving, back-up and deletion processes.  This means Data may be retained even after Holder&#8217;s Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  Participation in the Plan is voluntary and Holder is providing the consents herein on a purely voluntary basis.  Holder understands that he or she may withdraw consent at any time with future effect for any or no reason.  If Holder does not consent, or if Holder later seeks to revoke his or her consent, Holder&#8217;s employment or service with the Employer will not be affected&#59; the only consequence of refusing or withdrawing consent is that the Company would not be able to offer PSUs or other awards to Holder or administer or maintain Holder&#8217;s participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">.  Holder understands that data subject rights vary depending on applicable law and that, depending on where Holder is based and subject to the conditions under applicable law, Holder may have, without limitation, the rights to (i) request access or copies of Data the Company processes, (ii) rectification of incorrect Data, (iii) deletion of Data, (iv) restrictions on processing of Data, (v) portability of Data, (vi) lodge complaints with competent authorities in Holder&#8217;s jurisdiction, and&#47;or (vii) receive a list with the names and addresses of any potential recipients of Data.  To receive clarification regarding these rights or to exercise these rights, Holder understands that he or she can contact Holder&#8217;s local human resources representative.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Participants Outside of the United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in this Agreement, the PSUs shall be subject to any additional terms and conditions set forth in Appendix I hereto for Holder&#8217;s country.  Moreover, if Holder relocates to one of the countries included in Appendix I (if any), the terms and conditions for such country will apply to Holder, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The terms included in Appendix I constitute part of this Agreement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. The Company reserves the right to impose other requirements on Holder&#8217;s participation in the Plan, on the PSUs or any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable or legal or administrative reasons, and to require Holder to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Holder acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Holder or any other Holder. </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Holder acknowledges that, depending on Holder&#8217;s country, the broker&#8217;s country, or the country in which shares of Common Stock are listed, Holder may be subject to insider trading restrictions and&#47;or market abuse laws, which may affect Holder&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">., PSUs) or rights linked to the value of shares of Common Stock during such times as Holder is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws or regulations in the relevant jurisdiction).  Further, Holder understands that local insider trading laws and regulations prohibit the cancellation or amendment of orders Holder may have placed before processing insider information.  Holder also understands that he or she may be prohibited from (i) disclosing inside information to any third party, including fellow employees (other than on a &#8220;need to know&#8221; basis), and (ii) &#8220;tipping&#8221; third parties by sharing inside information with them, or otherwise </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">causing third parties to buy or sell Company securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company.  Holder is responsible for complying with any applicable restrictions, and Holder should consult with his or her personal legal and financial advisors on this matter before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Foreign Assets&#47;Account and Tax Reporting, Exchange Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Holder&#8217;s country may have certain foreign asset, account and&#47;or tax reporting requirements and exchange controls which may affect Holder&#8217;s ability to acquire or hold shares of Common Stock under the Plan or cash received from participating in the Plan (including from any dividends received or sale proceeds arising from the sale of shares of Common Stock) in a brokerage or bank account outside Holder&#8217;s country.  Holder understands that he or she may be required to report such accounts, assets or transactions to the tax or other authorities in Holder&#8217;s country.  Holder also may be required to repatriate sale proceeds or other funds received as a result of participation in the Plan to his or her country through a designated bank or broker and&#47;or within a certain time after receipt.  In addition, Holder may be subject to tax payment and&#47;or reporting obligations in connection with any income realized under the Plan and&#47;or from the sale of shares of Common Stock.  Holder acknowledges that he or she is responsible for complying with all such requirements, and that Holder should consult personal legal and tax advisors, as applicable, to ensure compliance.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Remainder of this page intentionally left blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#93;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereunto agree to the terms and conditions set forth in this Agreement and the Summary. </font></div><div style="text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RESMED INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HOLDER</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#91;ELECTRONIC SIGNATURE&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#47;s&#47; Michael J. Farrell</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Michael J. Farrell</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Acceptance designated electronically at the plan administrator's Web site)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div></div></div><div id="ie6462b52fb6744d2bb37908d1d6689f9_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX I </font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Certain capitalized terms used but not defined in this Appendix I have the meanings set forth in the Plan, the Agreement and&#47;or the Summary.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Appendix I includes special and&#47;or additional terms and conditions that govern the PSUs granted to Holder under the Plan if Holder resides and&#47;or works in one of the countries listed below.  These terms and conditions are in addition to or, if so indicated, in place of, the terms and conditions set forth in the Agreement.  If Holder is a citizen or resident of a country other than the one in which he or she is currently residing and&#47;or working, transfers residency and&#47;or employment to another country after the grant of PSUs, or is considered resident of another country for local law purposes, the Administrator shall, in its discretion, determine to what extent the terms and conditions contained herein shall be applicable to Holder.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Notifications </font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">This Appendix also includes information regarding tax, securities law, exchange controls and certain other issues of which Holder should be aware with respect to Holder&#8217;s participation in the Plan.  The information is based on the securities, exchange control and other laws in effect in the respective countries as of November 2021.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that Holder not rely on the information in this Appendix I as the only source of information relating to the consequences of Holder&#8217;s participation in the Plan because the information may be out of date at the time that the PSUs vest or shares of Common Stock acquired under the Plan are sold.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, the information contained herein is general in nature and may not apply to Holder&#8217;s particular situation and the Company is not in a position to assure Holder of any particular result.  Accordingly, Holder should seek appropriate professional advice as to how the relevant laws in his or her country may apply to Holder&#8217;s situation.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Finally, if Holder is a citizen or resident of a country other than the one in which he or she is currently residing and&#47;or working, transfers residency and&#47;or employment to another country after the grant of PSUs, or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to Holder in the same manner.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Australia</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Australian Offer Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The offering of the Plan in Australia is intended to qualify for exemption from the prospectus requirements under Class Order 14&#47;1000 issued by the Australian Securities and Investments Commission.  Holder&#8217;s participation in the Plan is subject to the terms and conditions set forth in the Australian Offer Document, the Plan and the Agreement.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Exchange control reporting is required for cash transactions exceeding AUD 10,000 and for international fund transfers, including for the remittance of proceeds related to the sale of shares of Common Stock acquired under the Plan and&#47;or dividends paid on such shares.  If an Australian bank is assisting with the transaction, then the bank will file the required exchange control report on Holder&#8217;s behalf.  If no Australian bank is assisting with the transaction, then Holder will have to file the required exchange control report.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies (subject to the conditions in the Act).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Germany</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  Cross-border payments in excess of &#8364;12,500 in connection with the sale of securities (including shares of Common Stock acquired under the Plan and&#47;or dividends) must be reported on a monthly basis to the German Federal Bank (Bundesbank).  If Holder receives a payment in excess of this amount, Holder must report the payment to Bundesbank electronically by the fifth day of the month following the month in which the payment was received.  The form of the report (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Allgemeine Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) can be accessed via the Bundesbank&#8217;s website (www.bundesbank.de) and is available in both German and English.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Singapore</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Sale of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  For any shares of Common Stock that are issued within six months of the Grant Date, Holder agrees that he or she will not dispose of the shares of Common Stock acquired prior to the six-month anniversary of the Grant Date, unless such sale or offer in Singapore is made pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the of the Singapore Securities and Futures Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;), or any other applicable provisions of the SFA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The offer of the Plan is being made pursuant to the &#8220;Qualifying Person&#8221; exemption under section 273(1)(f) of SFA and not with a view to the PSUs or shares of Common Stock being subsequently offered for sale to another party.  The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Director Notification Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The directors, associate directors and shadow directors of a Singapore Subsidiary are subject to certain notification requirements under the Singapore Companies Act.  The directors, associate directors and shadow directors must notify the Singapore Subsidiary in writing of an interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">., PSUs, shares of Common Stock, etc.) in the Company or any related company within two (2) business days of (i) its acquisition or disposal, (ii) any change in a previously disclosed interest (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">. when shares of Common Stock are sold), or (iii) becoming a director, associate director or shadow director.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div></div></div><div id="ie6462b52fb6744d2bb37908d1d6689f9_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX II</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Appendix II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%"> sets forth the performance goals (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8221;) for the PSUs and shall determine the extent to which the Performance Goals are achieved and the extent to which the PSUs will be eligible for vesting at the end of the applicable Performance Period.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Performance Goals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Absolute TSR.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Performance Goals shall be based on the Company&#8217;s absolute Total Stockholder Return (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Absolute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) over the four-year period beginning &#91;GRANT DATE&#93; and ending &#91;FOURTH YEAR ANNIVERSARY&#93;, or such shorter period as provided below (in the event the Accelerated Vesting Threshold is achieved), or in Section 2.2(c) due to a Change in Control or as provided in Section 2.4(b)(ii) for certain Terminations of Service (in any such case, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Performance Period&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">), as set forth below.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Calculation to Determine PSUs Earned</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Each Holder is entitled to vest in a number of shares of Common Stock underlying the corresponding number of PSUs (at a rate of one share for each underlying PSU), ranging from 0% to 225% of the target number of PSUs granted to such Holder (for each Holder, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Target PSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), based on the Company&#8217;s Absolute TSR over the four-year Performance Period and determined based on the table immediately below, subject to Holder&#8217;s continued service through the Certification Date (or the earlier Termination of Service date described in Section 2.4(b)(ii) or Change in Control date, as applicable).  In the event of a Change in Control or a Termination of Service described in Section 2.4(b)(ii), then the determination of the percentage of the Target PSUs eligible for vesting shall be calculated in accordance with the table immediately below, provided that the Regular Vesting Threshold and all other Performance Goal thresholds, which relate to a four-year Performance Period, shall be pro-rated based on compound annualized growth rates (CAGR) from the Base TSR Growth Rates provided in the below table, to correspond with the shortened Performance Period. Linear interpolation will be used to calculate actual awards for performance between the percentiles indicated below.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:0.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.660%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Cumulative Absolute TSR over the Performance Period</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Base TSR Growth rate</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-align:center;text-indent:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">% of Target PSUs Eligible for Vesting</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">22% (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Regular</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Vesting Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">50%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">34%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7.5%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">75%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">46%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">125%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">57%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">63%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">175%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">69%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">75%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">225%</font></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if the Company achieves an Absolute TSR over the three-year period beginning on &#91;GRANT DATE&#93; and ending on &#91;THIRD YEAR ANNIVERSARY&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Accelerated Performance Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;) of at least 16% (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:100%">Accelerated Vesting Threshold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221;), then the determination set forth in the paragraph and table above shall be disregarded and Holder instead shall be entitled to earn a number of shares of Common Stock underlying the corresponding PSUs (at a rate of one share for each underlying PSU), ranging from 0% to 225% of the Target PSUs, based on the Company&#8217;s Absolute TSR over the Accelerated Performance Period subject to Holder&#8217;s continued service through the Certification Date for such period.  Linear interpolation will be used to calculate actual awards for performance between the percentiles indicated below.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.516%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Cumulative Absolute TSR over the Three-Year Performance Period</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt;text-indent:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">% of Target PSUs Earned   </font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">50%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">24%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">75%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">33%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">100%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">37%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">125%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">40%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">150%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">44%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">175%</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">48%</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">200%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">52%</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">225%</font></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In addition, Holder shall have a one-time opportunity to be eligible to vest in 25% of the Target PSUs if and only if the Company&#8217;s cumulative Absolute TSR, for any period beginning on the Grant Date and ending on the last day of any fiscal quarter that ends during the Accelerated Performance Period, is greater than or equal to 33%.  In such an event, any such 25% of the Target PSUs shall vest on the earlier of (i) the Certification Date for the Accelerated Performance Period, irrespective of whether the Accelerated Vesting Threshold is achieved or not achieved, subject to Holder&#8217;s continued employment or services through such Certification Date, (ii) in the event of a Termination of Service described in Section 2.4(b)(ii), the date of such Termination of Service or (iii) a Change in Control, subject in each case to continued service through the applicable date. In the event that either the Accelerated Vesting Threshold or the Vesting Threshold is achieved, then the 25% of the Target PSUs eligible for vesting pursuant to this paragraph shall be part of, and not in addition to, the Target PSUs eligible for vesting in accordance with the applicable table above. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">In no event shall more than 225% of the Target PSUs be eligible for vesting.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:100%">Determination of Absolute TSR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Company&#8217;s Absolute TSR shall be determined by taking the closing per share price of the Company&#8217;s Common Stock on the Grant Date as the starting point for the Absolute TSR calculation.  The starting per share price will be compared to an ending per share price, which shall be the trailing 30-day average per share price of the Company&#8217;s Common Stock as of the end of the applicable Performance Period.  The calculation of Absolute TSR for the Company shall be based on the change in the per share price plus reinvested dividends over the applicable Performance Period.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Additionally, as set forth in, and pursuant to, Section 3.4 hereof, appropriate adjustments to Absolute TSR shall be made to take into account all stock dividends, stock splits, reverse stock splits and the other events set forth in Section 3.4 hereof that occur prior to the applicable Certification Date.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Compensation Certification</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The Compensation Committee shall certify in writing the extent to which the Performance Goals have been achieved, and the number of PSUs eligible for vesting based on the Performance Goals on the applicable Certification Date, which shall be as soon as practicable following the end of the applicable Performance Period, and in no event later than 90 days after the end of the applicable Performance Period.  Except in the event of the vesting of the PSUs upon a Termination of Service as provided in Section 2.4(b)(i) of the Agreement, no shares of Common Stock shall be delivered in respect of the PSUs prior to such written certification by the Compensation Committee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">Forfeiture of PSUs</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Any unvested PSUs which have are not eligible for vesting based on the Performance Goals (to the extent applicable) shall be automatically forfeited, terminated and cancelled effective as of the applicable Certification Date without the payment of any consideration by the Company, and Holder, or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Holder&#8217;s beneficiary or personal representative, as the case may be, shall have no further rights with respect to such PSUs under the Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>7
<FILENAME>ex1010-formofexecutiverest.htm
<DESCRIPTION>EX-10.10
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i1a3f804631d442a4b8bb44d532185b3b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 10.10</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">ResMed Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Summary for Restricted Stock Unit</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">Award Agreement</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">(Designated Executives)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;&#91;PARTICIPANT NAME&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;&#91;GRANT DATE&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Number of RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.&#160;&#160;&#160;&#160;&#91;TOTAL NUMBER OF RSUs GRANTED&#93;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">. &#160;&#160;&#160;&#160;Subject to the terms of the Agreement, including the terms requiring the satisfaction of a specified Performance Condition, the RSUs shall vest and become nonforfeitable in three equal installments on each of the first three anniversaries of the Grant Date, provided, however, that if the RSUs are granted as part of the Company&#8217;s annual grant, as determined by the Company in its sole discretion, the first installment shall vest on the first November 11 following the Grant Date with the remaining two installments vesting on the following two anniversaries of the first vesting date.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i1a3f804631d442a4b8bb44d532185b3b_47"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">RESMED INC. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">EXECUTIVE RESTRICTED STOCK UNIT AWARD AGREEMENT</font></div><div style="padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;This Executive Restricted Stock Unit Award Agreement, including any country-specific terms and conditions set forth in Appendix I hereto and the performance conditions set forth in Appendix II hereto (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), sets forth the terms and conditions of the restricted stock units (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">RSUs</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;) granted by ResMed Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), under the ResMed Inc. 2009 Incentive Award Plan, as amended from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), and pursuant to the Summary of Restricted Stock Unit Award Grant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Summary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;) displayed at the Web site of the Company&#8217;s plan administrator.  The Summary specifies the person to whom the RSUs are granted (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Holder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), the grant date of the RSUs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), the vesting schedule of the RSUs (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), the aggregate number of RSUs granted to Holder, and other specific details of the grant.  The Summary also indicates whether Holder has accepted the grant of RSUs.  The Summary is deemed part of this Agreement.</font></div><div style="padding-left:9pt;text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:232%">ARTICLE 1.<br>GENERAL</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Defined Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Capitalized terms not specifically defined herein shall have the meanings specified in the Plan and the Summary.  </font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">As used herein, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221; shall mean a &#8220;disability&#8221; as defined in Treasury Regulation Section 1.409A-3(i)(4).</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">As used herein, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Restricted Stock Unit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">RSU</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221; shall mean a non-voting unit of measurement which represents the right to receive one share of Common Stock for each unit that vests (subject to adjustment as provided in Section 11.3 of the Plan) solely for purposes of the Plan and this Agreement.  The RSUs shall be used solely as a device for the determination of the issuance of shares of Common Stock to eventually be made to Holder if and to the extent such RSUs vest pursuant to Section 2.2 hereof.  The RSUs shall not be treated as property or as a trust fund of any kind.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">As used herein, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221; shall mean a Termination of Service after (a) sixty (60) years of age and (b) completion of five (5) years of continuous service with the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">1.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Incorporation of Terms of Plan, Summary and Appendices I and II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The RSUs are subject to the terms and conditions of the Plan, the Summary, Appendix I hereto (which sets forth special and&#47;or additional legal requirements, terms and conditions as may be required by Holder&#8217;s country), and Appendix II hereto (which sets forth certain performance conditions applicable to the RSUs), each of which is incorporated herein by reference.  In the event of any inconsistency between the Plan and this Agreement, the terms of the Plan shall control.  To the extent applicable, in the event of any inconsistency between this Executive Restricted Stock Unit Award Agreement and Appendices I and II, the terms of Appendices I and II shall control.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:232%">ARTICLE 2.<br>GRANT OF RESTRICTED STOCK UNITS</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.1&#160;&#160;&#160;&#160;Grant of RSUs.  Effective as of the Grant Date, the Company grants to Holder an award of RSUs as set forth in the Summary, upon the terms and conditions set forth in the Summary, the Plan and this Agreement.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">RSUs subject to a Performance Condition&#59; Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Appendix II attached hereto sets forth a Performance Condition that must be satisfied in order for the RSUs to vest.  The Performance Condition is based on the Company&#8217;s financial performance compared to certain pre-established criteria over certain specified periods, as set forth on Appendix II.  The Compensation Committee shall certify in writing the extent to which the Performance Condition has been satisfied, with such certification occurring no later than the first November 11 following the Grant Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Certification Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;).  Except as set forth in Sections 2.2(c) and 2.2(d) hereof, any unvested RSUs for which the Performance Condition has not been satisfied shall be automatically forfeited, terminated and cancelled effective as of such Certification Date, without the payment of any consideration by the Company, and Holder, or Holder&#8217;s beneficiary or personal representative, as the case may be, shall have no further rights with respect to such RSUs under the Agreement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Subject to Sections 2.2(c), 2.2(d), 2.2(e) and 2.4 hereof, the RSUs awarded pursuant to the Summary and which have met the Performance Condition set forth in Appendix II will vest and become nonforfeitable with respect to the applicable portion thereof according to the Vesting Schedule set forth in the Summary, subject to Holder&#8217;s continued employment or services through the applicable vesting dates.  Unless otherwise determined by the Administrator and as otherwise provided in Section 2.2(e) hereof, partial employment or service, even if substantial, during any vesting period will not entitle Holder to any proportionate vesting or avoid or mitigate a termination of rights and benefits upon or following a Termination of Service as provided in Section 2.2 hereof or under the Plan.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Notwithstanding Sections 2.2(a) and 2.2(b) hereof, Appendix II and the Summary, the RSUs, to the extent then outstanding and not previously forfeited, shall become fully vested and nonforfeitable in the event of a Change in Control as of the date of such Change in Control,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">or if later, as of the date of Holder&#8217;s Separation from Service (as defined in the Executive Agreement), if either of the following occurs&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Holder provides Notice of Good Reason (as defined in the then-current &#8220;Executive Agreement&#8221; between the Company and Holder (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Executive Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;)) at any time during the six-month period prior to the date of a Change in Control, or during the twelve (12) month period commencing on the date of a Change in Control, and Holder has a Separation from Service by reason of Holder&#8217;s voluntary termination of employment for Good Reason (as defined in the Executive Agreement), or</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Holder has a Separation from Service reason by reason of the Company&#8217;s termination of Holder&#8217;s employment other than for Cause (as defined in the Executive Agreement) during the six-month period prior to the date of the Change in Control (and such termination is at the request of the successor entity of such Change in Control, or is otherwise made in anticipation of the Change in Control), or during the twelve (12) month period commencing on the date of the Change in Control.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Notwithstanding Sections 2.2(a) and 2.2(b) hereof, Appendix II and the Summary, if Holder dies or has a Termination of Service due to Disability while employed by, or serving as a Director or Consultant of, the Company or a Subsidiary, as applicable, the unvested RSUs shall become fully vested and nonforfeitable as of the date of such Holder&#8217;s death or Termination of Service due to Disability, as applicable.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Notwithstanding Section 2.2(b) hereof and the Summary, if Holder has a Termination of Service due to Retirement, then to the extent that the Performance Condition is met, a pro-rata portion of the unvested RSUs shall become vested and nonforfeitable as of the later of the date of such Holder&#8217;s Termination of Service due to Retirement and the first scheduled vesting date that occurs on or after the Certification Date (and such applicable date shall be considered a vesting date for purposes of this Agreement).  The number of the RSUs that will vest pursuant to this Section 2.2(e) will be determined by (i) dividing the number of days Holder was continuously </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">employed or rendering services during the vesting period prior to the termination date by the total number of days of the vesting period (as measured from the Grant Date to the final vesting date of the RSUs), and multiplying the result of such division by the aggregate number of RSUs determined to be eligible for vesting as of the Certification Date and (ii) subtracting from the result in 2.2(e)(i) any RSUs that previously vested pursuant to the Vesting Schedule.  Such pro-rata portion of the RSUs will be rounded down to the nearest whole share.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if the Company receives an opinion of counsel that there has been a legal judgment and&#47;or legal development in Holder&#8217;s jurisdiction that likely would result in the favorable Retirement treatment that otherwise would apply to the RSUs pursuant to this Section 2.2(e) being deemed unlawful and&#47;or discriminatory, then the Company will not apply this favorable Retirement treatment at the time of Holder&#8217;s Termination of Service and the RSUs will be treated as they would under the rules that otherwise would have applied if Holder&#8217;s Termination of Service did not qualify as a Retirement.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">No Right to Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Nothing in the Plan or this Agreement, nor Holder&#8217;s participation in the Plan, shall confer upon Holder any right to continue in the employ or service of the Company or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and any Subsidiary, which rights are hereby expressly reserved, to discharge or terminate the services of Holder at any time for any reason whatsoever, with or without cause, except to the extent expressly provided otherwise in a written agreement between the Company or a Subsidiary and Holder.  In the event that Holder is not an Employee, Director or Consultant of the Company, the grant will not be interpreted to form an employment or service contract with the Company.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Forfeiture, Termination and Cancellation upon Termination of Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Notwithstanding any contrary provision of this Agreement, upon Holder&#8217;s Termination of Service for any or no reason (other than Holder&#8217;s death or Termination of Service due to Disability, Retirement or in connection with a Change in Control as provided in Section 2.2(c)), all then unvested RSUs subject to this Agreement (including, without limitation, RSUs that have been earned in accordance with Appendix II) will thereupon be automatically forfeited, terminated and cancelled as of the applicable termination date without payment of any consideration by the Company, and Holder, or Holder&#8217;s beneficiary or personal representative, as the case may be, shall have no further rights hereunder.  For purposes of this Agreement, the employment relationship of Holder will be treated as continuing intact while he or she is on military or sick leave or other bona fide leave of absence if such leave does not exceed ninety days, provided, however, that the period of the leave may exceed ninety days so long as Holder&#8217;s right to re-employment is guaranteed either by statute or by contract, or in any other circumstance as may be required by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">For purposes of this Agreement, Holder&#8217;s Termination of Service is deemed to occur as of the date Holder is no longer actively providing services to the Company or a Subsidiary (regardless of the reason for such termination and whether or not later to be found invalid or in breach of applicable laws in the jurisdiction where Holder is employed or rendering services or the terms of Holder&#8217;s employment or service agreement, if any) and, unless otherwise provided in Sections 2.2(c), (d) and (e) hereof, Holder&#8217;s right to vest in the RSUs, if any, will terminate as of such date and will not be extended by any notice period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">g</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">., Holder&#8217;s period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under applicable laws in the jurisdiction where Holder is employed or providing services or the terms of Holder&#8217;s employment or service contract, if any).  The Administrator shall have the exclusive discretion to determine when Holder&#8217;s Termination of Service for purposes of the RSUs has occurred (including whether Holder may still be considered to be providing services while on a leave of absence).</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Issuance of Shares upon Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Subject to Appendix II, as soon as administratively practicable following the vesting of any RSUs pursuant to Section 2.2 hereof, but in no event later than sixty (60) days after such vesting date, the Company shall deliver to Holder (or any transferee permitted under Section </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.2 hereof) a number of shares of Common Stock equal to the number of such RSUs that vested on the applicable vesting date, less to the extent applicable, the number of shares of Common Stock withheld in accordance with Section 2.6(b).  The shares of Common Stock delivered hereby shall be represented either by one or more stock certificates or by book entry, as determined by the Company in its sole discretion.  Notwithstanding the foregoing&#58; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">in the event shares of Common Stock cannot be issued in the time frame specified above due to the effects of Sections 2.7(a), (b) or (c) hereof, then the shares of Common Stock shall be issued as soon as administratively practicable after the Administrator determines that shares of Common Stock can again be issued in accordance with Sections 2.7(a), (b) and (c) hereof, subject to compliance with Section 409A (as defined in Section 3.13 below)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">if the RSUs constitute &#8220;nonqualified deferred compensation&#8221; subject to Section 409A and Holder is subject to U.S. federal taxation, then&#58; (i) any RSUs that vest on a scheduled vesting date will be settled by the end of the calendar year of vesting&#59; (ii) to the extent that the RSUs vest upon a Change in Control under Section 2.2(c) and such event is not a &#8220;change in control event&#8221; within the meaning of Section 409A, any settlement of RSUs due upon such Change in Control shall instead be made on the originally scheduled vesting dates for such RSUs (as specified in the Vesting Schedule) that occur subsequent to the date of the Change in Control&#59; and (iii) to the extent that the RSUs vest upon Holder&#8217;s Termination of Service, the RSUs shall be paid on the date on which Holder experiences a &#8220;separation from service&#8221; within the meaning of Section 409A, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">if Holder is a &#8220;specified employee&#8221; within the meaning of Section 409A as of the date of Holder&#8217;s separation from service, Holder&#8217;s vested RSUs shall instead be settled during the thirty (30) day period commencing on the earlier of (A) the expiration of the six (6) month period measured from the date of Holder&#8217;s separation from service or (B) the date of Holder&#8217;s death, to the extent that such delayed payment is required to avoid a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code, or any successor provision thereto.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Responsibility for Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Regardless of any action the Company or, if different, the Subsidiary employing Holder or for which Holder otherwise provides services (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Employer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;) takes with respect to any or all income tax, social insurance, payroll tax, fringe benefit tax, payment on account or other tax-related items related to Holder&#8217;s participation in the Plan and legally applicable or deemed legally applicable to Holder (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Tax-Related Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;), Holder acknowledges that the ultimate liability for all Tax-Related Items is and remains Holder&#8217;s responsibility and may exceed the amount, if any, actually withheld by the Company or the Employer.  Holder further acknowledges that the Company and&#47;or the Employer (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the RSUs, including, but not limited to the grant of the RSUs, the vesting or settlement of the RSUs, the issuance of shares of Common Stock in settlement of the RSUs, the subsequent sale of the shares of Common Stock acquired at vesting and the receipt of any dividends&#59; and (ii) do not commit to and are under no obligation to structure the terms of the Award or any aspect of the RSUs to reduce or eliminate Holder&#8217;s liability for Tax-Related Items or achieve any particular tax result.  Furthermore, if Holder is subject to tax in more than one jurisdiction, Holder acknowledges that the Company and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">In connection with any relevant taxable or tax withholding event, as applicable, Holder must pay or make adequate arrangements satisfactory to the Company and&#47;or the Employer to satisfy all Tax-Related Items. In this regard, Holder hereby authorizes the Company and&#47;or the Employer, or their respective agents, in their sole discretion and without any notice to or additional authorization by Holder, to satisfy their withholding obligations, if any, with regard to all Tax-Related Items by one or a combination of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">withholding from Holder&#8217;s compensation or other wages payable to Holder by the Company, the Employer and&#47;or any other Subsidiary&#59;</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">causing Holder to tender a cash payment (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">i.e</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">., check or bank wire)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">withholding from the proceeds of the sale of shares of Common Stock issued upon vesting, either through a voluntary sale or through a mandatory sale arranged by the Company (on Holder&#8217;s behalf pursuant to this authorization)&#59;</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">withholding shares of Common Stock otherwise to be issued upon vesting&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">or</font></div><div style="margin-bottom:12pt;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">any other method determined by the Company, to the extent permitted under the Plan and applicable laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> that if Holder is a Section 16 officer of the Company under the Exchange Act, then the Company will withhold shares of Common Stock upon the relevant taxable or tax withholding event, as applicable, unless the use of such withholding method is not feasible under applicable tax or securities law or has materially adverse accounting consequences, in which case, the obligation for Tax-Related Items may be satisfied by one or a combination of methods (i)-(iii) or (v) above.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Further, notwithstanding anything herein to the contrary, the Company may cause a portion of the RSUs to vest prior to the dates set forth in the Vesting Schedule in order to satisfy any Tax-Related Items that arise prior to the date of settlement of the RSUs&#59; provided that to the extent necessary to avoid a prohibited distribution under Section 409A, the number of RSUs so accelerated and settled shall be with respect to a number of shares of Common Stock with a value that does not exceed the liability for the Tax-Related Items.</font></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">The Company may withhold or account for Tax-Related Items by considering statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in Holder&#8217;s jurisdiction(s) (to the extent permitted by the Plan).  In the event of over-withholding, Holder may receive a refund of any over-withheld amount in cash (with no entitlement to the Common Stock equivalent), or, if not refunded, Holder may be able to seek a refund from the applicable tax authorities.  In the event of under-withholding, Holder may be required to pay additional Tax-Related Items directly to the applicable tax authorities or to the Company and&#47;or the Employer.  If the obligation for Tax-Related Items is satisfied by withholding shares of Common Stock, for tax purposes, Holder will be deemed to have been issued the full number of shares of Common Stock subject to the vested RSUs, notwithstanding that a number of the shares of Common Stock is held back solely for the purpose of paying the Tax-Related Items.</font></div><div style="margin-top:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Holder agrees to pay to the Company and&#47;or the Employer any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of Holder&#8217;s participation in the Plan that cannot be satisfied by the means previously described.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">The Company shall not be obligated to deliver any new certificate representing shares of Common Stock to Holder or Holder&#8217;s legal representative or enter such shares of Common Stock in book entry form unless and until Holder or Holder&#8217;s legal representative shall have paid or otherwise satisfied Holder&#8217;s obligations in connection with the Tax-Related Items resulting from the RSUs or the shares of Common Stock subject to the RSUs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Conditions to Delivery of Common Stock&#59; Legal Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The shares of Common Stock deliverable hereunder, or any portion thereof, may be either previously authorized but unissued shares of Common Stock or issued shares of Common Stock which have then been reacquired by the Company.  Such shares of Common Stock shall be fully paid and nonassessable.  The Company shall not be required to issue or deliver any shares of Common Stock deliverable hereunder or portion thereof prior to fulfillment of all of the following conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">The admission of such shares of Common Stock to listing on all stock exchanges on which such Common Stock is then listed&#59; </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">The completion and maintenance of any registration or other qualification of such shares of Common Stock under any U.S. and non-U.S. state or federal law or under rulings or regulations of the U.S. Securities and Exchange Commission or of any other governmental regulatory body, which the Administrator shall, in its absolute discretion, deem necessary or advisable&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">The obtaining of any approval or other clearance from any U.S. or non-U.S. state or federal governmental agency which the Administrator shall, in its absolute discretion, determine to be necessary or advisable&#59; and</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">The lapse of such reasonable period of time following the vesting of any RSUs as the Administrator may from time to time establish for reasons of administrative convenience.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">2.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Rights as Stockholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Holder shall not be, nor have any of the rights or privileges of, a stockholder of the Company, including, without limitation, voting rights and rights to dividends, in respect of the RSUs and any shares of Common Stock underlying the RSUs and deliverable hereunder unless and until such shares of Common Stock shall have been issued by the Company and held of record by such Holder (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company).  No adjustment will be made for a dividend or other right for which the record date is prior to the date the shares of Common Stock are issued, except as provided in Section 11.3 of the Plan.  No Dividend Equivalent awards shall be awarded in respect of any unvested RSUs.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">ARTICLE 3.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">OTHER PROVISIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Administrator shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret, amend or revoke any such rules.  All actions taken and all interpretations and determinations made by the Administrator in good faith shall be final and binding upon Holder, the Company and all other interested persons.  No member of the Committee or the Board shall be personally liable for any action, determination or interpretation made in good faith with respect to the Plan, this Agreement or the RSUs.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.2 &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Grant is Not Transferable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Except as set forth in Section 3.2(b), during the lifetime of Holder, the RSUs may not be sold, pledged, assigned or transferred in any manner other than by will or the laws of descent and distribution, unless and until the shares of Common Stock underlying the vested RSUs have been issued.  Neither the RSUs nor any interest or right therein shall be liable for the debts, contracts or engagements of Holder or his or her successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect, except to the extent that such disposition is permitted by the preceding sentence.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Notwithstanding the foregoing provisions of subsection 3.2(a), for Holders who are exclusively subject to the laws of the United States, the Administrator, in its sole discretion, may permit the transfer of RSUs held by Holder (i) pursuant to a DRO, or (ii) by gift or contribution to a Permitted Transferee.  Any RSU that has been so transferred shall continue to be subject to all of the terms and conditions as applicable to the original Holder, and the transferee shall execute any and all such documents requested by the Administrator in connection with the transfer, including, without limitation, to evidence the transfer and to satisfy any requirements for an exemption for the transfer under applicable federal and state securities laws.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Binding Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Subject to the limitation on the transferability of the RSUs contained herein, this Agreement will be binding upon and inure to the benefit of the heirs, legatees, legal representatives, successors and assigns of the parties hereto.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Adjustments Upon Specified Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Administrator may accelerate the vesting of the RSUs and the issuance of shares of Common Stock with respect to vested RSUs in such circumstances as it, in its sole discretion, may determine&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">, that if the RSUs constitute &#8220;nonqualified deferred compensation&#8221; subject to Section 409A and Holder is subject to U.S. federal taxation, no acceleration of the issuance of the shares of Common Stock may occur other than as expressly permitted under Section 409A.  In addition, upon the occurrence of certain events relating to the Common Stock contemplated by Section 11.3 of the Plan, the Administrator shall make any appropriate adjustments in the number of RSUs then outstanding and the number and kind of securities that may be issued in respect of the RSUs.  Holder acknowledges that the RSUs are subject to amendment, modification and termination in certain events as provided in this Agreement and Section 11.3 of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.5&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  All notices required or permitted hereunder shall be in writing and shall be deemed to be properly given when personally delivered to the party entitled to receive the notice (which may include electronic delivery by email) or when sent by certified or registered mail, postage prepaid, properly addressed to the party entitled to receive such notice at the address stated below&#58;</font></div><div style="margin-bottom:0.12pt;text-align:center;text-indent:0.36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.820%"><tr><td style="width:1.0%"></td><td style="width:23.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.630%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">If to Company&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">ResMed Inc.<br>9001 Spectrum Center Blvd. <br>San Diego, CA 92123<br>USA<br>Attn&#58; David Pendarvis, Corporate Secretary</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">If to Holder&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Address of the Holder on file with ResMed Inc. or its Subsidiary</font></td></tr></table></div><div style="margin-bottom:0.12pt;text-align:justify;text-indent:0.36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.6&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Titles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.7&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Governing Law &#47; Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The laws of the State of Delaware shall govern the interpretation, validity, administration, enforcement and performance of the terms of this Agreement regardless of the law that might be applied under principles of conflicts of laws.  For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Award of RSUs or this Agreement, the parties hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that such litigation shall be conducted only in the courts of San Diego County, California, or the federal courts for the United States for the Southern District of California and no other courts, where this grant is made and&#47;or to be performed.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.8&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Conformity to Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Holder acknowledges that the Plan and this Agreement are intended to conform to the extent necessary with all provisions of the Securities Act and the Exchange Act and any and all regulations and rules promulgated by the U.S. Securities and Exchange Commission thereunder, and other U.S. or non-U.S. state and federal securities laws and regulations, as well as any other applicable U.S. or non-U.S. state and federal laws and regulations.  Notwithstanding anything herein to the contrary, the Plan shall be administered, and the RSUs are granted, only in such a manner as to conform to such laws, rules and regulations.  To the extent permitted by applicable law, the Plan and this Agreement shall be deemed amended to the extent necessary to conform to such laws, rules and regulations.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.9&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Amendments, Suspension and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  To the extent permitted by the Plan, this Agreement may be wholly or partially amended or otherwise modified, suspended or terminated at any time or from time to time by the Committee or the Board&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> that, except as may otherwise be provided by the Plan and subject to Section 3.8, Section 3.11, Section 3.13 and Section </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.21 hereof, no amendment, modification, suspension or termination of this Agreement shall adversely affect the RSUs in any material way without the prior written consent of Holder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.10&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Company may assign any of its rights under this Agreement to single or multiple assignees, and this Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth in Section 3.2 hereof, this Agreement shall be binding upon Holder and his or her heirs, executors, administrators, successors and assigns.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.11&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Limitations Applicable to Section 16 Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Notwithstanding any other provision of the Plan or this Agreement, if Holder is subject to Section 16 of the Exchange Act, the Plan, the RSUs and this Agreement shall be subject to any additional limitations set forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange Act) that are requirements for the application of such exemptive rule.  To the extent permitted by applicable law, this Agreement shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.12&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Plan, the Summary and this Agreement constitute the entire agreement of the parties and supersede in their entirety all prior undertakings and agreements of the Company and Holder with respect to the subject matter hereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.13&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The parties intend that this Agreement and the benefits provided hereunder be exempt from the requirements of Section 409A of the Code (together with any Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the date hereof, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;) to the maximum extent possible, whether pursuant to the short-term deferral exception described in Treasury Regulation Section 1.409A-1(b)(4) or otherwise.  However, to the extent that the RSUs (or any portion thereof) may be subject to Section 409A, the parties intend that this Agreement and such benefits comply with the deferral, payout, and other limitations and restrictions imposed under Section 409A and this Agreement shall be interpreted, operated and administered in a manner consistent with such intent.  Notwithstanding any other provision of the Plan, the Summary or this Agreement, the Administrator shall have the right in its sole discretion (without any obligation to do so or to indemnify Holder or any other person for failure to do so) to adopt such amendments to the Plan, the Summary or this Agreement, or adopt other policies and procedures (including amendments, policies and procedures with retroactive effect), or take any other actions, as the Administrator determines are necessary or appropriate either for the RSUs to be exempt from the application of Section 409A or to comply with the requirements of Section 409A.  Nothing in this Agreement, the Plan or the Summary shall provide a basis for any person to take action against the Company or any Subsidiary based on matters covered by Section 409A of the Code, including the tax treatment of any amount paid or RSUs granted under this Agreement, and neither the Company nor any of its Subsidiaries shall under any circumstances have any liability to Holder or his or her estate or any other party for any taxes, penalties or interest due on amounts paid or payable under this Agreement, including taxes, penalties or interest imposed under Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.14&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Limitation on Holder&#8217;s Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Participation in the Plan confers no rights or interests other than as herein provided.  This Agreement creates only a contractual obligation on the part of the Company as to amounts payable and shall not be construed as creating a trust.  Neither the Plan nor any underlying program, in and of itself, has any assets.  Unless and until the RSUs will have vested in the manner set forth in Article 2 hereof, Holder will have no right to the issuance of shares of Common Stock with respect to the RSUs.  Holder shall have only the rights of a general unsecured creditor of the Company with respect to amounts credited and benefits payable, if any, with respect to the RSUs, and rights no greater than the right to receive the Common Stock as a general unsecured creditor with respect to RSUs, as and when payable hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.15&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Holder acknowledges that he or she is proficient in the English language and understands the provisions in this Agreement and the Plan or has had the ability to consult with an advisor who is sufficiently proficient in the English language.  Further in the event </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Holder has received this Agreement, including Appendix I hereto (if any), or any other document related to the Plan translated into a language other than English, the English version will control to the extent the meaning of the translated version differs from the English version.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.16&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Electronic Delivery and Acceptance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Company may, in its sole discretion, decide (a) to deliver by electronic means any documents related to the RSUs granted under the Plan, Holder&#8217;s participation in the Plan, or future awards that may be granted under the Plan or (b) to request by electronic means Holder&#8217;s consent to participate in the Plan.  Holder hereby consents to receive such documents by electronic delivery and, if requested, to agree to participate in the Plan through an online or electronic system established and maintained by the Company or any third party designated by the Company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.17&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  By accepting the RSUs, Holder acknowledges, understands and agrees that&#58; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">the grant of RSUs is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted in the past&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">all decisions with respect to future awards of RSUs or other grants, if any, will be at the sole discretion of the Company&#59; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Holder is voluntarily participating in the Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">the RSUs and the shares of Common Stock subject to the RSUs, and the income from and value of same, are not intended to replace any pension rights or compensation&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">the RSUs and the shares of Common Stock subject to the RSUs, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose, including (without limitation) calculating any severance, resignation, redundancy or end of service payments, bonuses, long-service awards, holiday pay, pension or retirement or welfare benefits or similar payments&#59; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">no claim or entitlement to compensation or damages shall arise from termination of the RSUs resulting from a Termination of Service (for any reason whatsoever, whether or not later to be found invalid or in breach of employment laws in the jurisdiction where Holder is employed or rendering services or the terms of Holder&#8217;s employment or service agreement, if any)&#59;</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">unless otherwise agreed with the Company, the RSUs and the shares of Common Stock subject to the RSUs, and the income from and value of same, are not granted as consideration for, or in connection with, the service Holder may provide as a director of a Subsidiary&#59; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">the Company is not providing any tax, legal or financial advice with respect to the RSUs, nor is the Company making any recommendations regarding Holder&#8217;s participation in the Plan, or Holder&#8217;s acquisition or sale of the underlying shares of Common Stock&#59; </font></div><div style="margin-bottom:12pt;padding-left:9pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Holder should consult with his or her own personal tax, legal and financial advisors regarding Holder&#8217;s participation in the Plan before taking any action related to the Plan and the RSUs&#59; and</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">the following provisions apply only if Holder is providing services outside the United States&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;the RSUs and the shares of Common Stock subject to the RSUs, and the income from and value of same, are not part of normal or expected compensation or salary for any purpose&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:117pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">(2) neither the Company, the Employer nor any other Subsidiary shall be liable for any foreign exchange rate fluctuation between Holder&#8217;s local currency and the United States Dollar that may affect the value of the RSUs or of any amounts due to Holder pursuant to the settlement of the RSUs or the subsequent sale of any shares of Common Stock acquired upon settlement.</font></div><div style="margin-bottom:12pt;padding-left:45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.18&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Declaration of Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  Holder is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data (as defined below) by the Company and the transfer of Data to the recipients mentioned below, including recipients located in countries which may not have a similar level of protection from the perspective of the data protection laws in Holder&#8217;s country.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Collection and Usage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  The Company and the Employer collect, process and use certain personal information about Holder, including, but not limited to, Holder&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any shares or directorships held in the Company, details of all RSUs under the Plan or any other entitlement to shares awarded, canceled, exercised, vested, unvested or outstanding in Holder&#8217;s favor (&#8220;Data&#8221;), for the purposes of managing Holder&#8217;s participation in the Plan.  The legal basis, where required, for the processing of Data is Holder&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Stock Plan Administration Service Providers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  The Company transfers Data, or parts thereof, to Fidelity Stock Plan Services, LLC and certain of its affiliated companies (&#34;Fidelity&#34;), which assists the Company with the implementation, administration and management of the Plan.  Holder acknowledges and understands that Fidelity will open an account for Holder to receive and trade shares of Common Stock acquired under the Plan and that Holder will be asked to agree on separate terms and data processing practices with Fidelity, which is a condition of Holder&#8217;s ability to participate in the Plan.  In the future, the Company may select a different service provider and may share Data with such different service provider that serves in a similar manner.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">International Data Transfers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  The Company and Fidelity are based in the United States.  Holder understands that his or her country may have enacted data privacy laws that are different from the laws of the United States.  As a result, in the absence of appropriate safeguards such as standard data protection clauses, the processing of Holder&#8217;s Data in the United States or, as the case may be, other countries might not be subject to substantive data processing principles or supervision by data protection authorities.  In addition, Holder might not have enforceable rights regarding the processing of his or her Data in such countries.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">The Company provides appropriate safeguards for protecting Data that it receives in the United States through its adherence to data transfer agreements entered into between the Company and Subsidiaries within the European Union.  Otherwise, where required, the Company&#8217;s legal basis for the transfer of Data is Holder&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Retention</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  The Company will hold and use the Data only as long as is necessary to implement, administer and manage Holder&#8217;s participation in the Plan, or as required to comply with applicable law, exercise or defense of legal rights, and archiving, back-up </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">and deletion processes.  This means Data may be retained even after Holder&#8217;s Termination of Service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(f)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Voluntariness and Consequences of Consent Denial or Withdrawal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  Participation in the Plan is voluntary and Holder is providing the consents herein on a purely voluntary basis.  Holder understands that he or she may withdraw consent at any time with future effect for any or no reason.  If Holder does not consent, or if Holder later seeks to revoke his or her consent, Holder&#8217;s employment or service with the Employer will not be affected&#59; the only consequence of refusing or withdrawing consent is that the Company would not be able to offer RSUs or other awards to Holder or administer or maintain Holder&#8217;s participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">(g)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Data Subject Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">.  Holder understands that data subject rights vary depending on applicable law and that, depending on where Holder is based and subject to the conditions under applicable law, Holder may have, without limitation, the rights to (i) request access or copies of Data the Company processes, (ii) rectification of incorrect Data, (iii) deletion of Data, (iv) restrictions on processing of Data, (v) portability of Data, (vi) lodge complaints with competent authorities in Holder&#8217;s jurisdiction, and&#47;or (vii) receive a list with the names and addresses of any potential recipients of Data.  To receive clarification regarding these rights or to exercise these rights, Holder understands that he or she can contact Holder&#8217;s local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.19&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Participants Outside of the United States</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Notwithstanding any provisions in this Agreement, the RSUs shall be subject to any additional terms and conditions set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> hereto for Holder&#8217;s country.  Moreover, if Holder relocates to one of the countries included in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> (if any), the terms and conditions for such country will apply to Holder, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The terms included in Appendix I constitute part of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.20&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">. The provisions of this Agreement are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.21&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Imposition of Other Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">. The Company reserves the right to impose other requirements on Holder&#8217;s participation in the Plan, on the RSUs or any shares of Common Stock acquired under the Plan, to the extent the Company determines it is necessary or advisable or legal or administrative reasons, and to require Holder to sign any additional agreements or undertakings that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.22&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Holder acknowledges that a waiver by the Company of breach of any provision of this Agreement shall not operate or be construed as a waiver of any other provision of this Agreement, or of any subsequent breach by Holder or any other Holder. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.23&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Insider Trading&#47;Market Abuse Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Holder acknowledges that, depending on Holder&#8217;s country, the broker&#8217;s country, or the country in which shares of Common Stock are listed, Holder may be subject to insider trading restrictions and&#47;or market abuse laws, which may affect Holder&#8217;s ability to accept, acquire, sell or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (e.g., RSUs) or rights linked to the value of shares of Common Stock during such times as Holder is considered to have &#8220;inside information&#8221; regarding the Company (as defined by the laws or regulations in the relevant jurisdiction).  Further, Holder understands that local insider trading laws and regulations prohibit the cancellation or amendment of orders Holder may have placed before processing insider information.  Holder also understands that he or she may be prohibited from (i) disclosing inside information to any third party, including fellow employees (other than on a &#8220;need to know&#8221; basis), and (ii) &#8220;tipping&#8221; third parties by sharing inside information with them, or otherwise causing third parties to buy or sell Company securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under any applicable insider trading policy of the Company.  Holder is responsible for </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">complying with any applicable restrictions, and Holder should consult with his or her personal legal and financial advisors on this matter before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">3.24&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Foreign Assets&#47;Account and Tax Reporting, Exchange Controls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Holder&#8217;s country may have certain foreign asset, account and&#47;or tax reporting requirements and exchange controls which may affect Holder&#8217;s ability to acquire or hold shares of Common Stock under the Plan or cash received from participating in the Plan (including from any dividends received or sale proceeds arising from the sale of shares of Common Stock) in a brokerage or bank account outside Holder&#8217;s country.  Holder understands that he or she may be required to report such accounts, assets or transactions to the tax or other authorities in Holder&#8217;s country.  Holder also may be required to repatriate sale proceeds or other funds received as a result of participation in the Plan to his or her country through a designated bank or broker and&#47;or within a certain time after receipt.  In addition, Holder may be subject to tax payment and&#47;or reporting obligations in connection with any income realized under the Plan and&#47;or from the sale of shares of Common Stock.  Holder acknowledges that he or she is responsible for complying with all such requirements, and that Holder should consult personal legal and tax advisors, as applicable, to ensure compliance. </font></div><div style="margin-bottom:12pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Remainder of this page intentionally left blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#93;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the parties hereunto agree to the terms and conditions set forth in this Agreement and the Summary. </font></div><div style="text-indent:36pt"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">RESMED INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">HOLDER</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;text-decoration:underline">&#47;s&#47; Michael J. Farrell</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Michael J. Farrell</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(Acceptance designated electronically at the plan administrator's Web site)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX I</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Certain capitalized terms used but not defined in this Appendix I have the meanings set forth in the Plan, the Agreement and&#47;or the Summary.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">This Appendix I includes special and&#47;or additional terms and conditions that govern the RSUs granted to Holder under the Plan if Holder resides and&#47;or works in one of the countries listed below.  These terms and conditions are in addition to or, if so indicated, in place of, the terms and conditions set forth in the Agreement.  If Holder is a citizen or resident of a country other than the one in which he or she is currently residing and&#47;or working, transfers residency and&#47;or employment to another country after the grant of RSUs, or is considered resident of another country for local law purposes, the Administrator shall, in its discretion, determine to what extent the terms and conditions contained herein shall be applicable to Holder.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Notifications </font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">This Appendix I also includes information regarding tax, securities law, exchange controls and certain other issues of which Holder should be aware with respect to Holder&#8217;s participation in the Plan.  The information is based on the securities, exchange control and other laws in effect in the respective countries as of November 2021.  Such laws are often complex and change frequently.  As a result, the Company strongly recommends that Holder not rely on the information in this Appendix I as the only source of information relating to the consequences of Holder&#8217;s participation in the Plan because the information may be out of date at the time that the RSUs vest or shares of Common Stock acquired under the Plan are sold.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">In addition, the information contained herein is general in nature and may not apply to Holder&#8217;s particular situation and the Company is not in a position to assure Holder of any particular result.  Accordingly, Holder should seek appropriate professional advice as to how the relevant laws in his or her country may apply to Holder&#8217;s situation.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Finally, if Holder is a citizen or resident of a country other than the one in which he or she is currently residing and&#47;or working, transfers residency and&#47;or employment to another country after the grant of RSUs, or is considered a resident of another country for local law purposes, the information contained herein may not be applicable to Holder in the same manner.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Australia</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Australian Offer Document</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The offering of the Plan in Australia is intended to qualify for exemption from the prospectus requirements under Class Order 14&#47;1000 issued by the Australian Securities and Investments Commission.  Holder&#8217;s participation in the Plan is subject to the terms and conditions set forth in the Australian Offer Document, the Plan and the Agreement.</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;padding-right:-1.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Exchange control reporting is required for cash transactions exceeding AUD 10,000 and for international fund transfers, including for the remittance of proceeds related to the sale of shares of Common Stock acquired under the Plan and&#47;or dividends paid on such shares.  If an Australian bank is assisting with the transaction, then the bank will file the required exchange control report on Holder&#8217;s behalf.  If no Australian bank is assisting with the transaction, then Holder will have to file the required exchange control report.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Tax Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Plan is a plan to which Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies (subject to the conditions in the Act).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Germany</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Control Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  Cross-border payments in excess of &#8364;12,500 in connection with the sale of securities (including shares of Common Stock acquired under the Plan and&#47;or dividends) must be reported on a monthly basis to the German Federal Bank (Bundesbank).  If Holder receives a payment in excess of this amount, Holder must report the payment to Bundesbank electronically by the fifth day of the month following the month in which the payment was received.  The form of the report (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Allgemeine Meldeportal Statistik</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;) can be accessed via the Bundesbank&#8217;s website (www.bundesbank.de) and is available in both German and English.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Singapore</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Terms and Conditions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Sale of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  For any shares of Common Stock that are issued within six months of the Grant Date, Holder agrees that he or she will not dispose of the shares of Common Stock acquired prior to the six-month anniversary of the Grant Date, unless such sale or offer in Singapore is made pursuant to the exemptions under Part XIII Division (1) Subdivision (4) (other than section 280) of the of the Singapore Securities and Futures Act (Chapter 289, 2006 Ed.) (&#8220;SFA&#8221;), or any other applicable provisions of the SFA.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:400;line-height:100%">Notifications</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Securities Law Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">.  The offer of the Plan is being made pursuant to the &#8220; Qualifying Person&#8221;  exemption under section 273(1)(f) of SFA  and not with a view to the RSUs or shares of Common Stock being subsequently offered for sale to another party.  The Plan has not been lodged or registered as a prospectus with the Monetary Authority of Singapore.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Director Notification Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The directors, associate directors and shadow directors of a Singapore Subsidiary are subject to certain notification requirements under the Singapore Companies Act.  The directors, associate directors and shadow directors must notify the Singapore Subsidiary in writing of an interest (e.g., RSUs, shares of Common Stock, etc.) in the Company or any related company within two (2) business days of (i) its acquisition or disposal, (ii) any change in a previously disclosed interest (e.g. when shares of Common Stock are sold), or (iii) becoming a director, associate director or shadow director.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">16</font></div></div></div><div id="i1a3f804631d442a4b8bb44d532185b3b_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">APPENDIX II</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">This Appendix II sets forth the performance goals (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Performance Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%">&#8221;) for the RSUs and shall determine the extent to which the Performance Goals are achieved and the extent to which the RSUs will vest.  The RSUs shall be subject to the Performance Condition and shall be eligible for vesting to the extent the Performance Condition is satisfied, and shall be forfeited to the extent the Performance Condition is not satisfied, as determined below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Performance Goals</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">The Performance Goals shall be based on&#58; (i) the Company&#8217;s net profit after tax as a percentage of revenue (proforma) for the third fiscal quarter (&#8220;3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter&#8221;) of the Company&#8217;s fiscal year in which the Grant Date occurs, (ii) the Company&#8217;s net profit after tax as a percentage of revenue (proforma) for the Company&#8217;s fourth fiscal quarter (4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter&#8221;) of the Company&#8217;s fiscal year in which the Grant Date occurs, and (iii) the cumulative net profit after tax as a percentage of cumulative revenue (proforma) for the 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter and the 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline"> Quarter Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter Performance Goal is net profit after tax for the 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter, as a percentage of revenue for the 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter, of 50% or more. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-4.02pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline"> Quarter Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter Performance Goal is net profit after tax for the 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter, as a percentage of revenue for the 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter, of 50% or more.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Cumulative Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  The Cumulative Performance Goal is cumulative net profit after tax for the 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter and the 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter, as a percentage of the cumulative revenue (proforma) for the 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter and the 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter, of 50% or more.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Performance Condition</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">The performance condition (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-style:italic;font-weight:700;line-height:100%">Performance Condition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">&#8221;) shall be satisfied with respect to all or a portion of the RSUs, as determined below.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline"> Quarter Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  If the 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter Performance Goal is achieved, the Performance Condition shall be satisfied with respect to 50% of the RSUs. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-4.02pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline"> Quarter Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  If the 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter Performance Goal is achieved, the Performance Condition shall be satisfied with respect to 50% of the RSUs (which shall be in addition to any RSUs for which the Performance Condition has been satisfied upon the achievement of the 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.47pt;font-weight:400;line-height:100%;position:relative;top:-4.02pt;vertical-align:baseline">rd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%"> Quarter Performance Goal).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%;text-decoration:underline">Cumulative Performance Goal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">.  If the Cumulative Performance Goal is achieved, the Performance Condition shall be satisfied with respect to 100% of the RSUs.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">In no event shall the Performance Condition be treated as satisfied for more than 100% of the RSUs.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Compensation Certification</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">The Compensation Committee shall certify in writing whether the Performance Goals have been achieved, and the RSUs for which the Performance Condition has been satisfied, not later than the first November 11 following the Grant Date.  Except in the event of the vesting of the RSUs upon or in connection with a Change in Control as provided in Section 2.2(c) of the Agreement or Holder&#8217;s death or Termination of Service due to Disability as provided in Section 2.2(d) of the Agreement, no </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">shares of Common Stock shall be delivered in respect of the RSUs prior to such written certification by the Compensation Committee.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:100%;text-decoration:underline">Forfeiture of RSUs</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:100%">Except as set forth in Sections 2.2(c) and 2.2(d) of the Agreement, any unvested RSUs for which the Performance Condition has not been satisfied shall be automatically forfeited, terminated and cancelled effective as of the Certification Date without the payment of any consideration by the Company, and Holder, or Holder&#8217;s beneficiary or personal representative, as the case may be, shall have no further rights with respect to such RSUs under the Agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">18</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>8
<FILENAME>exhibit211-subsidiaries.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ie32dd50c942844d9b1ee1ff46b40f473_1"></div><div style="min-height:30.96pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.983%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">EXHIBIT 21.1</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESMED INC.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES OF THE REGISTRANT AS OF JUNE 30, 2022</font></div><div style="margin-top:1pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following is a list of subsidiaries of ResMed Inc. as of June&#160;30, 2022, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary as defined by Rule 1-02(w) of Regulation S-X.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.294%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:133%">Jurisdiction of Formation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Corp.</font></td><td colspan="3" style="background-color:#cceeff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Minnesota</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed (UK) Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Asia Pacific Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Beteiligungs GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Holdings Pty Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed GmbH and Co KG</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Motor Technologies Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed SAS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Paris SAS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed European Operations B.V</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Sensor Technologies Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Humidification Technologies GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Capital Holdings Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Brightree LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Brightree Home Health &#38; Hospice LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Brightree Patient Collections LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Curative Medical Technology (Beijing) Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Operations Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Global Holdings Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Asia Pte Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Healthcare</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">first</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">, Inc.</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">MatrixCare, Inc</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Reciprocal Labs Corp. (dba Propeller Health)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">ResMed Digital Health Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Delaware</font></td></tr></table></div><div><font><br></font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>9
<FILENAME>exhibit231-auditorconsent.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3699ed64e6a34a1ea9886172ba5d1b95_1"></div><div style="min-height:45.36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.983%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:133%">EXHIBIT 23.1</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Board of Directors</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ResMed Inc.&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We consent to the incorporation by reference in the registration statements (Nos. 333-08013, 333-88231, 333-115048, 333-140350, 333-140351, 333-156065, 333-164527, 333-167183, 333-181317, 333-186386, 333-194225, 333-224537, 333-245697, 333-256388) on Form S-8 of our reports dated August 11, 2022, with respect to the consolidated financial statements and financial statement schedule II of ResMed, Inc., and the effectiveness of internal control over financial reporting.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; KPMG LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</font></div><div style="height:45.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>10
<FILENAME>ex311-ceocertification.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ibd9b9cfa3a8b4f88b82f6716b33601f0_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 31.1</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael J. Farrell, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">I have reviewed this annual report on Form 10-K of ResMed Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.606%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MICHAEL J. FARRELL</font></div></td></tr><tr><td colspan="3" style="border-top:1pt dotted #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael J. Farrell</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief executive officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>11
<FILENAME>ex312-cfocertification.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ia863b9a8831c4b3bac1b68bbf0c30060_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 31.2</font></div></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brett A. Sandercock, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">I have reviewed this annual report on Form 10-K of ResMed Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58; </font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.727%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BRETT A. SANDERCOCK</font></div></td></tr><tr><td colspan="3" style="border-top:1pt dotted #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brett A. Sandercock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief financial officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>12
<FILENAME>ex321-ceoandcfocertificati.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if22eee94902c491e94cff9284680575e_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 32.1</font></div></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following certifications are being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350 and in accordance with SEC Release No. 33-8238.  These certifications shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be incorporated by reference in any filing made by ResMed Inc. under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Executive Officer</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of ResMed Inc., a Delaware corporation (the &#8220;Company&#8221;), hereby certifies, to his knowledge, that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.57pt">the accompanying Annual Report on Form 10-K of the Company for the year ended June 30, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.8pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.606%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MICHAEL J. FARRELL</font></div></td></tr><tr><td colspan="3" style="border-top:1pt dotted #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael J. Farrell</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief executive officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to ResMed Inc. and will be retained by ResMed Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">....................................................................................................................................................</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Chief Financial Officer</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. &#167; 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of ResMed Inc., a Delaware, corporation (the &#8220;Company&#8221;), hereby certifies, to his knowledge, that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.03pt">the accompanying Annual Report on Form 10-K of the Company for the year ended June 30, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:3.57pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.727%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 11, 2022</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> BRETT A. SANDERCOCK</font></div></td></tr><tr><td colspan="3" style="border-top:1pt dotted #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brett A. Sandercock</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief financial officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to ResMed Inc. and will be retained by ResMed Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>rmd-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:847d2812-be5d-4010-ae3d-4823a56f6339,g:501af745-9083-47bc-ad44-e407829835be-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rmd="http://investor.resmed.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://investor.resmed.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmd-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmd-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmd-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rmd-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://investor.resmed.com/role/DocumentAndEntityInformation">
        <link:definition>0001001 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://investor.resmed.com/role/AuditInformation">
        <link:definition>0002002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://investor.resmed.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfIncome" roleURI="http://investor.resmed.com/role/ConsolidatedStatementsOfIncome">
        <link:definition>1003005 - Statement - Consolidated Statements Of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncome" roleURI="http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1004006 - Statement - Consolidated Statements Of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005007 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>1406401 - Statement - Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1007008 - Statement - Consolidated Statements Of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndBasisOfPresentation" roleURI="http://investor.resmed.com/role/OrganizationAndBasisOfPresentation">
        <link:definition>2101101 - Disclosure - Organization And Basis Of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary Of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicy" roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy">
        <link:definition>2203201 - Disclosure - Summary Of Significant Accounting Policies (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2304301 - Disclosure - Summary Of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2405402 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails" roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails">
        <link:definition>2406403 - Disclosure - Summary Of Significant Accounting Policies (Summary Of Contract Balances) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewAccountingPronouncements" roleURI="http://investor.resmed.com/role/NewAccountingPronouncements">
        <link:definition>2107103 - Disclosure - New Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformation" roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformation">
        <link:definition>2108104 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationTables" roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables">
        <link:definition>2309302 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationScheduleOfInventoriesDetails" roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails">
        <link:definition>2410404 - Disclosure - Supplemental Balance Sheet Information (Schedule Of Inventories) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2411405 - Disclosure - Supplemental Balance Sheet Information (Schedule Of Prepaid Expenses and Other Current Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails" roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails">
        <link:definition>2412406 - Disclosure - Supplemental Balance Sheet Information (Components Of Property, Plant And Equipment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnet" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet">
        <link:definition>2113105 - Disclosure - Goodwill and Other Intangible Assets, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnetTables" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables">
        <link:definition>2314303 - Disclosure - Goodwill and Other Intangible Assets, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails">
        <link:definition>2415407 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails">
        <link:definition>2416408 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule Of Other Intangible Assets, Net) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnetNarrativeDetails" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails">
        <link:definition>2417409 - Disclosure - Goodwill and Other Intangible Assets, net (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails" roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails">
        <link:definition>2418410 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule Of Amortization Expense Related To Identifiable Intangible Assets, Including Patents) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://investor.resmed.com/role/Investments">
        <link:definition>2119106 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://investor.resmed.com/role/InvestmentsTables">
        <link:definition>2320304 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleOfInvestmentsDetails" roleURI="http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails">
        <link:definition>2421411 - Disclosure - Investments (Schedule Of Investments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleOfChangesInEquityInvestmentsDetails" roleURI="http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails">
        <link:definition>2422412 - Disclosure - Investments (Schedule Of Changes In Equity Investments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://investor.resmed.com/role/InvestmentsNarrativeDetails">
        <link:definition>2423413 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://investor.resmed.com/role/AccruedExpenses">
        <link:definition>2124107 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://investor.resmed.com/role/AccruedExpensesTables">
        <link:definition>2325305 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesScheduleOfAccruedExpensesDetails" roleURI="http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>2426414 - Disclosure - Accrued Expenses (Schedule Of Accrued Expenses) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductWarranties" roleURI="http://investor.resmed.com/role/ProductWarranties">
        <link:definition>2127108 - Disclosure - Product Warranties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductWarrantiesTables" roleURI="http://investor.resmed.com/role/ProductWarrantiesTables">
        <link:definition>2328306 - Disclosure - Product Warranties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails" roleURI="http://investor.resmed.com/role/ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails">
        <link:definition>2429415 - Disclosure - Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://investor.resmed.com/role/Debt">
        <link:definition>2130109 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://investor.resmed.com/role/DebtTables">
        <link:definition>2331307 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleOfDebtDetails" roleURI="http://investor.resmed.com/role/DebtScheduleOfDebtDetails">
        <link:definition>2432416 - Disclosure - Debt (Schedule Of Debt) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://investor.resmed.com/role/DebtNarrativeDetails">
        <link:definition>2433417 - Disclosure - Debt (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://investor.resmed.com/role/Leases">
        <link:definition>2134110 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://investor.resmed.com/role/LeasesTables">
        <link:definition>2335308 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://investor.resmed.com/role/LeasesNarrativeDetails">
        <link:definition>2436418 - Disclosure - Leases (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleOfFutureMinimumLeasePaymentsDetails" roleURI="http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails">
        <link:definition>2437419 - Disclosure - Leases (Schedule Of Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleOfFutureMinimumLeasePaymentsDetails_1" roleURI="http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails_1">
        <link:definition>2437419 - Disclosure - Leases (Schedule Of Future Minimum Lease Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleOfOperatingLeaseDisclosureDetails" roleURI="http://investor.resmed.com/role/LeasesScheduleOfOperatingLeaseDisclosureDetails">
        <link:definition>2438420 - Disclosure - Leases (Schedule Of Operating Lease Disclosure) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleOfComponentsOfLeaseRevenueDetails" roleURI="http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails">
        <link:definition>2439421 - Disclosure - Leases (Schedule Of Components Of Lease Revenue) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails" roleURI="http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails">
        <link:definition>2440422 - Disclosure - Leases (Schedule Of Sales-type Lease, Net Investment In Lease) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails" roleURI="http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails">
        <link:definition>2441423 - Disclosure - Leases (Schedule Of Maturities Of Sales-type Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1" roleURI="http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1">
        <link:definition>2441423 - Disclosure - Leases (Schedule Of Maturities Of Sales-type Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://investor.resmed.com/role/StockholdersEquity">
        <link:definition>2142111 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://investor.resmed.com/role/StockholdersEquityTables">
        <link:definition>2343309 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://investor.resmed.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2444424 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails" roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails">
        <link:definition>2445425 - Disclosure - Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleOfOptionActivityDetails" roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails">
        <link:definition>2446426 - Disclosure - Stockholders' Equity (Schedule Of Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails" roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails">
        <link:definition>2447427 - Disclosure - Stockholders' Equity (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails" roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails">
        <link:definition>2448428 - Disclosure - Stockholders' Equity (Schedule Of Total Stock-Based Compensation Costs Incurred And Associated Tax Benefit Recognized) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://investor.resmed.com/role/EarningsPerShare">
        <link:definition>2149112 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://investor.resmed.com/role/EarningsPerShareTables">
        <link:definition>2350310 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://investor.resmed.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>2451429 - Disclosure - Earnings Per Share (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" roleURI="http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails">
        <link:definition>2452430 - Disclosure - Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://investor.resmed.com/role/IncomeTaxes">
        <link:definition>2153113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://investor.resmed.com/role/IncomeTaxesTables">
        <link:definition>2354311 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails">
        <link:definition>2455431 - Disclosure - Income Taxes (Schedule Of Income Before Income Taxes Under The Jurisdictions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
        <link:definition>2456432 - Disclosure - Income Taxes (Schedule Of Provision For Income Taxes) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails">
        <link:definition>2457433 - Disclosure - Income Taxes (Schedule Of Provision For Income Tax Differ From The Amount Of Income Tax) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails">
        <link:definition>2458434 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Liabilities Classified As Current And Non-Current) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2459435 - Disclosure - Income Taxes (Components Of Deferred Tax Assets And Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://investor.resmed.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2460436 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://investor.resmed.com/role/SegmentInformation">
        <link:definition>2161114 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://investor.resmed.com/role/SegmentInformationTables">
        <link:definition>2362312 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://investor.resmed.com/role/SegmentInformationNarrativeDetails">
        <link:definition>2463437 - Disclosure - Segment Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails" roleURI="http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails">
        <link:definition>2464438 - Disclosure - Segment Information (Summary Of Revenue By Segment And Reconciling Items) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails" roleURI="http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails">
        <link:definition>2465439 - Disclosure - Segment Information (Schedule Of Revenue By Segment, Product, And Region) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleOfRevenueByGeographicAreaDetails" roleURI="http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails">
        <link:definition>2466440 - Disclosure - Segment Information (Schedule Of Revenue By Geographic Area) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails" roleURI="http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails">
        <link:definition>2467441 - Disclosure - Segment Information (Schedule Of Long-Lived Assets By Geographic Areas) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRetirementPlans" roleURI="http://investor.resmed.com/role/EmployeeRetirementPlans">
        <link:definition>2168115 - Disclosure - Employee Retirement Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRetirementPlansNarrativeDetails" roleURI="http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails">
        <link:definition>2469442 - Disclosure - Employee Retirement Plans (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalActionsContingenciesAndCommitments" roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitments">
        <link:definition>2170116 - Disclosure - Legal Actions, Contingencies And Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalActionsContingenciesAndCommitmentsTables" roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsTables">
        <link:definition>2371313 - Disclosure - Legal Actions, Contingencies And Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalActionsContingenciesAndCommitmentsNarrativeDetails" roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsNarrativeDetails">
        <link:definition>2472443 - Disclosure - Legal Actions, Contingencies And Commitments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails" roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails">
        <link:definition>2473444 - Disclosure - Legal Actions, Contingencies And Commitments (Obligations Under Purchase Agreements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails_1" roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails_1">
        <link:definition>2473444 - Disclosure - Legal Actions, Contingencies And Commitments (Obligations Under Purchase Agreements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringExpenses" roleURI="http://investor.resmed.com/role/RestructuringExpenses">
        <link:definition>2174117 - Disclosure - Restructuring Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringExpensesNarrativeDetails" roleURI="http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails">
        <link:definition>2475445 - Disclosure - Restructuring Expenses (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationAndQualifyingAccountsAndReserves" roleURI="http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReserves">
        <link:definition>2176118 - Disclosure - Schedule II Valuation And Qualifying Accounts And Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationAndQualifyingAccountsAndReservesDetails" roleURI="http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails">
        <link:definition>2477446 - Disclosure - Schedule II Valuation And Qualifying Accounts And Reserves (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rmd_IdentifiedIntangibleAssetsMember" abstract="false" name="IdentifiedIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_IncomeTaxExaminationGrossSettlement" abstract="false" name="IncomeTaxExaminationGrossSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_NonEmployeeDirectorMember" abstract="false" name="NonEmployeeDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_DeferredTaxLiabilitiesRightOfUseAssets" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_SoftwareAsServiceMember" abstract="false" name="SoftwareAsServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_ContractWithCustomerAssetAndLiabilityTable" abstract="true" name="ContractWithCustomerAssetAndLiabilityTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rmd_AccountsReceivableNetMember" abstract="false" name="AccountsReceivableNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" abstract="false" name="RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_IncomeTaxExaminationNetImpactOfSettlement" abstract="false" name="IncomeTaxExaminationNetImpactOfSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" abstract="false" name="ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rmd_NonMarketableSecuritiesMember" abstract="false" name="NonMarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" abstract="false" name="BusinessAcquisitionContingentConsiderationRecognizedLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" abstract="false" name="PrepaidTaxesAndOtherNonCurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_AdditionalEquityInvestments" abstract="false" name="AdditionalEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedCommitments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_AllowanceForDoubtfulAccountsPolicyTextBlock" abstract="false" name="AllowanceForDoubtfulAccountsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" abstract="false" name="ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rmd_EquityInvestments" abstract="false" name="EquityInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_PortableOxygenConcentratorBusinessClosureMember" abstract="false" name="PortableOxygenConcentratorBusinessClosureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_GlobalMember" abstract="false" name="GlobalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_CombinedEuropeAsiaAndOtherMarketsMember" abstract="false" name="CombinedEuropeAsiaAndOtherMarketsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_SaasMember" abstract="false" name="SaasMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_NumberOfOfferings" abstract="false" name="NumberOfOfferings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="rmd_RestructuringAndRelatedCostCostOfSales" abstract="false" name="RestructuringAndRelatedCostCostOfSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" abstract="false" name="ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_U.s.CanadaAndLatinAmericaMember" abstract="false" name="U.s.CanadaAndLatinAmericaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_UncommittedOptionToIncreaseCreditFacility" abstract="false" name="UncommittedOptionToIncreaseCreditFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_VestingAmountMaximumPercentageOfOriginalGrant" abstract="false" name="VestingAmountMaximumPercentageOfOriginalGrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rmd_AmendedAndRestated2009PlanMember" abstract="false" name="AmendedAndRestated2009PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_ReceivablesSoldWithLimitedRecourse" abstract="false" name="ReceivablesSoldWithLimitedRecourse" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_DevicesMember" abstract="false" name="DevicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_ReclassificationsInEquityInvestments" abstract="false" name="ReclassificationsInEquityInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" abstract="false" name="DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock" abstract="false" name="SalesTypeLeaseNetInvestmentInLeaseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rmd_EquityMethodInvestmentsRollForward" abstract="true" name="EquityMethodInvestmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_SeniorNotesOneMember" abstract="false" name="SeniorNotesOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rmd_ResmedInc2009IncentiveAwardPlanMember" abstract="false" name="ResmedInc2009IncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_EmployeeStockPurchasePlanPurchaseRightsMember" abstract="false" name="EmployeeStockPurchasePlanPurchaseRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_DebtToConsolidatedEbitdaRatio" abstract="false" name="DebtToConsolidatedEbitdaRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rmd_DeferredPaymentObligationsForAcquisitions" abstract="false" name="DeferredPaymentObligationsForAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets" abstract="false" name="SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="rmd_PrepaidInventory" abstract="false" name="PrepaidInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_SleepAndRespiratoryMember" abstract="false" name="SleepAndRespiratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" abstract="false" name="LineOfCreditFacilityCollateralPercentageOfTheCompany" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" abstract="false" name="DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rmd_MaximumNumberOfSharesSubjectToAwardsGranted" abstract="false" name="MaximumNumberOfSharesSubjectToAwardsGranted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rmd_ScheduleOfInvestmentsTableTextBlock" abstract="false" name="ScheduleOfInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rmd_ResmedLimitedMember" abstract="false" name="ResmedLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_NumberOfCommonStockGranted" abstract="false" name="NumberOfCommonStockGranted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="rmd_EquityInvestmentsTotalByMeasurementCategory" abstract="false" name="EquityInvestmentsTotalByMeasurementCategory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_LessorLeaseRevenue" abstract="false" name="LessorLeaseRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" abstract="false" name="ScheduleOfChangesInEquityInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rmd_OperatingLossCarryforwardsCapitalLoss" abstract="false" name="OperatingLossCarryforwardsCapitalLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_SeniorNotesTwoMember" abstract="false" name="SeniorNotesTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" abstract="false" name="ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="rmd_TermOfContractUnderRevenueRecognition" abstract="false" name="TermOfContractUnderRevenueRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rmd_MufgUnionBankMember" abstract="false" name="MufgUnionBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_VehiclesAndAircraftMember" abstract="true" name="VehiclesAndAircraftMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="rmd_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_DeferredRevenueFairValueAdjustment" abstract="false" name="DeferredRevenueFairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" abstract="false" name="PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rmd_ShortTermDebtGross" abstract="false" name="ShortTermDebtGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_SupplementalBalanceSheetInformationTextBlock" abstract="false" name="SupplementalBalanceSheetInformationTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rmd_DeferredTaxAssetsLeaseLiabilities" abstract="false" name="DeferredTaxAssetsLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_ClinicalDemonstrationAndRentalEquipmentMember" abstract="false" name="ClinicalDemonstrationAndRentalEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_AccruedInventoryInTransit" abstract="false" name="AccruedInventoryInTransit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_MasksAndOtherMember" abstract="true" name="MasksAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" abstract="false" name="RevolvingCreditFacilityAndTermLoanCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_DevelopedOrCoreProductTechnologyMember" abstract="false" name="DevelopedOrCoreProductTechnologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_MarketableSecuritiesMember" abstract="false" name="MarketableSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" abstract="false" name="PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" abstract="false" name="ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rmd_MarketableEquityInvestmentsFairValue" abstract="false" name="MarketableEquityInvestmentsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_EmployeeStockPurchasePlanOfferingPeriod" abstract="false" name="EmployeeStockPurchasePlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rmd_RestOfWorldMember" abstract="false" name="RestOfWorldMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_AmortizationOfAcquiredIntangibleAssets1" abstract="false" name="AmortizationOfAcquiredIntangibleAssets1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_UnallocatedCorporateCosts" abstract="false" name="UnallocatedCorporateCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" abstract="false" name="PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" abstract="false" name="ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment" abstract="false" name="RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_SupplementalBalanceSheetInformationAbstract" abstract="true" name="SupplementalBalanceSheetInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_IncomeTaxExaminationRemittedFinalPayment" abstract="false" name="IncomeTaxExaminationRemittedFinalPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_EmployeeStockPurchasePlanMember" abstract="false" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_AccruedLogisticsAndOccupancyExpensesCurrent" abstract="false" name="AccruedLogisticsAndOccupancyExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="rmd_DevicesAndMasksMember" abstract="false" name="DevicesAndMasksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" abstract="false" name="MufgUnionBankNaAndWestpacBankingCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" abstract="false" name="NoncashPartOfAcquisitionFairValueOfAssetsAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" abstract="false" name="NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_ContractWithCustomerAssetAndLiabilityLineItems" abstract="true" name="ContractWithCustomerAssetAndLiabilityLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="rmd_IncomeTaxExaminationPriorRemittancePayments" abstract="false" name="IncomeTaxExaminationPriorRemittancePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" abstract="false" name="GoodwillAcquiredDuringPeriodIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>rmd-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:847d2812-be5d-4010-ae3d-4823a56f6339,g:501af745-9083-47bc-ad44-e407829835be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_54682131-ac22-44a7-96ad-02f811bf0aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_99ca4d95-4d05-4fe5-8d0c-e7b2ae15a10b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_54682131-ac22-44a7-96ad-02f811bf0aa2" xlink:to="loc_us-gaap_AccountsPayableCurrent_99ca4d95-4d05-4fe5-8d0c-e7b2ae15a10b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_08016488-36ac-436f-82d9-3ac89444740b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_54682131-ac22-44a7-96ad-02f811bf0aa2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_08016488-36ac-436f-82d9-3ac89444740b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fea03f4d-4517-4cb3-8c03-c5f49116da61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_54682131-ac22-44a7-96ad-02f811bf0aa2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fea03f4d-4517-4cb3-8c03-c5f49116da61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a1977c74-5edf-4146-a7ae-c58f94c35a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_54682131-ac22-44a7-96ad-02f811bf0aa2" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_a1977c74-5edf-4146-a7ae-c58f94c35a90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_03f2f025-268b-4fce-9e38-04d078a536ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_54682131-ac22-44a7-96ad-02f811bf0aa2" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_03f2f025-268b-4fce-9e38-04d078a536ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_cd0b674a-2540-439a-a1b7-4444aa666105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_54682131-ac22-44a7-96ad-02f811bf0aa2" xlink:to="loc_us-gaap_ShortTermBorrowings_cd0b674a-2540-439a-a1b7-4444aa666105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_a05997a0-4174-4ba3-883b-22ad881480a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6b30d130-4e38-48b2-b315-4f6c71de94ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_a05997a0-4174-4ba3-883b-22ad881480a3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6b30d130-4e38-48b2-b315-4f6c71de94ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bc2be48a-5a7b-4549-8aa4-cd0295fb88dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_a05997a0-4174-4ba3-883b-22ad881480a3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bc2be48a-5a7b-4549-8aa4-cd0295fb88dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ad2d7048-52b6-4bc1-a6f1-70a10013eb99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_a05997a0-4174-4ba3-883b-22ad881480a3" xlink:to="loc_us-gaap_Goodwill_ad2d7048-52b6-4bc1-a6f1-70a10013eb99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87ff67c-c1e0-415c-9710-3eda5f4abef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_a05997a0-4174-4ba3-883b-22ad881480a3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87ff67c-c1e0-415c-9710-3eda5f4abef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_e2543784-5518-4322-9cb1-31f9ee030f85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_a05997a0-4174-4ba3-883b-22ad881480a3" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_e2543784-5518-4322-9cb1-31f9ee030f85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_dc097f59-6a90-4703-b003-9d16e6d890f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_a05997a0-4174-4ba3-883b-22ad881480a3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_dc097f59-6a90-4703-b003-9d16e6d890f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_53e407aa-5bd6-485c-880e-d8f0efadc6b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_30fbfee2-881a-407b-8761-699adc61c951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_53e407aa-5bd6-485c-880e-d8f0efadc6b0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_30fbfee2-881a-407b-8761-699adc61c951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_967d9100-3ad1-45b4-930c-5af257fddaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_53e407aa-5bd6-485c-880e-d8f0efadc6b0" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_967d9100-3ad1-45b4-930c-5af257fddaa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_43bffd6b-fafa-4159-9294-682b686ea1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_53e407aa-5bd6-485c-880e-d8f0efadc6b0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_43bffd6b-fafa-4159-9294-682b686ea1b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_721abd44-59b8-47d5-a81c-56047143dd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_53e407aa-5bd6-485c-880e-d8f0efadc6b0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_721abd44-59b8-47d5-a81c-56047143dd42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6a5de7f7-3dc3-4b3b-a2c7-2c4728b2ac85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_53e407aa-5bd6-485c-880e-d8f0efadc6b0" xlink:to="loc_us-gaap_LongTermDebt_6a5de7f7-3dc3-4b3b-a2c7-2c4728b2ac85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3b758db0-f613-434c-8568-b6f462b77daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_53e407aa-5bd6-485c-880e-d8f0efadc6b0" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_3b758db0-f613-434c-8568-b6f462b77daf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9b4c0445-1e2f-4582-9348-2c10563ac785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9d69cc2f-0a5f-4143-81b8-dbaa83877207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b4c0445-1e2f-4582-9348-2c10563ac785" xlink:to="loc_us-gaap_PreferredStockValue_9d69cc2f-0a5f-4143-81b8-dbaa83877207" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_95f6b1b5-6fe8-4691-801a-18982ac49c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b4c0445-1e2f-4582-9348-2c10563ac785" xlink:to="loc_us-gaap_TreasuryStockCommonValue_95f6b1b5-6fe8-4691-801a-18982ac49c36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fcd6338a-6ca7-4946-afbc-870267fda00c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b4c0445-1e2f-4582-9348-2c10563ac785" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fcd6338a-6ca7-4946-afbc-870267fda00c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_9e9a9f85-7a0f-48b4-933a-e51ee98605e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b4c0445-1e2f-4582-9348-2c10563ac785" xlink:to="loc_us-gaap_CommonStockValueOutstanding_9e9a9f85-7a0f-48b4-933a-e51ee98605e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5ccd1a5-97bc-473d-b1ab-0938045f2ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b4c0445-1e2f-4582-9348-2c10563ac785" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c5ccd1a5-97bc-473d-b1ab-0938045f2ff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2e31f81c-de8f-490a-98a0-f7f06a95b9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_9b4c0445-1e2f-4582-9348-2c10563ac785" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2e31f81c-de8f-490a-98a0-f7f06a95b9c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_a8f54543-b204-497c-bf1e-d181e49128e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9a3a7d6a-776a-4e3f-a3fe-30733c06e8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a8f54543-b204-497c-bf1e-d181e49128e2" xlink:to="loc_us-gaap_Liabilities_9a3a7d6a-776a-4e3f-a3fe-30733c06e8a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6fa3fc46-9e99-4f56-b3ff-b16ea9c4655d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_a8f54543-b204-497c-bf1e-d181e49128e2" xlink:to="loc_us-gaap_StockholdersEquity_6fa3fc46-9e99-4f56-b3ff-b16ea9c4655d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_538c6ea5-4664-4299-ae3e-5d3df835b6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_216f45bd-9e6b-4e2a-81a0-5f3923c4f2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_538c6ea5-4664-4299-ae3e-5d3df835b6c7" xlink:to="loc_us-gaap_AssetsCurrent_216f45bd-9e6b-4e2a-81a0-5f3923c4f2c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_3fa5a248-48ca-481d-878e-9a8448e19083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_538c6ea5-4664-4299-ae3e-5d3df835b6c7" xlink:to="loc_us-gaap_AssetsNoncurrent_3fa5a248-48ca-481d-878e-9a8448e19083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_25baa924-2e99-48b1-b92f-99560773a74b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5be98ad0-8079-490c-9c39-ee5a519f39a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_25baa924-2e99-48b1-b92f-99560773a74b" xlink:to="loc_us-gaap_LiabilitiesCurrent_5be98ad0-8079-490c-9c39-ee5a519f39a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_aabb9df1-33e0-4cb8-99c3-2086a1b67a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_25baa924-2e99-48b1-b92f-99560773a74b" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_aabb9df1-33e0-4cb8-99c3-2086a1b67a27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_13463fbe-525c-48e4-9e9c-38efe6ac6e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3161e05-3ccc-4e18-8f15-e2831432dfda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_13463fbe-525c-48e4-9e9c-38efe6ac6e47" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f3161e05-3ccc-4e18-8f15-e2831432dfda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_90df3b02-df7d-421c-99ac-f10838fdb3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_13463fbe-525c-48e4-9e9c-38efe6ac6e47" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_90df3b02-df7d-421c-99ac-f10838fdb3c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_dd324531-79b4-4de3-9d9e-acc47d5576a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_13463fbe-525c-48e4-9e9c-38efe6ac6e47" xlink:to="loc_us-gaap_InventoryNet_dd324531-79b4-4de3-9d9e-acc47d5576a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d816023-fcaa-477c-bcd6-78889c55e488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_13463fbe-525c-48e4-9e9c-38efe6ac6e47" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7d816023-fcaa-477c-bcd6-78889c55e488" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsOfIncome" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedStatementsOfIncome"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_84a8d82c-5b57-41bf-bcac-7ee14d4a63c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f885a92a-57a1-4255-8e57-030e0a3c2369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_84a8d82c-5b57-41bf-bcac-7ee14d4a63c1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f885a92a-57a1-4255-8e57-030e0a3c2369" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b856c1d0-faf9-4bf8-b01c-2304c5ec7fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_84a8d82c-5b57-41bf-bcac-7ee14d4a63c1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b856c1d0-faf9-4bf8-b01c-2304c5ec7fd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_cb5a3df9-5308-4cf3-93e1-5383be49cc5e" xlink:href="rmd-20220630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_84a8d82c-5b57-41bf-bcac-7ee14d4a63c1" xlink:to="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_cb5a3df9-5308-4cf3-93e1-5383be49cc5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_59f4142b-c138-4a0f-8818-b208e07ab58c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_84a8d82c-5b57-41bf-bcac-7ee14d4a63c1" xlink:to="loc_us-gaap_RestructuringCharges_59f4142b-c138-4a0f-8818-b208e07ab58c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_0ebfd31c-4722-49c9-bf66-e911a481359c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_84a8d82c-5b57-41bf-bcac-7ee14d4a63c1" xlink:to="loc_us-gaap_LitigationSettlementExpense_0ebfd31c-4722-49c9-bf66-e911a481359c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_79391353-b968-4530-bb8f-d591dfc176a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_428bb9ab-28b2-4a3a-8b41-dc99b6674abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_79391353-b968-4530-bb8f-d591dfc176a1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_428bb9ab-28b2-4a3a-8b41-dc99b6674abe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_148b93f2-2209-41c0-8abb-13e139c21635" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_79391353-b968-4530-bb8f-d591dfc176a1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_148b93f2-2209-41c0-8abb-13e139c21635" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d6cb46a0-f377-4baa-9f42-463ac4f29e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_39dfd252-ea91-4b78-ab8c-b77850816386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_d6cb46a0-f377-4baa-9f42-463ac4f29e0a" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_39dfd252-ea91-4b78-ab8c-b77850816386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_3202f471-826b-49d4-b084-09bd2cb44eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_d6cb46a0-f377-4baa-9f42-463ac4f29e0a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_3202f471-826b-49d4-b084-09bd2cb44eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3924c364-7578-47a8-be45-1509c232be1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_10a91362-3ff7-4e4d-af8a-a6a5b9c1ec89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3924c364-7578-47a8-be45-1509c232be1b" xlink:to="loc_us-gaap_GrossProfit_10a91362-3ff7-4e4d-af8a-a6a5b9c1ec89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3532c8d0-808f-4ead-b1ee-2e4503b58f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3924c364-7578-47a8-be45-1509c232be1b" xlink:to="loc_us-gaap_OperatingExpenses_3532c8d0-808f-4ead-b1ee-2e4503b58f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_513852e4-86c7-4946-ae11-1c412a9b400e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_b1749e6d-cf2b-486d-96df-e33d2536dc33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_513852e4-86c7-4946-ae11-1c412a9b400e" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_b1749e6d-cf2b-486d-96df-e33d2536dc33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_68b82aa6-44ed-458f-9e1f-c34faea165ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_513852e4-86c7-4946-ae11-1c412a9b400e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_68b82aa6-44ed-458f-9e1f-c34faea165ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_532ade02-140e-499a-92fb-256c30ae6961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_513852e4-86c7-4946-ae11-1c412a9b400e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_532ade02-140e-499a-92fb-256c30ae6961" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_660b6ea8-83be-4607-9c98-9d4ddbaf1899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_513852e4-86c7-4946-ae11-1c412a9b400e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_660b6ea8-83be-4607-9c98-9d4ddbaf1899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c68301ed-e29c-4941-9351-b3a80aa17597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_131409eb-3efe-4025-9b91-dee83ed60889" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c68301ed-e29c-4941-9351-b3a80aa17597" xlink:to="loc_us-gaap_OperatingIncomeLoss_131409eb-3efe-4025-9b91-dee83ed60889" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_75e55cd3-e34c-4945-9354-64f87f0fe425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c68301ed-e29c-4941-9351-b3a80aa17597" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_75e55cd3-e34c-4945-9354-64f87f0fe425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_45cce03a-2a57-445f-9345-9b3407aee2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a1705449-aa40-4c44-803f-daaa49fa845d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_45cce03a-2a57-445f-9345-9b3407aee2e2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a1705449-aa40-4c44-803f-daaa49fa845d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2ddb8bfe-70a9-43ca-b1b0-14cce1b0066c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_45cce03a-2a57-445f-9345-9b3407aee2e2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2ddb8bfe-70a9-43ca-b1b0-14cce1b0066c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedStatementsOfComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0742a286-82bb-4b5d-9c63-19ebc66cef1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_51373e6f-ac01-4dbc-bf4a-d3d6a9716806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0742a286-82bb-4b5d-9c63-19ebc66cef1e" xlink:to="loc_us-gaap_NetIncomeLoss_51373e6f-ac01-4dbc-bf4a-d3d6a9716806" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f8d1bba1-bf3b-4531-b31b-c66531b198f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_0742a286-82bb-4b5d-9c63-19ebc66cef1e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f8d1bba1-bf3b-4531-b31b-c66531b198f9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedStatementsOfCashFlows"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88e513cf-aa42-4b1c-a897-1337b9ba7733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_NetIncomeLoss_88e513cf-aa42-4b1c-a897-1337b9ba7733" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d06f4ea3-bb56-4dc1-9d36-0f8ed92b1a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d06f4ea3-bb56-4dc1-9d36-0f8ed92b1a79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_bc11c766-d253-4fd0-b7c2-5d70f8765d78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_bc11c766-d253-4fd0-b7c2-5d70f8765d78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b726a5cb-fc26-472a-b40b-7518e5d02ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_ShareBasedCompensation_b726a5cb-fc26-472a-b40b-7518e5d02ba2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bc6e9ddc-ed2c-4799-b634-75b1fbcb931b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_bc6e9ddc-ed2c-4799-b634-75b1fbcb931b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_1068db55-481e-4c89-a75a-df80cc8538c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_1068db55-481e-4c89-a75a-df80cc8538c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_70df9045-054a-4f18-b106-c8f8aa79663e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_RestructuringCharges_70df9045-054a-4f18-b106-c8f8aa79663e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f7ca1da5-fb7c-4f3c-b274-6ee0810cfa10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_f7ca1da5-fb7c-4f3c-b274-6ee0810cfa10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2410d276-fe0e-4b19-b147-08d7f7bd9e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2410d276-fe0e-4b19-b147-08d7f7bd9e7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_daf70789-35f2-4795-b2f4-dcd7b747d63c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_daf70789-35f2-4795-b2f4-dcd7b747d63c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dc55e1d9-0a76-40a4-8cc8-ae0b2678a202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dc55e1d9-0a76-40a4-8cc8-ae0b2678a202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f8936de1-87f2-4da0-8fc6-a34c0b0548a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1f77e400-77e8-453e-8763-8e147562c9f2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f8936de1-87f2-4da0-8fc6-a34c0b0548a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd1f7fb5-9f89-4ac6-864a-a96d67b1620e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8c606e73-bd20-4642-947d-8f031348bc26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd1f7fb5-9f89-4ac6-864a-a96d67b1620e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8c606e73-bd20-4642-947d-8f031348bc26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8654398e-6937-4981-8287-8313375ecc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd1f7fb5-9f89-4ac6-864a-a96d67b1620e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8654398e-6937-4981-8287-8313375ecc6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_566e4450-d318-4532-acc5-fdad4a6b1caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd1f7fb5-9f89-4ac6-864a-a96d67b1620e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_566e4450-d318-4532-acc5-fdad4a6b1caf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_72cfa78b-83cc-4b94-96c4-de4bba414973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd1f7fb5-9f89-4ac6-864a-a96d67b1620e" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_72cfa78b-83cc-4b94-96c4-de4bba414973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3ec26c8a-0b7c-4ca4-86c5-e4a7eae58701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd1f7fb5-9f89-4ac6-864a-a96d67b1620e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_3ec26c8a-0b7c-4ca4-86c5-e4a7eae58701" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_fb7ad79d-b339-4ffa-8d2d-9032ad9e92ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dd1f7fb5-9f89-4ac6-864a-a96d67b1620e" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_fb7ad79d-b339-4ffa-8d2d-9032ad9e92ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c3fc5918-758e-4477-8cb5-9188c609ccd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff7c03c5-15e5-4ef5-91c5-735dbd7ea959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c3fc5918-758e-4477-8cb5-9188c609ccd8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ff7c03c5-15e5-4ef5-91c5-735dbd7ea959" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d24bce51-befc-40b6-be5a-f20b36aed7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c3fc5918-758e-4477-8cb5-9188c609ccd8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d24bce51-befc-40b6-be5a-f20b36aed7d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34023224-ef40-4985-afcf-badf2b572687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c3fc5918-758e-4477-8cb5-9188c609ccd8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_34023224-ef40-4985-afcf-badf2b572687" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_279b5ccc-7993-4b56-90a6-460492f81261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c3fc5918-758e-4477-8cb5-9188c609ccd8" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_279b5ccc-7993-4b56-90a6-460492f81261" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c82ea371-4c5a-497d-9306-4ab9c5c1e0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_77e7d049-5528-4f86-9bb5-8576736aab58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c82ea371-4c5a-497d-9306-4ab9c5c1e0c9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_77e7d049-5528-4f86-9bb5-8576736aab58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8acdcae2-18d0-4022-b731-d594a7e78584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c82ea371-4c5a-497d-9306-4ab9c5c1e0c9" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8acdcae2-18d0-4022-b731-d594a7e78584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_4d29a1eb-fbcf-4281-9c38-44d00c141c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c82ea371-4c5a-497d-9306-4ab9c5c1e0c9" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_4d29a1eb-fbcf-4281-9c38-44d00c141c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3e644454-2899-4b86-855a-274e5025df8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c82ea371-4c5a-497d-9306-4ab9c5c1e0c9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_3e644454-2899-4b86-855a-274e5025df8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2f6b5aec-c339-429c-9dd4-4e4db62d6ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c82ea371-4c5a-497d-9306-4ab9c5c1e0c9" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2f6b5aec-c339-429c-9dd4-4e4db62d6ee8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_60229dd3-1740-42be-8dad-c6aee03eeeda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c82ea371-4c5a-497d-9306-4ab9c5c1e0c9" xlink:to="loc_us-gaap_PaymentsOfDividends_60229dd3-1740-42be-8dad-c6aee03eeeda" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SupplementalBalanceSheetInformationScheduleOfInventoriesDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4e5bbed2-2c8a-4be8-91e0-c9d57708f0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_13a48e5b-7478-45af-810e-7236b23b1c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4e5bbed2-2c8a-4be8-91e0-c9d57708f0e8" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_13a48e5b-7478-45af-810e-7236b23b1c66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_173e6bc5-1f47-4309-9621-6341ed4060f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4e5bbed2-2c8a-4be8-91e0-c9d57708f0e8" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_173e6bc5-1f47-4309-9621-6341ed4060f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_53e62241-27d3-44b6-aaac-ea5fcf6b3b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4e5bbed2-2c8a-4be8-91e0-c9d57708f0e8" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_53e62241-27d3-44b6-aaac-ea5fcf6b3b36" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_446ce6ac-aca0-4f5a-9959-3e5a773206b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_2b647f84-32b1-4968-8f06-dc70b5885011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_446ce6ac-aca0-4f5a-9959-3e5a773206b7" xlink:to="loc_us-gaap_PrepaidTaxes_2b647f84-32b1-4968-8f06-dc70b5885011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidInventory_10d4534c-61b8-4f62-a7f4-e0192326ce67" xlink:href="rmd-20220630.xsd#rmd_PrepaidInventory"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_446ce6ac-aca0-4f5a-9959-3e5a773206b7" xlink:to="loc_rmd_PrepaidInventory_10d4534c-61b8-4f62-a7f4-e0192326ce67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_59a5802d-9b01-4fcb-9754-e39e0e7e95bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_446ce6ac-aca0-4f5a-9959-3e5a773206b7" xlink:to="loc_us-gaap_OtherAssetsCurrent_59a5802d-9b01-4fcb-9754-e39e0e7e95bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c2dcd8f2-7df4-4b79-a68e-1749a5731154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_19b7c014-a615-472c-b51f-45d6a6539263" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c2dcd8f2-7df4-4b79-a68e-1749a5731154" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_19b7c014-a615-472c-b51f-45d6a6539263" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8563b50c-fc3d-4d91-89a5-884de7742ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_c2dcd8f2-7df4-4b79-a68e-1749a5731154" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8563b50c-fc3d-4d91-89a5-884de7742ebe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a50958f0-2c0c-4888-a032-ecc9a193c0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1afcb985-745e-4c14-9315-84dd277320f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a50958f0-2c0c-4888-a032-ecc9a193c0ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1afcb985-745e-4c14-9315-84dd277320f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ed75cd92-7568-47a1-b778-48e94a5ff3b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a50958f0-2c0c-4888-a032-ecc9a193c0ad" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ed75cd92-7568-47a1-b778-48e94a5ff3b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#InvestmentsScheduleOfInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_b74a89a1-f24e-470b-b938-1cfbf627d3af" xlink:href="rmd-20220630.xsd#rmd_EquityInvestmentsTotalByMeasurementCategory"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableEquityInvestmentsFairValue_130da4bc-e133-4bd5-b3ad-26076ea1d74a" xlink:href="rmd-20220630.xsd#rmd_MarketableEquityInvestmentsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_b74a89a1-f24e-470b-b938-1cfbf627d3af" xlink:to="loc_rmd_MarketableEquityInvestmentsFairValue_130da4bc-e133-4bd5-b3ad-26076ea1d74a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_64051895-8e27-4c2d-a84a-04c7aaeea5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_b74a89a1-f24e-470b-b938-1cfbf627d3af" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_64051895-8e27-4c2d-a84a-04c7aaeea5b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_f416a532-078c-49c3-8772-ec0215487342" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_b74a89a1-f24e-470b-b938-1cfbf627d3af" xlink:to="loc_us-gaap_EquityMethodInvestments_f416a532-078c-49c3-8772-ec0215487342" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#AccruedExpensesScheduleOfAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7660b52a-0edf-4d0a-a8a0-11949390692d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_56fa95e6-0c43-4d6b-9c86-c037d5054c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7660b52a-0edf-4d0a-a8a0-11949390692d" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_56fa95e6-0c43-4d6b-9c86-c037d5054c8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_53ae140f-d071-4484-8560-1a621e611046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7660b52a-0edf-4d0a-a8a0-11949390692d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_53ae140f-d071-4484-8560-1a621e611046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_94d258e7-a068-4c61-9e14-2de1f864d6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7660b52a-0edf-4d0a-a8a0-11949390692d" xlink:to="loc_us-gaap_TaxesPayableCurrent_94d258e7-a068-4c61-9e14-2de1f864d6f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0adb6157-89c6-4f29-9f35-76eedb2a5694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7660b52a-0edf-4d0a-a8a0-11949390692d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0adb6157-89c6-4f29-9f35-76eedb2a5694" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_ae376189-91f7-4468-a9ea-b56197cd9e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7660b52a-0edf-4d0a-a8a0-11949390692d" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_ae376189-91f7-4468-a9ea-b56197cd9e5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_6f3077b7-a6c6-44a2-87b8-a3e76180118e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7660b52a-0edf-4d0a-a8a0-11949390692d" xlink:to="loc_us-gaap_InterestPayableCurrent_6f3077b7-a6c6-44a2-87b8-a3e76180118e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_420ea83d-b028-4366-9074-56f4366fa2f9" xlink:href="rmd-20220630.xsd#rmd_AccruedLogisticsAndOccupancyExpensesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7660b52a-0edf-4d0a-a8a0-11949390692d" xlink:to="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_420ea83d-b028-4366-9074-56f4366fa2f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedInventoryInTransit_dc8d39c4-4104-42ae-b524-942e851c9cad" xlink:href="rmd-20220630.xsd#rmd_AccruedInventoryInTransit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7660b52a-0edf-4d0a-a8a0-11949390692d" xlink:to="loc_rmd_AccruedInventoryInTransit_dc8d39c4-4104-42ae-b524-942e851c9cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_01091e35-848a-4873-9774-5c7e661d2471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_7660b52a-0edf-4d0a-a8a0-11949390692d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_01091e35-848a-4873-9774-5c7e661d2471" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DebtScheduleOfDebtDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#DebtScheduleOfDebtDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_74210b03-315c-4b4b-bcf6-1233420c71ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_c568828b-28c2-4d03-b80e-af2a0c72013d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_74210b03-315c-4b4b-bcf6-1233420c71ce" xlink:to="loc_us-gaap_ShortTermBorrowings_c568828b-28c2-4d03-b80e-af2a0c72013d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_ef767d44-cfe6-4017-a47e-0ba32159e6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_74210b03-315c-4b4b-bcf6-1233420c71ce" xlink:to="loc_us-gaap_LongTermDebt_ef767d44-cfe6-4017-a47e-0ba32159e6ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e8dd4d3b-92a9-4e5a-a0cd-8d151e34c346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_0c4e446d-e425-4d91-811d-2a23536c55a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e8dd4d3b-92a9-4e5a-a0cd-8d151e34c346" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_0c4e446d-e425-4d91-811d-2a23536c55a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_4b3ba6c8-7747-4dfd-b70c-646a62219c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_e8dd4d3b-92a9-4e5a-a0cd-8d151e34c346" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_4b3ba6c8-7747-4dfd-b70c-646a62219c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_5ef2e41f-ba00-42b5-a178-3fb334cad6c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShortTermDebtGross_59c09835-cd00-42e0-93ba-87c2dc6ccdac" xlink:href="rmd-20220630.xsd#rmd_ShortTermDebtGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermBorrowings_5ef2e41f-ba00-42b5-a178-3fb334cad6c0" xlink:to="loc_rmd_ShortTermDebtGross_59c09835-cd00-42e0-93ba-87c2dc6ccdac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_18ebb1ea-0310-4aed-85eb-e69283b70d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermBorrowings_5ef2e41f-ba00-42b5-a178-3fb334cad6c0" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_18ebb1ea-0310-4aed-85eb-e69283b70d7e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e96d13a1-7e5e-4504-a9a4-5d9a59379687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bd4bb9c4-4f82-4fc9-a43d-d35ec196ceaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e96d13a1-7e5e-4504-a9a4-5d9a59379687" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_bd4bb9c4-4f82-4fc9-a43d-d35ec196ceaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_52bcd413-abcc-449b-b059-21152c55f032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e96d13a1-7e5e-4504-a9a4-5d9a59379687" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_52bcd413-abcc-449b-b059-21152c55f032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_22e2052a-b4a5-41b4-9e4c-67fd42ccc040" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e96d13a1-7e5e-4504-a9a4-5d9a59379687" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_22e2052a-b4a5-41b4-9e4c-67fd42ccc040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b8f00f32-1796-4bbb-9eb1-f43f5ffdb79a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e96d13a1-7e5e-4504-a9a4-5d9a59379687" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b8f00f32-1796-4bbb-9eb1-f43f5ffdb79a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2cb4701b-a0b3-4eed-bf1a-10350624e6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e96d13a1-7e5e-4504-a9a4-5d9a59379687" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2cb4701b-a0b3-4eed-bf1a-10350624e6a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2db165b8-5d04-4971-a223-5948c1781816" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e96d13a1-7e5e-4504-a9a4-5d9a59379687" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2db165b8-5d04-4971-a223-5948c1781816" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9145431e-2633-45f8-911a-ccbca7c518a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_8dc94e27-eded-4e53-8a8a-23c1ff216ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9145431e-2633-45f8-911a-ccbca7c518a2" xlink:to="loc_us-gaap_OperatingLeaseLiability_8dc94e27-eded-4e53-8a8a-23c1ff216ebb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_33f2af59-6aa4-4207-8f6c-37f8a2bcc302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9145431e-2633-45f8-911a-ccbca7c518a2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_33f2af59-6aa4-4207-8f6c-37f8a2bcc302" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfComponentsOfLeaseRevenueDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LessorLeaseRevenue_3d1229ac-a501-4bab-aac5-a85e066da34d" xlink:href="rmd-20220630.xsd#rmd_LessorLeaseRevenue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseIncome_f02d4d66-8a9d-4b59-80db-85f313054bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmd_LessorLeaseRevenue_3d1229ac-a501-4bab-aac5-a85e066da34d" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseIncome_f02d4d66-8a9d-4b59-80db-85f313054bc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_67992674-8a41-405f-877d-5c40792a505d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_rmd_LessorLeaseRevenue_3d1229ac-a501-4bab-aac5-a85e066da34d" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_67992674-8a41-405f-877d-5c40792a505d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_6dff1047-33af-4ed1-a45b-cfeb27eb010f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable_32cf7469-f050-4de1-b617-8f10d9fafbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_6dff1047-33af-4ed1-a45b-cfeb27eb010f" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseReceivable_32cf7469-f050-4de1-b617-8f10d9fafbed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets_bb7d5f1c-e8c2-451c-8ea9-ed7143865cdd" xlink:href="rmd-20220630.xsd#rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_6dff1047-33af-4ed1-a45b-cfeb27eb010f" xlink:to="loc_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets_bb7d5f1c-e8c2-451c-8ea9-ed7143865cdd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_9b2c8c29-76f7-4fe3-8587-3fee6e254638" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_67212342-b3c6-4110-9e9c-66c899e34f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_9b2c8c29-76f7-4fe3-8587-3fee6e254638" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_67212342-b3c6-4110-9e9c-66c899e34f44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_d387c3b8-7482-4521-9200-02028aeed4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_9b2c8c29-76f7-4fe3-8587-3fee6e254638" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_d387c3b8-7482-4521-9200-02028aeed4ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_1a5403ed-40fb-4993-bb99-6b7910906a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_b0d4b33b-bd4d-4807-ab89-8677e80d13e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_1a5403ed-40fb-4993-bb99-6b7910906a1a" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_b0d4b33b-bd4d-4807-ab89-8677e80d13e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_8c8cf6cd-197e-4cad-8ff0-7bf08826ba1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_1a5403ed-40fb-4993-bb99-6b7910906a1a" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_8c8cf6cd-197e-4cad-8ff0-7bf08826ba1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_0ef7c66b-3b16-49d9-bec3-6f75cd838c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_1a5403ed-40fb-4993-bb99-6b7910906a1a" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_0ef7c66b-3b16-49d9-bec3-6f75cd838c81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_2203b5dd-7523-4cb8-b0b3-436c9b8fdf6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_1a5403ed-40fb-4993-bb99-6b7910906a1a" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_2203b5dd-7523-4cb8-b0b3-436c9b8fdf6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_77d0e5ac-663f-47c0-a835-4ad09e898847" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_1a5403ed-40fb-4993-bb99-6b7910906a1a" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_77d0e5ac-663f-47c0-a835-4ad09e898847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_ad1df038-9c66-4de7-b468-4b502eadec50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_1a5403ed-40fb-4993-bb99-6b7910906a1a" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_ad1df038-9c66-4de7-b468-4b502eadec50" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_71c65b24-72b2-4a69-871f-e40010add3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1faaeabc-1d84-41f6-a32f-9bbb94d8b8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_71c65b24-72b2-4a69-871f-e40010add3a1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1faaeabc-1d84-41f6-a32f-9bbb94d8b8d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a2a4fbdd-7a91-478f-b85b-d61313d1fd78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_71c65b24-72b2-4a69-871f-e40010add3a1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_a2a4fbdd-7a91-478f-b85b-d61313d1fd78" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b4eccd5d-43b9-48c6-8f43-a3bd9da140dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5a6191c3-0da7-4b22-8ce6-c6845e1f1d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b4eccd5d-43b9-48c6-8f43-a3bd9da140dd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5a6191c3-0da7-4b22-8ce6-c6845e1f1d86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1e01b97c-234e-4377-a15a-490fb95b81b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b4eccd5d-43b9-48c6-8f43-a3bd9da140dd" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1e01b97c-234e-4377-a15a-490fb95b81b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2083e6a5-3d4b-48ae-8ba6-a3831266bc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d2bbd1c7-6ebb-4ea6-b337-ae718e96d4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2083e6a5-3d4b-48ae-8ba6-a3831266bc1f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d2bbd1c7-6ebb-4ea6-b337-ae718e96d4ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_469d8f89-d497-4315-b1d7-43ef1c20dd3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2083e6a5-3d4b-48ae-8ba6-a3831266bc1f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_469d8f89-d497-4315-b1d7-43ef1c20dd3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77dc8538-c1dc-4014-9b9c-755104eabba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1fe5d226-4fa2-4810-bac0-a2ed067ace3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77dc8538-c1dc-4014-9b9c-755104eabba0" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1fe5d226-4fa2-4810-bac0-a2ed067ace3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_58ef9491-d87a-474a-ba6c-f31e4ebf6c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77dc8538-c1dc-4014-9b9c-755104eabba0" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_58ef9491-d87a-474a-ba6c-f31e4ebf6c9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_43623631-9e79-452e-b29e-bed159d54775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_77dc8538-c1dc-4014-9b9c-755104eabba0" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_43623631-9e79-452e-b29e-bed159d54775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_970ca232-422f-4720-9391-f2ace6159b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4d699860-b4a9-49fb-9dd3-12811e3e92df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_970ca232-422f-4720-9391-f2ace6159b5a" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_4d699860-b4a9-49fb-9dd3-12811e3e92df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1adee1e3-57f1-49db-b9b4-007c91cb413c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_970ca232-422f-4720-9391-f2ace6159b5a" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1adee1e3-57f1-49db-b9b4-007c91cb413c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bfbe6b63-ffd5-438e-aae5-e8b2e9c9b4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_970ca232-422f-4720-9391-f2ace6159b5a" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_bfbe6b63-ffd5-438e-aae5-e8b2e9c9b4cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bf2e0afd-b514-4bbf-8e74-6bd62b48e0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e7876f4a-3dce-4fb9-acf4-1fb6306b3ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bf2e0afd-b514-4bbf-8e74-6bd62b48e0b5" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e7876f4a-3dce-4fb9-acf4-1fb6306b3ea9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f09063a1-4312-4974-bb3d-63d8741fa1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_bf2e0afd-b514-4bbf-8e74-6bd62b48e0b5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f09063a1-4312-4974-bb3d-63d8741fa1ab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6bc04e83-1325-4a69-8437-2904be255b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_cdfc31ed-47fc-47c3-ac57-b9ec88b70c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6bc04e83-1325-4a69-8437-2904be255b6c" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_cdfc31ed-47fc-47c3-ac57-b9ec88b70c19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ccb216fc-3ed5-4b60-8f07-6dc7c9027fca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6bc04e83-1325-4a69-8437-2904be255b6c" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_ccb216fc-3ed5-4b60-8f07-6dc7c9027fca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_96dfb75b-c1bf-4bb9-96d3-60fb0f724b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6bc04e83-1325-4a69-8437-2904be255b6c" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_96dfb75b-c1bf-4bb9-96d3-60fb0f724b47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_81b10533-51e1-40de-95a4-d318ca98c386" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6bc04e83-1325-4a69-8437-2904be255b6c" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_81b10533-51e1-40de-95a4-d318ca98c386" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7e693a1c-a5ac-4bcd-9914-b902b63bf4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6bc04e83-1325-4a69-8437-2904be255b6c" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7e693a1c-a5ac-4bcd-9914-b902b63bf4ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_56c19d85-9536-44b4-bc61-32c0c4284209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6bc04e83-1325-4a69-8437-2904be255b6c" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_56c19d85-9536-44b4-bc61-32c0c4284209" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_87bf9497-0d33-4d22-8192-43b2fdc24bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6bc04e83-1325-4a69-8437-2904be255b6c" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_87bf9497-0d33-4d22-8192-43b2fdc24bd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount_742cfa43-5aa5-4fbe-a9ac-2bf2f13b5d63" xlink:href="rmd-20220630.xsd#rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6bc04e83-1325-4a69-8437-2904be255b6c" xlink:to="loc_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount_742cfa43-5aa5-4fbe-a9ac-2bf2f13b5d63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_8582490a-ef38-40a8-8397-9068e8d73b85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6bc04e83-1325-4a69-8437-2904be255b6c" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_8582490a-ef38-40a8-8397-9068e8d73b85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8c179d07-96d0-4ff9-baf2-0c8712f49d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_cb837075-8586-42ce-9532-d6cc53583a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8c179d07-96d0-4ff9-baf2-0c8712f49d8a" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_cb837075-8586-42ce-9532-d6cc53583a1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_05aff7aa-c30c-472f-a407-6b6a7328753d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8c179d07-96d0-4ff9-baf2-0c8712f49d8a" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_05aff7aa-c30c-472f-a407-6b6a7328753d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0321727e-cabf-4572-b941-ceae456b00ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f6436ff2-96ed-4172-aa7a-1ddc7abf3fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0321727e-cabf-4572-b941-ceae456b00ec" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f6436ff2-96ed-4172-aa7a-1ddc7abf3fa3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_500fe8a7-2d68-4347-8e7f-183b79ae4162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_0321727e-cabf-4572-b941-ceae456b00ec" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_500fe8a7-2d68-4347-8e7f-183b79ae4162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_40095cf8-56a0-489b-851c-1ff808a9d9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_69f1585c-99b0-4d37-a4c2-b7dbe163d174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_40095cf8-56a0-489b-851c-1ff808a9d9e6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_69f1585c-99b0-4d37-a4c2-b7dbe163d174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets_0df524c6-2c14-47ae-9b98-4b5c21897751" xlink:href="rmd-20220630.xsd#rmd_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_40095cf8-56a0-489b-851c-1ff808a9d9e6" xlink:to="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets_0df524c6-2c14-47ae-9b98-4b5c21897751" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a2eab437-2ce0-47c8-9f7b-b84d96a3e2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_40095cf8-56a0-489b-851c-1ff808a9d9e6" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a2eab437-2ce0-47c8-9f7b-b84d96a3e2cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_31e714d6-257e-4d71-86d3-c760e79b868d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_31e714d6-257e-4d71-86d3-c760e79b868d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6787af4b-ce9f-4a6f-aece-dd683f44afc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6787af4b-ce9f-4a6f-aece-dd683f44afc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_0bd589d0-da9b-4cc1-b658-553b906ddd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_0bd589d0-da9b-4cc1-b658-553b906ddd3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_52be3244-9ccd-467f-9605-c1a3a2e394b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_52be3244-9ccd-467f-9605-c1a3a2e394b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_64b74153-a4e4-4b4a-b3e4-db2af36074f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_64b74153-a4e4-4b4a-b3e4-db2af36074f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_82417f9b-099b-4490-832f-5b13b697e879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_82417f9b-099b-4490-832f-5b13b697e879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_44388d94-0537-48bb-ad0f-dcbefe31cbef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_44388d94-0537-48bb-ad0f-dcbefe31cbef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c8eb4434-135e-41ea-9f96-f30a4d7c21a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_c8eb4434-135e-41ea-9f96-f30a4d7c21a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e796efb3-44f4-4d81-a668-529ba1a3b396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_e796efb3-44f4-4d81-a668-529ba1a3b396" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_37fc441d-4832-4728-9e50-11da05519551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_37fc441d-4832-4728-9e50-11da05519551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxAssetsLeaseLiabilities_c8df47de-5bd8-4324-b884-7a7fda9626e3" xlink:href="rmd-20220630.xsd#rmd_DeferredTaxAssetsLeaseLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_rmd_DeferredTaxAssetsLeaseLiabilities_c8df47de-5bd8-4324-b884-7a7fda9626e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_33a64a3f-e627-4f11-98cc-bada4094d05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_fe53cb10-9825-47ba-915e-9f740c8c51a4" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_33a64a3f-e627-4f11-98cc-bada4094d05b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3993348a-4501-4785-85a2-93998e3a1278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment_5601d325-bfd6-4f86-b51a-028198f2a976" xlink:href="rmd-20220630.xsd#rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3993348a-4501-4785-85a2-93998e3a1278" xlink:to="loc_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment_5601d325-bfd6-4f86-b51a-028198f2a976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueFairValueAdjustment_ae01c5e1-7142-42b8-bfc0-726b4ffaa7b4" xlink:href="rmd-20220630.xsd#rmd_DeferredRevenueFairValueAdjustment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3993348a-4501-4785-85a2-93998e3a1278" xlink:to="loc_rmd_DeferredRevenueFairValueAdjustment_ae01c5e1-7142-42b8-bfc0-726b4ffaa7b4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_cc3b828c-c8c4-480d-a3c4-816b774b48ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_707e9d39-fdc8-4f74-8a17-d85c961fc5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueAfterFifthYear_cc3b828c-c8c4-480d-a3c4-816b774b48ae" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_707e9d39-fdc8-4f74-8a17-d85c961fc5c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueAfterFifthYear_69e09893-6d2a-4efc-a4bc-268d35ab67d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueAfterFifthYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueAfterFifthYear_cc3b828c-c8c4-480d-a3c4-816b774b48ae" xlink:to="loc_us-gaap_OtherCommitmentDueAfterFifthYear_69e09893-6d2a-4efc-a4bc-268d35ab67d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_6e25dd5b-f56b-4fc6-a0b9-aea0309026e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_3b1286aa-459b-4286-8300-c62267220f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_6e25dd5b-f56b-4fc6-a0b9-aea0309026e7" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_3b1286aa-459b-4286-8300-c62267220f1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_5d353b45-dd86-441e-bdf6-4f244a0854f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_6e25dd5b-f56b-4fc6-a0b9-aea0309026e7" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_5d353b45-dd86-441e-bdf6-4f244a0854f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_1ae8943d-b03d-4630-8c3f-b531ced9f8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_6e25dd5b-f56b-4fc6-a0b9-aea0309026e7" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_1ae8943d-b03d-4630-8c3f-b531ced9f8cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_ee72e242-682a-4a60-b873-3155bdd1671a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_6e25dd5b-f56b-4fc6-a0b9-aea0309026e7" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_ee72e242-682a-4a60-b873-3155bdd1671a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_72b68593-02c3-4ba8-bc71-7c15be5bdaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_6e25dd5b-f56b-4fc6-a0b9-aea0309026e7" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_72b68593-02c3-4ba8-bc71-7c15be5bdaa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_616db44a-0205-4bf7-870c-d34514696948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_6e25dd5b-f56b-4fc6-a0b9-aea0309026e7" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_616db44a-0205-4bf7-870c-d34514696948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_d0c25158-afe8-41da-b649-f53bb3c4984a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_4f7c3fbc-442b-44d8-9016-3037831f9775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear_d0c25158-afe8-41da-b649-f53bb3c4984a" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_4f7c3fbc-442b-44d8-9016-3037831f9775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_de3616f9-ffe1-4e34-9c04-ab137b0f1e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear_d0c25158-afe8-41da-b649-f53bb3c4984a" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_de3616f9-ffe1-4e34-9c04-ab137b0f1e03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_d35b1275-1713-4f4e-8143-39c4c4dd5c1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_6e39a38b-eaa3-47b8-bec2-2fd394b86564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFourthYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear_d35b1275-1713-4f4e-8143-39c4c4dd5c1e" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_6e39a38b-eaa3-47b8-bec2-2fd394b86564" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_8a1d35bf-98e5-42ac-bf7f-256cde5549ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear_d35b1275-1713-4f4e-8143-39c4c4dd5c1e" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_8a1d35bf-98e5-42ac-bf7f-256cde5549ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_43ea4131-1568-41df-9fc9-88b8186b664a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4aec4666-ee29-4eb7-a73c-9925098453d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_43ea4131-1568-41df-9fc9-88b8186b664a" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_4aec4666-ee29-4eb7-a73c-9925098453d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_b625abeb-e7ea-44bb-af17-557743caf7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_43ea4131-1568-41df-9fc9-88b8186b664a" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_b625abeb-e7ea-44bb-af17-557743caf7c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_02543a40-d425-44b3-9d06-de14c03cc2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_43ea4131-1568-41df-9fc9-88b8186b664a" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_02543a40-d425-44b3-9d06-de14c03cc2fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_97e3a727-8b9e-43fe-8c77-503e8cfc0b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_43ea4131-1568-41df-9fc9-88b8186b664a" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_97e3a727-8b9e-43fe-8c77-503e8cfc0b09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_38328ec7-a167-47a7-91e1-49b165627d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_43ea4131-1568-41df-9fc9-88b8186b664a" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_38328ec7-a167-47a7-91e1-49b165627d20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_c50221b2-0be7-4bcd-b461-6445e9a13f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PurchaseObligation_43ea4131-1568-41df-9fc9-88b8186b664a" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_c50221b2-0be7-4bcd-b461-6445e9a13f08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_a50fd474-d193-4b27-8a0d-e7ae467647a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_7b6b4b00-bf24-4ffe-af28-ebfb470a369d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_a50fd474-d193-4b27-8a0d-e7ae467647a8" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_7b6b4b00-bf24-4ffe-af28-ebfb470a369d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_bdfa8542-edde-4157-9345-ffc2175eb477" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_a50fd474-d193-4b27-8a0d-e7ae467647a8" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_bdfa8542-edde-4157-9345-ffc2175eb477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_eecde5bb-2932-4041-b675-074e4b3ba2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear_a60f2aaa-8b48-409c-9c7a-984827c2eb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFifthYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInFifthYear_eecde5bb-2932-4041-b675-074e4b3ba2c0" xlink:to="loc_us-gaap_OtherCommitmentDueInFifthYear_a60f2aaa-8b48-409c-9c7a-984827c2eb0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_92e922d1-a4f7-4856-943f-ca5c30ab10d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInFifthYear_eecde5bb-2932-4041-b675-074e4b3ba2c0" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_92e922d1-a4f7-4856-943f-ca5c30ab10d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_97cd8a51-29f8-42bd-be50-56a6ce71d97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_feb51e11-e2fc-4ed4-9bb4-efc8d5a08d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInThirdYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear_97cd8a51-29f8-42bd-be50-56a6ce71d97e" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_feb51e11-e2fc-4ed4-9bb4-efc8d5a08d7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_bd7eb4a3-d871-44e6-9ddc-08bb4f4bb532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear_97cd8a51-29f8-42bd-be50-56a6ce71d97e" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_bd7eb4a3-d871-44e6-9ddc-08bb4f4bb532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_b8d94064-6fe7-43ed-97df-c0e7fa4b20b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_0fec9af8-2188-4d69-be88-9a33eb6982db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInThirdYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherCommitment_b8d94064-6fe7-43ed-97df-c0e7fa4b20b5" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_0fec9af8-2188-4d69-be88-9a33eb6982db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_326761a0-a3f8-48ad-95a3-66eb7427ba5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherCommitment_b8d94064-6fe7-43ed-97df-c0e7fa4b20b5" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_326761a0-a3f8-48ad-95a3-66eb7427ba5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_42e8125a-df6a-4302-9da9-2da89011993d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFourthYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherCommitment_b8d94064-6fe7-43ed-97df-c0e7fa4b20b5" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_42e8125a-df6a-4302-9da9-2da89011993d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueAfterFifthYear_5882874b-3221-4651-89cc-cffbbd3c1444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueAfterFifthYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherCommitment_b8d94064-6fe7-43ed-97df-c0e7fa4b20b5" xlink:to="loc_us-gaap_OtherCommitmentDueAfterFifthYear_5882874b-3221-4651-89cc-cffbbd3c1444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_dc7fc7d9-5416-4f3d-b91a-de1645078557" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherCommitment_b8d94064-6fe7-43ed-97df-c0e7fa4b20b5" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_dc7fc7d9-5416-4f3d-b91a-de1645078557" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear_286cd9e6-0948-42a4-9d68-1122aebc0f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFifthYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherCommitment_b8d94064-6fe7-43ed-97df-c0e7fa4b20b5" xlink:to="loc_us-gaap_OtherCommitmentDueInFifthYear_286cd9e6-0948-42a4-9d68-1122aebc0f8c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails_1" xlink:type="simple" xlink:href="rmd-20220630.xsd#LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails_1"/>
  <link:calculationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_53c8cf0a-a43e-404a-9380-c1103410b7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_e91c0dc9-73dc-4660-9737-5c61901ad2d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_53c8cf0a-a43e-404a-9380-c1103410b7f4" xlink:to="loc_us-gaap_PurchaseObligation_e91c0dc9-73dc-4660-9737-5c61901ad2d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_5c410b92-fbe2-41e7-9f4a-b4cfc43da41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_53c8cf0a-a43e-404a-9380-c1103410b7f4" xlink:to="loc_us-gaap_OtherCommitment_5c410b92-fbe2-41e7-9f4a-b4cfc43da41f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>rmd-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:847d2812-be5d-4010-ae3d-4823a56f6339,g:501af745-9083-47bc-ad44-e407829835be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsOfIncome" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedStatementsOfIncome"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended" id="i79391c26323e45fd9735a4e7810fea41_ConsolidatedStatementsOfIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4fdc0b8c-0a1b-46d5-93c2-450629228513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4fdc0b8c-0a1b-46d5-93c2-450629228513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_7d58fa2d-1d12-43d0-ba1c-9f75eca5e392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_7d58fa2d-1d12-43d0-ba1c-9f75eca5e392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_334b5554-31d3-4892-b819-7245f3c19c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_334b5554-31d3-4892-b819-7245f3c19c67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_175368c1-6ada-4259-a7b5-32705722c42d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_175368c1-6ada-4259-a7b5-32705722c42d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_51238a60-7638-4e74-921a-34e289c8fddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_GrossProfit_51238a60-7638-4e74-921a-34e289c8fddf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_62eeab46-5cc5-4d44-8dce-1cb9a3296332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_62eeab46-5cc5-4d44-8dce-1cb9a3296332" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7efe2071-99c6-42e6-80c5-d8a1a197c1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7efe2071-99c6-42e6-80c5-d8a1a197c1ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_32dfdf5d-cf7f-4953-acbe-29442a2a1a0a" xlink:href="rmd-20220630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_32dfdf5d-cf7f-4953-acbe-29442a2a1a0a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0d990c34-6453-492a-8885-dc181b197bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_us-gaap_RestructuringCharges_0d990c34-6453-492a-8885-dc181b197bfb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_36e44e93-633d-47d7-8df8-ca3cc7dd61f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_us-gaap_LitigationSettlementExpense_36e44e93-633d-47d7-8df8-ca3cc7dd61f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8f126ad4-235f-4a15-ae91-915165723b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_us-gaap_OperatingExpenses_8f126ad4-235f-4a15-ae91-915165723b96" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a5828bb4-8956-4665-994a-163dff750716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_OperatingIncomeLoss_a5828bb4-8956-4665-994a-163dff750716" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_88bcbc54-4ab9-407d-b0fb-43e61388f25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_88bcbc54-4ab9-407d-b0fb-43e61388f25b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5917c108-66b5-4ad5-9879-8f950a11f173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5917c108-66b5-4ad5-9879-8f950a11f173" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_58f43d7a-e6c8-444d-8d5b-773171f25269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_58f43d7a-e6c8-444d-8d5b-773171f25269" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7edcb65f-ebec-4cca-8acd-f9aa09438615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7edcb65f-ebec-4cca-8acd-f9aa09438615" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6134f8bc-e72b-4ddf-bacc-438fb51753a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6134f8bc-e72b-4ddf-bacc-438fb51753a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ee271b2a-8077-4d23-9fdc-e3a6a52eeaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ee271b2a-8077-4d23-9fdc-e3a6a52eeaa4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b393095f-b33a-4af2-9260-9407052792c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b393095f-b33a-4af2-9260-9407052792c1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49fa9420-984a-483b-be10-9248b107f900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_NetIncomeLoss_49fa9420-984a-483b-be10-9248b107f900" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c53fb013-c0f9-431b-ae45-197b6132f0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_EarningsPerShareBasic_c53fb013-c0f9-431b-ae45-197b6132f0d9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9b6cd33b-c7bc-4f14-969f-0e8a2c6f8995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9b6cd33b-c7bc-4f14-969f-0e8a2c6f8995" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_430efe52-70ac-492b-a808-3b17cc94e24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_430efe52-70ac-492b-a808-3b17cc94e24c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d04e3599-0048-4283-9996-ef8b70bfaf31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d04e3599-0048-4283-9996-ef8b70bfaf31" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74e95ed2-b0dd-4409-be06-d7b79df3075f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74e95ed2-b0dd-4409-be06-d7b79df3075f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ee9bbe43-fb70-432f-b712-6718b57341c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_StatementTable_ee9bbe43-fb70-432f-b712-6718b57341c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_10865e0a-65a4-4dff-be12-354726a66403" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ee9bbe43-fb70-432f-b712-6718b57341c8" xlink:to="loc_srt_ProductOrServiceAxis_10865e0a-65a4-4dff-be12-354726a66403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_10865e0a-65a4-4dff-be12-354726a66403_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_10865e0a-65a4-4dff-be12-354726a66403" xlink:to="loc_srt_ProductsAndServicesDomain_10865e0a-65a4-4dff-be12-354726a66403_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_40861486-f061-429e-8234-8637aa9edf1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_10865e0a-65a4-4dff-be12-354726a66403" xlink:to="loc_srt_ProductsAndServicesDomain_40861486-f061-429e-8234-8637aa9edf1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_2bc59c52-141d-4cce-9e62-9de88e028143" xlink:href="rmd-20220630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_40861486-f061-429e-8234-8637aa9edf1d" xlink:to="loc_rmd_SleepAndRespiratoryMember_2bc59c52-141d-4cce-9e62-9de88e028143" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsServiceMember_2129f84d-a8f8-4b62-99ba-be7fb649d553" xlink:href="rmd-20220630.xsd#rmd_SoftwareAsServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_40861486-f061-429e-8234-8637aa9edf1d" xlink:to="loc_rmd_SoftwareAsServiceMember_2129f84d-a8f8-4b62-99ba-be7fb649d553" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i7e391fe527d64cecbcd01c69d3a3681c_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ceaa0300-4814-462c-8b96-60f64083716c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ceaa0300-4814-462c-8b96-60f64083716c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_117f226d-7250-4625-aa95-64e5dd434591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_117f226d-7250-4625-aa95-64e5dd434591" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b510c378-c0e2-41b0-b341-16b4811104e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockholdersEquity_b510c378-c0e2-41b0-b341-16b4811104e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_a2a9f95d-9d12-4c75-9b76-f495abb22af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_TreasuryStockCommonShares_a2a9f95d-9d12-4c75-9b76-f495abb22af3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9edf3bba-9e8f-42cd-a810-81f3fd772235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9edf3bba-9e8f-42cd-a810-81f3fd772235" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cf3e1717-13eb-4f92-8637-bfe95885a91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cf3e1717-13eb-4f92-8637-bfe95885a91f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c083d72f-f23d-4246-823b-bf03cfb871cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c083d72f-f23d-4246-823b-bf03cfb871cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_3772da0d-7264-4596-860a-01e519484706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_3772da0d-7264-4596-860a-01e519484706" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_58e8ee3a-5d48-4f1e-85ba-9a839213d30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_58e8ee3a-5d48-4f1e-85ba-9a839213d30d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7ba691ce-7a57-4667-9d10-8403fbc307e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7ba691ce-7a57-4667-9d10-8403fbc307e1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_48c5fb63-9d85-4a72-b1d1-de196b63d112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_48c5fb63-9d85-4a72-b1d1-de196b63d112" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_270ff62e-6292-4002-9b83-d535c62bd6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_270ff62e-6292-4002-9b83-d535c62bd6aa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fec2fa73-cd98-49eb-b944-f8a61e6528d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_NetIncomeLoss_fec2fa73-cd98-49eb-b944-f8a61e6528d0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_bd0b7b34-b7a7-4382-bfb8-d9302d296a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_Dividends_bd0b7b34-b7a7-4382-bfb8-d9302d296a0a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_28b39d88-98b2-4733-ab6d-4a117a020fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_83779248-1a02-4b83-af53-cf841805d88f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_c9db4353-c9e6-45ab-93a0-c40ea2638317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f5698f8e-f81e-4629-8ed7-7bec1f1a6acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f5698f8e-f81e-4629-8ed7-7bec1f1a6acf" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0c5f3922-54e5-4e95-853c-63b19406c357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ceaa0300-4814-462c-8b96-60f64083716c" xlink:to="loc_us-gaap_StatementTable_0c5f3922-54e5-4e95-853c-63b19406c357" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3567521a-c566-4fb3-b04d-fcd663effe60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0c5f3922-54e5-4e95-853c-63b19406c357" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3567521a-c566-4fb3-b04d-fcd663effe60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3567521a-c566-4fb3-b04d-fcd663effe60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3567521a-c566-4fb3-b04d-fcd663effe60" xlink:to="loc_us-gaap_EquityComponentDomain_3567521a-c566-4fb3-b04d-fcd663effe60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3567521a-c566-4fb3-b04d-fcd663effe60" xlink:to="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_99b1f8ff-da39-4613-8790-346d2cb8a908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:to="loc_us-gaap_CommonStockMember_99b1f8ff-da39-4613-8790-346d2cb8a908" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c3bf1af4-4c05-41b1-9284-369db642381f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c3bf1af4-4c05-41b1-9284-369db642381f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_b75b1b35-2832-4859-a997-fde09317c410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:to="loc_us-gaap_TreasuryStockCommonMember_b75b1b35-2832-4859-a997-fde09317c410" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7d60afca-4586-4891-bcb6-cb360c75a318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:to="loc_us-gaap_RetainedEarningsMember_7d60afca-4586-4891-bcb6-cb360c75a318" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f831f694-5d02-4798-9b30-db3db8d7d1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f831f694-5d02-4798-9b30-db3db8d7d1e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fc16db91-02ac-4981-8f8d-aff3da1a546c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0c5f3922-54e5-4e95-853c-63b19406c357" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fc16db91-02ac-4981-8f8d-aff3da1a546c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fc16db91-02ac-4981-8f8d-aff3da1a546c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fc16db91-02ac-4981-8f8d-aff3da1a546c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fc16db91-02ac-4981-8f8d-aff3da1a546c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1b6c580-c5f4-4dff-ae65-46b87f8fa693" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fc16db91-02ac-4981-8f8d-aff3da1a546c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1b6c580-c5f4-4dff-ae65-46b87f8fa693" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_490daf8a-77a4-4a8d-a7de-6fe96178c444" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1b6c580-c5f4-4dff-ae65-46b87f8fa693" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_490daf8a-77a4-4a8d-a7de-6fe96178c444" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i755ce5705e9942e790857c8bb5500268_SummaryOfSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:href="rmd-20220630.xsd#rmd_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_94b80a33-cb2d-4821-a071-da3a5d2663c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_NumberOfOperatingSegments_94b80a33-cb2d-4821-a071-da3a5d2663c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_TermOfContractUnderRevenueRecognition_c1332514-1fc2-46dd-8d29-7dea3da43929" xlink:href="rmd-20220630.xsd#rmd_TermOfContractUnderRevenueRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_rmd_TermOfContractUnderRevenueRecognition_c1332514-1fc2-46dd-8d29-7dea3da43929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_be5e0456-e3b8-48af-8f4c-dd3dc988c98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_be5e0456-e3b8-48af-8f4c-dd3dc988c98d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e91ad90e-9618-4df2-b708-c4d0180e7c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_Depreciation_e91ad90e-9618-4df2-b708-c4d0180e7c8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_bc5ece88-825c-494f-93c5-5af406fe137b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_bc5ece88-825c-494f-93c5-5af406fe137b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_124508e0-e6ef-48ec-83e1-5ee919cb114f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_124508e0-e6ef-48ec-83e1-5ee919cb114f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7f2554a8-e3a5-4fb9-9599-84f487779801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7f2554a8-e3a5-4fb9-9599-84f487779801" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_c4537648-0d15-406b-bb00-0e5fa6df7aa3" xlink:href="rmd-20220630.xsd#rmd_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_c4537648-0d15-406b-bb00-0e5fa6df7aa3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7b48ce8b-906e-4140-a50a-40c0d2ff777a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_c4537648-0d15-406b-bb00-0e5fa6df7aa3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7b48ce8b-906e-4140-a50a-40c0d2ff777a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7b48ce8b-906e-4140-a50a-40c0d2ff777a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7b48ce8b-906e-4140-a50a-40c0d2ff777a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7b48ce8b-906e-4140-a50a-40c0d2ff777a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_363a2512-71e1-4afe-ad48-0e5e5f7924d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7b48ce8b-906e-4140-a50a-40c0d2ff777a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_363a2512-71e1-4afe-ad48-0e5e5f7924d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_332016b5-b452-4de2-b80b-201dd213cec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_363a2512-71e1-4afe-ad48-0e5e5f7924d2" xlink:to="loc_us-gaap_BuildingMember_332016b5-b452-4de2-b80b-201dd213cec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e1d68c9d-bf4e-4c4b-8b32-8293f5bea658" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_c4537648-0d15-406b-bb00-0e5fa6df7aa3" xlink:to="loc_srt_RangeAxis_e1d68c9d-bf4e-4c4b-8b32-8293f5bea658" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1d68c9d-bf4e-4c4b-8b32-8293f5bea658_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e1d68c9d-bf4e-4c4b-8b32-8293f5bea658" xlink:to="loc_srt_RangeMember_e1d68c9d-bf4e-4c4b-8b32-8293f5bea658_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74261fc2-274d-4247-a917-45889e81e9a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e1d68c9d-bf4e-4c4b-8b32-8293f5bea658" xlink:to="loc_srt_RangeMember_74261fc2-274d-4247-a917-45889e81e9a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a8cda674-7a21-4d2a-8f08-203014b44f0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74261fc2-274d-4247-a917-45889e81e9a1" xlink:to="loc_srt_MinimumMember_a8cda674-7a21-4d2a-8f08-203014b44f0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5dcbf373-5095-4c3d-a725-4bdb5799dd29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74261fc2-274d-4247-a917-45889e81e9a1" xlink:to="loc_srt_MaximumMember_5dcbf373-5095-4c3d-a725-4bdb5799dd29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79c60ea-9d43-40c0-8a28-a7386d12a041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_c4537648-0d15-406b-bb00-0e5fa6df7aa3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79c60ea-9d43-40c0-8a28-a7386d12a041" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e79c60ea-9d43-40c0-8a28-a7386d12a041_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79c60ea-9d43-40c0-8a28-a7386d12a041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e79c60ea-9d43-40c0-8a28-a7386d12a041_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_137baf9d-8e16-468b-85d0-0f56f7136774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79c60ea-9d43-40c0-8a28-a7386d12a041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_137baf9d-8e16-468b-85d0-0f56f7136774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_b987afa6-3a38-40b7-8d14-fa5e75e8b147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_137baf9d-8e16-468b-85d0-0f56f7136774" xlink:to="loc_us-gaap_PatentsMember_b987afa6-3a38-40b7-8d14-fa5e75e8b147" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails" xlink:type="extended" id="i70a1b966637349a5a998d3321d934c43_SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_c3053a55-67b4-4cec-b11b-abf7d73d5f43" xlink:href="rmd-20220630.xsd#rmd_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_a3a66d17-bcb3-4605-959d-9d1ac6c6b748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_c3053a55-67b4-4cec-b11b-abf7d73d5f43" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_a3a66d17-bcb3-4605-959d-9d1ac6c6b748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8bb55e09-ed8b-4149-b5f6-3be9c1d053ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_a3a66d17-bcb3-4605-959d-9d1ac6c6b748" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8bb55e09-ed8b-4149-b5f6-3be9c1d053ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_38d02238-ac79-4b15-9947-62419e529b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_a3a66d17-bcb3-4605-959d-9d1ac6c6b748" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_38d02238-ac79-4b15-9947-62419e529b77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_a017453d-dc54-4076-aa77-ef0bd99d2ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_a3a66d17-bcb3-4605-959d-9d1ac6c6b748" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_a017453d-dc54-4076-aa77-ef0bd99d2ce3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_46816b40-e033-4076-9f92-1d46ee38d3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_c3053a55-67b4-4cec-b11b-abf7d73d5f43" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_46816b40-e033-4076-9f92-1d46ee38d3b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_11a59b38-9c31-4458-acb4-0ca7ec0586d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_46816b40-e033-4076-9f92-1d46ee38d3b7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_11a59b38-9c31-4458-acb4-0ca7ec0586d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_618007e1-6b8c-4be6-83f0-c08a14dc83ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_46816b40-e033-4076-9f92-1d46ee38d3b7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_618007e1-6b8c-4be6-83f0-c08a14dc83ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_41e5e344-d189-424c-8dc6-7cf170a981d5" xlink:href="rmd-20220630.xsd#rmd_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_c3053a55-67b4-4cec-b11b-abf7d73d5f43" xlink:to="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_41e5e344-d189-424c-8dc6-7cf170a981d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_27567cde-e070-4a1d-bdf8-c86b5167f309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_41e5e344-d189-424c-8dc6-7cf170a981d5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_27567cde-e070-4a1d-bdf8-c86b5167f309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_27567cde-e070-4a1d-bdf8-c86b5167f309_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_27567cde-e070-4a1d-bdf8-c86b5167f309" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_27567cde-e070-4a1d-bdf8-c86b5167f309_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1167c8a3-e613-49d2-b39a-4c2cc474b2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_27567cde-e070-4a1d-bdf8-c86b5167f309" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1167c8a3-e613-49d2-b39a-4c2cc474b2d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccountsReceivableNetMember_13c834ff-1239-4e86-9da2-a20a98e336dc" xlink:href="rmd-20220630.xsd#rmd_AccountsReceivableNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1167c8a3-e613-49d2-b39a-4c2cc474b2d5" xlink:to="loc_rmd_AccountsReceivableNetMember_13c834ff-1239-4e86-9da2-a20a98e336dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_99c487f8-4b52-4904-b619-2c53237fcc0d" xlink:href="rmd-20220630.xsd#rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1167c8a3-e613-49d2-b39a-4c2cc474b2d5" xlink:to="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_99c487f8-4b52-4904-b619-2c53237fcc0d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails" xlink:type="extended" id="i1c072185e200484e891f8e12e44ad697_SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8362aed7-2895-4720-add6-d8f29e99cc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e4f37229-a9d0-4b0c-b640-3b04e5579ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8362aed7-2895-4720-add6-d8f29e99cc83" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e4f37229-a9d0-4b0c-b640-3b04e5579ed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f2a3d962-d721-4931-9360-78521198144d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8362aed7-2895-4720-add6-d8f29e99cc83" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f2a3d962-d721-4931-9360-78521198144d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_366946d2-6b4b-4d91-a641-ae1b3024fe4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8362aed7-2895-4720-add6-d8f29e99cc83" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_366946d2-6b4b-4d91-a641-ae1b3024fe4e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d2193a4-9c72-4ce7-9886-be9c8e61c1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8362aed7-2895-4720-add6-d8f29e99cc83" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d2193a4-9c72-4ce7-9886-be9c8e61c1f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23725eda-019c-4ec9-8f48-0eaa39681076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d2193a4-9c72-4ce7-9886-be9c8e61c1f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23725eda-019c-4ec9-8f48-0eaa39681076" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_23725eda-019c-4ec9-8f48-0eaa39681076_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23725eda-019c-4ec9-8f48-0eaa39681076" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_23725eda-019c-4ec9-8f48-0eaa39681076_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23725eda-019c-4ec9-8f48-0eaa39681076" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_121f2050-a23a-4226-80a1-3842be14bd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_121f2050-a23a-4226-80a1-3842be14bd9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ComputerEquipmentAndSoftwareMember_1dcebdee-7a7b-427f-8b7f-1865b717a821" xlink:href="rmd-20220630.xsd#rmd_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_rmd_ComputerEquipmentAndSoftwareMember_1dcebdee-7a7b-427f-8b7f-1865b717a821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3f342c9f-4b92-4fe3-a4ed-0d14e6fafb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3f342c9f-4b92-4fe3-a4ed-0d14e6fafb6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_VehiclesAndAircraftMember_6eb2fc57-50c0-4217-8a81-7e520e7b35c0" xlink:href="rmd-20220630.xsd#rmd_VehiclesAndAircraftMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_rmd_VehiclesAndAircraftMember_6eb2fc57-50c0-4217-8a81-7e520e7b35c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember_2b853f61-be8e-49d4-80c4-cce37ee2ac17" xlink:href="rmd-20220630.xsd#rmd_ClinicalDemonstrationAndRentalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember_2b853f61-be8e-49d4-80c4-cce37ee2ac17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_02401047-e4f1-4f8d-a321-127b08357b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_02401047-e4f1-4f8d-a321-127b08357b40" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3d085999-5c3e-48f3-a11e-1c3023da2e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_us-gaap_LandMember_3d085999-5c3e-48f3-a11e-1c3023da2e18" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_4af2486f-f462-4fb5-845f-95b822706955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_us-gaap_BuildingMember_4af2486f-f462-4fb5-845f-95b822706955" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:type="extended" id="i99743d57d0974f01b2b1824049400d92_GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_5a2dc137-ea95-4450-a8e5-0b9b73817626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_62373808-8991-4afa-9351-f3fc9d7f0ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_5a2dc137-ea95-4450-a8e5-0b9b73817626" xlink:to="loc_us-gaap_GoodwillRollForward_62373808-8991-4afa-9351-f3fc9d7f0ed0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9e6388c1-cbbf-4cf4-8180-c501ef06443d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_62373808-8991-4afa-9351-f3fc9d7f0ed0" xlink:to="loc_us-gaap_Goodwill_9e6388c1-cbbf-4cf4-8180-c501ef06443d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_287b058d-4850-4bd2-9597-9e68a7f7b1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_62373808-8991-4afa-9351-f3fc9d7f0ed0" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_287b058d-4850-4bd2-9597-9e68a7f7b1e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c73dce20-e458-427f-9ed0-977a92d789dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_62373808-8991-4afa-9351-f3fc9d7f0ed0" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c73dce20-e458-427f-9ed0-977a92d789dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bf332a4d-d8c7-4c9d-9a54-0fa62c1369ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_bb4ac62e-ebe6-40fd-8c67-9aabe1d497d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_5a2dc137-ea95-4450-a8e5-0b9b73817626" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_bb4ac62e-ebe6-40fd-8c67-9aabe1d497d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c927da0a-7034-477b-a0de-35c2c8b8e619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bb4ac62e-ebe6-40fd-8c67-9aabe1d497d5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c927da0a-7034-477b-a0de-35c2c8b8e619" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c927da0a-7034-477b-a0de-35c2c8b8e619_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c927da0a-7034-477b-a0de-35c2c8b8e619" xlink:to="loc_us-gaap_SegmentDomain_c927da0a-7034-477b-a0de-35c2c8b8e619_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_63210713-c752-4a2d-9db8-946b9b8426ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c927da0a-7034-477b-a0de-35c2c8b8e619" xlink:to="loc_us-gaap_SegmentDomain_63210713-c752-4a2d-9db8-946b9b8426ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_67e2634d-e0c9-4120-b231-86db40fd181c" xlink:href="rmd-20220630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_63210713-c752-4a2d-9db8-946b9b8426ef" xlink:to="loc_rmd_SleepAndRespiratoryMember_67e2634d-e0c9-4120-b231-86db40fd181c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SaasMember_3cb1a52d-4df3-4732-8beb-ec6f8e188d95" xlink:href="rmd-20220630.xsd#rmd_SaasMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_63210713-c752-4a2d-9db8-946b9b8426ef" xlink:to="loc_rmd_SaasMember_3cb1a52d-4df3-4732-8beb-ec6f8e188d95" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails" xlink:type="extended" id="ief08476bafc0474ea334b9721d54fc69_GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_605149b7-4e2a-45ff-b2c5-f65e087bee35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e896c850-9cde-4766-8fe9-3dacb23ed281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_605149b7-4e2a-45ff-b2c5-f65e087bee35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e896c850-9cde-4766-8fe9-3dacb23ed281" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7fe50ca7-c004-40cf-a7a4-2b61159c2a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_605149b7-4e2a-45ff-b2c5-f65e087bee35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7fe50ca7-c004-40cf-a7a4-2b61159c2a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_751d0fd0-6fa4-4d09-b98e-400ef60a1030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_605149b7-4e2a-45ff-b2c5-f65e087bee35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_751d0fd0-6fa4-4d09-b98e-400ef60a1030" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_15e3ca85-9c9a-4369-bd73-a23a7ccbb0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_605149b7-4e2a-45ff-b2c5-f65e087bee35" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_15e3ca85-9c9a-4369-bd73-a23a7ccbb0f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81df2cc2-9597-426c-850c-790e2e5bdeef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_15e3ca85-9c9a-4369-bd73-a23a7ccbb0f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81df2cc2-9597-426c-850c-790e2e5bdeef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81df2cc2-9597-426c-850c-790e2e5bdeef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81df2cc2-9597-426c-850c-790e2e5bdeef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_81df2cc2-9597-426c-850c-790e2e5bdeef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a73941d-6b9a-43fd-b44d-08bc13c3aaec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81df2cc2-9597-426c-850c-790e2e5bdeef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a73941d-6b9a-43fd-b44d-08bc13c3aaec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevelopedOrCoreProductTechnologyMember_7c785945-0eff-445f-ac86-80c4d6a0b156" xlink:href="rmd-20220630.xsd#rmd_DevelopedOrCoreProductTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a73941d-6b9a-43fd-b44d-08bc13c3aaec" xlink:to="loc_rmd_DevelopedOrCoreProductTechnologyMember_7c785945-0eff-445f-ac86-80c4d6a0b156" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_d123a30c-5237-4090-a96f-f0d2ee50a107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a73941d-6b9a-43fd-b44d-08bc13c3aaec" xlink:to="loc_us-gaap_CustomerRelationshipsMember_d123a30c-5237-4090-a96f-f0d2ee50a107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_6254a4c0-4e9a-420c-a309-38b070bcbf43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a73941d-6b9a-43fd-b44d-08bc13c3aaec" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_6254a4c0-4e9a-420c-a309-38b070bcbf43" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#GoodwillandOtherIntangibleAssetsnetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails" xlink:type="extended" id="ia9b48156c87c4164ab497897fb820210_GoodwillandOtherIntangibleAssetsnetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4df6e432-58f5-4b2f-a9b6-b3c74833dd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4348c20a-133c-4a81-a225-5a02707b1fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4df6e432-58f5-4b2f-a9b6-b3c74833dd37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4348c20a-133c-4a81-a225-5a02707b1fba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_984643a5-14f4-4474-ac16-2ec8a21ad1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4df6e432-58f5-4b2f-a9b6-b3c74833dd37" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_984643a5-14f4-4474-ac16-2ec8a21ad1f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f5bcef8-2dc9-45fb-aa0a-51f649867488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4df6e432-58f5-4b2f-a9b6-b3c74833dd37" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f5bcef8-2dc9-45fb-aa0a-51f649867488" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f06fc272-cbca-4100-91c3-9d50b70e36f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f5bcef8-2dc9-45fb-aa0a-51f649867488" xlink:to="loc_srt_RangeAxis_f06fc272-cbca-4100-91c3-9d50b70e36f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f06fc272-cbca-4100-91c3-9d50b70e36f4_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f06fc272-cbca-4100-91c3-9d50b70e36f4" xlink:to="loc_srt_RangeMember_f06fc272-cbca-4100-91c3-9d50b70e36f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bb9d51fb-1054-46c8-9725-a7d6ed8fd0fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f06fc272-cbca-4100-91c3-9d50b70e36f4" xlink:to="loc_srt_RangeMember_bb9d51fb-1054-46c8-9725-a7d6ed8fd0fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc7f2b62-43b7-4a51-ba0a-752bf6714e33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bb9d51fb-1054-46c8-9725-a7d6ed8fd0fb" xlink:to="loc_srt_MinimumMember_bc7f2b62-43b7-4a51-ba0a-752bf6714e33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_224971b4-fb3f-4848-a406-7cebbab72602" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bb9d51fb-1054-46c8-9725-a7d6ed8fd0fb" xlink:to="loc_srt_MaximumMember_224971b4-fb3f-4848-a406-7cebbab72602" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a39b968-ed80-41c7-ae2f-9cdbcdcfd0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f5bcef8-2dc9-45fb-aa0a-51f649867488" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a39b968-ed80-41c7-ae2f-9cdbcdcfd0e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a39b968-ed80-41c7-ae2f-9cdbcdcfd0e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a39b968-ed80-41c7-ae2f-9cdbcdcfd0e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a39b968-ed80-41c7-ae2f-9cdbcdcfd0e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347311bd-6ad0-4af6-936a-060f156f2cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a39b968-ed80-41c7-ae2f-9cdbcdcfd0e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347311bd-6ad0-4af6-936a-060f156f2cff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IdentifiedIntangibleAssetsMember_70111915-30be-4e85-b9ac-e9debf72a0f3" xlink:href="rmd-20220630.xsd#rmd_IdentifiedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347311bd-6ad0-4af6-936a-060f156f2cff" xlink:to="loc_rmd_IdentifiedIntangibleAssetsMember_70111915-30be-4e85-b9ac-e9debf72a0f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_388eba3f-6548-4e04-a7c3-93f70caee8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347311bd-6ad0-4af6-936a-060f156f2cff" xlink:to="loc_us-gaap_PatentsMember_388eba3f-6548-4e04-a7c3-93f70caee8c1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#InvestmentsScheduleOfChangesInEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails" xlink:type="extended" id="ief7ddeafa77c46d3b4fb313bf4a35a82_InvestmentsScheduleOfChangesInEquityInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bcbd0ac4-d608-4777-bc17-71f71bbf0709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:href="rmd-20220630.xsd#rmd_EquityMethodInvestmentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bcbd0ac4-d608-4777-bc17-71f71bbf0709" xlink:to="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestments_e7520be0-42c8-4ca9-af03-dd19f2ae429f" xlink:href="rmd-20220630.xsd#rmd_EquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_rmd_EquityInvestments_e7520be0-42c8-4ca9-af03-dd19f2ae429f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AdditionalEquityInvestments_1f095c44-c048-4f38-be41-30e8c8881063" xlink:href="rmd-20220630.xsd#rmd_AdditionalEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_rmd_AdditionalEquityInvestments_1f095c44-c048-4f38-be41-30e8c8881063" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_8b01b83a-8b79-4992-9b95-84f203b2b6f6" xlink:href="rmd-20220630.xsd#rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_8b01b83a-8b79-4992-9b95-84f203b2b6f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_66235fc8-a4db-453a-9807-31fed12f452b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_66235fc8-a4db-453a-9807-31fed12f452b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a352fe7d-cdb9-4c49-a684-debdffe435a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a352fe7d-cdb9-4c49-a684-debdffe435a7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments_08269224-5d1d-449f-b0d8-e79e5cf3ab43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_us-gaap_ImpairmentOfInvestments_08269224-5d1d-449f-b0d8-e79e5cf3ab43" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReclassificationsInEquityInvestments_772bfb10-63bd-47bd-bece-109a756b6ff6" xlink:href="rmd-20220630.xsd#rmd_ReclassificationsInEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_rmd_ReclassificationsInEquityInvestments_772bfb10-63bd-47bd-bece-109a756b6ff6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1f249e63-caee-4e8b-ab23-eabf2065fb04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1f249e63-caee-4e8b-ab23-eabf2065fb04" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestments_f64e40e4-0aed-476c-a871-8d7b57fa9da3" xlink:href="rmd-20220630.xsd#rmd_EquityInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f7262426-4041-4f37-adf3-c5e7a9e97224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bcbd0ac4-d608-4777-bc17-71f71bbf0709" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f7262426-4041-4f37-adf3-c5e7a9e97224" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_05af9976-038d-4600-9990-0ec455d16e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f7262426-4041-4f37-adf3-c5e7a9e97224" xlink:to="loc_us-gaap_FinancialInstrumentAxis_05af9976-038d-4600-9990-0ec455d16e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05af9976-038d-4600-9990-0ec455d16e16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_05af9976-038d-4600-9990-0ec455d16e16" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_05af9976-038d-4600-9990-0ec455d16e16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf822a06-e316-4e09-a587-05a59aff3919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_05af9976-038d-4600-9990-0ec455d16e16" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf822a06-e316-4e09-a587-05a59aff3919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonMarketableSecuritiesMember_5de6695e-71ef-4e8c-b290-dfc9344acbe1" xlink:href="rmd-20220630.xsd#rmd_NonMarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf822a06-e316-4e09-a587-05a59aff3919" xlink:to="loc_rmd_NonMarketableSecuritiesMember_5de6695e-71ef-4e8c-b290-dfc9344acbe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableSecuritiesMember_2fd200b0-c7e2-4cef-b9b5-c8b0d697b300" xlink:href="rmd-20220630.xsd#rmd_MarketableSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf822a06-e316-4e09-a587-05a59aff3919" xlink:to="loc_rmd_MarketableSecuritiesMember_2fd200b0-c7e2-4cef-b9b5-c8b0d697b300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_32f21de9-aa6c-4fb4-b80a-afba015c0673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf822a06-e316-4e09-a587-05a59aff3919" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_32f21de9-aa6c-4fb4-b80a-afba015c0673" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/DebtNarrativeDetails" xlink:type="extended" id="i0606658327094a54bcff98f460e61049_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e276520c-593b-4099-89e3-cc29c0b4a2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e276520c-593b-4099-89e3-cc29c0b4a2c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UncommittedOptionToIncreaseCreditFacility_e03634db-d126-4816-9e23-1954b0b9dd3d" xlink:href="rmd-20220630.xsd#rmd_UncommittedOptionToIncreaseCreditFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_rmd_UncommittedOptionToIncreaseCreditFacility_e03634db-d126-4816-9e23-1954b0b9dd3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_25dfa309-cd5e-4c5f-b464-0fe385b57938" xlink:href="rmd-20220630.xsd#rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_25dfa309-cd5e-4c5f-b464-0fe385b57938" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_70bddb18-ecd0-4583-98a0-39de34f85b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_70bddb18-ecd0-4583-98a0-39de34f85b3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e85d6585-d496-4abc-850f-d451202c671c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e85d6585-d496-4abc-850f-d451202c671c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2884a9c9-1851-4433-9b58-54af5e54ff61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2884a9c9-1851-4433-9b58-54af5e54ff61" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_8d39cb1e-7f94-4a6b-9a6d-9f65baa05a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_8d39cb1e-7f94-4a6b-9a6d-9f65baa05a47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_473dea0c-c74e-4cb1-a200-c43bc735baa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_473dea0c-c74e-4cb1-a200-c43bc735baa2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_285e3dff-90f5-4d2f-b444-a2a9c0619fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LongTermDebtFairValue_285e3dff-90f5-4d2f-b444-a2a9c0619fcf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_062929cc-8dcd-4f79-ba6c-ee73e9cb43bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_062929cc-8dcd-4f79-ba6c-ee73e9cb43bd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb31a5e4-b06a-43af-9d29-01c686d755d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb31a5e4-b06a-43af-9d29-01c686d755d8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtToConsolidatedEbitdaRatio_e1d7f68f-4a12-44c8-8a02-c912f7767c35" xlink:href="rmd-20220630.xsd#rmd_DebtToConsolidatedEbitdaRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_rmd_DebtToConsolidatedEbitdaRatio_e1d7f68f-4a12-44c8-8a02-c912f7767c35" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_5be954f1-4e4e-4dcb-b765-063c40397265" xlink:href="rmd-20220630.xsd#rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_5be954f1-4e4e-4dcb-b765-063c40397265" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_700a0bd9-dd25-45b6-9c69-243489d487e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LongTermDebt_700a0bd9-dd25-45b6-9c69-243489d487e9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_4c0b9dd6-b389-4cc1-8d4e-45244900c3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_4c0b9dd6-b389-4cc1-8d4e-45244900c3c9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_04a21b2e-425a-4401-89ad-4a0ee310f797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_04a21b2e-425a-4401-89ad-4a0ee310f797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_04a21b2e-425a-4401-89ad-4a0ee310f797_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_04a21b2e-425a-4401-89ad-4a0ee310f797" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_04a21b2e-425a-4401-89ad-4a0ee310f797_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_04a21b2e-425a-4401-89ad-4a0ee310f797" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesOneMember_7dcd08c4-5086-4289-af89-27e89b3fee6c" xlink:href="rmd-20220630.xsd#rmd_SeniorNotesOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:to="loc_rmd_SeniorNotesOneMember_7dcd08c4-5086-4289-af89-27e89b3fee6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesTwoMember_f2a66a93-cfbc-4710-b105-5a26de19b17f" xlink:href="rmd-20220630.xsd#rmd_SeniorNotesTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:to="loc_rmd_SeniorNotesTwoMember_f2a66a93-cfbc-4710-b105-5a26de19b17f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_18e0cecb-2060-4b34-8fbc-b9f7ec06fffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:to="loc_us-gaap_SeniorNotesMember_18e0cecb-2060-4b34-8fbc-b9f7ec06fffe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_2a01ea47-117c-451f-819e-b1eaa4ab7db3" xlink:href="rmd-20220630.xsd#rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:to="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_2a01ea47-117c-451f-819e-b1eaa4ab7db3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6c60f301-8239-40de-80a4-bc3718b1161e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_srt_RangeAxis_6c60f301-8239-40de-80a4-bc3718b1161e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c60f301-8239-40de-80a4-bc3718b1161e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6c60f301-8239-40de-80a4-bc3718b1161e" xlink:to="loc_srt_RangeMember_6c60f301-8239-40de-80a4-bc3718b1161e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f0628cf-9983-41c3-9004-d6e2367e30e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6c60f301-8239-40de-80a4-bc3718b1161e" xlink:to="loc_srt_RangeMember_3f0628cf-9983-41c3-9004-d6e2367e30e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_89880eba-462f-4afc-9fcb-7a9f88bc58b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3f0628cf-9983-41c3-9004-d6e2367e30e2" xlink:to="loc_srt_MinimumMember_89880eba-462f-4afc-9fcb-7a9f88bc58b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c96634dd-71f2-4e2f-96ad-d235419a5d5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3f0628cf-9983-41c3-9004-d6e2367e30e2" xlink:to="loc_srt_MaximumMember_c96634dd-71f2-4e2f-96ad-d235419a5d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_3d43797b-e2fb-4b10-b8cc-f29497a16288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_3d43797b-e2fb-4b10-b8cc-f29497a16288" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_3d43797b-e2fb-4b10-b8cc-f29497a16288_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_3d43797b-e2fb-4b10-b8cc-f29497a16288" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_3d43797b-e2fb-4b10-b8cc-f29497a16288_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_5a8f1750-e0cf-41cb-a37c-47cc9e291f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_3d43797b-e2fb-4b10-b8cc-f29497a16288" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_5a8f1750-e0cf-41cb-a37c-47cc9e291f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_32818b30-fa6c-4367-aac2-3ca4a85eea48" xlink:href="rmd-20220630.xsd#rmd_MufgUnionBankNaAndWestpacBankingCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5a8f1750-e0cf-41cb-a37c-47cc9e291f72" xlink:to="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_32818b30-fa6c-4367-aac2-3ca4a85eea48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankMember_b3283af4-c56b-4528-8e6c-072c76b98d44" xlink:href="rmd-20220630.xsd#rmd_MufgUnionBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5a8f1750-e0cf-41cb-a37c-47cc9e291f72" xlink:to="loc_rmd_MufgUnionBankMember_b3283af4-c56b-4528-8e6c-072c76b98d44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_647af4d9-57fd-402b-af2f-940133496330" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_dei_LegalEntityAxis_647af4d9-57fd-402b-af2f-940133496330" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_647af4d9-57fd-402b-af2f-940133496330_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_647af4d9-57fd-402b-af2f-940133496330" xlink:to="loc_dei_EntityDomain_647af4d9-57fd-402b-af2f-940133496330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_077b7c00-0660-4ead-938b-978e77045c14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_647af4d9-57fd-402b-af2f-940133496330" xlink:to="loc_dei_EntityDomain_077b7c00-0660-4ead-938b-978e77045c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedLimitedMember_f790deeb-9cdf-4edc-95da-4c2c9cfa2fab" xlink:href="rmd-20220630.xsd#rmd_ResmedLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_077b7c00-0660-4ead-938b-978e77045c14" xlink:to="loc_rmd_ResmedLimitedMember_f790deeb-9cdf-4edc-95da-4c2c9cfa2fab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_993a4b06-bb59-4d6b-96b5-7245fd7a9f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_us-gaap_CreditFacilityAxis_993a4b06-bb59-4d6b-96b5-7245fd7a9f4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_993a4b06-bb59-4d6b-96b5-7245fd7a9f4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_993a4b06-bb59-4d6b-96b5-7245fd7a9f4e" xlink:to="loc_us-gaap_CreditFacilityDomain_993a4b06-bb59-4d6b-96b5-7245fd7a9f4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1afbf703-cb82-47aa-aec5-fc8b71f82662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_993a4b06-bb59-4d6b-96b5-7245fd7a9f4e" xlink:to="loc_us-gaap_CreditFacilityDomain_1afbf703-cb82-47aa-aec5-fc8b71f82662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a94712cf-9180-4f4e-ad99-06ad4a75d311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1afbf703-cb82-47aa-aec5-fc8b71f82662" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a94712cf-9180-4f4e-ad99-06ad4a75d311" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_f13cb34b-f829-4bfa-a6c8-ae31bbfab99e" xlink:href="rmd-20220630.xsd#rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1afbf703-cb82-47aa-aec5-fc8b71f82662" xlink:to="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_f13cb34b-f829-4bfa-a6c8-ae31bbfab99e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_637509d7-4233-4d84-8ec5-8d674d7dfb93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_us-gaap_VariableRateAxis_637509d7-4233-4d84-8ec5-8d674d7dfb93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_637509d7-4233-4d84-8ec5-8d674d7dfb93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_637509d7-4233-4d84-8ec5-8d674d7dfb93" xlink:to="loc_us-gaap_VariableRateDomain_637509d7-4233-4d84-8ec5-8d674d7dfb93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_68c750cf-da1f-4bbc-b4de-1fa9e6d028dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_637509d7-4233-4d84-8ec5-8d674d7dfb93" xlink:to="loc_us-gaap_VariableRateDomain_68c750cf-da1f-4bbc-b4de-1fa9e6d028dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9eb8d341-0ea5-4df8-9249-795929ca2c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_68c750cf-da1f-4bbc-b4de-1fa9e6d028dc" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9eb8d341-0ea5-4df8-9249-795929ca2c3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_b76b971d-3709-4420-b47a-4aa1093ad60a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_68c750cf-da1f-4bbc-b4de-1fa9e6d028dc" xlink:to="loc_us-gaap_BaseRateMember_b76b971d-3709-4420-b47a-4aa1093ad60a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/LeasesNarrativeDetails" xlink:type="extended" id="id022fe38fdc34d22aab5e9236acc9890_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ef0ddbed-8af5-43be-a87b-8184402b2f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ef0ddbed-8af5-43be-a87b-8184402b2f25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_4219c1b8-c992-4921-b67a-971eb15b3c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:to="loc_us-gaap_OperatingLeaseCost_4219c1b8-c992-4921-b67a-971eb15b3c39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments_41869060-9a1b-47a2-a3b5-52c0576ae03a" xlink:href="rmd-20220630.xsd#rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:to="loc_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments_41869060-9a1b-47a2-a3b5-52c0576ae03a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_5a698744-dfbb-4d7f-8e41-bbe6bfcf4297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_5a698744-dfbb-4d7f-8e41-bbe6bfcf4297" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a4e11052-d5a3-406e-bde1-d51e573afc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a4e11052-d5a3-406e-bde1-d51e573afc99" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_964e0086-9ab3-4be8-bbc3-7184eeb5ba3c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a4e11052-d5a3-406e-bde1-d51e573afc99" xlink:to="loc_srt_RangeAxis_964e0086-9ab3-4be8-bbc3-7184eeb5ba3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_964e0086-9ab3-4be8-bbc3-7184eeb5ba3c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_964e0086-9ab3-4be8-bbc3-7184eeb5ba3c" xlink:to="loc_srt_RangeMember_964e0086-9ab3-4be8-bbc3-7184eeb5ba3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bd7367c9-421e-426b-8d7b-0f98c5ea3cb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_964e0086-9ab3-4be8-bbc3-7184eeb5ba3c" xlink:to="loc_srt_RangeMember_bd7367c9-421e-426b-8d7b-0f98c5ea3cb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c78695b4-66d7-4ff2-8270-a19996bc10d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bd7367c9-421e-426b-8d7b-0f98c5ea3cb0" xlink:to="loc_srt_MinimumMember_c78695b4-66d7-4ff2-8270-a19996bc10d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c3ba29b-a814-45b4-aee1-51fa4d295a34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_bd7367c9-421e-426b-8d7b-0f98c5ea3cb0" xlink:to="loc_srt_MaximumMember_5c3ba29b-a814-45b4-aee1-51fa4d295a34" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i112dd5bbc13e401c91bdd242fa01b178_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_8b636ce8-cf98-4320-8ecc-f30f668e08de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_8b636ce8-cf98-4320-8ecc-f30f668e08de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_8a5fce03-94da-44e9-bfb6-00c532251933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_TreasuryStockShares_8a5fce03-94da-44e9-bfb6-00c532251933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_937a4359-f4f4-4555-b83d-dc2e08d58c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_TreasuryStockValue_937a4359-f4f4-4555-b83d-dc2e08d58c92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_4844b10e-c7f2-470d-8750-13fc7d467550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_4844b10e-c7f2-470d-8750-13fc7d467550" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d73f23f4-eb60-4ba4-be0a-ec492ae327a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d73f23f4-eb60-4ba4-be0a-ec492ae327a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e6bc6f5e-7beb-42f7-88f8-110b564cf77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e6bc6f5e-7beb-42f7-88f8-110b564cf77f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f1411c83-0cdc-428c-943f-57ded6dba073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f1411c83-0cdc-428c-943f-57ded6dba073" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4e02f06e-d8cd-4d63-9624-8338c8f5ebf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4e02f06e-d8cd-4d63-9624-8338c8f5ebf6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_297dec95-9e82-4f00-ae2b-db61e186a829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_297dec95-9e82-4f00-ae2b-db61e186a829" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_171747ce-67a4-401d-abfe-0532238c5fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_171747ce-67a4-401d-abfe-0532238c5fa4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_VestingAmountMaximumPercentageOfOriginalGrant_5135a2b1-b046-4f63-b185-8747da7aa8ec" xlink:href="rmd-20220630.xsd#rmd_VestingAmountMaximumPercentageOfOriginalGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_VestingAmountMaximumPercentageOfOriginalGrant_5135a2b1-b046-4f63-b185-8747da7aa8ec" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_850aab17-83a1-4a1b-837f-93ff2f6fc4fb" xlink:href="rmd-20220630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_850aab17-83a1-4a1b-837f-93ff2f6fc4fb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_935104d4-e7c5-494b-a92f-8f1254303569" xlink:href="rmd-20220630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_935104d4-e7c5-494b-a92f-8f1254303569" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_38d4ea67-75b3-4ad2-9f98-2ae99bc53a58" xlink:href="rmd-20220630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_38d4ea67-75b3-4ad2-9f98-2ae99bc53a58" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_850b7d79-47c8-4f32-b125-5ad38c570b4a" xlink:href="rmd-20220630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_850b7d79-47c8-4f32-b125-5ad38c570b4a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_93c34c08-74ec-49c3-8826-3b698b742ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_93c34c08-74ec-49c3-8826-3b698b742ea4" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e02294f4-06cd-4b4c-bde3-e9522008bd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e02294f4-06cd-4b4c-bde3-e9522008bd7e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_83a50f86-4fa7-4d45-b71a-008177bd7b8e" xlink:href="rmd-20220630.xsd#rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_83a50f86-4fa7-4d45-b71a-008177bd7b8e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_e1e77aed-b743-41e9-adbb-bdc78207656c" xlink:href="rmd-20220630.xsd#rmd_MaximumNumberOfSharesSubjectToAwardsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_e1e77aed-b743-41e9-adbb-bdc78207656c" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfCommonStockGranted_5f102888-cd78-41f8-8c54-29a82a80ca29" xlink:href="rmd-20220630.xsd#rmd_NumberOfCommonStockGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_NumberOfCommonStockGranted_5f102888-cd78-41f8-8c54-29a82a80ca29" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_3ab603ce-bbe5-4ae1-a826-fc0289351cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_3ab603ce-bbe5-4ae1-a826-fc0289351cf2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_482f72f2-9658-4881-856b-e2178b162537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_482f72f2-9658-4881-856b-e2178b162537" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b1b95992-4064-40eb-b273-93b657f4a1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b1b95992-4064-40eb-b273-93b657f4a1a7" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8ded1aaa-6a7e-4cb9-a7d4-1365cf6c964b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8ded1aaa-6a7e-4cb9-a7d4-1365cf6c964b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_670a2807-48e7-40f5-bc1b-abc1fbe08035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_670a2807-48e7-40f5-bc1b-abc1fbe08035" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod_69642f31-31e9-4f3c-bd18-c7995bb61966" xlink:href="rmd-20220630.xsd#rmd_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod_69642f31-31e9-4f3c-bd18-c7995bb61966" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_b18d6d51-f40b-4ab5-a854-e7c00a1795e3" xlink:href="rmd-20220630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_b18d6d51-f40b-4ab5-a854-e7c00a1795e3" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_a429b752-880a-4d2c-a28e-94cbce2927c6" xlink:href="rmd-20220630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_a429b752-880a-4d2c-a28e-94cbce2927c6" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_4de407ea-4e49-4b78-ac27-74a15a4a9a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_4de407ea-4e49-4b78-ac27-74a15a4a9a58" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0c55ec13-2d18-4d0a-b624-44d4db1d089a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0c55ec13-2d18-4d0a-b624-44d4db1d089a" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfOfferings_ff4a22e4-6b75-4ea8-9376-29375819b7df" xlink:href="rmd-20220630.xsd#rmd_NumberOfOfferings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_NumberOfOfferings_ff4a22e4-6b75-4ea8-9376-29375819b7df" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6e9e7402-b3ff-4448-a332-c35783caedef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6e9e7402-b3ff-4448-a332-c35783caedef" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e5711c9-1e51-4935-8d57-18a419b4a16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e5711c9-1e51-4935-8d57-18a419b4a16a" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1bb48932-dad3-4a93-83cb-8a50accd9ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1bb48932-dad3-4a93-83cb-8a50accd9ca1" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b487d73e-ec8b-439f-ae74-b485917da598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:to="loc_us-gaap_AwardTypeAxis_b487d73e-ec8b-439f-ae74-b485917da598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b487d73e-ec8b-439f-ae74-b485917da598_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_b487d73e-ec8b-439f-ae74-b485917da598" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b487d73e-ec8b-439f-ae74-b485917da598_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a603e83-3a72-4c05-aa2b-d87ce50f6f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_b487d73e-ec8b-439f-ae74-b485917da598" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a603e83-3a72-4c05-aa2b-d87ce50f6f41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_12438f22-71e5-42dd-918f-a94f032c3dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a603e83-3a72-4c05-aa2b-d87ce50f6f41" xlink:to="loc_us-gaap_PerformanceSharesMember_12438f22-71e5-42dd-918f-a94f032c3dde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a34363e1-1d72-4a9e-aa60-78c63f8c4ffa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:to="loc_srt_RangeAxis_a34363e1-1d72-4a9e-aa60-78c63f8c4ffa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a34363e1-1d72-4a9e-aa60-78c63f8c4ffa_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a34363e1-1d72-4a9e-aa60-78c63f8c4ffa" xlink:to="loc_srt_RangeMember_a34363e1-1d72-4a9e-aa60-78c63f8c4ffa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a359ee52-3ab0-488e-9234-d0c6deeefc7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a34363e1-1d72-4a9e-aa60-78c63f8c4ffa" xlink:to="loc_srt_RangeMember_a359ee52-3ab0-488e-9234-d0c6deeefc7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d84714b7-5899-42b1-8584-7d9286a31549" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a359ee52-3ab0-488e-9234-d0c6deeefc7d" xlink:to="loc_srt_MinimumMember_d84714b7-5899-42b1-8584-7d9286a31549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1cc7b70-7746-46f7-a0ad-9035fc9d66bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a359ee52-3ab0-488e-9234-d0c6deeefc7d" xlink:to="loc_srt_MaximumMember_b1cc7b70-7746-46f7-a0ad-9035fc9d66bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0516630a-4c4b-417a-8f2e-55dca6e88f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:to="loc_us-gaap_PlanNameAxis_0516630a-4c4b-417a-8f2e-55dca6e88f13" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0516630a-4c4b-417a-8f2e-55dca6e88f13_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0516630a-4c4b-417a-8f2e-55dca6e88f13" xlink:to="loc_us-gaap_PlanNameDomain_0516630a-4c4b-417a-8f2e-55dca6e88f13_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_04408499-d8a6-414f-a747-770feabee0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0516630a-4c4b-417a-8f2e-55dca6e88f13" xlink:to="loc_us-gaap_PlanNameDomain_04408499-d8a6-414f-a747-770feabee0ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedInc2009IncentiveAwardPlanMember_11a20bdf-5005-43cb-867f-4c907e6c47b9" xlink:href="rmd-20220630.xsd#rmd_ResmedInc2009IncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_04408499-d8a6-414f-a747-770feabee0ac" xlink:to="loc_rmd_ResmedInc2009IncentiveAwardPlanMember_11a20bdf-5005-43cb-867f-4c907e6c47b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmendedAndRestated2009PlanMember_7708feb1-53f1-4a4e-bfa3-49881534a655" xlink:href="rmd-20220630.xsd#rmd_AmendedAndRestated2009PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_04408499-d8a6-414f-a747-770feabee0ac" xlink:to="loc_rmd_AmendedAndRestated2009PlanMember_7708feb1-53f1-4a4e-bfa3-49881534a655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanMember_657d23e1-1d7e-4363-8fe5-d9f45836a2e2" xlink:href="rmd-20220630.xsd#rmd_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_04408499-d8a6-414f-a747-770feabee0ac" xlink:to="loc_rmd_EmployeeStockPurchasePlanMember_657d23e1-1d7e-4363-8fe5-d9f45836a2e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_46bec4a6-195b-4ff1-84f8-e425cfc513cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_46bec4a6-195b-4ff1-84f8-e425cfc513cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_46bec4a6-195b-4ff1-84f8-e425cfc513cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_46bec4a6-195b-4ff1-84f8-e425cfc513cb" xlink:to="loc_us-gaap_EquityComponentDomain_46bec4a6-195b-4ff1-84f8-e425cfc513cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8dd00b3-241f-411a-8eda-95e517ed2642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_46bec4a6-195b-4ff1-84f8-e425cfc513cb" xlink:to="loc_us-gaap_EquityComponentDomain_e8dd00b3-241f-411a-8eda-95e517ed2642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_765ee45d-f337-48da-81e4-7ff5b93a0dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e8dd00b3-241f-411a-8eda-95e517ed2642" xlink:to="loc_us-gaap_TreasuryStockMember_765ee45d-f337-48da-81e4-7ff5b93a0dab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e69462f7-8e8b-4c8d-93f4-a67810631c5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:to="loc_srt_TitleOfIndividualAxis_e69462f7-8e8b-4c8d-93f4-a67810631c5f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e69462f7-8e8b-4c8d-93f4-a67810631c5f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_e69462f7-8e8b-4c8d-93f4-a67810631c5f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_e69462f7-8e8b-4c8d-93f4-a67810631c5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_663645a1-3ac0-4a12-aca1-a73154762d42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_e69462f7-8e8b-4c8d-93f4-a67810631c5f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_663645a1-3ac0-4a12-aca1-a73154762d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonEmployeeDirectorMember_6a32b227-dbfc-4fde-9799-5d619456a55b" xlink:href="rmd-20220630.xsd#rmd_NonEmployeeDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_663645a1-3ac0-4a12-aca1-a73154762d42" xlink:to="loc_rmd_NonEmployeeDirectorMember_6a32b227-dbfc-4fde-9799-5d619456a55b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_92a2b743-41b1-4d5e-8577-9aee75f16e70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_663645a1-3ac0-4a12-aca1-a73154762d42" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_92a2b743-41b1-4d5e-8577-9aee75f16e70" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails" xlink:type="extended" id="i259683a2dd6c4ef4b4f79deac92aea2d_StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d4a3b-9bdb-47a4-ba24-d37f9827781c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d4a3b-9bdb-47a4-ba24-d37f9827781c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_083d3a31-f945-450e-9faf-f2bdeeec2baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_083d3a31-f945-450e-9faf-f2bdeeec2baf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5de1e86a-3aba-4d00-8bdd-c3177d5ff0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5de1e86a-3aba-4d00-8bdd-c3177d5ff0eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_001d8072-28fe-423c-a623-e8ad7454c144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_001d8072-28fe-423c-a623-e8ad7454c144" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9a816457-1191-425d-88b0-dadf79dc9e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9a816457-1191-425d-88b0-dadf79dc9e05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75831495-2e0d-4844-ab84-0845c52d63d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fc7cbcca-a65c-4a78-9f79-5afebfe890f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fc7cbcca-a65c-4a78-9f79-5afebfe890f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cfc7c0d1-af60-4d32-a2e5-9fe42a003653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cfc7c0d1-af60-4d32-a2e5-9fe42a003653" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7c6feebf-f70f-4703-931b-56e54f506ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7c6feebf-f70f-4703-931b-56e54f506ae2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue_0c8f8c24-3987-448e-a2b9-8ceb369da0af" xlink:href="rmd-20220630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:to="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue_0c8f8c24-3987-448e-a2b9-8ceb369da0af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7871ef3d-795e-49e6-b5f4-1d126a15f3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7871ef3d-795e-49e6-b5f4-1d126a15f3cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_98e6748e-44e6-4125-9def-afb66542ead7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_94dabf5d-1579-42d0-b5dd-bbfe948e924b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_94dabf5d-1579-42d0-b5dd-bbfe948e924b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_e502ac5b-c29b-4fb4-9be8-e3021c559145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_94dabf5d-1579-42d0-b5dd-bbfe948e924b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_e502ac5b-c29b-4fb4-9be8-e3021c559145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_ce6a32b2-21a8-4590-a3c5-a437b369ff9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_ce6a32b2-21a8-4590-a3c5-a437b369ff9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cd44d13-5bf2-42d3-9ed7-1e2007a4d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cd44d13-5bf2-42d3-9ed7-1e2007a4d9f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc93fdbe-a03d-4af0-91af-e65d4891f81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cd44d13-5bf2-42d3-9ed7-1e2007a4d9f1" xlink:to="loc_us-gaap_AwardTypeAxis_dc93fdbe-a03d-4af0-91af-e65d4891f81b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc93fdbe-a03d-4af0-91af-e65d4891f81b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_dc93fdbe-a03d-4af0-91af-e65d4891f81b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dc93fdbe-a03d-4af0-91af-e65d4891f81b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79812de0-136d-4151-ac58-140085b9fc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_dc93fdbe-a03d-4af0-91af-e65d4891f81b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79812de0-136d-4151-ac58-140085b9fc2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_84380a7e-f3e5-44b8-a5d5-2883356caf49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79812de0-136d-4151-ac58-140085b9fc2b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_84380a7e-f3e5-44b8-a5d5-2883356caf49" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails" xlink:type="extended" id="i4e9d68b2d9644a0eab04e6f3eb03a413_StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50b4bea1-bd33-4e5a-9c14-89be744cc56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50b4bea1-bd33-4e5a-9c14-89be744cc56e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_32acd34f-a822-46f6-b40c-1650164a632f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_32acd34f-a822-46f6-b40c-1650164a632f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fdda5b0d-cfa7-4bb7-b993-46444ae49f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fdda5b0d-cfa7-4bb7-b993-46444ae49f04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_41de6d87-e21f-4b4e-8689-144e118594ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_41de6d87-e21f-4b4e-8689-144e118594ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35e8d069-265f-46f0-9541-562d810ff359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35e8d069-265f-46f0-9541-562d810ff359" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ab560676-aee3-4353-88c9-efd3eba40603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ab560676-aee3-4353-88c9-efd3eba40603" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_201295e5-237e-412c-936f-bce1b6b4ae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_201295e5-237e-412c-936f-bce1b6b4ae0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efbee29b-f264-4e55-bbd4-853cee3832ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efbee29b-f264-4e55-bbd4-853cee3832ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bf922fe4-c8dc-4cb7-9b36-80d0e3762310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efbee29b-f264-4e55-bbd4-853cee3832ec" xlink:to="loc_us-gaap_AwardTypeAxis_bf922fe4-c8dc-4cb7-9b36-80d0e3762310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf922fe4-c8dc-4cb7-9b36-80d0e3762310_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_bf922fe4-c8dc-4cb7-9b36-80d0e3762310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bf922fe4-c8dc-4cb7-9b36-80d0e3762310_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4aff9c5-928a-4f76-8c3e-1a7b3699c27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_bf922fe4-c8dc-4cb7-9b36-80d0e3762310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4aff9c5-928a-4f76-8c3e-1a7b3699c27b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bff5e1a4-2831-47f4-a357-c8f83d96cb02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4aff9c5-928a-4f76-8c3e-1a7b3699c27b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bff5e1a4-2831-47f4-a357-c8f83d96cb02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_6cb66e74-077c-423c-80b3-ea59de2797ec" xlink:href="rmd-20220630.xsd#rmd_EmployeeStockPurchasePlanPurchaseRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4aff9c5-928a-4f76-8c3e-1a7b3699c27b" xlink:to="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_6cb66e74-077c-423c-80b3-ea59de2797ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d79c12bd-fbeb-47c9-b8b7-361942783889" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efbee29b-f264-4e55-bbd4-853cee3832ec" xlink:to="loc_srt_RangeAxis_d79c12bd-fbeb-47c9-b8b7-361942783889" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d79c12bd-fbeb-47c9-b8b7-361942783889_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d79c12bd-fbeb-47c9-b8b7-361942783889" xlink:to="loc_srt_RangeMember_d79c12bd-fbeb-47c9-b8b7-361942783889_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db12a534-13e2-4479-a1e5-db14fb2e0ee9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d79c12bd-fbeb-47c9-b8b7-361942783889" xlink:to="loc_srt_RangeMember_db12a534-13e2-4479-a1e5-db14fb2e0ee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_734ed3ed-3c7d-4d10-b254-1a2f6e69d3c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_db12a534-13e2-4479-a1e5-db14fb2e0ee9" xlink:to="loc_srt_MinimumMember_734ed3ed-3c7d-4d10-b254-1a2f6e69d3c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f53a209-d88c-4f8a-bbd3-8455f5ddbbd4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_db12a534-13e2-4479-a1e5-db14fb2e0ee9" xlink:to="loc_srt_MaximumMember_8f53a209-d88c-4f8a-bbd3-8455f5ddbbd4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails" xlink:type="extended" id="i67bd31ff66f948a2a7604bdc3c2ee233_StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba9205db-dde7-4bba-a842-ce5de71c507c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_065c0746-1ec7-489f-8a7b-54f51a615308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba9205db-dde7-4bba-a842-ce5de71c507c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_065c0746-1ec7-489f-8a7b-54f51a615308" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_407e4a5e-9cf5-410e-b6d9-080d758ee69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba9205db-dde7-4bba-a842-ce5de71c507c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_407e4a5e-9cf5-410e-b6d9-080d758ee69a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_64f3df19-dc39-49e7-aab5-fdca0fd865ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba9205db-dde7-4bba-a842-ce5de71c507c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_64f3df19-dc39-49e7-aab5-fdca0fd865ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efc76623-3a91-476e-a913-58869e083689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba9205db-dde7-4bba-a842-ce5de71c507c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efc76623-3a91-476e-a913-58869e083689" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8e6f5846-53b0-4f50-ac66-ce6db9ac9695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efc76623-3a91-476e-a913-58869e083689" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8e6f5846-53b0-4f50-ac66-ce6db9ac9695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8e6f5846-53b0-4f50-ac66-ce6db9ac9695_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8e6f5846-53b0-4f50-ac66-ce6db9ac9695" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8e6f5846-53b0-4f50-ac66-ce6db9ac9695_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b2ca9b5b-8bf5-426b-b9bc-e21fbaf40603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8e6f5846-53b0-4f50-ac66-ce6db9ac9695" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b2ca9b5b-8bf5-426b-b9bc-e21fbaf40603" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_8549365e-7587-4644-963a-6f324e03a824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b2ca9b5b-8bf5-426b-b9bc-e21fbaf40603" xlink:to="loc_us-gaap_CostOfSalesMember_8549365e-7587-4644-963a-6f324e03a824" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_23bdbe45-6b34-4d71-b17a-92b32081cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b2ca9b5b-8bf5-426b-b9bc-e21fbaf40603" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_23bdbe45-6b34-4d71-b17a-92b32081cf32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69c67376-9b09-4db3-a259-0170045a5b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b2ca9b5b-8bf5-426b-b9bc-e21fbaf40603" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69c67376-9b09-4db3-a259-0170045a5b10" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i01099667b87e4f51aacea3c8095d9f40_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_627fbb7e-3007-4e4f-ac27-044e8a299088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_OperatingLossCarryforwards_627fbb7e-3007-4e4f-ac27-044e8a299088" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OperatingLossCarryforwardsCapitalLoss_24ad8f3e-affe-4221-bfaf-4c422008e0aa" xlink:href="rmd-20220630.xsd#rmd_OperatingLossCarryforwardsCapitalLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_OperatingLossCarryforwardsCapitalLoss_24ad8f3e-affe-4221-bfaf-4c422008e0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_77e9330f-c705-466f-911d-bc787dc70fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_77e9330f-c705-466f-911d-bc787dc70fe8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_1117d029-d1e9-4530-b9bf-b371b2d54e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_1117d029-d1e9-4530-b9bf-b371b2d54e95" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_4d4dd7ab-0f90-4147-99b9-4407ea5d2a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_4d4dd7ab-0f90-4147-99b9-4407ea5d2a56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_574bc72d-326d-4231-9177-13b4bf84d75d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_574bc72d-326d-4231-9177-13b4bf84d75d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_a88327b7-3166-4fc9-9cb2-d35f699c6c2d" xlink:href="rmd-20220630.xsd#rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_a88327b7-3166-4fc9-9cb2-d35f699c6c2d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement_c63c76c7-c2bf-4def-97f3-966b9a9d8d72" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationNetImpactOfSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement_c63c76c7-c2bf-4def-97f3-966b9a9d8d72" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationGrossSettlement_d5cf2ce1-5459-4061-bc79-2961aec0db65" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationGrossSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_IncomeTaxExaminationGrossSettlement_d5cf2ce1-5459-4061-bc79-2961aec0db65" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_dd8c6733-2206-42ee-9326-82ecf80cb044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_dd8c6733-2206-42ee-9326-82ecf80cb044" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_6d69c558-4300-4817-91ea-bb4757114b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_6d69c558-4300-4817-91ea-bb4757114b15" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e6b8c850-0ae2-430a-abe6-d0bc2bf0e426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e6b8c850-0ae2-430a-abe6-d0bc2bf0e426" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_d6d8b030-bb15-48d4-8d98-af035a13d9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_d6d8b030-bb15-48d4-8d98-af035a13d9a9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationRemittedFinalPayment_42b31bf3-7003-4622-9796-0c1476d3b81c" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationRemittedFinalPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_IncomeTaxExaminationRemittedFinalPayment_42b31bf3-7003-4622-9796-0c1476d3b81c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationPriorRemittancePayments_f6f55078-44dc-4b44-bf74-8560bdd42e9b" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationPriorRemittancePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_IncomeTaxExaminationPriorRemittancePayments_f6f55078-44dc-4b44-bf74-8560bdd42e9b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesTable_9ee1a29f-d189-4c6f-9e3c-2674454eab42" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_IncomeTaxesTable_9ee1a29f-d189-4c6f-9e3c-2674454eab42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_4e4954c9-c250-40ed-943d-add705bbb913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_IncomeTaxesTable_9ee1a29f-d189-4c6f-9e3c-2674454eab42" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_4e4954c9-c250-40ed-943d-add705bbb913" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_4e4954c9-c250-40ed-943d-add705bbb913_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_4e4954c9-c250-40ed-943d-add705bbb913" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_4e4954c9-c250-40ed-943d-add705bbb913_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0b6d1e3-42ac-44ab-918f-5a6238b7ea73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_4e4954c9-c250-40ed-943d-add705bbb913" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0b6d1e3-42ac-44ab-918f-5a6238b7ea73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_2957d1c3-93ad-4b38-a90d-d6c70d415ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0b6d1e3-42ac-44ab-918f-5a6238b7ea73" xlink:to="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_2957d1c3-93ad-4b38-a90d-d6c70d415ec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f45d0b3a-9753-4f79-8861-63c0600ee690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_IncomeTaxesTable_9ee1a29f-d189-4c6f-9e3c-2674454eab42" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f45d0b3a-9753-4f79-8861-63c0600ee690" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f45d0b3a-9753-4f79-8861-63c0600ee690_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f45d0b3a-9753-4f79-8861-63c0600ee690" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f45d0b3a-9753-4f79-8861-63c0600ee690_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_de1af89b-2231-46e7-9f44-8bd18f970886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f45d0b3a-9753-4f79-8861-63c0600ee690" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_de1af89b-2231-46e7-9f44-8bd18f970886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_05e2104d-e7d9-4caa-8411-bd006ba47330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_de1af89b-2231-46e7-9f44-8bd18f970886" xlink:to="loc_us-gaap_DomesticCountryMember_05e2104d-e7d9-4caa-8411-bd006ba47330" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_07b7d487-85ea-4187-b069-8aa6eb7fd81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_de1af89b-2231-46e7-9f44-8bd18f970886" xlink:to="loc_us-gaap_ForeignCountryMember_07b7d487-85ea-4187-b069-8aa6eb7fd81d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4491f1e8-64a2-4719-a0b9-1c566cd024ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_de1af89b-2231-46e7-9f44-8bd18f970886" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4491f1e8-64a2-4719-a0b9-1c566cd024ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d4b30d2-e5e7-425c-8879-4b7aeb8d0dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_rmd_IncomeTaxesTable_9ee1a29f-d189-4c6f-9e3c-2674454eab42" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d4b30d2-e5e7-425c-8879-4b7aeb8d0dd9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_6d4b30d2-e5e7-425c-8879-4b7aeb8d0dd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d4b30d2-e5e7-425c-8879-4b7aeb8d0dd9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_6d4b30d2-e5e7-425c-8879-4b7aeb8d0dd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_51ef2e7b-4b7b-4554-88a1-ced5f7701159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d4b30d2-e5e7-425c-8879-4b7aeb8d0dd9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_51ef2e7b-4b7b-4554-88a1-ced5f7701159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_f69e52ae-e088-4936-a329-2907f8a81d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_51ef2e7b-4b7b-4554-88a1-ced5f7701159" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_f69e52ae-e088-4936-a329-2907f8a81d1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails" xlink:type="extended" id="i9ddacfb6f5734fd68da768cbd974b37b_SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a24cb369-4c5b-498d-890b-fc46be648704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a24cb369-4c5b-498d-890b-fc46be648704" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment_87ba8d77-7b9a-4c70-9991-79830fa6a63a" xlink:href="rmd-20220630.xsd#rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment_87ba8d77-7b9a-4c70-9991-79830fa6a63a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueFairValueAdjustment_c9ac271c-dfb2-479f-acfe-6d7e023bb72e" xlink:href="rmd-20220630.xsd#rmd_DeferredRevenueFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_rmd_DeferredRevenueFairValueAdjustment_c9ac271c-dfb2-479f-acfe-6d7e023bb72e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c2496893-3324-40d5-9a6d-18c35de4f24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c2496893-3324-40d5-9a6d-18c35de4f24b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_78b9b36f-f170-46c5-b127-8248cd29dc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_OperatingIncomeLoss_78b9b36f-f170-46c5-b127-8248cd29dc35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UnallocatedCorporateCosts_05f72948-a146-45bf-b225-548d21a15844" xlink:href="rmd-20220630.xsd#rmd_UnallocatedCorporateCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_rmd_UnallocatedCorporateCosts_05f72948-a146-45bf-b225-548d21a15844" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_c20477c4-7dd7-47da-9098-bfb54631a854" xlink:href="rmd-20220630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_c20477c4-7dd7-47da-9098-bfb54631a854" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f2bea1f4-edc3-4e2f-a90f-15a32e055c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_RestructuringCharges_f2bea1f4-edc3-4e2f-a90f-15a32e055c60" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_cd910537-e21c-4576-bbc6-c0a999eb7b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_LitigationSettlementExpense_cd910537-e21c-4576-bbc6-c0a999eb7b10" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueFairValueAdjustment_7de24160-2b18-46ea-aeeb-6b5b13a0725f" xlink:href="rmd-20220630.xsd#rmd_DeferredRevenueFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1c0b7487-d295-401d-8bb7-63100e34dbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_InterestExpense_1c0b7487-d295-401d-8bb7-63100e34dbf7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_48edc813-cd3e-4c22-9db8-0fce84c500a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_48edc813-cd3e-4c22-9db8-0fce84c500a9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_260c0292-db4b-497e-9399-f540f7892568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_260c0292-db4b-497e-9399-f540f7892568" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fcbcddb4-921f-4e8a-86d4-97797b55dc69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fcbcddb4-921f-4e8a-86d4-97797b55dc69" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c846c3b4-217e-4f05-a434-45e79935b9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c846c3b4-217e-4f05-a434-45e79935b9aa" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_742e51db-3f68-4ae4-893e-f31e1835e3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_742e51db-3f68-4ae4-893e-f31e1835e3bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c07fb1c6-64f3-4128-8d56-eec1fd662bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_742e51db-3f68-4ae4-893e-f31e1835e3bf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c07fb1c6-64f3-4128-8d56-eec1fd662bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c07fb1c6-64f3-4128-8d56-eec1fd662bee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c07fb1c6-64f3-4128-8d56-eec1fd662bee" xlink:to="loc_us-gaap_SegmentDomain_c07fb1c6-64f3-4128-8d56-eec1fd662bee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_958672fd-8484-4674-85db-844831de476a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c07fb1c6-64f3-4128-8d56-eec1fd662bee" xlink:to="loc_us-gaap_SegmentDomain_958672fd-8484-4674-85db-844831de476a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevicesAndMasksMember_ed140835-e9c8-4f8f-ba39-88547388b289" xlink:href="rmd-20220630.xsd#rmd_DevicesAndMasksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_958672fd-8484-4674-85db-844831de476a" xlink:to="loc_rmd_DevicesAndMasksMember_ed140835-e9c8-4f8f-ba39-88547388b289" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsServiceMember_5f71ae45-18c8-4277-9c69-3deb9f2778b0" xlink:href="rmd-20220630.xsd#rmd_SoftwareAsServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_958672fd-8484-4674-85db-844831de476a" xlink:to="loc_rmd_SoftwareAsServiceMember_5f71ae45-18c8-4277-9c69-3deb9f2778b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_625fab71-72b3-4ce1-bb4d-00a16c3748a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_742e51db-3f68-4ae4-893e-f31e1835e3bf" xlink:to="loc_srt_ConsolidationItemsAxis_625fab71-72b3-4ce1-bb4d-00a16c3748a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_625fab71-72b3-4ce1-bb4d-00a16c3748a0_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_625fab71-72b3-4ce1-bb4d-00a16c3748a0" xlink:to="loc_srt_ConsolidationItemsDomain_625fab71-72b3-4ce1-bb4d-00a16c3748a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_483271d2-5ea8-4065-a39c-8ef66431795c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_625fab71-72b3-4ce1-bb4d-00a16c3748a0" xlink:to="loc_srt_ConsolidationItemsDomain_483271d2-5ea8-4065-a39c-8ef66431795c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f39ab79e-296b-4230-aa67-466b8a5c1f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_483271d2-5ea8-4065-a39c-8ef66431795c" xlink:to="loc_us-gaap_OperatingSegmentsMember_f39ab79e-296b-4230-aa67-466b8a5c1f49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_52bda8b8-685c-4c38-9a2f-30f738ce4664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_483271d2-5ea8-4065-a39c-8ef66431795c" xlink:to="loc_us-gaap_CorporateNonSegmentMember_52bda8b8-685c-4c38-9a2f-30f738ce4664" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_f519e0d4-b54f-46b3-b360-2045eadf872f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_483271d2-5ea8-4065-a39c-8ef66431795c" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_f519e0d4-b54f-46b3-b360-2045eadf872f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails" xlink:type="extended" id="i55b93bea352e43f496cccbf8214b4698_SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_eb6fad7c-1a30-4b1b-b825-dca16c0b59e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cdc5584-e9df-472e-ab07-a926abd96417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_eb6fad7c-1a30-4b1b-b825-dca16c0b59e5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cdc5584-e9df-472e-ab07-a926abd96417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_eb6fad7c-1a30-4b1b-b825-dca16c0b59e5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_fa72398f-e650-4569-8e0b-d36971a612ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:to="loc_srt_ConsolidationItemsAxis_fa72398f-e650-4569-8e0b-d36971a612ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_fa72398f-e650-4569-8e0b-d36971a612ca_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_fa72398f-e650-4569-8e0b-d36971a612ca" xlink:to="loc_srt_ConsolidationItemsDomain_fa72398f-e650-4569-8e0b-d36971a612ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cafcf45c-705b-4341-8ae0-4192341eda19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_fa72398f-e650-4569-8e0b-d36971a612ca" xlink:to="loc_srt_ConsolidationItemsDomain_cafcf45c-705b-4341-8ae0-4192341eda19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_bd815826-b09f-47fe-9b49-b5b90df14dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_cafcf45c-705b-4341-8ae0-4192341eda19" xlink:to="loc_us-gaap_OperatingSegmentsMember_bd815826-b09f-47fe-9b49-b5b90df14dd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7bffe0fc-4420-4125-9ba9-94ae9f79d033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7bffe0fc-4420-4125-9ba9-94ae9f79d033" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7bffe0fc-4420-4125-9ba9-94ae9f79d033_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7bffe0fc-4420-4125-9ba9-94ae9f79d033" xlink:to="loc_us-gaap_SegmentDomain_7bffe0fc-4420-4125-9ba9-94ae9f79d033_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dc0d1657-dd89-45de-a06f-a08d8e269179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7bffe0fc-4420-4125-9ba9-94ae9f79d033" xlink:to="loc_us-gaap_SegmentDomain_dc0d1657-dd89-45de-a06f-a08d8e269179" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_863e705a-c48e-4397-af5c-eff3f990acdf" xlink:href="rmd-20220630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dc0d1657-dd89-45de-a06f-a08d8e269179" xlink:to="loc_rmd_SleepAndRespiratoryMember_863e705a-c48e-4397-af5c-eff3f990acdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsServiceMember_dbcbfbcd-5592-4a85-ae3c-27cc68c9e3d2" xlink:href="rmd-20220630.xsd#rmd_SoftwareAsServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_dc0d1657-dd89-45de-a06f-a08d8e269179" xlink:to="loc_rmd_SoftwareAsServiceMember_dbcbfbcd-5592-4a85-ae3c-27cc68c9e3d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4d5f0f3a-f05c-4213-873c-f63ae3bdc1d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:to="loc_srt_StatementGeographicalAxis_4d5f0f3a-f05c-4213-873c-f63ae3bdc1d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4d5f0f3a-f05c-4213-873c-f63ae3bdc1d7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4d5f0f3a-f05c-4213-873c-f63ae3bdc1d7" xlink:to="loc_srt_SegmentGeographicalDomain_4d5f0f3a-f05c-4213-873c-f63ae3bdc1d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_de8c600d-4c87-46d6-9e19-099b38a643f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4d5f0f3a-f05c-4213-873c-f63ae3bdc1d7" xlink:to="loc_srt_SegmentGeographicalDomain_de8c600d-4c87-46d6-9e19-099b38a643f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_U.s.CanadaAndLatinAmericaMember_edb2d634-02d9-46e7-b882-1f1164c90200" xlink:href="rmd-20220630.xsd#rmd_U.s.CanadaAndLatinAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_de8c600d-4c87-46d6-9e19-099b38a643f1" xlink:to="loc_rmd_U.s.CanadaAndLatinAmericaMember_edb2d634-02d9-46e7-b882-1f1164c90200" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember_f07354c3-c716-4d43-a1b9-6c18eba89f1b" xlink:href="rmd-20220630.xsd#rmd_CombinedEuropeAsiaAndOtherMarketsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_de8c600d-4c87-46d6-9e19-099b38a643f1" xlink:to="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember_f07354c3-c716-4d43-a1b9-6c18eba89f1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_GlobalMember_f98e16d1-7806-4706-bc24-cbd5d4cc43ba" xlink:href="rmd-20220630.xsd#rmd_GlobalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_de8c600d-4c87-46d6-9e19-099b38a643f1" xlink:to="loc_rmd_GlobalMember_f98e16d1-7806-4706-bc24-cbd5d4cc43ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_571df874-95fc-4d75-89b9-142a57ae73a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:to="loc_us-gaap_SubsegmentsAxis_571df874-95fc-4d75-89b9-142a57ae73a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_571df874-95fc-4d75-89b9-142a57ae73a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_571df874-95fc-4d75-89b9-142a57ae73a2" xlink:to="loc_us-gaap_SubsegmentsDomain_571df874-95fc-4d75-89b9-142a57ae73a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_8edc5d21-f55c-44ca-853b-e5647af1027e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_571df874-95fc-4d75-89b9-142a57ae73a2" xlink:to="loc_us-gaap_SubsegmentsDomain_8edc5d21-f55c-44ca-853b-e5647af1027e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevicesMember_6f94f045-b660-4178-822d-493794146707" xlink:href="rmd-20220630.xsd#rmd_DevicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_8edc5d21-f55c-44ca-853b-e5647af1027e" xlink:to="loc_rmd_DevicesMember_6f94f045-b660-4178-822d-493794146707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MasksAndOtherMember_ee002840-6ccb-4eff-a479-ae1c970633ff" xlink:href="rmd-20220630.xsd#rmd_MasksAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_8edc5d21-f55c-44ca-853b-e5647af1027e" xlink:to="loc_rmd_MasksAndOtherMember_ee002840-6ccb-4eff-a479-ae1c970633ff" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformationScheduleOfRevenueByGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails" xlink:type="extended" id="ia83df856ff284512952231225a702e53_SegmentInformationScheduleOfRevenueByGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ee50e43d-144f-49c7-95f1-ea7ecc191c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76af72ab-77f9-4782-b3b0-7f39c73d4f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ee50e43d-144f-49c7-95f1-ea7ecc191c18" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76af72ab-77f9-4782-b3b0-7f39c73d4f0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ca47e3cd-64a0-43dc-8225-ff1054f824de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ee50e43d-144f-49c7-95f1-ea7ecc191c18" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ca47e3cd-64a0-43dc-8225-ff1054f824de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_36372dc0-a161-42ac-a93b-0095472fd74b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ca47e3cd-64a0-43dc-8225-ff1054f824de" xlink:to="loc_srt_StatementGeographicalAxis_36372dc0-a161-42ac-a93b-0095472fd74b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_36372dc0-a161-42ac-a93b-0095472fd74b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_36372dc0-a161-42ac-a93b-0095472fd74b" xlink:to="loc_srt_SegmentGeographicalDomain_36372dc0-a161-42ac-a93b-0095472fd74b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_29b6f000-4e1b-494a-a67a-e896ab34aaf6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_36372dc0-a161-42ac-a93b-0095472fd74b" xlink:to="loc_srt_SegmentGeographicalDomain_29b6f000-4e1b-494a-a67a-e896ab34aaf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1e3a680d-e9ef-447a-9ce2-22115a852d9a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_29b6f000-4e1b-494a-a67a-e896ab34aaf6" xlink:to="loc_country_US_1e3a680d-e9ef-447a-9ce2-22115a852d9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestOfWorldMember_ac0ac586-5942-4d23-94a9-7f8725f8c4bc" xlink:href="rmd-20220630.xsd#rmd_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_29b6f000-4e1b-494a-a67a-e896ab34aaf6" xlink:to="loc_rmd_RestOfWorldMember_ac0ac586-5942-4d23-94a9-7f8725f8c4bc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails" xlink:type="extended" id="id5228870fac94176af92e98200036940_SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_73629983-bac0-4b9e-825d-28fe86689598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_372a8e89-69db-409b-9552-c8808d91d5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_73629983-bac0-4b9e-825d-28fe86689598" xlink:to="loc_us-gaap_NoncurrentAssets_372a8e89-69db-409b-9552-c8808d91d5d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13e34b5d-f166-47a0-b68a-f38da830b71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_73629983-bac0-4b9e-825d-28fe86689598" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13e34b5d-f166-47a0-b68a-f38da830b71f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6fb87a28-279c-4403-8fbf-28d12b9b650b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13e34b5d-f166-47a0-b68a-f38da830b71f" xlink:to="loc_srt_StatementGeographicalAxis_6fb87a28-279c-4403-8fbf-28d12b9b650b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6fb87a28-279c-4403-8fbf-28d12b9b650b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6fb87a28-279c-4403-8fbf-28d12b9b650b" xlink:to="loc_srt_SegmentGeographicalDomain_6fb87a28-279c-4403-8fbf-28d12b9b650b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6fb87a28-279c-4403-8fbf-28d12b9b650b" xlink:to="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_c66c4537-e1b2-499b-b668-4f3b978715e6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:to="loc_country_AU_c66c4537-e1b2-499b-b668-4f3b978715e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ef2800c6-be07-49b8-986b-11a4c768c5a2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:to="loc_country_US_ef2800c6-be07-49b8-986b-11a4c768c5a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_SG_3d6babf3-eba8-4912-acbb-62941bafa08b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:to="loc_country_SG_3d6babf3-eba8-4912-acbb-62941bafa08b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestOfWorldMember_394e2802-a90c-4df0-8aa8-b97a16177c3b" xlink:href="rmd-20220630.xsd#rmd_RestOfWorldMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:to="loc_rmd_RestOfWorldMember_394e2802-a90c-4df0-8aa8-b97a16177c3b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#EmployeeRetirementPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails" xlink:type="extended" id="idcd487dc8ca74f1aa3c9ee6258ec8fee_EmployeeRetirementPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6965d9ef-e6c9-48b3-b032-e1c32cfc396b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_31159003-7a5b-4f86-81c4-bcd84d086345" xlink:href="rmd-20220630.xsd#rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6965d9ef-e6c9-48b3-b032-e1c32cfc396b" xlink:to="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_31159003-7a5b-4f86-81c4-bcd84d086345" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_87fb217d-22f8-45ee-964b-868fa6321348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6965d9ef-e6c9-48b3-b032-e1c32cfc396b" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_87fb217d-22f8-45ee-964b-868fa6321348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_94720ee6-557b-4e63-a88e-3cd3e7b360b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6965d9ef-e6c9-48b3-b032-e1c32cfc396b" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_94720ee6-557b-4e63-a88e-3cd3e7b360b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbb87c96-b3c7-497b-92bd-7cceb37b51f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_94720ee6-557b-4e63-a88e-3cd3e7b360b0" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbb87c96-b3c7-497b-92bd-7cceb37b51f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_bbb87c96-b3c7-497b-92bd-7cceb37b51f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbb87c96-b3c7-497b-92bd-7cceb37b51f2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_bbb87c96-b3c7-497b-92bd-7cceb37b51f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7b2f16ba-282d-40d2-a073-26f6b4ddad18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbb87c96-b3c7-497b-92bd-7cceb37b51f2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7b2f16ba-282d-40d2-a073-26f6b4ddad18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_1e8181b4-f6b1-4836-8419-f4f51cdf9526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7b2f16ba-282d-40d2-a073-26f6b4ddad18" xlink:to="loc_us-gaap_DomesticPlanMember_1e8181b4-f6b1-4836-8419-f4f51cdf9526" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ef9cfad7-a2ad-46c7-9860-6010657de37d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_1e8181b4-f6b1-4836-8419-f4f51cdf9526" xlink:to="loc_country_US_ef9cfad7-a2ad-46c7-9860-6010657de37d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_18fc6ae4-97e9-4487-8951-2028ae69000a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7b2f16ba-282d-40d2-a073-26f6b4ddad18" xlink:to="loc_us-gaap_ForeignPlanMember_18fc6ae4-97e9-4487-8951-2028ae69000a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_39dd7838-c6ea-47c7-9d04-3d5e96dfff13" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_18fc6ae4-97e9-4487-8951-2028ae69000a" xlink:to="loc_country_AU_39dd7838-c6ea-47c7-9d04-3d5e96dfff13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_SG_a04b25d4-af59-4888-b991-4ad693fafeb6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_18fc6ae4-97e9-4487-8951-2028ae69000a" xlink:to="loc_country_SG_a04b25d4-af59-4888-b991-4ad693fafeb6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#RestructuringExpensesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails" xlink:type="extended" id="i1d18fd2c844c437293dcec14d01fdac1_RestructuringExpensesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_15ca439b-3c8e-400d-96a0-0b8c62c5414f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_RestructuringCosts_15ca439b-3c8e-400d-96a0-0b8c62c5414f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_e4d962b8-c5f5-411c-b11e-66c8f6537268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_InventoryWriteDown_e4d962b8-c5f5-411c-b11e-66c8f6537268" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets_72d1c005-f665-4c20-abd6-cbab12dcdd28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets_72d1c005-f665-4c20-abd6-cbab12dcdd28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c4fcc306-6312-4ca0-83dd-09f6f811299f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_AssetImpairmentCharges_c4fcc306-6312-4ca0-83dd-09f6f811299f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_ff8229d8-8ef5-45b4-8cbd-d8bcfcc0499f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_SeveranceCosts1_ff8229d8-8ef5-45b4-8cbd-d8bcfcc0499f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_144fea0f-ad2e-49ba-a482-269811f7dadb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_BusinessExitCosts1_144fea0f-ad2e-49ba-a482-269811f7dadb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestructuringAndRelatedCostCostOfSales_2a2168af-aaa9-4a16-9729-a72eb555d02b" xlink:href="rmd-20220630.xsd#rmd_RestructuringAndRelatedCostCostOfSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_rmd_RestructuringAndRelatedCostCostOfSales_2a2168af-aaa9-4a16-9729-a72eb555d02b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_89ae75bd-272c-4f44-aa76-a0df4d069a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_RestructuringCharges_89ae75bd-272c-4f44-aa76-a0df4d069a74" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f8a0f20-c0b4-4346-aa98-fa00f9b25969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f8a0f20-c0b4-4346-aa98-fa00f9b25969" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d2e3f8fc-94f5-4ec5-8f09-1f9a38504485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f8a0f20-c0b4-4346-aa98-fa00f9b25969" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d2e3f8fc-94f5-4ec5-8f09-1f9a38504485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d2e3f8fc-94f5-4ec5-8f09-1f9a38504485_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d2e3f8fc-94f5-4ec5-8f09-1f9a38504485" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d2e3f8fc-94f5-4ec5-8f09-1f9a38504485_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6aaa8785-cd87-40fb-9b8c-b96ca238b200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d2e3f8fc-94f5-4ec5-8f09-1f9a38504485" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6aaa8785-cd87-40fb-9b8c-b96ca238b200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PortableOxygenConcentratorBusinessClosureMember_5bc33a13-3c9c-4241-9c31-13cb2a5a442e" xlink:href="rmd-20220630.xsd#rmd_PortableOxygenConcentratorBusinessClosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6aaa8785-cd87-40fb-9b8c-b96ca238b200" xlink:to="loc_rmd_PortableOxygenConcentratorBusinessClosureMember_5bc33a13-3c9c-4241-9c31-13cb2a5a442e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"/>
  <link:definitionLink xlink:role="http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails" xlink:type="extended" id="i0bed7683426e4bc0b7e9e2526c0535d5_ScheduleIIValuationAndQualifyingAccountsAndReservesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c016945-1a0d-4aca-be01-8f85dd564de0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0210e81b-24d3-49c8-8ee4-881185e285e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c016945-1a0d-4aca-be01-8f85dd564de0" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0210e81b-24d3-49c8-8ee4-881185e285e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9872cc02-9b87-406a-8796-839bb659a696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0210e81b-24d3-49c8-8ee4-881185e285e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9872cc02-9b87-406a-8796-839bb659a696" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_5444757c-52d3-487c-942e-eec6e5050d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0210e81b-24d3-49c8-8ee4-881185e285e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_5444757c-52d3-487c-942e-eec6e5050d7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_3e88c48d-50f6-4b79-a7e4-cacb3cab15d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0210e81b-24d3-49c8-8ee4-881185e285e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_3e88c48d-50f6-4b79-a7e4-cacb3cab15d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_33b72e82-a207-414b-a136-9c81ce305f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3812915b-aa73-484a-a7aa-d0d042c49172" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c016945-1a0d-4aca-be01-8f85dd564de0" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3812915b-aa73-484a-a7aa-d0d042c49172" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3b9c66f7-9e14-4bd5-b119-0855940abb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3812915b-aa73-484a-a7aa-d0d042c49172" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3b9c66f7-9e14-4bd5-b119-0855940abb2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_3b9c66f7-9e14-4bd5-b119-0855940abb2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3b9c66f7-9e14-4bd5-b119-0855940abb2f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_3b9c66f7-9e14-4bd5-b119-0855940abb2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_ec740541-481d-4638-ac52-3e25fbe732f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3b9c66f7-9e14-4bd5-b119-0855940abb2f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_ec740541-481d-4638-ac52-3e25fbe732f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_a4527549-36b2-424b-8f97-49790d46df73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ec740541-481d-4638-ac52-3e25fbe732f6" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_a4527549-36b2-424b-8f97-49790d46df73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_87206465-e6db-4df3-a1d5-ed5e0d24dd60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3812915b-aa73-484a-a7aa-d0d042c49172" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_87206465-e6db-4df3-a1d5-ed5e0d24dd60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_87206465-e6db-4df3-a1d5-ed5e0d24dd60_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_87206465-e6db-4df3-a1d5-ed5e0d24dd60" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_87206465-e6db-4df3-a1d5-ed5e0d24dd60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7ecf5695-aae9-4364-9088-c9014219d1c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_87206465-e6db-4df3-a1d5-ed5e0d24dd60" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7ecf5695-aae9-4364-9088-c9014219d1c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_dad84f68-67a4-4ae4-91a5-f3300a183ec0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7ecf5695-aae9-4364-9088-c9014219d1c6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_dad84f68-67a4-4ae4-91a5-f3300a183ec0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>rmd-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:847d2812-be5d-4010-ae3d-4823a56f6339,g:501af745-9083-47bc-ad44-e407829835be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_rmd_U.s.CanadaAndLatinAmericaMember_c452b9ba-8f71-49c9-b820-263a3e73e46c_terseLabel_en-US" xlink:label="lab_rmd_U.s.CanadaAndLatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S., Canada and Latin America</link:label>
    <link:label id="lab_rmd_U.s.CanadaAndLatinAmericaMember_label_en-US" xlink:label="lab_rmd_U.s.CanadaAndLatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.s. Canada And Latin America [Member]</link:label>
    <link:label id="lab_rmd_U.s.CanadaAndLatinAmericaMember_documentation_en-US" xlink:label="lab_rmd_U.s.CanadaAndLatinAmericaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S., Canada and Latin America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_U.s.CanadaAndLatinAmericaMember" xlink:href="rmd-20220630.xsd#rmd_U.s.CanadaAndLatinAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_U.s.CanadaAndLatinAmericaMember" xlink:to="lab_rmd_U.s.CanadaAndLatinAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncome_43e4fe54-8df7-45e7-acba-8ad1e07c79e3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease revenue</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncome_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncome" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_42e38026-5665-439a-9d4f-0cde461d8108_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_7464ea4e-6676-4396-8873-b8d8cb5cd7ac_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S.</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d5e5ca46-f808-448c-a972-06b977f40bef_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_517e69fb-ce03-4f6e-96f9-29435cafffbd_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_f6e3ea72-f41c-46e3-ae85-a79f236f5983_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6004a318-4f4a-4a5b-a204-f3c77fb47682_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_c7c159fd-2be5-4dbc-ad84-9157fa28323d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract cancellation costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0ff49a1d-ff8c-40c6-823c-a19126370e7d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_5f5a2c3b-8f1e-4239-832b-a3910111e214_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_b15ceb58-3339-48b5-bb50-d74d23af2993_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_07986353-7826-4b82-8633-673b9809ad68_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b8ee59e3-4ad6-4241-a1dd-472122e8c908_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_4902e347-2780-4aa0-9d3a-6eedd490425c_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (deductions)</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_9a1aa176-3189-4ff9-8e5c-e4aa3bcde2ce_terseLabel_en-US" xlink:label="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Logistics and occupancy costs</link:label>
    <link:label id="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_label_en-US" xlink:label="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Logistics And Occupancy Expenses Current</link:label>
    <link:label id="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_documentation_en-US" xlink:label="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Logistics And Occupancy Expenses Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:href="rmd-20220630.xsd#rmd_AccruedLogisticsAndOccupancyExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:to="lab_rmd_AccruedLogisticsAndOccupancyExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_9eb54e4f-d290-446a-add0-7092912e715d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTextBlock_0a72c198-d568-4c4e-9ad0-8a55b90066cf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTextBlock" xlink:to="lab_us-gaap_InvestmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AmortizationOfAcquiredIntangibleAssets1_d74758c0-d8e1-46f7-b2db-3805e89b2db7_terseLabel_en-US" xlink:label="lab_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_rmd_AmortizationOfAcquiredIntangibleAssets1_0d32579d-4015-4519-a39e-3d0342fc053f_verboseLabel_en-US" xlink:label="lab_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_rmd_AmortizationOfAcquiredIntangibleAssets1_label_en-US" xlink:label="lab_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets 1</link:label>
    <link:label id="lab_rmd_AmortizationOfAcquiredIntangibleAssets1_documentation_en-US" xlink:label="lab_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:href="rmd-20220630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:to="lab_rmd_AmortizationOfAcquiredIntangibleAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2e6fbe9b-6ece-47b5-badb-0b4aaf1f2015_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a656664b-7b21-48f2-b193-057d47c62c14_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility interest rate equal to reference rate plus</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems_d0ae6ce9-b2ed-4aa3-85f3-a367bfffaf08_terseLabel_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="rmd-20220630.xsd#rmd_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_rmd_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d32a13ef-ddca-40c8-8841-1e1964b25b9e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_c64db808-e1ce-415a-bd68-01c018123c21_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a22451ae-66d8-431a-be20-73aeb2207708_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued on exercise of options (note 11), shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c281ff70-cada-4091-8aed-2f08aee77ce9_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_48cc979a-879b-4e9f-be3f-fce70ca23f65_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_f6e06366-5621-4d5f-b44e-b12983786747_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11), shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_090f7d6e-eecc-46f7-be72-f4aa64ad721a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_039c1892-3879-4c36-839b-0f4be341acd0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement_143b6ee0-9302-49b1-92a0-64aaee98a0a2_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net impact of settlement</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement_label_en-US" xlink:label="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Net Impact of Settlement</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement_documentation_en-US" xlink:label="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Net Impact of Settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationNetImpactOfSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:to="lab_rmd_IncomeTaxExaminationNetImpactOfSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_8c1f001f-c99f-4aca-824c-6168ee70a9f6_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Actions, Contingencies And Commitments</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AccruedInventoryInTransit_c69185d3-691b-491a-9704-e148b4717a71_terseLabel_en-US" xlink:label="lab_rmd_AccruedInventoryInTransit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory in transit</link:label>
    <link:label id="lab_rmd_AccruedInventoryInTransit_label_en-US" xlink:label="lab_rmd_AccruedInventoryInTransit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Inventory In Transit</link:label>
    <link:label id="lab_rmd_AccruedInventoryInTransit_documentation_en-US" xlink:label="lab_rmd_AccruedInventoryInTransit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued inventory in transit.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedInventoryInTransit" xlink:href="rmd-20220630.xsd#rmd_AccruedInventoryInTransit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AccruedInventoryInTransit" xlink:to="lab_rmd_AccruedInventoryInTransit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_db15edc9-691b-4ac1-9692-5434fe50693b_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_bf864a9f-cfb4-4b03-a3e2-411577e08e40_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxExaminationPriorRemittancePayments_dfe1a26e-dab7-4ed8-9c9d-d5bdb4bfa71e_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior remittance payments</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationPriorRemittancePayments_label_en-US" xlink:label="lab_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Prior Remittance Payments</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationPriorRemittancePayments_documentation_en-US" xlink:label="lab_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Prior Remittance Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationPriorRemittancePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:to="lab_rmd_IncomeTaxExaminationPriorRemittancePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_5c0a13c1-0ced-4959-b34d-8569b36d4b2c_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4d3bd6a0-d576-4383-bd9c-2e9f57fffa8b_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_2ad4e5b1-ef75-4134-bed0-06a2ff5f448f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3ec7f310-5c23-4a76-b0a7-2e597b4fe46b_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6e6433dc-6af0-4685-a383-2cba3a4c0ff9_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a80ac24c-1c71-4209-8980-4029d96269b2_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_f5c61e15-b9fc-41e2-8b70-9303dfe6644d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21a72f48-168c-4d20-8c55-621434af3af5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and restricted stock units not included in the computation of diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_e19363e5-218d-45ec-93dd-f339b2750e9c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_1be8fa7c-b06e-4701-869c-3fb5975ae2a9_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f6a69905-a8ef-4cd0-8b65-2a8b10ec2cc2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_853e076a-0d45-4bc4-934e-f4259a2b4866_terseLabel_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized for issuance and pending registration (shares)</link:label>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_label_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Pending</link:label>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_documentation_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Pending</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:href="rmd-20220630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:to="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_abcfafe0-5c8a-4ac4-be16-7299ec5888c6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_10ed93d3-4b1d-470f-9b11-828e69a0dfad_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_3d37695c-4961-4bd7-9b73-4ef6458bd325_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ComputerEquipmentAndSoftwareMember_af03a696-8a3d-418a-94d3-d6e002aabef2_terseLabel_en-US" xlink:label="lab_rmd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_rmd_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_rmd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_rmd_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_rmd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ComputerEquipmentAndSoftwareMember" xlink:href="rmd-20220630.xsd#rmd_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ComputerEquipmentAndSoftwareMember" xlink:to="lab_rmd_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_edcd62c8-186b-432c-86f8-e4d106d86901_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease terms, not yet commenced</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IdentifiedIntangibleAssetsMember_c7e234d4-4a19-4236-93f1-9311bd94084c_terseLabel_en-US" xlink:label="lab_rmd_IdentifiedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified Intangible Assets</link:label>
    <link:label id="lab_rmd_IdentifiedIntangibleAssetsMember_label_en-US" xlink:label="lab_rmd_IdentifiedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified Intangible Assets [Member]</link:label>
    <link:label id="lab_rmd_IdentifiedIntangibleAssetsMember_documentation_en-US" xlink:label="lab_rmd_IdentifiedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IdentifiedIntangibleAssetsMember" xlink:href="rmd-20220630.xsd#rmd_IdentifiedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IdentifiedIntangibleAssetsMember" xlink:to="lab_rmd_IdentifiedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_f0826dfd-30ec-4ebe-8be7-4f86a2fac15a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1c91bb18-d189-43a0-9024-ff0f21fcfd16_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_7e8353ff-6849-4870-97af-ea41607179e8_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 41,836,234 shares at June&#160;30, 2022 and June&#160;30, 2021</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_287951a5-5a8f-4c95-8a59-10760c53394c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_a1033be5-b2c2-47a0-b6c4-a0026a59724d_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity investments (note 6)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_1b850b05-7541-4336-ba2d-56b1a68c51bb_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation costs, net of tax benefit</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2093dfb5-4f3a-4e6f-8336-efd207b8f552_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b8e29ea7-0922-4382-b104-b0de3ce0959b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_fea5a88d-f9a1-4e80-92b6-e9c7dced3a4f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_1da09ac9-c76b-46aa-b0f6-7162bef602f5_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_27ede6d8-f0fe-4f90-a58f-544df6ea9ef3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_100b5036-109b-4dfc-9ad0-a8798a25f42d_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_3871c6ff-0942-494f-b723-3b956a2d020c_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_b542c453-8747-4cd2-aa17-c466df4fe1c8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_0807cfce-f8dd-4fd6-9b54-b5e001e5d4e7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_960b8f56-600e-40d0-b4af-96ec60a12259_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_addd4c5a-ca35-4ba0-a726-5d647d15601f_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.004 par value, 350,000,000 shares authorized; &#8206;188,246,955 issued and 146,410,721 outstanding at June&#160;30, 2022 and &#8206;187,484,592 issued and 145,648,358 outstanding at June&#160;30, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_75340ae4-ec5d-42ed-82ff-8691212b568e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7e8909a6-87e6-43ef-a504-4837b2037bd0_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_85843f60-3c8c-42c8-8a1f-c41d675868bf_terseLabel_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase rights:</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_label_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Purchase Rights [Member]</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_documentation_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Purchase rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:href="rmd-20220630.xsd#rmd_EmployeeStockPurchasePlanPurchaseRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:to="lab_rmd_EmployeeStockPurchasePlanPurchaseRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_b7c93f44-c681-4a7e-9033-f2138a216f89_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b57eb448-a1b4-41bd-86a2-a3437a588ccc_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_7fc79f04-9c67-474b-8acc-51ff98fa6219_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring expenses</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8c08bd2e-a6ad-45bf-8855-d72192214343_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current (note 10)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorSalesTypeLeasesTextBlock_1148f9d5-9e2c-45f9-9438-5eb74226768f_terseLabel_en-US" xlink:label="lab_us-gaap_LessorSalesTypeLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LessorSalesTypeLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorSalesTypeLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Sales-type Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorSalesTypeLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorSalesTypeLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorSalesTypeLeasesTextBlock" xlink:to="lab_us-gaap_LessorSalesTypeLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0c69fee4-3b81-4f0e-80ee-1de4cb8c7d55_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_eb29dc2f-155e-45fd-9eab-d80f1b8adedc_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_8d974557-2973-40a6-8965-976986a0820c_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_e3d6e54a-b77d-48af-875f-e7d9ab26e586_terseLabel_en-US" xlink:label="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of contribution by the company to the retirement plans</link:label>
    <link:label id="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_label_en-US" xlink:label="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Maximum Annual Contributions By Employer Percent</link:label>
    <link:label id="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_documentation_en-US" xlink:label="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Maximum Annual Contributions By Employer Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:href="rmd-20220630.xsd#rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:to="lab_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_8ae97c84-177c-4a7d-a4c9-e0debcf053ab_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d683664b-2acf-423a-83db-c7ee0a8b0cc8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_31ccca9f-396d-4672-a284-399af4755574_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_3ead6171-f7fb-455b-a293-028cd7ed021b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_f2bfb239-ef33-4ede-a60d-009417ac0c97_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_71a2ca40-b8b2-4ab0-a1e0-81572d3ca88d_verboseLabel_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase</link:label>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_label_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Purchase Price Of Common Stock Lower Than The Fair Market Value Of Common Stock On The Date Of Purchase</link:label>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_documentation_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:href="rmd-20220630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:to="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d66f7a92-2330-4354-b574-2fabe152ec97_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_ddea06fe-692f-4e0b-a62b-d31a58e2f0a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_7679ebf5-aa7f-499e-9c6b-d33702882557_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66cc160a-6ebf-44df-a494-e16630074dac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3062d76-4a1f-496d-ae0e-67cda603e72d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_4931132e-e593-49b3-b672-8ad17d2f542b_negatedLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty costs incurred for the period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualPayments_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Decrease for Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualPayments" xlink:to="lab_us-gaap_ProductWarrantyAccrualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_539c00d8-930d-497e-8727-b23a7b3910a9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_b570c8bd-5f33-4bc0-bb5c-f6bf79aef8ea_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_736badd2-0113-42e4-a9b8-4a00c7d34007_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Property, Plant And Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_5fc1d35f-caf5-4b2e-a016-71cd3d4118d7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6a21d3e5-ece2-4367-a447-fcb58f8f1fc8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_40957282-474a-4f9c-be19-333fd780683c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3b5ec5eb-0990-49be-9747-5bd39c783849_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted &#8206;Average &#8206;Exercise &#8206;Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SupplementalBalanceSheetInformationTextBlock_96bfd37e-a193-412f-af69-b0a868af8a37_terseLabel_en-US" xlink:label="lab_rmd_SupplementalBalanceSheetInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_rmd_SupplementalBalanceSheetInformationTextBlock_label_en-US" xlink:label="lab_rmd_SupplementalBalanceSheetInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Text Block]</link:label>
    <link:label id="lab_rmd_SupplementalBalanceSheetInformationTextBlock_documentation_en-US" xlink:label="lab_rmd_SupplementalBalanceSheetInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationTextBlock" xlink:href="rmd-20220630.xsd#rmd_SupplementalBalanceSheetInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SupplementalBalanceSheetInformationTextBlock" xlink:to="lab_rmd_SupplementalBalanceSheetInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_d4ba6535-ad8a-4a22-a06b-c9a0b255edf7_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_ab9b8e7d-b98b-4472-92b4-c9cf4130355e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life of property, plant and equipment, years</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_ce27d9a7-df5d-4059-83b8-be6fc8ab6e9b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NonMarketableSecuritiesMember_21a583c6-53a9-4bc7-b863-32a40925b968_terseLabel_en-US" xlink:label="lab_rmd_NonMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-marketable securities</link:label>
    <link:label id="lab_rmd_NonMarketableSecuritiesMember_label_en-US" xlink:label="lab_rmd_NonMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Marketable Securities [Member]</link:label>
    <link:label id="lab_rmd_NonMarketableSecuritiesMember_documentation_en-US" xlink:label="lab_rmd_NonMarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonMarketableSecuritiesMember" xlink:href="rmd-20220630.xsd#rmd_NonMarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NonMarketableSecuritiesMember" xlink:to="lab_rmd_NonMarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9bd1f09-05bc-4ebe-b8b0-0ebc8ea9f85a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_55a7bc51-4e2b-4737-a65b-0cf66b475004_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_832629ba-85b8-4bf9-aed8-02639d8d0b04_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_42e28441-680c-46df-af77-79cef6896d1a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_27bf31a5-dbd5-4009-8a69-008cc205df27_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_dbda6239-f469-4578-8279-63490249ca31_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SleepAndRespiratoryMember_33f8930a-6257-421c-9e5d-773b048129ff_terseLabel_en-US" xlink:label="lab_rmd_SleepAndRespiratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sleep and Respiratory Care products</link:label>
    <link:label id="lab_rmd_SleepAndRespiratoryMember_5c646273-e437-4226-a69d-99e639e0d804_verboseLabel_en-US" xlink:label="lab_rmd_SleepAndRespiratoryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sleep and &#8206;Respiratory Care</link:label>
    <link:label id="lab_rmd_SleepAndRespiratoryMember_label_en-US" xlink:label="lab_rmd_SleepAndRespiratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sleep And Respiratory [Member]</link:label>
    <link:label id="lab_rmd_SleepAndRespiratoryMember_documentation_en-US" xlink:label="lab_rmd_SleepAndRespiratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sleep And Respiratory [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember" xlink:href="rmd-20220630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SleepAndRespiratoryMember" xlink:to="lab_rmd_SleepAndRespiratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_078a050a-c0b9-470c-8b90-044ad54e97bb_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_22423fd7-9b5a-4132-83e7-b69980fd1850_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_d365d5a2-5e6f-4845-917d-fb88e4f14d00_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MasksAndOtherMember_899c7104-9671-46aa-99d0-590f7eebfaf4_terseLabel_en-US" xlink:label="lab_rmd_MasksAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Masks and other</link:label>
    <link:label id="lab_rmd_MasksAndOtherMember_label_en-US" xlink:label="lab_rmd_MasksAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Masks and Other [Member]</link:label>
    <link:label id="lab_rmd_MasksAndOtherMember_documentation_en-US" xlink:label="lab_rmd_MasksAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Masks and Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MasksAndOtherMember" xlink:href="rmd-20220630.xsd#rmd_MasksAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MasksAndOtherMember" xlink:to="lab_rmd_MasksAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_eb4b7ffe-9458-4b14-893e-4d6b7883d966_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_40d3ac88-a64d-440f-9fd2-a38ffb1a7db3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_410ed213-9469-404d-a303-edf83b36f14a_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination_9f67a066-bd0e-483c-a2f7-380755f8c429_negatedLabel_en-US" xlink:label="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously held equity interest</link:label>
    <link:label id="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination_label_en-US" xlink:label="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:label id="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination_documentation_en-US" xlink:label="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Equity Interest in Acquiree Held Prior to Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:href="rmd-20220630.xsd#rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:to="lab_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_07fa3ae9-344a-40de-83fb-0efd6f547c06_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxExaminationRemittedFinalPayment_2db1f2e9-9de8-4efd-ad80-a47c0ed2a1cd_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remitted final payment</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationRemittedFinalPayment_label_en-US" xlink:label="lab_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Remitted Final Payment</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationRemittedFinalPayment_documentation_en-US" xlink:label="lab_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Remitted Final Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationRemittedFinalPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:to="lab_rmd_IncomeTaxExaminationRemittedFinalPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_61de1762-639b-458c-acf5-e6a4d333bdb7_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_81bc3260-c58d-4d21-8d18-154fcb5c6545_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Contract Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f8700249-1b81-4e76-afa5-5e6b69ca041f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_2e9d5f1b-654d-4f95-b6a5-875442fb4bc9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product warranties (note 8)</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_RestOfWorldMember_782f83d5-5598-4a13-8882-4e442b73195d_terseLabel_en-US" xlink:label="lab_rmd_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of the World</link:label>
    <link:label id="lab_rmd_RestOfWorldMember_label_en-US" xlink:label="lab_rmd_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:label id="lab_rmd_RestOfWorldMember_documentation_en-US" xlink:label="lab_rmd_RestOfWorldMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest Of World [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestOfWorldMember" xlink:href="rmd-20220630.xsd#rmd_RestOfWorldMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_RestOfWorldMember" xlink:to="lab_rmd_RestOfWorldMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFifthYear_b35d98dd-7898-4400-8763-76233bc81ecd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInFifthYear" xlink:to="lab_us-gaap_OtherCommitmentDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityTable_129e6cdf-689a-4800-bc99-bf1802f1c48c_terseLabel_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table]</link:label>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityTable_label_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table]</link:label>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityTable_documentation_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:href="rmd-20220630.xsd#rmd_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:to="lab_rmd_ContractWithCustomerAssetAndLiabilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_b164713b-530f-4cf8-acf2-b10d54989fed_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_2f8904c7-bfdb-4d5f-929a-1180f5979394_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_581b315e-9fa6-479f-acab-249dc1b34ef9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f81f2c33-5f8c-4542-88e1-217c0d219d7f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_ae0139ad-14cc-47d6-bffe-265ff36ab1f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_51038e1d-53eb-4488-a3a4-91e6840f6eb5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Penalties and interest</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_a1640ba8-cc7b-4e46-8ace-777c5d4fe8e4_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Restricted Stock Units (PRSUs)</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_be84654e-d6bf-4a62-ab48-64a58f500fdd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses (note 7)</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f8c516ba-1d5e-49bf-a47c-62ed2c57dda2_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0bd10c43-7bdf-459d-a013-b1045a2350f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_e07728fc-f5ad-4271-9c61-9978b0bab5c5_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a74f9eed-63f1-4dc6-a07e-5c0c03772b7a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_e9fc172c-d65a-491b-992f-e94a95dd15cd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_3ca14938-fd66-4117-b53c-bd0e10021e13_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_88379ca3-99a4-4737-b4d3-c9772a4e3614_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_32bec2a5-a5b2-478f-9001-7cebd6a0e062_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_0e0c6e06-315f-42ec-9bda-2306e070cb68_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_1cbd6465-278f-4368-8877-82126eec4e28_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f1e04d7e-c593-482f-a3b3-2a5b2bf5cb1b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related costs</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_25f4f680-5501-42fa-9239-75986b453cc1_terseLabel_en-US" xlink:label="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Observable price adjustments on non-marketable equity securities</link:label>
    <link:label id="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_label_en-US" xlink:label="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Observable price adjustments on non-marketable equity securities</link:label>
    <link:label id="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_documentation_en-US" xlink:label="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Observable price adjustments on non-marketable equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:href="rmd-20220630.xsd#rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:to="lab_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ReceivablesSoldWithLimitedRecourse_73aef5bb-7b9e-415e-bf6b-1b4db0212de4_terseLabel_en-US" xlink:label="lab_rmd_ReceivablesSoldWithLimitedRecourse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables sold with limited recourse</link:label>
    <link:label id="lab_rmd_ReceivablesSoldWithLimitedRecourse_label_en-US" xlink:label="lab_rmd_ReceivablesSoldWithLimitedRecourse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables Sold With Limited Recourse</link:label>
    <link:label id="lab_rmd_ReceivablesSoldWithLimitedRecourse_documentation_en-US" xlink:label="lab_rmd_ReceivablesSoldWithLimitedRecourse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables Sold With Limited Recourse</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReceivablesSoldWithLimitedRecourse" xlink:href="rmd-20220630.xsd#rmd_ReceivablesSoldWithLimitedRecourse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ReceivablesSoldWithLimitedRecourse" xlink:to="lab_rmd_ReceivablesSoldWithLimitedRecourse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b51468cf-8087-43b4-a7c5-01ea66795cd1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e964659c-d97c-452f-8620-4b35fe5afc0f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_78261cea-34b3-44cd-b903-289bffebbcdd_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets (note 4)</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0092f155-9e82-496e-a8e3-0e3ab80bd7de_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_7c424761-6f05-4177-9313-f36a8d6ae09b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_0e36c514-e781-4e58-aa17-71c636ba3234_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock_2bb17ce0-8515-4c8e-9b2b-06c4499d4f02_terseLabel_en-US" xlink:label="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Operating Lease Disclosure</link:label>
    <link:label id="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock_label_en-US" xlink:label="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Supplemental Information, Operating Leases [Table Text Block]</link:label>
    <link:label id="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock_documentation_en-US" xlink:label="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Operating Lease Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:href="rmd-20220630.xsd#rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:to="lab_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_afe9e357-8019-49ed-b66f-5b710cd6851c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9637d792-593f-4bfc-861c-3d5282563ee3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_0e97e24d-0dbb-463d-a6dd-7df532444a2c_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5ac5c26f-89cf-4d33-8c80-8ea171136e83_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_OperatingLossCarryforwardsCapitalLoss_bbb78432-1bce-42eb-97ee-bdd795c0298f_terseLabel_en-US" xlink:label="lab_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital loss</link:label>
    <link:label id="lab_rmd_OperatingLossCarryforwardsCapitalLoss_label_en-US" xlink:label="lab_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards Capital Loss</link:label>
    <link:label id="lab_rmd_OperatingLossCarryforwardsCapitalLoss_documentation_en-US" xlink:label="lab_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards capital loss.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:href="rmd-20220630.xsd#rmd_OperatingLossCarryforwardsCapitalLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:to="lab_rmd_OperatingLossCarryforwardsCapitalLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_13360dd4-f952-48ed-ad12-10cac66b4613_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ce3f757b-185b-4828-9235-7e595a764dc5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Provision For Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26894074-d8b9-4de0-a361-0cccb06bf77d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f54e47d5-b4f8-4d90-b12f-81b1473d1ef0_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AuditInformationAbstract_label_en-US" xlink:label="lab_rmd_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_rmd_AuditInformationAbstract_documentation_en-US" xlink:label="lab_rmd_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AuditInformationAbstract" xlink:href="rmd-20220630.xsd#rmd_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AuditInformationAbstract" xlink:to="lab_rmd_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1333e4a2-45c4-449e-afbe-7ead2e984a39_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5e90329f-f4a7-4d24-8dc2-2f1d0cd439eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Other Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_129cb15e-dd5c-4b18-9390-83b16588405f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_6d23d6a9-16c9-423c-83c4-dc884da2915d_terseLabel_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office</link:label>
    <link:label id="lab_us-gaap_AustralianTaxationOfficeMember_label_en-US" xlink:label="lab_us-gaap_AustralianTaxationOfficeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian Taxation Office [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AustralianTaxationOfficeMember" xlink:to="lab_us-gaap_AustralianTaxationOfficeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_f004c4bc-dd17-480b-a11d-871c45305f5a_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1dbe6332-e584-45ed-bef5-67f2e98cefef_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInThirdYear_c1324245-932a-4c72-8ea7-5ce3e9bd7e7b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInThirdYear" xlink:to="lab_us-gaap_OtherCommitmentDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_3b033ea2-69c0-4523-b32b-087a94765aa6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DevicesAndMasksMember_5116b5da-1271-4dd8-93f3-d9298815d9a9_terseLabel_en-US" xlink:label="lab_rmd_DevicesAndMasksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sleep and Respiratory Care</link:label>
    <link:label id="lab_rmd_DevicesAndMasksMember_label_en-US" xlink:label="lab_rmd_DevicesAndMasksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices And Masks [Member]</link:label>
    <link:label id="lab_rmd_DevicesAndMasksMember_documentation_en-US" xlink:label="lab_rmd_DevicesAndMasksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices And Masks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevicesAndMasksMember" xlink:href="rmd-20220630.xsd#rmd_DevicesAndMasksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DevicesAndMasksMember" xlink:to="lab_rmd_DevicesAndMasksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_120a7dba-1fdb-4e34-bcb7-b6ba9cee3867_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability (refund) adjustment from settlement with taxing authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:to="lab_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_358d9d3d-9778-478a-9a20-51f8979c7c24_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_cc1ea0a6-baa2-41b4-979d-fd22e033efe2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_RestructuringAndRelatedCostCostOfSales_4dba14a0-e50b-4b54-96b3-48153b95704e_terseLabel_en-US" xlink:label="lab_rmd_RestructuringAndRelatedCostCostOfSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_rmd_RestructuringAndRelatedCostCostOfSales_label_en-US" xlink:label="lab_rmd_RestructuringAndRelatedCostCostOfSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Cost Of Sales</link:label>
    <link:label id="lab_rmd_RestructuringAndRelatedCostCostOfSales_documentation_en-US" xlink:label="lab_rmd_RestructuringAndRelatedCostCostOfSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring And Related Cost, Cost Of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestructuringAndRelatedCostCostOfSales" xlink:href="rmd-20220630.xsd#rmd_RestructuringAndRelatedCostCostOfSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_RestructuringAndRelatedCostCostOfSales" xlink:to="lab_rmd_RestructuringAndRelatedCostCostOfSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_d4dc4184-1929-46f2-90b7-d7081c003bae_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_02236783-7ee0-4a31-bc53-a16c7b87e54b_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseIncome_7f7744f0-7fe8-4394-8bec-e0549360283a_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type lease revenue</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseIncome_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseLeaseIncome" xlink:to="lab_us-gaap_SalesTypeLeaseLeaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_484f9159-11c2-47fc-a42b-c4c92a4305da_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_GlobalMember_6ebec96c-7f7c-4194-a461-c21012b0c1c6_terseLabel_en-US" xlink:label="lab_rmd_GlobalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global revenue</link:label>
    <link:label id="lab_rmd_GlobalMember_label_en-US" xlink:label="lab_rmd_GlobalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global [Member]</link:label>
    <link:label id="lab_rmd_GlobalMember_documentation_en-US" xlink:label="lab_rmd_GlobalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_GlobalMember" xlink:href="rmd-20220630.xsd#rmd_GlobalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_GlobalMember" xlink:to="lab_rmd_GlobalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_bbe2b2f2-cd8b-46cc-8bad-33d0c6e6dd0f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_c31f519d-5218-4287-90fa-5a27ecd1b8d3_terseLabel_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount payable pursuant to cash denominated performance awards granted</link:label>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_label_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Performance Award Granted</link:label>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_documentation_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Performance Award Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:href="rmd-20220630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:to="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_9c5a5611-a942-4ea1-b8e7-69e965a16096_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_f66dfe0a-70e7-473d-91e3-2b3779b5d6aa_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_2768eaaf-af17-43c9-a99c-8c41bff73a96_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_59b2c3a6-d092-4eda-8b59-93530a48d51d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_7d1eaa3e-23cd-4981-a69d-5fdb8d3b220b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9c06c38b-fa6f-4457-b3ae-2ea879945d6b_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_b962c484-9d9e-4e45-ad26-7898fa8f7d06_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d6f4a3d1-8ce4-480c-aad2-ae502acc7770_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7dfe84a5-f381-4fdd-9a47-b11a313e7885_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_0b6713a4-c321-43cc-b1a5-c500df87a3ba_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9028de43-2ece-46cf-a89c-2f2a4af190e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_08cc7245-74b0-447c-a666-542e11a3effb_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-downs</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_fe3896b5-1717-459a-a2e6-d332126b8466_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_07931c02-2b72-4806-8161-11460a4acfad_terseLabel_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum award amount with other cash fees earned for services</link:label>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_label_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted and Other Cash Fees Earned</link:label>
    <link:label id="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_documentation_en-US" xlink:label="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted and Other Cash Fees Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:href="rmd-20220630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:to="lab_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_62c1a2f3-1e30-489e-bc5e-a7a8c24ba4ef_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_7e916aa3-fc79-4506-9d98-d114f6580bf1_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5b05f06c-63aa-49cb-b245-0fc5571b6550_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1495b65e-6207-4450-8413-0c7a0b688a60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NumberOfOfferings_662e611f-87f0-4455-86b8-48c355e88270_terseLabel_en-US" xlink:label="lab_rmd_NumberOfOfferings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of offerings</link:label>
    <link:label id="lab_rmd_NumberOfOfferings_label_en-US" xlink:label="lab_rmd_NumberOfOfferings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Offerings</link:label>
    <link:label id="lab_rmd_NumberOfOfferings_documentation_en-US" xlink:label="lab_rmd_NumberOfOfferings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Offerings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfOfferings" xlink:href="rmd-20220630.xsd#rmd_NumberOfOfferings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NumberOfOfferings" xlink:to="lab_rmd_NumberOfOfferings" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ShortTermDebtGross_e71af2a7-f524-4080-a3ec-b2055da49525_verboseLabel_en-US" xlink:label="lab_rmd_ShortTermDebtGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_rmd_ShortTermDebtGross_label_en-US" xlink:label="lab_rmd_ShortTermDebtGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Gross</link:label>
    <link:label id="lab_rmd_ShortTermDebtGross_documentation_en-US" xlink:label="lab_rmd_ShortTermDebtGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShortTermDebtGross" xlink:href="rmd-20220630.xsd#rmd_ShortTermDebtGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ShortTermDebtGross" xlink:to="lab_rmd_ShortTermDebtGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_e5a39c85-77bb-4ba2-ae30-499a584b6398_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_b57bdb97-54cd-4897-bcdb-17e60228ab47_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_f913ac19-a998-4900-a054-120817bf8e11_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0762e6e8-083e-4fc3-a6af-55bc2b5dfdbe_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3f54e9b8-50ae-4106-b083-0889d1fd8000_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_90361ed5-91b1-4cad-9688-f2d5f6aa0391_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_f071c5d3-9043-484d-b86b-7713fb7252f7_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, common, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_b690a6bc-308a-48e7-b550-56e746465935_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, common, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock_ca6641dd-8af7-43f6-a7d4-5c44aa231dab_terseLabel_en-US" xlink:label="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Changes In Equity Investments</link:label>
    <link:label id="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock_label_en-US" xlink:label="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Changes In Equity Investments [Table Text Block]</link:label>
    <link:label id="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Changes In Equity Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:href="rmd-20220630.xsd#rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:to="lab_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_43a27f67-3606-4b9f-8749-dfce28369009_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_215f4143-e26c-4d04-ad2d-7b736a58e2e7_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_4e4e962a-329f-47a8-af74-3e19b3d867a2_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_ddde22ff-5164-439c-bed0-5a926522f1b7_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_a4e76d2b-88c9-4fb1-8b1a-a76f2c640257_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment_06229613-29df-4b33-ad6c-8ce9d29198f7_terseLabel_en-US" xlink:label="lab_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue before deferred revenue fair value adjustment</link:label>
    <link:label id="lab_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment_label_en-US" xlink:label="lab_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Excluding Assessed Tax, Before Deferred Revenue Fair Value Adjustment</link:label>
    <link:label id="lab_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment_documentation_en-US" xlink:label="lab_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Contract With Customer, Excluding Assessed Tax, Before Deferred Revenue Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment" xlink:href="rmd-20220630.xsd#rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment" xlink:to="lab_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d3fc4c27-7264-4c79-bc97-660b7fcf36c1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S.</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_UncommittedOptionToIncreaseCreditFacility_1205bb53-35e9-43f8-bc08-b002854f2823_terseLabel_en-US" xlink:label="lab_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncommitted option to increase credit facility</link:label>
    <link:label id="lab_rmd_UncommittedOptionToIncreaseCreditFacility_label_en-US" xlink:label="lab_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncommitted option to increase credit facility</link:label>
    <link:label id="lab_rmd_UncommittedOptionToIncreaseCreditFacility_documentation_en-US" xlink:label="lab_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncommitted option to increase credit facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:href="rmd-20220630.xsd#rmd_UncommittedOptionToIncreaseCreditFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:to="lab_rmd_UncommittedOptionToIncreaseCreditFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_6139f735-d0aa-402b-a06f-2c40f224e47e_terseLabel_en-US" xlink:label="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement, Term Credit Agreement, And Senior Notes</link:label>
    <link:label id="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_label_en-US" xlink:label="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement Term Credit Agreement And Senior Notes [Member]</link:label>
    <link:label id="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_documentation_en-US" xlink:label="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Agreement, Term Credit Agreement, And Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:href="rmd-20220630.xsd#rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:to="lab_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_d049274f-f9b0-4264-b07f-4a52bd81f55a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to net earnings per diluted share from tax holidays and tax incentives program (usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday, Income Tax Benefits Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:to="lab_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets_2b006930-9e22-4e12-8ff9-e9a4cc3dc2f1_negatedLabel_en-US" xlink:label="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets</link:label>
    <link:label id="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets_label_en-US" xlink:label="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Assets</link:label>
    <link:label id="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets_documentation_en-US" xlink:label="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-of-use Assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:href="rmd-20220630.xsd#rmd_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="lab_rmd_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_f90e82a6-d582-4d86-9f5c-3871198e31bb_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_96b2d190-c475-4376-a479-fd968972a0f0_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Risk Management</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DeferredPaymentObligationsForAcquisitions_57faa25b-91d6-455f-b916-59958444f55a_verboseLabel_en-US" xlink:label="lab_rmd_DeferredPaymentObligationsForAcquisitions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred payments</link:label>
    <link:label id="lab_rmd_DeferredPaymentObligationsForAcquisitions_label_en-US" xlink:label="lab_rmd_DeferredPaymentObligationsForAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Payment Obligations For Acquisitions</link:label>
    <link:label id="lab_rmd_DeferredPaymentObligationsForAcquisitions_documentation_en-US" xlink:label="lab_rmd_DeferredPaymentObligationsForAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Payment Obligations For Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredPaymentObligationsForAcquisitions" xlink:href="rmd-20220630.xsd#rmd_DeferredPaymentObligationsForAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DeferredPaymentObligationsForAcquisitions" xlink:to="lab_rmd_DeferredPaymentObligationsForAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e5d1c1ca-9fb9-4724-8c69-d228bc1fd73f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_eff916f6-0bec-4831-af6d-8ca31b497de8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_TermOfContractUnderRevenueRecognition_7d39119e-aac0-4143-95d6-f12293fcdaf5_verboseLabel_en-US" xlink:label="lab_rmd_TermOfContractUnderRevenueRecognition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue recognized, term</link:label>
    <link:label id="lab_rmd_TermOfContractUnderRevenueRecognition_label_en-US" xlink:label="lab_rmd_TermOfContractUnderRevenueRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Contract Under Revenue Recognition</link:label>
    <link:label id="lab_rmd_TermOfContractUnderRevenueRecognition_documentation_en-US" xlink:label="lab_rmd_TermOfContractUnderRevenueRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Of Contract Under Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_TermOfContractUnderRevenueRecognition" xlink:href="rmd-20220630.xsd#rmd_TermOfContractUnderRevenueRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_TermOfContractUnderRevenueRecognition" xlink:to="lab_rmd_TermOfContractUnderRevenueRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInSecondYear_0fdbed4d-a3a4-4e9c-a716-3ee5e6b045b7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInSecondYear" xlink:to="lab_us-gaap_OtherCommitmentDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_66583707-382d-47cc-94cb-5cae54377605_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a4c6aaa2-e60c-4807-afe4-c270e90059a0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod_36e909f6-de36-4f56-8e47-104f5b21e641_terseLabel_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase program offering period</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod_label_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Offering Period</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod_documentation_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:href="rmd-20220630.xsd#rmd_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:to="lab_rmd_EmployeeStockPurchasePlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a05e02d4-3a24-4615-bb09-62db02f09c25_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_41e23b4e-31ca-4b43-b445-43fc13ba9d26_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_8cac6ccb-d5ae-4a01-85e9-15b39179f701_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AU_9ab3b414-3126-4b8b-a8de-f8fea8e78b7a_terseLabel_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia</link:label>
    <link:label id="lab_country_AU_label_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AUSTRALIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_df58a2ca-dc34-4a02-8adc-3521cbccbd07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_5deb2398-9047-4718-a06f-873b688ec432_periodStartLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_703032b7-9cbe-4803-9806-c0217a9e7078_periodEndLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrual_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard and Extended Product Warranty Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrual" xlink:to="lab_us-gaap_ProductWarrantyAccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_4b846bd1-5b73-43db-8caa-c36825d09adb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_09afe1a7-574f-4876-b132-2b49ad7dcd12_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_844332a0-2384-46f9-ac16-2897107372b6_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_26d1d5a2-7883-4116-912c-a2662f50ad1b_verboseLabel_en-US" xlink:label="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in the number of shares of common stock available for issuance (shares)</link:label>
    <link:label id="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_label_en-US" xlink:label="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction In The Number Of Shares Of Common Stock Available For Issuance</link:label>
    <link:label id="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_documentation_en-US" xlink:label="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in the number of shares of common stock available for issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:href="rmd-20220630.xsd#rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:to="lab_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_585fe08f-2dd5-4b56-b82c-fea146048a50_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_74e05214-aea4-423b-b796-84969bd0a146_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueAfterFifthYear_2a1cd869-7973-4644-ad4d-e8c8f16d3831_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueAfterFifthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:to="lab_us-gaap_PurchaseObligationDueAfterFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8e5934d5-ca99-46ea-9933-1364d0f4a278_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_005653fe-e63c-4cb9-899e-c428452811d6_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_8e792da7-62b6-482a-8a30-ab7e5b94d602_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Changes In Carrying Amount Of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_9e6e177c-40df-4a4b-8fad-94d740f990d0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_dd9af9cf-2731-4134-a1f9-56957c8bd779_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share (note 12) (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_c6236583-ca4f-4127-a24f-42b799be5879_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_89824c5c-9c3a-4153-afad-1de0f69a0d44_terseLabel_en-US" xlink:label="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of recognized tax benefit for uncertain tax position</link:label>
    <link:label id="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_label_en-US" xlink:label="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Recognized Tax Benefit For Uncertain Tax Position</link:label>
    <link:label id="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_documentation_en-US" xlink:label="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage threshold, above which a tax benefit would be recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:href="rmd-20220630.xsd#rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:to="lab_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3497b011-b558-4ce3-9a31-f5b2c0460edb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_2dfd0409-e54c-4a6b-8ca6-dd09d2fb0954_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_c3047e6d-a831-4c0b-8458-51f3be209eb7_totalLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_388dcff2-905f-4cb3-a556-6dc7a8737f5c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding debt</link:label>
    <link:label id="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount_label_en-US" xlink:label="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Long-Term and Short-Term, Combined Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="lab_us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_02eff045-975c-4afb-8738-4cb4fdb05aa6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_553526b9-99c0-4536-9347-af3fd2d916e5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_72942abe-9aa5-41a5-8da7-afbfdf82c818_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of RSUs and PRSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFourthYear_2f517cc2-948c-4e11-85e6-a25d6d7a2825_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInFourthYear" xlink:to="lab_us-gaap_OtherCommitmentDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_270563e8-b8c4-4121-948d-0a469b2368b7_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Costs</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_55033b7d-58a4-4fdb-b8b4-6f52108b3fec_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_d30135b4-fa64-4bba-9c77-1bcec42782de_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_761eeada-443b-4826-ba25-3307750ca151_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_8a54765f-8f50-453e-8614-3cbe8232a9f2_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_67ecd7db-53c5-45c5-910c-052a61808f5c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_111247a1-9517-45c7-a7e7-7bd58a6533c0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ee3a721b-59e5-4485-a51f-db5e8b7d52ae_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carry overs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_b7de9598-8982-4965-b06f-78206209d32f_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b0be69b0-6357-4ed2-ae53-6951978493b2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b54d2641-6172-46e7-be83-b166980b6e67_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EquityInvestmentsTotalByMeasurementCategory_8e1266aa-41f5-4be1-aeed-c0ec1af57594_totalLabel_en-US" xlink:label="lab_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_rmd_EquityInvestmentsTotalByMeasurementCategory_label_en-US" xlink:label="lab_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Total by Measurement Category</link:label>
    <link:label id="lab_rmd_EquityInvestmentsTotalByMeasurementCategory_documentation_en-US" xlink:label="lab_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Total by Measurement Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:href="rmd-20220630.xsd#rmd_EquityInvestmentsTotalByMeasurementCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:to="lab_rmd_EquityInvestmentsTotalByMeasurementCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e566bdec-6e46-4fa5-bc98-b3ab2625c780_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3079a17e-bf04-4a96-9b6f-8ba3d77aa766_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_47e5c4f8-2193-4adb-a961-22f3b66abd54_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract_c046a99f-8ddf-47c3-8bb7-06e65a607745_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_dfa4dfca-0606-4ba9-8c29-867cb138ae56_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4a222de4-d004-4c4f-9fc4-0cf356acc1c3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_9ff73f1a-5200-4f9d-81e3-d6dbd95f1084_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanMember_06831bea-6f71-4813-ae91-ee4f7524c0a1_terseLabel_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_rmd_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_rmd_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanMember" xlink:href="rmd-20220630.xsd#rmd_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EmployeeStockPurchasePlanMember" xlink:to="lab_rmd_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_60617410-da97-4455-9408-0ca2f78c787d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_522423ec-ec2f-44c1-ab13-68a781af1a27_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Total Stock-Based Compensation Costs Incurred And Associated Tax Benefit Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e8dda899-a1b2-4760-8678-c63497750cb7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock_8985d8c0-15a8-4389-b6fc-81e6a5e5520c_verboseLabel_en-US" xlink:label="lab_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Credit Losses</link:label>
    <link:label id="lab_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock_label_en-US" xlink:label="lab_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Doubtful Accounts [Policy Text Block]</link:label>
    <link:label id="lab_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock_documentation_en-US" xlink:label="lab_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Doubtful Accounts [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:href="rmd-20220630.xsd#rmd_AllowanceForDoubtfulAccountsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:to="lab_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_308d1dc3-e8cf-4669-b67b-97ba0ad79ceb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_fb7abc23-5a82-4a2d-92a2-653262a2fdc9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_4ead873d-d73e-415a-ba0f-4b99446389b2_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ffe230ae-83c5-4c56-be7a-6c76edfe57b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_1f9085f5-e604-4549-b38a-3cfa92afb71f_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_40e516d3-6266-43a0-98ba-efffd224c9cd_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b6409e0c-08e1-47cf-946c-8788d1b25453_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_a66f2ab2-ce48-455d-9bc3-76c371684ecf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on outstanding principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability_eb34b774-ceb7-4751-9cd0-5d6d50a1812f_negatedLabel_en-US" xlink:label="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:label id="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability_label_en-US" xlink:label="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration, Recognized Liability</link:label>
    <link:label id="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability_documentation_en-US" xlink:label="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration, Recognized Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:href="rmd-20220630.xsd#rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:to="lab_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SeniorNotesTwoMember_b31a7e03-cf6d-4feb-8323-b20290c94232_terseLabel_en-US" xlink:label="lab_rmd_SeniorNotesTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.45% Senior Notes Due July 10, 2029</link:label>
    <link:label id="lab_rmd_SeniorNotesTwoMember_label_en-US" xlink:label="lab_rmd_SeniorNotesTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two [Member]</link:label>
    <link:label id="lab_rmd_SeniorNotesTwoMember_documentation_en-US" xlink:label="lab_rmd_SeniorNotesTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesTwoMember" xlink:href="rmd-20220630.xsd#rmd_SeniorNotesTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SeniorNotesTwoMember" xlink:to="lab_rmd_SeniorNotesTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_785b421a-c252-49aa-9ef0-d20f9f049564_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a7ade3b1-383a-4ac9-95c1-557dbe6bcd5d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_fdf2df27-c716-4029-a296-56b7a04b30fa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, non-current (note 10)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_803e7f89-5678-4a8d-b2d7-df2aabcb1201_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contribution by the company to the employee retirement plans</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_fd3132e0-01bc-488c-b16a-52531e5da3c8_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_9a26032f-5e10-4c2f-9bd6-1a93bda7b81a_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains on marketable and non-marketable equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_e04b272a-6ba0-4a28-b769-04d52a391f09_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0b00db9e-497e-4a8b-8002-d3610c781811_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_314e4551-1242-44c6-99f1-1e65feb0ce96_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue By Geographic Area</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_ad1174c5-6aab-44d8-b595-d873483a9efd_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_4d15d9cc-d91c-462d-b540-12690864f903_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_024b235f-4020-47fd-9b9d-aaede270cb43_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of allowances of $23,259 and $32,138 &#8206;at June&#160;30, 2022 and June&#160;30, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f659de54-394b-4ac6-bb2c-b8936de03fb3_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_b9dc8178-0c9b-4fa2-a956-d9bfadaa3bf1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_bcda0472-3f81-4bcb-ad32-74c19be8a2e5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_fe292b0c-a3a7-4d7d-a18b-7314d4300bf3_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for doubtful debts</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c65e9132-b8a6-4b3b-94d6-732d688a21a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AccountsReceivableNetMember_27193754-206c-4ffc-9604-3a45329d7ea3_terseLabel_en-US" xlink:label="lab_rmd_AccountsReceivableNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_rmd_AccountsReceivableNetMember_label_en-US" xlink:label="lab_rmd_AccountsReceivableNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Net [Member]</link:label>
    <link:label id="lab_rmd_AccountsReceivableNetMember_documentation_en-US" xlink:label="lab_rmd_AccountsReceivableNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccountsReceivableNetMember" xlink:href="rmd-20220630.xsd#rmd_AccountsReceivableNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AccountsReceivableNetMember" xlink:to="lab_rmd_AccountsReceivableNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_effe2c87-1372-49a9-bf44-ba63667a0034_terseLabel_en-US" xlink:label="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes and other non-current assets</link:label>
    <link:label id="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_label_en-US" xlink:label="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes And Other Non Current Assets [Member]</link:label>
    <link:label id="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_documentation_en-US" xlink:label="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes And Other Non Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:href="rmd-20220630.xsd#rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:to="lab_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7ec8ca4b-13fb-4c35-a0e6-22274b40439b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_8fc0c021-cb09-4044-83cd-62edcf19994c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_34d9fdd2-61e7-464a-8474-ac218ec447fa_verboseLabel_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant</link:label>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_label_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Purchase Price Of Common Stock Lower Than The Fair Market Value Of Common Stock On The Date Of Grant</link:label>
    <link:label id="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_documentation_en-US" xlink:label="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:href="rmd-20220630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:to="lab_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_5a9273e5-4dc9-44c0-be3e-eb6cb9a438fb_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (exclusive of amortization shown separately below)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_baab1d8c-8a58-4c06-8859-9d616f00e4f1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_06cda539-489e-47f3-81b2-cce37c85a4ea_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_40ccf090-3b6c-4b07-971c-6e76cffd28c5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development capitalization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a0a463e4-2caa-4029-abce-87a40b946c08_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_fe929783-fd60-4909-968d-c07a4e67a4ad_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_9e1d9957-abf9-4087-93b6-2db1b0ca7109_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (loss), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_fc7ed8c8-731c-44b0-9ee8-02515f616900_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments_79ab4eba-0b8f-4b61-b07b-1df49d20ed10_terseLabel_en-US" xlink:label="lab_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease commitments not yet commenced</link:label>
    <link:label id="lab_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments_label_en-US" xlink:label="lab_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Commitments</link:label>
    <link:label id="lab_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments_documentation_en-US" xlink:label="lab_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments" xlink:href="rmd-20220630.xsd#rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments" xlink:to="lab_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_0faf8b97-b23c-4566-bb8d-81b45e929bf4_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangibles, gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9a50a56d-7ba8-4e51-8d8e-e8127d256174_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ReclassificationsInEquityInvestments_46cd72cc-7318-4ca6-be35-361978309257_terseLabel_en-US" xlink:label="lab_rmd_ReclassificationsInEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_rmd_ReclassificationsInEquityInvestments_label_en-US" xlink:label="lab_rmd_ReclassificationsInEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications In Equity Investments</link:label>
    <link:label id="lab_rmd_ReclassificationsInEquityInvestments_documentation_en-US" xlink:label="lab_rmd_ReclassificationsInEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications In Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReclassificationsInEquityInvestments" xlink:href="rmd-20220630.xsd#rmd_ReclassificationsInEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ReclassificationsInEquityInvestments" xlink:to="lab_rmd_ReclassificationsInEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_98a61f66-1053-4326-a05b-157a4d1ea84c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_0cd75014-d97d-4f53-b356-bd9e6189452c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Components Of Lease Revenue</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c264b076-5cfb-4f10-8b44-97ffc2184d60_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of business combination contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_406e90ce-9f42-45f7-a2b5-69c7509423af_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9cf2fcc1-97e4-4b7f-bf45-97a9da7ae671_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets (note 10)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c8dcb851-351c-4cc1-8592-c7e5828a43a1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated &#8206;Other &#8206;Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_53e39cc2-3acf-47f0-857b-fb9aca6700fa_terseLabel_en-US" xlink:label="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBITDA multiple of trailing twelve-month measurement period</link:label>
    <link:label id="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_label_en-US" xlink:label="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period</link:label>
    <link:label id="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_documentation_en-US" xlink:label="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:href="rmd-20220630.xsd#rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:to="lab_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_bebc4e1d-4fe7-4348-afc1-8af2ec66fb82_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_193c0169-b7b2-404d-a826-38cd1233c896_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_7094873c-db87-498e-9c73-6ea97f6a2d83_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_e30917a8-8cfb-4dba-98e4-d4c6006cf03c_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4ee3237e-4239-4e14-931a-8892b2fab736_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_d85a7efc-8fa9-40ac-8ad0-e3830e88f2de_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_fc30b007-f1d7-4075-89e5-f81e032ecf15_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_991484ec-65c7-4340-b99e-c4ea576cfd3d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9a01e0db-5e47-4491-b946-d89c83e1e0c6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7eba3343-420c-4e5e-b469-15c4568bed3b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_874e5d44-75f8-4b44-89e2-c81d4ea8e86b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ca5651d2-c225-4c8a-9771-fbced08d551d_netLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating profit by segment</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxesTable_b9a95039-34d1-404b-8937-6d08d2e6bf5a_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_rmd_IncomeTaxesTable_label_en-US" xlink:label="lab_rmd_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_rmd_IncomeTaxesTable_documentation_en-US" xlink:label="lab_rmd_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesTable" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxesTable" xlink:to="lab_rmd_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_f349112e-6d06-4a81-a05f-bc756d02678d_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4bb11876-8908-4503-9ac8-b1a10653f3e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_29e9db29-cd1a-4a9e-a442-9456b30f8e60_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear" xlink:to="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1b0b4182-2174-4484-8f1f-ce8e5d775464_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently issued accounting standards not yet adopted and Recently adopted accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8b7e2175-391c-466d-a04e-8f0c940b30f1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_857d8c72-f21e-4d6e-828d-9e7f9cdd6198_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available for draw</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_744c09f8-a5a7-4228-b384-b58eab5eb862_netLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement alternative</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0fdb21df-6ca0-4b0a-a0d1-c43fffef887c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses, net deferred income taxes and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_04abcf75-83f6-424d-a066-170ac5bf2f24_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_720ea931-6054-4881-9b8e-d04630ded12d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_28737ca1-c94d-4a27-abd8-9f7251182017_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7434a95a-00b0-4b78-a844-0b6480397450_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_6227bfb5-ca16-49f5-b95e-41bd55d8cfdc_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (note 5)</link:label>
    <link:label id="lab_us-gaap_Goodwill_5279507f-5973-463f-b3c0-a8b088bb022d_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_5c81d856-cc37-4c50-925c-a78ee3303374_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_e833104f-dc10-43b0-b202-18b58ff51c4c_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for warranties</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_6fceb8bd-03c8-4a4b-8b9a-eee6689923a4_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MufgUnionBankMember_da04fdd3-731b-4375-9e35-0c8310ecea42_terseLabel_en-US" xlink:label="lab_rmd_MufgUnionBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MUFG Union Bank</link:label>
    <link:label id="lab_rmd_MufgUnionBankMember_label_en-US" xlink:label="lab_rmd_MufgUnionBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mufg Union Bank [Member]</link:label>
    <link:label id="lab_rmd_MufgUnionBankMember_documentation_en-US" xlink:label="lab_rmd_MufgUnionBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MUFG Union Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankMember" xlink:href="rmd-20220630.xsd#rmd_MufgUnionBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MufgUnionBankMember" xlink:to="lab_rmd_MufgUnionBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_599aa62a-691d-4d73-95d2-1485e89af47e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of shares repurchased pursuant to the repurchase program (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0cf5310d-ea47-429a-903b-935a8dec49c7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGrossAbstract_23f5b580-437f-4305-bdbf-1bd5c16bfbf7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGrossAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGrossAbstract" xlink:to="lab_us-gaap_InventoryGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_0e469d65-6023-4279-9d11-e7a1f536fa15_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred borrowing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_2145ec0e-8e31-4c85-ab43-34506ca2ffab_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of non-U.S. tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_667f597d-e6c1-456e-9673-d7f4172b180a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred taxes that would have been recognized if the earnings has not been permanently reinvested</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d2c51a3a-ee6f-4156-8ad2-a8d4e649837c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_0307d0d2-89cc-4499-a52a-ddab4240872e_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets, net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5792efd3-f464-40ae-a39e-117af3066915_netLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes (note 13)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_291a4e6e-6375-44bf-9db5-24ed5f91ec8c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_10d47797-8254-4e46-8975-503ed3a6d332_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c5d5717d-0ed3-47ad-82a3-1d8e25614acf_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fa180d70-fa87-4090-a85d-ee52c397ef89_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant And Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_7cd2052e-1529-4970-b24d-d30eb1449af1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Changes In Liability For Warranty Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Warranty Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_3529e987-e184-4258-900d-5570fed91a97_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock at par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3ac0b359-96ab-40b0-90f6-26bf46f71f4f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_132d6fab-2630-4eaa-bef0-fd9b93187771_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bff78335-28a7-49c8-a1f9-4708b0b942b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_64efe047-3d8a-4991-9925-204023db812e_verboseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_dc71c3de-a011-4727-a70e-90ef313f7c79_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b7fc4c30-ea5b-42a1-bef3-7b05eae7f420_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional &#8206;Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_31715e87-bd10-478e-833b-0f2636085403_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_a70e5114-2510-400c-ba5f-79a6c2c4d0e5_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_34cc2e0f-b30e-48ba-bf9d-6a0c09618ec1_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NumberOfCommonStockGranted_5f55efd7-4b86-4e75-8a81-84677ecb95c3_terseLabel_en-US" xlink:label="lab_rmd_NumberOfCommonStockGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares granted in participant's initial year of hiring (shares)</link:label>
    <link:label id="lab_rmd_NumberOfCommonStockGranted_label_en-US" xlink:label="lab_rmd_NumberOfCommonStockGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Common Stock Granted</link:label>
    <link:label id="lab_rmd_NumberOfCommonStockGranted_documentation_en-US" xlink:label="lab_rmd_NumberOfCommonStockGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfCommonStockGranted" xlink:href="rmd-20220630.xsd#rmd_NumberOfCommonStockGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NumberOfCommonStockGranted" xlink:to="lab_rmd_NumberOfCommonStockGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a04684c4-2907-4791-83c6-aa2aafef879e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of the options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_7b008707-486e-4ce5-a60e-7d186c2f24a1_totalLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d31ab9d4-4db1-4f38-9ced-9d3119e26ffe_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted shares outstanding (000's) (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_891b8167-f952-4eb8-94f4-e9785d1530c7_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted weighted average shares (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_7f47095e-b4ac-4eec-b37c-0cc8b8fd540d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6f03a360-2d24-47a3-80df-07af22e56103_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_85559790-a47e-4173-9dc4-d601dd057a40_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets_b8929a1f-1de5-4bfd-a900-d7194a8f9f61_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated amortization</link:label>
    <link:label id="lab_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Depreciation of Decontaminating and Decommissioning Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets" xlink:to="lab_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7783e757-4374-4cb5-bf8e-711b92edfe89_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock_87d70bbf-a1c4-4bf5-be92-0e0f67bd6c9e_terseLabel_en-US" xlink:label="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue By Segment, Product, And Region</link:label>
    <link:label id="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock_label_en-US" xlink:label="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue By Segment, Product, And Region [Table Text Block]</link:label>
    <link:label id="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock_documentation_en-US" xlink:label="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue By Segment, Product, And Region [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:href="rmd-20220630.xsd#rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:to="lab_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DeferredRevenueFairValueAdjustment_6d54cb13-dcbc-40ee-8289-315b3fa59ba0_negatedLabel_en-US" xlink:label="lab_rmd_DeferredRevenueFairValueAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue fair value adjustment</link:label>
    <link:label id="lab_rmd_DeferredRevenueFairValueAdjustment_c00fec9b-e3ad-4b2f-b906-274ce3073713_verboseLabel_en-US" xlink:label="lab_rmd_DeferredRevenueFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue fair value adjustment</link:label>
    <link:label id="lab_rmd_DeferredRevenueFairValueAdjustment_label_en-US" xlink:label="lab_rmd_DeferredRevenueFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue Fair Value Adjustment</link:label>
    <link:label id="lab_rmd_DeferredRevenueFairValueAdjustment_documentation_en-US" xlink:label="lab_rmd_DeferredRevenueFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, fair value adjustment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueFairValueAdjustment" xlink:href="rmd-20220630.xsd#rmd_DeferredRevenueFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DeferredRevenueFairValueAdjustment" xlink:to="lab_rmd_DeferredRevenueFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_8198d547-471c-48c6-8507-e310a69cc2aa_terseLabel_en-US" xlink:label="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MUFG Union Bank NA and Westpac Banking Corporation</link:label>
    <link:label id="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_label_en-US" xlink:label="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mufg Union Bank Na And Westpac Banking Corporation [Member]</link:label>
    <link:label id="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_documentation_en-US" xlink:label="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MUFG Union Bank NA and Westpac Banking Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:href="rmd-20220630.xsd#rmd_MufgUnionBankNaAndWestpacBankingCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:to="lab_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets_b57b0e97-28a0-4c11-b6d2-24692e02e99b_terseLabel_en-US" xlink:label="lab_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes and other non-current assets</link:label>
    <link:label id="lab_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets_label_en-US" xlink:label="lab_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Lease Prepaid Taxes And Other Noncurrent Assets</link:label>
    <link:label id="lab_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets_documentation_en-US" xlink:label="lab_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Lease Prepaid Taxes And Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets" xlink:href="rmd-20220630.xsd#rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets" xlink:to="lab_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_de97c223-252e-4431-ba3c-a1fb2590e270_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, dividends per share, cash paid (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_8ee73020-e161-45d0-aa3b-84272bb7a5a9_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_dcf076ad-efec-4a9c-933c-a465f5d76720_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_f6879f13-33f9-4683-83c5-95850d010766_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payment</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_c0ada59a-7847-46de-8f53-dc76544d8432_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits and deductions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxCreditsAndAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Credits and Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:to="lab_us-gaap_IncomeTaxCreditsAndAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_b961b3d7-77d5-43b1-a7ce-068637fab891_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warranty accruals for the period</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Increase for Warranties Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:to="lab_us-gaap_ProductWarrantyAccrualWarrantiesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_01250e4a-a619-47ee-9499-3390b66cf095_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents allegedly infringed</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_223f210c-e283-4857-a6a9-ba00387ed076_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares subscribed</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesSubscriptions_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesSubscriptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Subscriptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesSubscriptions" xlink:to="lab_us-gaap_CommonStockSharesSubscriptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_683f9f7a-bfb1-4911-8e66-63d911bbd9bb_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_57e2e5ee-1d68-4339-9a83-3669b7b1fedb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_8d513cef-af91-47d1-a1ed-404fbac4ac34_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable shares, netted for tax (shares)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_label_en-US" xlink:label="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock, Shares Issued Net of Shares for Tax Withholdings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="lab_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ScheduleOfInvestmentsTableTextBlock_f32f6881-902b-4e38-971d-98bd5700555e_terseLabel_en-US" xlink:label="lab_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Investments</link:label>
    <link:label id="lab_rmd_ScheduleOfInvestmentsTableTextBlock_label_en-US" xlink:label="lab_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Investments [Table Text Block]</link:label>
    <link:label id="lab_rmd_ScheduleOfInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:href="rmd-20220630.xsd#rmd_ScheduleOfInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:to="lab_rmd_ScheduleOfInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesTable_40409e70-5837-41ba-8d4c-8fce2d682d61_terseLabel_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_rmd_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:href="rmd-20220630.xsd#rmd_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_rmd_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0cdfce0e-1baf-4847-ab49-4a492509b785_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount_19e61603-b67d-467f-a4a4-9383dcabb96e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase to net earnings from tax holidays and tax incentives program</link:label>
    <link:label id="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount_label_en-US" xlink:label="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Holiday, Aggregate Dollar Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:to="lab_us-gaap_IncomeTaxHolidayAggregateDollarAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_ce9ab4c9-2b7f-413c-ac98-3fa4588ca500_totalLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_7713c92b-d4d2-44dc-834e-194513df3778_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_45815178-31f7-4b38-8881-5dfa107a157f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_739b0169-8fc3-4430-9899-42a495088648_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of the stock-based compensation arrangements exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyDisclosureTextBlock_6d3a3856-3337-4e4a-a4e2-024e980ea4c2_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranties</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:to="lab_us-gaap_ProductWarrantyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_5962f996-6d8b-4759-bf2c-996e1be749dd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_a5af0285-9d07-47dd-b2f2-94badf5fd8b5_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4d6a9a49-f374-44c6-b135-d630c51bf01e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cdf06102-440e-41d4-8a4a-2d7a06de31fc_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0d01cd56-1b57-4bad-b2b6-3dbad305c17a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation (loss) gain adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_ed642f33-cf0e-4d1a-85ab-52ad7301797d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_7082e79d-952c-4c85-81b3-683a36766fc0_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:to="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_218310b6-b673-42c5-a2b0-19cd2e5ad5fa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c8a1c4c3-37ed-4724-9645-c47e620f72f0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings, net of borrowing costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_02242dbd-35b1-4dbc-983b-9e27f33e7873_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_5e7a2916-32e5-4b60-bdeb-6f45e69889ba_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_8100de5b-21eb-4373-8749-52d2a6bb9857_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_bd08bdc4-dbc1-42f3-81f7-66007432e2c6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_ab5a5f24-4219-4181-888f-9a1aa19234ea_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_930ce3b6-b4d9-4bef-8049-c0000dc2696c_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Of Directors Chairman</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_29f0b81f-9bc2-451f-9cf3-dd1cf9e8ccdb_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a2dc16a9-1b7a-4cb9-a003-ec1e38014488_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_2b2914a6-eb88-4e31-8e8e-36c89a4ede17_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_eb2fd38d-fdb5-4e2a-9f38-0482e0a020f8_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_b1e73f6f-9fc7-4ca6-afa4-fb26dd674fb6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ff6dc18e-83cd-462f-8f7c-424c5834e2ee_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, estimated useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_87ce80ef-5e22-4f79-9584-a3ebffd7d50c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_f4b9e598-b392-4d85-a181-c25b859248ab_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_6314238b-f14c-413c-ae83-008867b03c04_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_5d021a91-dc05-4625-b41d-85fc5a842630_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes (note 13)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_761153ca-15f2-4a42-9d35-cc8ba65c76cc_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_7a18dcf3-47f2-4421-b673-9595f1114465_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_b0819349-9405-4628-85b3-0506e84c5704_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5703bbe1-c723-4af9-8938-4b5ad0611df5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_befe9ec3-d531-4513-8142-f250d7fd8341_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued on employee stock purchase plan (note 11)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c0f520c9-f454-4053-8dc9-b32c27911657_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_77d92047-6596-428f-9cf0-a572c0c4fb17_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueAfterFifthYear_8178b456-d54c-42a5-94f5-ebcfc9e4f085_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueAfterFifthYear_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueAfterFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:to="lab_us-gaap_OtherCommitmentDueAfterFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_VestingAmountMaximumPercentageOfOriginalGrant_c6e50e91-fcd2-4427-ac7d-1f34199f9614_terseLabel_en-US" xlink:label="lab_rmd_VestingAmountMaximumPercentageOfOriginalGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount to be issued under award, percentage</link:label>
    <link:label id="lab_rmd_VestingAmountMaximumPercentageOfOriginalGrant_label_en-US" xlink:label="lab_rmd_VestingAmountMaximumPercentageOfOriginalGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Amount, Maximum Percentage Of Original Grant</link:label>
    <link:label id="lab_rmd_VestingAmountMaximumPercentageOfOriginalGrant_documentation_en-US" xlink:label="lab_rmd_VestingAmountMaximumPercentageOfOriginalGrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Amount, Maximum Percentage Of Original Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_VestingAmountMaximumPercentageOfOriginalGrant" xlink:href="rmd-20220630.xsd#rmd_VestingAmountMaximumPercentageOfOriginalGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_VestingAmountMaximumPercentageOfOriginalGrant" xlink:to="lab_rmd_VestingAmountMaximumPercentageOfOriginalGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems_b3290272-7341-43da-afc8-749ce2bc688c_terseLabel_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Line Items]</link:label>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems_label_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Line Items]</link:label>
    <link:label id="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems_documentation_en-US" xlink:label="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset and Liability [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:href="rmd-20220630.xsd#rmd_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:to="lab_rmd_ContractWithCustomerAssetAndLiabilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_589f5432-732a-4b80-bda6-7e55e4c15150_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Revenue By Segment And Reconciling Items</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_7af72adb-c824-43aa-8cc1-edad6b2bdf3d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of business combination contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Merger Related Costs, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_42d34394-d518-487d-a36a-cd70b909f7e2_verboseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_ffb5a214-ef78-4555-a1b9-90cdc3ab135c_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum purchase obligations</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_PurchaseObligationFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_aed5eb01-9cc6-4f04-94b6-4f499500d69d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxExaminationGrossSettlement_24ae850c-b099-4200-9b1e-a7e692de8811_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxExaminationGrossSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross settlement</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationGrossSettlement_label_en-US" xlink:label="lab_rmd_IncomeTaxExaminationGrossSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Gross Settlement</link:label>
    <link:label id="lab_rmd_IncomeTaxExaminationGrossSettlement_documentation_en-US" xlink:label="lab_rmd_IncomeTaxExaminationGrossSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Gross Settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationGrossSettlement" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationGrossSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxExaminationGrossSettlement" xlink:to="lab_rmd_IncomeTaxExaminationGrossSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8fd9c26d-4eae-44f8-ab9d-8db07a41cc28_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid taxes and other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_72caf6c7-e120-40cb-85c5-174d1b3ba451_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted &#8206;Average &#8206;Remaining &#8206;Contractual &#8206;Term in Years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_9b5ba413-cbe2-40e8-8548-20c454d450ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance factor adjustment (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_d6abfc0d-f79a-4f3e-b30d-8e14a8801fc5_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of remaining lease payments</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type and Direct Financing Leases, Lease Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_0a0e639d-06e9-4173-a4f2-3b07f58ac6de_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_01d0e0dd-4797-4a57-aa94-cbee84aff993_negatedLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NonEmployeeDirectorMember_5f639a28-a8a8-48fa-b630-55538472510f_terseLabel_en-US" xlink:label="lab_rmd_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Director</link:label>
    <link:label id="lab_rmd_NonEmployeeDirectorMember_label_en-US" xlink:label="lab_rmd_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Director [Member]</link:label>
    <link:label id="lab_rmd_NonEmployeeDirectorMember_documentation_en-US" xlink:label="lab_rmd_NonEmployeeDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonEmployeeDirectorMember" xlink:href="rmd-20220630.xsd#rmd_NonEmployeeDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NonEmployeeDirectorMember" xlink:to="lab_rmd_NonEmployeeDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_eae38863-5b0b-43e2-bd48-8606c3439a96_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charged to costs and expenses</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_1d9c7de8-a588-40ca-8032-46fb2cbaf5f4_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInSecondYear" xlink:to="lab_us-gaap_PurchaseObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss_bb689dcc-8308-49e6-8379-6acdeb943360_negatedLabel_en-US" xlink:label="lab_us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard and Extended Product Warranty Accrual, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_d0b8814e-ab1c-4db9-9abf-9ef66f73062c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued on employee stock purchase plan (note 11), shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_3adc057e-3bf9-4d99-ad45-75a510ea9ae8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued under Employee Stock Purchase Plan (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3e6dbe89-f114-4c0e-affe-97d795092c0b_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8fdb10cb-bc44-4fe1-847a-68029ecbafae_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SeniorNotesOneMember_56a4c784-5346-4d53-8384-c43f5540a546_terseLabel_en-US" xlink:label="lab_rmd_SeniorNotesOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.24% Senior Notes Due July 10, 2026</link:label>
    <link:label id="lab_rmd_SeniorNotesOneMember_label_en-US" xlink:label="lab_rmd_SeniorNotesOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes One [Member]</link:label>
    <link:label id="lab_rmd_SeniorNotesOneMember_documentation_en-US" xlink:label="lab_rmd_SeniorNotesOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesOneMember" xlink:href="rmd-20220630.xsd#rmd_SeniorNotesOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SeniorNotesOneMember" xlink:to="lab_rmd_SeniorNotesOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_27a8d03c-e884-47b0-937b-f964ec9fef84_terseLabel_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended period</link:label>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_label_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Extended Period</link:label>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_documentation_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Extended Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:href="rmd-20220630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:to="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_33a7819d-8acc-4a55-83cd-632c576a164c_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital loss carryover</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_9efb8aa1-385b-4a28-8df5-9178ef2329eb_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Promotional and marketing</link:label>
    <link:label id="lab_us-gaap_AccruedMarketingCostsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Marketing Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedMarketingCostsCurrent" xlink:to="lab_us-gaap_AccruedMarketingCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f3784492-2e12-4dbf-a9ca-9994514e2fee_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_336fede5-a0ca-4bee-90a1-2dcfa06e61b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted &#8206;Stock &#8206;Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef2caf44-3f55-4c5b-bf58-5d2afc7de1ce_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2d418726-81d0-43c3-94e6-3aea18130497_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net (note 4)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ffc5e623-e0c3-4bd7-b492-562563efb67e_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_450245bb-7192-4b65-826d-efe0720f3b39_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_c01e216e-9d84-4399-a3b5-273bc9f1151d_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_e8dc87fb-42f0-411b-b963-3cc123b052f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Amortization Expense Related To Identifiable Intangible Assets, Including Patents</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cf66a1a5-3c66-4fcc-ac4b-0c77c4686a35_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options:</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_ac3470a8-2977-4b60-8b6a-665d83f89959_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_3a2c7685-1ce6-46e5-ab80-2faf613e7c6f_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost of shares repurchased pursuant to the repurchase program</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_dc4fa235-adcf-46f8-9289-c9bbe2c4d127_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3cc43066-12c0-4171-a446-3a887eafe26b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_979774e7-d9d2-425d-97e3-9010943d72c0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_1d42359d-1c11-48f9-9678-5eb53ca8c937_negatedLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_8fb2d77a-44ee-43c6-b0f6-95773b6dd73f_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_8b38834d-131c-48e6-bb4e-1085f384fa19_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss, current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_28b2beea-60f3-41ee-b51e-d405089d193e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued on exercise of options (note 11)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1756d30b-cc28-45a0-925d-bb181c31c534_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_83294270-4570-46c6-a0f0-d9423abba104_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f4dd97fd-151e-4176-b65b-d975c17ff63f_netLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_48ab461d-bd44-4fef-b805-4641e4a3b724_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net (note 9)</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_4a7ab8f4-eed1-4046-bc9a-acc172a81dd5_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_08f2888c-20bb-4829-af1c-26a570f5dfda_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding loan balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_795f42d2-3791-44be-8427-df4fe78ec09f_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PortableOxygenConcentratorBusinessClosureMember_c7b6cfb4-db9f-4dc7-9ed6-78d5c8987253_terseLabel_en-US" xlink:label="lab_rmd_PortableOxygenConcentratorBusinessClosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portable Oxygen Concentrator Business Closure</link:label>
    <link:label id="lab_rmd_PortableOxygenConcentratorBusinessClosureMember_label_en-US" xlink:label="lab_rmd_PortableOxygenConcentratorBusinessClosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portable Oxygen Concentrator Business Closure [Member]</link:label>
    <link:label id="lab_rmd_PortableOxygenConcentratorBusinessClosureMember_documentation_en-US" xlink:label="lab_rmd_PortableOxygenConcentratorBusinessClosureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portable Oxygen Concentrator Business Closure [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PortableOxygenConcentratorBusinessClosureMember" xlink:href="rmd-20220630.xsd#rmd_PortableOxygenConcentratorBusinessClosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PortableOxygenConcentratorBusinessClosureMember" xlink:to="lab_rmd_PortableOxygenConcentratorBusinessClosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_93195581-d98f-45fb-ad59-a537ca6fc5e4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Expenses</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9993daf8-17db-440c-9550-1974c83b3e86_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_6bf01850-63c9-4fca-8943-eea46c17d20c_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_763d194e-73f7-48e6-b294-58e75a8c3947_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable (note 13)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_09f6390a-45fa-4638-8838-994f9f55b785_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ResmedInc2009IncentiveAwardPlanMember_03fd4e1a-27b0-416f-b6b2-5f6dc4499b68_terseLabel_en-US" xlink:label="lab_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2009 Plan</link:label>
    <link:label id="lab_rmd_ResmedInc2009IncentiveAwardPlanMember_label_en-US" xlink:label="lab_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resmed Inc2009 Incentive Award Plan [Member]</link:label>
    <link:label id="lab_rmd_ResmedInc2009IncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ResMed Inc 2009 Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:href="rmd-20220630.xsd#rmd_ResmedInc2009IncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:to="lab_rmd_ResmedInc2009IncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_c7cd4157-ec3f-4a55-b76e-16b8fd5a18d9_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_459853b2-2281-4789-8e59-27c482d3182a_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DocumentAndEntityInformationAbstract_50403cd6-229d-4d86-b779-9631d561cbd6_terseLabel_en-US" xlink:label="lab_rmd_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_rmd_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_rmd_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_rmd_DocumentAndEntityInformationAbstract_documentation_en-US" xlink:label="lab_rmd_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DocumentAndEntityInformationAbstract" xlink:href="rmd-20220630.xsd#rmd_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract" xlink:to="lab_rmd_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_75149af2-9796-4e77-bf4c-32398572e17c_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseReceivable_69d223ab-2eac-4a9f-8119-d33f2c18a265_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseLeaseReceivable_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Lease Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:to="lab_us-gaap_SalesTypeLeaseLeaseReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6ed0440f-1909-4d48-8e9e-7d5d5be52c21_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_8cb7593b-9bdc-49f8-ae66-6fd417231db7_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on equity investments (note 6)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_659403dc-a2cc-44f8-81d6-db1d81c9d6d0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_a8b244dd-f59c-45ed-a45c-d3014f73ab85_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_92e67f6b-3726-423a-95a4-2d6d728d5ea7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value added taxes and other taxes due</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_aff9057a-79c5-4378-9935-7c2cf023c208_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes paid, net of refunds</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a1a91be2-d1c9-4d82-a046-cc9e0c7c10ac_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_d79164af-221b-433f-b14e-c2a0657fe220_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFifthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_4f63a982-068f-41df-9879-a6967b30ef86_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Amounts Attributable to Parent, Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:to="lab_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a8765d94-b502-4e02-977e-30e9432a4cf4_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_74355b38-0754-4ced-8733-1a3cb8736f29_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_454e2214-5e31-4fca-9759-ce307820aa26_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend declared per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_a5173fce-4db9-4e33-9c67-1f6d213207fa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other intangible assets, net (note 5)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_a15f9362-6709-4620-9be1-ab6e6af9ce22_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other intangibles, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_4bba6e0d-0482-4a82-a05d-f7dc57440af4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0766eb4f-a040-41e5-81c3-7bbb7ad658b4_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_3b7cd7e2-ef33-49b7-97a5-4ffec7456e42_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs related to unvested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock_7db3d40c-f69d-4aab-a683-55984545affa_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Maturities Of Sales-type Leases</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_e448488d-c6d6-40d0-bc54-5f072c70b098_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_5a704dc2-a6a5-4b08-a1a2-b1ad542bf1be_terseLabel_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Obligations Under Purchase Agreements</link:label>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_label_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ef6c05c9-159e-461c-a803-2a8c90c50382_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_LessorLeaseRevenue_e59f244c-68ec-40f8-963f-7d920891fa33_totalLabel_en-US" xlink:label="lab_rmd_LessorLeaseRevenue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease revenue</link:label>
    <link:label id="lab_rmd_LessorLeaseRevenue_label_en-US" xlink:label="lab_rmd_LessorLeaseRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Lease Revenue</link:label>
    <link:label id="lab_rmd_LessorLeaseRevenue_documentation_en-US" xlink:label="lab_rmd_LessorLeaseRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Lease Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LessorLeaseRevenue" xlink:href="rmd-20220630.xsd#rmd_LessorLeaseRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_LessorLeaseRevenue" xlink:to="lab_rmd_LessorLeaseRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember_e057ae3a-f035-4b30-ab43-f4d2da7b8140_terseLabel_en-US" xlink:label="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, demonstration and rental equipment</link:label>
    <link:label id="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember_label_en-US" xlink:label="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Demonstration And Rental Equipment [Member]</link:label>
    <link:label id="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember_documentation_en-US" xlink:label="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical, Demonstration and Rental Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:href="rmd-20220630.xsd#rmd_ClinicalDemonstrationAndRentalEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:to="lab_rmd_ClinicalDemonstrationAndRentalEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_13aa1795-eefa-4d99-b6db-fc5391b3b08a_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_c631c459-8e84-4fb6-8bac-748ab8c8cfe2_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInFourthYear" xlink:to="lab_us-gaap_PurchaseObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_9e7f0dc3-6c59-4130-9d86-50c1ebcd463e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of the stock-based compensation arrangements outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_UnallocatedCorporateCosts_af870e81-40f4-44b1-a421-652fcb2979c6_terseLabel_en-US" xlink:label="lab_rmd_UnallocatedCorporateCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate costs</link:label>
    <link:label id="lab_rmd_UnallocatedCorporateCosts_label_en-US" xlink:label="lab_rmd_UnallocatedCorporateCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unallocated Corporate Costs</link:label>
    <link:label id="lab_rmd_UnallocatedCorporateCosts_documentation_en-US" xlink:label="lab_rmd_UnallocatedCorporateCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unallocated corporate costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UnallocatedCorporateCosts" xlink:href="rmd-20220630.xsd#rmd_UnallocatedCorporateCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_UnallocatedCorporateCosts" xlink:to="lab_rmd_UnallocatedCorporateCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_bb07f7c1-3983-4c5b-a5ea-e531fc9631b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_bc659165-3fa5-4cba-8b5a-d740206dff2c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_be35977a-7065-45c2-abf1-36690a6df830_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt, net (note 9)</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_88f18191-7387-4683-821d-ec51a6aa57d3_totalLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_1e3ed30d-c4bc-41d6-8e69-442d2394ad4e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a3284e3d-5dc2-467a-8143-44d3084e2c1d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_23cd2dab-7936-486f-a05c-c2a5597a9288_totalLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total remaining lease payments</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c71de566-6a45-4098-b7d0-7f07a148a45a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of investment (note 6)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_b8638138-d60f-40f8-aee5-c67a276fcbb2_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DebtToConsolidatedEbitdaRatio_e0419956-311b-4632-99ee-71be28884d36_terseLabel_en-US" xlink:label="lab_rmd_DebtToConsolidatedEbitdaRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt to consolidated EBITDA ratio</link:label>
    <link:label id="lab_rmd_DebtToConsolidatedEbitdaRatio_label_en-US" xlink:label="lab_rmd_DebtToConsolidatedEbitdaRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt To Consolidated EBITDA Ratio</link:label>
    <link:label id="lab_rmd_DebtToConsolidatedEbitdaRatio_documentation_en-US" xlink:label="lab_rmd_DebtToConsolidatedEbitdaRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt To Consolidated EBITDA Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtToConsolidatedEbitdaRatio" xlink:href="rmd-20220630.xsd#rmd_DebtToConsolidatedEbitdaRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DebtToConsolidatedEbitdaRatio" xlink:to="lab_rmd_DebtToConsolidatedEbitdaRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_72b2d568-3a25-4d81-8610-ebdbd0fc5505_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_15b5d571-dd74-4a11-8f86-f4aae5611bad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_78da0da4-d429-43ae-9273-887d560c3d19_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_72074efb-fd18-435a-8c28-1ade0eaeaa65_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_609ff10c-9803-4874-a166-d9e719b2ead6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at Beginning of Period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_ff982dea-855f-4a42-a524-5d022373f61d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_58897d35-e596-4cb1-be08-e40532edad29_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DeferredTaxAssetsLeaseLiabilities_63f0ddcc-6643-43da-9ea8-5f6716736703_terseLabel_en-US" xlink:label="lab_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_rmd_DeferredTaxAssetsLeaseLiabilities_label_en-US" xlink:label="lab_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities</link:label>
    <link:label id="lab_rmd_DeferredTaxAssetsLeaseLiabilities_documentation_en-US" xlink:label="lab_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:href="rmd-20220630.xsd#rmd_DeferredTaxAssetsLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:to="lab_rmd_DeferredTaxAssetsLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2104229d-6d4d-4874-95dd-e16992bba579_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_840119d6-c13c-4128-9a52-b75f25a69cb6_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease_87d850b5-85d8-43b0-9666-94933332f467_terseLabel_en-US" xlink:label="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill on acquisition</link:label>
    <link:label id="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease_label_en-US" xlink:label="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period, Increase (Decrease)</link:label>
    <link:label id="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease_documentation_en-US" xlink:label="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:href="rmd-20220630.xsd#rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:to="lab_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_22e67aa4-fae9-4630-8e77-a14c4ec251c2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_b4d937bd-7276-4059-8e14-a2701bd61053_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e29dce83-8126-49ae-ac9b-3fc399bba5e7_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_7de73ba9-a499-4c56-b3d3-8beb6b1f171c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent registration costs</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount_3a6d4392-fa89-461f-b38e-276460bc705b_terseLabel_en-US" xlink:label="lab_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax position</link:label>
    <link:label id="lab_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount_label_en-US" xlink:label="lab_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Amount</link:label>
    <link:label id="lab_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount_documentation_en-US" xlink:label="lab_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" xlink:href="rmd-20220630.xsd#rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" xlink:to="lab_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_163db475-d1d1-4029-91ae-3fc440bf7573_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MarketableEquityInvestmentsFairValue_8092e545-e7de-43d9-83ad-0fae1f835a44_terseLabel_en-US" xlink:label="lab_rmd_MarketableEquityInvestmentsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_rmd_MarketableEquityInvestmentsFairValue_label_en-US" xlink:label="lab_rmd_MarketableEquityInvestmentsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Equity Investments, Fair Value</link:label>
    <link:label id="lab_rmd_MarketableEquityInvestmentsFairValue_documentation_en-US" xlink:label="lab_rmd_MarketableEquityInvestmentsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Equity Investments, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableEquityInvestmentsFairValue" xlink:href="rmd-20220630.xsd#rmd_MarketableEquityInvestmentsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MarketableEquityInvestmentsFairValue" xlink:to="lab_rmd_MarketableEquityInvestmentsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_176448a7-c59e-469e-942e-bbdae4612b88_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (note 4)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_a99e2994-359c-4975-9033-04ae53931c2d_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue_70f81fcf-3e6e-4e5c-bbe0-e0f965d42e32_terseLabel_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance factor adjustments (usd per share)</link:label>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Adjustments In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Adjustments In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue" xlink:href="rmd-20220630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_080b77a2-5097-42e9-bb94-38be965585e5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_395b00a5-4b61-475a-b6a8-0867cb7886a4_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_af598b55-843b-4722-aa2b-3844eb36d0ba_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring expenses (note 17)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_59de123d-3d8a-4d0c-aa47-7be8685b3acc_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring expenses</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_78ec47dd-61cb-4d09-86c1-6bf8dba4891f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInFifthYear_f07c8d25-4da5-4f0c-b77b-efcd874615d4_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFifthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfInvestments_fe2c6547-df26-494e-9b44-1d9c27e3cc74_negatedNetLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of investments</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfInvestments_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment Losses, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfInvestments" xlink:to="lab_us-gaap_ImpairmentOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AdditionalEquityInvestments_d5bc594f-0801-4279-ad68-53301ccfef99_terseLabel_en-US" xlink:label="lab_rmd_AdditionalEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net additions (reductions) to investments</link:label>
    <link:label id="lab_rmd_AdditionalEquityInvestments_label_en-US" xlink:label="lab_rmd_AdditionalEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Equity Investments</link:label>
    <link:label id="lab_rmd_AdditionalEquityInvestments_documentation_en-US" xlink:label="lab_rmd_AdditionalEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AdditionalEquityInvestments" xlink:href="rmd-20220630.xsd#rmd_AdditionalEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AdditionalEquityInvestments" xlink:to="lab_rmd_AdditionalEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_ed1c9dad-5e00-43cc-8d24-c62370e20ee7_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_13831075-37e7-4b79-a7a5-20317f99f047_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_096f3019-31f5-44af-b07f-70cb79dc9e9c_terseLabel_en-US" xlink:label="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility And Term Credit Agreement</link:label>
    <link:label id="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_label_en-US" xlink:label="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility And Term Loan Credit Agreement [Member]</link:label>
    <link:label id="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_documentation_en-US" xlink:label="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility And Term Loan Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:href="rmd-20220630.xsd#rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:to="lab_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_1ba8d87b-fec6-4d43-b1fe-06ab92e9cba2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_de7317b0-fb5a-4eb1-aee3-8aef08e491da_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf6c0e98-6538-45fe-a56b-4920e1c2d00b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic shares outstanding (000's) (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8982b719-4416-4cb8-b056-6d324b2fb800_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic weighted-average common shares outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_bc52e8e0-cfd3-41dd-9aad-612139a385d6_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_a8473e96-c721-432b-8466-2f2b85e963da_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EquityMethodInvestmentsRollForward_cb46775d-3ca8-45fe-a2e5-d5e71fae4f66_terseLabel_en-US" xlink:label="lab_rmd_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_rmd_EquityMethodInvestmentsRollForward_label_en-US" xlink:label="lab_rmd_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_rmd_EquityMethodInvestmentsRollForward_documentation_en-US" xlink:label="lab_rmd_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityMethodInvestmentsRollForward" xlink:href="rmd-20220630.xsd#rmd_EquityMethodInvestmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward" xlink:to="lab_rmd_EquityMethodInvestmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_68c42114-2d5d-47c5-a5c4-c5ffb74d57a0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Payments) / proceeds on maturity of foreign currency contracts</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Derivative Instrument, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_f53c9b84-8eb2-49b4-8b8e-a2b144537775_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3ed508d7-1422-4a8e-9fce-96ea48e825e0_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d699efa9-b69c-4a6d-9e14-b21c67a7882f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation costs</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ec122d6d-0ff0-4a72-8708-523f01ab9c04_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (note 16)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_18f6fab0-d0e6-4cb1-a2ab-44c0049df1e9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3b0034b3-25d4-4536-9069-e4888c63bf0a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70fdd2c8-1265-4fde-940f-685d8a66bcfe_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueAfterFifthYear_b2287cb3-991a-415d-a61e-5f16facd40e3_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueAfterFifthYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="lab_us-gaap_ContractualObligationDueAfterFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_1f0c8e10-6ca4-4866-9bd5-d50fded80851_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted &#8206;Average &#8206;Remaining &#8206;Contractual &#8206;Term in Years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_4d81f63f-268b-47f0-8d46-dc0b18bd87be_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency instruments with notional amounts</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d11c0b5e-983f-46e0-ab02-7629dffca7ac_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_32cf44c6-1680-41f6-b09a-973cf6038dc7_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciling items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_1acd193d-6fd7-4c8d-84aa-24a283b3bd8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f0eb5cd2-b6eb-47f0-a906-a5ba73544ad1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_bdceb07d-af7b-4eb7-b015-3c59112307ba_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9f714349-c25e-4965-9142-04b14cf0ba35_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cbeaadd3-7b98-4893-92db-c098e39c7ba5_totalLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_12b545a9-a051-4045-88f8-807a562df042_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DevelopedOrCoreProductTechnologyMember_6ca2c808-28f2-4a6a-9742-16219d36b7e9_terseLabel_en-US" xlink:label="lab_rmd_DevelopedOrCoreProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed/core product technology</link:label>
    <link:label id="lab_rmd_DevelopedOrCoreProductTechnologyMember_label_en-US" xlink:label="lab_rmd_DevelopedOrCoreProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Or Core Product Technology [Member]</link:label>
    <link:label id="lab_rmd_DevelopedOrCoreProductTechnologyMember_documentation_en-US" xlink:label="lab_rmd_DevelopedOrCoreProductTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed/ Core Product Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevelopedOrCoreProductTechnologyMember" xlink:href="rmd-20220630.xsd#rmd_DevelopedOrCoreProductTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DevelopedOrCoreProductTechnologyMember" xlink:to="lab_rmd_DevelopedOrCoreProductTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_19e490c3-800e-46fb-8fc1-70a164c970f7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_ade52711-24cf-412d-8d8a-9521dfabb27d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_e7b8799e-07fa-44cf-9a80-08ae34717fc6_verboseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_faa183e1-d981-4011-8c76-b678d2a7d65e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_d44509e9-f54a-4796-9368-c95c1dd0b49a_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_eb5e3681-5491-45ad-bf5d-263f94d4a14f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_ce3cc91f-fe85-4edf-b28f-a92a56155ebf_verboseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed earnings</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_83305297-54aa-47a4-b970-355db305ac75_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_f27062fa-5496-46be-9557-4b000222a207_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_VehiclesAndAircraftMember_cfa14cd9-5f98-41f9-9146-651ccab73394_terseLabel_en-US" xlink:label="lab_rmd_VehiclesAndAircraftMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles and aircraft</link:label>
    <link:label id="lab_rmd_VehiclesAndAircraftMember_label_en-US" xlink:label="lab_rmd_VehiclesAndAircraftMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles and Aircraft [Member]</link:label>
    <link:label id="lab_rmd_VehiclesAndAircraftMember_documentation_en-US" xlink:label="lab_rmd_VehiclesAndAircraftMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vehicles and Aircraft</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_VehiclesAndAircraftMember" xlink:href="rmd-20220630.xsd#rmd_VehiclesAndAircraftMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_VehiclesAndAircraftMember" xlink:to="lab_rmd_VehiclesAndAircraftMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_e70c8b3d-fc35-44b4-8380-637cae35b61f_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease_84dec289-51b0-49ea-ae26-ab61dc1129e2_totalLabel_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease_label_en-US" xlink:label="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:to="lab_us-gaap_SalesTypeLeaseNetInvestmentInLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a714ad85-7fea-413e-a10c-a512515a30af_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_42230f56-7d07-4a2b-891e-83403354029d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (expense) income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_b37a0ad5-1544-4b1e-aaaf-1abb08b6fb66_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent provision</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualProvision_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual, Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualProvision" xlink:to="lab_us-gaap_LossContingencyAccrualProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_e367ab22-ac62-4318-b485-5b40d930c7b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_40eabf03-73ee-4fea-9450-802d619b2d46_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_country_SG_970c0033-e37f-4a0d-a30b-80b0bcb1cd6e_terseLabel_en-US" xlink:label="lab_country_SG" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Singapore</link:label>
    <link:label id="lab_country_SG_label_en-US" xlink:label="lab_country_SG" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SINGAPORE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_SG" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_SG" xlink:to="lab_country_SG" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_c8d6c40b-2b69-4ac9-b87b-4348e0afd03d_terseLabel_en-US" xlink:label="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares subject to awards granted (shares)</link:label>
    <link:label id="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_label_en-US" xlink:label="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Number Of Shares Subject To Awards Granted</link:label>
    <link:label id="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_documentation_en-US" xlink:label="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum number of shares subject to awards granted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:href="rmd-20220630.xsd#rmd_MaximumNumberOfSharesSubjectToAwardsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:to="lab_rmd_MaximumNumberOfSharesSubjectToAwardsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b6deafee-f821-4a6b-8d50-6f488eb16cc8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Deferred Tax Assets And Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_0b15dc06-b990-41e2-ad6b-746b0288a7a2_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_dc5a2c6c-d265-4099-b7a5-c3900477accc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_63d225ab-525e-46be-a010-03fdcd4cb709_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_7788a493-c0fc-4cb5-8642-fb74d0d4b557_terseLabel_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Warranty</link:label>
    <link:label id="lab_us-gaap_StandardProductWarrantyPolicy_label_en-US" xlink:label="lab_us-gaap_StandardProductWarrantyPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Product Warranty, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandardProductWarrantyPolicy" xlink:to="lab_us-gaap_StandardProductWarrantyPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_8f55d645-b604-4613-8ddf-9d844227ee07_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b5212f82-1623-4792-a076-73245cd2ae98_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_c70d9bf4-5358-4ff5-ae44-db7b550f6ebc_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, Gross</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_6d0f9784-864a-4854-af88-753fb2422d8c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Income Before Income Taxes Under The Jurisdictions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8cec1a67-964d-4f4c-ad02-582c851b062e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisitions, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_828b1845-3b5e-434a-b9ab-1b52dbb648ed_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_DevicesMember_065c6dea-1062-458f-a9e9-1c349a980203_terseLabel_en-US" xlink:label="lab_rmd_DevicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices</link:label>
    <link:label id="lab_rmd_DevicesMember_label_en-US" xlink:label="lab_rmd_DevicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices [Member]</link:label>
    <link:label id="lab_rmd_DevicesMember_documentation_en-US" xlink:label="lab_rmd_DevicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Devices [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevicesMember" xlink:href="rmd-20220630.xsd#rmd_DevicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_DevicesMember" xlink:to="lab_rmd_DevicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_9325679a-8064-44ae-b9ad-19d7c3aeeb09_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsMember" xlink:to="lab_us-gaap_EquityMethodInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_382cbd1f-d4fd-4d14-82c7-c3b468d51d35_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments (note 6)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SoftwareAsServiceMember_a65e2590-991a-4372-8864-f9b4464da093_terseLabel_en-US" xlink:label="lab_rmd_SoftwareAsServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software as a Service</link:label>
    <link:label id="lab_rmd_SoftwareAsServiceMember_label_en-US" xlink:label="lab_rmd_SoftwareAsServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software As Service [Member]</link:label>
    <link:label id="lab_rmd_SoftwareAsServiceMember_documentation_en-US" xlink:label="lab_rmd_SoftwareAsServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software As A Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsServiceMember" xlink:href="rmd-20220630.xsd#rmd_SoftwareAsServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SoftwareAsServiceMember" xlink:to="lab_rmd_SoftwareAsServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_364bf5bb-e52a-4efe-a7d2-7aa0ff3b9d1e_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_c94a2426-6863-4df5-a26b-0eea5e4ae93b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes (note 13)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_1f0e2cdb-3a18-4d19-8f15-11009647b3d2_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Other Tax Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1edaacaa-9b8c-43e5-b356-c54c744dc204_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_97bd8ba7-3cad-4caa-8601-1bce6f7dd682_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_cdac764d-c66e-443e-b34e-b03750ee69c9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_884ff138-53e1-4e3f-ae81-fdce4aa17667_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share (note 12) (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_90c140ae-83c4-4d46-8e46-46696fd378af_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share (usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_cfcd68c0-a966-44a1-82bd-370d3a7e44fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ccb91773-b648-42d2-8ff9-f4ff93e841bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_8b1892f4-5780-4b6c-bfe0-acbcbb8c1b32_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_03187aa3-6570-42f1-83b1-6b8f71dd8766_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_MarketableSecuritiesMember_b7b232c9-dde4-4236-bbbd-614eefd6b6bb_terseLabel_en-US" xlink:label="lab_rmd_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_rmd_MarketableSecuritiesMember_label_en-US" xlink:label="lab_rmd_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label id="lab_rmd_MarketableSecuritiesMember_documentation_en-US" xlink:label="lab_rmd_MarketableSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableSecuritiesMember" xlink:href="rmd-20220630.xsd#rmd_MarketableSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_MarketableSecuritiesMember" xlink:to="lab_rmd_MarketableSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SaasMember_f01e1ef5-5c30-429e-a1f5-595d727dfabc_terseLabel_en-US" xlink:label="lab_rmd_SaasMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SaaS</link:label>
    <link:label id="lab_rmd_SaasMember_label_en-US" xlink:label="lab_rmd_SaasMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saas [Member]</link:label>
    <link:label id="lab_rmd_SaasMember_documentation_en-US" xlink:label="lab_rmd_SaasMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Saas [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SaasMember" xlink:href="rmd-20220630.xsd#rmd_SaasMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SaasMember" xlink:to="lab_rmd_SaasMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_95c1f7ee-ec0b-4e11-94f0-97dc33b4fbf0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_efa935a2-72ec-46a3-8007-3933d1f03fc7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid expenses and current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_bbca4afd-1079-4db9-bc9b-d6f182ff9435_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_515a6aa8-a37d-4d34-a7f5-010e44ddb0bc_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term income taxes payable (note 13)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_0325204b-71b4-40bb-b3d6-e420c004b671_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths_9bd3f8e8-6ce4-414d-abf1-9ff849b9f5c5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitment, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="lab_us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_7d3af018-606d-4cc8-ac00-6deb583d8e92_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_9475eff1-c9be-4bf2-b138-1f477442dde5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Activity Of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_74af4065-0d6a-4a40-a075-991681b87b38_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_19b8711a-62df-4623-96ff-112c368a23d0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_4f229833-2b16-4bd3-ac15-a3cb30e0ed73_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fees percentage rate on unused portion of credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_0ae1980f-c920-4179-9dbf-3ab3589be9cd_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative effect adjustment from adoption of the credit loss standard, net of tax</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1d8bf276-5f4e-40bb-a1af-4594864d30c0_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (loss), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_0dade4e7-6b8d-4a70-92c1-9a7df277f790_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities, unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_407e627e-e7e0-466a-ae95-7ab1d552c1df_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1a9d260a-64d9-43e9-bb96-267922eef256_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_85553193-e5f2-48aa-8a8d-7785d88d4bbe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_EquityInvestments_b632f1e1-61d8-4e1d-abdb-f80f25058a12_periodStartLabel_en-US" xlink:label="lab_rmd_EquityInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_rmd_EquityInvestments_4b7bd726-d475-4176-95de-4301da3db643_periodEndLabel_en-US" xlink:label="lab_rmd_EquityInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value at the end of the period</link:label>
    <link:label id="lab_rmd_EquityInvestments_label_en-US" xlink:label="lab_rmd_EquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_rmd_EquityInvestments_documentation_en-US" xlink:label="lab_rmd_EquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestments" xlink:href="rmd-20220630.xsd#rmd_EquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_EquityInvestments" xlink:to="lab_rmd_EquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_8f2ca117-50fe-49aa-98f5-be5bc2552d1b_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_3ed51a38-0692-402a-a446-09f1f69dbcdd_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense (income), net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8c7cf26d-deba-4ba7-bbbe-47876ecb265d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of the stock-based compensation arrangements exercisable, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_935d1b28-443e-4ca8-bd50-a7e608fd957f_terseLabel_en-US" xlink:label="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, collateral, percentage of the company</link:label>
    <link:label id="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_label_en-US" xlink:label="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Collateral, Percentage of the Company</link:label>
    <link:label id="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_documentation_en-US" xlink:label="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Collateral, Percentage of the Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:href="rmd-20220630.xsd#rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:to="lab_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_e5d2dd4d-cfaf-4976-8d3c-d1fd91733ac5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_52e1b8eb-e58a-4510-9f2f-4cbe755d51ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_18815c3e-9419-4303-b6c3-75021d864916_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on marketable equity securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_b681c896-9a8a-49fa-9f9b-564dc475b68a_terseLabel_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_PrepaidInventory_a8a7ed8f-8e5a-422b-82e5-56bb2ab85fe4_terseLabel_en-US" xlink:label="lab_rmd_PrepaidInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid inventories</link:label>
    <link:label id="lab_rmd_PrepaidInventory_label_en-US" xlink:label="lab_rmd_PrepaidInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Inventory</link:label>
    <link:label id="lab_rmd_PrepaidInventory_documentation_en-US" xlink:label="lab_rmd_PrepaidInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidInventory" xlink:href="rmd-20220630.xsd#rmd_PrepaidInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_PrepaidInventory" xlink:to="lab_rmd_PrepaidInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_bf2a6e5e-be62-4d9c-85a1-269173a99c9a_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_AmendedAndRestated2009PlanMember_259c6cf3-92cb-462f-a6a7-5dd823c11549_terseLabel_en-US" xlink:label="lab_rmd_AmendedAndRestated2009PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated 2009 Plan</link:label>
    <link:label id="lab_rmd_AmendedAndRestated2009PlanMember_label_en-US" xlink:label="lab_rmd_AmendedAndRestated2009PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated2009 Plan [Member]</link:label>
    <link:label id="lab_rmd_AmendedAndRestated2009PlanMember_documentation_en-US" xlink:label="lab_rmd_AmendedAndRestated2009PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended And Restated 2009 Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmendedAndRestated2009PlanMember" xlink:href="rmd-20220630.xsd#rmd_AmendedAndRestated2009PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_AmendedAndRestated2009PlanMember" xlink:to="lab_rmd_AmendedAndRestated2009PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_2742233e-eed1-4733-addb-569b2374f9b3_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7a487b48-4230-4976-a36e-ecba45522976_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6739deef-1a60-4ed9-b7f9-27f65e474655_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_d9d2e749-dfb7-4c7a-b27d-0e08608a580d_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Long-Lived Assets By Geographic Areas</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b25eebcf-e66b-4c72-8b63-f81d9567aa6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized for issuance (shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_523fad03-6ca5-4d25-bea2-995a184b44a4_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_PurchaseObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligationDueInThirdYear" xlink:to="lab_us-gaap_PurchaseObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_1ea8812d-161d-4851-a5c5-73e38f0c45ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_88df11a6-fab9-47ed-a2bd-f61b2b846518_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_b19eb833-aa0c-4c44-98c2-ed700e225525_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_f8044061-ffc5-419c-b9ca-fceb5e942108_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:to="lab_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_04fdf9f7-59ee-4a62-8c94-9e7cec4a8b5e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Operating Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:to="lab_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock_3c5ac100-0216-49cc-86ec-7edcdedf5f38_terseLabel_en-US" xlink:label="lab_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Sales-type Lease, Net Investment In Lease</link:label>
    <link:label id="lab_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock_label_en-US" xlink:label="lab_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease [Table Text Block]</link:label>
    <link:label id="lab_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock_documentation_en-US" xlink:label="lab_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-type Lease, Net Investment in Lease [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock" xlink:href="rmd-20220630.xsd#rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock" xlink:to="lab_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_35cf265c-a6d8-4142-865e-da76f96bbb40_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum exposure on outstanding receivables</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_IncomeTaxesLineItems_6c7f400c-e898-4543-81ba-6e9cb2572135_terseLabel_en-US" xlink:label="lab_rmd_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_rmd_IncomeTaxesLineItems_label_en-US" xlink:label="lab_rmd_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_rmd_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_rmd_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesLineItems" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_IncomeTaxesLineItems" xlink:to="lab_rmd_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantiesDisclosuresAbstract_75b73af6-1250-45b4-9c61-9caab28f7e02_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranties Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ProductWarrantiesDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranties Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:to="lab_us-gaap_ProductWarrantiesDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3ec2c02b-4793-4e0c-9678-98d4f4841d29_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Provision For Income Tax Differ From The Amount Of Income Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_3168c97b-a08f-4536-ae2b-bdc7653bf712_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement expenses</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_249d00c3-7494-4fe8-8025-569603092d04_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement expenses</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_45748788-b7b2-4042-b1b5-1e2b1657fa55_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_6b76b0f2-5305-41b7-8082-7afea946f559_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of U.S. tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ecd15c4c-246e-4eb3-b1a3-ef0e060e43b8_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and restricted stock units (shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_efe1b3ad-b198-4a01-ac7c-8d6e12a5a79f_verboseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule II Valuation And Qualifying Accounts And Reserves</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_c752118b-81d0-43ac-a025-fba3e619eedd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3b63fcc1-3538-46f9-9506-131aaf804ffe_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_a9181fbe-2582-4415-a4be-966d7d6e0262_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_ef5cfc76-1fbf-4028-ad27-a6ed289c7948_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Applied Against Asset Account Allowance For Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForCreditLossMember_label_en-US" xlink:label="lab_us-gaap_AllowanceForCreditLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Credit Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForCreditLossMember" xlink:to="lab_us-gaap_AllowanceForCreditLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6b51bf3d-0de5-4e78-ba80-4695e30875d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted &#8206;Average &#8206;Grant-Date &#8206;Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9a44a035-ae5f-44ec-9692-80053e625933_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f4c64140-7bfe-4226-925b-06b8ad77b5a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_290007bc-4312-4f54-b3a9-9504e11d5f14_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_a50cb244-a975-406e-9393-ee47568d4e91_verboseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized to be repurchased under repurchase program (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_fbece699-04c2-4afc-96b4-a4e8f11c06e2_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7e2f1d15-01c4-40e4-9a2e-df5ff78321af_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_00b5ba31-9b2a-4984-8e68-71475ddd1e4f_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting and professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_32785447-e9b6-43e7-84de-ee304ea0cf3c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_f78f1c0e-9d72-49fc-9c6a-5f001cd7494f_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred borrowing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_f3c741e5-5775-4484-a456-d8efa22e0d80_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3e010865-c175-48a9-8d67-4faae8a3bee4_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_f2fb5cf1-a43d-4bd5-9ef8-43330ac4c48d_totalLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember_eb82bd37-c5da-49e1-ae15-a27472fa7a3c_terseLabel_en-US" xlink:label="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined Europe, Asia and other markets</link:label>
    <link:label id="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember_label_en-US" xlink:label="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined Europe Asia And Other Markets [Member]</link:label>
    <link:label id="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember_documentation_en-US" xlink:label="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Combined Europe Asia And Other Markets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:href="rmd-20220630.xsd#rmd_CombinedEuropeAsiaAndOtherMarketsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:to="lab_rmd_CombinedEuropeAsiaAndOtherMarketsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_SupplementalBalanceSheetInformationAbstract_5543069b-c3e9-4dcb-b67a-03b600b8564f_terseLabel_en-US" xlink:label="lab_rmd_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_rmd_SupplementalBalanceSheetInformationAbstract_label_en-US" xlink:label="lab_rmd_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:label id="lab_rmd_SupplementalBalanceSheetInformationAbstract_documentation_en-US" xlink:label="lab_rmd_SupplementalBalanceSheetInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract" xlink:href="rmd-20220630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract" xlink:to="lab_rmd_SupplementalBalanceSheetInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_8b649d71-1794-41b2-ab6a-4779cb8f29af_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_52be4f30-c6e5-4009-9268-152b605b3c09_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes computed at statutory U.S. rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b7281314-db23-4a2b-b752-7d747ed24830_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_a40fa24e-7a78-4eca-a3c2-68ee7f0abff4_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares that can be repurchased under the approved share repurchase program (shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_d93845ff-0f20-45f3-a51b-9ec5870bc9e6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_dbc3f1fa-a97f-413c-b022-2d3173df5b4c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation costs (note 11)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e75b8241-9adf-4f13-a6e7-e76d307c8468_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_e16d0fce-1e4e-4fe1-9539-4a4f81034671_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9ef50dec-d617-4762-9968-207355f65fec_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_b51e8728-c5f1-47fb-a0df-3b6d581d804b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_a62c7941-12bb-4ae5-916b-6e53cd1b524b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to equity method investments (note 6)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_e15806c2-9471-471b-9ab1-32662c013e01_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to equity method investments (note 6)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_70cb4abb-e702-42d9-b323-279e83db5f48_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss attributable to equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_32905f28-c2b4-4bea-8429-5964eb0316e5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_81bf7641-04aa-42bf-96e7-405511281878_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_b547ec01-6fef-4b62-b3ec-9390def4d8ac_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ResmedLimitedMember_3f1dbfc5-d183-47f1-8290-483909599b72_terseLabel_en-US" xlink:label="lab_rmd_ResmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ResMed Limited</link:label>
    <link:label id="lab_rmd_ResmedLimitedMember_label_en-US" xlink:label="lab_rmd_ResmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resmed Limited [Member]</link:label>
    <link:label id="lab_rmd_ResmedLimitedMember_documentation_en-US" xlink:label="lab_rmd_ResmedLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ResMed Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedLimitedMember" xlink:href="rmd-20220630.xsd#rmd_ResmedLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ResmedLimitedMember" xlink:to="lab_rmd_ResmedLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAbstract_dfb4e9da-475e-481f-94eb-3872068e77b2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEDIFOX DAN acquisition consideration</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAbstract" xlink:to="lab_us-gaap_OtherCommitmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_6ba5bc7a-3406-4d9b-8ad1-ef936a63c9b5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_375cc40a-ae98-459c-9d6e-832129729025_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Basic And Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e9d23064-6a41-4bab-b273-380b2f336ffa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, foreign currency translation adjustment, tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_faf3a745-c67a-4ba7-b62d-a2703dd73e05_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use assets obtained in exchange for new lease liabilities:</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_85292d8a-cf58-4481-b1d0-4441810d5d3e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired_fb587d84-7d21-4b6b-a797-16ca6df2b2b5_terseLabel_en-US" xlink:label="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired, excluding cash</link:label>
    <link:label id="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired_label_en-US" xlink:label="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Part Of Acquisition, Fair Value of Assets Acquired</link:label>
    <link:label id="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired_documentation_en-US" xlink:label="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The fair value of an asset or business acquired in a noncash acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:href="rmd-20220630.xsd#rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:to="lab_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock_971796a7-b6c2-4e13-94aa-fd8f0b8d11bb_terseLabel_en-US" xlink:label="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Deferred Tax Assets And Liabilities Classified As Current And Non-Current</link:label>
    <link:label id="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Net Deferred Income Tax Assets And Liabilities [Table Text Block]</link:label>
    <link:label id="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Net Deferred Income Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="rmd-20220630.xsd#rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock_2cabe1ad-120b-49b9-9bb3-9218d1688929_terseLabel_en-US" xlink:label="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Of Credit Risk And Significant Customers</link:label>
    <link:label id="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock_label_en-US" xlink:label="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Of Credit Risk And Significant Customers [Policy Text Block]</link:label>
    <link:label id="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock_documentation_en-US" xlink:label="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Of Credit Risk And Significant Customers [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:href="rmd-20220630.xsd#rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:to="lab_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_02ca0e7d-c1fd-4036-bf61-3e5aa62fa50f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201613Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-13 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201613Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201613Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201613Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>rmd-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:847d2812-be5d-4010-ae3d-4823a56f6339,g:501af745-9083-47bc-ad44-e407829835be-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://investor.resmed.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="rmd-20220630.xsd#DocumentAndEntityInformation"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:href="rmd-20220630.xsd#rmd_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_702a6ad0-2489-48c8-8df4-85bfa245242d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_DocumentType_702a6ad0-2489-48c8-8df4-85bfa245242d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_1e4f945b-4af3-4da8-add9-8000d9a41572" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_DocumentAnnualReport_1e4f945b-4af3-4da8-add9-8000d9a41572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5244b3f9-1add-41ac-99ef-d8392ab85dc9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_DocumentPeriodEndDate_5244b3f9-1add-41ac-99ef-d8392ab85dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_70fe16b1-47cc-4c21-943d-a686a55592b8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_CurrentFiscalYearEndDate_70fe16b1-47cc-4c21-943d-a686a55592b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fe0fa46a-6e24-4975-a88e-6748bc01360c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityFileNumber_fe0fa46a-6e24-4975-a88e-6748bc01360c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_ac099a63-17da-46f9-bf8c-56cb5fbfa3c7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityRegistrantName_ac099a63-17da-46f9-bf8c-56cb5fbfa3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_7450913f-f505-4f5d-889f-224fe89249a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_7450913f-f505-4f5d-889f-224fe89249a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9c1ce6cc-fd47-41e8-a052-f1b2567c47a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityTaxIdentificationNumber_9c1ce6cc-fd47-41e8-a052-f1b2567c47a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_81cdd56f-7dc0-46df-808d-e7557088c8e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityAddressAddressLine1_81cdd56f-7dc0-46df-808d-e7557088c8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ffd72f80-87d2-4478-a16a-9d9155460ebe" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityAddressCityOrTown_ffd72f80-87d2-4478-a16a-9d9155460ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f96f018e-a280-4104-bf4a-e6d9abccd4de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityAddressStateOrProvince_f96f018e-a280-4104-bf4a-e6d9abccd4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_36b2d095-cb78-4e5b-b3a2-ba017cbadb4c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityAddressPostalZipCode_36b2d095-cb78-4e5b-b3a2-ba017cbadb4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_3c9c5e29-db4a-488b-b479-47e91a5a94d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityAddressCountry_3c9c5e29-db4a-488b-b479-47e91a5a94d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_5cf78bec-94b6-411e-b527-503c01fcc10d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_CityAreaCode_5cf78bec-94b6-411e-b527-503c01fcc10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f9c8ff6e-850d-4867-8051-d59173d53083" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_LocalPhoneNumber_f9c8ff6e-850d-4867-8051-d59173d53083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4a1995e8-c027-48aa-9396-d86d7c4844de" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_Security12bTitle_4a1995e8-c027-48aa-9396-d86d7c4844de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6b97b27c-1729-49b2-9a78-6409ea273866" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_TradingSymbol_6b97b27c-1729-49b2-9a78-6409ea273866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_332e524a-e284-4763-8362-83b3ff77adfa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_SecurityExchangeName_332e524a-e284-4763-8362-83b3ff77adfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_49e9b805-ae90-4163-9df7-b7388da707dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_49e9b805-ae90-4163-9df7-b7388da707dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_7d8b1500-568f-4b39-8cdb-0fda2fadd126" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityVoluntaryFilers_7d8b1500-568f-4b39-8cdb-0fda2fadd126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b7967eba-a779-4eaa-96f8-02f842dfc57c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityCurrentReportingStatus_b7967eba-a779-4eaa-96f8-02f842dfc57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f1c2bf77-4426-4b22-86d6-56f83b04f7f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityInteractiveDataCurrent_f1c2bf77-4426-4b22-86d6-56f83b04f7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e20850e9-6c6b-4bcf-abdf-b20fabe97293" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityFilerCategory_e20850e9-6c6b-4bcf-abdf-b20fabe97293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_4be911ac-8f96-46d6-a544-37333f074e23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntitySmallBusiness_4be911ac-8f96-46d6-a544-37333f074e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_643cbfbc-7f55-4bfb-afb2-6049a3f5812a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityEmergingGrowthCompany_643cbfbc-7f55-4bfb-afb2-6049a3f5812a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_6e0c09f8-deb2-44fa-9f41-42885761dc1d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_IcfrAuditorAttestationFlag_6e0c09f8-deb2-44fa-9f41-42885761dc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b70351be-19fa-4371-96bb-34ddb9abf7dd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityShellCompany_b70351be-19fa-4371-96bb-34ddb9abf7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_777cb041-2b30-47bf-9b9d-1db74265490d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityPublicFloat_777cb041-2b30-47bf-9b9d-1db74265490d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e28687c3-047c-43d6-8087-38b9d9622e99" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e28687c3-047c-43d6-8087-38b9d9622e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f092d596-62a4-4378-8c28-20e33cca2b79" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_AmendmentFlag_f092d596-62a4-4378-8c28-20e33cca2b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_96864ba8-5e97-4940-9e34-0780dfd47ea0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_96864ba8-5e97-4940-9e34-0780dfd47ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_edcb422a-a105-4898-9347-c8346e8e2326" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_EntityCentralIndexKey_edcb422a-a105-4898-9347-c8346e8e2326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_44246f89-7506-46ca-9fcf-4032fda5cb9f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_DocumentFiscalYearFocus_44246f89-7506-46ca-9fcf-4032fda5cb9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_8f7b7fd0-e8aa-470e-b69f-727bcee94f70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_DocumentAndEntityInformationAbstract_eb0ccc9e-0caa-4a5a-8f66-a1e6251d09a1" xlink:to="loc_dei_DocumentTransitionReport_8f7b7fd0-e8aa-470e-b69f-727bcee94f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/AuditInformation" xlink:type="simple" xlink:href="rmd-20220630.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AuditInformationAbstract_8a72e085-f0f3-487c-b6b5-be1a0fc8a6eb" xlink:href="rmd-20220630.xsd#rmd_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_e595538f-f0ba-4a9c-97db-b872b3f88eb0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_AuditInformationAbstract_8a72e085-f0f3-487c-b6b5-be1a0fc8a6eb" xlink:to="loc_dei_AuditorName_e595538f-f0ba-4a9c-97db-b872b3f88eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_d333d3a0-67a5-4a10-91e7-15f86f28f0f2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_AuditInformationAbstract_8a72e085-f0f3-487c-b6b5-be1a0fc8a6eb" xlink:to="loc_dei_AuditorLocation_d333d3a0-67a5-4a10-91e7-15f86f28f0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_f2c5363e-e798-4636-92df-08e25bcd2ac2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_AuditInformationAbstract_8a72e085-f0f3-487c-b6b5-be1a0fc8a6eb" xlink:to="loc_dei_AuditorFirmId_f2c5363e-e798-4636-92df-08e25bcd2ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc53c16-e91d-4dad-a5ee-3777fa1e626e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_45a5339c-d022-436e-abca-5e3bcb7d3d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc53c16-e91d-4dad-a5ee-3777fa1e626e" xlink:to="loc_us-gaap_AssetsAbstract_45a5339c-d022-436e-abca-5e3bcb7d3d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c51c8fda-7362-4cc8-b5fc-ccba1fe831e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45a5339c-d022-436e-abca-5e3bcb7d3d35" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c51c8fda-7362-4cc8-b5fc-ccba1fe831e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9d98bc0-a18b-4865-a42c-43fb13b239fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c51c8fda-7362-4cc8-b5fc-ccba1fe831e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9d98bc0-a18b-4865-a42c-43fb13b239fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7a5bc55f-0862-4ae3-bf02-2c318c2b09ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c51c8fda-7362-4cc8-b5fc-ccba1fe831e0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7a5bc55f-0862-4ae3-bf02-2c318c2b09ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cd5746f5-5e0d-47fe-8a05-7552bb27cc72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c51c8fda-7362-4cc8-b5fc-ccba1fe831e0" xlink:to="loc_us-gaap_InventoryNet_cd5746f5-5e0d-47fe-8a05-7552bb27cc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa374220-b738-4bad-9cb9-10a6f6d5f481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c51c8fda-7362-4cc8-b5fc-ccba1fe831e0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_aa374220-b738-4bad-9cb9-10a6f6d5f481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_34623bd1-6ca7-4d0a-b35f-d2bdfe58d7e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c51c8fda-7362-4cc8-b5fc-ccba1fe831e0" xlink:to="loc_us-gaap_AssetsCurrent_34623bd1-6ca7-4d0a-b35f-d2bdfe58d7e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_0050ffc5-d977-426d-8bba-37711bd472c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45a5339c-d022-436e-abca-5e3bcb7d3d35" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_0050ffc5-d977-426d-8bba-37711bd472c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8819665f-1d79-4930-a4c4-5fb25c2c6a27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0050ffc5-d977-426d-8bba-37711bd472c7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8819665f-1d79-4930-a4c4-5fb25c2c6a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_308b7c3c-72de-4e84-81b5-0a30763ee00e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0050ffc5-d977-426d-8bba-37711bd472c7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_308b7c3c-72de-4e84-81b5-0a30763ee00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d05a06c0-64c1-41e5-bce9-561a763d8b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0050ffc5-d977-426d-8bba-37711bd472c7" xlink:to="loc_us-gaap_Goodwill_d05a06c0-64c1-41e5-bce9-561a763d8b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_825a16da-6411-41b7-b5d0-db482652e7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0050ffc5-d977-426d-8bba-37711bd472c7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_825a16da-6411-41b7-b5d0-db482652e7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_272cf925-4d87-4c06-aebf-18a455c80896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0050ffc5-d977-426d-8bba-37711bd472c7" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_272cf925-4d87-4c06-aebf-18a455c80896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_704fb721-7308-48e6-a29a-2136169b184d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0050ffc5-d977-426d-8bba-37711bd472c7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_704fb721-7308-48e6-a29a-2136169b184d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_2ed83138-e141-47ac-bfdd-0b46c78223f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_0050ffc5-d977-426d-8bba-37711bd472c7" xlink:to="loc_us-gaap_AssetsNoncurrent_2ed83138-e141-47ac-bfdd-0b46c78223f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ec43aff1-ff65-4aeb-ab6e-f604718e445a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_45a5339c-d022-436e-abca-5e3bcb7d3d35" xlink:to="loc_us-gaap_Assets_ec43aff1-ff65-4aeb-ab6e-f604718e445a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63ec5c5d-d02b-4ed8-b5c4-37bbc50414c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1bc53c16-e91d-4dad-a5ee-3777fa1e626e" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63ec5c5d-d02b-4ed8-b5c4-37bbc50414c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_875ca36e-92cb-4eba-9b26-6ea3f9e7cb20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63ec5c5d-d02b-4ed8-b5c4-37bbc50414c5" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_875ca36e-92cb-4eba-9b26-6ea3f9e7cb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8bec1546-8b86-44dd-b0c7-f063760843fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_875ca36e-92cb-4eba-9b26-6ea3f9e7cb20" xlink:to="loc_us-gaap_AccountsPayableCurrent_8bec1546-8b86-44dd-b0c7-f063760843fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3ff9b7b4-8aca-44ca-94b5-b0474b0d3b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_875ca36e-92cb-4eba-9b26-6ea3f9e7cb20" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3ff9b7b4-8aca-44ca-94b5-b0474b0d3b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c94ee980-a9a0-4800-8927-b291d4f79d54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_875ca36e-92cb-4eba-9b26-6ea3f9e7cb20" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c94ee980-a9a0-4800-8927-b291d4f79d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5e1f8537-19f2-4dd0-a532-ad3338dfb035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_875ca36e-92cb-4eba-9b26-6ea3f9e7cb20" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5e1f8537-19f2-4dd0-a532-ad3338dfb035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_4bd3f9f5-2ec0-4995-a046-741c0481e2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_875ca36e-92cb-4eba-9b26-6ea3f9e7cb20" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_4bd3f9f5-2ec0-4995-a046-741c0481e2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_0e1fd44f-bf50-456e-8f5d-273f6bd27f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_875ca36e-92cb-4eba-9b26-6ea3f9e7cb20" xlink:to="loc_us-gaap_ShortTermBorrowings_0e1fd44f-bf50-456e-8f5d-273f6bd27f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9af75ec9-8f4e-4984-a5f7-b753beba651d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_875ca36e-92cb-4eba-9b26-6ea3f9e7cb20" xlink:to="loc_us-gaap_LiabilitiesCurrent_9af75ec9-8f4e-4984-a5f7-b753beba651d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_9a60f691-b3f9-40f7-aea5-39257f89dafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63ec5c5d-d02b-4ed8-b5c4-37bbc50414c5" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_9a60f691-b3f9-40f7-aea5-39257f89dafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_051688e2-ad2e-4d59-b8c4-7876cd997dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_9a60f691-b3f9-40f7-aea5-39257f89dafb" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_051688e2-ad2e-4d59-b8c4-7876cd997dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_274e74fb-946f-449a-bf5d-2d1d954dd38e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_9a60f691-b3f9-40f7-aea5-39257f89dafb" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_274e74fb-946f-449a-bf5d-2d1d954dd38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2693d19-89b6-4ed9-92f0-0cb5905787d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_9a60f691-b3f9-40f7-aea5-39257f89dafb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f2693d19-89b6-4ed9-92f0-0cb5905787d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6be53ce7-a663-4087-8cec-2f839e2a54b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_9a60f691-b3f9-40f7-aea5-39257f89dafb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6be53ce7-a663-4087-8cec-2f839e2a54b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_eae70025-54b6-407b-b139-2845d065206c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_9a60f691-b3f9-40f7-aea5-39257f89dafb" xlink:to="loc_us-gaap_LongTermDebt_eae70025-54b6-407b-b139-2845d065206c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_ba8b5966-4354-48bc-b124-41382dac33f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_9a60f691-b3f9-40f7-aea5-39257f89dafb" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_ba8b5966-4354-48bc-b124-41382dac33f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_41f34cde-55e4-4b58-b9f5-2944e9789a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_9a60f691-b3f9-40f7-aea5-39257f89dafb" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_41f34cde-55e4-4b58-b9f5-2944e9789a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d39bdb34-10a6-4e2d-aed0-10a6a8e2c07d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63ec5c5d-d02b-4ed8-b5c4-37bbc50414c5" xlink:to="loc_us-gaap_Liabilities_d39bdb34-10a6-4e2d-aed0-10a6a8e2c07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_99fee409-115e-4c04-b3bc-e1897e8889c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63ec5c5d-d02b-4ed8-b5c4-37bbc50414c5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_99fee409-115e-4c04-b3bc-e1897e8889c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a2252241-45a3-4afa-8dc2-7eaecf1e7864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63ec5c5d-d02b-4ed8-b5c4-37bbc50414c5" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a2252241-45a3-4afa-8dc2-7eaecf1e7864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c38b960a-b59a-4ebd-8ce3-30db5b882e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2252241-45a3-4afa-8dc2-7eaecf1e7864" xlink:to="loc_us-gaap_PreferredStockValue_c38b960a-b59a-4ebd-8ce3-30db5b882e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_63deca56-cc92-4fc7-aa8e-2bd0d1b7b478" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2252241-45a3-4afa-8dc2-7eaecf1e7864" xlink:to="loc_us-gaap_CommonStockValueOutstanding_63deca56-cc92-4fc7-aa8e-2bd0d1b7b478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f9bf222f-41a9-44c7-a70c-84b71cff4825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2252241-45a3-4afa-8dc2-7eaecf1e7864" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f9bf222f-41a9-44c7-a70c-84b71cff4825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef69669f-8d3e-4c3b-854c-a48646cd2f30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2252241-45a3-4afa-8dc2-7eaecf1e7864" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ef69669f-8d3e-4c3b-854c-a48646cd2f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_eec69f98-94e3-411b-9932-6cd7b6c63c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2252241-45a3-4afa-8dc2-7eaecf1e7864" xlink:to="loc_us-gaap_TreasuryStockCommonValue_eec69f98-94e3-411b-9932-6cd7b6c63c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2588142e-4dca-42f3-925c-438a1267754b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2252241-45a3-4afa-8dc2-7eaecf1e7864" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2588142e-4dca-42f3-925c-438a1267754b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5a2dbd4a-1439-4251-bc75-ca5480c7fa23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a2252241-45a3-4afa-8dc2-7eaecf1e7864" xlink:to="loc_us-gaap_StockholdersEquity_5a2dbd4a-1439-4251-bc75-ca5480c7fa23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1f3113cd-704c-48b5-87b6-70dad9f35080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63ec5c5d-d02b-4ed8-b5c4-37bbc50414c5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1f3113cd-704c-48b5-87b6-70dad9f35080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_fc3e1abe-4d55-43ee-bd2a-7ab1d8090f6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b3012674-c156-477f-a9d8-5fc9c1d31b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc3e1abe-4d55-43ee-bd2a-7ab1d8090f6a" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b3012674-c156-477f-a9d8-5fc9c1d31b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e7b1b7ac-d991-497c-a883-53072b6891fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc3e1abe-4d55-43ee-bd2a-7ab1d8090f6a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e7b1b7ac-d991-497c-a883-53072b6891fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_946cab3a-415e-4989-9a7d-d933f95896b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc3e1abe-4d55-43ee-bd2a-7ab1d8090f6a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_946cab3a-415e-4989-9a7d-d933f95896b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5cf3dd2d-b7d7-48ba-b54a-592028a44015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc3e1abe-4d55-43ee-bd2a-7ab1d8090f6a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5cf3dd2d-b7d7-48ba-b54a-592028a44015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c15f097-799b-4f3b-bd3e-b4ba1f8a160c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc3e1abe-4d55-43ee-bd2a-7ab1d8090f6a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6c15f097-799b-4f3b-bd3e-b4ba1f8a160c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7e4bfd76-d4ad-4db2-8870-20c63a9ff4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc3e1abe-4d55-43ee-bd2a-7ab1d8090f6a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7e4bfd76-d4ad-4db2-8870-20c63a9ff4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0a92925b-d50a-4fc0-9c62-904d49db9165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc3e1abe-4d55-43ee-bd2a-7ab1d8090f6a" xlink:to="loc_us-gaap_CommonStockSharesIssued_0a92925b-d50a-4fc0-9c62-904d49db9165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c7be2b4f-4c24-4b0c-953f-c8d47afe025f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc3e1abe-4d55-43ee-bd2a-7ab1d8090f6a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c7be2b4f-4c24-4b0c-953f-c8d47afe025f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_892b977e-3771-4864-8618-1adc48fa8a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_fc3e1abe-4d55-43ee-bd2a-7ab1d8090f6a" xlink:to="loc_us-gaap_TreasuryStockCommonShares_892b977e-3771-4864-8618-1adc48fa8a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsOfIncome" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedStatementsOfIncome"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4f965c63-1501-4dad-b34b-a2a66ad78526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ee9bbe43-fb70-432f-b712-6718b57341c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4f965c63-1501-4dad-b34b-a2a66ad78526" xlink:to="loc_us-gaap_StatementTable_ee9bbe43-fb70-432f-b712-6718b57341c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_10865e0a-65a4-4dff-be12-354726a66403" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee9bbe43-fb70-432f-b712-6718b57341c8" xlink:to="loc_srt_ProductOrServiceAxis_10865e0a-65a4-4dff-be12-354726a66403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_40861486-f061-429e-8234-8637aa9edf1d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_10865e0a-65a4-4dff-be12-354726a66403" xlink:to="loc_srt_ProductsAndServicesDomain_40861486-f061-429e-8234-8637aa9edf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_2bc59c52-141d-4cce-9e62-9de88e028143" xlink:href="rmd-20220630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_40861486-f061-429e-8234-8637aa9edf1d" xlink:to="loc_rmd_SleepAndRespiratoryMember_2bc59c52-141d-4cce-9e62-9de88e028143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsServiceMember_2129f84d-a8f8-4b62-99ba-be7fb649d553" xlink:href="rmd-20220630.xsd#rmd_SoftwareAsServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_40861486-f061-429e-8234-8637aa9edf1d" xlink:to="loc_rmd_SoftwareAsServiceMember_2129f84d-a8f8-4b62-99ba-be7fb649d553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ee9bbe43-fb70-432f-b712-6718b57341c8" xlink:to="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4fdc0b8c-0a1b-46d5-93c2-450629228513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4fdc0b8c-0a1b-46d5-93c2-450629228513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_7d58fa2d-1d12-43d0-ba1c-9f75eca5e392" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_7d58fa2d-1d12-43d0-ba1c-9f75eca5e392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_334b5554-31d3-4892-b819-7245f3c19c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_334b5554-31d3-4892-b819-7245f3c19c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_175368c1-6ada-4259-a7b5-32705722c42d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_175368c1-6ada-4259-a7b5-32705722c42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_51238a60-7638-4e74-921a-34e289c8fddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_GrossProfit_51238a60-7638-4e74-921a-34e289c8fddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_62eeab46-5cc5-4d44-8dce-1cb9a3296332" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_62eeab46-5cc5-4d44-8dce-1cb9a3296332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7efe2071-99c6-42e6-80c5-d8a1a197c1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7efe2071-99c6-42e6-80c5-d8a1a197c1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_32dfdf5d-cf7f-4953-acbe-29442a2a1a0a" xlink:href="rmd-20220630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_32dfdf5d-cf7f-4953-acbe-29442a2a1a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0d990c34-6453-492a-8885-dc181b197bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_us-gaap_RestructuringCharges_0d990c34-6453-492a-8885-dc181b197bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_36e44e93-633d-47d7-8df8-ca3cc7dd61f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_us-gaap_LitigationSettlementExpense_36e44e93-633d-47d7-8df8-ca3cc7dd61f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8f126ad4-235f-4a15-ae91-915165723b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_25e161ad-11da-461e-a76b-345fb0ed088c" xlink:to="loc_us-gaap_OperatingExpenses_8f126ad4-235f-4a15-ae91-915165723b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a5828bb4-8956-4665-994a-163dff750716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_OperatingIncomeLoss_a5828bb4-8956-4665-994a-163dff750716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_88bcbc54-4ab9-407d-b0fb-43e61388f25b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_88bcbc54-4ab9-407d-b0fb-43e61388f25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5917c108-66b5-4ad5-9879-8f950a11f173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_5917c108-66b5-4ad5-9879-8f950a11f173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_58f43d7a-e6c8-444d-8d5b-773171f25269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_58f43d7a-e6c8-444d-8d5b-773171f25269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7edcb65f-ebec-4cca-8acd-f9aa09438615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7edcb65f-ebec-4cca-8acd-f9aa09438615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6134f8bc-e72b-4ddf-bacc-438fb51753a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_166110fb-bbef-4491-b5e2-6cdd2a793084" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6134f8bc-e72b-4ddf-bacc-438fb51753a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ee271b2a-8077-4d23-9fdc-e3a6a52eeaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ee271b2a-8077-4d23-9fdc-e3a6a52eeaa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b393095f-b33a-4af2-9260-9407052792c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b393095f-b33a-4af2-9260-9407052792c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49fa9420-984a-483b-be10-9248b107f900" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_NetIncomeLoss_49fa9420-984a-483b-be10-9248b107f900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c53fb013-c0f9-431b-ae45-197b6132f0d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_EarningsPerShareBasic_c53fb013-c0f9-431b-ae45-197b6132f0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9b6cd33b-c7bc-4f14-969f-0e8a2c6f8995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9b6cd33b-c7bc-4f14-969f-0e8a2c6f8995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_430efe52-70ac-492b-a808-3b17cc94e24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_430efe52-70ac-492b-a808-3b17cc94e24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d04e3599-0048-4283-9996-ef8b70bfaf31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d04e3599-0048-4283-9996-ef8b70bfaf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74e95ed2-b0dd-4409-be06-d7b79df3075f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8b38fca4-edcb-43a6-9f36-e68e2139a551" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_74e95ed2-b0dd-4409-be06-d7b79df3075f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedStatementsOfComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6b172a50-d3e5-4a84-a886-08a6aa736b08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1b8342f8-6a83-4ff5-a5e1-349d1ea971a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6b172a50-d3e5-4a84-a886-08a6aa736b08" xlink:to="loc_us-gaap_NetIncomeLoss_1b8342f8-6a83-4ff5-a5e1-349d1ea971a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ac02a451-c61f-4d85-ac40-0057bf8b95d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6b172a50-d3e5-4a84-a886-08a6aa736b08" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ac02a451-c61f-4d85-ac40-0057bf8b95d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9e621208-9c87-4727-b5d5-88bdc0ce095c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ac02a451-c61f-4d85-ac40-0057bf8b95d3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9e621208-9c87-4727-b5d5-88bdc0ce095c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a1bf7ed6-f8a7-4a0c-9f56-db427c26effb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_6b172a50-d3e5-4a84-a886-08a6aa736b08" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a1bf7ed6-f8a7-4a0c-9f56-db427c26effb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_fd930d6b-0932-465f-b133-03367798b650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0c5f3922-54e5-4e95-853c-63b19406c357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_fd930d6b-0932-465f-b133-03367798b650" xlink:to="loc_us-gaap_StatementTable_0c5f3922-54e5-4e95-853c-63b19406c357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3567521a-c566-4fb3-b04d-fcd663effe60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0c5f3922-54e5-4e95-853c-63b19406c357" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3567521a-c566-4fb3-b04d-fcd663effe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3567521a-c566-4fb3-b04d-fcd663effe60" xlink:to="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_99b1f8ff-da39-4613-8790-346d2cb8a908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:to="loc_us-gaap_CommonStockMember_99b1f8ff-da39-4613-8790-346d2cb8a908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c3bf1af4-4c05-41b1-9284-369db642381f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c3bf1af4-4c05-41b1-9284-369db642381f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_b75b1b35-2832-4859-a997-fde09317c410" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:to="loc_us-gaap_TreasuryStockCommonMember_b75b1b35-2832-4859-a997-fde09317c410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7d60afca-4586-4891-bcb6-cb360c75a318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:to="loc_us-gaap_RetainedEarningsMember_7d60afca-4586-4891-bcb6-cb360c75a318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f831f694-5d02-4798-9b30-db3db8d7d1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8707bd6d-aad6-44b3-af4d-1feba5a35404" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f831f694-5d02-4798-9b30-db3db8d7d1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fc16db91-02ac-4981-8f8d-aff3da1a546c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0c5f3922-54e5-4e95-853c-63b19406c357" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fc16db91-02ac-4981-8f8d-aff3da1a546c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1b6c580-c5f4-4dff-ae65-46b87f8fa693" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fc16db91-02ac-4981-8f8d-aff3da1a546c" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1b6c580-c5f4-4dff-ae65-46b87f8fa693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_490daf8a-77a4-4a8d-a7de-6fe96178c444" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_f1b6c580-c5f4-4dff-ae65-46b87f8fa693" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_490daf8a-77a4-4a8d-a7de-6fe96178c444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ceaa0300-4814-462c-8b96-60f64083716c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0c5f3922-54e5-4e95-853c-63b19406c357" xlink:to="loc_us-gaap_StatementLineItems_ceaa0300-4814-462c-8b96-60f64083716c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ceaa0300-4814-462c-8b96-60f64083716c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_117f226d-7250-4625-aa95-64e5dd434591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_117f226d-7250-4625-aa95-64e5dd434591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b510c378-c0e2-41b0-b341-16b4811104e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockholdersEquity_b510c378-c0e2-41b0-b341-16b4811104e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_a2a9f95d-9d12-4c75-9b76-f495abb22af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_TreasuryStockCommonShares_a2a9f95d-9d12-4c75-9b76-f495abb22af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9edf3bba-9e8f-42cd-a810-81f3fd772235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9edf3bba-9e8f-42cd-a810-81f3fd772235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cf3e1717-13eb-4f92-8637-bfe95885a91f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cf3e1717-13eb-4f92-8637-bfe95885a91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c083d72f-f23d-4246-823b-bf03cfb871cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_c083d72f-f23d-4246-823b-bf03cfb871cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_3772da0d-7264-4596-860a-01e519484706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_3772da0d-7264-4596-860a-01e519484706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_58e8ee3a-5d48-4f1e-85ba-9a839213d30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_58e8ee3a-5d48-4f1e-85ba-9a839213d30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7ba691ce-7a57-4667-9d10-8403fbc307e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7ba691ce-7a57-4667-9d10-8403fbc307e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_48c5fb63-9d85-4a72-b1d1-de196b63d112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_48c5fb63-9d85-4a72-b1d1-de196b63d112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_270ff62e-6292-4002-9b83-d535c62bd6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_270ff62e-6292-4002-9b83-d535c62bd6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fec2fa73-cd98-49eb-b944-f8a61e6528d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_NetIncomeLoss_fec2fa73-cd98-49eb-b944-f8a61e6528d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_bd0b7b34-b7a7-4382-bfb8-d9302d296a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_Dividends_bd0b7b34-b7a7-4382-bfb8-d9302d296a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_28b39d88-98b2-4733-ab6d-4a117a020fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_28b39d88-98b2-4733-ab6d-4a117a020fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_83779248-1a02-4b83-af53-cf841805d88f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_StockholdersEquity_83779248-1a02-4b83-af53-cf841805d88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_c9db4353-c9e6-45ab-93a0-c40ea2638317" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_TreasuryStockCommonShares_c9db4353-c9e6-45ab-93a0-c40ea2638317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f5698f8e-f81e-4629-8ed7-7bec1f1a6acf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d64b224a-e88a-4918-a77a-9d12d4a61c6d" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_f5698f8e-f81e-4629-8ed7-7bec1f1a6acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c3560304-8533-48b9-b2dd-2050e3fd7f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_6f8bea33-67d8-4671-be73-aa686d2dddc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c3560304-8533-48b9-b2dd-2050e3fd7f20" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_6f8bea33-67d8-4671-be73-aa686d2dddc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="rmd-20220630.xsd#ConsolidatedStatementsOfCashFlows"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_eaac36e3-fc9a-4a3a-a1a7-648cf0aa2ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_07b27323-7b9f-49ee-aef8-456e0506c551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaac36e3-fc9a-4a3a-a1a7-648cf0aa2ba5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_07b27323-7b9f-49ee-aef8-456e0506c551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6b4c0d3d-b6d6-4104-8b06-e2a7d80be445" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_07b27323-7b9f-49ee-aef8-456e0506c551" xlink:to="loc_us-gaap_NetIncomeLoss_6b4c0d3d-b6d6-4104-8b06-e2a7d80be445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf428810-abc8-42fc-9297-26a1a638f035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_07b27323-7b9f-49ee-aef8-456e0506c551" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf428810-abc8-42fc-9297-26a1a638f035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_aa2db3af-4203-4882-a63d-d2eff89b7a72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf428810-abc8-42fc-9297-26a1a638f035" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_aa2db3af-4203-4882-a63d-d2eff89b7a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1f2957ed-a7ed-435e-a176-47acd2b8a74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf428810-abc8-42fc-9297-26a1a638f035" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_1f2957ed-a7ed-435e-a176-47acd2b8a74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ac44707d-598c-484a-bb59-70c57a20306f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf428810-abc8-42fc-9297-26a1a638f035" xlink:to="loc_us-gaap_ShareBasedCompensation_ac44707d-598c-484a-bb59-70c57a20306f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c32faa1b-c9b1-4d2e-8bd8-4ebcebc25c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf428810-abc8-42fc-9297-26a1a638f035" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_c32faa1b-c9b1-4d2e-8bd8-4ebcebc25c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_26319acd-b8e6-415f-a6d3-785a7419247f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf428810-abc8-42fc-9297-26a1a638f035" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_26319acd-b8e6-415f-a6d3-785a7419247f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_6ff3f130-9946-4810-9c33-b9368cf8f9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf428810-abc8-42fc-9297-26a1a638f035" xlink:to="loc_us-gaap_RestructuringCharges_6ff3f130-9946-4810-9c33-b9368cf8f9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_44e0ec4f-19ae-4c92-8751-561afde461cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_cf428810-abc8-42fc-9297-26a1a638f035" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_44e0ec4f-19ae-4c92-8751-561afde461cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bfabe9d1-df43-4ffa-b18a-a0ff052d802a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_07b27323-7b9f-49ee-aef8-456e0506c551" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bfabe9d1-df43-4ffa-b18a-a0ff052d802a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58af8501-258d-4f10-a970-7e410614b2ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bfabe9d1-df43-4ffa-b18a-a0ff052d802a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58af8501-258d-4f10-a970-7e410614b2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_a424b91f-c881-47e2-8884-f0b01f38b5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bfabe9d1-df43-4ffa-b18a-a0ff052d802a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_a424b91f-c881-47e2-8884-f0b01f38b5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0647ffb6-05d9-4d38-8286-f1cc39819efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bfabe9d1-df43-4ffa-b18a-a0ff052d802a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0647ffb6-05d9-4d38-8286-f1cc39819efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e7de1af8-c59b-4528-bfa5-8a4b2ee03ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bfabe9d1-df43-4ffa-b18a-a0ff052d802a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_e7de1af8-c59b-4528-bfa5-8a4b2ee03ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce62ca28-2bb1-4048-9fc6-9f0c7ae5106b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_07b27323-7b9f-49ee-aef8-456e0506c551" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce62ca28-2bb1-4048-9fc6-9f0c7ae5106b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deb838e7-15f2-4ecf-bcc4-0408f6900434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaac36e3-fc9a-4a3a-a1a7-648cf0aa2ba5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deb838e7-15f2-4ecf-bcc4-0408f6900434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b8e63b90-0c70-49a5-9099-5aea367fb070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deb838e7-15f2-4ecf-bcc4-0408f6900434" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b8e63b90-0c70-49a5-9099-5aea367fb070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_b75cef81-ba9c-4daf-b33f-0173e1adfe41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deb838e7-15f2-4ecf-bcc4-0408f6900434" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_b75cef81-ba9c-4daf-b33f-0173e1adfe41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8857c5e8-fd6c-48d2-b5d8-bb03eb14a216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deb838e7-15f2-4ecf-bcc4-0408f6900434" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8857c5e8-fd6c-48d2-b5d8-bb03eb14a216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_9a43f418-77d6-43f0-8f87-facd5b3b0693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deb838e7-15f2-4ecf-bcc4-0408f6900434" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_9a43f418-77d6-43f0-8f87-facd5b3b0693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f190fc8d-f2b2-4f9a-9409-67a983d5e1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deb838e7-15f2-4ecf-bcc4-0408f6900434" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f190fc8d-f2b2-4f9a-9409-67a983d5e1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_68baa770-1f6d-4d5e-aa17-04f7959abcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deb838e7-15f2-4ecf-bcc4-0408f6900434" xlink:to="loc_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities_68baa770-1f6d-4d5e-aa17-04f7959abcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_346ea4b0-8796-47ee-bd74-b0f6296c6de5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_deb838e7-15f2-4ecf-bcc4-0408f6900434" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_346ea4b0-8796-47ee-bd74-b0f6296c6de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb3fe7a9-cb12-4869-8e97-1e2d6cb8da91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaac36e3-fc9a-4a3a-a1a7-648cf0aa2ba5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb3fe7a9-cb12-4869-8e97-1e2d6cb8da91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3877a70c-7808-406b-83bb-8de99f07c9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb3fe7a9-cb12-4869-8e97-1e2d6cb8da91" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3877a70c-7808-406b-83bb-8de99f07c9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2ac2eec5-8bbb-4dec-a1a9-bee41dc20f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb3fe7a9-cb12-4869-8e97-1e2d6cb8da91" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2ac2eec5-8bbb-4dec-a1a9-bee41dc20f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_5fe73ed5-d658-4436-94be-e6cc650fa826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb3fe7a9-cb12-4869-8e97-1e2d6cb8da91" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_5fe73ed5-d658-4436-94be-e6cc650fa826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fa65e16c-9b6d-46d7-b093-f9a0cbc166c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb3fe7a9-cb12-4869-8e97-1e2d6cb8da91" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_fa65e16c-9b6d-46d7-b093-f9a0cbc166c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_926d9924-5db1-4d9d-9708-a9e75631a654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb3fe7a9-cb12-4869-8e97-1e2d6cb8da91" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_926d9924-5db1-4d9d-9708-a9e75631a654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_bd08dcf2-0985-49ba-a709-1886c6d05e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb3fe7a9-cb12-4869-8e97-1e2d6cb8da91" xlink:to="loc_us-gaap_PaymentsOfDividends_bd08dcf2-0985-49ba-a709-1886c6d05e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f4bf5a1-2ac4-48e1-8e65-7d7590ea0426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_fb3fe7a9-cb12-4869-8e97-1e2d6cb8da91" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f4bf5a1-2ac4-48e1-8e65-7d7590ea0426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c698f3d-cf50-4bbc-8c26-0aa124630e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaac36e3-fc9a-4a3a-a1a7-648cf0aa2ba5" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5c698f3d-cf50-4bbc-8c26-0aa124630e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_84cf7041-4679-496d-b1de-3d524297113e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaac36e3-fc9a-4a3a-a1a7-648cf0aa2ba5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_84cf7041-4679-496d-b1de-3d524297113e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0af53ec6-bd34-4c8a-80c2-48b2699c8d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaac36e3-fc9a-4a3a-a1a7-648cf0aa2ba5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0af53ec6-bd34-4c8a-80c2-48b2699c8d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52c0f292-14d2-4f5b-85fd-300f22382d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaac36e3-fc9a-4a3a-a1a7-648cf0aa2ba5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52c0f292-14d2-4f5b-85fd-300f22382d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9ff168d-5787-4f66-a647-44acce84ebf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_eaac36e3-fc9a-4a3a-a1a7-648cf0aa2ba5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9ff168d-5787-4f66-a647-44acce84ebf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_9204db6d-332c-4f5f-8046-06490465b2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9ff168d-5787-4f66-a647-44acce84ebf0" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_9204db6d-332c-4f5f-8046-06490465b2a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_90100382-7391-4cf6-a5f9-fa5f5d3c65a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9ff168d-5787-4f66-a647-44acce84ebf0" xlink:to="loc_us-gaap_InterestPaidNet_90100382-7391-4cf6-a5f9-fa5f5d3c65a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired_77918b0d-3bec-4c0f-b238-fda3b8da8296" xlink:href="rmd-20220630.xsd#rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9ff168d-5787-4f66-a647-44acce84ebf0" xlink:to="loc_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired_77918b0d-3bec-4c0f-b238-fda3b8da8296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_32773414-2f93-4843-b0a4-8aba3ae1346f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9ff168d-5787-4f66-a647-44acce84ebf0" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_32773414-2f93-4843-b0a4-8aba3ae1346f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease_28f434d0-54b6-43c3-9b27-a355e0f6e2c2" xlink:href="rmd-20220630.xsd#rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9ff168d-5787-4f66-a647-44acce84ebf0" xlink:to="loc_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease_28f434d0-54b6-43c3-9b27-a355e0f6e2c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination_2cd9f4ad-d745-4d87-b288-8b0e6037f73f" xlink:href="rmd-20220630.xsd#rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9ff168d-5787-4f66-a647-44acce84ebf0" xlink:to="loc_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination_2cd9f4ad-d745-4d87-b288-8b0e6037f73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredPaymentObligationsForAcquisitions_0010a5b5-5dd8-44e6-8272-2e71557e6f30" xlink:href="rmd-20220630.xsd#rmd_DeferredPaymentObligationsForAcquisitions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9ff168d-5787-4f66-a647-44acce84ebf0" xlink:to="loc_rmd_DeferredPaymentObligationsForAcquisitions_0010a5b5-5dd8-44e6-8272-2e71557e6f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability_6f7b6db5-4048-47a3-957f-f43ad5f69f08" xlink:href="rmd-20220630.xsd#rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9ff168d-5787-4f66-a647-44acce84ebf0" xlink:to="loc_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability_6f7b6db5-4048-47a3-957f-f43ad5f69f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2f79a135-0e1b-482f-91ad-ca8da751e613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_f9ff168d-5787-4f66-a647-44acce84ebf0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2f79a135-0e1b-482f-91ad-ca8da751e613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/OrganizationAndBasisOfPresentation" xlink:type="simple" xlink:href="rmd-20220630.xsd#OrganizationAndBasisOfPresentation"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/OrganizationAndBasisOfPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e25ee41-6c3b-40ab-8f53-39ffe48b3204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8859bd1b-48d5-4375-b8f3-bba14d0faa96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1e25ee41-6c3b-40ab-8f53-39ffe48b3204" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_8859bd1b-48d5-4375-b8f3-bba14d0faa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="rmd-20220630.xsd#SummaryOfSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_70acd938-f31e-4cbf-9498-b92a124a8835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fe98f270-91a8-454e-8659-e1338e75558f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_70acd938-f31e-4cbf-9498-b92a124a8835" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_fe98f270-91a8-454e-8659-e1338e75558f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy" xlink:type="simple" xlink:href="rmd-20220630.xsd#SummaryOfSignificantAccountingPoliciesPolicy"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_b7c989ed-2da7-46c6-ab7b-3834512b0588" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_b7c989ed-2da7-46c6-ab7b-3834512b0588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_063c967e-6acd-473e-9f04-d489042347a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_063c967e-6acd-473e-9f04-d489042347a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock_02c9a3cc-7d12-43f0-85fc-7f9f6d18bdf2" xlink:href="rmd-20220630.xsd#rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock_02c9a3cc-7d12-43f0-85fc-7f9f6d18bdf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_36c1f55c-0185-4091-87d9-994d4a5c1482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_36c1f55c-0185-4091-87d9-994d4a5c1482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9bf61822-fadd-4e58-98ae-40de85f4e294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9bf61822-fadd-4e58-98ae-40de85f4e294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_8e1fedfb-931b-4a57-bb4b-d8ab726a6d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_8e1fedfb-931b-4a57-bb4b-d8ab726a6d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fcdd4529-44c8-46cd-98b5-1807d95d3106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_fcdd4529-44c8-46cd-98b5-1807d95d3106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_e5e181fd-e0fe-4106-bd65-bbd26ceb5da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_e5e181fd-e0fe-4106-bd65-bbd26ceb5da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4e2e5cd7-b6eb-4784-8b39-25ec9e11bfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_4e2e5cd7-b6eb-4784-8b39-25ec9e11bfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_6cb02293-d630-4251-ae4b-984f58eaa8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_6cb02293-d630-4251-ae4b-984f58eaa8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8cdf7a1e-f746-4548-b13c-5b395834d6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8cdf7a1e-f746-4548-b13c-5b395834d6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_760020f2-1ea1-4a9a-940f-e3559244efb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_760020f2-1ea1-4a9a-940f-e3559244efb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_b2749ddc-8173-41e3-883b-bc5da6c728aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_b2749ddc-8173-41e3-883b-bc5da6c728aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_63ad70d5-2a4e-4e73-b7c6-bd986bc6eeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_63ad70d5-2a4e-4e73-b7c6-bd986bc6eeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardProductWarrantyPolicy_9840c236-98da-47f3-9227-7c1d4ba86239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardProductWarrantyPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_StandardProductWarrantyPolicy_9840c236-98da-47f3-9227-7c1d4ba86239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock_d6e6aebb-7056-4fbc-aa1f-106080013726" xlink:href="rmd-20220630.xsd#rmd_AllowanceForDoubtfulAccountsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock_d6e6aebb-7056-4fbc-aa1f-106080013726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7e0f3b6e-4f90-4ed2-b286-ef3fdf8df7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_7e0f3b6e-4f90-4ed2-b286-ef3fdf8df7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_b6e9c207-0a75-4b5c-af2e-6ef443c35cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_b6e9c207-0a75-4b5c-af2e-6ef443c35cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dedfb131-26c4-4189-93dc-8f771bd5b80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a621fa6-1663-479f-b5df-730ca75bcd50" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dedfb131-26c4-4189-93dc-8f771bd5b80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#SummaryOfSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9956ae5c-69ff-4de8-8994-972b7d65d303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_10c181c6-aa3d-43e7-9417-4759991175ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9956ae5c-69ff-4de8-8994-972b7d65d303" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_10c181c6-aa3d-43e7-9417-4759991175ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_61417171-d596-4d0a-9d8f-97f5e450909e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_c4537648-0d15-406b-bb00-0e5fa6df7aa3" xlink:href="rmd-20220630.xsd#rmd_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_61417171-d596-4d0a-9d8f-97f5e450909e" xlink:to="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_c4537648-0d15-406b-bb00-0e5fa6df7aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7b48ce8b-906e-4140-a50a-40c0d2ff777a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_c4537648-0d15-406b-bb00-0e5fa6df7aa3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7b48ce8b-906e-4140-a50a-40c0d2ff777a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_363a2512-71e1-4afe-ad48-0e5e5f7924d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7b48ce8b-906e-4140-a50a-40c0d2ff777a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_363a2512-71e1-4afe-ad48-0e5e5f7924d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_332016b5-b452-4de2-b80b-201dd213cec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_363a2512-71e1-4afe-ad48-0e5e5f7924d2" xlink:to="loc_us-gaap_BuildingMember_332016b5-b452-4de2-b80b-201dd213cec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e1d68c9d-bf4e-4c4b-8b32-8293f5bea658" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_c4537648-0d15-406b-bb00-0e5fa6df7aa3" xlink:to="loc_srt_RangeAxis_e1d68c9d-bf4e-4c4b-8b32-8293f5bea658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74261fc2-274d-4247-a917-45889e81e9a1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e1d68c9d-bf4e-4c4b-8b32-8293f5bea658" xlink:to="loc_srt_RangeMember_74261fc2-274d-4247-a917-45889e81e9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a8cda674-7a21-4d2a-8f08-203014b44f0e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74261fc2-274d-4247-a917-45889e81e9a1" xlink:to="loc_srt_MinimumMember_a8cda674-7a21-4d2a-8f08-203014b44f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5dcbf373-5095-4c3d-a725-4bdb5799dd29" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74261fc2-274d-4247-a917-45889e81e9a1" xlink:to="loc_srt_MaximumMember_5dcbf373-5095-4c3d-a725-4bdb5799dd29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79c60ea-9d43-40c0-8a28-a7386d12a041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_c4537648-0d15-406b-bb00-0e5fa6df7aa3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79c60ea-9d43-40c0-8a28-a7386d12a041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_137baf9d-8e16-468b-85d0-0f56f7136774" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e79c60ea-9d43-40c0-8a28-a7386d12a041" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_137baf9d-8e16-468b-85d0-0f56f7136774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_b987afa6-3a38-40b7-8d14-fa5e75e8b147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_137baf9d-8e16-468b-85d0-0f56f7136774" xlink:to="loc_us-gaap_PatentsMember_b987afa6-3a38-40b7-8d14-fa5e75e8b147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:href="rmd-20220630.xsd#rmd_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesTable_c4537648-0d15-406b-bb00-0e5fa6df7aa3" xlink:to="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_94b80a33-cb2d-4821-a071-da3a5d2663c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_NumberOfOperatingSegments_94b80a33-cb2d-4821-a071-da3a5d2663c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_TermOfContractUnderRevenueRecognition_c1332514-1fc2-46dd-8d29-7dea3da43929" xlink:href="rmd-20220630.xsd#rmd_TermOfContractUnderRevenueRecognition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_rmd_TermOfContractUnderRevenueRecognition_c1332514-1fc2-46dd-8d29-7dea3da43929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_be5e0456-e3b8-48af-8f4c-dd3dc988c98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_be5e0456-e3b8-48af-8f4c-dd3dc988c98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_e91ad90e-9618-4df2-b708-c4d0180e7c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_Depreciation_e91ad90e-9618-4df2-b708-c4d0180e7c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_bc5ece88-825c-494f-93c5-5af406fe137b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_bc5ece88-825c-494f-93c5-5af406fe137b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_124508e0-e6ef-48ec-83e1-5ee919cb114f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_124508e0-e6ef-48ec-83e1-5ee919cb114f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7f2554a8-e3a5-4fb9-9599-84f487779801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SummaryOfSignificantAccountingPoliciesLineItems_472a1d8f-38a7-4b4d-a942-7c4db8e99306" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7f2554a8-e3a5-4fb9-9599-84f487779801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f5f6d162-c38d-4669-924f-12f5a685eb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_41e5e344-d189-424c-8dc6-7cf170a981d5" xlink:href="rmd-20220630.xsd#rmd_ContractWithCustomerAssetAndLiabilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f5f6d162-c38d-4669-924f-12f5a685eb64" xlink:to="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_41e5e344-d189-424c-8dc6-7cf170a981d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_27567cde-e070-4a1d-bdf8-c86b5167f309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_41e5e344-d189-424c-8dc6-7cf170a981d5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_27567cde-e070-4a1d-bdf8-c86b5167f309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1167c8a3-e613-49d2-b39a-4c2cc474b2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_27567cde-e070-4a1d-bdf8-c86b5167f309" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1167c8a3-e613-49d2-b39a-4c2cc474b2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccountsReceivableNetMember_13c834ff-1239-4e86-9da2-a20a98e336dc" xlink:href="rmd-20220630.xsd#rmd_AccountsReceivableNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1167c8a3-e613-49d2-b39a-4c2cc474b2d5" xlink:to="loc_rmd_AccountsReceivableNetMember_13c834ff-1239-4e86-9da2-a20a98e336dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_99c487f8-4b52-4904-b619-2c53237fcc0d" xlink:href="rmd-20220630.xsd#rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_1167c8a3-e613-49d2-b39a-4c2cc474b2d5" xlink:to="loc_rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember_99c487f8-4b52-4904-b619-2c53237fcc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_c3053a55-67b4-4cec-b11b-abf7d73d5f43" xlink:href="rmd-20220630.xsd#rmd_ContractWithCustomerAssetAndLiabilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityTable_41e5e344-d189-424c-8dc6-7cf170a981d5" xlink:to="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_c3053a55-67b4-4cec-b11b-abf7d73d5f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_a3a66d17-bcb3-4605-959d-9d1ac6c6b748" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_c3053a55-67b4-4cec-b11b-abf7d73d5f43" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_a3a66d17-bcb3-4605-959d-9d1ac6c6b748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8bb55e09-ed8b-4149-b5f6-3be9c1d053ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_a3a66d17-bcb3-4605-959d-9d1ac6c6b748" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8bb55e09-ed8b-4149-b5f6-3be9c1d053ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_38d02238-ac79-4b15-9947-62419e529b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_a3a66d17-bcb3-4605-959d-9d1ac6c6b748" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_38d02238-ac79-4b15-9947-62419e529b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_a017453d-dc54-4076-aa77-ef0bd99d2ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_a3a66d17-bcb3-4605-959d-9d1ac6c6b748" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_a017453d-dc54-4076-aa77-ef0bd99d2ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityAbstract_46816b40-e033-4076-9f92-1d46ee38d3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_ContractWithCustomerAssetAndLiabilityLineItems_c3053a55-67b4-4cec-b11b-abf7d73d5f43" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityAbstract_46816b40-e033-4076-9f92-1d46ee38d3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_11a59b38-9c31-4458-acb4-0ca7ec0586d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_46816b40-e033-4076-9f92-1d46ee38d3b7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_11a59b38-9c31-4458-acb4-0ca7ec0586d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_618007e1-6b8c-4be6-83f0-c08a14dc83ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityAbstract_46816b40-e033-4076-9f92-1d46ee38d3b7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_618007e1-6b8c-4be6-83f0-c08a14dc83ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/NewAccountingPronouncements" xlink:type="simple" xlink:href="rmd-20220630.xsd#NewAccountingPronouncements"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/NewAccountingPronouncements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6cd7d284-fdf0-417c-b9eb-4d5120746c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_eae5ee86-bd5d-46c8-9af9-f71e03b12480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_6cd7d284-fdf0-417c-b9eb-4d5120746c6b" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_eae5ee86-bd5d-46c8-9af9-f71e03b12480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformation" xlink:type="simple" xlink:href="rmd-20220630.xsd#SupplementalBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract_d68c652a-9b66-4a9f-aeb7-14a57d2ecc20" xlink:href="rmd-20220630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationTextBlock_2bbf3907-af5d-444d-8bad-25ad48ddca8f" xlink:href="rmd-20220630.xsd#rmd_SupplementalBalanceSheetInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_d68c652a-9b66-4a9f-aeb7-14a57d2ecc20" xlink:to="loc_rmd_SupplementalBalanceSheetInformationTextBlock_2bbf3907-af5d-444d-8bad-25ad48ddca8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#SupplementalBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract_b8500ece-6733-4afd-9f2c-7393a8f1ad69" xlink:href="rmd-20220630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_aa82aa39-3092-47e5-bf12-99b9d4778366" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_b8500ece-6733-4afd-9f2c-7393a8f1ad69" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_aa82aa39-3092-47e5-bf12-99b9d4778366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0511cd8d-2843-4bc8-ac84-4e7afb3631b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_b8500ece-6733-4afd-9f2c-7393a8f1ad69" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_0511cd8d-2843-4bc8-ac84-4e7afb3631b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_43d4e843-44ae-44bd-95c4-5bb64f7c5680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_b8500ece-6733-4afd-9f2c-7393a8f1ad69" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_43d4e843-44ae-44bd-95c4-5bb64f7c5680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SupplementalBalanceSheetInformationScheduleOfInventoriesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract_0d705d81-f858-4c2d-84ca-bc06c2b76509" xlink:href="rmd-20220630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGrossAbstract_8d5e2002-82e5-41e9-b1f6-8519d220f64b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_0d705d81-f858-4c2d-84ca-bc06c2b76509" xlink:to="loc_us-gaap_InventoryGrossAbstract_8d5e2002-82e5-41e9-b1f6-8519d220f64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_034093dc-bf46-4d29-8a8e-24e8c91a3b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_8d5e2002-82e5-41e9-b1f6-8519d220f64b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_034093dc-bf46-4d29-8a8e-24e8c91a3b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0441afae-a25c-45d6-bde9-921bc34f37a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_8d5e2002-82e5-41e9-b1f6-8519d220f64b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_0441afae-a25c-45d6-bde9-921bc34f37a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e7e9a641-ab4d-4111-add9-f06c4309a640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_8d5e2002-82e5-41e9-b1f6-8519d220f64b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e7e9a641-ab4d-4111-add9-f06c4309a640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e462dc42-b667-412e-b1d0-465f2188cb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryGrossAbstract_8d5e2002-82e5-41e9-b1f6-8519d220f64b" xlink:to="loc_us-gaap_InventoryNet_e462dc42-b667-412e-b1d0-465f2188cb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract_3244710d-c720-46a1-a497-a08053be0a25" xlink:href="rmd-20220630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_541707c8-ad14-44e3-8c20-9ea1734fd7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_3244710d-c720-46a1-a497-a08053be0a25" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_541707c8-ad14-44e3-8c20-9ea1734fd7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_019d108e-08ba-4317-97c2-5ba2b87ccb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_541707c8-ad14-44e3-8c20-9ea1734fd7b7" xlink:to="loc_us-gaap_PrepaidTaxes_019d108e-08ba-4317-97c2-5ba2b87ccb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PrepaidInventory_18389069-4f4a-4787-904e-2a50add058cf" xlink:href="rmd-20220630.xsd#rmd_PrepaidInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_541707c8-ad14-44e3-8c20-9ea1734fd7b7" xlink:to="loc_rmd_PrepaidInventory_18389069-4f4a-4787-904e-2a50add058cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_3da3dce6-75ff-4efd-90dc-fc1537d5e560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_541707c8-ad14-44e3-8c20-9ea1734fd7b7" xlink:to="loc_us-gaap_OtherAssetsCurrent_3da3dce6-75ff-4efd-90dc-fc1537d5e560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6afdfb0d-2464-419f-87fe-4ffd9295c4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_541707c8-ad14-44e3-8c20-9ea1734fd7b7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6afdfb0d-2464-419f-87fe-4ffd9295c4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SupplementalBalanceSheetInformationAbstract_6128b24e-43c9-47ea-ba06-ccc981753657" xlink:href="rmd-20220630.xsd#rmd_SupplementalBalanceSheetInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d2193a4-9c72-4ce7-9886-be9c8e61c1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_SupplementalBalanceSheetInformationAbstract_6128b24e-43c9-47ea-ba06-ccc981753657" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d2193a4-9c72-4ce7-9886-be9c8e61c1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23725eda-019c-4ec9-8f48-0eaa39681076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d2193a4-9c72-4ce7-9886-be9c8e61c1f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23725eda-019c-4ec9-8f48-0eaa39681076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_23725eda-019c-4ec9-8f48-0eaa39681076" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_121f2050-a23a-4226-80a1-3842be14bd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_121f2050-a23a-4226-80a1-3842be14bd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ComputerEquipmentAndSoftwareMember_1dcebdee-7a7b-427f-8b7f-1865b717a821" xlink:href="rmd-20220630.xsd#rmd_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_rmd_ComputerEquipmentAndSoftwareMember_1dcebdee-7a7b-427f-8b7f-1865b717a821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3f342c9f-4b92-4fe3-a4ed-0d14e6fafb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3f342c9f-4b92-4fe3-a4ed-0d14e6fafb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_VehiclesAndAircraftMember_6eb2fc57-50c0-4217-8a81-7e520e7b35c0" xlink:href="rmd-20220630.xsd#rmd_VehiclesAndAircraftMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_rmd_VehiclesAndAircraftMember_6eb2fc57-50c0-4217-8a81-7e520e7b35c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember_2b853f61-be8e-49d4-80c4-cce37ee2ac17" xlink:href="rmd-20220630.xsd#rmd_ClinicalDemonstrationAndRentalEquipmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_rmd_ClinicalDemonstrationAndRentalEquipmentMember_2b853f61-be8e-49d4-80c4-cce37ee2ac17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_02401047-e4f1-4f8d-a321-127b08357b40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_02401047-e4f1-4f8d-a321-127b08357b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3d085999-5c3e-48f3-a11e-1c3023da2e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_us-gaap_LandMember_3d085999-5c3e-48f3-a11e-1c3023da2e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_4af2486f-f462-4fb5-845f-95b822706955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ebf1157c-8bb5-4d1f-b179-88ef24da1909" xlink:to="loc_us-gaap_BuildingMember_4af2486f-f462-4fb5-845f-95b822706955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8362aed7-2895-4720-add6-d8f29e99cc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d2193a4-9c72-4ce7-9886-be9c8e61c1f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8362aed7-2895-4720-add6-d8f29e99cc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e4f37229-a9d0-4b0c-b640-3b04e5579ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8362aed7-2895-4720-add6-d8f29e99cc83" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e4f37229-a9d0-4b0c-b640-3b04e5579ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f2a3d962-d721-4931-9360-78521198144d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8362aed7-2895-4720-add6-d8f29e99cc83" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f2a3d962-d721-4931-9360-78521198144d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_366946d2-6b4b-4d91-a641-ae1b3024fe4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_8362aed7-2895-4720-add6-d8f29e99cc83" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_366946d2-6b4b-4d91-a641-ae1b3024fe4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet" xlink:type="simple" xlink:href="rmd-20220630.xsd#GoodwillandOtherIntangibleAssetsnet"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_15a280d1-06c0-4799-8b97-c9325a98c93f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d180d928-95ee-4c9e-98b0-ec40fc57f181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_15a280d1-06c0-4799-8b97-c9325a98c93f" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d180d928-95ee-4c9e-98b0-ec40fc57f181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#GoodwillandOtherIntangibleAssetsnetTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a4318ac-5476-421d-ac58-e5d312406776" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_f9561e4f-05cd-482f-b9e0-eaa951ce833a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a4318ac-5476-421d-ac58-e5d312406776" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_f9561e4f-05cd-482f-b9e0-eaa951ce833a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_7d7cbbde-c995-4d16-9fb9-ae06bcc9b4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a4318ac-5476-421d-ac58-e5d312406776" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_7d7cbbde-c995-4d16-9fb9-ae06bcc9b4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c62a29d9-7726-4f17-93db-56ea4abf4a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2a4318ac-5476-421d-ac58-e5d312406776" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c62a29d9-7726-4f17-93db-56ea4abf4a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd0bbdd8-1aa9-4501-bf5d-7c85c61afdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_bb4ac62e-ebe6-40fd-8c67-9aabe1d497d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cd0bbdd8-1aa9-4501-bf5d-7c85c61afdc9" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_bb4ac62e-ebe6-40fd-8c67-9aabe1d497d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c927da0a-7034-477b-a0de-35c2c8b8e619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bb4ac62e-ebe6-40fd-8c67-9aabe1d497d5" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c927da0a-7034-477b-a0de-35c2c8b8e619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_63210713-c752-4a2d-9db8-946b9b8426ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c927da0a-7034-477b-a0de-35c2c8b8e619" xlink:to="loc_us-gaap_SegmentDomain_63210713-c752-4a2d-9db8-946b9b8426ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_67e2634d-e0c9-4120-b231-86db40fd181c" xlink:href="rmd-20220630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_63210713-c752-4a2d-9db8-946b9b8426ef" xlink:to="loc_rmd_SleepAndRespiratoryMember_67e2634d-e0c9-4120-b231-86db40fd181c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SaasMember_3cb1a52d-4df3-4732-8beb-ec6f8e188d95" xlink:href="rmd-20220630.xsd#rmd_SaasMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_63210713-c752-4a2d-9db8-946b9b8426ef" xlink:to="loc_rmd_SaasMember_3cb1a52d-4df3-4732-8beb-ec6f8e188d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_5a2dc137-ea95-4450-a8e5-0b9b73817626" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_bb4ac62e-ebe6-40fd-8c67-9aabe1d497d5" xlink:to="loc_us-gaap_GoodwillLineItems_5a2dc137-ea95-4450-a8e5-0b9b73817626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_62373808-8991-4afa-9351-f3fc9d7f0ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_5a2dc137-ea95-4450-a8e5-0b9b73817626" xlink:to="loc_us-gaap_GoodwillRollForward_62373808-8991-4afa-9351-f3fc9d7f0ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9e6388c1-cbbf-4cf4-8180-c501ef06443d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_62373808-8991-4afa-9351-f3fc9d7f0ed0" xlink:to="loc_us-gaap_Goodwill_9e6388c1-cbbf-4cf4-8180-c501ef06443d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_287b058d-4850-4bd2-9597-9e68a7f7b1e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_62373808-8991-4afa-9351-f3fc9d7f0ed0" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_287b058d-4850-4bd2-9597-9e68a7f7b1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c73dce20-e458-427f-9ed0-977a92d789dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_62373808-8991-4afa-9351-f3fc9d7f0ed0" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c73dce20-e458-427f-9ed0-977a92d789dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bf332a4d-d8c7-4c9d-9a54-0fa62c1369ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_62373808-8991-4afa-9351-f3fc9d7f0ed0" xlink:to="loc_us-gaap_Goodwill_bf332a4d-d8c7-4c9d-9a54-0fa62c1369ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fafd1d4e-15cc-4aa6-ab7c-f5d4166b638e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_15e3ca85-9c9a-4369-bd73-a23a7ccbb0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fafd1d4e-15cc-4aa6-ab7c-f5d4166b638e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_15e3ca85-9c9a-4369-bd73-a23a7ccbb0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81df2cc2-9597-426c-850c-790e2e5bdeef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_15e3ca85-9c9a-4369-bd73-a23a7ccbb0f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81df2cc2-9597-426c-850c-790e2e5bdeef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a73941d-6b9a-43fd-b44d-08bc13c3aaec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_81df2cc2-9597-426c-850c-790e2e5bdeef" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a73941d-6b9a-43fd-b44d-08bc13c3aaec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevelopedOrCoreProductTechnologyMember_7c785945-0eff-445f-ac86-80c4d6a0b156" xlink:href="rmd-20220630.xsd#rmd_DevelopedOrCoreProductTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a73941d-6b9a-43fd-b44d-08bc13c3aaec" xlink:to="loc_rmd_DevelopedOrCoreProductTechnologyMember_7c785945-0eff-445f-ac86-80c4d6a0b156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_d123a30c-5237-4090-a96f-f0d2ee50a107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a73941d-6b9a-43fd-b44d-08bc13c3aaec" xlink:to="loc_us-gaap_CustomerRelationshipsMember_d123a30c-5237-4090-a96f-f0d2ee50a107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_6254a4c0-4e9a-420c-a309-38b070bcbf43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8a73941d-6b9a-43fd-b44d-08bc13c3aaec" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_6254a4c0-4e9a-420c-a309-38b070bcbf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_605149b7-4e2a-45ff-b2c5-f65e087bee35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_15e3ca85-9c9a-4369-bd73-a23a7ccbb0f7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_605149b7-4e2a-45ff-b2c5-f65e087bee35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e896c850-9cde-4766-8fe9-3dacb23ed281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_605149b7-4e2a-45ff-b2c5-f65e087bee35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e896c850-9cde-4766-8fe9-3dacb23ed281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7fe50ca7-c004-40cf-a7a4-2b61159c2a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_605149b7-4e2a-45ff-b2c5-f65e087bee35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7fe50ca7-c004-40cf-a7a4-2b61159c2a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_751d0fd0-6fa4-4d09-b98e-400ef60a1030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_605149b7-4e2a-45ff-b2c5-f65e087bee35" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_751d0fd0-6fa4-4d09-b98e-400ef60a1030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#GoodwillandOtherIntangibleAssetsnetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4cad61e9-e983-4ab6-8023-f99362eef4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f5bcef8-2dc9-45fb-aa0a-51f649867488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4cad61e9-e983-4ab6-8023-f99362eef4f7" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f5bcef8-2dc9-45fb-aa0a-51f649867488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f06fc272-cbca-4100-91c3-9d50b70e36f4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f5bcef8-2dc9-45fb-aa0a-51f649867488" xlink:to="loc_srt_RangeAxis_f06fc272-cbca-4100-91c3-9d50b70e36f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bb9d51fb-1054-46c8-9725-a7d6ed8fd0fb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f06fc272-cbca-4100-91c3-9d50b70e36f4" xlink:to="loc_srt_RangeMember_bb9d51fb-1054-46c8-9725-a7d6ed8fd0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc7f2b62-43b7-4a51-ba0a-752bf6714e33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bb9d51fb-1054-46c8-9725-a7d6ed8fd0fb" xlink:to="loc_srt_MinimumMember_bc7f2b62-43b7-4a51-ba0a-752bf6714e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_224971b4-fb3f-4848-a406-7cebbab72602" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bb9d51fb-1054-46c8-9725-a7d6ed8fd0fb" xlink:to="loc_srt_MaximumMember_224971b4-fb3f-4848-a406-7cebbab72602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a39b968-ed80-41c7-ae2f-9cdbcdcfd0e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f5bcef8-2dc9-45fb-aa0a-51f649867488" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a39b968-ed80-41c7-ae2f-9cdbcdcfd0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347311bd-6ad0-4af6-936a-060f156f2cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8a39b968-ed80-41c7-ae2f-9cdbcdcfd0e6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347311bd-6ad0-4af6-936a-060f156f2cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IdentifiedIntangibleAssetsMember_70111915-30be-4e85-b9ac-e9debf72a0f3" xlink:href="rmd-20220630.xsd#rmd_IdentifiedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347311bd-6ad0-4af6-936a-060f156f2cff" xlink:to="loc_rmd_IdentifiedIntangibleAssetsMember_70111915-30be-4e85-b9ac-e9debf72a0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_388eba3f-6548-4e04-a7c3-93f70caee8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_347311bd-6ad0-4af6-936a-060f156f2cff" xlink:to="loc_us-gaap_PatentsMember_388eba3f-6548-4e04-a7c3-93f70caee8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4df6e432-58f5-4b2f-a9b6-b3c74833dd37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_4f5bcef8-2dc9-45fb-aa0a-51f649867488" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4df6e432-58f5-4b2f-a9b6-b3c74833dd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4348c20a-133c-4a81-a225-5a02707b1fba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4df6e432-58f5-4b2f-a9b6-b3c74833dd37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_4348c20a-133c-4a81-a225-5a02707b1fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_984643a5-14f4-4474-ac16-2ec8a21ad1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_4df6e432-58f5-4b2f-a9b6-b3c74833dd37" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_984643a5-14f4-4474-ac16-2ec8a21ad1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_181a1f13-efc3-406c-92d1-4e690763317a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b1a72dd5-989b-4244-93b4-ee386b19da7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_181a1f13-efc3-406c-92d1-4e690763317a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b1a72dd5-989b-4244-93b4-ee386b19da7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2004db78-4a95-4913-bf00-7458375d6eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_181a1f13-efc3-406c-92d1-4e690763317a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2004db78-4a95-4913-bf00-7458375d6eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b0d9172e-d5fc-413f-b5e8-a4cd83253b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_181a1f13-efc3-406c-92d1-4e690763317a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b0d9172e-d5fc-413f-b5e8-a4cd83253b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_54848dfd-0222-4caf-86f4-b2f8da22f8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_181a1f13-efc3-406c-92d1-4e690763317a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_54848dfd-0222-4caf-86f4-b2f8da22f8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6356955b-5734-4faf-b327-04d8704278de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_181a1f13-efc3-406c-92d1-4e690763317a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6356955b-5734-4faf-b327-04d8704278de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/Investments" xlink:type="simple" xlink:href="rmd-20220630.xsd#Investments"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_ae0219ec-1c96-4f8a-a8b0-f10686c792fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTextBlock_5bd7cb7e-3e45-49c0-a80a-6b3b52fc141c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_ae0219ec-1c96-4f8a-a8b0-f10686c792fa" xlink:to="loc_us-gaap_InvestmentTextBlock_5bd7cb7e-3e45-49c0-a80a-6b3b52fc141c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_74b4ab91-2c15-43e4-954a-2d6851218879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfInvestmentsTableTextBlock_1039ba40-4b6c-415f-9f9b-51116b9d45d9" xlink:href="rmd-20220630.xsd#rmd_ScheduleOfInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_74b4ab91-2c15-43e4-954a-2d6851218879" xlink:to="loc_rmd_ScheduleOfInvestmentsTableTextBlock_1039ba40-4b6c-415f-9f9b-51116b9d45d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock_bee4da0e-a24a-45dc-8b50-fc77d3fdd525" xlink:href="rmd-20220630.xsd#rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_74b4ab91-2c15-43e4-954a-2d6851218879" xlink:to="loc_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock_bee4da0e-a24a-45dc-8b50-fc77d3fdd525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#InvestmentsScheduleOfInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_9c38c526-8326-48c4-8a01-9f7e6f12250f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableEquityInvestmentsFairValue_c911b945-5b96-4fa9-8ffe-5c1c73235ade" xlink:href="rmd-20220630.xsd#rmd_MarketableEquityInvestmentsFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_9c38c526-8326-48c4-8a01-9f7e6f12250f" xlink:to="loc_rmd_MarketableEquityInvestmentsFairValue_c911b945-5b96-4fa9-8ffe-5c1c73235ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_317de7d1-39f6-46dc-af6c-c343a3d058bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_9c38c526-8326-48c4-8a01-9f7e6f12250f" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_317de7d1-39f6-46dc-af6c-c343a3d058bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_107bdc14-f289-4e63-9ce7-64c7a3e30791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_9c38c526-8326-48c4-8a01-9f7e6f12250f" xlink:to="loc_us-gaap_EquityMethodInvestments_107bdc14-f289-4e63-9ce7-64c7a3e30791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_a00606f3-6581-41c2-91b6-1ee00d4545bd" xlink:href="rmd-20220630.xsd#rmd_EquityInvestmentsTotalByMeasurementCategory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_9c38c526-8326-48c4-8a01-9f7e6f12250f" xlink:to="loc_rmd_EquityInvestmentsTotalByMeasurementCategory_a00606f3-6581-41c2-91b6-1ee00d4545bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#InvestmentsScheduleOfChangesInEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f68cd439-3f15-4a7b-832e-d5a7e829e05a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f7262426-4041-4f37-adf3-c5e7a9e97224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f68cd439-3f15-4a7b-832e-d5a7e829e05a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f7262426-4041-4f37-adf3-c5e7a9e97224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_05af9976-038d-4600-9990-0ec455d16e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f7262426-4041-4f37-adf3-c5e7a9e97224" xlink:to="loc_us-gaap_FinancialInstrumentAxis_05af9976-038d-4600-9990-0ec455d16e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf822a06-e316-4e09-a587-05a59aff3919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_05af9976-038d-4600-9990-0ec455d16e16" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf822a06-e316-4e09-a587-05a59aff3919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonMarketableSecuritiesMember_5de6695e-71ef-4e8c-b290-dfc9344acbe1" xlink:href="rmd-20220630.xsd#rmd_NonMarketableSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf822a06-e316-4e09-a587-05a59aff3919" xlink:to="loc_rmd_NonMarketableSecuritiesMember_5de6695e-71ef-4e8c-b290-dfc9344acbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MarketableSecuritiesMember_2fd200b0-c7e2-4cef-b9b5-c8b0d697b300" xlink:href="rmd-20220630.xsd#rmd_MarketableSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf822a06-e316-4e09-a587-05a59aff3919" xlink:to="loc_rmd_MarketableSecuritiesMember_2fd200b0-c7e2-4cef-b9b5-c8b0d697b300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsMember_32f21de9-aa6c-4fb4-b80a-afba015c0673" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf822a06-e316-4e09-a587-05a59aff3919" xlink:to="loc_us-gaap_EquityMethodInvestmentsMember_32f21de9-aa6c-4fb4-b80a-afba015c0673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bcbd0ac4-d608-4777-bc17-71f71bbf0709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f7262426-4041-4f37-adf3-c5e7a9e97224" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bcbd0ac4-d608-4777-bc17-71f71bbf0709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:href="rmd-20220630.xsd#rmd_EquityMethodInvestmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_bcbd0ac4-d608-4777-bc17-71f71bbf0709" xlink:to="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestments_e7520be0-42c8-4ca9-af03-dd19f2ae429f" xlink:href="rmd-20220630.xsd#rmd_EquityInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_rmd_EquityInvestments_e7520be0-42c8-4ca9-af03-dd19f2ae429f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AdditionalEquityInvestments_1f095c44-c048-4f38-be41-30e8c8881063" xlink:href="rmd-20220630.xsd#rmd_AdditionalEquityInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_rmd_AdditionalEquityInvestments_1f095c44-c048-4f38-be41-30e8c8881063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_8b01b83a-8b79-4992-9b95-84f203b2b6f6" xlink:href="rmd-20220630.xsd#rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities_8b01b83a-8b79-4992-9b95-84f203b2b6f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_66235fc8-a4db-453a-9807-31fed12f452b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_66235fc8-a4db-453a-9807-31fed12f452b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a352fe7d-cdb9-4c49-a684-debdffe435a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_a352fe7d-cdb9-4c49-a684-debdffe435a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfInvestments_08269224-5d1d-449f-b0d8-e79e5cf3ab43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_us-gaap_ImpairmentOfInvestments_08269224-5d1d-449f-b0d8-e79e5cf3ab43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReclassificationsInEquityInvestments_772bfb10-63bd-47bd-bece-109a756b6ff6" xlink:href="rmd-20220630.xsd#rmd_ReclassificationsInEquityInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_rmd_ReclassificationsInEquityInvestments_772bfb10-63bd-47bd-bece-109a756b6ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1f249e63-caee-4e8b-ab23-eabf2065fb04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_1f249e63-caee-4e8b-ab23-eabf2065fb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EquityInvestments_f64e40e4-0aed-476c-a871-8d7b57fa9da3" xlink:href="rmd-20220630.xsd#rmd_EquityInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_EquityMethodInvestmentsRollForward_edf018e1-232f-42c4-a48c-0c65e93d8e6a" xlink:to="loc_rmd_EquityInvestments_f64e40e4-0aed-476c-a871-8d7b57fa9da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4874a30b-e391-4b13-ae03-43deb6f4fe0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1903c758-b8b7-475a-8dd2-bb3da977d0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4874a30b-e391-4b13-ae03-43deb6f4fe0a" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_1903c758-b8b7-475a-8dd2-bb3da977d0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/AccruedExpenses" xlink:type="simple" xlink:href="rmd-20220630.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_a2b7acbd-a5c9-4cdd-81b4-f47bfe59a3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_67b60fec-450e-41c8-acc8-55484ef04ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_a2b7acbd-a5c9-4cdd-81b4-f47bfe59a3a7" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_67b60fec-450e-41c8-acc8-55484ef04ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_bd13927a-e5ec-45d1-b1c6-cf7218665097" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d1d525b1-eaa9-41bd-8fac-423ad6f11007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_bd13927a-e5ec-45d1-b1c6-cf7218665097" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_d1d525b1-eaa9-41bd-8fac-423ad6f11007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#AccruedExpensesScheduleOfAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d24ad40a-c9aa-444b-a51e-9112b83e413b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_c0b94b6d-949e-435b-9b3b-0435b6da072d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d24ad40a-c9aa-444b-a51e-9112b83e413b" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_c0b94b6d-949e-435b-9b3b-0435b6da072d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_080b85d3-98e9-4703-a375-8c12ab0f2f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d24ad40a-c9aa-444b-a51e-9112b83e413b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_080b85d3-98e9-4703-a375-8c12ab0f2f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_9917e817-a89e-4145-b6b0-abf293e2807b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d24ad40a-c9aa-444b-a51e-9112b83e413b" xlink:to="loc_us-gaap_TaxesPayableCurrent_9917e817-a89e-4145-b6b0-abf293e2807b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5c72622a-2295-4759-91cd-3755a33391a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d24ad40a-c9aa-444b-a51e-9112b83e413b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5c72622a-2295-4759-91cd-3755a33391a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedMarketingCostsCurrent_94fdab00-9a6f-46e7-b5a4-f482f5fda2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedMarketingCostsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d24ad40a-c9aa-444b-a51e-9112b83e413b" xlink:to="loc_us-gaap_AccruedMarketingCostsCurrent_94fdab00-9a6f-46e7-b5a4-f482f5fda2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_28714113-d997-444b-bd54-716d4107ce6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d24ad40a-c9aa-444b-a51e-9112b83e413b" xlink:to="loc_us-gaap_InterestPayableCurrent_28714113-d997-444b-bd54-716d4107ce6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_71bb06f4-05be-4535-b502-5eb9760aef1c" xlink:href="rmd-20220630.xsd#rmd_AccruedLogisticsAndOccupancyExpensesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d24ad40a-c9aa-444b-a51e-9112b83e413b" xlink:to="loc_rmd_AccruedLogisticsAndOccupancyExpensesCurrent_71bb06f4-05be-4535-b502-5eb9760aef1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AccruedInventoryInTransit_8bd89dd5-71c7-42e1-865f-8ea283f350c6" xlink:href="rmd-20220630.xsd#rmd_AccruedInventoryInTransit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d24ad40a-c9aa-444b-a51e-9112b83e413b" xlink:to="loc_rmd_AccruedInventoryInTransit_8bd89dd5-71c7-42e1-865f-8ea283f350c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_42e1dcd3-4b04-41c4-9bc8-b4de82421d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d24ad40a-c9aa-444b-a51e-9112b83e413b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_42e1dcd3-4b04-41c4-9bc8-b4de82421d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9b088b9d-1a5a-4035-ad86-a2c2befca7f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d24ad40a-c9aa-444b-a51e-9112b83e413b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9b088b9d-1a5a-4035-ad86-a2c2befca7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ProductWarranties" xlink:type="simple" xlink:href="rmd-20220630.xsd#ProductWarranties"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ProductWarranties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_7bab0c8f-32c9-42d1-bf55-1828dd5a419c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyDisclosureTextBlock_1299f6db-2e0b-4040-a98e-f81ed304ad5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_7bab0c8f-32c9-42d1-bf55-1828dd5a419c" xlink:to="loc_us-gaap_ProductWarrantyDisclosureTextBlock_1299f6db-2e0b-4040-a98e-f81ed304ad5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ProductWarrantiesTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#ProductWarrantiesTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ProductWarrantiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_6fa71122-6f06-49ca-9904-2d61fbc82eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_a54e3439-98f7-4a3b-b26f-93f48e719d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_6fa71122-6f06-49ca-9904-2d61fbc82eb3" xlink:to="loc_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock_a54e3439-98f7-4a3b-b26f-93f48e719d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_ade4bba4-6194-4820-b693-5292805b6176" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantiesDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_454365c6-bb45-48e0-88df-5821d280752c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductWarrantiesDisclosuresAbstract_ade4bba4-6194-4820-b693-5292805b6176" xlink:to="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_454365c6-bb45-48e0-88df-5821d280752c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_0a8fee1a-5b65-4c60-9925-0e39762c6228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_454365c6-bb45-48e0-88df-5821d280752c" xlink:to="loc_us-gaap_ProductWarrantyAccrual_0a8fee1a-5b65-4c60-9925-0e39762c6228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_c2f94b8c-5ebe-4470-a7ed-08f44610ec33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualWarrantiesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_454365c6-bb45-48e0-88df-5821d280752c" xlink:to="loc_us-gaap_ProductWarrantyAccrualWarrantiesIssued_c2f94b8c-5ebe-4470-a7ed-08f44610ec33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualPayments_9491396c-5334-4185-8587-d61f0b6e6666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrualPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_454365c6-bb45-48e0-88df-5821d280752c" xlink:to="loc_us-gaap_ProductWarrantyAccrualPayments_9491396c-5334-4185-8587-d61f0b6e6666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss_35715fe8-3424-49e4-8e6a-a7e147c007d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_454365c6-bb45-48e0-88df-5821d280752c" xlink:to="loc_us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss_35715fe8-3424-49e4-8e6a-a7e147c007d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrual_c937b8fa-86bf-49bc-a910-21d90e9ad22c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductWarrantyAccrual"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward_454365c6-bb45-48e0-88df-5821d280752c" xlink:to="loc_us-gaap_ProductWarrantyAccrual_c937b8fa-86bf-49bc-a910-21d90e9ad22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/Debt" xlink:type="simple" xlink:href="rmd-20220630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c1812932-bf2b-45f7-9e87-a3cce9beddc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7cad90d7-01fa-4a5f-b754-fd8d173e2cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c1812932-bf2b-45f7-9e87-a3cce9beddc6" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_7cad90d7-01fa-4a5f-b754-fd8d173e2cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DebtTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_86599190-bf13-42c0-a587-40ee80edf51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_fa6a2f4e-f589-460c-b6ae-89bf487c347d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_86599190-bf13-42c0-a587-40ee80edf51c" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_fa6a2f4e-f589-460c-b6ae-89bf487c347d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DebtScheduleOfDebtDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#DebtScheduleOfDebtDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DebtScheduleOfDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ec1cf886-98b8-446c-814d-b1b01c2025b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShortTermDebtGross_a5539903-7547-4a18-a375-4c29cf257414" xlink:href="rmd-20220630.xsd#rmd_ShortTermDebtGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec1cf886-98b8-446c-814d-b1b01c2025b3" xlink:to="loc_rmd_ShortTermDebtGross_a5539903-7547-4a18-a375-4c29cf257414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_4a49e4eb-bd08-410b-84fb-c7d8c67bd822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec1cf886-98b8-446c-814d-b1b01c2025b3" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_4a49e4eb-bd08-410b-84fb-c7d8c67bd822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_0002f8ad-5567-4461-be99-eb82d8befbfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec1cf886-98b8-446c-814d-b1b01c2025b3" xlink:to="loc_us-gaap_ShortTermBorrowings_0002f8ad-5567-4461-be99-eb82d8befbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ebe4731e-3140-46a6-83da-986f93b65f23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec1cf886-98b8-446c-814d-b1b01c2025b3" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ebe4731e-3140-46a6-83da-986f93b65f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_2efcb927-d471-4965-a6be-29a3bd7c3234" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec1cf886-98b8-446c-814d-b1b01c2025b3" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_2efcb927-d471-4965-a6be-29a3bd7c3234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9709bc38-deb6-48db-8190-5fa7e5b35b2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec1cf886-98b8-446c-814d-b1b01c2025b3" xlink:to="loc_us-gaap_LongTermDebt_9709bc38-deb6-48db-8190-5fa7e5b35b2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d1ce2f62-1ae0-4f1d-9663-f1161c1aaec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ec1cf886-98b8-446c-814d-b1b01c2025b3" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_d1ce2f62-1ae0-4f1d-9663-f1161c1aaec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a32907d4-0b66-4916-aa0a-374c68fc2c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a32907d4-0b66-4916-aa0a-374c68fc2c33" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_04a21b2e-425a-4401-89ad-4a0ee310f797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_04a21b2e-425a-4401-89ad-4a0ee310f797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_04a21b2e-425a-4401-89ad-4a0ee310f797" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesOneMember_7dcd08c4-5086-4289-af89-27e89b3fee6c" xlink:href="rmd-20220630.xsd#rmd_SeniorNotesOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:to="loc_rmd_SeniorNotesOneMember_7dcd08c4-5086-4289-af89-27e89b3fee6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SeniorNotesTwoMember_f2a66a93-cfbc-4710-b105-5a26de19b17f" xlink:href="rmd-20220630.xsd#rmd_SeniorNotesTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:to="loc_rmd_SeniorNotesTwoMember_f2a66a93-cfbc-4710-b105-5a26de19b17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_18e0cecb-2060-4b34-8fbc-b9f7ec06fffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:to="loc_us-gaap_SeniorNotesMember_18e0cecb-2060-4b34-8fbc-b9f7ec06fffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_2a01ea47-117c-451f-819e-b1eaa4ab7db3" xlink:href="rmd-20220630.xsd#rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f90d1d9d-4f2c-45f3-b930-1471331a6f7e" xlink:to="loc_rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember_2a01ea47-117c-451f-819e-b1eaa4ab7db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6c60f301-8239-40de-80a4-bc3718b1161e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_srt_RangeAxis_6c60f301-8239-40de-80a4-bc3718b1161e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3f0628cf-9983-41c3-9004-d6e2367e30e2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6c60f301-8239-40de-80a4-bc3718b1161e" xlink:to="loc_srt_RangeMember_3f0628cf-9983-41c3-9004-d6e2367e30e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_89880eba-462f-4afc-9fcb-7a9f88bc58b5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3f0628cf-9983-41c3-9004-d6e2367e30e2" xlink:to="loc_srt_MinimumMember_89880eba-462f-4afc-9fcb-7a9f88bc58b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c96634dd-71f2-4e2f-96ad-d235419a5d5c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3f0628cf-9983-41c3-9004-d6e2367e30e2" xlink:to="loc_srt_MaximumMember_c96634dd-71f2-4e2f-96ad-d235419a5d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_3d43797b-e2fb-4b10-b8cc-f29497a16288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_3d43797b-e2fb-4b10-b8cc-f29497a16288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_5a8f1750-e0cf-41cb-a37c-47cc9e291f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_3d43797b-e2fb-4b10-b8cc-f29497a16288" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_5a8f1750-e0cf-41cb-a37c-47cc9e291f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_32818b30-fa6c-4367-aac2-3ca4a85eea48" xlink:href="rmd-20220630.xsd#rmd_MufgUnionBankNaAndWestpacBankingCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5a8f1750-e0cf-41cb-a37c-47cc9e291f72" xlink:to="loc_rmd_MufgUnionBankNaAndWestpacBankingCorporationMember_32818b30-fa6c-4367-aac2-3ca4a85eea48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MufgUnionBankMember_b3283af4-c56b-4528-8e6c-072c76b98d44" xlink:href="rmd-20220630.xsd#rmd_MufgUnionBankMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_5a8f1750-e0cf-41cb-a37c-47cc9e291f72" xlink:to="loc_rmd_MufgUnionBankMember_b3283af4-c56b-4528-8e6c-072c76b98d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_647af4d9-57fd-402b-af2f-940133496330" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_dei_LegalEntityAxis_647af4d9-57fd-402b-af2f-940133496330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_077b7c00-0660-4ead-938b-978e77045c14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_647af4d9-57fd-402b-af2f-940133496330" xlink:to="loc_dei_EntityDomain_077b7c00-0660-4ead-938b-978e77045c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedLimitedMember_f790deeb-9cdf-4edc-95da-4c2c9cfa2fab" xlink:href="rmd-20220630.xsd#rmd_ResmedLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_077b7c00-0660-4ead-938b-978e77045c14" xlink:to="loc_rmd_ResmedLimitedMember_f790deeb-9cdf-4edc-95da-4c2c9cfa2fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_993a4b06-bb59-4d6b-96b5-7245fd7a9f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_us-gaap_CreditFacilityAxis_993a4b06-bb59-4d6b-96b5-7245fd7a9f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_1afbf703-cb82-47aa-aec5-fc8b71f82662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_993a4b06-bb59-4d6b-96b5-7245fd7a9f4e" xlink:to="loc_us-gaap_CreditFacilityDomain_1afbf703-cb82-47aa-aec5-fc8b71f82662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a94712cf-9180-4f4e-ad99-06ad4a75d311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1afbf703-cb82-47aa-aec5-fc8b71f82662" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a94712cf-9180-4f4e-ad99-06ad4a75d311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_f13cb34b-f829-4bfa-a6c8-ae31bbfab99e" xlink:href="rmd-20220630.xsd#rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1afbf703-cb82-47aa-aec5-fc8b71f82662" xlink:to="loc_rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember_f13cb34b-f829-4bfa-a6c8-ae31bbfab99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_637509d7-4233-4d84-8ec5-8d674d7dfb93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_us-gaap_VariableRateAxis_637509d7-4233-4d84-8ec5-8d674d7dfb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_68c750cf-da1f-4bbc-b4de-1fa9e6d028dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_637509d7-4233-4d84-8ec5-8d674d7dfb93" xlink:to="loc_us-gaap_VariableRateDomain_68c750cf-da1f-4bbc-b4de-1fa9e6d028dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9eb8d341-0ea5-4df8-9249-795929ca2c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_68c750cf-da1f-4bbc-b4de-1fa9e6d028dc" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_9eb8d341-0ea5-4df8-9249-795929ca2c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_b76b971d-3709-4420-b47a-4aa1093ad60a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_68c750cf-da1f-4bbc-b4de-1fa9e6d028dc" xlink:to="loc_us-gaap_BaseRateMember_b76b971d-3709-4420-b47a-4aa1093ad60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_b2507a12-942d-4b8e-ba42-cf10a53a8ad2" xlink:to="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e276520c-593b-4099-89e3-cc29c0b4a2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e276520c-593b-4099-89e3-cc29c0b4a2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UncommittedOptionToIncreaseCreditFacility_e03634db-d126-4816-9e23-1954b0b9dd3d" xlink:href="rmd-20220630.xsd#rmd_UncommittedOptionToIncreaseCreditFacility"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_rmd_UncommittedOptionToIncreaseCreditFacility_e03634db-d126-4816-9e23-1954b0b9dd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_25dfa309-cd5e-4c5f-b464-0fe385b57938" xlink:href="rmd-20220630.xsd#rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod_25dfa309-cd5e-4c5f-b464-0fe385b57938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_70bddb18-ecd0-4583-98a0-39de34f85b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_70bddb18-ecd0-4583-98a0-39de34f85b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e85d6585-d496-4abc-850f-d451202c671c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e85d6585-d496-4abc-850f-d451202c671c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2884a9c9-1851-4433-9b58-54af5e54ff61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2884a9c9-1851-4433-9b58-54af5e54ff61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_8d39cb1e-7f94-4a6b-9a6d-9f65baa05a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_8d39cb1e-7f94-4a6b-9a6d-9f65baa05a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_473dea0c-c74e-4cb1-a200-c43bc735baa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_473dea0c-c74e-4cb1-a200-c43bc735baa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_285e3dff-90f5-4d2f-b444-a2a9c0619fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LongTermDebtFairValue_285e3dff-90f5-4d2f-b444-a2a9c0619fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_062929cc-8dcd-4f79-ba6c-ee73e9cb43bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_062929cc-8dcd-4f79-ba6c-ee73e9cb43bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb31a5e4-b06a-43af-9d29-01c686d755d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_bb31a5e4-b06a-43af-9d29-01c686d755d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DebtToConsolidatedEbitdaRatio_e1d7f68f-4a12-44c8-8a02-c912f7767c35" xlink:href="rmd-20220630.xsd#rmd_DebtToConsolidatedEbitdaRatio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_rmd_DebtToConsolidatedEbitdaRatio_e1d7f68f-4a12-44c8-8a02-c912f7767c35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_5be954f1-4e4e-4dcb-b765-063c40397265" xlink:href="rmd-20220630.xsd#rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany_5be954f1-4e4e-4dcb-b765-063c40397265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_700a0bd9-dd25-45b6-9c69-243489d487e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_LongTermDebt_700a0bd9-dd25-45b6-9c69-243489d487e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_4c0b9dd6-b389-4cc1-8d4e-45244900c3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_604cb2ee-6426-4c27-8578-62489c65bbe7" xlink:to="loc_us-gaap_DebtLongtermAndShorttermCombinedAmount_4c0b9dd6-b389-4cc1-8d4e-45244900c3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/Leases" xlink:type="simple" xlink:href="rmd-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8d520ce6-8c06-4aa3-b107-9a8dd8e2f59a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7d6f7682-e9c3-4b78-b1f9-862333816ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d520ce6-8c06-4aa3-b107-9a8dd8e2f59a" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7d6f7682-e9c3-4b78-b1f9-862333816ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_74f28e1f-194a-4170-8ac7-049f2b6f2cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d520ce6-8c06-4aa3-b107-9a8dd8e2f59a" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_74f28e1f-194a-4170-8ac7-049f2b6f2cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorSalesTypeLeasesTextBlock_a25de70b-df73-4167-82fd-386ab51a6516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorSalesTypeLeasesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8d520ce6-8c06-4aa3-b107-9a8dd8e2f59a" xlink:to="loc_us-gaap_LessorSalesTypeLeasesTextBlock_a25de70b-df73-4167-82fd-386ab51a6516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0ea875df-1742-4898-a978-0dfa79686f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ae5e9cbb-c50d-4eb7-92a3-0c02e95d4369" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ea875df-1742-4898-a978-0dfa79686f7a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ae5e9cbb-c50d-4eb7-92a3-0c02e95d4369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock_914123df-3a72-4b98-9510-3cd88cc4796d" xlink:href="rmd-20220630.xsd#rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ea875df-1742-4898-a978-0dfa79686f7a" xlink:to="loc_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock_914123df-3a72-4b98-9510-3cd88cc4796d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_2d086e77-cff2-4433-8bbc-e85f6059e033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ea875df-1742-4898-a978-0dfa79686f7a" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_2d086e77-cff2-4433-8bbc-e85f6059e033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock_e10cb2ee-304a-444c-9959-331983f03f9f" xlink:href="rmd-20220630.xsd#rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ea875df-1742-4898-a978-0dfa79686f7a" xlink:to="loc_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock_e10cb2ee-304a-444c-9959-331983f03f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock_25b11a40-6334-4f4a-8921-c734b2bd03cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0ea875df-1742-4898-a978-0dfa79686f7a" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock_25b11a40-6334-4f4a-8921-c734b2bd03cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b65ecef6-21bf-4878-972d-82f9ba2b98c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a4e11052-d5a3-406e-bde1-d51e573afc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b65ecef6-21bf-4878-972d-82f9ba2b98c4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a4e11052-d5a3-406e-bde1-d51e573afc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_964e0086-9ab3-4be8-bbc3-7184eeb5ba3c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a4e11052-d5a3-406e-bde1-d51e573afc99" xlink:to="loc_srt_RangeAxis_964e0086-9ab3-4be8-bbc3-7184eeb5ba3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bd7367c9-421e-426b-8d7b-0f98c5ea3cb0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_964e0086-9ab3-4be8-bbc3-7184eeb5ba3c" xlink:to="loc_srt_RangeMember_bd7367c9-421e-426b-8d7b-0f98c5ea3cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c78695b4-66d7-4ff2-8270-a19996bc10d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bd7367c9-421e-426b-8d7b-0f98c5ea3cb0" xlink:to="loc_srt_MinimumMember_c78695b4-66d7-4ff2-8270-a19996bc10d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c3ba29b-a814-45b4-aee1-51fa4d295a34" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_bd7367c9-421e-426b-8d7b-0f98c5ea3cb0" xlink:to="loc_srt_MaximumMember_5c3ba29b-a814-45b4-aee1-51fa4d295a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a4e11052-d5a3-406e-bde1-d51e573afc99" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ef0ddbed-8af5-43be-a87b-8184402b2f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_ef0ddbed-8af5-43be-a87b-8184402b2f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_4219c1b8-c992-4921-b67a-971eb15b3c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:to="loc_us-gaap_OperatingLeaseCost_4219c1b8-c992-4921-b67a-971eb15b3c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments_41869060-9a1b-47a2-a3b5-52c0576ae03a" xlink:href="rmd-20220630.xsd#rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:to="loc_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments_41869060-9a1b-47a2-a3b5-52c0576ae03a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_5a698744-dfbb-4d7f-8e41-bbe6bfcf4297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3a87b4fc-90ae-4799-b6d5-7b7fded75757" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_5a698744-dfbb-4d7f-8e41-bbe6bfcf4297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c35ad476-d6fd-4a0c-9345-5391663252c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7cff5370-77a8-4cd2-adc4-1b54eb5fb60c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c35ad476-d6fd-4a0c-9345-5391663252c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7cff5370-77a8-4cd2-adc4-1b54eb5fb60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d466094a-0d60-4dde-b5f2-f9d68f8c432d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c35ad476-d6fd-4a0c-9345-5391663252c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d466094a-0d60-4dde-b5f2-f9d68f8c432d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d84a13bd-decf-496f-ae4c-28bfeea1f0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c35ad476-d6fd-4a0c-9345-5391663252c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d84a13bd-decf-496f-ae4c-28bfeea1f0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b233f437-fc88-41ec-b45c-619fd3b0ebe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c35ad476-d6fd-4a0c-9345-5391663252c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_b233f437-fc88-41ec-b45c-619fd3b0ebe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_06955348-6933-4f67-98c2-bc60a2991b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c35ad476-d6fd-4a0c-9345-5391663252c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_06955348-6933-4f67-98c2-bc60a2991b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1d936073-6ef0-48f9-91d0-5b38566607f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c35ad476-d6fd-4a0c-9345-5391663252c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1d936073-6ef0-48f9-91d0-5b38566607f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e95746bc-b87f-412c-8ce7-c1f51b203089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c35ad476-d6fd-4a0c-9345-5391663252c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e95746bc-b87f-412c-8ce7-c1f51b203089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bff61942-2b06-4061-8c57-b461565d6f00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c35ad476-d6fd-4a0c-9345-5391663252c0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_bff61942-2b06-4061-8c57-b461565d6f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2baa6506-5f25-4702-a8be-20f11f3ff14d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c35ad476-d6fd-4a0c-9345-5391663252c0" xlink:to="loc_us-gaap_OperatingLeaseLiability_2baa6506-5f25-4702-a8be-20f11f3ff14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfOperatingLeaseDisclosureDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfOperatingLeaseDisclosureDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfOperatingLeaseDisclosureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_26de97ba-53aa-4e5b-a303-5f4594788679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f728d4e5-c8f2-4bfa-bed5-d1b9f6a0d575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_26de97ba-53aa-4e5b-a303-5f4594788679" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_f728d4e5-c8f2-4bfa-bed5-d1b9f6a0d575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_486a2ead-0a56-407c-8fdb-e3f8e8c15e03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_26de97ba-53aa-4e5b-a303-5f4594788679" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_486a2ead-0a56-407c-8fdb-e3f8e8c15e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_3a21cce6-66f4-4c82-b7a8-1bf6ef493627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_26de97ba-53aa-4e5b-a303-5f4594788679" xlink:to="loc_us-gaap_OperatingLeasePayments_3a21cce6-66f4-4c82-b7a8-1bf6ef493627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ae584c6e-e977-44cc-8e08-3754a1bbb077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_26de97ba-53aa-4e5b-a303-5f4594788679" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_ae584c6e-e977-44cc-8e08-3754a1bbb077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfComponentsOfLeaseRevenueDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_152648cb-af89-4d78-a6ab-97b16e6d3adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseIncome_97dd1dd8-c6eb-4fcf-a836-eb48c14f41ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_152648cb-af89-4d78-a6ab-97b16e6d3adb" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseIncome_97dd1dd8-c6eb-4fcf-a836-eb48c14f41ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_e386778d-b403-42ef-a89a-455fb3e8abbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_152648cb-af89-4d78-a6ab-97b16e6d3adb" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_e386778d-b403-42ef-a89a-455fb3e8abbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_LessorLeaseRevenue_02eee181-4122-406f-988e-889fc47cb804" xlink:href="rmd-20220630.xsd#rmd_LessorLeaseRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_152648cb-af89-4d78-a6ab-97b16e6d3adb" xlink:to="loc_rmd_LessorLeaseRevenue_02eee181-4122-406f-988e-889fc47cb804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_19dc0612-6b39-45cf-b7fd-256d0e00f071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseLeaseReceivable_b03aca3a-5b51-45c7-a5a0-a7815e0366db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseLeaseReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19dc0612-6b39-45cf-b7fd-256d0e00f071" xlink:to="loc_us-gaap_SalesTypeLeaseLeaseReceivable_b03aca3a-5b51-45c7-a5a0-a7815e0366db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets_9fbc1c38-099f-4a19-b1db-aa07093f1ea3" xlink:href="rmd-20220630.xsd#rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19dc0612-6b39-45cf-b7fd-256d0e00f071" xlink:to="loc_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets_9fbc1c38-099f-4a19-b1db-aa07093f1ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_51b706b5-bb7a-4cf3-a75d-cd552ec01288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeLeaseNetInvestmentInLease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_19dc0612-6b39-45cf-b7fd-256d0e00f071" xlink:to="loc_us-gaap_SalesTypeLeaseNetInvestmentInLease_51b706b5-bb7a-4cf3-a75d-cd552ec01288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_76786782-231f-4588-9037-473bc6f3faef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_d45cc700-82c8-4ae6-bd99-9c360e9e31c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_76786782-231f-4588-9037-473bc6f3faef" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths_d45cc700-82c8-4ae6-bd99-9c360e9e31c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_6842d309-bb99-4508-bbe7-8fa2c9d4cd7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_76786782-231f-4588-9037-473bc6f3faef" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears_6842d309-bb99-4508-bbe7-8fa2c9d4cd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_3d3e390e-ea9c-4b1f-99ff-43d0fdc8854c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_76786782-231f-4588-9037-473bc6f3faef" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears_3d3e390e-ea9c-4b1f-99ff-43d0fdc8854c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_7dd64fa2-1e96-416f-8f78-d5e7c7acd0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_76786782-231f-4588-9037-473bc6f3faef" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears_7dd64fa2-1e96-416f-8f78-d5e7c7acd0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_cb1d2346-7a7e-4610-a85d-cf8c4ef21b12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_76786782-231f-4588-9037-473bc6f3faef" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears_cb1d2346-7a7e-4610-a85d-cf8c4ef21b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_d5f32680-4bcb-4109-ab5f-d34f8dbee68e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_76786782-231f-4588-9037-473bc6f3faef" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter_d5f32680-4bcb-4109-ab5f-d34f8dbee68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_3dee1e09-24ab-4218-86d9-3b8467e2d323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_76786782-231f-4588-9037-473bc6f3faef" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived_3dee1e09-24ab-4218-86d9-3b8467e2d323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_52ee8328-9eab-4256-a8f2-c0e2cb328288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_76786782-231f-4588-9037-473bc6f3faef" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount_52ee8328-9eab-4256-a8f2-c0e2cb328288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_0678bec9-a5d9-4995-889e-7cb9ae1cd654" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_76786782-231f-4588-9037-473bc6f3faef" xlink:to="loc_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable_0678bec9-a5d9-4995-889e-7cb9ae1cd654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1" xlink:type="simple" xlink:href="rmd-20220630.xsd#LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquity" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e96c5755-ddf0-445b-b64f-11c0ff2aae19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_16221f47-be43-40cb-9860-e591f2fa42c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e96c5755-ddf0-445b-b64f-11c0ff2aae19" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_16221f47-be43-40cb-9860-e591f2fa42c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e901f4ad-96d4-4cd1-8d50-f5b4ff970c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_026a074a-c339-4811-8dda-c4d39dba4e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e901f4ad-96d4-4cd1-8d50-f5b4ff970c34" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_026a074a-c339-4811-8dda-c4d39dba4e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b3b8bcd5-a25f-4e2f-b3ca-35c8efe15ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e901f4ad-96d4-4cd1-8d50-f5b4ff970c34" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b3b8bcd5-a25f-4e2f-b3ca-35c8efe15ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_05446517-9d50-490d-ab5e-6873e6d26ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e901f4ad-96d4-4cd1-8d50-f5b4ff970c34" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_05446517-9d50-490d-ab5e-6873e6d26ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4c0c184f-b61c-472e-8d32-54bd139ed461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e901f4ad-96d4-4cd1-8d50-f5b4ff970c34" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4c0c184f-b61c-472e-8d32-54bd139ed461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_45fd0ab8-4c29-48f0-80e0-0018b5be6179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_45fd0ab8-4c29-48f0-80e0-0018b5be6179" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_b487d73e-ec8b-439f-ae74-b485917da598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:to="loc_us-gaap_AwardTypeAxis_b487d73e-ec8b-439f-ae74-b485917da598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a603e83-3a72-4c05-aa2b-d87ce50f6f41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_b487d73e-ec8b-439f-ae74-b485917da598" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a603e83-3a72-4c05-aa2b-d87ce50f6f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_12438f22-71e5-42dd-918f-a94f032c3dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8a603e83-3a72-4c05-aa2b-d87ce50f6f41" xlink:to="loc_us-gaap_PerformanceSharesMember_12438f22-71e5-42dd-918f-a94f032c3dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a34363e1-1d72-4a9e-aa60-78c63f8c4ffa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:to="loc_srt_RangeAxis_a34363e1-1d72-4a9e-aa60-78c63f8c4ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a359ee52-3ab0-488e-9234-d0c6deeefc7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a34363e1-1d72-4a9e-aa60-78c63f8c4ffa" xlink:to="loc_srt_RangeMember_a359ee52-3ab0-488e-9234-d0c6deeefc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d84714b7-5899-42b1-8584-7d9286a31549" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a359ee52-3ab0-488e-9234-d0c6deeefc7d" xlink:to="loc_srt_MinimumMember_d84714b7-5899-42b1-8584-7d9286a31549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b1cc7b70-7746-46f7-a0ad-9035fc9d66bb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a359ee52-3ab0-488e-9234-d0c6deeefc7d" xlink:to="loc_srt_MaximumMember_b1cc7b70-7746-46f7-a0ad-9035fc9d66bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0516630a-4c4b-417a-8f2e-55dca6e88f13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:to="loc_us-gaap_PlanNameAxis_0516630a-4c4b-417a-8f2e-55dca6e88f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_04408499-d8a6-414f-a747-770feabee0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0516630a-4c4b-417a-8f2e-55dca6e88f13" xlink:to="loc_us-gaap_PlanNameDomain_04408499-d8a6-414f-a747-770feabee0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ResmedInc2009IncentiveAwardPlanMember_11a20bdf-5005-43cb-867f-4c907e6c47b9" xlink:href="rmd-20220630.xsd#rmd_ResmedInc2009IncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_04408499-d8a6-414f-a747-770feabee0ac" xlink:to="loc_rmd_ResmedInc2009IncentiveAwardPlanMember_11a20bdf-5005-43cb-867f-4c907e6c47b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmendedAndRestated2009PlanMember_7708feb1-53f1-4a4e-bfa3-49881534a655" xlink:href="rmd-20220630.xsd#rmd_AmendedAndRestated2009PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_04408499-d8a6-414f-a747-770feabee0ac" xlink:to="loc_rmd_AmendedAndRestated2009PlanMember_7708feb1-53f1-4a4e-bfa3-49881534a655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanMember_657d23e1-1d7e-4363-8fe5-d9f45836a2e2" xlink:href="rmd-20220630.xsd#rmd_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_04408499-d8a6-414f-a747-770feabee0ac" xlink:to="loc_rmd_EmployeeStockPurchasePlanMember_657d23e1-1d7e-4363-8fe5-d9f45836a2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_46bec4a6-195b-4ff1-84f8-e425cfc513cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_46bec4a6-195b-4ff1-84f8-e425cfc513cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e8dd00b3-241f-411a-8eda-95e517ed2642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_46bec4a6-195b-4ff1-84f8-e425cfc513cb" xlink:to="loc_us-gaap_EquityComponentDomain_e8dd00b3-241f-411a-8eda-95e517ed2642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_765ee45d-f337-48da-81e4-7ff5b93a0dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e8dd00b3-241f-411a-8eda-95e517ed2642" xlink:to="loc_us-gaap_TreasuryStockMember_765ee45d-f337-48da-81e4-7ff5b93a0dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_e69462f7-8e8b-4c8d-93f4-a67810631c5f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:to="loc_srt_TitleOfIndividualAxis_e69462f7-8e8b-4c8d-93f4-a67810631c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_663645a1-3ac0-4a12-aca1-a73154762d42" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_e69462f7-8e8b-4c8d-93f4-a67810631c5f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_663645a1-3ac0-4a12-aca1-a73154762d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NonEmployeeDirectorMember_6a32b227-dbfc-4fde-9799-5d619456a55b" xlink:href="rmd-20220630.xsd#rmd_NonEmployeeDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_663645a1-3ac0-4a12-aca1-a73154762d42" xlink:to="loc_rmd_NonEmployeeDirectorMember_6a32b227-dbfc-4fde-9799-5d619456a55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_92a2b743-41b1-4d5e-8577-9aee75f16e70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_663645a1-3ac0-4a12-aca1-a73154762d42" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_92a2b743-41b1-4d5e-8577-9aee75f16e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc2373ff-3a31-44d8-8cab-283d5999d46b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_8b636ce8-cf98-4320-8ecc-f30f668e08de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_8b636ce8-cf98-4320-8ecc-f30f668e08de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_8a5fce03-94da-44e9-bfb6-00c532251933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_TreasuryStockShares_8a5fce03-94da-44e9-bfb6-00c532251933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_937a4359-f4f4-4555-b83d-dc2e08d58c92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_TreasuryStockValue_937a4359-f4f4-4555-b83d-dc2e08d58c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_4844b10e-c7f2-470d-8750-13fc7d467550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased_4844b10e-c7f2-470d-8750-13fc7d467550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d73f23f4-eb60-4ba4-be0a-ec492ae327a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d73f23f4-eb60-4ba4-be0a-ec492ae327a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e6bc6f5e-7beb-42f7-88f8-110b564cf77f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e6bc6f5e-7beb-42f7-88f8-110b564cf77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f1411c83-0cdc-428c-943f-57ded6dba073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f1411c83-0cdc-428c-943f-57ded6dba073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4e02f06e-d8cd-4d63-9624-8338c8f5ebf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4e02f06e-d8cd-4d63-9624-8338c8f5ebf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_297dec95-9e82-4f00-ae2b-db61e186a829" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_297dec95-9e82-4f00-ae2b-db61e186a829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_171747ce-67a4-401d-abfe-0532238c5fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_171747ce-67a4-401d-abfe-0532238c5fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_VestingAmountMaximumPercentageOfOriginalGrant_5135a2b1-b046-4f63-b185-8747da7aa8ec" xlink:href="rmd-20220630.xsd#rmd_VestingAmountMaximumPercentageOfOriginalGrant"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_VestingAmountMaximumPercentageOfOriginalGrant_5135a2b1-b046-4f63-b185-8747da7aa8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_850aab17-83a1-4a1b-837f-93ff2f6fc4fb" xlink:href="rmd-20220630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending_850aab17-83a1-4a1b-837f-93ff2f6fc4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_935104d4-e7c5-494b-a92f-8f1254303569" xlink:href="rmd-20220630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned_935104d4-e7c5-494b-a92f-8f1254303569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_38d4ea67-75b3-4ad2-9f98-2ae99bc53a58" xlink:href="rmd-20220630.xsd#rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted_38d4ea67-75b3-4ad2-9f98-2ae99bc53a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_850b7d79-47c8-4f32-b125-5ad38c570b4a" xlink:href="rmd-20220630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod_850b7d79-47c8-4f32-b125-5ad38c570b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_93c34c08-74ec-49c3-8826-3b698b742ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_93c34c08-74ec-49c3-8826-3b698b742ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e02294f4-06cd-4b4c-bde3-e9522008bd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_e02294f4-06cd-4b4c-bde3-e9522008bd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_83a50f86-4fa7-4d45-b71a-008177bd7b8e" xlink:href="rmd-20220630.xsd#rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance_83a50f86-4fa7-4d45-b71a-008177bd7b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_e1e77aed-b743-41e9-adbb-bdc78207656c" xlink:href="rmd-20220630.xsd#rmd_MaximumNumberOfSharesSubjectToAwardsGranted"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_MaximumNumberOfSharesSubjectToAwardsGranted_e1e77aed-b743-41e9-adbb-bdc78207656c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfCommonStockGranted_5f102888-cd78-41f8-8c54-29a82a80ca29" xlink:href="rmd-20220630.xsd#rmd_NumberOfCommonStockGranted"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_NumberOfCommonStockGranted_5f102888-cd78-41f8-8c54-29a82a80ca29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_3ab603ce-bbe5-4ae1-a826-fc0289351cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_3ab603ce-bbe5-4ae1-a826-fc0289351cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_482f72f2-9658-4881-856b-e2178b162537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_482f72f2-9658-4881-856b-e2178b162537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b1b95992-4064-40eb-b273-93b657f4a1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b1b95992-4064-40eb-b273-93b657f4a1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8ded1aaa-6a7e-4cb9-a7d4-1365cf6c964b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8ded1aaa-6a7e-4cb9-a7d4-1365cf6c964b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_670a2807-48e7-40f5-bc1b-abc1fbe08035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_670a2807-48e7-40f5-bc1b-abc1fbe08035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod_69642f31-31e9-4f3c-bd18-c7995bb61966" xlink:href="rmd-20220630.xsd#rmd_EmployeeStockPurchasePlanOfferingPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_EmployeeStockPurchasePlanOfferingPeriod_69642f31-31e9-4f3c-bd18-c7995bb61966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_b18d6d51-f40b-4ab5-a854-e7c00a1795e3" xlink:href="rmd-20220630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant_b18d6d51-f40b-4ab5-a854-e7c00a1795e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_a429b752-880a-4d2c-a28e-94cbce2927c6" xlink:href="rmd-20220630.xsd#rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase_a429b752-880a-4d2c-a28e-94cbce2927c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesSubscriptions_4de407ea-4e49-4b78-ac27-74a15a4a9a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesSubscriptions"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_CommonStockSharesSubscriptions_4de407ea-4e49-4b78-ac27-74a15a4a9a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0c55ec13-2d18-4d0a-b624-44d4db1d089a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0c55ec13-2d18-4d0a-b624-44d4db1d089a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_NumberOfOfferings_ff4a22e4-6b75-4ea8-9376-29375819b7df" xlink:href="rmd-20220630.xsd#rmd_NumberOfOfferings"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_rmd_NumberOfOfferings_ff4a22e4-6b75-4ea8-9376-29375819b7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6e9e7402-b3ff-4448-a332-c35783caedef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6e9e7402-b3ff-4448-a332-c35783caedef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e5711c9-1e51-4935-8d57-18a419b4a16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1e5711c9-1e51-4935-8d57-18a419b4a16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1bb48932-dad3-4a93-83cb-8a50accd9ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7d29bb33-4b17-4cdd-a6b1-77cc5e28695e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1bb48932-dad3-4a93-83cb-8a50accd9ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f4a13c74-015e-48c8-be12-5c0469565501" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cd44d13-5bf2-42d3-9ed7-1e2007a4d9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f4a13c74-015e-48c8-be12-5c0469565501" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cd44d13-5bf2-42d3-9ed7-1e2007a4d9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_dc93fdbe-a03d-4af0-91af-e65d4891f81b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cd44d13-5bf2-42d3-9ed7-1e2007a4d9f1" xlink:to="loc_us-gaap_AwardTypeAxis_dc93fdbe-a03d-4af0-91af-e65d4891f81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79812de0-136d-4151-ac58-140085b9fc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_dc93fdbe-a03d-4af0-91af-e65d4891f81b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79812de0-136d-4151-ac58-140085b9fc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_84380a7e-f3e5-44b8-a5d5-2883356caf49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_79812de0-136d-4151-ac58-140085b9fc2b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_84380a7e-f3e5-44b8-a5d5-2883356caf49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cd44d13-5bf2-42d3-9ed7-1e2007a4d9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d4a3b-9bdb-47a4-ba24-d37f9827781c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_019d4a3b-9bdb-47a4-ba24-d37f9827781c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_083d3a31-f945-450e-9faf-f2bdeeec2baf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_083d3a31-f945-450e-9faf-f2bdeeec2baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5de1e86a-3aba-4d00-8bdd-c3177d5ff0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5de1e86a-3aba-4d00-8bdd-c3177d5ff0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_001d8072-28fe-423c-a623-e8ad7454c144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease_001d8072-28fe-423c-a623-e8ad7454c144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9a816457-1191-425d-88b0-dadf79dc9e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9a816457-1191-425d-88b0-dadf79dc9e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75831495-2e0d-4844-ab84-0845c52d63d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_cd179afd-314d-4699-9952-a3f4c987bcad" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_75831495-2e0d-4844-ab84-0845c52d63d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fc7cbcca-a65c-4a78-9f79-5afebfe890f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fc7cbcca-a65c-4a78-9f79-5afebfe890f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cfc7c0d1-af60-4d32-a2e5-9fe42a003653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cfc7c0d1-af60-4d32-a2e5-9fe42a003653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7c6feebf-f70f-4703-931b-56e54f506ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7c6feebf-f70f-4703-931b-56e54f506ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue_0c8f8c24-3987-448e-a2b9-8ceb369da0af" xlink:href="rmd-20220630.xsd#rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:to="loc_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue_0c8f8c24-3987-448e-a2b9-8ceb369da0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7871ef3d-795e-49e6-b5f4-1d126a15f3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_7871ef3d-795e-49e6-b5f4-1d126a15f3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_98e6748e-44e6-4125-9def-afb66542ead7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ca5dc691-39d2-44ab-b85a-a8fb935d1cc9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_98e6748e-44e6-4125-9def-afb66542ead7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_94dabf5d-1579-42d0-b5dd-bbfe948e924b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_94dabf5d-1579-42d0-b5dd-bbfe948e924b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_e502ac5b-c29b-4fb4-9be8-e3021c559145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_94dabf5d-1579-42d0-b5dd-bbfe948e924b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_e502ac5b-c29b-4fb4-9be8-e3021c559145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_ce6a32b2-21a8-4590-a3c5-a437b369ff9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd23ae75-7266-4732-a905-80d01871627f" xlink:to="loc_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_ce6a32b2-21a8-4590-a3c5-a437b369ff9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquityScheduleOfOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_70004d0f-a3b4-4f09-ac19-33e0857634a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ba8088d9-5a69-45b4-9dad-fb8f5b31f0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_70004d0f-a3b4-4f09-ac19-33e0857634a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ba8088d9-5a69-45b4-9dad-fb8f5b31f0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_85826655-d2b2-46db-af15-e95af90de9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ba8088d9-5a69-45b4-9dad-fb8f5b31f0b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_85826655-d2b2-46db-af15-e95af90de9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dc8894b6-c7d5-4d88-aae2-d08dfe9a88cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ba8088d9-5a69-45b4-9dad-fb8f5b31f0b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dc8894b6-c7d5-4d88-aae2-d08dfe9a88cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8fe03532-8d78-4923-878a-ea4da0332570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ba8088d9-5a69-45b4-9dad-fb8f5b31f0b8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8fe03532-8d78-4923-878a-ea4da0332570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_14d688fb-7aa6-4499-b24c-700f1b92d7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ba8088d9-5a69-45b4-9dad-fb8f5b31f0b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_14d688fb-7aa6-4499-b24c-700f1b92d7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d7488b4-e8a6-4854-b3f5-2f8c85c7c480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ba8088d9-5a69-45b4-9dad-fb8f5b31f0b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9d7488b4-e8a6-4854-b3f5-2f8c85c7c480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_928178e1-b114-4a60-ad80-c96bdef13139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ba8088d9-5a69-45b4-9dad-fb8f5b31f0b8" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_928178e1-b114-4a60-ad80-c96bdef13139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9b256854-092d-4676-8347-c5aefdff6602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ba8088d9-5a69-45b4-9dad-fb8f5b31f0b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_9b256854-092d-4676-8347-c5aefdff6602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74ee34c9-3481-4ddf-8c4c-f1fe5971fdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_70004d0f-a3b4-4f09-ac19-33e0857634a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74ee34c9-3481-4ddf-8c4c-f1fe5971fdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_025d6456-26f1-4fc8-88ac-8f424a056e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74ee34c9-3481-4ddf-8c4c-f1fe5971fdaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_025d6456-26f1-4fc8-88ac-8f424a056e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32b71b4e-f847-4d78-b621-d6c623b0746d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74ee34c9-3481-4ddf-8c4c-f1fe5971fdaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32b71b4e-f847-4d78-b621-d6c623b0746d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c0464b48-0af8-41d9-bf0d-37602d771ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74ee34c9-3481-4ddf-8c4c-f1fe5971fdaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c0464b48-0af8-41d9-bf0d-37602d771ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_90d0efbf-0719-4755-9bd4-de34e6b12b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74ee34c9-3481-4ddf-8c4c-f1fe5971fdaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_90d0efbf-0719-4755-9bd4-de34e6b12b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95bceb10-83dc-402d-94e1-fd74e790aaef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74ee34c9-3481-4ddf-8c4c-f1fe5971fdaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_95bceb10-83dc-402d-94e1-fd74e790aaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5c754652-7b8d-4adc-9924-e1b516c6087a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74ee34c9-3481-4ddf-8c4c-f1fe5971fdaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5c754652-7b8d-4adc-9924-e1b516c6087a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6d3a848d-1e9f-430c-a62f-46ab1572cb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_74ee34c9-3481-4ddf-8c4c-f1fe5971fdaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6d3a848d-1e9f-430c-a62f-46ab1572cb67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_76056063-59be-4d45-bc1e-c631bcd69cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_70004d0f-a3b4-4f09-ac19-33e0857634a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_76056063-59be-4d45-bc1e-c631bcd69cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2f2e08f0-20e6-4568-9488-f8cc7b819123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_76056063-59be-4d45-bc1e-c631bcd69cc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2f2e08f0-20e6-4568-9488-f8cc7b819123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1e070f24-c15f-4969-b764-1912dca087f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_76056063-59be-4d45-bc1e-c631bcd69cc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1e070f24-c15f-4969-b764-1912dca087f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f6ab2f3e-e859-43a6-b7ee-4d1eb5c7590e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_76056063-59be-4d45-bc1e-c631bcd69cc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_f6ab2f3e-e859-43a6-b7ee-4d1eb5c7590e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_3a7a5eaf-c9c4-43cf-963f-0be26f4e8027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efbee29b-f264-4e55-bbd4-853cee3832ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_3a7a5eaf-c9c4-43cf-963f-0be26f4e8027" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efbee29b-f264-4e55-bbd4-853cee3832ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_bf922fe4-c8dc-4cb7-9b36-80d0e3762310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efbee29b-f264-4e55-bbd4-853cee3832ec" xlink:to="loc_us-gaap_AwardTypeAxis_bf922fe4-c8dc-4cb7-9b36-80d0e3762310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4aff9c5-928a-4f76-8c3e-1a7b3699c27b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_bf922fe4-c8dc-4cb7-9b36-80d0e3762310" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4aff9c5-928a-4f76-8c3e-1a7b3699c27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bff5e1a4-2831-47f4-a357-c8f83d96cb02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4aff9c5-928a-4f76-8c3e-1a7b3699c27b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bff5e1a4-2831-47f4-a357-c8f83d96cb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_6cb66e74-077c-423c-80b3-ea59de2797ec" xlink:href="rmd-20220630.xsd#rmd_EmployeeStockPurchasePlanPurchaseRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b4aff9c5-928a-4f76-8c3e-1a7b3699c27b" xlink:to="loc_rmd_EmployeeStockPurchasePlanPurchaseRightsMember_6cb66e74-077c-423c-80b3-ea59de2797ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d79c12bd-fbeb-47c9-b8b7-361942783889" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efbee29b-f264-4e55-bbd4-853cee3832ec" xlink:to="loc_srt_RangeAxis_d79c12bd-fbeb-47c9-b8b7-361942783889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db12a534-13e2-4479-a1e5-db14fb2e0ee9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d79c12bd-fbeb-47c9-b8b7-361942783889" xlink:to="loc_srt_RangeMember_db12a534-13e2-4479-a1e5-db14fb2e0ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_734ed3ed-3c7d-4d10-b254-1a2f6e69d3c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_db12a534-13e2-4479-a1e5-db14fb2e0ee9" xlink:to="loc_srt_MinimumMember_734ed3ed-3c7d-4d10-b254-1a2f6e69d3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8f53a209-d88c-4f8a-bbd3-8455f5ddbbd4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_db12a534-13e2-4479-a1e5-db14fb2e0ee9" xlink:to="loc_srt_MaximumMember_8f53a209-d88c-4f8a-bbd3-8455f5ddbbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efbee29b-f264-4e55-bbd4-853cee3832ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50b4bea1-bd33-4e5a-9c14-89be744cc56e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_50b4bea1-bd33-4e5a-9c14-89be744cc56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_32acd34f-a822-46f6-b40c-1650164a632f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_32acd34f-a822-46f6-b40c-1650164a632f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fdda5b0d-cfa7-4bb7-b993-46444ae49f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_fdda5b0d-cfa7-4bb7-b993-46444ae49f04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_41de6d87-e21f-4b4e-8689-144e118594ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_41de6d87-e21f-4b4e-8689-144e118594ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35e8d069-265f-46f0-9541-562d810ff359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_35e8d069-265f-46f0-9541-562d810ff359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ab560676-aee3-4353-88c9-efd3eba40603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_ab560676-aee3-4353-88c9-efd3eba40603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_201295e5-237e-412c-936f-bce1b6b4ae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_78953405-b3d3-4a9a-961e-07cba1c00b5b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_201295e5-237e-412c-936f-bce1b6b4ae0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_dc531cc0-7cdf-4446-ba56-5d1804fad255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efc76623-3a91-476e-a913-58869e083689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_dc531cc0-7cdf-4446-ba56-5d1804fad255" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efc76623-3a91-476e-a913-58869e083689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8e6f5846-53b0-4f50-ac66-ce6db9ac9695" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efc76623-3a91-476e-a913-58869e083689" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8e6f5846-53b0-4f50-ac66-ce6db9ac9695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b2ca9b5b-8bf5-426b-b9bc-e21fbaf40603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8e6f5846-53b0-4f50-ac66-ce6db9ac9695" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b2ca9b5b-8bf5-426b-b9bc-e21fbaf40603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_8549365e-7587-4644-963a-6f324e03a824" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b2ca9b5b-8bf5-426b-b9bc-e21fbaf40603" xlink:to="loc_us-gaap_CostOfSalesMember_8549365e-7587-4644-963a-6f324e03a824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_23bdbe45-6b34-4d71-b17a-92b32081cf32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b2ca9b5b-8bf5-426b-b9bc-e21fbaf40603" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_23bdbe45-6b34-4d71-b17a-92b32081cf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69c67376-9b09-4db3-a259-0170045a5b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b2ca9b5b-8bf5-426b-b9bc-e21fbaf40603" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_69c67376-9b09-4db3-a259-0170045a5b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba9205db-dde7-4bba-a842-ce5de71c507c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_efc76623-3a91-476e-a913-58869e083689" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba9205db-dde7-4bba-a842-ce5de71c507c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_065c0746-1ec7-489f-8a7b-54f51a615308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba9205db-dde7-4bba-a842-ce5de71c507c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_065c0746-1ec7-489f-8a7b-54f51a615308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_407e4a5e-9cf5-410e-b6d9-080d758ee69a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba9205db-dde7-4bba-a842-ce5de71c507c" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_407e4a5e-9cf5-410e-b6d9-080d758ee69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_64f3df19-dc39-49e7-aab5-fdca0fd865ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ba9205db-dde7-4bba-a842-ce5de71c507c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_64f3df19-dc39-49e7-aab5-fdca0fd865ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EarningsPerShare" xlink:type="simple" xlink:href="rmd-20220630.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_60128040-c789-4d74-afc7-4f03e5fcbbce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_916c00dd-f79f-4ca3-9522-ea40390cad91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_60128040-c789-4d74-afc7-4f03e5fcbbce" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_916c00dd-f79f-4ca3-9522-ea40390cad91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f991a841-2879-45c2-b56e-140301fb2a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8f5eea4d-e944-4e6b-bf9c-d2542db6cda7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f991a841-2879-45c2-b56e-140301fb2a5c" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_8f5eea4d-e944-4e6b-bf9c-d2542db6cda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2b8b0712-3b44-461e-a835-9ff7df4dcba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0c6a214e-170e-4644-90b3-4091f741a759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2b8b0712-3b44-461e-a835-9ff7df4dcba8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0c6a214e-170e-4644-90b3-4091f741a759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_453d44fc-cdae-496c-a67d-cb987c133771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_117fc207-348b-4a8a-aba8-1e3451f807a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_453d44fc-cdae-496c-a67d-cb987c133771" xlink:to="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_117fc207-348b-4a8a-aba8-1e3451f807a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d3b97c80-7e92-4631-81de-38e913ade2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract_117fc207-348b-4a8a-aba8-1e3451f807a4" xlink:to="loc_us-gaap_NetIncomeLoss_d3b97c80-7e92-4631-81de-38e913ade2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_068cef4c-2638-4fe5-94b8-aa5610014b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_453d44fc-cdae-496c-a67d-cb987c133771" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_068cef4c-2638-4fe5-94b8-aa5610014b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6235f082-6df7-485f-ad14-aa9962fd0536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_068cef4c-2638-4fe5-94b8-aa5610014b2c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6235f082-6df7-485f-ad14-aa9962fd0536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_eb488604-540e-4bd2-83b1-cc0b1eed519f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_068cef4c-2638-4fe5-94b8-aa5610014b2c" xlink:to="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_eb488604-540e-4bd2-83b1-cc0b1eed519f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_be2bda9b-03cd-4a7f-9ada-cedaeae858b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_eb488604-540e-4bd2-83b1-cc0b1eed519f" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_be2bda9b-03cd-4a7f-9ada-cedaeae858b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9842d372-cf85-42f2-bcb5-ac08f0bdb694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract_eb488604-540e-4bd2-83b1-cc0b1eed519f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9842d372-cf85-42f2-bcb5-ac08f0bdb694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_79677a56-dbf8-40b3-95df-540adb736543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_068cef4c-2638-4fe5-94b8-aa5610014b2c" xlink:to="loc_us-gaap_EarningsPerShareBasic_79677a56-dbf8-40b3-95df-540adb736543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0d76271f-99ed-4a56-b849-2528a3af039d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_068cef4c-2638-4fe5-94b8-aa5610014b2c" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0d76271f-99ed-4a56-b849-2528a3af039d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxes" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f816e184-f474-41df-9fc3-62fd1538dd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5203e76f-bb82-401d-951a-35838ab1cf92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f816e184-f474-41df-9fc3-62fd1538dd35" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5203e76f-bb82-401d-951a-35838ab1cf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_30f27149-fc8c-4d20-afa2-4b8e31871765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_ac3251ce-3cbc-4588-a3b1-1b2354735be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30f27149-fc8c-4d20-afa2-4b8e31871765" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_ac3251ce-3cbc-4588-a3b1-1b2354735be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2706bf1d-02b6-491a-9985-7ab6aaecf966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30f27149-fc8c-4d20-afa2-4b8e31871765" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2706bf1d-02b6-491a-9985-7ab6aaecf966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_39f0913c-407d-44ae-b106-1964634a0f73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30f27149-fc8c-4d20-afa2-4b8e31871765" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_39f0913c-407d-44ae-b106-1964634a0f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock_aa9c06ca-66e5-4f32-92ec-bf38180cf3b4" xlink:href="rmd-20220630.xsd#rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30f27149-fc8c-4d20-afa2-4b8e31871765" xlink:to="loc_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock_aa9c06ca-66e5-4f32-92ec-bf38180cf3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a54f054b-29a7-45db-936b-822bb7c722a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_30f27149-fc8c-4d20-afa2-4b8e31871765" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a54f054b-29a7-45db-936b-822bb7c722a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0982fd5b-81be-4795-849c-5e54af8d30bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_35d0259b-7266-4958-a9e6-994c1e4b256f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0982fd5b-81be-4795-849c-5e54af8d30bd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_35d0259b-7266-4958-a9e6-994c1e4b256f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_abd3339e-eacb-40c4-b01b-2533c3494901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0982fd5b-81be-4795-849c-5e54af8d30bd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_abd3339e-eacb-40c4-b01b-2533c3494901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac28626f-857d-4a30-a7af-c1874726d7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0982fd5b-81be-4795-849c-5e54af8d30bd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ac28626f-857d-4a30-a7af-c1874726d7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b7aa84e1-4181-4f95-97d7-ef02937e9261" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7b0f4ea1-d975-4716-a33f-afd40d842abe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b7aa84e1-4181-4f95-97d7-ef02937e9261" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7b0f4ea1-d975-4716-a33f-afd40d842abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0ec71d1d-3203-46b4-93f4-3ae68d4badc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7b0f4ea1-d975-4716-a33f-afd40d842abe" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0ec71d1d-3203-46b4-93f4-3ae68d4badc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cf62cbb7-6d37-42b5-a0e9-6b376d6acaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7b0f4ea1-d975-4716-a33f-afd40d842abe" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_cf62cbb7-6d37-42b5-a0e9-6b376d6acaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c1fe54b6-248d-484a-8f1d-30b50f802f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7b0f4ea1-d975-4716-a33f-afd40d842abe" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c1fe54b6-248d-484a-8f1d-30b50f802f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e4a2a787-8ffc-4ee1-ab7c-9ac50c5cf3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7b0f4ea1-d975-4716-a33f-afd40d842abe" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_e4a2a787-8ffc-4ee1-ab7c-9ac50c5cf3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1e7d9508-adf6-4d38-8513-c9dce838da82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b7aa84e1-4181-4f95-97d7-ef02937e9261" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1e7d9508-adf6-4d38-8513-c9dce838da82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_dcd975f8-8695-4917-a74f-c35bfd3251f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1e7d9508-adf6-4d38-8513-c9dce838da82" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_dcd975f8-8695-4917-a74f-c35bfd3251f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_309b1e33-9bd8-417e-bf65-d2467ee177f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1e7d9508-adf6-4d38-8513-c9dce838da82" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_309b1e33-9bd8-417e-bf65-d2467ee177f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_29078c36-9381-452d-b1ff-d5d366527bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1e7d9508-adf6-4d38-8513-c9dce838da82" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_29078c36-9381-452d-b1ff-d5d366527bde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06e61194-7062-45d0-a66f-f9da8a76053f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_1e7d9508-adf6-4d38-8513-c9dce838da82" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_06e61194-7062-45d0-a66f-f9da8a76053f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8b8018c1-f805-484e-a578-976eab54d3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b7aa84e1-4181-4f95-97d7-ef02937e9261" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8b8018c1-f805-484e-a578-976eab54d3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3b5f3c3b-5f47-4c7f-8f2d-83cc52560adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e42054ae-f19e-409d-b89f-8f4b3059357b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b5f3c3b-5f47-4c7f-8f2d-83cc52560adc" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e42054ae-f19e-409d-b89f-8f4b3059357b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d242cd76-b8fb-45b5-a780-0974abb554ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b5f3c3b-5f47-4c7f-8f2d-83cc52560adc" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_d242cd76-b8fb-45b5-a780-0974abb554ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_4292c4bd-6185-4c66-a539-c39fbcb4208d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b5f3c3b-5f47-4c7f-8f2d-83cc52560adc" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_4292c4bd-6185-4c66-a539-c39fbcb4208d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5ae015b6-ea06-47a4-9492-a4c716fb0b73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b5f3c3b-5f47-4c7f-8f2d-83cc52560adc" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5ae015b6-ea06-47a4-9492-a4c716fb0b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f6a45728-b26f-4791-aaf8-38d35597ddd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b5f3c3b-5f47-4c7f-8f2d-83cc52560adc" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_f6a45728-b26f-4791-aaf8-38d35597ddd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_4f858965-d673-4377-86b5-adf16c5797d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b5f3c3b-5f47-4c7f-8f2d-83cc52560adc" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_4f858965-d673-4377-86b5-adf16c5797d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c47ce92d-7148-4a3c-9fb0-c015dd4f7603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b5f3c3b-5f47-4c7f-8f2d-83cc52560adc" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c47ce92d-7148-4a3c-9fb0-c015dd4f7603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount_e529b241-2804-4b4e-afaf-fc872e71d469" xlink:href="rmd-20220630.xsd#rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b5f3c3b-5f47-4c7f-8f2d-83cc52560adc" xlink:to="loc_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount_e529b241-2804-4b4e-afaf-fc872e71d469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_07cfa4f1-fcbf-457e-be42-850566f0f9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b5f3c3b-5f47-4c7f-8f2d-83cc52560adc" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_07cfa4f1-fcbf-457e-be42-850566f0f9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a00158df-4f9e-473c-b005-72379278a1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3b5f3c3b-5f47-4c7f-8f2d-83cc52560adc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a00158df-4f9e-473c-b005-72379278a1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2a8872dd-67da-4678-9dfd-6e32961b563f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_8fd10e18-c188-44bf-8798-32cb8bda9d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a8872dd-67da-4678-9dfd-6e32961b563f" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent_8fd10e18-c188-44bf-8798-32cb8bda9d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_e1853b47-5cdb-4410-8a93-d2180d103589" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a8872dd-67da-4678-9dfd-6e32961b563f" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent_e1853b47-5cdb-4410-8a93-d2180d103589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ff8d079d-6ceb-4199-834b-36416c773569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a8872dd-67da-4678-9dfd-6e32961b563f" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_ff8d079d-6ceb-4199-834b-36416c773569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_803c4430-5676-4fd0-85de-132400734c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_803c4430-5676-4fd0-85de-132400734c44" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_e1954142-4c37-4149-9652-023c4509e3f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_e1954142-4c37-4149-9652-023c4509e3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_d1da1139-0ea8-4f7a-8a2d-6a8fb9a8aefd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_d1da1139-0ea8-4f7a-8a2d-6a8fb9a8aefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_9680a2c4-3be5-402a-a0a7-85dcdebbcb25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_9680a2c4-3be5-402a-a0a7-85dcdebbcb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_2c99c594-787f-4f53-baaa-9529e6ec5ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves_2c99c594-787f-4f53-baaa-9529e6ec5ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_03f3954b-c647-489e-8a4a-6495de2c5803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_03f3954b-c647-489e-8a4a-6495de2c5803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fdc8a70b-45f7-4994-b514-1802454ce5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fdc8a70b-45f7-4994-b514-1802454ce5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_68f9f6ba-d887-4797-b8fa-a0eacdb4167a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_68f9f6ba-d887-4797-b8fa-a0eacdb4167a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3a34843e-94a7-432c-8504-75b60faa56ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3a34843e-94a7-432c-8504-75b60faa56ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_7ef4fe2d-896b-4fb3-9987-12db3a4b4d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_7ef4fe2d-896b-4fb3-9987-12db3a4b4d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8c909843-e0eb-483d-8db5-955d9b79b014" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_8c909843-e0eb-483d-8db5-955d9b79b014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxAssetsLeaseLiabilities_d921feca-1a19-4e8d-9dcf-75043ee54b73" xlink:href="rmd-20220630.xsd#rmd_DeferredTaxAssetsLeaseLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_rmd_DeferredTaxAssetsLeaseLiabilities_d921feca-1a19-4e8d-9dcf-75043ee54b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_db1821ba-cd31-4b39-8859-2e6f6008030c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_db1821ba-cd31-4b39-8859-2e6f6008030c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6f5c574a-977a-46c9-bdfa-d6b403bb18ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_6485b163-6bef-4e18-8507-71ae09a0f453" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6f5c574a-977a-46c9-bdfa-d6b403bb18ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c048aac2-c2fc-481c-82c4-5c4eac23dfea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_803c4430-5676-4fd0-85de-132400734c44" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_c048aac2-c2fc-481c-82c4-5c4eac23dfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_abfb0338-e124-45e5-931f-ef0ee04d3861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_803c4430-5676-4fd0-85de-132400734c44" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_abfb0338-e124-45e5-931f-ef0ee04d3861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_cb04f918-6b7d-415a-ba18-757f8572a913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_803c4430-5676-4fd0-85de-132400734c44" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_cb04f918-6b7d-415a-ba18-757f8572a913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_e499b98d-22c0-4b5c-a195-f8e44ed5fb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_cb04f918-6b7d-415a-ba18-757f8572a913" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_e499b98d-22c0-4b5c-a195-f8e44ed5fb89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets_1637bab4-eafa-4f2a-9687-d31ced64c836" xlink:href="rmd-20220630.xsd#rmd_DeferredTaxLiabilitiesRightOfUseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_cb04f918-6b7d-415a-ba18-757f8572a913" xlink:to="loc_rmd_DeferredTaxLiabilitiesRightOfUseAssets_1637bab4-eafa-4f2a-9687-d31ced64c836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e91db93b-fba7-493f-9ef7-ffb5151c1cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_cb04f918-6b7d-415a-ba18-757f8572a913" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_e91db93b-fba7-493f-9ef7-ffb5151c1cb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_6988a37b-4f3d-4e88-9a84-81cf87fa663c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_803c4430-5676-4fd0-85de-132400734c44" xlink:to="loc_us-gaap_DeferredTaxLiabilities_6988a37b-4f3d-4e88-9a84-81cf87fa663c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_273ce587-f0ce-4e9f-bdb5-25403b4b88eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_803c4430-5676-4fd0-85de-132400734c44" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_273ce587-f0ce-4e9f-bdb5-25403b4b88eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ca9faca4-5502-4f4c-9678-639fa3d40eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesTable_9ee1a29f-d189-4c6f-9e3c-2674454eab42" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ca9faca4-5502-4f4c-9678-639fa3d40eb2" xlink:to="loc_rmd_IncomeTaxesTable_9ee1a29f-d189-4c6f-9e3c-2674454eab42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_4e4954c9-c250-40ed-943d-add705bbb913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesTable_9ee1a29f-d189-4c6f-9e3c-2674454eab42" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_4e4954c9-c250-40ed-943d-add705bbb913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0b6d1e3-42ac-44ab-918f-5a6238b7ea73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_4e4954c9-c250-40ed-943d-add705bbb913" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0b6d1e3-42ac-44ab-918f-5a6238b7ea73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_2957d1c3-93ad-4b38-a90d-d6c70d415ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_e0b6d1e3-42ac-44ab-918f-5a6238b7ea73" xlink:to="loc_us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember_2957d1c3-93ad-4b38-a90d-d6c70d415ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f45d0b3a-9753-4f79-8861-63c0600ee690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesTable_9ee1a29f-d189-4c6f-9e3c-2674454eab42" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f45d0b3a-9753-4f79-8861-63c0600ee690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_de1af89b-2231-46e7-9f44-8bd18f970886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f45d0b3a-9753-4f79-8861-63c0600ee690" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_de1af89b-2231-46e7-9f44-8bd18f970886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_05e2104d-e7d9-4caa-8411-bd006ba47330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_de1af89b-2231-46e7-9f44-8bd18f970886" xlink:to="loc_us-gaap_DomesticCountryMember_05e2104d-e7d9-4caa-8411-bd006ba47330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_07b7d487-85ea-4187-b069-8aa6eb7fd81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_de1af89b-2231-46e7-9f44-8bd18f970886" xlink:to="loc_us-gaap_ForeignCountryMember_07b7d487-85ea-4187-b069-8aa6eb7fd81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4491f1e8-64a2-4719-a0b9-1c566cd024ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_de1af89b-2231-46e7-9f44-8bd18f970886" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4491f1e8-64a2-4719-a0b9-1c566cd024ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d4b30d2-e5e7-425c-8879-4b7aeb8d0dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesTable_9ee1a29f-d189-4c6f-9e3c-2674454eab42" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d4b30d2-e5e7-425c-8879-4b7aeb8d0dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_51ef2e7b-4b7b-4554-88a1-ced5f7701159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_6d4b30d2-e5e7-425c-8879-4b7aeb8d0dd9" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_51ef2e7b-4b7b-4554-88a1-ced5f7701159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AustralianTaxationOfficeMember_f69e52ae-e088-4936-a329-2907f8a81d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AustralianTaxationOfficeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_51ef2e7b-4b7b-4554-88a1-ced5f7701159" xlink:to="loc_us-gaap_AustralianTaxationOfficeMember_f69e52ae-e088-4936-a329-2907f8a81d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesTable_9ee1a29f-d189-4c6f-9e3c-2674454eab42" xlink:to="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_627fbb7e-3007-4e4f-ac27-044e8a299088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_OperatingLossCarryforwards_627fbb7e-3007-4e4f-ac27-044e8a299088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_OperatingLossCarryforwardsCapitalLoss_24ad8f3e-affe-4221-bfaf-4c422008e0aa" xlink:href="rmd-20220630.xsd#rmd_OperatingLossCarryforwardsCapitalLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_OperatingLossCarryforwardsCapitalLoss_24ad8f3e-affe-4221-bfaf-4c422008e0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_77e9330f-c705-466f-911d-bc787dc70fe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayAggregateDollarAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_IncomeTaxHolidayAggregateDollarAmount_77e9330f-c705-466f-911d-bc787dc70fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_1117d029-d1e9-4530-b9bf-b371b2d54e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare_1117d029-d1e9-4530-b9bf-b371b2d54e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_4d4dd7ab-0f90-4147-99b9-4407ea5d2a56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_4d4dd7ab-0f90-4147-99b9-4407ea5d2a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_574bc72d-326d-4231-9177-13b4bf84d75d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_574bc72d-326d-4231-9177-13b4bf84d75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_a88327b7-3166-4fc9-9cb2-d35f699c6c2d" xlink:href="rmd-20220630.xsd#rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition_a88327b7-3166-4fc9-9cb2-d35f699c6c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement_c63c76c7-c2bf-4def-97f3-966b9a9d8d72" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationNetImpactOfSettlement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_IncomeTaxExaminationNetImpactOfSettlement_c63c76c7-c2bf-4def-97f3-966b9a9d8d72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationGrossSettlement_d5cf2ce1-5459-4061-bc79-2961aec0db65" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationGrossSettlement"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_IncomeTaxExaminationGrossSettlement_d5cf2ce1-5459-4061-bc79-2961aec0db65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_dd8c6733-2206-42ee-9326-82ecf80cb044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_dd8c6733-2206-42ee-9326-82ecf80cb044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_6d69c558-4300-4817-91ea-bb4757114b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority_6d69c558-4300-4817-91ea-bb4757114b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e6b8c850-0ae2-430a-abe6-d0bc2bf0e426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_e6b8c850-0ae2-430a-abe6-d0bc2bf0e426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxCreditsAndAdjustments_d6d8b030-bb15-48d4-8d98-af035a13d9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxCreditsAndAdjustments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_us-gaap_IncomeTaxCreditsAndAdjustments_d6d8b030-bb15-48d4-8d98-af035a13d9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationRemittedFinalPayment_42b31bf3-7003-4622-9796-0c1476d3b81c" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationRemittedFinalPayment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_IncomeTaxExaminationRemittedFinalPayment_42b31bf3-7003-4622-9796-0c1476d3b81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_IncomeTaxExaminationPriorRemittancePayments_f6f55078-44dc-4b44-bf74-8560bdd42e9b" xlink:href="rmd-20220630.xsd#rmd_IncomeTaxExaminationPriorRemittancePayments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_rmd_IncomeTaxesLineItems_7d3a7553-41f9-45f9-91e2-049e29a0bff9" xlink:to="loc_rmd_IncomeTaxExaminationPriorRemittancePayments_f6f55078-44dc-4b44-bf74-8560bdd42e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformation" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_35ecf4c9-27f3-48a6-92a5-45a2e217b9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_7fe644f9-64c6-4bb1-b798-e7c19b29f44f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_35ecf4c9-27f3-48a6-92a5-45a2e217b9e6" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_7fe644f9-64c6-4bb1-b798-e7c19b29f44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_78f808c0-24d0-4ba5-93aa-282182ec5e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_19343de2-acbb-4533-903f-93aa41f879e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_78f808c0-24d0-4ba5-93aa-282182ec5e97" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_19343de2-acbb-4533-903f-93aa41f879e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock_8270482f-b8a0-4ef6-91e6-5dcba3a4cefb" xlink:href="rmd-20220630.xsd#rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_78f808c0-24d0-4ba5-93aa-282182ec5e97" xlink:to="loc_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock_8270482f-b8a0-4ef6-91e6-5dcba3a4cefb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a21db99b-2921-449b-b0aa-bed01704f985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_78f808c0-24d0-4ba5-93aa-282182ec5e97" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_a21db99b-2921-449b-b0aa-bed01704f985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_f0993424-301e-435a-8ceb-33cf998a09db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_78f808c0-24d0-4ba5-93aa-282182ec5e97" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_f0993424-301e-435a-8ceb-33cf998a09db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f3419dbb-cba8-404c-825d-ea71e1a8d23e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1a068941-ceb7-4144-9d2f-9a5451122b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f3419dbb-cba8-404c-825d-ea71e1a8d23e" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1a068941-ceb7-4144-9d2f-9a5451122b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f7fc302b-66f3-4eb1-9bae-1a3da19f7da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_742e51db-3f68-4ae4-893e-f31e1835e3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f7fc302b-66f3-4eb1-9bae-1a3da19f7da3" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_742e51db-3f68-4ae4-893e-f31e1835e3bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_c07fb1c6-64f3-4128-8d56-eec1fd662bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_742e51db-3f68-4ae4-893e-f31e1835e3bf" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_c07fb1c6-64f3-4128-8d56-eec1fd662bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_958672fd-8484-4674-85db-844831de476a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_c07fb1c6-64f3-4128-8d56-eec1fd662bee" xlink:to="loc_us-gaap_SegmentDomain_958672fd-8484-4674-85db-844831de476a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevicesAndMasksMember_ed140835-e9c8-4f8f-ba39-88547388b289" xlink:href="rmd-20220630.xsd#rmd_DevicesAndMasksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_958672fd-8484-4674-85db-844831de476a" xlink:to="loc_rmd_DevicesAndMasksMember_ed140835-e9c8-4f8f-ba39-88547388b289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsServiceMember_5f71ae45-18c8-4277-9c69-3deb9f2778b0" xlink:href="rmd-20220630.xsd#rmd_SoftwareAsServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_958672fd-8484-4674-85db-844831de476a" xlink:to="loc_rmd_SoftwareAsServiceMember_5f71ae45-18c8-4277-9c69-3deb9f2778b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_625fab71-72b3-4ce1-bb4d-00a16c3748a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_742e51db-3f68-4ae4-893e-f31e1835e3bf" xlink:to="loc_srt_ConsolidationItemsAxis_625fab71-72b3-4ce1-bb4d-00a16c3748a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_483271d2-5ea8-4065-a39c-8ef66431795c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_625fab71-72b3-4ce1-bb4d-00a16c3748a0" xlink:to="loc_srt_ConsolidationItemsDomain_483271d2-5ea8-4065-a39c-8ef66431795c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_f39ab79e-296b-4230-aa67-466b8a5c1f49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_483271d2-5ea8-4065-a39c-8ef66431795c" xlink:to="loc_us-gaap_OperatingSegmentsMember_f39ab79e-296b-4230-aa67-466b8a5c1f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_52bda8b8-685c-4c38-9a2f-30f738ce4664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_483271d2-5ea8-4065-a39c-8ef66431795c" xlink:to="loc_us-gaap_CorporateNonSegmentMember_52bda8b8-685c-4c38-9a2f-30f738ce4664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_f519e0d4-b54f-46b3-b360-2045eadf872f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_483271d2-5ea8-4065-a39c-8ef66431795c" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_f519e0d4-b54f-46b3-b360-2045eadf872f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_742e51db-3f68-4ae4-893e-f31e1835e3bf" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a24cb369-4c5b-498d-890b-fc46be648704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a24cb369-4c5b-498d-890b-fc46be648704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment_87ba8d77-7b9a-4c70-9991-79830fa6a63a" xlink:href="rmd-20220630.xsd#rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment_87ba8d77-7b9a-4c70-9991-79830fa6a63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueFairValueAdjustment_c9ac271c-dfb2-479f-acfe-6d7e023bb72e" xlink:href="rmd-20220630.xsd#rmd_DeferredRevenueFairValueAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_rmd_DeferredRevenueFairValueAdjustment_c9ac271c-dfb2-479f-acfe-6d7e023bb72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_c2496893-3324-40d5-9a6d-18c35de4f24b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_c2496893-3324-40d5-9a6d-18c35de4f24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_78b9b36f-f170-46c5-b127-8248cd29dc35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_OperatingIncomeLoss_78b9b36f-f170-46c5-b127-8248cd29dc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_UnallocatedCorporateCosts_05f72948-a146-45bf-b225-548d21a15844" xlink:href="rmd-20220630.xsd#rmd_UnallocatedCorporateCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_rmd_UnallocatedCorporateCosts_05f72948-a146-45bf-b225-548d21a15844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_c20477c4-7dd7-47da-9098-bfb54631a854" xlink:href="rmd-20220630.xsd#rmd_AmortizationOfAcquiredIntangibleAssets1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_rmd_AmortizationOfAcquiredIntangibleAssets1_c20477c4-7dd7-47da-9098-bfb54631a854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f2bea1f4-edc3-4e2f-a90f-15a32e055c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_RestructuringCharges_f2bea1f4-edc3-4e2f-a90f-15a32e055c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_cd910537-e21c-4576-bbc6-c0a999eb7b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_LitigationSettlementExpense_cd910537-e21c-4576-bbc6-c0a999eb7b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DeferredRevenueFairValueAdjustment_7de24160-2b18-46ea-aeeb-6b5b13a0725f" xlink:href="rmd-20220630.xsd#rmd_DeferredRevenueFairValueAdjustment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_rmd_DeferredRevenueFairValueAdjustment_7de24160-2b18-46ea-aeeb-6b5b13a0725f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1c0b7487-d295-401d-8bb7-63100e34dbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_InterestExpense_1c0b7487-d295-401d-8bb7-63100e34dbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_48edc813-cd3e-4c22-9db8-0fce84c500a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_48edc813-cd3e-4c22-9db8-0fce84c500a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_260c0292-db4b-497e-9399-f540f7892568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_260c0292-db4b-497e-9399-f540f7892568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fcbcddb4-921f-4e8a-86d4-97797b55dc69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fcbcddb4-921f-4e8a-86d4-97797b55dc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c846c3b4-217e-4f05-a434-45e79935b9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_8526256a-1425-470f-acd4-145694c3edd8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c846c3b4-217e-4f05-a434-45e79935b9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_870d0d97-679a-4fdc-b6c0-c91de84573a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_870d0d97-679a-4fdc-b6c0-c91de84573a6" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_fa72398f-e650-4569-8e0b-d36971a612ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:to="loc_srt_ConsolidationItemsAxis_fa72398f-e650-4569-8e0b-d36971a612ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_cafcf45c-705b-4341-8ae0-4192341eda19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_fa72398f-e650-4569-8e0b-d36971a612ca" xlink:to="loc_srt_ConsolidationItemsDomain_cafcf45c-705b-4341-8ae0-4192341eda19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_bd815826-b09f-47fe-9b49-b5b90df14dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_cafcf45c-705b-4341-8ae0-4192341eda19" xlink:to="loc_us-gaap_OperatingSegmentsMember_bd815826-b09f-47fe-9b49-b5b90df14dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_7bffe0fc-4420-4125-9ba9-94ae9f79d033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_7bffe0fc-4420-4125-9ba9-94ae9f79d033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dc0d1657-dd89-45de-a06f-a08d8e269179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_7bffe0fc-4420-4125-9ba9-94ae9f79d033" xlink:to="loc_us-gaap_SegmentDomain_dc0d1657-dd89-45de-a06f-a08d8e269179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SleepAndRespiratoryMember_863e705a-c48e-4397-af5c-eff3f990acdf" xlink:href="rmd-20220630.xsd#rmd_SleepAndRespiratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dc0d1657-dd89-45de-a06f-a08d8e269179" xlink:to="loc_rmd_SleepAndRespiratoryMember_863e705a-c48e-4397-af5c-eff3f990acdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_SoftwareAsServiceMember_dbcbfbcd-5592-4a85-ae3c-27cc68c9e3d2" xlink:href="rmd-20220630.xsd#rmd_SoftwareAsServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_dc0d1657-dd89-45de-a06f-a08d8e269179" xlink:to="loc_rmd_SoftwareAsServiceMember_dbcbfbcd-5592-4a85-ae3c-27cc68c9e3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4d5f0f3a-f05c-4213-873c-f63ae3bdc1d7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:to="loc_srt_StatementGeographicalAxis_4d5f0f3a-f05c-4213-873c-f63ae3bdc1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_de8c600d-4c87-46d6-9e19-099b38a643f1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4d5f0f3a-f05c-4213-873c-f63ae3bdc1d7" xlink:to="loc_srt_SegmentGeographicalDomain_de8c600d-4c87-46d6-9e19-099b38a643f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_U.s.CanadaAndLatinAmericaMember_edb2d634-02d9-46e7-b882-1f1164c90200" xlink:href="rmd-20220630.xsd#rmd_U.s.CanadaAndLatinAmericaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_de8c600d-4c87-46d6-9e19-099b38a643f1" xlink:to="loc_rmd_U.s.CanadaAndLatinAmericaMember_edb2d634-02d9-46e7-b882-1f1164c90200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember_f07354c3-c716-4d43-a1b9-6c18eba89f1b" xlink:href="rmd-20220630.xsd#rmd_CombinedEuropeAsiaAndOtherMarketsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_de8c600d-4c87-46d6-9e19-099b38a643f1" xlink:to="loc_rmd_CombinedEuropeAsiaAndOtherMarketsMember_f07354c3-c716-4d43-a1b9-6c18eba89f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_GlobalMember_f98e16d1-7806-4706-bc24-cbd5d4cc43ba" xlink:href="rmd-20220630.xsd#rmd_GlobalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_de8c600d-4c87-46d6-9e19-099b38a643f1" xlink:to="loc_rmd_GlobalMember_f98e16d1-7806-4706-bc24-cbd5d4cc43ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_571df874-95fc-4d75-89b9-142a57ae73a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:to="loc_us-gaap_SubsegmentsAxis_571df874-95fc-4d75-89b9-142a57ae73a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_8edc5d21-f55c-44ca-853b-e5647af1027e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_571df874-95fc-4d75-89b9-142a57ae73a2" xlink:to="loc_us-gaap_SubsegmentsDomain_8edc5d21-f55c-44ca-853b-e5647af1027e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DevicesMember_6f94f045-b660-4178-822d-493794146707" xlink:href="rmd-20220630.xsd#rmd_DevicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_8edc5d21-f55c-44ca-853b-e5647af1027e" xlink:to="loc_rmd_DevicesMember_6f94f045-b660-4178-822d-493794146707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_MasksAndOtherMember_ee002840-6ccb-4eff-a479-ae1c970633ff" xlink:href="rmd-20220630.xsd#rmd_MasksAndOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_8edc5d21-f55c-44ca-853b-e5647af1027e" xlink:to="loc_rmd_MasksAndOtherMember_ee002840-6ccb-4eff-a479-ae1c970633ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_eb6fad7c-1a30-4b1b-b825-dca16c0b59e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_d498dbb0-30f2-4bd6-a929-39e0ad533c31" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_eb6fad7c-1a30-4b1b-b825-dca16c0b59e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cdc5584-e9df-472e-ab07-a926abd96417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_eb6fad7c-1a30-4b1b-b825-dca16c0b59e5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9cdc5584-e9df-472e-ab07-a926abd96417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformationScheduleOfRevenueByGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a20ddba0-fbeb-4495-b556-288f7d578080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ca47e3cd-64a0-43dc-8225-ff1054f824de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a20ddba0-fbeb-4495-b556-288f7d578080" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ca47e3cd-64a0-43dc-8225-ff1054f824de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_36372dc0-a161-42ac-a93b-0095472fd74b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ca47e3cd-64a0-43dc-8225-ff1054f824de" xlink:to="loc_srt_StatementGeographicalAxis_36372dc0-a161-42ac-a93b-0095472fd74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_29b6f000-4e1b-494a-a67a-e896ab34aaf6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_36372dc0-a161-42ac-a93b-0095472fd74b" xlink:to="loc_srt_SegmentGeographicalDomain_29b6f000-4e1b-494a-a67a-e896ab34aaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_1e3a680d-e9ef-447a-9ce2-22115a852d9a" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_29b6f000-4e1b-494a-a67a-e896ab34aaf6" xlink:to="loc_country_US_1e3a680d-e9ef-447a-9ce2-22115a852d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestOfWorldMember_ac0ac586-5942-4d23-94a9-7f8725f8c4bc" xlink:href="rmd-20220630.xsd#rmd_RestOfWorldMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_29b6f000-4e1b-494a-a67a-e896ab34aaf6" xlink:to="loc_rmd_RestOfWorldMember_ac0ac586-5942-4d23-94a9-7f8725f8c4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ee50e43d-144f-49c7-95f1-ea7ecc191c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ca47e3cd-64a0-43dc-8225-ff1054f824de" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ee50e43d-144f-49c7-95f1-ea7ecc191c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76af72ab-77f9-4782-b3b0-7f39c73d4f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_ee50e43d-144f-49c7-95f1-ea7ecc191c18" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_76af72ab-77f9-4782-b3b0-7f39c73d4f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_bd2f4365-0cd2-4560-ba66-71a212f533d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13e34b5d-f166-47a0-b68a-f38da830b71f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_bd2f4365-0cd2-4560-ba66-71a212f533d0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13e34b5d-f166-47a0-b68a-f38da830b71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6fb87a28-279c-4403-8fbf-28d12b9b650b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13e34b5d-f166-47a0-b68a-f38da830b71f" xlink:to="loc_srt_StatementGeographicalAxis_6fb87a28-279c-4403-8fbf-28d12b9b650b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6fb87a28-279c-4403-8fbf-28d12b9b650b" xlink:to="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_c66c4537-e1b2-499b-b668-4f3b978715e6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:to="loc_country_AU_c66c4537-e1b2-499b-b668-4f3b978715e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ef2800c6-be07-49b8-986b-11a4c768c5a2" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:to="loc_country_US_ef2800c6-be07-49b8-986b-11a4c768c5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_SG_3d6babf3-eba8-4912-acbb-62941bafa08b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:to="loc_country_SG_3d6babf3-eba8-4912-acbb-62941bafa08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestOfWorldMember_394e2802-a90c-4df0-8aa8-b97a16177c3b" xlink:href="rmd-20220630.xsd#rmd_RestOfWorldMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e16a023a-503f-4546-9cbb-e6a1afa0e131" xlink:to="loc_rmd_RestOfWorldMember_394e2802-a90c-4df0-8aa8-b97a16177c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_73629983-bac0-4b9e-825d-28fe86689598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_13e34b5d-f166-47a0-b68a-f38da830b71f" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_73629983-bac0-4b9e-825d-28fe86689598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_372a8e89-69db-409b-9552-c8808d91d5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_73629983-bac0-4b9e-825d-28fe86689598" xlink:to="loc_us-gaap_NoncurrentAssets_372a8e89-69db-409b-9552-c8808d91d5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EmployeeRetirementPlans" xlink:type="simple" xlink:href="rmd-20220630.xsd#EmployeeRetirementPlans"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EmployeeRetirementPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e78747b7-c7e7-47e9-bf06-d28bccda1ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_f7c76679-027b-4d42-ad19-db9b5f8339ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e78747b7-c7e7-47e9-bf06-d28bccda1ed3" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_f7c76679-027b-4d42-ad19-db9b5f8339ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#EmployeeRetirementPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8fd8b0b2-b88b-4532-b42f-95e672f8fd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_94720ee6-557b-4e63-a88e-3cd3e7b360b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8fd8b0b2-b88b-4532-b42f-95e672f8fd6c" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_94720ee6-557b-4e63-a88e-3cd3e7b360b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbb87c96-b3c7-497b-92bd-7cceb37b51f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_94720ee6-557b-4e63-a88e-3cd3e7b360b0" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbb87c96-b3c7-497b-92bd-7cceb37b51f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7b2f16ba-282d-40d2-a073-26f6b4ddad18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_bbb87c96-b3c7-497b-92bd-7cceb37b51f2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7b2f16ba-282d-40d2-a073-26f6b4ddad18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_1e8181b4-f6b1-4836-8419-f4f51cdf9526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7b2f16ba-282d-40d2-a073-26f6b4ddad18" xlink:to="loc_us-gaap_DomesticPlanMember_1e8181b4-f6b1-4836-8419-f4f51cdf9526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ef9cfad7-a2ad-46c7-9860-6010657de37d" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_1e8181b4-f6b1-4836-8419-f4f51cdf9526" xlink:to="loc_country_US_ef9cfad7-a2ad-46c7-9860-6010657de37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_18fc6ae4-97e9-4487-8951-2028ae69000a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7b2f16ba-282d-40d2-a073-26f6b4ddad18" xlink:to="loc_us-gaap_ForeignPlanMember_18fc6ae4-97e9-4487-8951-2028ae69000a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_39dd7838-c6ea-47c7-9d04-3d5e96dfff13" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AU"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_18fc6ae4-97e9-4487-8951-2028ae69000a" xlink:to="loc_country_AU_39dd7838-c6ea-47c7-9d04-3d5e96dfff13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_SG_a04b25d4-af59-4888-b991-4ad693fafeb6" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_SG"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_18fc6ae4-97e9-4487-8951-2028ae69000a" xlink:to="loc_country_SG_a04b25d4-af59-4888-b991-4ad693fafeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6965d9ef-e6c9-48b3-b032-e1c32cfc396b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_94720ee6-557b-4e63-a88e-3cd3e7b360b0" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6965d9ef-e6c9-48b3-b032-e1c32cfc396b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_31159003-7a5b-4f86-81c4-bcd84d086345" xlink:href="rmd-20220630.xsd#rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6965d9ef-e6c9-48b3-b032-e1c32cfc396b" xlink:to="loc_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent_31159003-7a5b-4f86-81c4-bcd84d086345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_87fb217d-22f8-45ee-964b-868fa6321348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6965d9ef-e6c9-48b3-b032-e1c32cfc396b" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_87fb217d-22f8-45ee-964b-868fa6321348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitments" xlink:type="simple" xlink:href="rmd-20220630.xsd#LegalActionsContingenciesAndCommitments"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_117aa9e0-da6d-4ffb-b488-af640efcc4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_328bba43-c7e3-4a2d-9767-e294038867ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_117aa9e0-da6d-4ffb-b488-af640efcc4b3" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_328bba43-c7e3-4a2d-9767-e294038867ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsTables" xlink:type="simple" xlink:href="rmd-20220630.xsd#LegalActionsContingenciesAndCommitmentsTables"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_465b8a54-49e8-4e99-a4f3-edb37ed0e835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_a3a78b62-ba78-4bc7-b493-9b48f38d212e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_465b8a54-49e8-4e99-a4f3-edb37ed0e835" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_a3a78b62-ba78-4bc7-b493-9b48f38d212e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LegalActionsContingenciesAndCommitmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_131611db-65e4-4013-8509-613b469e1fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_68b89f74-75ab-4c5f-908f-43d826fcee71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_131611db-65e4-4013-8509-613b469e1fc2" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_68b89f74-75ab-4c5f-908f-43d826fcee71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_ReceivablesSoldWithLimitedRecourse_c954cb22-80f9-4fa6-b525-529a20fd8378" xlink:href="rmd-20220630.xsd#rmd_ReceivablesSoldWithLimitedRecourse"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_131611db-65e4-4013-8509-613b469e1fc2" xlink:to="loc_rmd_ReceivablesSoldWithLimitedRecourse_c954cb22-80f9-4fa6-b525-529a20fd8378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_1e7d03ee-21c7-468d-8c43-cc30b34e4208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_131611db-65e4-4013-8509-613b469e1fc2" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_1e7d03ee-21c7-468d-8c43-cc30b34e4208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualProvision_9e899fe4-38cb-4255-87d6-4461ab39b580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualProvision"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_131611db-65e4-4013-8509-613b469e1fc2" xlink:to="loc_us-gaap_LossContingencyAccrualProvision_9e899fe4-38cb-4255-87d6-4461ab39b580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48bb0853-3728-4780-91fe-b192e7207d56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_197cf7ab-86e5-45b7-a0e3-fdc0500a0e24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationFiscalYearMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48bb0853-3728-4780-91fe-b192e7207d56" xlink:to="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_197cf7ab-86e5-45b7-a0e3-fdc0500a0e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_ab7b356d-1079-46d3-8947-3117133f9640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_197cf7ab-86e5-45b7-a0e3-fdc0500a0e24" xlink:to="loc_us-gaap_PurchaseObligationDueInNextTwelveMonths_ab7b356d-1079-46d3-8947-3117133f9640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInSecondYear_2e2d5f09-3c01-47df-a1f8-14e6bea7bc89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInSecondYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_197cf7ab-86e5-45b7-a0e3-fdc0500a0e24" xlink:to="loc_us-gaap_PurchaseObligationDueInSecondYear_2e2d5f09-3c01-47df-a1f8-14e6bea7bc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInThirdYear_b22168ce-1f97-4f1c-bd51-a3e7497afb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInThirdYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_197cf7ab-86e5-45b7-a0e3-fdc0500a0e24" xlink:to="loc_us-gaap_PurchaseObligationDueInThirdYear_b22168ce-1f97-4f1c-bd51-a3e7497afb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFourthYear_1e6586ca-2504-4144-a362-fc3b23aafc9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFourthYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_197cf7ab-86e5-45b7-a0e3-fdc0500a0e24" xlink:to="loc_us-gaap_PurchaseObligationDueInFourthYear_1e6586ca-2504-4144-a362-fc3b23aafc9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueInFifthYear_0cf8ab29-09b9-48c1-9aca-98b2f70cfc85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueInFifthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_197cf7ab-86e5-45b7-a0e3-fdc0500a0e24" xlink:to="loc_us-gaap_PurchaseObligationDueInFifthYear_0cf8ab29-09b9-48c1-9aca-98b2f70cfc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligationDueAfterFifthYear_46715946-b808-4c8f-9588-8d1bb75b6e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligationDueAfterFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_197cf7ab-86e5-45b7-a0e3-fdc0500a0e24" xlink:to="loc_us-gaap_PurchaseObligationDueAfterFifthYear_46715946-b808-4c8f-9588-8d1bb75b6e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_b5b26b51-4351-4a5f-bacd-bde5e9b9d05b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PurchaseObligationFiscalYearMaturityAbstract_197cf7ab-86e5-45b7-a0e3-fdc0500a0e24" xlink:to="loc_us-gaap_PurchaseObligation_b5b26b51-4351-4a5f-bacd-bde5e9b9d05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAbstract_613e7e32-4b4d-4e7e-ac8a-bab7f39e99eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48bb0853-3728-4780-91fe-b192e7207d56" xlink:to="loc_us-gaap_OtherCommitmentsAbstract_613e7e32-4b4d-4e7e-ac8a-bab7f39e99eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_b7453115-2d5c-45b0-89a6-21d94df2c216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_613e7e32-4b4d-4e7e-ac8a-bab7f39e99eb" xlink:to="loc_us-gaap_OtherCommitmentDueInNextTwelveMonths_b7453115-2d5c-45b0-89a6-21d94df2c216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInSecondYear_336f3432-5cea-4733-9490-f63e8cab1837" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInSecondYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_613e7e32-4b4d-4e7e-ac8a-bab7f39e99eb" xlink:to="loc_us-gaap_OtherCommitmentDueInSecondYear_336f3432-5cea-4733-9490-f63e8cab1837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInThirdYear_f4c3b65c-f98c-419e-b8e3-09008233a9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInThirdYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_613e7e32-4b4d-4e7e-ac8a-bab7f39e99eb" xlink:to="loc_us-gaap_OtherCommitmentDueInThirdYear_f4c3b65c-f98c-419e-b8e3-09008233a9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFourthYear_f2270ec6-fe4a-4d22-80d5-7fee31bfdb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFourthYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_613e7e32-4b4d-4e7e-ac8a-bab7f39e99eb" xlink:to="loc_us-gaap_OtherCommitmentDueInFourthYear_f2270ec6-fe4a-4d22-80d5-7fee31bfdb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueInFifthYear_ca290b69-2baa-4912-bb8f-5451e27c89da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueInFifthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_613e7e32-4b4d-4e7e-ac8a-bab7f39e99eb" xlink:to="loc_us-gaap_OtherCommitmentDueInFifthYear_ca290b69-2baa-4912-bb8f-5451e27c89da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentDueAfterFifthYear_29cea4b4-39b0-4282-a3b9-37967fd32b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentDueAfterFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_613e7e32-4b4d-4e7e-ac8a-bab7f39e99eb" xlink:to="loc_us-gaap_OtherCommitmentDueAfterFifthYear_29cea4b4-39b0-4282-a3b9-37967fd32b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_1f58e9f1-8954-4e52-86be-75b8c1efeb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAbstract_613e7e32-4b4d-4e7e-ac8a-bab7f39e99eb" xlink:to="loc_us-gaap_OtherCommitment_1f58e9f1-8954-4e52-86be-75b8c1efeb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_ed6b7ffd-f371-4bb0-84e7-382e925f8893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48bb0853-3728-4780-91fe-b192e7207d56" xlink:to="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_ed6b7ffd-f371-4bb0-84e7-382e925f8893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_f1e4ba0e-a510-4e35-8762-02f93d1aed2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_ed6b7ffd-f371-4bb0-84e7-382e925f8893" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_f1e4ba0e-a510-4e35-8762-02f93d1aed2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_56986d62-6cf4-4dc9-a4fc-cd3396c6b0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_ed6b7ffd-f371-4bb0-84e7-382e925f8893" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_56986d62-6cf4-4dc9-a4fc-cd3396c6b0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_2487ee82-7cc2-4e1d-9497-e99bcdf1dc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_ed6b7ffd-f371-4bb0-84e7-382e925f8893" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_2487ee82-7cc2-4e1d-9497-e99bcdf1dc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_7190e5a7-e18c-45d5-92d7-ee21e68dd155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_ed6b7ffd-f371-4bb0-84e7-382e925f8893" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_7190e5a7-e18c-45d5-92d7-ee21e68dd155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_d70af7c0-2339-447d-88f2-722360e2b209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_ed6b7ffd-f371-4bb0-84e7-382e925f8893" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_d70af7c0-2339-447d-88f2-722360e2b209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_23fa384c-a1f1-41b7-ba9b-f4f8d4d3c27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_ed6b7ffd-f371-4bb0-84e7-382e925f8893" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_23fa384c-a1f1-41b7-ba9b-f4f8d4d3c27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_1a2e0fa4-4c8c-4a9a-8125-71fd8987d693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_ed6b7ffd-f371-4bb0-84e7-382e925f8893" xlink:to="loc_us-gaap_ContractualObligation_1a2e0fa4-4c8c-4a9a-8125-71fd8987d693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails_1" xlink:type="simple" xlink:href="rmd-20220630.xsd#LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails_1"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://investor.resmed.com/role/RestructuringExpenses" xlink:type="simple" xlink:href="rmd-20220630.xsd#RestructuringExpenses"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/RestructuringExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_613de2f3-c4c9-443c-8b8c-247f43421172" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7d5a080c-001b-4e4a-84d8-09025b4f4162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_613de2f3-c4c9-443c-8b8c-247f43421172" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7d5a080c-001b-4e4a-84d8-09025b4f4162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#RestructuringExpensesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_abf7f2dc-daf8-40ac-97df-0e824d7756a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f8a0f20-c0b4-4346-aa98-fa00f9b25969" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_abf7f2dc-daf8-40ac-97df-0e824d7756a6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f8a0f20-c0b4-4346-aa98-fa00f9b25969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_d2e3f8fc-94f5-4ec5-8f09-1f9a38504485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f8a0f20-c0b4-4346-aa98-fa00f9b25969" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_d2e3f8fc-94f5-4ec5-8f09-1f9a38504485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6aaa8785-cd87-40fb-9b8c-b96ca238b200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_d2e3f8fc-94f5-4ec5-8f09-1f9a38504485" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6aaa8785-cd87-40fb-9b8c-b96ca238b200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_PortableOxygenConcentratorBusinessClosureMember_5bc33a13-3c9c-4241-9c31-13cb2a5a442e" xlink:href="rmd-20220630.xsd#rmd_PortableOxygenConcentratorBusinessClosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6aaa8785-cd87-40fb-9b8c-b96ca238b200" xlink:to="loc_rmd_PortableOxygenConcentratorBusinessClosureMember_5bc33a13-3c9c-4241-9c31-13cb2a5a442e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8f8a0f20-c0b4-4346-aa98-fa00f9b25969" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_15ca439b-3c8e-400d-96a0-0b8c62c5414f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_RestructuringCosts_15ca439b-3c8e-400d-96a0-0b8c62c5414f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_e4d962b8-c5f5-411c-b11e-66c8f6537268" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_InventoryWriteDown_e4d962b8-c5f5-411c-b11e-66c8f6537268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets_72d1c005-f665-4c20-abd6-cbab12dcdd28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets_72d1c005-f665-4c20-abd6-cbab12dcdd28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_c4fcc306-6312-4ca0-83dd-09f6f811299f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_AssetImpairmentCharges_c4fcc306-6312-4ca0-83dd-09f6f811299f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_ff8229d8-8ef5-45b4-8cbd-d8bcfcc0499f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_SeveranceCosts1_ff8229d8-8ef5-45b4-8cbd-d8bcfcc0499f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_144fea0f-ad2e-49ba-a482-269811f7dadb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_BusinessExitCosts1_144fea0f-ad2e-49ba-a482-269811f7dadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_rmd_RestructuringAndRelatedCostCostOfSales_2a2168af-aaa9-4a16-9729-a72eb555d02b" xlink:href="rmd-20220630.xsd#rmd_RestructuringAndRelatedCostCostOfSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_rmd_RestructuringAndRelatedCostCostOfSales_2a2168af-aaa9-4a16-9729-a72eb555d02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_89ae75bd-272c-4f44-aa76-a0df4d069a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_50f52964-abbe-41b1-aa62-97cf883024a4" xlink:to="loc_us-gaap_RestructuringCharges_89ae75bd-272c-4f44-aa76-a0df4d069a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReserves" xlink:type="simple" xlink:href="rmd-20220630.xsd#ScheduleIIValuationAndQualifyingAccountsAndReserves"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReserves" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_a3a5eda8-a72f-431d-86f9-c2ef625fad03" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_c3dc24da-f627-4eb9-a8c3-8616e74920c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_a3a5eda8-a72f-431d-86f9-c2ef625fad03" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_c3dc24da-f627-4eb9-a8c3-8616e74920c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails" xlink:type="simple" xlink:href="rmd-20220630.xsd#ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"/>
  <link:presentationLink xlink:role="http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_3b25a1b5-4edf-416f-89df-4bd57bd5a8a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3812915b-aa73-484a-a7aa-d0d042c49172" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_3b25a1b5-4edf-416f-89df-4bd57bd5a8a6" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3812915b-aa73-484a-a7aa-d0d042c49172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3b9c66f7-9e14-4bd5-b119-0855940abb2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3812915b-aa73-484a-a7aa-d0d042c49172" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3b9c66f7-9e14-4bd5-b119-0855940abb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_ec740541-481d-4638-ac52-3e25fbe732f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_3b9c66f7-9e14-4bd5-b119-0855940abb2f" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_ec740541-481d-4638-ac52-3e25fbe732f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForCreditLossMember_a4527549-36b2-424b-8f97-49790d46df73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForCreditLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_ec740541-481d-4638-ac52-3e25fbe732f6" xlink:to="loc_us-gaap_AllowanceForCreditLossMember_a4527549-36b2-424b-8f97-49790d46df73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_87206465-e6db-4df3-a1d5-ed5e0d24dd60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3812915b-aa73-484a-a7aa-d0d042c49172" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_87206465-e6db-4df3-a1d5-ed5e0d24dd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7ecf5695-aae9-4364-9088-c9014219d1c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_87206465-e6db-4df3-a1d5-ed5e0d24dd60" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7ecf5695-aae9-4364-9088-c9014219d1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_dad84f68-67a4-4ae4-91a5-f3300a183ec0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_7ecf5695-aae9-4364-9088-c9014219d1c6" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_dad84f68-67a4-4ae4-91a5-f3300a183ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c016945-1a0d-4aca-be01-8f85dd564de0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_3812915b-aa73-484a-a7aa-d0d042c49172" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c016945-1a0d-4aca-be01-8f85dd564de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0210e81b-24d3-49c8-8ee4-881185e285e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_4c016945-1a0d-4aca-be01-8f85dd564de0" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0210e81b-24d3-49c8-8ee4-881185e285e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_9872cc02-9b87-406a-8796-839bb659a696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0210e81b-24d3-49c8-8ee4-881185e285e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_9872cc02-9b87-406a-8796-839bb659a696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_5444757c-52d3-487c-942e-eec6e5050d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0210e81b-24d3-49c8-8ee4-881185e285e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_5444757c-52d3-487c-942e-eec6e5050d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_3e88c48d-50f6-4b79-a7e4-cacb3cab15d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0210e81b-24d3-49c8-8ee4-881185e285e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_3e88c48d-50f6-4b79-a7e4-cacb3cab15d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_33b72e82-a207-414b-a136-9c81ce305f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0210e81b-24d3-49c8-8ee4-881185e285e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_33b72e82-a207-414b-a136-9c81ce305f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>rmd-20220630_g1.jpg
<TEXT>
begin 644 rmd-20220630_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O'OVQ?VO]"_9,\+:')#X&U'Q;XK\7:RFD^#?"&DR".?5+ML9!
MD8$11KE=SX;!=>#G(]AKYN_X*#?LS_&CXNWOPZ^/'[-]QI<OCKX4>(9=3TC1
MM;D\NUU6"98UGMV?(V.PB0 DJ,%OF4X8 'E7PD_X*D_'3PIX^.A_MF_LW)X8
M\.:K\1[GPI9>+M%UR*[M]&U%0A6PNE4?,!NS]H!"L-Q"D(Q'OW[5?[:GA/\
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X
M275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!X7^UA_R6SX'_\ 8]R_^DS5[I7A?[6'_);/
M@?\ ]CW+_P"DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML/\ DMGP/_['N7_TF:O=* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM.ONZ-:CB*2J4I*47LT[I^C1Z491DKIW04445H,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOC/\ X*W^
M)9KO7?@K\#?&OCB\\-?#;Q[XYDL_B%JUI>&U$D$:1&&TEG&/+CE+R;B2!^[W
M'A* /K/P?\1/ OQ!.HCP1XLL-5.D:C)8:G]AN%D^S7*8WQ/CHPR.*V:_.G]G
M_P#X)TZ,?%^L_%_]CCQ-%X!\3>!?CKJ.GI<F_NIK/4?#T20DV$L>]O-!W<,3
MDAVW$G:5^BOVMOV;_CU^U'\;/"7@"?QY>^'_ (+V>G37?C*/P[K;6FI:S?;F
M$5HY0;A;@!&)!YW/D B-@ ?1E%?"W@CPQ#^Q?_P4P\!?LT_LZ?$77]3\'^-_
M#&HW/C'P-JVO2ZC'H+00O)!>QF5F>W\QE5,$_-R.=R!;OB_PYJ/_  4/_;Z\
M?_ ;QUXXU^Q^%GP=TK3X+SP_X?U:6R&M:O>1F3S+B2(AV2-4E0+D8,0((W-N
M /MRBOC+]GM?$G[%G_!0,_L36WC_ %S7OAYXZ\%R>(/!%KXAU%[N?1+V"1Q/
M:1RN=QA,<<CX/3Y.^]FYCX'_  BLO^"I?Q-^)WQQ_: \;^)Y/!7AKQO=>%_A
MYX3T7Q!/86MO':!"]\XA8%YI/,0[B>#O!W*$"@'WI17R5_P3[\<?$'X:?'_X
ML_L#_$CQ_JGBF+X>3V6I>"M=URX\Z]ETB\B606\TAYD,)>)0Q[LP&%55'UK0
M 4444 >%_M8?\EL^!_\ V/<O_I,U>Z5X7^UA_P EL^!__8]R_P#I,U>Z4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9
M_B?Q3X=\&:+-XA\4ZO#8V< S)/.V![ #JQ/8#)/85Q7QL_:2\$?!RW>PDD&H
MZRR9ATNWD&4R.&E;GRQ_X\>PQR/(O#/PI^,?[56M1>./BMJLVF: #NM+=$V;
MD/:",] 1_P M&R3Q][M\3G7&$</C/[-RFG]9Q;^ROAAYU);12[7OTTNCS\1C
ME"?LJ*YY]NB]66/&_P ?_BC^T'KLGPY^ ^D75K8-\MU? [)9(^A9WZ0Q^P.X
M],\[:]&^!O[*_@_X4+%KNM>7JVN@ _;)$_=VS>D2GH?]L_-Z;<D5WO@GP'X3
M^'6AQ^'?!^C16=LG+!!EI&_O.QY9O<_RK7K/)^#Y+&+,\[J?6,5TO_#I^5..
MVG\S5^NCNVJ&!?M/;8A\T_P7HOU"BBBONCT0HHHH **** "BBB@ HHHH ***
M* "BBB@ K \=?"[P!\2K/['XT\,6U[A<1SLNV6/_ '9%PR_0'%;]%88G"X;&
M471Q$%.#W4DFGZIZ$SA"I'EDKH^<_%7[&?B_P9J1\4_ ?QY<03QY*6ES<&*7
M']U94P&!_NL /4FJ^B?M8?%SX5:BGAKX]> YY@#@7B0B&=@.K#'[J8?[NWZU
M]*54UO0-#\2Z<^D>(=(MKZUD^_;W<*R(??##K[U\)6X$_LZHZ_#^)EA9O5P^
M.E)^<);>JVZ(\V66^R?-A9N#[;Q^YG/_  [^-OPS^*,2CPEXGADN2N6L)SY=
MPOK\C<G'JN1[UU=>%_$3]A[PAJTK:O\ #/6IM#O%;?';2LTD&[J,'.^/GOEL
M=A7*Q_$S]J?]G-Q:_$+17U[1HR%%U.QE7;_LW"C<I/82 _2L_P#6[/,A]SB'
M!M07_+ZC>=/UE'XH+UOY(7U[$8;3%4]/YHZKYK='T]17F7PV_:R^$GQ"\NRG
MU8Z-?O@?9-4(16/HLGW&]LD$^E>F*RLH96!!&00>M?:Y9F^69SA_;8&M&I'O
M%WMZK=/R:3/0HUZ->/-3DFA:***]$U"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *\B_:9\3_LH>+-<\-?LF?M+V%CJD_Q(
MEN%\/Z'J6FS2174ELF]W6=5VP2+N4*V]7RX"]:]=KR;]KC]CSX;?M@>$-,T3
MQEJNJZ+K'AW4EU'PKXJ\/W(AO](NUQB2)R#P=J[E/7:I!#*K  _/7Q%\+O%'
M_!/[X;?$+]K7]E3XQ>(-!L? 'QLNM"N?AU?:H]QH^K::)K>-8S'(2QF'FX,C
M%FV+E2K+N/Z1:G\:?@MXR\=M^R_K'BYK;Q7KOA!]4;P]MFAN?[.DS$TBRA0H
M8$L,*V\%6('RDCY:^ /_  2R\:>(?&.JZU^V)\:_%'BO1='^)E[K>B>%+I;:
M"PUR?$8CU6[2 MYA?!_=-MQM(/RNRM[W^U5^Q'X-_:7\1>'OBAI?CO7/!'C[
MPEO'ASQMX9E5;F")\[X)58%9H3N;Y#C[S#.'<, ?,?Q5^!7A'_@F+^UU\(/'
M7[*E[>VFG_%?QG!X5\:>$M3O&O\ [;!+)&!<Q2SEIE:,R;S\Y&X1] 6#>@_L
M**/"?_!1S]J[P/K!\J_OM7T#5[.-^LUL]O<-O7U"^=$,^K8KN?@W_P $]K7P
MO\9[#]HO]H?X]^)OBQXST2V>#PW>>(88;:RT@.,-)!:PC8LA!(+DGL<;@&&I
M^TE^POI7QJ^*6F?M!_##XP>(/AK\1-,TYM._X2CPXL<BWUD3N$%U;R#9.JMR
MN2.V=VU-H!YC\9E_X2C_ (+5_!W2](/FR^&/ACK&I:L(^?)AG%S;1[L=,NR]
M?[P]12_\$6E&@_ [XC_#;46V:MX9^,^N6>J6S\.C_N<,1UP2& /JA]*];_97
M_8H\-?LW^)O$7Q5\0_$77/'?C_Q:(T\0>-/$C)Y\D,>-EO#&@VP0C"G8,_=7
MG"J%YGXL?\$];G6?C-K7Q[_9O_:0\4?"?Q#XJBC3Q<F@VL%U9:LR#"SO;S#:
MD^"1Y@/<G 9G+ '$_LZ+_P )3_P6.^/OBO1SYMCH?@G0](O9X^4%S)%!($SZ
MCRI 1V*D=J^QZ\L_9/\ V2OAY^R/X'OO#/@_5-4UC5-<U.34_%'BC7KGSK_6
M+U_O33/@>^%' R2<LS,WJ= !1110!X/^UVMR_P 8_@DMI(J2GQQ-Y;.,@'[,
MV"17L'V+QO\ ]!NR_P# 8_XUY'^UA_R6SX'_ /8]R_\ I,U>Z4 8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL
M44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
MC1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-
M;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P
M&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8
M_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&
M[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;L
MO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+Q
MO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&_
M_0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_
M &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?
M8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q1
M0!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_
M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
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ML;:.&&) D442!511P  . !Z5)117Z&DHJRV/4V"BBBF 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M04445J4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@^'S:=#-\2_%7@7PW+>:CJ,#*=NGV[G;&H95'FMNY\T @A620 Z#XC^,[?\
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M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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M&'_OT*^RR3(\NX>P$<)@X6BM6]Y2?64GU;_X"LK([\/AZ6%I\E-:?GYLI_\
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M_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\
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M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC
M_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"
M8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H
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MCF9!E@AZ"I/[.T__ )\8?^_0I\5M;0$F"W1">I1 ,T /HHHH **** "BBB@
MHHHH P? GPS\&?#4ZT?!NE-:_P#"0:]<:SJVZX>3SKV<*)9!O)V@[%^5<*,<
M 5O444 %%%% !1110 4444 %%%% 'A?[6'_);/@?_P!CW+_Z3-7NE>%_M8?\
MEL^!_P#V/<O_ *3-7NE !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*E3H4U""LD%%%%=IH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;IIIKU3U/)E&479JP4445B(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*QO!_P 1/ OQ!.HCP1XLL-5.D:C)8:G]AN%D^S7*8WQ/CHPR.*V: "BBB@ H
MHHH **** "BBB@#PO]K#_DMGP/\ ^Q[E_P#29J]TKPO]K#_DMGP/_P"Q[E_]
M)FKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI?B37=%O]9\3>)W6V\&^!],C+:AK%XP7$2J 2JJ70.^#MW  ,S*K 'S;X_\
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M (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_
M\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
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M.'Z48<KJ5ZFE.E'XIO\ 2*ZRZ>;T.3%XR&%BE:\GLENS8^,G[07BKXQ^(?\
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MQ16/]B\;_P#0;LO_  &/^-'V+QO_ -!NR_\  8_XT ;%%8_V+QO_ -!NR_\
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M^&/P2\*Q>"OA1X)L-#TR+G[/8PX,C8QOD<Y:1_5G)8^M7/L7C?\ Z#=E_P"
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M!J*\<^#?[6WP>^/BQ1?"[X^>&[^[E VZ7,IMKS/IY$VV0X]0I'O7I?V+QO\
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ML/\ DMGP/_['N7_TF:O=*\+_ &L/^2V? _\ ['N7_P!)FKW2@ HHHH ****
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MRS#'S]MC*GQ5'LE_)!?9BMM+7\E9(PF#]C)U:CYJCW?Z+R"BBBOL#N"BBB@
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M/=O=A1117TQUA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!116=XL\7^%? ?A^Y\6>-O$=EI.F6<>^ZO\ 4;E888E]69B /ZU4(3J34(*[
M>B2W8)-NR-&N3^,'QR^$WP#\+/XR^+OCFQT2Q&1$;J3,EPP&=D4:Y>5O]E 3
MWKX\_:&_X+ W&N:[_P *F_8D\"7?B;6KN0P6^NW&G22*[_\ 3M:@;Y3W#.%
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M _\ ['N7_P!)FKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\B_:)_:=TWX8
M1OX0\&F.^\1S#;L WI99Z%P/O/Z)^)XP&R/VA/VH;C2[YOA?\'2U]KD\GD3W
MEJGF?9W)QY<0&=\O;/1?<_=N_L[?LO6_@61/'WQ'VW_B.8^:D<K^8MFQY)R<
M[Y?5NQZ?WC^=YMQ!F.>XZ>3\/O6.E6OO&DNJC_-4]-O6[CY=;%5<34=#"O\
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M6SZRC0I8>FH4U9(****](U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?)HW["NYAR?^);J<OR_14'YT?\ #W'_ (*=:EQH?[!&XOS%_P 49K4OR_\
M 7&>.]'^M.4O;F?_ &Y+_(/^($\?1_B*A'UQ%+_Y)GZ=45^8O_#S?_@L?JG_
M ""/V ML<GRI)_PJ_7VP?7<;@+^8H_X;V_X+>ZE\]K^Q?]G ^4C_ (5SJ*9/
MK^\G_P#K4?ZSX![0J/\ [<8?\0/XJC_$Q6$CZXFG_P $_3JBOS%_X:O_ ."\
MFH_+:_LU>1LZG_A#E7=_W\E_E1_PNG_@X*U0;;3X2_9BWS _V#I:8'I^\?\
M0\T?ZRT'MAZK_P"X;_S#_B"V:Q_B9M@(^N*C^D6?I9KWACPUXIM#I_B?P]8Z
ME >L%_:),G_?+@BO,?&/["G[*WC3?)>?"6RL96Z2Z-+):;?HD3!/S4U\0_\
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MPDHJZ2OSZWTM[71117Z$?R&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M $F:O=*\+_:P_P"2V? __L>Y?_29J]TH **** "BBB@ HHHH **** "BBB@
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M^#C%J7QM^(.O^-;M<&6TMB--LF]05C+3'ZB5?IZ<7]JYQC/]SPKBOYJCY?\
MR5:GT7^HGAUP[KQ%GL:LUO2P<?:OT]K*U-/I9HQ_C#_P<"_#"SNV\/?LX_ _
M6_%%](_E6UYK4HLX7<]"D48DEE!_NGRS7"?\)A_P73_;;./#^B7/PT\/W?\
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MNI6&L:=;ZOI=VD]K=0)-;3Q-E9(V 96![@@@_C7CO_#O+]CW_HD'_EP:A_\
M)%>J^"_!OAWX>^%K'P5X2LGMM-TV 0V5O)=23&*,$X7?*S,0,X&2<# '  KJ
MXNS+@W,H4GDF$>'<;J453IPBT]4[0D_>3OTU3WT1EPU3\0XXBK/B?,)8QRMR
MSG6JUJD6M+<U57Y6NE]&M%JS4HHHKXD^O"BBB@ HHHH **** "BBB@ HHHH
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M/_!:?X=:K\#]0MM4/P\\"ZD/B-K.E2+)!"DT5Q%;VDDB_*T@DF5MF21O/=&
ML_\ !*SQAX2^ ]]\8?V0/B/XCLM&\2>%/BCJ6I6MGJ5RL#7>DW*Q-!=1[R-Z
M$(6)'W5DC)QN%?5'P7_9^^"G[.WAN3PC\$/AEI'AG3YI1)<0Z7:A&G<# >1^
M6D8#@%B2!Q6#\=?V,OV6OVF-2M=;^.?P2T3Q#?V<8CM]0N86CN%C!)$9EB97
M9 22%)*C)XY- '@'[$&I:=\>_P#@HQ\?OVJO ]TE[X0@M-+\)Z'K,!W0:A-!
M#$;HQ..'57B4[AP5E0@D&OLVL7X>_#GP%\)O"-GX!^&?@_3M!T73T*V>F:7:
MK##$"<DA5 &2222>22222:VJ "BBB@#P?]KNVCO/C'\$K65F"R>.)E8HV#@V
MS=#VKV#_ (0?2/\ GYO?_ MJ\C_:P_Y+9\#_ /L>Y?\ TF:O=* ,?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH
MQ_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0
M?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!
M](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK
M8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,?_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJV** ,
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VK8HH Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJV*AU#4M.TFU:^U6_AMH$^_-<2A%7ZDG I2E&$7*3LD#:2NS-_
MX0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:N3\5?M5? WPINCE\:1W\R](=*C,^[
MZ.OR?^/5YUKG[=T^I7/]F?#7X97-W,_$+WTI+'_ME$"3_P!]U\GF/'7">62Y
M:N+BY?RP]]W[6A>S];'#5S'!4=)35_+7\CW'_A!](_Y^;W_P+:JNJZ#X0T&U
M-]KGB![* =9KO4O+0?BQ KPK[?\ MR?%7_CWM)/#]I)UQ&EEL_[[S-^56M*_
M8;\2>(+H:I\4_BK+<SG_ %BVJO,Y_P"VLQS_ ..FO*_URSK,=,IRJK-?S5;4
MH^JO=M>EF8_7\15_@T6_-^ZCJO%7[0'[.OA;=&OC2^U.9?\ ECI4DDN?HYPA
M_P"^J\]U;]JZYUZ[.E_"WX:ZE<SM_JVN[V69V_[90C/_ (]7K/A3]D;X&^%M
MLC^%WU.9?^6VJW!ES]4&$/\ WS7H6DZ'HN@6HL="T>ULH!TAM+=8T'X* */[
M.\0\T_WG&4L+%]*4.>5NSE/9^:#V6:5OCJ*"_NJ[^]GS'9^#OVS?B0P=FN-!
MM9.AFN?LH7\ 3-^E;>@_L'W.HW U'XD_$R>YE;_6I81%F/\ VUE))_[XKZ+H
MJZ?ASDE::J9E4JXJ7_3VI)J_E%65O)W&LJP\G>JW-^;/,= _9"^!V@*I'AR6
M\D7_ ):W]P9"?^ \+^E=A8_#?PSIEN+338Y[>)?NQ03%%'X#BMZBOKL!E&59
M5#EP="%-?W8I??9:_,[J5"C15J<4O1&/_P (/I'_ #\WO_@6U'_"#Z1_S\WO
M_@6U;%%>B:F/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%<E\0_CU\$OA,C-
M\3/BSX=T)D&?)U/5X8I6_P!V-FW,?8 FMJ&'KXFHJ=&#E)]$FW]R&HRD[)&K
M_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U?.'Q&_X+$_L9>!_,A\/:]K7BF=,@
M)H>CLJ;O]^Y,0(]UW>V:\9UC_@LW\;/B7J#Z#^S1^RI)?7.<1M=FXU*5L]"8
M+5$*_3>:^PP/AWQCCH>T^JNG#K*HU32\WSM/\#KA@,7-7Y;+ST_,^]?^$'TC
M_GYO?_ MJ\[_ &F_C)\'/V5/AI<?$;XCZU>=X]+TN&^/VC4;C&1%&"?Q9CPH
MY/8'Y$_L_P#X+9_M&_\ 'Q>S^"--GZ?O;;2?*S_N;KL?CG\ZMZ1_P14^*GC^
M[.O_ +0W[5,E[?LAW?8[:?4'+'OY]S(C8SVV<^U>MAN#N&LLQ$9YWFM+E3UA
M1YJDG_=O%>Z^[L_U-8X3#TY)UJJ]%J?%'[17[1/Q"_:7^(EQX^\>W[;<E-,T
MQ)F:'3X,Y$4>[\RW5CR>P'T9^RG_ ,%6[SX2?#EO 7QP\+:SXI?3T5-"U*RU
M413>4!CR9R^=P7C:XR<<$' -?/7[3?[,GQ,_94^)EQ\./B/I_K)I>J0H?L^H
MV^<"6,G\F4\J>#V)^R_^"9W_  3$CFCL?VB/VE/#:NKJL_AGPI?PY!!Y6ZN4
M;KZI$1Z,PZ"OW/BVIP#2X/I3QD(SPR2]C&#LV^B@TTU?[3]>;4]G%/ K")S5
MX]+?I^ID7/\ P5T^)7CB9K/X-?LIWMS*#M0R:W=7[$]LI!"F/IG\:(_CM_P5
M\^*/_(G?L\W>@K)_JW/AR6U '8YU"4C\>E?I+;6UM9P+:VEND42#"1QH%51Z
M #I3Z_!/]<.&L+_N62TE_P!?)SJ_G8\3ZWAX_!17S;9^<-M^R_\ \%F?B7SX
MI^,#^'?,^]YGBJ*VV_\ @N5\?A5J#_@C/^T7X^82?&G]KF.9F.9-D=YJ?ZSR
M19K]%**7_$3>(*/^Y4Z.'_Z]T8*W_@7,']HUU\"4?1(^'O"G_!"[X#6(5O&O
MQA\6:DPZC3H[:S5C]&24X_'\:]'\,?\ !(G]A[PZ%:[^'VI:M(O234]>N#^:
MQ,BG\17TU17E8OCWC+&_Q,=47^&7)_Z1RF4L=BY[S?Y?D>3>&OV%_P!DWP@R
MR>'O@9X>@D3[L[:9%)*/^!NI;]:[G3OAIX6TBU%EI,$MK"OW8;>4HH_!<"N@
MHKYO$X[&XR5\15E-_P!Z3?YLYY3G/XG<Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJV**Y23'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ MJV** ,?_ (0?2/\
MGYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P# MJ/^$'TC_GYO?_ M
MJV** ,?_ (0?2/\ GYO?_ MJ/^$'TC_GYO?_  +:MBB@#'_X0?2/^?F]_P#
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M1_S\WO\ X%M6Q178?.&/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[9/<Z"^L7*\^=J\GF+G_ *Y@!,?4'ZUZ596-EIMJECIUG%;PQC$<,$815'H
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M'YJPY4\CN#]T^+O^"ZWP[CL88OAO\ ]=U&_EB0/'JVHQ6T<<I RJ^4)6D /
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M'\IFKP/4O^"F/_!(+PEE=!_9UUK62H^0P^%+=U)]_M5PI[>E8&I?\%JOV+-
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M59;'Y/4J5*LW.;;;U;>K?JPHHHID!1110 4444 %%%% !1110 4444 %%%%
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M/_@.1[5Z5X(_9,^"G@O9,WALZM<I_P O&L/YV3_USP(__':\\\>?\%7/V(/
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M::'G^VOB)H5GMZ_:M7ACQ_WTPKY+B_X)/>)]8<3^+OVB3(W4A=$>8_\ ?3W
M_E6WI?\ P22^&L./[:^+.N7'][[+:0PY_P"^M]?D?]A\#T?XF;.7E&A/\V[&
MO]N\=UOX>4*'G*O!_@E<]VU3]JO]FO1\B\^.GA=B.HM]9BF/_D,M7.:I^W[^
MR/I61-\7H96'1;72[N7/XK$1^M<?I?\ P2Q_9KL,&\U7Q3>D=1<:G$H/_?N%
M:Z/2_P#@G1^R1IV#-\-Y[QAT:ZUN[_DDBC]*/8>&]'XZV)J?X8TX_P#I0?6/
M$NM\%'#4_P#%*I+_ -),G5/^"G7[+FGY^R7^NWV.GV71R,_]_&2N<U3_ (*R
M_!2'(T;X=^*+C'0W$=M"#^4KUZYI?[&G[+FCX^R?!'0WQT^U6YG_ /1A;-='
MI?P+^">B8_L;X/>%K0CH;?P_;(?S"4?7O#RC\&$KS_Q5(Q_])#ZCXCUOCQE"
MG_AIRE_Z4SY?U#_@KG9N_DZ!\!;B=FX0W'B *?\ OE8&S^=5_P#AX]^TKXA_
MY$O]F02;ON?Z)>77_HM5S7V5I^D:3I,?E:5I=O;+C[MO J#]!5BC_6+@^E_!
MR=>LJTY?A:P?ZM\95OXV<OTC1IQ_&]SXM_X:C_X*4>)_^0/^SO\ 8 WW6_X1
M*ZCX^MQ(11_;7_!6_P 3_P#'GI)T^-NO^CZ3#C_OZ2WY5]F7VH6&EVS7NIWT
M-O"GWY9Y0BK]2>!7!^*OVM/V6? ^X>+_ -H_P+ISIUBN_%=HDA]@ADW$^P%9
MU..<MPJO3RS"Q_QQ<OSDCKPOASGF:2Y8YCC*K[4W;\(Q9\W_ /"C_P#@J-XG
M_P"0M\7CIV[K_P 5 L./_ 9#^E'_  P;^VQXBY\9?M1[@WWA_P )'J-SC\'5
M17H_BK_@K/\ \$]?".Y=0_:2TVY=>B:5IMY>;CZ PPLOZXKS;Q5_P7H_8:T#
M<-&M?&NN$?=.FZ!'&&_\")HB!^'X5P5?%QX;^&\-3_P4X?\ !/K<%]&[BG-+
M?[#CZJ?6;JI/YM17XCXO^"3WB?6'$_B[]HDR-U(71'F/_?3W _E6WI?_  22
M^&L./[:^+.N7'][[+:0PY_[ZWUXQXI_X.*?AK:EAX(_9EUW4/[AU7Q!#:9^H
MCBFK _X?4_MR_$8?\61_896X\S_4_P#$KU/5<^G_ ![K%G\*\RMXX9O/W(8Y
MORA37Z07YGUF%^A]G$8^UQ&4QI1_FK8B*^].JW^!]4Z7_P $L?V:[#!O-5\4
MWI'47&IQ*#_W[A6NCTO_ ()T?LD:=@S?#>>\8=&NM;N_Y)(H_2OC/_AIW_@O
M=\4O^12_9];PYYGW?^*1AL]O_@RD;'XT']GO_@OY\4O^1M^-K>'/,^]_Q4]E
M9[/_  6HV/PKRZWBGQ3BOX<\5+TO%?>FCV*/T:N%<NUQV.RNCY.K&I/_ ,!4
M'^9]WZ7^QI^RYH^/LGP1T-\=/M5N9_\ T86S5K4_"'[*/PM3S-;\,_#WPZ$&
M=]W9V-I@>N6"_G7P-_PYL_X*#?$;GXU_MTK.)/\ 6@Z_JNI_I/Y0-;/AC_@W
M6\$1.)O'7[4>KW[,<RC3/#45J2>_S232Y^N/PKRZW%?&6,_Y<U'YSK?I=L]6
MCX7>#&5?[QGU*Z^S1P<Y?=+2/X'UUK7[=O[!?PWC:&;]I3X?VX08>'2-9@N&
M'MMMBQ_#%?/?[;/_  6(_9;D_9U\7>%/V;?C5-J'C74-,-GI$MGH5[$L)E=8
MY9%FEB1598FD96!.&"XR>*TO"O\ P0._8DT+:^N:WXXUMA]];[7(8T/T$$"$
M#_@1^M=];?\ !'3_ ()YV6@W>BVGP(VRW=I)"=1EU^^FGB+*5\Q/,F9%=<Y!
M"XR!P:\VM/BW$PDDJ<&UO>3DO1[7/;R^'@%DN,I5:E3&XKDE%V4*,*<K-.TH
MR?,XOJDTVM#\*79G8N[$L3DDGDFO=?V!/VW?B/\ L1?%6\\7>"_#3>(;+6=.
M:SU+PV]V\273 [HI055\/&P.#M)VLZ\;LCUSXS?\$+?VT/!/C2?3/A-I.E^-
M-#>8_8=4@UBWLI5BS\OG17,B;7QU"%QZ'M7V/_P2O_X)7ZM^QYJUW\:OC5J]
MC>^,[VQ:ST_3]-<R0:5 Y!D)D('F3-M"DJ-JJ& +;R1\'E&19]#-(\L94FF[
MS:T7>U])7VLKW]#^J>/_ !6\*Z_!%;VM:EC858I1P\9VE)W32DE[]*S5W)I.
M-M/>LCQ__A\/_P %&O''_)*/V$!-N^Y_Q3&KZA]/]28\T?\ #5?_  7F^(0/
M_"-_LX'0]_W?^*.2VVY_Z_Y#^M?IW17WW]B8^?\ %QM1_P"&T?R/Y-_XB=PI
MA?\ <N&<)'_KXYUO_2FKGYB'X?\ _!PW\0_^0YXU.AQOR/\ B9Z':[1_VZ*6
M'X\T?\.V/^"QOC_YO'?[<7V*!^9+8_$+5FY_ZYPPB/\ 6OT[HH_U9PLOXM:K
M/UF_TL+_ (C7G=#_ '++<#A_^O>&BO\ TIR/S$'_  0.^.7C9@_Q7_;6$Y;F
M3&D7.H9/UFN8\_6NG\._\&[?P=M=O_"6_M&^)K[ ^?\ L[2+>US]-YEQ^M?H
MI151X5R*+NZ5WYRD_P!3&OX[^*=6')#'^SCVA2HQ7X4[_B?$WAW_ (((?L/Z
M+M.JZQXZU<C[POM>A0,?^V%O&0/QKO/#G_!'+_@G;X=VR?\ "@_MTJ_\M=1\
M1ZA+GZKYX3_QVOIVBNRGD>3TOAP\/G%/\SYW%^*'B-C?XN;8C_MVK.*^Z+1X
M]X=_X)\_L/\ A8+_ &5^RIX%<I]UK_P]#=$>^9U<UW?AWX+?!SP?M_X1+X3>
M&=+V?<_L[0;>#;]-B#%=-17;3PF%I?!3BO1)'S.+S[/,?_O.*J5/\4Y2_-L1
M555"J  !@ =J6BBN@\D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS\0_V*6%GJ5M.A>VOH%<[E61 25/3*GY=^Q?H.@ HHHH \+_ &L/^2V? _\
M['N7_P!)FKW2O"_VL/\ DMGP/_['N7_TF:O=* "BBB@ HHHH **** "BBB@
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M>(Y(-,A1=>@A$:W\84;)@ [@[DVDL&(8Y;OBOYJZ^_\ ]FC_ ()&_M1?M/\
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M%6/EZU>MB)\]63D^[;;^]A1115&04444 %%%% !1110 4444 %%%% !1110
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M4+W_ +Z6O(_VL/\ DMGP/_['N7_TF:O=* ,?_A)=7_Z%"]_[Z6C_ (275_\
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MX275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^
MA0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_
M^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_
M +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^
M^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH
MQ_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X2
M75_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X
M275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H
M4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A
M0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK
M8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^E
MH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@
M#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275
M_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7
M_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?
M^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O
M?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6
MMBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_
MX275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^
MA0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_
M^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_
M +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^
M^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X275_^A0O?^^EK8HH
MQ_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X275_^A0O?^^EH_X2
M75_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6MBB@#'_X
M275_^A0O?^^EH_X275_^A0O?^^EK8HH Q_\ A)=7_P"A0O?^^EH_X275_P#H
M4+W_ +Z6MBB@#'_X275_^A0O?^^EJUI6JWNH2.EUHD]J%7(:4C#>W%7J* "B
MBB@ HHHH **** "BBB@!L<446[RHU7<VYMHQD^I]Z=110 4444 %%%% !111
M0 4444 >%_M8?\EL^!__ &/<O_I,U>Z5X7^UA_R6SX'_ /8]R_\ I,U>Z4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'A?[6'_);/@?_P!C
MW+_Z3-7NE>%_M8?\EL^!_P#V/<O_ *3-7NE !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!X7^UA_R6SX'_\ 8]R_^DS5[I7A?[6'_);/@?\
M]CW+_P"DS5[I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M $F:O=*\'_:[MH[SXQ_!*UE9@LGCB96*-@X-LW0]J]@_X0?2/^?F]_\  MJ
M-BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**
MQ_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0
M?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!
M](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH
M V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_
M ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ
M-BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\
MA!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^
M?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y
M^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\
M MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\
M"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**
MQ_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0
M?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!
M](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F
M]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?
MF]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH
M V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"V
MH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL
M?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2
M/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](
M_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_
M\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_
M ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_X0?2/^?F]_\  MJ
M-BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\ A!](_P"?F]_\"VH_
MX0?2/^?F]_\  MJ -BBL?_A!](_Y^;W_ ,"VH_X0?2/^?F]_\"VH V**Q_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \+_:P
M_P"2V? __L>Y?_29J]TKPO\ :P_Y+9\#_P#L>Y?_ $F:O=* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#PO]K#_ )+9\#_^Q[E_])FKW2O"
M_P!K#_DMGP/_ .Q[E_\ 29J]TH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /"_VL/\ DMGP/_['N7_TF:O=*\+_ &L/^2V? _\ ['N7_P!)
MFKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
MH4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI
M: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_O
MI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V
M**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$E
MU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (27
M5_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+
MW_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4
M+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^
MEH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:
M/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_
M (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?
M_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU
M?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]
M_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W
M_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -B
MBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^
M$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_
M^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
MH4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI
M: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_O
MI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V
M**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$E
MU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (27
M5_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+
MW_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^EH V**Q_^$EU?_H4
M+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\ H4+W_OI:/^$EU?\ Z%"]_P"^
MEH V**Q_^$EU?_H4+W_OI:M:5JM[J$CI=:)/:A5R&E(PWMQ0!>HHHH ****
M"BBB@ HHHH **** "O@+]M_]F/\ :1_9XN_CY^T!^SM'H6N^!/BK\/M0_P"%
MC^'-6O6MKK2I8["='U"U;!67:CRR%"<L79<'Y&7[]I)(TE1HI4#*P(96&01Z
M&@#X]_9)_9I_:,^)GQ_\-_MH_M6VVA:'_P (OX(31?AWX.T&]-T;:*6+;)=W
M,V ID='<;5SPXSMV ,1_ 7]M']C;XV>//%O[('@3POX\\#?$?7'UZZ\*ZWKO
M]F7.B:M+@3RQR%2DD+G!V_>PJJ NS<_V& % 51@#H!10!\]_L,_LL_$SX/:O
MXZ^/O[1>OZ9J7Q,^)^JPWGB'^Q0QL]-MH$*6UE S_,PC1B"QZX49;9O;Z$HH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "L'XIZ[J7A?X8^(_$VC3".\T[0;RZM9&0,%DCA=U)!X."!P:WJ\*\6?M9
M?"#XD_"3XWZ3;ZE-I%Q\-X]6T7Q'#KAB@;>EH66XC D8F"3?B-VVEBC#;TR
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M3N '6@#Z-U+]K+]FW1O!V@?$+6?C-H5GH?BFWN)_#^JW=WY4%['!$TLK*[
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MM8'Q"@\:>%K^?48;@S3?;/[2=;I0TV.02H.SR\#I7V;_ ,$^]'_X1_\ 8O\
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M_P"T9\9= \>^$_B!XGMO#&L+8>%$TR7P_JETKFU>!TD;S[8R*8V,H# ;6ZG
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MI#]HCX<_LM?"/4OC%\3KR9;"QV1V]G:1[[F_N7.V*V@3(WR.W '  RQ(520
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M[(VA^+/@U\)[.3XG:CXV_P"$-\20&WEGTWPU>13O#=ZA,JG>;9%02!=V1YR
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MOA_^S+X:T7QA\2X;\:;K/BJPT+[99Q1M'8RW3E$N+AI'01VZ$9=QD@$85NE
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M&2 1RLB*P]U%+\1_AKX ^+_@R^^'GQ/\(6&NZ)J,82]TS4K<2Q2@$,#@]"&
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ME!R'GB1A'.V>ID5B>^:]AHH CL[.STZSBT_3[6."W@C6.""&,*D:*,*JJ.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?QAX_\&^
M+:&\\9>(;?3HKARD+W#$!V R0,#TK!_X:0^!G_13-,_[^-_A5[XG_"'P;\7K
M"UTWQE!</%9S&6$6\YC(8C!SCKQ7&?\ #%'P,_Z!^I?^#%O\*^1S:MQQ#'26
M6TJ$J.EG.4U+;6Z6F^WD<->68JH_91BX^;=SRCXT_M8?$FQ^)FIVOPO^(D3:
M$OD_83#I]O(O,,9?#/&6/S[^I_2CX+?M8?$F^^)FF6OQ0^(D2Z$WG?;C-I]O
M&O$,A3+)&&'S[.A_2JWQ2_8]^)%MX[OH/A?X*EN-"7ROL,TVJVX9OW2;\[Y%
M;[^\<CMZ4?"W]CWXD7/CNQ@^*'@J6WT)O-^W30ZK;EE_=/LQLD9OO[!P._I7
MX;S>*7^M7-RU[>VVO6]A\>U]O8^>W(?.WSCZY>TOB_O<N_\ Z3^A]"_\-(?
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M:3KGCF3QN;VT2VGC,4TEO8K%YN_8S; [D!L9Z9KY$^Q*O_!3+7?#.O\ P/\
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M/@!IGPU\1Z_#JVOS7=UJGB?5;="L=UJ5W,T\[(" =@9]BD@$J@) )(K"\5?
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M4]--B'C@O=--W+?-Y.<?\>]F3CL9EKV#2/VLO%7Q;^.7P2\#_"2XM$TGQAX
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M)[;5O&?[-5Y\0/%H RT)O/$#W*Q@'IY5HL$6WMY6..@]F_;(_87^+/QO\:^
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MVE?@;'HGC+Q7X5\#OX3\:Z'?-#HL?B"QD=)S+:F*,PVDBW*M($*;"K8R"/F
M///A8GQZ\!_\%$?BBOQN\3:/K^LZ3^S]#)I&OV&D_9$U2T6]E>.6:VWNL<@D
M\R-E4[#Y8( W8&CX+_;#^/WCWX&_L]?#'X4'PYIGC_XQZ3=WE]K]SH^ZPT*Q
MLX_,N)X[2-D#R'<BQH6";L[NN1T?PX^!O[7'C3]ISQ]^T3\;O!WA_0;;Q1\(
M_P#A&_#^A:9KWVR3376XD=8)I=B"1B6:5I%&P>:%&=I)PO#/[%O[17PM^#'[
M/WCWX>V&AW?Q(^"VEWECJ7AG4-4,5GK5E>1^7<VZW*HPCE4*C1N5VAL[N."
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M_P""<GP=\/+XT\/VGBGQ/XEO_"FF>,?&ESMTW3-.LKF9&OYB77S/*@6*-$+
M,VW).-K>Y^,]=_X*M_%GP[>?#[1/@Y\-?AU_:ML]M<>+)_&<^IRV$;C:\L$,
M4";I@I)3<=N[&:I_%7_@G1-X7^ 'PD\'?LY+HVH:[\%=2^VZ/8>+8?\ 0O$"
M3*POX9]JMY33L[2!L$*W' .Y0#"^#O[;FN^'OVF?"/P"US]L;P#\9](^(,%Y
M;V6N^%;.TM;_ ,/ZC!#YJ+-#;321R02@,$8@,'&"<#YNA\&?MU>-/"7[$?Q+
M^*'QL6RD^(7PIUC5?#^MVUK:^5#>ZI'-LL&CB!)$<_GVN",YRQ'I6K\(?AU^
MTYXR^/.@^._%W[//@/X0^#_#MK<-?Z-I;Z?J^I:_>2)MC(N([5?LD,1RV499
M&/!R&^3#^-G[!_Q#^(/[<ND_$W0-0L8OACKVI:1K_P 1]+DFQ-=ZOH\=RMCM
MCZ-')YEN)!W\@$YP!0!I^%OCK\9/!G[3_@'X7_'*YT>2XE^ UWXC\9WEOH\:
M31:A%<1"5(G'*PJ&<;!PVT$\US?PU^(/_!2#]I'X%+^U[\)?B'X1TE-5$U_X
M.^$MWX826._L4E=8H;K47G5XYYE7.Y-L:DKG:"=GJ7CW]G3Q=XT_;HT?XUWE
MC;2>$(OA-J7AK4R;H+,;BXNTD"A.I4QAOF[&O+/A[\,O^"BO[/WP%;]C/X6>
M O"VI6UA#<:9X1^+T_BP6_\ 9UA*[F.:XL/):1KF%'P!&2A95Z@'< 1_'7]N
MCQA>?M#K^S=!\?O _P "_P"P/"EAJOC+7O&#VE[='4+J,2)IEG'-*D,@C0[I
M)LM]Y=H'!;.\&_\ !1SXGK\#/CC::)JWA3XH^,?A%I]K>:+XF\')NT[Q#9W2
MY2Y>&&1]CV^V0SQH^/W>%(^]70^-_P!DKXW?"'X^_P##0GPZ^'?ASXS)XB\'
M:9HWCK1O%UW;V-_<7]C$(HM4MYI8GA4NF1)$0O/0G(V[_@#X+?ML2?"SXD>)
M['6?!'PS\:>)GMV^'_A[0-#LKFU\.108/E75R+4&[><[@[%76+=NC /RJ 8/
M[*WQ[^-GQ-^(/AG4_ O[;7PW^,OAK4XY/^$QT6VT6#1M3T-?*+)/;Q)*TKJ)
M"%9)D!VCKDY7Z[KXIN/V6?CK\>_C[\-OB=XM_9$\"_"'4?!/BRWUSQ+XX\/^
M(X+J^UU(58-8Q);PHQAF9AO,[$JF0,G(?[6H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647616864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 08, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-15317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ResMed Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0152841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9001 Spectrum Center Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">836-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.004 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,771,141,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,424,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000943819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647605584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854648495936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 273,710<span></span>
</td>
<td class="nump">$ 295,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowances of $23,259 and $32,138 &#8206;at June&#160;30, 2022 and June&#160;30, 2021, respectively</a></td>
<td class="nump">575,950<span></span>
</td>
<td class="nump">614,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (note 4)</a></td>
<td class="nump">743,910<span></span>
</td>
<td class="nump">457,033<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets (note 4)</a></td>
<td class="nump">337,908<span></span>
</td>
<td class="nump">208,154<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,931,478<span></span>
</td>
<td class="nump">1,574,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net (note 4)</a></td>
<td class="nump">498,181<span></span>
</td>
<td class="nump">463,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets (note 10)</a></td>
<td class="nump">132,314<span></span>
</td>
<td class="nump">128,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (note 5)</a></td>
<td class="nump">1,936,442<span></span>
</td>
<td class="nump">1,927,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Other intangible assets, net (note 5)</a></td>
<td class="nump">345,944<span></span>
</td>
<td class="nump">392,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Deferred income taxes (note 13)</a></td>
<td class="nump">79,746<span></span>
</td>
<td class="nump">79,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Prepaid taxes and other non-current assets</a></td>
<td class="nump">171,748<span></span>
</td>
<td class="nump">160,916<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">3,164,375<span></span>
</td>
<td class="nump">3,153,368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,095,853<span></span>
</td>
<td class="nump">4,728,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">159,245<span></span>
</td>
<td class="nump">138,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses (note 7)</a></td>
<td class="nump">344,722<span></span>
</td>
<td class="nump">320,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current (note 10)</a></td>
<td class="nump">21,856<span></span>
</td>
<td class="nump">23,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">108,667<span></span>
</td>
<td class="nump">109,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable (note 13)</a></td>
<td class="nump">44,893<span></span>
</td>
<td class="nump">307,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt, net (note 9)</a></td>
<td class="nump">9,916<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">689,299<span></span>
</td>
<td class="nump">911,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">95,455<span></span>
</td>
<td class="nump">91,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent', window );">Deferred income taxes (note 13)</a></td>
<td class="nump">9,714<span></span>
</td>
<td class="nump">11,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current (note 10)</a></td>
<td class="nump">120,453<span></span>
</td>
<td class="nump">114,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">5,974<span></span>
</td>
<td class="nump">6,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net (note 9)</a></td>
<td class="nump">765,325<span></span>
</td>
<td class="nump">643,351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term income taxes payable (note 13)</a></td>
<td class="nump">48,882<span></span>
</td>
<td class="nump">62,933<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">1,045,803<span></span>
</td>
<td class="nump">930,680<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,735,102<span></span>
</td>
<td class="nump">1,842,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (note 16)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.004 par value, 350,000,000 shares authorized; &#8206;188,246,955 issued and 146,410,721 outstanding at June&#160;30, 2022 and &#8206;187,484,592 issued and 145,648,358 outstanding at June&#160;30, 2021</a></td>
<td class="nump">586<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,682,432<span></span>
</td>
<td class="nump">1,622,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">3,613,736<span></span>
</td>
<td class="nump">3,079,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, at cost, 41,836,234 shares at June&#160;30, 2022 and June&#160;30, 2021</a></td>
<td class="num">(1,623,256)<span></span>
</td>
<td class="num">(1,623,256)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(312,747)<span></span>
</td>
<td class="num">(193,487)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">3,360,751<span></span>
</td>
<td class="nump">2,885,679<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 5,095,853<span></span>
</td>
<td class="nump">$ 4,728,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854745213872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for credit loss, current</a></td>
<td class="nump">$ 23,259<span></span>
</td>
<td class="nump">$ 32,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock at par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.004<span></span>
</td>
<td class="nump">$ 0.004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (shares)</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (shares)</a></td>
<td class="nump">188,246,955<span></span>
</td>
<td class="nump">187,484,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (shares)</a></td>
<td class="nump">146,410,721<span></span>
</td>
<td class="nump">145,648,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock (shares)</a></td>
<td class="nump">41,836,234<span></span>
</td>
<td class="nump">41,836,234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647848176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 3,578,127<span></span>
</td>
<td class="nump">$ 3,196,825<span></span>
</td>
<td class="nump">$ 2,957,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of sales (exclusive of amortization shown separately below)</a></td>
<td class="nump">1,514,166<span></span>
</td>
<td class="nump">1,312,598<span></span>
</td>
<td class="nump">1,189,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">39,650<span></span>
</td>
<td class="nump">45,127<span></span>
</td>
<td class="nump">49,603<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Total cost of sales</a></td>
<td class="nump">1,553,816<span></span>
</td>
<td class="nump">1,357,725<span></span>
</td>
<td class="nump">1,239,227<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">2,024,311<span></span>
</td>
<td class="nump">1,839,100<span></span>
</td>
<td class="nump">1,717,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">739,372<span></span>
</td>
<td class="nump">670,387<span></span>
</td>
<td class="nump">676,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">253,575<span></span>
</td>
<td class="nump">225,284<span></span>
</td>
<td class="nump">201,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_AmortizationOfAcquiredIntangibleAssets1', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">31,078<span></span>
</td>
<td class="nump">31,078<span></span>
</td>
<td class="nump">30,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses (note 17)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,673<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,024,025<span></span>
</td>
<td class="nump">935,422<span></span>
</td>
<td class="nump">908,127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">1,000,286<span></span>
</td>
<td class="nump">903,678<span></span>
</td>
<td class="nump">809,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (loss), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (expense) income, net</a></td>
<td class="num">(22,312)<span></span>
</td>
<td class="num">(23,627)<span></span>
</td>
<td class="num">(39,356)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments (note 6)</a></td>
<td class="num">(8,486)<span></span>
</td>
<td class="num">(11,205)<span></span>
</td>
<td class="num">(25,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Gain (loss) on equity investments (note 6)</a></td>
<td class="num">(12,202)<span></span>
</td>
<td class="nump">14,515<span></span>
</td>
<td class="num">(14,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">3,197<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (loss), net</a></td>
<td class="num">(39,803)<span></span>
</td>
<td class="num">(20,016)<span></span>
</td>
<td class="num">(76,571)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">960,483<span></span>
</td>
<td class="nump">883,662<span></span>
</td>
<td class="nump">733,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes (note 13)</a></td>
<td class="nump">181,046<span></span>
</td>
<td class="nump">409,157<span></span>
</td>
<td class="nump">111,414<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 779,437<span></span>
</td>
<td class="nump">$ 474,505<span></span>
</td>
<td class="nump">$ 621,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (note 12) (usd per share)</a></td>
<td class="nump">$ 5.34<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="nump">$ 4.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (note 12) (usd per share)</a></td>
<td class="nump">5.30<span></span>
</td>
<td class="nump">3.24<span></span>
</td>
<td class="nump">4.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend declared per share (usd per share)</a></td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares outstanding (000's) (shares)</a></td>
<td class="nump">146,066<span></span>
</td>
<td class="nump">145,313<span></span>
</td>
<td class="nump">144,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares outstanding (000's) (shares)</a></td>
<td class="nump">147,043<span></span>
</td>
<td class="nump">146,451<span></span>
</td>
<td class="nump">145,652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rmd_SleepAndRespiratoryMember', window );">Sleep and Respiratory Care products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 3,177,298<span></span>
</td>
<td class="nump">$ 2,823,235<span></span>
</td>
<td class="nump">$ 2,602,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of sales (exclusive of amortization shown separately below)</a></td>
<td class="nump">1,365,421<span></span>
</td>
<td class="nump">1,177,309<span></span>
</td>
<td class="nump">1,067,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">4,105<span></span>
</td>
<td class="nump">4,895<span></span>
</td>
<td class="nump">8,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=rmd_SoftwareAsServiceMember', window );">Software as a Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">400,829<span></span>
</td>
<td class="nump">373,590<span></span>
</td>
<td class="nump">354,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of sales (exclusive of amortization shown separately below)</a></td>
<td class="nump">148,745<span></span>
</td>
<td class="nump">135,289<span></span>
</td>
<td class="nump">121,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">$ 35,545<span></span>
</td>
<td class="nump">$ 40,232<span></span>
</td>
<td class="nump">$ 41,019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AmortizationOfAcquiredIntangibleAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AmortizationOfAcquiredIntangibleAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmd_SleepAndRespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmd_SleepAndRespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=rmd_SoftwareAsServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=rmd_SoftwareAsServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854650861904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 779,437<span></span>
</td>
<td class="nump">$ 474,505<span></span>
</td>
<td class="nump">$ 621,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation (loss) gain adjustments</a></td>
<td class="num">(119,260)<span></span>
</td>
<td class="nump">90,495<span></span>
</td>
<td class="num">(30,973)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 660,177<span></span>
</td>
<td class="nump">$ 565,000<span></span>
</td>
<td class="nump">$ 590,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854644764240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative effect adjustment from adoption of the credit loss standard, net of tax</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional &#8206;Paid-in Capital</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Cumulative effect adjustment from adoption of the credit loss standard, net of tax</div>
</th>
<th class="th"><div>Accumulated &#8206;Other &#8206;Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, beginning balance (shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,491,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2019</a></td>
<td class="nump">$ 2,072,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">$ 1,511,473<span></span>
</td>
<td class="num">$ (1,623,256)<span></span>
</td>
<td class="nump">$ 2,436,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (253,009)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, beginning balance (shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,836,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued on exercise of options (note 11), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued on exercise of options (note 11)</a></td>
<td class="nump">19,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">19,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11)</a></td>
<td class="num">$ (46,058)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(46,061)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued on employee stock purchase plan (note 11), shares</a></td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued on employee stock purchase plan (note 11)</a></td>
<td class="nump">$ 28,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">28,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation costs</a></td>
<td class="nump">57,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(30,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,973)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">621,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">621,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(225,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(225,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">$ 2,497,027<span></span>
</td>
<td class="num">$ (1,143)<span></span>
</td>
<td class="nump">$ 580<span></span>
</td>
<td class="nump">1,570,694<span></span>
</td>
<td class="num">$ (1,623,256)<span></span>
</td>
<td class="nump">2,832,991<span></span>
</td>
<td class="num">$ (1,143)<span></span>
</td>
<td class="num">(283,982)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, ending balance (shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,836,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible Enumeration]</a></td>
<td class="text">Accounting Standards Update 2016-13 [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued on exercise of options (note 11), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued on exercise of options (note 11)</a></td>
<td class="nump">$ 3,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11)</a></td>
<td class="num">$ (50,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(50,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued on employee stock purchase plan (note 11), shares</a></td>
<td class="nump">229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued on employee stock purchase plan (note 11)</a></td>
<td class="nump">$ 33,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">33,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation costs</a></td>
<td class="nump">63,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">90,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">474,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">474,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (226,713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(226,713)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (shares) at Jun. 30, 2021</a></td>
<td class="nump">145,648,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 2,885,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 583<span></span>
</td>
<td class="nump">1,622,199<span></span>
</td>
<td class="num">$ (1,623,256)<span></span>
</td>
<td class="nump">3,079,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193,487)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, ending balance (shares) at Jun. 30, 2021</a></td>
<td class="num">(41,836,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,836,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued on exercise of options (note 11), shares</a></td>
<td class="nump">177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued on exercise of options (note 11)</a></td>
<td class="nump">$ 11,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11), shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11)</a></td>
<td class="num">$ (52,406)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(52,408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock issued on employee stock purchase plan (note 11), shares</a></td>
<td class="nump">216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Common stock issued on employee stock purchase plan (note 11)</a></td>
<td class="nump">$ 36,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">36,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation costs</a></td>
<td class="nump">65,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(119,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(119,260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">779,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">779,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">$ (245,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(245,341)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding, ending balance (shares) at Jun. 30, 2022</a></td>
<td class="nump">146,410,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 3,360,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
<td class="nump">$ 1,682,432<span></span>
</td>
<td class="num">$ (1,623,256)<span></span>
</td>
<td class="nump">$ 3,613,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (312,747)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, common, ending balance (shares) at Jun. 30, 2022</a></td>
<td class="num">(41,836,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,836,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092918&amp;loc=SL128093175-196984<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 32: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL122642865-165497<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL120254526-165497<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 832<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128342835&amp;loc=SL128342857-244232<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647622864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements Of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 779,437<span></span>
</td>
<td class="nump">$ 474,505<span></span>
</td>
<td class="nump">$ 621,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">159,609<span></span>
</td>
<td class="nump">156,758<span></span>
</td>
<td class="nump">154,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">34,232<span></span>
</td>
<td class="nump">34,760<span></span>
</td>
<td class="nump">26,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation costs (note 11)</a></td>
<td class="nump">65,257<span></span>
</td>
<td class="nump">63,927<span></span>
</td>
<td class="nump">57,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments (note 6)</a></td>
<td class="nump">8,486<span></span>
</td>
<td class="nump">11,205<span></span>
</td>
<td class="nump">25,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount', window );">(Gain) loss on equity investments (note 6)</a></td>
<td class="nump">12,202<span></span>
</td>
<td class="num">(14,515)<span></span>
</td>
<td class="nump">14,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses (note 17)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,673<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of business combination contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">19,346<span></span>
</td>
<td class="num">(129,195)<span></span>
</td>
<td class="nump">54,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(311,681)<span></span>
</td>
<td class="num">(21,954)<span></span>
</td>
<td class="num">(69,881)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, net deferred income taxes and other current assets</a></td>
<td class="num">(168,109)<span></span>
</td>
<td class="num">(58,154)<span></span>
</td>
<td class="num">(58,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other</a></td>
<td class="num">(247,632)<span></span>
</td>
<td class="nump">210,708<span></span>
</td>
<td class="num">(23,424)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">351,147<span></span>
</td>
<td class="nump">736,718<span></span>
</td>
<td class="nump">802,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(134,835)<span></span>
</td>
<td class="num">(102,712)<span></span>
</td>
<td class="num">(95,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent registration costs</a></td>
<td class="num">(21,201)<span></span>
</td>
<td class="num">(14,114)<span></span>
</td>
<td class="num">(10,608)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Business acquisitions, net of cash acquired</a></td>
<td class="num">(42,784)<span></span>
</td>
<td class="num">(39,067)<span></span>
</td>
<td class="num">(27,910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments (note 6)</a></td>
<td class="num">(20,724)<span></span>
</td>
<td class="num">(21,788)<span></span>
</td>
<td class="num">(31,616)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sale of investment (note 6)</a></td>
<td class="nump">6,802<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities', window );">(Payments) / proceeds on maturity of foreign currency contracts</a></td>
<td class="num">(17,176)<span></span>
</td>
<td class="nump">19,219<span></span>
</td>
<td class="num">(14,397)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(229,918)<span></span>
</td>
<td class="num">(158,462)<span></span>
</td>
<td class="num">(179,861)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">47,384<span></span>
</td>
<td class="nump">37,790<span></span>
</td>
<td class="nump">48,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(52,406)<span></span>
</td>
<td class="num">(50,209)<span></span>
</td>
<td class="num">(46,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Payments of business combination contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,500)<span></span>
</td>
<td class="num">(302)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings, net of borrowing costs</a></td>
<td class="nump">288,000<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">1,190,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings</a></td>
<td class="num">(166,000)<span></span>
</td>
<td class="num">(612,000)<span></span>
</td>
<td class="num">(1,284,012)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(245,341)<span></span>
</td>
<td class="num">(226,713)<span></span>
</td>
<td class="num">(225,093)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(128,363)<span></span>
</td>
<td class="num">(764,632)<span></span>
</td>
<td class="num">(317,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash</a></td>
<td class="num">(14,434)<span></span>
</td>
<td class="nump">18,498<span></span>
</td>
<td class="nump">10,920<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(21,568)<span></span>
</td>
<td class="num">(167,878)<span></span>
</td>
<td class="nump">316,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">295,278<span></span>
</td>
<td class="nump">463,156<span></span>
</td>
<td class="nump">147,128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">273,710<span></span>
</td>
<td class="nump">295,278<span></span>
</td>
<td class="nump">463,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid, net of refunds</a></td>
<td class="nump">478,120<span></span>
</td>
<td class="nump">221,359<span></span>
</td>
<td class="nump">180,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">22,312<span></span>
</td>
<td class="nump">23,989<span></span>
</td>
<td class="nump">40,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired', window );">Fair value of assets acquired, excluding cash</a></td>
<td class="nump">15,648<span></span>
</td>
<td class="nump">16,671<span></span>
</td>
<td class="nump">14,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Liabilities assumed</a></td>
<td class="num">(4,672)<span></span>
</td>
<td class="num">(1,543)<span></span>
</td>
<td class="num">(4,292)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease', window );">Goodwill on acquisition</a></td>
<td class="nump">38,953<span></span>
</td>
<td class="nump">24,671<span></span>
</td>
<td class="nump">20,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination', window );">Previously held equity interest</a></td>
<td class="num">(4,078)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DeferredPaymentObligationsForAcquisitions', window );">Deferred payments</a></td>
<td class="num">(3,067)<span></span>
</td>
<td class="nump">3,768<span></span>
</td>
<td class="nump">408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability', window );">Fair value of contingent consideration</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash paid for acquisitions</a></td>
<td class="nump">$ 42,784<span></span>
</td>
<td class="nump">$ 43,567<span></span>
</td>
<td class="nump">$ 27,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Contingent Consideration, Recognized Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DeferredPaymentObligationsForAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Payment Obligations For Acquisitions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DeferredPaymentObligationsForAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill, Acquired During Period, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Equity Interest in Acquiree Held Prior to Combination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of an asset or business acquired in a noncash acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow from derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854734257632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, dividends per share, cash paid (usd per share)</a></td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854735178464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization And Basis Of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization And Basis Of Presentation</a></td>
<td class="text">Organization and Basis of Presentation ResMed Inc. (referred to herein as &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221; or the &#8220;Company&#8221;) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (&#8220;SaaS&#8221;) business in the United States that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653861232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary Of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Basis of Consolidation </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Certain prior period amounts have been reclassified to conform to the current period presentation. Actual results could differ from management&#8217;s estimates.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Revenue Recognition </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standard Codification (&#8220;ASC&#8221;) Topic 606, &#8220;Revenue from Contracts with Customers&#8221;, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#8220;Sleep and Respiratory Care&#8221;) and the supply of business management software as a service to out-of-hospital health providers (&#8220;SaaS&#8221;). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 14 &#8211; Segment Information for our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2022, 2021 and 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance obligations and contract balances</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with professional services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances as of June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">614,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (current liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95,455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(91,496)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (non-current liabilities)</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction price determination</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns offered to our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty-related returns, are infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#8217;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates on a quarterly basis based on actual sales results and updated forecasts for the remaining rebate periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting and practical expedient elections</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have adopted two practical expedients including the &#8220;right to invoice&#8221; practical expedient, which allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date and which is relevant for some of our SaaS contracts. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Concentration of Credit Risk and Significant Customers</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, derivatives and trade receivables. Our cash and cash equivalents are generally held with large, diverse financial institutions to reduce the amount of exposure to any single financial institution. Our derivative contracts are transacted with various financial institutions with high credit standings and any exposure to counterparty credit-related losses in these contracts is largely mitigated with collateralization and master-netting agreements. The risk with respect to trade receivables is mitigated by credit evaluations we perform on our customers, the short duration of our payment terms for the significant majority of our customer contracts and by the diversification of our customer base. No single customer accounted for 10% or more of our total revenues for any of the periods presented.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"> Fair Value of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We measure our financial instruments at fair value at each reporting period using a fair value hierarchy that requires that we maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Other inputs that are directly or indirectly observable in the marketplace.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt related to our Revolving Credit and Term Credit Agreements approximates its fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates which are regularly reset. The carrying value of long-term debt related to our Senior Notes can differ to its fair value as the principal amounts outstanding are subject to fixed interest rates as outlined in Note 9 - Debt. Foreign currency hedging instruments are marked to market and therefore reflect their fair value. In addition, we measure investments in publicly held equity securities and privately held equity securities for which there has been an observable price change in an identical or similar security, at fair value. We do not hold or issue financial instruments for trading purposes. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Cash and Cash Equivalents </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include certificates of deposit and other highly liquid investments and we state them at cost, which approximates market. We consider investments with original maturities of 90 days or less to be cash equivalents for purposes of the consolidated statements of cash flows.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt">Inventories </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We state inventories at the lower of cost (determined principally by the first-in, first-out method) or net realizable value. We include material, labor and manufacturing overhead costs in finished goods and work-in-process inventories. We review and provide for any product obsolescence in our manufacturing and distribution operations by assessing throughout the year individual products and components (based on estimated future usage and sales).</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Property, Plant and Equipment </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record property, plant and equipment, including rental and demonstration equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally two years to ten years except for buildings which are depreciated over an estimated useful life of forty years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for property, plant, and equipment was $81.0 million, $78.4 million, and $65.6 million for the years ended June&#160;30, 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Intangible Assets </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We capitalize the registration costs for new patents and amortize the costs over the estimated useful life of the patent, which is generally ten years. If a patent is superseded or a product is retired, any unamortized costs are written off immediately.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We amortize all of our other intangible assets on a straight-line basis over their estimated useful lives, which range from two years to fifteen years. We take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists and, at least annually, evaluate the recoverability of intangible assets. We have not identified any impairment of intangible assets during any of the periods presented. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt">Goodwill </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our annual review for goodwill impairment during the final quarter of the fiscal year. Our goodwill impairment review is performed at our reporting unit level, which is one level below our operating segments and involves the following steps: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 0 or Qualitative assessment &#8211; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 1 &#8211; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#8217;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the annual reviews for the years ended June&#160;30, 2022, 2021 and 2020, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt">Equity investments </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our accounting for investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the consolidated statements of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments whereby we have significant influence but not control over the investee, and are not the primary beneficiary of the investee&#8217;s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the consolidated statements of operations. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Research and Development </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record all research and development expenses in the period we incur them.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(l)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt">Foreign Currency </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of our non-U.S. subsidiaries, whose functional currencies are other than the U.S. dollar, are translated into U.S. dollars for financial reporting purposes. We translate assets and liabilities of non-U.S. subsidiaries whose functional currencies are other than the U.S. dollar at period end exchange rates, but translate revenue and expense transactions at average exchange rates for the period. We recognize cumulative translation adjustments as part of comprehensive income, as detailed in the consolidated statements of comprehensive income, and include those adjustments in accumulated other comprehensive income in the consolidated balance sheets until such time the relevant subsidiary is sold or substantially or completely liquidated. We reflect gains and losses on transactions denominated in other than the functional currency of an entity in our results of operations.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(m)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.01pt">Foreign Exchange Risk Management </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our consolidated statements of income and through changes in our operating assets and liabilities within our consolidated statements of cash flows. We classify purchases of foreign currency derivatives and proceeds received from the exercise of foreign currency derivatives as an investing activity within our consolidated statements of cash flows. We do not enter into financial instruments for trading or speculative purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held foreign currency instruments with notional amounts totaling $602.0 million and $556.4 million at June&#160;30, 2022 and June&#160;30, 2021, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to June&#160;30, 2024. </span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(n)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Income Taxes </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using the enacted tax rates we expect to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions are reflected in income tax expense.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(o)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Provision for Warranty</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(p)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Allowance for Credit Losses</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses on customer receivables based on our historical write-off experience, an assessment of our customers&#8217; financial conditions and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions. Customer receivables are charged against the allowance when they are deemed uncollectible. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also contingently liable, within certain limits, in the event of a customer default, to independent financing companies in connection with customer financing programs. We monitor the collection status of these installment receivables and provide for estimated losses separately under accrued expenses within our consolidated balance sheets based upon our historical collection experience with such receivables and a current assessment of our credit exposure.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(q)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Impairment of Long-Lived Assets </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, we recognize as the impairment the amount by which the carrying amount of the assets exceeds the fair value of the assets. We report assets to be disposed of at the lower of the carrying amount or fair value less costs to sell. We did not recognize impairment charges in relation to long-lived assets during the fiscal years ended June&#160;30, 2022, 2021 and 2020.</span></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(r)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Contingencies</span></div>We record a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653648688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text">New Accounting Pronouncements <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ASU No. 2021-08 &#8220;Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, &#8220;Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221; (Topic 805), which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The guidance is effective for us beginning in the first quarter of the year ending June 30, 2024 and early adoption is permitted. We elected to early adopt this standard in the second quarter of our fiscal year ending June 30, 2022. Adoption of ASU 2021-08 did not have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653941408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SupplementalBalanceSheetInformationTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text">Supplemental Balance Sheet Information<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in the consolidated balance sheets consisted of the following as of June&#160;30, 2022 and June&#160;30, 2021 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventories</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">355,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457,033&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vehicles and aircraft</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical, demonstration and rental equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,085,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(633,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(622,139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498,181&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SupplementalBalanceSheetInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SupplementalBalanceSheetInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653783424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets, net</a></td>
<td class="text">Goodwill and Other Intangible Assets, net<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the years ended June&#160;30, 2022 and June&#160;30, 2021, we have not recorded any goodwill impairments. Changes in the carrying amount of goodwill is comprised of the following for the year ended June&#160;30, 2022 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sleep and <br/>Respiratory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SaaS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,294,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,927,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">641,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,294,718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,936,442&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangibles, net are comprised of the following as of June&#160;30, 2022 and June&#160;30, 2021 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(239,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(239,049)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257,034&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(91,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(90,976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,727&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(131,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other intangibles, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, and we amortize them over the estimated useful life of the assets, generally between two years and fifteen years. There are no expected residual values related to these intangible assets. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense related to identified intangible assets for the years ended June&#160;30, 2022 and June&#160;30, 2021 was $70.7 million and $76.2 million, respectively. Amortization expense related to patents for the years ended June&#160;30, 2022 and June&#160;30, 2021 was $6.2 million and $5.3 million, respectively. Total estimated annual amortization expense for the years ending June 30, 2023 through June 30, 2027, is shown below (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June&#160;30</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854650860400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments by measurement category as of June&#160;30, 2022 and June&#160;30, 2021 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement alternative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,240&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2022 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net additions (reductions) to investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains on marketable and non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,290&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Net additions (reductions) to investments includes additions from purchases, reductions due to exits of securities, or reclassifications due to our acquisition of an investee in which we held a prior equity interest. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2021(in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">During the year ended June&#160;30, 2021, one of our investments, which was previously accounted for under the measurement alternative, completed its initial public offering which resulted in a change of accounting methodology to fair value. </span></div>Net unrealized gains and losses recognized in the years ended June&#160;30, 2022, 2021 and 2020 for equity investments in non-marketable and marketable securities still held as of those respective dates were a loss of $16.2 million, a gain of $14.5 million, and a loss of $14.5 million, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI https://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI https://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI https://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653725200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses at June&#160;30, 2022 and June&#160;30, 2021 consist of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product warranties (note 8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting and professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value added taxes and other taxes due</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promotional and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Logistics and occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory in transit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344,722&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653843312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Warranties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantiesDisclosuresAbstract', window );"><strong>Product Warranties Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyDisclosureTextBlock', window );">Product Warranties</a></td>
<td class="text">Product Warranties<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We include the liability for warranty costs in accrued expenses in our consolidated balance sheets. Changes in the liability for product warranty for the years ended June&#160;30, 2022 and June&#160;30, 2021 are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warranty accruals for the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warranty costs incurred for the period </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,461)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantiesDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantiesDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -URI https://asc.fasb.org/topic&amp;trid=2155896<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653919072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at June&#160;30, 2022 and June&#160;30, 2021 consists of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">770,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,675)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,649)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">765,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">775,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">655,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;29, 2022, we entered into a second amended and restated credit agreement (the &#8220;Revolving Credit Agreement&#8221;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, and Wells Fargo Bank, National Association, as documentation agent. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $1,500.0 million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $1,000.0 million and 1.00 times the EBITDA (as defined in the Revolving Credit Agreement) for the trailing twelve-month measurement period. The Revolving Credit Facility amends and restates that certain Amended and Restated Credit Agreement, dated as of April 17, 2018, among ResMed, MUFG Union Bank, N.A., Westpac Banking Corporation and the lenders party thereto which provided ResMed with a senior unsecured revolving credit facility in an aggregate amount of $1,600.0 million with an uncommitted option to increase such facility by an additional $300.0 million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on June&#160;29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement (the &#8220;Term Credit Agreement&#8221;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner, which amends that certain Syndicated Facility Agreement dated as of April 17, 2018. The Term Credit Agreement, among other things, provides ResMed Pty a senior unsecured term credit facility of $200.0 million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Pty Limited&#8217;s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Revolving Credit Agreement and Term Credit Agreement each terminate on June&#160;29, 2027, when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a $5.0 million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to the Adjusted Term SOFR (as defined in the Revolving Credit Facility) plus 0.75% to 1.50% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus 0.0% to 0.50% (depending on the then-applicable leverage ratio). At June&#160;30, 2022, the interest rate that was being charged on the outstanding principal amounts was 3.00%. An applicable commitment fee of 0.075% to 0.150% (depending on the then-applicable leverage ratio) applies </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the unused portion of the revolving credit facility. As of June&#160;30, 2022, we had $1.4 billion available for draw down under the revolving credit facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As the Revolving Credit and Term Credit Agreements&#8217; interest rate is calculated as Adjusted Term SOFR plus the spreads described above, its carrying amount is equivalent to its fair value as at June&#160;30, 2022 and June&#160;30, 2021, which was $280.0 million and $158.0 million, respectively. Quoted market prices in active markets for identical liabilities based inputs (Level 2) were used to estimate fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July&#160;10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July&#160;10, 2029 (collectively referred to as the &#8220;Senior Notes&#8221;). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA (as defined in the Note Purchase Agreement) of no more than 3.50 to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed 10.0% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter. This ratio is calculated at the end of each reporting period for which the Note Purchase Agreement requires us to deliver financial statements, using the results of the 12 consecutive month period ending with such reporting period.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of June&#160;30, 2022, the Senior Notes have a carrying amount of $500.0 million, excluding deferred borrowing costs, and an estimated fair value of $477.7 million. Quoted market prices in active markets for identical liabilities based inputs (Level 2) were used to estimate fair value.</span></div>At June&#160;30, 2022, we were in compliance with our debt covenants and there was $780.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854650746080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Leases where ResMed is the Lessee</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether a contract is, or contains, a lease at inception. ROU assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the lease term as the non-cancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 14 years, some of which include options to extend or terminate the leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs for the years ended June&#160;30, 2022, 2021 and 2020 were $35.3 million, $35.5 million and $26.5 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2022, 2021 and 2020. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancellable operating leases as of June&#160;30, 2022 are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had additional operating lease commitments of $0.7 million for office space that have not yet commenced. These leases will commence during the year ended June 30, 2023 with lease terms of 1 year to 5 years.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental information related to operating leases for the years ended June&#160;30, 2022 and June&#160;30, 2021 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average inputs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Leases where ResMed is the Lessor</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease sleep and respiratory medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts include sales-type and operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease revenue for the years ended June&#160;30, 2022, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment in sales-type leases were classified in the consolidated balance sheets as of June&#160;30, 2022 and June&#160;30, 2021 as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of sales-type leases as of June&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Leases where ResMed is the Lessee</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether a contract is, or contains, a lease at inception. ROU assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the lease term as the non-cancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 14 years, some of which include options to extend or terminate the leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs for the years ended June&#160;30, 2022, 2021 and 2020 were $35.3 million, $35.5 million and $26.5 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2022, 2021 and 2020. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancellable operating leases as of June&#160;30, 2022 are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had additional operating lease commitments of $0.7 million for office space that have not yet commenced. These leases will commence during the year ended June 30, 2023 with lease terms of 1 year to 5 years.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental information related to operating leases for the years ended June&#160;30, 2022 and June&#160;30, 2021 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average inputs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Leases where ResMed is the Lessor</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease sleep and respiratory medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts include sales-type and operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease revenue for the years ended June&#160;30, 2022, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment in sales-type leases were classified in the consolidated balance sheets as of June&#160;30, 2022 and June&#160;30, 2021 as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of sales-type leases as of June&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorSalesTypeLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Leases where ResMed is the Lessee</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine whether a contract is, or contains, a lease at inception. ROU assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the lease term as the non-cancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 14 years, some of which include options to extend or terminate the leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs for the years ended June&#160;30, 2022, 2021 and 2020 were $35.3 million, $35.5 million and $26.5 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2022, 2021 and 2020. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancellable operating leases as of June&#160;30, 2022 are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had additional operating lease commitments of $0.7 million for office space that have not yet commenced. These leases will commence during the year ended June 30, 2023 with lease terms of 1 year to 5 years.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental information related to operating leases for the years ended June&#160;30, 2022 and June&#160;30, 2021 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average inputs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Leases where ResMed is the Lessor</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease sleep and respiratory medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts include sales-type and operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease revenue for the years ended June&#160;30, 2022, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment in sales-type leases were classified in the consolidated balance sheets as of June&#160;30, 2022 and June&#160;30, 2021 as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of sales-type leases as of June&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorSalesTypeLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of lessor's sales-type leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888252<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorSalesTypeLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888252<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653698304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On February&#160;21, 2014, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. The 20.0 million shares the program authorizes us to purchase are in addition to the shares we repurchased on or before February&#160;21, 2014 under our previous programs. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases since February&#160;21, 2014 have been executed in accordance with this program. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have temporarily suspended our repurchase program and, accordingly, did not repurchase any shares during fiscal years 2022 or 2021. As of June&#160;30, 2022, we have repurchased a total of 41.8 million shares at a cost of $1.6 billion. Shares that are repurchased are classified as &#8220;treasury stock pending future use&#8221; and reduce the number of shares outstanding used in calculating earnings per share. At June&#160;30, 2022, 12.9 million additional shares can be repurchased under the approved share repurchase program.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In April 1997, our board of directors authorized 2.0 million shares of 0.01 par value preferred stock. No such shares were issued or outstanding at June&#160;30, 2022. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options and Restricted Stock Units.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have granted stock options, restricted stock units (&#8220;RSUs&#8221;) and performance restricted stock units (&#8220;PRSUs&#8221;) to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the &#8220;2009 Plan&#8221;). Options and restricted stock units vest over one year to four years and the options have expiration dates of seven years from the date of grant. We have granted the options with an exercise price equal to the market value as determined at the date of grant. We have granted PRSUs that are subject to a market condition, with the ultimate realizable number of PRSUs dependent on relative total stockholder return over a period of three years, up to a maximum amount to be issued under the award of 225% of the original grant.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the annual meeting of our stockholders in November 2017, our stockholders approved an amendment and restatement to the 2009 Plan to increase the number of shares of common stock that may be issued or transferred pursuant to awards under the 2009 Plan by 7.4 million. The amendment and restatement imposes a maximum award amount which may be granted under the 2009 Plan to non-employee director in a calendar year, which when taken together with any other cash fees earned for services as a non-employee director during the calendar year, has a total value of $0.7 million, or $1.2 million in the case of a non-employee director who is also serving as chairman of our board of directors. The amendment and restatement also increased the maximum amount payable pursuant to cash-denominated performance awards granted in any calendar year from $3.0 million to $5.0 million. In addition, the amendment and restatement extended the existing prohibition on the payment of dividends or dividend equivalents on unvested awards to apply to all awards, including time-based restricted stock, deferred stock and stock payment. The term of the 2009 Plan was extended by four years so that the plan expires on September&#160;11, 2027.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 51.1 million. The number of securities remaining available for future issuance under the 2009 Plan at June&#160;30, 2022 is 15.3 million. The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any &#8220;full-value award,&#8221; which is any award other than a stock option, stock appreciation right or other award for which the holder pays a purchase price and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, which may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant&#8217;s initial year of hiring up to 4.5 million shares of our common stock may be granted). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain regions, shares are withheld on behalf of employees to satisfy statutory tax withholding requirements upon exercise or vesting of awards. The number of shares withheld is based upon the closing price of our common stock on the trading day of the applicable settlement date. The remaining shares are delivered to the recipient as shares of our common stock. The amount remitted to the tax authorities for the employees&#8217; tax obligation is reflected as a financing activity on our consolidated statements of cash flows. Shares withheld by us as a result of the net settlement are not considered issued and outstanding and are added to the reserves of the 2009 Plan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of RSUs and PRSUs that vested during the years ended June&#160;30, 2022, 2021 and 2020, was $65.5 million, $59.6 million and $56.8 million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of RSUs, including PRSUs, during year ended June&#160;30, 2022 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant-Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance factor adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.46&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6</span></td></tr></table></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt">Includes 206 thousand shares netted for tax.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity during the year ended June&#160;30, 2022 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the fiscal years 2022, 2021 and 2020, was $33.7 million, $8.9 million and $31.2 million, respectively. As at June&#160;30, 2022, the aggregate intrinsic value of options outstanding, exercisable, and vested and expected to vest were $93.5 million, $89.9 million and $93.4 million respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan (the &#8220;ESPP&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors&#8217; compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year. At June&#160;30, 2022, the number of shares remaining available for future issuance under the ESPP is 1.5 million shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During years ended June&#160;30, 2022, 2021 and 2020, we issued 216,000, 229,000 and 265,000 shares to our employees in two offerings and we recognized $11.0 million, $10.9 million and $8.0 million, respectively, of stock compensation expense associated with the ESPP.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock&#8211;based Employee compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the ESPP using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period. The fair value of performance restricted stock units is measured using a Monte-Carlo simulation valuation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the assumptions in the following tables. The risk-free interest rate is estimated using the U.S. Treasury yield curve and is based on the term of the award. The expected term of awards is estimated from the vesting period of the award, as well as historical exercise behavior, and represents the period of time the awards granted are expected to be outstanding. Expected volatility is estimated based upon the historical volatility of ResMed stock.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June&#160;30, 2022, 2021 and 2020: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$72.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$53.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$32.14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.37%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.58%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.07%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESPP purchase rights:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$50.46</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$48.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$31.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.63% - 0.98%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.79% - 0.98%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.98% - 1.42%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20% - 34%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30% - 60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23% - 60%</span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June&#160;30, 2022, 2021 and 2020 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,257&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,559&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs, net of tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,995&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,581&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>At June&#160;30, 2022, there was $104.0 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.2 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653757120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share We compute basic earnings per share by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock equivalents such as stock options and restricted stock units. The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were 67,000, 141,000 and 164,000 for the years ended June&#160;30, 2022, 2021 and 2020, respectively, as the effect would have been anti-dilutive. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share for the years ended June&#160;30, 2022, 2021 and 2020 are calculated as follows (in thousands except per share data): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">779,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted average shares </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653762976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes for the years ended June&#160;30, 2022, 2021 and 2020, was taxed under the following jurisdictions (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85,919)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,046,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">811,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">672,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">883,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733,088&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is presented below (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:28.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115,109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">531,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192,864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred: </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,612)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,791)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,541)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,818)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,587)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,876)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. federal income tax rate of 21% for the years ended June&#160;30, 2022, 2021 and 2020, to pretax income as a result of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes computed at statutory U.S. rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase (decrease) in income taxes resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of U.S. tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of non-U.S. tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,384)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,935)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,696)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Uncertain tax position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported net deferred tax assets and liabilities in our consolidated balance sheets at June&#160;30, 2022 and June&#160;30, 2021, as follows (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,319)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our deferred tax assets and liabilities at June&#160;30, 2022 and June&#160;30, 2021, are as follows (in thousands): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Employee liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">28,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">30,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Tax credit carry overs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">7,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">13,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">10,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">11,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">4,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">4,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for doubtful debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">5,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">7,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">27,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">33,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Capital loss carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">4,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">25,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">17,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Research and development capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">82,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">58,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">21,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">25,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(3,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(4,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">221,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">210,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(13,572)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(13,106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">207,946&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">197,781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Goodwill and other intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(108,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(104,563)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(20,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(23,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(9,491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(940)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(137,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(129,196)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">70,032&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">68,585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had $19.8 million of U.S. federal and state net operating loss carryforwards and $6.9 million of non-U.S. net operating loss carryforwards, which expire in various years beginning in 2023 or carry forward indefinitely. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowance at June&#160;30, 2022 relates to a provision for uncertainty of the utilization of net operating loss carryforwards of $0.8 million and capital loss and other items of $12.7 million. We believe that it is more likely than not that the benefits of deferred tax assets, net of any valuation allowance, will be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our manufacturing operations and administrative functions in Singapore operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2030. The end of certain tax holidays may be extended if specific conditions are met. The net impact of these tax holidays and tax incentive programs increased our net income by $38.0 million ($0.26 per diluted share) for the year ended June&#160;30, 2022, $33.6 million ($0.23 per diluted share) for the year ended June&#160;30, 2021, and $43.8 million ($0.30 per diluted share) for the year ended June&#160;30, 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Tax Cuts and Jobs Act of 2017 (the &#8221;U.S. Tax Act&#8221;), we have treated all non-U.S. historical earnings as taxable. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax if repatriated. The total amount of these undistributed earnings at June&#160;30, 2022 amounted to approximately $3.6 billion. On June 14, 2019, the U.S. Treasury Department issued final and temporary regulations relating to the repatriation of non-U.S. earnings. As a result, in the event our non-U.S. earnings had not been permanently reinvested, approximately $194.9&#160;million in U.S. federal deferred taxes and $5.2&#160;million in U.S. state deferred taxes would have been recognized in the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accounting for uncertainty in income taxes, we recognize a tax benefit in the financial statements for an uncertain tax position only if management&#8217;s assessment is that the position is &#8220;more likely than not&#8221; (that is, a likelihood greater than 50 percent) to be allowed by the tax jurisdiction based solely on the technical merits of the position. The term &#8220;tax position&#8221; refers to a position in a previously filed tax return or a position expected to be taken in a future tax return that is reflected in measuring current or deferred income tax assets and liabilities for annual periods. We recognize interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying consolidated statements of income. Accrued interest and penalties are included within the related tax liability line in the consolidated balance sheets. Based on all known facts and circumstances and current tax law, we believe the total amount of unrecognized tax benefits on June 30, 2022, is not material to our results of operations, financial condition or cash flows, and if recognized, would not have a material impact on our effective tax rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2021, we concluded the settlement agreement with the Australian Taxation Office (&#8220;ATO&#8221;) in relation to the previously disclosed transfer pricing dispute for the tax years 2009 through 2018 (&#8220;ATO settlement&#8221;). The ATO settlement fully resolved the dispute for all prior years, with no admission of liability and provides clarity in relation to certain future taxation principles.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final net impact of the ATO settlement was $238.7&#160;million, which represents a gross amount of $381.7&#160;million, including interest and penalties of $48.1&#160;million, and adjustments for credits and deductions of $143.0&#160;million. As a result of the ATO settlement and due to movements in foreign currencies, we recorded a benefit of $14.1&#160;million within other comprehensive income, and a $4.1&#160;million reduction of tax credits, which was recorded to income tax expense. As a result of the ATO settlement, we reversed our previously recorded uncertain tax position.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2021, we remitted final payment to the ATO of $284.8&#160;million, consisting of the agreed settlement amount of $381.7&#160;million less prior remittances made to the ATO of $96.9&#160;million.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax years 2018 to 2021 remain subject to future examination by the major tax jurisdictions in which we are subject to tax.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653723968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment. We evaluate the performance of our segments based on net sales and income from operations. The accounting policies of the segments are the same as those described in note 2 &#8211; Summary of Significant Accounting Policies. Segment net sales and segment income from operations do not include inter-segment profits and revenue is allocated to a geographic area based on where the products are shipped to or where the services are performed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate headquarters costs including stock-based compensation, amortization expense of acquired intangibles, restructuring expenses, litigation settlement expenses, deferred revenue fair value adjustment, net interest expense (income), loss attributable to equity method investments, gains and losses on equity investments, and other, net. We neither discretely allocate assets to our operating segments, nor does our Chief Operating Decision Maker evaluate the operating segments using discrete asset information.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a reconciliation of net revenues, depreciation and amortization and net operating profit by reportable segments for the years ended June&#160;30, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net revenue by segment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,177,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,602,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue fair value adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,196,825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,957,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation and amortization by segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets and corporate assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159,609&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156,758&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154,850&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net operating profit by segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,132,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">934,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,226,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,129,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,016,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciling items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue fair value adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">883,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733,088&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The deferred revenue fair value adjustment is a purchase price accounting adjustment related to MatrixCare which was acquired on November 13, 2018.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S., Canada and Latin America</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">863,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">841,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">779,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,981,807&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,705,113&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,572,327&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,382,636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,078,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,926,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Europe, Asia and other markets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">746,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">715,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,195,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,118,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,030,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,866,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,610,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,507,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,310,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,213,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,094,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,177,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823,235&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,602,381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,196,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,957,013&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue information by geographic area for the years ended June&#160;30, 2022, 2021 and 2020 is summarized below (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,249,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,962,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,234,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,128,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,196,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,957,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets of geographic areas are those assets used in our operations in each geographical area, and excludes goodwill, other intangible assets, and deferred tax assets. Long-lived assets by geographic area as of June&#160;30, 2022 and 2021 is summarized below (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653947504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Retirement Plans</a></td>
<td class="text">Employee Retirement Plans <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contribute to a number of employee retirement plans for the benefit of our employees. Details of the main plans are as follows: </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Australia </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contribute to defined contribution plans for each employee resident in Australia at the rate of approximately 10.0% of salaries. Employees may contribute additional funds to the plans. All Australian employees, after serving a qualifying period, are entitled to benefits on retirement, disability or death. Our total contributions to the plans for the years ended June&#160;30, 2022, 2021 and 2020, were $11.8 million, $10.7 million and $9.5 million, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">United States </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a defined contribution plan available to substantially all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of 4.0% of the employee&#8217;s salary. Our total contributions to the plan were $11.9 million, $9.6 million and $9.3 million in fiscal 2022, 2021 and 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Singapore </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor a defined contribution plan available to substantially all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of 17.0% of the employee&#8217;s salary. Our total contributions to the plan were $3.1 million, $2.5 million and $2.9 million in fiscal 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854650744464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Actions, Contingencies And Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Actions, Contingencies And Commitments</a></td>
<td class="text">Legal Actions, Contingencies and Commitments<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, New York University filed a complaint for patent infringement in the United States District Court, District of Delaware against ResMed Inc., case no. 1:21-cv-00813 (CFC). The complaint alleges that the AutoSet or AutoRamp features of ResMed&#8217;s AirSense 10 AutoSet flow generators infringe one or more claims of various NYU patents, including U.S. Patent Nos. 6,988,994; 9,108,009; 9,168,344; 9,427,539; 9,533,115; 9,867,955; and 10,384,024. According to the complaint, the NYU patents are directed to systems and methods for diagnosis and treating sleeping disorders during different sleep states. The complaint seeks monetary damages and attorneys&#8217; fees. ResMed answered the complaint on September 30, 2021 and filed a motion to dismiss the complaint on the basis that the patents are invalid because the subject matter of the patents is not patentable under the Supreme Court and Federal Circuit precedent. The motion to dismiss was granted in part and denied in part. The matter is proceeding to discovery. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2021, the International Trade Commission instituted In Re Certain UMTS and LTE Cellular Communications Modules and Products Containing the Same, Investigation No. 337-TA-1240, by complainants Philips RS North America, LLC and Koninklijke Philips N.V. (collectively &#8220;Philips&#8221;) against Quectel Wireless Solutions Co., Ltd; Thales DIS AIS USA, LLC, Thales DIS AIS Deutschland GmbH; Telit Wireless Solutions, Inc., Telit Communications PLC, CalAmp. Corp., Xirgo Technologies, LLC, and Laird Connectivity, Inc. (collectively &#8220;respondents&#8221;). In the ITC investigation, Philips seeks an order excluding communications modules, and products that contain them, from importation into the United States based on alleged infringement of 3G and 4G standard essential patents held by Philips. On October 6-14, 2021, the administrative law judge held a hearing on the merits. The administrative law judge issued an initial determination on April 1, 2022, finding no violation of any of the Philips patents asserted in the ITC. Philips sought review by the full International Trade Commission. On July 6, 2022, the Commission affirmed the administrative law judge&#8217;s determination that there was no violation of asserted Philips patents. The Commission terminated the ITC proceedings. Philips may appeal the ITC&#8217;s decision or return to the district court to pursue its civil case for damages and an injunction. On December 17, 2020, Philips filed companion cases for patent infringement against the same defendants in the United States District Court for the District of Delaware, case nos. 1:20-cv-01707, 01708, 01709, 01710, 01711, and 01713 (CFC) seeking damages, an injunction, and a declaration from the court on the amount of a fair reasonable and non-discriminatory license rate for the standard essential patents it is asserting against the communications module defendants. The district court cases have been stayed pending the resolution of the ITC proceedings. ResMed is not a party to the ITC investigation or the district court cases but sells products that incorporate some of the communications modules at issue in the cases. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, Cleveland Medical Devices Inc. filed suit for patent infringement against ResMed Inc. in the United States District Court for the District of Delaware, case no. 1:22-cv-00794. Cleveland Medical asserts that numerous ResMed connected devices, when combined with ResMed&#8217;s AirView and ResScan data platforms, infringe one or more of eight Cleveland Medical patents, including U.S. Patent Nos. 10,076,269; 10,426,399; 10,925,535; 11,064,937; 10,028,698; 10,478,118; 11,202,603; and 11,234,637. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on currently available information, we are unable to make a reasonable estimate of loss or range of losses, if any, arising from matters that remain open.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Obligations Under Recourse Provisions</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use independent financing institutions to offer some of our customers financing for the purchase of some of our products. Under these arrangements, if the customer qualifies under the financing institutions&#8217; credit criteria and finances the transaction, the customers repay the financing institution on a fixed payment plan. For some of these arrangements, the customer&#8217;s receivable balance is with limited recourse whereby we are responsible for repaying the financing company should the customer default. We record a contingent provision, which is estimated based on historical default rates. This is applied to receivables sold with recourse and is recorded in accrued expenses.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended June&#160;30, 2022 and 2021, receivables sold with limited recourse were $157.6 million and $153.0 million, respectively. As of June&#160;30, 2022, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $24.2 million and $2.1 million, respectively. As of June&#160;30, 2021, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $30.2 million and $8.2 million, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, we enter into agreements to purchase goods or services that are not cancelable without penalty, primarily related to supply arrangements. In addition, in June 2022 we signed a definitive agreement to acquire MEDIFOX DAN which is expected to close during our fiscal year 2023. The MEDIFOX DAN acquisition remains subject to regulatory clearances and other customary closing conditions. Upon closing, acquisition consideration will be paid, in part, with funds available for draw under our Revolving Credit Agreement. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations under our purchase agreements and the MEDIFOX DAN acquisition agreement at June&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.997%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June&#160;30</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum purchase obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,707,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,251,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MEDIFOX DAN acquisition consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,702,196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,245,721&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653853920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Expenses</a></td>
<td class="text">Restructuring Expenses <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we closed our Portable Oxygen Concentrator business, which was part of the Sleep and Respiratory Care segment. During the year ended June 30, 2021, we recognized restructuring expenses of $13.9&#160;million primarily related to inventory write-downs of $5.2&#160;million, accelerated amortization of acquired intangible assets of $5.1&#160;million, asset impairments of $2.3&#160;million, employee-related costs of $0.7&#160;million and contract cancellation costs of $0.6&#160;million. Of the total expense recognized during year ended June 30, 2021, the inventory write-down of $5.2&#160;million is presented within cost of sales and the remaining $8.7&#160;million in restructuring costs is separately disclosed as restructuring expenses on the consolidated statements of operations. The restructure was completed as of June 30, 2021.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended June&#160;30, 2022 and 2020 we did not incur material restructuring expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653723968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II Valuation And Qualifying Accounts And Reserves<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II Valuation And Qualifying Accounts And Reserves</a></td>
<td class="text"><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCHEDULE II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RESMED INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VALUATION AND QUALIFYING ACCOUNTS AND RESERVES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022, 2021 and 2020</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning<br/>of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Charged to costs and expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other<br/>(deductions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of<br/>Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,499)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2021</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,680)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended June&#160;30, 2020</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Applied against asset account</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allowance for trade accounts receivable</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,171&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,283&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,946)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,508&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Beginning balance is adjusted to reflect the cumulative pre-tax effect of adopting Accounting Standards Update No. 2016-13, &#8220;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments&#8221; (Topic 326), effective July 1, 2021. </span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying report of independent registered public accounting firm.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854648419552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Policy)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis Of Consolidation</a></td>
<td class="text">Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Certain prior period amounts have been reclassified to conform to the current period presentation. Actual results could differ from management&#8217;s estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standard Codification (&#8220;ASC&#8221;) Topic 606, &#8220;Revenue from Contracts with Customers&#8221;, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#8220;Sleep and Respiratory Care&#8221;) and the supply of business management software as a service to out-of-hospital health providers (&#8220;SaaS&#8221;). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Disaggregation of revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 14 &#8211; Segment Information for our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2022, 2021 and 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Performance obligations and contract balances</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with professional services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances as of June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">614,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (current liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95,455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(91,496)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (non-current liabilities)</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transaction price determination</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns offered to our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty-related returns, are infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#8217;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates on a quarterly basis based on actual sales results and updated forecasts for the remaining rebate periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Accounting and practical expedient elections</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have adopted two practical expedients including the &#8220;right to invoice&#8221; practical expedient, which allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date and which is relevant for some of our SaaS contracts. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock', window );">Concentration Of Credit Risk And Significant Customers</a></td>
<td class="text">Concentration of Credit Risk and Significant CustomersFinancial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, derivatives and trade receivables. Our cash and cash equivalents are generally held with large, diverse financial institutions to reduce the amount of exposure to any single financial institution. Our derivative contracts are transacted with various financial institutions with high credit standings and any exposure to counterparty credit-related losses in these contracts is largely mitigated with collateralization and master-netting agreements. The risk with respect to trade receivables is mitigated by credit evaluations we perform on our customers, the short duration of our payment terms for the significant majority of our customer contracts and by the diversification of our customer base. No single customer accounted for 10% or more of our total revenues for any of the periods presented.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We measure our financial instruments at fair value at each reporting period using a fair value hierarchy that requires that we maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#8217;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Other inputs that are directly or indirectly observable in the marketplace.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs that are supported by little or no market activity.</span></div>The carrying value of cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt related to our Revolving Credit and Term Credit Agreements approximates its fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates which are regularly reset. The carrying value of long-term debt related to our Senior Notes can differ to its fair value as the principal amounts outstanding are subject to fixed interest rates as outlined in Note 9 - Debt. Foreign currency hedging instruments are marked to market and therefore reflect their fair value. In addition, we measure investments in publicly held equity securities and privately held equity securities for which there has been an observable price change in an identical or similar security, at fair value. We do not hold or issue financial instruments for trading purposes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash And Cash Equivalents</a></td>
<td class="text">Cash and Cash Equivalents Cash equivalents include certificates of deposit and other highly liquid investments and we state them at cost, which approximates market. We consider investments with original maturities of 90 days or less to be cash equivalents for purposes of the consolidated statements of cash flows.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">Inventories We state inventories at the lower of cost (determined principally by the first-in, first-out method) or net realizable value. We include material, labor and manufacturing overhead costs in finished goods and work-in-process inventories. We review and provide for any product obsolescence in our manufacturing and distribution operations by assessing throughout the year individual products and components (based on estimated future usage and sales).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant And Equipment</a></td>
<td class="text">Property, Plant and Equipment We record property, plant and equipment, including rental and demonstration equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally two years to ten years except for buildings which are depreciated over an estimated useful life of forty years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text">Intangible Assets We capitalize the registration costs for new patents and amortize the costs over the estimated useful life of the patent, which is generally ten years. If a patent is superseded or a product is retired, any unamortized costs are written off immediately.We amortize all of our other intangible assets on a straight-line basis over their estimated useful lives, which range from two years to fifteen years. We take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists and, at least annually, evaluate the recoverability of intangible assets. We have not identified any impairment of intangible assets during any of the periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">Goodwill <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our annual review for goodwill impairment during the final quarter of the fiscal year. Our goodwill impairment review is performed at our reporting unit level, which is one level below our operating segments and involves the following steps: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 0 or Qualitative assessment &#8211; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Step 1 &#8211; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#8217;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the annual reviews for the years ended June&#160;30, 2022, 2021 and 2020, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Equity Investments</a></td>
<td class="text">Equity investments <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our accounting for investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the consolidated balance sheets.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the consolidated statements of operations.</span></div>Equity investments whereby we have significant influence but not control over the investee, and are not the primary beneficiary of the investee&#8217;s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research And Development</a></td>
<td class="text">Research and Development We record all research and development expenses in the period we incur them.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text">Foreign Currency The consolidated financial statements of our non-U.S. subsidiaries, whose functional currencies are other than the U.S. dollar, are translated into U.S. dollars for financial reporting purposes. We translate assets and liabilities of non-U.S. subsidiaries whose functional currencies are other than the U.S. dollar at period end exchange rates, but translate revenue and expense transactions at average exchange rates for the period. We recognize cumulative translation adjustments as part of comprehensive income, as detailed in the consolidated statements of comprehensive income, and include those adjustments in accumulated other comprehensive income in the consolidated balance sheets until such time the relevant subsidiary is sold or substantially or completely liquidated. We reflect gains and losses on transactions denominated in other than the functional currency of an entity in our results of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Foreign Exchange Risk Management</a></td>
<td class="text">Foreign Exchange Risk Management <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our consolidated statements of income and through changes in our operating assets and liabilities within our consolidated statements of cash flows. We classify purchases of foreign currency derivatives and proceeds received from the exercise of foreign currency derivatives as an investing activity within our consolidated statements of cash flows. We do not enter into financial instruments for trading or speculative purposes.</span></div>We held foreign currency instruments with notional amounts totaling $602.0 million and $556.4 million at June&#160;30, 2022 and June&#160;30, 2021, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to June&#160;30, 2024.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using the enacted tax rates we expect to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions are reflected in income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardProductWarrantyPolicy', window );">Provision For Warranty</a></td>
<td class="text">Provision for WarrantyWe provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock', window );">Allowance For Credit Losses</a></td>
<td class="text">Allowance for Credit Losses<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an allowance for credit losses on customer receivables based on our historical write-off experience, an assessment of our customers&#8217; financial conditions and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions. Customer receivables are charged against the allowance when they are deemed uncollectible. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also contingently liable, within certain limits, in the event of a customer default, to independent financing companies in connection with customer financing programs. We monitor the collection status of these installment receivables and provide for estimated losses separately under accrued expenses within our consolidated balance sheets based upon our historical collection experience with such receivables and a current assessment of our credit exposure.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment Of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived Assets We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, we recognize as the impairment the amount by which the carrying amount of the assets exceeds the fair value of the assets. We report assets to be disposed of at the lower of the carrying amount or fair value less costs to sell. We did not recognize impairment charges in relation to long-lived assets during the fiscal years ended June&#160;30, 2022, 2021 and 2020.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text">ContingenciesWe record a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting standards not yet adopted and Recently adopted accounting pronouncements</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ASU No. 2021-08 &#8220;Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued ASU No. 2021-08, &#8220;Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#8221; (Topic 805), which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The guidance is effective for us beginning in the first quarter of the year ending June 30, 2024 and early adoption is permitted. We elected to early adopt this standard in the second quarter of our fiscal year ending June 30, 2022. Adoption of ASU 2021-08 did not have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AllowanceForDoubtfulAccountsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for Doubtful Accounts [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AllowanceForDoubtfulAccountsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Of Credit Risk And Significant Customers [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653873040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary Of Contract Balances</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our contract balances as of June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:34.811%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance sheet caption</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">614,292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unbilled revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,840&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(108,667)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109,611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (current liabilities)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95,455)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(91,496)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue (non-current liabilities)</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854648425056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SupplementalBalanceSheetInformationAbstract', window );"><strong>Supplemental Balance Sheet Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule Of Inventories</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of selected captions in the consolidated balance sheets consisted of the following as of June&#160;30, 2022 and June&#160;30, 2021 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inventories</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">355,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventories</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743,910&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457,033&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,952&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other prepaid expenses and current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">337,908&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components Of Property, Plant And Equipment</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Property, plant and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349,022&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199,671&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194,386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vehicles and aircraft</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Clinical, demonstration and rental equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,855&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,864&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, at cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,131,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,085,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(633,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(622,139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498,181&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SupplementalBalanceSheetInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental Balance Sheet Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SupplementalBalanceSheetInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653726528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule Of Changes In Carrying Amount Of Goodwill</a></td>
<td class="text">Changes in the carrying amount of goodwill is comprised of the following for the year ended June&#160;30, 2022 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sleep and <br/>Respiratory Care</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SaaS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">633,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,294,718&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,927,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business acquisitions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(30,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">641,724&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,294,718&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,936,442&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule Of Other Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other intangibles, net are comprised of the following as of June&#160;30, 2022 and June&#160;30, 2021 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350,671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(239,647)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(239,049)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed/core product technology, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144,270&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257,034&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(91,731)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(90,976)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,727&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,662&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(134,963)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(131,077)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other intangibles, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66,585&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other intangibles, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392,582&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule Of Amortization Expense Related To Identifiable Intangible Assets, Including Patents</a></td>
<td class="text">Total estimated annual amortization expense for the years ending June 30, 2023 through June 30, 2027, is shown below (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June&#160;30</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated amortization expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,157&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653948912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ScheduleOfInvestmentsTableTextBlock', window );">Schedule Of Investments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments by measurement category as of June&#160;30, 2022 and June&#160;30, 2021 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Measurement alternative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,002&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,240&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock', window );">Schedule Of Changes In Equity Investments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2022 (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,084&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net additions (reductions) to investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,202)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized losses on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains on marketable and non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,209)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8,486)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,290&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,167&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,375&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Net additions (reductions) to investments includes additions from purchases, reductions due to exits of securities, or reclassifications due to our acquisition of an investee in which we held a prior equity interest. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2021(in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity method investments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,109&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,788&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Observable price adjustments on non-marketable equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains on marketable equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,515&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassifications </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,569)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying value at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,002&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(2)During the year ended June&#160;30, 2021, one of our investments, which was previously accounted for under the measurement alternative, completed its initial public offering which resulted in a change of accounting methodology to fair value.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Changes In Equity Investments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ScheduleOfInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Investments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ScheduleOfInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653944192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule Of Accrued Expenses</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses at June&#160;30, 2022 and June&#160;30, 2021 consist of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product warranties (note 8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,889&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Consulting and professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,073&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value added taxes and other taxes due</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Promotional and marketing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Logistics and occupancy costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory in transit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344,722&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854648645248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Warranties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantiesDisclosuresAbstract', window );"><strong>Product Warranties Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock', window );">Schedule Of Changes In Liability For Warranty Costs</a></td>
<td class="text">Changes in the liability for product warranty for the years ended June&#160;30, 2022 and June&#160;30, 2021 are as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warranty accruals for the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warranty costs incurred for the period </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,124)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,461)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at the end of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,889&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantiesDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantiesDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653894416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule Of Debt</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt at June&#160;30, 2022 and June&#160;30, 2021 consists of the following (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,916&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">770,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">646,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred borrowing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,675)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,649)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term debt, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">765,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643,351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">775,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">655,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647443216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule Of Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future lease payments under non-cancellable operating leases as of June&#160;30, 2022 are as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.055%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161,219&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,488&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,617&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,254&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18,910)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock', window );">Schedule Of Operating Lease Disclosure</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental information related to operating leases for the years ended June&#160;30, 2022 and June&#160;30, 2021 was as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average inputs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating cash flows paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Right of use assets obtained in exchange for new lease liabilities:</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36,130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule Of Components Of Lease Revenue</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease revenue for the years ended June&#160;30, 2022, 2021 and 2020 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales-type lease revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,758&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,457&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99,418&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103,189&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101,331&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock', window );">Schedule Of Sales-type Lease, Net Investment In Lease</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment in sales-type leases were classified in the consolidated balance sheets as of June&#160;30, 2022 and June&#160;30, 2021 as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,026&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid taxes and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,240&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock', window );">Schedule Of Maturities Of Sales-type Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of sales-type leases as of June&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Remaining lease payments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,757&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,960)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Present value of remaining lease payments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,108&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales-type Lease, Net Investment in Lease [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Operating Lease Disclosure [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854650836400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule Of Activity Of Restricted Stock Units</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of RSUs, including PRSUs, during year ended June&#160;30, 2022 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted<br/>Stock<br/>Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant-Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested*</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(575)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance factor adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">681&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">203.46&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6</span></td></tr></table></div><div style="margin-top:10pt;padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt">Includes 206 thousand shares netted for tax.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule Of Option Activity</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity during the year ended June&#160;30, 2022 (in thousands, except years and per share amounts):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term in Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.01&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">938&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.91&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options exercisable at end of period</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Options vested and expected to vest at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">932&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112.10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June&#160;30, 2022, 2021 and 2020: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock options:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$72.16</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$53.67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$32.14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.29%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.37%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.58%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.66%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.75%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.07%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ESPP purchase rights:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average grant date fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$50.46</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$48.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$31.82</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life in years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 months</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.63% - 0.98%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.79% - 0.98%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.98% - 1.42%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20% - 34%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30% - 60%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23% - 60%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule Of Total Stock-Based Compensation Costs Incurred And Associated Tax Benefit Recognized</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June&#160;30, 2022, 2021 and 2020 (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,218&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,153&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65,257&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,927&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57,559&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,262)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39,534)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation costs, net of tax benefit</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,995&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,581&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18,025&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653848144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule Of Basic And Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted earnings per share for the years ended June&#160;30, 2022, 2021 and 2020 are calculated as follows (in thousands except per share data): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">779,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474,505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted weighted average shares </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147,043&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145,652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.27&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.24&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647835648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule Of Income Before Income Taxes Under The Jurisdictions</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income before income taxes for the years ended June&#160;30, 2022, 2021 and 2020, was taxed under the following jurisdictions (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85,919)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60,548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,046,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">811,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">672,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">883,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733,088&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule Of Provision For Income Taxes</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is presented below (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:28.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.106%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115,109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,790&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177,788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">531,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124,602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192,864&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred: </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,612)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22,791)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,000)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,773)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,205)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,335)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,541)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,818)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16,587)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29,876)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule Of Provision For Income Tax Differ From The Amount Of Income Tax</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. federal income tax rate of 21% for the years ended June&#160;30, 2022, 2021 and 2020, to pretax income as a result of the following (in thousands): </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes computed at statutory U.S. rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase (decrease) in income taxes resulting from:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State income taxes, net of U.S. tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17,517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,785)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of non-U.S. tax rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,384)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12,130)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,935)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,026)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,294)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,498)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20,696)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Uncertain tax position</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">248,773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181,046&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409,157&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111,414&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule Of Deferred Tax Assets And Liabilities Classified As Current And Non-Current</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported net deferred tax assets and liabilities in our consolidated balance sheets at June&#160;30, 2022 and June&#160;30, 2021, as follows (in thousands): </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax asset</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,746&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9,714)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11,319)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68,585&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components Of Deferred Tax Assets And Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of our deferred tax assets and liabilities at June&#160;30, 2022 and June&#160;30, 2021, are as follows (in thousands): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Employee liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">28,556&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">30,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Tax credit carry overs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">7,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">13,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">10,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">11,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for warranties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">4,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">4,149&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Provision for doubtful debts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">5,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">7,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">27,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">33,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Capital loss carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">4,715&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,912&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">6,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">25,748&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">17,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Research and development capitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">82,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">58,789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">21,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">25,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(3,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(4,911)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">221,518&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">210,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Less valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(13,572)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(13,106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">207,946&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">197,781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Goodwill and other intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(108,078)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(104,563)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Right of use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(20,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(23,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(9,491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(940)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(137,914)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">(129,196)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">70,032&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%">68,585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Components Of Net Deferred Income Tax Assets and Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854654869264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summary Of Revenue By Segment And Reconciling Items</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents a reconciliation of net revenues, depreciation and amortization and net operating profit by reportable segments for the years ended June&#160;30, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net revenue by segment</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,177,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823,235&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,602,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue fair value adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,196,825&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,957,013&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Depreciation and amortization by segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,230&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets and corporate assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159,609&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">156,758&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154,850&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net operating profit by segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,132,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036,712&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">934,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,037&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,226,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,129,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,016,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciling items</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of acquired intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70,728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue fair value adjustment </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss attributable to equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,486&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on equity investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14,515)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,197)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,362)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">960,483&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">883,662&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733,088&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The deferred revenue fair value adjustment is a purchase price accounting adjustment related to MatrixCare which was acquired on November 13, 2018.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock', window );">Schedule Of Revenue By Segment, Product, And Region</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2022, 2021 and 2020 (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">U.S., Canada and Latin America</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,070,420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">863,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792,766&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">841,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">779,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,981,807&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,705,113&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,572,327&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354,632&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,382,636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,078,703&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,926,959&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Combined Europe, Asia and other markets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">796,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">746,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">715,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">399,003&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314,998&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,195,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,118,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,030,054&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Global revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Devices</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,866,908&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,610,040&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,507,822&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Masks and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,310,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,213,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,094,559&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sleep and Respiratory Care</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,177,298&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,823,235&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,602,381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Software as a Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">373,590&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,196,825&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,957,013&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule Of Revenue By Geographic Area</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue information by geographic area for the years ended June&#160;30, 2022, 2021 and 2020 is summarized below (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,249,381&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,962,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,328,746&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,234,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,128,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,578,127&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,196,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,957,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule Of Long-Lived Assets By Geographic Areas</a></td>
<td class="text">Long-lived assets by geographic area as of June&#160;30, 2022 and 2021 is summarized below (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Australia</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Singapore</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of the World</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63,309&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498,053&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">463,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue By Segment, Product, And Region [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854759029552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Actions, Contingencies And Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Obligations Under Purchase Agreements</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obligations under our purchase agreements and the MEDIFOX DAN acquisition agreement at June&#160;30, 2022 were as follows (in thousands):</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.997%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal Years Ending June&#160;30</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minimum purchase obligations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,707,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,251,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440,067&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MEDIFOX DAN acquisition consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">994,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,702,196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,245,721&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440,067&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13,152&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,825&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854649540304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 81,000,000<span></span>
</td>
<td class="nump">$ 78,400,000<span></span>
</td>
<td class="nump">$ 65,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Foreign currency instruments with notional amounts</a></td>
<td class="nump">$ 602,000,000<span></span>
</td>
<td class="nump">$ 556,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_TermOfContractUnderRevenueRecognition', window );">Deferred revenue recognized, term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment, years</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_TermOfContractUnderRevenueRecognition', window );">Deferred revenue recognized, term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment, years</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property, plant and equipment, years</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_TermOfContractUnderRevenueRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Of Contract Under Revenue Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_TermOfContractUnderRevenueRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854649516064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary Of Significant Accounting Policies (Summary Of Contract Balances) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 575,950<span></span>
</td>
<td class="nump">$ 614,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Contract liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="num">(108,667)<span></span>
</td>
<td class="num">(109,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="num">(95,455)<span></span>
</td>
<td class="num">(91,496)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rmd_AccountsReceivableNetMember', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">575,950<span></span>
</td>
<td class="nump">614,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember', window );">Prepaid taxes and other non-current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Unbilled revenue, current</a></td>
<td class="nump">25,692<span></span>
</td>
<td class="nump">10,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Unbilled revenue, non-current</a></td>
<td class="nump">$ 8,840<span></span>
</td>
<td class="nump">$ 6,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rmd_AccountsReceivableNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rmd_AccountsReceivableNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854734363328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Schedule Of Inventories) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGrossAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 355,225<span></span>
</td>
<td class="nump">$ 155,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">3,077<span></span>
</td>
<td class="nump">4,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">385,608<span></span>
</td>
<td class="nump">296,967<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 743,910<span></span>
</td>
<td class="nump">$ 457,033<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647459552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Schedule Of Prepaid Expenses and Other Current Assets) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">$ 99,352<span></span>
</td>
<td class="nump">$ 72,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_PrepaidInventory', window );">Prepaid inventories</a></td>
<td class="nump">107,291<span></span>
</td>
<td class="nump">6,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other prepaid expenses and current assets</a></td>
<td class="nump">131,265<span></span>
</td>
<td class="nump">128,793<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 337,908<span></span>
</td>
<td class="nump">$ 208,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_PrepaidInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_PrepaidInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854649300576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Components Of Property, Plant And Equipment) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">$ 1,131,295<span></span>
</td>
<td class="nump">$ 1,085,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(633,114)<span></span>
</td>
<td class="num">(622,139)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">498,181<span></span>
</td>
<td class="nump">463,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">390,634<span></span>
</td>
<td class="nump">349,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">199,671<span></span>
</td>
<td class="nump">194,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">54,098<span></span>
</td>
<td class="nump">54,435<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_VehiclesAndAircraftMember', window );">Vehicles and aircraft</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">19,231<span></span>
</td>
<td class="nump">5,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ClinicalDemonstrationAndRentalEquipmentMember', window );">Clinical, demonstration and rental equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">105,440<span></span>
</td>
<td class="nump">110,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">80,855<span></span>
</td>
<td class="nump">77,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">51,864<span></span>
</td>
<td class="nump">54,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, at cost</a></td>
<td class="nump">$ 229,502<span></span>
</td>
<td class="nump">$ 239,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_VehiclesAndAircraftMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_VehiclesAndAircraftMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ClinicalDemonstrationAndRentalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=rmd_ClinicalDemonstrationAndRentalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854649531472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 1,927,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Business acquisitions</a></td>
<td class="nump">38,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="num">(30,412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">1,936,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember', window );">Sleep and &#8206;Respiratory Care</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">633,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Business acquisitions</a></td>
<td class="nump">38,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="num">(30,412)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">641,724<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SaasMember', window );">SaaS</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the beginning of the period</a></td>
<td class="nump">1,294,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Business acquisitions</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance at the end of the period</a></td>
<td class="nump">$ 1,294,718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SaasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_SaasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647961872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net (Schedule Of Other Intangible Assets, Net) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total other intangibles, net</a></td>
<td class="nump">$ 345,944<span></span>
</td>
<td class="nump">$ 392,582<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_DevelopedOrCoreProductTechnologyMember', window );">Developed/core product technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangibles, gross</a></td>
<td class="nump">350,671<span></span>
</td>
<td class="nump">383,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(239,647)<span></span>
</td>
<td class="num">(239,049)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total other intangibles, net</a></td>
<td class="nump">111,024<span></span>
</td>
<td class="nump">144,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangibles, gross</a></td>
<td class="nump">257,034<span></span>
</td>
<td class="nump">272,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(91,731)<span></span>
</td>
<td class="num">(90,976)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total other intangibles, net</a></td>
<td class="nump">165,303<span></span>
</td>
<td class="nump">181,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Other intangibles, gross</a></td>
<td class="nump">204,580<span></span>
</td>
<td class="nump">197,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(134,963)<span></span>
</td>
<td class="num">(131,077)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total other intangibles, net</a></td>
<td class="nump">$ 69,617<span></span>
</td>
<td class="nump">$ 66,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_DevelopedOrCoreProductTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_DevelopedOrCoreProductTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854649526496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 39,650<span></span>
</td>
<td class="nump">$ 45,127<span></span>
</td>
<td class="nump">$ 49,603<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_IdentifiedIntangibleAssetsMember', window );">Identified Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 70,700<span></span>
</td>
<td class="nump">76,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets, estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_IdentifiedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=rmd_IdentifiedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647515008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets, net (Schedule Of Amortization Expense Related To Identifiable Intangible Assets, Including Patents) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 61,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">57,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">53,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">47,902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">$ 29,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647508576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Schedule Of Investments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_MarketableEquityInvestmentsFairValue', window );">Fair value</a></td>
<td class="nump">$ 9,167<span></span>
</td>
<td class="nump">$ 29,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Measurement alternative</a></td>
<td class="nump">39,290<span></span>
</td>
<td class="nump">23,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method</a></td>
<td class="nump">9,918<span></span>
</td>
<td class="nump">17,154<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityInvestmentsTotalByMeasurementCategory', window );">Total</a></td>
<td class="nump">$ 58,375<span></span>
</td>
<td class="nump">$ 69,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_EquityInvestmentsTotalByMeasurementCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Total by Measurement Category</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_EquityInvestmentsTotalByMeasurementCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_MarketableEquityInvestmentsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Equity Investments, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_MarketableEquityInvestmentsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854645069680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Schedule Of Changes In Equity Investments) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 69,240<span></span>
</td>
<td class="nump">$ 44,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_AdditionalEquityInvestments', window );">Net additions (reductions) to investments</a></td>
<td class="nump">9,823<span></span>
</td>
<td class="nump">21,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities', window );">Observable price adjustments on non-marketable equity securities</a></td>
<td class="nump">5,367<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gains (losses) on marketable equity securities</a></td>
<td class="num">(18,341)<span></span>
</td>
<td class="nump">13,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Realized gains on marketable and non-marketable equity securities</a></td>
<td class="nump">3,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairment of investments</a></td>
<td class="num">(3,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ReclassificationsInEquityInvestments', window );">Reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments</a></td>
<td class="num">(8,486)<span></span>
</td>
<td class="num">(11,205)<span></span>
</td>
<td class="num">$ (25,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Carrying value at the end of the period</a></td>
<td class="nump">58,375<span></span>
</td>
<td class="nump">69,240<span></span>
</td>
<td class="nump">44,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rmd_NonMarketableSecuritiesMember', window );">Non-marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Balance at the beginning of the period</a></td>
<td class="nump">23,002<span></span>
</td>
<td class="nump">30,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_AdditionalEquityInvestments', window );">Net additions (reductions) to investments</a></td>
<td class="nump">11,775<span></span>
</td>
<td class="nump">2,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities', window );">Observable price adjustments on non-marketable equity securities</a></td>
<td class="nump">5,367<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Realized gains on marketable and non-marketable equity securities</a></td>
<td class="nump">2,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfInvestments', window );">Impairment of investments</a></td>
<td class="num">(3,209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ReclassificationsInEquityInvestments', window );">Reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Carrying value at the end of the period</a></td>
<td class="nump">39,290<span></span>
</td>
<td class="nump">23,002<span></span>
</td>
<td class="nump">30,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=rmd_MarketableSecuritiesMember', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Balance at the beginning of the period</a></td>
<td class="nump">29,084<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_AdditionalEquityInvestments', window );">Net additions (reductions) to investments</a></td>
<td class="num">(3,202)<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gains (losses) on marketable equity securities</a></td>
<td class="num">(18,341)<span></span>
</td>
<td class="nump">13,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Realized gains on marketable and non-marketable equity securities</a></td>
<td class="nump">1,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ReclassificationsInEquityInvestments', window );">Reclassifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Carrying value at the end of the period</a></td>
<td class="nump">9,167<span></span>
</td>
<td class="nump">29,084<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquityMethodInvestmentsMember', window );">Equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Balance at the beginning of the period</a></td>
<td class="nump">17,154<span></span>
</td>
<td class="nump">14,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_AdditionalEquityInvestments', window );">Net additions (reductions) to investments</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">14,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments</a></td>
<td class="num">(8,486)<span></span>
</td>
<td class="num">(11,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EquityInvestments', window );">Carrying value at the end of the period</a></td>
<td class="nump">$ 9,918<span></span>
</td>
<td class="nump">$ 17,154<span></span>
</td>
<td class="nump">$ 14,109<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AdditionalEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AdditionalEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_EquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_EquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_EquityMethodInvestmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_EquityMethodInvestmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Observable price adjustments on non-marketable equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ReclassificationsInEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassifications In Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ReclassificationsInEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rmd_NonMarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rmd_NonMarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=rmd_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=rmd_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854644721792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Equity securities, unrealized gain (loss)</a></td>
<td class="num">$ (16.2)<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
<td class="num">$ (14.5)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854649422528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Schedule Of Accrued Expenses) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Product warranties (note 8)</a></td>
<td class="nump">$ 25,889<span></span>
</td>
<td class="nump">$ 22,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Consulting and professional fees</a></td>
<td class="nump">25,073<span></span>
</td>
<td class="nump">21,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Value added taxes and other taxes due</a></td>
<td class="nump">26,340<span></span>
</td>
<td class="nump">26,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee related costs</a></td>
<td class="nump">194,736<span></span>
</td>
<td class="nump">199,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Promotional and marketing</a></td>
<td class="nump">6,485<span></span>
</td>
<td class="nump">4,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">7,983<span></span>
</td>
<td class="nump">8,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_AccruedLogisticsAndOccupancyExpensesCurrent', window );">Logistics and occupancy costs</a></td>
<td class="nump">32,160<span></span>
</td>
<td class="nump">14,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_AccruedInventoryInTransit', window );">Inventory in transit</a></td>
<td class="nump">11,554<span></span>
</td>
<td class="nump">7,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">14,502<span></span>
</td>
<td class="nump">16,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 344,722<span></span>
</td>
<td class="nump">$ 320,599<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AccruedInventoryInTransit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued inventory in transit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AccruedInventoryInTransit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AccruedLogisticsAndOccupancyExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Logistics And Occupancy Expenses Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AccruedLogisticsAndOccupancyExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126907644&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854645158304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward', window );"><strong>Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Balance at the beginning of the period</a></td>
<td class="nump">$ 22,032<span></span>
</td>
<td class="nump">$ 21,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued', window );">Warranty accruals for the period</a></td>
<td class="nump">17,442<span></span>
</td>
<td class="nump">14,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualPayments', window );">Warranty costs incurred for the period</a></td>
<td class="num">(12,124)<span></span>
</td>
<td class="num">(14,858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments</a></td>
<td class="num">(1,461)<span></span>
</td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrual', window );">Balance at the end of the period</a></td>
<td class="nump">$ 25,889<span></span>
</td>
<td class="nump">$ 22,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualWarrantiesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the standard and extended product warranty accrual from warranties issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph ((c)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualWarrantiesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which decreases (increases) the standard and extended product warranty accrual.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854649544016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Schedule Of Debt) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ShortTermDebtGross', window );">Short-term debt</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred borrowing costs</a></td>
<td class="num">(84)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term debt</a></td>
<td class="nump">9,916<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">770,000<span></span>
</td>
<td class="nump">646,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred borrowing costs</a></td>
<td class="num">(4,675)<span></span>
</td>
<td class="num">(2,649)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt, net</a></td>
<td class="nump">765,325<span></span>
</td>
<td class="nump">643,351<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total debt</a></td>
<td class="nump">$ 775,241<span></span>
</td>
<td class="nump">$ 655,351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ShortTermDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term Debt, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ShortTermDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854644017888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 29, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 17, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 10, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DebtToConsolidatedEbitdaRatio', window );">Debt to consolidated EBITDA ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany', window );">Line of credit facility, collateral, percentage of the company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765,325,000<span></span>
</td>
<td class="nump">$ 643,351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">775,241,000<span></span>
</td>
<td class="nump">655,351,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember', window );">Revolving Credit Facility And Term Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal', window );">Principal payment</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Available for draw</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000,000<span></span>
</td>
<td class="nump">$ 158,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=rmd_MufgUnionBankNaAndWestpacBankingCorporationMember', window );">MUFG Union Bank NA and Westpac Banking Corporation | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">1,500,000,000<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_UncommittedOptionToIncreaseCreditFacility', window );">Uncommitted option to increase credit facility</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod', window );">EBITDA multiple of trailing twelve-month measurement period</a></td>
<td class="nump">1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=rmd_MufgUnionBankNaAndWestpacBankingCorporationMember', window );">MUFG Union Bank NA and Westpac Banking Corporation | Revolving Credit Facility And Term Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate on outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=rmd_MufgUnionBankMember', window );">MUFG Union Bank | ResMed Limited | Revolving Credit Facility And Term Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Revolving Credit Facility And Term Credit Agreement | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit facility interest rate equal to reference rate plus</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Revolving Credit Facility And Term Credit Agreement | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit facility interest rate equal to reference rate plus</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | MUFG Union Bank NA and Westpac Banking Corporation | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fees percentage rate on unused portion of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.075%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Revolving Credit Facility And Term Credit Agreement | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit facility interest rate equal to reference rate plus</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Revolving Credit Facility And Term Credit Agreement | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Credit facility interest rate equal to reference rate plus</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | MUFG Union Bank NA and Westpac Banking Corporation | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fees percentage rate on unused portion of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesOneMember', window );">3.24% Senior Notes Due July 10, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.24%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesTwoMember', window );">3.45% Senior Notes Due July 10, 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 477,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding loan balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember', window );">Revolving Credit Agreement, Term Credit Agreement, And Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 780,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DebtToConsolidatedEbitdaRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt To Consolidated EBITDA Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DebtToConsolidatedEbitdaRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Collateral, Percentage of the Company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_UncommittedOptionToIncreaseCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Uncommitted option to increase credit facility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_UncommittedOptionToIncreaseCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payment applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=rmd_MufgUnionBankNaAndWestpacBankingCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=rmd_MufgUnionBankNaAndWestpacBankingCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=rmd_MufgUnionBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=rmd_MufgUnionBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=rmd_ResmedLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=rmd_ResmedLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=rmd_SeniorNotesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854649476336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 35.3<span></span>
</td>
<td class="nump">$ 35.5<span></span>
</td>
<td class="nump">$ 26.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments', window );">Operating lease commitments not yet commenced</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease terms</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease terms, not yet commenced</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease terms</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease terms, not yet commenced</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Not yet Commenced, Commitments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647876832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule Of Future Minimum Lease Payments) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 25,488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">19,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">16,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">15,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">15,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">68,516<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">161,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(18,910)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 142,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854734318528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Schedule Of Operating Lease Disclosure) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">8 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 26,462<span></span>
</td>
<td class="nump">$ 27,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new lease liabilities:</a></td>
<td class="nump">$ 41,382<span></span>
</td>
<td class="nump">$ 36,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647862640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Schedule Of Components Of Lease Revenue) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseIncome', window );">Sales-type lease revenue</a></td>
<td class="nump">$ 9,342<span></span>
</td>
<td class="nump">$ 9,758<span></span>
</td>
<td class="nump">$ 13,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncome', window );">Operating lease revenue</a></td>
<td class="nump">90,076<span></span>
</td>
<td class="nump">93,431<span></span>
</td>
<td class="nump">87,874<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_LessorLeaseRevenue', window );">Total lease revenue</a></td>
<td class="nump">$ 99,418<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
<td class="nump">$ 101,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_LessorLeaseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessor, Lease Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_LessorLeaseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123420820&amp;loc=SL77919311-209978<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease income from variable lease payments, interest income from net investment on sales-type lease, and profit (loss) recognized at commencement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123420820&amp;loc=SL77919311-209978<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647528768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule Of Sales-type Lease, Net Investment In Lease) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseLeaseReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">$ 6,473<span></span>
</td>
<td class="nump">$ 8,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets', window );">Prepaid taxes and other non-current assets</a></td>
<td class="nump">7,635<span></span>
</td>
<td class="nump">6,214<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeLeaseNetInvestmentInLease', window );">Total</a></td>
<td class="nump">$ 14,108<span></span>
</td>
<td class="nump">$ 14,240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales-type Lease, Lease Prepaid Taxes And Other Noncurrent Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseLeaseReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919379-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseLeaseReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeLeaseNetInvestmentInLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of net investment in sales-type lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919379-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeLeaseNetInvestmentInLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854650761472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Schedule Of Maturities Of Sales-type Leases) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 6,757<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears', window );">2024</a></td>
<td class="nump">4,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears', window );">2025</a></td>
<td class="nump">2,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears', window );">2026</a></td>
<td class="nump">1,915<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears', window );">2027</a></td>
<td class="nump">1,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived', window );">Total remaining lease payments</a></td>
<td class="nump">16,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable', window );">Present value of remaining lease payments</a></td>
<td class="nump">$ 14,108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919379-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undiscounted lease receivable in excess of discounted receivable for sales-type and direct financing leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919391-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854643019104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>offering </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 21, 2014 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 1997 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Shares authorized to be repurchased under repurchase program (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased', window );">Additional shares that can be repurchased under the approved share repurchase program (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock at par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance', window );">Reduction in the number of shares of common stock available for issuance (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_MaximumNumberOfSharesSubjectToAwardsGranted', window );">Maximum number of shares subject to awards granted (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_NumberOfCommonStockGranted', window );">Number of common stock shares granted in participant's initial year of hiring (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of RSUs and PRSUs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,500<span></span>
</td>
<td class="nump">$ 59,600<span></span>
</td>
<td class="nump">$ 56,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of the options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,700<span></span>
</td>
<td class="nump">$ 8,900<span></span>
</td>
<td class="nump">$ 31,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of the stock-based compensation arrangements outstanding | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of the stock-based compensation arrangements exercisable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value of the stock-based compensation arrangements exercisable, vested and expected to vest | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued under Employee Stock Purchase Plan (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216,000<span></span>
</td>
<td class="nump">229,000<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,257<span></span>
</td>
<td class="nump">$ 63,927<span></span>
</td>
<td class="nump">$ 57,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation costs related to unvested stock-based compensation arrangements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Total number of shares repurchased pursuant to the repurchase program (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Total cost of shares repurchased pursuant to the repurchase program | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rmd_ResmedInc2009IncentiveAwardPlanMember', window );">2009 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending', window );">Common stock authorized for issuance and pending registration (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod', window );">Extended period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Common stock authorized for issuance (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for future issuance (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rmd_AmendedAndRestated2009PlanMember', window );">Amended And Restated 2009 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted', window );">Maximum amount payable pursuant to cash denominated performance awards granted | $</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rmd_AmendedAndRestated2009PlanMember', window );">Amended And Restated 2009 Plan | Non Employee Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned', window );">Maximum award amount with other cash fees earned for services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rmd_AmendedAndRestated2009PlanMember', window );">Amended And Restated 2009 Plan | Board Of Directors Chairman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned', window );">Maximum award amount with other cash fees earned for services | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=rmd_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for future issuance (shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant', window );">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase', window );">Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_NumberOfOfferings', window );">Number of offerings | offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EmployeeStockPurchasePlanOfferingPeriod', window );">Employee stock purchase program offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EmployeeStockPurchasePlanOfferingPeriod', window );">Employee stock purchase program offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscriptions', window );">Common stock shares subscribed | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Restricted Stock Units (PRSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_VestingAmountMaximumPercentageOfOriginalGrant', window );">Maximum amount to be issued under award, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_EmployeeStockPurchasePlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan Offering Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_EmployeeStockPurchasePlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_MaximumNumberOfSharesSubjectToAwardsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares subject to awards granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_MaximumNumberOfSharesSubjectToAwardsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_NumberOfCommonStockGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock shares granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_NumberOfCommonStockGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_NumberOfOfferings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Offerings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_NumberOfOfferings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares of common stock available for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Extended Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Pending</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted and Other Cash Fees Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sharebased Compensation Arrangement By Sharebased Payment Performance Award Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_VestingAmountMaximumPercentageOfOriginalGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Amount, Maximum Percentage Of Original Grant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_VestingAmountMaximumPercentageOfOriginalGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscriptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscriptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rmd_ResmedInc2009IncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rmd_ResmedInc2009IncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rmd_AmendedAndRestated2009PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rmd_AmendedAndRestated2009PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=rmd_NonEmployeeDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=rmd_NonEmployeeDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=rmd_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=rmd_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647926704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Restricted &#8206;Stock &#8206;Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (shares)</a></td>
<td class="nump">875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (shares)</a></td>
<td class="nump">288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (shares)</a></td>
<td class="num">(575,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease', window );">Performance factor adjustment (shares)</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(82,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (shares)</a></td>
<td class="nump">681,000<span></span>
</td>
<td class="nump">875,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted &#8206;Average &#8206;Grant-Date &#8206;Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (usd per share)</a></td>
<td class="nump">$ 145.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (usd per share)</a></td>
<td class="nump">259.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (usd per share)</a></td>
<td class="nump">113.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue', window );">Performance factor adjustments (usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (usd per share)</a></td>
<td class="nump">184.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (usd per share)</a></td>
<td class="nump">$ 203.46<span></span>
</td>
<td class="nump">$ 145.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted &#8206;Average &#8206;Remaining &#8206;Contractual &#8206;Term in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Exercisable shares, netted for tax (shares)</a></td>
<td class="nump">206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Adjustments In Period Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854649352528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule Of Option Activity) (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (shares)</a></td>
<td class="nump">1,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (shares)</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (shares)</a></td>
<td class="num">(177)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (shares)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (shares)</a></td>
<td class="nump">938<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable at end of period (shares)</a></td>
<td class="nump">792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at end of period (shares)</a></td>
<td class="nump">932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted &#8206;Average &#8206;Exercise &#8206;Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (usd per share)</a></td>
<td class="nump">$ 97.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">256.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">63.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (usd per share)</a></td>
<td class="nump">110.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (usd per share)</a></td>
<td class="nump">112.91<span></span>
</td>
<td class="nump">$ 97.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at end of period (usd per share)</a></td>
<td class="nump">96.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at end of period (usd per share)</a></td>
<td class="nump">$ 112.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted &#8206;Average &#8206;Remaining &#8206;Contractual &#8206;Term in Years</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at end of period</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at end of period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest at end of period</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854643905504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (usd per share)</a></td>
<td class="nump">$ 72.16<span></span>
</td>
<td class="nump">$ 53.67<span></span>
</td>
<td class="nump">$ 32.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">1.29%<span></span>
</td>
<td class="nump">0.37%<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.66%<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="nump">1.07%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmd_EmployeeStockPurchasePlanPurchaseRightsMember', window );">ESPP purchase rights:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (usd per share)</a></td>
<td class="nump">$ 50.46<span></span>
</td>
<td class="nump">$ 48.18<span></span>
</td>
<td class="nump">$ 31.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmd_EmployeeStockPurchasePlanPurchaseRightsMember', window );">ESPP purchase rights: | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.63%<span></span>
</td>
<td class="nump">0.79%<span></span>
</td>
<td class="nump">0.98%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=rmd_EmployeeStockPurchasePlanPurchaseRightsMember', window );">ESPP purchase rights: | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.98%<span></span>
</td>
<td class="nump">0.98%<span></span>
</td>
<td class="nump">1.42%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=rmd_EmployeeStockPurchasePlanPurchaseRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=rmd_EmployeeStockPurchasePlanPurchaseRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854649412448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule Of Total Stock-Based Compensation Costs Incurred And Associated Tax Benefit Recognized) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 65,257<span></span>
</td>
<td class="nump">$ 63,927<span></span>
</td>
<td class="nump">$ 57,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit</a></td>
<td class="num">(29,262)<span></span>
</td>
<td class="num">(23,346)<span></span>
</td>
<td class="num">(39,534)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Stock-based compensation costs, net of tax benefit</a></td>
<td class="nump">35,995<span></span>
</td>
<td class="nump">40,581<span></span>
</td>
<td class="nump">18,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">5,218<span></span>
</td>
<td class="nump">4,153<span></span>
</td>
<td class="nump">3,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">50,791<span></span>
</td>
<td class="nump">51,727<span></span>
</td>
<td class="nump">47,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs</a></td>
<td class="nump">$ 9,248<span></span>
</td>
<td class="nump">$ 8,047<span></span>
</td>
<td class="nump">$ 6,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647421056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Narrative) (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options and restricted stock units not included in the computation of diluted earnings per share</a></td>
<td class="nump">67,000,000<span></span>
</td>
<td class="nump">141,000,000<span></span>
</td>
<td class="nump">164,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854644795808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 779,437<span></span>
</td>
<td class="nump">$ 474,505<span></span>
</td>
<td class="nump">$ 621,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted-average common shares outstanding (shares)</a></td>
<td class="nump">146,066<span></span>
</td>
<td class="nump">145,313<span></span>
</td>
<td class="nump">144,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Stock options and restricted stock units (shares)</a></td>
<td class="nump">977<span></span>
</td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">1,314<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average shares (shares)</a></td>
<td class="nump">147,043<span></span>
</td>
<td class="nump">146,451<span></span>
</td>
<td class="nump">145,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (usd per share)</a></td>
<td class="nump">$ 5.34<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="nump">$ 4.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (usd per share)</a></td>
<td class="nump">$ 5.30<span></span>
</td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="nump">$ 4.27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854648612304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule Of Income Before Income Taxes Under The Jurisdictions) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (85,919)<span></span>
</td>
<td class="nump">$ 71,867<span></span>
</td>
<td class="nump">$ 60,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Non-U.S.</a></td>
<td class="nump">1,046,402<span></span>
</td>
<td class="nump">811,795<span></span>
</td>
<td class="nump">672,540<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">$ 960,483<span></span>
</td>
<td class="nump">$ 883,662<span></span>
</td>
<td class="nump">$ 733,088<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854649427456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule Of Provision For Income Taxes) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 4,376<span></span>
</td>
<td class="num">$ (115,109)<span></span>
</td>
<td class="nump">$ 9,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">10,700<span></span>
</td>
<td class="nump">9,041<span></span>
</td>
<td class="nump">6,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Non-U.S.</a></td>
<td class="nump">177,788<span></span>
</td>
<td class="nump">531,812<span></span>
</td>
<td class="nump">124,602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">192,864<span></span>
</td>
<td class="nump">425,744<span></span>
</td>
<td class="nump">141,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(12,612)<span></span>
</td>
<td class="num">(22,791)<span></span>
</td>
<td class="num">(13,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(2,773)<span></span>
</td>
<td class="num">(4,205)<span></span>
</td>
<td class="num">(3,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Non-U.S.</a></td>
<td class="nump">3,567<span></span>
</td>
<td class="nump">10,409<span></span>
</td>
<td class="num">(13,541)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">(11,818)<span></span>
</td>
<td class="num">(16,587)<span></span>
</td>
<td class="num">(29,876)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 181,046<span></span>
</td>
<td class="nump">$ 409,157<span></span>
</td>
<td class="nump">$ 111,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854645193072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Schedule Of Provision For Income Tax Differ From The Amount Of Income Tax) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Taxes computed at statutory U.S. rate</a></td>
<td class="nump">$ 201,701<span></span>
</td>
<td class="nump">$ 185,569<span></span>
</td>
<td class="nump">$ 153,949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of U.S. tax benefit</a></td>
<td class="nump">5,703<span></span>
</td>
<td class="nump">4,836<span></span>
</td>
<td class="nump">3,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credit</a></td>
<td class="num">(17,517)<span></span>
</td>
<td class="num">(20,257)<span></span>
</td>
<td class="num">(13,595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">858<span></span>
</td>
<td class="num">(3,785)<span></span>
</td>
<td class="nump">7,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Effect of non-U.S. tax rates</a></td>
<td class="num">(4,384)<span></span>
</td>
<td class="num">(12,130)<span></span>
</td>
<td class="num">(20,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">Foreign tax credits</a></td>
<td class="num">(2,299)<span></span>
</td>
<td class="num">(7,210)<span></span>
</td>
<td class="num">(4,026)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="num">(11,294)<span></span>
</td>
<td class="num">(4,498)<span></span>
</td>
<td class="num">(20,696)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount', window );">Uncertain tax position</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">248,773<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">8,278<span></span>
</td>
<td class="nump">17,859<span></span>
</td>
<td class="nump">5,938<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 181,046<span></span>
</td>
<td class="nump">$ 409,157<span></span>
</td>
<td class="nump">$ 111,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653693344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Schedule Of Deferred Tax Assets And Liabilities Classified As Current And Non-Current) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent', window );">Non-current deferred tax asset</a></td>
<td class="nump">$ 79,746<span></span>
</td>
<td class="nump">$ 79,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent', window );">Non-current deferred tax liability</a></td>
<td class="num">(9,714)<span></span>
</td>
<td class="num">(11,319)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 70,032<span></span>
</td>
<td class="nump">$ 68,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647390352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Components Of Deferred Tax Assets And Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Employee liabilities</a></td>
<td class="nump">$ 28,556<span></span>
</td>
<td class="nump">$ 30,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carry overs</a></td>
<td class="nump">7,723<span></span>
</td>
<td class="nump">13,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventories</a></td>
<td class="nump">10,570<span></span>
</td>
<td class="nump">11,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves', window );">Provision for warranties</a></td>
<td class="nump">4,814<span></span>
</td>
<td class="nump">4,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Provision for doubtful debts</a></td>
<td class="nump">5,096<span></span>
</td>
<td class="nump">7,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">27,490<span></span>
</td>
<td class="nump">33,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Capital loss carryover</a></td>
<td class="nump">4,715<span></span>
</td>
<td class="nump">6,912<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">6,425<span></span>
</td>
<td class="nump">6,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">25,748<span></span>
</td>
<td class="nump">17,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development capitalization</a></td>
<td class="nump">82,074<span></span>
</td>
<td class="nump">58,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DeferredTaxAssetsLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">21,702<span></span>
</td>
<td class="nump">25,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="num">(3,395)<span></span>
</td>
<td class="num">(4,911)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets, Gross</a></td>
<td class="nump">221,518<span></span>
</td>
<td class="nump">210,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(13,572)<span></span>
</td>
<td class="num">(13,106)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">207,946<span></span>
</td>
<td class="nump">197,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Goodwill and other intangibles</a></td>
<td class="num">(108,078)<span></span>
</td>
<td class="num">(104,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right of use assets</a></td>
<td class="num">(20,345)<span></span>
</td>
<td class="num">(23,693)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="num">(9,491)<span></span>
</td>
<td class="num">(940)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(137,914)<span></span>
</td>
<td class="num">(129,196)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 70,032<span></span>
</td>
<td class="nump">$ 68,585<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DeferredTaxAssetsLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DeferredTaxAssetsLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-of-use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647650528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 28, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount', window );">Increase to net earnings from tax holidays and tax incentives program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.0<span></span>
</td>
<td class="nump">$ 33.6<span></span>
</td>
<td class="nump">$ 43.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare', window );">Increase to net earnings per diluted share from tax holidays and tax incentives program (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.23<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Undistributed earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember', window );">Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition', window );">Percentage of recognized tax benefit for uncertain tax position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries', window );">Amount of deferred taxes that would have been recognized if the earnings has not been permanently reinvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority | Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxExaminationNetImpactOfSettlement', window );">Net impact of settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxExaminationGrossSettlement', window );">Gross settlement</a></td>
<td class="nump">$ 381.7<span></span>
</td>
<td class="nump">381.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Penalties and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority', window );">Liability (refund) adjustment from settlement with taxing authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxExaminationRemittedFinalPayment', window );">Remitted final payment</a></td>
<td class="nump">284.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxExaminationPriorRemittancePayments', window );">Prior remittance payments</a></td>
<td class="nump">$ 96.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority | Australian Taxation Office</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Other comprehensive income, foreign currency translation adjustment, tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxCreditsAndAdjustments', window );">Tax credits and deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries', window );">Amount of deferred taxes that would have been recognized if the earnings has not been permanently reinvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember', window );">Valuation Allowance | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_OperatingLossCarryforwardsCapitalLoss', window );">Capital loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_IncomeTaxExaminationGrossSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Examination, Gross Settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_IncomeTaxExaminationGrossSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_IncomeTaxExaminationNetImpactOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Examination, Net Impact of Settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_IncomeTaxExaminationNetImpactOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_IncomeTaxExaminationPriorRemittancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Examination, Prior Remittance Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_IncomeTaxExaminationPriorRemittancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_IncomeTaxExaminationRemittedFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax Examination, Remitted Final Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_IncomeTaxExaminationRemittedFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_OperatingLossCarryforwardsCapitalLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards capital loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_OperatingLossCarryforwardsCapitalLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage threshold, above which a tax benefit would be recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of foreign subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxCreditsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxCreditsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the additional liability or refund received or expected based on a final settlement with a taxing authority.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayAggregateDollarAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayAggregateDollarAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6487024&amp;loc=d3e29054-158556<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6479915&amp;loc=d3e66715-112838<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126928070&amp;loc=d3e28200-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_AustralianTaxationOfficeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854653961424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854643017024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Summary Of Revenue By Segment And Reconciling Items) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 3,578,127<span></span>
</td>
<td class="nump">$ 3,196,825<span></span>
</td>
<td class="nump">$ 2,957,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">159,609<span></span>
</td>
<td class="nump">156,758<span></span>
</td>
<td class="nump">154,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating profit by segment</a></td>
<td class="nump">1,000,286<span></span>
</td>
<td class="nump">903,678<span></span>
</td>
<td class="nump">809,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_AmortizationOfAcquiredIntangibleAssets1', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">31,078<span></span>
</td>
<td class="nump">31,078<span></span>
</td>
<td class="nump">30,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,673<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments</a></td>
<td class="num">(8,486)<span></span>
</td>
<td class="num">(11,205)<span></span>
</td>
<td class="num">(25,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">(Gain) loss on equity investments</a></td>
<td class="num">(12,202)<span></span>
</td>
<td class="nump">14,515<span></span>
</td>
<td class="num">(14,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">3,197<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">960,483<span></span>
</td>
<td class="nump">883,662<span></span>
</td>
<td class="nump">733,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating profit by segment</a></td>
<td class="nump">1,226,331<span></span>
</td>
<td class="nump">1,129,749<span></span>
</td>
<td class="nump">1,016,849<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">72,927<span></span>
</td>
<td class="nump">78,377<span></span>
</td>
<td class="nump">81,556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DeferredRevenueFairValueAdjustment', window );">Deferred revenue fair value adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_UnallocatedCorporateCosts', window );">Corporate costs</a></td>
<td class="nump">155,317<span></span>
</td>
<td class="nump">141,193<span></span>
</td>
<td class="nump">125,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_AmortizationOfAcquiredIntangibleAssets1', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">70,728<span></span>
</td>
<td class="nump">76,205<span></span>
</td>
<td class="nump">79,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,673<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DeferredRevenueFairValueAdjustment', window );">Deferred revenue fair value adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense (income), net</a></td>
<td class="nump">22,312<span></span>
</td>
<td class="nump">23,627<span></span>
</td>
<td class="nump">39,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss attributable to equity method investments</a></td>
<td class="nump">8,486<span></span>
</td>
<td class="nump">11,205<span></span>
</td>
<td class="nump">25,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">(Gain) loss on equity investments</a></td>
<td class="nump">12,202<span></span>
</td>
<td class="num">(14,515)<span></span>
</td>
<td class="nump">14,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(3,197)<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="num">(2,362)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income taxes</a></td>
<td class="nump">960,483<span></span>
</td>
<td class="nump">883,662<span></span>
</td>
<td class="nump">733,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_DevicesAndMasksMember', window );">Total Sleep and Respiratory Care | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">3,177,298<span></span>
</td>
<td class="nump">2,823,235<span></span>
</td>
<td class="nump">2,602,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">79,367<span></span>
</td>
<td class="nump">73,151<span></span>
</td>
<td class="nump">69,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating profit by segment</a></td>
<td class="nump">1,132,510<span></span>
</td>
<td class="nump">1,036,712<span></span>
</td>
<td class="nump">934,697<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsServiceMember', window );">Software as a Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DeferredRevenueFairValueAdjustment', window );">Deferred revenue fair value adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DeferredRevenueFairValueAdjustment', window );">Deferred revenue fair value adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsServiceMember', window );">Software as a Service | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">400,829<span></span>
</td>
<td class="nump">373,590<span></span>
</td>
<td class="nump">354,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment', window );">Revenue before deferred revenue fair value adjustment</a></td>
<td class="nump">400,829<span></span>
</td>
<td class="nump">373,590<span></span>
</td>
<td class="nump">356,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">7,315<span></span>
</td>
<td class="nump">5,230<span></span>
</td>
<td class="nump">3,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net operating profit by segment</a></td>
<td class="nump">$ 93,821<span></span>
</td>
<td class="nump">$ 93,037<span></span>
</td>
<td class="nump">$ 82,152<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_AmortizationOfAcquiredIntangibleAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_AmortizationOfAcquiredIntangibleAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DeferredRevenueFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred revenue, fair value adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DeferredRevenueFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Excluding Assessed Tax, Before Deferred Revenue Fair Value Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_UnallocatedCorporateCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unallocated corporate costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_UnallocatedCorporateCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_DevicesAndMasksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_DevicesAndMasksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854643505920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Schedule Of Revenue By Segment, Product, And Region) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 3,578,127<span></span>
</td>
<td class="nump">$ 3,196,825<span></span>
</td>
<td class="nump">$ 2,957,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rmd_U.s.CanadaAndLatinAmericaMember', window );">U.S., Canada and Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">2,382,636<span></span>
</td>
<td class="nump">2,078,703<span></span>
</td>
<td class="nump">1,926,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rmd_GlobalMember', window );">Global revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">3,578,127<span></span>
</td>
<td class="nump">3,196,825<span></span>
</td>
<td class="nump">2,957,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | U.S., Canada and Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,981,807<span></span>
</td>
<td class="nump">1,705,113<span></span>
</td>
<td class="nump">1,572,327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | U.S., Canada and Latin America | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,070,420<span></span>
</td>
<td class="nump">863,661<span></span>
</td>
<td class="nump">792,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | U.S., Canada and Latin America | Masks and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">911,387<span></span>
</td>
<td class="nump">841,452<span></span>
</td>
<td class="nump">779,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Combined Europe, Asia and other markets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,195,491<span></span>
</td>
<td class="nump">1,118,122<span></span>
</td>
<td class="nump">1,030,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Combined Europe, Asia and other markets | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">796,488<span></span>
</td>
<td class="nump">746,379<span></span>
</td>
<td class="nump">715,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Combined Europe, Asia and other markets | Masks and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">399,003<span></span>
</td>
<td class="nump">371,743<span></span>
</td>
<td class="nump">314,998<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Global revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">3,177,298<span></span>
</td>
<td class="nump">2,823,235<span></span>
</td>
<td class="nump">2,602,381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Global revenue | Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,866,908<span></span>
</td>
<td class="nump">1,610,040<span></span>
</td>
<td class="nump">1,507,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Sleep and &#8206;Respiratory Care | Global revenue | Masks and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">1,310,390<span></span>
</td>
<td class="nump">1,213,195<span></span>
</td>
<td class="nump">1,094,559<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Software as a Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">400,829<span></span>
</td>
<td class="nump">373,590<span></span>
</td>
<td class="nump">354,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Software as a Service | U.S., Canada and Latin America</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">400,829<span></span>
</td>
<td class="nump">373,590<span></span>
</td>
<td class="nump">354,632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Software as a Service | Global revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 400,829<span></span>
</td>
<td class="nump">$ 373,590<span></span>
</td>
<td class="nump">$ 354,632<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rmd_U.s.CanadaAndLatinAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rmd_U.s.CanadaAndLatinAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rmd_GlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rmd_GlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_SleepAndRespiratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=rmd_DevicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=rmd_DevicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=rmd_MasksAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=rmd_MasksAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rmd_CombinedEuropeAsiaAndOtherMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rmd_CombinedEuropeAsiaAndOtherMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=rmd_SoftwareAsServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854647371296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Schedule Of Revenue By Geographic Area) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 3,578,127<span></span>
</td>
<td class="nump">$ 3,196,825<span></span>
</td>
<td class="nump">$ 2,957,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">2,249,381<span></span>
</td>
<td class="nump">1,962,721<span></span>
</td>
<td class="nump">1,828,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rmd_RestOfWorldMember', window );">Rest of the World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net revenue</a></td>
<td class="nump">$ 1,328,746<span></span>
</td>
<td class="nump">$ 1,234,104<span></span>
</td>
<td class="nump">$ 1,128,438<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rmd_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rmd_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854643834832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information (Schedule Of Long-Lived Assets By Geographic Areas) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long lived assets</a></td>
<td class="nump">$ 498,053<span></span>
</td>
<td class="nump">$ 463,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long lived assets</a></td>
<td class="nump">192,833<span></span>
</td>
<td class="nump">186,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long lived assets</a></td>
<td class="nump">169,090<span></span>
</td>
<td class="nump">159,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_SG', window );">Singapore</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long lived assets</a></td>
<td class="nump">72,821<span></span>
</td>
<td class="nump">64,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=rmd_RestOfWorldMember', window );">Rest of the World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long lived assets</a></td>
<td class="nump">$ 63,309<span></span>
</td>
<td class="nump">$ 53,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=rmd_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=rmd_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854651299744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Retirement Plans (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent', window );">Percentage of contribution by the company to the retirement plans</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total contribution by the company to the employee retirement plans</a></td>
<td class="nump">$ 11.9<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent', window );">Percentage of contribution by the company to the retirement plans</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total contribution by the company to the employee retirement plans</a></td>
<td class="nump">$ 11.8<span></span>
</td>
<td class="nump">10.7<span></span>
</td>
<td class="nump">9.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_SG', window );">Singapore</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent', window );">Percentage of contribution by the company to the retirement plans</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Total contribution by the company to the employee retirement plans</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan Maximum Annual Contributions By Employer Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854648560976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Actions, Contingencies And Commitments (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 16, 2022 </div>
<div>patent</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Patents allegedly infringed | patent</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_ReceivablesSoldWithLimitedRecourse', window );">Receivables sold with limited recourse</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157.6<span></span>
</td>
<td class="nump">$ 153.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Maximum exposure on outstanding receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">30.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualProvision', window );">Contingent provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_ReceivablesSoldWithLimitedRecourse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables Sold With Limited Recourse</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_ReceivablesSoldWithLimitedRecourse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854645020304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Legal Actions, Contingencies And Commitments (Obligations Under Purchase Agreements) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract', window );"><strong>Minimum purchase obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,251,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">2024</a></td>
<td class="nump">440,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInThirdYear', window );">2025</a></td>
<td class="nump">13,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFourthYear', window );">2026</a></td>
<td class="nump">1,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInFifthYear', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">1,825<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Total</a></td>
<td class="nump">1,707,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>MEDIFOX DAN acquisition consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">2023</a></td>
<td class="nump">994,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInSecondYear', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInThirdYear', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFourthYear', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInFifthYear', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Total</a></td>
<td class="nump">994,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2023</a></td>
<td class="nump">2,245,721<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2024</a></td>
<td class="nump">440,067<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2025</a></td>
<td class="nump">13,152<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2026</a></td>
<td class="nump">1,431<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">1,825<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">$ 2,702,196<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854645269040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Expenses (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,673<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=rmd_PortableOxygenConcentratorBusinessClosureMember', window );">Portable Oxygen Concentrator Business Closure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets', window );">Accelerated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Contract cancellation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_rmd_RestructuringAndRelatedCostCostOfSales', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rmd_RestructuringAndRelatedCostCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Cost, Cost Of Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rmd_RestructuringAndRelatedCostCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on decontaminating and decommissioning of facilities used in the normal conduct of business and not intended for resale to allocate or recognize the cost of the assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=rmd_PortableOxygenConcentratorBusinessClosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=rmd_PortableOxygenConcentratorBusinessClosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139854643833728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II Valuation And Qualifying Accounts And Reserves (Details) - Applied Against Asset Account Allowance For Doubtful Accounts - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Period</a></td>
<td class="nump">$ 32,138<span></span>
</td>
<td class="nump">$ 28,508<span></span>
</td>
<td class="nump">$ 25,171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">2,620<span></span>
</td>
<td class="nump">7,805<span></span>
</td>
<td class="nump">18,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Other (deductions)</a></td>
<td class="num">(11,499)<span></span>
</td>
<td class="num">(5,680)<span></span>
</td>
<td class="num">(14,946)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 23,259<span></span>
</td>
<td class="nump">32,138<span></span>
</td>
<td class="nump">28,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember', window );">Cumulative Effect, Period of Adoption, Adjusted Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning of Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_AllowanceForCreditLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>rmd-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rmd="http://investor.resmed.com/20220630"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rmd-20220630.xsd" xlink:type="simple"/>
    <context id="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibbdef3fca1f842ffb539ee7a7469d218_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie905261def8d433cbf089eb034507510_I20220808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2022-08-08</instant>
        </period>
    </context>
    <context id="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i60b746abe48d479dab43b5fa3772e0b6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6e67c47d1fc44c41b072ad44589d1ad5_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6a9b9cae84c447429471e59078cc7791_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1e1f5a8c9d8a4df7afb7de1694802ffb_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia1968e917afd4a069dcce0cf81596189_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i55f3256c15f5423dae9d0f83d1016c16_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib50fa129c39f4e95a4ced80f5095f914_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if72cc941e4114d088386f9562860391b_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i607c9c75962444d08f128d8d1dd51b12_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i79dd5c34ff9f422d9e66e42855b0fe44_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i5eec134b8bd6450baec5eba43690fb81_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i4f27f1170fa649259d40577a59061c34_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0e9c77435e45485c85034973f776a026_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6113f72766ae4bf3a6b6822df9ec9799_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie1d7efe198194679bd87c4519fbad23e_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i08a4d2be57e74a8ab5b264970b29954e_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i747690daf6804d479047c828f5efc32a_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6592376d0e874a54b0c74878697fe0fa_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia0787de141ff41878aae7892528f698a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i37d85afb3c0245f5af0854c9191a8cb0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i88f72c5541674f6592c342e22fc4e04e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia8394569b4f94ef8955d0f57473de626_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaeeb2746c953419385544cd7004bbac7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iade2a38a39f64c389d5899176b764aea_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic737aa421e0a4e9782bc67d50120cb7f_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia1c1ddd15e1e47c9af2f8d75690aff1e_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i514c68b0178849528b98da7c305b377b_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if89490bfd4ff476b8ef0c46da716b643_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ic9052a046d6444bdb2321e25b6d1995e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5143bf6786f34585b5c51f7be503d02b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie47e6eabf77f427ba2b95ab6114f5051_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iacae05028f8d4777a29f62e32c114e8d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6a5cda1b02464bfd8426853a49a7491c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia489861770004d4582aa5f3dc793010f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie65c792136c946adbf377040f6366deb_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iece2a9fb6a58447ab6a18eaf650b57f8_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id598a508533f4a93af0cf893cdbc877c_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib389da5f9ca94f9e9783af8916ff3c69_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9c44d305aea24f8c93d48ef038dd79ea_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i546cf7e76487425b8bfe97c8dd15a832_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i12b80b9e773a48ddbfec64e8038faa6d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i77cc3f7b15ee461d972d81d7d0806848_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i395a6823166d44c89daa1c281c702cd0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:AccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3515d2e0a2ec4ac79cc7dc24382770f9_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:AccountsReceivableNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0c52baae5bad475ebef7771a9b519ff5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie196dbd7b3fd443b991a4e53f748a874_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">rmd:PrepaidTaxesAndOtherNonCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if99f07887f7a46228ef1235e19d7b4a5_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i28a3ce23547b4f28a6b1d773a88cbc9b_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i209e45ce8baa40da9ad533b396e1a091_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie01fa7efbed74149bb3ddb5b137cf86b_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i44cbe9d650c44532ad24d4a6fe3dfc94_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i633d55b64edf4c93a09ab4cc0f22c9e6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ic4960aeb688d4da1892eaa0e59da4d2e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie4cdad6ff0a54f4a86b3bb451325b302_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5a380d27436f42cd821417665d91070c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:VehiclesAndAircraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5c114ee233de43edb2dac04cb12f71bc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:VehiclesAndAircraftMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8c2b6d7ce5de4befb6c1ee57c860ff72_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ClinicalDemonstrationAndRentalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib42c790c4b0d45ecb0af64685365f55f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">rmd:ClinicalDemonstrationAndRentalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iffb9a63338dc4ffe875023dc79c7905a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i59a6908e2b224904a2ee86392a3bed03_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i930755293b68471bac0a4f69a1579932_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieba697dd91864c6794a754cb2f07b007_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i62e565965d9f49f2aa99102b8387476a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1327c3ca8f3445da9935a8f2dc5e53a2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia68dbe4ac6c24607ab0fe9092c69e114_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i673b7f5418864027b262473e75a24496_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i585a12bee5294dd7a4971ee1e63765a6_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic386a2f3fc574a6eaa1bc26205d89225_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9d3f3a2e554e4ce498a8c2eac0e1773c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie5920b8d4566429aacc99c4cb598b86b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SaasMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i383529560350461f9474da7a3e151953_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:DevelopedOrCoreProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if91504ce254047b09ff93066ad7e7365_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:DevelopedOrCoreProductTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i27a41c0bc031463eb9e124aa25b7e462_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie60c3c5babf44f189d82c62d83c1ba0e_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id414856654b6425f94e23c727ecf7d42_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i26192f7e58a3451690f985df3d035304_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i275c6f7ccc89416f8b114a73abdb1eb2_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:IdentifiedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide28368adb344db981e13dc7ab3f39e6_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">rmd:IdentifiedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5e17c04c42c84b1da53be06c8c07c44b_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i346adc043b664e69a5d86956607aa19d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i15585071980b44609c4244d0667080d3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i1ecaa50f2b0842ebaa2fada9c7ce2d1a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i28ab83892aae4ba397a55655fbf05f29_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i12742f5ecfc34a62988f7e0587db5dd6_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ida2475934ea241ca9c2d0a10c164d26b_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i986baaa416044ab0b8a0147a14087047_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia249219ca61d4c4ea23e703cf2260422_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1b6f2c0aa8974e7cb7f65b5033462701_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i84ec92f010cb4996b46b1526ee19a1bc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5e4cd11b6bc34d7895326f826a7c3f0d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ifd1dcdc316cf456186c44ff5d3915ada_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if003111e277449988551264e5889944a_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:NonMarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i01c095726ae74638a2cadaaac6191673_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">rmd:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd4cbd01865547d0b68850bcd7ca2e04_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i15e467c7054a4a68be2dda7a759368b3_I20220629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-29</instant>
        </period>
    </context>
    <context id="i423b2284861f4712a8115af92f3cb518_D20220629-20220629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="ifa80124e3bf34fd6856246349e38455b_I20180417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-17</instant>
        </period>
    </context>
    <context id="ibeda0a0993ea40a2b71c2c39f3e0b04e_D20180417-20180417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-17</startDate>
            <endDate>2018-04-17</endDate>
        </period>
    </context>
    <context id="i1310207dfcac4a1e9c44860aeeda4bc2_I20220629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">rmd:ResmedLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-29</instant>
        </period>
    </context>
    <context id="i979ebcc3a5a0402b874813dc295d674e_D20220629-20220629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="ie7f649a73f7b49bb986cbfd39350e44a_D20220629-20220629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="ifd7c672f30f84268aabf143857e5170f_D20220629-20220629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="i97c8b018596f4013a44574b3fd63633c_D20220629-20220629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="i20f542b063f24d7092707acc8b5cf64c_D20220629-20220629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-29</startDate>
            <endDate>2022-06-29</endDate>
        </period>
    </context>
    <context id="i806485f7ccaf4c9d9c68aad92130fec2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i59e7501df49b4377bbb3fff86c0f16b9_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if7e0730b8e7c4927a93f00a20c7493ce_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">rmd:MufgUnionBankNaAndWestpacBankingCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie854b85863de4deb8101483d69a0c966_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia73b672018ee4f70af77e8d5c26893a7_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">rmd:RevolvingCreditFacilityAndTermLoanCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5f8645a6deef4fda9ef586462b0c447a_I20190710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-10</instant>
        </period>
    </context>
    <context id="i5bc2d01b0be2456a84c67fc7a3d70988_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9bb1537c0dcc4eacb698500930b3471e_I20190710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-10</instant>
        </period>
    </context>
    <context id="i6b7a51beb7fb4fe981c3f830e45c4d63_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:SeniorNotesTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i378917c231c447fcbef3c0d8863c6fc3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i54370628e55148a3a1429b5d08709d48_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">rmd:RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7df9e6108fe8406e80413d06c6ed765e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie375d6fcc5c94de8a1dfe85679cc6bdb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icb4434050d394cafb018a6065a45a957_I20140221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>2014-02-21</instant>
        </period>
    </context>
    <context id="i9d6484ce8c1e4238876a0b1d7f21a064_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie03f859a83a14b7c9c6464075801b456_I19970430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <instant>1997-04-30</instant>
        </period>
    </context>
    <context id="i13c812eb8e4e4d0aad3396a4505d0c90_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i656e88285e1a478db38df173815049c6_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="iac8a769569584c06896d492161d46522_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">rmd:NonEmployeeDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i526a12fca7d14513aa82f1d9a8b37b84_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="ib6fbf790ad4041668dd19efbe5c7bd93_D20171031-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-31</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i344f9115454b46148a3452f1abac3c9d_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:AmendedAndRestated2009PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i1b10950bdf1f4749b316223621791474_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="icb58c060ef9941f3a97cea8bbad422e5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:ResmedInc2009IncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1e2263b05ec742b9a74b344a4f2f2337_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i59e177a09e1f49aca07dc9b8742b6dd6_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ica54b0da1e614213bd2547419b667106_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6090a2e6715142fabdaedef101bd1b85_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iec931243b75f437e8ee3cf1efa936e50_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i26cfb703ae174ae99bbfb51030982257_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i139858d21bb440a48d56f47a4a84ed88_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib903a532663446a585c6512ab8c06b0b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i612e2c48c8604ebb820bf12238b6faad_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia01026de6a5a497cb302f143e7c8b8da_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i545f14bf17d3466d878853ee4c40b693_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">rmd:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if26c7573938546c58712775f705c6f91_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i86d83628870e4c1298a21564eac48efe_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia1957b8b04bc43568cb3bf406005b986_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8173e7992c53414cbda9b33e54540412_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7b1efe55196841488562ed5eb81ff415_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic6a5f8517549459ba24dc64abf4f2a39_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i626584014ac5497faaf5bbe0805c20a9_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3568fe5aef9349ee949f734d37ba293a_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">rmd:EmployeeStockPurchasePlanPurchaseRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if8f8a68565f04e4593882f783d3a8493_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i75b466de52734147a35094bafe68a210_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id24b9ea32ab54d4ebbb79eacdf21d5a2_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ie1b4834996c24c4697613536e66c2ae0_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1fb5f975b0f146af9d0eacbd9ea5d417_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i042c41ef5a4940c9bbbd03a03a164b31_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia284c8ce0cc44849a9f6fd2717f955a6_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7bbffc1218e846ceaa11fd8c25583530_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iefa02d71c77a4a088959735053a1a4df_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic89b566ef2524af98f09b1c2e5a3555c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0fd69e2cd46e4080ad9064bd38b12c4c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0e1c0e023852448f9bf3bd384a272726_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOperatingLossCarryforwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie01584a76c914617a10b30795533bc02_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia4b678d1321a48be9f80648f4a12cf05_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6fd3564ce052488e9f5ba664a5d9dcec_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8d4e9f2528d046f9a73bbe9b0ae46a0e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9b2d239a762c46e39be91927daa68806_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i01201a3e634542d49bf58f119957d890_D20210928-20210928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:AustralianTaxationOfficeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-28</startDate>
            <endDate>2021-09-28</endDate>
        </period>
    </context>
    <context id="i9615d030beef4655919952e7c42dddb0_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:DevicesAndMasksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3e575d821d774882967b5b2ac809400a_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:DevicesAndMasksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2565ea6b2b0f49e596d06ef86c0ee019_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:DevicesAndMasksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4f176c13cb464db58e7e974bbe583ad2_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9dd1b88dba5e4ed4b2bc90aa0129b7e1_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5bcaef51aed54c3cbc31f6f73f6fc4dc_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0095199e4b29470582f73f47f8ae065a_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id8d1e579aaa5456ba8a0c4cb4315ddc8_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i46269d456ce141c8be9efcf422648c0d_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3b423ab980a64f30b1a30f8d6aab58ed_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic40263e3a7e448478aaec5362e3d5ac0_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5dc746d3d9604ed8b657848caa1d88b5_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i25c6b0cc200a4b599e158f399e3c9bc6_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic4aa667d360a42a0a82284e45233a24c_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0034c7a4e6a54939a36c81c60d8ae04f_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iddb9b1ba3cc948fbbeafc80d5fb888c0_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0fdc782505914ae19cc4a5145a64302a_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie3506717407b495e8b465b435329e9fa_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i683f2eada0d04fcaad952c8b3d263517_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8ceba21d091145f1abfd5e8ee8280f34_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i028290f735164715bb94548227192afe_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i4ad2b08ec7164637b1de52cff54bc7fc_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i768e903ad73a409983ef36a9cb3bcdd6_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i44e5f807c4204737a2770ffd84a1ef8f_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibd4f488d02b44960a0dd40ec6011ee0a_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaeb162e7018f4f9389dece5e2798edd4_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i69ea25fdac2444049f2441242da65d68_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i40bcfef9b6e54021ae8c2ff8aa045971_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4299c9c5641b4278bb02f064ee36224e_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic5f83c48a7d8454394b43a87b7ab93e4_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:U.s.CanadaAndLatinAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic436f1cc5c3141c789df791a0cf3e876_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i88324fb286c04ba5950e6cd05648d664_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic1959ef64c9d48daae526f9ad86dc1e1_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i90adc12d32e34e8fb47d50b8d5bfd24e_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id83a2708a5314366ab3b2d2063c1580c_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic087066b2dfa4a2e80b6055dc86ad478_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="idf3b5cebac484aafa9c12aabc31f71fb_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibfe214ef394c40078ff0a1c3b2002cd8_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if7afa8a0a280436aaa2a6358ed31ae72_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:CombinedEuropeAsiaAndOtherMarketsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="iafa91ad16e1d42898125c674a44f12c7_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if750331b61d34ff6a35ce16115a39bd1_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i20ac972a28ea4f66852dc6a23c05796a_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:DevicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3c0e3f2f8bd246a08869b10ecf87c8d4_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0f9858995a6f4d25962cfd62c79b79f3_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idce2674b8c0341a2b7fc01fb9809ffb6_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">rmd:MasksAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i499a1d7dca454b16aab049bf997c138b_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idbe3bf1b0b23497a9f774cd1b2469607_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i02220a87b54b4e30a843706e1e0d6a7e_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SleepAndRespiratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic3f7bb52ca32454e94bfcd08e2c8c5f7_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic07d827f23644728992537f14148e061_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i337e5645c4c44331a1f07eba81269258_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">rmd:SoftwareAsServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i0ceddc8dd80a49a4bd587e39d47f45e3_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idf573c1bd70f41baafb0fa6b1cf4e06c_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8cabc22c13c84f4f933c6296d351e8b4_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:GlobalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if647eaf645944411be01eae84919f4b8_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibc7308901fa84fdeb1d8b362b2f75a0d_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iac5bed93d8d840fca4ddaeae7fa58ef1_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i6fa8a519bc734ac19f7310d6f9acfb13_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i24ea923c1eda4ec59fcf09d914cfe556_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d85bfd9205c4954829266c748d0e737_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i78fc5da4e0e04d37ac8a97438b29039d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5e84ef532ade41228f75e995126162ff_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i801dcbebc4da489dbeb89de396b518f1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i93b19ef8b4f64d11a5fe3c85245bf6bd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if07211d598314591ab29d17f48c0e9b1_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i064d1782e2d845f99c9be5eafe7335b0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5fc521c6602c417dab7cde075c1c6ca0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iccd6677e07da4b36bdfc0d4628b747e6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">rmd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i8a85455cff5b488bb43b5e15307964ce_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2dc2d374954548eeae4da26ee6deb2da_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9d640c7e949347a48920659088e1b6d5_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if2897b37cef246bfbcd8a111b95babe4_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3265cc74d27c4d9c9e39b63c16e194b9_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0a3c9df979694466b84d35627592feac_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i78253a41a7f9462cae9e61f99722631b_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i38c21a3a43d242b5971df394c22e9de8_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i21c42c4d4e154021ad486dec830521c6_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ieaaf7972675048e690091ac44e072096_D20220616-20220616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
        </entity>
        <period>
            <startDate>2022-06-16</startDate>
            <endDate>2022-06-16</endDate>
        </period>
    </context>
    <context id="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">rmd:PortableOxygenConcentratorBusinessClosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i88d0acfca2694a179ae914e7b68a3e34_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iff6f98dd6cf448e09b965f01db37b08e_D20210701-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i89a45cd403ed4145a2219c018be81ad4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib8bfa1b0d361426ca8e6bfee5712cfe9_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id60995957b3746049536126104cd8336_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6c57ecbf703c4d4b8b48d4fd7f8af6fe_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic5d3ead733d44cfc87b7a8de6f4c25ba_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i3c161b6547684d3dbda4b1b823202c32_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000943819</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:AllowanceForCreditLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>rmd:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="offering">
        <measure>rmd:offering</measure>
    </unit>
    <unit id="patent">
        <measure>rmd:patent</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl80L2ZyYWc6OWIxZmJiNjllOWE1NDA1Mjk4NjZkNTEyYjI2YmUzNjgvdGFibGU6Yzc3NDljNzg0ZWUxNDFkZWE3NTBlYTM3YTQ1OWM4MTkvdGFibGVyYW5nZTpjNzc0OWM3ODRlZTE0MWRlYTc1MGVhMzdhNDU5YzgxOV80LTEtMS0xLTI4NzY5_ba9732cf-c420-44a4-9879-69a0fb2ff3be">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl80L2ZyYWc6OWIxZmJiNjllOWE1NDA1Mjk4NjZkNTEyYjI2YmUzNjgvdGFibGU6Yzc3NDljNzg0ZWUxNDFkZWE3NTBlYTM3YTQ1OWM4MTkvdGFibGVyYW5nZTpjNzc0OWM3ODRlZTE0MWRlYTc1MGVhMzdhNDU5YzgxOV81LTEtMS0xLTI4NzY5_80deab20-2d0d-47e2-8cea-7d5d5c153fe6">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl80L2ZyYWc6OWIxZmJiNjllOWE1NDA1Mjk4NjZkNTEyYjI2YmUzNjgvdGFibGU6Yzc3NDljNzg0ZWUxNDFkZWE3NTBlYTM3YTQ1OWM4MTkvdGFibGVyYW5nZTpjNzc0OWM3ODRlZTE0MWRlYTc1MGVhMzdhNDU5YzgxOV82LTEtMS0xLTI4NzY5_86c63fe3-5b22-4767-a9ec-9db11f3d58ec">0000943819</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl80L2ZyYWc6OWIxZmJiNjllOWE1NDA1Mjk4NjZkNTEyYjI2YmUzNjgvdGFibGU6Yzc3NDljNzg0ZWUxNDFkZWE3NTBlYTM3YTQ1OWM4MTkvdGFibGVyYW5nZTpjNzc0OWM3ODRlZTE0MWRlYTc1MGVhMzdhNDU5YzgxOV83LTEtMS0xLTMxMTg3_10f6d05a-1bbb-49a6-8413-41339f295ee1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl80L2ZyYWc6OWIxZmJiNjllOWE1NDA1Mjk4NjZkNTEyYjI2YmUzNjgvdGV4dHJlZ2lvbjo5YjFmYmI2OWU5YTU0MDUyOTg2NmQ1MTJiMjZiZTM2OF8zMjk4NTM0ODgzMzM3_24b691e5-e80d-4ef1-9b6f-a46ad70b0a55">false</dei:DocumentTransitionReport>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTgtMC0xLTEtMzI2Mjg_0c2fd2af-5aa3-40db-a89c-1b133efc80c3">http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <dei:DocumentType
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDUx_a29ccd3a-27e1-4277-b871-6688dadbe11e">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDYz_f10083cf-4376-46f4-889d-ea2f254c26d4">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8zMjk4NTM0ODg4MTUy_07f57489-363a-48a0-ba46-0c9abad751cb">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8zMjk4NTM0ODg4MTUy_38804042-7412-4a45-a431-bc7521cb77d7">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:EntityFileNumber
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDU0_463350aa-76c0-4bee-8fae-67f2ac2f5463">001-15317</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDY5_eb6c7c8a-3bdb-4ece-ba3e-3ff06a9de255">ResMed Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDYw_e454bb39-ae2b-4a04-afd7-37102dd6f0d3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDY1_0703618d-ee96-48e4-883a-4afe635ead24">98-0152841</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8xMDk5NTExNjMyNDEw_e6fb7e96-0e50-4d80-934d-255e8d11b511">9001 Spectrum Center Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8xMDk5NTExNjMyNDY3_6d546b2b-44a1-48fa-ad3b-3c2b569c64e9">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8xMDk5NTExNjMyNDc0_e55eb118-ef95-41dd-b4d2-5e7d7e800cd5">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8xMDk5NTExNjMyNDM2_74990f51-352e-4fc3-8340-877172d9c332">92123</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8zMjk4NTM0ODg4MTkx_12560661-44ab-4e58-89f7-86df6f5525a4">US</dei:EntityAddressCountry>
    <dei:CityAreaCode
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDcy_9133d9f2-eb64-42cb-b4bf-697b5e11a379">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDU2_851060c3-d225-4cd3-92a5-93e37c0ce91e">836-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDA5NjZjMWY3ZmEwNDZiMmI3YjE2MDVkZmRlODQxYTIvdGFibGVyYW5nZTo0MDk2NmMxZjdmYTA0NmIyYjdiMTYwNWRmZGU4NDFhMl8xLTAtMS0xLTI4NzY5_02cd059a-d7ed-4f48-9427-cf0f6d863c6f">Common Stock, par value $0.004 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDA5NjZjMWY3ZmEwNDZiMmI3YjE2MDVkZmRlODQxYTIvdGFibGVyYW5nZTo0MDk2NmMxZjdmYTA0NmIyYjdiMTYwNWRmZGU4NDFhMl8xLTItMS0xLTI4NzY5_243fcb6b-50ea-4de8-9bfb-bab9e9204266">RMD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDA5NjZjMWY3ZmEwNDZiMmI3YjE2MDVkZmRlODQxYTIvdGFibGVyYW5nZTo0MDk2NmMxZjdmYTA0NmIyYjdiMTYwNWRmZGU4NDFhMl8xLTQtMS0xLTI4NzY5_68ce2832-7e41-45b6-be8e-abba97a305af">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDUw_79757c81-e61e-4894-a506-78297d64489c">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDcz_da45da5c-4fd3-4d84-9641-a75e7feaa300">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDc0_e2f5e15b-8f24-4b18-a361-29c5dfa58a3d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDU4_4cf06f8e-21f5-4701-932d-1f4c956ba749">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDYx_fb5a8ede-00fd-400a-8fcf-701afaa1edfe">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityFilerCategory
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDEwYTdlNTM3YWE5NGZkMThiZDQ0OTQwY2Q2ZDkzMGMvdGFibGVyYW5nZTo0MTBhN2U1MzdhYTk0ZmQxOGJkNDQ5NDBjZDZkOTMwY18wLTAtMS0xLTI4NzY5_1a4194f3-aa98-4f9f-bb4a-161d0b3d92b0">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDEwYTdlNTM3YWE5NGZkMThiZDQ0OTQwY2Q2ZDkzMGMvdGFibGVyYW5nZTo0MTBhN2U1MzdhYTk0ZmQxOGJkNDQ5NDBjZDZkOTMwY18xLTMtMS0xLTI4NzY5_e8990d8f-eac3-42d0-b419-5da423cf9bb0">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGFibGU6NDEwYTdlNTM3YWE5NGZkMThiZDQ0OTQwY2Q2ZDkzMGMvdGFibGVyYW5nZTo0MTBhN2U1MzdhYTk0ZmQxOGJkNDQ5NDBjZDZkOTMwY18yLTEtMS0xLTI4NzY5_8cacd345-b786-4449-b3d1-ef5d977065b9">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDY2_13450e07-5c64-40fb-aad7-bf3f3b6ee8b8">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF80MDY3_2e61c3a8-14d5-4f0e-a9db-cb3644c0e1e3">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="ibbdef3fca1f842ffb539ee7a7469d218_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8xMDk5NTExNjMyNTE0_51dd1083-cbc7-47fe-92d4-f750457e5519"
      unitRef="usd">37771141000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ie905261def8d433cbf089eb034507510_I20220808"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xL2ZyYWc6MmMzNzViNmRjMzcxNGNiNGFiNDY2NDgzOWFkZGEwMDQvdGV4dHJlZ2lvbjoyYzM3NWI2ZGMzNzE0Y2I0YWI0NjY0ODM5YWRkYTAwNF8zMjk4NTM0ODg4MTE0_3486d6db-4ce8-4c47-81b3-5ee8b2276400"
      unitRef="shares">146424981</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84Mi9mcmFnOjAyNzliZjgxMzY5ZTRhYTQ5ZTllMDFkZDkwMTU4MDk4L3RhYmxlOjFjOTYwNmFhZGFkYjRlYThiMTAyYTMyNDBmZDdjYTgwL3RhYmxlcmFuZ2U6MWM5NjA2YWFkYWRiNGVhOGIxMDJhMzI0MGZkN2NhODBfMC0wLTEtMS00ODg1OS90ZXh0cmVnaW9uOjY2ZDlmMjczZDE2MTRjMTBiMmMzNjQ3MGRkY2NkMDVhXzMyOTg1MzQ4ODM3MTM_b2bde88a-bab1-4e12-9b86-363a5131743f">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84Mi9mcmFnOjAyNzliZjgxMzY5ZTRhYTQ5ZTllMDFkZDkwMTU4MDk4L3RhYmxlOjFjOTYwNmFhZGFkYjRlYThiMTAyYTMyNDBmZDdjYTgwL3RhYmxlcmFuZ2U6MWM5NjA2YWFkYWRiNGVhOGIxMDJhMzI0MGZkN2NhODBfMC0wLTEtMS00ODg1OS90ZXh0cmVnaW9uOjY2ZDlmMjczZDE2MTRjMTBiMmMzNjQ3MGRkY2NkMDVhXzMyOTg1MzQ4ODM3Mjk_58e7adfd-0c8c-4dae-a29e-1f66375ed216">San Diego, CA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84Mi9mcmFnOjAyNzliZjgxMzY5ZTRhYTQ5ZTllMDFkZDkwMTU4MDk4L3RhYmxlOjFjOTYwNmFhZGFkYjRlYThiMTAyYTMyNDBmZDdjYTgwL3RhYmxlcmFuZ2U6MWM5NjA2YWFkYWRiNGVhOGIxMDJhMzI0MGZkN2NhODBfMC0wLTEtMS00ODg1OS90ZXh0cmVnaW9uOjY2ZDlmMjczZDE2MTRjMTBiMmMzNjQ3MGRkY2NkMDVhXzMyOTg1MzQ4ODM3MzU_cd7606ec-3161-484b-9458-84fcce531ed4">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMy0xLTEtMS0yODc2OQ_4d4fff31-b5f9-49b6-b309-a04415165147"
      unitRef="usd">273710000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMy0zLTEtMS0yODc2OQ_2b1f3152-56e6-4c76-ac49-1622a9c1bdc1"
      unitRef="usd">295278000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNC0wLTEtMS0yODc2OS90ZXh0cmVnaW9uOmRkMTBiNGFiMTU2NjQ0ZWM4ZDQxOTg1MWNkNTU3Y2MwXzQzOTgwNDY1MTExOTI_d1ad8520-3759-4f9f-8eee-5401e81b6823"
      unitRef="usd">23259000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNC0wLTEtMS0yODc2OS90ZXh0cmVnaW9uOmRkMTBiNGFiMTU2NjQ0ZWM4ZDQxOTg1MWNkNTU3Y2MwXzQzOTgwNDY1MTExOTY_d48d17fa-5b95-40ee-8b56-b8ffa4405424"
      unitRef="usd">32138000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNC0xLTEtMS0yODc2OQ_090fc419-9c08-4cc6-bcd4-1d199f0240d5"
      unitRef="usd">575950000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNC0zLTEtMS0yODc2OQ_2412db8b-696c-49d5-a531-4a8dde6fdf92"
      unitRef="usd">614292000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNS0xLTEtMS0yODc2OQ_6fb1a7b1-5bd5-4a15-a8b7-a9a1bd20f717"
      unitRef="usd">743910000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNS0zLTEtMS0yODc2OQ_872abad2-465d-4cd7-85d2-452525646ff5"
      unitRef="usd">457033000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNy0xLTEtMS0yODc2OQ_44c5db3c-dc77-4993-80c6-b6e7c1836839"
      unitRef="usd">337908000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNy0zLTEtMS0yODc2OQ_c1185f6c-0b22-4f3d-823f-e78bf39f2e39"
      unitRef="usd">208154000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfOC0xLTEtMS0yODc2OQ_2b4a5cdb-77c6-47b3-a9fc-8408aa31e1aa"
      unitRef="usd">1931478000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfOC0zLTEtMS0yODc2OQ_e912178d-eb1e-40a1-b65d-3b6e0f7ba0da"
      unitRef="usd">1574757000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTAtMS0xLTEtMjg3Njk_290d47f7-ed19-4f1d-af92-2d47099e337a"
      unitRef="usd">498181000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTAtMy0xLTEtMjg3Njk_a8c95fcc-f1dc-4521-af4a-1db2d0f36370"
      unitRef="usd">463490000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTEtMS0xLTEtMjg3Njk_d58df8db-74a3-4d34-a27b-049e78422c81"
      unitRef="usd">132314000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTEtMy0xLTEtMjg3Njk_add4b120-bab9-4bef-bcce-b688044d7030"
      unitRef="usd">128575000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTItMS0xLTEtMjg3Njk_d19a549f-1b55-41ef-83fa-35dadb4a4275"
      unitRef="usd">1936442000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTItMy0xLTEtMjg3Njk_6cc56a87-cba8-4508-a807-52809ec381a7"
      unitRef="usd">1927901000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTMtMS0xLTEtMjg3Njk_c933d4b1-2923-457a-af9c-34b58b38a387"
      unitRef="usd">345944000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTMtMy0xLTEtMjg3Njk_3dfeaa92-86f9-4842-8108-9424fa687fd0"
      unitRef="usd">392582000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTQtMS0xLTEtMjg3Njk_e27752bd-4ee4-49f3-99e4-c99066dba718"
      unitRef="usd">79746000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTQtMy0xLTEtMjg3Njk_f578adbb-defd-4edf-8684-bc1fc2e6bd73"
      unitRef="usd">79904000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTUtMS0xLTEtMjg3Njk_e0854e77-0179-419a-be10-5a384f3a4b25"
      unitRef="usd">171748000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTUtMy0xLTEtMjg3Njk_235d08a3-2f79-496e-9b19-1232b9cb14fb"
      unitRef="usd">160916000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTYtMS0xLTEtMjg3Njk_11984e2f-9fba-4482-9f70-63237ebfcf94"
      unitRef="usd">3164375000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTYtMy0xLTEtMjg3Njk_b6ea646b-c76f-4858-a04c-d7c947165ca4"
      unitRef="usd">3153368000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTctMS0xLTEtMjg3Njk_9678080a-b005-4ff2-9aad-566d3e31be9a"
      unitRef="usd">5095853000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMTctMy0xLTEtMjg3Njk_a5908e21-8c24-4aa7-a30e-c62da3558725"
      unitRef="usd">4728125000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjAtMS0xLTEtMjg3Njk_cf89916d-747b-470c-9dcd-d5ef1238b045"
      unitRef="usd">159245000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjAtMy0xLTEtMjg3Njk_65e2e077-3a4f-492c-bdfa-1903207ea682"
      unitRef="usd">138008000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjEtMS0xLTEtMjg3Njk_efa32ff4-561f-4f97-bd7a-afe010d1ceaa"
      unitRef="usd">344722000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjEtMy0xLTEtMjg3Njk_b591c108-851c-4178-bd66-d459d526b972"
      unitRef="usd">320599000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjItMS0xLTEtMjg3Njk_64edfd01-c896-4b10-8a3d-af99598210f2"
      unitRef="usd">21856000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjItMy0xLTEtMjg3Njk_30a284ab-7005-482b-965b-80152afd01ff"
      unitRef="usd">23585000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjMtMS0xLTEtMjg3Njk_05af2c77-7f15-4384-95ff-1599400ddd7c"
      unitRef="usd">108667000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjMtMy0xLTEtMjg3Njk_dc2e1210-a3b9-4f8d-b827-b3119f77bd48"
      unitRef="usd">109611000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjQtMS0xLTEtMjg3Njk_029bfc0d-7698-480a-9b7c-cb87056dc683"
      unitRef="usd">44893000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjQtMy0xLTEtMjg3Njk_ab176395-ec2f-4582-918b-1142a4c5df72"
      unitRef="usd">307963000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjUtMS0xLTEtMjg3Njk_89fb83fd-a781-49ec-9115-f304b9f78bf4"
      unitRef="usd">9916000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjUtMy0xLTEtMjg3Njk_62ad52e0-7971-4699-9fb9-7aa601cb4189"
      unitRef="usd">12000000</us-gaap:ShortTermBorrowings>
    <us-gaap:LiabilitiesCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjYtMS0xLTEtMjg3Njk_ce8c1b8d-02ae-4066-abde-55aaff018b10"
      unitRef="usd">689299000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjYtMy0xLTEtMjg3Njk_f5e30c8b-f6b3-434d-a163-bb8fa64380ef"
      unitRef="usd">911766000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjgtMS0xLTEtMjg3Njk_645a01bf-c8af-4133-94d6-9b85e5fbe33e"
      unitRef="usd">95455000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjgtMy0xLTEtMjg3Njk_f792d645-73d0-4810-a91a-2a1fbe4207a6"
      unitRef="usd">91496000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjktMS0xLTEtMjg3Njk_db2c02dc-12aa-451b-87b1-11e625ea1128"
      unitRef="usd">9714000</us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMjktMy0xLTEtMjg3Njk_c8dc72c7-09bd-46b6-be18-3e03d71864a1"
      unitRef="usd">11319000</us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzAtMS0xLTEtMjg3Njk_bc8d94b6-44d2-413c-bcfc-3d53e2138566"
      unitRef="usd">120453000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzAtMy0xLTEtMjg3Njk_a3eff863-abe1-4642-b4a3-4a570b455c66"
      unitRef="usd">114779000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzEtMS0xLTEtMjg3Njk_495de5d3-2a2b-42b3-8e77-2a10bc0e8517"
      unitRef="usd">5974000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzEtMy0xLTEtMjg3Njk_b0a54dd1-43fb-438a-86fd-773f976bed87"
      unitRef="usd">6802000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzItMS0xLTEtMjg3Njk_eeddd6a0-e93c-4b52-8474-dc7e0e24820f"
      unitRef="usd">765325000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzItMy0xLTEtMjg3Njk_cb5a182b-34fc-4061-a938-8266ed293314"
      unitRef="usd">643351000</us-gaap:LongTermDebt>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzMtMS0xLTEtMjg3Njk_df7eaf17-174f-48d4-ab73-dfb3fc3f1698"
      unitRef="usd">48882000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzMtMy0xLTEtMjg3Njk_e068fe1d-89b1-4c77-8ffb-8ab9cbc52547"
      unitRef="usd">62933000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzQtMS0xLTEtMjg3Njk_b76f41be-50fb-4d2f-b76a-3091fef8a16b"
      unitRef="usd">1045803000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzQtMy0xLTEtMjg3Njk_dbe3d244-141a-469f-87b3-1a48d8100dab"
      unitRef="usd">930680000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzUtMS0xLTEtMjg3Njk_7d367104-8049-4348-81be-b940d9e4bf5d"
      unitRef="usd">1735102000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzUtMy0xLTEtMjg3Njk_4efb3567-ec0c-4dc0-9e67-9c80650a8551"
      unitRef="usd">1842446000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzYtMS0xLTEtMjg3Njk_c2c6eb6a-1322-4e98-9a30-5a4094fa6948"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzYtMy0xLTEtMjg3Njk_210085c8-8371-4e84-abcc-e23af165caa4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTcx_e3cc88ff-60ef-49fa-bbe2-1f752eb6a0d4"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTcx_eaba2288-df04-4670-a4f1-eec1b4623eef"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTc1_36d3c7ff-726b-4bec-816c-bcebb58c677f"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTc1_ca0c5f7f-8c7d-421c-9af4-5118b045ef6c"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTc5_b94bd01f-199b-4222-9fa0-fbbfcf6240f6"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjowMDVhNWE4MmQ1OTA0YzU2YTg1OTBjNTc2NzZhYjFiNV80Mzk4MDQ2NTExMTc5_f692d70f-fde0-418d-96fa-32de7052a92c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMS0xLTEtMjg3Njk_c2530a30-15d0-4617-bf4d-0353bbec04ab"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzgtMy0xLTEtMjg3Njk_9f041d19-20e2-4594-9a0d-ea74c3719b91"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV8xOA_38582792-ef0f-4fa5-a6a8-bfa4708aeeca"
      unitRef="usdPerShare">0.004</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV8xOA_cbe19e59-bf4f-49fd-af9a-3d88f1249ecb"
      unitRef="usdPerShare">0.004</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjM0_227b93dd-370e-42f0-b6ab-fa3852b7ffa7"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjM0_470985a6-1fcc-4590-8840-a2bf0ac0ef79"
      unitRef="shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjM4_91b3a2ad-c295-41c8-8500-3eaaefe5a5d4"
      unitRef="shares">188246955</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjQy_d7eec664-1502-4ae3-9ffb-1b5cc8bdc273"
      unitRef="shares">146410721</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjUw_d25996c4-5121-4bc1-90c0-218a823f05ec"
      unitRef="shares">187484592</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjpmODNjNDQyMWQ1ZGU0ZTM1YWJiZjgwOTg5Y2FlNDM5OV80Mzk4MDQ2NTExMjU0_b9f62a7d-4fd6-45bf-afbe-2aa66066e609"
      unitRef="shares">145648358</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMS0xLTEtMjg3Njk_dee8229e-5707-49e9-9383-8220aa1c4ece"
      unitRef="usd">586000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfMzktMy0xLTEtMjg3Njk_eb1d31f4-19d6-4108-b722-3285774ca778"
      unitRef="usd">583000</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDAtMS0xLTEtMjg3Njk_03c7e85f-5a61-4328-b36f-7ca3838c5df6"
      unitRef="usd">1682432000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDAtMy0xLTEtMjg3Njk_12c348ea-7bb3-49e2-b201-cdcded328091"
      unitRef="usd">1622199000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDEtMS0xLTEtMjg3Njk_52b2e355-19c6-4f2a-808a-301e8ef2a29e"
      unitRef="usd">3613736000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDEtMy0xLTEtMjg3Njk_17e8acd1-5dcc-4088-a57d-697f77c642d7"
      unitRef="usd">3079640000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDItMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjplZmJlM2E5Zjk0ZDM0MDA1ODZkMDg3NTViMzljNmNjY180Mzk4MDQ2NTExMTU2_6ba1b7e2-323b-4367-88e7-2cfdebafeb01"
      unitRef="shares">41836234</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDItMC0xLTEtMjg3NjkvdGV4dHJlZ2lvbjplZmJlM2E5Zjk0ZDM0MDA1ODZkMDg3NTViMzljNmNjY180Mzk4MDQ2NTExMTU2_ff116868-affc-4014-a141-0f613b043abf"
      unitRef="shares">41836234</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDItMS0xLTEtMjg3Njk_4dc5819f-427a-4088-b4c9-4082af233bc2"
      unitRef="usd">1623256000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDItMy0xLTEtMjg3Njk_bf0e9787-8257-435c-aa74-4995dbb7205d"
      unitRef="usd">1623256000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDMtMS0xLTEtMjg3Njk_6a2754f1-0f13-4c6f-92bb-87e2ccf54789"
      unitRef="usd">-312747000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDMtMy0xLTEtMjg3Njk_321f3643-fa54-4ec2-8c4b-6ea5549c641e"
      unitRef="usd">-193487000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDQtMS0xLTEtMjg3Njk_e3e33d01-9c11-469e-b415-b6dc61fb8f76"
      unitRef="usd">3360751000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDQtMy0xLTEtMjg3Njk_076e6310-e1dc-48ba-aee2-a3c10abf90cd"
      unitRef="usd">2885679000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDUtMS0xLTEtMjg3Njk_3411bf3f-5eaa-46df-b31e-2330f09a09a7"
      unitRef="usd">5095853000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl84OC9mcmFnOjliODYyOTkxZjgyMTQ5MDE4Nzg5NmVlZDMxZTU3YTYxL3RhYmxlOjAyNThjMzUwODgxMjRjMTI5OWVkZDM2ZmViMWIxNDM2L3RhYmxlcmFuZ2U6MDI1OGMzNTA4ODEyNGMxMjk5ZWRkMzZmZWIxYjE0MzZfNDUtMy0xLTEtMjg3Njk_1540d727-d0d2-4c7c-8d0a-4e601fb6cfff"
      unitRef="usd">4728125000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6e67c47d1fc44c41b072ad44589d1ad5_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMS0xLTEtMS0yODc2OQ_15dcc600-36be-411c-812d-2bef46b3e2b5"
      unitRef="usd">3177298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a9b9cae84c447429471e59078cc7791_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMS0zLTEtMS0yODc2OQ_169cf5f4-82b9-448d-89e8-cf8037839e2d"
      unitRef="usd">2823235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e1f5a8c9d8a4df7afb7de1694802ffb_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMS01LTEtMS0yODc2OQ_01d3b3a8-91cd-4448-900e-0ec09a6d894d"
      unitRef="usd">2602381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1968e917afd4a069dcce0cf81596189_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMi0xLTEtMS0yODc2OQ_c3efcfa1-ff4f-4a6a-9325-7d8a8e6985ab"
      unitRef="usd">400829000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i55f3256c15f5423dae9d0f83d1016c16_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMi0zLTEtMS0yODc2OQ_34fc1f6d-b50b-4619-93f5-3bc58597f7fe"
      unitRef="usd">373590000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib50fa129c39f4e95a4ced80f5095f914_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMi01LTEtMS0yODc2OQ_8de7151b-8ae6-4046-85ea-17670c34a819"
      unitRef="usd">354632000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMy0xLTEtMS0yODc2OQ_822fa376-6528-43f2-919a-dd21f258a0be"
      unitRef="usd">3578127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMy0zLTEtMS0yODc2OQ_227a2034-b64b-4859-850a-edd502484986"
      unitRef="usd">3196825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMy01LTEtMS0yODc2OQ_77acf33c-fbd6-4589-a56e-0518c8bd1d5e"
      unitRef="usd">2957013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i6e67c47d1fc44c41b072ad44589d1ad5_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNS0xLTEtMS0yODc2OQ_53de7f24-6e74-4383-a55e-2dde4b698bc3"
      unitRef="usd">1365421000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i6a9b9cae84c447429471e59078cc7791_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNS0zLTEtMS0yODc2OQ_5306f785-423d-4560-9d0b-63663c81de88"
      unitRef="usd">1177309000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i1e1f5a8c9d8a4df7afb7de1694802ffb_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNS01LTEtMS0yODc2OQ_3f971b17-d48e-415c-826a-768828871e7f"
      unitRef="usd">1067967000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ia1968e917afd4a069dcce0cf81596189_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNi0xLTEtMS0yODc2OQ_60094c60-5423-4e89-8b86-4fe175eab5eb"
      unitRef="usd">148745000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i55f3256c15f5423dae9d0f83d1016c16_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNi0zLTEtMS0yODc2OQ_024f7592-33ca-4828-aa0f-ef8a8082ae74"
      unitRef="usd">135289000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="ib50fa129c39f4e95a4ced80f5095f914_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNi01LTEtMS0yODc2OQ_bc47fcc6-f788-44b6-aaf2-9db5d047c435"
      unitRef="usd">121657000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNy0xLTEtMS0yODc2OQ_e38b4ee8-bb0e-41d4-896e-5e3ff3386ade"
      unitRef="usd">1514166000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNy0zLTEtMS0yODc2OQ_bc53e09d-0cd3-4f99-b80e-1caefc855384"
      unitRef="usd">1312598000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfNy01LTEtMS0yODc2OQ_97d0e88e-6ce7-433f-a35d-44e79baa425b"
      unitRef="usd">1189624000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6e67c47d1fc44c41b072ad44589d1ad5_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfOS0xLTEtMS0yODc2OQ_a857617d-d935-4fca-892c-7f08ed6590a4"
      unitRef="usd">4105000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6a9b9cae84c447429471e59078cc7791_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfOS0zLTEtMS0yODc2OQ_0acd15c3-3478-43a3-80fa-a367ad4a7798"
      unitRef="usd">4895000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i1e1f5a8c9d8a4df7afb7de1694802ffb_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfOS01LTEtMS0yODc2OQ_39bb27d7-1888-4b39-928d-4fe04ce07c17"
      unitRef="usd">8584000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia1968e917afd4a069dcce0cf81596189_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTAtMS0xLTEtMjg3Njk_7204dd00-4660-4b3b-a1c8-4d3594c049f3"
      unitRef="usd">35545000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i55f3256c15f5423dae9d0f83d1016c16_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTAtMy0xLTEtMjg3Njk_1e54f0ad-e7e9-4080-a462-d75476e8862b"
      unitRef="usd">40232000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib50fa129c39f4e95a4ced80f5095f914_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTAtNS0xLTEtMjg3Njk_a90dc633-7a41-4e6c-aba1-f04031b3e507"
      unitRef="usd">41019000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTEtMS0xLTEtMjg3Njk_089e3d7f-9c70-4b68-a08a-c74c8501d8f4"
      unitRef="usd">39650000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTEtMy0xLTEtMjg3Njk_edd956f8-2e46-4ded-98d0-fde08cf30dbf"
      unitRef="usd">45127000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTEtNS0xLTEtMjg3Njk_65adb489-eb72-4dbd-815f-d25e1effed13"
      unitRef="usd">49603000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTItMS0xLTEtMjg3Njk_783b4260-0638-4840-ac40-56063be85d16"
      unitRef="usd">1553816000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTItMy0xLTEtMjg3Njk_86ffd1e2-25b1-4e47-87a8-1a5024ebc352"
      unitRef="usd">1357725000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTItNS0xLTEtMjg3Njk_2e5f7909-1804-430b-9b2d-30286dd7c0ac"
      unitRef="usd">1239227000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTMtMS0xLTEtMjg3Njk_09a23d20-5ab5-4392-a6da-6bc14f44313b"
      unitRef="usd">2024311000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTMtMy0xLTEtMjg3Njk_dfc6384a-9e58-4c3a-9582-01ec50087837"
      unitRef="usd">1839100000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTMtNS0xLTEtMjg3Njk_6f0a918c-bc06-47e8-8286-18e4b899745f"
      unitRef="usd">1717786000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTUtMS0xLTEtMjg3Njk_a9c0dbc7-6880-47b2-89dd-3a14161b904f"
      unitRef="usd">739372000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTUtMy0xLTEtMjg3Njk_37e7f527-6a9d-4c79-9fc4-5f5b8619d4a1"
      unitRef="usd">670387000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTUtNS0xLTEtMjg3Njk_802b7d89-e4bc-492d-aac3-ab2597445f4d"
      unitRef="usd">676689000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTYtMS0xLTEtMjg3Njk_70b0b189-8931-46a7-9191-785b8be17d4f"
      unitRef="usd">253575000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTYtMy0xLTEtMjg3Njk_b2101ee6-eb0b-406e-9d1c-e0945be77a69"
      unitRef="usd">225284000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTYtNS0xLTEtMjg3Njk_350d48d1-14eb-421b-be8f-b3d3169da69b"
      unitRef="usd">201946000</us-gaap:ResearchAndDevelopmentExpense>
    <rmd:AmortizationOfAcquiredIntangibleAssets1
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTctMS0xLTEtMjg3Njk_1842e7ef-bcab-43af-aa62-92c22b0b5d48"
      unitRef="usd">31078000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <rmd:AmortizationOfAcquiredIntangibleAssets1
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTctMy0xLTEtMjg3Njk_254a95b9-b90f-42e8-a2d2-20ee93fc2511"
      unitRef="usd">31078000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <rmd:AmortizationOfAcquiredIntangibleAssets1
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTctNS0xLTEtMjg3Njk_8c819f29-ddfe-43b5-93c2-6182747e5836"
      unitRef="usd">30092000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <us-gaap:RestructuringCharges
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTgtMS0xLTEtMjg3Njk_d45e4390-540f-4c14-92ef-aed34a434fd5"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTgtMy0xLTEtMjg3Njk_acb0b8a9-ccfb-4b04-856c-73933728bb36"
      unitRef="usd">8673000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTgtNS0xLTEtMjg3Njk_497bdad2-6fac-443c-a622-b0ed66c78524"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTktMS0xLTEtMjg3Njk_41cc15bd-f927-42fd-b906-9d7476f4459b"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTktMy0xLTEtMjg3Njk_16b3e167-67ba-4bbc-b7ee-c5ac0c9175a0"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMTktNS0xLTEtMjg3Njk_7474bb4f-d676-40cd-b052-2c3e1cbc8c41"
      unitRef="usd">-600000</us-gaap:LitigationSettlementExpense>
    <us-gaap:OperatingExpenses
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjEtMS0xLTEtMjg3Njk_9dc9b323-7dce-4757-8778-89ff6afc6292"
      unitRef="usd">1024025000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjEtMy0xLTEtMjg3Njk_d29052bf-f7fd-4c24-a834-04993079688e"
      unitRef="usd">935422000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjEtNS0xLTEtMjg3Njk_edec9b21-19d0-435d-8242-0a832d7626e6"
      unitRef="usd">908127000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjItMS0xLTEtMjg3Njk_d0a94909-7f60-440f-b4e5-e12d543dc0ca"
      unitRef="usd">1000286000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjItMy0xLTEtMjg3Njk_c49e3681-df65-43c2-96cd-accce731a68e"
      unitRef="usd">903678000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjItNS0xLTEtMjg3Njk_1dfa0b83-5878-4553-9cc8-a8971b12c1a4"
      unitRef="usd">809659000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjQtMS0xLTEtMjg3Njk_56117148-a66e-420c-a28a-1e2b394a097a"
      unitRef="usd">-22312000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjQtMy0xLTEtMjg3Njk_4afb7dd5-209f-4c7d-a6d6-b384b1ff9e86"
      unitRef="usd">-23627000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjQtNS0xLTEtMjg3Njk_2f3419fe-93bf-4281-b70f-f1c3597a7304"
      unitRef="usd">-39356000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjUtMS0xLTEtMjg3Njk_42dd9bc3-1ea6-47ec-966d-ea46143a162d"
      unitRef="usd">-8486000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjUtMy0xLTEtMjg3Njk_13d15082-272c-4744-8824-90ab7629d7f6"
      unitRef="usd">-11205000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjUtNS0xLTEtMjg3Njk_36083b66-4bb1-4554-a69a-ca4972df89df"
      unitRef="usd">-25058000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjYtMS0xLTEtMjg3Njk_aa3663ba-4b25-4659-9e26-c110deae2fe0"
      unitRef="usd">-12202000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjYtMy0xLTEtMjg3Njk_53cdadd1-14e7-4ebf-ab23-c6559bb2f2bd"
      unitRef="usd">14515000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjYtNS0xLTEtMjg3Njk_9fc11c08-afe1-4589-af2d-e360c4b4d3b9"
      unitRef="usd">-14519000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjctMS0xLTEtMjg3Njk_3fcd12ea-13ef-4c7d-8288-74fff4cf309b"
      unitRef="usd">3197000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjctMy0xLTEtMjg3Njk_d5e194af-06c3-44f4-9e96-dedd9681b21a"
      unitRef="usd">301000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjctNS0xLTEtMjg3Njk_402e94e4-8602-4aac-a6ee-0f019c3a3fd7"
      unitRef="usd">2362000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjgtMS0xLTEtMjg3Njk_99ecdc05-75c5-4506-9e9c-9c38c9a7fc20"
      unitRef="usd">-39803000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjgtMy0xLTEtMjg3Njk_c2bead58-4eaa-4c6e-b03f-d54b8cb71256"
      unitRef="usd">-20016000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjgtNS0xLTEtMjg3Njk_02ef9d61-ecfd-49c4-8415-b5113a3dbdef"
      unitRef="usd">-76571000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjktMS0xLTEtMjg3Njk_45e368be-fa4c-4fba-9dbb-9694031a9bb0"
      unitRef="usd">960483000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjktMy0xLTEtMjg3Njk_905bdc80-d74e-4b59-bbb0-470b5865906e"
      unitRef="usd">883662000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMjktNS0xLTEtMjg3Njk_6394be87-c60e-4f01-afa8-fe911451bf27"
      unitRef="usd">733088000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzAtMS0xLTEtMjg3Njk_b0bdb219-1685-4996-b785-14cf3e77772c"
      unitRef="usd">181046000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzAtMy0xLTEtMjg3Njk_dc925bd9-aad1-4cf8-9d37-33a15d329338"
      unitRef="usd">409157000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzAtNS0xLTEtMjg3Njk_d1f32b6a-c1c0-420b-845f-dc4c559c1b5d"
      unitRef="usd">111414000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzEtMS0xLTEtMjg3Njk_b0c06fce-a788-4e86-9c05-f6534ba74852"
      unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzEtMy0xLTEtMjg3Njk_042778dd-8240-41f4-9ca7-6efb5fdbbcef"
      unitRef="usd">474505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzEtNS0xLTEtMjg3Njk_2d6dfa79-2e8b-4367-b106-6ee3257f19db"
      unitRef="usd">621674000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzMtMS0xLTEtMjg3Njk_ad7be7e7-0f95-4846-901d-b33bf19e841b"
      unitRef="usdPerShare">5.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzMtMy0xLTEtMjg3Njk_dba79c2a-0c30-43d2-b8ca-de42666df6ec"
      unitRef="usdPerShare">3.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzMtNS0xLTEtMjg3Njk_9fa7865d-5b41-49b6-895f-893b6d9210d8"
      unitRef="usdPerShare">4.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzQtMS0xLTEtMjg3Njk_303837ea-ae14-4e75-a7e1-71fa95ef76a0"
      unitRef="usdPerShare">5.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzQtMy0xLTEtMjg3Njk_9515fc52-b90b-4013-bb5e-e46be04662d7"
      unitRef="usdPerShare">3.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzQtNS0xLTEtMjg3Njk_44e4ccb0-fcb9-46d1-b538-36734fe853ef"
      unitRef="usdPerShare">4.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzUtMS0xLTEtMjg3Njk_9b01bda4-5504-40c9-af8d-688879a08284"
      unitRef="usdPerShare">1.68</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzUtMy0xLTEtMjg3Njk_70e3f666-0b0e-4a0c-b557-a0df8f36eff2"
      unitRef="usdPerShare">1.56</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzUtNS0xLTEtMjg3Njk_81806d47-73e5-4027-9614-00a20d151720"
      unitRef="usdPerShare">1.56</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzYtMS0xLTEtMjg3Njk_8ca515f1-a545-44b5-b8f4-762555fc5951"
      unitRef="shares">146066000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzYtMy0xLTEtMjg3Njk_38a0427b-3cfe-41d5-b3aa-7c00dc3d7d80"
      unitRef="shares">145313000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzYtNS0xLTEtMjg3Njk_051ef519-0ce3-4d37-914d-d6d432af1810"
      unitRef="shares">144338000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzctMS0xLTEtMjg3Njk_917a6c9f-5142-43a1-ad1b-081e99fd6406"
      unitRef="shares">147043000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzctMy0xLTEtMjg3Njk_d53acd1f-65c5-4330-bf36-c0deb0cda4ef"
      unitRef="shares">146451000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85MS9mcmFnOjY1YzE2NGYxYzg0YzQ5NDNiZmE4Mzc4ZDMxZGNlNzNhL3RhYmxlOmNiY2FkODM5YjRiZDQ4NDJhYjllYjRjYTg1YjY2ZGVmL3RhYmxlcmFuZ2U6Y2JjYWQ4MzliNGJkNDg0MmFiOWViNGNhODViNjZkZWZfMzctNS0xLTEtMjg3Njk_bd6323ed-3454-4a6b-9856-e77c40288961"
      unitRef="shares">145652000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMS0xLTEtMS0yODc2OQ_b98de0fb-72cb-4acc-94f5-b50a77216cc6"
      unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMS0zLTEtMS0yODc2OQ_04e71553-98e6-4c95-9db8-0e397173554f"
      unitRef="usd">474505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMS01LTEtMS0yODc2OQ_521b3c3f-db49-4a3c-b6e1-12275f8b75ea"
      unitRef="usd">621674000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMy0xLTEtMS0yODc2OQ_26a9d11a-e114-4133-93ea-e9ba7a012024"
      unitRef="usd">-119260000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMy0zLTEtMS0yODc2OQ_2e5eb6be-2d6c-46d0-8993-8689da61540c"
      unitRef="usd">90495000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfMy01LTEtMS0yODc2OQ_152a50b8-4ce5-4839-9123-8959acec9f6b"
      unitRef="usd">-30973000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfNC0xLTEtMS0yODc2OQ_4e75c1de-c75d-4313-be64-8fd77900ba72"
      unitRef="usd">660177000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfNC0zLTEtMS0yODc2OQ_95d45051-59ff-490a-917c-955cfeb164a6"
      unitRef="usd">565000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85NC9mcmFnOmMzYjZjNDRiYWZiZDQ2ZmI4ODM4NmQxNjdjNjE5ZGMxL3RhYmxlOjczMGZhNmFhYWFkYzRmNzQ5N2Y1ZWZmMTZlZTI4YjFkL3RhYmxlcmFuZ2U6NzMwZmE2YWFhYWRjNGY3NDk3ZjVlZmYxNmVlMjhiMWRfNC01LTEtMS0yODc2OQ_f1a7889b-f726-4f71-ac96-a9745af71db0"
      unitRef="usd">590701000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i607c9c75962444d08f128d8d1dd51b12_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi0xLTEtMS0yODc2OQ_20663a6c-c513-4b47-b96c-3ae54b5b4fa4"
      unitRef="shares">185491000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i607c9c75962444d08f128d8d1dd51b12_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi0zLTEtMS0yODc2OQ_d44e0aea-83ef-46e6-ba6d-0d2a490cff88"
      unitRef="usd">575000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i79dd5c34ff9f422d9e66e42855b0fe44_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi01LTEtMS0yODc2OQ_ff27b437-ab1b-4b2a-8742-4568f253cff7"
      unitRef="usd">1511473000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i5eec134b8bd6450baec5eba43690fb81_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi03LTEtMS0yODc2OQ_bd32af8e-e6fd-4e37-a355-b52fb52522ed"
      unitRef="shares">41836000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i5eec134b8bd6450baec5eba43690fb81_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi05LTEtMS0yODc2OQ_09af3568-e4ab-4de8-b668-b51629f1d184"
      unitRef="usd">-1623256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4f27f1170fa649259d40577a59061c34_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi0xMS0xLTEtMjg3Njk_7acefa27-c327-433c-a14c-aa41b49f76c1"
      unitRef="usd">2436410000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0e9c77435e45485c85034973f776a026_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi0xMy0xLTEtMjg3Njk_f45ba878-7225-4c05-8d8f-1adc50f257f9"
      unitRef="usd">-253009000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6113f72766ae4bf3a6b6822df9ec9799_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMi0xNS0xLTEtMjg3Njk_6e46f3b2-ce0a-4dd2-99b4-c3ae4c620338"
      unitRef="usd">2072193000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMy0xLTEtMS0yODc2OQ_18934e6b-968b-4abb-9bc2-9bf0773d3e42"
      unitRef="shares">350000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMy0zLTEtMS0yODc2OQ_5f6eafb6-f883-44ef-9c1f-64a567f47271"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie1d7efe198194679bd87c4519fbad23e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMy01LTEtMS0yODc2OQ_da3222ec-bb3d-48fc-9f7b-9b0734017a11"
      unitRef="usd">19986000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMy0xNS0xLTEtMjg3Njk_48b8518d-fb40-467e-a170-fd97fbe94ccb"
      unitRef="usd">19987000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNC0xLTEtMS0yODc2OQ_3e362d9a-a499-4715-b8e0-939002311f47"
      unitRef="shares">617000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNC0zLTEtMS0yODc2OQ_1ff5316f-948a-4189-b28b-028d47f49825"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ie1d7efe198194679bd87c4519fbad23e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNC01LTEtMS0yODc2OQ_8e417eec-0c9d-4f05-9e4b-1257162be8c8"
      unitRef="usd">-46061000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNC0xNS0xLTEtMjg3Njk_ca9b14cf-c638-4bca-8f8b-ab95ff045466"
      unitRef="usd">-46058000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNS0xLTEtMS0yODc2OQ_a20968c5-d0bc-4a0f-a036-28f66b12a448"
      unitRef="shares">265000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i0eb9ed67967b4782965b7cf502c6bf13_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNS0zLTEtMS0yODc2OQ_c8244c6e-d51c-484f-bf8b-79332a1e1965"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie1d7efe198194679bd87c4519fbad23e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNS01LTEtMS0yODc2OQ_fa3f02d0-f7b5-4c88-934d-4611fbec8d1e"
      unitRef="usd">28196000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNS0xNS0xLTEtMjg3Njk_13c80f57-5dc1-4568-9e69-ebf6402bf756"
      unitRef="usd">28197000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie1d7efe198194679bd87c4519fbad23e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNy01LTEtMS0yODc2OQ_e0b8c0af-8f38-444b-9b55-d7f01670bf6d"
      unitRef="usd">57100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfNy0xNS0xLTEtMjg3Njk_b6d11b62-0315-4e18-9f2f-a194f4e35d2d"
      unitRef="usd">57100000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i08a4d2be57e74a8ab5b264970b29954e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfOC0xMy0xLTEtMjg3Njk_33d4a0d1-06bf-4f07-97e5-9aaf03905d22"
      unitRef="usd">-30973000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfOC0xNS0xLTEtMjg3Njk_17cea6f3-c6dc-48b1-b61f-24b73b8d951d"
      unitRef="usd">-30973000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i747690daf6804d479047c828f5efc32a_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfOS0xMS0xLTEtMjg3Njk_be736e8e-4539-432a-b828-45e85ca3f890"
      unitRef="usd">621674000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfOS0xNS0xLTEtMjg3Njk_bcf88d16-3717-4bd0-857e-d91972bc0a55"
      unitRef="usd">621674000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTEtMC0xLTEtMjkzNTMvdGV4dHJlZ2lvbjo5MTFlYzgxMWFlMDI0NTgyYTBkNDgzMWRmNWRjMzZjMV80Mzk4MDQ2NTExMTYw_ec03ea38-22e8-4069-b8c4-7066d574dbe0"
      unitRef="usdPerShare">1.56</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:Dividends
      contextRef="i747690daf6804d479047c828f5efc32a_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTEtMTEtMS0xLTI4NzY5_24c41966-b291-479e-9316-788ebc9f1ffe"
      unitRef="usd">225093000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTEtMTUtMS0xLTI4NzY5_25e89762-0be5-40d4-b0e9-0e44c16446e2"
      unitRef="usd">225093000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6592376d0e874a54b0c74878697fe0fa_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItMS0xLTEtMjg3Njk_cd3fdd7d-0142-4472-b939-cf758ebebd29"
      unitRef="shares">186723000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6592376d0e874a54b0c74878697fe0fa_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItMy0xLTEtMjg3Njk_3b9ea6a2-eaa0-46ed-a59c-54f947f9ca9f"
      unitRef="usd">580000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia0787de141ff41878aae7892528f698a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItNS0xLTEtMjg3Njk_b2d4318e-762e-4370-971e-e7ae9f14d2b0"
      unitRef="usd">1570694000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i37d85afb3c0245f5af0854c9191a8cb0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItNy0xLTEtMjg3Njk_f5364c79-70fd-4fb1-a16f-41589bf0bbcf"
      unitRef="shares">41836000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i37d85afb3c0245f5af0854c9191a8cb0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItOS0xLTEtMjg3Njk_6b293d30-0097-49de-99a5-e63ab69fb060"
      unitRef="usd">-1623256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i88f72c5541674f6592c342e22fc4e04e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItMTEtMS0xLTI4NzY5_89873027-e0dc-4d66-bd0c-69d4e722ccac"
      unitRef="usd">2832991000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8394569b4f94ef8955d0f57473de626_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItMTMtMS0xLTI4NzY5_3665210d-e58a-4fe6-85c7-6e427fa95570"
      unitRef="usd">-283982000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTItMTUtMS0xLTI4NzY5_5d9541f4-5736-4fc0-8840-cd9a66aa78f1"
      unitRef="usd">2497027000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTMtMS0xLTEtMjg3Njk_0aeed296-8f68-4a72-a8de-3c887e5611d7"
      unitRef="shares">64000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTMtMy0xLTEtMjg3Njk_5834eac9-be45-4bca-b928-ea777425c80a"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ic737aa421e0a4e9782bc67d50120cb7f_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTMtNS0xLTEtMjg3Njk_895116fc-b72e-480a-a9cc-20cd3507f52f"
      unitRef="usd">3954000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTMtMTUtMS0xLTI4NzY5_0ff723f7-5702-4d80-b3df-4c65319f5a57"
      unitRef="usd">3954000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTQtMS0xLTEtMjg3Njk_dd546484-0915-4ec1-850c-a9ee1d44ec22"
      unitRef="shares">469000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTQtMy0xLTEtMjg3Njk_77023d9d-556a-4649-b80e-5f6d39b5c1c7"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ic737aa421e0a4e9782bc67d50120cb7f_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTQtNS0xLTEtMjg3Njk_10ccb5b0-8221-4d43-9583-57a06a6c8c05"
      unitRef="usd">-50209000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTQtMTUtMS0xLTI4NzY5_d2ea2c7e-1363-4e16-aa07-89e8603cee7a"
      unitRef="usd">-50207000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTUtMS0xLTEtMjg3Njk_c5bb7af5-96bd-41bf-91ba-a2fed518d86c"
      unitRef="shares">229000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="iade2a38a39f64c389d5899176b764aea_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTUtMy0xLTEtMjg3Njk_51ed60b7-8bf3-42e0-b8d8-dfb225449912"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic737aa421e0a4e9782bc67d50120cb7f_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTUtNS0xLTEtMjg3Njk_9826ed03-c532-496f-98da-9fcac826263d"
      unitRef="usd">33833000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTUtMTUtMS0xLTI4NzY5_e38b7a6d-ef41-43ac-a2e0-10f39662891f"
      unitRef="usd">33834000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic737aa421e0a4e9782bc67d50120cb7f_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTYtNS0xLTEtMjg3Njk_1663f8f4-7be7-4ef9-9b00-38a911355dd7"
      unitRef="usd">63927000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTYtMTUtMS0xLTI4NzY5_1db25e78-2359-4eb0-b4c3-492645330c3d"
      unitRef="usd">63927000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia1c1ddd15e1e47c9af2f8d75690aff1e_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTctMTMtMS0xLTI4NzY5_6dce46cf-e065-43db-ae29-d26404748cee"
      unitRef="usd">90495000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTctMTUtMS0xLTI4NzY5_a5495d35-3451-49f2-b648-34446e4b782a"
      unitRef="usd">90495000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i514c68b0178849528b98da7c305b377b_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTgtMTEtMS0xLTI4NzY5_c63c11ed-bf24-4e39-b4cf-576fa0eb322b"
      unitRef="usd">474505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTgtMTUtMS0xLTI4NzY5_67a4b00a-51d4-46eb-a735-167d4ef6a795"
      unitRef="usd">474505000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquity
      contextRef="if89490bfd4ff476b8ef0c46da716b643_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTctMTEtMS0xLTMyNjg2_459e075d-322f-4e1e-96b6-1a0fd016a8e3"
      unitRef="usd">-1143000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic9052a046d6444bdb2321e25b6d1995e_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTctMTUtMS0xLTMyNjg2_fe9f123a-fc12-4fd7-8fd6-b331d1482316"
      unitRef="usd">-1143000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTktMC0xLTEtMjkzNTkvdGV4dHJlZ2lvbjo3YjI1ZmQ3YmMyMjU0ZDQ5OGZlYzUxMjAwNGYwZjY0Zl80Mzk4MDQ2NTExMTYw_3e64c28f-e591-4c90-b084-068531c3acb3"
      unitRef="usdPerShare">1.56</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:Dividends
      contextRef="i514c68b0178849528b98da7c305b377b_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTktMTEtMS0xLTI4NzY5_b2b6c712-ac8d-4b7c-bb4a-863628813024"
      unitRef="usd">226713000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMTktMTUtMS0xLTI4NzY5_e0f5403d-8372-49a4-b1d2-fe756c743cf9"
      unitRef="usd">226713000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5143bf6786f34585b5c51f7be503d02b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtMS0xLTEtMjg3Njk_e0ec0255-586f-4ad9-be81-9f6900942674"
      unitRef="shares">187485000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5143bf6786f34585b5c51f7be503d02b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtMy0xLTEtMjg3Njk_8254b1b1-011c-41f9-9db9-0215afc72299"
      unitRef="usd">583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie47e6eabf77f427ba2b95ab6114f5051_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtNS0xLTEtMjg3Njk_ba538c5a-d27d-441a-9a19-bc25724d709e"
      unitRef="usd">1622199000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="iacae05028f8d4777a29f62e32c114e8d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtNy0xLTEtMjg3Njk_7bdeea47-3af1-40ee-90aa-9475acd27293"
      unitRef="shares">41836000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="iacae05028f8d4777a29f62e32c114e8d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtOS0xLTEtMjg3Njk_c5576e50-a197-4f61-88c7-85219d85b040"
      unitRef="usd">-1623256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a5cda1b02464bfd8426853a49a7491c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtMTEtMS0xLTI4NzY5_bda172a2-4658-4f5a-b95f-76eed2118ece"
      unitRef="usd">3079640000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia489861770004d4582aa5f3dc793010f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtMTMtMS0xLTI4NzY5_79dfc92d-1220-45e2-8de1-67c24fc4d9c4"
      unitRef="usd">-193487000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjAtMTUtMS0xLTI4NzY5_b1255898-d761-4622-bdbe-4c64167c7647"
      unitRef="usd">2885679000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjEtMS0xLTEtMjg3Njk_3b4fa790-864a-4811-9a36-a0f80e3e40dd"
      unitRef="shares">177000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjEtMy0xLTEtMjg3Njk_211ac075-a93b-4007-acf7-902b1714e88b"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie65c792136c946adbf377040f6366deb_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjEtNS0xLTEtMjg3Njk_593e4646-04cf-4f14-b8c5-0c718505577b"
      unitRef="usd">11205000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjEtMTUtMS0xLTI4NzY5_23c4038e-c880-4e96-9b99-405ba3c0c8a8"
      unitRef="usd">11205000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjItMS0xLTEtMjg3Njk_788a739a-5fd7-4945-a7ae-fa6645ddee98"
      unitRef="shares">369000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjItMy0xLTEtMjg3Njk_0bef8c75-1ef7-421e-b32d-2df0413e3926"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="ie65c792136c946adbf377040f6366deb_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjItNS0xLTEtMjg3Njk_908ee341-e543-4980-8a67-c71fac2a0955"
      unitRef="usd">-52408000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjItMTUtMS0xLTI4NzY5_78d826ee-7aa1-4b96-ba18-55e7a10d292a"
      unitRef="usd">-52406000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjMtMS0xLTEtMjg3Njk_2df04a1d-9b71-4d7f-8dbf-a93d0cfb6945"
      unitRef="shares">216000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i9556dfb2e5374ba4b5e6ba7d80f38cdc_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjMtMy0xLTEtMjg3Njk_d0c267c8-ccb3-4e27-8552-e7ce933ee9dc"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ie65c792136c946adbf377040f6366deb_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjMtNS0xLTEtMjg3Njk_c3ab8d06-762e-4c75-ab89-69c3f80f6b77"
      unitRef="usd">36179000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjMtMTUtMS0xLTI4NzY5_7510e3a1-5bd8-49bf-b0e3-3768e58760be"
      unitRef="usd">36180000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie65c792136c946adbf377040f6366deb_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjQtNS0xLTEtMjg3Njk_1ebfc995-869d-4da8-8711-24a38c4d6fbf"
      unitRef="usd">65257000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjQtMTUtMS0xLTI4NzY5_7989be7b-0f2e-4d00-b949-32edd16b83b1"
      unitRef="usd">65257000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="iece2a9fb6a58447ab6a18eaf650b57f8_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjUtMTMtMS0xLTI4NzY5_d9851501-bf66-4cc2-a56e-18f073b603b0"
      unitRef="usd">-119260000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjUtMTUtMS0xLTI4NzY5_fcdfd029-1667-4774-b884-515983828692"
      unitRef="usd">-119260000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="id598a508533f4a93af0cf893cdbc877c_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjYtMTEtMS0xLTI4NzY5_230386a4-ce1e-43d2-873d-a22ba81835cc"
      unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjYtMTUtMS0xLTI4NzY5_218e6338-50af-489a-a16e-8935d3b36967"
      unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjgtMC0xLTEtMjkzNjUvdGV4dHJlZ2lvbjpkNTdlNDk0NGQzYTE0YjM1YTE1YzllZDcwNzE2ODlkYl80Mzk4MDQ2NTExMTYw_5b46a93b-a003-4b8f-a197-9597fa7d7676"
      unitRef="usdPerShare">1.68</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:Dividends
      contextRef="id598a508533f4a93af0cf893cdbc877c_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjgtMTEtMS0xLTI4NzY5_bbc0b369-22c8-44eb-97de-df8ef8fd6acc"
      unitRef="usd">245341000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjgtMTUtMS0xLTI4NzY5_82908ccb-e5c1-4bb1-a7c5-5abc4eec9502"
      unitRef="usd">245341000</us-gaap:Dividends>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib389da5f9ca94f9e9783af8916ff3c69_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktMS0xLTEtMjg3Njk_77eefe95-a815-4383-a90b-56617b6d8ff6"
      unitRef="shares">188247000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib389da5f9ca94f9e9783af8916ff3c69_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktMy0xLTEtMjg3Njk_adfffab0-a613-4b1b-b032-6a79a3350e44"
      unitRef="usd">586000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c44d305aea24f8c93d48ef038dd79ea_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktNS0xLTEtMjg3Njk_5e533c17-0385-4068-b064-9256221f6d9c"
      unitRef="usd">1682432000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i546cf7e76487425b8bfe97c8dd15a832_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktNy0xLTEtMjg3Njk_12dcb0d1-91fa-4965-b7fb-f35344350326"
      unitRef="shares">41836000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i546cf7e76487425b8bfe97c8dd15a832_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktOS0xLTEtMjg3Njk_5044d8a5-25dc-40d0-adbc-d7c58f01c682"
      unitRef="usd">-1623256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i12b80b9e773a48ddbfec64e8038faa6d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktMTEtMS0xLTI4NzY5_f867fbc3-4a9a-4600-9c84-5f9d4e66e3b3"
      unitRef="usd">3613736000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i77cc3f7b15ee461d972d81d7d0806848_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktMTMtMS0xLTI4NzY5_f9fa95b0-0a94-4224-89aa-5cd7707cea93"
      unitRef="usd">-312747000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl85Ny9mcmFnOjdhOWM1OGRlNmFjNjQ3NmRhYTc3NGQ0MjllNTc1YWNmL3RhYmxlOjZlM2NhZmUwYzkzMzQwZWJhYmZjZGQxOGQxZTE4YmM2L3RhYmxlcmFuZ2U6NmUzY2FmZTBjOTMzNDBlYmFiZmNkZDE4ZDFlMThiYzZfMjktMTUtMS0xLTI4NzY5_2fb13893-b486-48b6-9680-178713509e3e"
      unitRef="usd">3360751000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzItMS0xLTEtMjg3Njk_fcc3c9a7-289f-4cd2-b8bf-d90829e8319f"
      unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzItMy0xLTEtMjg3Njk_ae07bdea-e10c-4181-8fa8-d29eaeb88a12"
      unitRef="usd">474505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzItNS0xLTEtMjg3Njk_fc372edc-2330-4254-8db5-e54c1627cc8f"
      unitRef="usd">621674000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQtMS0xLTEtMjg3Njk_bd0a424d-e0cb-4ad0-a678-194dbbcc5ae5"
      unitRef="usd">159609000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQtMy0xLTEtMjg3Njk_493b6d23-7f91-4b6f-8946-aae0b8d63896"
      unitRef="usd">156758000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQtNS0xLTEtMjg3Njk_316d8da2-f7d1-43d8-9530-ad36ea4af7d8"
      unitRef="usd">154850000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzUtMS0xLTEtMjg3Njk_07aa1c45-0ee8-46aa-a45a-9e0b4052c777"
      unitRef="usd">34232000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzUtMy0xLTEtMjg3Njk_1671f293-eb44-4f9a-92e0-5b4afa0efcef"
      unitRef="usd">34760000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzUtNS0xLTEtMjg3Njk_31bbbcd9-e804-4509-af2c-f6b739c9f066"
      unitRef="usd">26523000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzYtMS0xLTEtMjg3Njk_0e09d417-faef-44e1-acf9-f4ab45585f2f"
      unitRef="usd">65257000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzYtMy0xLTEtMjg3Njk_cf347719-2d9e-4029-9e2a-36b1a3e1a3f7"
      unitRef="usd">63927000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzYtNS0xLTEtMjg3Njk_63a4b88b-c889-477c-b31c-2a31a960ef1f"
      unitRef="usd">57559000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzctMS0xLTEtMjg3Njk_5b989f2a-2534-4c42-b76f-7a1d10d0ec6b"
      unitRef="usd">-8486000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzctMy0xLTEtMjg3Njk_bb90bab9-f452-4e98-bf2e-e60a00dbce15"
      unitRef="usd">-11205000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzctNS0xLTEtMjg3Njk_42a28ff9-afbd-4746-bd01-d3b05a00d848"
      unitRef="usd">-25058000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzgtMS0xLTEtMjg3Njk_e697e3e9-a4e9-4612-b777-c118a13dbac2"
      unitRef="usd">12202000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzgtMy0xLTEtMjg3Njk_5875c12d-658e-4775-921b-079c03598648"
      unitRef="usd">-14515000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzgtNS0xLTEtMjg3Njk_50ccb31b-011f-4319-a520-d37c11e066d9"
      unitRef="usd">14519000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <us-gaap:RestructuringCharges
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzktMS0xLTEtMjg3Njk_39910764-8d09-4c01-aae3-1ee6d943d6c0"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzktMy0xLTEtMjg3Njk_8b616095-d382-4a8a-aa11-23d89cdc24fa"
      unitRef="usd">8673000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzktNS0xLTEtMjg3Njk_94effe38-f6c1-44d9-b70a-4a249937f671"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzExLTEtMS0xLTI4NzY5_306b41a7-1fba-4d61-ae94-96b28b099419"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzExLTMtMS0xLTI4NzY5_046c1354-6159-4dab-8ac0-ef634c6be96b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzExLTUtMS0xLTI4NzY5_20582fae-53dd-4b13-adc6-8ffb6cdec97c"
      unitRef="usd">-7000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzEzLTEtMS0xLTI4NzY5_e0bcba6f-73fe-43a6-a3b0-6816c007f6fb"
      unitRef="usd">-19346000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzEzLTMtMS0xLTI4NzY5_56437ed0-60c7-44ed-98bb-74f7313bf737"
      unitRef="usd">129195000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzEzLTUtMS0xLTI4NzY5_8cdc6a5e-5ada-47e0-89e1-909f5d8cf788"
      unitRef="usd">-54383000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE0LTEtMS0xLTI4NzY5_319b9e9b-604b-403d-8315-55d71523779b"
      unitRef="usd">311681000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE0LTMtMS0xLTI4NzY5_050c677d-2265-44ce-8fd1-870ea2477f6f"
      unitRef="usd">21954000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE0LTUtMS0xLTI4NzY5_b3904d90-8aa1-42ae-9396-ea50608a4783"
      unitRef="usd">69881000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE1LTEtMS0xLTI4NzY5_a3d39413-13fc-49df-8569-7e151e3733ca"
      unitRef="usd">168109000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE1LTMtMS0xLTI4NzY5_e5bb0dec-7e85-4c4a-93a1-ff11188fb1f6"
      unitRef="usd">58154000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE1LTUtMS0xLTI4NzY5_3ac3baef-eacd-4eda-8512-c73095230a77"
      unitRef="usd">58999000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE2LTEtMS0xLTI4NzY5_bbc57bb5-c281-460e-b3f2-ed058dcc6a54"
      unitRef="usd">-247632000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE2LTMtMS0xLTI4NzY5_7ce171b7-1022-4b94-a84a-dbedfa0a2083"
      unitRef="usd">210708000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE2LTUtMS0xLTI4NzY5_98f3aac0-975f-4ec2-a8fd-079966e094db"
      unitRef="usd">-23424000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE3LTEtMS0xLTI4NzY5_edb3f7e8-e5ab-451b-9625-6941b8f7fb60"
      unitRef="usd">351147000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE3LTMtMS0xLTI4NzY5_9610fa70-8cce-4992-a287-c4f2f30b6ba6"
      unitRef="usd">736718000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE3LTUtMS0xLTI4NzY5_69b0974d-c9a1-4c53-bbd7-c0efbccc2187"
      unitRef="usd">802255000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE5LTEtMS0xLTI4NzY5_0fea0a49-f6ea-40a8-9f9e-49d4358f203f"
      unitRef="usd">134835000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE5LTMtMS0xLTI4NzY5_5ac6df44-23a3-4a0e-a4c3-90d5e980d242"
      unitRef="usd">102712000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzE5LTUtMS0xLTI4NzY5_a4118f81-7a3c-46ed-bc47-3042a3ce0b37"
      unitRef="usd">95330000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIwLTEtMS0xLTI4NzY5_59862611-3064-465b-a3bd-bf34dd92b556"
      unitRef="usd">21201000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIwLTMtMS0xLTI4NzY5_11dbb0fa-8967-47ba-862b-f31b27b66aba"
      unitRef="usd">14114000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIwLTUtMS0xLTI4NzY5_896929a6-16d6-4e67-90f5-f8f2b99e4b60"
      unitRef="usd">10608000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIxLTEtMS0xLTI4NzY5_586299e4-c73f-4c1c-9ca5-047bcfbf799f"
      unitRef="usd">42784000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIxLTMtMS0xLTI4NzY5_d721f266-be1b-4c25-9a55-0fdb0cb76fd4"
      unitRef="usd">39067000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIxLTUtMS0xLTI4NzY5_2ca3b0f7-2efd-4b0a-9032-3e8c1a96ba07"
      unitRef="usd">27910000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIyLTEtMS0xLTI4NzY5_25dae9f6-118a-40b8-aa9a-97ca82361d24"
      unitRef="usd">20724000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIyLTMtMS0xLTI4NzY5_fd8167da-5151-4c85-8d24-c69332ebbcf7"
      unitRef="usd">21788000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIyLTUtMS0xLTI4NzY5_b3eb91ed-d3a8-49f3-aead-00d0378df42f"
      unitRef="usd">31616000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIzLTEtMS0xLTMyNzky_0c0456dc-23af-4f87-9f16-160ce52ff33f"
      unitRef="usd">6802000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIyLTMtMS0xLTMyODM2_940667c3-9319-419f-8fc4-40c290f071f9"
      unitRef="usd">0</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIyLTUtMS0xLTMyODM2_87a161dd-2b0c-4bfb-a1a2-202d29316f54"
      unitRef="usd">0</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIzLTEtMS0xLTI4NzY5_bf0c0e88-3707-4ea6-831e-29ab11d80d18"
      unitRef="usd">17176000</us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIzLTMtMS0xLTI4NzY5_ff2a563b-c4eb-41e9-9d2c-c754753e2e8f"
      unitRef="usd">-19219000</us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities>
    <us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzIzLTUtMS0xLTI4NzY5_267eec75-09ad-40d5-ad64-26062e223844"
      unitRef="usd">14397000</us-gaap:PaymentsForProceedsFromDerivativeInstrumentInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI0LTEtMS0xLTI4NzY5_37c62d4d-7447-469c-a9d5-b872fa071e5d"
      unitRef="usd">-229918000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI0LTMtMS0xLTI4NzY5_ffe55260-0c28-40db-b56a-f1bc103f30bb"
      unitRef="usd">-158462000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI0LTUtMS0xLTI4NzY5_d16f38be-121f-4ff8-bf93-affa93664d09"
      unitRef="usd">-179861000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI2LTEtMS0xLTI4NzY5_7f014e80-1208-4580-8cbd-4f6240f38b12"
      unitRef="usd">47384000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI2LTMtMS0xLTI4NzY5_619c9377-c7fc-4dc0-a7eb-1e6d22ab348b"
      unitRef="usd">37790000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI2LTUtMS0xLTI4NzY5_33511085-adc1-48ba-a4fd-2e182f49036e"
      unitRef="usd">48182000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI3LTEtMS0xLTI4NzY5_dbf2dd53-b6f5-4568-afc5-5fd5b74ba4d2"
      unitRef="usd">52406000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI3LTMtMS0xLTI4NzY5_2070a870-096e-4d25-977f-24136e5af8a5"
      unitRef="usd">50209000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI3LTUtMS0xLTI4NzY5_6501e559-51e7-4644-91e4-52ed1d7088a9"
      unitRef="usd">46061000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI5LTEtMS0xLTI4NzY5_c86baff0-cb82-4d74-a873-241a359ca646"
      unitRef="usd">0</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI5LTMtMS0xLTI4NzY5_5423321e-0357-48da-84fe-5b75b8b93cf7"
      unitRef="usd">3500000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzI5LTUtMS0xLTI4NzY5_60146410-89da-468d-b07f-47089373161c"
      unitRef="usd">302000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMwLTEtMS0xLTI4NzY5_1eae7688-d0ca-43e0-8c36-1b8276ab256f"
      unitRef="usd">288000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMwLTMtMS0xLTI4NzY5_2d4eb4ae-b20a-4559-9df5-cc840dd0cc0a"
      unitRef="usd">90000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMwLTUtMS0xLTI4NzY5_07f1ea98-9071-4624-94e3-528cef807a07"
      unitRef="usd">1190000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMxLTEtMS0xLTI4NzY5_d8cc56d7-b3ae-4fb2-a9b2-20fbac011f86"
      unitRef="usd">166000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMxLTMtMS0xLTI4NzY5_1f0fb139-3f77-4bb8-bdd7-9af56b447f24"
      unitRef="usd">612000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMxLTUtMS0xLTI4NzY5_ef618279-f1cb-400a-8904-72c1059213a0"
      unitRef="usd">1284012000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDividends
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMyLTEtMS0xLTI4NzY5_aadc6920-108e-46b8-a3aa-144db42a233e"
      unitRef="usd">245341000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMyLTMtMS0xLTI4NzY5_b4d75bfe-af6e-4abb-b0c9-35821efbae14"
      unitRef="usd">226713000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMyLTUtMS0xLTI4NzY5_0283c8f7-43d4-44c3-aaa4-6c2ce29a9eea"
      unitRef="usd">225093000</us-gaap:PaymentsOfDividends>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMzLTEtMS0xLTI4NzY5_61d39867-a1a0-43f7-b172-c0f632e175af"
      unitRef="usd">-128363000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMzLTMtMS0xLTI4NzY5_d516ba33-b632-4dae-b4f6-6b02791b4396"
      unitRef="usd">-764632000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzMzLTUtMS0xLTI4NzY5_4bf530d1-6012-4804-81e4-44b5b41ca7fe"
      unitRef="usd">-317286000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM0LTEtMS0xLTI4NzY5_e759d3ed-127a-495a-a875-e4ff13d8c93b"
      unitRef="usd">-14434000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM0LTMtMS0xLTI4NzY5_44c19765-c384-4868-a802-4bedf5f5e8ce"
      unitRef="usd">18498000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM0LTUtMS0xLTI4NzY5_e45b5656-92f8-4195-94e0-4987eed85333"
      unitRef="usd">10920000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM1LTEtMS0xLTI4NzY5_36ec29df-aa7c-45bd-80c6-52dc4a37b5db"
      unitRef="usd">-21568000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM1LTMtMS0xLTI4NzY5_0901e557-1689-4306-a886-270c5dab16ff"
      unitRef="usd">-167878000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM1LTUtMS0xLTI4NzY5_7f65a64e-112e-42f6-83e7-99d66d92c7aa"
      unitRef="usd">316028000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM2LTEtMS0xLTI4NzY5_95c7b01d-64e1-4e07-89b2-124ed3b1343d"
      unitRef="usd">295278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM2LTMtMS0xLTI4NzY5_326240e1-5b11-44a3-a9e9-f0034f21f1da"
      unitRef="usd">463156000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6113f72766ae4bf3a6b6822df9ec9799_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM2LTUtMS0xLTI4NzY5_d7faabb1-5c23-482d-96e6-dde960e6a001"
      unitRef="usd">147128000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM3LTEtMS0xLTI4NzY5_8ec1d0fe-a35a-4ba6-8e68-da6f37032174"
      unitRef="usd">273710000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM3LTMtMS0xLTI4NzY5_3fd963b6-5804-493f-afc8-5c394823a0fa"
      unitRef="usd">295278000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM3LTUtMS0xLTI4NzY5_59e878e1-0093-4a58-bd81-2a7fb577be97"
      unitRef="usd">463156000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM5LTEtMS0xLTI4NzY5_29c87a51-7a42-43bb-b282-08a19fc9a871"
      unitRef="usd">478120000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM5LTMtMS0xLTI4NzY5_8b284f02-0c73-4d0f-8200-46a6e737a0ac"
      unitRef="usd">221359000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzM5LTUtMS0xLTI4NzY5_9268499c-4f1a-4f62-9f89-9e94c75c92bf"
      unitRef="usd">180359000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQwLTEtMS0xLTI4NzY5_a1015100-33f5-47f8-8635-6d63c6fc42e4"
      unitRef="usd">22312000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQwLTMtMS0xLTI4NzY5_d58e2796-0b32-43d8-9b2c-ad9ecff96a95"
      unitRef="usd">23989000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQwLTUtMS0xLTI4NzY5_08cf37b8-c7bf-4982-9f4a-96aa839d3ef7"
      unitRef="usd">40377000</us-gaap:InterestPaidNet>
    <rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQxLTEtMS0xLTI4NzY5_c5f9ca1c-509a-4fbd-a5b7-d264b0c782d6"
      unitRef="usd">15648000</rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired>
    <rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQxLTMtMS0xLTI4NzY5_02e15f20-78e8-4981-84c8-7a6ca5f268cf"
      unitRef="usd">16671000</rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired>
    <rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQxLTUtMS0xLTI4NzY5_e0940ae8-59d2-4613-9570-06d53ab66545"
      unitRef="usd">14919000</rmd:NoncashPartOfAcquisitionFairValueOfAssetsAcquired>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQyLTEtMS0xLTI4NzY5_15eb194d-d7f3-4592-ad81-896a858cd1bb"
      unitRef="usd">4672000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQyLTMtMS0xLTI4NzY5_7bee8254-a317-4eaf-93de-e14bc8d9e9d3"
      unitRef="usd">1543000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQyLTUtMS0xLTI4NzY5_3ee4214a-d88b-49b3-8995-678739fd9b68"
      unitRef="usd">4292000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTEtMS0xLTI4NzY5_0ac034a2-721c-411a-a938-4d788b5a47c3"
      unitRef="usd">38953000</rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease>
    <rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTMtMS0xLTI4NzY5_0e8db78b-01e5-486b-9d03-58c7421ed008"
      unitRef="usd">24671000</rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease>
    <rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTUtMS0xLTI4NzY5_8578f782-85ea-4d83-9b6c-db1b3eb27652"
      unitRef="usd">20375000</rmd:GoodwillAcquiredDuringPeriodIncreaseDecrease>
    <rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTEtMS0xLTMyODQ3_b5778fb4-d028-4020-90fd-8b8e116bc00c"
      unitRef="usd">4078000</rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination>
    <rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTMtMS0xLTMyODQ3_51aa0302-6149-420d-bcf9-39bc2883f854"
      unitRef="usd">0</rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination>
    <rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQzLTUtMS0xLTMyODQ3_a62a15fb-8988-41a7-9b63-cea191fb3ee0"
      unitRef="usd">0</rmd:NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination>
    <rmd:DeferredPaymentObligationsForAcquisitions
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ0LTEtMS0xLTI4NzY5_e4d5d7b0-7e6a-4d73-95dc-68546a7da49d"
      unitRef="usd">-3067000</rmd:DeferredPaymentObligationsForAcquisitions>
    <rmd:DeferredPaymentObligationsForAcquisitions
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ0LTMtMS0xLTI4NzY5_9b5e8991-8b51-46d7-a7d4-d637594a016f"
      unitRef="usd">3768000</rmd:DeferredPaymentObligationsForAcquisitions>
    <rmd:DeferredPaymentObligationsForAcquisitions
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ0LTUtMS0xLTI4NzY5_17913938-790b-4a0d-9b14-e68e18bb1ccb"
      unitRef="usd">408000</rmd:DeferredPaymentObligationsForAcquisitions>
    <rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ1LTEtMS0xLTI4NzY5_32081517-1331-4ac2-9158-6643a47b560d"
      unitRef="usd"
      xsi:nil="true"/>
    <rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ1LTMtMS0xLTI4NzY5_c2fb0ab0-476a-4e21-8bc6-c50259490f2f"
      unitRef="usd">0</rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability>
    <rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ1LTUtMS0xLTI4NzY5_51e0bee4-0816-4ee7-9118-9ae979028660"
      unitRef="usd">3500000</rmd:BusinessAcquisitionContingentConsiderationRecognizedLiability>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ2LTEtMS0xLTI4NzY5_93f01a0e-3cdc-4394-96ae-da00c4845af7"
      unitRef="usd">42784000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ2LTMtMS0xLTI4NzY5_56391dd7-2a8d-48a9-9d39-095f6ccaa480"
      unitRef="usd">43567000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDAvZnJhZzoyY2VjNmI0MTQwYzk0MDFlYjkzMzgyZTNkNTViZDlhNi90YWJsZTpkMThiYWYyNTJhYTE0YjViODg2ZmIyMDdhNmU4ZTRkMy90YWJsZXJhbmdlOmQxOGJhZjI1MmFhMTRiNWI4ODZmYjIwN2E2ZThlNGQzXzQ2LTUtMS0xLTI4NzY5_5116ec29-d97c-41f5-8554-724061a408f3"
      unitRef="usd">27910000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDYvZnJhZzo3MGQ1MGI3YWU2OWU0OThkOGMwY2E4OTMzYmYzNmYyMy90ZXh0cmVnaW9uOjcwZDUwYjdhZTY5ZTQ5OGQ4YzBjYTg5MzNiZjM2ZjIzXzk0OQ_3bbbc1b0-67df-4d6c-ba68-2a7ba357e114">Organization and Basis of Presentation ResMed Inc. (referred to herein as &#x201c;we&#x201d;, &#x201c;us&#x201d;, &#x201c;our&#x201d; or the &#x201c;Company&#x201d;) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Finland, Norway and Sweden. We also operate a Software as a Service (&#x201c;SaaS&#x201d;) business in the United States that includes out-of-hospital software platforms designed to support the professionals and caregivers who help people stay healthy in the home or care setting of their choice.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjk3_24905f9a-04e6-4780-a244-67e5981a489d">Summary of Significant Accounting Policies &lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Basis of Consolidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Certain prior period amounts have been reclassified to conform to the current period presentation. Actual results could differ from management&#x2019;s estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d;, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#x201c;Sleep and Respiratory Care&#x201d;) and the supply of business management software as a service to out-of-hospital health providers (&#x201c;SaaS&#x201d;). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Disaggregation of revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 14 &#x2013; Segment Information for our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Performance obligations and contract balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with professional services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our contract balances as of June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance sheet caption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;614,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unbilled revenue, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unbilled revenue, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes and other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue (current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(91,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue (non-current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Transaction price determination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns offered to our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty-related returns, are infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#x2019;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates on a quarterly basis based on actual sales results and updated forecasts for the remaining rebate periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounting and practical expedient elections&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have adopted two practical expedients including the &#x201c;right to invoice&#x201d; practical expedient, which allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date and which is relevant for some of our SaaS contracts. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Concentration of Credit Risk and Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, derivatives and trade receivables. Our cash and cash equivalents are generally held with large, diverse financial institutions to reduce the amount of exposure to any single financial institution. Our derivative contracts are transacted with various financial institutions with high credit standings and any exposure to counterparty credit-related losses in these contracts is largely mitigated with collateralization and master-netting agreements. The risk with respect to trade receivables is mitigated by credit evaluations we perform on our customers, the short duration of our payment terms for the significant majority of our customer contracts and by the diversification of our customer base. No single customer accounted for 10% or more of our total revenues for any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt; Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We measure our financial instruments at fair value at each reporting period using a fair value hierarchy that requires that we maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#x2019;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Other inputs that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt related to our Revolving Credit and Term Credit Agreements approximates its fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates which are regularly reset. The carrying value of long-term debt related to our Senior Notes can differ to its fair value as the principal amounts outstanding are subject to fixed interest rates as outlined in Note 9 - Debt. Foreign currency hedging instruments are marked to market and therefore reflect their fair value. In addition, we measure investments in publicly held equity securities and privately held equity securities for which there has been an observable price change in an identical or similar security, at fair value. We do not hold or issue financial instruments for trading purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include certificates of deposit and other highly liquid investments and we state them at cost, which approximates market. We consider investments with original maturities of 90 days or less to be cash equivalents for purposes of the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(f)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt"&gt;Inventories &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We state inventories at the lower of cost (determined principally by the first-in, first-out method) or net realizable value. We include material, labor and manufacturing overhead costs in finished goods and work-in-process inventories. We review and provide for any product obsolescence in our manufacturing and distribution operations by assessing throughout the year individual products and components (based on estimated future usage and sales).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(g)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Property, Plant and Equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record property, plant and equipment, including rental and demonstration equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally two years to ten years except for buildings which are depreciated over an estimated useful life of forty years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for property, plant, and equipment was $81.0 million, $78.4 million, and $65.6 million for the years ended June&#160;30, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(h)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Intangible Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We capitalize the registration costs for new patents and amortize the costs over the estimated useful life of the patent, which is generally ten years. If a patent is superseded or a product is retired, any unamortized costs are written off immediately.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We amortize all of our other intangible assets on a straight-line basis over their estimated useful lives, which range from two years to fifteen years. We take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists and, at least annually, evaluate the recoverability of intangible assets. We have not identified any impairment of intangible assets during any of the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(i)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct our annual review for goodwill impairment during the final quarter of the fiscal year. Our goodwill impairment review is performed at our reporting unit level, which is one level below our operating segments and involves the following steps: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Step 0 or Qualitative assessment &#x2013; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Step 1 &#x2013; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#x2019;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the annual reviews for the years ended June&#160;30, 2022, 2021 and 2020, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(j)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.01pt"&gt;Equity investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our accounting for investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments whereby we have significant influence but not control over the investee, and are not the primary beneficiary of the investee&#x2019;s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(k)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Research and Development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record all research and development expenses in the period we incur them.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(l)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.57pt"&gt;Foreign Currency &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of our non-U.S. subsidiaries, whose functional currencies are other than the U.S. dollar, are translated into U.S. dollars for financial reporting purposes. We translate assets and liabilities of non-U.S. subsidiaries whose functional currencies are other than the U.S. dollar at period end exchange rates, but translate revenue and expense transactions at average exchange rates for the period. We recognize cumulative translation adjustments as part of comprehensive income, as detailed in the consolidated statements of comprehensive income, and include those adjustments in accumulated other comprehensive income in the consolidated balance sheets until such time the relevant subsidiary is sold or substantially or completely liquidated. We reflect gains and losses on transactions denominated in other than the functional currency of an entity in our results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(m)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:3.01pt"&gt;Foreign Exchange Risk Management &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our consolidated statements of income and through changes in our operating assets and liabilities within our consolidated statements of cash flows. We classify purchases of foreign currency derivatives and proceeds received from the exercise of foreign currency derivatives as an investing activity within our consolidated statements of cash flows. We do not enter into financial instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held foreign currency instruments with notional amounts totaling $602.0 million and $556.4 million at June&#160;30, 2022 and June&#160;30, 2021, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to June&#160;30, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(n)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using the enacted tax rates we expect to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions are reflected in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(o)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Provision for Warranty&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(p)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain an allowance for credit losses on customer receivables based on our historical write-off experience, an assessment of our customers&#x2019; financial conditions and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions. Customer receivables are charged against the allowance when they are deemed uncollectible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also contingently liable, within certain limits, in the event of a customer default, to independent financing companies in connection with customer financing programs. We monitor the collection status of these installment receivables and provide for estimated losses separately under accrued expenses within our consolidated balance sheets based upon our historical collection experience with such receivables and a current assessment of our credit exposure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(q)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, we recognize as the impairment the amount by which the carrying amount of the assets exceeds the fair value of the assets. We report assets to be disposed of at the lower of the carrying amount or fair value less costs to sell. We did not recognize impairment charges in relation to long-lived assets during the fiscal years ended June&#160;30, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(r)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;We record a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjkz_4b1e4306-018f-4441-ae7f-96f63f96b478">Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Certain prior period amounts have been reclassified to conform to the current period presentation. Actual results could differ from management&#x2019;s estimates.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg5_92a74d9a-32bc-4387-86a4-b3d942b9df75">Revenue Recognition &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with Accounting Standard Codification (&#x201c;ASC&#x201d;) Topic 606, &#x201c;Revenue from Contracts with Customers&#x201d;, we account for a contract with a customer when there is a legally enforceable contract, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We have determined that we have two operating segments, which are the sleep and respiratory disorders sector of the medical device industry (&#x201c;Sleep and Respiratory Care&#x201d;) and the supply of business management software as a service to out-of-hospital health providers (&#x201c;SaaS&#x201d;). Our Sleep and Respiratory Care revenue relates primarily to the sale of our products that are therapy-based equipment. Some contracts include additional performance obligations such as the provision of extended warranties and data for patient monitoring. Our SaaS revenue relates to the provision of software access with ongoing support and maintenance services as well as professional services such as training and consulting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Disaggregation of revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 14 &#x2013; Segment Information for our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Performance obligations and contract balances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized when performance obligations under the terms of a contract with a customer are satisfied; generally, this occurs with the transfer of risk and/or control of our products at a point in time. For products in our Sleep and Respiratory Care business, we transfer control and recognize a sale when products are shipped to the customer in accordance with the contractual shipping terms. For our SaaS business, revenue associated with professional services are recognized as they are provided. We defer the recognition of a portion of the consideration received when performance obligations are not yet satisfied. Consideration received from customers in advance of revenue recognition is classified as deferred revenue. Performance obligations resulting in deferred revenue in our Sleep and Respiratory Care business relate primarily to extended warranties on our devices and the provision of data for patient monitoring. Performance obligations resulting in deferred revenue in our SaaS business relate primarily to the provision of software access with maintenance and support over an agreed term and material rights associated with future discounts upon renewal of some SaaS contracts. Generally, deferred revenue will be recognized over a period of one year to five years. Our contracts do not contain significant financing components. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our contract balances as of June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance sheet caption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;614,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unbilled revenue, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unbilled revenue, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes and other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue (current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(91,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue (non-current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Transaction price determination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or providing services. In our Sleep and Respiratory Care segment, the amount of consideration received and revenue recognized varies with changes in marketing incentives (e.g. rebates, discounts, free goods) and returns offered to our customers and their customers. When we give customers the right to return eligible products and receive credit, returns are estimated based on an analysis of historical experience. However, returns of products, excluding warranty-related returns, are infrequent and insignificant. We adjust the estimate of revenue at the earlier of when the most likely amount of consideration can be estimated, the amount expected to be received changes, or when the consideration becomes fixed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We offer our Sleep and Respiratory Care customers cash or product rebates based on volume or sales targets measured over quarterly or annual periods. We estimate rebates based on each customer&#x2019;s expected achievement of its targets. In accounting for these rebate programs, we reduce revenue ratably as sales occur over the rebate period by the expected value of the rebates to be returned to the customer. Rebates measured over a quarterly period are updated based on actual sales results and, therefore, no estimation is required to determine the reduction to revenue. For rebates measured over annual periods, we update our estimates on a quarterly basis based on actual sales results and updated forecasts for the remaining rebate periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We participate in programs where we issue credits to our Sleep and Respiratory Care distributors when they are required to sell our products below negotiated list prices if we have preexisting contracts with the distributors' customers. We reduce revenue for future credits at the time of sale to the distributor, which we estimate based on historical experience using the expected value method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also offer discounts to both our Sleep and Respiratory Care as well as our SaaS customers as part of normal business practice and these are deducted from revenue when the sale occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When Sleep and Respiratory Care or SaaS contracts have multiple performance obligations, we generally use an observable price to determine the stand-alone selling price by reference to pricing and discounting practices for the specific product or service when sold separately to similar customers. Revenue is then allocated proportionately, based on the determined stand-alone selling price, to each performance obligation. An allocation is not required for many of our Sleep and Respiratory Care contracts that have a single performance obligation, which is the shipment of our therapy-based equipment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Accounting and practical expedient elections&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected to account for shipping and handling activities associated with our Sleep and Respiratory Care segment as a fulfillment cost within cost of sales, and record shipping and handling costs collected from customers in net revenue. We have also elected for all taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, to be excluded from revenue and presented on a net basis. We have adopted two practical expedients including the &#x201c;right to invoice&#x201d; practical expedient, which allows us to recognize revenue in the amount of the invoice when it corresponds directly with the value of performance completed to date and which is relevant for some of our SaaS contracts. The second practical expedient adopted permits relief from considering a significant financing component when the payment for the good or service is expected to be one year or less.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzMyOTg1MzQ5MTU5OTY_e4da161c-7f34-4bf9-85f2-5020b2bd0320"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <rmd:TermOfContractUnderRevenueRecognition
      contextRef="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE1OTg_8a0cf1c7-d9ed-4fbf-8495-294d3c5058db">P1Y</rmd:TermOfContractUnderRevenueRecognition>
    <rmd:TermOfContractUnderRevenueRecognition
      contextRef="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2MDM_1cbf6f31-e5fa-465c-8a28-0999caac7a83">P5Y</rmd:TermOfContractUnderRevenueRecognition>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjkw_a60cb440-4383-460e-90ff-4f54a628f9d6">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our contract balances as of June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance sheet caption&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;614,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unbilled revenue, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unbilled revenue, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes and other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(108,667)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue (current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(91,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue (non-current liabilities)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i395a6823166d44c89daa1c281c702cd0_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzItMS0xLTEtMjg3Njk_562c25d5-cbdd-48ea-abca-2d22aa0c57c8"
      unitRef="usd">575950000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3515d2e0a2ec4ac79cc7dc24382770f9_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzItMy0xLTEtMjg3Njk_7939e1ec-1508-4b3c-a2f3-409e4ee0ffa1"
      unitRef="usd">614292000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i0c52baae5bad475ebef7771a9b519ff5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzMtMS0xLTEtMjg3Njk_789263b1-f027-424c-bdc8-2ac3aa87a6ca"
      unitRef="usd">25692000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="ie196dbd7b3fd443b991a4e53f748a874_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzMtMy0xLTEtMjg3Njk_abe94fe9-8ce8-42a4-9f2f-eb2d9a15bee4"
      unitRef="usd">10893000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i0c52baae5bad475ebef7771a9b519ff5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzQtMS0xLTEtMjg3Njk_0e6dd7db-ffbf-44b5-b6ee-dd73fac27b32"
      unitRef="usd">8840000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="ie196dbd7b3fd443b991a4e53f748a874_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzQtMy0xLTEtMjg3Njk_9e9f5f82-5e92-4ead-933d-cfb89b3e89ca"
      unitRef="usd">6214000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzctMS0xLTEtMjg3Njk_41a7625a-f59c-48c3-b805-3885fffbb6ac"
      unitRef="usd">108667000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzctMy0xLTEtMjg3Njk_d4d1e0ff-37d5-4036-9da1-23cc45dd607f"
      unitRef="usd">109611000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzgtMS0xLTEtMjg3Njk_16f81069-11d5-48ae-b32e-94339193303f"
      unitRef="usd">95455000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90YWJsZToxNmNmM2E4NDlhMmY0NzU3YTI0ODI4ZWZmMzA0N2QzMi90YWJsZXJhbmdlOjE2Y2YzYTg0OWEyZjQ3NTdhMjQ4MjhlZmYzMDQ3ZDMyXzgtMy0xLTEtMjg3Njk_d3376135-2473-4ead-9751-981654e6b743"
      unitRef="usd">91496000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <rmd:ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg4_d4c1cdc3-2dcb-46fb-a4c7-0b42dca91f50">Concentration of Credit Risk and Significant CustomersFinancial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities, derivatives and trade receivables. Our cash and cash equivalents are generally held with large, diverse financial institutions to reduce the amount of exposure to any single financial institution. Our derivative contracts are transacted with various financial institutions with high credit standings and any exposure to counterparty credit-related losses in these contracts is largely mitigated with collateralization and master-netting agreements. The risk with respect to trade receivables is mitigated by credit evaluations we perform on our customers, the short duration of our payment terms for the significant majority of our customer contracts and by the diversification of our customer base. No single customer accounted for 10% or more of our total revenues for any of the periods presented.</rmd:ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjgz_a018afda-52e8-43c4-9d23-535f00482bc7">Fair Value of Financial Instruments&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of financial instruments is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. We measure our financial instruments at fair value at each reporting period using a fair value hierarchy that requires that we maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument&#x2019;s classification within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Other inputs that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs that are supported by little or no market activity.&lt;/span&gt;&lt;/div&gt;The carrying value of cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt related to our Revolving Credit and Term Credit Agreements approximates its fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates which are regularly reset. The carrying value of long-term debt related to our Senior Notes can differ to its fair value as the principal amounts outstanding are subject to fixed interest rates as outlined in Note 9 - Debt. Foreign currency hedging instruments are marked to market and therefore reflect their fair value. In addition, we measure investments in publicly held equity securities and privately held equity securities for which there has been an observable price change in an identical or similar security, at fair value. We do not hold or issue financial instruments for trading purposes.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjk0_79620629-52f1-4aa0-85ca-d85934552960">Cash and Cash Equivalents Cash equivalents include certificates of deposit and other highly liquid investments and we state them at cost, which approximates market. We consider investments with original maturities of 90 days or less to be cash equivalents for purposes of the consolidated statements of cash flows.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjgy_d3ac9cb8-afbe-48a4-bc47-3cb4ef0b1069">Inventories We state inventories at the lower of cost (determined principally by the first-in, first-out method) or net realizable value. We include material, labor and manufacturing overhead costs in finished goods and work-in-process inventories. We review and provide for any product obsolescence in our manufacturing and distribution operations by assessing throughout the year individual products and components (based on estimated future usage and sales).</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjkx_c6b8f918-3f26-4a45-818e-ee8f8ae72e11">Property, Plant and Equipment We record property, plant and equipment, including rental and demonstration equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally two years to ten years except for buildings which are depreciated over an estimated useful life of forty years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2MTc_ce90ca2e-78b6-4034-9c3e-10ddf195c444">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2MjI_963024d7-4b44-4128-8db0-99b19d098e80">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if99f07887f7a46228ef1235e19d7b4a5_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2Mjc_af04786f-7ae8-4598-9b54-23b34ffd3d6a">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2MzI_de64f410-2c57-455d-912d-c0601bab61d3"
      unitRef="usd">81000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2NDA_dd08a4b2-276a-4d29-ba5e-0388dcbdc73f"
      unitRef="usd">78400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2NDQ_addd031d-349e-4fad-a669-899cc44286ba"
      unitRef="usd">65600000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjk1_d387a622-749c-43fb-b2a2-9d7f7afde145">Intangible Assets We capitalize the registration costs for new patents and amortize the costs over the estimated useful life of the patent, which is generally ten years. If a patent is superseded or a product is retired, any unamortized costs are written off immediately.We amortize all of our other intangible assets on a straight-line basis over their estimated useful lives, which range from two years to fifteen years. We take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists and, at least annually, evaluate the recoverability of intangible assets. We have not identified any impairment of intangible assets during any of the periods presented.</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i28a3ce23547b4f28a6b1d773a88cbc9b_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzMyOTg1MzQ5MTUxNzE_2581100a-2b30-4036-aff8-d5370d99165f">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2NjU_3f050888-59c7-4bd2-abf7-668aadbead29">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2NzA_0fc8d6f0-b8db-44cb-985c-61525203fefc">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzM4NDgyOTA3MTk5NTQ_20a12df2-55d9-4045-b2cc-6098b491f4a0"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzM4NDgyOTA3MTk5NTQ_ddcae2ad-5f9a-4f7a-a620-42be896540b4"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzM4NDgyOTA3MTk5NTQ_f635ffe3-0b37-4b5a-8317-e09783115a05"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjc4_e4e69fb3-a67d-4c6a-911f-b100bad06f0d">Goodwill &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct our annual review for goodwill impairment during the final quarter of the fiscal year. Our goodwill impairment review is performed at our reporting unit level, which is one level below our operating segments and involves the following steps: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Step 0 or Qualitative assessment &#x2013; Evaluate qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount, including goodwill. The factors we consider include, but are not limited to, macroeconomic conditions, industry and market considerations, cost factors, overall financial performance or events-specific to that reporting unit. If or when we determine it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill, we would move to Step 1 of the quantitative method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Step 1 &#x2013; Compare the fair value for each reporting unit to its carrying value, including goodwill. Fair value is determined based on estimated discounted cash flows. A goodwill impairment charge is recognized for the amount that the carrying amount of a reporting unit, including goodwill, exceeds its fair value, limited to the total amount of goodwill allocated to that reporting unit. If a reporting unit&#x2019;s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the annual reviews for the years ended June&#160;30, 2022, 2021 and 2020, we completed a Step 0 or Qualitative assessment and determined it was more likely than not that the fair value of our reporting units exceeded their carrying amounts, including goodwill, and therefore goodwill was not impaired.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjky_90fbfa53-539e-4f6e-98b8-b02f7680af51">Equity investments &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have equity investments in privately and publicly held companies that are unconsolidated entities. The following discusses our accounting for investments in marketable equity securities, non-marketable equity securities, and investments accounted for under the equity method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities are publicly traded stocks measured at fair value and classified within Level 1 in the fair value hierarchy because we use quoted prices for identical assets in active markets. Marketable equity securities are recorded in prepaid expenses and other current assets on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-marketable equity securities consist of investments in privately held companies without readily determinable fair values and are recorded in prepaid taxes and other non-current assets on the consolidated balance sheets. Non-marketable equity securities are reported at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. We assess non-marketable equity securities at least quarterly for impairment and consider qualitative and quantitative factors including the investee's financial metrics, product and commercial outlook and cash usage. All gains and losses on marketable and non-marketable equity securities, realized and unrealized, are recognized in gain (loss) on equity investments as a component of other income (loss), net on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;Equity investments whereby we have significant influence but not control over the investee, and are not the primary beneficiary of the investee&#x2019;s activities, are accounted for under the equity method. Under this method, we record our share of gains or losses attributable to equity method investments as a component of other income (loss), net on the consolidated statements of operations.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg0_4192664e-0ddf-406a-bf97-08ca5576e3b7">Research and Development We record all research and development expenses in the period we incur them.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjk2_bc821e98-a9f9-454b-817f-23307a7c3a11">Foreign Currency The consolidated financial statements of our non-U.S. subsidiaries, whose functional currencies are other than the U.S. dollar, are translated into U.S. dollars for financial reporting purposes. We translate assets and liabilities of non-U.S. subsidiaries whose functional currencies are other than the U.S. dollar at period end exchange rates, but translate revenue and expense transactions at average exchange rates for the period. We recognize cumulative translation adjustments as part of comprehensive income, as detailed in the consolidated statements of comprehensive income, and include those adjustments in accumulated other comprehensive income in the consolidated balance sheets until such time the relevant subsidiary is sold or substantially or completely liquidated. We reflect gains and losses on transactions denominated in other than the functional currency of an entity in our results of operations.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg1_ec5421ff-447c-4972-8627-fa27e900d5aa">Foreign Exchange Risk Management &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singaporean manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our consolidated statements of income and through changes in our operating assets and liabilities within our consolidated statements of cash flows. We classify purchases of foreign currency derivatives and proceeds received from the exercise of foreign currency derivatives as an investing activity within our consolidated statements of cash flows. We do not enter into financial instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;We held foreign currency instruments with notional amounts totaling $602.0 million and $556.4 million at June&#160;30, 2022 and June&#160;30, 2021, respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to June&#160;30, 2024.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2ODg_9bc7bafe-f680-40f9-947f-cbf96b388113"
      unitRef="usd">602000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzQzOTgwNDY1NDE2OTQ_58b12b34-b529-4bd9-aa6d-cf8f8b8ff91c"
      unitRef="usd">556400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg2_a0a4fada-6200-4cf1-ad02-3432c19f7414">Income Taxes &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using the enacted tax rates we expect to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in the consolidated financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions are reflected in income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:StandardProductWarrantyPolicy
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjc5_b455d506-4092-4a8c-a415-10ff99ecb760">Provision for WarrantyWe provide for the estimated cost of product warranties on our Sleep and Respiratory Care products at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.</us-gaap:StandardProductWarrantyPolicy>
    <rmd:AllowanceForDoubtfulAccountsPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjgw_a59c6225-ddb7-40ed-80b1-1755d939914e">Allowance for Credit Losses&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain an allowance for credit losses on customer receivables based on our historical write-off experience, an assessment of our customers&#x2019; financial conditions and available information that is relevant to assessing the collectability of cash flows, which includes current conditions and forecasts about future economic conditions. Customer receivables are charged against the allowance when they are deemed uncollectible. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also contingently liable, within certain limits, in the event of a customer default, to independent financing companies in connection with customer financing programs. We monitor the collection status of these installment receivables and provide for estimated losses separately under accrued expenses within our consolidated balance sheets based upon our historical collection experience with such receivables and a current assessment of our credit exposure.&lt;/span&gt;&lt;/div&gt;</rmd:AllowanceForDoubtfulAccountsPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjg3_b7dea212-ca60-40fa-bb47-ea8e751b084e">Impairment of Long-Lived Assets We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If assets are considered to be impaired, we recognize as the impairment the amount by which the carrying amount of the assets exceeds the fair value of the assets. We report assets to be disposed of at the lower of the carrying amount or fair value less costs to sell. We did not recognize impairment charges in relation to long-lived assets during the fiscal years ended June&#160;30, 2022, 2021 and 2020.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMDkvZnJhZzozZThmMmZmMGY0NTc0MzkwOWI3NGI1OTFhZTM0NWYxNC90ZXh0cmVnaW9uOjNlOGYyZmYwZjQ1NzQzOTA5Yjc0YjU5MWFlMzQ1ZjE0XzIyNjgx_d4f33a23-4878-448b-9f5e-5bf40610f88f">ContingenciesWe record a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTIvZnJhZzo3ZDNkMWNhMmQ5NWM0MTE1ODg2NDAyYTBiOGFlMGJjZC90ZXh0cmVnaW9uOjdkM2QxY2EyZDk1YzQxMTU4ODY0MDJhMGI4YWUwYmNkXzI5ODg_e2bb1cf9-d032-4b80-b238-4a35bcf1f89d">New Accounting Pronouncements &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;ASU No. 2021-08 &#x201c;Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &#x201c;Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d; (Topic 805), which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The guidance is effective for us beginning in the first quarter of the year ending June 30, 2024 and early adoption is permitted. We elected to early adopt this standard in the second quarter of our fiscal year ending June 30, 2022. Adoption of ASU 2021-08 did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTIvZnJhZzo3ZDNkMWNhMmQ5NWM0MTE1ODg2NDAyYTBiOGFlMGJjZC90ZXh0cmVnaW9uOjdkM2QxY2EyZDk1YzQxMTU4ODY0MDJhMGI4YWUwYmNkXzM4NDgyOTA3MDAyMDY_369be4dd-7ac5-4e90-b744-3d697e6572a9">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently adopted accounting pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;ASU No. 2021-08 &#x201c;Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, the FASB issued ASU No. 2021-08, &#x201c;Accounting for Contract Assets and Contract Liabilities from Contracts with Customers&#x201d; (Topic 805), which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The guidance is effective for us beginning in the first quarter of the year ending June 30, 2024 and early adoption is permitted. We elected to early adopt this standard in the second quarter of our fiscal year ending June 30, 2022. Adoption of ASU 2021-08 did not have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <rmd:SupplementalBalanceSheetInformationTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90ZXh0cmVnaW9uOmQxZWI2NGQ1ZjJiNTQ0MTM5ZGZkMTUyMWE2NzNjZjhiXzE3Nw_8a7012a8-bc9d-472a-a464-c763f9777627">Supplemental Balance Sheet Information&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of selected captions in the consolidated balance sheets consisted of the following as of June&#160;30, 2022 and June&#160;30, 2021 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;355,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;743,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;457,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vehicles and aircraft&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical, demonstration and rental equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,131,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,085,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(633,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(622,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rmd:SupplementalBalanceSheetInformationTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90ZXh0cmVnaW9uOmQxZWI2NGQ1ZjJiNTQ0MTM5ZGZkMTUyMWE2NzNjZjhiXzE3OA_a0dec28d-646e-4c70-af26-96f058aaa4d4">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of selected captions in the consolidated balance sheets consisted of the following as of June&#160;30, 2022 and June&#160;30, 2021 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;355,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;743,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;457,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzEtMS0xLTEtMjg3Njk_4f80c2f3-56d4-45a0-8b31-5c643e3420d6"
      unitRef="usd">355225000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzEtMy0xLTEtMjg3Njk_9bb9ad4a-d8bb-4c5f-aab8-1c67171ab731"
      unitRef="usd">155419000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzItMS0xLTEtMjg3Njk_9b2845be-49a1-47ba-841b-e54b7cb0b950"
      unitRef="usd">3077000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzItMy0xLTEtMjg3Njk_795bac3b-a812-43d1-a1e4-8a444d26cc06"
      unitRef="usd">4647000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzMtMS0xLTEtMjg3Njk_46a8abf2-1df3-4ddc-b19d-40d1c3044ae6"
      unitRef="usd">385608000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzMtMy0xLTEtMjg3Njk_703d7be7-ff2d-49d3-b493-b0bf03b1cf2d"
      unitRef="usd">296967000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzQtMS0xLTEtMjg3Njk_bb4512a6-9bbd-451f-88bd-fffeb79cbdbf"
      unitRef="usd">743910000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTpiNDk5NmY0YTcyOTE0OWE4YWVhOGJlZjZmYjg0OGFjYS90YWJsZXJhbmdlOmI0OTk2ZjRhNzI5MTQ5YThhZWE4YmVmNmZiODQ4YWNhXzQtMy0xLTEtMjg3Njk_c0cad105-efc2-4c0f-84b6-6e4f2e433c8c"
      unitRef="usd">457033000</us-gaap:InventoryNet>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90ZXh0cmVnaW9uOmQxZWI2NGQ1ZjJiNTQ0MTM5ZGZkMTUyMWE2NzNjZjhiXzMyOTg1MzQ4ODM1NDc_b8969683-21dc-49c3-b833-c612e429812c">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,952&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other prepaid expenses and current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;337,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidTaxes
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzEtMS0xLTEtNTU4Mzk_edc3273b-96cf-4b2e-9b3c-48487197e12f"
      unitRef="usd">99352000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzEtMy0xLTEtNTU4Mzk_a8fd54b4-5d90-48f1-87da-7287a50e579a"
      unitRef="usd">72409000</us-gaap:PrepaidTaxes>
    <rmd:PrepaidInventory
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzItMS0xLTEtNTU4Mzk_d694e4bc-cad3-45af-a5f3-5358c0b47990"
      unitRef="usd">107291000</rmd:PrepaidInventory>
    <rmd:PrepaidInventory
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzItMy0xLTEtNTU4Mzk_1d972d19-a2bb-4c9b-ae0c-b1c981549e5a"
      unitRef="usd">6952000</rmd:PrepaidInventory>
    <us-gaap:OtherAssetsCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzMtMS0xLTEtNTU4Mzk_f6b30b40-0981-4815-a205-89ab77776d28"
      unitRef="usd">131265000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzMtMy0xLTEtNTU4Mzk_8810a373-c2ac-41bc-ba9a-142f29044a43"
      unitRef="usd">128793000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzQtMS0xLTEtNTU4Mzk_66734cd8-3882-4af5-a90c-27fb416a7ccc"
      unitRef="usd">337908000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTo1OTU0ZWU5MDFkN2U0NWU5OTFjOTAwOTE3NDRiNjYyYy90YWJsZXJhbmdlOjU5NTRlZTkwMWQ3ZTQ1ZTk5MWM5MDA5MTc0NGI2NjJjXzQtMy0xLTEtNTU4Mzk_3feb3022-7cc1-4cec-9f4d-427e1f3e8a7f"
      unitRef="usd">208154000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90ZXh0cmVnaW9uOmQxZWI2NGQ1ZjJiNTQ0MTM5ZGZkMTUyMWE2NzNjZjhiXzE3OQ_05aa1a4e-8058-45e9-93bd-475d96cf133e">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vehicles and aircraft&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Clinical, demonstration and rental equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;105,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;229,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;239,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,131,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,085,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(633,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(622,139)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i209e45ce8baa40da9ad533b396e1a091_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzEtMS0xLTEtMjg3Njk_df5445f1-a2ee-49a3-9751-1e337ffee82e"
      unitRef="usd">390634000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie01fa7efbed74149bb3ddb5b137cf86b_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzEtMy0xLTEtMjg3Njk_e1815257-1f15-48c1-879a-2847712db1dd"
      unitRef="usd">349022000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i44cbe9d650c44532ad24d4a6fe3dfc94_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzItMS0xLTEtMjg3Njk_4ee8d646-3a06-480d-b8c5-2110a10269c0"
      unitRef="usd">199671000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i633d55b64edf4c93a09ab4cc0f22c9e6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzItMy0xLTEtMjg3Njk_a112e3b7-7d30-4a84-9834-84a1dcf77d7a"
      unitRef="usd">194386000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic4960aeb688d4da1892eaa0e59da4d2e_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzMtMS0xLTEtMjg3Njk_1c46a408-3226-4bb0-ad44-26955c430193"
      unitRef="usd">54098000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie4cdad6ff0a54f4a86b3bb451325b302_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzMtMy0xLTEtMjg3Njk_8bb395b2-d706-4d0d-9bd3-0805a92a6e98"
      unitRef="usd">54435000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5a380d27436f42cd821417665d91070c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzQtMS0xLTEtMjg3Njk_62033174-eeca-433e-a15e-ef207b7ec5ae"
      unitRef="usd">19231000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5c114ee233de43edb2dac04cb12f71bc_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzQtMy0xLTEtMjg3Njk_435affb1-ec3f-4820-81b4-9e703d50aa66"
      unitRef="usd">5959000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8c2b6d7ce5de4befb6c1ee57c860ff72_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzUtMS0xLTEtMjg3Njk_b3dc9b86-cc5e-4b9c-aff5-304fd7f7d545"
      unitRef="usd">105440000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib42c790c4b0d45ecb0af64685365f55f_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzUtMy0xLTEtMjg3Njk_6b6c1a41-6b44-453f-8c8d-931103e68d50"
      unitRef="usd">110620000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="iffb9a63338dc4ffe875023dc79c7905a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzYtMS0xLTEtMjg3Njk_7131c0aa-c2a9-456b-a91c-3f7d1d0ec5da"
      unitRef="usd">80855000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i59a6908e2b224904a2ee86392a3bed03_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzYtMy0xLTEtMjg3Njk_9f22e399-6f0c-4004-8243-ca5ebec34a42"
      unitRef="usd">77392000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i930755293b68471bac0a4f69a1579932_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzctMS0xLTEtMjg3Njk_91014786-28c2-43ec-94a2-8803e97944ff"
      unitRef="usd">51864000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ieba697dd91864c6794a754cb2f07b007_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzctMy0xLTEtMjg3Njk_1cedaa4c-1eab-469e-a3f3-bcbcefda19a9"
      unitRef="usd">54458000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i62e565965d9f49f2aa99102b8387476a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzgtMS0xLTEtMjg3Njk_ae5950e5-8491-493b-b5fa-0feb0007ae60"
      unitRef="usd">229502000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1327c3ca8f3445da9935a8f2dc5e53a2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzgtMy0xLTEtMjg3Njk_cd35176a-bff9-40ca-b9bd-317befebb054"
      unitRef="usd">239357000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzktMS0xLTEtMjg3Njk_f9352641-678c-4b38-9637-620e864e4fe3"
      unitRef="usd">1131295000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzktMy0xLTEtMjg3Njk_efad08f5-b8cb-4242-9eb4-655dac10f68a"
      unitRef="usd">1085629000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzEwLTEtMS0xLTI4NzY5_8d8d7d02-1022-4328-ac44-dcef24765613"
      unitRef="usd">633114000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzEwLTMtMS0xLTI4NzY5_167cebdf-079b-4ef5-9223-e44aa2bf4236"
      unitRef="usd">622139000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzExLTEtMS0xLTI4NzY5_70b06218-fe00-45db-b1d9-45527d4dcb1f"
      unitRef="usd">498181000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTUvZnJhZzpkMWViNjRkNWYyYjU0NDEzOWRmZDE1MjFhNjczY2Y4Yi90YWJsZTowMDZlNWY4OTlhYTU0M2MyYjY5MTMxYzE4Y2E4Y2JlNy90YWJsZXJhbmdlOjAwNmU1Zjg5OWFhNTQzYzJiNjkxMzFjMThjYThjYmU3XzExLTMtMS0xLTI4NzY5_b35ad260-4f29-4249-a56c-f92fc93b53c6"
      unitRef="usd">463490000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzEwMzY_510c5617-479a-4bd6-af20-941f772a6d4b">Goodwill and Other Intangible Assets, net&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each of the years ended June&#160;30, 2022 and June&#160;30, 2021, we have not recorded any goodwill impairments. Changes in the carrying amount of goodwill is comprised of the following for the year ended June&#160;30, 2022 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sleep and &lt;br/&gt;Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SaaS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;633,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,294,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,927,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Business acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;641,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,294,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,936,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangibles, net are comprised of the following as of June&#160;30, 2022 and June&#160;30, 2021 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed/core product technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;383,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(239,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(239,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed/core product technology, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;272,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(91,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(90,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(134,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(131,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, and we amortize them over the estimated useful life of the assets, generally between two years and fifteen years. There are no expected residual values related to these intangible assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense related to identified intangible assets for the years ended June&#160;30, 2022 and June&#160;30, 2021 was $70.7 million and $76.2 million, respectively. Amortization expense related to patents for the years ended June&#160;30, 2022 and June&#160;30, 2021 was $6.2 million and $5.3 million, respectively. Total estimated annual amortization expense for the years ending June 30, 2023 through June 30, 2027, is shown below (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Years Ending June&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzEwMzc_ae7c4507-dc5c-440f-8c68-62227c188904">Changes in the carrying amount of goodwill is comprised of the following for the year ended June&#160;30, 2022 (in thousands): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Sleep and &lt;br/&gt;Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;SaaS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;633,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,294,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,927,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Business acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(30,412)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;641,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,294,718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,936,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ia68dbe4ac6c24607ab0fe9092c69e114_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzItMS0xLTEtMjg3Njk_ad09954a-737b-4405-823e-5e162de1ff54"
      unitRef="usd">633183000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i673b7f5418864027b262473e75a24496_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzItMy0xLTEtMjg3Njk_f3fb2f2e-3146-4daf-9d80-6d9c8c3b00ff"
      unitRef="usd">1294718000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzItNS0xLTEtMjg3Njk_a95d3e66-d1f9-444e-9286-14d256f7b528"
      unitRef="usd">1927901000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i585a12bee5294dd7a4971ee1e63765a6_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzMtMS0xLTEtMjg3Njk_c887e8cb-05c5-4972-bc03-a2973b63ce53"
      unitRef="usd">38953000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic386a2f3fc574a6eaa1bc26205d89225_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzMtMy0xLTEtMjg3Njk_c08e7546-a492-46b1-875c-7cea5a9ff92a"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzMtNS0xLTEtMjg3Njk_7b7ae1d6-e980-478e-89bc-e7918fc53025"
      unitRef="usd">38953000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i585a12bee5294dd7a4971ee1e63765a6_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzQtMS0xLTEtMjg3Njk_8efbded4-5a9a-472b-97c1-8baf6d9da6bf"
      unitRef="usd">-30412000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ic386a2f3fc574a6eaa1bc26205d89225_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzQtMy0xLTEtMjg3Njk_831b6bd6-51ee-4462-aa93-ede8a9a73f37"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzQtNS0xLTEtMjg3Njk_4d987d0a-f2cc-4eaf-951a-bd00264d61c1"
      unitRef="usd">-30412000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="i9d3f3a2e554e4ce498a8c2eac0e1773c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzUtMS0xLTEtMjg3Njk_f25c1b14-60c7-4091-b05b-04bb1f59c984"
      unitRef="usd">641724000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie5920b8d4566429aacc99c4cb598b86b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzUtMy0xLTEtMjg3Njk_faa415e2-dc3a-4bf9-8f9b-0fcd6b93dcf9"
      unitRef="usd">1294718000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTphNTc2Y2M5MjViNmM0M2RkYWRmZWI3ZTQ3ZGJiZDBmMC90YWJsZXJhbmdlOmE1NzZjYzkyNWI2YzQzZGRhZGZlYjdlNDdkYmJkMGYwXzUtNS0xLTEtMjg3Njk_4cdeff73-e264-479a-bf4a-9f1dae173de5"
      unitRef="usd">1936442000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzM4NDgyOTA2OTgyNzE_7c8f89db-dc83-4225-858d-249f61552867">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other intangibles, net are comprised of the following as of June&#160;30, 2022 and June&#160;30, 2021 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed/core product technology&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;383,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(239,647)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(239,049)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed/core product technology, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;257,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;272,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(91,731)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(90,976)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(134,963)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(131,077)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i383529560350461f9474da7a3e151953_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzEtMS0xLTEtMjg3Njk_1e844e6b-9093-42c0-96e4-320122abf61e"
      unitRef="usd">350671000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if91504ce254047b09ff93066ad7e7365_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzEtMy0xLTEtMjg3Njk_6239015e-0a0e-443d-9d84-46255bc39f59"
      unitRef="usd">383319000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i383529560350461f9474da7a3e151953_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzItMS0xLTEtMjg3Njk_3d240e5d-4ee4-443c-a1df-4f4e5a18d13e"
      unitRef="usd">239647000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if91504ce254047b09ff93066ad7e7365_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzItMy0xLTEtMjg3Njk_61b651f1-abe4-470d-9eb3-c9e616ea475b"
      unitRef="usd">239049000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i383529560350461f9474da7a3e151953_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzMtMS0xLTEtMjg3Njk_093540ef-bb52-4e6f-84b8-646bad34cdba"
      unitRef="usd">111024000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if91504ce254047b09ff93066ad7e7365_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzMtMy0xLTEtMjg3Njk_3e23d714-c1fb-4dd4-afb5-e2d02f2687e9"
      unitRef="usd">144270000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i27a41c0bc031463eb9e124aa25b7e462_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzQtMS0xLTEtMjg3Njk_dd2845da-35e9-4352-89ab-82d6e8e73fff"
      unitRef="usd">257034000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie60c3c5babf44f189d82c62d83c1ba0e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzQtMy0xLTEtMjg3Njk_eb6e44ed-172a-48d4-b09d-7a62ab262447"
      unitRef="usd">272703000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i27a41c0bc031463eb9e124aa25b7e462_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzUtMS0xLTEtMjg3Njk_e5d8ee3a-57b5-42e6-94ff-0dde17323736"
      unitRef="usd">91731000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie60c3c5babf44f189d82c62d83c1ba0e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzUtMy0xLTEtMjg3Njk_ebcc9713-a6c9-42ce-82fe-b5cec8d93e72"
      unitRef="usd">90976000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i27a41c0bc031463eb9e124aa25b7e462_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzYtMS0xLTEtMjg3Njk_b9c18ee7-8d6d-4b9b-9ae3-98c9ccec8f69"
      unitRef="usd">165303000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie60c3c5babf44f189d82c62d83c1ba0e_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzYtMy0xLTEtMjg3Njk_568c30a5-d828-4a4a-8e35-43e97cd0b673"
      unitRef="usd">181727000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id414856654b6425f94e23c727ecf7d42_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzctMS0xLTEtMjg3Njk_6d1839c9-5f59-4b27-a144-92dd77119870"
      unitRef="usd">204580000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i26192f7e58a3451690f985df3d035304_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzctMy0xLTEtMjg3Njk_7e684987-f976-4bf8-b521-f96743417517"
      unitRef="usd">197662000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id414856654b6425f94e23c727ecf7d42_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzgtMS0xLTEtMjg3Njk_1e80fdff-88b0-4b34-abc4-d8abb3316958"
      unitRef="usd">134963000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i26192f7e58a3451690f985df3d035304_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzgtMy0xLTEtMjg3Njk_c3cd3e52-9103-46f4-a675-4110de49cc97"
      unitRef="usd">131077000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id414856654b6425f94e23c727ecf7d42_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzktMS0xLTEtMjg3Njk_2b1d3102-abc6-4990-9357-4f9def9c1495"
      unitRef="usd">69617000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i26192f7e58a3451690f985df3d035304_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzktMy0xLTEtMjg3Njk_d852100b-4ddc-41b5-b6b0-8942000112ee"
      unitRef="usd">66585000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzEwLTEtMS0xLTI4NzY5_cfb07f85-1431-4291-9cf6-33957ce85b82"
      unitRef="usd">345944000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTo2OGNkYjM2ZWIyZTg0ODI1YjM5ZDkwMjFiM2RmMzgwMC90YWJsZXJhbmdlOjY4Y2RiMzZlYjJlODQ4MjViMzlkOTAyMWIzZGYzODAwXzEwLTMtMS0xLTI4NzY5_f1026d7a-dc1b-478a-9fe6-30fdbdf5f2dd"
      unitRef="usd">392582000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIxODM_3f050888-59c7-4bd2-abf7-668aadbead29">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIxODg_0fc8d6f0-b8db-44cb-985c-61525203fefc">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i275c6f7ccc89416f8b114a73abdb1eb2_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIyMDE_b6dc7354-1986-4004-b1c6-7ebc6d839125"
      unitRef="usd">70700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ide28368adb344db981e13dc7ab3f39e6_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIyMDU_a67be815-f226-4f06-ace4-59260a0e7b56"
      unitRef="usd">76200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i28a3ce23547b4f28a6b1d773a88cbc9b_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIyMTc_0ff29332-61f4-44c0-bc05-ad60b17b3ee8"
      unitRef="usd">6200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i5e17c04c42c84b1da53be06c8c07c44b_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzQzOTgwNDY1MTIyMjE_053b3926-4445-4e54-94f8-287ca7ee758f"
      unitRef="usd">5300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90ZXh0cmVnaW9uOmM4ZDIwZGEzYzk4OTQ0NDBhNWYzNDNmN2JhYjNmODRjXzEwMzU_1a35170f-1405-4e76-9650-35631b2df1c1">Total estimated annual amortization expense for the years ending June 30, 2023 through June 30, 2027, is shown below (in thousands): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Years Ending June&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTpiYzVhOWVkMTJhNTM0MzVmOTdmMGY3YTA4ZWEwOTNiZC90YWJsZXJhbmdlOmJjNWE5ZWQxMmE1MzQzNWY5N2YwZjdhMDhlYTA5M2JkXzItMS0xLTEtMjg3Njk_bd3f3638-0d00-46d6-98e2-fd1f45492d58"
      unitRef="usd">61374000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTpiYzVhOWVkMTJhNTM0MzVmOTdmMGY3YTA4ZWEwOTNiZC90YWJsZXJhbmdlOmJjNWE5ZWQxMmE1MzQzNWY5N2YwZjdhMDhlYTA5M2JkXzItMy0xLTEtMjg3Njk_433d1392-5a16-4822-a2fd-bb6f421c5a3d"
      unitRef="usd">57594000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTpiYzVhOWVkMTJhNTM0MzVmOTdmMGY3YTA4ZWEwOTNiZC90YWJsZXJhbmdlOmJjNWE5ZWQxMmE1MzQzNWY5N2YwZjdhMDhlYTA5M2JkXzItNS0xLTEtMjg3Njk_78289868-62d9-45c1-b313-4fc9b34db03f"
      unitRef="usd">53157000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTpiYzVhOWVkMTJhNTM0MzVmOTdmMGY3YTA4ZWEwOTNiZC90YWJsZXJhbmdlOmJjNWE5ZWQxMmE1MzQzNWY5N2YwZjdhMDhlYTA5M2JkXzItNy0xLTEtMjg3Njk_521672a7-853e-4306-9252-5af2d45034af"
      unitRef="usd">47902000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMTgvZnJhZzpjOGQyMGRhM2M5ODk0NDQwYTVmMzQzZjdiYWIzZjg0Yy90YWJsZTpiYzVhOWVkMTJhNTM0MzVmOTdmMGY3YTA4ZWEwOTNiZC90YWJsZXJhbmdlOmJjNWE5ZWQxMmE1MzQzNWY5N2YwZjdhMDhlYTA5M2JkXzItOS0xLTEtMjg3Njk_018811ff-1ac5-4c3e-8873-da34d6635a6b"
      unitRef="usd">29667000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:InvestmentTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzgzNw_286e4d88-893f-4710-b005-63d742d8b840">Investments&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments by measurement category as of June&#160;30, 2022 and June&#160;30, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Measurement category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Measurement alternative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net additions (reductions) to investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Observable price adjustments on non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized losses on marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains on marketable and non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying value at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Net additions (reductions) to investments includes additions from purchases, reductions due to exits of securities, or reclassifications due to our acquisition of an investee in which we held a prior equity interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2021(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions to investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Observable price adjustments on non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains on marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassifications &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying value at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;During the year ended June&#160;30, 2021, one of our investments, which was previously accounted for under the measurement alternative, completed its initial public offering which resulted in a change of accounting methodology to fair value. &lt;/span&gt;&lt;/div&gt;Net unrealized gains and losses recognized in the years ended June&#160;30, 2022, 2021 and 2020 for equity investments in non-marketable and marketable securities still held as of those respective dates were a loss of $16.2 million, a gain of $14.5 million, and a loss of $14.5 million, respectively.</us-gaap:InvestmentTextBlock>
    <rmd:ScheduleOfInvestmentsTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzgzOA_bb99fec1-0315-4b6c-8d25-91740cc64ff4">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity investments by measurement category as of June&#160;30, 2022 and June&#160;30, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Measurement category&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Measurement alternative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rmd:ScheduleOfInvestmentsTableTextBlock>
    <rmd:MarketableEquityInvestmentsFairValue
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzEtMS0xLTEtMjg3Njk_29c0fd30-0a25-46fe-9075-b3168d5641c6"
      unitRef="usd">9167000</rmd:MarketableEquityInvestmentsFairValue>
    <rmd:MarketableEquityInvestmentsFairValue
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzEtMy0xLTEtMjg3Njk_aa099215-e9f3-47d5-9069-a0b438af9245"
      unitRef="usd">29084000</rmd:MarketableEquityInvestmentsFairValue>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzItMS0xLTEtMjg3Njk_fb2beecf-f1af-4a15-8efb-5359ff48ec19"
      unitRef="usd">39290000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzItMy0xLTEtMjg3Njk_7c3f090d-46ea-40ae-bb7d-85c33bcc1d95"
      unitRef="usd">23002000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzMtMS0xLTEtMjg3Njk_8df02a8f-5c1b-484a-8e29-fad2e5c2276e"
      unitRef="usd">9918000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzMtMy0xLTEtMjg3Njk_be704870-e20b-434a-af7e-496f307e55ad"
      unitRef="usd">17154000</us-gaap:EquityMethodInvestments>
    <rmd:EquityInvestmentsTotalByMeasurementCategory
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzQtMS0xLTEtMjg3Njk_026d23d9-31d5-4218-85e4-f6fa49087517"
      unitRef="usd">58375000</rmd:EquityInvestmentsTotalByMeasurementCategory>
    <rmd:EquityInvestmentsTotalByMeasurementCategory
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTo0MjA5NWI5OGE2NTE0NmM2ODE3ZWY5N2U5YTM1NzlkNy90YWJsZXJhbmdlOjQyMDk1Yjk4YTY1MTQ2YzY4MTdlZjk3ZTlhMzU3OWQ3XzQtMy0xLTEtMjg3Njk_c5274aa9-99cd-4241-8ced-42b62c56bff2"
      unitRef="usd">69240000</rmd:EquityInvestmentsTotalByMeasurementCategory>
    <rmd:ScheduleOfChangesInEquityInvestmentsTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzgzOQ_6afeefa3-9445-46ca-b2b0-c2f4120a5967">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net additions (reductions) to investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,202)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Observable price adjustments on non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized losses on marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains on marketable and non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Impairment of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,209)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8,486)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying value at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Net additions (reductions) to investments includes additions from purchases, reductions due to exits of securities, or reclassifications due to our acquisition of an investee in which we held a prior equity interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows a reconciliation of the changes in our equity investments for the year ended June&#160;30, 2021(in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Non-marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions to investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Observable price adjustments on non-marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains on marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassifications &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying value at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(2)During the year ended June&#160;30, 2021, one of our investments, which was previously accounted for under the measurement alternative, completed its initial public offering which resulted in a change of accounting methodology to fair value.</rmd:ScheduleOfChangesInEquityInvestmentsTableTextBlock>
    <rmd:EquityInvestments
      contextRef="i346adc043b664e69a5d86956607aa19d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzEtMS0xLTEtMjg3Njk_5fb84cd4-86c3-4989-9a15-ffe1d7929922"
      unitRef="usd">23002000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="i15585071980b44609c4244d0667080d3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzEtMy0xLTEtMjg3Njk_949536e2-11d1-4a4c-83b7-36daf6c82a3e"
      unitRef="usd">29084000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="i1ecaa50f2b0842ebaa2fada9c7ce2d1a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzEtNS0xLTEtMjg3Njk_76058318-b70b-4d7d-b556-efcea6087f1c"
      unitRef="usd">17154000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzEtNy0xLTEtMjg3Njk_8c20c570-fcf5-43bc-acdd-98a713a3a42c"
      unitRef="usd">69240000</rmd:EquityInvestments>
    <rmd:AdditionalEquityInvestments
      contextRef="i28ab83892aae4ba397a55655fbf05f29_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzItMS0xLTEtMjg3Njk_894ab772-1705-409d-9479-3bf9ba7bb45c"
      unitRef="usd">11775000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments
      contextRef="i12742f5ecfc34a62988f7e0587db5dd6_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzItMy0xLTEtMjg3Njk_4ea81470-5886-478a-abcb-ce30aecda9b6"
      unitRef="usd">-3202000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments
      contextRef="ida2475934ea241ca9c2d0a10c164d26b_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzItNS0xLTEtMjg3Njk_a72d4418-9732-4827-bc7e-21b8acc9883f"
      unitRef="usd">1250000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzItNy0xLTEtMjg3Njk_e1e15fca-98bc-4f4b-bc24-32e3833ce532"
      unitRef="usd">9823000</rmd:AdditionalEquityInvestments>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities
      contextRef="i28ab83892aae4ba397a55655fbf05f29_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzMtMS0xLTEtMjg3Njk_63238a08-47bf-4338-b4a0-3bffa7a1dcb0"
      unitRef="usd">5367000</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzMtNy0xLTEtMjg3Njk_537712fb-0448-498d-a0c6-299086713433"
      unitRef="usd">5367000</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i12742f5ecfc34a62988f7e0587db5dd6_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzQtMy0xLTEtMjg3Njk_90f18c59-8c24-4d9c-84bf-a9db6f9c473d"
      unitRef="usd">-18341000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzQtNy0xLTEtMjg3Njk_07ff6f3f-5a4c-453b-95c5-17dad620a986"
      unitRef="usd">-18341000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i28ab83892aae4ba397a55655fbf05f29_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzUtMS0xLTEtMjg3Njk_05a761d3-4d54-4cc5-aeb0-c478b74a4e50"
      unitRef="usd">2355000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i12742f5ecfc34a62988f7e0587db5dd6_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzUtMy0xLTEtMjg3Njk_a6da4433-da84-44b8-a3dc-dc8ca8a5fe54"
      unitRef="usd">1626000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzUtNy0xLTEtMjg3Njk_64a4fa49-8d17-4ec4-9380-a1a1182f6700"
      unitRef="usd">3981000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:ImpairmentOfInvestments
      contextRef="i28ab83892aae4ba397a55655fbf05f29_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzYtMS0xLTEtMzM2MTA_7a6a3c27-0f39-4daf-9fbc-4a99e1357598"
      unitRef="usd">3209000</us-gaap:ImpairmentOfInvestments>
    <us-gaap:ImpairmentOfInvestments
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzYtNy0xLTEtMzM2MTA_d0fdb045-88e6-42f3-98b7-8a6a903cbc5d"
      unitRef="usd">3209000</us-gaap:ImpairmentOfInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ida2475934ea241ca9c2d0a10c164d26b_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzYtNS0xLTEtMjg3Njk_a8b21223-8a3d-4d2f-bce8-83f3ef694450"
      unitRef="usd">-8486000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzYtNy0xLTEtMjg3Njk_879dda50-bc18-4b9f-9c80-7a77018fd165"
      unitRef="usd">-8486000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <rmd:EquityInvestments
      contextRef="i986baaa416044ab0b8a0147a14087047_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzctMS0xLTEtMjg3Njk_ad3fc8ce-1e53-46f8-8d9f-003a08b83ee5"
      unitRef="usd">39290000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="ia249219ca61d4c4ea23e703cf2260422_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzctMy0xLTEtMjg3Njk_8b43a982-736f-4ccc-92bf-d0d11e2dc9e7"
      unitRef="usd">9167000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="i1b6f2c0aa8974e7cb7f65b5033462701_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzctNS0xLTEtMjg3Njk_074d509c-6a39-43db-8a23-484a0e382b92"
      unitRef="usd">9918000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZToxYjkxYWUzNzdjOGY0MmY3OGM5M2VmYmNmYTc3ZjAwZS90YWJsZXJhbmdlOjFiOTFhZTM3N2M4ZjQyZjc4YzkzZWZiY2ZhNzdmMDBlXzctNy0xLTEtMjg3Njk_05a5f0f8-ae7c-466d-9de6-f5d3e546a298"
      unitRef="usd">58375000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="i84ec92f010cb4996b46b1526ee19a1bc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzEtMS0xLTEtMjg3Njk_13ac187c-bef9-4d57-b44a-246af6b5fa80"
      unitRef="usd">30033000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="i5e4cd11b6bc34d7895326f826a7c3f0d_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzEtMy0xLTEtMjg3Njk_a5fd00e6-7033-44d5-bced-309cb0d4af98"
      unitRef="usd">0</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="ifd1dcdc316cf456186c44ff5d3915ada_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzEtNS0xLTEtMjg3Njk_6106b7df-548a-4365-947b-d5652c37858b"
      unitRef="usd">14109000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzEtNy0xLTEtMjg3Njk_3c42abc8-1d9b-4f6a-83c6-ef28800ae9ee"
      unitRef="usd">44142000</rmd:EquityInvestments>
    <rmd:AdditionalEquityInvestments
      contextRef="if003111e277449988551264e5889944a_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzItMS0xLTEtMjg3Njk_e36849a3-f054-4f04-95be-8fa67d67f5fe"
      unitRef="usd">2538000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments
      contextRef="i01c095726ae74638a2cadaaac6191673_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzItMy0xLTEtMjg3Njk_bc21f7dc-8b7d-44aa-97f6-681818efc601"
      unitRef="usd">5000000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments
      contextRef="idd4cbd01865547d0b68850bcd7ca2e04_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzItNS0xLTEtMjg3Njk_50e1ccb8-b777-428e-831a-2a037a78614f"
      unitRef="usd">14250000</rmd:AdditionalEquityInvestments>
    <rmd:AdditionalEquityInvestments
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzItNy0xLTEtMjg3Njk_e364894d-7ed6-480b-85f5-c0584fc2a7b1"
      unitRef="usd">21788000</rmd:AdditionalEquityInvestments>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities
      contextRef="if003111e277449988551264e5889944a_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzMtMS0xLTEtMzM1NjU_1c8031ef-41be-40c8-ab0c-cb95cc17216c"
      unitRef="usd">1000000</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzMtNy0xLTEtMzM1NjU_54b55d55-3935-4970-adb4-b7e085aa2784"
      unitRef="usd">1000000</rmd:ObservablePriceAdjustmentsOnNonMarketableEquitySecurities>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i01c095726ae74638a2cadaaac6191673_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzQtMy0xLTEtMzM1NjU_f045bd68-2428-4f86-92c7-604b5e10ee2f"
      unitRef="usd">13515000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzQtNy0xLTEtMzM1NjU_1498af72-94fe-40f5-9534-de0f0c32522b"
      unitRef="usd">13515000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <rmd:ReclassificationsInEquityInvestments
      contextRef="if003111e277449988551264e5889944a_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzMtMS0xLTEtMjg3Njk_384ab9bd-2429-4978-8484-8fbe415e89d2"
      unitRef="usd">-10569000</rmd:ReclassificationsInEquityInvestments>
    <rmd:ReclassificationsInEquityInvestments
      contextRef="i01c095726ae74638a2cadaaac6191673_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzMtMy0xLTEtMjg3Njk_6ad21bfe-8e4f-4b24-adc3-8d712c19a930"
      unitRef="usd">10569000</rmd:ReclassificationsInEquityInvestments>
    <rmd:ReclassificationsInEquityInvestments
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzMtNy0xLTEtMjg3Njk_c4c9ffe6-3547-4cc7-811a-6a3259a46007"
      unitRef="usd">0</rmd:ReclassificationsInEquityInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idd4cbd01865547d0b68850bcd7ca2e04_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzQtNS0xLTEtMjg3Njk_cf9c04d4-68b2-4608-8976-4360cf5f59f6"
      unitRef="usd">-11205000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzQtNy0xLTEtMjg3Njk_3cbd8b96-d248-4fed-9c67-e4708d19fbec"
      unitRef="usd">-11205000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <rmd:EquityInvestments
      contextRef="i346adc043b664e69a5d86956607aa19d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzUtMS0xLTEtMjg3Njk_d3a57df8-e1c4-48ad-9547-2db195bbaa99"
      unitRef="usd">23002000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="i15585071980b44609c4244d0667080d3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzUtMy0xLTEtMjg3Njk_53b15f65-ce01-4bee-89b2-63a4f7c3c98c"
      unitRef="usd">29084000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="i1ecaa50f2b0842ebaa2fada9c7ce2d1a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzUtNS0xLTEtMjg3Njk_b91012fb-604c-47c1-8389-0caf691c778b"
      unitRef="usd">17154000</rmd:EquityInvestments>
    <rmd:EquityInvestments
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90YWJsZTpiYWNhYTJlMmRiMWI0ZDVjODAyODU2Y2RiYzI5M2I2Ni90YWJsZXJhbmdlOmJhY2FhMmUyZGIxYjRkNWM4MDI4NTZjZGJjMjkzYjY2XzUtNy0xLTEtMjg3Njk_cb57f293-b05a-4286-a039-0e87a4eb68f1"
      unitRef="usd">69240000</rmd:EquityInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzQzOTgwNDY1MTM0NDc_91d1f50d-001f-4e6b-9c0b-8fa43006f394"
      unitRef="usd">-16200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzQzOTgwNDY1MTM0NjQ_d5092c65-0a65-42f7-8be0-8556fa7d54ca"
      unitRef="usd">14500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjEvZnJhZzpkOTliYjNkNDJmYTQ0ZjZlOWNhMjg5YjNiMzJlYjYzMS90ZXh0cmVnaW9uOmQ5OWJiM2Q0MmZhNDRmNmU5Y2EyODliM2IzMmViNjMxXzQzOTgwNDY1MTM0ODE_d9f908d4-6983-46b1-bcad-14a57d2b9127"
      unitRef="usd">-14500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90ZXh0cmVnaW9uOmJkOTlkNzNmZGVmYTRiMWVhY2E2MGJkMTA1MjRjN2E1Xzk5_5e20447c-51dc-4a9c-81a7-6de18c63c8cc">Accrued Expenses &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses at June&#160;30, 2022 and June&#160;30, 2021 consist of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product warranties (note 8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Consulting and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value added taxes and other taxes due&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Promotional and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Logistics and occupancy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory in transit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90ZXh0cmVnaW9uOmJkOTlkNzNmZGVmYTRiMWVhY2E2MGJkMTA1MjRjN2E1XzEwMA_9e518cc3-508d-43c4-a5a6-2b6fb5779fa2">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses at June&#160;30, 2022 and June&#160;30, 2021 consist of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product warranties (note 8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Consulting and professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Value added taxes and other taxes due&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee related costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Promotional and marketing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Logistics and occupancy costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory in transit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzEtMS0xLTEtMjg3Njk_b04e99ff-3f17-4fad-93df-d790f8c48fee"
      unitRef="usd">25889000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzEtMy0xLTEtMjg3Njk_ea30f838-43d0-4992-9785-79f1ccf85e29"
      unitRef="usd">22032000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzItMS0xLTEtMjg3Njk_26e919f9-059c-4001-b5a1-c3c304ca9452"
      unitRef="usd">25073000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzItMy0xLTEtMjg3Njk_eb85dfe4-0be9-4d27-a6e0-c0b65529d6a1"
      unitRef="usd">21246000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzMtMS0xLTEtMjg3Njk_0b189980-83f7-4056-a03f-05e0d82cda21"
      unitRef="usd">26340000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzMtMy0xLTEtMjg3Njk_16c8c46f-b4a1-4757-a4d2-2101268a10a6"
      unitRef="usd">26542000</us-gaap:TaxesPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzQtMS0xLTEtMjg3Njk_1480d4f3-9380-486b-9b03-42e26ce6c0e1"
      unitRef="usd">194736000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzQtMy0xLTEtMjg3Njk_0d00ab98-1fe1-4034-90d9-56ed769574ba"
      unitRef="usd">199917000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzUtMS0xLTEtMjg3Njk_834dd4c9-55bb-4338-ab13-2f2abe304976"
      unitRef="usd">6485000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzUtMy0xLTEtMjg3Njk_1b3aed69-740a-476e-b781-cfcb6f2e84d3"
      unitRef="usd">4127000</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzYtMS0xLTEtMjg3Njk_66e0ba83-3fb8-422b-9c40-f253b1b914cc"
      unitRef="usd">7983000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzYtMy0xLTEtMjg3Njk_c73242e7-a6a6-4be9-a515-08c284959949"
      unitRef="usd">8338000</us-gaap:InterestPayableCurrent>
    <rmd:AccruedLogisticsAndOccupancyExpensesCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzctMS0xLTEtMjg3Njk_18909ebf-1e75-4327-bf5c-11d15896f757"
      unitRef="usd">32160000</rmd:AccruedLogisticsAndOccupancyExpensesCurrent>
    <rmd:AccruedLogisticsAndOccupancyExpensesCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzctMy0xLTEtMjg3Njk_40bcc186-b67e-443c-9a35-c6bd7fd304d0"
      unitRef="usd">14954000</rmd:AccruedLogisticsAndOccupancyExpensesCurrent>
    <rmd:AccruedInventoryInTransit
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzgtMS0xLTEtMjg3Njk_b9930382-3ad0-4118-a38c-060f625f41e5"
      unitRef="usd">11554000</rmd:AccruedInventoryInTransit>
    <rmd:AccruedInventoryInTransit
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzgtMy0xLTEtMjg3Njk_669e3c8a-cf65-4842-ad67-a0f002500b1b"
      unitRef="usd">7146000</rmd:AccruedInventoryInTransit>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzktMS0xLTEtMjg3Njk_2a2e8a55-672f-45c2-979c-b7c79d0e89cd"
      unitRef="usd">14502000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzktMy0xLTEtMjg3Njk_318fad8b-de95-4b80-9208-34ead81ec615"
      unitRef="usd">16297000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzEwLTEtMS0xLTI4NzY5_0af66513-70e4-4b41-b234-f49becf7a4a6"
      unitRef="usd">344722000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjQvZnJhZzpiZDk5ZDczZmRlZmE0YjFlYWNhNjBiZDEwNTI0YzdhNS90YWJsZTo5ZGU0N2Y3MDEwYWQ0YTYxYmEwMjhiZTFmMWUzMWRkNy90YWJsZXJhbmdlOjlkZTQ3ZjcwMTBhZDRhNjFiYTAyOGJlMWYxZTMxZGQ3XzEwLTMtMS0xLTI4NzY5_a2ec5704-c6d7-4b3d-a00a-6862bd6181f5"
      unitRef="usd">320599000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ProductWarrantyDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90ZXh0cmVnaW9uOjMzNmYyMDczZWI5NTQ1NTc4MWY1Y2QyNDZmZTI4MDkzXzIzNg_bb23abde-fa67-4804-ac31-d016aab29e7f">Product Warranties&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We include the liability for warranty costs in accrued expenses in our consolidated balance sheets. Changes in the liability for product warranty for the years ended June&#160;30, 2022 and June&#160;30, 2021 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warranty accruals for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warranty costs incurred for the period &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ProductWarrantyDisclosureTextBlock>
    <us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90ZXh0cmVnaW9uOjMzNmYyMDczZWI5NTQ1NTc4MWY1Y2QyNDZmZTI4MDkzXzIzNQ_9a3ec0fc-3de3-4217-b785-d4ed2cd44257">Changes in the liability for product warranty for the years ended June&#160;30, 2022 and June&#160;30, 2021 are as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warranty accruals for the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Warranty costs incurred for the period &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,124)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at the end of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock>
    <us-gaap:ProductWarrantyAccrual
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzEtMS0xLTEtMjg3Njk_dbf9d2d9-f47b-44d1-86da-f66798412cfb"
      unitRef="usd">22032000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual
      contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzEtMy0xLTEtMjg3Njk_32b770ee-a15a-4aee-843c-80ba42c938c4"
      unitRef="usd">21132000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzItMS0xLTEtMjg3Njk_10a1f5ab-f798-408f-88da-cf50373f965e"
      unitRef="usd">17442000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualWarrantiesIssued
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzItMy0xLTEtMjg3Njk_174d661e-ad47-47c5-8c88-ba7e6143e810"
      unitRef="usd">14366000</us-gaap:ProductWarrantyAccrualWarrantiesIssued>
    <us-gaap:ProductWarrantyAccrualPayments
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzMtMS0xLTEtMjg3Njk_37e4f016-72db-4998-a03a-9e34f458a26e"
      unitRef="usd">12124000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:ProductWarrantyAccrualPayments
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzMtMy0xLTEtMjg3Njk_2f33d89d-1c21-4002-ae55-b6dd417edd57"
      unitRef="usd">14858000</us-gaap:ProductWarrantyAccrualPayments>
    <us-gaap:StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzQtMS0xLTEtMjg3Njk_03ec23ba-77fc-4249-88bb-1e52c3562ff3"
      unitRef="usd">1461000</us-gaap:StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss>
    <us-gaap:StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzQtMy0xLTEtMjg3Njk_ba05d745-b42d-4cc3-af9b-3e8050ccea04"
      unitRef="usd">-1392000</us-gaap:StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss>
    <us-gaap:ProductWarrantyAccrual
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzUtMS0xLTEtMjg3Njk_0a8b6442-ee06-43e2-97de-a4e69627fb4c"
      unitRef="usd">25889000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:ProductWarrantyAccrual
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMjcvZnJhZzozMzZmMjA3M2ViOTU0NTU3ODFmNWNkMjQ2ZmUyODA5My90YWJsZTo1YzFlNThiYTQ1NmE0ZTJjYTQ2NGJkOTdlMWVkM2YwZS90YWJsZXJhbmdlOjVjMWU1OGJhNDU2YTRlMmNhNDY0YmQ5N2UxZWQzZjBlXzUtMy0xLTEtMjg3Njk_ec8edf7b-a04b-4af5-81f0-513e1f164d1d"
      unitRef="usd">22032000</us-gaap:ProductWarrantyAccrual>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzY4NTQ_c6d8955e-d0b7-4d79-ac94-78a69dae67db">Debt &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt at June&#160;30, 2022 and June&#160;30, 2021 consists of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred borrowing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;770,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;646,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred borrowing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;765,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;643,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;775,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;655,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;29, 2022, we entered into a second amended and restated credit agreement (the &#x201c;Revolving Credit Agreement&#x201d;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger, sole book runner, swing line lender and letter of credit issuer, Westpac Banking Corporation, as syndication agent and joint lead arranger, HSBC Bank USA, National Association, as syndication agent and joint lead arranger, and Wells Fargo Bank, National Association, as documentation agent. The Revolving Credit Agreement, among other things, provided a senior unsecured revolving credit facility of $1,500.0 million, with an uncommitted option to increase the revolving credit facility by an additional amount equal to the greater of $1,000.0 million and 1.00 times the EBITDA (as defined in the Revolving Credit Agreement) for the trailing twelve-month measurement period. The Revolving Credit Facility amends and restates that certain Amended and Restated Credit Agreement, dated as of April 17, 2018, among ResMed, MUFG Union Bank, N.A., Westpac Banking Corporation and the lenders party thereto which provided ResMed with a senior unsecured revolving credit facility in an aggregate amount of $1,600.0 million with an uncommitted option to increase such facility by an additional $300.0 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, on June&#160;29, 2022, ResMed Pty Limited entered into a Second Amendment to the Syndicated Facility Agreement and First Amendment to Unconditional Guaranty Agreement (the &#x201c;Term Credit Agreement&#x201d;), as borrower, with lenders MUFG Union Bank, N.A., as administrative agent, joint lead arranger and joint book runner, and Westpac Banking Corporation, as syndication agent, joint lead arranger and joint book runner, which amends that certain Syndicated Facility Agreement dated as of April 17, 2018. The Term Credit Agreement, among other things, provides ResMed Pty a senior unsecured term credit facility of $200.0 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our obligations under the Revolving Credit Agreement are guaranteed by certain of our direct and indirect U.S. subsidiaries, and ResMed Pty Limited&#x2019;s obligations under the Term Credit Agreement are guaranteed by us and certain of our direct and indirect U.S. subsidiaries. The Revolving Credit Agreement and Term Credit Agreement contain customary covenants, including, in each case, a financial covenant that requires that we maintain a maximum leverage ratio of funded debt to EBITDA (as defined in the Revolving Credit Agreement and Term Credit Agreement, as applicable). The entire principal amounts of the revolving credit facility and term credit facility, and, in each case, any accrued but unpaid interest may be declared immediately due and payable if an event of default occurs, as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable. Events of default under the Revolving Credit Agreement and the Term Credit Agreement include, in each case, failure to make payments when due, the occurrence of a default in the performance of any covenants in the respective agreements or related documents, or certain changes of control of us, or the respective guarantors of the obligations borrowed under the Revolving Credit Agreement and Term Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Revolving Credit Agreement and Term Credit Agreement each terminate on June&#160;29, 2027, when all unpaid principal and interest under the loans must be repaid. Amounts borrowed under the Term Credit Agreement will also amortize on a semi-annual basis, with a $5.0 million principal payment required on each such semi-annual amortization date. The outstanding principal amounts will bear interest at a rate equal to the Adjusted Term SOFR (as defined in the Revolving Credit Facility) plus 0.75% to 1.50% (depending on the then-applicable leverage ratio) or the Base Rate (as defined in the Revolving Credit Agreement and the Term Credit Agreement, as applicable) plus 0.0% to 0.50% (depending on the then-applicable leverage ratio). At June&#160;30, 2022, the interest rate that was being charged on the outstanding principal amounts was 3.00%. An applicable commitment fee of 0.075% to 0.150% (depending on the then-applicable leverage ratio) applies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the unused portion of the revolving credit facility. As of June&#160;30, 2022, we had $1.4 billion available for draw down under the revolving credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As the Revolving Credit and Term Credit Agreements&#x2019; interest rate is calculated as Adjusted Term SOFR plus the spreads described above, its carrying amount is equivalent to its fair value as at June&#160;30, 2022 and June&#160;30, 2021, which was $280.0 million and $158.0 million, respectively. Quoted market prices in active markets for identical liabilities based inputs (Level 2) were used to estimate fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;10, 2019, we entered into a Note Purchase Agreement with the purchasers to that agreement, in connection with the issuance and sale of $250.0 million principal amount of our 3.24% senior notes due July&#160;10, 2026, and $250.0 million principal amount of our 3.45% senior notes due July&#160;10, 2029 (collectively referred to as the &#x201c;Senior Notes&#x201d;). Our obligations under the Note Purchase Agreement and the Senior Notes are unconditionally and irrevocably guaranteed by certain of our direct and indirect U.S. subsidiaries. The net proceeds from this transaction were used to pay down borrowings on our Revolving Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Note Purchase Agreement, we agreed to customary covenants including with respect to our corporate existence, transactions with affiliates, and mergers and other extraordinary transactions. We also agreed that, subject to limited exceptions, we will maintain a ratio of consolidated funded debt to consolidated EBITDA (as defined in the Note Purchase Agreement) of no more than 3.50 to 1.00 as of the last day of any fiscal quarter, and will not at any time permit the amount of all priority secured and unsecured debt of us and our subsidiaries to exceed 10.0% of our consolidated tangible assets, determined as of the end of our most recently ended fiscal quarter. This ratio is calculated at the end of each reporting period for which the Note Purchase Agreement requires us to deliver financial statements, using the results of the 12 consecutive month period ending with such reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are required to disclose the fair value of financial instruments for which it is practicable to estimate the value, even though these instruments are not recognized at fair value in the consolidated balance sheets. As of June&#160;30, 2022, the Senior Notes have a carrying amount of $500.0 million, excluding deferred borrowing costs, and an estimated fair value of $477.7 million. Quoted market prices in active markets for identical liabilities based inputs (Level 2) were used to estimate fair value.&lt;/span&gt;&lt;/div&gt;At June&#160;30, 2022, we were in compliance with our debt covenants and there was $780.0 million outstanding under the Revolving Credit Agreement, Term Credit Agreement and Senior Notes.</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzY4NTU_351c0fce-a01b-46a6-87b9-9f2634dadfb3">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt at June&#160;30, 2022 and June&#160;30, 2021 consists of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred borrowing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;770,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;646,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred borrowing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Long-term debt, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;765,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;643,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;775,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;655,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <rmd:ShortTermDebtGross
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzMtMS0xLTEtMjg3Njk_9a405bf2-d5c7-48e5-9a4a-f8b5c76220aa"
      unitRef="usd">10000000</rmd:ShortTermDebtGross>
    <rmd:ShortTermDebtGross
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzMtMy0xLTEtMjg3Njk_91e711f3-33ed-4cdd-bdfd-68f3e4ee8b18"
      unitRef="usd">12000000</rmd:ShortTermDebtGross>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzItMS0xLTEtNDcxMDY_089bca7d-b9f8-4c0f-8250-caf40a8b694e"
      unitRef="usd">84000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzItMy0xLTEtNDcxMDY_e5b8c6f8-91c9-4709-bf31-9c85888e5dad"
      unitRef="usd">0</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:ShortTermBorrowings
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzMtMS0xLTEtNDcxMDY_0cbc7496-274d-4245-8f3a-5294eef6dbd6"
      unitRef="usd">9916000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzMtMy0xLTEtNDcxMDY_c8b68f31-ae02-48e5-a13d-a1ca340936d1"
      unitRef="usd">12000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzUtMS0xLTEtMjg3Njk_f4b444f7-8ea3-402f-9592-568de026b8ed"
      unitRef="usd">770000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzUtMy0xLTEtMjg3Njk_02714b06-8fed-438a-9a37-0d4a7837dc5b"
      unitRef="usd">646000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzYtMS0xLTEtMjg3Njk_5a3807ca-e42c-4331-aeca-7acfdc198fce"
      unitRef="usd">4675000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzYtMy0xLTEtMjg3Njk_36abbfc8-0e1f-44dc-874a-51d567571212"
      unitRef="usd">2649000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebt
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzctMS0xLTEtMjg3Njk_63215acf-ad26-4564-8377-3588ea2335fe"
      unitRef="usd">765325000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzctMy0xLTEtMjg3Njk_c65285f3-e784-4d88-8f20-6e58750a33db"
      unitRef="usd">643351000</us-gaap:LongTermDebt>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzgtMS0xLTEtMjg3Njk_6ea89b50-c449-45e8-8eb5-5b8a3d0c365f"
      unitRef="usd">775241000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90YWJsZToxZmI5YjI0ZmY0NTU0NDc0ODlkZjU2YzQ1OGVkYmM1OS90YWJsZXJhbmdlOjFmYjliMjRmZjQ1NTQ0NzQ4OWRmNTZjNDU4ZWRiYzU5XzgtMy0xLTEtMjg3Njk_751b4b5b-b1b9-4ea9-9345-edcf681e9368"
      unitRef="usd">655351000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i15e467c7054a4a68be2dda7a759368b3_I20220629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwMDc_fa2d7143-bcdf-4d4d-8a0b-cce8302b1c0f"
      unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <rmd:UncommittedOptionToIncreaseCreditFacility
      contextRef="i423b2284861f4712a8115af92f3cb518_D20220629-20220629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwMTE_53e180b8-0a9e-499c-964e-f361eaf589b1"
      unitRef="usd">1000000000</rmd:UncommittedOptionToIncreaseCreditFacility>
    <rmd:DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod
      contextRef="i15e467c7054a4a68be2dda7a759368b3_I20220629"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzMyOTg1MzQ4OTk4ODY_9558863d-d3b7-49e3-9cd8-1eac124c9352"
      unitRef="number">1.00</rmd:DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ifa80124e3bf34fd6856246349e38455b_I20180417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzMyOTg1MzQ5MDA2ODg_9105e895-295a-4c68-a319-2b3ffc336248"
      unitRef="usd">1600000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <rmd:UncommittedOptionToIncreaseCreditFacility
      contextRef="ibeda0a0993ea40a2b71c2c39f3e0b04e_D20180417-20180417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzMyOTg1MzQ5MDA3MDQ_8c8991fa-8dbc-4b82-9ad0-ee8c15e1739d"
      unitRef="usd">300000000</rmd:UncommittedOptionToIncreaseCreditFacility>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i1310207dfcac4a1e9c44860aeeda4bc2_I20220629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwMTk_5bfadd19-79da-4ffc-b969-77eba02b8728"
      unitRef="usd">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal
      contextRef="i979ebcc3a5a0402b874813dc295d674e_D20220629-20220629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwNTc_f7f0df8f-d3e4-4918-92ef-b6509e1f569d"
      unitRef="usd">5000000</us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie7f649a73f7b49bb986cbfd39350e44a_D20220629-20220629"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwNjE_e2464cf0-0d48-4d96-a8d1-dd286c1a36f1"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifd7c672f30f84268aabf143857e5170f_D20220629-20220629"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwNjU_0a6b7b6f-26a6-449a-bf03-17eeb872f1d8"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i97c8b018596f4013a44574b3fd63633c_D20220629-20220629"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwNjk_58a17c9a-4546-4767-846d-904535f241ab"
      unitRef="number">0.000</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i20f542b063f24d7092707acc8b5cf64c_D20220629-20220629"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwNzM_7a38097a-43da-4193-b4de-78a118a49007"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i806485f7ccaf4c9d9c68aad92130fec2_I20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwODE_0f1e70d1-6643-4b7d-8164-e5b9630152e1"
      unitRef="number">0.0300</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i59e7501df49b4377bbb3fff86c0f16b9_D20210701-20220630"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwODU_28618f5c-06fe-4762-96b1-c725cab9f40e"
      unitRef="number">0.00075</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="if7e0730b8e7c4927a93f00a20c7493ce_D20210701-20220630"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwOTA_b466152c-2362-4cbb-90a9-712692ff6ed4"
      unitRef="number">0.00150</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="ie854b85863de4deb8101483d69a0c966_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgwOTg_250dd10b-52a6-4bdf-b1cc-16bcba6c9be9"
      unitRef="usd">1400000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LongTermDebtFairValue
      contextRef="ie854b85863de4deb8101483d69a0c966_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxMTE_b9d2cb8d-7f1c-4f5e-94df-0f28fb4a10b6"
      unitRef="usd">280000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="ia73b672018ee4f70af77e8d5c26893a7_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxMTU_76ce444e-f9e5-457d-9422-c877f2080529"
      unitRef="usd">158000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5f8645a6deef4fda9ef586462b0c447a_I20190710"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxMjQ_041b3a49-8e66-443f-8436-43fd92ee8f12"
      unitRef="usd">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5bc2d01b0be2456a84c67fc7a3d70988_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxMjg_9f43ac14-2f4c-4d4c-bf0c-7666b329ab46"
      unitRef="number">0.0324</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9bb1537c0dcc4eacb698500930b3471e_I20190710"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxNDk_d759b172-4c20-4b72-94f2-c5c9036fbf73"
      unitRef="usd">250000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6b7a51beb7fb4fe981c3f830e45c4d63_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxNTM_3d5dc3fa-996c-44fc-b27d-6949ee237539"
      unitRef="number">0.0345</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <rmd:DebtToConsolidatedEbitdaRatio
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxODI_47be0962-d6ad-4e13-9c67-e282f1de7848"
      unitRef="number">3.50</rmd:DebtToConsolidatedEbitdaRatio>
    <rmd:LineOfCreditFacilityCollateralPercentageOfTheCompany
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxOTA_d581a82b-8251-4634-a66e-2c1a2437e75e"
      unitRef="number">0.100</rmd:LineOfCreditFacilityCollateralPercentageOfTheCompany>
    <us-gaap:LongTermDebt
      contextRef="i378917c231c447fcbef3c0d8863c6fc3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxOTU_a091e0d1-6d62-42e2-a602-dcb9e3b6b87b"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtFairValue
      contextRef="i378917c231c447fcbef3c0d8863c6fc3_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgxOTk_5c952c0b-d11c-49eb-8de1-e53241915848"
      unitRef="usd">477700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="i54370628e55148a3a1429b5d08709d48_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzAvZnJhZzplMjRiZjkxYzEwY2E0ZWZjOTBhYjdiOGJlMDBhMjYwMC90ZXh0cmVnaW9uOmUyNGJmOTFjMTBjYTRlZmM5MGFiN2I4YmUwMGEyNjAwXzQzOTgwNDY1MTgyMDM_ea48eb2a-4a83-42b8-8477-2479fc3131fe"
      unitRef="usd">780000000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDQ_1f8cd600-693b-4bcc-89d3-b138591f93f5">Leases&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Leases where ResMed is the Lessee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine whether a contract is, or contains, a lease at inception. ROU assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the lease term as the non-cancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 14 years, some of which include options to extend or terminate the leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs for the years ended June&#160;30, 2022, 2021 and 2020 were $35.3 million, $35.5 million and $26.5 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2022, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancellable operating leases as of June&#160;30, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, we had additional operating lease commitments of $0.7 million for office space that have not yet commenced. These leases will commence during the year ended June 30, 2023 with lease terms of 1 year to 5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental information related to operating leases for the years ended June&#160;30, 2022 and June&#160;30, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets obtained in exchange for new lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Leases where ResMed is the Lessor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease sleep and respiratory medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts include sales-type and operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease revenue for the years ended June&#160;30, 2022, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales-type lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our net investment in sales-type leases were classified in the consolidated balance sheets as of June&#160;30, 2022 and June&#160;30, 2021 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes and other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of sales-type leases as of June&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LessorSalesTypeLeasesTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDQ_ccbd6cdd-f660-4678-b41b-ecf73103644b">Leases&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Leases where ResMed is the Lessee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine whether a contract is, or contains, a lease at inception. ROU assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the lease term as the non-cancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 14 years, some of which include options to extend or terminate the leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs for the years ended June&#160;30, 2022, 2021 and 2020 were $35.3 million, $35.5 million and $26.5 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2022, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancellable operating leases as of June&#160;30, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, we had additional operating lease commitments of $0.7 million for office space that have not yet commenced. These leases will commence during the year ended June 30, 2023 with lease terms of 1 year to 5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental information related to operating leases for the years ended June&#160;30, 2022 and June&#160;30, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets obtained in exchange for new lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Leases where ResMed is the Lessor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease sleep and respiratory medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts include sales-type and operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease revenue for the years ended June&#160;30, 2022, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales-type lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our net investment in sales-type leases were classified in the consolidated balance sheets as of June&#160;30, 2022 and June&#160;30, 2021 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes and other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of sales-type leases as of June&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LessorSalesTypeLeasesTextBlock>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDQ_d291c509-90cd-4f72-962e-2675790aed56">Leases&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt"&gt;Leases where ResMed is the Lessee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine whether a contract is, or contains, a lease at inception. ROU assets represent our right to use an underlying asset during the lease term, and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at lease commencement based upon the estimated present value of unpaid lease payments over the lease term. We use our incremental borrowing rate based on the information available at lease commencement in determining the present value of unpaid lease payments. ROU assets also include any lease payments made at or before lease commencement and any initial direct costs incurred, and exclude any lease incentives received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determine the lease term as the non-cancellable period of the lease, and may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Leases with a term of 12 months or less are not recognized on the balance sheet. Some of our leases include variable lease payments that are based on costs incurred or actual usage, or adjusted periodically based on an index or a rate. Our leases do not contain any residual value guarantees and we do not account for lease and non-lease components as a single lease component. Operating leases are included in operating lease right-of-use assets and operating lease liabilities on our consolidated balance sheets. We lease certain office space, warehouses and distribution centers, manufacturing facilities, vehicles, and equipment with remaining lease terms ranging from less than 1 year to 14 years, some of which include options to extend or terminate the leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs for the years ended June&#160;30, 2022, 2021 and 2020 were $35.3 million, $35.5 million and $26.5 million, respectively. Short-term and variable lease costs were not material for the years ended June&#160;30, 2022, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancellable operating leases as of June&#160;30, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, we had additional operating lease commitments of $0.7 million for office space that have not yet commenced. These leases will commence during the year ended June 30, 2023 with lease terms of 1 year to 5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental information related to operating leases for the years ended June&#160;30, 2022 and June&#160;30, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets obtained in exchange for new lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt"&gt;Leases where ResMed is the Lessor&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease sleep and respiratory medical devices to customers primarily as a means to comply with local health insurer requirements in certain foreign geographies. Device rental contracts include sales-type and operating leases, and contract terms vary by customer and include options to terminate or extend the contract. When lease contracts also include the sale of masks and accessories, we allocate contract consideration to those items on a relative standalone price basis and recognize revenue when control transfers to the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease revenue for the years ended June&#160;30, 2022, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales-type lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our net investment in sales-type leases were classified in the consolidated balance sheets as of June&#160;30, 2022 and June&#160;30, 2021 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes and other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of sales-type leases as of June&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i7df9e6108fe8406e80413d06c6ed765e_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQzNTg_90e8f943-1316-4999-8535-32edca3e691b">P1Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ie375d6fcc5c94de8a1dfe85679cc6bdb_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQzNjI_77d3a070-c8f6-44e1-9535-f06e81537b82">P14Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQzNjY_64b582cf-5207-4d22-9f57-2c9b41bd213f"
      unitRef="usd">35300000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzEwOTk1MTE2MzExMzY_57834613-9353-46d8-8e60-95ca20e8a08f"
      unitRef="usd">35500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzEwOTk1MTE2MzEzMTc_2c89cab3-6993-4569-acb5-def00500ede2"
      unitRef="usd">26500000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDU_7488d0fc-914c-496d-9656-4218842f63fb">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future lease payments under non-cancellable operating leases as of June&#160;30, 2022 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.055%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18,910)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;142,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtMS0xLTEtMjg3Njk_5b943f07-7758-47e4-b8ad-1a3bf710475e"
      unitRef="usd">161219000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtMy0xLTEtMjg3Njk_89caa28c-3333-48a0-81f2-cf00ed5bd2d5"
      unitRef="usd">25488000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtNS0xLTEtMjg3Njk_8a7ab0ad-01f9-479a-a224-e1280bb26b21"
      unitRef="usd">19561000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtNy0xLTEtMjg3Njk_bb496c6b-519e-4d30-91b3-db05ba15af9f"
      unitRef="usd">16617000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtOS0xLTEtMjg3Njk_f256fc02-f17c-499b-b262-ed0d98176a00"
      unitRef="usd">15783000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtMTEtMS0xLTI4NzY5_baa83654-e4fc-49c5-9511-42eb2591ab33"
      unitRef="usd">15254000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzEtMTMtMS0xLTI4NzY5_73dbc832-af13-426a-8ac3-5b8908039bd1"
      unitRef="usd">68516000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzItMS0xLTEtMjg3Njk_5ac6e2b6-be06-4d7e-9a0a-292d8b6af311"
      unitRef="usd">18910000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZToyOWY0MGIzNGYwZDk0YzY5ODFlYjc0ZjhjNGRlNmE1NC90YWJsZXJhbmdlOjI5ZjQwYjM0ZjBkOTRjNjk4MWViNzRmOGM0ZGU2YTU0XzMtMS0xLTEtMjg3Njk_1605becb-f3e4-4c54-8d49-ebcd4eaa08ae"
      unitRef="usd">142309000</us-gaap:OperatingLeaseLiability>
    <rmd:LesseeOperatingLeaseLeaseNotYetCommencedCommitments
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQ0MTc_9dde02b7-1370-4fd2-95e0-85308f6b7243"
      unitRef="usd">700000</rmd:LesseeOperatingLeaseLeaseNotYetCommencedCommitments>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="i7df9e6108fe8406e80413d06c6ed765e_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQ0MzA_333a7ecd-a89a-44cf-9b1e-9d59c35266a4">P1Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="ie375d6fcc5c94de8a1dfe85679cc6bdb_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzQzOTgwNDY1MTQ0MjY_ae6fe994-2a9d-4046-a824-c1fb1d43537f">P5Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <rmd:ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDA_846a0f24-622e-4f07-b014-d57084d6441c">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The supplemental information related to operating leases for the years ended June&#160;30, 2022 and June&#160;30, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash flow information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating cash flows paid for amounts included in the measurement of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Right of use assets obtained in exchange for new lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rmd:ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzMtMS0xLTEtMjg3Njk_8a3b2e9c-9467-4c51-9e87-3df4b0ef37fa">P8Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzMtMy0xLTEtMjg3Njk_b14c1b4b-0c82-4290-97ed-42595ee91ebf">P8Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzQtMS0xLTEtMjg3Njk_dfd3afbe-013e-47b5-83cf-0f3825f60499"
      unitRef="number">0.028</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzQtMy0xLTEtMjg3Njk_57fe47c3-c176-487a-9966-01750ac4e1cc"
      unitRef="number">0.030</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzctMS0xLTEtMjg3Njk_920a4c7f-4809-4e43-bb82-7feeafd8cc6c"
      unitRef="usd">26462000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzctMy0xLTEtMjg3Njk_8951cb7b-0fcf-4948-b7e2-899b86479734"
      unitRef="usd">27734000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzgtMS0xLTEtMjg3Njk_cbbbaaa6-760a-4d35-b996-592e448c0b6a"
      unitRef="usd">41382000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpiNDVjZGE4Zjk4ZDc0ZDUyOWQ4NWY2MjcyOTEwOWI2MC90YWJsZXJhbmdlOmI0NWNkYThmOThkNzRkNTI5ZDg1ZjYyNzI5MTA5YjYwXzgtMy0xLTEtMjg3Njk_75661c88-6299-4dbb-820b-27a1f5821bf2"
      unitRef="usd">36130000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDE_748003ce-aeba-4587-82bc-9787981bffc2">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease revenue for the years ended June&#160;30, 2022, 2021 and 2020 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sales-type lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;90,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total lease revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:SalesTypeLeaseLeaseIncome
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzEtMS0xLTEtMjg3Njk_9271ebde-3f15-4270-9bfe-e0eb7a6f9e3b"
      unitRef="usd">9342000</us-gaap:SalesTypeLeaseLeaseIncome>
    <us-gaap:SalesTypeLeaseLeaseIncome
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzEtMy0xLTEtMjg3Njk_75e7c31e-b9fd-48fc-aae0-cd6f9fea85ff"
      unitRef="usd">9758000</us-gaap:SalesTypeLeaseLeaseIncome>
    <us-gaap:SalesTypeLeaseLeaseIncome
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzEtNS0xLTEtNDQ0MjQ_755e3204-14f3-45eb-9a97-403419199b7b"
      unitRef="usd">13457000</us-gaap:SalesTypeLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzItMS0xLTEtMjg3Njk_46621917-1385-4d21-893f-e62edb370e75"
      unitRef="usd">90076000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzItMy0xLTEtMjg3Njk_2f1db708-f9d7-4916-ad6b-e4a32ea8ef60"
      unitRef="usd">93431000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzItNS0xLTEtNDQ0MjQ_da0a5637-2e90-41ac-b56e-e7b8d96182cd"
      unitRef="usd">87874000</us-gaap:OperatingLeaseLeaseIncome>
    <rmd:LessorLeaseRevenue
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzMtMS0xLTEtMjg3Njk_b81b51b7-9ea5-4fd4-8cc3-54b0ff27b0d3"
      unitRef="usd">99418000</rmd:LessorLeaseRevenue>
    <rmd:LessorLeaseRevenue
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzMtMy0xLTEtMjg3Njk_b612dd81-aa5c-437e-be43-052152186426"
      unitRef="usd">103189000</rmd:LessorLeaseRevenue>
    <rmd:LessorLeaseRevenue
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpmOWVlNWFkZDU4MWU0ZGZlYWVlNWQxOTRlMGNmYWM4NS90YWJsZXJhbmdlOmY5ZWU1YWRkNTgxZTRkZmVhZWU1ZDE5NGUwY2ZhYzg1XzMtNS0xLTEtNDQ0MjQ_d4e3a5ee-dd81-477e-8eb5-be4ecb4d6396"
      unitRef="usd">101331000</rmd:LessorLeaseRevenue>
    <rmd:SalesTypeLeaseNetInvestmentInLeaseTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDI_b0ab6897-218e-486e-95fa-1a3ef8066d04">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our net investment in sales-type leases were classified in the consolidated balance sheets as of June&#160;30, 2022 and June&#160;30, 2021 as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid taxes and other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rmd:SalesTypeLeaseNetInvestmentInLeaseTableTextBlock>
    <us-gaap:SalesTypeLeaseLeaseReceivable
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzEtMS0xLTEtMjg3Njk_def8206b-af3a-45ad-8a0b-677fee6b32df"
      unitRef="usd">6473000</us-gaap:SalesTypeLeaseLeaseReceivable>
    <us-gaap:SalesTypeLeaseLeaseReceivable
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzEtMy0xLTEtMjg3Njk_bccd8c19-7b04-4be3-85fa-a74fe74b8a0c"
      unitRef="usd">8026000</us-gaap:SalesTypeLeaseLeaseReceivable>
    <rmd:SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzItMS0xLTEtMjg3Njk_03f8c016-40f6-44eb-a3f3-8ee254e7cf18"
      unitRef="usd">7635000</rmd:SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets>
    <rmd:SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzItMy0xLTEtMjg3Njk_338b4081-d25d-438f-b359-ad45e7e1b0f6"
      unitRef="usd">6214000</rmd:SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets>
    <us-gaap:SalesTypeLeaseNetInvestmentInLease
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzMtMS0xLTEtMjg3Njk_46157842-a89d-45c8-91c6-d7ebb2155ac0"
      unitRef="usd">14108000</us-gaap:SalesTypeLeaseNetInvestmentInLease>
    <us-gaap:SalesTypeLeaseNetInvestmentInLease
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpkMjg2NTVmYzRiNmE0MmZlOGVlODMyOGQ5YmZmYjQ5Yy90YWJsZXJhbmdlOmQyODY1NWZjNGI2YTQyZmU4ZWU4MzI4ZDliZmZiNDljXzMtMy0xLTEtMjg3Njk_2a2d81b9-a831-403c-8ce5-d07420bb3785"
      unitRef="usd">14240000</us-gaap:SalesTypeLeaseNetInvestmentInLease>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90ZXh0cmVnaW9uOjAxZDE1YzI5ZTJiNDRjOWY5NTE1Yjk5ZWFjZmVlNGJiXzMyNDM_f01c1650-1f4f-4630-8da4-aed271d12b08">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of sales-type leases as of June&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Present value of remaining lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtMS0xLTEtMjg3Njk_51df47c8-3a2d-413e-9d1b-df8e4cb8b3ff"
      unitRef="usd">16068000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtMy0xLTEtMjg3Njk_98acbbab-6422-4ae9-8515-814a7aff6067"
      unitRef="usd">6757000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtNS0xLTEtMjg3Njk_25329ceb-a592-45f9-8a79-39b5cd4a0781"
      unitRef="usd">4207000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtNy0xLTEtMjg3Njk_b8f82e15-4cca-472b-a2d3-736e20d63cdb"
      unitRef="usd">2057000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtOS0xLTEtMjg3Njk_78cc0509-28c7-445b-a85a-5d8b79dc8eb4"
      unitRef="usd">1915000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtMTEtMS0xLTI4NzY5_2604c8d8-f7de-4239-9958-a8c9d5ac24fe"
      unitRef="usd">1132000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzEtMTMtMS0xLTI4NzY5_faed0581-9f0e-46c5-a36d-dba39b81f320"
      unitRef="usd">0</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzItMS0xLTEtMjg3Njk_846254c0-05e4-49cd-906e-8611abeaaede"
      unitRef="usd">1960000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount>
    <us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivable
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzMvZnJhZzowMWQxNWMyOWUyYjQ0YzlmOTUxNWI5OWVhY2ZlZTRiYi90YWJsZTpjOTFhMzdmNTJkODM0MjM1OTg3MDdmNzhmMjgxMTdhZS90YWJsZXJhbmdlOmM5MWEzN2Y1MmQ4MzQyMzU5ODcwN2Y3OGYyODExN2FlXzMtMS0xLTEtMjg3Njk_4cc6c567-9410-4faa-9267-c054a3f1a541"
      unitRef="usd">14108000</us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzg0ODg_0bd11a8b-ea05-4cda-ab77-63618682a9d4">Stockholders&#x2019; Equity &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On February&#160;21, 2014, our board of directors approved a new share repurchase program, authorizing us to acquire up to an aggregate of 20.0 million shares of our common stock. The program allows us to repurchase shares of our common stock from time to time for cash in the open market, or in negotiated or block transactions, as market and business conditions warrant and subject to applicable legal requirements. The 20.0 million shares the program authorizes us to purchase are in addition to the shares we repurchased on or before February&#160;21, 2014 under our previous programs. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. All share repurchases since February&#160;21, 2014 have been executed in accordance with this program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have temporarily suspended our repurchase program and, accordingly, did not repurchase any shares during fiscal years 2022 or 2021. As of June&#160;30, 2022, we have repurchased a total of 41.8 million shares at a cost of $1.6 billion. Shares that are repurchased are classified as &#x201c;treasury stock pending future use&#x201d; and reduce the number of shares outstanding used in calculating earnings per share. At June&#160;30, 2022, 12.9 million additional shares can be repurchased under the approved share repurchase program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In April 1997, our board of directors authorized 2.0 million shares of 0.01 par value preferred stock. No such shares were issued or outstanding at June&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options and Restricted Stock Units.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We have granted stock options, restricted stock units (&#x201c;RSUs&#x201d;) and performance restricted stock units (&#x201c;PRSUs&#x201d;) to personnel, including officers and directors, in accordance with the ResMed Inc. 2009 Incentive Award Plan (the &#x201c;2009 Plan&#x201d;). Options and restricted stock units vest over one year to four years and the options have expiration dates of seven years from the date of grant. We have granted the options with an exercise price equal to the market value as determined at the date of grant. We have granted PRSUs that are subject to a market condition, with the ultimate realizable number of PRSUs dependent on relative total stockholder return over a period of three years, up to a maximum amount to be issued under the award of 225% of the original grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the annual meeting of our stockholders in November 2017, our stockholders approved an amendment and restatement to the 2009 Plan to increase the number of shares of common stock that may be issued or transferred pursuant to awards under the 2009 Plan by 7.4 million. The amendment and restatement imposes a maximum award amount which may be granted under the 2009 Plan to non-employee director in a calendar year, which when taken together with any other cash fees earned for services as a non-employee director during the calendar year, has a total value of $0.7 million, or $1.2 million in the case of a non-employee director who is also serving as chairman of our board of directors. The amendment and restatement also increased the maximum amount payable pursuant to cash-denominated performance awards granted in any calendar year from $3.0 million to $5.0 million. In addition, the amendment and restatement extended the existing prohibition on the payment of dividends or dividend equivalents on unvested awards to apply to all awards, including time-based restricted stock, deferred stock and stock payment. The term of the 2009 Plan was extended by four years so that the plan expires on September&#160;11, 2027.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 51.1 million. The number of securities remaining available for future issuance under the 2009 Plan at June&#160;30, 2022 is 15.3 million. The number of shares of our common stock available for issuance under the 2009 Plan will be reduced by (i) 2.8 shares for each one share of common stock delivered in settlement of any &#x201c;full-value award,&#x201d; which is any award other than a stock option, stock appreciation right or other award for which the holder pays a purchase price and (ii) one share for each share of common stock delivered in settlement of all other awards. The maximum number of shares, which may be subject to awards granted under the 2009 Plan to any individual during any calendar year, may not exceed 3 million shares of our common stock (except in a participant&#x2019;s initial year of hiring up to 4.5 million shares of our common stock may be granted). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain regions, shares are withheld on behalf of employees to satisfy statutory tax withholding requirements upon exercise or vesting of awards. The number of shares withheld is based upon the closing price of our common stock on the trading day of the applicable settlement date. The remaining shares are delivered to the recipient as shares of our common stock. The amount remitted to the tax authorities for the employees&#x2019; tax obligation is reflected as a financing activity on our consolidated statements of cash flows. Shares withheld by us as a result of the net settlement are not considered issued and outstanding and are added to the reserves of the 2009 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of RSUs and PRSUs that vested during the years ended June&#160;30, 2022, 2021 and 2020, was $65.5 million, $59.6 million and $56.8 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of RSUs, including PRSUs, during year ended June&#160;30, 2022 (in thousands, except years and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance factor adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt"&gt;Includes 206 thousand shares netted for tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity during the year ended June&#160;30, 2022 (in thousands, except years and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options exercised during the fiscal years 2022, 2021 and 2020, was $33.7 million, $8.9 million and $31.2 million, respectively. As at June&#160;30, 2022, the aggregate intrinsic value of options outstanding, exercisable, and vested and expected to vest were $93.5 million, $89.9 million and $93.4 million respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the board of directors&#x2019; compensation committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year. At June&#160;30, 2022, the number of shares remaining available for future issuance under the ESPP is 1.5 million shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During years ended June&#160;30, 2022, 2021 and 2020, we issued 216,000, 229,000 and 265,000 shares to our employees in two offerings and we recognized $11.0 million, $10.9 million and $8.0 million, respectively, of stock compensation expense associated with the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock&#x2013;based Employee compensation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We measure the compensation expense of all stock-based awards at fair value on the grant date. We estimate the fair value of stock options and purchase rights granted under the ESPP using the Black-Scholes valuation model. The fair value of restricted stock units is equal to the market value of the underlying shares as determined at the grant date less the fair value of dividends that holders are not entitled to, during the vesting period. The fair value of performance restricted stock units is measured using a Monte-Carlo simulation valuation model. We recognize the fair value as compensation expense using the straight-line method over the service period for awards expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the assumptions in the following tables. The risk-free interest rate is estimated using the U.S. Treasury yield curve and is based on the term of the award. The expected term of awards is estimated from the vesting period of the award, as well as historical exercise behavior, and represents the period of time the awards granted are expected to be outstanding. Expected volatility is estimated based upon the historical volatility of ResMed stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June&#160;30, 2022, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$72.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$53.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$32.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.37%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.58%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.66%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.07%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ESPP purchase rights:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$50.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$48.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$31.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.63% - 0.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.79% - 0.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.98% - 1.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20% - 34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June&#160;30, 2022, 2021 and 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation costs, net of tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;At June&#160;30, 2022, there was $104.0 million in unrecognized compensation costs related to unvested stock-based compensation arrangements. This is expected to be recognized over a weighted average period of 2.2 years.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="icb4434050d394cafb018a6065a45a957_I20140221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2MTA_87f2de80-a485-404b-a9e5-329846259ff8"
      unitRef="shares">20000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="icb4434050d394cafb018a6065a45a957_I20140221"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2MTc_87f2de80-a485-404b-a9e5-329846259ff8"
      unitRef="shares">20000000</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:TreasuryStockShares
      contextRef="i9d6484ce8c1e4238876a0b1d7f21a064_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2NTc_b2195d26-a051-4689-bc3f-27700a8c9906"
      unitRef="shares">41800000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i9d6484ce8c1e4238876a0b1d7f21a064_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2NjI_079858f3-adca-4ef5-af09-4f83d27425e7"
      unitRef="usd">1600000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2NzE_bd62a09c-fbb7-4b70-aeab-441cd963a378"
      unitRef="shares">12900000</us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie03f859a83a14b7c9c6464075801b456_I19970430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2ODE_3cf7a9d7-2412-45d6-b860-e0b1138d63de"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie03f859a83a14b7c9c6464075801b456_I19970430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2ODU_eae776a6-2e35-4224-bcf6-16696e2cc10a"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2OTM_3facc649-52b7-4364-90a9-2b01775e97f9"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk2OTM_b33a7f03-4ddf-4a6e-b448-30e68b92d34a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i142a4596d3684bea8116ce8c52b27f02_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MDQ_9d11f36e-f635-4522-8f73-6c8ed6c1311d">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8e81aa8e74474cdbbcec971cc4e11a85_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MDk_a22bfa4d-eb51-4d03-9a59-b06e8cc76765">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MTQ_922f511f-8a5d-41c5-97e6-1f09bb9c388d">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i13c812eb8e4e4d0aad3396a4505d0c90_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MTk_9932109c-e295-4cbc-80c1-9c42b0011095">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <rmd:VestingAmountMaximumPercentageOfOriginalGrant
      contextRef="i13c812eb8e4e4d0aad3396a4505d0c90_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MjQ_a2c1597f-538b-4154-98f9-54fcca78748d"
      unitRef="number">2.25</rmd:VestingAmountMaximumPercentageOfOriginalGrant>
    <rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending
      contextRef="i656e88285e1a478db38df173815049c6_I20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3MzQ_8a8dec6f-f046-4363-95f9-a962bb433f1f"
      unitRef="shares">7400000</rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending>
    <rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned
      contextRef="iac8a769569584c06896d492161d46522_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3Mzk_db0d0b50-9a72-454f-bc28-18ec6465cb8c"
      unitRef="usd">700000</rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned>
    <rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned
      contextRef="i526a12fca7d14513aa82f1d9a8b37b84_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3NDg_63c46899-6a86-4bdc-95a6-1c8f66a3d82f"
      unitRef="usd">1200000</rmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned>
    <rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted
      contextRef="ib6fbf790ad4041668dd19efbe5c7bd93_D20171031-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3NTQ_4304f846-fd2d-4402-9419-a799b46f6f23"
      unitRef="usd">3000000</rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted>
    <rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted
      contextRef="i344f9115454b46148a3452f1abac3c9d_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3NTk_0f344b02-4b08-4041-b2a3-4a7a61035985"
      unitRef="usd">5000000</rmd:SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted>
    <rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod
      contextRef="i1b10950bdf1f4749b316223621791474_D20171101-20171130"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3NjQ_f066bea0-e345-472f-96f0-ce0919fd7524">P4Y</rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="icb58c060ef9941f3a97cea8bbad422e5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3NzM_d778ad7a-692d-499c-930c-8f365404ddf6"
      unitRef="shares">51100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="icb58c060ef9941f3a97cea8bbad422e5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3ODI_0d38b8b8-3dcd-4dea-809d-99ad7d86aba8"
      unitRef="shares">15300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <rmd:ReductionInNumberOfSharesOfCommonStockAvailableForIssuance
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3OTQ_c2491cad-5620-4e5d-bfab-f4c426b5376f"
      unitRef="number">2.8</rmd:ReductionInNumberOfSharesOfCommonStockAvailableForIssuance>
    <rmd:MaximumNumberOfSharesSubjectToAwardsGranted
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk3OTg_f9203288-0462-41b4-9aa6-2788922c765b"
      unitRef="shares">3000000</rmd:MaximumNumberOfSharesSubjectToAwardsGranted>
    <rmd:NumberOfCommonStockGranted
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4MTE_5bf8f86d-21df-4013-89bd-9b4bd43bc92f"
      unitRef="shares">4500000</rmd:NumberOfCommonStockGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4NTk_820977f1-3507-484b-8e0b-77df6805262a"
      unitRef="usd">65500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4NjY_0608396e-bc08-482a-9691-6b189120bf52"
      unitRef="usd">59600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4NzA_27b376fc-5517-4f22-b9b1-520f4e7496b3"
      unitRef="usd">56800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzg0ODk_49afd047-18ff-4a52-b1d9-8c771b03fb4f">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of RSUs, including PRSUs, during year ended June&#160;30, 2022 (in thousands, except years and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted&lt;br/&gt;Stock&lt;br/&gt;Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant-Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(575)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;113.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance factor adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;203.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:5pt"&gt;Includes 206 thousand shares netted for tax.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1e2263b05ec742b9a74b344a4f2f2337_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzEtMS0xLTEtMjg3Njk_5d1edca4-ef91-447f-8ba7-32ab3a409ede"
      unitRef="shares">875000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1e2263b05ec742b9a74b344a4f2f2337_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzEtMy0xLTEtMjg3Njk_5f956007-2581-42e8-b138-09f3bd27851e"
      unitRef="usdPerShare">145.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i59e177a09e1f49aca07dc9b8742b6dd6_D20200701-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzEtNS0xLTEtMjg3Njk_a2c13bde-e3d5-4158-b12f-1abfbfc8d626">P1Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzItMS0xLTEtMjg3Njk_f6aae33d-99a3-4eab-9e55-13a83f45879e"
      unitRef="shares">288000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzItMy0xLTEtMjg3Njk_fb99f5f6-620f-4840-93b4-0803523b30fc"
      unitRef="usdPerShare">259.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzMtMS0xLTEtMjg3Njk_626242d3-2793-490f-88ab-c50b48304ade"
      unitRef="shares">575000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzMtMy0xLTEtMjg3Njk_e2179669-ce77-4818-b8ab-c7f70637755f"
      unitRef="usdPerShare">113.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease
      contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzQtMS0xLTEtMjg3Njk_fa8e67bc-1dc9-46aa-998f-93badf2d72ee"
      unitRef="shares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease>
    <rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzQtMy0xLTEtMjg3Njk_8c3393d8-f9f4-4727-84f4-01a4636cda22"
      unitRef="usdPerShare">0</rmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzYtMS0xLTEtMjg3Njk_273b23cf-6ad7-4a02-b224-5ebab4c29e1f"
      unitRef="shares">82000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzYtMy0xLTEtMjg3Njk_6414a6d5-c9ca-48cb-a2d8-2a00f04c1000"
      unitRef="usdPerShare">184.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6090a2e6715142fabdaedef101bd1b85_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzctMS0xLTEtMjg3Njk_dee12f4d-bf1a-45fb-bdec-b2b4718d3004"
      unitRef="shares">681000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i6090a2e6715142fabdaedef101bd1b85_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzctMy0xLTEtMjg3Njk_51fdd5f4-6b33-4848-ac39-dd6c3f45dd30"
      unitRef="usdPerShare">203.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTpiODM2NmQxYzc2ZmQ0MmMzODRmNjEyN2E4N2U2NTY2YS90YWJsZXJhbmdlOmI4MzY2ZDFjNzZmZDQyYzM4NGY2MTI3YTg3ZTY1NjZhXzctNS0xLTEtMjg3Njk_756469c1-14e8-4f4d-b622-4e941681e6c2">P1Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="ica54b0da1e614213bd2547419b667106_D20210701-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4NDY_e48e65bf-dbef-4de9-8e0e-814ba4ac2273"
      unitRef="shares">206000</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzg0OTE_b3fb2dc0-afc7-45e0-95d6-869ff2aac227">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes option activity during the year ended June&#160;30, 2022 (in thousands, except years and per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term in Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options exercisable at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;96.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;112.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzEtMS0xLTEtMjg3Njk_34ba8cc8-6f9d-40fc-bc55-ff1a87fface0"
      unitRef="shares">1060000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzEtMy0xLTEtMjg3Njk_7cb19a28-7f06-4472-85e9-010948dcd0fc"
      unitRef="usdPerShare">97.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzEtNS0xLTEtMjg3Njk_80aa2828-f1e6-40a7-9e1c-cc74ba1d014d">P3Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzItMS0xLTEtMjg3Njk_e254bf4b-30ab-4ccb-b6e6-03f004ae4ed0"
      unitRef="shares">56000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzItMy0xLTEtMjg3Njk_09955a82-d533-4ee0-bc6a-12852ce6290f"
      unitRef="usdPerShare">256.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzMtMS0xLTEtMjg3Njk_dcd2f932-8dbd-41a4-8ff3-0351af797588"
      unitRef="shares">177000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzMtMy0xLTEtMjg3Njk_8d859fbc-d8d1-4818-bd4c-dac56b98fa78"
      unitRef="usdPerShare">63.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzQtMS0xLTEtMjg3Njk_db718a71-b13a-4d57-b8ff-353a3a57bdac"
      unitRef="shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzQtMy0xLTEtMjg3Njk_ce01b098-5fe5-42ae-a179-20bd98069bd7"
      unitRef="usdPerShare">110.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzUtMS0xLTEtMjg3Njk_9770d8fb-747c-467b-a8cc-c73c054f8bd6"
      unitRef="shares">938000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzUtMy0xLTEtMjg3Njk_632328fa-b3eb-433d-91c1-1a8425ad525a"
      unitRef="usdPerShare">112.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzUtNS0xLTEtMjg3Njk_573b7519-fc61-4214-aa44-da391c097e4b">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzYtMS0xLTEtMjg3Njk_0601f53f-7a90-4c3e-a029-db83859dc99e"
      unitRef="shares">792000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzYtMy0xLTEtMjg3Njk_acc1b646-3a4a-4c71-9a99-e26cf2aafa1c"
      unitRef="usdPerShare">96.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzYtNS0xLTEtMjg3Njk_4333fe02-19b0-421d-bbe1-80d6b915ce4e">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzctMS0xLTEtMjg3Njk_088555e1-4159-41a5-a3a5-6e67d528a2e8"
      unitRef="shares">932000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzctMy0xLTEtMjg3Njk_a31ef05e-bfae-4c8b-8a5d-382915476adb"
      unitRef="usdPerShare">112.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTozNjdmZTZkMmEzYWQ0YTVhYWQ0Y2UwZDU1NzQ3YzgxNy90YWJsZXJhbmdlOjM2N2ZlNmQyYTNhZDRhNWFhZDRjZTBkNTU3NDdjODE3XzctNS0xLTEtMjg3Njk_b27d7534-df47-4c44-87a4-b5fc9464fed5">P3Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk4OTY_34539ae1-ac26-4e1e-99a2-bebd4fd70230"
      unitRef="usd">33700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5MDA_b1f7d037-7291-476a-8fee-d8901cf10e19"
      unitRef="usd">8900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5MDQ_59cd5922-f96a-4f0a-84b2-1947a224580d"
      unitRef="usd">31200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5MjA_5decf4e4-f0b1-4c69-b02f-0fbf6bdf02df"
      unitRef="usd">93500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5MjQ_f1097883-37f9-4f99-b968-2712ecae52c4"
      unitRef="usd">89900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5Mjg_2892098f-0611-4b4b-bd5f-31a41bd41b8a"
      unitRef="usd">93400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <rmd:EmployeeStockPurchasePlanOfferingPeriod
      contextRef="iec931243b75f437e8ee3cf1efa936e50_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5NDE_a26e39fb-21aa-4a3e-8826-314987b2b625">P3M</rmd:EmployeeStockPurchasePlanOfferingPeriod>
    <rmd:EmployeeStockPurchasePlanOfferingPeriod
      contextRef="i26cfb703ae174ae99bbfb51030982257_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5NDU_7eafe8db-d579-40e1-9202-a0eff86a4a87">P27M</rmd:EmployeeStockPurchasePlanOfferingPeriod>
    <rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant
      contextRef="i139858d21bb440a48d56f47a4a84ed88_D20210701-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5NDk_816a7489-cce4-416c-bdd1-ee4b1da70efa"
      unitRef="number">0.85</rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant>
    <rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase
      contextRef="i139858d21bb440a48d56f47a4a84ed88_D20210701-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5NTY_ef764f3e-bd10-493e-ae4a-be0d8c254b77"
      unitRef="number">0.85</rmd:PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase>
    <us-gaap:CommonStockSharesSubscriptions
      contextRef="ib903a532663446a585c6512ab8c06b0b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5NjM_cb9c26dd-e292-4c06-8bc6-e3143c4c1ecd"
      unitRef="usd">25000</us-gaap:CommonStockSharesSubscriptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i612e2c48c8604ebb820bf12238b6faad_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5Nzk_ae960a2b-ab2a-4e69-9350-a11c552c0ccb"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5OTI_97c904eb-b2c7-437a-a4db-5f4b6a83a618"
      unitRef="shares">216000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAwMDE_b060f438-7e89-46b6-b217-bb73afc6eadb"
      unitRef="shares">229000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAwMDU_793ce748-2a7c-4095-ba05-d8f4fd7c8fc2"
      unitRef="shares">265000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <rmd:NumberOfOfferings
      contextRef="i139858d21bb440a48d56f47a4a84ed88_D20210701-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MTk5OTY_c8c73648-c7ad-4500-ae6e-5560132a2751"
      unitRef="offering">2</rmd:NumberOfOfferings>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i139858d21bb440a48d56f47a4a84ed88_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAwMDk_4be44aff-9767-4c09-912c-c105dc0d2166"
      unitRef="usd">11000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia01026de6a5a497cb302f143e7c8b8da_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAwMTM_c1b49e2a-c539-46b1-8fd0-6432d2346e24"
      unitRef="usd">10900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i545f14bf17d3466d878853ee4c40b693_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAwMjM_1745ffc0-b4e9-427c-92c6-4a8a0e21dab4"
      unitRef="usd">8000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzg0OTI_f0296d1d-4ec3-40cd-8c24-1755f2fb0816">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of stock options granted under our stock option plans and purchase rights granted under the ESPP using the following assumptions for the years ended June&#160;30, 2022, 2021 and 2020: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock options:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$72.16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$53.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$32.14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.29%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.37%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.58%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.66%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.75%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.07%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ESPP purchase rights:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average grant date fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$50.46&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$48.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$31.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected life in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6 months&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.63% - 0.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.79% - 0.98%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.98% - 1.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20% - 34%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23% - 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzItMS0xLTEtMjg3Njk_2b561c53-1c88-4b0c-877c-f9c2e84f7335"
      unitRef="usdPerShare">72.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if26c7573938546c58712775f705c6f91_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzItMy0xLTEtMjg3Njk_910f236c-4a34-4534-9c92-c40669867f2b"
      unitRef="usdPerShare">53.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i86d83628870e4c1298a21564eac48efe_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzItNS0xLTEtMjg3Njk_017969e1-cedc-4670-b299-1b6e359afa11"
      unitRef="usdPerShare">32.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzMtMS0xLTEtMjg3Njk_bf6a9029-08af-4004-90db-99f54d90b3ba"
      unitRef="number">0.0129</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="if26c7573938546c58712775f705c6f91_D20200701-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzMtMy0xLTEtMjg3Njk_fef12e44-e2d3-4130-818a-87b8cc99ae5d"
      unitRef="number">0.0037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i86d83628870e4c1298a21564eac48efe_D20190701-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzMtNS0xLTEtMjg3Njk_383ada63-fce1-4f44-834c-3143f41657dc"
      unitRef="number">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzQtMS0xLTEtMjg3Njk_1e39d1e7-f87e-45ac-bf97-e184acad47fd">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="if26c7573938546c58712775f705c6f91_D20200701-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzQtMy0xLTEtMjg3Njk_3c3b11a4-12fa-47fe-acd5-4de3e94da3ca">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i86d83628870e4c1298a21564eac48efe_D20190701-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzQtNS0xLTEtMjg3Njk_02a86aa1-b6be-4d5e-b0c7-9c8aa100a6f8">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzUtMS0xLTEtMjg3Njk_b4066833-1900-4b23-9db8-da5370b8fbfe"
      unitRef="number">0.0066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="if26c7573938546c58712775f705c6f91_D20200701-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzUtMy0xLTEtMjg3Njk_8cd433b4-fe31-48ca-9643-59dee46b6913"
      unitRef="number">0.0075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i86d83628870e4c1298a21564eac48efe_D20190701-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzUtNS0xLTEtMjg3Njk_fec3e1e8-493d-4e7e-8795-22483b5e11ab"
      unitRef="number">0.0107</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzYtMS0xLTEtMjg3Njk_bb8815aa-44db-4ccc-9af0-1b857761f263"
      unitRef="number">0.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="if26c7573938546c58712775f705c6f91_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzYtMy0xLTEtMjg3Njk_10ffe52d-6461-4629-96e2-63f6988cd5c8"
      unitRef="number">0.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i86d83628870e4c1298a21564eac48efe_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzYtNS0xLTEtMjg3Njk_657e053c-9aae-48d1-b10c-835cb51f16d0"
      unitRef="number">0.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzktMS0xLTEtMjg3Njk_c3ce13c5-49a9-44cb-8f66-630e01982331"
      unitRef="usdPerShare">50.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzktMy0xLTEtMjg3Njk_47f15316-4229-4704-bcd1-b27db4b7999d"
      unitRef="usdPerShare">48.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzktNS0xLTEtMjg3Njk_59ef2b4e-e3f5-448b-8993-e55c177f35b8"
      unitRef="usdPerShare">31.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEwLTEtMS0xLTI4NzY5_8695d0e8-31c5-4ca0-8335-7c14a4ea77ed"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEwLTMtMS0xLTI4NzY5_b9ba4ac6-163f-4aed-bb57-156a7d47ad21"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEwLTUtMS0xLTI4NzY5_fd6cbfad-3ff8-4a99-bcd8-a2406a35b71c"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzExLTEtMS0xLTI4NzY5_f29d6418-8b88-4e29-8503-f008edd912b6">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzExLTMtMS0xLTI4NzY5_f86cf328-4988-40e6-8eda-d35bf65a3575">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzExLTUtMS0xLTI4NzY5_0c1edd3c-162f-4474-a9b5-856d0016c6ed">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia1957b8b04bc43568cb3bf406005b986_D20210701-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTEtMS0xLTI4NzY5L3RleHRyZWdpb246YjdkODA5NzIyN2Q0NDc3ZGFlYTdhMjkyMTQ3MzMzMDFfNDM5ODA0NjUxMTEzOA_96db433d-2b76-445d-b4b8-686ca40ef4db"
      unitRef="number">0.0063</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i8173e7992c53414cbda9b33e54540412_D20210701-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTEtMS0xLTI4NzY5L3RleHRyZWdpb246YjdkODA5NzIyN2Q0NDc3ZGFlYTdhMjkyMTQ3MzMzMDFfNDM5ODA0NjUxMTE0Mg_6b3fd004-a2c1-45de-8bf2-3cd231f04f07"
      unitRef="number">0.0098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7b1efe55196841488562ed5eb81ff415_D20200701-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTMtMS0xLTI4NzY5L3RleHRyZWdpb246NjNlNmVlZjJiNTU1NGE2ZmIyYWMxNTZkNWM2OWFkZGVfNDM5ODA0NjUxMTE0MA_41b53981-5ebf-44cc-b0c8-393f7b246c2c"
      unitRef="number">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic6a5f8517549459ba24dc64abf4f2a39_D20200701-20210630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTMtMS0xLTI4NzY5L3RleHRyZWdpb246NjNlNmVlZjJiNTU1NGE2ZmIyYWMxNTZkNWM2OWFkZGVfNDM5ODA0NjUxMTE0NA_b1063405-64bb-4b5d-aca0-07c2ae7f1abd"
      unitRef="number">0.0098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i626584014ac5497faaf5bbe0805c20a9_D20190701-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTUtMS0xLTI4NzY5L3RleHRyZWdpb246N2IzMjAwMWFkMzk5NGE2NGI0ZjUyNWFkMTBlY2JhOTBfNDM5ODA0NjUxMTEzOA_ad723028-1b10-498e-90be-54ff9328508f"
      unitRef="number">0.0098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3568fe5aef9349ee949f734d37ba293a_D20190701-20200630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEyLTUtMS0xLTI4NzY5L3RleHRyZWdpb246N2IzMjAwMWFkMzk5NGE2NGI0ZjUyNWFkMTBlY2JhOTBfNDM5ODA0NjUxMTE0Mg_9c87ad12-f9b5-4566-8e3f-c9034d5a01c3"
      unitRef="number">0.0142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTEtMS0xLTI4NzY5L3RleHRyZWdpb246ZDM5YzQyZjIwMThiNGQ3M2I3YzM1NzYyOWIwZDEwNGRfNDM5ODA0NjUxMTEzMA_be28b58f-c9ee-4f9a-b6a3-31ad11281bcf"
      unitRef="number">0.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i61c233d8c3ec4ab181fddd77219a6844_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTEtMS0xLTI4NzY5L3RleHRyZWdpb246ZDM5YzQyZjIwMThiNGQ3M2I3YzM1NzYyOWIwZDEwNGRfNDM5ODA0NjUxMTEzNA_371c377a-bedd-4316-ad01-055c96b587c8"
      unitRef="number">0.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTMtMS0xLTI4NzY5L3RleHRyZWdpb246MDljM2Y5MGExZWU3NDllNDkwZTE1YzM3OTUzOGQ2OTlfNDM5ODA0NjUxMTEzMA_8596487f-25e7-4384-9492-d6f2af457761"
      unitRef="number">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="id093a49d43d84ea4b639ddc8261d00d2_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTMtMS0xLTI4NzY5L3RleHRyZWdpb246MDljM2Y5MGExZWU3NDllNDkwZTE1YzM3OTUzOGQ2OTlfNDM5ODA0NjUxMTEzNA_0146aad5-c084-48bb-91d9-f710dc1a5a4d"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTUtMS0xLTI4NzY5L3RleHRyZWdpb246NDY0Nzc1ZTZhNDZlNGIxOTg2YTViNWIxOTFmZmZjMmJfMTA5OTUxMTYyNzc5Mw_8507f1b6-54e5-4bf8-8830-1c122dafe001"
      unitRef="number">0.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i23d9121a0ebf413ca35ebca975273c99_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZTphNTU4ODZhZjhjNWM0MDJmOTdkOWFkOWNjY2ViODViZi90YWJsZXJhbmdlOmE1NTg4NmFmOGM1YzQwMmY5N2Q5YWQ5Y2NjZWI4NWJmXzEzLTUtMS0xLTI4NzY5L3RleHRyZWdpb246NDY0Nzc1ZTZhNDZlNGIxOTg2YTViNWIxOTFmZmZjMmJfMTA5OTUxMTYyNzgwMA_8660120c-6fb5-4fbb-9ef9-33524d16cade"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzg0OTM_c45a62b7-be84-45ca-a5dd-099fbc17c843">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the total stock-based compensation costs incurred and the associated tax benefit recognized during the years ended June&#160;30, 2022, 2021 and 2020 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29,262)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23,346)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation costs, net of tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if8f8a68565f04e4593882f783d3a8493_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzEtMS0xLTEtMjg3Njk_c66ffbed-8bc3-49bf-bc48-95b287b82764"
      unitRef="usd">5218000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i75b466de52734147a35094bafe68a210_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzEtMy0xLTEtMjg3Njk_80ee8330-79a7-4e58-9f5b-b39eec2c2f97"
      unitRef="usd">4153000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id24b9ea32ab54d4ebbb79eacdf21d5a2_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzEtNS0xLTEtMjg3Njk_e87b5f65-e55a-4ba0-9aed-f6864ed18556"
      unitRef="usd">3703000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie1b4834996c24c4697613536e66c2ae0_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzItMS0xLTEtMjg3Njk_cddd0362-d9e6-4834-9f85-d622b7f3aac8"
      unitRef="usd">50791000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1fb5f975b0f146af9d0eacbd9ea5d417_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzItMy0xLTEtMjg3Njk_21961bad-a167-4ca3-882c-671465db2ff0"
      unitRef="usd">51727000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i042c41ef5a4940c9bbbd03a03a164b31_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzItNS0xLTEtMjg3Njk_5be8c3a2-af92-47cc-bfa8-2d016f441763"
      unitRef="usd">47265000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia284c8ce0cc44849a9f6fd2717f955a6_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzMtMS0xLTEtMjg3Njk_b6eec7d8-0dfb-4bd6-ad06-e2d94eca14af"
      unitRef="usd">9248000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7bbffc1218e846ceaa11fd8c25583530_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzMtMy0xLTEtMjg3Njk_b19d3518-48cf-4b74-9b0c-33612d06450c"
      unitRef="usd">8047000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iefa02d71c77a4a088959735053a1a4df_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzMtNS0xLTEtMjg3Njk_ddc10136-fa27-47ff-a786-54af8acb867a"
      unitRef="usd">6591000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzQtMS0xLTEtMjg3Njk_79206d93-31e7-48c6-a9a0-788e0a2da5a5"
      unitRef="usd">65257000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzQtMy0xLTEtMjg3Njk_a6147f32-be04-4b7e-8390-645196012f25"
      unitRef="usd">63927000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzQtNS0xLTEtMjg3Njk_61bde3f4-3a1a-48b3-bf87-e6449a7832d0"
      unitRef="usd">57559000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzUtMS0xLTEtMjg3Njk_dabc51b7-759a-4fe2-9ef1-2d68195613f6"
      unitRef="usd">29262000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzUtMy0xLTEtMjg3Njk_5cd96dac-2115-48ad-91df-e2ff59fdee28"
      unitRef="usd">23346000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzUtNS0xLTEtMjg3Njk_b240716e-ddb8-4caf-8869-35de6b61cae7"
      unitRef="usd">39534000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzYtMS0xLTEtMjg3Njk_a3b49c09-3592-49a9-918c-4fce2d19cf1b"
      unitRef="usd">35995000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzYtMy0xLTEtMjg3Njk_16e8b328-1902-4ade-b44c-6e3c64293761"
      unitRef="usd">40581000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90YWJsZToyZDk0ZjViZTljMTI0OWEyOTg0ZTFlMDA0ZWM1YTJiZC90YWJsZXJhbmdlOjJkOTRmNWJlOWMxMjQ5YTI5ODRlMWUwMDRlYzVhMmJkXzYtNS0xLTEtMjg3Njk_226589e7-54bb-45d7-8886-36ed1218af9f"
      unitRef="usd">18025000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAxMDM_fbdc1969-3ed4-4291-9ed8-6e4404fbdb91"
      unitRef="usd">104000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzYvZnJhZzpkODllNDM3NzU4MzA0YTU2YTM2NzNhZGY3NzdjZDlkZS90ZXh0cmVnaW9uOmQ4OWU0Mzc3NTgzMDRhNTZhMzY3M2FkZjc3N2NkOWRlXzQzOTgwNDY1MjAxMDg_b9c4903f-760f-428a-a6a8-e6ce3b8ca96b">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90ZXh0cmVnaW9uOmRmYzRjNGM0ZGZkYzRlNWY5Njc0MWFlODczNzg0N2UwXzg0Nw_d480ca9a-18c6-4b2d-969b-7c5d9e13327f">Earnings Per Share We compute basic earnings per share by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;common stock equivalents such as stock options and restricted stock units. The weighted average number of outstanding stock options and restricted stock units not included in the computation of diluted earnings per share were 67,000, 141,000 and 164,000 for the years ended June&#160;30, 2022, 2021 and 2020, respectively, as the effect would have been anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted earnings per share for the years ended June&#160;30, 2022, 2021 and 2020 are calculated as follows (in thousands except per share data): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;779,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90ZXh0cmVnaW9uOmRmYzRjNGM0ZGZkYzRlNWY5Njc0MWFlODczNzg0N2UwXzQzOTgwNDY1MTIwMTY_69ee3ad4-3e72-4d78-b551-aa131644c497"
      unitRef="shares">67000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90ZXh0cmVnaW9uOmRmYzRjNGM0ZGZkYzRlNWY5Njc0MWFlODczNzg0N2UwXzQzOTgwNDY1MTIwMjA_f5f1c7a3-a3b3-45a9-8df2-e3cda15bcc0b"
      unitRef="shares">141000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90ZXh0cmVnaW9uOmRmYzRjNGM0ZGZkYzRlNWY5Njc0MWFlODczNzg0N2UwXzQzOTgwNDY1MTIwMjQ_d08df6cc-6906-44e8-8fc2-cd8ad7c3a1d7"
      unitRef="shares">164000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90ZXh0cmVnaW9uOmRmYzRjNGM0ZGZkYzRlNWY5Njc0MWFlODczNzg0N2UwXzg0Ng_bdc01fa1-7328-4681-b880-d3a7ee494a7d">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted earnings per share for the years ended June&#160;30, 2022, 2021 and 2020 are calculated as follows (in thousands except per share data): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;779,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;621,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic weighted-average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options and restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted weighted average shares &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzItMS0xLTEtMjg3Njk_6f22673d-bf77-4c52-9ef8-244838e72c06"
      unitRef="usd">779437000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzItMy0xLTEtMjg3Njk_738e886d-274a-4ecb-8739-709699c3b50b"
      unitRef="usd">474505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzItNS0xLTEtMjg3Njk_31c79214-a275-487d-aaa2-98338c531deb"
      unitRef="usd">621674000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzQtMS0xLTEtMjg3Njk_01795855-f0cb-4f23-9136-db132868ddbf"
      unitRef="shares">146066000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzQtMy0xLTEtMjg3Njk_c5d5e820-6b44-4fd9-ac04-5598100ba916"
      unitRef="shares">145313000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzQtNS0xLTEtMjg3Njk_54c7270a-7bdc-469e-8909-d4ce8f7fe5f7"
      unitRef="shares">144338000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzYtMS0xLTEtMjg3Njk_d999ec2f-75ca-4a12-b819-ea08c1968619"
      unitRef="shares">977000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzYtMy0xLTEtMjg3Njk_b1d68146-2323-4f71-b03e-47ba1a553a26"
      unitRef="shares">1138000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzYtNS0xLTEtMjg3Njk_034bb6be-a2eb-4a23-8f7e-469197f0a1c0"
      unitRef="shares">1314000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzctMS0xLTEtMjg3Njk_d7d72267-407b-49d9-9fb9-b056219ceb90"
      unitRef="shares">147043000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzctMy0xLTEtMjg3Njk_c072d0c1-d0e4-4026-97f5-16c9c8ba04c6"
      unitRef="shares">146451000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzctNS0xLTEtMjg3Njk_3867b0cc-84cc-4312-a6d8-96f04356b290"
      unitRef="shares">145652000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzgtMS0xLTEtMjg3Njk_c1c20131-1272-4f64-af5e-62a1d7b7d7af"
      unitRef="usdPerShare">5.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzgtMy0xLTEtMjg3Njk_49cb813f-31f0-4bae-be5d-8a1cfc2039e7"
      unitRef="usdPerShare">3.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzgtNS0xLTEtMjg3Njk_86987e20-c744-43a2-b5a3-ad368e8fd990"
      unitRef="usdPerShare">4.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzktMS0xLTEtMjg3Njk_83bd6869-150e-4695-acba-e3a1a29e0e69"
      unitRef="usdPerShare">5.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzktMy0xLTEtMjg3Njk_429e2514-8135-42ee-a1f3-051feb9b6f35"
      unitRef="usdPerShare">3.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xMzkvZnJhZzpkZmM0YzRjNGRmZGM0ZTVmOTY3NDFhZTg3Mzc4NDdlMC90YWJsZToxN2YyYmJiMzBkYWQ0ZTRmOGYyZDY2MjU2OGE5MzZkOC90YWJsZXJhbmdlOjE3ZjJiYmIzMGRhZDRlNGY4ZjJkNjYyNTY4YTkzNmQ4XzktNS0xLTEtMjg3Njk_fb360192-d81d-4067-a8cf-47fa2d4d3500"
      unitRef="usdPerShare">4.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MjM_b665cb87-54a1-4788-af71-0e920248e81b">Income Taxes &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes for the years ended June&#160;30, 2022, 2021 and 2020, was taxed under the following jurisdictions (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,046,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;811,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;672,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;960,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;883,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is presented below (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;531,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;425,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. federal income tax rate of 21% for the years ended June&#160;30, 2022, 2021 and 2020, to pretax income as a result of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes computed at statutory U.S. rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in income taxes resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of U.S. tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of non-U.S. tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Uncertain tax position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reported net deferred tax assets and liabilities in our consolidated balance sheets at June&#160;30, 2022 and June&#160;30, 2021, as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our deferred tax assets and liabilities at June&#160;30, 2022 and June&#160;30, 2021, are as follows (in thousands): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Employee liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;28,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;30,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Tax credit carry overs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;7,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;13,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;10,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;11,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Provision for warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;4,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;4,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Provision for doubtful debts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;5,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;7,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;27,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;33,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Capital loss carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;4,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;25,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;17,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Research and development capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;82,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;58,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;21,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;25,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(3,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(4,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;221,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;210,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(13,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(13,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;207,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;197,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Goodwill and other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(108,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(104,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(20,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(23,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(9,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(137,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(129,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;70,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;68,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, we had $19.8 million of U.S. federal and state net operating loss carryforwards and $6.9 million of non-U.S. net operating loss carryforwards, which expire in various years beginning in 2023 or carry forward indefinitely. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowance at June&#160;30, 2022 relates to a provision for uncertainty of the utilization of net operating loss carryforwards of $0.8 million and capital loss and other items of $12.7 million. We believe that it is more likely than not that the benefits of deferred tax assets, net of any valuation allowance, will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A substantial portion of our manufacturing operations and administrative functions in Singapore operate under certain tax holidays and tax incentive programs that will expire in whole or in part at various dates through June 30, 2030. The end of certain tax holidays may be extended if specific conditions are met. The net impact of these tax holidays and tax incentive programs increased our net income by $38.0 million ($0.26 per diluted share) for the year ended June&#160;30, 2022, $33.6 million ($0.23 per diluted share) for the year ended June&#160;30, 2021, and $43.8 million ($0.30 per diluted share) for the year ended June&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Tax Cuts and Jobs Act of 2017 (the &#x201d;U.S. Tax Act&#x201d;), we have treated all non-U.S. historical earnings as taxable. Therefore, future repatriation of cash held by our non-U.S. subsidiaries will generally not be subject to U.S. federal tax if repatriated. The total amount of these undistributed earnings at June&#160;30, 2022 amounted to approximately $3.6 billion. On June 14, 2019, the U.S. Treasury Department issued final and temporary regulations relating to the repatriation of non-U.S. earnings. As a result, in the event our non-U.S. earnings had not been permanently reinvested, approximately $194.9&#160;million in U.S. federal deferred taxes and $5.2&#160;million in U.S. state deferred taxes would have been recognized in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accounting for uncertainty in income taxes, we recognize a tax benefit in the financial statements for an uncertain tax position only if management&#x2019;s assessment is that the position is &#x201c;more likely than not&#x201d; (that is, a likelihood greater than 50 percent) to be allowed by the tax jurisdiction based solely on the technical merits of the position. The term &#x201c;tax position&#x201d; refers to a position in a previously filed tax return or a position expected to be taken in a future tax return that is reflected in measuring current or deferred income tax assets and liabilities for annual periods. We recognize interest and penalties related to unrecognized tax benefits within the income tax expense line in the accompanying consolidated statements of income. Accrued interest and penalties are included within the related tax liability line in the consolidated balance sheets. Based on all known facts and circumstances and current tax law, we believe the total amount of unrecognized tax benefits on June 30, 2022, is not material to our results of operations, financial condition or cash flows, and if recognized, would not have a material impact on our effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 19, 2021, we concluded the settlement agreement with the Australian Taxation Office (&#x201c;ATO&#x201d;) in relation to the previously disclosed transfer pricing dispute for the tax years 2009 through 2018 (&#x201c;ATO settlement&#x201d;). The ATO settlement fully resolved the dispute for all prior years, with no admission of liability and provides clarity in relation to certain future taxation principles.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The final net impact of the ATO settlement was $238.7&#160;million, which represents a gross amount of $381.7&#160;million, including interest and penalties of $48.1&#160;million, and adjustments for credits and deductions of $143.0&#160;million. As a result of the ATO settlement and due to movements in foreign currencies, we recorded a benefit of $14.1&#160;million within other comprehensive income, and a $4.1&#160;million reduction of tax credits, which was recorded to income tax expense. As a result of the ATO settlement, we reversed our previously recorded uncertain tax position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 28, 2021, we remitted final payment to the ATO of $284.8&#160;million, consisting of the agreed settlement amount of $381.7&#160;million less prior remittances made to the ATO of $96.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tax years 2018 to 2021 remain subject to future examination by the major tax jurisdictions in which we are subject to tax.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MTg_12dc79dd-a864-41e7-8dce-e32b5d5c6463">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income before income taxes for the years ended June&#160;30, 2022, 2021 and 2020, was taxed under the following jurisdictions (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85,919)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,046,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;811,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;672,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;960,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;883,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzEtMS0xLTEtMjg3Njk_24daa3ca-49ef-40b9-a7a1-4915f83495ab"
      unitRef="usd">-85919000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzEtMy0xLTEtMjg3Njk_fac78196-85de-40bf-900b-bd1a8d281355"
      unitRef="usd">71867000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzEtNS0xLTEtMjg3Njk_879100ae-0496-4f04-9873-1f68bb558e28"
      unitRef="usd">60548000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzItMS0xLTEtMjg3Njk_431b57d4-5b39-45df-a830-5e0316d95ce1"
      unitRef="usd">1046402000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzItMy0xLTEtMjg3Njk_7193dcc9-824f-4676-8b42-ee31edbcfb96"
      unitRef="usd">811795000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzItNS0xLTEtMjg3Njk_c2d36d6e-4212-4b8b-9cb9-4197d2203b04"
      unitRef="usd">672540000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzMtMS0xLTEtMjg3Njk_46cd9249-e662-41ee-93bc-9ed24d6d7b84"
      unitRef="usd">960483000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzMtMy0xLTEtMjg3Njk_e1023777-6b18-47f3-97ee-6b9ebb6ce529"
      unitRef="usd">883662000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZToxMDljNmM2NzZhOGE0ZTNlOTJhZWUwYzE1YjU1NTVhYS90YWJsZXJhbmdlOjEwOWM2YzY3NmE4YTRlM2U5MmFlZTBjMTViNTU1NWFhXzMtNS0xLTEtMjg3Njk_56962dc6-f037-49e8-a233-0fed6a21afdc"
      unitRef="usd">733088000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MTk_f211683b-fe34-4e0d-bbba-a01980fba2ba">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is presented below (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.101%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.106%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(115,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177,788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;531,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;425,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(22,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,541)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16,587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29,876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzEtMi0xLTEtMjg3Njk_00007b36-175e-4b1f-8d7e-8442820a047c"
      unitRef="usd">4376000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzEtNC0xLTEtMjg3Njk_2663b88c-d599-4277-bb00-5d09504efad0"
      unitRef="usd">-115109000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzEtNi0xLTEtMjg3Njk_bc40daf3-bed5-4bb4-8a15-67ec771679e5"
      unitRef="usd">9790000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzItMi0xLTEtMjg3Njk_dc4e128d-c7dd-4b81-986f-f8efc7292113"
      unitRef="usd">10700000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzItNC0xLTEtMjg3Njk_53d691c5-56f0-4b8c-9818-eb3655a0dd77"
      unitRef="usd">9041000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzItNi0xLTEtMjg3Njk_a7726d2d-0fd7-44e1-adf4-396eedba9bc0"
      unitRef="usd">6898000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzMtMi0xLTEtMjg3Njk_e29cd60a-ed9c-4ec9-877c-c2f261c4c8a9"
      unitRef="usd">177788000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzMtNC0xLTEtMjg3Njk_bb7c83fc-99b2-4785-89fb-63af87e0713a"
      unitRef="usd">531812000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzMtNi0xLTEtMjg3Njk_2212e573-81d4-4dc8-a26c-a1a7b1a5a148"
      unitRef="usd">124602000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzQtMi0xLTEtMjg3Njk_6b18cdc7-31d1-4acc-bae2-1b768a2fa2e7"
      unitRef="usd">192864000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzQtNC0xLTEtMjg3Njk_7c212615-1850-4d85-85ed-715a106290b2"
      unitRef="usd">425744000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzQtNi0xLTEtMjg3Njk_99d56105-3a39-4da2-8824-49822a7e1621"
      unitRef="usd">141290000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzUtMi0xLTEtMjg3Njk_30cf1652-7dbe-41bf-a497-6b0c02f3df52"
      unitRef="usd">-12612000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzUtNC0xLTEtMjg3Njk_1b9d368c-3462-49dd-9344-64f3d2cea104"
      unitRef="usd">-22791000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzUtNi0xLTEtMjg3Njk_a324572c-367a-4060-a6c7-f5e995b8e9d1"
      unitRef="usd">-13000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzYtMi0xLTEtMjg3Njk_1ecbad81-1251-45a4-9c3f-795bb7b734ea"
      unitRef="usd">-2773000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzYtNC0xLTEtMjg3Njk_13ffebfb-e956-438c-af74-019c2b18b593"
      unitRef="usd">-4205000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzYtNi0xLTEtMjg3Njk_72ebf7ca-8bb3-476f-91ed-3ba1b712879b"
      unitRef="usd">-3335000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzctMi0xLTEtMjg3Njk_9ebbb0ce-9157-4bb6-b409-f7e40ae382ff"
      unitRef="usd">3567000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzctNC0xLTEtMjg3Njk_6e3bf86e-85f3-424d-99ba-1cf4484a34f1"
      unitRef="usd">10409000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzctNi0xLTEtMjg3Njk_ed0c8edc-85d2-4f7f-9b87-f174da77710b"
      unitRef="usd">-13541000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzgtMi0xLTEtMjg3Njk_c0c9a41b-75a3-429e-a5b5-3999a8546151"
      unitRef="usd">-11818000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzgtNC0xLTEtMjg3Njk_cd1bb379-f403-4d5b-9e4f-891487382c6f"
      unitRef="usd">-16587000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzgtNi0xLTEtMjg3Njk_937857a2-28e4-4105-b95b-b99caab3c656"
      unitRef="usd">-29876000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzktMi0xLTEtMjg3Njk_42a717cc-d079-4e1b-9415-5c92bd2a600a"
      unitRef="usd">181046000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzktNC0xLTEtMjg3Njk_d0c3bd74-bd85-4805-9409-bbcd561bceee"
      unitRef="usd">409157000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5OGNjNWNlZDliMzE0OTVhOWMwYzUxZmI3N2QwNzljOS90YWJsZXJhbmdlOjk4Y2M1Y2VkOWIzMTQ5NWE5YzBjNTFmYjc3ZDA3OWM5XzktNi0xLTEtMjg3Njk_b0c2bb83-08bf-427d-b099-c7703ba5c95e"
      unitRef="usd">111414000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MjA_ebc67721-3e51-49f3-90ac-7c4afae351ba">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. federal income tax rate of 21% for the years ended June&#160;30, 2022, 2021 and 2020, to pretax income as a result of the following (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes computed at statutory U.S. rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Increase (decrease) in income taxes resulting from:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State income taxes, net of U.S. tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,785)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of non-U.S. tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,384)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12,130)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,026)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,498)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20,696)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Uncertain tax position&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;248,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;409,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;111,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEtMS0xLTEtMjg3Njk_c6f46f3d-2f93-4d03-a1f6-dda387d09934"
      unitRef="usd">201701000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEtMy0xLTEtMjg3Njk_ad0bb3d3-c011-4355-867a-207d4c3d401e"
      unitRef="usd">185569000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEtNS0xLTEtMjg3Njk_e0a55229-f3be-4c67-b2d5-010e4e8a1e39"
      unitRef="usd">153949000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzMtMS0xLTEtMjg3Njk_ad11dfc5-dee5-468e-8b91-e3efd2e33dc1"
      unitRef="usd">5703000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzMtMy0xLTEtMjg3Njk_d8a24cde-865f-4eb2-aedd-1735ea1eea27"
      unitRef="usd">4836000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzMtNS0xLTEtMjg3Njk_7e84d6b3-28f0-48b0-813e-a39086888327"
      unitRef="usd">3563000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzQtMS0xLTEtMjg3Njk_d20a8d5c-c0dc-45ae-adcd-4029ab0e6972"
      unitRef="usd">17517000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzQtMy0xLTEtMjg3Njk_74622a0c-9aa6-4c78-ba9d-76efd9acfe1e"
      unitRef="usd">20257000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzQtNS0xLTEtMjg3Njk_9015cbcf-974a-4602-8a3d-873712a986d6"
      unitRef="usd">13595000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzUtMS0xLTEtMjg3Njk_23121f08-6e1b-4b03-a7b5-dc00e3cd3d6e"
      unitRef="usd">858000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzUtMy0xLTEtMjg3Njk_ffa6f363-5a92-4e97-b0a5-0a22767dbe04"
      unitRef="usd">-3785000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzUtNS0xLTEtMjg3Njk_aa625075-eac3-43a7-ac58-b040e4f9348a"
      unitRef="usd">7216000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzYtMS0xLTEtMjg3Njk_d3b0c8a1-a17b-453a-b474-3757e2a32168"
      unitRef="usd">-4384000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzYtMy0xLTEtMjg3Njk_3e2c62cb-71f3-4770-af41-a1138f7b4520"
      unitRef="usd">-12130000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzYtNS0xLTEtMjg3Njk_2caeafba-b402-4dcf-b34c-22cc2ea409e2"
      unitRef="usd">-20935000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzctMS0xLTEtMjg3Njk_70b7adef-2d00-4172-a1c9-388804796caf"
      unitRef="usd">2299000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzctMy0xLTEtMjg3Njk_d00cd68f-c815-4ce3-baff-b8f1816e6a93"
      unitRef="usd">7210000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzctNS0xLTEtMjg3Njk_2e68c436-cee8-4f8a-9034-a3c524949f05"
      unitRef="usd">4026000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzgtMS0xLTEtMjg3Njk_0f1ef5e7-6a48-403c-bead-3b9c9bd116b5"
      unitRef="usd">-11294000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzgtMy0xLTEtMjg3Njk_cfb6c579-5527-4e48-93b8-b1ef5bac4b28"
      unitRef="usd">-4498000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzgtNS0xLTEtMjg3Njk_159baf53-ee86-43b6-8ab5-a6db4ddb3020"
      unitRef="usd">-20696000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <rmd:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzktMS0xLTEtMjg3Njk_b4c1d05e-83f4-46e1-b4ab-6c4f32ca3e64"
      unitRef="usd">0</rmd:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount>
    <rmd:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzktMy0xLTEtMjg3Njk_03ff2d22-4b47-40c7-90c5-2a21d2edfef6"
      unitRef="usd">248773000</rmd:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount>
    <rmd:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzktNS0xLTEtMjg3Njk_cf296345-c45b-47a0-b29c-96197d9d354d"
      unitRef="usd">0</rmd:EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzExLTEtMS0xLTI4NzY5_fac2055d-8587-4fce-949c-3bef719a042e"
      unitRef="usd">8278000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzExLTMtMS0xLTI4NzY5_10d9835f-81e7-4f07-8f83-fa9000738a48"
      unitRef="usd">17859000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzExLTUtMS0xLTI4NzY5_b42b02f2-3891-43f6-8b31-c5e2feff8b56"
      unitRef="usd">5938000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEyLTEtMS0xLTI4NzY5_9ef46c07-606b-408f-91f8-ab3c8d7d93bf"
      unitRef="usd">181046000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEyLTMtMS0xLTI4NzY5_131e7920-c98f-4b81-af00-2c81a49619d1"
      unitRef="usd">409157000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo0OGRmMGZlYzc5ZWQ0NzA0YmU0Mzc2YTJjYWM3NmI5ZS90YWJsZXJhbmdlOjQ4ZGYwZmVjNzllZDQ3MDRiZTQzNzZhMmNhYzc2YjllXzEyLTUtMS0xLTI4NzY5_3ce21bf5-c0d8-415a-a12d-c80e48496e66"
      unitRef="usd">111414000</us-gaap:IncomeTaxExpenseBenefit>
    <rmd:ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MjE_56618620-92cd-4990-8eee-59761f9c85a3">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reported net deferred tax assets and liabilities in our consolidated balance sheets at June&#160;30, 2022 and June&#160;30, 2021, as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9,714)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rmd:ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzEtMS0xLTEtMjg3Njk_181435aa-a03e-4190-8e2a-37fae4c19d5d"
      unitRef="usd">79746000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzEtMy0xLTEtMjg3Njk_bfa28096-cf27-4569-be29-a0cbf3c59a81"
      unitRef="usd">79904000</us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzItMS0xLTEtMjg3Njk_57d13408-85ca-4efd-8b48-52b9edca6b13"
      unitRef="usd">9714000</us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzItMy0xLTEtMjg3Njk_3318b7f9-714d-40d3-9bce-a9a773a3f59c"
      unitRef="usd">11319000</us-gaap:DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzMtMS0xLTEtMjg3Njk_51cc6035-ad04-4b0e-ac3a-75b9f45a8954"
      unitRef="usd">70032000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTpmZGYyYzY5ODFkOWQ0ZjcyYjQyNDFlYzQxN2ZjZDZkNS90YWJsZXJhbmdlOmZkZjJjNjk4MWQ5ZDRmNzJiNDI0MWVjNDE3ZmNkNmQ1XzMtMy0xLTEtMjg3Njk_d7fd4c22-13df-454b-93a2-feea2ece5252"
      unitRef="usd">68585000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzY1MjI_c0d425e3-0743-4b49-8cd8-ba9f33e940f8">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of our deferred tax assets and liabilities at June&#160;30, 2022 and June&#160;30, 2021, are as follows (in thousands): &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Employee liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;28,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;30,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Tax credit carry overs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;7,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;13,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;10,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;11,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Provision for warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;4,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;4,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Provision for doubtful debts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;5,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;7,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;27,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;33,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Capital loss carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;4,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;6,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;25,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;17,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Research and development capitalization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;82,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;58,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;21,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;25,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(3,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(4,911)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;221,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;210,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(13,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(13,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;207,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;197,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:108%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Goodwill and other intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(108,078)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(104,563)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Right of use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(20,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(23,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(9,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(137,914)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;(129,196)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;70,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:108%"&gt;68,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzItMS0xLTEtMjg3Njk_1c7bb43e-ee67-473d-bad2-d6bc4e66e1eb"
      unitRef="usd">28556000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzItMy0xLTEtMjg3Njk_348347d6-ce73-4416-b85e-788da61f66e2"
      unitRef="usd">30080000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzMtMS0xLTEtMjg3Njk_36459634-f026-4a83-a628-d4a5fc88a356"
      unitRef="usd">7723000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzMtMy0xLTEtMjg3Njk_f1f058bd-6cae-4896-a7fc-a2ee511b42ca"
      unitRef="usd">13753000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzQtMS0xLTEtMjg3Njk_ca31213c-c764-41f9-ab65-35f8fdee612d"
      unitRef="usd">10570000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzQtMy0xLTEtMjg3Njk_6dae30a2-ec36-4ace-a31b-40408dda3a12"
      unitRef="usd">11734000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzUtMS0xLTEtMjg3Njk_0dfed984-1a12-4acb-922e-b714e30a8189"
      unitRef="usd">4814000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzUtMy0xLTEtMjg3Njk_b26acabf-b427-4064-bc66-ee7e09d7d830"
      unitRef="usd">4149000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzYtMS0xLTEtMjg3Njk_1b1a59a9-e980-45c1-9c05-bf77c381b9f4"
      unitRef="usd">5096000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzYtMy0xLTEtMjg3Njk_7c312a6d-c0d9-461f-baf9-5819321c30d4"
      unitRef="usd">7334000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzctMS0xLTEtMjg3Njk_f0cb4f66-aa48-4fcc-80d6-110a7af7a0e1"
      unitRef="usd">27490000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzctMy0xLTEtMjg3Njk_1ecca42e-4118-4ba6-ba13-d5a937c80638"
      unitRef="usd">33377000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzgtMS0xLTEtMjg3Njk_793f12fe-3e7d-48af-b652-acfd7742c842"
      unitRef="usd">4715000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzgtMy0xLTEtMjg3Njk_f8da2c39-c665-4ded-9a0e-03c54954ec43"
      unitRef="usd">6912000</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzktMS0xLTEtMjg3Njk_27c62c1e-4a1b-4e60-acf3-cce4d5f7270d"
      unitRef="usd">6425000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzktMy0xLTEtMjg3Njk_1aa15bdf-00e1-42cc-8be4-e7fd914d79ef"
      unitRef="usd">6080000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEwLTEtMS0xLTI4NzY5_1ce1e093-206a-4cb3-9683-a79740fbe9f8"
      unitRef="usd">25748000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEwLTMtMS0xLTI4NzY5_40faa700-6757-497d-9340-d37dcabcee98"
      unitRef="usd">17839000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzExLTEtMS0xLTI4NzY5_4781fb2b-659a-4861-9822-7599498f8882"
      unitRef="usd">82074000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzExLTMtMS0xLTI4NzY5_fe6f7a12-0544-491c-ad59-1089b402e8f9"
      unitRef="usd">58789000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <rmd:DeferredTaxAssetsLeaseLiabilities
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEyLTEtMS0xLTI4NzY5_5e47296e-5294-452a-bafd-66d93a48a62d"
      unitRef="usd">21702000</rmd:DeferredTaxAssetsLeaseLiabilities>
    <rmd:DeferredTaxAssetsLeaseLiabilities
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEyLTMtMS0xLTI4NzY5_7fc49019-9831-4c23-82e4-e29bbfd57793"
      unitRef="usd">25751000</rmd:DeferredTaxAssetsLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEzLTEtMS0xLTI4NzY5_e4f4d8ca-44c9-4500-9435-9045bce9d39c"
      unitRef="usd">-3395000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzEzLTMtMS0xLTI4NzY5_a1a8d9cd-0656-45db-947f-76fca655ed3b"
      unitRef="usd">-4911000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE0LTEtMS0xLTI4NzY5_f0f1525d-6fb0-4b7a-9a68-77e246d3de1a"
      unitRef="usd">221518000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE0LTMtMS0xLTI4NzY5_c5fd02c3-8ac3-4aa8-aa2b-1dbf8040dd5d"
      unitRef="usd">210887000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE1LTEtMS0xLTI4NzY5_4f8659f3-f34c-4203-99a4-cab3a4fbfcae"
      unitRef="usd">13572000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE1LTMtMS0xLTI4NzY5_0b9c790d-8796-48bd-89e2-0e6f9d553aa6"
      unitRef="usd">13106000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE2LTEtMS0xLTI4NzY5_a28369f1-4179-431a-9460-b69965c97dc7"
      unitRef="usd">207946000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE2LTMtMS0xLTI4NzY5_d6be09d3-9906-4e95-8dbb-e00da3fa9236"
      unitRef="usd">197781000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE4LTEtMS0xLTI4NzY5_3495aef9-de86-4afb-9573-743eff56d82c"
      unitRef="usd">108078000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE4LTMtMS0xLTI4NzY5_954d8782-cb5e-4265-89a0-328352a60d55"
      unitRef="usd">104563000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <rmd:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE5LTEtMS0xLTI4NzY5_557dc333-22e2-4b86-b96f-da3b8828e6c3"
      unitRef="usd">20345000</rmd:DeferredTaxLiabilitiesRightOfUseAssets>
    <rmd:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzE5LTMtMS0xLTI4NzY5_03d794ee-306c-4da5-93c2-31f53cc1d52f"
      unitRef="usd">23693000</rmd:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIxLTEtMS0xLTUwNjgz_206dc147-0107-47c8-9d08-2a8e9ba82e7d"
      unitRef="usd">9491000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIxLTMtMS0xLTUwNjgz_6c6636d2-2cc7-41f6-ba63-ecc8ba3cbb91"
      unitRef="usd">940000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIwLTEtMS0xLTI4NzY5_2eac27c8-3f0e-4ae0-840b-7ba9137efe67"
      unitRef="usd">137914000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIwLTMtMS0xLTI4NzY5_14f6aca9-d9f7-4157-bffb-e78c9b401aa3"
      unitRef="usd">129196000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIxLTEtMS0xLTI4NzY5_1212ca5e-1483-4145-9d3b-bba42243f93a"
      unitRef="usd">70032000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90YWJsZTo5MDVjODlkOWRkZDE0ZDdlODM2MDYyNzFjMTVjOTk5Yy90YWJsZXJhbmdlOjkwNWM4OWQ5ZGRkMTRkN2U4MzYwNjI3MWMxNWM5OTljXzIxLTMtMS0xLTI4NzY5_f46cd8f3-ac32-4de4-91c1-ebcb2df98ca3"
      unitRef="usd">68585000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ic89b566ef2524af98f09b1c2e5a3555c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTc5NTU_4269d733-0483-43c5-820d-f5ddcde0450c"
      unitRef="usd">19800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0fd69e2cd46e4080ad9064bd38b12c4c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTc5NTk_5841bb4d-9d46-48a1-aff3-cb1a3b68be45"
      unitRef="usd">6900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i0e1c0e023852448f9bf3bd384a272726_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNDY_50366eba-f83d-4490-81a5-a36055aeba21"
      unitRef="usd">800000</us-gaap:OperatingLossCarryforwards>
    <rmd:OperatingLossCarryforwardsCapitalLoss
      contextRef="i0e1c0e023852448f9bf3bd384a272726_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNTA_853e71fc-2159-480a-9dc9-b6efc29f795c"
      unitRef="usd">12700000</rmd:OperatingLossCarryforwardsCapitalLoss>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNjA_23f74c42-6327-4d49-ac08-6b922a2d1b02"
      unitRef="usd">38000000</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNjQ_fb22b40b-628e-4cb2-b542-974b6c59c4b3"
      unitRef="usdPerShare">0.26</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNzQ_5f6f0f75-cd99-4ea3-b7cd-6d561af6a562"
      unitRef="usd">33600000</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxNzg_7fee4998-a773-4624-ab0d-edac7dc41032"
      unitRef="usdPerShare">0.23</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:IncomeTaxHolidayAggregateDollarAmount
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxODI_06370ca2-aca6-43a6-bf3d-49e8a229ad09"
      unitRef="usd">43800000</us-gaap:IncomeTaxHolidayAggregateDollarAmount>
    <us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MTgxODY_7458f6ba-0d47-4a3c-a4b4-694b08519d89"
      unitRef="usdPerShare">0.30</us-gaap:IncomeTaxHolidayIncomeTaxBenefitsPerShare>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MzEzNDk_2dc0c63d-8ca0-4a9a-8f18-cf084089dea7"
      unitRef="usd">3600000000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries
      contextRef="ic89b566ef2524af98f09b1c2e5a3555c_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MzEzNTc_5cbfc8a1-bed9-434b-8739-e33ba53c6852"
      unitRef="usd">194900000</us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries
      contextRef="ie01584a76c914617a10b30795533bc02_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzQzOTgwNDY1MzEzNDE_696c9cd3-3a56-4216-90e6-19347bc8b664"
      unitRef="usd">5200000</us-gaap:DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries>
    <rmd:PercentageOfRecognizedTaxBenefitForUncertainTaxPosition
      contextRef="ia4b678d1321a48be9f80648f4a12cf05_D20210701-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTAyNzM_b15a819c-c05b-454f-bc12-8bfee6ec2e03"
      unitRef="number">0.50</rmd:PercentageOfRecognizedTaxBenefitForUncertainTaxPosition>
    <rmd:IncomeTaxExaminationNetImpactOfSettlement
      contextRef="i6fd3564ce052488e9f5ba664a5d9dcec_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUxOTc_be59de5d-4728-4188-a77f-2e26d616af01"
      unitRef="usd">238700000</rmd:IncomeTaxExaminationNetImpactOfSettlement>
    <rmd:IncomeTaxExaminationGrossSettlement
      contextRef="i6fd3564ce052488e9f5ba664a5d9dcec_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyMTM_7137e92d-deec-4140-b840-0fb9a4b10c43"
      unitRef="usd">381700000</rmd:IncomeTaxExaminationGrossSettlement>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="i6fd3564ce052488e9f5ba664a5d9dcec_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyMjk_5f0c6fbc-0959-4b1d-bb22-23a13eac21a6"
      unitRef="usd">48100000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority
      contextRef="i8d4e9f2528d046f9a73bbe9b0ae46a0e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyNDQ_08b2a467-3b90-4fdd-baa2-d6fd6fbeb062"
      unitRef="usd">143000000</us-gaap:IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i9b2d239a762c46e39be91927daa68806_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyNjA_2c37edbe-3ad5-4b18-939b-e276d4a01c20"
      unitRef="usd">14100000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:IncomeTaxCreditsAndAdjustments
      contextRef="i9b2d239a762c46e39be91927daa68806_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyNzU_cf30d83d-8a78-49f5-a396-e8bee9535894"
      unitRef="usd">4100000</us-gaap:IncomeTaxCreditsAndAdjustments>
    <rmd:IncomeTaxExaminationRemittedFinalPayment
      contextRef="i01201a3e634542d49bf58f119957d890_D20210928-20210928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUyODk_c2663f44-5483-4c91-a2b1-bab5363d0b9b"
      unitRef="usd">284800000</rmd:IncomeTaxExaminationRemittedFinalPayment>
    <rmd:IncomeTaxExaminationGrossSettlement
      contextRef="i01201a3e634542d49bf58f119957d890_D20210928-20210928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUzMDU_2c1cae61-57e2-4cff-a70f-be74729d2b86"
      unitRef="usd">381700000</rmd:IncomeTaxExaminationGrossSettlement>
    <rmd:IncomeTaxExaminationPriorRemittancePayments
      contextRef="i01201a3e634542d49bf58f119957d890_D20210928-20210928"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDUvZnJhZzo4NWE4MzBjMmEzYzg0MGNhODA0NTkwODM4Y2ZiNjFiZi90ZXh0cmVnaW9uOjg1YTgzMGMyYTNjODQwY2E4MDQ1OTA4MzhjZmI2MWJmXzMyOTg1MzQ4OTUzMjE_3692d3f4-66d3-4ad4-8c42-589eb20c6e4e"
      unitRef="usd">96900000</rmd:IncomeTaxExaminationPriorRemittancePayments>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzIwNDM_d9517905-974a-463a-b15d-1089e0eb487c">Segment Information &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have two operating segments, which are the Sleep and Respiratory Care segment and the SaaS segment. We evaluate the performance of our segments based on net sales and income from operations. The accounting policies of the segments are the same as those described in note 2 &#x2013; Summary of Significant Accounting Policies. Segment net sales and segment income from operations do not include inter-segment profits and revenue is allocated to a geographic area based on where the products are shipped to or where the services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain items are maintained at the corporate level and are not allocated to the segments. The non-allocated items include corporate headquarters costs including stock-based compensation, amortization expense of acquired intangibles, restructuring expenses, litigation settlement expenses, deferred revenue fair value adjustment, net interest expense (income), loss attributable to equity method investments, gains and losses on equity investments, and other, net. We neither discretely allocate assets to our operating segments, nor does our Chief Operating Decision Maker evaluate the operating segments using discrete asset information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents a reconciliation of net revenues, depreciation and amortization and net operating profit by reportable segments for the years ended June&#160;30, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net revenue by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,177,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,602,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;356,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue fair value adjustment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,196,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,957,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Depreciation and amortization by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets and corporate assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net operating profit by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,132,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;934,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,226,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,129,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,016,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reconciling items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue fair value adjustment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) loss on equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;960,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;883,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The deferred revenue fair value adjustment is a purchase price accounting adjustment related to MatrixCare which was acquired on November 13, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S., Canada and Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,070,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;863,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;841,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;779,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,981,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,705,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,572,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,382,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,078,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,926,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Combined Europe, Asia and other markets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;796,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;746,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;715,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;371,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,195,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,118,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,030,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Global revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,866,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,610,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,507,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,310,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,213,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,094,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,177,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,602,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,196,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,957,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue information by geographic area for the years ended June&#160;30, 2022, 2021 and 2020 is summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,249,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,962,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,328,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,234,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,128,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,196,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,957,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets of geographic areas are those assets used in our operations in each geographical area, and excludes goodwill, other intangible assets, and deferred tax assets. Long-lived assets by geographic area as of June&#160;30, 2022 and 2021 is summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzMyOTg1MzQ4ODU1MTU_1d36c621-febe-4851-8009-5e727ad476aa"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzIwNDQ_6f58e94b-e0f7-4589-aaf4-947dd0dd3a0c">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents a reconciliation of net revenues, depreciation and amortization and net operating profit by reportable segments for the years ended June&#160;30, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net revenue by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,177,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,602,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;356,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue fair value adjustment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,196,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,957,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Depreciation and amortization by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets and corporate assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;156,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net operating profit by segment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,132,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,036,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;934,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,226,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,129,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,016,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Reconciling items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;155,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;125,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;76,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred revenue fair value adjustment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense (income), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Loss attributable to equity method investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gain) loss on equity investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,515)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3,197)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2,362)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;960,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;883,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;The deferred revenue fair value adjustment is a purchase price accounting adjustment related to MatrixCare which was acquired on November 13, 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9615d030beef4655919952e7c42dddb0_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzItMS0xLTEtMjg3Njk_7e20d86e-fdb7-4a20-a042-7d67d18c3353"
      unitRef="usd">3177298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e575d821d774882967b5b2ac809400a_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzItMy0xLTEtMjg3Njk_cce1f64a-63d6-46e7-af4d-d06005549570"
      unitRef="usd">2823235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2565ea6b2b0f49e596d06ef86c0ee019_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzItNS0xLTEtMjg3Njk_1813016a-95c0-4c87-8a65-5621fa3e9802"
      unitRef="usd">2602381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <rmd:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment
      contextRef="i4f176c13cb464db58e7e974bbe583ad2_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzQtMS0xLTEtMjg3Njk_d6ff136e-9ea6-4ea3-aa3a-829768e7b7bb"
      unitRef="usd">400829000</rmd:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment>
    <rmd:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment
      contextRef="i9dd1b88dba5e4ed4b2bc90aa0129b7e1_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzQtMy0xLTEtMjg3Njk_0df029ee-cc35-43ed-9006-c07814463894"
      unitRef="usd">373590000</rmd:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment>
    <rmd:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment
      contextRef="i5bcaef51aed54c3cbc31f6f73f6fc4dc_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzQtNS0xLTEtMjg3Njk_c484b1c2-aa28-4a5e-ac7a-cd1d72d5d7d6"
      unitRef="usd">356734000</rmd:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment>
    <rmd:DeferredRevenueFairValueAdjustment
      contextRef="i0095199e4b29470582f73f47f8ae065a_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzUtMS0xLTEtMjg3Njk_951f17db-2099-4faa-bb0a-cf8674d7456a"
      unitRef="usd">0</rmd:DeferredRevenueFairValueAdjustment>
    <rmd:DeferredRevenueFairValueAdjustment
      contextRef="id8d1e579aaa5456ba8a0c4cb4315ddc8_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzUtMy0xLTEtMjg3Njk_81fa88d6-5483-4caf-bc77-b91a345a8829"
      unitRef="usd">0</rmd:DeferredRevenueFairValueAdjustment>
    <rmd:DeferredRevenueFairValueAdjustment
      contextRef="i46269d456ce141c8be9efcf422648c0d_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzUtNS0xLTEtMjg3Njk_0851f1a5-9be2-4fad-aa1c-2a5c2904566e"
      unitRef="usd">2102000</rmd:DeferredRevenueFairValueAdjustment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f176c13cb464db58e7e974bbe583ad2_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzYtMS0xLTEtMjg3Njk_0c75c916-202b-4ae2-86af-eff14290d4d2"
      unitRef="usd">400829000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9dd1b88dba5e4ed4b2bc90aa0129b7e1_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzYtMy0xLTEtMjg3Njk_1c374056-34d1-4b5d-a719-9f3b716af29b"
      unitRef="usd">373590000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bcaef51aed54c3cbc31f6f73f6fc4dc_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzYtNS0xLTEtMjg3Njk_7f3146ef-3b10-494d-9c57-cd72b217ae2b"
      unitRef="usd">354632000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzctMS0xLTEtMjg3Njk_676afb92-71e0-442f-b6f9-52fa658bb671"
      unitRef="usd">3578127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzctMy0xLTEtMjg3Njk_19ee5fcd-68f2-462f-a9f6-2c8ab272f5cd"
      unitRef="usd">3196825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzctNS0xLTEtMjg3Njk_4032e9ca-c571-4128-a07c-88a69d375cf2"
      unitRef="usd">2957013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9615d030beef4655919952e7c42dddb0_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEwLTEtMS0xLTI4NzY5_009784c2-8e15-4237-a627-d108bd048263"
      unitRef="usd">79367000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3e575d821d774882967b5b2ac809400a_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEwLTMtMS0xLTI4NzY5_b7314aa2-1cac-420b-8efb-e53fe52aed20"
      unitRef="usd">73151000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2565ea6b2b0f49e596d06ef86c0ee019_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEwLTUtMS0xLTI4NzY5_b08abc2e-0c25-4dd2-85bd-fb215c41d1ad"
      unitRef="usd">69444000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4f176c13cb464db58e7e974bbe583ad2_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzExLTEtMS0xLTI4NzY5_18fd156a-9f9d-4534-a109-a664082e666e"
      unitRef="usd">7315000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9dd1b88dba5e4ed4b2bc90aa0129b7e1_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzExLTMtMS0xLTI4NzY5_15639d27-9a9f-4b31-948f-a7cde524f953"
      unitRef="usd">5230000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5bcaef51aed54c3cbc31f6f73f6fc4dc_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzExLTUtMS0xLTI4NzY5_9325361b-20de-4487-8c03-61072f869d45"
      unitRef="usd">3850000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3b423ab980a64f30b1a30f8d6aab58ed_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEyLTEtMS0xLTI4NzY5_a4179cda-2e52-4f50-96e6-21c0cc2219b4"
      unitRef="usd">72927000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ic40263e3a7e448478aaec5362e3d5ac0_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEyLTMtMS0xLTI4NzY5_4b37547b-7835-4f7e-8fba-b50defb43475"
      unitRef="usd">78377000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5dc746d3d9604ed8b657848caa1d88b5_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEyLTUtMS0xLTI4NzY5_bfdfdc5d-ca28-478e-85e1-2f81d4b5b258"
      unitRef="usd">81556000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEzLTEtMS0xLTI4NzY5_e1272e33-64a1-4915-9cad-002fe64bed4b"
      unitRef="usd">159609000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEzLTMtMS0xLTI4NzY5_a17f8749-9e70-4565-9135-0acb63beef8a"
      unitRef="usd">156758000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzEzLTUtMS0xLTI4NzY5_f11d2a0a-5559-401c-a846-4987f1f60c2e"
      unitRef="usd">154850000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9615d030beef4655919952e7c42dddb0_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE2LTEtMS0xLTI4NzY5_be690ee7-3438-4409-8668-a9798522c73f"
      unitRef="usd">1132510000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3e575d821d774882967b5b2ac809400a_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE2LTMtMS0xLTI4NzY5_ed188bdc-6c67-4d28-afd8-9819264f5914"
      unitRef="usd">1036712000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2565ea6b2b0f49e596d06ef86c0ee019_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE2LTUtMS0xLTI4NzY5_5bea979c-050f-4609-a25c-e474d88792fd"
      unitRef="usd">934697000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4f176c13cb464db58e7e974bbe583ad2_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE3LTEtMS0xLTI4NzY5_1a44ddbe-da76-49e7-b3fc-eebfe7c0cfba"
      unitRef="usd">93821000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9dd1b88dba5e4ed4b2bc90aa0129b7e1_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE3LTMtMS0xLTI4NzY5_5db67901-7132-4e88-b4ed-7c6f064e4c2c"
      unitRef="usd">93037000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5bcaef51aed54c3cbc31f6f73f6fc4dc_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE3LTUtMS0xLTI4NzY5_86c12e4b-fdcd-46e2-8b49-893155c2e96e"
      unitRef="usd">82152000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i25c6b0cc200a4b599e158f399e3c9bc6_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE4LTEtMS0xLTI4NzY5_0b191cc2-8aba-4997-b1ad-e1cb634f2f4e"
      unitRef="usd">1226331000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic4aa667d360a42a0a82284e45233a24c_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE4LTMtMS0xLTI4NzY5_d50e69d3-f8f4-4f45-98a0-90e1b4b7851a"
      unitRef="usd">1129749000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0034c7a4e6a54939a36c81c60d8ae04f_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzE4LTUtMS0xLTI4NzY5_edf97cf8-970d-4f21-a957-16512b57fcaa"
      unitRef="usd">1016849000</us-gaap:OperatingIncomeLoss>
    <rmd:UnallocatedCorporateCosts
      contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIxLTEtMS0xLTI4NzY5_c16cca75-c7e3-4648-a31a-95c10f2bc8b0"
      unitRef="usd">155317000</rmd:UnallocatedCorporateCosts>
    <rmd:UnallocatedCorporateCosts
      contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIxLTMtMS0xLTI4NzY5_cc84c244-fa75-4e2f-91cd-9865c140f8d7"
      unitRef="usd">141193000</rmd:UnallocatedCorporateCosts>
    <rmd:UnallocatedCorporateCosts
      contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIxLTUtMS0xLTI4NzY5_e999843a-8136-42d3-8ee5-cbb0de21da95"
      unitRef="usd">125993000</rmd:UnallocatedCorporateCosts>
    <rmd:AmortizationOfAcquiredIntangibleAssets1
      contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIyLTEtMS0xLTI4NzY5_af24df31-5cf5-49d1-9eb7-6328a4eac4c2"
      unitRef="usd">70728000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <rmd:AmortizationOfAcquiredIntangibleAssets1
      contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIyLTMtMS0xLTI4NzY5_e0df6ff6-da01-4c10-bd40-4a373eec09b8"
      unitRef="usd">76205000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <rmd:AmortizationOfAcquiredIntangibleAssets1
      contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIyLTUtMS0xLTI4NzY5_1f106dac-2ea9-49c5-a3c8-3ddd53362a28"
      unitRef="usd">79695000</rmd:AmortizationOfAcquiredIntangibleAssets1>
    <us-gaap:RestructuringCharges
      contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIzLTEtMS0xLTI4NzY5_d85db423-2ae9-43ab-be19-c0b1da2c4552"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIzLTMtMS0xLTI4NzY5_ce0ef0f8-f6ab-496e-ac80-6930dc97298b"
      unitRef="usd">8673000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzIzLTUtMS0xLTI4NzY5_cf2952db-0e31-4de2-876f-94dfcca397ed"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI0LTEtMS0xLTI4NzY5_705c5c9b-0286-429e-ab62-e823567499b9"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI0LTMtMS0xLTI4NzY5_fdb9de49-2b3c-46dc-85ac-df04d291967d"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI0LTUtMS0xLTI4NzY5_4ca9542c-7440-4463-9293-4424ded6c1b2"
      unitRef="usd">-600000</us-gaap:LitigationSettlementExpense>
    <rmd:DeferredRevenueFairValueAdjustment
      contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI2LTEtMS0xLTI4NzY5_5749dc31-02b4-46ae-bfe1-926cce4dc317"
      unitRef="usd">0</rmd:DeferredRevenueFairValueAdjustment>
    <rmd:DeferredRevenueFairValueAdjustment
      contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI2LTMtMS0xLTI4NzY5_0179159d-8708-4453-9c80-5e7f534e4c41"
      unitRef="usd">0</rmd:DeferredRevenueFairValueAdjustment>
    <rmd:DeferredRevenueFairValueAdjustment
      contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI2LTUtMS0xLTI4NzY5_848bdec9-8b97-46b2-bf3a-8909d0708761"
      unitRef="usd">2102000</rmd:DeferredRevenueFairValueAdjustment>
    <us-gaap:InterestExpense
      contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI3LTEtMS0xLTI4NzY5_65bf1cc7-7df7-4e25-9cd8-acecf0a1e1c5"
      unitRef="usd">22312000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI3LTMtMS0xLTI4NzY5_c7cd3a49-90ca-4982-92a8-d3d9260d0a42"
      unitRef="usd">23627000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI3LTUtMS0xLTI4NzY5_45ff0835-38de-4027-9359-9d214ca38607"
      unitRef="usd">39356000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTEtMS0xLTI4NzY5_00fee2b7-9c3b-44a7-85aa-0c99c82a7944"
      unitRef="usd">8486000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTMtMS0xLTI4NzY5_9e915339-2919-4793-85c3-5605dea17247"
      unitRef="usd">11205000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTUtMS0xLTI4NzY5_5fcafc6e-b039-4a24-9c77-b9de8736b36f"
      unitRef="usd">25058000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTEtMS0xLTM4Mzc4_690206fc-f1c0-42a8-8f98-837dc59c835e"
      unitRef="usd">12202000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTMtMS0xLTM4Mzc4_43f2f49f-bd59-41b6-a0d9-ce3a37298bd9"
      unitRef="usd">-14515000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI4LTUtMS0xLTM4Mzc4_341a8546-4e46-49e9-961d-e43e9c1b5c43"
      unitRef="usd">14519000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI5LTEtMS0xLTI4NzY5_2d9d2d31-a723-4939-94e1-73f18e9a67bf"
      unitRef="usd">-3197000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI5LTMtMS0xLTI4NzY5_ec79a8c1-e5a2-4b91-91b3-ed3627d3681d"
      unitRef="usd">-301000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzI5LTUtMS0xLTI4NzY5_3d0d7fc7-de13-4d38-a132-08fa4df8b26d"
      unitRef="usd">-2362000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i9e1c0ad03d7d4d8fa4202c1d27736a06_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzMwLTEtMS0xLTI4NzY5_90d14428-d17a-4241-bfe3-70cff636ec52"
      unitRef="usd">960483000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i66b9fd36ceff4904b86492c7d4151d94_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzMwLTMtMS0xLTI4NzY5_7be746c5-e220-456a-8353-429e8d93dabc"
      unitRef="usd">883662000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia72906c5bbad4b54b69aa30cb6568e3e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTphMjEyNDJmOTgyZjY0Mzc1YTZkYTI1NTdjMDgzMWNkNi90YWJsZXJhbmdlOmEyMTI0MmY5ODJmNjQzNzVhNmRhMjU1N2MwODMxY2Q2XzMwLTUtMS0xLTI4NzY5_eff902fa-e74d-4833-b9c1-2e8609a42989"
      unitRef="usd">733088000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <rmd:ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzIwNDY_14cf95bc-cd47-43be-8286-ff03699dd7ab">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our net revenue disaggregated by segment, product and region for the years ended June&#160;30, 2022, 2021 and 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;U.S., Canada and Latin America&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,070,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;863,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;792,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;841,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;779,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,981,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,705,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,572,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,382,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,078,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,926,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Combined Europe, Asia and other markets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;796,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;746,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;715,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;399,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;371,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,195,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,118,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,030,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Global revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Devices&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,866,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,610,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,507,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Masks and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,310,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,213,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,094,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sleep and Respiratory Care&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,177,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,823,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,602,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Software as a Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;373,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,196,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,957,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</rmd:ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddb9b1ba3cc948fbbeafc80d5fb888c0_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzItMS0xLTEtMjg3Njk_6694a93d-54e5-41d1-ae82-0b8ddd34a732"
      unitRef="usd">1070420000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fdc782505914ae19cc4a5145a64302a_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzItMy0xLTEtMjg3Njk_7e406a41-8cc9-4351-9281-69083de9146f"
      unitRef="usd">863661000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie3506717407b495e8b465b435329e9fa_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzItNS0xLTEtMjg3Njk_4fe6c4e0-0023-4ff5-bb71-961550c041ee"
      unitRef="usd">792766000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i683f2eada0d04fcaad952c8b3d263517_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzMtMS0xLTEtMjg3Njk_438f5489-1b98-4240-b062-d6dccd776d17"
      unitRef="usd">911387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ceba21d091145f1abfd5e8ee8280f34_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzMtMy0xLTEtMjg3Njk_e7a3efd6-a32f-449c-8c9c-78de80429718"
      unitRef="usd">841452000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i028290f735164715bb94548227192afe_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzMtNS0xLTEtMjg3Njk_a020b048-4ebe-4a60-ad29-531db5304cd9"
      unitRef="usd">779561000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ad2b08ec7164637b1de52cff54bc7fc_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzQtMS0xLTEtMjg3Njk_15a3f6b0-0ea7-4163-a976-a28c2ae0874c"
      unitRef="usd">1981807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i768e903ad73a409983ef36a9cb3bcdd6_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzQtMy0xLTEtMjg3Njk_dc1d9ed2-c162-4ca1-a64b-df4f94e1a170"
      unitRef="usd">1705113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44e5f807c4204737a2770ffd84a1ef8f_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzQtNS0xLTEtMjg3Njk_5d6a54cf-1a2d-4695-bbbf-10696440cdee"
      unitRef="usd">1572327000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd4f488d02b44960a0dd40ec6011ee0a_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzUtMS0xLTEtMjg3Njk_5e0b2a60-67f8-4ea7-aaa7-063199613f5b"
      unitRef="usd">400829000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaeb162e7018f4f9389dece5e2798edd4_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzUtMy0xLTEtMjg3Njk_27719889-4302-40a3-88d1-1c51c05ff029"
      unitRef="usd">373590000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69ea25fdac2444049f2441242da65d68_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzUtNS0xLTEtMjg3Njk_75b453e6-d056-4458-ac63-1f18d090a174"
      unitRef="usd">354632000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i40bcfef9b6e54021ae8c2ff8aa045971_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzYtMS0xLTEtMjg3Njk_dfdab53c-5c31-4c2b-8f83-7fff444da122"
      unitRef="usd">2382636000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4299c9c5641b4278bb02f064ee36224e_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzYtMy0xLTEtMjg3Njk_15c8668a-5d85-4545-b1e6-637d34b05fef"
      unitRef="usd">2078703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5f83c48a7d8454394b43a87b7ab93e4_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzYtNS0xLTEtMjg3Njk_612bac24-fbbc-4fc6-83af-f5bdd54d8b06"
      unitRef="usd">1926959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic436f1cc5c3141c789df791a0cf3e876_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzktMS0xLTEtMjg3Njk_fd45fa68-faf7-4e6f-82e8-fdb78afa7658"
      unitRef="usd">796488000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88324fb286c04ba5950e6cd05648d664_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzktMy0xLTEtMjg3Njk_26695a16-c42e-4b2c-bd86-5ac5a5d53cdf"
      unitRef="usd">746379000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1959ef64c9d48daae526f9ad86dc1e1_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzktNS0xLTEtMjg3Njk_1fd27115-5782-4435-a9d2-2fbeeeb32049"
      unitRef="usd">715056000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i90adc12d32e34e8fb47d50b8d5bfd24e_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzEwLTEtMS0xLTI4NzY5_a9140573-f784-4630-a723-f246f806411e"
      unitRef="usd">399003000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id83a2708a5314366ab3b2d2063c1580c_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzEwLTMtMS0xLTI4NzY5_4ccc020b-c7d5-4285-a792-ffbed2ad637c"
      unitRef="usd">371743000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic087066b2dfa4a2e80b6055dc86ad478_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzEwLTUtMS0xLTI4NzY5_5b904f84-ce5c-43ba-a1e8-ea1cede760ba"
      unitRef="usd">314998000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf3b5cebac484aafa9c12aabc31f71fb_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzExLTEtMS0xLTI4NzY5_cdb8cfb7-5196-48be-adda-6f117eb0264d"
      unitRef="usd">1195491000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibfe214ef394c40078ff0a1c3b2002cd8_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzExLTMtMS0xLTI4NzY5_ce4c6ca7-e93b-4d93-bd57-5814c433bb37"
      unitRef="usd">1118122000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if7afa8a0a280436aaa2a6358ed31ae72_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzExLTUtMS0xLTI4NzY5_0caf8368-23d4-443b-971f-143743df9ca0"
      unitRef="usd">1030054000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafa91ad16e1d42898125c674a44f12c7_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE0LTEtMS0xLTI4NzY5_df20859c-0c11-4fb2-8a34-da2d0c3b0b46"
      unitRef="usd">1866908000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if750331b61d34ff6a35ce16115a39bd1_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE0LTMtMS0xLTI4NzY5_71d0a5be-3794-4881-95cb-f9fb5660e542"
      unitRef="usd">1610040000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20ac972a28ea4f66852dc6a23c05796a_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE0LTUtMS0xLTI4NzY5_6b0fe553-db5f-4ed6-9ca7-a4e8daed66ce"
      unitRef="usd">1507822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c0e3f2f8bd246a08869b10ecf87c8d4_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE1LTEtMS0xLTI4NzY5_3b793570-8baf-4c92-8672-1d10095fbe4c"
      unitRef="usd">1310390000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f9858995a6f4d25962cfd62c79b79f3_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE1LTMtMS0xLTI4NzY5_fd206006-1d77-4c27-8beb-aa6f1069fa3c"
      unitRef="usd">1213195000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idce2674b8c0341a2b7fc01fb9809ffb6_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE1LTUtMS0xLTI4NzY5_d4402c21-101e-4bac-9ff8-6fcb224e6f15"
      unitRef="usd">1094559000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i499a1d7dca454b16aab049bf997c138b_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE2LTEtMS0xLTI4NzY5_53ec5e07-7203-4513-b90f-1894e0c084d9"
      unitRef="usd">3177298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idbe3bf1b0b23497a9f774cd1b2469607_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE2LTMtMS0xLTI4NzY5_9d0e6955-b43f-42b1-9e6f-a2d6c43dd0d4"
      unitRef="usd">2823235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02220a87b54b4e30a843706e1e0d6a7e_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE2LTUtMS0xLTI4NzY5_e422032e-6701-4a63-ac4f-9c0a2a696de1"
      unitRef="usd">2602381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3f7bb52ca32454e94bfcd08e2c8c5f7_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE3LTEtMS0xLTI4NzY5_0f58ab89-3920-4189-ac11-c0ff995cdc4d"
      unitRef="usd">400829000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic07d827f23644728992537f14148e061_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE3LTMtMS0xLTI4NzY5_d9ccfb1a-3224-47ff-a181-5c43a6b41448"
      unitRef="usd">373590000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i337e5645c4c44331a1f07eba81269258_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE3LTUtMS0xLTI4NzY5_3acb0d9a-c23f-4942-93bd-899ec3aaef49"
      unitRef="usd">354632000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ceddc8dd80a49a4bd587e39d47f45e3_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE4LTEtMS0xLTI4NzY5_555e071c-6b23-4bd1-8dbf-acc60ca77076"
      unitRef="usd">3578127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf573c1bd70f41baafb0fa6b1cf4e06c_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE4LTMtMS0xLTI4NzY5_d0e9fa3a-38e3-48e5-8552-bb8cc0107670"
      unitRef="usd">3196825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cabc22c13c84f4f933c6296d351e8b4_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo5NjU4YzljODU5NWQ0NWRhYjc1NmZkMGNlOWUxMDBmZC90YWJsZXJhbmdlOjk2NThjOWM4NTk1ZDQ1ZGFiNzU2ZmQwY2U5ZTEwMGZkXzE4LTUtMS0xLTI4NzY5_d5d6e790-2823-4c77-940c-487b9a7bf13e"
      unitRef="usd">2957013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzIwNDc_6ac81370-fc71-49d5-823f-30e79eb004d7">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue information by geographic area for the years ended June&#160;30, 2022, 2021 and 2020 is summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.084%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,249,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,962,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,328,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,234,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,128,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,578,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,196,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,957,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if647eaf645944411be01eae84919f4b8_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzEtMS0xLTEtMjg3Njk_538bc06c-3bec-4d05-9f49-945c5d8dfad9"
      unitRef="usd">2249381000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc7308901fa84fdeb1d8b362b2f75a0d_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzEtMy0xLTEtMjg3Njk_825efd37-7b63-4fec-900c-d9d773dc9326"
      unitRef="usd">1962721000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac5bed93d8d840fca4ddaeae7fa58ef1_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzEtNS0xLTEtMjg3Njk_a5532df1-920e-4ab7-af3e-0aaaf882c599"
      unitRef="usd">1828575000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fa8a519bc734ac19f7310d6f9acfb13_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzItMS0xLTEtMjg3Njk_811fd0a6-59e4-4758-acbb-b17b8840acef"
      unitRef="usd">1328746000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24ea923c1eda4ec59fcf09d914cfe556_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzItMy0xLTEtMjg3Njk_9e0be08c-3dac-476e-86fc-4c320d8fc4fd"
      unitRef="usd">1234104000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d85bfd9205c4954829266c748d0e737_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzItNS0xLTEtMjg3Njk_1e1a5653-48d6-4020-a39a-717eeceba67d"
      unitRef="usd">1128438000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzMtMS0xLTEtMjg3Njk_61dbde4e-f6ee-4846-b038-6b14790d858f"
      unitRef="usd">3578127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzMtMy0xLTEtMjg3Njk_eed0f502-9b6f-4255-a6ca-1c70dadf3308"
      unitRef="usd">3196825000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo4NGE5OGMzMzcyYzE0YTljYTYxYmZkZmQ1YTVlMjBkYy90YWJsZXJhbmdlOjg0YTk4YzMzNzJjMTRhOWNhNjFiZmRmZDVhNWUyMGRjXzMtNS0xLTEtMjg3Njk_5ee9a902-deb7-46f4-ad47-ea022b0163f3"
      unitRef="usd">2957013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90ZXh0cmVnaW9uOmE5ZWQ5MGIwZjBkMDQ5M2M5NGJjODQ0OGY1MjQ5Yjk5XzIwNDg_7bb9057c-851d-4591-a420-e2e5a02edae5">Long-lived assets by geographic area as of June&#160;30, 2022 and 2021 is summarized below (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.083%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Australia&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;159,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Singapore&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rest of the World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;463,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets
      contextRef="i78fc5da4e0e04d37ac8a97438b29039d_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzEtMS0xLTEtMjg3Njk_435bc936-1846-47de-a63f-73c5f78b8d85"
      unitRef="usd">192833000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i5e84ef532ade41228f75e995126162ff_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzEtMy0xLTEtMjg3Njk_1663c8a1-f5e5-45b4-8588-9a55bd500a6d"
      unitRef="usd">186289000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i801dcbebc4da489dbeb89de396b518f1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzItMS0xLTEtMjg3Njk_6c96a81c-9e5f-4869-b534-96e7513cac6a"
      unitRef="usd">169090000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i93b19ef8b4f64d11a5fe3c85245bf6bd_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzItMy0xLTEtMjg3Njk_04448d62-b4d5-487d-be3b-f7d289cfbb87"
      unitRef="usd">159815000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="if07211d598314591ab29d17f48c0e9b1_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzMtMS0xLTEtMjg3Njk_05e31368-8fa1-4cde-b3f8-1f8a272bb139"
      unitRef="usd">72821000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i064d1782e2d845f99c9be5eafe7335b0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzMtMy0xLTEtMjg3Njk_f02c5f2b-68a9-45ed-8c1e-2c528e6ebde3"
      unitRef="usd">64182000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i5fc521c6602c417dab7cde075c1c6ca0_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzQtMS0xLTEtMjg3Njk_5bb30bfc-18ad-4094-9bf2-695bdca770fa"
      unitRef="usd">63309000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="iccd6677e07da4b36bdfc0d4628b747e6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzQtMy0xLTEtMjg3Njk_fe1000c9-b32b-4a5c-be85-7010ac8ac7bb"
      unitRef="usd">53204000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzUtMS0xLTEtMjg3Njk_e86cb03c-db97-47af-89ea-47fb5803449d"
      unitRef="usd">498053000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="iaeeb2746c953419385544cd7004bbac7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNDgvZnJhZzphOWVkOTBiMGYwZDA0OTNjOTRiYzg0NDhmNTI0OWI5OS90YWJsZTo0NzM0YWM3ZGQ0MDA0ZWJkYWY0MDU3OWFjYzM2ODgyMy90YWJsZXJhbmdlOjQ3MzRhYzdkZDQwMDRlYmRhZjQwNTc5YWNjMzY4ODIzXzUtMy0xLTEtMjg3Njk_b516dbe3-c4ab-49b4-b024-8f738372ff70"
      unitRef="usd">463490000</us-gaap:NoncurrentAssets>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzEyNDg_01c525d9-cffe-452e-8e62-8b787d5a52a3">Employee Retirement Plans &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We contribute to a number of employee retirement plans for the benefit of our employees. Details of the main plans are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Australia &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We contribute to defined contribution plans for each employee resident in Australia at the rate of approximately 10.0% of salaries. Employees may contribute additional funds to the plans. All Australian employees, after serving a qualifying period, are entitled to benefits on retirement, disability or death. Our total contributions to the plans for the years ended June&#160;30, 2022, 2021 and 2020, were $11.8 million, $10.7 million and $9.5 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;United States &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor a defined contribution plan available to substantially all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of 4.0% of the employee&#x2019;s salary. Our total contributions to the plan were $11.9 million, $9.6 million and $9.3 million in fiscal 2022, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Singapore &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor a defined contribution plan available to substantially all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of 17.0% of the employee&#x2019;s salary. Our total contributions to the plan were $3.1 million, $2.5 million and $2.9 million in fiscal 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent
      contextRef="i8a85455cff5b488bb43b5e15307964ce_D20210701-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTIzODM_877f1a4d-4e77-4687-aee8-f41f35f47e69"
      unitRef="number">0.100</rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i8a85455cff5b488bb43b5e15307964ce_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTIzODc_61d1783e-b17b-4eea-a81c-f6408374be32"
      unitRef="usd">11800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i2dc2d374954548eeae4da26ee6deb2da_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTIzOTE_ef3bb145-2aa9-46c5-a6ae-54935794d1d8"
      unitRef="usd">10700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i9d640c7e949347a48920659088e1b6d5_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTIzOTU_e1b16af2-7db8-46f1-aaff-f66bab377f91"
      unitRef="usd">9500000</us-gaap:DefinedContributionPlanCostRecognized>
    <rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent
      contextRef="if2897b37cef246bfbcd8a111b95babe4_D20210701-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0MTE_a6889b2c-e82c-49ae-9639-0d7c4fed2bbc"
      unitRef="number">0.040</rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="if2897b37cef246bfbcd8a111b95babe4_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0MTU_edf60f73-3ddf-4713-ad0f-a2930f57c3b4"
      unitRef="usd">11900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i3265cc74d27c4d9c9e39b63c16e194b9_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0MTk_68e8853b-9ec8-4e0a-bae8-c661dce75234"
      unitRef="usd">9600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i0a3c9df979694466b84d35627592feac_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0MjM_681dec84-4709-4354-84c4-2fa15a045957"
      unitRef="usd">9300000</us-gaap:DefinedContributionPlanCostRecognized>
    <rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent
      contextRef="i78253a41a7f9462cae9e61f99722631b_D20210701-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0NjY_2205cbec-32b2-4bcf-bd9b-94b52cbcaa9f"
      unitRef="number">0.170</rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i78253a41a7f9462cae9e61f99722631b_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0NzA_e7b00f22-efcc-42a9-9c9b-2281fe506436"
      unitRef="usd">3100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i38c21a3a43d242b5971df394c22e9de8_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0NzQ_5d4369ca-ab2c-410a-b795-ba617a9765ed"
      unitRef="usd">2500000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i21c42c4d4e154021ad486dec830521c6_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTEvZnJhZzo0Y2NhMjkxZTRkYjY0MjYxODc2YzEzZjhlZGJlZGE2MC90ZXh0cmVnaW9uOjRjY2EyOTFlNGRiNjQyNjE4NzZjMTNmOGVkYmVkYTYwXzQzOTgwNDY1MTI0Nzg_5b03e3e4-1fbc-491d-9532-afd44440acba"
      unitRef="usd">2900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzIwNTU_3e2590e7-e70d-4991-b891-d3352df436e3">Legal Actions, Contingencies and Commitments&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2021, New York University filed a complaint for patent infringement in the United States District Court, District of Delaware against ResMed Inc., case no. 1:21-cv-00813 (CFC). The complaint alleges that the AutoSet or AutoRamp features of ResMed&#x2019;s AirSense 10 AutoSet flow generators infringe one or more claims of various NYU patents, including U.S. Patent Nos. 6,988,994; 9,108,009; 9,168,344; 9,427,539; 9,533,115; 9,867,955; and 10,384,024. According to the complaint, the NYU patents are directed to systems and methods for diagnosis and treating sleeping disorders during different sleep states. The complaint seeks monetary damages and attorneys&#x2019; fees. ResMed answered the complaint on September 30, 2021 and filed a motion to dismiss the complaint on the basis that the patents are invalid because the subject matter of the patents is not patentable under the Supreme Court and Federal Circuit precedent. The motion to dismiss was granted in part and denied in part. The matter is proceeding to discovery. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 27, 2021, the International Trade Commission instituted In Re Certain UMTS and LTE Cellular Communications Modules and Products Containing the Same, Investigation No. 337-TA-1240, by complainants Philips RS North America, LLC and Koninklijke Philips N.V. (collectively &#x201c;Philips&#x201d;) against Quectel Wireless Solutions Co., Ltd; Thales DIS AIS USA, LLC, Thales DIS AIS Deutschland GmbH; Telit Wireless Solutions, Inc., Telit Communications PLC, CalAmp. Corp., Xirgo Technologies, LLC, and Laird Connectivity, Inc. (collectively &#x201c;respondents&#x201d;). In the ITC investigation, Philips seeks an order excluding communications modules, and products that contain them, from importation into the United States based on alleged infringement of 3G and 4G standard essential patents held by Philips. On October 6-14, 2021, the administrative law judge held a hearing on the merits. The administrative law judge issued an initial determination on April 1, 2022, finding no violation of any of the Philips patents asserted in the ITC. Philips sought review by the full International Trade Commission. On July 6, 2022, the Commission affirmed the administrative law judge&#x2019;s determination that there was no violation of asserted Philips patents. The Commission terminated the ITC proceedings. Philips may appeal the ITC&#x2019;s decision or return to the district court to pursue its civil case for damages and an injunction. On December 17, 2020, Philips filed companion cases for patent infringement against the same defendants in the United States District Court for the District of Delaware, case nos. 1:20-cv-01707, 01708, 01709, 01710, 01711, and 01713 (CFC) seeking damages, an injunction, and a declaration from the court on the amount of a fair reasonable and non-discriminatory license rate for the standard essential patents it is asserting against the communications module defendants. The district court cases have been stayed pending the resolution of the ITC proceedings. ResMed is not a party to the ITC investigation or the district court cases but sells products that incorporate some of the communications modules at issue in the cases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2022, Cleveland Medical Devices Inc. filed suit for patent infringement against ResMed Inc. in the United States District Court for the District of Delaware, case no. 1:22-cv-00794. Cleveland Medical asserts that numerous ResMed connected devices, when combined with ResMed&#x2019;s AirView and ResScan data platforms, infringe one or more of eight Cleveland Medical patents, including U.S. Patent Nos. 10,076,269; 10,426,399; 10,925,535; 11,064,937; 10,028,698; 10,478,118; 11,202,603; and 11,234,637. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on currently available information, we are unable to make a reasonable estimate of loss or range of losses, if any, arising from matters that remain open.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Obligations Under Recourse Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use independent financing institutions to offer some of our customers financing for the purchase of some of our products. Under these arrangements, if the customer qualifies under the financing institutions&#x2019; credit criteria and finances the transaction, the customers repay the financing institution on a fixed payment plan. For some of these arrangements, the customer&#x2019;s receivable balance is with limited recourse whereby we are responsible for repaying the financing company should the customer default. We record a contingent provision, which is estimated based on historical default rates. This is applied to receivables sold with recourse and is recorded in accrued expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended June&#160;30, 2022 and 2021, receivables sold with limited recourse were $157.6 million and $153.0 million, respectively. As of June&#160;30, 2022, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $24.2 million and $2.1 million, respectively. As of June&#160;30, 2021, the maximum exposure on outstanding receivables sold with recourse and contingent provision were $30.2 million and $8.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, we enter into agreements to purchase goods or services that are not cancelable without penalty, primarily related to supply arrangements. In addition, in June 2022 we signed a definitive agreement to acquire MEDIFOX DAN which is expected to close during our fiscal year 2023. The MEDIFOX DAN acquisition remains subject to regulatory clearances and other customary closing conditions. Upon closing, acquisition consideration will be paid, in part, with funds available for draw under our Revolving Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Obligations under our purchase agreements and the MEDIFOX DAN acquisition agreement at June&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Years Ending June&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum purchase obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,707,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,251,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;MEDIFOX DAN acquisition consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;994,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;994,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,702,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,245,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="ieaaf7972675048e690091ac44e072096_D20220616-20220616"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzMyOTg1MzQ5MjYxODA_743a2177-b7e8-4650-8187-8f2b36c6fe5c"
      unitRef="patent">8</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <rmd:ReceivablesSoldWithLimitedRecourse
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMxODE_09cfaeb3-6412-42c4-a5cb-f740e4fd56c3"
      unitRef="usd">157600000</rmd:ReceivablesSoldWithLimitedRecourse>
    <rmd:ReceivablesSoldWithLimitedRecourse
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMxODU_079b9b21-289c-45ad-aae2-3ea882b75b42"
      unitRef="usd">153000000</rmd:ReceivablesSoldWithLimitedRecourse>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMxODk_c2d26372-d551-4a95-8b9d-97f02226e5dc"
      unitRef="usd">24200000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMyNjM_bc511a55-49e6-4902-a789-5821e61c3f3e"
      unitRef="usd">2100000</us-gaap:LossContingencyAccrualProvision>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="i60b746abe48d479dab43b5fa3772e0b6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMyNjc_a869da0c-80c9-43df-b870-1b34bda667de"
      unitRef="usd">30200000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:LossContingencyAccrualProvision
      contextRef="i9fb6fd7632264f819733be6a8672d653_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzQzOTgwNDY1MTMyMDE_7337cd38-576c-4c10-8ea6-cd3f0831db9c"
      unitRef="usd">8200000</us-gaap:LossContingencyAccrualProvision>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90ZXh0cmVnaW9uOmRkNTAwOTg2ZjBiYTQxZWNhMzQwMmJkNGM3ZDYyODZmXzIwNTY_2d813be4-50eb-43b1-845e-c7e6d82a39e2">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Obligations under our purchase agreements and the MEDIFOX DAN acquisition agreement at June&#160;30, 2022 were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fiscal Years Ending June&#160;30&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Minimum purchase obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,707,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,251,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;MEDIFOX DAN acquisition consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;994,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;994,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,702,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,245,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItMS0xLTEtMjg3Njk_f8fff202-0046-4991-975f-c1cd3f09ff55"
      unitRef="usd">1707951000</us-gaap:PurchaseObligation>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItMy0xLTEtMjg3Njk_2c8d2b8c-11cf-462f-ac43-2007a6deecd9"
      unitRef="usd">1251476000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItNS0xLTEtMjg3Njk_a6b20b8c-6f27-4abf-aa7d-868f5d04331e"
      unitRef="usd">440067000</us-gaap:PurchaseObligationDueInSecondYear>
    <us-gaap:PurchaseObligationDueInThirdYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItNy0xLTEtMjg3Njk_ce3b69f0-4fab-471a-938e-826bfa756c47"
      unitRef="usd">13152000</us-gaap:PurchaseObligationDueInThirdYear>
    <us-gaap:PurchaseObligationDueInFourthYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItOS0xLTEtMjg3Njk_31b88ce7-4401-4d57-83ee-ff39a14a500f"
      unitRef="usd">1431000</us-gaap:PurchaseObligationDueInFourthYear>
    <us-gaap:PurchaseObligationDueInFifthYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItMTEtMS0xLTI4NzY5_6645e90d-f22d-42b6-9225-a1e425ed1533"
      unitRef="usd">0</us-gaap:PurchaseObligationDueInFifthYear>
    <us-gaap:PurchaseObligationDueAfterFifthYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzItMTMtMS0xLTI4NzY5_f35885b2-c87b-443a-af7a-24424c64b89a"
      unitRef="usd">1825000</us-gaap:PurchaseObligationDueAfterFifthYear>
    <us-gaap:OtherCommitment
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtMS0xLTEtNTM5NTM_75985930-5594-4555-bfb3-e9728ae23971"
      unitRef="usd">994245000</us-gaap:OtherCommitment>
    <us-gaap:OtherCommitmentDueInNextTwelveMonths
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtMy0xLTEtNTM5NTM_e4880aa6-0952-4544-abc5-9901a35d52e8"
      unitRef="usd">994245000</us-gaap:OtherCommitmentDueInNextTwelveMonths>
    <us-gaap:OtherCommitmentDueInSecondYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtNS0xLTEtNTM5NTM_e7b9d537-ef0e-45fa-a4fd-6db7127d7ca4"
      unitRef="usd">0</us-gaap:OtherCommitmentDueInSecondYear>
    <us-gaap:OtherCommitmentDueInThirdYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtNy0xLTEtNTM5NTM_c8cfaefc-89cd-40bb-9630-bc4e69c0151a"
      unitRef="usd">0</us-gaap:OtherCommitmentDueInThirdYear>
    <us-gaap:OtherCommitmentDueInFourthYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtOS0xLTEtNTM5NTM_2969147a-d0a1-40fd-8e2e-87cda8df5fa0"
      unitRef="usd">0</us-gaap:OtherCommitmentDueInFourthYear>
    <us-gaap:OtherCommitmentDueInFifthYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtMTEtMS0xLTUzOTUz_ff270439-9737-428d-9764-0aa9ef9d95ad"
      unitRef="usd">0</us-gaap:OtherCommitmentDueInFifthYear>
    <us-gaap:OtherCommitmentDueAfterFifthYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzMtMTMtMS0xLTUzOTUz_eceadaea-3342-4f8a-ab7d-704fd66d0c12"
      unitRef="usd">0</us-gaap:OtherCommitmentDueAfterFifthYear>
    <us-gaap:ContractualObligation
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtMS0xLTEtNTM5NTM_8cf6a3cf-c9d7-4ac4-8438-0c3cec06db0a"
      unitRef="usd">2702196000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtMy0xLTEtNTM5NTM_5f91bb3e-8164-4da7-b28a-c610948b84eb"
      unitRef="usd">2245721000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtNS0xLTEtNTM5NTM_a51919a0-0119-4e9e-9733-a3cf075473fc"
      unitRef="usd">440067000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtNy0xLTEtNTM5NTM_affcb191-4cae-4a90-9fa5-9a19e379fc43"
      unitRef="usd">13152000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtOS0xLTEtNTM5NTM_c479de26-4e87-400f-884d-5fc7b8c53f9a"
      unitRef="usd">1431000</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtMTEtMS0xLTUzOTUz_3cf235c4-16bb-4c88-a302-7d1e212353b9"
      unitRef="usd">0</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueAfterFifthYear
      contextRef="i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNTQvZnJhZzpkZDUwMDk4NmYwYmE0MWVjYTM0MDJiZDRjN2Q2Mjg2Zi90YWJsZTo5MmMyYTJjZjAzYzk0M2ZmYjc5YzMwYzMxZWEzZjM1Yi90YWJsZXJhbmdlOjkyYzJhMmNmMDNjOTQzZmZiNzljMzBjMzFlYTNmMzViXzQtMTMtMS0xLTUzOTUz_343ac9e0-8532-4c14-aef7-41715e64ae0a"
      unitRef="usd">1825000</us-gaap:ContractualObligationDueAfterFifthYear>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzE0NTU_9d363214-f03b-4559-8c7d-6456dc2f9292">Restructuring Expenses &lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, we closed our Portable Oxygen Concentrator business, which was part of the Sleep and Respiratory Care segment. During the year ended June 30, 2021, we recognized restructuring expenses of $13.9&#160;million primarily related to inventory write-downs of $5.2&#160;million, accelerated amortization of acquired intangible assets of $5.1&#160;million, asset impairments of $2.3&#160;million, employee-related costs of $0.7&#160;million and contract cancellation costs of $0.6&#160;million. Of the total expense recognized during year ended June 30, 2021, the inventory write-down of $5.2&#160;million is presented within cost of sales and the remaining $8.7&#160;million in restructuring costs is separately disclosed as restructuring expenses on the consolidated statements of operations. The restructure was completed as of June 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended June&#160;30, 2022 and 2020 we did not incur material restructuring expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCosts
      contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwMjI_c911dc95-ddfe-47a2-b7be-f30b69548ec2"
      unitRef="usd">13900000</us-gaap:RestructuringCosts>
    <us-gaap:InventoryWriteDown
      contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwMzc_f1d293ca-fce8-4cdb-9ec3-db660a7c2d72"
      unitRef="usd">5200000</us-gaap:InventoryWriteDown>
    <us-gaap:AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets
      contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwNTE_ba92233a-9da3-4f75-8d88-279c2fb01b5d"
      unitRef="usd">5100000</us-gaap:AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwNjU_e6f908a3-c3fa-4562-b507-40e02fac0836"
      unitRef="usd">2300000</us-gaap:AssetImpairmentCharges>
    <us-gaap:SeveranceCosts1
      contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwNzk_8e668d21-bae0-4959-8a3b-46cbaa0880a4"
      unitRef="usd">700000</us-gaap:SeveranceCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUwOTM_68a28adf-720a-4636-a9b1-8579a7ccd76d"
      unitRef="usd">600000</us-gaap:BusinessExitCosts1>
    <rmd:RestructuringAndRelatedCostCostOfSales
      contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUxMDc_421194a5-2f5f-4383-ae0f-054376270544"
      unitRef="usd">5200000</rmd:RestructuringAndRelatedCostCostOfSales>
    <us-gaap:RestructuringCharges
      contextRef="ic30d8c9044fb4e40a01228e07b665fad_D20200701-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUxMjE_f567664e-b955-4429-bfb4-aab697ef9e6a"
      unitRef="usd">8700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCosts
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUxNDE_6084e065-ede1-453f-b81d-2343e8ca4b69"
      unitRef="usd">0</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="if72cc941e4114d088386f9562860391b_D20190701-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjAvZnJhZzpjM2RlY2Q5ODM0ZDA0ZGZhYTdhNzM1ZmIwM2JmYjRlNC90ZXh0cmVnaW9uOmMzZGVjZDk4MzRkMDRkZmFhN2E3MzVmYjAzYmZiNGU0XzMyOTg1MzQ4ODUxNDE_b357e216-7e74-4d45-b73a-156eb1c1fca3"
      unitRef="usd">0</us-gaap:RestructuringCosts>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90ZXh0cmVnaW9uOmZiOTYzZGI1MzdlMTQxMjI4ZWJjODc5ZWFkZTNjZGE3XzYwMQ_94b7dee3-8406-4383-8d85-af2e2d9a65ba">&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SCHEDULE II&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RESMED INC. AND SUBSIDIARIES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;VALUATION AND QUALIFYING ACCOUNTS AND RESERVES&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022, 2021 and 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.085%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;Beginning&lt;br/&gt;of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Charged to costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;br/&gt;(deductions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at&lt;br/&gt;End of&lt;br/&gt;Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Applied against asset account&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allowance for trade accounts receivable &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11,499)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Applied against asset account&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allowance for trade accounts receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,680)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended June&#160;30, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Applied against asset account&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Allowance for trade accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt"&gt;Beginning balance is adjusted to reflect the cumulative pre-tax effect of adopting Accounting Standards Update No. 2016-13, &#x201c;Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments&#x201d; (Topic 326), effective July 1, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See accompanying report of independent registered public accounting firm.&lt;/span&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i88d0acfca2694a179ae914e7b68a3e34_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzMtMS0xLTEtMjg3Njk_972bdfef-429d-48b5-aac4-c2e368d700af"
      unitRef="usd">32138000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="iff6f98dd6cf448e09b965f01db37b08e_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzMtMy0xLTEtMjg3Njk_80459b1e-e5e8-4a4d-b3ed-145e325f3ce3"
      unitRef="usd">2620000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="iff6f98dd6cf448e09b965f01db37b08e_D20210701-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzMtNS0xLTEtMjg3Njk_7c521c8e-43e5-47ea-9acb-8cb0a43878a4"
      unitRef="usd">11499000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i89a45cd403ed4145a2219c018be81ad4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzMtNy0xLTEtMjg3Njk_196c566a-1872-4a93-9e35-b58c9a15cc3d"
      unitRef="usd">23259000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib8bfa1b0d361426ca8e6bfee5712cfe9_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzYtMS0xLTEtMjg3Njk_60c93c89-4a8b-4c77-a0ee-d16cb65b54e1"
      unitRef="usd">30013000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="id60995957b3746049536126104cd8336_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzYtMy0xLTEtMjg3Njk_2fefbb58-d82d-4540-8631-38a0d5ed10ce"
      unitRef="usd">7805000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="id60995957b3746049536126104cd8336_D20200701-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzYtNS0xLTEtMjg3Njk_78e5db47-11f3-43db-8c82-6987c3293651"
      unitRef="usd">5680000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i88d0acfca2694a179ae914e7b68a3e34_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzYtNy0xLTEtMjg3Njk_20d715fe-b3b3-41d9-84e2-1df97bc04c89"
      unitRef="usd">32138000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6c57ecbf703c4d4b8b48d4fd7f8af6fe_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzktMS0xLTEtMjg3Njk_01cfda94-dbb1-4e79-b0d0-c5d6267b7902"
      unitRef="usd">25171000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="ic5d3ead733d44cfc87b7a8de6f4c25ba_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzktMy0xLTEtMjg3Njk_55fa629b-feb0-496f-ba62-f539bae3c678"
      unitRef="usd">18283000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="ic5d3ead733d44cfc87b7a8de6f4c25ba_D20190701-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzktNS0xLTEtMjg3Njk_387c1569-7dcd-4c1b-a350-628a4f36c501"
      unitRef="usd">14946000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i3c161b6547684d3dbda4b1b823202c32_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjFmNjA5ODRiYjUxNTQ0YTQ4Mjg1MWIwOGQ0YTNiZjZiL3NlYzoxZjYwOTg0YmI1MTU0NGE0ODI4NTFiMDhkNGEzYmY2Yl8xNjYvZnJhZzpmYjk2M2RiNTM3ZTE0MTIyOGViYzg3OWVhZGUzY2RhNy90YWJsZTo3YzQ1MzY5YTllYzU0ZTIzODM0MGZmYzVkN2NhNDEzOC90YWJsZXJhbmdlOjdjNDUzNjlhOWVjNTRlMjM4MzQwZmZjNWQ3Y2E0MTM4XzktNy0xLTEtMjg3Njk_2729a14c-cfde-4846-a665-ea1f237ceb95"
      unitRef="usd">28508000</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #.I"U4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  SJ0M5%V;]W>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2@,Q$(9?17+?G20%T;#-1?'4@F!!\1:2:1O<[(9D9+=O[VYLMX@^@,?,_/GF
M&YC&1F7[A,^ICYC(8[X90]ME9>.:'8FB LCVB,'D>DIT4W/?IV!H>J8#1&,_
MS %!<GX+ <DX0P9F8!47(M.-L\HF--2G,][9!1\_4UM@S@*V&+"C#*(6P/0\
M,9[&MH$K8(81II"_"^@68JG^B2T=8.?DF/V2&H:A'E8E-^T@X&V[>2GK5K[+
M9#J+TZ_L%9TBKMEE\NOJX7'WQ+3D4E;\KA)RQX7B]TJ*]]GUA]]5./3.[_T_
M-KX(Z@9^W87^ E!+ P04    "  SJ0M5F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #.I"U4C_]T]'@<  &TN   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9IK;]LV&(7_"N$50PO$L4CYVB4&'+O9LC:I$:<MLF$?:(FQA4BB1U*Y_/N1
MDBU9*45+ _TE\>T]%A^3U#G2>_9,V2-?$R+ 2Q3&_+RU%F+SL=/AWII$F)_2
M#8GE.P^415C(IVS5X1M&L)\616$'.4Z_$^$@;HW/TM?F;'Q&$Q$&,9DSP),H
MPNSU@H3T^;P%6[L7;H/56J@7.N.S#5Z1!1'?-G,FGW5R%3^(2,P#&@-&'LY;
M$_AQY@Y40?J)[P%YYGN/@1K*DM)']>3*/V\YZHA(2#RA)+#\]T2F) R5DCR.
M?[>BK?P[5>'^XYWZ93IX.9@EYF1*PQ^!+];GK6$+^.0!)Z&XI<]_D.V >DK/
MHR%/_X+G[+/=;@MX"1<TVA;+(XB"./N/7[8@]@M@10':%J W!;#J&]QM@?NV
MH%]1T-T6=%,RV5!2#C,L\/B,T6? U*>EFGJ0PDRKY?"#6/WN"\'DNX&L$^,9
M]1+Y,PHPB7WP*1:!> 57<3:?U._2!M\6,_#^W8>SCI!?IXHZWE;Z(I-&%=(0
M@6L:BS67NC[QRP(=>9SYP:+=P5X@H^*?27P*7.<$( <AS0%-S>639'4*G&%E
M^<Q</B.>_':8ED/#:-P<O9OJN?\3_=^3)1=,+HQ_=.PS[:Y>6^T6'_D&>^2\
M);<#3M@3:8U__07VG=]TW&R*S2R)E9AV<Z9=DWK!].YU0W38S.70:7_6\3%6
M->5C2:S$IY?SZ=7C,XGC!(?@EFPH$SI09AW!$AW>J;&J*2A+8B50_1Q4OQZH
M.6$!5>O3!W*#U<XILU*^:57N6L;ZIM LB96@#7)H ^-0IPECBMEEP#TYN>X)
M9D9P9K5VV^FW74='S%C8E)@EL1*Q84YL:!SC=MN_#$(";I)H29B.DUG#<6 ;
M]EPXT)$REC8E94FL1&J4DQK5(75+5H$Z*\I9=H,C[:PRZ]P2?DU\>:+U3G6\
MC,5->5D2*_&"3N'LG#K$Y$@ID[M\:BI.P$+(Q0@H U.:Q(*]RO^^%N,!]=DG
M'3YS45-^MM3* />L,:P#\ Z_@"M?[FO!0^!EUJQZJ1Z0' W;#NRA81=JZ1F+
M&].SI%:FAPIZJ Z]B>]+=7ZR>P"^R,^!K[%^SIDE1W*K XN-C(PLB<!4_B2$
M@8OPR=<N9;-88YJ6U,HTBZP C;;Y)YI3]4RNXCOZ'&M)FN46. :S@*RH%IS5
M.&!+K0RN" 30;.G?@LOWOSFC3T'LZ>>A67,ZT6*SFA)LJ96Q%3D!F@W^6VQS
MRH6T='\%F^H3AEEQA"!RM=RLA@9;:F5N16R 9K?_TSK-SK):7F:E;PLM+*MA
MP99:&581%^"!O)"B8@17SRFSP+ WU$*RF@]LJ94A%0D!FNW]%ZJRU'Q-8U-$
M." R=/OMGN-HPY2YM#&M8X0$6*0$:+;W=X&048H^ (C>+S^ !?$2)F>9%IE9
M:4JC2%J]A:#>XPG8R"C[A,.$@'?.J>-TP49:#[[&3'L9Q"S=&.DQ<@0J<@0R
M._T[AOT@7H'%:[2DH8[D 8';ZYGV8JW5K&!+K0RIR K(;.QW$PU\>O'6.%Z1
MRGAZ0.CF?J%-5N:RQK2.D0U0D0U0K6SP@X1A^S&6%E8N5,SE#B>#.>>)?HL[
MH'E/N):;U11@2ZW,K4@!J%8*^$Y#Z2HPRRX<,=VX+PXHW6B=O[FH,:QC.']4
M.']4R_GO+DIFE[K3C4Q&@$0/S:Q8-<6L&G];:F5JA?%'M8S_E<K6V4U9=?D6
M[S!JJ9D5JZA9M?VVU,K4"MN/:MG^=#F"J4R8*ZHW_0=TOF F3QT3SR-22,KX
MF:26G]4D8$NMS*]( LALY+?\%A$.0W"1</DVUZ]0L\X##KG6D9GK&M,Z1B1
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M"DS2RPCZ5'5OM'071N_:=SSNM3%ZV_[<J&RIJ@8 _Z\TB/O^HGG X;VBV?\
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M[C;@?[^MJO;+A^X=UJ<WN]_\'U!+ P04    "  SJ0M5D:B<A4$*  "X+P
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MRK W'@9(U3I:&T:67EF6TEB=\LO<_GI N0"[OY+2[ QW0/LS2_\!4$L#!!0
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MIP/BN XJXV9UM31B9'R/0_(B9MB<5PMH[SL+7UX0>\C BOS1GLC4&);W#<T
M%JX=Z:4C([?4[1-##C:JVQNLD'A/5M.KFKEFZ5B.Z-C(TO&2B#B)&*9=C\B#
MYBU%>/B79EW0!++1."#NK*7',:6H00-CQ,2^K[Q9+EN[C%8_4'UK;?%W,I/%
MY0LV#9>77]-W+-AD?20^QB-@ TZJH9 Z/%NF68EYLUW0B$DX3U6"99@ ?-E9
M0R(E_*;(Q\;(A_]_R8_0'Q?3XL.1<]3-B39'!Q@,6@7/P1;TGSA1F*-C M$3
M$4(4U)U-T .6#<?GZ4D/@_1U\H2P30@;YN0@]&1Y2KAJF'\PN_*?0?8SX@'/
M3Q'QON1#[HL-"43'#H]RA&GQO<L&T+?N894+6L_V.JX?%I2S4,[  D#_A#^1
M!FQQ56TVX@#%Z^GVJT-7E)M5>#]^%.+'[!3R75"31%P0'_*UCNPW9(>G&Y=M
ML27Q0$5_=_RU6JB2#3<E+7J8;>9 ^4BA7?HA!!+) =!H2RG4(Z*"Y2B:(.GM
MDA!,.5 <F8J=:N <GYPI[V3.168O$IDD/UGL07ODW;2V#*./:X.$'. Z+;/_
MV+\@-&J_AG9ZS#(ZF5+\E8_.9V#O'K2<OV\GN2R-TOPTXYL;6FPA&&%W!U6G
M R.[!BT@25;#3'\BV-!P95]X%WW7MVP2-?3O-RP1C=V:6J@@O\741^<U+?Z<
MC,C!AK<5F?S90/B%N!"!PH(T8E"Q[P6)GEA7<4[)1Y:.91=?( S.TPN-HXGG
M")MIN@9D(4M84!3EMJS-'+0)P$%D>#Z'0P-LV( .3'HPYI?%*0?QKO?TC3_[
M2G[E7][*\X6@-7/#&4&,2,%G2UNX"1F5Z!@HFK O^J)X^>7+R>N7%_37]>6+
MR=7KJ^.#?VDH)JP3CR<QJ+]Z.;FF)R\O)J]>/R\^($.J*.RXW]C&JY [A"3Q
M :7K<,;&->=AT*O)JQ<7Q?7DBIQKF+,S]X,)\_$Z:=Q\74D0"[5[OR<?B?;3
MRXM7D^OK+\_PU^O)]>7EV<'HXC2,SN8\'#8D__3UR\F+ER]IWM>7DQ>OK\>F
MS<</IOZ84E7HYSQ%U6(L,W^]ML;W;33NFII!FH:FFKP:3H080^*NQA9VP=[/
M5Z996HDQU._!UA1+YTH2RU9=A43MXEBF2*X>L8TQGGF(JFCUQ<$.C#N4]HXS
M>[$20B=[!%*FSU:MW1QYSAU0"#LE ]G:&2+)2;(F$W(I%*CQ=LYT(;(W#52.
M]BKNFM4R.AVURU7V'?E)^#ABXQ*<2V-C&B:,Q<R $985%#]%!Q) ,-?GM&;5
M32(9X%;(9\M"@G; D_C/U#O%52A.@A- NH.#)+[0UJ?%7]R6V-9.LDW%52<X
M78KPP2AU0KMS,?N1"1/)%IL%0 ?6(^ L36;G.$(PY:^T8]YL(#7WQT9_,FU=
M2=@6<EGR7A[2_=D"]S@B!K0,K'5DPD!H1&SEF,2DB\BH/$P@HG&UX;PSDJ0U
MB<:BNM=(AX_\,=%-ASLW?E6D0#)(5SJD.U?WY)MH"$)"D@;3+F&&HEJRV_FM
MI\S<ML@OX2";7C(M<D2>J8HL/9C?&LI. CT)_0@LH5\K.@+..(BKP,>4@FG
M/Q3OT!3"AS6PI65KUA+P$J7]/,L[#?S6#C9%ML4!NNQ%HD290GPI)2]\^(&H
M.U/W-@2,84?A\"!TAQ'RE Y!Q@T99S+6!>R)#JC?E'NZHD&T$?A,@"0ZVXG
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M45@G5?TNB /WK?V87A;P*8E0:L6F>6//U+"8R:J:?*@IFGX]$ZB)^WV*[WJ
MQZ89J$!J"<>V;@!?D$LSC3;0-4NS0<ZAVIHPMT&WWWY5-?5D22$E=:<?6\ T
M^[6:W%4T6N:5:VOQ:D/.T9CB>!A[*2^90\I"O5?O,&B1@VP-G0$R_W28FW31
MG6;9XA4?64NSXYEL6. \/'>>BTTR:V*U)@.3=5@IR^&%C_F->%:&HWM)9"7$
M6^NUDFWB&&R\E_J16R[E0BS[U'V>5%*<4("+IY-76$0<4XN^%.S-.RVOC O
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MM[OPA#*U$2N'$(0G##+,9 57V#JJ%BW!.=!AV>(],8T:M#!3J[PR8A3+*J7
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MQR^/^)!M?<B.H?^_!!Z%/DS\F^W!]B2U#R"O&M +( 58(S<6T!<%4$IQF]*
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M1?71*99CAVEGRZF_ITR1>\IK( =DZH>3$WQ&4S](QQNJE!M0@EI:DWCJ1].
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M1I)%]88PYLWU@/>0M59U7UDX<*VYM T%>BV512C>P"M@>5@4I9NP,$X9W%$
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M-=D4CSUOEO&"X8N#OI ^FJX<SM;57!1TC//BPY=WOX@OAACN0IIO??'[X'S
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MOG;,B:[S?-FLUTP&.T;C0-#QR/ !Q7,DFV;./.^GSNEC:)L,1VU+ Q[>@RD
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MW.]ZWUO\W"ZMN'9^16^?B0M:0GUB'+UD\J'E6.!?77KJHWR"6WE6 &Y&JMH
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MS5PFF5)?W>!#L0IB1P@%YM8A +T>\ :%<$!$X]L1,QA".L?I=X_^J\^=<LG
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M"I%+[?U="O0 15KWPJAO+EUM)!(,B9W+QD>8Z* &R8GLC&BQWP5*A!3Q5BX
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M;VI>I*'9$G-*"=0%Q&.NE=T95(,HWAYD-8^5L@#8L$JZ.["D (2,7J\J%5O
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M9#_:W* CVQ746:DK>'//Q7;H5ADQMK?(B@'G,N+DC^#,<WAG--4.WN@2RX<
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M'ZTWX.\[8VA<^ #3GXC-/U!+ P04    "  SJ0M5(1P21^4#  "K"   &0
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M.% *O*V^>T/AG0=1O<$C<WXYSG(P\5H/?(M7PPHM>6W@#*(D(8PE*%&48EK
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M&UP1A78*>+Y2RNX?',!AZ9S_ U!+ P04    "  SJ0M5/ LU<I0$  !="P
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MT2'MBUOJUZ(EI[^LX**D"-!0*'#!M7X2<@W+6K72NMU=M&,1'+0Q'L'.F)!
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MJ2S"[ K> ,O#V6SN)BR,4P;WY(!>E:-TWENM*C2N#7 !%1*6 /$T!9:$+)O
M5RXZ!%[2I0/+7X;Z*M*FAW5)YVP2IEGLACQC\-"T0AT0J;$(;@E8*&,-)/,L
MG*83&N?A/)DZW8VRO6='2HWK";VP29C-<LC"A$W'VM32(F76PC2<SU*8A6DZ
M@[_5EI)5%X.JHNA:+HO#X#!E(5T62+)PGF?P03ZCM$H?P&62,F5J"TD2YG0V
M#1.*]9./BLSSF$$R"=E\"E^4=?)^K>0;2#.*ADI ,Q:'^7P.YRYE=-(]&M1;
MWR,-Z>ND[1O)N#NVX=N^^_PP[WOX1ZZWM30@L")H?#W- ]!]7^P75K6^%VV4
MI<[FISOZE:!V!G1>*;H4P\(Y&'].J_\!4$L#!!0    ( #.I"U5GIJV-Z0(
M '$&   9    >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;(U546_3,!#^*Z>
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M-&B"%@[S3MUYJX[]0)W/X(.LS5S#95V(XJF"(6+K ;(5P'.V5>-O3>U"X#G
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M)(#_Y\Z%[0T9V'VUNOX?4$L#!!0    ( #.I"U7LKN\8/0<  .H2   9
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M;6_:,!#^*U9:59L4-8D)KP4D**W6::RH+WO1M \F'(G5Q*:V4[I_O[,#*94
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M^Y4 @SO&).LF+X"$[KE'7)V#--T*^56E !I]SS.N9DZJ=7'INBI.(:?J0A3
MS9NUD#G5IBDWKBHDT*0*RC.7>%[HYI1Q9SZM^F[E?"I*G3$.MQ*I,L^I?%A
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MPX1[^?U)-/+[LX=M]G PNRF343 WFI,2>/R M*1<9;3VCN1?(T5C1KJ74'A
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MO9Z#LD8J7O5@G4%%6/?&CWT=]@"^_PS [P&^S;L3LEDNL,)I(GB+A-FMV<S
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MMH1)1*'0..\\U@2BZUU=H'AM^\6&*]U][+#4[1Z$V:#7"\[54V!:T/ #2?\
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MP=6 F'339YN)5:NZ5<V5I<97#POZ-$'M#.C_A5)V/W$O:#]VQO\#4$L#!!0
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M<OE<I.6;6LZ;Y_C<R[J6>?/R42134>H$ZO.95*&\?:,+6#V=ZNPO4$L#!!0
M   ( #.I"U4=*1R[:P,  ((1   9    >&PO=V]R:W-H965T<R]S:&5E=#4X
M+GAM;+6874_;,!2&_XJ5H0DD1K[:\K$V$I!-8X(-@=@NIEV8]+2U%MN9[5+X
M][.=$!J6AG8S-TWL^'WM\S@^M3-<</%+S@ 4NJ<YDR-OIE1QY/LRFP'%<H\7
MP/23"1<4*UT44U\6 O#8BFCN1T$P\"DFS$N&MNY2)$,^5SEA<"F0G%.*Q<,)
MY'PQ\D+OL>**3&?*5/C)L,!3N 9U4UP*7?)KES&AP"3A# F8C+SC\"@-8R.P
M+;X16,BE>V1"N>7\ERF<C4=>8$8$.63*6&!]N8-3R'/CI,?QNS+UZCZ-</G^
MT?VC#5X'<XLEG/+\.QFKV<@[\- 8)GB>JRN^^ 150'WCE_%<VE^T*-OV8P]E
M<ZDXK<1Z!)2P\HKO*Q!+@G"P0A!5@NBYH+="$%>">%U!KQ+T+)DR%,LAQ0HG
M0\$72)C6VLW<6)A6K<,GS,S[M1+Z*=$ZE9R#AB;1]A<L!#93L(.V4U"8Y'('
MO4,WURG:WMI!6X@P=$'R7,^5'/I*]VST?E;U<E+V$JWH)8S0!6=J)M$'-H9Q
MT\#70Z[''3V.^R3J=/P\9WLH#G91%$11RX!.UY>'+?)T?7G0$4U<ST)L_>*5
MLR EP"ZRL[&+4I"9((5=&#_.=5MTIH#*GVW@2^->N[')&D>RP!F,/)T6)(@[
M\)*W;\)!\+X-FDNSU)%9 VBO!MKK<D^^%F!>9S9%N4&*,BY5ZWM;VH2!]3%)
M\BZ)^WOQT+];YM+>JM]LE;:TB@9+K1J1].M(^AM&0BE1.O,JB1A7Z$'_-Y@Z
M8-GSA55&V/][5,'>_K, .\>PZ<0[,FO@&M2X!IVX+@@C=$[;0'0*-UTI+LU2
M1V8-8/LUL/W72CW[+H&Z-$L=F36 'M1 #SK?0 L2*1"T->%TBT.]GK%HX].I
MVY2/([,&G\.:S^&Z?';7RV#=?JN1=>HV1>;(K($L#)YV:4%W6L/WJ]):MW+3
M9>C4+77EUJ2VM+<-7RNW5<ZNJ+IT2UVY-:E&3U2C_TEP+ZC#GEVO;=+3;NG&
MF!RY-3$];>G#S@WN/^2Y%PS['>"<;MQ=N97@_*7#*04QM8=\J4G,F2K/>W5M
M_2'AV!Z?G]6?F \,]M#[9%-^G;C 8DJ8U#ODB;;4NUN] Q7E@;\L*%[8(_ M
M5_I ;6]G@,<@3 /]?,*Y>BR8#NK/+LD?4$L#!!0    ( #.I"U6N8:+BQ0(
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MOP&V6>A7%X19H.=7G*N7CGD(^G<\^PU02P,$%     @ ,ZD+59@1W1(J P
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M(D<(!>;6(3!Z;7&)0C@@HO%?AQGTGW2.^^,']'=>.VE9,8-+);[QPI:+8!9
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M6P&^OR? WP3XM>\&5+N\88;%8R771-G5J&8;=:IU-)KCA3V5F5$XRS'.Q'>
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M )IH"*4Q*(VC:*8JM4'@V!T"O"K?D4>1JZ&#ZJR)[RLYH-VL]%"7CTH6:C!
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M099I3RJ.'Y53IUY3&S;;&^^?#;R"N24"9BS[GB9R.7$B!R4P)T4F+]GZ+ZB
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MPFVV]K2=LO$D:NQM#U?/6LZ_&Q6Q+>:G]\"5.-IT32DX5N=V/?*9I!S=D*R
MSL/1>\DR_U+>GN:F(3SP;U?Z0B2Z7>J%S@VN%ADV?X;]00^/=G;8'LRAL/X6
MUM^OZ.]!5'H:-8O_8-3KA[M$UA4/)=H*%6R5 77]WP,H: %A'/2BP2[0:^@.
MO!4>V*X\K">!V NTK3YV"XT]AD,9M](#V[5'XT#8 V?0WK>HWPMVD5Y#A>"M
M#,%V'6(_&O:@#%L%Q/>"CI];>]Y.H7D*L!4@>/@[9\0EZ(]Q35<-S-0'$%?O
M9T&RS= _P'.44O0O$-[]5?5"*J1*Q6MH&KP5-=BN:AH[WLEJM\;H464)#5%>
M?DB&*"&/74F;[><HK!S9T+8R!]MUSOD#\#@5Y%9]>I>JY@.B(/7;H6H3DN3!
MJG9P6\>HUZ,M=^Q1_.H&NHW;AQSXPES*"!2S@LKR0[P>K2]^3LUUQ\[XF;X0
M,K<:6S?E;=)7PI4Z$"B#N7+I]8:JYO#R@J;L2+8R=QRW3$J6F^822 )<3U#/
MYXS)34<O4%^33?\'4$L#!!0    ( #.I"U7/I0/V? 0  $06   9    >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;+68;6^C.!#'OXK%GO9:Z39@TY#032*U
MV=Z3M&K5[MWJ7KIADJ "SMHF:;_]V4 @ >K0;-,7#3;,>'YC[/GCT8;Q)[$$
MD.@YCA(QMI92KBYM6\R6$%/18RM(U)TYXS&5JLD7MEAQH$%F%$<V<1S/CFF8
M6)-1UG?')R.6RBA,X(XCD<8QY2_7$+'-V,+6MN,^7"RE[K GHQ5=P /(?U9W
M7+7LTDL0QI"(D"6(PWQL7>'+*2':('OBWQ V8N<::91'QIYTXZ]@;#DZ(HA@
M)K4+JG[6,(4HTIY4'#\*IU8YIC;<O=YZ_SV#5S"/5,"41=_#0"['UM!" <QI
M&LE[MOD3"J"^]C=CD<C^HTWQK&.A62HDBPMC%4$<)ODO?2X2L6- ^J\8D,*
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MXJ)'Y,SS<5]FX\8-XT88;E@J5P*NTY"&50!'B5 H@1^5N,2MB+]OTCYX[@?
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M#MKY#HH6#H5VK.>^^;7=CR[2WO;[W>(/B18.A78L_KY-M_O[]/]0I%[K>R&
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M(.T 7NJP+<7K,.?(LXG1.V9<-+&Y@1?3HZE\H5S;EVAH5Q .LP_<**$VEBW
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M]?HJ*%XWKGHBV;(JY3,F56.HAIGJ]< U0.W/&9.;B3Z@_?<0_0502P,$%
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MT%7-C2P?4:ZJ:K\F 1M2ZV^ B<-!691V)]^U"L.0,3]NVN"F@[A7?"T-SX]
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MIH#^?<FY>OQB&MB^;[?X%U!+ P04    "  SJ0M55\GOSR8"  "H!   &0
M 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6R%5&UKVS 0_BM"@]'"B!PES49F
M&Y)V8RVTA(1M'\8^*/;9%K4E3Y+C[M]/+XZ709I]L772/<\]=[I3W$OUK"L
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M%V0'NS)FR3H*B0&((SD8]T;=!;;K7 F=3/<#@\Z:Y^DW@_4!:I?(*&6D7^2
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M..14?),L*>J_Z*'!X@&:K(HR6S3&<@2+.%W_C[XW@=@R(.X. ]H8T+8!WV'
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M1%.15P#Y_6V6E8]OJ@ML'J(<_0=02P,$%     @ ,ZD+52>LH11F P  L@T
M !D   !X;"]W;W)K<VAE971S+W-H965T.# N>&ULQ5==;]LV%/TK%UHQ), :
M2=2G,UM ''5;AG0+XF5]&/; 6->64(GT2,I.__U(25%M5S%25$!?+)&ZY_">
M0UZ:G.ZX^"AS1 5/5<GDS,J5VES:MESF6%%YP3?(])<5%Q55NBG6MMP(I%D#
MJDJ;.$YH5[1@5C)M^NY$,N6U*@N&=P)D7554?)ICR7<SR[6>.^Z+=:Y,AYU,
M-W2-"U0/FSNA6W;/DA45,EEP!@)7,^O*O4Q=QP":B+\+W,F]=S!2'CG_:!HW
MV<QR3$98XE(9"JH?6[S&LC1,.H__.E*K'], ]]^?V7]IQ&LQCU3B-2\_%)G*
M9U9L088K6I?JGN]^PTY08/B6O)3-+^RZ6,>"92T5KSJPSJ J6/ND3YT1>P W
M? % .@ Y!O@O +P.X+T6X'< OW&FE=+XD%)%DZG@.Q F6K.9E\;,!JWE%\S,
M^T()_;70.)4L<*UG4<$-:]>0F8NSA5Y=65TB_+F">]PBJQ'FG^!7Y&M!-WFQ
MA"N]QL[A+$5%BU*>PUMX6*1P]N8<WD#!X*^<UY*R3$YMI9,T0]G++J%YFQ!Y
M(2&7P'O.5"[A'<LP.R2PM;I>(GF6."<G&7^OV05XSD] '$(&$KI^/=P=@*>O
MASLGU'C]A'D-G_<"7S<?$E:"5_#N2:%@M(3K9JF@D*!MAUO.UF]O=4%E<"4E
M*@G_W&H>N%%8R7^')J4=U!\>U&P^EW)#ESBS].XB46S12G[\P0V=GX<,'9,L
M'8GLP&R_-]L_Q9[\H3=>T1H^9%H+#AJPV6"WB1=$L4NBJ;W=]V,@SIV$,0D.
MX](OX\@DB!S7Z^,.5 2]BN"DB@=6*+T2%HHJ'*S(D_"OG?PQR=*1R YL"WO;
MPN]1:>&89H])EHY$=F!VU)L=?4NEM>!POS*(/_%B]ZC2OHS3A48B<A27#L3%
M) ZB8+C2XEY%?%+%/4H%? 4J1_C 19D-:3E)\;4+8$RR="2R ^LFO763[U%M
MDS'-'I,L'8GLP&S7^7SL<[ZEWCKT_E^1ZY$X\L.C@AL*))[O.OY1Q0T%NB3V
MO?BHY.R]PZR>^'5S*9"PY#53[:&O[^TO'E?-<?NH?VXN),TA^3-->YMY3\6Z
M8!)*7&E*YR+268GV@M V%-\T1^9'KO3J:UYS?:E"80+T]Q7GZKEA!NBO:<G_
M4$L#!!0    ( #.I"U7B17)J> ,  !H0   9    >&PO=V]R:W-H965T<R]S
M:&5E=#@Q+GAM;,5876^C.!3]*Q8[&G6DG?)-H9,@M>E^=-755LUVYV$T#VZX
M"6B,S=A.TOGW:QM*H*6HU2#U);'AWN-[C@_D.K,]X]]$#B#1?4FHF%NYE-6I
M;8M5#B46QZP"JNZL&2^Q5%.^L47% 6<FJ22VYSB17>*"6NG,7+OFZ8QM)2DH
M7',DMF6)^8]S(&P_MUSKX<)-L<FEOF"GLPIO8 GRMKKF:F:W*%E1 A4%HXC#
M>FZ=N:<+-]0))N*_ O:B,T::RAUCW_3D,IM;CJX("*RDAL#J:P<+($0CJ3J^
M-Z!6NZ9.[(X?T'\WY!69.RQ@P<CG(I/YW(HME,$:;XF\8?L_H2%D"EPQ(LPG
MVC>QCH566R%9V22K"LJ"UM_XOA&BD^ &SR1X38+WT@2_2? -T;HR0^L"2YS.
M.-LCKJ,5FAX8;4RV8E-0O8U+R=7=0N7)= D;M2D27=+:$EK:HZ4R2[8E@/Y9
MHRM&-Q^OE-09.A,"I$#G/] ?P#8<5WFQ0F?*/.(#.KH B0NB1A_1[?("';W[
M@-ZA@J)_<[85F&9B9DM5KU[57C6UG=>U><_4]M>6'B/?^15YCN<.I"]>GN[T
MTVVE4BN5UTKE&3S_&;P;V '=@D!KSDKTV[T$3C%!"[-)P 52+ ?D^G*E<-"E
MA%)\'=*@7C087E0_Q:>BPBN86^HQ%<!W8*7O?W$CY].0(A.!]?3Q6WW\,?14
M4T?$4,>&^A#;&B(T$/H5LTN#)'9"?V;ONCP&PB(_2)PVK%=AT%88C%9XIK:*
M8U+@H<I&4U^[#Q.!]5B&+<OP+7P:3JG/1& ]?:)6G^CG?5I#1!T#NHD7^X]]
M.A 61UZ<#/OTI*WP9+3"6UI(5=U28@F#U8VFOW8O)@+K,8U;IO%;>#6>4I^)
MP'KZ)*T^R<][-7EJPBAQ.B_+FL= 6)C$;CCL5=<Y=!#.:(W+@FYPQ3@,_L*/
MYKYV*Z9"ZS/M]$KN6[BU674JC29"ZVMT:)+<T1[C98YM,+I>//%BW>3U'#L0
M%@5N[#WCV$.CXHYW*C<@)&)K)'- GQDGV6"-HQBOWI6)T/J,#XV/&[R)<R=M
MFJ9"ZVMT:)O<T:[CA<X-GW2FD>\[R6/G/@T+?<\)'CG7[AS<]*GY;\PW!16(
MP%KE.<<G"H#7!]%Z(EEESG)W3*J-,\-<'=Z!ZP!U?\V8?)CHXV'[=T#Z/U!+
M P04    "  SJ0M5F&TCU;\#  #Z$@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970X,BYX;6S%6%UOVS84_2N$5@P)L%D?5OR1V0;BJ,4Z+(,1+]M#T0?:NK:)
M4J1&TG'S[T=*LBRILN  3.L'FZ3N.>0],H_$.SEP\47N !3ZFE FI\Y.J?36
M=>5Z!PF6/9X"TU<V7"18Z:[8NC(5@.,,E% W\+R!FV#"G-DD&UN(V83O%24,
M%@+)?9)@\3('R@]3QW>. X]DNU-FP)U-4KR%):BG="%TSRU98I( DX0S)& S
M=>[\V\@/#2"+^(? 05;:R*2RXOR+Z7R,IXYG5@04ULI08/WS#/= J6'2Z_BO
M('7*.0VPVCZR?\B2U\FLL(1[3O\EL=I-G9&#8MC@/56/_/ [% G=&+XUIS+[
M1H<\=A@X:+V7BB<%6*\@(2S_Q5\+(2H ?W &$!2 H D(SP#Z!:!_*2 L )G4
M;IY*ID.$%9Y-!#\@8:(UFVED8F9HG3YAYKXOE=!7B<:IV?LDI?P% #V"(@+T
M'55H03&3Z.HO+ 0V=^4:746@,*'R&OV*GI81NGIWC=XAPM #H53?/CEQE5Z,
MH737Q<3S?.+@S,1^@!XX4SN)WK,8XCJ!J[,H4PF.J<R#3L8_]JR'^MXO*/""
MH&5!]Y?#_19X=#G<Z\BF7]Z8?L87GN%[8D1!C)8**VB5MQ-N[.)6IG@-4T?[
M@03Q#,[LYY_\@?=;FS0VR2)+9#79PE*V,&/OGY$M@HT>B=$<F&[E_V44$;FF
M7.X%H$]_ZLOHHX)$?FY3-;2IJDVRR!)93=6;4M6;SC_C L1:.X-^$""^06N]
M;P59[3/C7KT@M0,]EJ28Z3;/NN+D)JEQDS:I\RG]W)G,\^EYYO6\<.(^5S7L
M7-AK-;1$5M-P4&HXZ-3P;ZXPO40[.%KR)2+F<_I>143?[XT;(K9$C7N#>E#4
M&M3WJA^_A-0D&)82##LEN-//,X$IP6V9=$)?N_-LDD66R&J2C4K)1F_J9R.;
MJMHDBRR1U50=EZJ.O[^?C=O\S&_LQ,YUO59"2V0U"7WO].;H_0!#*R9M.MJH
MH>,Q+*R&>;UAP]/:PL:]FW8;\RLOS7YGZDO"MCCE EHSZ,2^=L]998MLL=5U
M"TZZ!6_J9@6]+6EMLD6VV.K2GHX+?O=YX4TLK9BSZ6G#YF:T>GRPQ587\G2
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MIQ#GG<MYH/C1[A8>N-)[#WM:Z-T>$6:"OK_G7#T-S :DW3]F_P!02P,$%
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M<VV@OB>,R7U'3]"4JHO_ %!+ P04    "  SJ0M5:_@#]E,#  "N%0  #0
M 'AL+W-T>6QE<RYX;6S=6%U/VS 4_2M1&!-($VF:D3:CK;150IJT34CPL#?D
M-DYKR;$SQV7M?OU\[33]P!<5'D99*XA]C\^YQ_9-8AC4>L7I[9Q2'2Q++NIA
M.->Z^A1%]71.2U)?R(H*@Q12E42;KII%=:4HR6L@E3SJ=CII5!(FPM% +,KK
M4M?!5"Z$'H;]-A2XR]=\&,;IQS!P<F.9TV%X?_;^UT+JJW>!NYY\.#GIW)]?
M[<?/+' >1E[1RP-$+SJXKL$PZ?0PZ2>U4?'>0>)/2&/"_5UA._K4Z#C>*4;+
M/#3C?\.$#D+N=?SD739.C[WT+:XE1DV5C0:%%)MB2T(7,,JDI,$#X<-P3#B;
M* :L@I2,KURX"X&IY%(%VE2Y215#I/[CX-CUX 9H=$HFI+*Y70;W>](,WP/6
M/3#(.&\-=D,7& TJHC55XMIT[& ;? 0%3?MN51F',T56<?<RW!#LQ2292)53
MU::)PW5H-."T #N*S>9PU;** -1:EJ:1,S*3@E@/:T;3,+)3RODM/!U^%CO:
MRV)KS^R&B[9I##5-)^,ZH+^MYK2W92]?I!M4[$'J+PLS'6'[<%_0&T4+MK3]
M9=$:P-1C7)U4%5]]YFPF2NHF?W#"T8"L><%<*O;'9(-2F9H 56'P0)5FT^W(
M;T6J.[K4ZW):%KCG[AOT_&_7>48%581OFS:U?\RK_&+'S>OT-3S;Q\J^8Z_)
MI'?\'ILCQ+&;3(_?9)(=O\?FX'7L)OMOP>1;V.[>JSW9GV,R/DJ347-<VSH3
M[IP(VV@ )^]A^ /.\'R3-)@L&-=,-+TYRW,J'AT,C;PF$_/'Z(Z^&9_3@BRX
MOFO!8;AI?Z<Y6Y19.^H&%J(9M6E_@^G%:7OL-[F8R.F2YN.FJV83VPQ,PV1M
M/D#81Z[MQX]@'(?Y$<"P/)@#C.-86)[_:3Y]=#X.P[SUO4@?Y?11CF/YD+']
M8GG\G,Q\_#/-LB1)4VQ%QV.O@S&V;FD*/WXUS!LPL#R0Z7EKC>\V7B%/UP&V
MIT]5"#93O!*QF>)K#8A_W8"19?[=QO(  ]L%K'8@OS\/U)2?DR2PJY@W[ [&
MD2S#$*A%?XVF*;(Z*7S]^X/=)4F297X$,+^#),$0N!MQ!', 'C D2>Q[<.]]
M%*W?4]'F/[2COU!+ P04    "  SJ0M5EXJ[',     3 @  "P   %]R96QS
M+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0
M"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#
ML%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S
M##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H
M5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( #.I"U7C .@.'@8  (\X   /
M    >&PO=V]R:V)O;VLN>&ULQ9M;;]LX$$;_BN"7;8'M.I9U<8NF0)JDW0!I
MDZV+[N."D6B;J$1Z*2J7_OI2,NP,:^7;?9GX*9'DR,=#:\X,R;R],_;[C3'?
MH_NZTLWQ:.7<^LUXW!0K68OF#[.6VE]9&%L+YP_M<MRLK11ELY+2U=4X/CK*
MQK50>O3N[?9>UW9,#XR3A5-&^Y/=B6]*WC6/U[O#Z%8UZD95RCT<C_K?*SF*
M:J55K7[(\GAT-(J:E;G[TUCUPV@GJGEA354=CR:;"]^D=:K8.SWO(+^*FZ8_
MX\3-%^%!CD?9D;_A0MG&]:_H[R\\XZWT+]X<M<Y\4)63]DPX^=&:=JWTLKN-
M_Q1C\C'Z.&Q_;H+XQOZ?,)K%0A7RS!1M+;7;Q-'*J@/4S4JMFU&D12V/1]N7
M1">ZC,ZU\T&*+O3F5OZUW2?U;WU1;CZU\[@DAO:-\A?L1=F#\T&>M*5R3V#%
M "OFQ3KUQZ92I7_W,GHO*J$+&?5CWA# *0"<'@PP>G$M"&0"()-GA)QW$-T?
M--'5PH]X80AD"B#3@T&>FGI-(#, F1T&TBS\D2D(9 X@\\-%4C0K CD#D+,#
M1O*?F$"^!I"O>2&O[%)H]:._T*?O]Z)1?2"OK6PD3=U'*'<?\6+.V[H6]J'C
MFJNE5O[/1.>;HC"M]PW%A(IA=LQG7RALF?32A]!H_WNQ&7@*B80S83;.O%VO
MJQY)5&%"[^U(,9%V)LS>^6A,>:>J*A+^6WGE5M)Z/"?TLN.(3B@F$L^$V3P7
M^E8V;F^ D68FS)[QWT#;^IQS?N]OTLB "YEEPJP6_SB4;>&BOX6U_NE5(1G2
MR839)V?RQE$69(T)LS8NI?AES) >)LQ^Z)S_?66J4MKFM^C\W];7]K1P1E*(
MF:5P+JSV:;:)KGUNF*^$I;J*D0=B9@]T-6<MHZ_B/AC)&/89W&E?+OL>[8D.
M"*7ZF#G5G]?KRCQ(&7V13ME>3=&U]U(0.Y3D8^8D?RF7WI4G_1Q!\[NOUGN_
M2UWX'.:K)HJ)$G_,G/B_>!-9GV%;VU4? ^D_1ND_9D[_<W^/LO7NOKB(OHFJ
M?:PY_VI%16NX&+D@9G8!+#6#LCU&FHB9-8$QIQ03^2/F]@<J-H-H3I%*ILPJ
M@<5FB(F\,F7WRJ[8C%Y\%?[-FY>4#?EERNR77ZO.04 XC\5LF?WR<Q 1>6;*
M[)FN#AV$0E:9,EME4Y .8B&=3+EU,E"9#D(BF4R99;)?H@XB(I%,F45":]5!
M.*2/*;<^]HO6(<8$N2-A=@<L#@-W),@=";,[<,&04$RDD81]=@IAIA03R21A
ME@FN:VCYE<!E$6:A8,Q@T)%B$F;%8,Q@T)%R$F;EX"HQ&'0DG819.A@S&'0D
MGH19/!@S&'2DH(1901@SHTN+R$(ILX6"UF#7:O?KG]T%BHDLE#YG!T,Q3U<^
MI'0"+T462IDM1#%?19^[CJ';>Q&].)-.J(IB(@NES!;:[[EH2.D:28HLE#);
M:*CS(J 4$R[/,UMHTWW1"'9G7@X-.K)0RFRA#>;N.[GC"RKB% DH91;0MF/\
M+T9DG_19EEG"X?[0NM9W:)^4IK.1*;)/RFR?(<RKM>S"JI?1)=TS@NR3L?=
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MPS^.7YYI;]KA.3];_CQQ\PM02P$"% ,4    "  SJ0M5!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M #.I"U479OW=[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( #.I"U697)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ,ZD+52/_
MW3T>!P  ;2X  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( #.I"U5:?-*H, (  *D%   8
M  " @6$/  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  S
MJ0M5+Y2T2@0(  "H(P  &               @(''$0  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ ,ZD+5>.&9HE< P   0L  !@
M         ("! 1H  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( #.I"U5ZB 0Y @@  &,D   8              " @9,=  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  SJ0M5NWX]WBL#  #$"0
M&               @('+)0  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ ,ZD+56Y6V<PA#   Y7T  !@              ("!+"D  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #.I"U61J)R%00H
M +@O   8              " @8,U  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    "  SJ0M5/7,[I98"  #8!@  &               @('Z
M/P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ,ZD+57F_
M1-\*!   T0@  !D              ("!QD(  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    "  SJ0M5E &5KUH?  #;7P  &0
M    @($'1P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M #.I"U5\)OL$VP,  #8)   9              " @9AF  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ ,ZD+5=S)X\8F!   .0D  !D
M             ("!JFH  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    "  SJ0M5Z8+?9"D%  #@#   &0              @($';P  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( #.I"U68E3=C P4
M *L-   9              " @6=T  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ ,ZD+51H<TA8F P  I 8  !D              ("!
MH7D  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  SJ0M5
MU6E&]?8"  "^!@  &0              @('^?   >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( #.I"U6[5OU6) L  ) A   9
M      " @2N   !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ ,ZD+5=*F/HT."0  6SD  !D              ("!AHL  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  SJ0M5[I-?=<T/  !$+0
M&0              @('+E   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( #.I"U7K3222VP,  )D)   9              " @<^D  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ ,ZD+560"0 GC
M#0  >",  !D              ("!X:@  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    "  SJ0M5]95X.8H(   5%@  &0
M@('[M@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #.I
M"U5Z&;[7O0,  /X)   9              " @;R_  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ ,ZD+5>IJR.2*#   >QX  !D
M         ("!L,,  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    "  SJ0M5>"M#?9,#  !0"   &0              @(%QT   >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #.I"U4A'!)'Y0,  *L(
M   9              " @3O4  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ ,ZD+5>K22;N3(   6&D  !D              ("!5]@
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    "  SJ0M5-L==
M@0D#  #_!@  &0              @($A^0  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( #.I"U5PAO35>00  ( *   9
M  " @6'\  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M,ZD+53P+-7*4!   70L  !D              ("!$0$! 'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    "  SJ0M5@].1G\<$  !V#0  &0
M            @('<!0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( #.I"U6&)"LW- ,  *@&   9              " @=H* 0!X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ,ZD+56>FK8WI @
M<08  !D              ("!10X! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    "  SJ0M5&:%SN*D"  #T!0  &0              @(%E
M$0$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #.I"U7Y
MJ\>5' 4  .L-   9              " @444 0!X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ ,ZD+51Q1.RP$!@  ;@\  !D
M     ("!F!D! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #.I"U4CF/'6S00  (4>   9              "
M@6,U 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ,ZD+
M57\5T5U' P  60T  !D              ("!9SH! 'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    "  SJ0M58R,_ Y8"  #T!@  &0
M        @('E/0$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( #.I"U40F3I"L (  &P'   9              " @;)  0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ,ZD+50/#;.W=!   HQP
M !D              ("!F4,! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    "  SJ0M5G=U4U9T#  ";#0  &0              @(&M2 $
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( #.I"U7I:,WF
MW ,  '01   9              " @8%, 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ ,ZD+509!U@#G P  J!8  !D
M ("!E% ! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  S
MJ0M515:V\9$"  !,!@  &0              @(&R5 $ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( #.I"U687+BOH@(  /8&   9
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M970U-2YX;6Q02P$"% ,4    "  SJ0M5=[@S8LH"  "_"   &0
M    @('W:@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    (
M #.I"U6>3<_%]PD  *EJ   9              " @?AM 0!X;"]W;W)K<VAE
M971S+W-H965T-3<N>&UL4$L! A0#%     @ ,ZD+51TI'+MK P  @A$  !D
M             ("!)G@! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"
M% ,4    "  SJ0M5KF&BXL4"  #3!P  &0              @('(>P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( #.I"U68$=T2*@,
M ',(   9              " @<1^ 0!X;"]W;W)K<VAE971S+W-H965T-C N
M>&UL4$L! A0#%     @ ,ZD+5<&.6(S/ @  ,0@  !D              ("!
M)8(! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    "  SJ0M5
M@1)JI(X"  !L!@  &0              @($KA0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8R+GAM;%!+ 0(4 Q0    ( #.I"U5DG0.=Q0(  -T'   9
M      " @?"' 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%
M  @ ,ZD+5;GFMP)U#@  "*4  !D              ("![(H! 'AL+W=O<FMS
M:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    "  SJ0M51L NQF$$   R$P
M&0              @(&8F0$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+
M 0(4 Q0    ( #.I"U7/I0/V? 0  $06   9              " @3"> 0!X
M;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ ,ZD+5:C!?F\$
M!0  G!H  !D              ("!XZ(! 'AL+W=O<FMS:&5E=',O<VAE970V
M-RYX;6Q02P$"% ,4    "  SJ0M5Q-=;;D<$  "B$P  &0
M@($>J $ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( #.I
M"U4^6)B DP(  . &   9              " @9RL 0!X;"]W;W)K<VAE971S
M+W-H965T-CDN>&UL4$L! A0#%     @ ,ZD+5<FF2<?1 P  NPT  !D
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M=#<T+GAM;%!+ 0(4 Q0    ( #.I"U5*O6OW\00  *\2   9
M  " @;O! 0!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @
M,ZD+55HRD[9Q!P  >S<  !D              ("!X\8! 'AL+W=O<FMS:&5E
M=',O<VAE970W-BYX;6Q02P$"% ,4    "  SJ0M55\GOSR8"  "H!   &0
M            @(&+S@$ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4
M Q0    ( #.I"U7D(BJ@!0@  (LP   9              " @>C0 0!X;"]W
M;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ ,ZD+51(;)^\B!P
M4#D  !D              ("!)-D! 'AL+W=O<FMS:&5E=',O<VAE970W.2YX
M;6Q02P$"% ,4    "  SJ0M5)ZRA%&8#  "R#0  &0              @(%]
MX $ >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( #.I"U7B
M17)J> ,  !H0   9              " @1KD 0!X;"]W;W)K<VAE971S+W-H
M965T.#$N>&UL4$L! A0#%     @ ,ZD+59AM(]6_ P  ^A(  !D
M     ("!R><! 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #.I"U5K^ /V4P,  *X5   -              "
M 3'[ 0!X;"]S='EL97,N>&UL4$L! A0#%     @ ,ZD+59>*NQS     $P(
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9>&UL4$L%!@    !> %X R1D   0+ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>268</ContextCount>
  <ElementCount>492</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003005 - Statement - Consolidated Statements Of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements Of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004006 - Statement - Consolidated Statements Of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Consolidated Statements Of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1005007 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements Of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements Of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1406401 - Statement - Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization And Basis Of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/OrganizationAndBasisOfPresentation</Role>
      <ShortName>Organization And Basis Of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary Of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary Of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/NewAccountingPronouncements</Role>
      <ShortName>New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2108104 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Goodwill and Other Intangible Assets, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet</Role>
      <ShortName>Goodwill and Other Intangible Assets, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2124107 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2127108 - Disclosure - Product Warranties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ProductWarranties</Role>
      <ShortName>Product Warranties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2130109 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2134110 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2142111 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2153113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2161114 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2168115 - Disclosure - Employee Retirement Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EmployeeRetirementPlans</Role>
      <ShortName>Employee Retirement Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2170116 - Disclosure - Legal Actions, Contingencies And Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LegalActionsContingenciesAndCommitments</Role>
      <ShortName>Legal Actions, Contingencies And Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2174117 - Disclosure - Restructuring Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/RestructuringExpenses</Role>
      <ShortName>Restructuring Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2176118 - Disclosure - Schedule II Valuation And Qualifying Accounts And Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReserves</Role>
      <ShortName>Schedule II Valuation And Qualifying Accounts And Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary Of Significant Accounting Policies (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy</Role>
      <ShortName>Summary Of Significant Accounting Policies (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Summary Of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary Of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SupplementalBalanceSheetInformation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Goodwill and Other Intangible Assets, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables</Role>
      <ShortName>Goodwill and Other Intangible Assets, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2320304 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/Investments</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/AccruedExpenses</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Product Warranties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ProductWarrantiesTables</Role>
      <ShortName>Product Warranties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/ProductWarranties</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/Debt</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2335308 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2343309 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2350310 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/EarningsPerShare</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2354311 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2362312 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2371313 - Disclosure - Legal Actions, Contingencies And Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsTables</Role>
      <ShortName>Legal Actions, Contingencies And Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LegalActionsContingenciesAndCommitments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Summary Of Significant Accounting Policies (Summary Of Contract Balances) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails</Role>
      <ShortName>Summary Of Significant Accounting Policies (Summary Of Contract Balances) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Supplemental Balance Sheet Information (Schedule Of Inventories) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails</Role>
      <ShortName>Supplemental Balance Sheet Information (Schedule Of Inventories) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Supplemental Balance Sheet Information (Schedule Of Prepaid Expenses and Other Current Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Supplemental Balance Sheet Information (Schedule Of Prepaid Expenses and Other Current Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Supplemental Balance Sheet Information (Components Of Property, Plant And Equipment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Supplemental Balance Sheet Information (Components Of Property, Plant And Equipment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule Of Other Intangible Assets, Net) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, net (Schedule Of Other Intangible Assets, Net) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Goodwill and Other Intangible Assets, net (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, net (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule Of Amortization Expense Related To Identifiable Intangible Assets, Including Patents) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets, net (Schedule Of Amortization Expense Related To Identifiable Intangible Assets, Including Patents) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Investments (Schedule Of Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails</Role>
      <ShortName>Investments (Schedule Of Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/InvestmentsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Investments (Schedule Of Changes In Equity Investments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails</Role>
      <ShortName>Investments (Schedule Of Changes In Equity Investments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/InvestmentsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Accrued Expenses (Schedule Of Accrued Expenses) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Schedule Of Accrued Expenses) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/AccruedExpensesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails</Role>
      <ShortName>Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/ProductWarrantiesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Debt (Schedule Of Debt) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DebtScheduleOfDebtDetails</Role>
      <ShortName>Debt (Schedule Of Debt) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/DebtTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2433417 - Disclosure - Debt (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/DebtTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2436418 - Disclosure - Leases (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LeasesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2437419 - Disclosure - Leases (Schedule Of Future Minimum Lease Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases (Schedule Of Future Minimum Lease Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LeasesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2438420 - Disclosure - Leases (Schedule Of Operating Lease Disclosure) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LeasesScheduleOfOperatingLeaseDisclosureDetails</Role>
      <ShortName>Leases (Schedule Of Operating Lease Disclosure) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LeasesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2439421 - Disclosure - Leases (Schedule Of Components Of Lease Revenue) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails</Role>
      <ShortName>Leases (Schedule Of Components Of Lease Revenue) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LeasesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2440422 - Disclosure - Leases (Schedule Of Sales-type Lease, Net Investment In Lease) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails</Role>
      <ShortName>Leases (Schedule Of Sales-type Lease, Net Investment In Lease) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LeasesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Leases (Schedule Of Maturities Of Sales-type Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails</Role>
      <ShortName>Leases (Schedule Of Maturities Of Sales-type Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LeasesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2444424 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquityTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2445425 - Disclosure - Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails</Role>
      <ShortName>Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquityTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Stockholders' Equity (Schedule Of Option Activity) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity (Schedule Of Option Activity) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquityTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Stockholders' Equity (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails</Role>
      <ShortName>Stockholders' Equity (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquityTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Stockholders' Equity (Schedule Of Total Stock-Based Compensation Costs Incurred And Associated Tax Benefit Recognized) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails</Role>
      <ShortName>Stockholders' Equity (Schedule Of Total Stock-Based Compensation Costs Incurred And Associated Tax Benefit Recognized) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/StockholdersEquityTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Earnings Per Share (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/EarningsPerShareTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/EarningsPerShareTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Income Taxes (Schedule Of Income Before Income Taxes Under The Jurisdictions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails</Role>
      <ShortName>Income Taxes (Schedule Of Income Before Income Taxes Under The Jurisdictions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Income Taxes (Schedule Of Provision For Income Taxes) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Schedule Of Provision For Income Taxes) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Income Taxes (Schedule Of Provision For Income Tax Differ From The Amount Of Income Tax) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails</Role>
      <ShortName>Income Taxes (Schedule Of Provision For Income Tax Differ From The Amount Of Income Tax) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2458434 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Liabilities Classified As Current And Non-Current) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails</Role>
      <ShortName>Income Taxes (Schedule Of Deferred Tax Assets And Liabilities Classified As Current And Non-Current) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2459435 - Disclosure - Income Taxes (Components Of Deferred Tax Assets And Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes (Components Of Deferred Tax Assets And Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2460436 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/IncomeTaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2463437 - Disclosure - Segment Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformationTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2464438 - Disclosure - Segment Information (Summary Of Revenue By Segment And Reconciling Items) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails</Role>
      <ShortName>Segment Information (Summary Of Revenue By Segment And Reconciling Items) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformationTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2465439 - Disclosure - Segment Information (Schedule Of Revenue By Segment, Product, And Region) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails</Role>
      <ShortName>Segment Information (Schedule Of Revenue By Segment, Product, And Region) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformationTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2466440 - Disclosure - Segment Information (Schedule Of Revenue By Geographic Area) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails</Role>
      <ShortName>Segment Information (Schedule Of Revenue By Geographic Area) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformationTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2467441 - Disclosure - Segment Information (Schedule Of Long-Lived Assets By Geographic Areas) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails</Role>
      <ShortName>Segment Information (Schedule Of Long-Lived Assets By Geographic Areas) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/SegmentInformationTables</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2469442 - Disclosure - Employee Retirement Plans (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails</Role>
      <ShortName>Employee Retirement Plans (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/EmployeeRetirementPlans</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2472443 - Disclosure - Legal Actions, Contingencies And Commitments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsNarrativeDetails</Role>
      <ShortName>Legal Actions, Contingencies And Commitments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2473444 - Disclosure - Legal Actions, Contingencies And Commitments (Obligations Under Purchase Agreements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails</Role>
      <ShortName>Legal Actions, Contingencies And Commitments (Obligations Under Purchase Agreements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsTables</ParentRole>
      <Position>84</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2475445 - Disclosure - Restructuring Expenses (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails</Role>
      <ShortName>Restructuring Expenses (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/RestructuringExpenses</ParentRole>
      <Position>85</Position>
    </Report>
    <Report instance="rmd-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2477446 - Disclosure - Schedule II Valuation And Qualifying Accounts And Reserves (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails</Role>
      <ShortName>Schedule II Valuation And Qualifying Accounts And Reserves (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReserves</ParentRole>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="rmd-20220630.htm">rmd-20220630.htm</File>
    <File>ex1010-formofexecutiverest.htm</File>
    <File>ex103-updatedformofexecuti.htm</File>
    <File>ex106-formofrestrictedstoc.htm</File>
    <File>ex107-formofstockoptiongra.htm</File>
    <File>ex108-formofstockoptiongra.htm</File>
    <File>ex109-formofpsuagreementfo.htm</File>
    <File>ex311-ceocertification.htm</File>
    <File>ex312-cfocertification.htm</File>
    <File>ex321-ceoandcfocertificati.htm</File>
    <File>exhibit211-subsidiaries.htm</File>
    <File>exhibit231-auditorconsent.htm</File>
    <File>rmd-20220630.xsd</File>
    <File>rmd-20220630_cal.xml</File>
    <File>rmd-20220630_def.xml</File>
    <File>rmd-20220630_lab.xml</File>
    <File>rmd-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>rmd-20220630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1108">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>112
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "rmd-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "contextCount": 268,
   "dts": {
    "calculationLink": {
     "local": [
      "rmd-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rmd-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "rmd-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "rmd-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rmd-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "rmd-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 720,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 61,
   "keyStandard": 431,
   "memberCustom": 32,
   "memberStandard": 42,
   "nsprefix": "rmd",
   "nsuri": "http://investor.resmed.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document And Entity Information",
     "role": "http://investor.resmed.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization And Basis Of Presentation",
     "role": "http://investor.resmed.com/role/OrganizationAndBasisOfPresentation",
     "shortName": "Organization And Basis Of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary Of Significant Accounting Policies",
     "role": "http://investor.resmed.com/role/SummaryOfSignificantAccountingPolicies",
     "shortName": "Summary Of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - New Accounting Pronouncements",
     "role": "http://investor.resmed.com/role/NewAccountingPronouncements",
     "shortName": "New Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rmd:SupplementalBalanceSheetInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108104 - Disclosure - Supplemental Balance Sheet Information",
     "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformation",
     "shortName": "Supplemental Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rmd:SupplementalBalanceSheetInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Goodwill and Other Intangible Assets, net",
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet",
     "shortName": "Goodwill and Other Intangible Assets, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Investments",
     "role": "http://investor.resmed.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124107 - Disclosure - Accrued Expenses",
     "role": "http://investor.resmed.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127108 - Disclosure - Product Warranties",
     "role": "http://investor.resmed.com/role/ProductWarranties",
     "shortName": "Product Warranties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130109 - Disclosure - Debt",
     "role": "http://investor.resmed.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2134110 - Disclosure - Leases",
     "role": "http://investor.resmed.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0002002 - Document - Audit Information",
     "role": "http://investor.resmed.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142111 - Disclosure - Stockholders' Equity",
     "role": "http://investor.resmed.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Earnings Per Share",
     "role": "http://investor.resmed.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153113 - Disclosure - Income Taxes",
     "role": "http://investor.resmed.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161114 - Disclosure - Segment Information",
     "role": "http://investor.resmed.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168115 - Disclosure - Employee Retirement Plans",
     "role": "http://investor.resmed.com/role/EmployeeRetirementPlans",
     "shortName": "Employee Retirement Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2170116 - Disclosure - Legal Actions, Contingencies And Commitments",
     "role": "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitments",
     "shortName": "Legal Actions, Contingencies And Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2174117 - Disclosure - Restructuring Expenses",
     "role": "http://investor.resmed.com/role/RestructuringExpenses",
     "shortName": "Restructuring Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2176118 - Disclosure - Schedule II Valuation And Qualifying Accounts And Reserves",
     "role": "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReserves",
     "shortName": "Schedule II Valuation And Qualifying Accounts And Reserves",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary Of Significant Accounting Policies (Policy)",
     "role": "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy",
     "shortName": "Summary Of Significant Accounting Policies (Policy)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Summary Of Significant Accounting Policies (Tables)",
     "role": "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary Of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001003 - Statement - Consolidated Balance Sheets",
     "role": "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Goodwill and Other Intangible Assets, net (Tables)",
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables",
     "shortName": "Goodwill and Other Intangible Assets, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rmd:ScheduleOfInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320304 - Disclosure - Investments (Tables)",
     "role": "http://investor.resmed.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "rmd:ScheduleOfInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Accrued Expenses (Tables)",
     "role": "http://investor.resmed.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Product Warranties (Tables)",
     "role": "http://investor.resmed.com/role/ProductWarrantiesTables",
     "shortName": "Product Warranties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - Debt (Tables)",
     "role": "http://investor.resmed.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2335308 - Disclosure - Leases (Tables)",
     "role": "http://investor.resmed.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343309 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://investor.resmed.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350310 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://investor.resmed.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2354311 - Disclosure - Income Taxes (Tables)",
     "role": "http://investor.resmed.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2362312 - Disclosure - Segment Information (Tables)",
     "role": "http://investor.resmed.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2371313 - Disclosure - Legal Actions, Contingencies And Commitments (Tables)",
     "role": "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsTables",
     "shortName": "Legal Actions, Contingencies And Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary Of Significant Accounting Policies (Narrative) (Details)",
     "role": "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary Of Significant Accounting Policies (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Summary Of Significant Accounting Policies (Summary Of Contract Balances) (Details)",
     "role": "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails",
     "shortName": "Summary Of Significant Accounting Policies (Summary Of Contract Balances) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i395a6823166d44c89daa1c281c702cd0_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Supplemental Balance Sheet Information (Schedule Of Inventories) (Details)",
     "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails",
     "shortName": "Supplemental Balance Sheet Information (Schedule Of Inventories) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Supplemental Balance Sheet Information (Schedule Of Prepaid Expenses and Other Current Assets) (Details)",
     "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Supplemental Balance Sheet Information (Schedule Of Prepaid Expenses and Other Current Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Supplemental Balance Sheet Information (Components Of Property, Plant And Equipment) (Details)",
     "role": "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails",
     "shortName": "Supplemental Balance Sheet Information (Components Of Property, Plant And Equipment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i60b746abe48d479dab43b5fa3772e0b6_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details)",
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails",
     "shortName": "Goodwill and Other Intangible Assets, net (Schedule Of Changes In Carrying Amount Of Goodwill) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule Of Other Intangible Assets, Net) (Details)",
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails",
     "shortName": "Goodwill and Other Intangible Assets, net (Schedule Of Other Intangible Assets, Net) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i383529560350461f9474da7a3e151953_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Goodwill and Other Intangible Assets, net (Narrative) (Details)",
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
     "shortName": "Goodwill and Other Intangible Assets, net (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i275c6f7ccc89416f8b114a73abdb1eb2_D20210701-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003005 - Statement - Consolidated Statements Of Income",
     "role": "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
     "shortName": "Consolidated Statements Of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Goodwill and Other Intangible Assets, net (Schedule Of Amortization Expense Related To Identifiable Intangible Assets, Including Patents) (Details)",
     "role": "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails",
     "shortName": "Goodwill and Other Intangible Assets, net (Schedule Of Amortization Expense Related To Identifiable Intangible Assets, Including Patents) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rmd:MarketableEquityInvestmentsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Investments (Schedule Of Investments) (Details)",
     "role": "http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails",
     "shortName": "Investments (Schedule Of Investments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rmd:MarketableEquityInvestmentsFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i60b746abe48d479dab43b5fa3772e0b6_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rmd:EquityInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Investments (Schedule Of Changes In Equity Investments) (Details)",
     "role": "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails",
     "shortName": "Investments (Schedule Of Changes In Equity Investments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfChangesInEquityInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "rmd:AdditionalEquityInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Investments - Narrative (Details)",
     "role": "http://investor.resmed.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyAccrualClassifiedCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Accrued Expenses (Schedule Of Accrued Expenses) (Details)",
     "role": "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued Expenses (Schedule Of Accrued Expenses) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyAccrualClassifiedCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i60b746abe48d479dab43b5fa3772e0b6_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details)",
     "role": "http://investor.resmed.com/role/ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails",
     "shortName": "Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "iaeeb2746c953419385544cd7004bbac7_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ProductWarrantyAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rmd:ShortTermDebtGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Debt (Schedule Of Debt) (Details)",
     "role": "http://investor.resmed.com/role/DebtScheduleOfDebtDetails",
     "shortName": "Debt (Schedule Of Debt) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "rmd:ShortTermDebtGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "rmd:DebtToConsolidatedEbitdaRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433417 - Disclosure - Debt (Narrative) (Details)",
     "role": "http://investor.resmed.com/role/DebtNarrativeDetails",
     "shortName": "Debt (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "rmd:DebtToConsolidatedEbitdaRatio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436418 - Disclosure - Leases (Narrative) (Details)",
     "role": "http://investor.resmed.com/role/LeasesNarrativeDetails",
     "shortName": "Leases (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437419 - Disclosure - Leases (Schedule Of Future Minimum Lease Payments) (Details)",
     "role": "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases (Schedule Of Future Minimum Lease Payments) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004006 - Statement - Consolidated Statements Of Comprehensive Income",
     "role": "http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "Consolidated Statements Of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438420 - Disclosure - Leases (Schedule Of Operating Lease Disclosure) (Details)",
     "role": "http://investor.resmed.com/role/LeasesScheduleOfOperatingLeaseDisclosureDetails",
     "shortName": "Leases (Schedule Of Operating Lease Disclosure) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeLeaseLeaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439421 - Disclosure - Leases (Schedule Of Components Of Lease Revenue) (Details)",
     "role": "http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails",
     "shortName": "Leases (Schedule Of Components Of Lease Revenue) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeLeaseLeaseIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:SalesTypeLeaseNetInvestmentInLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeLeaseLeaseReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440422 - Disclosure - Leases (Schedule Of Sales-type Lease, Net Investment In Lease) (Details)",
     "role": "http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails",
     "shortName": "Leases (Schedule Of Sales-type Lease, Net Investment In Lease) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:SalesTypeLeaseNetInvestmentInLeaseTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeLeaseLeaseReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Leases (Schedule Of Maturities Of Sales-type Leases) (Details)",
     "role": "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails",
     "shortName": "Leases (Schedule Of Maturities Of Sales-type Leases) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "icb4434050d394cafb018a6065a45a957_I20140221",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444424 - Disclosure - Stockholders' Equity (Narrative) (Details)",
     "role": "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "icb4434050d394cafb018a6065a45a957_I20140221",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i1e2263b05ec742b9a74b344a4f2f2337_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445425 - Disclosure - Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details)",
     "role": "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails",
     "shortName": "Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "ica54b0da1e614213bd2547419b667106_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i60b746abe48d479dab43b5fa3772e0b6_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Stockholders' Equity (Schedule Of Option Activity) (Details)",
     "role": "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails",
     "shortName": "Stockholders' Equity (Schedule Of Option Activity) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Stockholders' Equity (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details)",
     "role": "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails",
     "shortName": "Stockholders' Equity (Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i1e2f5bde60014f57b95e3dec354f034e_D20210701-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Stockholders' Equity (Schedule Of Total Stock-Based Compensation Costs Incurred And Associated Tax Benefit Recognized) (Details)",
     "role": "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails",
     "shortName": "Stockholders' Equity (Schedule Of Total Stock-Based Compensation Costs Incurred And Associated Tax Benefit Recognized) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Earnings Per Share (Narrative) (Details)",
     "role": "http://investor.resmed.com/role/EarningsPerShareNarrativeDetails",
     "shortName": "Earnings Per Share (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i607c9c75962444d08f128d8d1dd51b12_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005007 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "role": "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i607c9c75962444d08f128d8d1dd51b12_I20190630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details)",
     "role": "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails",
     "shortName": "Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Income Taxes (Schedule Of Income Before Income Taxes Under The Jurisdictions) (Details)",
     "role": "http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails",
     "shortName": "Income Taxes (Schedule Of Income Before Income Taxes Under The Jurisdictions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Income Taxes (Schedule Of Provision For Income Taxes) (Details)",
     "role": "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails",
     "shortName": "Income Taxes (Schedule Of Provision For Income Taxes) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Income Taxes (Schedule Of Provision For Income Tax Differ From The Amount Of Income Tax) (Details)",
     "role": "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails",
     "shortName": "Income Taxes (Schedule Of Provision For Income Tax Differ From The Amount Of Income Tax) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458434 - Disclosure - Income Taxes (Schedule Of Deferred Tax Assets And Liabilities Classified As Current And Non-Current) (Details)",
     "role": "http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails",
     "shortName": "Income Taxes (Schedule Of Deferred Tax Assets And Liabilities Classified As Current And Non-Current) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459435 - Disclosure - Income Taxes (Components Of Deferred Tax Assets And Liabilities) (Details)",
     "role": "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes (Components Of Deferred Tax Assets And Liabilities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxHolidayAggregateDollarAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460436 - Disclosure - Income Taxes (Narrative) (Details)",
     "role": "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxHolidayAggregateDollarAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463437 - Disclosure - Segment Information (Narrative) (Details)",
     "role": "http://investor.resmed.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2464438 - Disclosure - Segment Information (Summary Of Revenue By Segment And Reconciling Items) (Details)",
     "role": "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails",
     "shortName": "Segment Information (Summary Of Revenue By Segment And Reconciling Items) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i25c6b0cc200a4b599e158f399e3c9bc6_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465439 - Disclosure - Segment Information (Schedule Of Revenue By Segment, Product, And Region) (Details)",
     "role": "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails",
     "shortName": "Segment Information (Schedule Of Revenue By Segment, Product, And Region) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "rmd:ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i40bcfef9b6e54021ae8c2ff8aa045971_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements Of Cash Flows",
     "role": "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements Of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466440 - Disclosure - Segment Information (Schedule Of Revenue By Geographic Area) (Details)",
     "role": "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails",
     "shortName": "Segment Information (Schedule Of Revenue By Geographic Area) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "if647eaf645944411be01eae84919f4b8_D20210701-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i60b746abe48d479dab43b5fa3772e0b6_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467441 - Disclosure - Segment Information (Schedule Of Long-Lived Assets By Geographic Areas) (Details)",
     "role": "http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails",
     "shortName": "Segment Information (Schedule Of Long-Lived Assets By Geographic Areas) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i60b746abe48d479dab43b5fa3772e0b6_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NoncurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "if2897b37cef246bfbcd8a111b95babe4_D20210701-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2469442 - Disclosure - Employee Retirement Plans (Narrative) (Details)",
     "role": "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails",
     "shortName": "Employee Retirement Plans (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "if2897b37cef246bfbcd8a111b95babe4_D20210701-20220630",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "rmd:DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "ieaaf7972675048e690091ac44e072096_D20220616-20220616",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2472443 - Disclosure - Legal Actions, Contingencies And Commitments (Narrative) (Details)",
     "role": "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsNarrativeDetails",
     "shortName": "Legal Actions, Contingencies And Commitments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "ieaaf7972675048e690091ac44e072096_D20220616-20220616",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patent",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473444 - Disclosure - Legal Actions, Contingencies And Commitments (Obligations Under Purchase Agreements) (Details)",
     "role": "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails",
     "shortName": "Legal Actions, Contingencies And Commitments (Obligations Under Purchase Agreements) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i56b4a3bfff1a47d89f5ec94779d38a1a_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475445 - Disclosure - Restructuring Expenses (Narrative) (Details)",
     "role": "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails",
     "shortName": "Restructuring Expenses (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i88d0acfca2694a179ae914e7b68a3e34_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2477446 - Disclosure - Schedule II Valuation And Qualifying Accounts And Reserves (Details)",
     "role": "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails",
     "shortName": "Schedule II Valuation And Qualifying Accounts And Reserves (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i6c57ecbf703c4d4b8b48d4fd7f8af6fe_I20190630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1406401 - Statement - Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "role": "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "rmd-20220630.htm",
      "contextRef": "i870433195a3d4b7a8061e9accf81cbc1_D20210701-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 79,
   "tag": {
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_SG": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SINGAPORE",
        "terseLabel": "Singapore"
       }
      }
     },
     "localname": "SG",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r795",
      "r796",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r795",
      "r796",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r795",
      "r796",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r795",
      "r796",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "verboseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "verboseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "verboseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r795",
      "r796",
      "r797"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r794"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://investor.resmed.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "rmd_AccountsReceivableNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable Net [Member]",
        "label": "Accounts Receivable Net [Member]",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_AccruedInventoryInTransit": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued inventory in transit.",
        "label": "Accrued Inventory In Transit",
        "terseLabel": "Inventory in transit"
       }
      }
     },
     "localname": "AccruedInventoryInTransit",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_AccruedLogisticsAndOccupancyExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Logistics And Occupancy Expenses Current",
        "label": "Accrued Logistics And Occupancy Expenses Current",
        "terseLabel": "Logistics and occupancy costs"
       }
      }
     },
     "localname": "AccruedLogisticsAndOccupancyExpensesCurrent",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_AdditionalEquityInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Equity Investments",
        "label": "Additional Equity Investments",
        "terseLabel": "Net additions (reductions) to investments"
       }
      }
     },
     "localname": "AdditionalEquityInvestments",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_AllowanceForDoubtfulAccountsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for Doubtful Accounts [Policy Text Block]",
        "label": "Allowance For Doubtful Accounts [Policy Text Block]",
        "verboseLabel": "Allowance For Credit Losses"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsPolicyTextBlock",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rmd_AmendedAndRestated2009PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended And Restated 2009 Plan [Member]",
        "label": "Amended And Restated2009 Plan [Member]",
        "terseLabel": "Amended And Restated 2009 Plan"
       }
      }
     },
     "localname": "AmendedAndRestated2009PlanMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_AmortizationOfAcquiredIntangibleAssets1": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets.",
        "label": "Amortization of acquired intangible assets 1",
        "terseLabel": "Amortization of acquired intangible assets",
        "verboseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfAcquiredIntangibleAssets1",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://investor.resmed.com/20220630",
     "xbrltype": "stringItemType"
    },
    "rmd_BusinessAcquisitionContingentConsiderationRecognizedLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Contingent Consideration, Recognized Liability",
        "label": "Business Acquisition, Contingent Consideration, Recognized Liability",
        "negatedLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationRecognizedLiability",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_ClinicalDemonstrationAndRentalEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical, Demonstration and Rental Equipment [Member]",
        "label": "Clinical Demonstration And Rental Equipment [Member]",
        "terseLabel": "Clinical, demonstration and rental equipment"
       }
      }
     },
     "localname": "ClinicalDemonstrationAndRentalEquipmentMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_CombinedEuropeAsiaAndOtherMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined Europe Asia And Other Markets [Member]",
        "label": "Combined Europe Asia And Other Markets [Member]",
        "terseLabel": "Combined Europe, Asia and other markets"
       }
      }
     },
     "localname": "CombinedEuropeAsiaAndOtherMarketsMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components Of Net Deferred Income Tax Assets and Liabilities [Table Text Block]",
        "label": "Components Of Net Deferred Income Tax Assets And Liabilities [Table Text Block]",
        "terseLabel": "Schedule Of Deferred Tax Assets And Liabilities Classified As Current And Non-Current"
       }
      }
     },
     "localname": "ComponentsOfNetDeferredIncomeTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rmd_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Of Credit Risk And Significant Customers [Policy Text Block]",
        "label": "Concentration Of Credit Risk And Significant Customers [Policy Text Block]",
        "terseLabel": "Concentration Of Credit Risk And Significant Customers"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskAndSignificantCustomersPolicyTextBlock",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rmd_ContractWithCustomerAssetAndLiabilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Asset and Liability [Line Items]",
        "label": "Contract with Customer, Asset and Liability [Line Items]",
        "terseLabel": "Contract with Customer, Asset and Liability [Line Items]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityLineItems",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rmd_ContractWithCustomerAssetAndLiabilityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Asset and Liability [Table]",
        "label": "Contract with Customer, Asset and Liability [Table]",
        "terseLabel": "Contract with Customer, Asset and Liability [Table]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTable",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rmd_DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period",
        "label": "Debt Instrument, EBITDA Multiple of Trailing Twelve-Month Measurement Period",
        "terseLabel": "EBITDA multiple of trailing twelve-month measurement period"
       }
      }
     },
     "localname": "DebtInstrumentEBITDAMultipleOfTrailingTwelveMonthMeasurementPeriod",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rmd_DebtToConsolidatedEbitdaRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt To Consolidated EBITDA Ratio",
        "label": "Debt To Consolidated EBITDA Ratio",
        "terseLabel": "Debt to consolidated EBITDA ratio"
       }
      }
     },
     "localname": "DebtToConsolidatedEbitdaRatio",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rmd_DeferredPaymentObligationsForAcquisitions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Payment Obligations For Acquisitions",
        "label": "Deferred Payment Obligations For Acquisitions",
        "verboseLabel": "Deferred payments"
       }
      }
     },
     "localname": "DeferredPaymentObligationsForAcquisitions",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_DeferredRevenueFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue, fair value adjustment.",
        "label": "Deferred Revenue Fair Value Adjustment",
        "negatedLabel": "Deferred revenue fair value adjustment",
        "verboseLabel": "Deferred revenue fair value adjustment"
       }
      }
     },
     "localname": "DeferredRevenueFairValueAdjustment",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_DeferredTaxAssetsLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liabilities.",
        "label": "Deferred Tax Assets, Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiabilities",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right-of-use Assets.",
        "label": "Deferred Tax Liabilities, Right-of-use Assets",
        "negatedLabel": "Right of use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan Maximum Annual Contributions By Employer Percent",
        "label": "Defined Contribution Plan Maximum Annual Contributions By Employer Percent",
        "terseLabel": "Percentage of contribution by the company to the retirement plans"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsByEmployerPercent",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmd_DevelopedOrCoreProductTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed/ Core Product Technology [Member]",
        "label": "Developed Or Core Product Technology [Member]",
        "terseLabel": "Developed/core product technology"
       }
      }
     },
     "localname": "DevelopedOrCoreProductTechnologyMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_DevicesAndMasksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Devices And Masks [Member]",
        "label": "Devices And Masks [Member]",
        "terseLabel": "Total Sleep and Respiratory Care"
       }
      }
     },
     "localname": "DevicesAndMasksMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_DevicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Devices [Member]",
        "label": "Devices [Member]",
        "terseLabel": "Devices"
       }
      }
     },
     "localname": "DevicesMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Document And Entity Information [Abstract]",
        "label": "Document And Entity Information [Abstract]",
        "terseLabel": "Document And Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://investor.resmed.com/20220630",
     "xbrltype": "stringItemType"
    },
    "rmd_EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Uncertain Tax Position, Amount",
        "terseLabel": "Uncertain tax position"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationUncertainTaxPositionAmount",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_EmployeeStockPurchasePlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan Offering Period",
        "label": "Employee Stock Purchase Plan Offering Period",
        "terseLabel": "Employee stock purchase program offering period"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanOfferingPeriod",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rmd_EmployeeStockPurchasePlanPurchaseRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan Purchase rights [Member]",
        "label": "Employee Stock Purchase Plan Purchase Rights [Member]",
        "terseLabel": "ESPP purchase rights:"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanPurchaseRightsMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_EquityInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments",
        "label": "Equity Investments",
        "periodEndLabel": "Carrying value at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period"
       }
      }
     },
     "localname": "EquityInvestments",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_EquityInvestmentsTotalByMeasurementCategory": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments, Total by Measurement Category",
        "label": "Equity Investments, Total by Measurement Category",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EquityInvestmentsTotalByMeasurementCategory",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_EquityMethodInvestmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments",
        "label": "Equity Method Investments [Roll Forward]",
        "terseLabel": "Equity Method Investments [Roll Forward]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsRollForward",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rmd_GlobalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global [Member]",
        "label": "Global [Member]",
        "terseLabel": "Global revenue"
       }
      }
     },
     "localname": "GlobalMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_GoodwillAcquiredDuringPeriodIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill, Acquired During Period, Increase (Decrease)",
        "label": "Goodwill, Acquired During Period, Increase (Decrease)",
        "terseLabel": "Goodwill on acquisition"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriodIncreaseDecrease",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_IdentifiedIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified Intangible Assets [Member]",
        "label": "Identified Intangible Assets [Member]",
        "terseLabel": "Identified Intangible Assets"
       }
      }
     },
     "localname": "IdentifiedIntangibleAssetsMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_IncomeTaxExaminationGrossSettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Examination, Gross Settlement.",
        "label": "Income Tax Examination, Gross Settlement",
        "terseLabel": "Gross settlement"
       }
      }
     },
     "localname": "IncomeTaxExaminationGrossSettlement",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_IncomeTaxExaminationNetImpactOfSettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Examination, Net Impact of Settlement.",
        "label": "Income Tax Examination, Net Impact of Settlement",
        "terseLabel": "Net impact of settlement"
       }
      }
     },
     "localname": "IncomeTaxExaminationNetImpactOfSettlement",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_IncomeTaxExaminationPriorRemittancePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Examination, Prior Remittance Payments",
        "label": "Income Tax Examination, Prior Remittance Payments",
        "terseLabel": "Prior remittance payments"
       }
      }
     },
     "localname": "IncomeTaxExaminationPriorRemittancePayments",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_IncomeTaxExaminationRemittedFinalPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Examination, Remitted Final Payment",
        "label": "Income Tax Examination, Remitted Final Payment",
        "terseLabel": "Remitted final payment"
       }
      }
     },
     "localname": "IncomeTaxExaminationRemittedFinalPayment",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rmd_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rmd_LesseeOperatingLeaseLeaseNotYetCommencedCommitments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Not yet Commenced, Commitments",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Commitments",
        "terseLabel": "Operating lease commitments not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedCommitments",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_LessorLeaseRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Lease Revenue",
        "label": "Lessor, Lease Revenue",
        "totalLabel": "Total lease revenue"
       }
      }
     },
     "localname": "LessorLeaseRevenue",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_LineOfCreditFacilityCollateralPercentageOfTheCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Collateral, Percentage of the Company",
        "label": "Line of Credit Facility, Collateral, Percentage of the Company",
        "terseLabel": "Line of credit facility, collateral, percentage of the company"
       }
      }
     },
     "localname": "LineOfCreditFacilityCollateralPercentageOfTheCompany",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmd_MarketableEquityInvestmentsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "rmd_EquityInvestmentsTotalByMeasurementCategory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Equity Investments, Fair Value",
        "label": "Marketable Equity Investments, Fair Value",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "MarketableEquityInvestmentsFairValue",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable Securities [Member]",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_MasksAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Masks and Other",
        "label": "Masks and Other [Member]",
        "terseLabel": "Masks and other"
       }
      }
     },
     "localname": "MasksAndOtherMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_MaximumNumberOfSharesSubjectToAwardsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares subject to awards granted.",
        "label": "Maximum Number Of Shares Subject To Awards Granted",
        "terseLabel": "Maximum number of shares subject to awards granted (shares)"
       }
      }
     },
     "localname": "MaximumNumberOfSharesSubjectToAwardsGranted",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rmd_MufgUnionBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MUFG Union Bank [Member]",
        "label": "Mufg Union Bank [Member]",
        "terseLabel": "MUFG Union Bank"
       }
      }
     },
     "localname": "MufgUnionBankMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_MufgUnionBankNaAndWestpacBankingCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MUFG Union Bank NA and Westpac Banking Corporation [Member]",
        "label": "Mufg Union Bank Na And Westpac Banking Corporation [Member]",
        "terseLabel": "MUFG Union Bank NA and Westpac Banking Corporation"
       }
      }
     },
     "localname": "MufgUnionBankNaAndWestpacBankingCorporationMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_NonEmployeeDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Employee Director [Member]",
        "label": "Non Employee Director [Member]",
        "terseLabel": "Non Employee Director"
       }
      }
     },
     "localname": "NonEmployeeDirectorMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_NonMarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-marketable Securities [Member]",
        "label": "Non Marketable Securities [Member]",
        "terseLabel": "Non-marketable securities"
       }
      }
     },
     "localname": "NonMarketableSecuritiesMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Equity Interest in Acquiree Held Prior to Combination",
        "label": "Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Equity Interest in Acquiree Held Prior to Combination",
        "negatedLabel": "Previously held equity interest"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationEquityInterestInAcquireeHeldPriorToCombination",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_NoncashPartOfAcquisitionFairValueOfAssetsAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of an asset or business acquired in a noncash acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash Part Of Acquisition, Fair Value of Assets Acquired",
        "terseLabel": "Fair value of assets acquired, excluding cash"
       }
      }
     },
     "localname": "NoncashPartOfAcquisitionFairValueOfAssetsAcquired",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_NumberOfCommonStockGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock shares granted.",
        "label": "Number Of Common Stock Granted",
        "terseLabel": "Number of common stock shares granted in participant's initial year of hiring (shares)"
       }
      }
     },
     "localname": "NumberOfCommonStockGranted",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rmd_NumberOfOfferings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Offerings",
        "label": "Number of Offerings",
        "terseLabel": "Number of offerings"
       }
      }
     },
     "localname": "NumberOfOfferings",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "rmd_ObservablePriceAdjustmentsOnNonMarketableEquitySecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Observable price adjustments on non-marketable equity securities.",
        "label": "Observable price adjustments on non-marketable equity securities",
        "terseLabel": "Observable price adjustments on non-marketable equity securities"
       }
      }
     },
     "localname": "ObservablePriceAdjustmentsOnNonMarketableEquitySecurities",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_OperatingLossCarryforwardsCapitalLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards capital loss.",
        "label": "Operating Loss Carryforwards Capital Loss",
        "terseLabel": "Capital loss"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsCapitalLoss",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant.",
        "label": "Percentage Of Purchase Price Of Common Stock Lower Than The Fair Market Value Of Common Stock On The Date Of Grant",
        "verboseLabel": "Percentage of purchase price of common stock lower than the fair market value of common stock on the date of grant"
       }
      }
     },
     "localname": "PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfGrant",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmd_PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase.",
        "label": "Percentage Of Purchase Price Of Common Stock Lower Than The Fair Market Value Of Common Stock On The Date Of Purchase",
        "verboseLabel": "Percentage of purchase price of common stock lower than the fair market value of common stock on the date of purchase"
       }
      }
     },
     "localname": "PercentageOfPurchasePriceOfCommonStockLowerThanFairMarketValueOfCommonStockOnDateOfPurchase",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmd_PercentageOfRecognizedTaxBenefitForUncertainTaxPosition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage threshold, above which a tax benefit would be recognized.",
        "label": "Percentage Of Recognized Tax Benefit For Uncertain Tax Position",
        "terseLabel": "Percentage of recognized tax benefit for uncertain tax position"
       }
      }
     },
     "localname": "PercentageOfRecognizedTaxBenefitForUncertainTaxPosition",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "rmd_PortableOxygenConcentratorBusinessClosureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portable Oxygen Concentrator Business Closure [Member]",
        "label": "Portable Oxygen Concentrator Business Closure [Member]",
        "terseLabel": "Portable Oxygen Concentrator Business Closure"
       }
      }
     },
     "localname": "PortableOxygenConcentratorBusinessClosureMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_PrepaidInventory": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Inventory",
        "label": "Prepaid Inventory",
        "terseLabel": "Prepaid inventories"
       }
      }
     },
     "localname": "PrepaidInventory",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_PrepaidTaxesAndOtherNonCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Taxes And Other Non Current Assets [Member]",
        "label": "Prepaid Taxes And Other Non Current Assets [Member]",
        "terseLabel": "Prepaid taxes and other non-current assets"
       }
      }
     },
     "localname": "PrepaidTaxesAndOtherNonCurrentAssetsMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_ReceivablesSoldWithLimitedRecourse": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables Sold With Limited Recourse",
        "label": "Receivables Sold With Limited Recourse",
        "terseLabel": "Receivables sold with limited recourse"
       }
      }
     },
     "localname": "ReceivablesSoldWithLimitedRecourse",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_ReclassificationsInEquityInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassifications In Equity Investments",
        "label": "Reclassifications In Equity Investments",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "ReclassificationsInEquityInvestments",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_ReductionInNumberOfSharesOfCommonStockAvailableForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares of common stock available for issuance.",
        "label": "Reduction In The Number Of Shares Of Common Stock Available For Issuance",
        "verboseLabel": "Reduction in the number of shares of common stock available for issuance (shares)"
       }
      }
     },
     "localname": "ReductionInNumberOfSharesOfCommonStockAvailableForIssuance",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "rmd_ResmedInc2009IncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ResMed Inc 2009 Incentive Award Plan [Member]",
        "label": "Resmed Inc2009 Incentive Award Plan [Member]",
        "terseLabel": "2009 Plan"
       }
      }
     },
     "localname": "ResmedInc2009IncentiveAwardPlanMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_ResmedLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ResMed Limited [Member]",
        "label": "Resmed Limited [Member]",
        "terseLabel": "ResMed Limited"
       }
      }
     },
     "localname": "ResmedLimitedMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_RestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest Of World [Member]",
        "label": "Rest Of World [Member]",
        "terseLabel": "Rest of the World"
       }
      }
     },
     "localname": "RestOfWorldMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_RestructuringAndRelatedCostCostOfSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring And Related Cost, Cost Of Sales",
        "label": "Restructuring And Related Cost, Cost Of Sales",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostOfSales",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Contract With Customer, Excluding Assessed Tax, Before Deferred Revenue Fair Value Adjustment",
        "label": "Revenue From Contract With Customer, Excluding Assessed Tax, Before Deferred Revenue Fair Value Adjustment",
        "terseLabel": "Revenue before deferred revenue fair value adjustment"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxBeforeDeferredRevenueFairValueAdjustment",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Agreement, Term Credit Agreement, And Senior Notes [Member]",
        "label": "Revolving Credit Agreement Term Credit Agreement And Senior Notes [Member]",
        "terseLabel": "Revolving Credit Agreement, Term Credit Agreement, And Senior Notes"
       }
      }
     },
     "localname": "RevolvingCreditAgreementTermCreditAgreementAndSeniorNotesMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_RevolvingCreditFacilityAndTermLoanCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revolving Credit Facility And Term Loan Credit Agreement [Member]",
        "label": "Revolving Credit Facility And Term Loan Credit Agreement [Member]",
        "terseLabel": "Revolving Credit Facility And Term Credit Agreement"
       }
      }
     },
     "localname": "RevolvingCreditFacilityAndTermLoanCreditAgreementMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_SaasMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Saas [Member]",
        "label": "Saas [Member]",
        "terseLabel": "SaaS"
       }
      }
     },
     "localname": "SaasMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-type Lease, Lease Prepaid Taxes And Other Noncurrent Assets",
        "label": "Sales-type Lease, Lease Prepaid Taxes And Other Noncurrent Assets",
        "terseLabel": "Prepaid taxes and other non-current assets"
       }
      }
     },
     "localname": "SalesTypeLeaseLeasePrepaidTaxesAndOtherNoncurrentAssets",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_SalesTypeLeaseNetInvestmentInLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-type Lease, Net Investment in Lease [Table Text Block]",
        "label": "Sales-type Lease, Net Investment in Lease [Table Text Block]",
        "terseLabel": "Schedule Of Sales-type Lease, Net Investment In Lease"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLeaseTableTextBlock",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rmd_ScheduleOfChangesInEquityInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Changes In Equity Investments [Table Text Block]",
        "label": "Schedule Of Changes In Equity Investments [Table Text Block]",
        "terseLabel": "Schedule Of Changes In Equity Investments"
       }
      }
     },
     "localname": "ScheduleOfChangesInEquityInvestmentsTableTextBlock",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rmd_ScheduleOfInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Investments [Table Text Block]",
        "label": "Schedule Of Investments [Table Text Block]",
        "terseLabel": "Schedule Of Investments"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTableTextBlock",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rmd_ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Revenue By Segment, Product, And Region [Table Text Block]",
        "label": "Schedule Of Revenue By Segment, Product, And Region [Table Text Block]",
        "terseLabel": "Schedule Of Revenue By Segment, Product, And Region"
       }
      }
     },
     "localname": "ScheduleOfRevenueBySegmentProductAndRegionTableTextBlock",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rmd_ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Operating Lease Disclosure [Table Text Block]",
        "label": "Schedule Of Supplemental Information, Operating Leases [Table Text Block]",
        "terseLabel": "Schedule Of Operating Lease Disclosure"
       }
      }
     },
     "localname": "ScheduleOfSupplementalInformationOperatingLeasesTableTextBlock",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rmd_SeniorNotesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes One [Member]",
        "label": "Senior Notes One [Member]",
        "terseLabel": "3.24% Senior Notes Due July 10, 2026"
       }
      }
     },
     "localname": "SeniorNotesOneMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_SeniorNotesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Two [Member]",
        "label": "Senior Notes Two [Member]",
        "terseLabel": "3.45% Senior Notes Due July 10, 2029"
       }
      }
     },
     "localname": "SeniorNotesTwoMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Adjustments In Period Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Adjustments In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Performance factor adjustments (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdjustmentsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Extended Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Extended Period",
        "terseLabel": "Extended period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExtendedPeriod",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Pending",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Pending",
        "terseLabel": "Common stock authorized for issuance and pending registration (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPending",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "rmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted and Other Cash Fees Earned",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted and Other Cash Fees Earned",
        "terseLabel": "Maximum award amount with other cash fees earned for services"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedAndOtherCashFeesEarned",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased Compensation Arrangement By Sharebased Payment Performance Award Granted",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Performance Award Granted",
        "terseLabel": "Maximum amount payable pursuant to cash denominated performance awards granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentPerformanceAwardGranted",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_ShortTermDebtGross": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ShortTermBorrowings",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Debt, Gross",
        "label": "Short-Term Debt, Gross",
        "verboseLabel": "Short-term debt"
       }
      }
     },
     "localname": "ShortTermDebtGross",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_SleepAndRespiratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sleep And Respiratory [Member]",
        "label": "Sleep And Respiratory [Member]",
        "terseLabel": "Sleep and Respiratory Care products",
        "verboseLabel": "Sleep and \u200eRespiratory Care"
       }
      }
     },
     "localname": "SleepAndRespiratoryMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_SoftwareAsServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Software As A Service [Member]",
        "label": "Software As Service [Member]",
        "terseLabel": "Software as a Service"
       }
      }
     },
     "localname": "SoftwareAsServiceMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rmd_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "rmd_SupplementalBalanceSheetInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Information [Abstract]",
        "label": "Supplemental Balance Sheet Information [Abstract]",
        "terseLabel": "Supplemental Balance Sheet Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationAbstract",
     "nsuri": "http://investor.resmed.com/20220630",
     "xbrltype": "stringItemType"
    },
    "rmd_SupplementalBalanceSheetInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental Balance Sheet Information [Text Block]",
        "label": "Supplemental Balance Sheet Information [Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationTextBlock",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "rmd_TermOfContractUnderRevenueRecognition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Of Contract Under Revenue Recognition",
        "label": "Term Of Contract Under Revenue Recognition",
        "verboseLabel": "Deferred revenue recognized, term"
       }
      }
     },
     "localname": "TermOfContractUnderRevenueRecognition",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "rmd_U.s.CanadaAndLatinAmericaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S., Canada and Latin America [Member]",
        "label": "U.s. Canada And Latin America [Member]",
        "terseLabel": "U.S., Canada and Latin America"
       }
      }
     },
     "localname": "U.s.CanadaAndLatinAmericaMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_UnallocatedCorporateCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unallocated corporate costs.",
        "label": "Unallocated Corporate Costs",
        "terseLabel": "Corporate costs"
       }
      }
     },
     "localname": "UnallocatedCorporateCosts",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_UncommittedOptionToIncreaseCreditFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncommitted option to increase credit facility",
        "label": "Uncommitted option to increase credit facility",
        "terseLabel": "Uncommitted option to increase credit facility"
       }
      }
     },
     "localname": "UncommittedOptionToIncreaseCreditFacility",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "rmd_VehiclesAndAircraftMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vehicles and Aircraft",
        "label": "Vehicles and Aircraft [Member]",
        "terseLabel": "Vehicles and aircraft"
       }
      }
     },
     "localname": "VehiclesAndAircraftMember",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "rmd_VestingAmountMaximumPercentageOfOriginalGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Amount, Maximum Percentage Of Original Grant",
        "label": "Vesting Amount, Maximum Percentage Of Original Grant",
        "terseLabel": "Maximum amount to be issued under award, percentage"
       }
      }
     },
     "localname": "VestingAmountMaximumPercentageOfOriginalGrant",
     "nsuri": "http://investor.resmed.com/20220630",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leader of board of directors.",
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board Of Directors Chairman"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r135",
      "r187",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r207",
      "r211",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r350",
      "r352",
      "r353",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r135",
      "r187",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r207",
      "r211",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r347",
      "r348",
      "r350",
      "r352",
      "r353",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Obligations Under Purchase Agreements"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {
     "auth_ref": [
      "r2",
      "r147",
      "r157",
      "r251",
      "r524",
      "r525",
      "r526",
      "r551",
      "r552",
      "r597",
      "r603",
      "r604",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount after cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r2",
      "r147",
      "r157",
      "r163",
      "r251",
      "r524",
      "r525",
      "r526",
      "r551",
      "r552",
      "r597",
      "r600",
      "r603",
      "r604",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect adjustment from adoption of the credit loss standard, net of tax"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r147",
      "r157",
      "r163",
      "r251",
      "r524",
      "r525",
      "r526",
      "r551",
      "r552",
      "r597",
      "r600",
      "r603",
      "r604",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r147",
      "r157",
      "r163",
      "r251",
      "r524",
      "r525",
      "r526",
      "r551",
      "r552",
      "r597",
      "r600",
      "r603",
      "r604",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards.",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r322",
      "r324",
      "r325",
      "r326",
      "r357",
      "r380",
      "r483",
      "r485",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r706",
      "r759",
      "r762",
      "r789",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/LeasesNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r322",
      "r324",
      "r325",
      "r326",
      "r357",
      "r380",
      "r483",
      "r485",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r706",
      "r759",
      "r762",
      "r789",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/LeasesNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r214",
      "r324",
      "r325",
      "r403",
      "r405",
      "r712",
      "r758",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r214",
      "r324",
      "r325",
      "r403",
      "r405",
      "r712",
      "r758",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r306",
      "r322",
      "r324",
      "r325",
      "r326",
      "r357",
      "r380",
      "r428",
      "r483",
      "r485",
      "r516",
      "r517",
      "r518",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r706",
      "r759",
      "r762",
      "r789",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/LeasesNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r306",
      "r322",
      "r324",
      "r325",
      "r326",
      "r357",
      "r380",
      "r428",
      "r483",
      "r485",
      "r516",
      "r517",
      "r518",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r706",
      "r759",
      "r762",
      "r789",
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/LeasesNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r142",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "verboseLabel": "Schedule II Valuation And Qualifying Accounts And Reserves"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReserves"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r215",
      "r216",
      "r403",
      "r406",
      "r761",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r808",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Segment, Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r215",
      "r216",
      "r403",
      "r406",
      "r761",
      "r776",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r808",
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r222",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r140",
      "r141",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r150",
      "r151",
      "r152",
      "r154",
      "r228",
      "r229",
      "r248",
      "r249",
      "r250",
      "r251",
      "r254",
      "r255",
      "r524",
      "r525",
      "r526",
      "r551",
      "r552",
      "r571",
      "r572",
      "r573",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r620",
      "r621",
      "r633",
      "r634",
      "r640",
      "r641",
      "r642",
      "r664",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "terseLabel": "Accounting Standards Update [Extensible Enumeration]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49",
      "r675"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r223",
      "r224"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net",
        "verboseLabel": "Accounts receivable, net of allowances of $23,259 and $32,138 \u200eat June\u00a030, 2022 and June\u00a030, 2021, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r27",
      "r722",
      "r741"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Income taxes payable (note 13)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r30",
      "r722",
      "r741"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term income taxes payable (note 13)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses (note 7)",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Marketing Costs, Current",
        "terseLabel": "Promotional and marketing"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Consulting and professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r21",
      "r301"
     ],
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r35",
      "r65",
      "r67",
      "r68",
      "r744",
      "r770",
      "r774"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r64",
      "r68",
      "r76",
      "r77",
      "r78",
      "r144",
      "r145",
      "r146",
      "r579",
      "r670",
      "r765",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated \u200eOther \u200eComprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r524",
      "r525",
      "r526",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional \u200ePaid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r521"
     ],
     "calculation": {
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation costs"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Stock-based compensation costs, net of tax benefit"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForCreditLossMember": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]",
        "terseLabel": "Applied Against Asset Account Allowance For Doubtful Accounts"
       }
      }
     },
     "localname": "AllowanceForCreditLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r39",
      "r225",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for credit loss, current"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on decontaminating and decommissioning of facilities used in the normal conduct of business and not intended for resale to allocate or recognize the cost of the assets over their useful lives.",
        "label": "Amortization and Depreciation of Decontaminating and Decommissioning Assets",
        "terseLabel": "Accelerated amortization"
       }
      }
     },
     "localname": "AmortizationAndDepreciationOfDecontaminatingAndDecommissioningAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r111",
      "r287",
      "r292"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostOfGoodsAndServicesSold",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense",
        "verboseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options and restricted stock units not included in the computation of diluted earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r111",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairments"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r25",
      "r129",
      "r195",
      "r202",
      "r209",
      "r245",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r351",
      "r353",
      "r354",
      "r576",
      "r580",
      "r610",
      "r673",
      "r675",
      "r720",
      "r740"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r12",
      "r48",
      "r129",
      "r245",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r351",
      "r353",
      "r354",
      "r576",
      "r580",
      "r610",
      "r673",
      "r675"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r129",
      "r245",
      "r340",
      "r341",
      "r342",
      "r344",
      "r345",
      "r346",
      "r347",
      "r349",
      "r351",
      "r353",
      "r354",
      "r576",
      "r580",
      "r610",
      "r673"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AustralianTaxationOfficeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Australia.",
        "label": "Australian Taxation Office [Member]",
        "terseLabel": "Australian Taxation Office"
       }
      }
     },
     "localname": "AustralianTaxationOfficeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r509",
      "r510",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r589",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r110",
      "r575"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Changes in fair value of business combination contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Contract cancellation costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r9",
      "r18",
      "r113"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash And Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r107",
      "r113",
      "r119"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r107",
      "r623"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r59",
      "r726",
      "r748"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (note 16)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r333",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock, dividends per share, cash paid (usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividend declared per share (usd per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r144",
      "r145",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r32",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common stock, shares outstanding, ending balance (shares)",
        "periodStartLabel": "Common stock, shares outstanding, beginning balance (shares)",
        "terseLabel": "Common stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscriptions": {
     "auth_ref": [
      "r32",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Value, Subscriptions",
        "verboseLabel": "Common stock shares subscribed"
       }
      }
     },
     "localname": "CommonStockSharesSubscriptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "verboseLabel": "Common stock, $0.004 par value, 350,000,000 shares authorized; \u200e188,246,955 issued and 146,410,721 outstanding at June\u00a030, 2022 and \u200e187,484,592 issued and 145,648,358 outstanding at June\u00a030, 2021"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r71",
      "r73",
      "r74",
      "r88",
      "r731",
      "r752"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Basis Of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary Of Contract Balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r398",
      "r400",
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "terseLabel": "Unbilled revenue, current"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r398",
      "r400",
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "verboseLabel": "Unbilled revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r398",
      "r399",
      "r404"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "negatedLabel": "Deferred revenue, current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r398",
      "r399",
      "r404"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "negatedLabel": "Deferred revenue, non-current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueAfterFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, after Year Five",
        "totalLabel": "Thereafter"
       }
      }
     },
     "localname": "ContractualObligationDueAfterFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Five",
        "totalLabel": "2027"
       }
      }
     },
     "localname": "ContractualObligationDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Four",
        "totalLabel": "2026"
       }
      }
     },
     "localname": "ContractualObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year One",
        "totalLabel": "2023"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Two",
        "totalLabel": "2024"
       }
      }
     },
     "localname": "ContractualObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Contractual Obligation, to be Paid, Year Three",
        "totalLabel": "2025"
       }
      }
     },
     "localname": "ContractualObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate Costs"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r84",
      "r85"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostOfGoodsAndServicesSold",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "terseLabel": "Cost of sales (exclusive of amortization shown separately below)"
       }
      }
     },
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r93",
      "r712"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "totalLabel": "Total cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r548",
      "r558"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r548"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "verboseLabel": "Non-U.S."
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r548",
      "r558",
      "r560"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r548",
      "r558"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r126",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r370",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "verboseLabel": "Credit facility interest rate equal to reference rate plus"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r28",
      "r371",
      "r723",
      "r739"
     ],
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r355",
      "r374",
      "r375",
      "r636",
      "r638",
      "r639"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r56",
      "r373",
      "r636",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Interest rate on outstanding principal amount"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r56",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "terseLabel": "Outstanding debt",
        "totalLabel": "Total debt"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails",
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r549",
      "r558"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r637"
     ],
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ShortTermBorrowings",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Current, Net",
        "negatedTerseLabel": "Deferred borrowing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r637"
     ],
     "calculation": {
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedLabel": "Deferred borrowing costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r549",
      "r558"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "verboseLabel": "Non-U.S."
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r111",
      "r130",
      "r549",
      "r558",
      "r559",
      "r560"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Assets, Noncurrent",
        "terseLabel": "Deferred income taxes (note 13)",
        "verboseLabel": "Non-current deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences, after deferred tax asset, and other tax liabilities expected to be paid after one year or operating cycle, if longer.",
        "label": "Deferred Income Taxes and Other Tax Liabilities, Noncurrent",
        "negatedLabel": "Non-current deferred tax liability",
        "terseLabel": "Deferred income taxes (note 13)"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndOtherTaxLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r130",
      "r549",
      "r558"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "verboseLabel": "Capital loss carryover"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets, Gross"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development capitalization"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails",
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesClassifiedAsCurrentAndNonCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r545",
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carry overs"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "terseLabel": "Employee liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "verboseLabel": "Provision for doubtful debts"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves",
        "verboseLabel": "Provision for warranties"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r532",
      "r542"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Liabilities, Goodwill and Intangible Assets",
        "negatedLabel": "Goodwill and other intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r546",
      "r547"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries": {
     "auth_ref": [
      "r567"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability not recognized because of the exceptions to comprehensive recognition of deferred taxes related to undistributed earnings of foreign subsidiaries.",
        "label": "Deferred Tax Liability Not Recognized, Amount of Unrecognized Deferred Tax Liability, Undistributed Earnings of Foreign Subsidiaries",
        "terseLabel": "Amount of deferred taxes that would have been recognized if the earnings has not been permanently reinvested"
       }
      }
     },
     "localname": "DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r461",
      "r462",
      "r465",
      "r466",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r480"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "verboseLabel": "Total contribution by the company to the employee retirement plans"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r111",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r111",
      "r190"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r584",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Foreign currency instruments with notional amounts"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r583",
      "r585",
      "r587",
      "r588",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "verboseLabel": "Foreign Exchange Risk Management"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r394",
      "r737"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedLabel": "Dividends declared"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r481",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r89",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r166",
      "r168",
      "r170",
      "r171",
      "r172",
      "r176",
      "r177",
      "r604",
      "r605",
      "r732",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic earnings per share (note 12) (usd per share)",
        "verboseLabel": "Basic earnings per share (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r89",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r168",
      "r170",
      "r171",
      "r172",
      "r176",
      "r177",
      "r604",
      "r605",
      "r732",
      "r753"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted earnings per share (usd per share)",
        "verboseLabel": "Diluted earnings per share (note 12) (usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, Other Disclosure [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r623"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee related costs"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "verboseLabel": "Unrecognized compensation costs related to unvested stock-based compensation arrangements"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Expected weighted average period of unrecognized compensation costs related to unvested stock-based compensation arrangements"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r521"
     ],
     "calculation": {
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options:"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r76",
      "r77",
      "r78",
      "r144",
      "r145",
      "r146",
      "r151",
      "r160",
      "r162",
      "r181",
      "r251",
      "r393",
      "r394",
      "r524",
      "r525",
      "r526",
      "r551",
      "r552",
      "r603",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r631",
      "r670",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r19",
      "r196",
      "r242"
     ],
     "calculation": {
      "http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "rmd_EquityInvestmentsTotalByMeasurementCategory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "verboseLabel": "Equity method"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition.",
        "label": "Equity Method Investments [Member]",
        "terseLabel": "Equity method investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "terseLabel": "(Gain) loss on equity investments",
        "verboseLabel": "Gain (loss) on equity investments (note 6)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r239",
      "r755"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "verboseLabel": "Realized gains on marketable and non-marketable equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r239",
      "r755"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Equity securities, unrealized gain (loss)"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "rmd_EquityInvestmentsTotalByMeasurementCategory",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "netLabel": "Measurement alternative"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": {
     "auth_ref": [
      "r237"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount",
        "terseLabel": "(Gain) loss on equity investments (note 6)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r369",
      "r391",
      "r592",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Intangible assets, estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r23",
      "r291"
     ],
     "calculation": {
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfAmortizationExpenseRelatedToIdentifiableIntangibleAssetsIncludingPatentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r288",
      "r289",
      "r291",
      "r294",
      "r713",
      "r717"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r291",
      "r717"
     ],
     "calculation": {
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Other intangibles, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r291",
      "r713"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Other intangible assets, net (note 5)",
        "totalLabel": "Total other intangibles, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "verboseLabel": "Foreign Currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r481",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r22",
      "r273",
      "r274",
      "r281",
      "r285",
      "r675",
      "r719"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Goodwill (note 5)"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r275",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Business acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Other Intangible Assets, net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r284",
      "r285",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r92",
      "r129",
      "r195",
      "r201",
      "r205",
      "r208",
      "r211",
      "r245",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r347",
      "r349",
      "r351",
      "r353",
      "r354",
      "r610"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.",
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "terseLabel": "Maximum exposure on outstanding receivables"
       }
      }
     },
     "localname": "GuaranteeObligationsMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r111",
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfInvestments": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.",
        "label": "Other than Temporary Impairment Losses, Investments",
        "negatedNetLabel": "Impairment of investments"
       }
      }
     },
     "localname": "ImpairmentOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r297",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Impairment Of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeAmountsAttributableToReportingEntityDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Amounts Attributable to Parent, Disclosures [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "IncomeAmountsAttributableToReportingEntityDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r131",
      "r561"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "verboseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r82",
      "r195",
      "r201",
      "r205",
      "r208",
      "r211",
      "r718",
      "r728",
      "r735",
      "r756"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r131",
      "r561"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "verboseLabel": "Non-U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfIncomeBeforeIncomeTaxesUnderTheJurisdictionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r83",
      "r111",
      "r192",
      "r242",
      "r727",
      "r749"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Loss attributable to equity method investments (note 6)",
        "terseLabel": "Loss attributable to equity method investments",
        "verboseLabel": "Loss attributable to equity method investments (note 6)"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r303",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxCreditsAndAdjustments": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A credit or adjustment for government or taxing authority authorized decrease in taxes owed as a result of meeting certain tax policy conditions.",
        "label": "Income Tax Credits and Adjustments",
        "terseLabel": "Tax credits and deductions"
       }
      }
     },
     "localname": "IncomeTaxCreditsAndAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r535",
      "r538",
      "r544",
      "r556",
      "r562",
      "r564",
      "r565",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the additional liability or refund received or expected based on a final settlement with a taxing authority.",
        "label": "Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority",
        "terseLabel": "Liability (refund) adjustment from settlement with taxing authority"
       }
      }
     },
     "localname": "IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r536"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Penalties and interest"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r161",
      "r162",
      "r193",
      "r533",
      "r557",
      "r563",
      "r757"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "netLabel": "Income taxes (note 13)",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails",
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxHolidayAggregateDollarAmount": {
     "auth_ref": [
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income taxes from which a reporting entity is exempt or for which it will receive a reduction in income taxes as a result of the income tax holiday granted by the taxing jurisdiction.",
        "label": "Income Tax Holiday, Aggregate Dollar Amount",
        "terseLabel": "Increase to net earnings from tax holidays and tax incentives program"
       }
      }
     },
     "localname": "IncomeTaxHolidayAggregateDollarAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxHolidayIncomeTaxBenefitsPerShare": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount effect of the income tax benefit resulting from the income tax holidays granted by taxing jurisdictions.",
        "label": "Income Tax Holiday, Income Tax Benefits Per Share",
        "terseLabel": "Increase to net earnings per diluted share from tax holidays and tax incentives program (usd per share)"
       }
      }
     },
     "localname": "IncomeTaxHolidayIncomeTaxBenefitsPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r530",
      "r531",
      "r538",
      "r539",
      "r543",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "verboseLabel": "Effect of non-U.S. tax rates"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "verboseLabel": "Taxes computed at statutory U.S. rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "verboseLabel": "State income taxes, net of U.S. tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "negatedLabel": "Foreign tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research and development credit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesScheduleOfProvisionForIncomeTaxDifferFromTheAmountOfIncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid, net of refunds"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued expenses and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses, net deferred income taxes and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r122",
      "r290",
      "r709",
      "r710",
      "r711",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "verboseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r80",
      "r189",
      "r635",
      "r637",
      "r734"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "verboseLabel": "Interest expense (income), net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r733"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Interest (expense) income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r106",
      "r108",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r40",
      "r269"
     ],
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Gross [Abstract]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r10",
      "r46",
      "r675"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories (note 4)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r44",
      "r123",
      "r179",
      "r266",
      "r268",
      "r270",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r42",
      "r269"
     ],
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r41",
      "r269"
     ],
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-downs"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r243",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "verboseLabel": "Equity Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r235",
      "r240",
      "r246",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Actions, Contingencies And Commitments"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease terms, not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule Of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r656"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lease terms"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorSalesTypeLeasesTextBlock": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of lessor's sales-type leases.",
        "label": "Lessor, Sales-type Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LessorSalesTypeLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r53",
      "r129",
      "r203",
      "r245",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r347",
      "r349",
      "r351",
      "r353",
      "r354",
      "r577",
      "r580",
      "r581",
      "r610",
      "r673",
      "r674"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r38",
      "r129",
      "r245",
      "r610",
      "r675",
      "r724",
      "r746"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r55",
      "r129",
      "r245",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r347",
      "r349",
      "r351",
      "r353",
      "r354",
      "r577",
      "r580",
      "r581",
      "r610",
      "r673",
      "r674",
      "r675"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r28",
      "r29",
      "r129",
      "r245",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r347",
      "r349",
      "r351",
      "r353",
      "r354",
      "r577",
      "r580",
      "r581",
      "r610",
      "r673",
      "r674"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r51",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "verboseLabel": "Commitment fees percentage rate on unused portion of credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Available for draw"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r51",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payment applied to principal.",
        "label": "Line of Credit Facility, Periodic Payment, Principal",
        "terseLabel": "Principal payment"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r51",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement expenses",
        "verboseLabel": "Litigation settlement expenses"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule Of Long-Lived Assets By Geographic Areas"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r28",
      "r365",
      "r372",
      "r374",
      "r375",
      "r723",
      "r743"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Outstanding loan balance",
        "totalLabel": "Long-term debt, net",
        "verboseLabel": "Long-term debt, net (note 9)"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/DebtNarrativeDetails",
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r57",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyAccrualProvision": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges.",
        "label": "Loss Contingency Accrual, Provision",
        "terseLabel": "Contingent provision"
       }
      }
     },
     "localname": "LossContingencyAccrualProvision",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [
      "r321",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Patents allegedly infringed"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "verboseLabel": "Unrealized gains (losses) on marketable equity securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Reconciling items"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]",
        "terseLabel": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]"
       }
      }
     },
     "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r107",
      "r109",
      "r112"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r7",
      "r69",
      "r72",
      "r78",
      "r86",
      "r112",
      "r129",
      "r150",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r162",
      "r169",
      "r195",
      "r201",
      "r205",
      "r208",
      "r211",
      "r245",
      "r340",
      "r341",
      "r342",
      "r345",
      "r346",
      "r347",
      "r349",
      "r351",
      "r353",
      "r354",
      "r605",
      "r610",
      "r729",
      "r750"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome",
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r5",
      "r148",
      "r149",
      "r152",
      "r153",
      "r163",
      "r164",
      "r165",
      "r230",
      "r231",
      "r252",
      "r253",
      "r553",
      "r554",
      "r555",
      "r601",
      "r607",
      "r608",
      "r609",
      "r617",
      "r618",
      "r619",
      "r643",
      "r644",
      "r665",
      "r671",
      "r714",
      "r715",
      "r716",
      "r769",
      "r770",
      "r771",
      "r772",
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "New Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/NewAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting standards not yet adopted and Recently adopted accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r116",
      "r117",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "verboseLabel": "Long lived assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (loss), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (loss), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationNarrativeDetails",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating Expenses [Abstract]"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r195",
      "r201",
      "r205",
      "r208",
      "r211"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "netLabel": "Net operating profit by segment",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r651",
      "r657"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncome": {
     "auth_ref": [
      "r180",
      "r659",
      "r661"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails": {
       "order": 2.0,
       "parentTag": "rmd_LessorLeaseRevenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.",
        "label": "Operating Lease, Lease Income",
        "terseLabel": "Operating lease revenue"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r180",
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "terseLabel": "Schedule Of Components Of Lease Revenue"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r646"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r646"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities, current (note 10)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r646"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, non-current (note 10)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r647",
      "r652"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfOperatingLeaseDisclosureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r645"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets (note 10)"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r655",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfOperatingLeaseDisclosureDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r654",
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfOperatingLeaseDisclosureDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessor's operating leases.",
        "label": "Lessor, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r545"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r8",
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization And Basis Of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/OrganizationAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r47",
      "r675"
     ],
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other prepaid expenses and current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Prepaid taxes and other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitment": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.",
        "label": "Other Commitment",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherCommitment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueAfterFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherCommitment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "OtherCommitmentDueAfterFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherCommitment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "OtherCommitmentDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherCommitment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OtherCommitmentDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherCommitment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OtherCommitmentDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherCommitment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OtherCommitmentDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherCommitment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commitment classified as other to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Other Commitment, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OtherCommitmentDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Abstract]",
        "terseLabel": "MEDIFOX DAN acquisition consideration"
       }
      }
     },
     "localname": "OtherCommitmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation (loss) gain adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r622",
      "r630"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Other comprehensive income, foreign currency translation adjustment, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r70",
      "r73",
      "r76",
      "r77",
      "r79",
      "r87",
      "r393",
      "r624",
      "r629",
      "r631",
      "r730",
      "r751"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other intangibles"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "netLabel": "Other, net",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForProceedsFromDerivativeInstrumentInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash outflow or inflow from derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments.",
        "label": "Payments for (Proceeds from) Derivative Instrument, Investing Activities",
        "negatedLabel": "(Payments) / proceeds on maturity of foreign currency contracts"
       }
      }
     },
     "localname": "PaymentsForProceedsFromDerivativeInstrumentInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for financing costs associated with business combinations.",
        "label": "Payments of Merger Related Costs, Financing Activities",
        "negatedLabel": "Payments of business combination contingent consideration"
       }
      }
     },
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r98",
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Cash paid for acquisitions"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Business acquisitions, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Patent registration costs"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments (note 6)"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r428",
      "r430",
      "r436",
      "r454",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r477",
      "r478",
      "r479",
      "r480",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "verboseLabel": "Employee Retirement Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Restricted Stock Units (PRSUs)"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r509",
      "r510",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r509",
      "r510",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock at par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r31",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r31",
      "r675"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets (note 4)",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidTaxes": {
     "auth_ref": [
      "r11",
      "r271",
      "r272"
     ],
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Taxes",
        "terseLabel": "Prepaid taxes"
       }
      }
     },
     "localname": "PrepaidTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationScheduleOfPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from borrowings, net of borrowing costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from sale of investment (note 6)"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantiesDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Warranties Disclosures [Abstract]",
        "terseLabel": "Product Warranties Disclosures [Abstract]"
       }
      }
     },
     "localname": "ProductWarrantiesDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductWarrantyAccrual": {
     "auth_ref": [
      "r335",
      "r336",
      "r725"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.",
        "label": "Standard and Extended Product Warranty Accrual",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period"
       }
      }
     },
     "localname": "ProductWarrantyAccrual",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r54",
      "r328",
      "r330"
     ],
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Product warranties (note 8)"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualPayments": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.",
        "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments",
        "negatedLabel": "Warranty costs incurred for the period"
       }
      }
     },
     "localname": "ProductWarrantyAccrualPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualWarrantiesIssued": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.",
        "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued",
        "verboseLabel": "Warranty accruals for the period"
       }
      }
     },
     "localname": "ProductWarrantyAccrualWarrantiesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyDisclosureTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.",
        "label": "Product Warranty Disclosure [Text Block]",
        "terseLabel": "Product Warranties"
       }
      }
     },
     "localname": "ProductWarrantyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ProductWarranties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r20",
      "r300"
     ],
     "calculation": {
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Property, plant and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r302",
      "r675",
      "r736",
      "r747"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net (note 4)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r302",
      "r778",
      "r779"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Property, Plant And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Components Of Property, Plant And Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life of property, plant and equipment, years"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueAfterFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid after fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "PurchaseObligationDueAfterFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in fifth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "PurchaseObligationDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in fourth fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "PurchaseObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractualObligationDueInNextTwelveMonths",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "PurchaseObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PurchaseObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Purchase Obligation, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "PurchaseObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligationFiscalYearMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Minimum purchase obligations"
       }
      }
     },
     "localname": "PurchaseObligationFiscalYearMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LegalActionsContingenciesAndCommitmentsObligationsUnderPurchaseAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of borrowings"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r528",
      "r708",
      "r791"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "verboseLabel": "Research And Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.",
        "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings",
        "terseLabel": "Exercisable shares, netted for tax (shares)"
       }
      }
     },
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r308",
      "r310",
      "r313",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Expenses"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r111",
      "r307",
      "r314",
      "r315"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring expenses (note 17)",
        "verboseLabel": "Restructuring expenses"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows",
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r309",
      "r310",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Restructuring expenses"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r34",
      "r394",
      "r675",
      "r745",
      "r769",
      "r774"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r144",
      "r145",
      "r146",
      "r151",
      "r160",
      "r162",
      "r251",
      "r524",
      "r525",
      "r526",
      "r551",
      "r552",
      "r603",
      "r765",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r458",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r481",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r458",
      "r463",
      "r464",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r481",
      "r482",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EmployeeRetirementPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r186",
      "r187",
      "r200",
      "r206",
      "r207",
      "r214",
      "r215",
      "r220",
      "r402",
      "r403",
      "r712"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Net revenue",
        "totalLabel": "Net revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule Of Revenue By Geographic Area"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "verboseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r653",
      "r657"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for new lease liabilities:"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfOperatingLeaseDisclosureDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivable": {
     "auth_ref": [
      "r660",
      "r662"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type and direct financing leases.",
        "label": "Sales-type and Direct Financing Leases, Lease Receivable",
        "terseLabel": "Present value of remaining lease payments"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received on annual basis for sales-type and direct financing leases receivable. Includes, but is not limited to, reconciliation to lease receivable recognized in statement of financial position.",
        "label": "Sales-type and Direct Financing Leases, Lease Receivable, Maturity [Table Text Block]",
        "terseLabel": "Schedule Of Maturities Of Sales-type Leases"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases.",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, Payments to be Received",
        "totalLabel": "Total remaining lease payments"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted cash flows to be received by lessor for sales-type and direct financing leases in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Sales-Type and Direct Financing Leases, Lease Receivable, to be Received, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount": {
     "auth_ref": [
      "r660"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undiscounted lease receivable in excess of discounted receivable for sales-type and direct financing leases.",
        "label": "Sales-type and Direct Financing Leases, Lease Receivable, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfMaturitiesOfSalestypeLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseLeaseIncome": {
     "auth_ref": [
      "r180",
      "r659",
      "r661"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails": {
       "order": 1.0,
       "parentTag": "rmd_LessorLeaseRevenue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease income from variable lease payments, interest income from net investment on sales-type lease, and profit (loss) recognized at commencement.",
        "label": "Sales-type Lease, Lease Income",
        "terseLabel": "Sales-type lease revenue"
       }
      }
     },
     "localname": "SalesTypeLeaseLeaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfComponentsOfLeaseRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseLeaseReceivable": {
     "auth_ref": [
      "r662"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_SalesTypeLeaseNetInvestmentInLease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lease payments not yet received by lessor and amount expected to be derived from underlying asset, following end of lease term guaranteed by lessee or other third party unrelated to lessor, from sales-type lease.",
        "label": "Sales-type Lease, Lease Receivable",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "SalesTypeLeaseLeaseReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesTypeLeaseNetInvestmentInLease": {
     "auth_ref": [
      "r226",
      "r256",
      "r259",
      "r662"
     ],
     "calculation": {
      "http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of net investment in sales-type lease.",
        "label": "Sales-Type Lease, Net Investment in Lease, before Allowance for Credit Loss",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "SalesTypeLeaseNetInvestmentInLease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/LeasesScheduleOfSalestypeLeaseNetInvestmentInLeaseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule Of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "verboseLabel": "Schedule Of Provision For Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule Of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Components Of Deferred Tax Assets And Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule Of Basic And Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule Of Provision For Income Tax Differ From The Amount Of Income Tax"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r520",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfTotalStockBasedCompensationCostsIncurredAndAssociatedTaxBenefitRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule Of Total Stock-Based Compensation Costs Incurred And Associated Tax Benefit Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r7",
      "r129",
      "r244",
      "r245",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r288",
      "r290",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetNarrativeDetails",
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfOtherIntangibleAssetsNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r288",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule Of Other Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Schedule Of Changes In Carrying Amount Of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "verboseLabel": "Schedule Of Income Before Income Taxes Under The Jurisdictions"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r14",
      "r43",
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule Of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.",
        "label": "Schedule of Product Warranty Liability [Table Text Block]",
        "verboseLabel": "Schedule Of Changes In Liability For Warranty Costs"
       }
      }
     },
     "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ProductWarrantiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SupplementalBalanceSheetInformationComponentsOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r81",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfLongLivedAssetsByGeographicAreasDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueByGeographicAreaDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r195",
      "r198",
      "r204",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r195",
      "r198",
      "r204",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Summary Of Revenue By Segment And Reconciling Items"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r509",
      "r510",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "verboseLabel": "Schedule Of Activity Of Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r492",
      "r508",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Schedule Of Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule Of Assumptions For Fair Value Of Stock Option Plans And Purchase Rights Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule Of Amortization Expense Related To Identifiable Intangible Assets, Including Patents"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r182",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r220",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r312",
      "r317",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r182",
      "r184",
      "r185",
      "r195",
      "r199",
      "r205",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r219",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "verboseLabel": "Employee-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation costs (note 11)"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted \u200eAverage \u200eRemaining \u200eContractual \u200eTerm in Years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding at end of period (shares)",
        "periodStartLabel": "Outstanding at beginning of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding at end of period (usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted \u200eAverage \u200eGrant-Date \u200eFair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "verboseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net total number of shares (or other type of equity) under an equity-based award plan, other than a stock option plan, that were granted, vested and forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Period Increase (Decrease)",
        "terseLabel": "Performance factor adjustment (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of RSUs and PRSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Vested (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Weighted average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Restricted \u200eStock \u200eUnits"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Common stock authorized for issuance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Common stock reserved for future issuance (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted \u200eAverage \u200eRemaining \u200eContractual \u200eTerm in Years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Options exercisable at end of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of the options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value of the stock-based compensation arrangements outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (shares)",
        "periodStartLabel": "Outstanding at beginning of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted \u200eAverage \u200eExercise \u200ePrice"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of the stock-based compensation arrangements exercisable, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest at end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest at end of period (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r489",
      "r490",
      "r491",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r509",
      "r510",
      "r512",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Award Type and Plan Name [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfActivityOfRestrictedStockUnitsDetails",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "verboseLabel": "Options exercisable at end of period (shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfAssumptionsForFairValueOfStockOptionPlansAndPurchaseRightsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r523"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate intrinsic value of the stock-based compensation arrangements exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r26",
      "r675",
      "r721",
      "r742"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Short-term debt, net (note 9)",
        "totalLabel": "Short-term debt"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/DebtScheduleOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r120",
      "r143"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary Of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the standard and extended product warranty accrual.",
        "label": "Standard and Extended Product Warranty Accrual, Foreign Currency Translation Gain (Loss)",
        "negatedLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ProductWarrantiesScheduleOfChangesInLiabilityForWarrantyCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StandardProductWarrantyPolicy": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.",
        "label": "Standard Product Warranty, Policy [Policy Text Block]",
        "terseLabel": "Provision For Warranty"
       }
      }
     },
     "localname": "StandardProductWarrantyPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SummaryOfSignificantAccountingPoliciesPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r6",
      "r182",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r220",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r285",
      "r304",
      "r312",
      "r317",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/GoodwillandOtherIntangibleAssetsnetScheduleOfChangesInCarryingAmountOfGoodwillDetails",
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails",
      "http://investor.resmed.com/role/SegmentInformationSummaryOfRevenueBySegmentAndReconcilingItemsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r61",
      "r76",
      "r77",
      "r78",
      "r144",
      "r145",
      "r146",
      "r151",
      "r160",
      "r162",
      "r181",
      "r251",
      "r393",
      "r394",
      "r524",
      "r525",
      "r526",
      "r551",
      "r552",
      "r603",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r631",
      "r670",
      "r765",
      "r766",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r181",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r31",
      "r32",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued under Employee Stock Purchase Plan (shares)",
        "verboseLabel": "Common stock issued on employee stock purchase plan (note 11), shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r31",
      "r32",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11), shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r32",
      "r393",
      "r394",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (shares)",
        "terseLabel": "Common stock issued on exercise of options (note 11), shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://investor.resmed.com/role/StockholdersEquityScheduleOfOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r31",
      "r32",
      "r393",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "verboseLabel": "Common stock issued on employee stock purchase plan (note 11)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r393",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Common stock issued on vesting of restricted stock units, net of shares withheld for tax (note 11)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r31",
      "r32",
      "r394",
      "r509"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Stock-based compensation costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r393",
      "r394"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Common stock issued on exercise of options (note 11)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "verboseLabel": "Shares authorized to be repurchased under repurchase program (shares)"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The remaining number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased",
        "terseLabel": "Additional shares that can be repurchased under the approved share repurchase program (shares)"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r32",
      "r36",
      "r37",
      "r129",
      "r227",
      "r245",
      "r610",
      "r675"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r127",
      "r379",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r394",
      "r397",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/SegmentInformationScheduleOfRevenueBySegmentProductAndRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Value added taxes and other taxes due"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/AccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r233",
      "r234",
      "r236",
      "r237",
      "r238",
      "r369",
      "r391",
      "r592",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/InvestmentsScheduleOfChangesInEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "negatedPeriodEndLabel": "Treasury stock, common, ending balance (shares)",
        "negatedPeriodStartLabel": "Treasury stock, common, beginning balance (shares)",
        "verboseLabel": "Treasury stock (shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://investor.resmed.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r62",
      "r395",
      "r396"
     ],
     "calculation": {
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Treasury stock, at cost, 41,836,234 shares at June\u00a030, 2022 and June\u00a030, 2021"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r60",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r60",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Total number of shares repurchased pursuant to the repurchase program (shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r60",
      "r395",
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "terseLabel": "Total cost of shares repurchased pursuant to the repurchase program"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r309",
      "r310",
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/RestructuringExpensesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UndistributedEarningsOfForeignSubsidiaries": {
     "auth_ref": [
      "r529",
      "r566",
      "r738",
      "r775"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.",
        "label": "Undistributed Earnings of Foreign Subsidiaries",
        "verboseLabel": "Undistributed earnings"
       }
      }
     },
     "localname": "UndistributedEarningsOfForeignSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceOperatingLossCarryforwardsMember": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to operating loss carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Operating Loss Carryforward [Member]",
        "terseLabel": "Valuation Allowance"
       }
      }
     },
     "localname": "ValuationAllowanceOperatingLossCarryforwardsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r136",
      "r141"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at Beginning of Period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "verboseLabel": "Charged to costs and expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedLabel": "Other (deductions)"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails",
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r140",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/IncomeTaxesNarrativeDetails",
      "http://investor.resmed.com/role/ScheduleIIValuationAndQualifyingAccountsAndReservesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r172"
     ],
     "calculation": {
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "netLabel": "Stock options and restricted stock units (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r167",
      "r172"
     ],
     "calculation": {
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted shares outstanding (000's) (shares)",
        "totalLabel": "Diluted weighted average shares (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r166",
      "r172"
     ],
     "calculation": {
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic shares outstanding (000's) (shares)",
        "verboseLabel": "Basic weighted-average common shares outstanding (shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://investor.resmed.com/role/ConsolidatedStatementsOfIncome",
      "http://investor.resmed.com/role/EarningsPerShareScheduleOfBasicAndDilutedEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org/topic&trid=75115024"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=123583895&loc=d3e30768-111565"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "https://asc.fasb.org/topic&trid=2196965"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org/topic&trid=2197064"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907644&loc=d3e11281-110244"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12524-110249"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(2))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "((c)(3))",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(5)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "460",
   "URI": "https://asc.fasb.org/topic&trid=2155896"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28200-109314"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123420820&loc=SL77919311-209978"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919391-209981"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919379-209981"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888252"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r792": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r793": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r794": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r795": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r796": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r797": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r798": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r799": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r800": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r801": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r802": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r803": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r804": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r805": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r806": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r807": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r808": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r809": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r810": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r811": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r812": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r813": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r814": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r815": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r816": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r817": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r818": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r819": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r820": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "02"
  },
  "r821": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(ii)",
   "Subsection": "01"
  },
  "r822": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)",
   "Subsection": "01"
  },
  "r823": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "01"
  },
  "r824": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "02"
  },
  "r825": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "01"
  },
  "r826": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "02"
  },
  "r827": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(C)",
   "Subsection": "02"
  },
  "r828": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01"
  },
  "r829": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r830": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>113
<FILENAME>0000943819-22-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000943819-22-000010-xbrl.zip
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MCW41Y=/HX\7OY9"WP^5OE\?OHO>___K3V<?HMY]IO!'MD;/3AVZ0MPL5QV#
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MJT<RE@>NAA#C.3@\0*\;L\GOSJ+]71SP+V?OSSX>O_OLH&KWD@09(B_NN@Y
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MJH"U0SK)8-A(3\+,5&&NATG%W+F4XDQ?*B$ZY-]G20BGU41 2-HKA+ WN.9
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M6*0.DP+SI:-8]'\HYUE095.M2N(?:U61X0,I/#RIL:D6C!=.K"%?Q8@_=B'
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M'8[O1UQ-RCW4:7J_? SHAK2/X&RK0%8G#3KFWLA(Q.@"A0_)4YTZV2HSPM_
MBS-Y_K^(Q!UJ"P*3Y4:ZDM*<J153B/0=RQAXISUVR!*0R4,RX$3<Z<B$5T9
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M([EQE>+O+!X87GM0"N&U3_G -<%K/Z@=7J@XN=;5#XJY.X)^?:V7@V8QK:#
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M@X&E2Z9@&Y_K;.-&>D:>18E7A,5.<%HI_DO?ZF*2E/C/:\',UIE4RN$LO9Z
M;8DR5=>("A8Z"]RXAKAA9 NV?1Y_V(;JZB%1(-/W@&)+5$MMF.1-9S;O04[J
M&Y&=].&1'[,,7"/&Z:O)0'9;:%L?!ZTJ;![P V<PBF]?NOME4M&8$27MR)%A
M4RX-#PA!U'].$,->W47>O&6BL.'?O3MADT?$II37@[>9I(DR40.5H5T!9_'P
MZ*VY'_VQ/1)K RD3RRI, %CS*P&I3>)" !YAAQ !O,/I#3S2$+\?5."UB^G
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M\-7$_C]-.5QF@KF4],+,]\3$ IAAX%1G"8,I_@#Q%A?J1J7#FN<]1&]>\5_
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M^A?W( X'Y$&L:RN=OX_^.+]\?W9Q$?WQC[./9[_]+.64XFAS\V"_+5PO4B%
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M43P!]OK2@>%'ZBHCW:LUFI7IWBG;']7F[J9SOBWPH(-ZHD1I@?5:[O:--K<
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MUFR3B()PZ#88WG(S5_(V%!0QJC)MTHM;1]SE[9L:$P[W3='2A.<J>[];/^3
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M7)R.3UP$U6L8)-HA"V(C;3\SZC;*MEH]4:_>,IA(@-$IZ.#) YU]"C CPA(
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M9]'::OMAQMCG0]P_=1"]6-=)ODK=K_+<>=FR#6:UD&.=7(8E1U0:Z1AJVJC
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MSP4(D"$':)[$3VP[=1[?>%/0):"P8;VMR6Q/S/VRC3+*S67\3^G1'@Q4+.J
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MW6]%VJKM[B!#A''"A/8'JU [IW\?&[I0&^+#O8XRG:WP_7 \J3$5501/ J8
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M-$RDG KGC+:\M8CD,4,-(F*K+$C=4-'!WMXK_ D6#?LA^_XQ4SF\!%8*FY'
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M:)I.X=5C>U)'&JLQE$5.[:(E0P-8B)ZH-*/*=_1F5(\ICYA3FK2$.1'P2Y/
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M1-[M%55INSB[_/7L-#I_?Q*68/MBA?L>PR;\\N'=Z=G%/8H:[C_[BE4-5U8
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M&NGKAG(&V5E'_5*Q^6+2L<G Y$6=>-"CO+1X".LR/5L$FV KP,0*"^13^L[
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M?7EZC%U)5$4,446:#U (.3$=(5'M6/=VQ_9*&)!E,X@'2],!UA_(R8(P *.
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M*8A9W97:G:3C&MN)#O*Q/+]G&O*-JA7ZJ#<*A.Z<>=\?S"KT<OW[_5X3 QI
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M3D.:UX.<G1U?"6=0FKK[SW![I1AE4C5:]71G)2F4UGH&M-[#*&UNNZ(,K@Z
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MX_M?O=B?5Z]ODKB:OMK;W?W+D^9SJKB&1\=Y5>6S5WOX:*4_53LJ3:ZS5[0
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MR'Y_EM).<$-NUOZCJE)R#(00$ZD\;$^GGFLEZ"F%,Q3@+5:6@S<@NCO&'A9
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MT$3(T+.6KFB]K6'S*;;-/"'+;IZ>-'\/KL6.W+8RZC>>1[=!:"NW4V10V9(
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ML-EAN  FY&ZV&4#7UUXUTF,U>%*85DLZB8@*T]0I/CX51T0EX)B(J[$N2J"
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M_NS@F=UT='2]V9_>!7O^L84:N+[DO-HK4B,79Y>_GYT&YQ].[($MTY\SL]V
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MY^L&W*ZSV<AJ2>IB=]"FQE]J<.RHFR/FCMDT4$WD+NPB!@QI"."MO@QI/A]
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M,ZIU[XAX_C\.EN-EGZ@<6C,%V<@Y;RVS3UX>P);:&M%F 2FE#8$*@PNQP4:
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M+N*QQ0RM'#3L;<4$;N:@;W]_:[@=1!4'9(,3X_9K( =&&IPA>-\]W!IL4\2
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MO8,MQRW?(MP>QS0.5V!QI' &?3;\,KR:E*A37MG-FU#&3 "A4O<4<K"N#!I
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M]I:O?-=4_,\_L;(?>QW^ U!+ P04    "  TJ0M5;S)@> H&   */@  &P
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MNKAY;A_"T\/R]-GXX+/\AI,+SOM7-SX[.WMZQB>WIL_^>^OU7CB"KFL7O?[
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ME <OE(A>&M!@M<"@3!KN8E-6(,VS%.V5:7#F*EC%8]7I@@;V-N;2EB9Z)T%
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M.IM=0#%JY4$8IS%4E8);X05W1GOMO.4@&N)IYA/2&96A%UPE&H(,/"^?U4B
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M>NL[;>0[Y#*9S_1_RCJ>/XAE_HI7V"YG\]+_^0^JS&]W,1_BLHK&')N*7CG
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M4OJ]P-.OH/C=1B75?^Y%F9>@70<-@Y$1B?Q)_5L"]D" J947FV@R6U]3M3D
M;.DNOP_/20KAS!%=NL"?5\ZIN< YY\1+X*\#;R=6>77F/'9IEJ=AEA'0W:+_
ML?72U7,4,T=U:9I_7D,9NZ?PY(=L\Y(Q/PSRC$UL\Q\S)UA+VSP%VYP!?=NK
MH%]V3D<;G:715-D4AI&6''H>U%4L2?1C1%Z.#?77W/0< +:TT]^'YYNJ/,G=
M#$L&O0CJ.3W#O&30#4+>C TSGSF[6AKF:1AFQ/,U'+I.3H9"NUIGU,\<VJ5]
M_GDM%5,;X5@2Y^8@S^G8/HN9DZRE?9Z"?<YX;N$EK3V78'#16B_Z>8W%L%JR
MZ(70U>E9Z24#?B#4Q"1-9IDGTQ#$]-@GROD%;.D3OP_/K=':REQ68_?SY1?C
MQ3(;]7K*)WA&IUXT<6WY16LK%VVH^O6"F='N6JTWPRH<N?YHO<WHVFN;<\Q<
M=I;N]N?-@/C:L,4R*%I@Y 49.P U<\Z\= !3<  9S[U)#::7EY5Q\HX8,P=X
M::5_7E?%UP8OEE,+BXP\'UMI/7.JM;32T[#2/-/TS\J@Y1&L8;]?C&NGK?9<
MYZ)?U)S[RI2OE;TXJI^7S]F%_K SJ$_9.8%1DY9\?!'T77R-D2WY^ (CKR<I
M\GJ9(K\0ICX#^F<N2%H,ZO(1M=7&'SJ3[]>F+5JKOAP.6N,!G'SB9,U3*V?9
M+Z<U%D&[I5TR^,>'O)FDUYN9D[.E69^"6<]X(A/OEYTBNIMC+5?%&FH3OC<\
M.>G4WW.AARD,Q"SI^3PHLUHFWS]"Y*F:\/.O>?$Y0&QIQ[\3T+6ZPFI=Q"Y;
M;&3D[K""L0VO:]FMCFJ^N_Q#V9M\G92KO3;.?DGF9RX>2R,_!56WR[6PCQ%Z
M/6'K]F='899T?3[,O![Q];QKR(B6USG]<0K)HDLZ/A?J.CU+O>3C#8+>3)+Z
M[<^6+5@2\OFPU!G1G7H7F<W>J((ZWFKFV"YM]!04U7XMRWB9T3^WL%VE]"]S
M^IN"V22IGY+YA6SI$[\3T?6KC6 V+C>"V1EO!%.'-&N3/1!:K_+&B'E,ZF>'
MH9;!S5QHLUWF CU&Z.TD.9_^;!GC97 S'X8\(WIEO?/>A]#K+R.<A='6Z1GJ
MY7Q!DZ"?Y.?3GRW*MF3<<V*H>5Y'52]PO6CMG/608Q\5)_5N<]CUKNBU_H >
M(/G.L[ZCXS4'O\KJ'Z?G?W5Y[<P%96GPIZ#U2V;^.*&_W%_D9XN]+9GYG!A\
M1'1BVFNKG1=2H<GOW[#C^Q4V<[0#Z7CSW<FP3&L3GXIL/L+/C[HLR?Q<*/B2
MS#].Z"]W*?G90G%+,C\GMMWF$LM%+Q0GR-:O)6^^!!@GZ4-U6H1E+M!B:.^]
MD?*ET;TGV!AADWGFOV9.GI:0W0VRR48$]&>+QRUCH+GPDS6B&^='A2\&DQGE
M;Z]P:^V%(XC##K[&S$5@Z3FGH,_V:P5FEB'/0D,_V;J _FP9N&7(,R>F'!%]
M658Y!ZS][];>L-MUU<7,L5W:Z"DHJOU:"8$F3CG, O7__ =5Y+?+#EPRU3EI
MRW?H :4K+_:P:]U@6>Y_$>Q:QM-^LS#.LX'S'9C\?JW/T;$=%KWVH#P9M?4:
M!L?#_J!(%P\/ LL@K/9;PS[&346O-3@J^K4G?H(?H86"T>VW<MD_1GX[@_H#
M_>W)Y)=A__8OY; :_U2'9>-?\ZUR"IGK74R.8H=#U1J4N2[@%CY[LQ>>/FFY
MUCITW)FK !5BE".,((WFKW*HUQ_Z?A$+5Q70?Y+7MSL\[UKDYUV_P /#7B>7
MHBKSXIRSH@_8H?GPTYN078-FW!U"8G^=E/VZ:N'SJIY<.X7?SHHX.)H([+6K
M1HKUG%Q=XCRV93CX^B5WEH$7O_OJV6T9N_9WOF<1_[ERAX%&LC*YZ*B:M./$
M'4+;5^ ^MEU"E)^[SIF[Z*\\N]E:;.JX:TPV-'=\JUMB_%5^-GT[KK\@WW?S
M*?/;R.\HVK7R8C_;GCKY!Q_XY?USOXR;_)HPUM;L2N(K;%;NH8X[Z</SR8??
M8M$_Z;B+YT6O?K/ZHM_&MQ^K27["+<]4/W!T^$JVGI*1?(WYX?C)X\-/ZT,3
MIWGCF#!/+?GZ8?*4?O78E&[[-[2V2<SSS>KN?FOS+LQS)!%CC/&U6K4U;N4F
M?HNH5/EA<_7*HV&%&Z_\14#5[7>OS=Z=7_Q+4'>+&#MP9T_Q0(SM2W9JY<7N
MQM[6QGIK<WOM:6MU>[VU]_:/O<WUS=7=S8V]NU&B[R%&,WW56TKPO7Z7K_S]
MN\[HS=;<,'N97.=MNQQ WG[%5;&>:"XKI%^Q_;HL/^;OUVK$W<6-S!>QW<]L
MM@+DD8/,$W/*%++"JM5U%Y/OK3!.I4KC%^^,7[Q_LSA><;7$&YFQ&[0R1T6Z
MB:2S_@6_0*> 5!>X1A:,S[C*K^VWSJ#3R?\"=@?>93R9[_K]8?>DSM'"\R/>
MX^+)9T\+PZK"NW0N6N[4%9W:'0_*)[<>@LJ(3[C6Z)K\YJ;VKO]:70*-73,H
MJVR$6LF%_);X0E_OA*>M?7S',[1XE_% _<*G\&1"Z<<_P_D)A,'M7XM,1^+M
M7W.UV9SK,/CL+F<%OD[&J.@-OWCPL\>.>_;V[TA+>K=_2\,<C5\/5$:]U2]0
M"%W5PE? 8+U_E3O7PVZK%\)<[^"$X4@XNGGR(?2@<AT$JXAX%HK^-_KT">(<
M.L,,1_[8.G'9*PRQ!4^^C-FH:T<9?_GYH_? $TX!>RE+-KBJEW=_?5*?V^OG
M,*F'RG12E7$8!JV(IW;*DWSCFP<Z;M@+1Y/3NW5AWWZ]-5.6L_%9>+2#@<[A
M."H;N',\.L@O5O=2UH("HSR\76:@.W]MKK>IK26G_RW9JD6OEO]<URP@!XYY
M1>BHH%F^:=\E:!VY"AUN;LIIT9_T0#[ZIBI.\UK2JVV>6J\O6XFF+:M2:W74
M*&JM?-HZ*(?U,\/(#*(.]\I!#D916/"YR+V'N5<[1=V,D7Y_\PV>7MK-+[P=
MTO>\S4G=UM,"SKYH(D:'481A],9?Z)S:8N 7#(*/Z_N5&/[VAEV/DHMWK'+A
MY1S[CBW:H(Z1OVIP;@A?[NE<T+F#"C"X'G,C'G%<Q!\?AR=A-XPENYB,&.1A
M@G.D/VBG<OQ4OWU6C.N"_J4K1UD4_S][;]H<-Y)DB_X5V#SK>R6S)%N4:FT]
MNV8L2FIIIK1<454U\[Z!F4@F6D@@&PNI[%___!QWCP@@DRQ-5W>+G,HO512)
M)1#AX>'+\>.S3 VO4]^<()#.7N2L($ZW:%%UQ;7LTB+$*52S'Z?T&ZJ;Y6]!
M-8<)F&']BGG>83PB19A#G0B5=GE<)]M'!MY$3; N9.0+.:XN(58EF/<P!*KC
M9!U&DZXS/>\'4:W8F3W/G'G9SH>US(E<VO$$6I1+Q$ PN+:DSEBVS=IOP4/&
M]Y@<)8&:Y)@XSGZ:!CU,,6&D#'_(,HLP7V"8Q<(?L) #NI53Y\+XNWTV9HE:
M7.1]KF/3&9>+PES)JE\5VPX*2V2I,'WIT\<[912BV1"=V>Y,];)$@"F^2D;5
M+E01%A11']^Z6/"LPJ6F9+/-<%')+VT5+UE*SMV$UXX'TLE^DSF\.0)T9VV8
M5W$+SJ!=9?[EU.29+1L$PH<(6(EZ'1&+XBJOAKP/>_ 6I:O;7Y2@<4J*C":G
M SDF5T5>]:MYSC,&HB;+W !8(7I%WMJLRWF4EXH=R.4I<E[)&2:CVXX%.-$X
MDZ-"%])>E\U%DQ6=CE],)EQ:R]K"NFEAJ<D-<D2(]7I5MD.7/?"#YF$($U[E
MLJ'P#=0&;D5PLCJ1QEQ$J&HNL.6>AL_'@T4G^S[ AURVS76_XFO[XG*+7\GZ
MEW5^45:HMI+'%2R1+7AKN ZG!]9E_&2793P&WZ0SN(TF@X9<977:RX+GSI)G
ML0T$LS9'&6Y?*K?"HNS:P8Q'?/BBJ/)MYRJY YGS%F,H:WVP%0/@>;)P77*$
M3K:<KQ$?419XUUQ&WJSUQS@&W8QAVV%W#J(N]0R&+=1L&M@+OF]=9K B*M$<
M+M2R[+/L+W)Z=[++]0^JZD5C+9I$.>$Q6-UF< O7-H*<P$.+7ZSE:1#*>FOV
M@6A"'HV\=Z*H80-$\WHMG\O#2105+G8W <*#!;THQM<PK&W")Q-8+PI\W*XE
M) />8D(W9JCL3)NHPTT#8\U<"SD7<*<(33+QA;RZV1:863DA%C[_493\Z)$5
M6@^U&D(ZBW*-S :[[A1R7"XSSDY-BQ'S-9TI^?5XHOR,$KTUT[\B.LF/B@8&
MMD?BT,!0PUDM>Q6%)S,_$EMK!(39Q<R(CKZL94[G.5>!YXR:"W: Z8&'V;C-
ME+:YH%578ZGJAL-I:<-Q7C%5MRA$\PB3\]5<1_HB$%2NYUPD9L\Y\IE!@6\^
M(RCP)0Z?_7&"5Q^>O\Y.LA]^.G_UYOGY^5T^/?=_P)]5N=[E@>\_]G\IJ)UR
M.ZGD=,WMB%^4ER64AIV6W/%5,R!O4==J'[JQ).<Y:@6.,WG:HL ^DP?(66J^
M+%)5W*HP[>58U$K@CT6QR3:BNY%(&'KWLF1';O!>*J+F6KY*C_$U[J[P/!V0
M'!BS;"5?4K1'?V7WF"W_+*-X*UMX,OJ^F*]J-Z\_XU,R] CNZ-'-+6#A8Z6W
MV%48?;ZI"S$ YRNQ$D0C-Q=R[HK[BD%NAFJM@2\Y/PMQ$JC/SMZ^>Y9:O'ZG
M76-CQ]'7%BMQJ_$DF9NC9GGD\R+3N>R9N10GLL<(.YZ@4""8/U&'2PT3Y$;L
MB@^XE">U4-.-S$@5YEVTTM:F:.LG^DK. 3H2] &+GD:>+DZ)$3<R/\?9#]NL
M$ .EPA\O"M1O\X;9R(W'V43M[ LDCY%CK8!=+Q<4D_-K,ALZ415D0*:DLS !
MK-!A[=7EB>78;3O1L/?1]'[15)4:7G;XF(\I"W+R_7??TY_"85NT<ST;Q>W3
MC40OA,&31/1&LBE_>WM^BMA(V<5[9ID;'#!P-*V,3DRE'%K;C*?AT)K(OCM]
M)R,P UG\J XN^%SV2+<<*CG]ZK*^RBFIXR'QM;C;5P:6(\30GZ\?4LHV[K<;
M;+X*IH[X]I>B;>38[C[.&"MAV GFM>8 75&(S,NS;,B+@7J"GWX/)>"\K&TW
M)*X1@ULZ^XA*7=%0@?6W&'L08B':710AF9/Y7X>2\Y'&;1*-'/8G7=>@GK%J
M>7;1-N*XM/ I&.X1F[%LU<V2C<E45)=Z6*EF->.5]CS-F]2=]IV;1/FPL*66
M%KOFA<.17]:RWT43Q"LA#D&0,-"A*Z+&,M5(C2#J:P:]L+@4US_1M3EEMFE#
M\&"A1G%Z>#6,E.03#>QGB<^4R'_9VYD@8X]-$:#>U3SM5^M\[(?"T,2*72*T
MDU<TM9. O>RCH["1&AS ]G,R18A )4[ZM1_=.+/5[F^NZ*!#E_)\T^A4.#'\
M*,?Z6#S#9D(//3V[$;1I_&%9/")5OP>M/Y?_@NU#SW6-,:J5'R:E !E?:5X/
M'#,Z'/)5<$+3;(4_DQ>))2_6]"6_R)YD#4'E,*@OCP 6DFE@?&Q.APFWW6G,
MS9?"OE&Y')T<W8SO.4!U#E"= U3G -4Y0'4.4)W[ =7YLI8ZN"F[I<:X0^*X
M9*2]S3=;6I'B>$?[*4F^!CL,)@MB[S"9]3IU_L:.OMI;T8:\&'KFCYD\52.-
MOKK;V(58_99Q%P/RY>OG,_U[$L#AL^?RU.YC657(1P]MQ\PLW')$%.H0UA43
MK2OJ4AXE7ANOP1,\MKP8Q)WOC"3B^!YB=GXI+-*=(4*>?3>3+>]A$;I%L$W'
MP8Q:+SWYZE%&PHR6+D_P6&7B+LI:G1DY;J]7#3S:YAH&=0HHMXRWDR/U<*OD
M6;*\R"_<OYE$R.JZD.]#RF&Q@'./#/;U]?6Q_"S2>2PS,\Z>QQ!XHQ%WO[_L
M*.+($A&]T&I@7UF\,6M$!R0Y^5^PPSYJ8FPCXV]D+\3T<=]<%G3^N%.1C<AE
M@RP\E!]P3N-1S+)E6Q0:D9))+^BK= W* /#BO&O@KR!. CTPYQ-H,L,E*Y [
M9QQ+4^UE17]N.;1UV2G,Q(87<2<)H@2R\?R3IO10RV 9-&[I\^=G"H^2'^2K
M2P.:,5<H;Z\+43$</J:^*^;'E\V5_&-5SE<1EA;F1N3ZTW8'!39-=:COG%X1
M84(RM '! "8]^*&3CX\?*"/_7,'^4E#%P!7_DHBU[?W<B*?(_>9 %$6=(YK<
MJE]>-A56#L EGB$:V&O$\A+%16W57N8U W,6?$1TZ5E[G+TK(-\O\K:%7L0!
MQB!3H7FT'_)/^/,9K1 &1E[;H?3>$1COY+P(;Y4+]!9-&=/R4XR!H21#5&F;
MJ:N.&$JCX<089DQ""/HXBQ-T6?%)%A$W\0Z-;X2(V;&/U[YA,1F$0HW" '0F
MOO5@V2)])D^%,.<Z&7+Q=QGXE/3\X$LTAN"ARS"0^R=CGU5&!:&"PE Q>LWU
M/_G^^Z\<9C%4FLO-5BJ/C+=!.SL.4'/("@Z(!R?C7_\^U 7A=1X6EP,;1P.U
MH,QRP.MH,,^2%S!JJ-V:N6((&\VSQ%]>B%JKD?916TPCBV].SY^=_M_L#;]+
MGOR:&!2.X[S8B*)$;%4&HS%ZS1D5;6L1VDU@V*I,&DVXL!;_U;0?E04WZ'ON
MBS?_=2Z&FX^#/K]!]N8? 1W=KB^:*F#87C\SZ!K']$;LD_&0B@YVMAP\S!ET
M2. OD)3R 1E"<#035R+(9RN<XL\*1K]PPZL:"08[&) 6>/9**^,PMD3IC+\H
M>U WU]E'^4_M:Y]>&X\]O^$A'WYZ_I\SM:+C]]_\X1^*FL,)HSG_3YQRP'XA
MB"[BTJUR!1_L?*NOLTSZ?31B-6\0SV9/% 3%EB8 7.N,T3>I\3E+L3B64\ !
M+S?O.!G<1:VQ@.ZD5X.K$V+F'IQ6#*LH:$!<Z-]P!7ZJ2Z6%5H@'8$Z:QN);
M8@J"J;Z8O] W$"5CF@GG^/$L[/$PD++3*\.FE--.[L(U/U#UP^13PFJ9CT]G
MAH"-RN<N2\=^D^:\N.1*I9;W7?Z*&QTU@Q115JX;46.7IHC4MLT5>I2=!XEY
MGTB,KJ1-A2.9SETL1"OE3G:H1G:>G\_\^F/Y4Z&E*R=?4?><G#S-]LVKG>RX
ME#;$'FZH+GM@C<,,B_S=0QYXRW#I?C/;QZZ6N_SF.'EZ>DM^01S%T#I2OU.#
MQ!#9 -I7S=P<J0"'BZZL;!$J74-L!MAU[1^EZC.I@XY#3S#J=UG$]F\4^%1Z
MM-_EL=\*X%DV\R$I$DJ5IZKH'25JM1>S[$)\/ U88#-=6X71E3[7 :QZ$F\*
M<3+5%0^WXR4!1.FWC@(G ,HY$L0R>@AVR4&,HV@.<[X(N4(&Q=P.3&")"EM9
M;3O+.6HPRLX4AZ!8%G(")+%Y(.($$1SYGEW@B$),CK-3RZ\J4G9TA,1,^9X9
MWQ>]"YCEG:DML35S[FO:K@N=7P34[-]A2CO10 ET490AU  C= JH<J"2XM!3
MC*-/^G1LR<?'\%6$'R]WH#V^:A:2Y&-C#IA)]#F+91R*9!GVEI%##4]0B1NB
M.9^W#;#/^^;,($>?KT>^R,:[+85X\SGTY3^)3_P39KN<?XX)@4^Y?TI15P#G
MF7F(G[*Z&%I:J!#7#7J==Q:YLN.NHVVQH&,T[_5 Z_Z4M?FF7&3%%MB&JR*$
MU]\_?SU+M"S@&S=<B3_%JX]QI_[H:@'#Y,G]^-'1XZ__0%.B(=Z$CT>!70O%
M:(#Q!5#-,]R%Z&0^!V+Z;_8W B*S"I8[+7[6,2!(><5X_L70=EI1N&^L\MD(
M;A9$U;7]R/2F1:+530>PQ:U@B\<'L,4!;'$ 6QS %@>PQ0%L<0!;_*;#="/V
M324>GT8@D2!8#]V\0B;@C5I59B.5I&R33RH7GB5>:JED?NG5;I$R@8^M"C>P
M%L6F7SW5:[,3/ O^7(5Q%)V:0?JWK_QO"[E-_G2G(QTW,95,@/,K8H^1_"H7
MH8Z$2>$.+O<"L;>:MJ46%R"/W!K\119E]*QD<=JU^L^&RX\KI7#C G?13.72
MUNEBSO8^E'&,3R%^9W^L\[9MKID8XN(/J'EAUEG_,GH4*P<W#6H1^4RQLFL-
M<H@[4!.5TZ/FJ$6^PT_6[E?+#689DMWPVE%QX16"C3@<>0L8-BHI]C_%[EMM
M-PUO=08+V(7]BD6/5\;L@%)&LB1H/8RE;BZJII$5^K05V<;*0#%Y#FZ>*]H<
M;]7?5S*D]@H%'Q;QD$'*FY19@"*?(R.R] <J^,)<@CE8,5 4UGPJC2,"L8:\
M\G=<-(NM/A$UI@OY%B_JT!QO&58(6Q51Q#FJ:X$,%[.O\UAEF-(X>H0H9/^Z
M(&@E.H5P1NGTZW1612L2BI%G2]DREWG'J@B=4@2[TBDS"?2OC"6U<:R(76'Z
MUP#:F^"J)&N&E].[A32U\K<<,*&^*ZKE<78^(/]HZ9.WYZ=)E4MTZ43BZE =
MRTIT/JP#EB5;B0H[SGY9 5FA9;/Y=?Z1']QEE_@BC?'DBC]+JZQL&B<?8^B:
MVK9GIJG;4)2;5'I/2@TP?&B*BZ+ =,R;2P4),'J.M>)31)#E7$71!(+1-3..
M2>!*//&FO2@7&"("?.IEAF*OKF^;C[8&\J#L,0I!+HK^CJ=>;J Z34H5"G&U
MBW6I8 +05VPU0\VDK.SIQX].GH3RYH4>5H^_81Q G7V !;,GCXZ^?:39O0ZH
M/H;\L%GW5W[)-JB-;&CWC3Z?_^H8T_ZY^A&5T_TH5D;TB%SX3Q[HK<.RI?E^
MNC3R*NKW3I2'[!YL#2UA['07DPKK^R??X,**F4^K&VW::B%.RPC3^?57X;+3
M=0&:+.R]MTLGLN&#@9@I>Z(JIF,)+_SJ<7S2=3/($"DJZV:AJ;,XX)&0/,.D
M]YH^8^P(U79YY;P0\G$SJW9G,,T94?RDH )1&@O5<?FZ@;9M#/?E6>. *0TJ
M=LRM(NJ&;#J3SZLL1H>%T+@89X4'O*JDJT)UDM6,(1S?*D"HD"/H-4S&)-@]
MJ8VE[H,"'FIC.PO/X>,O"E5MI#7 U7*=XG<Q.&IK6"[=IIA#QP&BL!'_J6-)
MTR<$&%D]EF])M\1Y-WJ)3E0P(;6IRC0JI+:5G>-Q\K9(HGPLB=.)OH<J4<^Q
M1/KBB1)7CR:.5B R12 OFZ?Y5;&4ALHL'#V Y31B@1FW")X8C]G)LU4VU=<[
M$I6*HN^:)=&4A LY H^SEV)>70&7EB1KK$J9C#BZ+]*O*+'A\*0R6!*RM'P]
M=G@\+6=FF<JQ)W_]2B4:S"N DX6:.;UK6<@)+<,YY;&(RKB.C#B<BV3>NCD2
M6HC^%OTU?I6.3(_@" "9(Z'<7.4=N=^4>J0066NJ40GZN3(LV5FS G9'!3[]
MZ"YS@ V6; ,P*7>N?-EW3_AEX]+(13M<'LD=94=:H8G<C^[_]ML]]V-Y&,.>
M7/O-GFL]_:<&QC(O*[#7<3;&-S_><_/_!-O#CGQ=($B^4@,\'Y"$R^O147LN
M8E6(JGGP_/WY0['Z "1VN-N92)["N:&!'Y]H07[.C.#=M2?.7CX___#/'M.M
M(]#I>HP81&U'F;HSA*]JI0@.B05;)=.[JJ>I6_=)TETW+8<%9FZNSJ76:-#J
M+%I%B:L4P"U4- ?'D9)8W& Z4B4Z']%B-.9K6 )/OO^#&AY5^1';"*;%T%ZQ
M</F*GI=X;$5QM(4#K)A\/<1QIL;-ML)INZCM6_KC !6&RY3,G+),X?D@]8$M
M<YEO1*VNM8 @]3"N5X42.UHWT[1"V^<, :'9! 8P,YB[[)BC@!R.Y%$SH]$8
M+!RP@"]YIQ7#+<G<HV=6Q"]S]T,(-. #WR;BH G44S42O^16TC$OXIA#<$31
M6L]^F+%B7 QE(!LS+*K#/BS+ZP% ->;R"W5_DRB+B BT7C=FD8#U6"X!H'4&
M,>6QHTWL$94IU\89_LA*J^VF2=D-NFV]: %XT;&0W6GROI<WWD(@3@A?NBD@
MDS$^&O?QT%2#8CQ#?(-Y<,12: /87X[5C='HYKKI>D?)NI<I\WRG!?XV&( #
M;0PD9PY(U70A*K<3D-1EI< PL8[9@8X&TX+2\=UFW2O4""F+RUJ)599#/3=F
MQ>#ZK8LUSE^.0\]5]:DF<;Q%X;2_.^Z!KEH7XDP$[R6Q)4+B[1A1ED4QAUIG
MAI._%O+% ;ZHD3'G?G'9C/$MN'L6ICPOJ#XSX^)DB&E.+],5M@78%D6'AD1Y
M^/81P" ,1<>!J1Z/8;P ('(#N\A$_.-302JWQ\Z-42=:O##CZ5P9?6)>H_AE
M%'\R_$/?RY(<9^]&]N'8[S3SN-%?:2Q.1N)2(4M!>"96@ZX-. 4+#='M2D=*
MJR*Z2US2-9):6GSIW'V9N)L&$;LJ.T3UUDU/7J0&<-&$5+=+[7C9'!_E-L8A
MFV3.J(A(I*&[H<V!PU,$6M-^5*)B.5))J7L?K>$_1]I+[H<8A2X*,O.-68NL
MU$#]> MJL-S0ZCJ(L@G!"V9"2.W<*DVR*@Y&!'+46"C 5QDC VDJF%Q@H)EK
M6NZ)$+<% ?P(*=7@P/2MZ$"\].2 >5^4RG'CFHNX/&< M9M"<12J@H^S9_H(
M\D-BOC)DNX*HN7N 7-D:M5^&Z^?CPX%I6](&"1<WAP5JYQ*'=*74.2((D6IU
MLOWWQ.1%QY3 ;;4<%>BF:3][T94_"#D^&BD_BGAGI^"2>H-O>7M=\3AF_=4@
M:YF33>@&GJM(/60?@@N657,]R?,0IMEIT=$ )^@ @[H1!O7D (,ZP* .,*@#
M#.H @SK H XPJ-\&@VJ;2['".O56\FK[MR)8*&Z*.7:$YA*B(/*WU!9TGKZ%
MV'+SGE08AGX2*W5H+S20Z':50UD"-(6]*A+81H)$N(]ULS^@RP#*R+\[F1EK
M;HE^X+L4ILRZ@FTUGZ\*<;36\",0CTP*"1:#<OI8)5..LO9 3CDUOJ_%!=F4
M&^1V*HNU7Q7Q@6$ YK>5]95X@.)XF(4_7 U5L\G1]V"SDA'7EXV<>!W"/S+@
MG]Z]>\>26JTLP%,+^:JR<T\TUBN-D$C$[: 2P"(;64]N#X<R=1C5&M.H_M$J
MWP0:5GL"P$)K\ ?URCMJE N0V$4$EAG0"!55&3]"I@%CIMM0,+&5*T3+*&;I
M)#R5"?6L'"*\\5M*PI[^8OZSNAUKL L<*6)O])&[BX;(K@)IBO$;8XIM7N4E
M*&QL>RG'3[$8/2..1[Q#9-'1"L5<P+^1_$>60>/(;6$-D^B&D'N%ZXOG,7:O
MGKVFI3=Y68-C%RG$*ZRC!M/A'.T1%SP;Z!YOT\'R3+#U^KHQ@A^8>=^JPYC(
M8/JLI /8(M^&V&>==\1O4:S8_6!17F@R<7$%%:(\5_YW8U@EWZBUYN"J XJD
MPH)<>+.N@PSK"]S-L]C0O-?^80 '6/;7I0^(-FT)$,"'Z;;"%EGG\V+0YA ^
M"9-9T\):9=2Z*(QS("'BO8=1C],TTA2F,U0D0C8L.! UGB$+LM>(_S(E7BM8
MMM>N08&]=48J,K*@$!7"#E84EI'V1"B>F!.E>'"$B&)+IU)ZE$JI* 5%E-T@
M8(%[99)Q9[20.D29+O2AS<;9M$/R*0(^X,_S2S@= 5U"D(\19Q,:9V\,@! ;
M6N4ZLKX,O3LV V&=U@%"/]@*,1ELEG6N1XW%4BUUG,SKB!-X7>1V!R892C82
M;)-OA7L]SL#N2:8\-H^<T>=,[,1:-$E5E3*S=@S*+LS.5C(4^3PGS' JG]/%
M%=(PV^R'QK\++YXPDR\=@)/(U%Z2!SVPCL^/ P>$V)]'&&$7@E-COA]H:P^
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M1V:F]MEJ8QRYG_D.4==;ZZIG@>]W/7V+]1>O40U,   0VJ"KEW\X)'$B_Q_
M_KX7]*3OE!V=C%!/26\JEIV<?!V*OI.^:]:?]?-J@ Z'SC_TT/ES@4XBY)%\
MQ_KP^1<NO_C%<PX:I?"(D@@I99VTSR=?30C:TKXF8Q#:7(T?1DYF8U^+[ %'
M8+,'I_VV:=6/8G7:(NV)J(ZH/,+QN!@>K>LE(K,A7BJ*43S"303DC;(FILV4
M#WRC*1B]2Z>=3R'\$3OPR)(LEW%]1%5JI?\K/VD.@+D; 7/?' !S!\#< 3!W
M ,P= ','P-R] \S=\8#8=9*TFB9$U7"Z*KH ]#E;E74>T'(A?T?CQZR<2(4B
M]R0IV5G,$>XD&T%4@R>[/?2]IB]]7"]_L!R81@ER=UM1&'F-Z#]*)&*>LM/:
M[P"Q6QB IEN)A;A-7)J8,]XWJ-"'J,[.T=0D^P\Q6GV(CT_&0_R ,I>27IC5
MO1B2X)878-2A8&+\%M2:EK58I*2@X.?07V0R-T3\@T]*F)(Z;>:3\>.2!R:U
M\^K_&QO%='T^EQ__X-_]"_V[5^Z\O!LN'$%WY@&R4X?W?7%?+P4N)GHAU#@I
M[H.9LR0^/?+.1EC%_<K#9-,_/Q8*6Q6<?/J%-2OSVE&,0J1+A*W='H6-Z=$.
M[]9RT_# <MWK'E2JIXVWJ0--OUB)C7%E3P%X7BL7&\8G^3CE3R,Z4G^OK5IP
M"^K*1O<XI;8",P+)^4R1EO$9 6_9]2GW=1C'<)$\ELQ\@<&\2TNNS:5&7B@I
MPW6^+\LJR(+;U-A#-1B+PX)LD"/X#R;N36Z3>]ZWS<<B.[5'LYH-%YR*4D:8
M&<J^[<=_Y_*_"-EN'V'R4,Y?O()(H^70<@;VRY<2M^M:=JMR$^#3"I*E-KR9
M<V$T'6%9#?L:^WS(O^2QA;9;%1M)N\/IZBA7BS4>\S:PQK.F%.7</Q:9X#YA
M5-Z25HSL;OU+%D!SM=.-DQ*P,^\TGP\;G[,DF-SERP*T,84M9A4(-ID,L%9F
MNH4B:@Z!3'0O):E1V;'PDI:<0F##'O70N4MB3%OUGDP%L8I]S9D(Z!)\$K+M
MST4<GI7%91/ZR"W+HEKL?*;#F0_9KB\0>)2-W_ U\5!*$!QWY5RB4'=%\9$[
M"4LJ*\Q40HHW";BS%&33IDFP;*C7HO5<E@F(F] )A U!)%C8!WG4:*FN4319
M0W(P:L:4MW5%76A$"[-(>XFVL3(D=J!-]P$I(IT]=:1R&HU&&AU#[(?V/FQ&
MY4_#9P6JU_39;,@9VMU4N^TI+JMAWA!@WS=5P?R/926ZH5+JB!+ ?L2E3Q=Z
MV"A92E (IOB4OL- %."$V"5H4.ZT1<A/W5@9L,-YD?(J>A<?@$W5+C8"U< C
M%1 DZ-$I%Z!G;UC10.076EOTFKSQ\XGE18@#)_D]9J"H1-'^ JT^M.T)B\DU
MD18/I=@%,Y1[P% 1.0?.)S8\49NK(J.JB+1+YTBT'=T4(O%C#,/!IO\7JLX?
M"^M$!REY'LD!O"UKQ'9]*/+UEP<(6/(XP9SU,B[N37:?XK9+2 Z\'L?DT+!B
M;D(DG:I"XO+&PWVVZSI'.D.+'\ N0FM48Z9$+ H6VR0+E'HH5;H *3N#1C40
MSNJ\#SIUFN<X#?5G.U=]"X7Z7+&):PN(FRN$%).3EA+0YHI ^7R2I=JQ4[%R
M0*3Y?,J# +2TGL74EE-S**EQNDDW^MP?,<N6]B2;:M $5?P/#!#<+0([KW^Y
MRR._I>]=6@J1Y%J=)MYALU89TT=F;U:M G7HK=Y XG99Y&VRU*,V;M;Y/07#
MI_C4 '])MV7B;K\@?7@+OWE/.9D(T'SHE./D&@<S$#6&F&,G9K"M6+]:[_&4
M]GQ" B=RR80/OX?R^$Q'?I<'?J/-K:)5F%Q$2#8(.6?9*?]K!12JA$[/?QZW
M;74RG2G!9^C<&@%F.^UT9\[7F*MDPQG-ZUI.! 4YG<:FP2+.@:[\=.B;\Z)7
M:'G !+.8:".2WR,&,RX-]:*1,:TG8A@TIKW/LYUNH2AMEE2D*0PAK5HEVZG1
MUB]E-\A60]$7 N/?<D]4^5#/X5N<ENUKL41GNUW027P:(3L\0O*U<O=$ZQ:]
M<;W9FXU1'GE>H-7%R2/C['>8<7:-:BUR$D_Z]0907WC]J"'T+QJM4'9[\L2+
MFT/$FF-I]8/P[?'U)QC1^/,9=%?VP;PSE:%G7QX,;7N4"0<J9";/>'P\>4DH
MH(/=O)1E(5N;!W1R66;\V,G)7.# K"[1?G"U5G,Z>!:X6<]\3BQ!BJ$H@D1O
MUL<P[2L;L/;#9@$87@HRBQTQDZ(B<DXA1+("KJTX"BVG78P&8(R'-GJ%B79,
M"Y@" ?VOU,3M+L+)-\?9LY@:Z9L^PKX*;3>8CW#,7S_^PRS[^M$?.):O3P*H
MN2YZ$NJ*/=9-7M,9LA!+SMNT%6;+Z)2J]IOU^0$P\^T!,', S!P ,P? S $P
M<P#,W#O S-WR99";X]"!T8?KZ66F>5*EEWC<Q FK1R%V*3,);8Y6S.W'S_=!
M[Y/./?G^^-'7-^O5OU?G?OO=\;=???]/UKFZB_XU*NB[7]M:G/[H'V?_*U]O
MGF8_O/KQ^<_/?_Q_+]H__I]W[]\^^^GLP_EGZ.1[]='/GI^?O7_U[L.KMV]^
M7?<FY\Z.O3:?%^*N/OV'*65Y@FKD+S(MB9MZH^(8YQ:^\T_RO,OW__BTRW3L
M^T]25ER=_'.R+I\S@G'2A1D7B^X<IO*W3R6TU&$>?_L\/J_*OMAC,7U9??<%
MUN8L1"HM6+;#"9+$72=AR5$L<Q:">[+<XAX_18SOU+M ,2JZ)@-%J*6/!"+D
M7^AZ) \C<%<)#QT,0.H(T%196YD2S!437H80^^RUP@UY1K$=ETUKQ%9U<0V4
MG(;B9I-HI*5K1K'(JI2!O2O:CJBM#_:]IYVB*32$S/+DLU4Q_WCTJM[+B]+G
M)> !B^QR*!?$9L@?,2%#QX(Z@+F,9Z+0$E/B>M*(IO&7T30E/T2UQ=WR68RV
MAP%[AP(&&*_DO0Y3%D/9:$="DDA#GT@0Z4 8/2_JOS3:WPP\D1W2D:VW&=-\
M+$@S.L[M5H=R_-M,!POUW%,#X=%!&Q\,A+LWE<P&O"S:PY0>;*Z[,H][;*[#
M1/Y= IFW"U!9G2'%_QN,V-]R\GZ!E=BQ+Q\!&-O4CA4#BK.*%"=K-#6\%OM+
M327V'2H5]Q*:DYZF9BD,ROEJ9,$Y%()D D[FX789$ZY.%C(F++.&[B^F9IE<
M/I05I#ID\HMV!O0V4K;,&[5-13B$TX6,NE<'L(/9@S->^CY?;WQ2DN(RM*N'
ML=MKK'3F #L'C 4\1PM>KF7VX/F[]_:8A[_1IC/WZ+[9=&<#"OE$KGY0@,Q!
M6?T##))D6L\/$_J/G="?L?T/D_J/G=33\Y\/4_I/D-.;"\0.L_HOM_U^RPG]
M96P_"E-B^SD+N)MO6*PGWS\U4\O^U5\WT<[1ZYV&[4]V26[_5\HV^T>XYWI5
MU-FV&<+3P1]NX4C['7G?PEO\Q4#2(JXIQE_OD4J6"N$!1$+&8]&[ TSVBU8^
M$__?7'1].VC8=52@<;V2:<@FZDMOBC30H\8+IU6<L]L-4R]W__MLTZ0@]%\>
M%_PRYB,0P6,@\.=@>.[/A^_?FL!I$ .-:/$8!MUX:R"REO3*>N@3%6+6 2(-
MTNJC?$'8B4*G?P4JG6@#B*76<UO!$P&\X1U!NG^HAJ)OL+&<8O**[*7*1_Y9
M>&L%/K_$7_YS;Q'?#="; ^KD@#J9;IZ?G[_Y\.K'4P(P#D"3_YF)U_TS<MX7
M%9@M3KY^]'>=$O=P(O:?'U9K;O,15/K7CY+B,@3ZT%Z)2E+[N%A-)3O?W%AD
MZ<5(O;*9\D:Q=78YGX^S5VR<43<]BSV613:MQVS:XRQ9-"_:M[1Q^?/INW,?
M_ /40U4RK4A%_]Q4P[HX.J5UN"!!+"W+<WW^P^QD4MJD)R!^VI)ZRAL_I,6>
MRGWP^S*P.MJR\@\N^M^[;^[L5]^Z._3CH[VC<^!3(M+H9OC&P KDIZ"$:Z:^
MZQ$1MCAY#B89]F!MV-[HIKW4;*Q*6N[:&L4Z=H<,3P=MP7+9:)_FQ<;(;2YR
M1,2WNHL4MY%O%##B<F[L4SYH[T>V;IQ,'@SI1:Y5^>NR7GS!>/07#D6??S@Z
M_2T'Q-W[YOV"_LS3+BSN(^FZ4R@E% 03SK&<)GOB>WJ-']BPVE*M^6K0XF;O
M=YJRD)#.8+MI1J?&GF #5L&J.M47:8^6H"U85%LOJR29 ) [@U;-AII8W0/:
MD*><)WZ/ 9]&!?_F\R0M9E+HCY+0=.+/R^N+XC>X''>GV!J=>K)SKX!_%HOD
MWP5@_VFL@><4*.C)__[9O97O3FT#OGD_(X *2_*]?7-9.!' C96>3[[]PRQ[
M\IU6>C[Y]A]5Z7FG9_;7I>DNC_YFN7 V"*(DD^PV\]GEFA$6]-ZRQK\WMXBV
MYQRS%Y8^+@^,AD@+MW*RYD:/LJ=/:FZUV.M\R[8O:C^O-\5BU%=UU$$U[>.1
MMG>U)L;*%> =7D%3R^+Y.N] 1\/_99L2U>6Z$=!7]8@Z=*T[YF*;M*J9#EIC
MH?)1Y5H;=V'JM7]),08JWAN!"$50XQHHS [WN)QD5^B\:?L]91/!7(%/[%(.
MSD/]TR$2]6OU3Z<?GO_Y[?O_.D2>_N<$7/;/"*+O:U+1_KX#3]:9^\631S/O
MTOWNY-',DW'X]YLGC_0\X7198V\SX*EPZ0L7Z/B$+&#'MI=+G$+J&"O%<33Y
M XA^'8[D93,?C.\F.;G@4^3S/K*%V%D7$&8\%-F'D&P_B"RQTE5YQ=JV["?-
M:7\7,:(7XA0MFO7O(3 4);2,XLM_)/(KLEUF2YT4-Z&4Q\>%6,;/9F9%OLCZ
MX8(\8!3=I/UN57PJ(]L]<MG@<Q71G#O4T*E;NM\J;W<V:+%?WGZJ^C;/SIOE
M;U*E=^]K;\[TBF!]("W3B\>/7-+T%V_D%V,%F;/62$EV&:&A91EN$+VW4F:D
M"+BU(C2O%Q-K]O>))C!>;G&'9!O_CM19(E74;D&FIB6#RQ*)&L"[LQ;\ZSA:
M<29VV4)91G%HOJJ7)9C:SPN 8$2#S=G/VN1.(XB(33,6-]3E7^56>4BIW0UZ
M.>"#OG2"T"Y"KZTA:V?\J;WU&L%YW*$+R<?\LM@GMC>&Z [\6=\=^+,._%D'
M_JP#?]:!/^O GW7@S_IM),:[F;3[%_^.C8S5T43S#:9QF00;4?LJ]7K9ZQDT
M38N$EGA)?V/MWVTI-X4(>4NJ)#/GX71]-8KEBBMD3=*\-$GE^?A%WN=N,UI'
MK+S.J^W?G"Y7+XOMH)!4"=TDV!4#M_6 G2MO!$+]S/9M6G3\8-^2F.1!/V/Y
M(4R'Q8D^/W5WGT[)0\3_'^EC'K"F__,BW3?@B: "?RSKC_"K?^=!_UBBD.AX
MJQG0HAUQ\S58_TG>V[?;<1<4;0HW0QM!=)G3G#5;(_ 0J)N6<-)?&@3C&;Z7
M.?\9.=IX((_ ;TBAM\7*&KFD!X\U;F#_%)Y:Z#?T^P)]OL'/;Z^KWT4(+(CF
M;-J]848D!'N\;)KNLZ3W].6KV$D!/78V@&946=Z*NB[98K@NL@?O3C\\G+'K
MYF6;BQUB;6A-] DP4, <&JYAL)3=>;YAA/<JET<EF$TP667Y52-:85UVP33[
M;:4Q7\)X/@M],\Z]?<H>Y-F]M*<)R\D)IR]&'6LT'CJ)LS(+E"T++7%LE@4;
MQ(1>3.B>H>1KH1\#2ZG6&RV*]%^RD9%L4&MN"I)>HY=KAEXTH'==: MK8,N&
M<$"_)^UM'.^3-.W@R^I+_Z<8J#TZWR3='DS[SF*O#.-!LPXB\IO9N"5$+TJ$
M!O&J:?K06<11^#)CMM^\D'26_72D35##*PSMF8QYWK#D\C)IG@*AD&&MQ<K7
MR@39F+E"5F4'S=%PEN%J(*3(<;>5;YDE75>2#T^ZS>DZ!J!0=$O4SY$?F;Z;
M-VFK%5T6.8>NV.QJS&:"FP\(HH,_<? G#OZ$)^N@4W_OGL2H]1JC1+<<,CNG
MB)^-IF:GI\IQ\!M8:+:'2J K@;U=;MF]=!DPLU2P%TC%V,DLTRVN@S6.G;=-
MU^U%%+%8J"YZ/.WWY63P8/V=>!AI>5@HL$_LJ<2.&'792GC%-*"J!H;6W+"0
M44P9L2.3)O%J1@4K2GECM7A3<^F+O98,\&N:65\D\/+?5P&8&92_!U#1:5I#
MD*C+&/V .:O$"UWV\O5S.A,=(N!K-F53T]5P:&TC;NR:E\#>+EB!0(*^BZ$K
MV=>5M84F=]'Y^%TIO+.4^N*UN']5\?M0?VM^:Z*[YD55H5UQ8 -)&L33_139
M%%F!/[.OF=^#XOCR>&9UN#,O#W^H,12TN]0CW L)K0'Y[TJ5O6N;C<R*[,#?
M@S8+7_N_46\'JB<V\.[0'U<#(-I'FE(T=(B>J#X2%6;MYBER-?[>B3?<:Q @
M.9=GV66IY4])D6S>]:MUCC""EK6ZUB,2!USU"[,Z55M:KVA]=]NL]82.YS*9
M]@MCJ@_)1@6SQP5]IS$&^0%QRPKC CXNA*II9O8RN]76RQH'FJ6A/;%&'I3.
M(-3#VM!CCG-1S,ON)G3Q_2MX/<_S\YT0XI<(!M[I\L[]0WX1NE6OAZHO(?])
M']5N9H0<N. 'HG3: N*6G6[:LF(/U5GV\OGICQ]>GIV^?_Y/GGP^\4_ &)3S
MS_BV9=G&DIPO(@\R4?\^R&:5>?J.._9UWK?EIS-M*9Z]$9M\?5&P%^UW[(=<
M-]<T_RLT7.M92&"HBMAF(L27T["RDZO0$1V%E;6-,V - $"'WABF[$25;2UR
MO'4V,*=V2?E<HJJ;KQ!+/<ZXZZP6^M9:ZI.3/\RRD\=:2XW_[]92_R.;YA["
MIX?PZ2%\^C\T<KA_1N+)Y$YN]_L.I<8)<3]_>II0MS?MI1C&?\N- *;Q.)%I
M^N#A;XJ6]F5MW"O.XF^&Y4[B\;13YI:%F#;M]J@J<O4-D_!NPACVZH.9Z-M9
M8F/$?-LH7]RA/A^>HN+S&C'YZP7K0,<? ]Y5'&-K:_Y>B$VS"?&PS2J7SYG+
M"^7,7#7(^9OE+F9_(?_4K#V?(+;UT/W^*C\32^6W;:H[^]W[MT[\[A#(?_[R
M?;2^\H[]<EO-+4391/^O3C&IW<>R JEI/;2=)RK$9RT;E#>KIVF.GMC7)/42
MPZ/&)E@/M=C=B(.<G;T_ZQXF8FB;3/\MFWA^R_;U!,7<^7W4)2VB&^NM-V3?
M<  ![:I6(7U(?.3O+$P</1GZ#ADI1*/XXU__Z_\Y^>;1T]]#Z&4Z&:2KZS*V
MBFZ;6G2FR:0"N:%+L55F8:_,0"E>A51=H\D-4^#>@?!*>R02TZU(OAB>OE'R
M\TL3;A%Z<.JMP4MC[@FC)0@>+D'&P]I#?1/8 #JBV:]XO( 2JO@M4*J[$P&Q
MX$?V#(3L33SGSFPRL@] J-U'8J\$7P6AN[2@G]4.B/HR]B-$OLQ]M:0::T<3
MICMH:"U]$ OE59V=?/_=]_2Y2[#-H<A40\PJ[*R7UJBTN+HE(W<H(;A.:9B@
ML<N^-V!7G<GX&E/OR)HD8# 7]+ RB[A2Q]G9T+9,)\\X K]G,5E-%VV9 TBU
M F=W2"_ N-K45<KKQ,"[OB,\G+L9>7$^6LPH11W*GAUZS9!'W!B[9Z*/9_B:
M&#WM;JF,.-3??G^HOSW4WQ[J;P_UMX?ZVT/][:'^]K>:@B 1*6OQ70&X+HJ/
M='K1TPJH/1@HJ6'B>8:$#!YN+G(F;$ BQM!0KXL^Q(B4 SX[3ZM<Q3SJNF9>
M$GMN">5Z8-(&!;';]4;V2"?FX+9A,T@X%2P[RK=(U*HQ&G$R2B2FIA;8[X<%
MO!A:E$6'=2F[%;RA:.OYZU,@Q5 SEULL1@ RAAD(B(!KMMV(5*,&"@GN19G+
MO7"ZY$AK:O"5LFQEZXGK&<WKCVC$I,;ELKQHQ7FS!/E\%1R^ML^6>5D-K35M
M6C-5S<^Y?][%:41OWN(U)$40U[&-P=@:9\11Q@/V:BQ/&7I!6>>=[*>Z9/E+
MGW,A_EP@H"KV]ANR$5<(8\ZR%RV\A%GV[[G,QBR][S_D.8MF/<O.10K_IC?,
MLK.5.+GRNTU>RN5GXD4O\$^Y-I=!VA*=#H33E+EV8*53P=T2A2S=-M@DXWVC
MI23P"6P#%FG*L6.Z<&D][MM+L/:E<MF9E",D*PXXIO5BZS%E1@<\"-"!8Z_K
M=4@("( >B#Q^5>4[6@2_.F)CVCA\%F-LQ/5"BRXQ@K30R M#8M5+*/\*>*,4
MNY9@)@FM]-)U&[\7H4</\')@*>%FX+:=Q0)$'U<IVX\57CEMV3WU-K,I2MG"
M==!(/3 N"95P@B%!B$0Q'S<ZC.8=WD.*7M7SW5 96V,HYN\RMH#[B\BGJVP]
M?#M?ZV;H8^/BT>$011U(VM V0?=O@12"10\B2F9,>#"+_/:XK&'=6D*?/STF
M>J,]H'H567J3N,\RJMSXH]GS1 =9:O18:8<1IV"XK,^72RCP%KS\75YIZL,2
M,88N9PT58ENE..\-HLIS64'9EOPQPH<2:;_;@G$3SJ>R+?LZS,]=_HJ;Q=OC
M/<[%D6QB/4A09B"[O,Y.OGJ4G"BQUNV&E0] R5V!427>BWFP82\<(\,8BQN1
M&VC:35Y*^7^=6Q,2O686*]R *.%?<L1Z:>%,*$*8*K'HK3Q6C$XYOB(UASC2
M18LRV W[F]2T3F3?K[7YXU*5G7Y2U6"GMD6YOAC:SFH3Q<)'$%CLJ*+(WB"_
M<?)59BU&Y7>7O.I5 HVS0PJ7,G0L;CG=!.[:%R%<S"-:N> ?O(/!\^K5+*-#
M\MU#GHXQLIP"[_(+J!_,YV71L/@7:44  ._A7IM8*VY98"U^E,^MLU-9)E&?
MQU\47_4VW3?0I_UV YTN.VLSM/-5WCE+3)))F&M)+J&DH(=A7+<KJJIS])25
M[S9C ACMA:C(23WW]0VCW3N#U#=B&'4:%>Y735>X)X(TM^PS5='B6JSSA?70
M6E9#01,(!T#-7U('F,0N TJOE -'C(P!%B=V;YH"_).-O^CFH@\8B Z;S<XM
M /MQHCR-0*^=2=&_B>TB-GX;#KPP#:_J?>;LC0*B(>TNJ.Y$URA@GCG*EF<^
M9C QW'+9:(6<XWIS^JDZ<\-&#4+30Z)#VI+F95M@$F2T##1WLQ"03PVDR!C4
MF=EOS]'7J0*5E3JFE-TR$J84+,D+(4H%Z :QNX"9OZ)6\^8[(_OELW??_3S_
MK !O]^C32:](BYR:?8$-RLBFCK-WH8Y*=C!G5KD1W/P"J1.IGM10V]OSR&UM
M;A?+_MR@3?2LTOV9DF2-]EC3CD;)I-!-$D#&U:I*=^Q&^<4_W+@Q <9UTUB%
M+["9Z_A&PQ%_!2\0NQ2D6,D6)G47L[CNF@9PS(RTJ^FUX0TI8Q9YA%7@]6IS
M8D*39U>=<6[9*OH^BBLV/Z&N8ZR'_&N1D,ZHIY:LF,PQN#Q0^[\#Y T%J9&,
MS;4'93""H ("*ZDHC$B4"(=*!C<:D_DT/QV?'P?+T!O6!,4ECWKY^ODL 46-
M<$\1(Q6P) :2,M5HNCUJ<YA((R!7W%'[E/SMZIT9>U'-<\<8VURP\1CO+% !
M7!1F_.YH[U\*5_NSO;.= )TL1SPBPV"ZD@"%.>)AZ/SWV^9ZA 1Z.@4+/=T/
M"'J:J@1;H'GN 9X=6(38(-<%-W\<O\X>\T>[X#]=R60J1@*7"KY^$ADON 5L
M&4?^!O$6>^8K;!QMQ'[3K2CJK@OX!6U?R]3>0_/Y3#O;+;+G ZI[4-%6V@&N
M!Y(C$;ZH^1SUSZX#VGFH)8UG>L>^\7?M^:S0KDJ.9YR?S35NZH:+KI2CTY\6
M I,S_1$_6$3S[&^%&$CO"P;7YK/L65'CV3.X:1KZ]%!I"*2^DF-=[GP%B<<%
M%D/]#[&C\TF8%1/X_\E>XG5OFO8:?=3?-?KO\^MB4=230.N'O+S&TSZLQ&WF
M;]PP'L=G^>4#*L%LKH+GN=\KUZQ O2@V1;U@;5;JS2/*ZGHJ79[_SC+H47_S
M.^1Q]/1UG;=3"IN/=7,M^DD)X5,SBB$XU LK"XYB82QZ.FZ@YBW,7M6),%TC
MF,EX^LX'ZBR!F$?=?M.8IO?A.&$<:(#FW8MM7D.P@A/,%TY"\GO?=Z.=3A<K
MTIJ.G,7;?$5]=1#,1,Q'@H>).Q?K8.4R>FVFL2PIR_JFHXKF0+,H*A9GQ:!T
M:%B;-CX,<.F191U&>4#NW(C<.7ET@.X<H#L'Z,X!NG. [AR@.P?HSF^-^1&2
M'&PO1E12BW8GZ@F/]QH\J;!M-)(%TXA.A=K/93"QY.%B2;\ONM?%(E3M)&7L
MT.,RUZ]>O/W/[-GI&UB0Y,@I^N)NAZ1N:LE<#\M\W@_MO<V NH6;9Y=5<Y$;
M%:\Z)>R\F'ZAYSK3>O=0]6&53,@==KVWCI^1)4,),.C?PDE( >R.^0]A8"NZ
MGXM[A\PD>ELA(:-QD?%P=.P,:%@79L:I8@,"R%93)V![OB2&9/*N*]87QN&!
M9I=67T\/L;#J&.O2-6Y>+L/1A%"-+"F"BVU^G:'.GABD&4,FSEIG@^B25!B+
M\_WM#H^C>U8,7@29$F8KU6G943\G.2YN.L8@K^ .TPUKT1'1.22NQ-/TZ!OW
M;4B6:5>PBF'X97DYM,5HK'R,1TZY*"5#?1%+1;B11_T1,JN*HTX^9%[$Z_FA
M RI1ZZUV$%,U(-Z<.%,,@.MZ\W6Q)WB7/D.\QFJ152)F&A_)8\O&*!#C[!_>
MX-"B >Q&(N!M(0:=57[XPZ&!EH0$8<8IPH!_<+HNBQKDT 0'Q+= Y ?CM(U)
M*OG,8IY[!HL)!>OFP<C?O!!O39^*O76ESK)AN##!5C"XMJS 6,Y#B93"QK3D
M%_0,1TU]A/]/;Q=7=C/TMA,M5,S=9GOT.'N>L_UY^I8.K,FZ$?(UUW3JW$/>
MDWI%9];51\/5V%A%C9':\"$I4_>H=MF?Y+S>J6@Y:B9;%L4"CLS=/AUN[G!^
M]O;G5\^.3K[/4,&C>-"\"^"]A=6*HA\N)E=5\$@%SI(XK\=IH>SZ-B?*#OB/
M5/,H;W2L#(P[>K1U,13- $ .5^4F@.S2A_.,U_$5"TL:;T?00QO\+;LRM2UD
MR>56IB;J B*-J#2"5$ ; AOFRRY3Q<",=9OA_J^+RUPI1]*WBN"(JE.(<3@.
M1-TL-+.([3L+2,'F@J6T"RH#UT4R+D;!R_HB* +90/H/F8FZ(WD]KYWG\F)2
MPG=\!K%Q0 8J#K51@GJKS,^W>\%H011" T8PE Y,859-C<!:Q9ZUE$4>@E ?
MI%X=K32+P?2@L .;/6U17 GH\F73+)CS\O-EO-W1#;+B6LS2(S$R92U;"C.5
M2.0PSXWVA=2L2GZ9B5XN+V%$$*Y@:Z/'(]I8=IL6WS,ZV!5*=%EJSXBRZX;B
MMBC8G=WC,$J"(DLR-<J9*RNKZF_8:!A7UE)LX=8P33)'K\[?9N*,G\SXT\F3
MK[[[>I:]>'::_5][Z+D^Z7UQ.521O/2UH2Z?N9&BX6?Y_O%?TOL>P"!__.CI
MZV?O^=/)TX>*:Y[<\HP!2IQ1#[Y_\L>O'O_Q^?.SATE(VR#*.!3:\/38M<HS
M;&E$%-Z&&W [IQO.'<M)PH<D^E*$*LR'FEX0/=%=U$.]O=A.X2ML!F*+WC1V
M_P_-8CM5 O1VMHNZD)\_#+E,VKG,U[.RN&QFV6E?B6K2R/UK.<OK)OM9;D/Q
M_9[A,92U;^[.:05EIQ@IB-"T^%36Z]GYZ;L9^UWQ3[+R#IRUC'VB,MM G'RS
M9"5*,YAZMAJ*NXEB=JQOUS=/D[^<-OT[*GDO:]+G\E+:PFDN6/FK:C3L"(@)
M5FKP<_:,XB^RP!WPTQ009Y2,,?@?VOQO9151-98GFN1SU O%.PQK\_!.IR%O
MUA-[9#\J8:X+84@%TE NH5X_\#2(;IB_I]G9*N^[:X ",(=BN39MC=__>[-"
MXC]?M<,L>YWC(,*O3<:1J)-UM335^?"W53-8MN]8],52,3&,'3U6/R5L(Q%6
M@%4[2TIU/-U1WE+>=>V]WW__L"K;Q1&0I=OL#)TRG+7R?8IOO<O?=;/E2=L_
MT3,.AM$PC9[.HXQRT-8>$H!K!$VW4#?M F2;?9DK' ":XQ)35D<N'W%LE -3
MS"":^4Y:G&;A>&E,LYEO),_<ZJ$8\F/T"$W*\JWZL*NR8JIRT;"Z/GIH_AC+
M/X:G>0E-L$+Y5'T>/26K'K!Y,(SD0$<_TSRM2WLP<!.&>WJ#%WW.3' B/_E"
M%##F8@R4MD]JDD^Z?\*U'W:Z ]F+L8[HP(C,W)#?39M63M![K/<13Z/6UC$]
M]^R&>];6,8I,TXYG_#A[!B(LA%#VW*?^4)'*L?W%6^SH\6X0+_U'N?"HCIQ&
MA)X;L#X1^PK=S,R?LB?"<5H43($G<C(6CW*I?#^B90L49%E]4>XV@FQ(2#WY
M)6!#ST&]P3?2MX!]$B011E0HH%D7(G2 6S0,>!2?T#4+?P$[RU!'7XP0Z 1@
MJ"!(>"5'&))6Z(C07^?MHJ.*02D7WJJ@1?=0U6!)R<7X;MUM52%V?Q787]#V
M2YLNM04+J=*;U/6S8&(V+AJ%(^AX;76L @Y\A  ,J?<D$N*A.3S=W#B9N4I;
M.[6!URR5:BHQQKP0[)%AN*D;.S+M(&'P$K-J$B&;K'J7E*$D83ST* @?!+G&
M<KDO%R. HIC_ I77-R/7W8?$C_$)Y-X"D,VB5@RIN<O\:@0#,O0/([(L*^32
M[7QY3_#(Z!/X4(1\6I'6J0),PG*4;<HH,,+WT*9[&47,)'=?^B2$2RCB%^;R
MQ,IG-DXI G!E1TUE1$K-\TW!)7K\Z.1$W;8SJ[B+_J ,Y'_EZ\W3J*G. \<3
M^+-?G\_@GE=<"^V2D3T3G05Q<T?F>40@OXOXTMD!H'(+0.7D % Y %0. )4#
M0.4 4#D 5 X E=\6*!N5N)QKFK;+'CQ[_?S=V_.'H7(3SL-%R27W,$/(IZA;
MM\CD'K4RKT?QU93V;Z9P@:56E\V4;7#*/6*56Z$UCMA2%R7KJ/QWQ@_K)1Z=
M#WL'-2 VF,*F&9]E_+7*K]7YT4\K+.9!DSVGI](C(81H#AP=('&8"BP*I>BG
M6>@Q.C4-Q4A\Y(5Y,./Z(N(K3D%'L> )P_J24P*\Y2WK@K$>JZM3XU8OP6W/
M0P>T]S)0E)08%0[O9S*;=!],#NDH3L].9_%+\>7XS(; H][B3WL7D\$7AY!7
M]$KS!<327;,2Y(KUT;[;6>8]4Z@#$//$>S!2+3?(17C8>Z;VGOBU3%CVS#/N
M&P[?>,'6$=_H FXTKF'6/M L+2W]"W%LZQIW_;M(&_SIDYEUYO"8ME\XS^%'
MLO-UL5Q:OH4=*NP6];R#M3XJFT_'F8*KO+AV1<P!G%H=)7.=Q2)Z"18>H^OP
M&1+_><(=$JDW+HLR9=RV</AJJT:K1:R1Z5R3#Z#*WJ.]%1.%_*;7^=::=7!+
MA:PEB[3!/S]?%>R(E:\1W%,WR2,D4 PF0Q )'1PUA2) F-]MA]982G3(XL5=
M JLQ"YTXTFG43:M/PK__?:@+6\OO(&'/BKEV&'GBOV1DY^M'?_SZ42:;D7MO
M["PS")L6@:",<^_<[;G/!4XWSOYG:]&H8PIV'GL/7?)G0RAYI9&,'3/YLE2Q
M,JNTLS*S=$N.-O+WL[B'+HJZ +FWUE!Y)$FCT) OQGH1[_8[CHH:RB_NH#9;
M:!8(#;/7&W%#Y$67^<85RRU'72 @FXR/RS[YH,>/CN4,0(70I54L_<KNI.#/
MLBCQDXTR0J^PPLIE;-_&&T6H\AJ<<:3[(+O(.T:G7HGP?\H>G+U[]=">M5;
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M.6O01F^LW^K4MWARG+W40KB9>B3)-U%=#A?< $R"=T.W&<73R$;C<L</G0!
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M2;3RY$G&DG8/B85HP6CZB,();V8@E+&SPDBDU<D@5:0'^53B'C]"!#34F(=
M!L:<YI<U,,&0&*/MP%%8U.#F]!.*1"IVSHHAH;%?FULTLF.,KIY@DI*TEZ[I
M$T,(>3CZ0_Y)9ES>^+ZHRF*9K.[C__;JAB#^#:@7(_-4CS?I_QU=GU"*-#-2
MT!1<8NNA#;M#^43J>I+)(59[&+8+[A#^LU^RK#(,H"X2DE\YN.O^14M^*5A@
M1-FT=" #EHJ001A)5K!+"LI7.W443@GBH;PMDCFN.BP"N!R(Y<,?8P'/*&09
M-G99C[,@.Z]%F2/3FVSU(&JW(:5/4.OSMB3IPDRIBRS>'I.L 0V55,HVUS6R
M49&*/6!X2F\<E90_[M0IIIRA4_8<JJV=NL+PB:'0*JUK<T=\,E^RLT0$\G9O
M1L&K):VNTTL6]P/3 NN3%8/%10SCV5EH'8ZUE79B"W0ADRT1F21J(_I@"%I[
M2( <7S= ^'=HFVPT($AHYMTJ6U;-M?>5V$<5<I<WV W=EXQJ'M_TBY@J>=UO
M[V$=Z8AAB4VPLZ*DG#1R*6F-H$RO&_W90_37^L6EAOT3IJY8GZ<-1(R**8']
MA5Y<D=]77^LIS!N?';)2/)0#]#95.4X,-1DG6O:-GLJ6#<KBX!W#V^S[1^A3
M:>3O(U)HFY*VV.3E1$5H3S;RC!FBC-F&@3N.[Q35U:VTG"MI@=[Y4!/V :V<
MU7>T*5,6B5]<2[6%Z-S8SW-<5*TY-S1GP<.<.0PG)\L+?X$Y*&.\*N*YH!AJ
MTEGK@[4R51OP(!-E9>C&[A;:8/"^+ND*DMYWL1V3:9 3SK1<$)5?(DTSDTYQ
MB513Z' "?D#;)886AW>[;/M&(GQ%?#3U71[\S5E/)Y:Y]:CDCEK)G>2U"QB7
M_>(G!UL]+S=(D"1P& B.L0,0\N;D2;%QA,-8EN(Y*G/955X-Q9&H K@VWF4!
MCD95.FN ,22 R?#,::ZL<2<NW Q]9%D1VQX>:DH0SS^%/H5,9J)ZU ;+[_/Z
M 5QIXSVZV!X9\:+(<FDZP_<F;LAK GN\=:AC"64>+ND8)SW6Z#@5 &[,)C0F
MXW92<I6FB3,VSAO,9$"L45X,J)EA.8R_RR[6I/7^)EVT$]P.GY)O]=HL<E28
M[NWDS*#!):.>, M4.F\G;HI/PO3EG'=9$I0\:$8IGB1Z>>A)BG&N@5(HL798
M1@PR0-&*X*&M[[8.N9G%QCNIG(<VO>^3P@'MWI+,G<=BWJUD^C9=]L//3[,7
M("AKK5;Y7;[]*(= 4DQ]UK0;BZ=G/^II^E1\TI_+ZJ(4'S1>^53\Z^)3*%U.
M[GN:_?#Z+/G#<?9COSA^.FXO1B2N3$P!'%G=3TX-=+4VO"#C=JD6.%:8L+-*
M!4TT6F0Q?K6M*2M:%JHH:O#/R;*5:Z?E2AO@+BS3A\,\9\O%E&DUU,HG3DS2
MWN'("S3VMMCR39CT71/1Q><3*%@W5X&0(0S6A]8X-ZFJ"F<6T"Y%Y"N%<D##
M/&8+=V@51G-T@3HG9I*1K*.^(D0Z4<$AHL+GX#4C#\ H-KWS8_C$.VW*[]]0
M+^PL(PNS-Y68&826:EMT]NYQ)II8%F,!P^>JJ:XB,C>!OB(.1_D-S:-GX+<8
M!3<A^?)KL1&7_8AV4VF].,^M1:E2HM[.9><&=_6S)"UV([I=<I+K#J*3=$RO
MM]-VT\'^9ZB0AWAR\A!S9&VWYH@.!B96^VTGTP7H=;UC7R@!5%HA1T>&81F>
MON7:F)-=:E-6YTD-SEAF?''EO:2S 8&>U0]VF\)I,P,W%8*%CD_;_Z!98!1/
M&L,;M;.I?X<ZS2NQ9IRHRAAVC2-&VX='CA\CKTR=J-%;/5KK$]P6R23NL2ZG
M =(Q?VH\1ZIJ1+=Z462Q>5!3.U.5%A)N(NB7&C=G)CDY+,"6R"+-04\E,+=M
M#[UG;H-E/#G ,@ZPC ,LXP#+., R#K", RSC-WWKN\0@>4>&P:)').$]KNDL
ME* N[(_** [K\?Y9Y@R8PUBL=WM/FE$V,\<>OEZ;@^V^_>@_BQ\U;TFN-V\V
M6^YL2T2C7E&.!N.9S_++MBC27')?S$,#T3"[T?]3\Y?/.\[.+=;5&TFE#4M_
M\$JG/J11;+A& L$,>L)AY_AU>E<6%)TF"28AV&(Z,SH0_UP$7R_E^T K/Z,Y
M3>?",H1N6L\Y$C;-M+>Y#UTD5!+X?6QD$AN?SHP @,57>6_30786C<J""_?:
MFI7(H&5&BAH) 1TDZ]E1W_6IQ,!DP;^?B>[S8D+4R%0LMY+[+Q%@ A5JL@5L
M2ME!??I+?6$8="B? @EG-^:$".@1C73&0I\)_7:,3UX4.X&"@E6FB=<PR[[^
MYFNM-DC'?#+[ZLG7@04R_ 4\KNJ@%)\VI?(,*S7*ISX%,^R-PO.6B1CXD^D
MH:3M\W+$(S?3O(][Z-HGVB]4]4=TFLWM)K?>+K:D.Q<80()A'NUPZ[-J%19D
M;YA-=8?O0"W@6!1+!M835LIYE9?K3HO*E@C_*P;!,H]>SA45D.T6;% &>3P\
MM,1F<G^[8T%$JB/M/2DNQ\MT_2])VPH,K40NQ_=!]'A;9].$CU\L%"2$.,*%
M E7JSDMUT'$#O S=L.8&1M!(9Q-9"9:4UO.4+!N?V@S]G%W:._'MKYK6RT.'
ML+,5[P)=UH8R?%N2,:4T%^<*<\:$JO<!9D" /QH- /:?%R#9A]0-.'L,CLBM
M9;.HK35"1?10@R5^S3(RL;"N4$;&\"[J0MCCEX/EY1X&&2QME&1AVWAD*P]*
M?Q^!%'^.^)CW22>+N_PA^Q3&;2[YBV>G]^US/,V4<(DGQQ6Q&IV"$4)K$]W]
MZ A2D;J)W3&6!=! 3*7F\ZWAL[!GS&RXM<O*F/)JTK!$U, "><;CD&&R&LZ;
M!AT097AGC,?MEG=M1RU5]M:Z,NP80%OQ8E$A?BZ'2K'\HFUR*QG'J^UZ*XM7
M6V.61NK3%.^F+4( E07IDVCJ;!3E35/"L-@6=,HZ7E?E./3QDQS6'_-+A=IY
MOG@V2G+/S+@S7A0UQ+S.K5UD'XMB0ZJ&IM60=&3"AM;W.L&BIHFL^$%;I*2M
M>6QPN'^.L7PB0)Z,MRI; W>6>JX0,31TQ1[^/<RUG ?Y("='RXXJ&%('OZWL
M5J%R,;!R1RBHX65XB$2%;J>JRO1X4.Q"#MNXB7QMQ]D;(UG3-**J[U'?GJ1@
M%R=(S+C8[(."OK9X^A(6M1R98E=6MHU0":B%?["TBCJOM)%46?]EJ.=V7X0:
M,X4H7HO58R8A>"5((-06#?0JY7@ORK\-:O+'U8VPOA8<#J6_18[#H5-B]%W@
MK?$OA$2)"M38O5%JH^8:YUQ(]A)I[!VKG&A$!7'>DARA2LV6^YC,_\D@W:RS
M76\BPT7112DV23$D;C[*D8?]KQQFR/!-:MJUW%Q^#Z]D'MM7#0KRX*NM6'5Z
MIS;5,/1;GIT;@^77)X\>?'P(W629EIHMG^S9,:'#-\>K7,QH[+Q[?8HZ>VC+
MT2>4!M\/==9ZLZK/?KLI8H*+7VR[.W?D>T0SRF1_M)P]'-T*=(IAD.YQ\D.C
M;O:KBAV. AU5Z(T)]"$O!A7I&7[(7LVR5Z_P::]>O7HX=@\7!:($W'5E]S&L
M:V@QT5E::=JH+C2=<"Z)!*L7$VA6C+% '&(Q[ND7-+!_:BC]ODF-W6D+\C,L
ME=@"087DMM,E7+$9V@Y=$3%E4;B/HI@%F>Y"(S3;%;;VI/;7'U_%$^##*F0U
MQR7P.WLI;IJTG4[8]C1D0##@WEG2QA-82+5GEG)<1 L!OX]LO(JKFN<0V.!W
MF14W4R?3Z\B3L$#L>6)]ZY(.1  ^R !E0\M\6S,[JGN_2^'U>6C=XQ@XW?0G
MWW_[C?FWXSN"MZTM88VZ _M%-\GGCT1!,EQ*ODW?,M-?+0HE34V^L47?K59U
M1AX^&==";01MX6\XC0BXF6D/7\31V8[8@**;?4X#)L.%0SE!G$. Y@&H(GJ&
MU. 13^R;T7K&@T+K"OCJ"7$,B K09@X/N4('8[  U445NGNRI5QKE61X<^&5
M$ARARK(H;?]%TC<3UBH;>GI;Z5%SD=QHP6Y:+V6DW&;3:0[ <2!OCJ@W1U H
M1 /""]B-QXP%V!:T2SN>7JM!MHD<!LMBQODA?9%7'BF /(^D>_LV6_1VIMUS
MPUXK:_[^OEHAKR=GG2F(H!])0Q?HWX(9T25<03UZ)A%WB$V@ 5<GWCK.3I4?
MRI=VE?1CWM6 NAF<]V1DYL\H*AHMQ1O6S2*>Z92&<6LB)>'J2!MC)Y[<-3KP
M(I8NW],2Q@\/=].2YN):>:3F2-+_NIT,>+0GN3UV/EC-H6 ?:3C.ZIO40L/F
MEJ>Q%;.'[M1VR+V=NDC_]:K0THU6&<C&TZ.PKGWS<XM],)TM['>E?Z&)52S[
M"+I)C%)MI!O[*&'\ET/)/EE/LU5D<$KU%I448__CCX,= VRW-[=-;!\&Y4/
M4S]7)OX IKD93//5 4QS -,<P#0',,T!3', TQS -+_I-/6()KP0L4OAJ(5L
ML-M\.[81*0=1095$L32TGEL_[V#'F+D\@!3[U\U&,9PTPN $M:/78DRL6QLC
M#U*3-S&L&&[&&T)<^3[Z-8#GNT^SK_U02$&,(D#C *;/;A*'F"26Q"LT^G*E
M#"927&/D(3F6WEU';D%R/894D7>K]7(M%Z^JC,CYD, P6N3+,G#_C4EVK(BP
MJ#9>8HQ7,2E2$RD48$6-%3?'?,#<JP'@%$V"PJE0S<;%F;<T54^F*[Y>P5EB
M5/5HLZNUD7&B"%11F@+K7H1( 9.'EE6(F928@7->_"4ZLENK=) Y_OGUNRD+
M$2^V"\W-^[_G[WWF[.)12FW,4)+B,287@3ZD83X#$B9^)*I(S84,F3L+W,ZR
M13,?(HU#7)*_6F(TYJ!B85AH6P*,P"JWI$YT54T/I4L20CEOM%HGS4LIXB<D
M5<?YJ!LH7C0C-<HV:7HJR46I5NN2A%(WSBCU#1OJMIH^9I%'X,:)%S+H=6N2
MB>"N7]>1L46!\O0LVOQ:?YUH8T^'W9AIV@.B4IX"#Q),ZW)])3U6GZRC=83?
MLR#8!,$?OX$<^#YJ99FZ-9BE>!KQN[=&HX!6UEX'-;1712G>@X93PP9/-^!$
M,REB4!5O$GX=;>>$\R4A;V7,T.(8JJ)9Z*R$N %H-*J@#)PI\YS!1S9?JT-&
MVZ+:.2*X$'W%$&*O $ TF@%[_:^^DU&S=5XM;;LAL[%T<I[P6RNZJ\J/ $-R
M<..QW3HT/+&T!A9*F32T]S C]*-A'1S8MF[ZR)!UM?=4ZN8MCJ'MY*1FJ#U0
MEY2M*&H#H,W"E<6"L>0/Q V?-6L+'4^!*5UL1( %L3!I\CJ(%.)V%X6-V4+J
M0YW>*.MLMPZ,_5,I7X,#/73:L\0%^H00]>$)BS 3,>$9#YN(5['^@0&QV&M#
M H^3Q[-6GK<J+\H^M+7QY],D\+?;.+7?D;(=&#T\T'K,\8#.#WNI7&M!G-;1
MZ0R,G[,'.YM:L('I(5432>9!3.M: 9'AC+H93G#_Y/Z<#>5QF$TD3TPL9)9N
M0MDD(*G]QXRN%U&1U_*<ZA9PY'V;M=O"?\^?WT/@WBLU99\/V$KR^N>B^YMU
M.<].VR*?90]"W@Y[L2UY>*E%]?A;$1QR#AH'O?T^/$I$!T"_2LZ+-TU[G<LV
M>S4O*F[M&@4CQ7R%7%E?E/5#PCQD!F<[THC"=J^P];,_I'O&UHTZ1./SO"#[
M2^A&%=3>OSWO.FN1\CZYX=\RKJC"L1MTW,F>_Q1T\S,;TS.Y7 %F#\Y$E,5Y
M27[U_9,_?O7XC\^?G_&;7C][]C#  .3E@%&3<_[?_JRY^^P\@BO>)2G#=%39
M@S^?OWO_,!T<<D-[1A;QD-F#].?G/ST$-^.W?_SVJZ]M7.\?BFVQ*BO/DR2O
MVW%UY&I^0,0;3 F>-,=:D4%UZ.-]ST2&%)VR!'%'Z-;Q4!,Z^"ZM1BCD4"TO
M -U4E(^Y8WH(M!&;LW_=CMF0:VH3[[\V>Q"GD<MCN4J.9?2W]P\)"H0 <7ZZ
MLO>B;@>-@V7F$R\_>TZWP!A(]G8MP<PD&5 YA>P(C\G3=M0T17:$B/48;['/
M^-__H7_4V87P[1GEQ%G==Q+0[N2$7#8*.8!XFI<IWF&$)2R((=5ON](&F[FS
M _C*!4#6V!(G82? ."/0U7'VG+)"HT9\8TWJ3P?H:"J=B;HQ"D/M#%;'%LHZ
ML( N0%JV*A[.K"_93M0-#BUA^$BG/C\#O6J5QXJ7LS@/L5^9;)IJ>93,2VC]
M&RY& 4;?3>C@?F7Y9K\^[V,X @LHKA0*JE2R;PBXDV'^T"RV"10C'P4EFO8R
MKQT;I\XIL64 @CB] 0K'%$.G7X/9>7XZ/MEK[1>W;\BR2Y\57A)B.!\T\KQ2
MRH5?$2Y</?H4\UYR,=P<?(R&%[J>'U!$1UEY4581$^>^M=+Y!9C"" F=Q$26
MM//2(%0*!32@RWA05KZ18Z>=(3*_5*#*6&XTX*,&IQ-". U&6+A?6W>;;*=%
MKD(&G)^T?Y>-Y-QFI6S35WV.5.+#18+2[V,KI\J$<!K#ODE+EKO]G:P]F)CX
M&H8J5/LKB)[$2GE ^=^V->^A1<X(JAVQ;/\RFS1L(2]+JDYVYBXLZ%BW?]9!
M06WO/1CWA_%LTQK"PH>4@@@=5>5N7@(=30%1L>K, /ZJM&O\/6'YX:E$Q/YY
MTMEH-H4U<^2W81+S^0K1-\7V!,C-"!AY^P!F\9%F0BK@3 S.0L/*<CRYXRHN
MJU<['L E-X-+OCZ 2P[@D@.XY  N.8!+#N"2 [CD-YVF*'QGGAJ5*F*.K5G#
M2&M$F0.A&J^!T^=C\+?+'/7Q-&F\(MP]U'T6TLR,2X.O&*? &FF,_ *!#=IS
M$\R[ X.7(V.,461:B>I?=D.I RQ04%FCQNH>&N]5-3&ZP<B^FWGL8LE:H%[T
M6(\:LFFDDW^8AOFRG\O+4I.=6@9]G/V41JUF(3?8!:->$X?L5(G:2(3PRFGL
M]Z=GI]@P,./A V0/0-NK/39;F1FO$&'AJQ:)6CZ:W/.&//*G(%]#DD,/Q.35
MP]D$:% 857,*VF#)Q0NRTEMD]*QI/;9ZZM@!\=M?G)^=.AD&Q5]Y\-%"!BXB
MPD5,X$]REX2+E\Y6;'.@T!JYW!I%36OK<(V70$X]:\].Y948J8NM3L9B7,>D
M')TA8=N%*# J">KM*"?+*J,]8YRO<M2TRA]$S.?T]?Y(S-7(J_*RB1'7AJ:+
M9:O^=4!AO3W0B[P]_NGM3$.Q!AVO#Q;^]7JC+ONWF 8V*?NWS DW7.RLV\^"
M4?%JJY4._J]9QF;(:^P>^3'GNJ- @[]0YIX8\+45Q*=9__-,Q\;:!2<IP3QT
M%(W\UJ4NV^EBS[3TU&_:#!=5.7=!0/%FKLL'>7-6<R*N-'P%CW0V*IY /V$M
M"&$LR>=4Q;-GZY/>R%?3LE+*<]BO8#(=:H960MYWY/-B1F6BJ^*215MH6J.H
M(.60940U<)Z;K-B,HK@,\]=-%+-WDQKM/D2WM $#8Z7,+F_:DBQ/4RIMXU[E
MV2/3K9J%.]S"/G8FA<I9;H";BR/OXSGPUGN(L7\P>D&/E.R[7'RE7 -Y>>@!
M3:7MV!,T"_?\.95)YZD*Z'F -6Q?R5)'&GN3F]#FQYMO,5F4F^IF9MX3=3AO
MT@S>+"V8408J!E@OBKB/$R#=@_*X.(YY#4U*><MR='ZR\%#R'J:1=1!AG!8H
M6C_T]@T[XPKILV"6H,BG8A(>^1 MXB5YOW*%!!Z.!%.Y+UC& -=T>%U0>?M#
M8&4W'D?@B,B=JF>FQR7BEN#GT%I%-7"4\INUABD8D2#:5J2"_0_S>=MT75BC
MW<[S.B-6KIVSYC$6>R<!-]-AUTSR)7$YI_1&EN6&).$WV8-7/S][CQ,[KKB2
MKZ'_W.-OV&;N\<Q9,+H02M__2?$A!'5F5Z4H0EFR_+)N<)Q-O_ >1F_]H$01
M\[HP># )T(O1]R?-B#34K2>.K0$ZGV&"'SU^]/ X>^G%;Z$SX>,GVOJ/AH^R
M8$!(P@[W_ P!E;5G)B[D>,(O)J97Q/-H Q4B4>74,,M-7CJTEYIS*.VA(?9N
MJN7L[<^OGAV=?(\*X46Q+N<3?>?Y<::WH^[SUG")^.&K_OCU-R<S0OLV3>TA
M9&?Z2SA 7(=AOL%%7^N,1FNE7PUDG\_'D]_4J?B>)-??9.!RANG:F#4_KD^/
M$%$G89BD?8RY#;J-^=!QWA;Y<36;DV%]-;,\?X"2)2TA7C=MT81Z2 P][, 0
MH8[)I:G>^'O'"+-GPFJNGE\HVIQ,"Z3:R#FLR<#N=W[]><?[-TE_580D_O3D
MF[W;7G]5DFG]3T<GW^U$=_]5BH (NF^>^K=] 932:+I.OCK^&G/A$)%]_LE-
MH&*L/?<^6ZTF.X>-60ZK=T=63\^1='UF'M,A%,*;O460S2TZ[SX:W;=8;'\Z
M2.F_3DH[=/4B'XC:KTABD]+%3\^ ,1W++WV=4B'$W1C.WUC;:26," ?.T\.R
M_NN6-3@Y!1L^HAE[GUI)["V36);_FQVM$#"Z2-M51MOD:-BX"6>(G-DML>/%
M+;KO( ?_0CD@Y/[*XA%@V$OI<*>VID63/#;@U'PK6+0Q$'7D@3R/[7D0BN[T
M7\7<9$0Q,I/4 WSUP[+_*[4ZVFC*CLT]>1!3! D/IBV@>)E)WT9T>O:6\P&>
MY#%6XR@6H2I61IJ4<"/QV CTK,'1\*S%3P<3] L>[GJPNU(?HU[=;=WAXHKL
M28C^Y4GE<2B0 PVWXXU'S>'GJV+^$;X^&P>S*R&9X8)EL#?M<O\LV5\*G8C
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M0UEM-:RD,>4!;)LU<_<((WDWEKHP5IO>WP$/-:M?Y3%^_SVT9;<UVVME BD
M-9WV9JJZ3I+=,=T=CGQWK,$0GTDR.W@R)MU ;;IUV8M4D..EB/UQS=IV55M$
M&9]U(50PKM+*M]55J.PU#G0(X%3L8<_7M%>0C^,?83KQ#7DA U4-W&14S$@!
M.>$YEX5K>N''9KR/%WC7O)BIUB&OX."--X6_WC8_4' 89>]H-5\WK8"O$('3
MQ,@" 5=8-4#!#G9%JF?E,4 F/9QL"IS)?(\4;])KX>9G]FFPJ8W.RG6E*;TN
M"]MM0$.?/C%]=^B-3&:?,YO1Z#W7 [EL-=X*GS.9)'I\--.OF[/(V]J (K('
M-@-;C,H@&JU2HPGQ=C->*IFM!:EPB""]TFI',7K^C26&V=CAYT6*+(0G,+1:
MXT?N)M[F'^J<?\X$[( +;.1@?\N:;#PV#Q-E*JR6FN!G[,A!>+<45A J![$$
M!=D'KL+AF(UR1D 5&T^]_DX+"4\?/_Y*"PD_?7OUO57];MD.5E5A F> V^$(
M[^R)^!F>LSY!;ZV/>F6^V_<#O3Y-0*NMCWR#[]]F@@D5PITS2H5X-;Z#3646
MYY&O_$W+]3*5G=#2X!L^L)0,DTS81NE8W5+H[!(BE,G?*0)%F*OBX4E??_\R
M6YE4(5FO3=5T,NY(W1?13W;/K==*,;'.CXH;TM@UNX2ETBY--MI,$TY_&0N5
M/\2(%8#P07W4%$NX"LNK?R-)&[9N6\T8RZMU\C[!8Y'G1$'2_!JMFX^O:PWH
M_#:Q6, -I_H;!P".8 _^9CC:8'3D/7SNV;RKY*0)YTO4F4LNBLEWV,.7:0+:
MZE^S<Y^L.$$6 &SIL-M=Y.B3HT<<G7HGPY"'LERRH%#UP!$4]Z*<PVTQ8G_S
MMAFN.G1;CI5*O,3&4T[ =0-+<)E),^\=WX,'KQ1?!4X#/IWHOO]!L26#79X(
M4YKX;/QUBA/9?W=WH"-!"4N+7T!@1IN2[8_XZIN-'1_;HBJDZ%*VLR]+CW7L
MH7SE&J!G1X7!4D[&&[BWH#SLORBLRGNA'SMS6R[X#[HSQ?62V9*-%&'>KDV?
M6V]U1T-2EHO(<4 V.N12=1=&L:(]\'T,L:ZE^,_]TI?B=_PQWX23X7(F]Q>C
M@>E,>G#NG=Q\)>2"([G@T09+^6Y#-16S"<=2BH'\(]B)-8RH585++  QB< \
MJ:_LOKKB6.M:G_ R$".#1_<V0CK1J,#V,2B=>=/.MU?0YUTVV+"?%B-$&29G
M?!$^36TJURVUS4)L)9#8M!#46]+V</6Y9A?5=BS2!*/Z2_\(LQ+@(J/:4]2#
MECP*R'RTR!6R.F0-(K2,02^T&H;:UD4DB8G"*N).1B\2"T-I>&62)'0,P=&F
MZ=03#<Y\Q(Z2P2$O=&_\>6[EFXUY(_O?3,W5ZS=D9J)]28W+L\SQM-K9+98)
M8:@6VYR/CA6E<X_S)7KD/-HVPS:O:73B^1#,-JJ]TFGE[\=>&<FX\1U%5I6W
MI<AE)4$C#C5FA6^%-IM_(2^F1DTWH,[2H-C5KD#3_XUL$SJ(>GEID6H&'(-/
M%KJG&^;Q^T-)]A0R)[K_H+T6I%AO4E9:K0)7VR@Z[D!P_MQ+[*X=5VYE3@[/
M^*!9($]P!6@_%U?L ^?;)EO]L63WN=0A^T.?[[7&KQR78KX9C9MRG8R'0E(/
MB*U9/!68IG2+;<WUD6ANM!;%<,ZP9(9V+&D;<3//&UOL"YR!LC8(ME+9BOJT
MA,X>CX28 TSMR9(,>] !I9*-* 1 W-DRZOW2Q0L\C8A+2:)B^C;60#7R).3]
MFCAB_G%$%;"0C,3MI'6-4PC8X&)GG7<O6QG_178 ?..2P6H.!6AK_6J;GT^.
M8B-T'3$^YU0&$<T><_TGLY.^\!T1,,O4U9J&4JK01ZNW"H2P1\1%L#"1*N-6
M CCU1AJJ?J,0"<ONT;>5Q?_@(F6HV_K=+8/Y(9N0$5PX2W,0U$,F@VE[%8*1
M;&^,:^?DR8*QTO/ PDCV$B$EUE%<DU_KF19],9[O=4DKBPLFIB46MY?>&X#[
MHGCG!)@+',E/OP[Y2NVO[(-J@7XA7MT0)G*Z/@(=+-+$NY34?9"6,?83&( 8
MKYA-7?V-L86G].YY?*G8MB#M$3%I]V$[<^:'/KFW8%K.8UJ^7# M"Z9EP;0L
MF)8%T[)@6A9,R]^(:8F1$(1_I!QQBZ1$+!\<$!]%AOSH5ZU<-+VC.!F)N-3U
M0N2E4-])^!6#'.<?QBQ+T[J(RKREV[*SN,RJ8?0_FV)2<18GR\-G7/G[0<8
M'4MPS!08(WN-B%?=-!5$IY%0JIIA>R'R[EVSZV_9,]V6U]R>%%3"8G J?JCD
MTJ<Y.?5[M9!1:[0-_DH_K>-@4+X?:C]OH A]KOHC:1'+/#MNYMVTH*27<AE3
MX*O(QP_+<.8E\FL*@13)PO[^+1I[ 9?GKF]@ H9VG*0,(E19T/%Q#OY?5/EP
M<?.6?MH\[(A4\@K?J=RWEFY#'!J%41!_???\-2M$:>=9HPG)55"+>?*E9'_X
M>YIUY$01EP.@C32*<B?I/ZD6SF:&\=N)5J 55B]I.>()O_WVTCV",-]83@X;
MST,/=K[JD]0N "=12,RH3.':SCF&-C):Z?T+Y"=X7$F*9I"TXZY\P1;2ZVUQ
M,7 JH(.B:5WN1A/]ON>R<V%VHT+J#+'BENF65C"M#:@<:=95\#A(=C6H_Y3-
MUKI!.#7#V3K5$?3A\V=IA8"3WWG+W83*%/!Y9H,Y ?P<9<=K+YH:)KP-$F]=
M,6R;^B1RH*K8]:XX77!U=/MY_"*6S"C%[%/3*AT:,"-FI,IVJW@T73T\2&?Z
MK]+U%?O0==+<ZL&YYU<QW3!("2@4-+3%IPM5*TV]B&<E974ERJA1GQ&MKZ^M
MFUID]+:<^VJ. 4JE G;26J7]A3#2Q2]:3>5*,5T;)TG2W)H^55#@8*VFN0>9
M*80Z":6#$G.$)*[^]C_IWENZ<I*/XH2[U6(2C,^FRI&ZE\-(W)10QF<O(XSJ
MN8>W)Z+;GWV8S#M YST7R2SS+@_Y7@PB[NA&DO?:AHS(Q9H6+5=[Z$@N)4\L
M^F>&]-M*CBKBVE1#2=7AN$@GA8.:>X+Y(RS,]XW6H_C6,ZG"D?C25+J.AP!^
M8"P"[*0 -4^2%JS(=,.0(2]ZUM>*Z;0(1I"2C8=*X4IC?-2@GITP=HQV3JN_
M%-X7.<J[ODL*HI"5R]O#-/<^FX,^,R#B,TM=<E0?BUI7BA TV #6!+\2V";:
MIF;1N  <CW*9XJ>^^/ 4NU@<7<L.JA DU28E*Z W[<YW2BH:WYU6J93K9,=]
MK_1D__:_OGSVQ:^_?OKXT>,5^1I5*8VC\L=?_\JNVC?L<]XV;;6]Y5J[=H%3
MU%"SJQ6,*9LR.4/"5+ HFBX+KF9Q=4<*?9D7?SN#8_3^H3M@E6D/%4$'N'^(
ML4%2"Y[8U,Y7\%9_^,\/\-56G_T+?X]6U+]\;ML1A]E>?>Q8DN[MA$M\X/%:
MDQ4C*P+<.3B%,.?_]K^>?/'LZR>_??0;OWADV5Q7S=HMD0?H*/^>B]L1IXWM
ME"4,)REB.Y[SH3(^JNJ,;:UA[2<U&G([NP+BHK%DHUB@OLG>CX52(9,IK,/S
M3<P"7Y+HX*JI:;;5NB*$M09@.?6@QLPOS$?8><9-.VX^!!=H?"7"?X;<@7V4
M/"=KG?_F<5(-4S%;/,>H_F7P.@6:AU,#IS^*R"7+SHNR0RD"KKGWR&.DSKT6
M1Q\8 *=E%:(0:HHK^4(7RT\M<[Q%+TH:0'ZZRB)13J>@EM5E3VY^79RZL-G%
MM^(];(19'MKBH8/T<!VH('2Z?$S!K@L,ZE!3%-M::P$3GQUA=7.NMC6MR^)$
MBB]ZU@FMF98H9X,6W1)^S> MR+!CG$(K/!8,_.H8@$7DB80^.:_3-;C\9 %9
MCJ$_'<^#N/BY3ZL]TPX+?V7,0?GS. #"I'Q::"#F\(JC./4L8,RJY+%;/W29
MC)$""0>G8%HMJ-$H)Z#:K(7?7B!"ZG2)T<P$^P[IU"A!8GKQHH51*CZ?#/4U
MV+0^NWSY>13$"<?"NL1IN[I\";G=6F)%!BCZ50=,!3DJ)Z?,.H80Z_WI0AJ\
MN_8!LN@LX\%]->$==0E+W9>'D2] OV92,"'S] 7CGTV.65RLV&V3E-?=LF%I
MY]F5DM>3Y!=_UWEB9E0TV%+7.""H=F(>DFNZS!;G:.EHQVYSX5UZO3A8:2F[
M)6_S1K5\D\*X9WAX@,?KU53L4[W[V$SC9F "<PD[=/;@*4'S6%XW.,$QP?3P
M%U@P0%UH9",6>#Y2%/U8D?7Q <*A8 11V1TZB0#5^Y](EP+G.DY[L:TSJ,&H
MLTD67JT\3N+5MZF_H ^ZXR?R3ILX:=@_P7=VRV@6LF/6*)L+G'1 9]I5K+=(
M4_C6JR.AK1U_=ICU+7VRR.K<@8KX:D%%+*B(!16QH"(65,2"BEA0$7_3NTK#
MXU4.!L\'F R\[%=OBNY'YBIGY\I*+IQ=13F"@@MA<Y#TSD8YK]G7;(;^HME=
M&'TIJ*PELA!R@[*NFQO)KL)5"BD#<DSW%UMRKHM:N[>EQH1KL_#'OBQN!/NJ
M72Z',L+JB]T./*#HG&&Y'NDKDS@0?K:G(A"/%/G##FS*+1-@<A.'((\I-*JO
MA2J_KAIA6DEBTPQ)GN!M\I58EN04D"M%<ZR*X&]^C#6XNI^;GQ==NFJV&,UO
M+-E K@40/_^6'XY?K[[M]X!V/R_1H*_9PY>U40 $/8PQ,VT(T*%!(H70VZ9]
M)^$1$[;?E,Q&R)DQ 4^$L&"?M[F(LV8!N%*;O+9$8 5%0,VIB.2748U]!<&,
M,:6%RH.@2R,'^V;>]\H/DL4*N"+<8]C] "/E2T1@_S'4!2?<'W_]['&F/,.W
M7!G>"F/S+R4SE5*(]V5&7PH#VDE5#0H8*#G2E $*$W@-TE\_RW[]Y6.Z,/,G
MR"6V4DWO4-6>R &YUC#.U(4\*:.5]HWH7$BYRNB6L,&?9,]^\Y@O') &HWG"
MOY]ESY[A6[AM-I(FRA-QKT>K5V($XIMKM77RZN,W?OST\>JS9[_]U>?RWM"J
ME=>>5,DS+Q+V V>85Y<4\))S0'.2/?LM7>CI5W0A_KSCABQZ49J-SY[\5C\T
M^3%<X$GVZR?NCU+G16:+;"';7>U_A7BYY/_'X"CTNTF[9!;E;E0&U]5==7=H
M7(^4)W3OD?*4K%A=5(_T  H=EJ,RS@K<%D!"T3;7\AX6(TUX-QI8>JT/WFV?
M'I%%L(]B-X.%?'CV@T\%,)UWHU.V#%9?VH#LC7=@B9?U]IDV"W_S\OE;;0K^
MG-/XH'?OI!./SVI9I J)ZM(#.13/V8/Q26#%_;3,HL/,R)U@3L6M:9 :YHR4
MK#)^=N8N$GQD+PX$K;3K<K/BIPOGE&P:!NW<*&Q+>H_E83(G$^\3SI*+;H +
MQ ^-&D'Z\OFNW]HA]4:1JZOOR+LZQD'Z]LUW-D9*!VZV2IF?4:Y77AI=6-[F
M-4>FR1EJ,ZW@ZF>4%Y_G_(HRC9D10IRL^";S9SQ->ZFCQ'-;[J0]B =Y=S*3
M^[P3IC"I+1IL19^K[,Q\A'4B5&--+X W<_'HA;9*46]N@-W22>KAE/^%!C!4
M#!4Q 9;QME>6>RFR8'CI>Y]V27_> SRW2F;=T@_)8_WC^JLC$7?-M ,@HMH,
M31U7WT78_BI +_L[!A6C_9-C7%>;H:+CBTOV[)/4L9Z-C+?MQNYK\3-9>896
M%I]?6ZY]60!%=BUGJ^G<"[51M.F]BAP>00*F^-7;?:.(IQS+OJF#?(-X5[83
M[!6SA,K.&XE,+:94'80NL-"7+,:VIJ.=H.P-YC!H4E_[JI4!SMYCL\^//:/>
M/-9G:Q V&A-4<?O;HKIA) @OZ]^MOJF@@LG^SH4Z0_7%ZUQXXU]V%;.:4&#P
MPW??_/1?+R__WVSU?<F+33F1X$1EJS\63._'Y86?&WI-_1\>G+?B^[E_YV^S
MU6N>RQZ!C)H]>KK+=:4]K3\V7:Y-IB^YH% +Y=T+T7?0THCC5D+EE%>;Z,SF
M;MU4)_%KCFTI](:3Y<C4>I]X9\+\YO\A/8J>^Z-HMWJ.3U^N_HA#YYZBZGE#
M@;-9SQDZK=JF$S!3TU[30E*B)/;O8\T]E.&>XY,&#D3TZM@MT$,TH9&)1H*<
M"Z": SR];%DG1IGR0P!6Y4.]V4/O8)LC$Q$.>-;1S"'?<VW,+]$DT /@BX(W
M%ZJ=;1*41_<LO$L/=0^ZQQ]JQM]LP"/Y39FSDDNBV90^&'P';K 6@(;3K;+R
M__P@ 5B@YH0N%'@=X]!(?%"=/NFP>G[QOPW>X\O@RCR?211\E/5^N?I.(J\K
M.L,V)216+P_KO.OR+;M7AZ)@1 ;$1/I;  S8[09>YJ94CY !45V7@ XR5ELI
MVIO(<"@>>*&RBTY B:*$AE?QN46IN;]T-PS'+7[/!PI../306,J(+Q#<H^_I
M7^NF 8T <!,5#5# XYA[*?YG..YGUKF\I6(DR=)?#UR=UC8)1"7BA6TT,38!
M49#;T?,#>$RW<#*!EBDZNCA<34R%8N9CT0,V3DYNR?RI?* W "4]P.WP0_3B
MOV5?ISB["?ZY?=:KB[=#29/^K0@RW2"VX9 Z*,%<O7HE;(_?OC*9YH*3+>06
MMG0PR1818J2PM6(;S-2]"!MM(LO'MU <4$U1UWM/2'AOY_:S"WT90+[=AA08
MT() ?/,OXIM<-W1 /%I]RV<<>X_ER/_E+BT;I=7;(]F7YM,& I\Y*#0852_I
M3;%I![1(//K8P1/.807BV$/!#9+$N<( -9+:65Y %D ASLPH]6.!=\BM%!$B
MI5&Z>",T.6+<_0+3:$P/'%F9@T(A]9[(U8]PQMJW&A9\GFR,;K]NN#4&S1@]
M0\^1ID/+C-3)E%!&XST%C>&P"ZSD*0EP:^E@C-,9?VY#LYW3ZDM@E18TP+O3
M$0A[]SKG>HD?8@;D'I6W+3[+ H@Z#XAZ^G@!1"V J 40M0"B%D#4 HCZ!P5$
MW6,$]9?6/7\2,(5/!9K;JY"*3]F!GW<JO@F.);JM/&T#^X^*'SF6QX)_BYC_
M('CWF\ 7KO50J1(B'\Q1#Q<V%7T"['V+1 ;X1Z$30N\NR11-*Z38!/HFN3&M
M]D8)T+]=[8IB"TW735.S%VF<L\@0^EL@_!KC)C*Y6^#[X5K*A?^55@JRT/6B
M-+EU K&Y!3,[.^8" ),QD)C@]&FGNM^+K;M5/H6@;<NUZ**=(%".Y,Z#0CQ,
MY,XKXK9-51C3!)=4\L@U$;HEN%L$DZS@)P 4 ^^1S$%(%X_OCSO1V'5:K;$4
M=0,?A5L[VLX*8)#KI@>ZL,=3&E])K$7A,O*L M1*>"0"2LLM$EKE<@]%6I%#
MU%R@Z<1NROD"]Y*>>)>9DZ5%5%^FV/JR%+(*%PP-BK=)N+/##490E+/ -F05
M%=9V)KF1K?[P]GV:7$"J"3I-+)[@TT9OHCC('_RD>6/)0?4H0E:RH8M#CN@U
MW]Z4';>(/EALS)57N9.Q^L9@>P_/,KP:4AJ!U7%?5DW7'/>G5:DI=8,B(JO.
MSQS)ID)+;ZBPFIG,1JP4*!-*8R#73F^332W0M@L\2"^<YA,QP8"-%%(P^I0^
MV>SYIU+L;6^X;UA(<K U]$RI!-.#!DA-$0C+,CW.=<X41;'-\%BD3:8X[V+V
MCS.=%R+(4+,?AUXZ,BZLW:3D^O4[R*?%WM>$I</Q.#B+H^8JIU>K1&!L)P1'
M%Z.[QN'4PUQK.#%[B6&5GNDZ&KNN9Y#2D>SNGEE$6#IEHIRMQE*;*E$*W'8A
MSU/1N?<MS;W!9'A$ZZ:^Z.B)VU.<'$- ZN<*<)"7K,H=5Y!IIN3?H4,_?(*W
M4M[L* 2_HSBUN>VT.CVFH@\H&WI !O4Y'(06-_/3BAL;U9HISKL*+:7TY[CH
M0[Y/NNH#C5]HA1R73FD(E27@Y-J(W3WU2!"?PM72/]R/^.1,8*ABO95#0JS@
MU:L_OGQ^\>0K.KJDC/:CTKX_/*OH,*B&$I'4+*V03EG&^8 41Y;U ?@36<\G
MY%91NG N)8.XNTY71\2VF1<>H8+J*)AF$V-D^'K8U[*?#98:!3^<O QZQ)D1
M#7@ WJ5\>>P<)O]75X-Q-+'=07L9-%,[P:@[)RZH)!I[E; #<5XY/RI@#C*<
MS$YGZR+?0(+2\'0FBJ#5&NX/Q_5U>Y.!+L:!AAQ$LO]FG11(SC2=G1RU:5<*
M=Y(T?_ II>:(<0.*O QHZWB "6HHH(<5 H4TN&JRJ+ HAIA)X0HC^4'):&CQ
MC:*3+_ SBGL-K$,!J5&4 1[>OKCLM,:G.QV:34Q#V!TID)+H(E",%:G0)A-?
M>+9)Z%!$*LLM0Z .^!IPZ%J^7@M(3-%BS0CD;M03BE;=RHB#,&W/[!L[9HH+
MRW++@P?%!29.P$&;%.<]V;^N?+5@82/QB<?U3U<^L?.V8Y> 3J<+\I1K(UWD
MR2Y$ZS&A/9.U?AS6='M;TM=#*0^EB!PZLYM*PR0/%#18K+Q<501[$^ H_P G
M2ZS"ZU;_N:BJ-;FBUP]OU_Q<.%<4VA'!,0OI#JUC,T\#&R2D.W@%Q28C,T1J
M_8LX0.;Z8BNY[$<\5""4R[@VMDP],(X.ZR)'C3P3OA:9@+"\>4'SDP/"*>T8
M?,/ D*!/QH\L7$XB7XMCI>:0EJV[U%LGQ!)"#*%:?KV]G'B]&Y-#$3DX=;24
M<<4<*WI">%8A&!!'// ^9XGV*/_)" ^WP?W'$[?"M,$!@& ['Z*!U@8":50T
M-;6 F.790=^+',/PQ\<FU2K%)?/]TA.&,,CY!;>V%R/T5_#WPN;#>M,GM?VG
MT$F@R^*B$RB$%UX+_G]+T5^KBSJ_ <8.2R-;=551',DCJ(M\U6W:H@CYAYY3
M>))AZ@X-#"'[['KB7Y\.2@D(< _WY_'S\16%6JDB.SJL;LA)T:8][K2"1Q?>
MN&/3'0.40Z1H":_/CEL;O:>3ZP7 R6*XRAD$%PZ/Y- ,0P4(LB2"5L_S4SB%
MXL8.R%V9,7GPS.#=.$C48]4G6ZKO=U3?G]Q1?><7*+?_W[^\OY#[Y*M_64KV
M2\E^*=E_[)+]7UO=7NKY'_^5I9Y_.2WHI]7H^;WUQ<.LN'^"7N;\.[W\Z=L?
M:7)6;UZ^_<_5B\NKGUZ]>?M)^LJXXN^8$Z3<?$BI7#1!Z%0HC;+><N99(-/L
MF-C0V$"@N]MP ]BI&3AG+P3>=( ,DF\3FE@AOBZ[=RBG;MIRS<6THFINQUEX
MH):%ZC('40EGT4$B*K2)Z& ?78@"I +IY0CSE$MX2L8@-9I):J7LR+-$'D'J
M$I*OP,]VY/6SZQT:;]Y^>^79+041L.Z*/PWLJ;>X#+S0%V@D>/+XXK]PU2\O
M_E-X.N6)^:,@-HPFQ?%@<.S"[05X!8XY&V;V UD@QZ+1=SY[130G,*T"6N+>
MU<SX#N)UT2V77%/LZ-L69&;* _?LMR7JU=KW,T,5".)"^/ZF"RJ79\KP6OY3
MG@H?^(<22GM^G0W=6@<VW%/Y"34%BW$<NNQO82F,_)F\-9JA0^]B>RBV0/M*
MGN!&\!)[J[YQ8+TI0HSA5[?P+*AP-.T.WCFRUGC5\YA5H)'GC=$"*<W/<Y(V
M&%.B_:NP[Q_5=+\=:&&TF.\WK,O\(N<FL0=8SO@)FMY<1 -T&_1#\=VB;0I@
M"F2JQ83%+6H,M.%"G=)Z8N_^[J$-RUUARAL,QYN8(N,$R#>^D/NRWC*9R>E#
MWIK=$76^+MBW_-VS+V:'03XJ:RXO_N[BR9<?*3_[+_\_:!R^^/KC]7>DP_7D
MUX]^PV/Q"O;$T;H(7B#0P\B"U:-,C)HP*4\4,S[(%BW3]O>9MBO.]U7<_%&B
M\]^181N+F^PE/;8,O9">B\;JT_+!-1AY^MSI]V%YVV5V_WZ;\F]S4WQM:UVH
MHZ)RT]$IVIVI/+)';DKK23F-3BWH!RV+X?X6P\\3!?&;' ZH.AB23I;(2I%%
MZL\[4C5/W1V]<";@ H2K;7:E@0F6V;WOK1Y[QT,M4.::-BC'!2@U]!S7=(;#
MD\UL(8UA_!K0\%G(&97LT',I.E'!9 BV0DGJ6<'CIFFUM@=)"C09;TW>(_Q1
M"N?Q2#D7<MG1<J<9RY8#Y]-8A5,;XV!WJN];E>8EJEH6; HOH.*73:%L"=V&
MQ051GCMP3=!*H:$>*5*J^741-/6PF(I?(!LE_&_Q3CN$_?@Q]\_BOLO*N/_X
M@#5>"M$09*QET0+!=M+,D(BA>!8,;.Q_M\JJ%V IZQT$7*V5?/[:HG4J#HHS
M8LO4W^?4IY(B2O>9);WXROOYKO#49 F;*,]Y-S".88D/[WG;,LP',"'IE5GW
M 8?N57 _0,_EDV;8^)O34#^F/,(O?UJ]%4!N!GTU\H3X%'P5(RP>SM< 5_'Q
M] +B4<S(>-OOER5^?TO\>=EQTY6(,RDODU"#L-M,'G%3B\0:(U>EO,(\'HS3
MDS4?-4SS!$5+KL:PL;R*TE,+>M0%2<M,W[MW&N7"D4)G@FK%7R8B?<5F7]/#
M7I\"L%Z*<;LV[_IVV(C6VS)_]S=_E^+=<;]83Q,"^5F1>!0":1->8Y6&?.CW
M30MI=Z>(F6K+LP]2LU'&;[6UJN_SS3NM2!82P!Y5M3'OHTJ?^:6BP,K2;>AO
M$$K[H(&:K"A-?E. T@FI'5=[V//%<Q?9C#D)07'5",-Z#(.YR-OG<A=1:(_A
M#O)NT1 AQ:X=55$7;3$]]VMZ+,YQNMVT=D$M""58FLI->80W$3KV<.;DFS\-
MI0 XNU3'?-;;TMQ'?1T)=9>9_C@Y=SU=NAG5 ZWKA]8NZ4?=TH)@QX(IT;A'
MQC'2I^J:0%Q+3F^9WWN?7R9ZGDZRL\A QT31R160$DK-UC"4OBYN14[H>-WF
M@0$D$OHKM^%U6SB!7SK%AJBLFJW0=ES1?]>=43:@H:NH0ZN2]2.Y*P'@,C#:
MO0Z $3N;[(GE"7/N<)(G%+46/%_WOG!/9' 7._31LRZ-+=5@.RP)H_WMFBBK
MX#&429K&LC-%O>?%I!2]:.#GB0>F**SOC$ZL#12U8^+7'"K/\$)WN<W;EO9(
M2/X&JD2QA]+')/?0M7G'LEG:(IX^74@)EPZ'I<-AZ7#X'S$R2X?#TN&P^&1_
M3Y^L%ZH9Y;II0^99P!+!4R+'C-89^T<=^D4Y*Q"(G5QJLFE'&4D!<A2_E!U<
M;[A_,0Z1*KLUD,<ZSM S2U(6O#&(8)W[U98<K%/(E5/T8ZWI)F%@J@6+PW__
M959>64-M"::@TC:T <JW!<57OT^[&-3GUA+K,G'WB<&MH$NIK"M:#Y>R8IV+
M0!A+WK&(AX=EH4FDH\CKU.BN!;E.4UDBN2ZN<TTMJ<Y@,N%-6HF<@54]/)*%
MOZA@^_NFOKB*_(XPKS_DMS3&;T8T9M_'-)SU%JS>[LM=_T'])LL^^?OL$S<+
M;8'TA?0/? A\,,#8[81;P((??3Z_8P1?U,T^MN6-R-@9Q$^89ZQNDF^+/PVB
MW]L6Y6'-;*Q)TC(R047XF*^6Q,):J,QWL32OW:-"G +NU?'5EM5QGZOC15Y6
MT+N25B+3S>/\^L6[<O,N,#.1]SML$^;)\73[4NFQJ,F*&*N8$9V5];FS<9GT
M^RZN#)TBS9*R?2B\)_7[V/<<^(K\7SN?D-X56^Y2R*1C6Y:.\B[#]&Q.2O0E
M( *_HF)@M)M?E?V>\^%^#0J_H;-94N17K&H$!3#)4%-MIVO6U>^3PGXLX#-O
M4-X>EA7ZT<J[KC%F!'MGBNT:TGQQ4<@JXB;UZ2KZ.[9"-(MS\PFLD]?:[=")
M1G#)D5EP.FB*#LU6)$_Q@;;/(+-2@,EBPQY0)8TSN=D%FL\7SR_'=L9:[,R:
M)8;+.T";?%"7:8Q&%)*T]];;EG5R#QTSWEN)4^DY(8TF,)(,J[*<9GVDGNK0
MR*:.B%\%WFRA#CQ[HC&)1KS#A[3__K6&:5EO'P?MG N9"YL4^#=(*UV[J.RZ
MJ$' "\.!3L'=(/@4,."#69]F58E!K;>W87Z5X(;O>2Z,,ML!H/9E*Z22$(IL
M-8^,%I J"K[&YQ('L"ZJF *[+2%DB$084M;!KA9;AWE@#)TP8@:QC&RU87$3
M,;6@LKY1LQN0^H". H3)O*\5F+998Q+H4Z9326WKW<FV98G?IXNVVUU4^;JH
M%%2BZC))"]D'A8C+K-WCK''F-9QWS!/+VD6'0K+:>9RS.SN,?%*;=[,H2%G\
MM$SI_4[I3_DOJPH)]4DL78ALC:A9!;4C88!NJAOS63X\P3OK6;#,;K=?[:!0
MDA8Y#/NU+(B/ZNSVM$3R80OIH%,@I)!/T<"!X+JLA=CYO\F;[;;EYL/=Q@=;
MG *UGZ2B> 1^5,8D7L2O;FOUCFBQLPM_)71P;YD.;EG.]YL+FB?/T7C>;%8X
MK,2)-I6 #2NQL,J?Q4C=BCQN4*F<?&[3_=UXWH(=4RJMQ8S=\[Q3--WV IT>
MX]S'-FY7,31'HGB(G<'.%<+SWX+I?IF_>XV!R<S>0A$NO[4DV$W9V09#37&/
MZ56?DQ6#5F4/(86294IE'FLE@U5-#<[W<ZL6(W#NF- %M/[TV0):7T#K"VA]
M :W_CQB9!;2^@-8_-;KJA\)1??[I_WZ4RY_6N_T=B8M7'\_1%1YQ>[QS.#A6
M?"-?E>;LK4AVT<R]*;IC20=ZTYY65Y-&<_0/-(P)9]6!#*'-GNZJ>J4F" U@
M0PL(,R?S"B'>X'I1JT($QO[GI#WE#B'?%[L:5&'T/5.B;=>03&!>MVRFRUX+
M/IDKAZHNK+2;FOXHO0+7CR+2[X6.X!WC%*N=T@81E=;!,C)[81-I=T2;QC0"
M]3,Z3A 5YI7RK]+O@X::-(D$/L5-$+\48;^0(P!125+MP"5\+)/\M6YJ/Y?\
MYAQ:%"R#?"5J#"DS*+\1?<A]O+PD-CG8?@TEQ3&14I"V)^63M6YB_B7]M[2O
MGW])O%JF$FFTS?)-,>"872'DD;=LQN\]?6691U[#B9@"CYDCEHL"NLVN1UQ8
M=C.+/%NU^;'<TH>V9#,?Y0-*F*[CS/1$;U?KO&U+E=3EH:._=0P@1WK'FNY5
MAAV81MTV(]S(+EU-@E<3.H!'3$"&ZGYW5+7@"(P5'3O(/;#4:U+LTK+J*#].
M$T#CR4EY42FLHAIO4"?6HJXJ=KQG2.L@9IDV'F32$L7@E<SR9A0-T_LQ] V\
MG:QPH0M)>R10TTWO;BL#FT0$EP'!:^IBTIBDWY&]_BD?66>4?A.9PHX;[_4-
MO5W!G%^C M;&B>5:3%?D[6:O='[!;&4SF)%80'7K@:8 HL"-Z,?0><(41J"
M7IWHTGKKKBA0/:?989_A5F$D9_GF4[IY%;[I[SC5'L5FC/2RX^*N#4+8S'SK
MZ8#1?Z^9"T/657CA;.Z[D#&59 _..9\)XGP]-K[==S1V]-_2QS-S7>51R'>L
M\Q.[_N).EHF&N'+9)6\D;ZWD9L!%= *>K94.%ZAW)89.D>[CZGACB2]!C,G/
MPY4!(..S5Q6WSRTHE2DWI%E82]#JF;2JV1%QYN3,@E9UXGCP"\ 2X^B!S&D\
M H2K7,K(7>"B5BK[O%M=-PWP=8+>G6ZA;(25NVX;6#<V"U:.WA8Z*IZ%^ [7
M\%.T,O..\<>3AO@8-A6'I^-<DE<T/B:!?_<7S>Z"ULJQ= JT=M9T*NX;!HU7
M921'G[-&]09>E)Q:.Y,SP[YL;KD+4R7=SPRZW4DTS*,A8'X7>2BL\-1-D)VL
MUP =,I..U;W5K&!^(#$$(J&NB#+NYW[$'T+&RTRG:5;Q2_!?ZN*ZZ=F:J8P5
MWKSK#*7ANG'8Q!^*+5P]]1.5*3[0<,KV-MYZ;TN *-@Z2R<V#1>A%Q/PZ^ZN
M(R@=XBQ=N/RJ8;=;/X";!0IE\K:6,.D<1_V_ ]D;( E_(:GQIV4?/G5QD8]I
M3593I(.*XHW:^=,G[_=L&SI?^^5WUWKQ9 C,OL#R[O-M@,SX@1V;94,GTCDJ
M*GCT3$<;Z?3,8N\.C0QX ;G7_%S@QK0Q$)+V%&'6TF8'/?%"/'R)(\;(R.P<
M<N=,3[+(W4GLSR^A9&/.[>CT25VJ(BC^A41%K.3!6K+)Z<W2)==2A?2,'K@/
M$H@5K3O)A&7V /P6+>-EB[!D;\IV4-)8NA#7?"U@U@@6XX3TAC@V\4=<7=QN
MV8/#;V7<HH)D3_?GXV5;DITJUT/L+BGXM;B5B9Y!=-/5@JJ41PBS/VV/Y$S<
M0WND&:[W2J+![5T]KP8?ST9QQ]-DL\VN79":K8NJ+&X*O]OHC]HBMF)\,=F9
MWA3C92Q;EQ RG@4[LP"7YH 7B1=WS[[$JJ)C?D6&ZYIAC&N.DPY%#_G'0]/U
M%O#P_.;7-7U".XQ^NN?J)QY(Z!_S8UWD<4J]U1!A>5IO$5R7K;[_\=NX8N#>
M3J@DQ5K8D[4%,E)%#-]HIUR$3<^\\!4MI!_*=P5#L27=H9G2E"*1N]SXRLV:
M_1!.00@!]I_QL#(J.!,ET9HZ6CB4NZ+O(7PJ>T'."1O83_KT/)^NG=I17A>1
MIR-:3+<NE9N</,62]CRY-_2*);.'[EOL#?9(R*DL:U$K;?/; $/2A"NK9+1-
M#>"1N55F^_ZZ7TLXS-*L\KP"6K)8F.:3A7;M?-E2S,R)X.!EB;DN.ST)A"9S
ME2=QGKYU49-];*0[@1TZ='[2J,*=[GJ<)AR4\^<2M3*@OX25)Y-9'H9#4 U.
MU MR7J-D2O).$J3#<4?W(1\V/\DYH&TU@?O]T>K%T+(=R,S]E!:#O*J:#4R.
M'3EW4LAGZDX/M.?0)$JK0)29V%/<ET?=I7J/?C]T>J/H[=HMA?UWZ->,$'!A
M<)-VR8=CSG6"2'[0=M:<&^&.;I=?7T NYT$NOUY +@O(90&Y+""7!>2R@%SN
M"^3R<9U:S<T%YO'J%-T0\H3^-'"0AGZ&NN ,8"Z9PXXL;;<[Q4*HQ%X?TF!Y
M)I.<5L@FT4>>:O/0@F;F$/&;--4K_^ :=\>1G1:6<KIQB<@R:<I'[*=D)9V6
M0<"1.!>!CK,W91=<V:JIKXL6_:_H.NTDB\)E"]3@$F\<%54E2M$L +N%Y.5V
M>R;Y0^J7WL3\[K2Z1_^E+7&9=WZMR(,2-,^L^-7F,YZ!?H2HH=@F\8FOSJ?*
M.YH\[?!TRI%@R:QNU@&-?7]N^D>"L]_1 TD:A0:R01#@T@$MK: V)-6V@V;>
MA7B_5^#&^1R!E*MBTLP0"&<N%",I*X'XD7F $>O/^Y+\C]L"5* ;E]48S]1T
MI[XGTYBMKL/$ 6.1 H- @EA,LVK\KR3=L^;5'O-E/.Z\_;C3PKZ?M-Z(:=CD
MM<A/(@DHN>=1TI,"2*0=7<>I7L@;'0T(#T R:%IP+C.-E<0J0"4[=%$(MZSY
MC0LMZ+<<U]E+2_*8(4)#QYN37O6F^*37T/RA]_$TJ#_*CBD2W%FJ#Z*SF];=
M-5/"4_Z'&BGFMTQ6924\7H(),Q0?/%H]3"Y$>ZUNZHL_/'K[*'2(K=ZBD"T9
MB35L];<#ZS]DJ\NNS%UFTP 7^6;#VKN%9$%!D_ +J$KI\9_]]E?XQ;.O?F5W
MKXL^5LLTG2UX$%98VZ[^8ZB+?_M?3[YX_/6SQ]GJZ>.G3W&%R<=/D%HU61P!
M \8BO._PCHDEC!B_[9A,17$I(=]OS&^RWK"4)+UXS%NC!=N"/)DNH# C1@=
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M\[DEF<U#0[0R8)0NUE\W_\,H>"%U\E7>"D?S/HY_WFOZ/$"B1G?<H)P=@"W
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M(+;ODH.UPY A[ZV*1$7$NW]A84ZCO2?))QHOFOHN;LY@93[MP^]./L6(@PH
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ME38P/UR=H/&"55DBFYZNJKM\D;'@XXU =SW@;E[E_I->@F<1:+-<M/1L?Y:
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M7E->0F6*^\OG+?!R FG&,P?<^"Z_:0(!PZ##H'6;9%(>8%9>!P^'401^*&R
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M7N;?%#0!M:),:'<^RYBQH(R:2>[[6<P/MDIZ,+JZYNT\>RR6$3-N;[@03J^
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MWEY6D960G/F*F_KB['T$M-8K%F$ZQ-)SPU<_BN*7)MW8"HEZ2(3()+ 7@\H
MM23=^0X@,U3A:XHKLMG<:_DU @^ML)K,[7NVDP(KMM9SY+\L8T9WU\,SOD#
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MAYGRT%7.MF]NZ>DSC!N\_95EDXTW8&*MV1![D< UESAY70N12*==O.3TT)G
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MC5+!.YIT<?I,R@L4XAUB0OR+CD):[Q')UQ5]7Q5)@\ ,B_\C\&DW=6R@\?=
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M@<P?)WF(,BA(.%<2:XN\[O=2*U%1O3QQJH"^NG93XQ&R>H%''G6T?D/)V<I
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M8DJW8-TA#IT,)!"OC\D4ZM^AJWWL*]LC]+595SFL]$QY\^OK*ALTT[ (7>-
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MU^CM.=&X1M$W*W#'LS6OT:U_KYX5."MP5N"LP&T0N(Z]4JW /:G [>JH/Z+
MG4#:Z=_T%S%Q?%B4/]MS:.RV""3V&?89W^(9CQ3@8&7?/.X3RW72%.%(G3C/
MTLR/<!,67F7GRZ73<YN]^EO0SYU+7;?M[5EE9;GT9%SJN.UV_9V#Y\ZEMNMY
M>Y9Y62X]&9=:;K]7?WB56IA3JNYNW:!R#@V&7$?)[;O-SIYXQT>46G_N7.JY
MG>ZNMX#ETM/;O;WNGKWUEDM/:/=V!O4OEWSN7&J[P\$!:PS)HOJ1!L7#_TZ"
MZY__ ?]1KU[XR2R(&#Z@26SAD?)J9=Q? :L*_64J?E)_>#T)TF7HW_X41+1E
M^M%K^3"VJ7[J+M=61BOGCU_?!)-LCD1J-(E0RNJ3;Y8?-^BC%7KQ9YUFH]OK
M;?RXV?#V_*S3W.^I=RUVV!CV-G]JUVK7>GQK[6SUU'L\MAT"[_=?$/VU[U9<
M 6,192(YC*/7K[P#SL"YFSK_S"/AM)MNZ1+8DGI'E<ZKWN1Y'!'XC(\N[2]^
MZ$=CX5S-A<B<-W[F.R\O(R>;QSF\8I+^L$VR;Y><S284G+L2HL<G**UFJ[6-
MZW_O;D^*9)XEV:XD:UJ2[4@R;VA)MBO)!KM<=;LCG-6JV"5._L# [MA?!ID?
M'A6P]GYE9X>DYN,A!>Y8D';(37MNJ]-RO?Z>W3Q;'Z,MHPR:%%:&K0QO#4#<
M:[G#X9[Q?RO!5H(/ONEAJ^GVAH\-UFHEV$KPDX&Z#(9NN__8\PRL!%L)?C()
M[G;<SLX=MD\BP2?0[_XE!@?6\=-49#4=K'E0V76;PZX[Z#YI5?%^6O:D^=1Q
M^ZV!Z[6>=""@Y=,>?.H.^F#//&DOA>73'GSRFGVW-]BUJLSRZ6GYU':;O;8[
M;!WP?CJ!WM=W<31[E8EDX4S$*'.=4*2I,\Z31$29L_"S/ FR8,^YY0<OMSLD
M8?N]KMO>^=)^4+G=-W%AGS>7>IVVVW[:,G#+I3T23EX/KNWVDS956#[MDQCL
M#MQ!SYZGX^93JS=TA_O.>;/!J1V"4VD6C_^8Q^%$).G?_S9H>?W7CO@S#[+;
MVB SUB.H7+7#HSZ#8'?TFFY_9]OC^-Q0*W7UD;J6.QATW=[.I3M6ZJS4/43J
M.L.^V]QW>)^5.BMU>TE=L]]RO6']$UQ6ZFHE=> ##W>>K?#88>N-C;9RM1WL
MBEW&:9 %,3Q5A'X67(NB&1;;ZHQ?R5;:9O$3?Y3&"!NR\2<K';WK30*/S2!Z
MRYT<:N$:7W6ZKS1;B#KF?W$#P>1_O@N\::\Y''1&HZ[7[73\SJ UZ'JCYF#2
M\=NC:6_T_SKM[]2/YDG1*C83KT:)\/]XY4]ACS_YX8U_FW[W8YDT0!>YID&W
M@9S8DH@K)-LH1@8MI]-'H>5:;P70DEDZ$>,X\4DF8"$BP6_!.OWC7Z0S3\3T
M?[[[V_V\[H-#3^WH\=0YAQ>"_*;_^-'_N2Q'U7SKEF7_OWF:!=-;H%!]&MP'
MC6%SOX;A1WIL';I3[U<_M-E/9Y^_.)>7VS=Q229OWW+TA'?BEGN^S,3"Z=_?
MA-6K3^_95KKGNY\_7UR]OWCC7'XX;SAG']XX5[__<G7YYO+L\^7%U3]&R8\_
MO_<CN#(6L'(9'TR=-T$ZSM,4=)7C1Q/G+/+#VS2@UNVW0>1'X\ /40M-Z"*F
M[WP6:1YF])6/2\&*+EVG=]DHN ^#HUIK'8**EU\NWCM]Y_W9A[-?+]Y??/@B
M:77EO+F\.O_]ZNKRXP<B+WSAW7^N+J^<CV^=MY<?SCZ<7YZ]<\X_?GAS^45]
M!UCR^[LO])6/GRX^G^$'5^N*?$LCH/==G0CY$<[&=0#/VN;B.M32J\VVBH,R
M*1\4WS@H4WU0QJ6#DA0')=8'Q7F)CVPU7[]_\W=_L7Q]1G_U7O_@P,,"O.TG
M8N)DL3,7X=+)Y@(>XX-Z<LB4(*P\)\Z3#0_'3RN6TW N,WS^,HEQ;!,L'[[J
MI/ER&=(NX7TN_3:=QWDX<4;\5E@//N._>32F3=T$V9R6E(I0C!'RH'C7!.$.
M\!%C$Q*A^!Q6GM&[>)%1G G<[SC,<3T!PB3  A.QC).L43^)^;=P_ 3^WYF%
M\0BV&S+3:%_"F8AK$<9+W+[KP+ORJ3_&<I=HYJ)@94DPRK78P![_$!GVS0)O
M%V*"UPL^(1@+IMTXC//)JY&?(HQB/,UNZ,W 2_@FBT$V]S-XL#^+XE2X3@;,
MS.2S4;!1>)8!R$R<W.+[Z?Y+7<D.?//5FU]<4&6?WKA.)/(D7N0@_:&?X+<%
MO)@>%L/6$F<\3^(H&*M/T@;^6'$6Y',$V\O'Z/ Y:2C$$E8:"=]X0.5B> OQ
M> RB/B%*\:\;SD?X%Y#C"3R3R4&N(4M_@J1.01KX" 4+%'CA+($L*.5_YB J
MV2W2-0RF0)A$P&,$L0B^"SS!CU8V1.\(XQM8Z5SX838?XVO&<8JO3Q6_C8_2
MVQ0D/<6# %S,!:YDDN#^X<C-@VE&QPJ_.07".O,XI>[H%+^'*YG'"_.E^"8X
M<!E*1,K;-P5@$LSPUW(!)3& (QW&0#@ZMJ@SI!"Y:X22>@&7'/'!IO55D##.
MLW&\D((HIM-@#/\,_Y\ZTSBAEX"6!!,(6%C#4WP51%(<C!-+,L&\C'/0H124
M0&X&";C;0#N1IGE"/TO\Y:WKW  /??B"^ I;0.V&9!GE*;PN39W1K7HX'?'$
M\<=_Y@%)N.]$^6($/(<W;A!QI++OC)*8U$OB1S/R$ZO/4'&>,S&>1T#$&7(*
MV#J2"H-5KU(R2GWGP#Z] ->Y!B($(<E4(4)2NX#Q:WQSX:=_:/G'I>9P?J0.
M5').;T$9=U%F)S,!6J50!OX8G@[K#^@=\.)"][F;E5\0P<L6L,)Q:M *]BGU
M7:7T*D&EO\@38/ )_@67(N29FR7Q#1RC.1SYD1"1,\WA#IP@-V<BG@'CYT )
MXCC:"*ZZHV%WX[EZ U*I)%EP@."ZPYVA#'"P*Y7V!7(/]'9*@H&[I%4!KU&]
M5FM/?=^GH-_^$%J3F3IXF8>+./)93EB_ <W@Z 5PEGU8DU0D\*RQ2"+8??V.
ML;R,@=6+(,M8Q8$BC)&4070MTHRH#X)9XI#)&9-C(IHCKA,9+PWG#=]&4[ '
M039O47P1P8B./3\<7OBBU6TW>@[L+<13$]_U)N0+%;["(T"(YF@$X;?15.HW
MO.^1YY'(X)_A(.9 )=+GOKY?P,J*09;Q):N:BP_T H0<;;#@+S[#]+P;O.ZC
M^-IGJ:C6-G0);[H"7 ?E,Q/W7 -\WM&87<[!8H:%2!%71PX/%' I48=U^_MW
M(S.0%P5YD"JA#T;L'+=^%B17(H+G>IXB.)C=M']8/A#&F0JL18:_I#GR"TWE
M+,8_IK!A$>&U.@,-E<VEDI.$X1_S)8X7 7-:7L^F#/'IO<:0PUR\@FO$R9=H
M+B-.BC\*0A(&W!O=P LP\P.PTTLZPK35?J$8#*P,!?ILF00AT,#KN<YO%V?O
MOOQV?O;Y8AJ YX ?_S,/;_'3 :WAO0^6Y]=SUJ#.!U@2W3[X.2M;9.12,#JW
M\7HDX_N+-Y=O/_Y_SINS#XJ**>H_-A]@W:"H@<B32@:U@;2C_\)7\8N)F(%I
MR0H,S.8$Z92R C4\FRB^448E2N"K>/I*WRCZ'EC"<_ F2$O6#?HYH&9)#D#H
MIH+<.+2XZ'S #V=P!D .;^;2[5J*>$GA4KC?6>ANBVL,K#-@.IMZ;)8A/>"S
M (WA&*ZJAO-E#@?86 X<&&!,*FA75[Y_I>\9_5U]B<8K%EXB%N L.:"U R 2
ML2*::"%;:%=57KS,.=])8GA%II78,E@*U)2N\O%,\U39?[E6+G!AH.FH=D!R
M/LWQ6,B;L*;W AEF$X%=" &)!VHX9;!E-[$2.?0WQ(R.J](2/MMXRHMA![_"
MZDI!KN-$RL2* P=2- $2P/=5&.!*/^VS\30\DSHP(-G-_CIY+]I(,;FO/4'R
M[3'V,B;FKIX6><$7ZE<O!>12O;2&QON'XH[$P[IV)TA[BG7"B[;;[0\:GKJB
M7</B(HO::WU/IQ8H2C]8>9S7<'Y-8C83IT%F/!Q/"G*+OLG1' 3!Y!1MN^GR
M8G )+;?9ZC3:Q1+('WSAN8/VL%C95@_TUM;_PAMT&ZW" DD<K_D]F[)H3,!7
M49%MM]@;$*D7_?ZPT3&?]Z+;:#=I_/?$G.E0HIKQ*EQ3I]]I=$O/:#=:G8IG
M;+7GAO-[E(AQ#+;K7_@Z_RM8$I$ =I!G#E? . E&&.W*X'(#%>JU'8KG>:^=
M2U[4%_\KAJ'(]Y>.FEH(O#E"E[L8<([&_@NOT6]N6IZC5U:_T\,UQ(7V&_OI
MW)F"W<6J?\W 0I%H=SU#3NG:R2KD1UYI^$"^<.$/6)A\[8=D#F7X:C*:^^U&
M7SVOX9QM?EAFM..#^@;>@#1ZSLA8"GYM<TFTW !(]$B][M]HX@9X=?Z9^PG<
M$"%J=1YS3]+;;'1:AC2431NF"E^><G6+..?HP8M6IUN<<WX+VB7&ZC9+C*VA
MZ/3NJ*&PY1"V',*60]AR"%L.8<LA;#G$X]^^EVBG8V#<"!/XX*GX"W$3)W]P
M0@+#Y!2HGH.]B(87*_I;_"?EJPJRI#&8(":N([[JU,2<(HB"DV_P.;P]DK
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M,DGKV@&M!$0U*!<<U#*T_0U9V2&8K;PECXRFN14VC-& F52WA@GG+$>LL#
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MXR$5(;(T=OK.!&=?=S( :*VJMRJMBHR-9T:2*=OFJJE<(F7C6<I#VK)CN[)
M=4.VW%4[BHDDT&='DFL]4)L6&H<H%1&E(J\,1R^>H[L%RL37>]-/MDM3,&5M
MY5$70E%X9D7!=&5GY;QPH2FLK83LT8:$N)*$XO"D0MRV1=G(RY:3;:^S092<
M;@*6'-DQ5NTU)%2(E>8A?[HG&WV[5 =-DVU'A"^ZC:0WFB%;IK?\$&^A-CRH
MVE0DS6QKRH%KJ6"\=VWD@4B:$12\M.;HJK*M=Y*"MT"K/%A86_@8=;*%%@-@
M'V9#+ #8T)$RFNG(JOE !\B2D-@@+?25X=:63>OQ _Z> K=;H,#>4R<ME-GM
M4@6LW8?ZD(0F*\CWQ0]M[.JKYL (-7;-GI U7";+>MNZ!H.5Y]MN#F=9N\X#
M!]AV2,D6!+=)!&>\=,1[ME%4'/YKY_XF(Y:[<W]1_DMTEYK?VN!S_)]A'&(H
M"SL0[)-!7)($.Q%DPSR@K8Z)'3S1_"8_I\-<&N1Q&L0#.$E]CBR2DO%1<>(G
M_(S>Q@4+\P>DZ#$ L']@;.^:)!C4D_DGES3%C #LFC7541(?(J!&% 4V><)%
M<WJ=)==LU9S"ZZ2(!'$"K]V5JJT!Z$;2L."[8NOWR#65?$I3EKF(3;1('O =
MA?2:)MD 0XSPHC*^CLL8\Q$*FB3X$OP-+/B3LH.T?Q%4R&0Y#+ 1["<%S^$T
M4WH9!^U.7OP<K6"F##?Y=1S"<]* C-A'U635ZD_<>DA]^%\?<,Z!L2M]I^QM
M02F5/5+RLPWR#%<*)7_42JP8;Q1V/Y*B!-,O8&.P"2D:XEY1=8BS$-X+_T&8
M#!.>LP4 R>%8 -8RRV&G@.IDB$S?K,*'L*8,'>-7\B7@@9M>#,#EC\$+^P-8
MJ>"8Q7Y@^Z=_'1THF@<G3T/:CP, VG PP'Y=/0*KAG&1#P=5,[.;+/_)*8@#
M.Z>L?&4,L?J+D Z2C(,NI$%<,(!M)G=5^)E[Y)LX86=%RLE2P&TZJC'50A0B
M!L3W3=G#[FL,Z1A# ]:AZ9#*@(8X#Y4!R8%9<QKW_6%>T)KL,L9%63AD6 -^
MP0\"@$K6IT@/B,,R[M?, 9"K'BP8'\#'P*F(T2POQ[S6YC.P">"[:BD@:(!7
M59U4<9U<282$\W\(+XL98\7 QVT>;.T%GH[3DN^;CS^.X- WS5&:MS7,.C.Q
M>) 5!19$U1AH<[#<9E\)H0++C8<68Z\Y/TYYF17L-"U(T#S71DL-H];:N-/C
MPX.CCZ?_E@[V3F0N+.YEFUUI#^B!S5W&#<1IEE^2% 1/A?E:$B&<X&<H!E+*
MF^4Q?JL0#GN*L3U$2A)@P;$D9L(EPNYX##;H.@<Q4PO\7>DH8B]GC?BJDC)8
MN9;5L&$FOKCH9!OP:1(#$7#1!7\S4O9A"80X;HH&0[8:*;*4?0AV(QR%R1;8
M4L$.C$1;4^GXQJG..I*;A0-@M1B('5?N9VE<-H2<YWCN!.D1%VI,J>9^8H>N
M ,%Z!R&884E2L!6(SZZ;J=/R@^)K$4PLT:WL906MU^<OA#-LGDS:8[R$O6"X
MSFBHLH0]3QC$9C[6& YZ)%Q\Z^-RO^F.L>M(L-VD[L_TF^Z!8EI_Q!I9XET'
M/)]4E_OB%7LTX4S,.CE2Z1M@'"CRK$3"D8#@EMX^[!ZH\#='W54G=Z>I]GC#
M\W8',AKNK[OT'<DG"4F#%7<D5UO2U1F(::Z[:S\$8JV=P-(,>K"E'F =A$"E
MBC5MM.(4R*\<EAMZIRZBWX90?]-V3<FOX7I-XH2)'U;EDI,;*<QN4HEU1.0-
M31=IH/RVJJX")@_Q_D9BUP!Q]0N 0ANLC%\VEF5+O&@3I<AWRK3;,N<7[F^L
MC]DD-5NVNJLU'_&FKE.<' XKT4JE$4C60J)-HZHYO,2YI\T5,K]0&Z$_ON\
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M_;E<-8GXN3^Y$^=%O?5ZVW-( !UE<[&OMX%^'^DQI,R7#,S7R-UQZ+KC,)X
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M-'K+)&'>28T-I<G K@5C[81%:[(;^"E(B %>VV5<<EVC35H3.P"3&,5/O0/
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M*1HFK'JS0.N0G[O]1G3!P$[@7^R=,C]_"N00]F/.F!C3CNLH.,NSX Z(0@I
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M_'QSM9&-@8B4B9<(=51V3?.,_>8-4I@QLL4/V(7=RJ6MLO>P$@9T75@IW<A
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M-!/C_1\,?14/NE3GG'XSZ.R-K<KP@N7%]7P\/ZD@6%8)?I4(,C39\)P5!8%
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M"32L?8U-U*7GF\>'W[Z*8*UXI0C6KB=8NXGR_S&!QVV],P7,N@FS)YN$W '
M/><DY&4L98&E29^-[;T<AC91(>U*V+8#?:2::M5-BB0* (M0[=H;3^_O/:SQ
M="5+GRYVMT:M36Q2;%*$:E_#[:)YLJD;6QRH%*':]9' 1@<635N$:M<,45-$
M:CL:J;UKU''[4M\( =:VD$#[EK1=W5.7FAWT#$K3O2#NB'(G2.'E0;PII#"K
MZD^.ON[6T.OY<\*/D'1I44I?<3 U3O1^W #IISW#_,'=WRF;LTUO!UDU:CN'
M<TBD*+(@AF.%TDU<]B1^9Q12G,)_JE.SJ=D2B2(:E(!2-GH[I^4P3Z4,_C/,
MI8 4/3;VG/V#_F<87Y.$#>_&#T/JE[O27BGAM#'N-<:18SBT399NJ-2C27C'
M$EDD_:8[QJXC 5B2&%XYR.,TB =L>'B0]>'/ O<%/_1)^E.";??AI7#0N-H!
M*160.8E$@H /'V<? CCB]!I.2/$7$I!R3RIZ65XJ;(4HOH4OIJ$ #UZ3/&8C
MP">_6WA$@!>\ZH84< Y7W56;<V3#LBAA1=S\>*IY3J^SY!H_"W(:QGR>/-M1
MD@'=1"2HAGP"\'IQT ,0PO+%T+\"_"!B%^]/ZHT&<$K*1+"DJ?]5X7L.NL-A
M7N-ZA),8*>POG(_!; CX2[-2ZI%KP"8!:$I]6"1GH^#[ [2(&=9H26[A/8 R
MT%6^4_[[-)M\-9!#>(FO)I<YI=4,^=,47IV,^*LU]FHP19!XV+7"\92QW9YD
ML,:780XG*ZBT5R_"R1M_,*B^R]EH^;('J&]>)2,D0(M*D=1AS\U#<5$,21I0
MAHP"*).3I=5&9T.6E?V//T'N,'9U\[^D@J9QEB.<&'3IS(%T6V:K+[VJ:2VS
MJK<KG?>F: '1 :<J:/5@7%34CN]'3+:H*4J&J% B.':7%7LO)J>CA&UT\\1S
MLW62CY#%RPS(LQ@"=Q,4QB )@&*96$9J#+*BH8-!GH6 (9 &4<Y6E*4,M*P>
M)2'['0C0'(1/90@4P)DCB83PBX*"^.12G2V4#2C\ CD/Z&28(-N= 4P([!79
MJ[4_X&1@AWR\GV@(MP%E2S.>!OA5KY!H]0)^4? !Q2.DJSXLC(M+P3#/D4$3
M>DT3)NY!X2APHX@K1I+CK<']15.$!("%2/ QZI5X.'@LI24*3YH"&\01"@<4
M\<.4R4)X8Q9%!2TY5'L *9"W'$!E#S2<RQZR6D#'T%Y,[A7J3 MPRZX9 ,R[
MG"*$KNG[:N(\4S+;3U6ZDCI^A/B@- W+Q8_<0:]<H7XA<E5L59F$3ON_\0!Q
M^*^=6(MLU7--W[<TRS2)Z>JNI?FJ&YK$\"/;_]O5=^J'>OG8XK^DB@\X^*F0
M",[XCB0W9%3L_#X)&H!+M2<7;8TE03@%L%G]-F+_[WT+DE'T9#*+(S2D098S
M[GK'U #\%>R3='^34B^GT;]V_G$_IIV=#^>,$8%1T4^.]_H_?R<?EA'5UB))
MS2R)J30_@$E"!@5]5__C?1@7@X2,WL4I.QE[Z'VU?,63^(8ITY2]D'\]IJU=
ME=-7Y4NJWEQ]O<N^FG)?\>],=]=3%W^M[FH+OUO3LILP _Y^X<,.^V7OZ[ET
M=+1\%N]<(_4N9\4S=DA8\LQ')>U+DZ,QYF+4OC_KM2M-3Y94ZKX>GAT?'DA'
M)_M@P)P<2&??_C@[.CC:^WIT>#8+CTGG0E?UU//#8\F5]D]/SDX_'QWLG</Y
M/AZ=[)WL'^U]EL[.X8/CPY/SL^J\7[Y\9G_O?;V0X,=[TN:IM]P"B;*\SVX0
M4-/ P$>SS0==L ?F!Z/OF*FZ63[ BX9_"=<+F"UH>%7F712G8(>A90FJ:<GM
M0PG5.E@<;#50&-E2FH47S1>2E]+17_A/]I:<PM*@(&,@3U??'][V8K_V$<"E
MQ'B$O?EC\Y:S^BW260"6Z3 !O9 ]KKWO,AKF$]X;\E8Z@LO[%J%YWX&+I>EL
MDVYB3]MU''?M-[&]J^KZ2U[$+>Q42RCX^W>:>Y>86Y/6.._.6DZU??&]+*_!
MNA9<1DR H#Q!-AJ@4PPDPU=Z&1?<#?5EZ"=Q(.UQ1R-:K!_CO"^U-=T%J*#T
M15#QYI_Q[;LT2T^&?5@Z8"%$^/57!$KL.JII&)IG$2,T?8>XJJU1CP1!Y&J!
M'VA_'^BJKJF.JBGH"U1M0]V14M*'DX4T?K<W#.,RRT_@@QUN$(;&7R/_(+O^
MK'^]OC".A^'5X?6/3][5Z=7'_LG5GG5Z\#6^N/IV>W+^IWIQ_J=Y?'6I'7\_
MNCG]A'^?Q#^N?L2?C9/DXE=V^^/JXN;T_%*]Z!]IQ^??U)-/A^KIP9%Y<OXQ
M/C[H_82_?UWT+_2+Q#6/8Z\?]#^FIU=[HY-?":QS>7O\Z\+Z<?ZU!^^!_TV2
MXX.//W\<_+R!M<SC@Y_F9P.^Z]\FL+>KT_.+FY/^Q]Z/3Q]_7EQ]32[.>_'Q
M^=[HXOQX='+P1__'07AU<7YY4S\#[QK^T+_9Q]^/+3B7?O$=GOO^-3[Y]%?O
M]-/1[?'!__:.?QVIQY]^_#S13WJG!W]$Q_OJS>?SP_+X3(5S7&JG9Y[ZX]\]
M->C_E9+OWO#TZD+_<9#TCZ^"7S\.#O7C\Z]7Q^=_Q,?]XU\G5W\:QY^^_KS0
M3WX>'_S5^_>OXQ' 1CO^]:=Y>G!L')\?_^WK?DA=ER@^\37%I)JN>+YK*X9M
M$$LS-,<THIT/__?E^)/T^?.7?_X^01<?9.GI">5S%C#Z%,3RLL1R]?-ORZ4.
M":-040,W4,R04(7H'E5 2MJ&8]%0U^R=#V<@R0YB>IG)TO[>+,54:.4B\.C@
MW3.0$+[J*!0$]+($].O;WT'HV*I- \70;) V<+$JGFFYBFM&04 M0Z.AN?-!
M<ZUILGD[Y5=\4.;<LJK2M,W_0M;]7'WH"=\XHQ  _%=5A6Q]UGTG%-R-5G!=
MEL(\-@K_( F+>9[U*"U9R 447PP!2U7TEU' IAYULW?/?!:;C@)M@0@1\KYC
M\AYP99M"WK\N>>]I4_*^Y?IC'@Y,U$&_:I,%5+32@#;^#L#C;_;N-Q_^VD;O
MGM_!&WV$#:<?52@0&Z% (*YL2R@0KTR!,.]4(/8Q-9OV:%K$U_3UJQ/F1JL3
MYL:K$^9&JQ-F8])O]!ET<2-OR(T,R+)M<2._LAO9N?-&/BNSX&<O2V#A@C4S
M<-Y+A_\98D;^Z[V7G8V^EYV-OY>=C;Z7G5=P+SOB7MZ<>QF093OB7GY=]S(L
M=+>IC$7/'Y/LIGB]%S&#P89O_Q5@8'/O8K;]3;^,.1>(VW@S;F.&+=L5U_%K
MNXZ-G0\GK/7!,H4P@EDWA%D!J[8GF/65,:N-F>95\9UT=,2J]S3MO?0727A?
M$J83_#D$S$0C++G9:[?Y^4IAZ]=4,/&&,#%BVUN4&+BA#<3>^&^EL^%@D+#[
M!%NH')"2K%)?^1)%N\!1>0GL.FI=BD>M(MXWPY1@U04-WU:=<;',]S_-4U4;
MF846[60CJ3JA56-=6XIA'X  FPTEGX)=++UAK6:R(1PH+&3L;DD')3: D8H>
M/L";(Q5OW[W*JE7=V_7LA_6/N/L[4[777@NKZ;NJ^] -B<V*S;[49I=;=A,Z
MJ=P_@@)!@6+WA9N9O^3Q/\9Y4;+VK]5-M\6P. .%+0T%,%3>K23.!2PJ)LF&
M>=D3P*@D1@$;8<"X &7V_G9,ZQJ8TJG+9+ZA>3+NOO@4/;0?#,;[A^MU#9*_
MK3I3;\FSOU"'L^4.[:FFK&K6PX8*+MWK;,GI$0T@! 4+"E[VT*YGRJYC"@H6
M%+RI%&R;LJ6J@H(%!6\H!7N:*3N&(RA84/"&4K A6XXK:WHG:7AE&[?J4[Y!
M9NPG-GM@D&=1O,P SWN/_*"Q\'/ MOP<OY>$GJ7:LNZN.AI^/I4\J93=<BR9
MLJ&Y DN=QI+I:;+FK7H/""P],R_I.MA,ML!2I[&DRZJ.,D][.3P]-#ZP0;H3
MA@#X>+<GG:)Y%X7. =J&4*AJR+9F/$SK[Y!]^MJQI,F.M:H4$5AZ7BQICB>K
MFBZPU&TL>9:LVH*7NHTE!WC)?*A'5?B<EH+Q'Z2( XF2/(4-%^.D9N%_6EFF
M[)JKAJ^$*?;<*#*$YZGK*-)759X$BIZ=BU:U%06*GMDSN&NLF@PDW$VK /@@
MQMG9X;H4IZU6\T&>K!JU$Y;8LZ/H!<TP@:*G49P$BCJO. D4/;OB], <U+4I
M3H]K,2#*RD4]L=BLV.SVEI5K6UTD*LK*15FY*"L79>6BK%R4E7<'DEM93N-8
MFNR9HBA74/"F4K"KJK*Z<N*RH&!!P5TYM&.[LF-WLJ!14+"@X&5DL&/+FOK
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MF(15K'#2"\?B3^/\A4FSA>NF+26Q\9C7&FJ#D%JWCG *!)W6,E.2C- 4:9-
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M>_3;%TX]HLOANM6KJ]GN4$'D>IYFAXIC.KYB.FJ@>&$0*J%%(TTW7%\U,1O
M\F3=7)>SOD,N>2&17J5$6O<,.R&1GE B35>.6A1PY#B*0<Q(,3T]4/PP(HKF
MJ8:N.I38KHZ-8UQ9??PP!Y%!^5!%+Q_2U@P:7L#AB%K19]"1$/(M\UH(I;4+
MI=EN5A3N#CV*3,6RM0@GH#L@E%BM*%4U-=0"BMW?#1/]4%TJ+1-)DYU5+ 0;
M/P,;3R<J6)X68$FH:VF!8FJ."VQLVTIH6EYHZ;;O.3K.CE=ER_,ZQ,;;Y$2:
M[J#9\A+*S>"9Q[70W(;"LJ=IH5D+K)$05VL75[/-KVPL'PM530E<SU9,7U,5
MEQBL?[=G>2Y<-!&(*UV374O4B+Y>5GZ:%IJ"E9^4E:=[4ZA$=TWB*PY+S'%U
M7_%LRU=<5;-T@DP>1<#*AFRY77*S;I-3HVE-D=-KF@YGHE?""%JS:K$/B^+K
MOL=E;W]8P-%I+J32TTFEV>Y7JD4B'6?F.I$&4LEP3<6SHDC1P/P!,@G#T EV
M/H#!)-OVHT=<";=&9SEZ71J&X.AGY^@I/2,,=*H!JA00T#CMQPT5W]4=Q3<T
MS8L<QP]-%SG:DVWMT5TWA8?C08QYU&Y]5:7*B!98SQU":77*$9)I[9)IMN&5
MJGM^%*BAXMB>"Q:02A3/=P(E\%U'M>PPL%UCYX-IRJ[WZ+H$X<SH+!>O.8(B
MN/B)N7@Z'=_7'-OP+(4&>J28%I9W:ZZO:)JI$S.PPHA%4%1']NPNL?$V.3+.
M>EE>*B7-^\!!_L2D4T]D:#RU>L&@?P[ _R/+\^P&X"4JA-8HDF8;6@&F?->(
M0H4XKJ:8'@U )&F6$AFJZ8/-X_J1N?/!ZU@O'.'"Z*9>(=CWJ=EW.M]3)Z$%
M*%(<SP'VM3T/6\=XBD.(K6J!;VJNA]/%9*"T#O'OJZKANZL_1#!;K26:6;V8
M=B$RQIY2.LVVLPJH&VB^&RJJ3JABJK:M$#^DBF41$D4JF#Z:NO/!=CU9?WS&
MF&AF]:IX?ETJB>#Y)^;YF1;>U% #UU<BVS<4TS#!M-!L0_%]-R*V:;@JC<"@
MT#39L=>5=]6QA@.;5U1^TFJYN:["\ON1\M(EYRON<)NB;&M)Y]D&C_RSI/.(
M5HQ/<7==SDD9MHBJ^9$2N"123,TP%,\,;<7S78M:D4\-@\+=9<FFU:4\0Q%E
MZZ;J*7CZ)7AZ6A]U/#T$QE8<(U05T\7L'D\CBDXT8&A35QUBHSXJFUZ7R@"V
M*>3V%&/MML%K_PQC[>"/E@$M9-93R*R?,WI(Z.N!JH>!HNF$**:E^8KK^)JB
M:=36+4HT37<Q*.=H8JKNZV7O9YAN)]C[6=A[2B4)W#!P],!15 ]'6-J^C4.D
M7,6@JA$ZFFN;1-OYH&FRH8DZZ@[64;<'U(A:ZA>NI19"ZPF$UJ_97G<^2"W/
M!%%EFJ&.OI% \8,H4(S0,JBN&:YEVYAIH,KFXUNC"^=(9]GYB>NI!3L_$3M/
MIR(;0*FN;2B 24P<,G4%Q;1B$LM1?=.R L;.FBF#H.X0.V^37X2IZ%*2I9<\
M'_FQ243;8#2M=;:NL(V>6"[-]HHS/2ND5F@H.M%]Q=1]0W%QWJY.--4/5.I:
MFH,S6#Q'N#Y>+Q>O=;RNX.*GY^+I5G$JL<PP!,7"B'QLC4 4UXY"Q7&,R'-L
MGX8N<+$MNVJ7^CUNDX/C<Z-5K*G*:1MLG[7E(0/PL4KB $ O!-'Z!-%L$SA*
MPS"TB:I0SP@4T[=TQ34=4PD#AZI4-UU=C78^.+8E&X\??R2\%IWEW+5E$PO.
M?2K.G0Z2^!;1L-.;848!U@YH"O$,5W%UVZ:A[AF&9H(*81JR83VZ%XMP4#Q2
MB8C7WY5E&^R<I^O*(BR=IQ!3LTW@PLBA)-(<17-PX ;<+@KQ'4,)(]^( B/2
M;,_=^6"ZLNMVR=01#HMNZA>"D9^-D:?T#:K:;D2U4'$]7U-,[.OH1I&ON,3W
M C^P=,M$EX4N@^;1(4;>FDKJ='Z)DJBF[D(UM1!23R&D9MO ^8X=F9I/%4M%
MOVJH1PI\1!1#];2(1H ]V]_YH,FJ:<FNNJXT#%%2_3H8_PE*J@7C/Q'C3W>F
M]:D1ZJ:I:*9&L,]+A!GAA@(2W U=H 1 YLX'SU!EVWUTHQ=15;U.Q65-61M;
M*K.>0%D1DFI]DFJVH9P3&K:CJ:;BJJ:'_1]<Q46-Q?=,-?2HZ4=6B"J*8UBR
MMK;P;S=4E#5Z2[:4W9] 11'LOE9VGU),3!KYAF4["@W4 "R20%4\"G]Z@:O:
MEDI<R\):%MDU==DTU]5#LF.JR0;G@>QG_7Y<]D&!+R22AHP;X0PT#>)Q#:Z]
M.(*S!%B6;[/R-&K!;1&_2^/D7SME/J2S-?K-^??2<+]]>B$;5I(-<]J_Z8%-
M?9LHFJ'KBDD]5_&(H2H6,57/C(CMX3B-&9'P-&Z!%R+452XT0:C/1:A3EQ@@
M0'6M #15 [NH4A>#>$&@4-T@D69; 2'F0D+= D/VK,R"G[TL >XH_OL?KJXY
M[R7ZGV%<CMY)CVD1UI5&8$_9[FMIO(;Q]8L@]TM>M]\H$,VR]-M=XNT+S<]Z
M)*=K,=./3CY.B[EF-XSFOI#\-#\K24G#OT@RI..W5Q)/%1)O"8EW61[O3TB\
MZ_#37V;X/_^;_-"3:_\JNSD^^*MW\OW0/.[_J9V>[ZD7O[[I%^>7\.\_KD[.
M _WDUX_>Q=7'^.0O%];\:1X?_*F?G!_>'I\'MW]3(PA<-XH46Z618GH147R?
MZHH6.9:."H :FG=?F@NHZF'6H*"JUT%5Q">Z[KI*&*FF8MJ.JA STA1* \TW
M;=V@V$A4W55GL_]F/I &))>N$=>RM) ."Z2!XGE(D-%;L3<L>UD.HCI<SDDA
MZ/+%Z5+[V[!#(W! VCFZ[2NF3P/%U6RLAJ>^;[F![3C1'=)N+I4]T?4IJ&QC
MJ2P@:F!%3J2X@1,JIJX%8#M'IF)IFNNKID4C.]CYP.8ZS)WM,"L".>%)I*&&
M]RN*PB<ETJ.B&$X3:!3?TE#Y1?-,T&9W:-/ZV_=,'V>N*YKG88VNKBN@\ZE*
MY/M1$-FZJ4;VJA+P2>]905R;0UR1[>FAHT9*%%)5,34W5#P;+ I##ZFC6CKQ
M=!!\0%AT"9D7,\0W+@IF8HO:J"<*L4]R'K.L[F4YX;%<DN5F7.N6H:(O7;.P
MJZVM.8H?F:&B&I8!MG>@FI@/Q'QU^OL.54>)NL9NQLL%[SXA[TY%&[Q(-;50
M\Q1=I;IB6IX)JKT:*I0X9F XFN=[6A=Y][D#'7!;UVM72RCX^W>:6R\2IR%-
MRW>*QX3#"T7/L[03CG.^%>'?7!_G_KQ'T1WT3P].KDX._AP=?_]3^_'IF_KC
M_%B[^/Z_ )=+A(5UH7],8!_6Z5_N[>G>WX9KN;KCZ0J-0+\U(V(IQ"8NW-R
M>M4EE ;D9?WD@H@Z3T2!3S6/6A[J>RS8$BHD\L ^"ETWTG2<X.LSM[@ZVR"K
MBW[Q%LD)=^6&T.&DU7YUK/ZMZX[O&6&H&(Y*%5./5,4'ZH!+%X2>[CM11)P7
M<XH+$GL-) 97I.=:Q%:T* A0;585US55A>A^I)) I9'C[7PP+'4C?>(S-#K/
M9RGHL[/T:?[M:;Y!= +6C^Y9BJEA.IFEJHI!"0'CVB(69D%HKBOKIBU[<R:(
M5>Y*EH?;%3(\'99%"1L"ZTO0XF;0XI^COT,'; G;-A7-4G7%)-10/&QFH/E6
M$+A^&.B. ;0(=&AJJNSHLRD44C9&O$1*Z7^'*>6N!T.5):2F!Y#ITRF-0EIN
M$H5^N_D[U"W/LP,,:.N:8OJ!IGAJH"JZYA)7-R(5!!A*2T<V75.VO-E"L8=+
MRZ<C0R$M-X\6U;]]+[)U@FD646B#9NE'8%+[5-$)L6W5MJFM>B@M+=DV7=FP
MW-6EI?:(&.0V]$]:WQC=AB.9UVJ"(47<8C6>FVYU1JFKZQY5+$=U%-.CGN(9
MKJ' ARHA6F#2@.Y\L-QU%?EM:.7NJ^;3]8W&%7RZ-CZ=[F3F:Z&A1:#\>WB=
M::JK^(ZN*X;N6HYC!L1Q7.335]C&;"-*;O=@RPANDD@#$H=*G$H!&<0E243C
M]:?ND]J _@M _BC=YW!O22/1+6!=HNGD8':(G&H$#G6M2+&(C<,A=!!-AATI
M3D! DW #*\3,44VV75V&;SN4_" 2E[JI2 B.?F:.GE(V-#TP3)<2Q?%] XT"
M7?%U55.", AI^/_8>]>FMI*D6_BO*'@ZWK<G0NFI^\7]!!%N@_O0,4"W37<?
M^-)1ERPC+"1&$K[]^E.U)6PL83>8#6R@)F8\@$#:NW*O5;DRLS(SP(EM^G\H
MQOK4UDER=P/,ESAS^8>QAVXRRA=?Y\?=M*=QMN*;BP5_%L+I\>FPE--L8!J$
M06V8V"(OK<Z1D\PSY%)F$12R"$K,@2&F=$JE:#!_RRRNK?.^HKRO>0U9/%Q$
MM^5I5$3?,J*7/8VL'%R(%&0L]1_$&'!21U!6)ZV#$BSJ@FBB;5^):S=![5YP
MX]J%TW=6)KTW03<]G7PX*Y1VL[P.T]E5:PY;JW(XNYY&'RRDPN(#:]*N+01O
M_5/2;GAP_.MPFVW*@Z,W)'\VV=YX1G<W#MYL;^3?W\O7\7%XM)-7<I\NGQ/\
M@_VMO*->8PEK\C)B4FDP!C6PD")ZE] 3>F>'4.L#=O\?L,PR5!F5=YG4#""C
M AP5%$C*/J,G@CN?UM8%[1NN^HQ?IMKZK-SPJ^4TK>:-[VT8Z<<[T&L7(/:"
M4W#5I[LF8)>G?<<@#;4)!--N[M-Y$6SYBKG$./>!S:-'O,_DJDI;Z4M:0\'W
M$,-M*;2*X5O!\/*L[T30:I/=+R9U=L1D .>T &&MC-YK1N8-WSN%X<<4_#T7
MJ.B-9X<XR7=\?#+!0QQ-!V^Q-QQ/'UD\^'8<C&F^S?S5!2/^SLRQ6ZSQ_+PQ
MYH/__I,MLH.SW;3GWE?R:H^\5L=W*L>T+%T%2:(<1% )+/,>3%:6(20IM"F'
MBBCK:Z&O05TU/MQ=A'^_^U$1WD&$+[DGG-'$E>#Y,9/9*<' P 3A0:&34MB@
M!,7LGEC>%Z8C"'\T,SVG7^TK7L=ZWEGF^GRS]\W&&)6@VB.HU9F>R)'S2"C8
M0&D9[8?@!97@50R*)F^25B6OQ17I:[EZ4J^+P_WJ3,_[EMVNJ+]AU"^Y)40K
M5)P20!H#".,=.$0&C@=*G$^6A%CZ^QHC^TJW53?7L;E9]V\2RLI(SR9M<WD_
MYI*#S>:W^)1G0\3QJ1_BW$C7X+BN+>0/=[(R#X7U;V JZK-1K'O 3>X!JZ-2
MN:#4)YY HBM#G6,"SRD"XYPD8EW^KUY;EWUB9=_(MHYKM0&D.XY=51:M+-HA
MW[FRZ*VRZ')=J!0D:J8ADLA !!W 1)+Y%!7)\EF%_-ROK8N^9J9/V6K7I?O'
MHHV?_>^9RQ]W5AATKN3SV$U>#T;SSU[*3 ;,3_^D;5PVG_)-8+)FB"!BSX62
M>G2C#Z5/1IDM.^W-Q@64S0HU&<HT&+E1&#31P?R#9N#EDR^KH,[=[.(3A,R7
M<#*>-D?!GDYPZ&:#M_C3NT&<'9[QPKF_6EB-?/X3Y_,5G,Z^_B==7550 I9J
MQ,[]6VZ@(16:%+%&>"\S7(03AAE)/<F\5]Q(Y?\NI[06?W0X^5P]_!K!3]"]
M 9?R/3YUPW?NPW3MWU\N35Z7Q369LE]><@F7%NRK2#NWDBFULI+Z@I6<&S1S
M\GCBFB<B7PA.RF_EZW3=O\C>X:3L:?_SSY;.AMXKU-$;IUX9(UL ]K__=NM?
MQ=@YN\DOG_RCT^ELD#[D%6K(Z#.\&O;+:S)T)U-\>O;%3W$P/1FZ#T\'H^;.
MFC_Z:?'V"TR63U@BO^8#YR]_?K:>D/GSM0@W+#YY\?*3YJ4E*I^_IO038NA7
M7R9/OO[:M]Z6DR>:VDN][3]%2;[86+Z]>]R-:_K/S#2?*_KLY5YO:^LR\V&_
M\Y9OT?>\Y#UOY0VK9[ZXY0LVZPYNV1>QS=KZR\U7VYL;O:V=YT]ZSW8V>J_^
M^/G5UL;6LY=;FZ^^2A==V1F?G_<J7GWR)0KMS7/PG;^#?723:6\S<_P%E>%L
M7A_>Q!_S%Z3S=_/CUJCWQZL?F@L>C'JSP_%I?KLX[??P?< "^E(=W[Q\@I/%
M=]EZ[E^7V9D6'L6]V8>D>4(%:WT?HNR[M[=OOR:(JA=K1!L[_!4FEG]C\YMC
M^6XB+RN[18.!0E&],W:ZQ+;_&-:!UG7H?[D]/;9N7SLXZTWP+8Y.L0>]5T/$
MDV:/>XG3DT&6<>/)A][SLM6=3,;Q-,Q62K%OL/"A:VMU^7#VU>[]P02L4>D@
M=*0I"!%$EO6:N2B$-#92%^7?&TW 6A,*E^U2TCR8+R;CXQ(**)?PUV!V^#SK
M^NP@3S;?A^%I6<9GTRGF_\;[4JTJMU^=!;/WZ?['3;;SR_[[_8_Y;S_^+G<V
M\OL>;XKMCT$TP>Q?=H8['W<./P6SCW<&^^S%F]V-;;E_]')PL/&[V-GX]7#_
M:#C,WQ^54:;[1_OLX)<_CY>#V?OLUZ/]O_)]?!P.=G[Y]<W.QFNR??QBL/O7
MG_G[G</=C?S_1P=O#OXZ2)_2@:_(A]V-P'9__YN6W@:J# U0'D%06F:+LPC,
M8Q+*<V1>EEHPJG6?V=4^Q%VL"FFI%JS28*7!,QITUMO@T&0.%%HP*S1%:8DV
M(6AM:4.#Y(P&+]7:I=+@7=+@QV4:5#8DF008YBT(82(8BP9",H1KPRVR>7%<
M.5+(KYW2JS18:; K-WT%&J1(DW0FV&B<B$F[Y'7$C!UA"$O)%QJD]HP&2:7!
MKM,@7:)!0B/WW!FP-,1,@R)_10@"P4"L4]%8T="@(JS/S?TX&?"8#EXO2?]Q
MFKUK(MS3GNN]PLG;0<#'=>[Z"N3FJ%4&+<VL%H4CRF9AA"0[ %1:18VM4O=>
MD=M@1>H&CBDD1R$U<VR=<F YDZ#S;F90E5&/?FT]/T?9R[OV\8=Z_+JS0)<R
M9;.K0&62@O'HT$:2#(^4T/Q35<7</0/ZLICC(@6:5 0OB0>A:!D;E"1P'Z21
MI7EG*IUX->]G"5^!_F"!GLV?Z9[9P&T2:*43 :,A21(KDZ6BRI5[!O1EN6(B
M:BJI!^-0@2!"@9'H@&JE2>#"&=H,:!9]=?W1'K7=PG<JD=I9X<K,9301G--,
M63P*KYTABJ)UH:B1X .M6N1>,=>'%2UB&"NG?A0HR0P(GAA8:AW$R&ABTCCB
MFV$!4I<C)*M=8KH8:*DM&&Z+'FSR*D6=-S6F1*8$JSGWJ)Q1FD4E>54P]XP>
MEA4,8]HQP@5X);*"R:(E.S;$ <8H"1-&6--T:*%6]<WU3YA5>GA0]) T"\$*
MBH)2$8DQW*ADI6)&$6YI3=/<-WI8UCU:NY X#Y!\,S[<6'!2(1!)33 ^TBBQ
MI&FLU'U"KWV,_S;3-$O'+*F<%]FW'!FYQ'O\\]U>Y]WK%5[P[H^I2/?Y>#HK
M!X.FF0>GWU>F>Y6=\$'O=ZT7J1;C[*9?QN/8M%>8)TX_[7(;>#+)?]R<A\U?
M#[%\D7_OV?$XK]['YN=U^VMK^]M9K5F5/*).3(#"TO6=&YZW/XG 8D3AE34^
M\-+_G2O9%ZRM*H5[Z@,_;.2W79=9D=\IY"_K8LF)2MI(*'G;[/@J C82#XHK
MQ8.A$8TIR"_5ZIQT:?9O17['2Q$K\CN%_&7)RY/5U%,-49AR3D4&,$PYT,H8
M9DRF?9T*\HG2?:O:"IC7^L-KJII:@7B7%8B5TSK$::L%B8H0*T+V84H9&@@T
M%HPW978X4BW1>8D^<YHP?2W:ZB)7ZY2ZA_O6"Q(K[CN%^V450YA(6EH&G <'
MI5\:.$<28#+.E#F4J$7&/9=]9FHA\L/%?>OUB17WG<+]LH;Q0>@4@H*DC0$A
MO,JX+Y4_T<M(A Z"RXQ[1OM*7EO!U'+%[Q<N/V+!3#.J,O_,G<-';WHX?I?_
MQ1,W<3,<?NAY'([?K0SMJE4*MU_C6-FO0^RW6O*(W'B!:,![4B(X48"Q"D$B
M3XESHUPL8_'ZDHH^5:M3>[M8M%!KFNYMR6-EBTZQQ;)&\D%R)#8""9&#2-:"
M-YDW:'"8@I&2&]'D>"GKR\?5EZBRQ>U70%:VZ!1;+"LKJR-!8Q!40 W9K4S@
MN"P=+%!;[YQ@TC=Y86/[BHE[P1:U(/+17^%C*H@\SY6-Z@[_/1U,L'3NGKG1
MZT'ILNVF4YS5:LF.54N>M]QNVOIDKF>-M>J^U]:^M[M:">F,U(KJ"-%RF;WD
MX+*F9@%T(@:S+++$B3*)BI*VS@C=4S_X82.Z[2K(BNA;0_1*;M"%2&7@P(4N
M!X,=!T.2R^ZLTIFE7;:G*8@VMB+ZX2*Z]>K&BNA;0_1*Y:+UGNFH@9J2]?/<
M@F4FEBH?(@(2':A>6S=]:=K2I;5J\2:E1RUIO,N2QDIDMW3J>._9RO1PS8B(
MD1 02I'"9!X<#9G3(I=6!")LXJ7=4E_6<L4'C.G6RQ4KIF\1T\NSK%&*1%P$
MU&A!$$/ "<4@:BFT0F,4:YJB]EFG.JA53'>\%+%B^O8PO;.T3SM+8E"<@W:"
MEJGT 9PO?8^)()QZCI)DQ2%H/YNT0YA^!&6&EU<:M:#P[@L**X?=%H=MKF@-
M8BSRJ!/8H(O64 8<,0Z"%L%(0J-)(FL-VU?RVBV<:_'/@^*!UDL%*P_<(@\L
MZ1.,T4J5## 4"D3$"-9$ BDB,2%Q$GW*OHRL75(K#]QT$6#E@=OC@65-HZ2+
M7A@+Z#7+/. C&"H31":1YH<<(^69![(_0.Y5O\/K)EBZK';VQC,WS#=W[FC5
M=1(ECY3&;N><U/35>!@KA;5'85NKZ1/#O6"*0#:1 6$$ 1?R/U+E'W@T,E+5
M'("2O&_HM0] 70DU]R@.^TAIX'8.0%4::)\&EA1-=D)3I,B 25^BLT*#R:P.
MU)76[N@#EZPYV21U7U^_MWNE@0=% [=SLJG20.LTL"QH&,JD+;% #2E-;(D'
MZUD$3K(I8]2!N%!H@'';9]>/;=P*#3R"#,XOD_%T6@Z9I,&LYFCN7LPT]OBM
M,4?EJ_;X:GLU(6,=XY%EN>*\S'QE&3@5':AL-9&$X)3[,G,B^S!]3N_':/ :
MB[VWZJ7B_J9POR178@J*&^' HC0@ L]?2<. 4 R2$*,-U\5/,=E/R8]%Q7W%
M_4W*E8K[&\+]2L(E$6>I"> #42 T&C#9:EFNH/#&6BUDTW!;4]W7YGZT:ZHM
M%1[]%3ZFE@JO<)A_^+K?>XTCG+AAO^F8X.+Q8#28SB9N-GA[K>',#WKG:EVI
M+JSQR]P6I3O0%X;8?'^"HRG63:V]3>V/%1'K;"#1!PW*&)(W-<_ V!B!.RJH
MHMX2D3<UG5U9KJ]]W*&>K^XLN%N7HQ7<=P#N):7*->HD60:WLS$K56W!IB!
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M-=J%\+YJ[11&1?_#0/_-:9>*_IM!_[)ZH3$YX@T':;0!(24'&X(!9ZRFGK)
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M!NJ1M33HBL@XB^.]F(R/-QL;;3<FVOILH<IE[7'9ZNP7P6*T/O L,5PST"R
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MR<IPE>$> L-=@>!$EAZ)4DV24\(R::,@4FLG,ZG1K"2K8NP$K[W?7IIHK5W
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M> S:<D))JLYCYSAV:32#MC$%RR)0Q@@(B0Q,1 I*!R92$-&&DB:VO"_,ZL#
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MK;S72,9YEZHM(>/G"!&]"0&MA8A^!!#1;3[U_7*T]18W!7.9 D42>WA18&O
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MC]5\-9&;O,@+HGB01( NBF4N%!0067KO9)YE&7 /VE7\KFI<MLPB>YPQJ][
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ML36W/;+:FL76WD^[&-R=-"'=1H,*F-SW?#RB86O8L=RE#\&.]^&(#3!=M^7
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M6AA.>%EH(AQ7Q.C<$YI)Z:QQML16!:7<76\M.M]WY #?LO>AY-8JP;Q@3,
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M7U]\H,%*5P1*C'2&"&$-43*WI& YSSG-@@]V9R_TPM1?SJB!CTSUIUCS-L=
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M];L>Q*J&60S.IBL2R"6:,!/L<8V<"),\+@'#C,NV >M\KO)NQ,F<KWMMU4Y
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M1@S#^#EUS&94".W1U2/S;D'E'9D_6^30:0GZOC2+EJ ?B*!7-0N:N=+XDH3
M@8R!'Q,C%/Q#3: 9EM)QM[/'5=%5Q:UUBSLDZ&?@M3C&1HFQ\^4EH>'KYKJ<
M#YK!2KOA#%,AHN_H63J?[W)EG@HOOW/E#-AWR[3OCFG_M::%&2-RQG5!E#'
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MM0^  9+9Z5>2Y.UP> I[<CYB.NZ/LX!=",,([M4[&G9&("93R4N#;G=PDG\
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M%[= HN8\2H<,-IDJ>HR,C!PQB@FEU@%?!'((2]R4ZGFDSY>2( 7I%HMTR1"
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M4J%2C>5R?SPIY_@PMOU@AV&]'S:_C:OHE>MA:[IVKZ9+MW.Q<F]LI__OP:@
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M]1O@6R7P[4^I?(D*F3RF*!&5T\V,0Z#G410##D83)2W&N6/:NM*S6<P-\#7
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M[M9Z_3UKI']W8))_RQ^MAU$^E5\=#V7CTIHM>(C<"+$%-D7_RG0!PJGEPLC
MI.8N6DV(S X70$L*NXHNDRZ0-\P?V:#YLW<"9OJ@^)A?YWC+YQ)(^>/LXB-U
MV55YTO+C'Q@FS"(H,NU>()<0#R3&OPJC_G>8PT'LOFRL8[M;;X],("0Q0+@D
MLV8C*$4Z*8:DUS%(3Q@A86VSUXW%?3N=*) E^,K4D:B)M3HJSA7WP3D/IYHB
MWO.8\QU$(PN/1Q:^'EE*7;(\H.BR@S; "6BL,,AA"?O7*ZFD6-M,V=(MOOP9
M:1A'>VHDK4!V*D@T:?[<6;I1%@AWO<RX:9G9/A]K)3&-P"P6F , #TJ3 /Q
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MOX[LW?;[W>VMUL[>GQNMUWM;K?<?_GB_L[7S^MW.]ON%2/-8!I^Y30?CM$'
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M:_FD%C8N3+BT-@CD,0@LU\XA0X)!21$</+'"\ISI,D=JJXUKA8]M5!O72D'
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M5W2V:WBEVR]%MS&GGI.8A.6&8V^ A #D6_B72.X8J4C("NCV3.\3%[5GEB+
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M&#EJ/#(2\#V8P 0/R[BYOZ8XR\[P*/9?5S!E"7.UYOE0BI6IC)$%%L@OP:D
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M3SF!)S#:X(]KGKP*R!X#R+9GC#>A F$<:Z2%MXC'%)!V7"-!G8G!6^D(6]L
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M[7Y]"G9^ <Z>4:3KO%T^LY4160Z\>@IG4 E>6 @,VYG2-+!7PALB\_XYQ"T
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M0ZDH(@&HQ8CDXK W'0,1B\VM'/<">3H+LX_[!R>CA39&6)EXH,)(ZE. '\H
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M3AV*-5_"X+]TN^&TU6XWAIT X;J![7QIY:T;/F#X_1!3[/7@20/[;?3!:O7
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MG*A@G8)#""OAX4UO<1$;GAYYWD\7NG..89<\(MH&Q+'AR+A$D33"A;J?4+*
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M@<[?GS:/_H3G-=GN^L[9N_7=H[I[Q_:G/1:I,#@J%!4.0.B&(*?A1V!,T)
M&.-4O+3F1@05$@XF\>2"\XXJ0R+080S!BJGN'7G]J[6:/_J-ZMKZUQP!.L%1
M:S!R6=PYW/O'P[D^?)# X&LZ9[[#I3HZ:R0L@S? 4PQH;4F<&G^U!JTO]3(L
MLI)[LWJYV:G%ZTX^C;+H?=+KU\J=.^G#=_O]''Y9JX&@4QX 2F9YO->%4ZT3
MJ_;%O %B?1WX#/> +^2H]?$-5JO/^ZVLEN[7X=$G[<$H?!UTS"LW\+;3Z0XJ
M!Y)^+X:6SUZBT]9@O_*Q-["MSN"L'HF+[5;\FN\V#*IN]0#:<S@L#,F#CEOE
M_D4PFT$#A@3KWPHGM0[<S=V,*OOE2P\X8! ;U;Z%NV0]%: HN^IL^!KSU&-*
M>9;=81,E?]6OER[\>OT+OUXUL(>QDR/O;76ZWVW'U>4C@7>=.@JW&IV,C?J^
M.]W>8?6IT\JKDD-]4RN'!5M8$5#@\G[4T;S'=C",=D^]C"-'H]#WO-?7/7WK
MK3Y(0["P;V!987,N_@926(]M>UKG+WR!&_<'U8?8;\*EFQV_V@#"Z&?R7*W(
M*TJ0_XHPUH15O[SYX\VOJ]7V?KPR)-CJ^"5[94?44:V=#+H?XR!O?W[YP1X=
M5RG:P0E08G[T\$D7NNA:J_<Q=N!Y!%]<FG)K(H#(W$VKV^M?S!5().;['F4#
MD8?G']5W_&I[K>X)[,W.I]'J]#,ICCK?59]6/ZY6?P]7;:L+S"$;1NN&,?RW
MRC0(U@V,3?U2Z@;C];N<JH9@];N"L08A(K_44C6,@)<9M@EN,,T;F/)50'??
M[=4/&ZG.%^O3J/^\,K*:L4.K%VMVRX:CLSX0]O H.(J#_6X81FV'EOW2Z?9;
MPT\&/5C"_(!^.\;C_"*T^G4 0[\*)[WA&\!'.55S^)TAQ_0G]ZL?XV$?5K 3
M![9W5@5[9+^,#B*0$;J]3CSKCS8'MBU?/R(-H/9L"PC7YY>Y]F,\AAGD5)M1
M//E0TAN3[U&W1IN<U]'J'[7Z_>D[U!DX-L_U@HRN+E>K\]7FX P7O3WI#W%M
MC(U'M60S-G6,KX([96@;_EF;Z.J0K/H['T^.<US]D"WJD?X1X3/ F#>MGC]I
M#3(<^IBA=;AXTQ,X!?#YTK.=P;#WV[$=W0BN:5V^-;IZ.,!LWNMU?8QC,H%[
M^2ZP^H+;:6_'+PMR"% 0<,H(P_+B;N;PD(X=)4QL]VR(0P&GWQ^>63#JP<F@
MAAJ@K.K-\*BI/C6W/]9+^-?V!KS9;I^T;:^^$O1(/VJJU^R&D_:(6/_NP1\>
MMCH+5'"'>E7S[H+PVX";?\VVU]%!MP50QIA"VVN(4 XTZLXNZ,]F<OD;CLO6
M<;_Z\!&^VX,3<*V6OVRC^NNO-_7C_K\N/.&PW3HXC!??WEK]9[7Z)4?1C569
M*G,.Q;^-OE'_17[[]0)EWY]DMF]7GX'_82+]ZF,.5:WG]J8+P/O7(/P&1&/S
M)-<W/U9K\._3Q[5Z&(W)#];CR:#O]]MY>&^/W/^#*^&D'MQP\\8(UX>?3RSJ
MW_G6;VQ[[>@XVZ=[Q_#%?UN]+UWXNM_O $%]:>5TEGH(]0[95B]+K9U./>U6
M%A/R_6]>BJSI=3N9F2Z68[4:24";VV\R;U_N5.-B;8<P!81=8]RH7V+>8W]]
M]$=#DAB.['A,$S6*^"%AY"<=-:K4ZQY5K:-CV-ZQ^#3"ZNNGYJ7IO3[8PO6#
M%F"&O:V?Q=]F@.T$"VN1.ZO6EO\+_-F/[9"I;#2=U0H8YIT?=#-(2D3X59:Q
MX0C(-V<0Y96KX&"N#DX"G';U32S\LC6^CW R4^9@!.NW7@KL=E)C-@R_58\L
M1&!,^/9P\O#_VG&OU:[(. $H9=D-GM+I5E];W?;H:ZG*WHH1N([WY@*:8=J]
M$02.MG/U<@.[)P 7('Y^;0'DP%+D;Z03D!2_#Q'U4OUY @0DQT,;1GM=8(A-
MJ=4[&AU$MZW A7QQ?=[CXP4.E8SA4Y,=SVABJL/5OC*&\3U'H\B$?(GN_<M5
MR+ED]O@X9AE]^+TK _.M^EYPUO<BB$>=L? 0QH*:KT\H>/<85(03V%58= \<
MUQY*:+64</7\SKM]<-*I5<UZ'=?A'*L/9C($:7S)8,/3V=?^J*$RT(_]6P7,
M,8#5)R\@;-V0%(B_/FM_+'Q>I*'=)(->R)O]6N#$M<!)%(8AYU]Z^,O4OT#H
MJG^1(</GER.YM$:,6@P:KDCC^G(,OY^]>2 W#J.TAY PE$7R&$?\98^Z)T-.
MMU4"J*MRKU,@U;HE*]P#U'.4S^Y>JZ: +AR![9:O1=@ZVW0\U>^@ X!P:\P^
M=6[@E=6]$=^N+/>0%"=(9+AYM7[E8LS2@#V#O3B.0YX>Z8&CXV#,SE-$.Q+T
M1K*3K668LS%13F%U-9KGC4-Q)UG2;+?[$Y@,4CF<,-UZH?I9=QR-Y694SUF\
M-9*-::R^^;+*2UG?(Q>@]J8-.G5]=C>S[@W4L0Y0Z>&1]5DZ9,]^ED9_Q)-7
M5+?Y\6+-BG2H^RD#*L[T>(?T.]K83K98925L-!H_% ]BEHGK:35 5P?*A(UV
MM3N]-C1,ZX+_Y-,B/P4^^NAAHX(=V.R)'&3C?:W7W: +?L_E/5RZ"0]$M#8I
MHZA4 G,=I0$5D%C/><2*8E-[(+(YE4@T?G'5 [&Y]<=TM^1^_]*V=S;4-_MK
M0R&B?;8Y&G;8&GG@K_@B@*A\]D><@JP#4''ABL OSBK;/(/O$?A,#%T=:WN*
M,PO$H9!3,:>D"8PTT0KI1!V37J8H_,KKFM6FG1'3-#N+>0#.&*QD@TI0_^$U
MI[+!S/"UH:(AF(#7I($E;QBFZO<QU0UI]/#[2C<(T?5W@'8:$K.1P0#^9KPA
MF5I&!/M]+!>/ZD'E()>+^!=@RIJ<ZX-V9+P\Z8Q#8X[L8;;[73E'\RER-"K-
MT ;&J64@V_ER\4;&BU8M?.8D>9"38*/JXWJH38] !]3X+.!WX9R;R8E4,@W'
MF8:F9!J63,.2:5@R#4NF8<DT+)F&3YUI^$R<\A?ZSZ!ZY]HC.T$?M-%LPLV!
M6+6G^^]>]VMM^>HOGQ3\&>3:?I9W0\S&E3S3D8L:!-2Q<V,<0]O-_K@+,T?M
MVX;!PY^]_I6KQNKX\4G/[]MA),#5:\8&E-71.L)W^UG"KN7EHY$V,[*BC&X_
M*C65 TPNW5XWCW/LZO,Y F  OUJU<W[DP,M7Q*&_;@#/Z]N1+>WJP_H@AA_;
ML]N?,8QC3ZUOV2)ESRZ*[ZU6?W1[5ZU 4].Z^I@+(T'VS;6^UM*&L^T\P&RQ
MJLT)[=91;??HC4GM-%MZW=E8)1GZ(OJM?&VJS:XPGK&!['+L?A2DW]_OGK3#
M]94-,=F3]F"U^ASKQ_2&#OH+NC\>$W>V=[3\?A[;6-L)E\Z%_1;<KU>KI*,[
MUL;#VKK7JMV7]OBXW1IZB"]GG,WJ[9'MY&*2>:M:_=%HAM9XZWTOV__CM^-L
MF.PO883$^M"I/:Y==FOILG%0(6G<LD[31''GVF8_$X1W4[AJ3I#X<#G(CS#&
MSS#$OX8C' /DLL2I/K9QZ&J<:O/;N_6-/6Q\LM$Q)#FA*(<4(RM\;CO*<>0I
M".E9;CNJYIED9Y*3*2C)*)4<*, HQER45DM%@Q1LYGCV0@WSI(9/>U@99QR%
M9=?&(RYL0-9&BEBT6E.GA..YQ)U@-^3*W%:_:JT.,+JI8.*P%NPPXPI@MJZ5
M/ QA&]2>GPQ>,P#W34?'W1%*2%<K]RD7PP09TB01O>%*F<"T);8N]SY#JLW;
M$UM'M<0KXMLH=6MC-,="C[/1X^&>IX%*IB@*0A#$K1%(.Q.040DV@\HH@E]Y
M3?GJ=(O#GP:GN1U5M[@UUK)@8=L7(GRAAAFHX6SKH+GGO,C=S 7B)DKX@2FR
M2ALD0*R-DGB66,PY%=]+NYH)F\B"8=-/MN\IV/1PU.CW0%J!G< >Z=Q.C;.0
MD /L0,0Q[H*54@6@1H;GB4US$YP*-LV1&IH@1\-&* ^2 A)*@N3D"48Z6HG@
MO80U(\$9.*GT=XCANQE=,WN 'L].=27C9MD4XYFR1VK;Z3#$T7[IQ7'B1/?2
MRO2EFP/-NZ,"Y7X<P9_-)#GZQV?#RM"YFP\&.#ER-)%MYV#/XQYP4 ]F5M5.
MTU$8^\GQ<?8)7S'@U'&>X_+IV>4^RGG(6CN,L0]K&<.XPD*KCM^[&&Q=TL#_
M[TD+QM/<6-_\X]V_U?K:UA6CRK?CBQ#ZW*HDCL/@L\ULE'I8&P[@<6P8-'7U
M/O6]AW[<D1NY?RW=)GXY:0^#NWP[YH/'CX+LNCEZ<&0/LO7'W?[0:-093C0;
MZHZSGWSX0>/:HW)R2RL'F]=_U8DS.?W&MD)C'#7>&)[$PUKSER[V.MBO9T]'
M%KT\RP_Q:[==%Y=_,[3>K8U7;S+ X&$R#/N]P:LZY1;  (#W\ES^HU[^'5BW
M9L[[: W./OK]F$.Z:K_CR\XZW-FC01,X^3@2.#HX?!U!FHN(O(HR:&J9B70R
MBW IH.FJT?^23"\@YPH2U2DMWV')2QP 3+K!Z%=+H9>]5ZI?ZL"W[@F,/O1_
M?76'\V=I_-:,K$JJYNZW5JO&_)PW_/N?<2S+6,M8RUB7:*RSH<LHV&$BFH[0
M(9Q^-Z3EUG[T\-4>X/A$;_KO1$<,HP.>ICOGE%)QV0*[FB$2YL>+<?]8H,<,
MJ9AM>88R8;53]R':&-J@KA[LM\50S)_0[O[5GXK?63P*S9K0[)%:WYGMBUHR
M7I;LKDLFRI+==<ED6;*[+IDJ2W8W 24'0]5Q_#^.7;U#!_LEZ"7?;'5J7]AE
MB-VEH>(G^V7_J)%\M03+\M\/-/<G"M^>;=(/'U7!ICINC\CNTCPVFVN*+:E]
M=.?SG_W=[:YH'C7/=K;_/-@]6#O?.3_$3;I[M'/@Q<YY\Q3^?=O]G,L8-LG.
M^)I__]QW1Z'][N#P;.?\S_WFT=91<WWKX-WV^_/=H]W6UGG[H'G^._S[HPWS
M.FJ>_]/Z]WQST/R(O_VUO3& Y[.M@\.]I&'+8&L0QEP.J[H9)1+RI'9HF92$
M6'E-&CG%W(AIA_M0)7D8YL@?W9%)OG<R_0B<)T^W@FX%W1X<W=9/XF9G"QZT
M?1K;7V,3GKK?+Y W5\@[NPYYU.M G?:($)\0ES0AZSE#.9["RA"C#[D/=H,*
MTN!J.AJV0%Z!O )Y]X2\CS$' 60+9P&[>8+=UH1\9Z6C.(.=3%0A;AV G54!
M::F3"'4X0UQYS3EN8#G=O;I 78&Z G7WA+KM_5:O(-W\D6Y"K/.1.6D21CQ9
MEYO*6628CDA3Z9)50GJN0*QC#2*F8S,+T!6@*T!W3Z#[(Y=,VR](-V^D>S<A
MTS'BM/81Q#F.">)!**19C"@E9BSA5F"<^UPU."OVN@)T!>CF#W2M=!/.U64;
MT'GL=0O$W=5&E^&MACF8Q_F.V).2BVAP0(G2@#AU$AE*!;(D<BIB(")7>JD+
M7=#?"LH5E"LH-U^46\O!#[< 71'H[HMVS>MHEYC06CB*O%:@NW)FD4W*(LHY
MY5YRIXW-$IVFTYT%%Q'K[APG,RH,N4QQ,K=DXUS+6IMY5VZ8_S.#Z)MF6(#X
M.A"_R_F2EPFW!73G![K-B\B7K>VF@'][2A@M#,-(",,1%T(@EQQ#T2BJ;:3,
M*++RVAC>H/S>J'LSOCVH'#GQR)GER )%!8JFH*B$J3P\/IU=QZ?(M<;62H2-
MH(!/G"/KO$#&8&*9"()&7?"IX-,"3&U!\.FVF))BE_MI4-J:$)JB<B8(IE!,
M. (H)5!4>0I(!J<(54%YR^=FEBN@5$!IZ4'IENB/@DD_CTD3@I+7N;)M\D@;
M'Q#'SB$#6X6<YU$:CXD@MF!2P:0%F-J"8-)M@1H%E'X:E-Y-"$K42$.XLBA@
M2P"40$;2D4:DE0]6AP22$RZ@5$!I ::V**!4@BKF;5&Z"*KX=/X._NVE1',%
M0X., A6.4YT+;$N.L+4F)A.,L*& 4@&E!9C:0H#2]V(@"B[= Y>:UW$I^FB#
MC18QQBGB25MDG0H(P"H%*0/VA"XB+KV <B!UI;:?#"X9%?MDL+JA>Y)+A]8!
M)B5"[9XK4X#[.G#?6%>Y."?G!]GOIX(GM$_2,I^0-R&GE7J.-&<:8<]\]%@&
MA^W*:]I0F#:(F7,._;VX9SG"=PMT%NA\,N@LP1X/CZ<3/@R1#'&.1:0)Z.,\
M6(4<!3'82X(-UT[SZ#*>4BX:BLXYK:O@:<'3@J</C*>EX,G#(.EDA(H5Q!!C
M,<*$&,2CB=G:R5"65K$27+'D'ZC@2<'1@J,%1Q\81TLUE8>!T0F!U*;D'2 I
MXM[&W) 5(Y.L0,82$YDRR7/V,-54"HH6%"TH^L H6DJU/ R,3H8!^=S%-U()
M@JA6" @C(:UY0")YY;07+ T3>^=>JJ6@:$'1@J(/C:(E-&#>=M')D"70VBD3
MGB,BG0-A5&O0Y#%%*I!("7S$G'F@.C %0@N$%@A]4 @M168>$DHGHJP89]:;
MB)$6C.;.]1S9F$ J)8J(*+F-^&&*S#P)D-:Q6?^IFP]?-$J\UMI[^'<F]U;G
MI";(82O(FKA(DMAH[IP@@G/+-=6".*Q#S0[2[<%RK+S^8<_DIV@W/=70JFXW
M_0M1OU8/U-M\S.4?8G_0._&#NK?\6B=\&':\7P,2^MH:M&)_O=7/G=Y/>HO3
MUOQ@;<S,!TWZH;U#W\.SFGAW?0WOOMW=W]D.^UOG3;)[M'G:I'\"HWYH;[V9
M;&O>/-]]^\_!+@!!\_S#87/]P^'NT1_[6W2# 3/"-<#HF5'??L+_GF_@K>U/
M>X"?DE'@P(29R\5'#-)>!22YD,'39*BA0RP&XH0ES)@8B1?2.D*LX9P9;J7%
MPI&@N'7.1#G9!OW:=E0;WXYCIP\$-<T&(Z:N:7F")8:[\\,G+QH/W-QR?;-3
M;76_QB,7>[DS.FY4I['*!!E#W7S][VYOV.'\W;>S+[%3P:F5.]/U[*#;J]Q)
M'V[8[\-%^RV_7YW:?G5L>X.JF^KN[!_;,1[7O=IAW8];]45GU1O;BU4_?LD!
MQ:O5^G K\M?/X+RK8B? HW-GUVK4K9W48^I%W_W2@9D%>'EU$^-X$^&A_WV'
M<]PS'+0WF//D>.388D*ICE@Y*46RH69N/&9N,G6@B^^R^IMN?S!C?(A\<?S>
M/(.QD>;Y>_XN"PL'FWO>$!*\$2B$%!%7EB*G7$2)82>-X#IZFDWKJ^:68QA8
MHYTW_+@':]L#/@$JJ9&V&G2K5N<KT%JFO=->:Q!A%TX[3T\OF^-1?<Z#6H<Q
M%7J9B5[._5XB@1KF+4H^:I#;@D,F>H8"; :VRM.@@%[$ZFU^F!&Y-"HXS&,[
M5Z8#2K%' ':M\R'( W74)>QZ\$&K,["=+ZT,@[;?CX.GIYVU*T,%J6(]'@,^
MMNH_WZ7U'%8Q@-.B V_44D=^Y^BHU>_#Y_F=>A*%VF:AMJWMC3UG#:6,662"
M98@G)9 .6B.J#,@E#A,G0J:VV^S5E]26%[YJ'1W;5B\??PM 2'E$FQ<#>K,/
M@DHLI#$;:1Q\VHLR&:R!*CQ+%H16"0>7P-FM$3%-UF/-0!2DJ^Q'I!&/CMO=
MLQC1^-SR68)X<OKX&$&CM"#SU0(-*80Q$V&<'^[I**4.E"!G(T;<9&W&9KU&
M>F<MSG7,^,IKO'I;O-58H,G2LQ^9BBJ?=Z+=MJ.JJHM (+^/=("-;ZU!H9'9
M:>3==G-/:DNU#0DIB@$\))/(&D>0%LJ $..#DB'3R&VY(B,:6:W>#?6M04Y,
M&RM$5S6F,%25;E>P\M4W2<E/1EZ]HW";[2136?[W+GT$2BIGU2SD]JVY[O<X
M)<1P*Q!-(B'.-$. 30EAP9F25,%O/H/07+5 RP<=/#>H#]5I:[#?&H)1)I9^
MWI(:M#))]>*1;66)<Y$T\R+BW(%L#C;VDI!*2AZ1,T(@SJG)18$YLA94<Q63
MB=*NO-8_/,F 2JY;;H8'&%!3/Q[;K(*!UAZ&YM"LC?5O-?1T:N+*5<6S?;R6
MEOH#^'4A4G>/1\7&^ZO5=DV'XQO%VD@%VM!Q.PZ&3X'O7T/#U>O6OV6PXDT8
MT?I70'ZX!Z.YT9HS,_=DDUIHA>H.;/E3UO#[&,QNB!G +YP?M]8W]B36/&(I
M4 R1@,K!$G*:!$099U%[RX$M[^313(IZ;SB)G! >0#1E&K0:4&6TQ,P0ES>6
MF/'&XK*Q#[2QC@D5*9%(1943WKA 3C&+B)#1$4^2MVSE=:<[A;-3;PP ;/W)
M_]_>MW:GK21K_Y5>F77FV&<!UA5$,F_6PA@[9-O@ $YV\F562VJ,$EEB2V#'
M^?5O5;=NW&S %\#HP\R.04C=I>JG[E4! 8H#H(!..!])IY!N?NPO@K((;S0=
M &GHB\$.[[FMZMRR#W>./1K$L?3,KZ(PIY3^A)H VN/1XI\\ +(8>6#!AC"V
M6)6*4_3*_/\J4=)R$B4=!/$NAO0:!&S Z*\BQ02 ]]2]H_?ANZ-)V@!AHD49
MF&2R) VG*+:P_T>&E/W^BP5>Q1L%_/"%C'X/"V$!7@7KI-N_2#(($#;_]?BK
MKKS[V./!,U Q,-T#U9/_'-&/RR@8^B+]0H3CDO/%\P6 )BX=ANQ]_(\/H$<-
M77K_WO'XSOB//D2WCPXE/F$J78 _4'R=\E9)$OP5-76)GAQ]7>)?324_B.\T
MHU25%G\ME>2%WSW3;1_K13.1BO%POL5F\KD>AR9.B<M:IT>:S>E4E&?<\BLF
M;"VYYR:H^\28V/*\])8X@/\"*1YA,'K?M0;,'KNLW?]*W7$<CODR!@+U[]%K
M85D 8:.MS/+X'BL\H)C\4D#I<5J]"_5'KR%=])KW[;.OSO<_UVK[V]?!C[.K
M/]^5SJ!U/ZWP_'#:O>^@],#S_MCN1>\+6(Q-[<>WSS_;)Y;^X]OIKQ^]UL\?
M9PWU[S_?[RZ^_+<*1+894XN&)I6%#\*P#1V$GL(4NTK+NDFGDS:V2SN8GTO4
MK7]JG%R=-[+'<!K=MT63Z32Z%XT3TFS52Z36.B'=J^-N\Z19ZS0;W:U?_-?:
M^56MUVRW^-*_7-7.FZ??FZTS4JO7VU>M7I=_#EML=+[NP'9F373AA$@,]76<
M$1L]"0<.NF?\,=S##@^?M/S=476TDJIKSZ[JR$I),A;_]*';/OP=8&^^V-U:
MK/X<&N^BTH@'+IVC#(KSN9GT_1G,X0?VF+H8&25T]!\S./IXS.#L8]B!_P7&
MUR7<U;>7T(_?*H%$T(,GPPFO.XJ7V VTQW3A_6TYEQS8H,AS[UE&:.T?0:9.
M4@/8Q._S?\XY0Z_=ZY7K$!NH#OH^&3>?U->F?()K%*P]7O2Q!)>M7 Z7KW"K
M5[@'XZ)KPZ'K8 SVFCI>.(JR(ZEPF2SCS%JUV7U^CRV\QQXT#*^YKG_'Q6K?
M#\@HH#:+V1R3'"SFW')+=]5:PK=?>?PF*X@-PY:HU;>H4JYJ5*Y4*:O*&JN8
M98.J3-5X!?%L6M-,!7'J<H[Y*^19<K"!6Q9&FMR.%!"OZ8V."HC5[W^^R!=_
MONO?>RX\^TKZT6O^P?#]Q=F/F^]_OOYJ*:U!ZZ3QIUV?+B"V?[9.KOZT?KH#
MN/?/5J_C7OR\T"[^?+G[<?/C9^O;%_6[@FNXT+(#TV'?:NOGK_]6*XII]UF_
MJ"E5NZ@9IEZDV/C;4IA:-FS0L6G_W4=5*<BJ\4P%Q#O442''I^W9VBKY0/UR
MOVK8=MGJ:YK!I*I9+>M]2;9-M6)*!GLLT6M%H(I\$ST?,X7@\Z@J-P>N9P6N
M^TG@,B1-KYHR*S(="^BH9A=-E=E%6=.9JNA]U6(J-M<N8P0BQZT<MS:UM8/M
M!:Z3Q&.88]5S8E5K2LFJ6+HB6P8K:BK3BUJ%T6*56F;1L$R):JI1,;"42I8+
M6G6V/'S&F9OC5(Y3&[;_JE33+5N30.!J('"IHL@XD]LPF2%36UNV@U1N_[T^
M-$VI47*U;.GE,BW*1D7!EM!JL<I4O6CJAE6ELFY9J@UJE%I0]$6=*S:!3Z_M
M7-[&P(W\A,!-1(X7"CH\H\<U7^&KKW ?_-G/'KAYQCA;?H]7NL>^")%5HS?/
MND2]I"RQR#D560A71:5DS&8^FC1DHMKF0#Z<+P17>85OS/!XRU/!3</L4]F4
M;+4L:TK9H@8KFWW&](JL6'U6Y8;';'UG;GALVO#X/A-X*DM65;6,*M@<!O8
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MA\N'@(H;_9.O+6")VQK1TF/HMZ8!-_6'++AQ1DNAU!/PJ)!ZL9%A>/'I,#M
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MB8#BX4T$UQ)!P TPJCG?'YKUF":XR[&2TUQD!$P4P&7=K?P7D:2-@W$Q<B[
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M:6^WU_8J\NN;/8NC?C8!O0I!&]V+E;Y,!5C++^J;K;J4S:;LV+$SGF$6OZ5
M:^5M.Z>@>\Z\T U^2#M/@WH[Z;-US6;NQ,ZF["(:5D*DS9U?V]0543 ;N]-^
M-GC- M%&<Y?ISQQG^8:@$?'!@;UF/"KX=L'$.E[Y5MB9#>.98V<FMCRL"USU
M!7<+V,<5WBPE0#LMYB4>U5D;5\6-=K'?M;/9:UFM99U:V_BE*AGM71^Z..-?
MR\IMM'"RW8F5D;_JFZUB&D9;U)?+=ODXI*V/?-)>T[)!(B"WNAF1OF,7C(R6
MKXG=8%0OXH\JF"V]8V?7B73%UG5M;6N_5,UL[R&8SP0:NGH;+;YN^09VI8"
MV;) 0%Z(P=ZV+"4\KL, ^N<;,)B%,_7R'KVMF>>O3]L,XXEC9WS3&,;TI*WY
M6!$C7<2*6>UAK@3%W^U= @W4]U#_'T%]-\?2P-&)>I'TZ.;CN8RR&>)3IU?@
M?ZSLB(NY1.@F%?;XJN1,ZIB#>O> GS$-MX!O&64SOF=.+[/HGH?O\OD(C7'$
M: ^PA.$1@9,H;^M5+V[E&9=X671(]=#;&.KJ/(R@.UVGEUF%SP-=\5.?;]"O
MU?[6U'JO2O?)%WL5D/!\0S#-$9D<785J"VY9!>)FT&VGEUFZSP,]892G OOI
MNB(:&[EFE<COX=X9W!M=K%GO LT> &5G-[ZEB?Q[^R[(S/9A_=L-BD@8,T%.
MOY]=6LD#HXUYH6R7;G*]4SDQLX5SG%[V H)<I%J>/<KV='KK#/0+/+D;/P!,
MG+CJ*E$H_QW8KW.3P,:\S* ?.;WLE0&YH"_OW-&<Y=\);UW14MSWFK&*UMU<
M,HE[;KN:D$_;C/RQT\N>[B]%7G-:*, >YLR@%"*<J4X2UXQ?(\)_1WXH@TU9
M27>?O 1!#*AW'W)W*C,,\EN(XJO<V(&]+=N(;8EC5J83IY=9Q:Q@1A+AU.86
M*9ZEY%.^L[(FD<(I&=6]$;&4EA;3BN3<:^(J]$\L0+XJ< [=Y<F,$Z8BNB1$
MJ(-V\C(7#SH5@& N46?ST.LYIB!B\(!=-J'DSVUKY-;%,FOFJ=/+K(*5:Z82
M4I?K*#&MM)QZ\Y452ZK4,I'5 F&M2%HK$;>="GJ%."5T(NXQ?YPB7N?C&)FJ
MYJCOS,X>A8E)6$##4D1:W/6U([X" L9X[ZC;SVZPR,+0QFAOM3LWB/5*21EM
MXI'M]#(Q>1Y&+8_S5GLYF</D)P%<L/J7Q _!XJ\6W!S0VJS,@/><?J5!F9X"
M%6,UM46L<VJT4R_T]Y)@EJ]YTCJI99S)COIVWJ% 6=M2U=O9U6L<;5^M:YZY
MG'[>>>FDV]LX9Z7Z,'T273X\QV/&<:K =PK^]-,4_U?(B?"(J^*Z=0[3;HFE
MV21*N,UH+Q^/5V^T ,OEE P6"&$M2=%ZTYB^X)0]$P$,(,9/%=B2:I10-VO!
ML=//.3]?I 4+5BI;D2ZW1]N,QR49CS&_YFP& R6^MRYYNT--J,;9K"4G3M\X
M(5?3$DN+8DE9E+U(KLI+"NT5*76J!7J+J]R/OEH)?-'X,!S!XL)'0I QP=Y
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M"?8:4HC95\PF',VGQ!UPC':D&/E,S/H )B.S%E5''Q*>EF2Z5X%5=&X8G=S
M).OI.&\5I>U,)+6YF97BQ'&R6_;+E$*R[BC><4B;58^63B)7L[G/WC!^P 'A
MZG--:@-=G17I @KF^.G4SMYU%5.R$E)Z.]\>CTVV@%2D:!YW9XZ3W315A%?K
M'?@;/$'^0*_OR0\3@Z>*J?QD,7@D%VPV([6ONZ]*T3CJ3KIV]E8G1=F*2'^P
MEH@K#RI%?@_A:H>O<3=.';K&Q,>)W<_N_Z@#9QLS(A7[?Z,[>-;C8#3 )ST(
MH#?#>F^3J\!R-_+)1(FJ-XW$IP@&$X[QVC?];)FU657ZCI/)3==3E90DT;:5
MQ6&*1)B]&FT#RYK'U;?.?*]*[Z9*ZD!DZ,IK .ADC2\7Y-<W>X".G;U%<HE.
M&[]BD-N1&W@ U>B91]Z1XV0"Y'R@6C^SQZF>X5 >"53"@!GZ[Q#Y9*P^?^JZ
M<O^44/EH@?ESO47)-:B;Q^"QG;UO<9&N&@ZM!1]E31-.5LPJ2FQK9GN@35"L
MD<-<GXEY1)\X3O8<]=JP_[./]-\.7\4G-)\3.F;RB?Y-*=.RJT?P!.MOS"OU
MX#/O[^JT2>:\Z$#>A3]1)<_?DB+138B#%\2]VW VPOQNK-Z*01A,&9>G,>\Q
ME9]H/+#0"(PO<H//!V/D"WQ@433#H),[8TCE!S0A//]\ $8?^+V.N$\^S3$G
MS)/]]/F 4!$@&AQ8(@3A2!!*UE\Y"^>?#W1I$N#9@16HTOJ)4.SDLJFD<7!8
MU)'QQRNQM_K=S6]8"E[8(>45RQOFA3S:P5.I95[ U=5)XI/'9HC0"JV+]V%=
MO:(9H2@B+\0C#@)=MKB!5>K6::-^-T(^HJY\@4>D'J8S1L$6\+?R=M\R&F=M
M+PG'+AC $C@--1J 8VJ/9&J'HCKP?S?^+B+%*VQ<U>HUAN(*F"Y0WQF:CVP<
M@"D!,1]A3B N+L&RL'P#D)1AI!3Y!PFF%R',S#/,5?>G=KWJBZ32S=/BZM;5
MH;"%!GO!IRF4Y&XXPL.LF0UXM#_&W.QX;G_ +B;/4J1;')3 :*S3 "@?\#/S
MGZ'Y%TKY%V'^$^:SE4< S2.FA/%;%N"RF65CN@WHF[S)0]XG.IM#>\$96&_Z
M*:#0T$DH=:]J.)_KE\A/K=XOWYRLUT*>\&MP[C/W9[%UVY#L#K4CB+E4FJ&_
M(?X3NA)$><1N=$=D^2QMJM4 Q3\/!:%8B('[1TB$"@@6F<, _A+$PUJ$Y":4
MA=4N;/>&5#<8(#N=V.\YGB/BJ8W]8,K4)^F3HT*5W/ Z)!J@'@//4^@A/_.!
MX^)YT%2GH;;O!I05XV5+I"^59L'_X$"FSC$(L;Q+H*#]:]%JJBLKP])1>1@]
M6@VC];5?\25DL:9?(#&]QEC(FRBP9P[>=\>UH3HX\'WV(ME<,W[)PE$P#OW8
MI[QG/G'?RB?;6C2:,;/"=.!B&2(H7V"L/<8'(GY*9Y' W# F+L 9APZ5NV)C
MNLWHGNIV=RUK6V15=JGH]XPKA^CN]0W\@00GQF._X4)G8LOFTKIT&C"A?O49
M]'%)PY8+-4!J,,,CZ%#O*N1LC@>"H-BV:O>VS.NI7+\!;7U$J*PYZ2(-D#A.
M6=_)ZPGD!4_%\4BVY-;ECY[ !#S!O$I6(K5XJA9O?'D)H[RA4?X7W?=O2#Y4
MJ][0.?]N))>-I&#WG+AXX/TCC(SW'5T*'J-;.!<A9&&';$"QH7WT_:/X>($H
M\J31N)$^]0#F:YB\2T9I:;T&#%WIWX8!YA*,>9PAB]+!V>8MIU7+:S:@@=]E
M6@S"'!B3VCE_8D/JRH,=6'MDU\@UYQ)J4&AJWN!W,%+2/*G[8KZA5_G5MWO,
MI;N")O+Z;TXF!.)E%;<4=D1-*CL$?ZZY5@AIX)>G C%IIZ5A[G6[9_(P0EDN
MO;1B W1[$(+*I!*9@Z@M14.VN/R.)N&JJQW)BH5X9+XG5VIN" PYK X5AUQ@
MP_Q;7K6IP_(2R\6V,F=OI50#] YZ-KH=R-4[.(>T>I18K7)#70'Y8>TAE1Z?
M?'QU/GRZ''P+_8#,U<WD'*G3YT\OV'_&WQ@-IM]@F@BCXU5*> /,FY/>S=:0
M.7"I$K; $)1%"K^%5W6]IC:A)B5*ON%@RKR4+C\PW[]F7&8'B^QRE9KO;*%3
MJZ9WM'0_06[A!ABNQ?45J?Q;E)V$7E ).!(M !9A58M$8[83/*C-C."V2B]F
MJ/)4Y!FKE'4%9ZAB[08 '&])4A]>B \42!F7/TU2TMZ:5!K0;CEY/#&YL D*
MZ$EW]0HF00\]2+;&*<=0:T<FI]IT$F_!BE974L=%P"2FEG7+-W%5H-!0;V-Y
M)M1?!,]?OG73R[<59]8:])J9QE^]G[O(9&?+-<8N1]TO)WT:,%Z<A,@6;"8F
MCS[&<QTUSXE:"GDK<Q:*:S3 L-X0BN.UNSC/<P%^&1A+COQT]N-IBF5*#-%B
M$-<CUH0\RJ7<K2^SVA04>Z3(JYE?)X$&E(;(3[\4YV_1),JC9IG,],:DF]!%
MD<#+V_<?P]$_L N3K'*6XGT!A7U1B\;[G@-(7ZV_B%AJ[\@SU&U&4*==WRBC
M5,E-7BG; !L6JY/<[\.H<FK+%-%4Y7WU+I,K4E]:.W]+94,NP)Y.3)-I+1K-
MG&?E'B_&E0L776UFW ZV6K2I&='$,EQ,Y5ZKO.1@;2-3G50S;$ZR<X\)<8$X
M?QOK+!#\F!/05/F\>/VU6NVF[O=+4D=/+ZQZGBE5N $6]P'+BR:!YI NS^5+
M%G7PC(B25'YN0HA0=J]A<EF?Y'NFA>4A#"FB/H.C;GJ(K%"T\UH#4=#JBK5W
ME*F(*U5P_L+QY#LH(SU']&>)UN:6;8#2_HZGQ/55&F! N,O1..? 43JN-E1H
M0'/6/H ;SQ+Q4HQ029$GF$2BW;VI+2U#JI=>?F"9$<3>X!F,[P0K7^D27(C%
M]Y*W?TYX1V+N-I123:D0;C(WC+:47-% -;/R(G>UNN^\G!+G)B-CMNC_!+/2
MM*:I:E/SF6MLJP?%5?"!<$KMRR*7K?)H:#^F,T6+Y0FYV6[)%[AA+]H>2!71
MV^ZB3[>G"MU1.?X3,L4)R%WR;$+^YG'*N#HR*E=%U+E]@XYEBS;5GTX=>3S7
M'!^G&"]]2Z,\E*I%I!E!5.8K27K-(SG-7^7P?U'-9N8$+GQ"B8O\2PQU1'3P
M1&76)7"+?9IE6^7K46F IS=P76"=K(T,Z1,8<$&*YU!#C8:.XV](_%PLT)G=
M\MRB#8!IY9A^O  "DDI3>L,073FL7^_8?W5Z#>B+2W#>?#;'WAV_8!Q'7Z9X
MPNZ4,I]-RM;,JE9O0$M3BZ]R^4M6$!46:E-EWWOG4Z4-/Z5MJTWFG9N]QF4#
M#;]I8 <>K'F__.X8-L%?3G^2\A8'L=>T&,-YWZ:LF+K?!NEF>*&KIYU2:P_E
MJ:%JE9OIBQ9NH8M/_I7LAJY<_]U3O_)\R-WX!^-^A?7AU9(-,(N#&02SY,_H
ME+K:%\>S=_39AI,R%>LW-)GRG2(?!K,^M,GG#$3 \N1F<8!HJ-'0-J9GHN3"
M&["DYYCB,?C.C'\'(7@ &@-/[YDP+\NL3:\)$U?U[]/57FFN2[ 9DU2<2>9L
MEG=7WM6KZX?RZE$YDN&?QGD,<<<&6>R=\FSL[H;R/%K9ZD8M$N\<0N3=2/>
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MW2(DE9721UV2^4R<?H (PZ_%^T%P+RZ;!A?X07O/!*@CD'![D$PZ$E3&A3Z
MBRRA9&+MT_O[\!Q^4ZVOP?5E#?<7?R_5B38/?@E1V(0:Q&W?1^.(#.@N.R<-
MT5PR!XJ[8&K;61U@G2!1:BNCA]3V^R"^G8SC J6GS$@E$DE1X8I*C2;>&T,@
MTY"<2SQ"[1:,W9 ],];LJ)(>XE#K4%YMQ5=R0!>EM ^E!*@0<Y"NM%MC26H
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M4%G[/'!+B$^4+X=0R%W^N#[X<V4,?8!\64ZS_G4YG16RE^S8:^J73I/X#]%
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ME8VAC%5O:7UX<FSM//3/C6WDWD>]RLM2_&(T]"49?E'.*P_CLK1!U@X4]T
M]T=2RJ<0+WC)F:4F6X_V3G6C\GY$QV!1[*J]U>*2]42_T<>H7O]]?I[[>IPG
MS7F+^>/E^;EOOI?+%E]A? F_?E]\I@W7QLDX#O%5G]M#[#T*NU=Y;Z6*[?5E
ML%+3PJ7D8PXZ*R-D3MHF;_[_]JYMN8TCR;[OOZ2W[I7ULA&R)#L<(5G:T7CG
M$5%7&CL4P 5(69JOWRR ("F0!+N!Z@8)382M$"0*?2HSN_*>:3"&Y"S=0C9,
MVD XT!M9?__?\L5\4:/F=\"\NZE:0"V,T,8#IRN3+&-6AQXD11^U<2K*G%+K
M#O,NN Z?S;,B\GH&,3F(/JZ*<E_3&TUWQ>+MUWA^E6I][G*9Z;_:?C3Q0L6Z
M$HML3DU7A<,$Z%B $I4)V9!;R5K7\^\!\PAKR5K+T?T1/L,RJ_&PCCW@_IR)
M9'G3)+GY@ILEXS>UF1.TP6.R%FQPGLYF&3CG.%B'DA5OO)%=1GP,"/&$Y.\Y
M,;.AY5B/U0%=='6Z#8^02J@Q$5<I5C*89#,3,@0KGE+ZW9YT8A+3F+0#A)O>
MY(M%KAM<ZH2U3+;;BMJSVKA-Y/C7ZL\G42AGT$F04BA0+&EPWB3@&*5.616A
M6B\&[H+KA(1E,'8,$)ZZ*:VX[2V96 QUP7&!PNGF4B9J"%Q80*$P)N$2(6O=
M[7,?Q@D*Q*'$;C@-I%YH?\S\9HO"Z_F"#DV_6PT(GS!RD853")XK0\YS'6<C
MZ+A:81+<<XW;':X/JHA''W!"O&U'R,;S+>[>,A_*J_A_5U-27K_-+OWL;!K.
M<S5L+I><+B"FK(T*;$J6#IT\..800@E:&<D]ZBZ\[OBX$^/\$$1N.,/BUM%:
M7BZNXN75@@CP^D^_.,O+21$A>UX49+IC0&51:M%< :Z]%)EI'<T (VKOX3@A
MB6A&[H;#+#:8WA%1S]8!J9MVY4W_?$R.,RUMG;L;Z9:R!D*(!B+SY+?D8-L/
M*]X!YP0%HA7Q&PZ_Z.C1V)2%XH:!"!QK<MZ#SSF "3IPZ9D5N@S@+.Z30OM^
M)@2/+-A:$4(V%+&+\01(_A?09<M8EBJ%8IMGS8XTA&,T.3Z$R$/,-KC3$$_$
M6*\^?9\O_YR3"JXY@G7WHT*Z<I%+B$EF4+&VOZ: P$K,J*)F;* N\R> G:2
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M71&;>DVBD0YE,*9J^BTGI*XB-D3%L/6P-7[EEQ+N@&3-,H(&P&NH!?":R+]
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M$#Y\*2$>I]/8Y?LY_EK.ZOF4<+V*E[8*EQW-4>>1L^V?V\6_UM*GX2QHW;A
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MCQ<TX*@!^83:[&;DCN?"R!+B:,_.B]'9^2/?XJZ=^O4@]MQ5G8<??(J*5[O
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M](<3/;'QRUGK&7N?1P3N)'])6TB;1/>7T!NGOG+C/Z5;]FNHK!PD1;(#L28
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M\@#X^"P-"%/&X&Z#Q_FGD^)(E^#7\5)D<1K 0]8]$SJ##*_^4:?YWE7BRO/
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M.?CW)XUG9Y1\N3LO]_AU,@'WLM@ !,4X:.:3ZT(9T(A8M4A9ND7"R*V@(2:
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M@P]5F3+Y(UF4DV27EC<^M9Q*SO7B=)LKU#.:S/*.LNX^IM?2AQA]S"5?.-;
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M^@,N>QO]?>4;"G.Q4OG]J009BZW$M*@=9$N3@0"KT;!EX/9V,!/PVDV?=N%
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M>$P[1D^K%+F_8J);D=JVM\GROK'&NEJ/EKL_F8 WM:Q$FD?/ODZ,P.;#^)^
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MX;]+#L(F#WQ[VM=JJ%>JL,>C/S@Z]9./\N"7Y YF*3,2Q\/4IHHUC0@L$2"
MW,U?RT]XAM:CU.0?L2%U]G?D;</EIW+N99M[>+E7]"W\-!_9.9Y\;]_I3]_.
M/?F8X"(JZE]R9-?]I*P6@= D:6QYW0EG\P!_5BX\5 M+NBU_R]O-W#?K,$OT
M1XYYNJYM1JRM1^NRZ.QVUC*<H3JW)88_JJ78['-X^\==*#/4LJKC+IW%BEG/
M>UVGI"-_,((C-=KQ+78R&P0CG,#L(([\\*Q!MQ#VXXPYY<@+ ::US>GMWF#F
MT)(WO%.#P_P7Z=8]:W0#EB_CJ'9[>@R> 7RSGLGFV- !.'/P1A1UM45,?,Y#
MIOPE]#N<8(KCHOE@PWA@2=/,I6=FE:LOYM#W!]%X=3#.:R%)?M)&!^2==5R=
MFH/N\I!S)/.WO=J-9TP_> SZ($#I*XQ;0!CX%W'HC7[U"C;-U@8[5V8]@$:K
M4Z8(YN'!X,8M-S;$PPFO)'SI2K4IX4Q=5Q9GTBQ_W@Z8A+;A=J,%0 X_>]F_
M^9WS]X5EA%%YTZ[I%4:/FO^-=S9MY62;3(P6V >K@#,5\4=&QM$VM%.)]CZ9
M(\GW5?(5QY%G1V9.MBL^.CLUZ6M,_5S?$M"YQ(8P;H&DG56W%^;(H<T6\R_C
M*1D9YEXV#=+O9H[O4]L*G9TY=WU#)BYU@P0/OC!$/M/]\=W#_E-X]8K(7+W1
M_J[A92LG[[)!X]= XI[+]IY5:LH/<I^R;+/Z%D[>':O)/W.Z%3[VM.+CMI0N
MVHHSX&=!WFH"[3.PNF3UA0UI[F[E6#M$!=MT<J=04<VUG_F,6X$Q5JM*S%-B
M[8#=Z4)_$'^+XTGO/EW MG8\661>>,J,%=CHN9#-/)+.B4DMHM".DN6SCWMT
MD!()S\Q$?)P>[]H::.$(Z!7\< 3G@C&Y]!02OI8-$>8;P;$.%+C\XESHI*KA
M]6NP5T1GQYCJE]2UF]C53Y7;ONDL*[(DMN6G#,<"7=E*O;!^V_.<RR0@Z!NN
MGLRNC;J/-"AYYLW^/O2SM.'E17J4J4C;3&/AAL"P,?U9=[%2W664KKC/-8J4
MXT. YU1=0.'.,7^T9I!'O[;2XH7G[>+G'D;@ ,''9H8&= %6B!9_ FUV6?A*
MNAY8Z&JKT)-_+U#GQC[F@D,B*B ,GOVV-S%3$<$ZDWRG%948C5>$R@<'IM@B
M62>EIS]CADG%Y>_PI4RW;BGHVLJC9#9$-SOO"F?@G6&<&)S2I:E9)4";D!_'
ML6JO!/IKY$VI!*;@0(,FL0+KO"J $ =_-TS&?X'%9\MI-Q:J*@UK@ON<)D;S
M-);\WW_[V>ZF\'32C[D_+'%[X.CMMD8M)9JRZA3+N06C.-M%OB0_OR?):J'J
MWCF&:7,[S:1H53*,*<I#?UC<.93<K(Z:IP?*'F!#2-_$F$E-O;")/#R7G:P+
M7H )U]:0^% >"?WN2.#J)4Y\@E%O*NUW\(8.#5CVW\*]:2(;^)D&@GU/LBHR
M'[@BJ):$P9*KG4QY-F104<(7]V9L>+[_$0M=F0F6-=V-K($VN1OEL5R56$47
MYPM3N5DGUQ0*J5E8CA'9D"P'85*9 ""?%3+928<W2&W5:G?E9R"^G\J!4C>,
M7VF0I$59[]43&'B:2@*'AEQ][C5<(]T$\H71U)NYE1J,!P6,KQN=^*WH6#L+
M#EJVI=:>!3B6C,4V/-+"_@:DZ%"&B%*S'Q=Y)0_[6[9G7^?T?6SS36HW;&7K
MKX5GC%L$ZO3-#2S%4LL'QXST"A?W6$"8FV]E?TOM84/XEQFN;F@ 3K<:EUK!
MMES.ML;.':A*!R4U05YWBL 6#YJ'<=@?VZ*@<I\-(?Z&&@_,VY[3"F!#> ZB
MKT-ILE27+ADL9S +C?$.<('CWQX"7GK,"SBF6!Q%C!F)+XWYM>G#AH1_<R]B
M0X($H=TXX/70=3;$A]S+F2H2J@!G2+Y^^F.>#?G:&7V^<"6[/R)Q3!R35<J&
M(#G3PEH5/%>**)+G_,2-[A/U;$AY!G[QW@9V'[;!".RD$\71MJ5=)SR*;=WH
M:M]AXJ&:]/5M> RV*04[D59WZ2M0Q/![O?G^&QLBJD;X[#3 >H)31=YD0U[X
MIM54JH]KL H*"J8QCZQ@^\BO.0POUD8-NYH$HYQVZF2-'&O2ZV@] RJ$,:\B
M^>;<WGGVGT"673)/PD3)QE103H-J\PPB&<8Q0R**3Z]A:WFE3JG&P_A#M'96
M='P#$-&"YU[R$Y#FW&<I7^03-F2H9R'I$R;5],A 'N '\B^SXI?*B>':2B@Z
M*\RLM+*DW%Q[8J2J[1>H.L;Y?)\?&\+-AG1QV)H+(-\LV<H#&]8^E>(7B'X!
MG==C_M4IA&#40?GUP%'CW[=A%,% R2>DU6>I]AQ-SWN'"/+(3%YQHR0N"3Z4
MMT9@!J6/#1SQ[:Z3LG$ HWRT,"Q=KZ3$93W&'I<JP\MUYQ9^$IN]H]2^B3.$
M/>5W;5BRY'=V\E:#^S?)@<0A?,GA,,5Q_+"ZF#H>CY>?I16L<20RSQ*>?#2?
MC!]*KE<S2CE900U)^@80$RO!4R79;:"BG4K"0R,^QM^3VRV2/1/XM$^(_"-Q
M$J^PZYN"[5A;_8M4'7HD0" CPU/5Q4@"I?GVQK_<\_O.Y97ESF6]UX8]DU$Q
M2?N-@G %\9RJ%,],V&^.DGWD_>#KW.!9O>L"]H@B(O4N'I#-P?3Z'8:)$IV\
MTN=2S_;DZ:;,X%3LAGON/M=_=/9K9;3#*%S6W>?L?IL@_)LZC@=HX,.Z"TBA
MNODO4G[&90)*.OIA(V7Z&Q$!0Y;GF..WS;NU9]NN3O-D+R->TP[;M%S^%'!7
M.&*&8)Y>G>TNG0"?EU)02--W^<AJ(V>]EA:8JH,^I%8%WKK/*XZJ9-F:;I)S
M/;XQ^JR3G\Z$Q\7Y,P;T[!FJ.[DX8*Y8X/1JDR'?Y.8R%\.&I!Y:IJ/<O8PL
M\"C3;+DO%SL6%B\O>\<A[;&HX\14Y'OX((R;.!%!*FSCQ-53# OJR=DHU7V%
MF '*2(]*0#4;DMXJ)%3W,VI#=1W;B O5%@24=LXN&T]H"B/3 :QA^/=&]<=%
M?UE[V+?.VB?8C[U-W?@U,/K@DI="T_6+N89&F?'3\NVVU?-UP]!O[^&34 FG
M^SF#Z+UG[S^&JM2F:.B;EBINW?7NCD.7S]0D>6Q+C!^FAKUD\J?KDCOWH.R-
MNM;G]AXK[%Y*KPB%;9J>%\'L+N4HY_6_S1+:IC;.WLM5OUP^TE>1B\D[G1;^
MZ#_/(OR_I_V#(GG_0$?_YS\E:F76KQ*U]UN9@M>]\I(*8^*5WD5)I;ZW0?+M
M3"3#$2U%_<0(/+4]:55E'93DC:CNK,$]Q_F,V9H[I4YM*6BC?5 <CRL,QT3X
M_;[=6GXJ]"B'15YQ_-#K<T5=KR10Q[SW6%E%I*/^BL.^\"M#KW;7><31<:Q,
MC-+7?OP^C'0RGY,L7^6'M7"&1.;NXUM<IO.DHM46["OXZSRT"Y"Z]1/]\EU!
MALG8-3LA&'"0C) !:P=^L$8CN.X*#C^U_8XGJ)1A$FZ3P>YX]_.]HS5T1( F
M&R*%&<3O8<K4D8S[9OH+X#AY@XBG3N,W&F-6,G,[Y5A96&=LQ$557 ,Q;&_W
M7DW=X:L>$MK%7[D- %QKK5X#K)C08,S].$F)MR#S*?[W6FY%JO[&X-5K&WQ)
M)%HBA_2\P/*ZO\1< 1+)G0)Z0N@BUZ2:PX-'@^ / 8C\+2U8&U-']8BM\IT(
M-B01Y5RAQ)10>@:C?@HM'$HX"?[..KLL2ACO%"IFQ6JKH&]],81/&C</1#H]
M*1=6[7V] /D:S7E.O3)_>##L46=P*M_01=3CA8$S;(B29-/6$&RC<S>,Z5NS
MUH:GFG4.OJ@?(4=0,KY,-_I4_/)^-]/9?</L%8<6^$Q*<Z9I\ )*])0:@A?F
MQ$*:Q=X8X5K4^-L\(Y54'>*HL#ZJ7;99 YLXI30<X&_Q:.&>/^,6@ZC9YX+N
MUL-(A76CO\<A:X@3>)3E\/#@2&9F?.F3%O%FS[^>F^E]X'IN"I^%,]5YF*(O
M)G$KH "F0TZG+!&\LII.+1V<!9/'*V))P>$P\AOB!(%T5!L;3BR51ST=1P!
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M0SNHB4]I,7P-*8IM\(<]S.=ZTI6/=BL0W#1*_J GCF3N2SK!0P;@>Q!BTE(
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M5#D',IEV%[A":KBX/.+R@66T6?IY2R;RI&Y0R5NAH?;%<#.;;PI?S5!II:"
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M_=Q>=";B!E?FZ:OP0<2B",$P(SP R")-I+\RN20?/?MRX9$)[2$:Z,I</O&
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M(42#;@;'RE\K'#'C)A4;)KG$-;S#P?J[ WV0C9GZBJ==IMB.*T\&\+/ZB.G
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M@IB%B]-!$.>!E_^IW#U.;2CO$XP& ]:IW-"3J,O,<@:L8?.[J'W=9XO^EP=
M,N\O^;020%5C0CL))B#UIG^#.[K85SN._K?XXXIA,E:$H0M@" _+TY0$*6%E
MCRNNO(U4??\@O-I:V>N4WI<D3,[CC#^E&^SSE_FWZ(.G;WL>3HME/A3:+>="
M2P:5<OTI6R$+?.(<C;S%\]FMU#5(SM:IILF4?U?^^(&GN">!WB<GM1CZI#OR
M<Q>F&\G+RW\&_GSV3R6I<>F%9_/Z'[YG*7MX[@'JWV&.WJML*HC(A36ST7B2
M;O_=U6-N>#OYCVOOG=J!#PN(,95,HJ]*H5CQ,;? '?>MJVX:R"\S&'DVU40<
M1-DS2]K+YV,'3*2S*KZ5YF9W^>?431MZ;%#3+K:HZ+0<H.9_/?Q&Z>JST.SD
MC38G[K#_._;H"<"O4!QQGQ##WBHS9@A2^7SY8.Q"6?T=S:]5\3<%4QTRUF[M
MV(U@-,;PY9'>*]:@&VC.OX/0 G"I",%H2!*+!["N= ?@[L67]1$B69:J#8MG
M,PODQ/8.+M4E)#,G+[/S#.97/I]'BY@-9]A2G E?BRJ"#6=)RR26F$KK[\/)
M7UX4M.K=_,+9;(>X?[-OY.D%"UF$.%0.*4!B>Z\ B@Q^0F!AT\1\IFGT9NWR
M"9WNH9.C<H?%WKW)'/QL#<%C4K$@ $<8W4XKEV <\7WYK33;%Q(U?G;)0?*)
M:!]A]TB"SR"W'9>HA7XG.[BW^U;F;6DQS-(%6D02F&]W_, =>Y>(;1\1S;%O
MN&CYH,O5QTV/D:N:&JTJ,T''_V/].SSR!7L _6:E-6 +VX&C5*!%-J *A1=!
MB*4%Y9Z?=<:\4V_&UCB^:)&?_,S<#3[.^;9]FYW1%E3;H2"H(3*9=H>R-I?Q
MM5/FU/>+"X<<C;Z<IW*NF3WY^56W>,)X0G_JO\0AY, G@NK[H%3O S.L(^XH
M-QRE]P56>6KW]XLHYI7[OS]XGNVOSCA_LSTS"4GVCEU= =3VMORIIB.M#$?J
MRM8VD7S:H_OUY>T?WCQG>N\?2BM3\3U$+GMJ?37^:V]J)BCW_?N)\ZU9\&FR
M7](R[ZS1X53M9_+'!Y[7$=B )EST=1^DL _ZUW'GSFJBK*FUA!]%#=\-8KXN
M"]G =17R5-9U])I:3$=&4=EG&2.YCK?])3DF@'^'26[B#K+=*V;>F7:'>FW9
M!#"EV-I,ZL<]";2IX.\I."UQJ.VFG%S/?96=9C+/5.]9=H;A>% 'IE&:=#M@
MFI9^N4%\<^BV5LG3AR$.KK;J@:K'@I::?ZI$Z#B%\4L=/E]=Z%$N_U<T)R/:
MW%+)/4>HW41R6H;>J"DQ+LR_KEYV]9'RDWL@VS&II3NR<[YL&JY-W@<1'N&:
M]A+,W)X"J_VX5D3J+AG!MC,_S^$Z$O'%/X?[IZQ'HP4YP&<7@6FZ-&L4U@;+
M"&/X4TL(+_->!K^BD;AGCET^6FQG^2;3)N/^NX0=L;WC;U<+O2O8$;L/PF_/
MN]&B@%'"9S!Q'3^1_.=8?042$T$[EJ_Y<C1>\=E:7:[1NQ0.J!.H[Q#_5Q0/
M.^%VF)E066 0#B021.9'![M<6ZN7LG),+[2GX(MW<K.KF]=+:>SP>\>"L/"P
M%LP(3G:$RD/:[OLLXS%[4273T>H:<IFD=[C2<:TE8\;'QTX6I#/5:WAN6N^S
MC&/'9%L85,#!U$Y<P=/!O=B(F&/A<L8%=)*M(VZ AN#_J7'*EW)IF,\^Z-,^
M:+4<+PD\HP;0,!161V.=Y;&J:,Z#KWE!".,+21,)!_*T#=^!OH$:/2L3C.&9
MX ,L$500<!LMB;H(1%9O>BOBKYH?^S$3Y_3/L.A(Q\%C%^Z]N"O*!TH(X22Z
M;<71=1BB,WID/Z)M_QV9,[U3%S="(QJ.^IDPGQS^IRU[Z(O6T6SQM5Q1D(74
MQB4G'D/"-ON\!+%@X-@Z<2393"&@-M#MEM?;R*>>S\3LY@3'C0^7KP9<13]M
MB5Z9+Z1AJ+#^342"DC+@4+F"-!B6S!P9W'--)+SB>YQJQG@S6IAZ4?8:X>>5
MCY(<ZRN<.'_8_ HMU' *)09<>!HH\3T>TP9A8\OX&W"T-QM;_!6MBONVU%_-
M[0H)#'FHKJ3VP*L\OIM$,[L75]P1GB^:ELX04G,F$P6KQ7F5N>0[V,</&X!]
M\J/9 1*K8E1.(KRO0<9^MBJCZM6,R[52ATNA/]S-9GU!1_X14UKF4Q0^N0\:
M 7_Z.^.)6?U+73-D-;:?J>Z-G28&AD&^BEO?:"JP3Q^54&^+TXC142\VNQ4R
M%?A$1!>8HY]"GB+!MWI?L$:Q8A_:KHB<F8GRG]8(LWG0-0?/-BG*/Y)S3R8[
M3^>@Q4\IAVO7P&<FV^JO"-BU36K$QAG$3/8+_RQLESS^]L>-DVRE2U(ZQG9Z
M8:P!EB[U6 4;PR598RP%[,POSXT(?87%]&NZ7G#UD@(;T]_7KZO02[<8/'0(
M:P(CB)7]CN!FB%"RSC13RIHU6H*Q8.DD!\]715(JNLH_A#HO</#0*[O?'><<
M8_&B1V"MX*V5%Y^!/$)M_[BZU4Q$PU#O$..H?<".)<_;RZK7 U??\%R]ASN^
MFIB+8%-04@"K'WODXX]V9@3-AS(^3OXU5B(3JSMX),X_1N/'"$:E6849\IFM
M(1!$F?Z(% R'F1).A"4,'!T=_*/K]?9&5TQ9M8TJ*CQ4/,X(7.1)&1F$<" A
M^*Z];)0F,=Y3$3XD<\$+2*)Q']FNR=61-_VR8P6J4JR/^3])1%V!)#.(.\!P
MIX3M@P97,KPEFN?T',]#M/9!YV8:\$UC3U+EG)>T!7F_B/(>3@BYSL:M\H3R
M%L.M>3JD89MQ')'\!Y[Z929!9L\@?=OLN["57LLI8XLX@>Y ,U*K_K]#(YMZ
M3CQ2->CWY5QZIF#>C2[;P3 #7C-NE3P"4&4S?/]]RJ&A"3E7Y4>4D*O[(&))
M0CLLW14LM<V A$#2=WNA(8HP-W]HE/144]!1YT=A5Y^4F;J2)3E6E\W_EFJA
MAQ$2/?$P_(HBZSU+:4:_OCNEC+5&B'*8MWP31[(1>S___9JK&C9D+G1K:W?3
MJ(T)G372).3X)?'Z\>=79I]\GLOF$=#&1;:W#Z#B:,9_ZS(#R5?G\ AYM/"&
MQW)50'@88>;:SR.O=\Y'2C@(*/>@.M[@&\>07^8N$QOOLE,;I4@A0\4 !)&5
MYT=$;I5]0*)7X-F7_SDD2FUS7^CO,-A*[KZI9JS_@?T3GI0(FAJS"!:P(NVX
MVIB,XXH*DW K/7@W6+3^K8J.SJBM6/[#MU9P=:4/=T[N)6,Y@K#2S&I4$/V,
MQFQ&-*E7QF':L;VF7KFH3;Q0[X?[[P+#?^H,4OCOJ5VT;SQ3F6"T#\J!M>Z#
M^AL7U =CED6!SQ3:(+[4_S&EYU7+C$OVS?=B'^Q RE_Y?T"S0^Y2, R)$IH2
MA2=S=^40TI 60EE^7+\A,^D=5$*C&!4L(S^9V'6&5R0H;WC/L8$!,US^J8-V
MF5G!<(A8A63CN*/N1+IT=(AJ5>B^E6RQ$CYS4>_<TTL\]_(Z;>"'2C\ C^DG
M6>_+Y5 *50PSX $%<^9C%$2$S,)/J;;/1_BUF[6+C<@Y/5%[!Y+E3/1.9//:
M1,+?N^6(9MM!L&S0/DC4C(-NC(P].QOU,/]F;;!!T^N"Y0N3]XO-?E[^4\*0
M4*;Q?/PE]RL,3KM"&=LS=#:;DW@KF%*=GW']:NR.O<I<]P6+0W,#$<DX0307
MH M.*^=%R00\";SGJ-*T\8K_3."/Q<<)*CMP_:G)_^];R?[_8KFI4TM6 P:V
MYW_VQ8(ET#K(+D41J_;2X[4S:JGV4DJVO%FO]*\;7^7A[(U3 5-<R@&UL;F;
MEW%DS1K/MHD6P][I1I\\Z+;*R?I?*OR@/]*9C=7?%[Q[:Q9#2I5J(N+]X\(+
MYY<]V-[8['Q%_N3,O7>67*(W+,?=GQS(5$\&,NAPU$' D7IJ$,.#/LJP;9OJ
ML2=MN,*$@V)%WWG\6K 4?]Y28:WZYD)GJKTDQ_*%RU@=:FPJF[0=G*ESV>WI
M;4QEFZ;2/6=LN:DFF62U8_>)BW"RL$\M<PRPI*81.T9P::_ 4F@QY%/-D,$_
M#^Z[!SM9']48/N&M-O#F^:"X<N/A.RMG01N!E?D/+C@T]W&J?#@PZ;4WT)BY
M(H(U9,"FL2=0ZE0-C^'$>F7LXV>G)2K'GBG;X#4R7VA_&[QG<BD6(<-2F$>Y
MMP-RT:1_"H=BNY2_T[IT,AUW+JN4.9]3"!_C^7W#$SK#P8[F_X>A:9=9)ZF(
M5)00L7M%%CF!E[[M6O1TL7VXHNZ[C("D ?7XJ&FWJ*2(L[<ZH1PXL;T%IHH,
M2Y=Q4T;(8D]?5=1Y\>KM@SHVYHIC]BX6)N1[>5G=>V/?Q^'UY=Y!^R<BMRL[
M5S)QTF@%ABA%?QO?F*6DW?JAS=S\TN=@F9=6SZY*N5AP/YY/Y\\4T#$"E>(!
M,?IYA@#SJ=ZX[27@Q.JW]L1JKP9L?8CJ?5J)ZRUMU3.O]G1&-'P35!V."[41
M'LF#M@,;)0'</HA;AIF%/H"RP@$NU-A5;'DED'Q.3(%L$"_0$7BW6>59<>XQ
MY_M1X7R;FU=@?9B%"5H$L_9H=R'!<%@(C,_S>3[WZI6S5!FW&D>9W($WS^$<
MF82R4Q9*&=;^P-QPF1002=2T'2DSF@O;'0?;M<8W.#AUA=I&\ NV-N\>Z.GN
M@U&<&C\UDDJRV_9!:2LBF, )X>\+L_6P_-J@V5;C@CCM\Q^Y;8T.)I@79^[\
M!>-7>5L==%.@0(0'Y0],5'\K;1AJ>GT%>D&E983#2/Q-L[)LE5H5]J.1&26D
M%0=44%8= .2*C+Z(XH8.\K(>$;U\Y(X5K)EYO\Y7^Z'I65%+KD.'LJ.?""VH
MCZ-Y6)\0K;9DY>?+@3!N*"2HE,Q,Z5KR^G1&)?4FQV&^8N,BN=6W%WHMO9K6
M\[V+_O<]TJ76P(K[H' 8V]L$4KEQ=[%Z*-^6J5_Q_W!-!DG/NAG.H2^\5PG4
M]"LXXYR<Z@\BK%:\+"&DD04HSK1\RD/D"B$6?\<0?SLT,LY0POW-Z<6WV5O%
MAARD4!]R- ^/^7'.ELJ>-)(,>9-^%*4._+/":W:'VG%^^M>WET>2=@ZVORX0
M..&_#W(M,3RA8!DZQGOX[+<;D5/=N"R8-$L1)0#$UZ%<@482LBU"9,-!;$;?
MN#+6[DQ!M7U1SN5<[S/>'/3E^QR3DPC3;_L@BBL$4 OO?&9=<QD]L\#O<"K%
MIJ>CJR-;@KFAFG'!MEM4_9NI^J+YV?>*MN>[,TG+)-4"/L(]$[MLW1<OC XG
M\2HG"8$<K.,BAB&+?K2+S/(>#RPG,$Z=.$VA-<T&176A*T[QF95H2%$D*6<[
MUCS+!)E5+"Z&)> 621T< $OIQ>-X+_/EK*=C9Y3;$ZQ93=W8 RD_'$$Q,VX/
M4&+,%LQUR(*I9Q=EKC\BV\.[\]GE18$';0#^WGL?%1%CY0=BU7DJ0M_X&8-E
MUM;4$MH<LP@7L")E3<!DP^1W<V3<BC^'"Y=#'FC<&Q@1T*A4B5#E^S85QC.;
M8'XVL[YR\[9AAEX\0A2(=7F%:\)V.&2I+QK/NK\\&BU8H/SL2%'B7QQ\X;"=
MM0\2VEW)G(5Q05#.DNB3,VUQ^IZ:AX:._0Y=O9-WW*<;)#0L$+"08.*A7@H\
MIF*(N/['ZO!9UC'@J>:Q.9?9L+;'T*#*?/Q<8;.[+X=4NH:EG)%2M9O#?T32
M6!!8#BT;@CU%10R23PT;--8#2NKV9FXAAP.'2TNTVRAZN81C\JH!;U1 QD.6
M+QA(P/+) N#@-(.*]Z-%**Y8!A$%ZF]-6S\?U;-QOPN7]3^RRITL+IG+^,!S
MY5_/FI!P/ 0X4;X%H>"&]M#<5 R9IU:KJG9\+?C$TXVY$NKE-\+\X_HO=*W%
M> ZG^5Q*$M8.^<206T7P,JPI[7FY9MPD3T4_VYDG$N[!M\/>C7/C X"BF7MQ
M7/&BEE^<#C[^WZ;'8]**-!#0AY;#4DNRVT?##!VFPTKC-S<[#]@*!AM?Q=1>
MO,%S+(\/V3$(-:.,YV7W*+ST#/;PK@EM_;3B8:=D7.4[R,DT2;X7)U7;7+_5
MVZB^UML8!NEM;"<WI 6$[.H%5F:.65K?*I=C&3+4F64H'AA^.QL+2;/ZT' ]
M4^Z7'+' VC8_Z0D^>'Q4U,2M&'F:Q5_T=[ 9]3TN@E@N@I[Q5J3[SR0920/P
MP&P\0407.<FAEEC\1 1=F7 :Q*; &_\3_B,]&H?V0:E_U(84U0G89Z1_*JC0
MSEHXIB9(4S+EAR;QL,-A=@AXY?+Q?'#B<?B_/.6+1(A#(0Q#P)K)=K(""D,Z
M01A*(5 P9_$!]:D:T_[=S;3GX<WF\P*AH=(#V;>L@Y#3PTKR0!R!Z3:R?.KC
MQ1&[2;WY[5^>\V(/PL@5.=4%5I+B5I7-?5S4OB=")NJ&_5@(91T/Y@WR-J?$
MU)4LV'0^[:\+<FNN.KGDZ2C_5C)!F^N@C7,2Q_H]]12 3O=#CX-;F..YY=01
MTE!N5ORS(P6#YQSB?FRK6=@MOZ*]5:G1Y?W<(<<5D&RA],#Z!HP#$PQ) +?]
MR(M]B>(#*FJ!5$WH!:4*H=?(EYJRZX'%?"ZJ64:AX1<>U\KUOTPF8?X6)*'D
M*-(U5!@I(KUJ*DKQJ)A63=VX0E=?2A''$:E_&&,\H%]/A+ZK\Q#_5GIPH (H
M2@^I,&):AL^LGJ*WA-;C9Y[J7 ].ZXIS@@8%7_ >%K64RB%.+, ()5E8_4U,
M:V,JZ_""-W)ZL%@]KB'P@K46W4ZD*#5 ?:W\%_6&;#XNO[^/)^)?.W]K#B./
ME?G$L)C!2E\!NB3G=C'".;$7I\_IAB>?UWJC)1"V8//%-\'AYE0CR@C((N"R
MR@Y.0U51)G-5'_7,K\]X!97>O="E016W\#ET4%'$Z3AG^+^:B*R'H3509KU
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M6J[4_8]J_,=TFS]2[VT4'/[-+B\NVJ"]FT%P$L&O7#CV'\ A&1&"G(QLIVL
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M&:X9;I2N"[IRX=$PE@/55\ZV%3PRUVH<(A7(^N>]TZI>WSGN4?J!G<U7HZ[
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M^L&:6B,\D_(?><-^(9)B;UO2Q[XX; M61^J-Z!;:XQE3@^\$_40Q>"Q Y22
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M%=/)RMMQ-)1.9ZD]5R@0$Q7KZ;JF@?S\VOABG-:\1P=%#(%!:O"$])L0@=4
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MH>?9GP&%+.K'8-5O\E@1%0,OC^?B-[;A-?#A!&4_W)<?7/-3;*[0N(MN0=[
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MW&8<%86Q)&H;C#V!_>O:&OO@UK05,LT4:NUN0*=?:9I--2#X^W0,1]G3!V:
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MR'1ZU%6PDQZTXH-._CHHY@:T*HS5)]X>O%':QUM,_X)=Y>W!Z6\V[S".CT#
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M.QZ:=AW&)JW:%6E<QGMYC::6*7BNW0W8+=6)=C!@JR38:NG_=-X?\IZXTH-
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M)+GW"-RIO0I+]2.@?[-?RQK4R@*CK?Y# J,R:'1NVP,>WG#77&BTWQ]^'H^
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MR5P!FUI&L-1"UM77MD% C]L@(-GI<P/J,C">@JGV5L3V6,PKSJ.?C_6$4]V
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M5_>WF^K+NM W+,(HH)E@FB&58!#)&$'&6099RBCA4L8XS5R,-[_BS8U>MYJ
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MN28@34H\"0*A<$9C9A5^<F&>N1%/F_G1R0H:84$KK6MVS&EH^_G%(V C4\I
MK ;DR?0B<46NS.EQ)\Z7Z57N.&>F__*A_@1S$%.[7C_0XJZH>:?QS'Z011T;
MO"!!A(5$,8PDER913D&*"8>1BBCZ_[A[V^:V<25M^*^P:N]G-Z=*F 5)D 1V
M/WGR,D^V,G&>)'.FMN:#"J\.[R-+7KTXD_/K'P D)=J2*( ":<Y6365L661W
M7R ;0*/[:JIB J53"R8/F5-S#NWSJEGT0-?1HV6%?54N([%:+.AZ8^I;JF,I
MS[,GER%P#3P$!7;P^(/%]$N%J5;8U-E5*M><NUKIJFHA9 3"&:)@@8C+$D>.
M1SA#<!R6<+^T;V^D1[WH6:U__+XNM_*-*2N%F//"]+8M$(, H8(#FN<YR% B
MS<9(*N7%^W4L8FK>9J]A]-VH"(36T?.HY02.;C[D.G0&=AD'8'[? Q.R;<\Y
MTX.UWCD2,'+[G',&'K? .?O-*]_KS_3[K]IIK/5^9F//>3_+C5P_RLU<R123
MG&4@+DP2;48HH(G,@4CU/B3)&4:Y5Q+M99%3>^^UHM%]HVG/]_T\OI[O?Q#4
MQO('L\A@M]=WGV/2Z#R D[B(3VBG<5[@RSB1BP"<=2J7KQR'!, FF]Q6;/EU
ME6-3^O.:;KZ]DW+SEJZ74LQA0=*8PP0DK$C,44D.<)S'((Y1#O4FB"OJE!L\
MN*93<VE[H@!;75S3!=CV>RO;F<FR!"BM?B2M_C:1SSP,INOFL&7E[J/?[3DG
M-:9#QY)[EYI7Y>6UN4V9>:M%ES$Y,C9'E=%3&?MA208&>08F3SL0[%D8G(W
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MH;W?5[F^?R/9]I>UZ:,LBYBJA!9 90D""&((:"JYWJ7"+!-4K^62S.TPY;2
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MB/DXHEO3R<IDW#W8 .G81T*^S\; 1T(#COCTCX3VASY_/SPP;UL/C/E8?^L
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M[Q;_,L2N._V@P V^X:^UG45[^*S"^T*=1NF0&W]GA(+M_R]+'#D,X S!<33
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ME::W\]RNO55/HE6YV4BYW]%],$5S367<CYH@8O-F)\T!U%<]4G*>(E(P&,>
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M)!V!"MQ&\I+4%^D@Z0C%N>:1KI<'\DS62\ZUKY$D(Q@8\BN 2)X!!G,%"IS
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M G-T]D(S)(>GGP+C<WSV N@D!VB_._D'-HWS_6[8;_5#\V:U8UNU6]QP;M8
MF^=M%C#!F< <@CBC&* 4$\!RQ<V92TXSF64)=&Q:X2EY>AYPK[QYV1H^JP^K
MS<:UIX4O]I?CGP/A.;"C>PIDHW?4*.[5_^(J@-VCI ,!/5+$] "XNAIPK_AI
M#]@Z8JD^=QLMKMK#Q':,M<_E([-"?]R9*-&MJM8G-X^T7)A]HE;8$E;.4XA%
M+'@*).8*H#PW4T3! "D8A504A$LV$L_S!56G-Z?4,4_;.2'2-]9[)KW.,V^I
MVIG%7%3J-8%]<U]91N?-6)3.EP;=<3T^@8$<,>S2DW:Y,M:D*]9;@+V]]DFP
M%D^ 0-EQ3%Z:$OF2FG\-DF-'L(/1%KO*ZUUMO+J77^F?SU=@BA64\20%>G>1
M $03 4A"$Y!G:9+K'Y3@Q+<GWFE1T_/]E:8FON[?%.\,G&Y>.01$ WO5 S9C
M=<7KAB1<J>]I,6,7]G8:>Z*,M_O[?1.]'^5R)^OPK_%3SQ]G)*G 12J *%()
M4)Q1H)>4>HW)"$$H3S%AB9]WN"AS>FZB5CEJZ>R;!'X)9S>W$12[@?U' ]J@
M3L,9D&!IXI?DC9PQ[FC^<?*XZX5]SWSH5AYH?I2220JI!-CV.N-9#I@L*,AY
MD4NA9%8PISS-T[>?6D[17KN>Y$E/L7,]=NF+R-";,V<P>AR.G+(YV,''DYN/
M?*AQRK#C XN3W^I=\E56-&PFN_#+PVJY6:T_U ?$-W^6FWFL",29RH#,3?57
MA@A@*:8@Y8KJ#8/>1L3*L_JK6^+47NN#PE6>:ZURU.@<_6&T]GS9+^/NNC((
MB.;@*X/K@.Q30>8&3KABL@ORQJXK<S/_1(F9XX4]\X\K'O-W4E]"%]:?W2R%
M$;#06YTZ6:I.?-MS-2 HLS@7*<B3/ <HI1 0S"B02BF1)(@3[I>BW$.)J;FF
MV@9/QK->\+NYHZ%!'=A#U>I'M?ZSR%I@L_:L#54_I=J,Z%5MR-^&H<ZX LI0
M>=5]5!@W]?H*D(ZRLZ^YU]3:Q?Y=;K:&[*A*9KG<^9/E"!)IVE!C&1ON(04(
MRCG !<8B9DF&LG0J'6,];9M>7*DR8*H=8WT?G8'/(U_R<9C^ :9CW]CZB2N7
M4872_Z;FL3W'_Z4/2X/;]=<X71UJ.,?K(MM7P;[M&MGVH(QM"*7E?]82WBHE
M;6LHK0@WF6QW<D[S7"64)8!+A '*,@$(XRDH<IX6<8Z1Y%[!&B_I4]L=->I&
M:^/4M%M=[;:;K5[,&Y*)AW6YY.4#79C633O7IF_]1L5MAAP,ZX%G,:-W:P*:
M17O<C>YZBFJTCP[JAVPDV0.U8/TE?62/W':R!RS'W2C[W,0_*_[GW:9<RLWF
MAFO?N[''4H;64+^F^M;ZITTI+'?U:GDH6/I0$[[_F$N6(E842/L\5NBM2Q8#
MP@4$F<A%!FF,XT2Y\0]>K8O36SDJ2Z%=RCV:><@DN?&])>;'@RGN.=[7#56W
M(QP'_G&<8F-'U#)D%AU,B9[8,FN5]T9[<\8:%?=<_-%&9Z3L_$%'R2M=/PBR
M'0G\U]U_M)3^(#"TD_S#W-!_2OLBE^5J_7&UE9NOWU<U40A+8UI(F *N<@&0
MD@S@-$D!T\-%("<H29WZ+9\3,+4%>/H3ROZ?J-(TLJI&;_1$]%^[Q8\HAK/(
MF.WNY$Y">GE&N1:HH6- ;72T@CT8J4X"X^[4KP5H)%_M#Y27 ^Y"H<.OGKQL
M-'?9I73;"W9^KV??E]UZ:8N>;Y;B7?FG^:GAN"UPQE 24\"3+ &(4 J(5!"(
M!"JB(")9[M?:Y:RHJ3F\O:;VR%#5NGKV<SD/K%L<(0Q< [N]IT@U:@[ /749
MC5!]5<X+&K=URD6#C[JC7+ZBGX^H.JS4YZK[3 ):4"%3%H,4IQ0@R@D@&8]!
MEA6"R9QQD7DE<IR4,C7/T&065"WK/!,V3N/HY@VN1F=@1] T=&\ &B*5HA.#
M0*__:1FCOOF=9CY_Z;N_W.]]W[>8^V!:SNVW41]7%;_9<CM70B7ZOP+P(LX!
MTNM_0!.2@RQG!86(I5!1GW?_HL2I^8%#0\6%;;?8ZELYBY:K):CUCEXM]6I-
M[Y(\TP(N#X&;VP@*[, NY("I579VB,W,HH/"X=R),S:!7,ME>:.Z&6?SG[L<
M]PO['I4JTQC!=D0JV<Y6M^@'Q9":'8([<PQ362A,M,\IL%Y^8 %8(@J@W1*E
MC+,X@;%?II.3W.EE(574E+REM<DUV7Z3EF2,+O7/*_NK;%B?UX<$[@=]*\^-
MC=OPN)Z5!H9\\#-2JV_45M@FP<\L!6C(XU /8((=@[K('/GXTP.&XV-/GXO]
M?-5FO9U_-BDHML9#B31.$PD!C!D'"&,.6)R;!BM9&LM,T)1CE^70D[M.;<EC
M,FG+S;8T'0=_U9Y_5[L0G[*9I[!U^XC>8 P=Z>V'@[,+.&EWURNN+VB]WOJW
MPZO]]%ZCO+HGU6]>S=-_[+=,J!*\ODAN&B/J=?>[QX_E9UD1\OY"RZ7AE9L3
MFN0P313(9 P!,BS8A(D<Q)2D3-""X9CZK1)<Q$YOD=!H&-UI%3<FB>J>KO\A
MMY8BQX3NS)ZE]9&L\E$W>S/]U@A.8^.V1 B-]\#>H4[D/>@[B][]'7Q\;PZ=
MZR$P6D>OC-[G-X7>"P8?F *M%YQ$CKI<\ 'A^6K!Z]I^'NN#7H[<JHKV\AWE
M=M?T02[U#=ZL[K6(N82()45"0<XH-%P^&+ B)P BD24T);&"Q">L<DG@U)88
M1E^3WU0S@S8JSZ)*Z>B/2FW/&MV+L+LYHI!@#NR$KL;1V_VX@A/(]5P4-ZK;
M<37^N<MQOJZGNS'AF6^KA7A__[!>/=I5:G,$"1F$@A$)$"FDB9XP@"%,@$CS
M&/("QSCV8O3HD#4Y)].H&I4M73U=2@>TCMXD#&!#.Y(]5FTU!SC>=8 CE.OH
MD#2NU[AL\I'#<+CD*B:Q=UK+MW_JMW!)%Z]WF^WJ7K^0/__X1:[NUO3A6\EO
MUEH%2UARX+Y*8R11EL4@3E!BF@SE@!"E?Y5YIB2#7)+<CUFDMRY3\S7M%D(-
MH=;//Z*##9$QHA<96:^A<O--(PW P+ZKP=N\>5%C1[0WQ 3)GXW#9M#^/0%0
M#<N"UDN3E^!'NP:R,\QI5]VR;[?&I3V<_[W<?FM$VM/[C_J_P[DN%7%<()Z!
MG%*FO:G0>\",9,#0."*<4B*5\(M8N0F>7LSJMR4K%PLIHG4U9D\.UGV;/3IA
M[^8>P^,YL"=L%(Z^:XWW'G 66:6;]C=/.QRT>G,,<_CN!V*P!I-.0D?N.ND#
MQ'$K2J^K>Y/+47.2]I:NE^7R;G/#^>Y^MS!E;^:,C9?;.1)Q)@CG0)"8 Y0G
M0GLM!/62,"<0YT@1F'JRRUT0.;6E7J-Q)&N5O8GD+F'LNG@+B=S@:[0:M$;;
MZ%5+WZA6.&"8W!V=<%QREP2.32;G", )-CG7*WNF&==-6SY++LM'L_323JS.
M;)S#!+$DS91)-H0 %<HP(A !*)5")@7D#'D2&W6)F]YB:-]I:+U75Z^'Y-:$
M>6DS=6_,;_\G26=)1NRIWO])DUF<XNA?_P4G,/]/NHW^:[>4__HO<0[_,ZTJ
MMQ+[Q:./XYEIIO)058<O'&M8G492Y1D1,D,@)8B9O/$<,)9PP#!)<R%AJIC7
M5!%J',>8),Z-8D!XW6:)4* -/#_L\?K<PNOB>O5UZ,6J"UJA\L^[1(V;ANY@
M]%$VNLLUUS9)?U<NRZW\H/V2>+_<ZL>EU'*J//B*<EO/"QS'!0:0$^UA%$T
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M&%.BA3&X:NEJ"#F5:>I5D6ZU>WNU+EA57Q2V\:&*[@P&'AN<H1X6A]WF!!Z
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M)$L DDR/"U((2%+@3,19"DV+<'=O/N2XC.#BFW'Y7IL1T<J.9J#&&12WR6!
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M7//Y\D\7Z7&-!+_JM5[]T.LW=WQUJ]7-TE6/VM^_^^D.2_5,<YU16F0P%XF
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M='/6YP==+X$CGJ8..$*19J8A-!QU#AH0XI>SS9"B>G('K);VK=T\N0SYBI'
M/OG!36.?]&:6*HPH20M(D4H@SF0&&=8%S+CFB*(LP8R$!:9.B9M>+*K5]JJJ
MR*I9.G2K\158Z$U3I84#LY!/HFZ,S'619E G%G L%('"G9_E19H7F3:B('9:
M7KH0P*B8[T2^)N(1@?:;(V/!-_!DMT/NRQ:Y=SOD/IU +IRTP0.26'P-IT2-
M2]7@8?0>2X///3U;-=:+C8:XL-F9K&<X3U*<"P$)LBX#BR*'U+5NU$8G)$U,
M)C(6U*OQH)BI+<NW6E:K;V#FRS_7H&K?:%S3F(JS<0W*A9P_JHK)%6SN-+BW
M)CVNZH,+NTBLJ?CG)1?EO-R4H06W1P;$S\E<#O/ [F6'<*7A57NT$W&I>QJ#
M6,T=#PL9M[OC24/WVCN>OKJ?]_BJVY83G\W'Y>+6=01\J\5F)A.D4U1HR)3+
MU,U<^7<F<IB23$AF$,J1"N-J.2;*Z^4>E7AEJZGS!F*Y6BW_M+ 'NH&CR/HY
M@HO0&L<5[%1T.#DE8=50TJD9SQN< R*2/S@J9E2/<,[8ES[A[/4]8VT-I^'2
MO"\7Y49_+']H]6&QL:-?BKFNTX_>/V[LI-FEMF]8[&X<8_*-_KGYS9KVWS--
ME:3$"(A38S>/" DH6)'!3$J49B+)4Q/6!"BB<E-;O[2V@<_F68^'EA,2?-5S
MYP#!S1)\4';<2U,Z@\#._FV.WX=JE5,1(]A;PGFB8KX#GM&T5QK9H0-F[:!:
M+UD;!BO+#@U:;=WAL?]>60B<B:"R,68X; #H8T6\8JHV;E!K %#WXE9#R.@9
MFNHR;M0QL:8T49JBX(CGUN<7!<1&2L@E%C"1A$A<T()G05/ 44F3\^=5OL.R
MKC;^S\!HT%$X/6,Z,4 :,9=@FR.PB[FV?  1*S^]T8D5%3DJ9]S8QCES]R(4
M9V_H60VSM&_#II3N)*QYG;G,,$DXA2DCQ!U5)9"*@L.BR!7-#&4L#SJJVA<Q
M-;?0:E@=T0:6M.SCY^<.+D-E8#_P#) !OO;CQL<J.MD7,&YUR5$#]\I(CE_9
M[XN^657'IT^5IW"TYWJ6\522@N8026WG^\+E4@J:P-1P4Z!,$UEX=; Y+F)J
M7_2-BXE5O1;<*K]F) (KW3(Y*L?IN'YT\9C-LCISWOT;>%@M;U?\/LP/'$#=
MSP]<AN7 ?J!5KJ;LJWLI1&R$<-SV2&[@@(!1W<!Q U^Z@1-7AKF!]6HSNRDW
M<_W9?%BH\D>I'OG\G^7FKCJJ<.O>N_+A9EDGB%OGP\O%3$EL>)I9KZ"D<<T'
M*&0I95 R(70JL4*I5X9U#]F3<QQ.?><S=@: [[6JGH0P?0;@M*L8&-:A?4@?
M1+U=R078G/(Q]K$=_V+_MO,M?22.XG0N@*+U1I<\8N0RDO>\7%5^\GJ]?KRO
M=_3N%,6E8OUCZ;2=6QU=(M<LDQ)G25% E$IWXDT0Y!B[="E*B>9&IX4(), >
M7NOI95VU>H(?6T5'JA8)&&O/D^UIC=^(ISH]*T2<W?7J#W0LOP+;=V)G?)7+
M.X'"D/"A>NV2D "-_QK%(.%#$*T,I(?H?A.8RS-?<;EQL^2;Q_7&;N=7'YM<
MI:=KL:[^<<8((P1K A53*<1IKB C.H,L00G#F2)V9@K9@7M)G=K:NE6Z?RZ7
M']A^<T!T" ?VXEOT_K0*@U;C*[#5&7QOM8YX4A>$4B0'ZB=S5!<8!,-+)Q9V
M<\]S?+=8UPNUGB&%[5:>*8@D0JY=-8.L(!3F6N29Y%2RC(1EBFV?/;W4L*UJ
M0&DYMQ.!)]'?/FR>I_9!4(QT6-_J%/%\_J69L8[EM\\=]S3^I3E[A_![%URV
M&+"[YA<- -_;X=[<5?TIJ1&I(H1#C+5VU3L%%(DI(,L)R42A%,E,2!V)C]"@
MI< (]23^Q--!T(;-_+$ &VGB=P=G)QN .NWCS_P^*$6>^$^*?)5YWP>$8].^
MU[T]N>':9L;OEZNWRT>Q,8_S:RFKLHJO6NKRATLH:LG,J,@HS;!=&62N$1S5
MUO$(K"%*:&XRB@U'08'](.E3VXQLE:]*4:1=.92;BMSRJFGP&5C1%C84?HYJ
M,( ']EBMCF"GY!5X#OB;&O"/%>#Q^>?Z !>+D"Y(]K@,=7U@V:.LZ_60J"TO
MJX.=3B;4^MU/O9+E6JM92D4JM.:P2$P&,;(K+)$C#15.\H0RA5BFHS2[/*[#
M]$[NC[6Y;#1VP;DF)W+7W3)*?\03 ^5Y4#\D^$,?NY_HB5@9<-5T0FQL %LC
M!F^&>!Z_8=L@GI _A0:(Y^'Q;'WH\:"1PZ;[K$B;.[VZN>,-:]+:>G6CRXU+
M6F\:&2"2%RI+!)0RI1#G/(','6 +@2B2=BF99SBP3?QXVD_OR&JKXMB=\GH,
M_<#1U(&&\R\35=TGVP,5 F!C(=CUWMN],>4B6AN,5QR\UXZS]M#\KQ%O[3\D
MT>*N%ZC0DV_#/?_3<K%LR_$=Z>V];@JJ9C1+&4Y)8N<M]Y]"%I G)H'*_C;C
M0G"4>'6X\A,WM4..2ML>]#QG0#58*4:,@LAMK3 B!11%+BRH))>(&%-DQJX(
M/!LC1X!T.X$/WMUX&$#]YMEX[][ 4V,]B74U!;6JX)=&V>-KGG!Z$B]48M&4
MG!8V+EV)E^%[M"5^=_5SQL^(-3#E A?(;A14W5[;0$&3W#IAC#3FF2 I#CN*
MZ4N\,<XI2\6XL7&,&\KJUZ6A8X%+_.<P<L(%-1AJK1#$";;.5C(.N;2N-N44
M*96'A O[@CA&6/  A!<@EU"34DJE_8R%@)BF#'*#[%\+;A<#)E=&\9"YOS=R
M8\ST'8[N^=+N'@2?NT/:"^#SFY0F2H8S%/W-@)0WKT=SXT-M$Y'.YK?ZU?QV
MI^UZS2'NMA8_R_6,L-S@5*4P(\RZ.BPTI';Q#I6QLP>A6B8LJ$[QF*"I?;R-
MGJ!2%+2:@N].5\^JH[/8^GW-,1 ;^,ON!U;PAWX.B4@?_5$QHSJ <\:^= 9G
MKP]O:?UEN=JXP.'GGT^W>O'&Z>W2)^P@_?:X+A=ZO7XS7SI:R);#A(A"&H&A
M$LQ K"2!3*L"$JIR21DE:9[YMJX.E#TU]]&J#VK]0=< T%H &A/\&R&'CLAI
M#S,PS@,[G2"(SQ,F7(RU?W/I 3$?J8ET9.R#&D7W1.]$0^C0)X[6^+FGJ=T&
MSWT?T9<KU1TRRTT5;ZVH^"LNOFNY*7]4M25OR[6LY>V8[UB&6)Y3!!6C=MK(
MC8!<Y79CF&=$\L)1O >=!_=18FKSQS,;6GJ[8'K5'H/AMR8=&N*!IX[GZ-9]
M2VK2R)T%8&<"^#X(H> E($:C=.VAPLATK_U!VJ>"O>!9?:L/7)I7E6Y2!>?6
MUX^;N^6J_)=6,\98IKBA$!$E[-8ZD=#ZP00B1K"DF<@T+<(*$(_*FII[ZV:_
M7;5<0'RK;L\TC%-@^_FU2! .[+X:]!H"H%I1L-,T9KW!63BBE1D<ES1R=<%9
MD_>+"L[?TL][[)&4[OA+ORSGI7R:%<(DB%JG4622.=I0#BG#&=2:XT):QY(F
M,BR@<U;F]*(\>R3!86[C/,I^SB,J<@.[D$.\RAW>Y2M0:PR^-W\.L@#R!BR2
MDSDO;U17XVW^2X?C?V//$B8I5X\N&\A%H6_X3[UN:V1(D2G$L(8D,Z0I5TH9
MACG5).=49@P'=CD[*FN*;J;*E]@X)<$#?ZH.0)KD_"QPJ7(<8C]?$P6V@7U,
MHV.;9U)I.41AT3DH8A41'94S;L'0.7/WBH/.WM#32U2^YY/5NG[<ENLC8:;(
M6,+=48[]3Y%12*G]#V/8,)/G@M @*O-C@J:VJ7$MNQL5 :]T#J0S/XJHIT^(
M@-/0+J%9:^R4'(0AY1P2L3S",3'C.H0SQN[Y@W/7AP<*O^KU?>5A7-[GA^J(
MV2Y&JN3C#@EWDAF%->(P)<)Q_A4&BD*D,#>%DA@S)@KJ&Q[TDC@U!^%T#> S
M]T?V?)@O.E[#G]#>UTN'"K2MQG69AB<'>D\T_0-YT5$=*7QG]?Z]1A=< &]0
MU"X(JA.Q.K_GC!:A"S*K&Y<+N_'"OJ=M_&@FB508Y01JF1F(>9Y#00H-42&H
M43E'5+&0Q-4]"4$N=X3LU9IT?I?SKGM%TO:!]%N1703/P!YVUZ7T;'2Q?WO2
MEW;'[DRZ??[K-"5]:=[1?J1[%X83R/_.?Y;WC_?-'(5S1O/,+I[2E"*("660
MZIS9I97$-%49HJE7'O7>DZ>V9FJ4\^=Y?X[3Z>_T(NL'_CX;O2).PT>MO8!U
M_?GS1N-4/VA&ES']\ 7A.YNWS8+,-22O&-8_+,QR=5]G5[;;\SS!229583]&
MIB!6M+"S*G$<CQE2>8&D4%Z!7%^!4_M&6YV!51K46H..VCY;_'[ G]_WQ(9S
MX(_^U9#TW_/$1G2D+4\$9(/V.R$PG=CN>#UFM-U.B%'=S4[0?;UC5H_WCU4^
M3U5.Z6KD5_K.KKKLMJH^^W;$9I_TYK.YX3]G)$>8<9-"1E@!L28$"H,ES-+,
MKJQ(JA$)#)P':C"]^%;' +"LRH5EUX2*B2\XRA4T*-ZQKZ& 'CXBMD6X+LA^
MIONV(MNI_^L5L!8X'C!K0]1H61_PXL70@J2/'5GK \V!>%NOQ_1DG>)SO;ZQ
M]W[4?%W_9\?X-RN82AVG!DPUEQ!S9B!%B$&592:5B/*T"&LL?TK:U):E6\K+
M58?R,KA\^33 ?AXK&FP#^Z=*3^B>"RHEK^H_.IRA$4F.?#")14MT4M:X1$(^
M9N]1_WC=U#-#F:_O[+K,_>&(@GY84?:;N=Z\X:O54[FXK1MG%EHE&"<&(I8P
MN\7%%%+--"0J5[G0>2I3%)2K["-U:@[%:5M5"TCW@][I'9BF[(6XGV>)CN/
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MN2L]?7 O0=,24SOB/YUQ:)+,'0]D">0"9]!@E2I.!$78BU0H6/+45J2M\E=
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MH6M=*P[P6MLV$?WC,/B%!/\CXCA: H /GI$8R+P!.ID*<.X9(Z8#>)KS/"7
M]Z9^N^GWY:+<Z(HIZH-]>VJJJ%J273C;+?R_NCSHCK;XYL_E+$4)3E.F8*&P
MJG?7+%<*:E0PE@K!<^*UE+I(BZFY9?ONX;#M7#_P_;9W@T,ZL.>N]6\XS'86
MU$ZG;NX@7?91UYB&_]P:$F^[=Q&.D;9__708=3MX$4POMX>7/:QOHL/6T7:G
M<XH3A)@JH$29H]](*60\3Z$@N4ES7C IBBTOFG\UYF%I7I_?"R:T$<HLMY/^
MQD[ZO4.<1P#V\V87X/4*"\V.BE?@DXYX^'0:AVCI#@>%C)SM<,K0_62'DU>'
M[T#_OERJ/\OY_%K^[\?2/OCMXZI<W-9GY2^)TF:4*)HG(H<T5R[(*1+(BJ*
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M]"QAA;'['08S9'*(,3=0),1 DDCK591DFDG?75!/':;F8K9F@%I=T!H"K"7
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M\_3%O@:;ZT5UGO+@YHZ/Y4)7CFEF$BURJ5(H"MT<9G"6%)#G@I,LQYBKH/C
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M# M,$58N]&4QYMR(RUAJE(:>MIM[?5_'_30;D.TXR3-T([/1P=H%: "L+5X
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MYB<BHBI FFB"V C%<+V$T1$'C(5D)(U$*C.KW%N70>=&-,]L!L;H<JNV-GN
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MOEGO].WNA-B:;GK5_\Q>'5HBFHDP#BC4R\',]$C.(&-9#,,XR<)02A62V(8
M.T>9&\55AH+:Q$7S%U!N2'=5/S@ V\U=WN :._+JBY0U_5@A<8%@=(3]E_O-
MM_^FKZ^X1?_E2"G==YV$-*P<:VC![L-#DN5,7=I^][ QO/)Z\ZA#KF5*"(E0
M%D%)5 AQ:EK_4KUV2Y*4B#05F#'I$OQ<&VANC_\QL0H<+ 5_5+8ZUFU<Q=8N
M=/&!V,@,T ^LGLEHUY'PFFEV89@72".[[NSE'+&.S[NKDE8KLG?K;[+:D2Z6
M+(Y"A22",1*ID0PTA:2"094&.@@(2$I1N*RREK[LZ';7S0D7QW#Y6I^.--XW
M_!>Z,K71@.[*XRXF[_.U40MISK]<,K4N0XM9PD02QE#@A)CSQQAF1$@=;@5(
MT$BP&$<UM&_6-[JL>P*V&6?$XRVZW?XP,'ZCJ_T!7;D6_G#M)MG!2$VSJ]4R
M;@@6]AJR@S"92$K6 1LG/=FKOG?(RIY?,YFZ[%5SVR*SUS_DGEKQ:;L1>[[[
MN/TBM]]R+JNN.RKD%*$$DD!ITLITG)BEBD F">,A(:% 5M+]UP:86WQ8VUC6
MH=9F.O?<N0AD-U_Y@&=DRNJ!C%-*0I?[ ](.+MYVLM2"+J?:Z0.=G^N[]-//
MBZ:%^D!P&4E!$(U2&,297O$%(844XQ@&F4(JS@3C0KC6/CT;P>6[.DUZ9V-@
M(ZX*?JK2 :I$ -?5WG,X;1=YO2$:?6U78U.;YG,Y=]%G;ZNXYW>?>/%VT;7S
M-=OECTW<EOICF7E4F-ZI4MRM3=ZY-%6:7S=_+8V36YX79IOY[OY^*^_I3FK#
MM_FZR+G1CY++E"=<A;& 0C(*,:.)Z=NCPX D36+)61@3J]S)%_=D;E'&P4R0
M-W;62Z5Z?5280EI85@X WJY4H4>P"DUK!\<7X%L)3OEZEC4\1M['_'BB;MJ#
MOV]VG/HO\2T:F;T]5#+5:"S 7X]?G#>M+X[YL:EW:GW%CE_; S"ETIS'E\>+
M3^Y+-P,?[,>_1N=P7]/EK<VX-X/<]V/?7ZR<6*WT&%NZ.I9-?%1?'Z1QBZY_
M++.(Z*5WF$*,(_U&YC2%3)  TD3&0:I$1A*K[)6^!LSME?J^+B@ZJ<Y:Z-=G
MX\BB7=_5%#A4WMCOOO6:K-N;E6-/P<COH_?7R[F.Z'\Z0__5).C;;X^./0L3
M[:".-!M.NZU#H.S8D.UUV\GV;(<XW=[6'72??JO,YX.56Y:2B% (+"!7IG D
M2V*8BHA#@?3K!2511-WD9<^'F-M+Y.2!<=KY[0#2;ETS#)Z1"=X1&>>X_[KS
MG@+R"P-,&BE?=_ TA.WXY% UQ5JQOM7W^23KEH02L50R*$E*(28H@)D*]<//
MF4P($01)IYQH^Z'G1@7/]0^KW@OU?EYOM<.;\%MN@(P"ZM@[%@V>FR.>+;LG
MDB"T!<R[NN#-@5](.- 6D.N:@-9WZ$=>E_HR7ZA^0FF*"-<KX0PCD\L<1)#%
M/(()"4(DTAAG*'8[W;(;>'Z'7K\_+SDKJIHS6?QLU$P>CXW#Y6FUFANK6<Z+
M':/YQWID-KO8@'W\DC0WG#R1F.6@DQ*8&Q"GY.5X=<^HBZXT%>IK[];B=;Z5
M?/<V7],U;RH^BO+/SY++_)LQI2FM^KKYI?ZI%&=M*5B<(IYF,<RHB<\R175\
MEC%(8BPX3HC^/76*ST8P<FZ1G'N'D%&FSC*V>^$)&3L*-.Y!XU]YWE1Y" XN
M5O5OFDBK:L.CFTVGDL;%,;J5C F]KWAR#!.GC3Q'!/DL1AUS+/=CGD]5IV>3
MK+G6W\0?2TWAB12I@JDDFLS#D,$TE$23.6,A92E1$ML>X9S>?&XD7-L'\MI
MZWCS(G*WSU.&X#$R!S90'&P; (3]T<800"8ZMK 'QNDDXIKG':<,9Y=,=H)P
MS=CVZ<#5S_1=8?.'?"VW/\RIMUX4/K5$V)@*:2R)A$S&(<0BXS E%,$P-@<
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ML60AD9)Q!64<,T.-(4Q9'$&5(I&1.*$TMI+<&LW"N;&GZ3*G8X=2,P/0@YE
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MG=_*L#&Z7/2US'8+9FP MXM</(,X,BD<T*//T3LJ?U8F@S_J_X^2;^J F:>
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M2BJWCUZ-1N4NWY:'KT?5BL.+3P<""4:20)*8XPN<FGTU$D.12D7#4 8B=>I
MZ3#VW,*(HZW@ETKFL7]/))<IL*.AD8 =F9!Z8NHNY>N.CB\=7H>1IQ71=8?D
M3 &WQRUZ]N?8K._U,_YH7F"F16^]F1W)  5I3"!'AIU2FAGYL 1B1:E,:<2D
M=.L9<7&8N1&1L1(:,X&Q<P&,I8[' C=PM:.<X6B-S"XE4%]=@7)O$=&)@Z_N
M$)<'F;8Q1*>C9STANC_=LYEC?7IX['^[5*%BA"ND Y-(0,P$@9E4*<11% 64
M8XY3X=*RX7P()P*8H*W"5S.&8Q/&<]SL'O)A:(S\@#?&M5I9>VRE>-5S7XT3
MSP>8MDWB50?/FB)>_Z1[EVD=-;!\+<6;_7;S).^*G.K8H<S@^HUN_R%W!ZD%
MEH9,1 GD1)A3#JF?<&ET7\($)Z&B";7;I'08<VYO^L9L4-F] ,;R\M1C4R8C
M/E;&VS=@ML6^FQM&0G3L(\WG8%98&AV=*K&S-ONVR$)O4.T;78\ [D2]KWV!
M[-01VQ&NCB;9MG>:K&^VHVOM5MJNE[HS^9?]TU/5ZXNN?J$KLUGUY4'*W;NU
MVFP?JV5ALXM!"(Z".&.01S*#6' &69Q0&$0L#@*6DMCNS-IQW+DQ>MMT4-L.
M2N-!RWKG?277V;C-[R-A/#+'SP1>>Z8?">:)V-X?W$Y\WP.T#LYWN=MDO-_#
MQ3;W][F\;W4$W94#?51E-O##9J4O+BK%@\,#D;(89R)!$"6FN2MB(:0LUE%]
MDF2<I2K,[)(&G4:='?<W1I<Y\RVS_VLCQ-+W.,%N$NP6_-ZA'9OR?:#:HPK!
M 25OU08V8TY<5>  PWGU@,O%7OO>'7Y<"T?6AT]WN[=2WYNNC&E[_0WX\:P!
M^9*$3&(5!9#'1AHM"#*8A7$*D?Y%'! 6\<!/5[Q^]KD\E=,4=Y5MNH V\<DT
MH0%T!XK&\JIIWE:;[:5;7L\9M>/$%YNED;G3MM.>F;C:)W!PZO2:R1KN#8-]
MW'9\/6V;0[.^8;!:MO(;.$B_E\ 'N3/M5S]M-]]R(<4O/WXOC/Q,E5]3=FW1
MST!9,7R(E5@2IBA"& H61A#3D$&6D! F(L&)%"%.(Z>\%W<3YA:]ECV:U6KS
M9P',5PJHQG1 #[;_NQN5]Y@7.[X>%^V12=DT32_!;LPWZBH_&0] OOX9')P
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M3"X?(7$T&L@Z#=R-LVQ0MR,KSUB.S%+/8&S9VR0L>A22ZP&0)U:R&7%2.G*
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M$WB;(T1G*3XOSA'J#PM#KA8;KR]6$RW=B#OV%.'8(>@9V:_/F_1-LI0RR\#
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M,A]:G]>/T3-.A#0<H)K)?M12@ MN7I$C.J=?^4Y,3%+65IFBR5;75\RV(+C
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M@_Z&GZ9IMNF3^FQ*\@WEPI :C*(D;4'78<-*<%M+UCA8U(*AC5*G;1Z(/KC
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M-D)@Y!))G41RL5ZPMMY.CQ+4RXNJ U1^&T;-Y-\#F,YH/Z_Y,%)P9KF$9+4
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MTU0',<@OY)#.TC1<O)^1C"XK(^M>4A)$\=X:8+(N_3)U;(;W#!@FI77F!OD
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M%[4H^I?YXBI21T*NK]50S-04050)8D8)Z#79<^9BMMU4IK_ RVY'Y+6F'KM
MR*COYU<S;/)EJHR_G]WGZV,AL7S;[ VZRV1-E56O;T)!NV;%U>>J0,+/2D.T
M/ "QR*TE+J-[:<'"<13LAM_7EL8\H=9&1^?FW?0^C[]?QO_!M/H\7POS.KJ>
M($=K V;8=$JAAY!CI+.7K!/,&FUV>=[>XRMWP]]KRSD.J9>QNV4W_-PY0]=<
MZ,*9<,Y!RI9B EYJ3Y16('QP(CB6PL/L^/9VV2>_8;>6AM>6OFLH]7-V.J]F
M;KR?+5>+RW6#WOJA\//7,+M>:H;+51TU=Q6A?IZOPL4O8;JXJM*7(1HF$T*,
M=?AY0 ZANN8ED?#J\V(JK8M\Q^%TMS/RVK*)9X2N<SZ#&UF\^PL7:;K$Y3UQ
MO)^M%M/9<IJN9**<*%84 =YH5T<4UZG2)@(*;EWD1FC9?+/O"?C:[7R]MA1G
MM\AY!:?I3BWO T%$'KWV7H!BII;9('F$PDKP,AIMBPH\]':$GF1FMW/SVE*C
M?6'DO"L1[YN0&K/?%P6?N(R9AQ# A#H7-$4*HVQ6P*71J9CDC6H^2G,P;G8[
M,*\MU=H92OHY,4<8CRO7]<VLUG%B6M5^SOJC.R)Z\^7+ K^$U0-938QE03A6
MAP\B_<**AIAXA$"_EHC,,:D[NX .9G:W\_;:<L*CBWTOC/4ZXOMC(5INV@,F
MADR(*)*#K"]YJLB:W> .DO5>QVBX-P_ZF/8;]7W_ZW8#[FO+X@ZECY$A=K?\
M^8:CQ33AO;>_7^?_OGJ<J$\0?P^+?^%J?9CN_:6/LY_IM'TL5QFWR%TV67,H
MBD50(6H(3J\KZA@+W)*(Y0Z8'(J^W4#\VO*LW6A\]"S6 %*X_IA)4*09JP4X
M5[?:9)& ;AP$3[Y?0N&%3;N8XP%)W W]KS%+VXO>NW#T[S!SDRY<IL7TRL6:
MJ(R*62164-$U%JV#D(0%2T&^#BKX1^7 1WOCSU.T&VQ?6W)W &UU@;XU)U=-
MWC]?WGI/5[P]Z6HM)RQIC8E+$-6G4IG.6JP-X4IEE2//S/F=5O3N.PIJ?U)W
M&UWVVO+'I]1O)\4)U_[_<E**"D*@ D,W 1W%X,!+:T#0K]IQNA]RV>'N?_3!
MNT'IM:59CY=Q!_F:-Q?KOX-YNQ#K \:,O >#'JUB F(=\ZN4(OLMI8 DM74R
M!<S8>B;3;I3M!KW7FH$<0'L=8/+&_.+B.SF_VWG[,)]]OWIF6Q>/K5.G=__\
M[7RY^C!?_6]<?<(T_S);UZ1SU);SY('^@X/R4H/+V@)W0='1)&?$M+Z=!V-F
M-^2_UAQB'QCIPE4=3!17+M$O\\7F1_7O\0F/43E/UB.'7/OUO 2WWE$:- LI
M99\"/Y<SM)7#W0[6:\TU=HRFAJ?M__OO1\HE\?UK_4?K/ZG_[A.6_Z?^_Q^?
MWM]\PW3-^'SQ7XOU+M__2O-O5]^QCA6^SB\('<NK^KG;_0IOTFKZG7[RL=3-
MKHMI30FM__X?)(;ES[@*TXOE?2Z74]+#2]T0QW_G?]]R_% 6FZ^^A^U3<8^;
M_LK_MT$0?X\J B6^B41%2*M)K0>1R2I@7",HEQQ$Y )T8HJ.B-&:M;9DSU-T
M]*-%LXT>,F6*:"G,U;$.-19T-CUFN@213I4-*OO27#2MB!][B68SS#UZLQA%
MO1T$!%>4TU]>;VW+R<N2(T)@,M.541AX'@J@T9GN$EX<;UW8=(^ D?$U#@@>
M!IX':Z0#.!TNN%NV9_G!>F_K'1<9Z]QW0S+@%#N$I!UPQ9C3T9<D!BFW:\S'
MN. ^ E;[EO ,K>,.<+[-W?KT^Q^;'7%.2<=JT5^1M4U#10=!9PW".2FU2:&H
MUN-;GR6H\T51@^-E/I3R.D!B@Y@V9R$#6@U6& /*4L@8/-/@6&;<66Y$\ZT
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M6]<.U)NQ@/<4'71.ADR8]%F 4B%"=#I <"5ZJ3-/J9O-H<.(X$Q??D9.;G0
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MR<=[H0!YU)S<?.9LZ.PD[LC:J\D*GL-)' )NK^)&?#FY\ZR\3);!*1(51U]
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M "9(N)IYE*7U ^#AU/;1/=@",R_!<1@%=@K5JP3FV[!8_"CSQ;_#(B\GF>?
MN?3 ,-2M7S:0XRK(W0BN1!]<P-*Z<&Q'TOIH%SP1"(]538^(>T]NT:R6 T^\
M<2R(I$#&.AJ=B0"!!5NOD90QQA1%Z]T^3U/31^/?*7!UF *Z>C-YQE#7^LK%
M]W5L_B:EQ66X6/Z3SD^8K7Y<_]%$).^3KJUESM;W>"TAAA# :^'18-(AMYY6
MTH;R/GH$Q[F!6ROVC %]4X+YRWSQ\_PRKLKE!?U939DO)TP6Z>M$_V1J[LIY
MI/M!!3#*DWLNDG;-*W':<S%N'6-W0&^F\#Y!OYG<._M2A_K>]W9*3BY85OLR
M"C'GZ6Q'S15PQX32*J$.0Z5==B!OW%K'4\*TD8KZQ-_;\.>T/G4^8LVXXHN)
M ;)SMA80V]HD5+TD#"E'Q8T=''U/$3=NY>(IL==$/7TB;^>'AF?*-&60RBF)
MX%5=X2-%JK(F'TA'PTK=TXU#S5)IR<>XQ8]=OBXU4GJ?T+^?3YU8+*I@K;'R
MAJZ2$F7=,FF!BQQE4%'EY@MO7B!IW,K'4P+R"%7T^<+TVV*><'G3:TE'ZF?\
MCA?S/[^M2T629YX.#R"KR5,GB=,<-46).OMH?62\=49K7QI'KHT\[7-4.VV-
MB,9:[?XX:X]DO._D<"?9"UXP!>"!>Y*<R^!S*F2V&1GS.A+X80/LUC:#%[]H
M-_R<4ZZFO7Q[-%U7Q>8Y<B<X^;4I2PXJ2@_.:0\"33&,43S/6H^&V4[);C!Z
M%=F6_27?IUNU%M'$%)VT50&\M;7V*'F(F2*C;*)B,A*78?#\W9J2W1#T*O(J
M^TN^@[%UN_3Y)Z9<"$E $G5ZN.,4:]2LD4Z*XFPA<\'!7T$.',LP2I5IT\J8
M(_719U5I+6$,L40FI0/D0H'22"Z=Y*4._4-D=99D\^U8V^CHMWZT*8SVE7A?
MINF.BW<CGA29*IXLMHEU51_7 6*@WUIMB]-6!,\'S'-MH:C?.3&-D'2L%OIR
MN.]P\[?Y//][>G%!D>=[4MGL2VW_O#HW$U3>1T]QA!")D4>H$U!HH:$X5 JS
M+G&PEHN=B>RF,.]HA.P$OE;J&O5N?!#/WF'OT_3+U]7'\L?RFB=R4&T,40$&
M<B15$>1<&F>!0I2$V:CDY(,BT9<>#9[YMF[JZUIA:2!!]^98W>'KM\7\3URL
M?OQV$=9MH^_^S^7TZBT-/<_1RP@EUJR!EP4\%@NE1,TU3SQ%=Q)C]B2)W93A
MG<:4M5%5QUB<&.]<H&-%QTGF^B+GP >G@**6XFP)QL@!W[+V?1(=931:>_=L
M+ZD?BY[/PSU&/.AZ$U8FU&20"TM(7/D"L:8"A*Y/*RHZUWRI9HONPU&&G36-
M'H_0PWET'WZHE:1U3E&3WL)'GS9 Y^#S%)^@+S %7T(*"K1F@@"F$CE+ENY&
M23^763&,K=?M#= 76+W#.U+]'"B4F'A$'@2A.G/GZVC>>O?*!,)8I;1"<A'%
M#@[WP\_MMY=O'UW>]:N/DEP'SP&/'U=KU>UU >YG^I0W?TV7$T51I5;)0Q*:
M@DJ&&;RB>S7D;)F.,;9_:MJ-LG$0=;SFYX.KH7MP_3S_%J:S";)H,D<)2H0$
M2H4(%& 4T,$(Z:+%T'PB]BYTC6NJAL##7I [0#E= N[IJNV_X[>(BXGPVF:>
M)'@9<LUW.PB>9<@F698IPL7F>YOWI[)G,!Z"E!>AV%1M'0#SYK)X<[GZ.E],
M5S_6Y[?4I6Y1UE2YEK63M19;&$Y>1V*&,43C6X-O.R7CO'DVOT8;B+E+L&S.
M6";)%.<C"%%K<PQ:\$4I<)%D5;QEQ-7@<.GA>FRAYQ>A<X#0.P /44V1\S2]
MK:UQBQ\;<\DT"LY4AKJND@Y5". 4YQ S8R8&9:5LWN^[C9#>8'.(CA\^%1TM
M\ Y0LYG=_X '&VU6KG;#8ZB;*2U$9NA,A6 PVI(=;UU"MXV.3LJ<6F+F:'%W
M )E[V\3^U^5BNLS35+6R84<ISPM'!T8% <IR#X%%#SQI8U)F0L76-7,OD-1)
MH5-+(+540@>8>BRC#^';5:AK<EV*F 6@)@$IH1/=[73!J_C_M_=ES6T=R9KO
M\U^R;^W+RT10LNQ1A&QI+&LZY@E1*X7;(*#!(IO]ZV_6(;B(Z\%!'9RBYT:T
MU:1(H;(RO\K*S,I%N^1-)#'6SD)YFIIID'0"<WD0NYL%SOZ 29HR2^4IT)<_
MI,2S91R%4+)AM":4RM- ITW3>9C,>T%I@  : -/9KCP*+.:NS./H!/,QYWE(
M>YV:E4V2N02)E#[+EBMPG%E@ENAL'-[2U<VBYREJ$5!#)+\:30P35\7=4=H?
MYLOT?ILN-C,=N=.R^*DTV](YPH*EB0$1-C&+MW3.?>;M//;9T^3A5KN>JK"L
M 3WR3,<0Q73V7B?@A*"J32*#"TSC3D0RR"^+F*ZL0X[LX3+V&]I *:]&8?G$
M^N+I7=QI!#)CPD63>1D(E1->UXR"+Z.A1,"O"3&)W&\,]*@"Z;58$_'AXR R
M#F,;4#,W'/I?J\4\NLNS\_-UEY?VTVJQ<.O](#&MD^6<9 B:2/0RBR*F-((/
MVNB(?YE3;8W3B[ F7*DZRJ>^(!I$U\WWURU:/J5UUZ5E1BG5D: %%FDJK.,$
MO/49/-?4LXB7O:W=S+0W<4U81..@K(Y &D#:EV6<H\4_][MMBN_<>HEZ>O,Q
M[V.EGW=^,X]SMR[)O2**&+7S0+(EI>>TAE+T D(0G9R,S,G:#V']J9LFS7H4
MK(TDDM;Z!EPG]U[^MMJ6<8CGR_F_4[S2UQ_SE^7ZYN\>^T<',$EJ@6J>1>!,
M1;0L.$59: VTY QG(Z*6(S8E.-4VITD)'^4 M Z2B1T5O&I"D>UY^IAO>7)[
M%^'V'IMM.W/&<*:]!DY52<T/*)+@&40NL[(VJ,!B#]=EX/+3](VL[LR<@OFM
M!,[>_>4NYLNK";5I^_[BFPMXZ#ZG[7:1NF*QH'C0*F@(K$RGC0FM:ITY6*6\
M=3::J ]*6']IP6EZ-5;'T#@,;A U76N:.]N),F06$@4I)#*,*%H<L!(]5M2E
M0*)7<B!>[BTU31/%DR#E&*8VX' \MJ5/:>D67<EK5UJ?4%S;?8O268PF*,TY
M%!#@Q9P26+RCP; 4LB&E-G:T.6#]2)RH:>*X?NX(TFD4?#?6XN\I[Y;Q+/[G
M;K,M)^MG9/7M.?OG?/L5_R%:D#=/;C,5E0U2&A"<D-(121=.._!>:*DI%9Z.
M%GRILH.)^C6>#+HGDFT#R.[Z")9VS>OT%4_F_'NZXD>)K5\GOG738</E'VNW
MW"RNI'S#$-S^+"EO@I$$B$.>X[X=X$(*(O'%_B!)L-H!G@ID3]0L<IR7M!-+
ML0'@WO#P:NA8-W[D9C^;6531>%*"J'C>\!A& 29: RX3+AWE$<W@L53LHQ1-
MU%ER7)5Y/.\;]#Y^3Q?S[3;%G_'[Q2=WV5G+@GE./;I0&BD H1A#C\HJ(($*
MK2+WAH:!+LACZ_5#2]MO(*/QMT',?%K/5^NKC96*N/VN-K.LLI1$HS4@8@#A
MA0"?-9X'J8B/$0U?ZP?"YHDE^R&G[1>-,;E<#3SU&WQ\3N=E/^^7>;6^Z#[P
M1Z)[]?5XY$-JM?-XB;Y*73SVR_R>OJW6)?WCINT#E^@<E@)J5F)9PC@%ECF\
M8:1CB5'M;:IM9SY%R]'U&/<^][;)Q1_(Q3?XJ_^:Z9R4$'A>E CH(^-E"E[C
M-9ITH-:S4G90>\1(#[*FS5^M@HT'=1F5A5'QQ?042J;+_1S20NC)CQI/X3Q&
MZ]AJ1YMLB D$F(BE1Z<K?8B= V88+?$JF:Q^+6HG?$UQMTCEL>#'%>[P^,WE
M_H>WZ*>6"Q[QUG;!E\QPSL&2TN(/^8#WNM&V>C[:0%(;54^'8.B!>CJ!T"8V
MJ6^W^'OZGI:[=+.=3^M5W(5MU\+B_%H!W.[1,$V$81F\<<C7E%6Q+A7(&+SC
M3H24^]C70]>?MMJU*MI.)H8&8D?[W95@[CN\/-;HA[[=X0UT@2N\N?PEK<[7
M[MO7>3A;)[>YMU7'2J/34@!J&46' [_R!'GK4R14EX:KIG;L_@ARIZVB'44=
MGDIX#>#TPVIY_F'^/<6KMI8O[2X3BRJ?">"$)A!<.C A>> \9&OQ9-I8N]_H
M811..W)@%#2.**)7%:FHT)&TQX>.YUB<I#_IDPC,7%"4O >\+@T((LJ('!DA
M.4T3=28R7GLF[E@NQF^[4O#Y,=]4[^P7VLRH(\I84>I)O2Y)QP)L1)O!.BDD
MI8QY5;MWX)/$-.HF'(*#^YJH#N-?E=+YO+NX<.O+A^9J9Z>&U3+,%\5-*H'H
MFGIIR+KCJ:ZCN3"Z=M,Y<,(\*%5B<\E3L-XEH(Y'1VW6T=4^^(T$4+JJ:BU8
MDFAW L\*#[5+ HSE"3+',VVX3-Q7C^,>3F:K&O$ [!P9.#E86 UX"%U+H4+]
MF]UFODPEP?-*Z7<]0@+1V=.@0(G"/,H,F"@5I!1HCDHQGZJ;%<\1-#'&QH;#
M8^V>JLBF!:!=T;[O%&*E49KE"$88 4)U;ZW()2.$X30FH57U=F%W"9@82/4$
M^_A+U  N3SY*_/O\JM/PKV[SK^N^ORE20?"40+(!3T\V&;R[FE$L-#?&L_O#
MZ)Z8!/;(AS=Q7PT1U*HFUZ:.VZ_R]D]DV!D>@?7WVW8_,I>1Q$("-64+3&NP
M05G@,7F;\5OC20_!/_'Q343=CQ1]#<Y-*/S->CM[NUINNJKVPOG.N[AJ3,9D
M=EY3T,RC_BL5)MZ+"(0XJ@+7PKA>W6MQB3OW GYW>R<\O?K$T#B1A5&)^\WA
M9W^F1"EYI)&!3%T41$E _1? I*R4X%1;V6L&V\$(FM*XJ"739R$R@,$-V)X/
M(EK73>6X1;;85$K6?*F])N"<TJ5-BS=.HKDE:N=X/T%*2Y 9(N.G&G,=P? &
M</-VM4;UB[;Z;ZOE?B?7MRSST1EO0!D9\$3Q,F^09> DHX45$FZH=G'@D\1,
M<V6-AITZ3&\ /;_B'M9SM[@?0KT^"Y+:1*( +T7&$X":V7-%4/ "N1:S0:NP
M,H2>IVB:I_[1<%21_0V Z1E[\,--JKR1#*]ZY8 *)D%H4IH>XA:ID,KB>4DQ
M5L^RZT'7Q#DDIX[:U994 ^B[DS*#9[4+K)?2U>NTF7=_A<4NEJC[9I/P?Z4M
MR<PQ$?!$E3:P$N_Z,J/>6.(A!SQL20FC2>TK<@"9342!*F+EZ5RG4017;=KM
ML/#1@.V]2<CB=-VTZ?H#W'Q=QI*EVRK$F='>F:@U:&\=\D(3L-:B#V4-&AQ.
M.<7[-%P=D<0FPECUL=N28">/BK^XFV!+7V,:(&9?9G[8PN&<0$6="./>:_92
M?D*_E=K*!*V*MLIL/G; ?*6&A[AVF'<<PJ\7J9/4LK2P0P;^N_O[66#"*K1L
M@',FT+Z.$CTJ%4OLF,N81&:B_H#YE^EJ*\VS^J5<730-6(@W$9_;OA$S;;Q%
M0R)#IJACA0H2/&4:#!,F1&8C[F2L\-HM&=,T:#T9F(YE_!'*:GOT_?9EZ1;=
M;Z1X$_9YN]IL-S,BLV96&'!4*!"R-#)FR!PI3&3446GN=]]Z]%I[<H%INI:>
MY#:KP]2)+9^[NO!C/@O_;S=' MZCC);G<W31K[+E*:I)(K0. G2,&ID4'5AB
M#?CLI5"<.B/[X*3G<M/T$CT):L9@>!.=GW]/F^UZ%[:[-;+L[5>W/D^;668^
M.9H%)-2%(!++9:!T!BH=9XE(&53M":F/T3%-7]$31A^.9'T3 /HPW\[/KQ*E
M;QJW7;<A#-%2(KF&Q- W$%(K\#XH",2A3YF\]K0VCIXA9YKFHR>#4RU!M._4
MZYB8H.4UPE-3AH0Z<"EY4%YZRAW13.8>MUHEI[Y^"]%6O/I#^-R$+KK?!I4&
MXG69(HQ6/?*&T C&>PUX$1.2N(@^UVXM,:@)[>N-H!_#\48@<]/(L50\HUVW
MO?PU;;^NT+@K)4)7)5["X'5L*(<0>0(12ONTZ V0')(101(R4KO#%PB;J,GF
M">%56SH-!(.NMO$Y!33\2O_FG[__-O_%S9=7\]84"819!M&+\KRD2^=F:R%+
M0;(V%CE9^Y'Z.7HF:JMY,H!5DT4#N.JZU/ZV6JY^C'E=J^8<?(BX$[",9BAS
M'L$H9)/5VFHO90RJ>CK?LQ1-U(3S=+''>O*8+ SYN"(NCX[SY0ZWM(^OKI:;
MJP?&.STJW_VU73N4XGSIUI<=-Y$7H3Q7KA:+CAM7IL,L&*$"1T8PBB=,9"+!
M"2[034G:6BZ]O3^[L_+E6G4[$S4(G>A*G@X)U7(K3E))W[OS4]4Z^H-7';&*
M_C@.C%U#;S2))%IT5'3)>L@Q@%>!0+ TH@TI-7>OIO?I@(R^6/*8O"<E69B!
M\%&!L\P"MXFX*#D/G-;>_M^FAOX0[-2HH3]$6,W5('45-]EIQJW)D)0D4"X=
M,(EXB%Q939VB+/2Z\<>K86NJ2OX@@;]<PW8(]YO#SS[U/;@<LI !-"E9F%Q0
M,"Z56:N6X3>I-*\8!4&-UK =)-,^-6R',+@%W_>)DBH?#96&*?#$HI.E,[KP
M7ECP:$N2F*F(L?;%]GIJV Z2<<\:MD,8W@!NGN\UH7W.B>0 0K#"%G26K'<6
MK'#)9FTCX=4[*QW=X*6I\NLA5U=]V;0 M!_:&L1 (E52 SK:96I'3."(0B^<
MF&@24Y;JVK&X5]/@Y2#!/MO@Y1 N3]WI8Y'2M\X%WGR;K\LO7NX5JE$\H7YV
M$(0I+4W1SW 9=7;*F6=KB0NQSV/WDPLTX50-$=BJ-O<F?8]\KFE)],%G'R)(
M:5&).B/!)1Z Z1"4"3;QV&>>\RMH]S(8 !4X-[&K<Z,4;SL<NT6G$$64F63N
M()-2V,TH!Z-Q$UEQW(R/@<9>60PO^#I/$O#Z"E2'.LQU9# UD*XX<7<+UZ<K
MF: (B2""*5TED"TV40O$6L^-4X+G7L[02T!ZBH#I7*!*@EW5YO+$5L>7?VS^
M\=8M771X>7XH[MS915KC7FY:I7D6%1= 6+0E 4R#-X8!S90J$2Q!@OJ4&3R_
MS(2PJ"/$U3@<G1@<;U<7'JWS^&ZW7GW#FW5>MM2]:?_JUO]*MUUKB.92! Y!
M4P4B"@Z.>@LJ4).\,S;3/C-B>BXW73N7^F 9@\,3@^:7Q<J[Q37=UB2J(@5M
MRA1ZC7_XP 0$'V44(0CN^]2(W_W,Z;JPU!?_8%ZU$,[8^<U=IUUJ6IK""+"R
M>.Y12S 6(4H%<U*[I+EC?4R+0P(:/Y(P<57LJ6-C1_"_+?CL#U%)X9214<BR
MV&$B.#"2>TA2">TR)4Q7[Z5]GXB)0R''B/1I> S@[^05(%W;WKUB5-F*3(0$
MKU0)!VH#AC%4MI9K*ZA0FN@>E\@/']J,H(<(YV&#XP&<FEC$73_F&V-G;QHG
M0I@1!,V:X,N0NPQ.: LNT6#Q/N0\]PET/O+1$T>XJHG[6*ZUH/C[I"<FK[*+
M.I0I%&5@&/7H)#$),92&K,1+FVIW1JC6J&V\Q,Y36QBU)=4 ^H;T^[(!#ZLT
M I*-Y4&;)7">Z,)(Y7RT"A5M93#^/1NU'825"HW:#A'<ZQK+]3"5]L>IB"/G
M$#^^V$E3AWOL=^R,8<=(C-X1R#[Y,NL4[2XI%3!CLHX2W7A3N[9]_(SA/8,W
MCTY_+1'-'\=Q7MTR 0V.Q$,$)<IT8A[+5#T\V!DM&2FR82)6=]V.HK@M93D(
M44_G$8\NPJF?MYY\RN&*:Q8# ;Q/**"7'%#7HUE-B)6B#!'1_=JUC?I.>H+$
MXO$1T.O)]!!Q3(VI)V.[S*+50D@9NDY+":APX)1VD(Q%(X(+YW*ONI"_TY/I
M08+M]61Z")<GA$I8[=#VO)Q]^3RCB3ME2$3C,J%QB6X[V) 8,$:I=$:R:)^K
M8-BD\(_SU??_V'_B%33VW]PBXW:]%I](#Q+:ZB@.3ARM*HV:/N9_KM:+N(^Z
MN$!<D$:!M (=Z\AX24^TH$MC?)E-$#Z\8&H_^L$MOFX.D?/Q7&LG6M#W'KWC
MZ29)$EZA0$49GF"#+C%\6L9,IQ"HI8'6[N$PE-96,LI/9K.<5+CM@/B@R(E6
M+FOF/&B=+0AM&'CN"9Y3CMOE4612VZ%[=2&OT^"G0ACL$&&^TC#8/5[?#P_5
MG4U_\*JG"(P-XL#8$3(?619<22 ALE*32, [I4!3QRC+DO/X_TF$C/+$A9<1
M,E4EN0=O*Z^,@\Q-=(83K^EX(^K_1A&R0Q!5.4)VB BGCF8\Z;FK[(UVS #3
MMCP\$PXF^PS,1,H\VOF2_'>$K H">D7(#A''U)AZTCU,5#G"N -).-HS4BCT
MX[V'I!QUV9%$^[4.^3M%R X2;*\(V2%<;B!"=O9E%I0*HFLY3,M(&&M]R4LJ
M ]>YM]IH*M-SD=/#(F1G7UJ,D!TDM-51'&Q YE\^SU)FAI"@P">BD6)OP!KE
M@5(G@E8FR&>S@$>)BIXX6G:,S _D8 ,R__S+C$?EG<\<2B4"4DP9N+)AQ:R@
MOFS9/&=3'";SS[^T6 !PC,P/Y&!SD7!N14+(LC*EH&0I9P+&X3900Y7G(:T#
M[U/],RP27CV=O[Z<C^=:.T'$PX-=FB.(K>'HIH62\V43&(8F-#,Y&;S+K+3_
M'0F?R#<YJ7 ; ''I.;I;%V%<;63&-7,F&0O*1@^"H'UEI600C"$F6EH*KRJ#
M\SX-KS2&?9#D5Q7%4+%%1_T0];N+;XO59<)_M)VO.\?PT\(MAX2=G_JD6J'D
M7I16"@^_75V4?M=N/\7Q=LF?YINP6&UVZW03WTOHU0CM-02=RO2L9,%GHB R
MXT.(CJ98N]_6 >0=JX ^X3I7JW0%')]6^+$WR[U)RY3GV\WMLG^@ -[@O__7
M+&LT_96V0)CVI?X7[89(+41OO<R&<^MJO\<-I75:A386UN[KL)-(\C7JNM_<
MNG0%_)Z&/[GU_>21=>'S.YE -YH<C2>>E7X1"!W)\2O!,MZ526F6\<<JO%[=
M^!,>F66*^[/32>#9T]7]QBT9>S/8"LU(2@JD+,<K*0[.F 2\#(;1GBOB:[\X
M5B'\]6C-0U#X<+#SJ67<@-?QHUKY_*WT8EU_*/^L<+L\%GCOC0Y6@>>AA/QP
M5Y;Y"#J$Y+GVDN;:K1->)&I:0$X E <^<4VIM0[#?7A+>Y:I\@[=N%(U3B(:
M)T1S8"HK+V)$2Z5^L.9%LJ9VD:L"X1"8#9!* T!#JM'.FH>RH7VPDR9##?4"
MD& *PG %1J#1FT66-,1L):L]6^,A%0W#:(B@[U^MQW&]@9>D[NW+AE(A#(XY
M9( JF9%&$5"$$B5U3%S'9W#R.FHJ:DGLL:?#_NQK0%'\O%JG^?GR[OY-#LJE
M,@$-G7%1IH@:*VF1G7%)64)([3E@#XB8]A5@;#5Q',\;T!)G7V;<QJ@--Q#*
M/&*A"\PC$<"C3%;%G#-]+D;X.O)**@GL84[)(=QK0-Z??YDY(CR3492^W;AA
M8\HKJ47]Z**R/+N<?+T\HI[Y!:,I@+KR/I![#5P*#SV_6[?N]OE)625CJ1I,
M*I1->0Z>< :)!LY"#MRJ7FFL1X5Y'B%L6NQ,[S77E][DG>BZ#76U-G._*Y+L
MCJ;[:WZQNSA;+G=N<?>'FS>7^W#R^E-:!^3UC%,J\9!RT*[,V,D&C3H:!/@0
MC8C$*"[N];)ZHGW=L92T%M(Y&AJKR>34CJ*\O^.W>-!_3V%UOIS_.\69T=DS
MJA%/+)LR136!5<*#428[Q1GEHG9$IQ=AK2G*6E@<3SI-/P9^2.=N<1:ZDW4U
M$/@\+<,\E?OG[>KB8K[MNA\.> SL^\FU'@,'[:3>8^#UYW>KW5G]D8<82K5S
M-A&(3J$;F+,'C^8=VGE*D)1#$'Z$5(G^!!ZKX#I)_.JVVZM4I!]6NWU/Y\QX
M[T3IC)XX&K7H$5NM-"1F!>'&*.UJ6X*]")O\06\D)-U7=/6EU' )<D_ET-G1
M(RJ[_>>?6.4]MJM)%)]0TALG!0B;\-9,UH(3)7D^>JY3),GPVLUA3Z+X]I,Z
MN\] <_6C7\S/.XG^C$NXQ?]-;HT';;>>;R^ODX4[F=P>,\>=-EXQ\/C_('S0
M>) M+_,W34D$9I3U2A-[>2;N<")?DV(\!&GW9NJ>2(JO7UE62!@;NM*)%>BI
M$LH.N?DY591&#THF1#DILZ\DL: H]T+91'.HG7ER6AMRM;DCD<M/;MNMNUBD
M\Q07E^^7>5U^%'_;7?7/-][8K 5HZ3R((#-88G)I+&28RB$E77M6]&$4OB;E
M>0BV'EB5X\EM\OJYD.;?.U/J\VH12_.>#W/D:HHE+K##)6;!2A$\8V!(Z=>3
MG0(OF03)K&,D1\.U>4$C]EMIVB#,^&@:@=\-!/Y^V;FU6VY3NC4M-OLXY[N_
MOG5<F]&D(^$I :,E)4F9""84]RMPXKE(@I':8;\>9$T[1O1TVJNVA!H W3V%
M?!;"&HW;3^O5]WFI@YBA?6QM1DYQ4X:0,"G!Z*A "$6=Y];+ZKW07R!IVFE@
MDUV51TGF]7L3=T[<%[2FUY]VZ_#5;=+9^3JEJPD\8[L9_4DXL?\QD#?3Q'B,
M]\1(#EPS4WH6$K T)_#4LJ09T5'6SA@]J6-RS?OGP@.WZL'JD+4K[T))@I!>
M@R.)0XZ!2$+P:U:[3/D0^EZ34W((KA[4_(TELP;N]X=[^VF7WB]_P\/_QY]I
M\3W]BHS]NIDYKSV7*@(ENDPOCGA36:&!4ZHIY]DJ4?N>[TG:M"@<#QLO@O!X
M0;6+O\_HHRUC8>*,)58&M5O@@5 \N3&#H]D %4GYY+0/QIX&>;=$3>M 3XVY
M@<)I%VU_?)VOK_;C&:/*A 0T6_3.,@W@HZ3@>-+":I<]J6U^O$33M,[SU%@;
M)IIVH?;S:K?>?NTV1).21@4'3!)T_J@0N!?%( ?N&7<N!UN[K/M%HJ9UGJ<&
MVT#A-(RV>=[OAX1LG&=E-+TO.6V!@G6X/6L\RQI_&DSMM_.7:)IVJ.KD6!LD
MFE:A=I9Q@=LM":6IM$*!-P2]K6!*FP!CP$3JO99>)5V[ZWD/LGH!3OT] 7>$
M@)K$W,Q+SY3'^U_P\H>3N;0DBV@3))GP($4B:^?_/:2B%Z+TWQ!1![%_.(!6
M6[>H J"N%N9NQ.B:+8JB^9AX&9$M(@C\&EPP#C?CRYB49&VJ#:.G:'E-K[+'
MA-.JR*(!I71O'X^'8[P6LA28 /K)H1P[ L8Z!8Q&*V)F 9V:<?'58-"L#@*>
MA]7QXF@48G>B+YRKS 6R2X:NI)>7J7J60%8\F> \-;SV@/KG*9I6A9T,5@-%
MT"B@;D,L6:!WJ_!@9&OP=%"+"MV@C4 L(89Q[FSU)FK/$C1MZ.MD<!HF@$;1
M=">&DAG3) 4%.0E7AGZ63*LH0>>4./4Y^F?G ]2"4RO1K9/A:: (6@74C=,:
M'+/$*PO,.W<U+<%[]%RED#0Q'8R-M;O$/$O0M &LT\%ID ":1-.]* BS>&DC
MEX"C7@7!# /'O46GQBJ=(V>^>MN[EVB:-D9U(DP=(8;V8#6C69ID,RW=603R
M1J*.53Z!EMX$BC3Z?L57PU$T;1CJ%* YB,D-Q)MZ%H+=MB2/"GF2(V2N*?*K
M^*7(,."&)5L&I!M;OZ;[(!)?4P[W,=&I,277@/)Z='N/QTHR3<([@H=64E3+
MB9<$8L6 L&QYI"Y%5OL1IS]U4^<>C@B2/H \7F*M*LG[ 1:IK%$1-Z%"1L4?
M0U>*&R!$SJT*RI/J?1[ZT#5UL+X%_ V44M/(NXW%,&%T2FB+ZA#0A$DTELB>
M!C1;?(B9QD!JFW4]R)KZ&FX!=\-DU#3L[H1L-+4D25=FOY88H(P2+(OX;6(T
M*1,CE?6[7+Q,U]1E52T ;Z"4VD;>C1L>-7%9!P(,=38(H2,8D_%L,<852<PS
M4CO1N@=9TP;9&L'=(!DU#+O[ 2">'3<BE-QQY!KU&KRSOK0_-U%$'ECU=+%^
ME$T;C6L!?$=(JE7\S:ACB60G2MX;ZFYG'1C*)&B:H[&E2/8TP99IPW:3H^L@
M.50#4_L5RK-[+4LFJ5%&(EJM4K[/GYLZY?\X0HAE4/=Z%PKFE^?O_BI3T09U
M\GO\<VJQL@>5E:JV?UBI&PVW<-L4BQB_S[=%>'>B_#&QS"&(TBU7\ #&XWEF
M0F?!!:-4UQ]BUI.XXV=GO;#08Y,^=92.&!* $%KZJ M4:R*:DL3!I!=94'5R
MAC0WKW4<?#V<LC6R_!ING/&HKJC0=*_?YXZJ\4[24*\_0IW/.K,8(+K2S9NX
M +94PI)DF(A:2^5JY_B>3 ->MZK\F)]8LG0VWP^0,-DXDAF!0#P:=5PH<,X:
MR(Z0;#V35M4.(!Q WFO1=X>@Z;Z^&TM:#3Q<_K"ALHUN4YNT_IZZ88R1)9Y-
M1F:)+%%K!PFF%*;3;-%CE42(Z@6.+Y T+>!&@\)S5^R1<FD 9G_@[]UCV7[Z
MFG+.&6TDA&@TGLOLP18[Q%L5'./&(SF5 ?8D,0WILF-%OAJ#_Q/W^ORT6F_+
MP?KXUR6ZNNCSECDSZ_(/WNPV\V7:;-Y>&9W[25_2!\X=Y<"##2"8H& #IT!Y
M\,Q))\3]#+)'&W\>N.RT(*HDZ-5IN-Z 9GKFU'VX&5TC29;,*@'.^U3BLQ0U
MN6)0BC^-X80)5[MC6!^ZILV6:. J'":A%E&WF5$9G.#6X[DQN -"(ECE"! \
MI(H%*:BH_5KSD(IF;\"!DGX)2H>QO0'@O$>/?HF_<OG/]7R;?EK]N9PE$:UB
MWD"0Q2Z@I8,/I0F4"B8KR353M=/M'U(Q]9C?D8%S)-L; ,[9!=[C\W]?B609
M?TI(2)AWWW[,/Y64LZV[F"_=]DJ%E[^YN)AO2L_;\C>;3<+#HEFD@1 )62G<
M<T"%[GQ4$+SS%)WK&%EMJ-6@>]KLKM'!>7+1M@#G0O7[BV]NOBZ/6&^_NO5Y
MVLR"R*7CMP+%*<-=H"(W/$8@-JML*&76UKY$'Z=DVKRN\2%W//L; -'G]#VM
M'3HTG2E 9SD;QFPT8%+NFKD(,,%'B,8'W!@1]=%SCX1IT[)&A\TQ#*\XL',X
M8JY=WG=_S;?[/5 A<D+G!EQDR _K'3AA&#!E$?%91Q=K9](_I&+:C*K1<7,D
MVR>?4?.D>US^^Y@_NP4J3^9*)TZ'.T+7&(2C"GG#+#C-DI=21L+N >F).35]
M5ILV26HTP(S$[@;NJA]9MK]OC75)2U283+, (I=VFDXK<"1F$8FR3H\;ESK
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M2P$"% ,4    "  SJ0M5X:U>KSE-  !D&P( '@              @ $
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MQ0  97@Q,#<M9F]R;6]F<W1O8VMO<'1I;VYG<F$N:'1M4$L! A0#%     @
M,ZD+53*7,&O*,   6R0! !X              ( !.08! &5X,3 X+69O<FUO
M9G-T;V-K;W!T:6]N9W)A+FAT;5!+ 0(4 Q0    ( #.I"U7]K <(#E$  /0\
M @ >              "  3\W 0!E>#$P.2UF;W)M;V9P<W5A9W)E96UE;G1F
M;RYH=&U02P$"% ,4    "  SJ0M581)[82 (  !0*0  &@
M@ &)B $ 97@S,3$M8V5O8V5R=&EF:6-A=&EO;BYH=&U02P$"% ,4    "  S
MJ0M5 5%.'1T(  !5*0  &@              @ 'AD $ 97@S,3(M8V9O8V5R
M=&EF:6-A=&EO;BYH=&U02P$"% ,4    "  TJ0M5ZO<8HH0&  !')@  '@
M            @ $VF0$ 97@S,C$M8V5O86YD8V9O8V5R=&EF:6-A=&DN:'1M
M4$L! A0#%     @ -*D+56\R8'@*!@  "CX  !L              ( !]I\!
M &5X:&EB:70R,3$M<W5B<VED:6%R:65S+FAT;5!+ 0(4 Q0    ( #2I"U53
ML$;QS ,  " ,   =              "  3FF 0!E>&AI8FET,C,Q+6%U9&ET
M;W)C;VYS96YT+FAT;5!+ 0(4 Q0    ( #2I"U4(C@3>$0P$ )8!*P 0
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M2P$"% ,4    "  TJ0M5K"'4<,TG 0!$E $ $P              @ $$:P8
M<FUD+3(P,C(P-C,P7V<Q+FIP9U!+ 0(4 Q0    ( #2I"U6<)DT9HUH! -\J
M#@ 4              "  0*3!P!R;60M,C R,C V,S!?;&%B+GAM;%!+ 0(4
M Q0    ( #2I"U628"K=B,$  &O0"  4              "  =?M" !R;60M
F,C R,C V,S!?<')E+GAM;%!+!08     $@ 2 /T$  "1KPD    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
